PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Levine, TP; Rabouille, C; Kieckbusch, RH; Warren, G				Levine, TP; Rabouille, C; Kieckbusch, RH; Warren, G			Binding of the vesicle docking protein p115 to golgi membranes is inhibited under mitotic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; HELA-CELLS; POTENT INHIBITOR; PLASMA-MEMBRANE; RAB PROTEINS; CYCLIN-A; TRANSPORT; FUSION; PHOSPHORYLATION; KINASE	The vesicle docking protein p115 showed saturable, high affinity binding to interphase Golgi membranes. The affinity of binding was up to 20-fold lower using membranes preincubated with mitotic cytosol. In contrast, binding was not affected by mitotic pretreatment of p115. The reduction in p115 binding was mediated by phosphorylation, could be induced by a cyclin-dependent kinase, and was fully reversible. A shift of p115 from membranes to cytosol was also found after fractionating mitotic cells. The functional significance of the decreased binding was addressed by in vitro mitotic incubations which disassemble Golgi cisternae, predominantly producing transport vesicles. The addition of excess p115 decreased loss of membrane from cisternae, indicating that p115's action is limiting while transport vesicles accumulate. The cessation of intra-Golgi traffic in mitosis has been hypothesized to result from an inhibition of membrane fusion while budding of transport vesicles continues. This process also contributes to mitotic Golgi disassembly. Our results imply that there is a mitotic modification to Golgi membranes leading to a reduction in the affinity of the p115 receptor. Reduced p115 binding may play a part in the inhibition of membrane fusion by preventing prior vesicle docking.	IMPERIAL CANC RES FUND, CELL BIOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Levine, Timothy/0000-0002-7231-0775				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BIRKY CW, 1983, INT REV CYTOL, P49; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GOW A, 1993, EUR J CELL BIOL, V61, P184; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MACKAY D, 1993, FEBS LETT, V336, P549, DOI 10.1016/0014-5793(93)80874-T; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MISTELI T, 1995, J CELL SCI, V108, P2715; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, V1, P509; SLUSAREWICZ P, 1994, THESIS U LONDON; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; STUART RA, 1993, J BIOL CHEM, V268, P4050; SZTUL E, 1993, J BIOL CHEM, V268, P1876; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; ZELIGS JD, 1979, J ULTRA MOL STRUCT R, V66, P53, DOI 10.1016/S0022-5320(79)80065-9	60	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17304	17311		10.1074/jbc.271.29.17304	http://dx.doi.org/10.1074/jbc.271.29.17304			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663393	hybrid			2022-12-25	WOS:A1996UX94300051
J	Nelson, JW; Zhu, J; Smith, CC; Kulka, M; Aurelian, L				Nelson, JW; Zhu, J; Smith, CC; Kulka, M; Aurelian, L			ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; DELETION MUTANT; DNA-SEQUENCE; DOMAINS; GRB2; TRANSFORMATION; REPLICATION; ACTIVATION	The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is a multifunctional protein. It consists of a ribonucleotide reductase and a serine/threonine protein kinase (PK) domain, which has three proline rich motifs consistent with SH3-binding sites at positions 140, 149, and 396. We used site directed mutagenesis to identify amino acids required for kinase activity and interaction with signaling proteins. Mutation of Lys(176) or LyS(259) reduced PK activity (5-8-fold) and binding of the C-14-labeled ATP analog rho-fluorosulfonylbenzoyl 5'-adenosine (FSBA) but did not abrogate them. Enzymatic activity and FSBA binding were abrogated by mutation of both Lys residues, suggesting that either one can bind ATP. Mutation of GlU(209) (Ph catalytic motif III) virtually abrogated kinase activity in the presence of Mg2+ or Mn2+ ions, suggesting that Glu(209) functions in ion dependent Ph activity. ICP10 bound the adaptor protein Grb2 in vitro. Mutation of the ICP10 proline-rich motifs at positions 396 and 149 reduced Grb2 binding 20- and 2-fold, respectively, Binding was abrogated by mutation of both motifs. Grb2 binding to wild type ICP10 was competed by a peptide for the Grrb2 C-terminal SH3 motif, indicating that it involves the Grb2 C-terminal SH3.	UNIV MARYLAND,SCH MED,VIROL LAB,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,IMMUNOL LAB,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MICROBIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,MOL CELL BIOL PROGRAM,BALTIMORE,MD 21201; JOHNS HOPKINS MED INST,DEPT BIOCHEM,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine				Zhu, Jia/0000-0002-8676-5105	NATIONAL CANCER INSTITUTE [R01CA039691] Funding Source: NIH RePORTER; NCI NIH HHS [CA39691] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDERSON KP, 1981, J VIROL, V37, P1011, DOI 10.1128/JVI.37.3.1011-1027.1981; AURELIAN L, 1989, CANCER CEL, V7, P187; AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHUNG TD, 1990, VIROLOGY, V179, P168, DOI 10.1016/0042-6822(90)90286-Z; CHUNG TD, 1991, J GEN VIROL, V72, P1139, DOI 10.1099/0022-1317-72-5-1139; CHUNG TD, 1989, J VIROL, V63, P3389, DOI 10.1128/JVI.63.8.3389-3398.1989; COHEN JC, 1977, P SOC EXP BIOL MED, V155, P395, DOI 10.3181/00379727-155-39815; CONNER J, 1992, J VIROL, V66, P7511, DOI 10.1128/JVI.66.12.7511-7516.1992; COOPER J, 1995, J VIROL, V69, P4979, DOI 10.1128/JVI.69.8.4979-4985.1995; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DUTIA BM, 1983, J GEN VIROL, V64, P513, DOI 10.1099/0022-1317-64-3-513; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GATICA M, 1993, FEBS LETT, V315, P173, DOI 10.1016/0014-5793(93)81157-U; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GOURDEAU N, 1994, NAT STRUCT BIOL, V1, P898; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYASHI Y, 1985, P NATL ACAD SCI USA, V82, P8493, DOI 10.1073/pnas.82.24.8493; HENRY BE, 1978, VIROLOGY, V89, P262, DOI 10.1016/0042-6822(78)90058-2; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HONNEGER AM, 1987, CELL, V51, P199; HUNTER JCR, 1995, VIROLOGY, V210, P345, DOI 10.1006/viro.1995.1351; HUNTER JCR, 1995, VIROLOGY, V7, P515; IWASAKA T, 1985, JPN J CANCER RES, V76, P946; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; JARIWALLA RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2279, DOI 10.1073/pnas.77.4.2279; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LANGELIER Y, 1981, J GEN VIROL, V57, P21, DOI 10.1099/0022-1317-57-1-21; LANKINEN H, 1982, J VIROL, V41, P893, DOI 10.1128/JVI.41.3.893-900.1982; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUO JH, 1991, J BIOL CHEM, V266, P20976; LUO JH, 1992, J BIOL CHEM, V267, P9645; MCLAUCHLAN J, 1983, EMBO J, V2, P1953, DOI 10.1002/j.1460-2075.1983.tb01684.x; NIKAS I, 1986, Proteins Structure Function and Genetics, V1, P376, DOI 10.1002/prot.340010411; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peng T, 1996, VIROLOGY, V216, P184, DOI 10.1006/viro.1996.0045; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRESTON VG, 1988, VIROLOGY, V167, P458, DOI 10.1016/S0042-6822(88)90108-0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SMITH CC, 1994, VIROLOGY, V200, P598, DOI 10.1006/viro.1994.1223; Smith CC, 1996, VIROLOGY, V217, P425, DOI 10.1006/viro.1996.0136; SMITH CC, 1992, J GEN VIROL, V73, P1417, DOI 10.1099/0022-1317-73-6-1417; SWAIN MA, 1986, J VIROL, V57, P802, DOI 10.1128/JVI.57.3.802-808.1986; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WYMER JP, 1989, J VIROL, V63, P2773, DOI 10.1128/JVI.63.6.2773-2784.1989; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	63	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17021	17027		10.1074/jbc.271.29.17021	http://dx.doi.org/10.1074/jbc.271.29.17021			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663276	hybrid			2022-12-25	WOS:A1996UX94300009
J	Rogers, JA; Read, RD; Li, JZ; Peters, KL; Smithgall, TE				Rogers, JA; Read, RD; Li, JZ; Peters, KL; Smithgall, TE			Autophosphorylation of the Fes tyrosine kinase - Evidence for an intermolecular mechanism involving two kinase domain tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; FPS FES; V-FPS; MYELOID DIFFERENTIATION; PROTOONCOGENE PRODUCT; LEUKEMIA-CELLS; PROTEIN; EXPRESSION; PHOSPHORYLATION; RECEPTOR	The human c-fes proto oncogene encodes a cytoplasmic tyrosine kinase (Fes) that is associated with multiple hematopoietic cytokine receptors, Fes tyrosine autophosphorylation sites may regulate kinase activity and recruit downstream signaling proteins with SH2 domains, To localize the Fes autophosphorylation sites, full-length Fes and deletion mutants lacking either the unique N-terminal or SH2 domain were autophosphorylated in vitro and analyzed by CNBr cleavage, Identical phosphopeptides of 10 and 4 kDa were produced with all three proteins, localizing the tyrosine autophosphorylation sites to the C-terminal kinase domain, Substitution of kinase domain tyrosine residues 713 or 811 with phenylalanine resulted in a loss of the 10- and 4-kDa phosphopeptides, respectively, identifying these tyrosines as in vitro autophosphorylation sites, CNBr cleavage analysis of Fes isolated from (PO4)-P-32-labeled 293T cells showed that Tyr-713 and Tyr-811 are also autophosphorylated in vivo. Mutagenesis of Tyr-713 reduced both autophosphorylation of Tyr-811 and transphosphorylation of Bcr, a recently identified Fes substrate, supporting a major regulatory role for Tyr-713, Wild-type Fes transphosphorylated a kinase-inactive Fes mutant on Tyr-713 and Tyr-811, suggesting that Fes autophosphorylation occurs via an intermolecular mechanism analogous to receptor tyrosine kinases.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center			Rogers, John/L-2798-2016		NCI NIH HHS [P30 CA36727, CA58667] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058667, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI Y, 1995, J BIOL CHEM, V270, P15658, DOI 10.1074/jbc.270.26.15658; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; CARE A, 1994, ONCOGENE, V9, P739; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANG F, 1993, BIOCHEMISTRY-US, V32, P6995, DOI 10.1021/bi00078a026; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITHGALL TE, 1992, BIOCHEMISTRY-US, V31, P4828, DOI 10.1021/bi00135a013; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; YU G, 1989, J BIOL CHEM, V264, P10276; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	63	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17519	17525		10.1074/jbc.271.29.17519	http://dx.doi.org/10.1074/jbc.271.29.17519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663427	hybrid			2022-12-25	WOS:A1996UX94300082
J	Lui, VCH; Ng, LJ; Sat, EWY; Nicholls, J; Cheah, KSE				Lui, VCH; Ng, LJ; Sat, EWY; Nicholls, J; Cheah, KSE			Extensive alternative splicing within the amino-propeptide coding domain of alpha 2(XI) procollagen mRNAs - Expression of transcripts encoding truncated pro-alpha chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-RICH PROTEIN; NH2-TERMINAL DOMAIN; TERMINAL PROPEPTIDE; SEQUENCE-ANALYSIS; HUMAN CARTILAGE; MESSENGER-RNA; III COLLAGEN; XI COLLAGEN; V COLLAGEN; FIBRILLOGENESIS	Heterogeneity in type XI procollagen structure is extensive because all three alpha(XI) collagen genes undergo complex alternative splicing within the amino-propeptide coding domain, Exon 7 of the human and exons 6-8 of the mouse alpha 2(XI) collagen genes, encoding part of the amino-propeptide variable region, have recently been shown to be alternatively spliced. We show that exon 6-containing mRNAs for human alpha 2(XI) procollagen are expressed at 28 weeks in fetal tendon and cartilage but not at 38-44 days or 11 weeks, In the mouse, exon 6 is expressed in chondrocytes from 13.5 days onward, We recently identified conserved sequences within intron 6 of the human and mouse alpha 2(XI) collagen genes, containing additional consensus splice acceptor and donor sites that potentially increase the size of exon 7, dividing it into three parts, designated 7A, 7B, and 7C. We show by reverse transcription polymerase chain reaction and in situ hybridization that these potential splice sites are used to yield additional alpha 2(XI) procollagen mRNA splice variants that are expressed in fetal tissues, In human, expression of exon 7B-containing transcripts may be developmental stage-specific, Interestingly, inclusion of exon 7A or exon 7B in human and mouse alpha 2(XI) procollagen mRNAs, respectively, would result in the insertion of an in-frame termination codon, suggesting that some of the additional splice variants encode a truncated pro-alpha 2(XI) chain.	UNIV HONG KONG,DEPT BIOCHEM,HONG KONG,HONG KONG; UNIV HONG KONG,DEPT PATHOL,HONG KONG,HONG KONG	University of Hong Kong; University of Hong Kong			Cheah, Kathryn/C-4222-2009; Nicholls, John Malcolm/C-4375-2009; /C-4359-2009	Nicholls, John Malcolm/0000-0001-7217-7444; /0000-0002-1758-8854				AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BIRK DE, 1990, J CELL SCI, V95, P649; Birk DE., 1991, MATRIX ASSEMBLY, P221; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; Chu Mon-Li, 1993, P149; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FLEISCHMAJER R, 1990, ANN NY ACAD SCI, V580, P161, DOI 10.1111/j.1749-6632.1990.tb17927.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; JUVONEN M, 1993, LAB INVEST, V69, P541; Kielty Cay M., 1993, P103; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KUHN K, 1982, CONNECT TISSUE RES, V10, P43, DOI 10.3109/03008208209034405; LIM SK, 1992, MOL CELL BIOL, V12, P1149, DOI 10.1128/MCB.12.3.1149; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; LOVELLBADGE RH, 1987, TERATOCARCINOMAS EMB, P153; LUI VCH, 1995, BIOCHEM J, V311, P511, DOI 10.1042/bj3110511; Lui VCH, 1996, GENOMICS, V32, P401, DOI 10.1006/geno.1996.0135; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; NAH HD, 1994, J BIOL CHEM, V269, P16443; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; O'Rahilly R., 1987, DEV STAGES HUMAN EMB; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; PAGLIA L, 1979, BIOCHEMISTRY-US, V18, P5030, DOI 10.1021/bi00589a034; Patten B. V, 1976, HUMAN EMBRYOLOGY; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Sanger F, 1992, Biotechnology, V24, P104; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; THOM JR, 1991, J BIOL CHEM, V266, P7262; TILLET E, 1995, EUR J BIOCHEM, V228, P160, DOI 10.1111/j.1432-1033.1995.tb20245.x; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WU CH, 1991, J BIOL CHEM, V266, P2983; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	47	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16945	16951		10.1074/jbc.271.28.16945	http://dx.doi.org/10.1074/jbc.271.28.16945			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663204	hybrid, Green Published			2022-12-25	WOS:A1996UX12600079
J	DellaRagione, F; Russo, GL; Oliva, A; Mercurio, C; Mastropietro, S; DellaPietra, V; Zappia, V				DellaRagione, F; Russo, GL; Oliva, A; Mercurio, C; Mastropietro, S; DellaPietra, V; Zappia, V			Biochemical characterization of p16(INK4)- and p18-containing complexes in human cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENES; NUCLEAR ANTIGEN; HOMOZYGOUS DELETIONS; POTENTIAL MEDIATOR; AUXILIARY PROTEIN; G1 PHASE; P16 GENE; EXPRESSION	The regulation of the D-type cyclin-dependent kinase (CDK4 and CDK6) activity appears to be the key step in the progression of eukaryotic cells through the G(1) cell cycle phase, One of the mechanisms involved in this process is the binding of some small proteic inhibitors, with a molecular mass ranging between 14 and 20 kDa, to these CDKs, We have evaluated the amount of two such inhibitors, namely p16(INK4) and p18, in normal and transformed cells, as well as the biochemical features of the macromolecular complexes containing these proteins, The results obtained indicated that Ii) p18 gene expression, unlike p16(INK4) gene, is not regulated by pRb status, (ii) no evident relationship exists between the expression of p16(INK4) and p18 genes, (iii) significant amounts of the two proteins are not bound to CDKs but occur as free molecules, (iv) each inhibitor forms a complex with the CDK protein with a 1:1 stoichiometry, and Iv) a competition exists between cyclin D and the inhibitor protein toward the CDK protein resulting in the absence of detectable cellular free kinase. Moreover, employing the human native partially purified p16(INK4) or the pure recombinant protein, we have been able to demonstrate in vitro the dissociation of CDR4-cyclin D1 complex and the formation of CDK4-p16INK4 bimolecular complex, Our findings suggest that during the cell division cycle the members of the p16(INK4) protein family and cyclin Ds compete for binding to CDK4/CDK6 and that their quantitative ratio is essential for G(1) --> S transition.	CNR,INST FOOD SCI & TECHNOL,I-83100 AVELLINO,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR)	DellaRagione, F (corresponding author), UNIV NAPLES 2,FAC MED & CHIRURG,IST BIOCHIM MACROMOLEC,SCH MED,VIA COSTANTINOPOLI 16,I-80138 NAPLES,ITALY.		RUSSO, GIAN LUIGI/GQB-0962-2022	Della Ragione, Fulvio/0000-0002-0592-4283; RUSSO, GIAN LUIGI/0000-0001-9321-1613; Mercurio, Ciro/0000-0001-6240-4607				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BATES S, 1994, ONCOGENE, V9, P71; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DELLARAGIONE F, 1995, ONCOGENE, V10, P827; DELLARAGIONE F, 1993, ADV EXP MED BIOL, V348, P31; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEE SH, 1991, J BIOL CHEM, V266, P594; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MULLER F, 1994, J BIOL CHEM, V269, P17086; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLIVA A, 1993, BIOCHEM BIOPH RES CO, V191, P908, DOI 10.1006/bbrc.1993.1303; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAM SW, 1994, ONCOGENE, V9, P2663; TAN CK, 1986, J BIOL CHEM, V261, P2310; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENG XR, 1994, J BIOL CHEM, V269, P13748	53	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15942	15949		10.1074/jbc.271.27.15942	http://dx.doi.org/10.1074/jbc.271.27.15942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663131	hybrid			2022-12-25	WOS:A1996UW35200019
J	Elia, G; DeMarco, A; Rossi, A; Santoro, MG				Elia, G; DeMarco, A; Rossi, A; Santoro, MG			Inhibition of HSP70 expression by calcium ionophore A23187 in human cells - An effect independent of the acquisition of DNA-binding activity by the heat shock transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; TUMOR PROMOTER; ACTIVATION; THAPSIGARGIN; HYPERTHERMIA; FLAVONOIDS; STRESS; BRAIN; PROSTAGLANDINS; FIBROBLASTS	Heat shock proteins (HSPs) are induced in mammalian cells in a variety of pathophysiological states and have an important role in cytoprotection in vitro and in vivo., In this study, we report that the calcium ionophore A23187, a glucose-regulated protein (GRP) inducer, dramatically inhibits HSP70 synthesis and HSP70 mRNA transcription after induction by heat shock, sodium arsenite, or prostaglandin A(1) treatment in human K562 cells, A23187 does not suppress, and it actually prolongs, the DNA-binding activity of the human heat shock transcription factor (HSF), while it alters HSF1 phosphorylation in heat shock-treated cells, To inhibit HSP70 expression, A23187 needs to be present during heat shock, while treatment before or after heat shock does not affect HSP70 mRNA transcription. The GRP inducer thapsigargin, which specifically inhibits the endoplasmic reticulum Ca2+-ATPase, has no effect on heat induced HSP70 synthesis, indicating that A23187 inhibitory activity is not due to depletion of intracellular calcium stores and is independent of the concomitant induction of GRP genes, Inhibition of HSP70 expression is correlated with alterations in HSF1 phosphorylation in heat-shocked cells, but not in sodium arsenite-treated cells, indicating that different mechanisms may be involved in mediating A23187 inhibitory activity.	CNR,INST EXPTL MED,I-00137 ROME,ITALY; UNIV LAQUILA,DEPT EXPTL MED,I-67100 LAQUILA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of L'Aquila			Elia, Giuliano/P-4725-2019; Elia, Giuliano/H-3438-2011	Elia, Giuliano/0000-0002-7941-223X; Elia, Giuliano/0000-0001-8216-9560; Santoro, Maria Gabriella/0000-0003-1432-4949; De Marco, Alessandra/0000-0001-7200-2257; ROSSI, ANTONIO/0000-0003-0383-3828				AMICI C, 1994, J VIROL, V68, P6890, DOI 10.1128/JVI.68.11.6890-6899.1994; AMICI C, 1995, CANCER RES, V55, P4452; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; BENNARDINI F, 1995, BIOCHEM BIOPH RES CO, V208, P742, DOI 10.1006/bbrc.1995.1400; CHOI AMK, 1994, FASEB J, V8, P1048, DOI 10.1096/fasebj.8.13.7926370; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSGROVE JW, 1983, P NATL ACAD SCI-BIOL, V80, P569, DOI 10.1073/pnas.80.2.569; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; CUTHBERT AW, 1987, BRIT J PHARMACOL, V91, P503, DOI 10.1111/j.1476-5381.1987.tb11243.x; DAIBATA M, 1994, VIROLOGY, V198, P446, DOI 10.1006/viro.1994.1056; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; ELIA G, 1994, BIOCHEM J, V300, P201, DOI 10.1042/bj3000201; ELIA G, 1993, CANCER RES, V56, P210; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FRANKLIN RA, 1994, J IMMUNOL, V153, P4890; HIGHTOWER LE, 1980, J CELL PHYSL, V102, P402; HOJ A, 1994, EMBO J, V13, P2617; HOSOKAWA N, 1992, MOL CELL BIOL, V12, P3490, DOI 10.1128/MCB.12.8.3490; HOSOKAWA N, 1990, CELL STRUCT FUNCT, V15, P393, DOI 10.1247/csf.15.393; HUCKLE WR, 1994, BIOCHEMISTRY-US, V33, P1518, DOI 10.1021/bi00172a031; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KANTENGWA S, 1991, BIOCHEM BIOPH RES CO, V180, P308, DOI 10.1016/S0006-291X(05)81293-8; KIM SH, 1993, BIOCHEM BIOPH RES CO, V193, P759, DOI 10.1006/bbrc.1993.1690; KOLLER M, 1991, BIOCHEM BIOPH RES CO, V175, P804, DOI 10.1016/0006-291X(91)91636-Q; LAMARCHE S, 1985, BIOCHEM BIOPH RES CO, V131, P868, DOI 10.1016/0006-291X(85)91320-8; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LEVINSON W, 1980, BIOCHIM BIOPHYS ACTA, V606, P170, DOI 10.1016/0005-2787(80)90108-2; LI WWF, 1993, J BIOL CHEM, V268, P12003; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MALHOTRA A, 1986, J CELL PHYSIOL, V128, P279, DOI 10.1002/jcp.1041280220; MARBER MS, 1994, J CLIN INVEST, V93, P1087, DOI 10.1172/JCI117059; MIVECHI NF, 1994, INT J HYPERTHER, V10, P371, DOI 10.3109/02656739409010281; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; NOWAK TS, 1990, J NEUROCHEM, V54, P451, DOI 10.1111/j.1471-4159.1990.tb01893.x; NOWAK TS, 1988, J NEUROCHEM, V50, P285, DOI 10.1111/j.1471-4159.1988.tb13262.x; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; SANTORO MG, 1994, EXPERIENTIA, V50, P1039, DOI 10.1007/BF01923459; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SMITH PL, 1984, AM J PHYSIOL, V247, pG695, DOI 10.1152/ajpgi.1984.247.6.G695; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330	56	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16111	16118		10.1074/jbc.271.27.16111	http://dx.doi.org/10.1074/jbc.271.27.16111			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663271	hybrid			2022-12-25	WOS:A1996UW35200040
J	Varner, JA				Varner, JA			Isolation of a sponge-derived extracellular matrix adhesion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING-SITE; AGGREGATION FACTOR; DISCOIDIN-I; DICTYOSTELIUM-DISCOIDEUM; MICROCIONA-PROLIFERA; AVIAN EMBRYOS; FIBRONECTIN; GASTRULATION; ATTACHMENT; RECEPTORS	The development of stable intercellular adhesions in the animal kingdom permitted the evolution of the metazoans, of which the sponges are primitive examples. Intercellular adhesion in these simple animals is mediated by a high affinity interaction between the sponge cell. surface and aggregation factor, a 2 x 10(7)-Da proteoglycan that is one of the major components of the sponge extracellular matrix. This report describes a sponge cell surface and extracellular matrix ligand for the sponge proteoglycan, aggregation factor. The 210-kDa protein binds aggregation factor proteoglycan with high affinity (K-d = 7 x 10(-9) M). Importantly, in soluble form, it also inhibits aggregation factor-mediated cell adhesion. This glycoprotein is expressed on the sponge cell surface and within the extracellular matrix. This novel sponge extracellular matrix protein may represent a primitive antecedent of the extracellular matrix adhesion proteins of higher organisms.			Varner, JA (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED 0063, SAN DIEGO, CA 92093 USA.			Varner, Judith/0000-0002-9251-0600				ADELSON DL, 1992, J CELL BIOL, V116, P1283, DOI 10.1083/jcb.116.5.1283; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARONDES SH, 1985, J CELL BIOL, V100, P1825, DOI 10.1083/jcb.100.6.1825; BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BRONNERFRASER M, 1992, DEVELOPMENT, V115, P197; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Cheresh D.A., 1993, ADV MOL CELL BIOL, V6, P225; DESIMONE DW, 1994, INTEGRINS BIOL PROBL, P217; EDELMAN GM, 1988, CURR OPIN CELL BIOL, V5, P869; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; GABIUS HJ, 1985, CELL, V42, P449, DOI 10.1016/0092-8674(85)90102-3; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HARDIN J, 1990, DEV BIOL, V142, P86, DOI 10.1016/0012-1606(90)90153-A; HELMER ME, 1990, ANNU REV IMMUNOL, V8, P365; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HUMBERTDAVID N, 1993, EUR J BIOCHEM, V216, P255, DOI 10.1111/j.1432-1033.1993.tb18140.x; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JUMBLATT J, 1980, BIOCHEMISTRY-US, V12, P3045; KASSNER PD, 1992, MECHANISMS LYMPHOCYT, V4, P163; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; Lallier T, 1994, INTEGRINS MOL BIOL R, P111; LASKY LA, 1994, N HORIZ TH, P37; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; McClay DR, 1991, CURR OPIN GENET DEV, V1, P191, DOI 10.1016/S0959-437X(05)80069-3; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1982, J BIOL CHEM, V257, P6931; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; PAN Y, 1992, P NATL ACAD SCI USA, V89, P2066, DOI 10.1073/pnas.89.6.2066; Righetti PG, 1989, PROTEIN STRUCTURE PR, P23; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VARNER JA, 1995, J CELL SCI, V108, P3119; VARNER JA, 1988, J BIOL CHEM, V263, P8498; Wilson H.V., 1910, B BUR FISH, V30, P1; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; XUN X, 1990, P NATL ACAD SCI USA, V87, P2097, DOI 10.1073/pnas.87.6.2097; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	50	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16119	16125						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663195				2022-12-25	WOS:A1996UW35200041
J	Isakov, N; Wange, RL; Watts, JD; Aebersold, R; Samelson, LE				Isakov, N; Wange, RL; Watts, JD; Aebersold, R; Samelson, LE			Purification and characterization of human ZAP-70 protein-tyrosine kinase from a baculovirus expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; T-CELL; ZETA-CHAIN; CYTOPLASMIC DOMAIN; INITIAL CHARACTERIZATION; HUMAN PLATELETS; SH2 DOMAINS; ACTIVATION; P56LCK; ASSOCIATION	The ZAP-70 protein tyrosine kinase is essential for T cell antigen receptor (TCR)-mediated signaling. The absence of ZAP-70 results in impaired differentiation of T cells and a lack of responsiveness to antigenic stimulation. In order to study the characteristics of ZAP-70 in vitro, we overexpressed an epitopically tagged human ZAP-70 in a recombinant baculovirus expression system and purified it by column chromatography. The kinase activity of purified, recombinant ZAP-70 required cation and exhibited a strong preference for Mn2+ over Mg2+. The apparent K-m of ZAP-70 for ATP was similar to 3.0 mu M. The activity of the recombinant ZAP-70, unlike that of the homologous protein tyrosine kinase, Syk, was not affected by binding of TCR-derived tyrosine phosphorylated immunoreceptor tyrosine-based activation motif peptides. Several proteins were tested as potential in vitro substrates of ZAP-70. Only alpha-tubulin and the cytoplasmic fragment of human erythrocyte band 3 (cfb3), which have a region of sequence identity at the phosphorylation site, proved to be good substrates, exhibiting K-m values of similar to 3.3 and similar to 2.5 mu M respectively ([ATP] = 50 mu M). alpha- and beta-Casein were poor substrates for ZAP-70, and no activity toward enolase, myelin basic protein, calmodulin, histone proteins, or angiotensin could be detected. In contrast to the T cell protein tyrosine kinase, Lck, ZAP-70 did not phosphorylate the cytoplasmic portion of the TCR zeta chain or short peptides corresponding to the CD3 epsilon or the TCR zeta immunoreceptor tyrosine-based activation motifs. Our studies suggest that ZAP-70 exhibits a high degree of substrate specificity.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; BEN GURION UNIV NEGEV, DEPT MICROBIOL & IMMUNOL, IL-84105 BEER SHEVA, ISRAEL; BEN GURION UNIV NEGEV, CANC RES CTR, IL-84105 BEER SHEVA, ISRAEL; UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA 98195 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Ben Gurion University; Ben Gurion University; University of Washington; University of Washington Seattle			ISAKOV, NOAH/F-1659-2012	Isakov, Noah/0000-0002-1412-0957; Wange, Ronald/0000-0001-9593-3572				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COLE PA, 1994, J BIOL CHEM, V269, P30880; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEDER D, 1990, J BIOL CHEM, V265, P8205; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Huby RDJ, 1995, J BIOL CHEM, V270, P30241, DOI 10.1074/jbc.270.51.30241; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAUL RK, 1983, J BIOL CHEM, V258, P7891; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEY SC, 1994, EUR J IMMUNOL, V24, P99, DOI 10.1002/eji.1830240116; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; OFFRINGA R, 1993, J BIOL CHEM, V268, P4979; OKADA M, 1989, J BIOL CHEM, V264, P20886; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; REUTER C, 1990, EUR J BIOCHEM, V190, P343, DOI 10.1111/j.1432-1033.1990.tb15581.x; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; ROZDZIAL MM, 1995, IMMUNITY, V3, P623, DOI 10.1016/1074-7613(95)90133-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WATTS JD, 1992, J BIOL CHEM, V267, P901; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YANG C, 1994, EUR J BIOCHEM, V221, P973, DOI 10.1111/j.1432-1033.1994.tb18813.x; YANNOUKAKOS D, 1989, BIOCHIM BIOPHYS ACTA, V998, P43, DOI 10.1016/0167-4838(89)90116-7; YU G, 1987, J BIOL CHEM, V262, P17543; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	66	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15753	15761		10.1074/jbc.271.26.15753	http://dx.doi.org/10.1074/jbc.271.26.15753			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663155	hybrid			2022-12-25	WOS:A1996UV29900068
J	Jan, CR; Ribar, TJ; Means, AR; Augustine, GJ				Jan, CR; Ribar, TJ; Means, AR; Augustine, GJ			Alterations in calcium channel currents underlie defective insulin secretion in a transgenic mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PROTEIN KINASE-II; CA2+ CHANNELS; K+-CHANNELS; B-CELLS; CALMODULIN; GLUCOSE; ISLETS; ATP; MICE	A transgenic mouse overexpressing a mutant form of calmodulin (CaM-8) that is selectively targeted to pancreatic beta-cells has an impaired ability to secrete insulin in response to elevated blood glucose, Fluorescence measurements of cytosolic Ca2+ concentration ([Ca2+](i)) showed that intracellular Ca2+ rises produced by glucose were smaller than normal in beta-cells of CaM-8 mice, Glucose utilization rates were not different between the CaM-8 and control beta-cells, suggesting that glucose metabolism was unperturbed by CaM-8, Ion channel defects were implicated in the phenotype of CaM-8 beta-cells because treatment of these cells with tolbutamide, a blocker of ATP-sensitive K+ channels, produced smaller than normal amounts of insulin secretion and Ca2+ rises, Depolarization with elevated extracellular K+ also produced smaller Ca2+ rises in beta-cells from CaM-8 mice, Whole-cell patch-clamp recordings revealed that Ca2+ channel currents of beta-cells from CaM-8 mice were half as large as Ca2+ currents in control cells, while the currents carried by delayed rectifier and ATP-sensitive K+ channels were similar in magnitude in both cell types, We conclude that expression of the CaM-8 form of calmodulin causes a down-regulation of Ca2+ channel currents, which reduces Ca2+ entry and accumulation when glucose stimulates closure of the ATP-sensitive K+ channels, The reduction in intracellular Ca2+ accumulation then prevents an adequate amount of insulin from being secreted from beta-cells of CaM-8 mice.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA	Duke University; Duke University			Augustine, George James/J-9228-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021624] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43017] Funding Source: Medline; NINDS NIH HHS [NS-21624] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; BOLAFFI JL, 1991, ENDOCRINOLOGY, V129, P2131, DOI 10.1210/endo-129-4-2131; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; EPSTEIN PN, 1992, ENDOCRINOLOGY, V130, P1387, DOI 10.1210/en.130.3.1387; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; GRODSKY GM, 1966, DIABETES, V15, P910, DOI 10.2337/diab.15.12.910; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEDESKOV CJ, 1991, MOL CELL ENDOCRINOL, V78, P187, DOI 10.1016/0303-7207(91)90122-9; HENQUIN JC, 1981, BIOCHEM J, V196, P771, DOI 10.1042/bj1960771; HERCHUELZ A, 1991, CELL CALCIUM, V12, P577, DOI 10.1016/0143-4160(91)90076-Q; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; KUNG C, 1992, CELL CALCIUM, V13, P413, DOI 10.1016/0143-4160(92)90054-V; LEECH CA, 1994, ENDOCRINOLOGY, V135, P365, DOI 10.1210/en.135.1.365; LI GD, 1992, MOL PHARMACOL, V42, P489; LLEDO PM, 1992, NEURON, V9, P943, DOI 10.1016/0896-6273(92)90246-A; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PENNER R, 1988, J EXP BIOL, V139, P329; POLLO A, 1993, PFLUG ARCH EUR J PHY, V423, P462, DOI 10.1007/BF00374942; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RIBAR TJ, 1995, J BIOL CHEM, V270, P28688, DOI 10.1074/jbc.270.48.28688; RIBAR TJ, 1995, ENDOCRINOLOGY, V136, P106, DOI 10.1210/en.136.1.106; RORSMAN P, 1985, PFLUG ARCH EUR J PHY, V405, P305, DOI 10.1007/BF00595682; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; SMITH PA, 1993, J GEN PHYSIOL, V101, P767, DOI 10.1085/jgp.101.5.767; SMOLEN P, 1993, BIOPHYS J, V64, P1668, DOI 10.1016/S0006-3495(93)81539-X; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUGDEN MC, 1979, FEBS LETT, V105, P95, DOI 10.1016/0014-5793(79)80894-7; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VALVERDE I, 1984, EXPERIENTIA, V40, P1061, DOI 10.1007/BF01971452; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WANG J, 1992, ENDOCRINOLOGY, V131, P146, DOI 10.1210/en.131.1.146; WENHAM RM, 1992, BIOCHEM BIOPH RES CO, V189, P128, DOI 10.1016/0006-291X(92)91534-W; YAN HM, 1994, ENDOCRINOLOGY, V134, P42	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15478	15485		10.1074/jbc.271.26.15478	http://dx.doi.org/10.1074/jbc.271.26.15478			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663103	hybrid			2022-12-25	WOS:A1996UV29900028
J	Liu, J; Nurse, P; Marians, KJ				Liu, J; Nurse, P; Marians, KJ			The ordered assembly of the phi X174-type primosome .3. PriB facilitates complex formation between PriA and DnaT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-Y; DEPENDENT ATPASE ACTIVITY; ESCHERICHIA-COLI PRIA; GENE PRODUCT; PROTEIN PRIA; HELICASE; SEQUENCE; MUTANTS	The properties of two mutant PriA proteins, PriA C439Y and PriA. C445Y have been used to reveal the role of PriB during assembly of the phi X174-type primosome, The replication defects of both mutant PriA proteins could be rescued by high concentrations of DnaT. Analysis of the formation of intermediate complexes in primosome assembly and the effect of PriB on PriA binding to DNA demonstrated that the mutant PriA proteins could not form a PriA-PriB complex on DNA carrying a primosome assembly site, Consequently, the mutant proteins also could not form PriA-PriB-DnaT complexes at concentrations of DnaT sufficient to form such a complex with wild-type PriA. In addition, PriB was found to stabilize wild-type but not mutant PriA proteins on DNA. At high concentrations of DnaT, both mutant and wild-type PriA proteins could form a PricA-DnaT complex and support PriB-independent phi X174 complementary strand DNA replication, Thus, during primosome assembly, PriB facilitates complex formation between PriA and DnaT.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Liu, J (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE MS, 1990, J BIOL CHEM, V265, P17078; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MOK M, 1987, J BIOL CHEM, V262, P2304; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SANDLER SJ, 1996, GENETICS, V143, P5313; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WRIGHT M, 1973, P NATL ACAD SCI USA, V70, P3120, DOI 10.1073/pnas.70.11.3120; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	22	71	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15656	15661		10.1074/jbc.271.26.15656	http://dx.doi.org/10.1074/jbc.271.26.15656			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663106	hybrid			2022-12-25	WOS:A1996UV29900054
J	Stephen, AG; TrauschAzar, JS; Ciechanover, A; Schwartz, AL				Stephen, AG; TrauschAzar, JS; Ciechanover, A; Schwartz, AL			The ubiquitin-activating enzyme E1 is phosphorylated and localized to the nucleus in a cell cycle-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PURIFICATION; PROTEOLYSIS; SEQUENCE; EXTRACTS; SYSTEM; KINASE	The ubiquitin-activating enzyme E1 exists as two isoforms, E1a (117 kDa) and E1b (110 kDa). E1a is phosphorylated, whereas E1b is not. In the present study we have demonstrated the cell cycle dependence of Ela phosphorylation: a 2-fold increase in the specific phosphorylation of E1a in G(2) compared with the basal level of phosphorylation in the other stages of the cell cycle, Two-dimensional gel electrophoresis resolved E1 into the two isoforms E1a and E1b; E1a resolved further as three phosphorylated forms and one nonphosphorylated form, while E1b resolved as one nonphosphorylated form, E1a is found predominantly in the phosphorylated forms. However, the distribution of E1a among these different phosphorylated forms was not cell cycle-dependent. We next evaluated the enzymatic activity of E1 as well as its subcellular localization throughout the cell cycle, P-32-Pyrophosphate exchange activity of E1 did not vary along the cell cycle; however, the amount of ubiquitin-protein conjugates decreased by 50% in G(2), Nuclear and cytosolic fractionation of cells revealed the nuclear to cytosolic ratio of phosphorylated Ela was 3-fold greater in G(2) compared with the other stages of the cell cycle. Finally, purified nuclear extracts supported E1-dependent ubiquitin conjugation of exogenous substrates as did purified cytosol, However, in nuclear extracts but not in cytosol the amount of E1 activity was rate-limiting. Thus we establish nuclear E1-dependent protein ubiquitination and propose that an increase in phosphorylation of E1a in G(2) functions to increase the import and/or retention of E1a in the nucleus and may modulate nuclear protein ubiquitination.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; CHILDRENS HOSP, DIV PEDIAT HEMATOL ONCOL, ST LOUIS, MO 63110 USA; TECHNION ISRAEL INST TECHNOL, FAC MED, BIOCHEM UNIT, IL-31096 HAIFA, ISRAEL; TECHNION ISRAEL INST TECHNOL, FAC MED, RAPPAPORT FAMILY INST RES MED SCI, IL-31096 HAIFA, ISRAEL	Washington University (WUSTL); St. Louis Children's Hospital; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Stephen, AG (corresponding author), WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA.		Ciechanover, Aaron J/C-9166-2017; Stephen, Andrew/W-2636-2019	Stephen, Andrew/0000-0002-8259-621X				CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK JC, 1995, P NATL ACAD SCI USA, V92, P3454, DOI 10.1073/pnas.92.8.3454; COOK JC, 1992, J BIOL CHEM, V267, P24315; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HANDLEYGEARHART PM, 1994, BIOCHEM J, V304, P1015, DOI 10.1042/bj3041015; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1994, ONCOGENE, V9, P2961; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KONG SK, 1992, J BIOL CHEM, V267, P14189; KULKA RG, 1988, J BIOL CHEM, V263, P15726; MAHAFFEY D, 1993, J BIOL CHEM, V268, P21205; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NAGAI Y, 1995, J CELL SCI, V108, P2145; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TRAUSCH JS, 1993, AM J PHYSIOL, V264, pC93, DOI 10.1152/ajpcell.1993.264.1.C93; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	41	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15608	15614		10.1074/jbc.271.26.15608	http://dx.doi.org/10.1074/jbc.271.26.15608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663123	hybrid			2022-12-25	WOS:A1996UV29900047
J	Tang, Y; Jiang, N; Parakh, C; Hilvert, D				Tang, Y; Jiang, N; Parakh, C; Hilvert, D			Selection of linkers for a catalytic single-chain antibody using phage display technology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; BINDING; EXPRESSION; LIBRARIES; AFFINITY	Phage display has been evaluated as a means of rapidly selecting tailored linkers for single chain antibodies (scFvs) from protein linker libraries. Preliminary experiments with a conventional linker failed to yield a functional single-chain version of a catalytic antibody with chorismate mutase activity. A random linker library was therefore constructed in which the genes for the heavy and light chain variable domains were linked by a segment encoding an 18-amino acid polypeptide of variable composition, The scFv repertoire (approximate to 5 x 10(6) different members) was displayed on filamentous phage and subjected to affinity selection with hapten. The population of selected variants exhibited significant increases in binding activity but retained considerable sequence diversity, Screening 1054 individual variants subsequently yielded a catalytically active scFv that was produced efficiently in soluble form, Sequence analysis revealed a conserved proline in the linker two residues after the V-H C terminus and an abundance of arginines and prolines at other positions as the only common features of the selected tethers, There are apparently many viable solutions to the problem of linking individual V-H and V-L domains, but subtle differences in sequence dramatically influence the production, stability, and recognition properties of the scFv. The success of these experiments suggests that phage display will be generally useful for identifying peptide sequences for covalently linking any two protein domains.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOWDISH K, 1991, J BIOL CHEM, V266, P11901; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CAMPBELL AP, 1993, P NATL ACAD SCI USA, V90, P8663, DOI 10.1073/pnas.90.18.8663; COLCHER D, 1990, JNCI-J NATL CANCER I, V82, P1191, DOI 10.1093/jnci/82.14.1191; DOPHEIDE TA, 1972, J BIOL CHEM, V247, P4447; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; KORTT AA, 1994, EUR J BIOCHEM, V221, P151, DOI 10.1111/j.1432-1033.1994.tb18724.x; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; ONEIL KT, 1995, CURR OPIN STRUC BIOL, V5, P443, DOI 10.1016/0959-440X(95)80027-1; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; RATH S, 1988, J IMMUNOL METHODS, V106, P245, DOI 10.1016/0022-1759(88)90204-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STEMMER WPC, 1993, BIOTECHNIQUES, V14, P256; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURNBULL J, 1990, BIOCHEMISTRY-US, V29, P10245, DOI 10.1021/bi00496a014; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; ZDANOV A, 1994, P NATL ACAD SCI USA, V91, P6423, DOI 10.1073/pnas.91.14.6423	24	52	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15682	15686		10.1074/jbc.271.26.15682	http://dx.doi.org/10.1074/jbc.271.26.15682			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663068	hybrid			2022-12-25	WOS:A1996UV29900058
J	Wymore, RS; Negulescu, D; Kinoshita, K; Kalman, K; Aiyar, J; Gutman, GA; Chandy, KG				Wymore, RS; Negulescu, D; Kinoshita, K; Kalman, K; Aiyar, J; Gutman, GA; Chandy, KG			Characterization of the transcription unit of mouse Kv1.4, a voltage-gated potassium channel gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; BETA MESSENGER-RNA; UA-RICH SEQUENCES; MOLECULAR-BASIS; TATA-LESS; EXPRESSION; PROMOTER; TRANSLATION; METHYLATION; PROTEIN	The mouse voltage-gated K+ channel gene, Kv1.4, is expressed in brain and heart as similar to 4.5- and similar to 3.5-kilobase kb) transcripts. Both mRNAs begin at a common site 1338 bp upstream of the initiation codon, contain 3477 and 4411 nucleotides, respectively, and are encoded by two exons; exon 1 contains 0.5 kb of the 5'-noncoding region (NCR), while exon 2 encodes the remaining 0.8 kb of the 5'-NCR, the entire coding region (2 kb), and all of the 3'-NCR. The 3.5-kb transcript terminates at a polyadenylation signal 177 bp 3' of the stop codon, while the 4.5-kb mRNA utilizes a signal 94 bp farther downstream. Although the proteins generated hom either transcript are identical, the two mRNAs are functionally different, the 3.5-kb transcript producing similar to 4-5-fold larger currents when expressed in Xenopus oocytes compared to the 4.5-kb mRNA. The decreased expression of the longer transcript is due to the presence of five ATTTA repeats in the 3'-NCR which inhibit translation; such motifs have also been reported to destabilize the messages of many other genes and might therefore shorten the life of the 4,5-kb transcript during its natural expression. The Kv1.4 basal promoter is GC-rich, contains three SP1 repeats (CCGCCC, -65 to -35), lacks canonical TATAAA and GGCAATCT motifs, and has no apparent tissue specificity. One region enhances activity of this promoter. Thus, transcriptional and post-transcriptional regulation of mKv1.4, coupled with selective usage of the two alternate Kv1.4 mRNAs, may modulate the levels of functional Kv1.4 channels.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	University of California System; University of California Irvine; University of California System; University of California Irvine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024783] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24783] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKASHI M, 1994, BLOOD, V83, P3182; ALBINI A, 1990, NUCLEIC ACIDS RES, V18, P5181, DOI 10.1093/nar/18.17.5181; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; AYTE J, 1993, BIOCHEM J, V295, P807, DOI 10.1042/bj2950807; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHANDY KG, 1995, HDB RECEPTORS CHANNE; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS V, 1990, ENZYME, V44, P193, DOI 10.1159/000468757; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MARINX O, 1994, FEBS LETT, V345, P107, DOI 10.1016/0014-5793(94)00413-7; MATSUBARA H, 1993, J CLIN INVEST, V92, P1659, DOI 10.1172/JCI116751; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MURRAY KT, 1994, CIRC RES, V75, P999, DOI 10.1161/01.RES.75.6.999; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENG ZH, 1994, DNA CELL BIOL, V13, P9, DOI 10.1089/dna.1994.13.9; SINGER J, 1979, SCIENCE, V203, P1019, DOI 10.1126/science.424726; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153; YATANI A, 1993, CIRC RES, V73, P351, DOI 10.1161/01.RES.73.2.351	36	32	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15629	15634		10.1074/jbc.271.26.15629	http://dx.doi.org/10.1074/jbc.271.26.15629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663090	hybrid			2022-12-25	WOS:A1996UV29900050
J	Song, KS; Scherer, PE; Tang, ZL; Okamoto, T; Li, SW; Chafel, M; Chu, C; Kohtz, DS; Lisanti, MP				Song, KS; Scherer, PE; Tang, ZL; Okamoto, T; Li, SW; Chafel, M; Chu, C; Kohtz, DS; Lisanti, MP			Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells - Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; MUSCULAR-DYSTROPHY; PROTEIN-COMPONENT; COMPLEX; PHOSPHORYLATION; DIFFERENTIATION; VESICLES; TYROSINE; SEQUENCE	Caveolae are microdomains of the plasma membrane that have been implicated in signal transduction, Caveolin, a 21-24-kDa integral membrane protein, is a principal component of the caveolae membrane, Recently, we and others have identified a family of caveolin-related proteins; caveolin has been retermed caveolin-1. Caveolin-3 is most closely related to caveolin-1, but caveolin-3 mRNA is expressed only in muscle tissue types, Here, we examine (i) the expression of caveolin-3 protein in muscle tissue types and (ii) its localization within skeletal muscle fibers by immunofluorescence microscopy and subcellular fractionation, For this purpose, we generated a novel monoclonal antibody (mAb) probe that recognizes the unique N-terminal region of caveolin-3, but not other members of the caveolin gene family, A survey of tissues and muscle cell types by Western blot analysis reveals that the caveolin 3 protein is selectively expressed only in heart and skeletal muscle tissues, cardiac myocytes, and smooth muscle cells, Immunolocalization of caveolin-3 in skeletal muscle fibers demonstrates that caveolin-3 is localized to the sarcolemma (muscle cell plasma membrane) and coincides with the distribution of another muscle-specific plasma membrane marker protein, dystrophin, In addition, caveolin-3 protein expression is dramatically induced during the differentiation of C2C12 skeletal myoblasts in culture, Using differentiated C2C12 skeletal myoblasts as a model system, we observe that caveolin-3 co-fractionates with cytoplasmic signaling molecules (G-proteins and Src-like kinases) and members of the dystrophin complex (dystrophin, alpha-sarcoglycan, and beta-dystroglycan), but is clearly separated from the bulk of cellular proteins. Caveolin-3 co-immunoprecipitates with antibodies directed against dystrophin, suggesting that they are physically associated as a discrete complex. These results are consistent with previous immunoelectron microscopic studies demonstrating that dystrophin is localized to plasma membrane caveolae in smooth muscle cells.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SHRINERS HOSP CRIPPLED CHILDREN,SCH MED, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MT SINAI SCH MED, DEPT PATHOL, NEW YORK, NY 10029 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Icahn School of Medicine at Mount Sinai			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012; Li, Shengwen Calvin/H-1725-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Li, Shengwen Calvin/0000-0002-9699-9204	NCI NIH HHS [CA071326, F32 CA071326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BONILLA E, 1981, AM J PATHOL, V104, P167; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COLE F, 1993, J BIOL CHEM, V268, P1580; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HARLOW E, 1988, ANTIBIOTICS LAB MANU; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755	45	585	594	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15160	15165		10.1074/jbc.271.25.15160	http://dx.doi.org/10.1074/jbc.271.25.15160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663016	hybrid			2022-12-25	WOS:A1996UT10600076
J	Fukuda, R; Umebayashi, K; Horiuchi, H; Ohta, A; Takagi, M				Fukuda, R; Umebayashi, K; Horiuchi, H; Ohta, A; Takagi, M			Degradation of Rhizopus niveus aspartic proteinase-I with mutated prosequences occurs in the endoplasmic reticulum of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PATHWAY; LOCALIZATION; TRANSPORT; MEMBRANE	Rhizopus niveus aspartic proteinase-I (RNAP-I) is secreted by Saccharomyces cerevisiae extracellularly (Horiuchi, H., Ashikari, T., Amachi, T., Yoshizumi, H., Takagi, M., and Yano, K. (1990) Agric. Biol. Chem. 54, 1771-1779). The prosequence of RNAP-I has the function to promote correct folding of its mature part. Deletion (Delta pro) and amino acid substitutions (M1) in the prosequence block secretion of RNAP-I (Fukuda, R., Horiuchi, H., Ohta, A., and Takagi, M. (1994) J. Biol. Chem. 269, 9556-9561). In this study, little accumulation of Delta pro was observed in Western blot analysis of the cell extracts of the transformants producing Delta pro using anti-RNAP-I antisera. In contrast, M1 was accumulated in the yeast cells. Pulse-chase analysis revealed that they were synthesized at almost the same rates and that Delta pro was degraded in the cells more rapidly than M1. In subcellular fractionation analysis, Delta pro was found in the fraction that contained most of the activity of an endoplasmic reticulum (ER) marker enzyme, NADPH-cytochrome c reductase. In indirect immunofluorescence microscopy, Delta pro was observed in the ER. Similar result was also observed in a mutant which is deficient of the two vacuolar proteases, proteinase A and proteinase B. So, the vacuolar proteases are not involved in degradation of Delta pro. From these results, we concluded that RNAP-Is with the mutated prosequences, which probably could not be folded correctly, were retained and degraded in the ER.	UNIV TOKYO, DEPT BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BORDALLO C, 1984, FEBS LETT, V173, P199, DOI 10.1016/0014-5793(84)81046-7; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Halvorson H., 1966, METHODS ENZYMOL, V8, P559, DOI [10.1016/0076-6879(66)08101-1, DOI 10.1016/0076-6879(66)08101-1]; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HORIUCHI H, 1988, J BACTERIOL, V170, P272, DOI 10.1128/jb.170.1.272-278.1988; HORIUCHI H, 1990, AGR BIOL CHEM TOKYO, V54, P1771, DOI 10.1080/00021369.1990.10870223; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, J BIOL CHEM, V266, P7963; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCRACKEN AA, 1993, MOL BIOL CELL, V4, P729, DOI 10.1091/mbc.4.7.729; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Sakaguchi K, 1992, APPL MOL GENETICS FI, P54; Sambrook J., 1989, MOL CLONING LAB MANU, V2; WADA Y, 1992, J BIOL CHEM, V267, P18665; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	26	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14252	14255		10.1074/jbc.271.24.14252	http://dx.doi.org/10.1074/jbc.271.24.14252			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662920	hybrid			2022-12-25	WOS:A1996UQ66000049
J	Zhuang, P; Blackburn, MN; Peterson, CB				Zhuang, P; Blackburn, MN; Peterson, CB			Characterization of the denaturation and renaturation of human plasma vitronectin .1. Biophysical characterization of protein unfolding and multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; RECEPTOR-MEDIATED ENDOCYTOSIS; S-PROTEIN; ANTITHROMBIN-III; ALPHA-THROMBIN; HEPARIN; COMPLEMENT; BINDING; CLEAVAGE; UREA	Upon treatment with denaturing agents, vitronectin has been observed to exhibit conformational alterations which are similar to the structural changes detected when vitronectin binds the thrombin-antithrombin complex or associates with the terminal attack complex of complement. Denaturation and renaturation of vitronectin isolated from human plasma were characterized by changes in intrinsic fluorescence. Unfolding by chemical denaturants was irreversible and accompanied by self-association of the protein to form vitronectin multimers. Self-association was evaluated by equilibrium analytical ultracentrifugation which demonstrated that multimers form only during the refolding process after removal of denaturant, that multimeric vitronectin dissociates to constituent subunits readily upon treatment with chemical denaturant, and that intermolecular disulfide crosslinking occurs primarily at the dimer level among a subset of constituent vitronectin subunits within the multimer. The monomeric form of vitronectin isolated from human plasma partially unfolds at intermediate concentrations of denaturant to an altered conformation with a high propensity to associate into multimers. Folding of vitronectin in vivo appears to be regulated by partitioning of folding intermediates toward either of two conformations, one that exists as a stable monomer and another that associates into a multimeric form.	UNIV TENNESSEE, DEPT BIOCHEM & CELLULAR & MOLEC BIOL, KNOXVILLE, TN 37996 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	University of Tennessee System; University of Tennessee Knoxville; GlaxoSmithKline					NHLBI NIH HHS [HL50676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050676, R29HL050676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BROOKS I, 1994, METHOD ENZYMOL, V240, P459; BROOKS I, 1994, MODERN ANAL ULTRACEN, P15; CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; GEBB C, 1986, J BIOL CHEM, V261, P6698; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; KOLB WP, 1975, J EXP MED, V141, P724; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MUNSON M, 1994, PROTEIN SCI, V3, P2015, DOI 10.1002/pro.5560031114; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NEET KE, 1994, J PROETIN SCI, V3, P2167; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PETERSON CB, 1993, INT CONGR SER, V1042, P67; PITT WG, 1989, J COLLOID INTERF SCI, V129, P231, DOI 10.1016/0021-9797(89)90435-9; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1986, EUR J BIOCHEM, V156, P645, DOI 10.1111/j.1432-1033.1986.tb09626.x; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P189; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1994, J BIOL CHEM, V269, P19836; STEIF C, 1993, BIOCHEMISTRY-US, V32, P3867, DOI 10.1021/bi00066a005; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; WEI Y, 1994, J BIOL CHEM, V269, P32380; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZANETTI A, 1994, BLOOD, V84, P1116, DOI 10.1182/blood.V84.4.1116.bloodjournal8441116; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333	40	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14323	14332		10.1074/jbc.271.24.14323	http://dx.doi.org/10.1074/jbc.271.24.14323			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663084	hybrid			2022-12-25	WOS:A1996UQ66000060
J	Chen, QM; Lin, TH; Der, CJ; Juliano, RL				Chen, QM; Lin, TH; Der, CJ; Juliano, RL			Integrin-mediated activation of mitogen activated protein (MAP) or extracellular signal-related kinase kinase (MEK) and kinase is independent of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE KINASE; CELL-ADHESION; CYTOPLASMIC DOMAIN; RAF-1 KINASE; PHOSPHORYLATION; TRANSDUCTION; PATHWAY; BINDING; MATRIX	The integrins are a family of cell surface receptors that mediate adhesive interactions with the extracellular matrix and also generate signals that influence cell growth and differentiation. Ligation and clustering of integrins causes activation and autophosphorylation of focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase, and results in the transient activation of p42 and p44 mitogen-activated protein (MAP) kinases, Initial evidence has suggested that the integrin signaling pathway may share common elements with the canonical Pas signal transduction cascade activated by peptide mitogens such as epidermal growth factor (EGF), In this report we demonstrate that Raf-1 and MAP or extracellular signal-related kinase kinase (MEK), key cytoplasmic kinases of the Pas cascade, are activated subsequent to integrin-mediated adhesion of mouse NIH 3T3 fibroblasts, We also show that MAP kinase is downstream of MEK in the integrin signaling pathway, However, in contrast to the receptor tyrosine kinase signaling cascade, integrin-mediated signal transduction seems to be largely independent of Ras, Dominant negative inhibitors of Ras-dependent signaling failed to block integrin-mediated activation of MEK, In addition, while treatment with the peptide mitogen EGF clearly increased GTP-loading of Ras, little effect was observed in response to integrin dependent cell adhesion, Thus, integrin-mediated activation of MEK and MAP kinase in 3T3 cells occurs primarily by a mechanism that is distinct from the Ras signal transduction cascade.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Der, Channing/0000-0002-7751-2747	NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM26065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GARDNER AM, 1994, METHOD ENZYMOL, V238, P259; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	56	168	170	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18122	18127		10.1074/jbc.271.30.18122	http://dx.doi.org/10.1074/jbc.271.30.18122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663436	hybrid			2022-12-25	WOS:A1996UY93500080
J	Hermoso, J; Pignol, D; Kerfelec, B; Crenon, I; Chapus, C; FontecillaCamps, JC				Hermoso, J; Pignol, D; Kerfelec, B; Crenon, I; Chapus, C; FontecillaCamps, JC			Lipase activation by nonionic detergents - The crystal structure of the porcine lipase-colipase-tetraethylene glycol monooctyl ether complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE PANCREATIC LIPASE; MOLECULAR-REPLACEMENT; PROCOLIPASE COMPLEX; SULFHYDRYL-GROUPS; MESSENGER-RNA; BILE-SALTS; X-RAY; CLONING; CDNA; SEQUENCE	The crystal structure of the ternary porcine lipase-colipase-tetra ethylene glycol monooctyl ether (TGME) complex has been determined at 2.8 Angstrom resolution, The crystals belong to the cubic space group F23 with a = 289.1 Angstrom and display a strong pseudo-symmetry corresponding to a P23 lattice, Unexpectedly, the crystalline two-domain lipase is found in its open configuration, This indicates that in the presence of colipase, pure micelles of the nonionic detergent TGME are able to activate the enzyme; a process that includes the movement of an N-terminal domain loop (the flap), The effects of TGME and colipase have been confirmed by chemical modification of the active site serine residue using diisopropyl p-nitrophenylphosphate (E600), In addition, the presence of a TGME molecule tightly bound to the active site pocket shows that TGME acts as a substrate analog, thus possibly explaining the inhibitory effect of this nonionic detergent on emulsified substrate hydrolysis at submicellar concentrations, A comparison of the lipase-colipase interactions between our porcine complex and the human-porcine complex (van Tilbeurgh, H., Egloff, M.-P., Martinez, C., Rugani, N., Verger, R., and Cambillau, C. (1993) Nature 362, 814-820) indicates that except for one salt bridge interaction, they are conserved, Analysis of the superimposed complexes shows a 5.4 degrees rotation on the relative position of the N-terminal domains excepting the flap that moves in a concerted fashion with the C-terminal domain, This flexibility may be important for the binding of the complex to the water-lipid interface.	INST BIOL STRUCT JEAN PIERRE EBEL,CEA,CNRS,LAB CRISTALLOG & CRISTALLOGENESE PROT,F-38027 GRENOBLE 1,FRANCE; LAB BIOENERGET & INGN PROT,UPR 9036 CNRS,F-13002 MARSEILLE 9,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite			Hermoso, Juan/J-3433-2012	Hermoso, Juan/0000-0002-1862-8950; PIGNOL, David/0000-0002-8070-0319				ABOUSALHAM A, 1992, PROTEIN ENG, V5, P105, DOI 10.1093/protein/5.1.105; ALEMANGOMEZ JA, 1992, BIOCHEM BIOPH RES CO, V188, P964, DOI 10.1016/0006-291X(92)91326-L; BENKOUKA F, 1982, EUR J BIOCHEM, V128, P331; BORGSTRO.B, 1973, EUR J BIOCHEM, V37, P60, DOI 10.1111/j.1432-1033.1973.tb02957.x; BORGSTROM B, 1977, BIOCHIM BIOPHYS ACTA, V488, P381, DOI 10.1016/0005-2760(77)90197-7; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; CARRIERE F, 1994, FEBS LETT, V338, P63, DOI 10.1016/0014-5793(94)80117-7; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; CHAILLAN C, 1989, FEBS LETT, V257, P443, DOI 10.1016/0014-5793(89)81592-3; CHAPUS C, 1975, FEBS LETT, V58, P155, DOI 10.1016/0014-5793(75)80247-X; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; CHARLES M, 1974, BIOCHIM BIOPHYS ACTA, V359, P186, DOI 10.1016/0005-2795(74)90142-1; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COLWELL NC, 1992, GENBANK L 06329; CRENON I, 1994, BBA-LIPID LIPID MET, V1213, P357, DOI 10.1016/0005-2760(94)00096-4; DECARO A, 1977, BIOCHIM BIOPHYS ACTA, V490, P411, DOI 10.1016/0005-2795(77)90016-2; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2751, DOI 10.1021/bi00009a003; EGLOFF MP, 1995, PROTEIN SCI, V4, P44; ERLANSON C, 1977, BIOCHIM BIOPHYS ACTA, V489, P150, DOI 10.1016/0005-2760(77)90241-7; FOURNET B, 1987, EUR J BIOCHEM, V170, P369, DOI 10.1111/j.1432-1033.1987.tb13709.x; FUKUOKA S, 1990, NUCLEIC ACIDS RES, V18, P5549, DOI 10.1093/nar/18.18.5549; GARNER CW, 1972, J BIOL CHEM, V247, P561; GILLER T, 1992, J BIOL CHEM, V267, P16509; GRANON S, 1986, BIOCHIM BIOPHYS ACTA, V874, P54, DOI 10.1016/0167-4838(86)90101-9; GUIDONI A, 1981, BIOCHIM BIOPHYS ACTA, V660, P148, DOI 10.1016/0005-2744(81)90120-0; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERFELEC B, 1992, EUR J BIOCHEM, V206, P279, DOI 10.1111/j.1432-1033.1992.tb16926.x; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1987, COMPUTATIONAL ASPECT, P39; LOMBARDO D, 1989, J MOL BIOL, V205, P259, DOI 10.1016/0022-2836(89)90380-X; LOWE ME, 1989, J BIOL CHEM, V264, P20042; MAHEGOUHIER N, 1988, BIOCHIM BIOPHYS ACTA, V962, P91, DOI 10.1016/0005-2760(88)90099-9; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAYLIE MF, 1972, BIOCHIM BIOPHYS ACTA, V276, P162, DOI 10.1016/0005-2744(72)90017-4; MCPHERSON A, 1985, METHOD ENZYMOL, V114, P112; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; PLUMMER TH, 1973, J BIOL CHEM, V248, P7865; SIMS HF, 1992, GENBANK M 58369; THIRSTRUP K, 1994, BIOCHEMISTRY-US, V33, P2748, DOI 10.1021/bi00176a002; THIRSTRUP K, 1995, EUR J BIOCHEM, V227, P186, DOI 10.1111/j.1432-1033.1995.tb20375.x; VANDERMEERS A, 1975, FEBS LETT, V49, P334, DOI 10.1016/0014-5793(75)80779-4; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; VANTILBEURGH H, 1993, J MOL BIOL, V229, P552, DOI 10.1006/jmbi.1993.1054; VERGER R, 1971, BIOCHIM BIOPHYS ACTA, V242, P580, DOI 10.1016/0005-2744(71)90151-3; WALLACE A, BIOMOLECULAR STRUCTU; WICKER C, 1990, BIOCHEM BIOPH RES CO, V167, P130, DOI 10.1016/0006-291X(90)91740-J; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WINKLER FK, 1994, LIPASES THEIR STRUCT, P139; WISHART MJ, 1993, J BIOL CHEM, V268, P10303; 1979, 4 DAR LAB	58	181	186	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18007	18016		10.1074/jbc.271.30.18007	http://dx.doi.org/10.1074/jbc.271.30.18007			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663362	Green Submitted, hybrid			2022-12-25	WOS:A1996UY93500065
J	Wu, CH; Lee, MF; Liao, SC; Luo, SF				Wu, CH; Lee, MF; Liao, SC; Luo, SF			Sequencing analysis of cDNA clones encoding the American cockroach Cr-PI allergens - Homology with insect hemolymph proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMAN BLATTELLA-GERMANICA; MONOCLONAL-ANTIBODIES; ARTHROPOD HEMOCYANINS; CALLIPHORA-VICINA; PERIPLANETA-AMERICANA; TARANTULA HEMOCYANIN; MOLECULAR-CLONING; BRONCHIAL-ASTHMA; MAJOR ALLERGENS; RNA-POLYMERASE	A previous article described the isolation of several lambda gt22A cDNA clones expressing the American cockroach (Periplaneta americana) Cr-PI allergens recognized by both human atopic IgE antibodies and anti Cr-PI monoclonal antibodies (Wu, C, H., Lee, M. F., and Liao, S. C. (1995) J. Allergy Clin, Immunol, 96, 352-359), This article presents the nucleotide and deduced amino acid sequences of two cDNA clones encoding major allergens of P. americana, Clones C12 and C20 encode proteins of 685 and 631 amino acids with two potential N-glycosylation sites each, The predicted molecular weights for C12 and C20 cloned proteins are 79,300 and 75,500 with isoelectric point values of 6.26 and 6.63, which are compatible with the determined sizes (M(r) 78,000 and 72,000) and isoelectric point value (6.2) of the Cr-PI allergens of P. americana, A high degree of identity (69.1%), including several overlapped predicted central antigenic determinant residues, was found between two allergens, The anti-fusion protein antibody-based enzyme-linked immunosorbent assay was able to detect crude American cockroach extract, Cr-PI, recombinant proteins, and commercial cockroach extracts, which provides further evidence that two allergens share common antigen de terminants. Recombinant allergens of clones C12 and C20 both showed 47.4% skin reactivities on 19 cockroach-sensitive asthmatic patients. Unexpectedly, although no sequence similarity was found to other known allergens, two aromatic amino acid-rich allergens were found to have a striking sequence identity to insect storage proteins (20.1-33.9%), insect juvenile hormone-suppressible proteins (30.9-36.4%), and arthropod hemocyanins (29.7-34.6%), Results suggested that two prominent allergens of P. americana are ancestrally related to these insect hemolymph proteins and represent a new group of proteins in the hemocyanin superfamily, These data will now facilitate epitope-mapping studies, and the recombinant allergens may be valuable for diagnostic and therapeutic purposes.	CHANG GUNG MEM HOSP, DEPT INTERNAL MED, SECT RHEUMATOL ALLERGY & IMMUNOL, TAIPEI 10590, TAIWAN	Chang Gung Memorial Hospital	Wu, CH (corresponding author), TAICHUNG VET GEN HOSP, DEPT MED RES, 160 CHUNG KANG RD, SECT 3, TAICHUNG 40705, TAIWAN.							Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1984, J ALLERGY, V35, P505; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FAHRENBACH WH, 1970, J CELL BIOL, V44, P445, DOI 10.1083/jcb.44.2.445; FUJII T, 1989, J BIOL CHEM, V264, P11020; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154, DOI 10.1159/000235207; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; Jeng KCG, 1996, CLIN EXP ALLERGY, V26, P349, DOI 10.1111/j.1365-2222.1996.tb00102.x; JONES G, 1988, J BIOL CHEM, V263, P1089; JONES G, 1993, J BIOL CHEM, V268, P1284; JONES G, 1990, J BIOL CHEM, V265, P8596; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; LEVENBOOK L, 1984, INSECT BIOCHEM, V14, P77, DOI 10.1016/0020-1790(84)90086-6; Levenbook L., 1985, P307; LOMBARDERO M, 1994, CLIN EXP ALLERGY, V24, P765, DOI 10.1111/j.1365-2222.1994.tb00988.x; MAHANA W, 1993, J IMMUNOL METHODS, V161, P187, DOI 10.1016/0022-1759(93)90294-H; Marchand A M, 1966, Bol Asoc Med P R, V58, P49; MARKL J, 1989, J COMP PHYSIOL B, V159, P139, DOI 10.1007/BF00691734; MARKL J, 1992, J COMP PHYSIOL B, V162, P665, DOI 10.1007/BF00301616; MARKL J, 1990, INVERTEBRATE DIOXYGEN CARRIERS, P497; Marx R., 1983, P50; MENDOZA J, 1970, ANN ALLERGY, V28, P159; NAUMANN U, 1991, BIOCHEM BIOPH RES CO, V177, P963, DOI 10.1016/0006-291X(91)90632-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBERTS DB, 1981, EXPERIENTIA, V37, P103, DOI 10.1007/BF01963174; RYAN RO, 1985, J BIOL CHEM, V260, P782; SAKURAI H, 1988, J BIOL CHEM, V263, P7876; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINER O, 1992, INT ARCH ALLERGY IMM, V98, P93, DOI 10.1159/000236170; SCHELLER K, 1980, Z NATURFORSCH C, V35, P387; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULANER FA, 1970, PEDIATRICS, V45, P465; STANKUS R P, 1988, Journal of Allergy and Clinical Immunology, V81, P563, DOI 10.1016/0091-6749(88)90195-9; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI M, 1995, ALLERGY, V50, P23, DOI 10.1111/j.1398-9995.1995.tb02479.x; Telfer W.H., 1987, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V49, P305; TELFER WH, 1983, INSECT BIOCHEM, V13, P601, DOI 10.1016/0020-1790(83)90034-3; THOMSON JA, 1975, ADV INSECT PHYSIOL, V11, P821; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VOIT R, 1990, J BIOL CHEM, V265, P19447; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WILLOTT E, 1989, J BIOL CHEM, V264, P19052; Wu CH, 1996, ANN ALLERG ASTHMA IM, V76, P195, DOI 10.1016/S1081-1206(10)63422-9; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; WU CH, 1995, J ALLERGY CLIN IMMUN, V96, P352, DOI 10.1016/S0091-6749(95)70054-4; WU CH, 1993, CLIN EXP ALLERGY, V23, P493, DOI 10.1111/j.1365-2222.1993.tb03236.x; WU CH, 1990, CLIN EXP ALLERGY, V20, P675, DOI 10.1111/j.1365-2222.1990.tb02707.x; WYATT GR, 1978, ANNU REV BIOCHEM, V47, P779, DOI 10.1146/annurev.bi.47.070178.004023	68	75	82	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17937	17943		10.1074/jbc.271.30.17937	http://dx.doi.org/10.1074/jbc.271.30.17937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663281	hybrid			2022-12-25	WOS:A1996UY93500054
J	Davis, GJ; Bosron, WF; Stone, CL; OwusuDekyi, K; Hurley, TD				Davis, GJ; Bosron, WF; Stone, CL; OwusuDekyi, K; Hurley, TD			X-ray structure of human beta(3)beta(3) alcohol dehydrogenase - The contribution of ionic interactions to coenzyme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER ALCOHOL; HUMAN BETA-1-BETA-1; KINETIC CHARACTERIZATION; SUBSTITUTIONS; METABOLISM; RESOLUTION; VARIANTS	The three-dimensional structure of the human beta(3) beta(3) dimeric alcohol dehydrogenase (beta(3)) was determined to 2.4-Angstrom resolution. beta(3) was crystallized as a ternary complex with the coenzyme NAD(+) and the competitive inhibitor 4-iodopyrazole. beta(3) is a polymorphic variant at ADH2 that differs from beta(1) by a single amino acid substitution of Arg-369 --> Cys. The available x-ray structures of mammalian alcohol dehydrogenases show that the side chain of Arg-369 forms an ion pair with the NAD(H) pyrophosphate to stabilize the E NAD(H) complex. The Cys-369 side chain of beta(3) cannot form this interaction. The three-dimensional structures of beta(3) and beta(1) are virtually identical, with the exception that Cys-369 and two water molecules in beta(3) occupy the position of Arg-369 in beta(1) The two waters occupy the same positions as two guanidino nitrogens of Arg-369. Hence, the number of hydrogen bonding interactions between the enzyme and NAD(H) are the same for both isoenzymes. However, beta(3) differs from beta(1) by the loss of the electrostatic interaction between the NAD(H) pyrophosphate and the Arg-369 side chain, The equilibrium dissociation constants of beta(3) for NAD(+) and NADH are 350-fold and 4000-fold higher, respectively, than those for beta(1). These changes correspond to binding free energy differences of 3.5 kcal/mol for NAD(+) and 4.9 kcal/mol for NADH. Thus, the Arg-369 --> Cys substitution of beta(3) isoenzyme destabilizes the interaction between coenzyme and beta(3) alcohol dehydrogenase.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				HURLEY, THOMAS/0000-0002-5942-1163	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K21AA000148, K21AA000150, R37AA007117] Funding Source: NIH RePORTER; NIAAA NIH HHS [R37-AA07117, K21-AA00150, K21-AA00148] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOSRON WF, 1988, INT CONGR SER, V805, P31; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BOSRON WF, 1983, BIOCHEM GENET, V21, P735, DOI 10.1007/BF00498920; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURNELL JC, 1987, BIOCHEM BIOPH RES CO, V146, P1227, DOI 10.1016/0006-291X(87)90779-0; BURNELL JC, 1989, BIOCHEMISTRY-US, V28, P6810, DOI 10.1021/bi00443a005; Burnell JC, 1989, HUMAN METABOLISM ALC, V2, P65; Cleland W W, 1979, Methods Enzymol, V63, P103; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CRABB DW, 1983, ARCH BIOCHEM BIOPHYS, V224, P299, DOI 10.1016/0003-9861(83)90213-8; DAVIS GJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P307, DOI 10.1006/abbi.1994.1242; EDENBERG HJ, 1989, ENZYMOLOGY MOL BIOL, V2, P181; EDENBERG HJ, 1996, IN PRESS COMPREHENSI, V3; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1982, BIOCHEMISTRY-US, V21, P4858, DOI 10.1021/bi00263a005; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1992, BIOCHEM BIOPH RES CO, V183, P93, DOI 10.1016/0006-291X(92)91613-U; HURLEY TD, 1994, J MOL BIOL, V239, P415, DOI 10.1006/jmbi.1994.1382; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JORNVALL H, 1994, EXS, V71, P221; JORNVALL H, 1984, P NATL ACAD SCI-BIOL, V81, P3024, DOI 10.1073/pnas.81.10.3024; KUSNADI AR, 1989, HUMAN LIVER ALCOHOL, P51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUMENG L, 1994, GASTROENTEROLOGY, V107, P572, DOI 10.1016/0016-5085(94)90185-6; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; PLAPP BV, 1984, ARCH BIOCHEM BIOPHYS, V230, P30, DOI 10.1016/0003-9861(84)90083-3; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; STONE CL, 1993, J BIOL CHEM, V268, P892; STONE CL, 1993, ENZYMOLOGY MOL BIOL, V4, P429; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; WRAY W, 1981, ANAL BIOCHEM, V11, P97	32	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17057	17061		10.1074/jbc.271.29.17057	http://dx.doi.org/10.1074/jbc.271.29.17057			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663387	hybrid			2022-12-25	WOS:A1996UX94300014
J	Farrow, KN; Manning, N; Schaufele, F; GutierrezHartmann, A				Farrow, KN; Manning, N; Schaufele, F; GutierrezHartmann, A			The c-Jun delta-domain inhibits neuroendocrine promoter activity in a DNA sequence- and pituitary-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PROLACTIN PROMOTER; TRANSCRIPTION FACTOR AP-1; CELL-SPECIFIC INHIBITOR; PROTEIN-KINASE; HA-RAS; SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; V-JUN; PHOSPHORYLATION; GENE	'The transcription and transformation activity of c-Jun is governed by a 27-amino acid regulatory motif, labeled the delta-domain, which is deleted in v-Jun. We have previously shown that c-jun is a potent inhibitor of the rat prolactin (rPRL) promoter activity induced by either oncogenic Has or phorbol esters. Here, we have characterized the structural and cell-specific requirements for this c-Jun inhibitory response, and we show that this c-Jun inhibitory response mapped to the rPRL footprint II repressor site, was pituitary-specific and required the c-Jun delta-domain. Moreover, alteration of any one of these features (e.g., cis-element, trans-factor, or cell-specific background) switched c-Jun to a transcriptional activator of the rPRL promoter. In HeLa nonpituitary cells, c-Jun alone activated the rPRL promoter via the most proximal GHF-1/Pit-1 binding site, footprint I, and synergized with GHF-1. Finally, recombinant GHF-1 interacted directly with c-jun but not c-Fos proteins. These data provide important fundamental insights into the molecular mechanisms by which the c-Jun delta-domain functions as a modulatory switch and further imply that the functional role of c-Jun is dictated by cell-specific influences and the delta-domain motif.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,PROGRAM MOLEC BIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,COLORADO CANC CTR,DENVER,CO 80262; UNIV CALIF SAN FRANCISCO,METAB RES UNIT HSW1143,SAN FRANCISCO,CA 94143	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Francisco			Gutierrez-Hartmann, Arthur/F-1295-2011	Farrow, Kathryn/0000-0002-8604-7023				ADLER V, 1992, J BIOL CHEM, V267, P17001; ALANI V, 1991, MOL CELL BIOL, V12, P6276; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DAI TN, 1995, ONCOGENE, V10, P849; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; RAJNARAYAN S, 1995, MOL ENDOCRINOL, V9, P502, DOI 10.1210/me.9.4.502; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	47	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17139	17146		10.1074/jbc.271.29.17139	http://dx.doi.org/10.1074/jbc.271.29.17139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663380	hybrid			2022-12-25	WOS:A1996UX94300026
J	Oancea, E; Meyer, T				Oancea, E; Meyer, T			Reversible desensitization of inositol trisphosphate-induced calcium release provides a mechanism for repetitive calcium spikes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; ACINAR-CELLS; 1,4,5-TRISPHOSPHATE; OSCILLATIONS; CALMODULIN; STORES; PHOTOLYSIS; FEEDBACK; CHANNELS; RECEPTOR	Repetitive transient increases in cytosolic calcium concentration (calcium spikes or calcium oscillations) are a common mode of signal transduction in receptor-mediated cell activation. Repetitive calcium spikes are initiated by phospholipase C-mediated production of inositol 1,4,5-trisphosphate (InsP(3)) and are thought to be generated by a positive feedback mechanism in which calcium potentiates its own release, a negative feedback mechanism by which calcium release is terminated, and a slow recovery process that defines the time interval between calcium spikes. The molecular mechanisms that terminate each calcium spike and define the spike frequency are not yet known. Here we show, in intact rat basophilic leukemia cells, that calcium responses induced by InsP(3) are diminished for a period of 30-60 s following an InsP(3)-induced calcium spike. The sensitivity of calcium release for InsP(3) was probed by UV laser-mediated photorelease of InsP(3), and calcium responses were monitored by fluorescence calcium imaging. A maximal loss in sensitivity (desensitization) was observed for InsP(3) increases that resulted in a near maximal calcium spike and was expressed as an 80-100% reduction in the calcium response to an equal amount of InsP(3), released 10 s after the first UV pulse. When the amount of released InsP(3) in the second pulse was increased 2-3-fold, desensitization was overcome and a second calcium response of equal amplitude to the first was produced. A power dependence of 3.2 was measured between the amount of released InsP(3) and the amplitude of the triggered calcium response, explaining how a small decrease in InsP(3) sensitivity can lead to a nearly complete reduction in the calcium response. Desensitization was abolished by the addition of the calcium buffers BAPTA and EGTA and could be induced by microinjection of calcium, suggesting that it is a calcium-dependent process, Half-maximal desensitization was observed at a free calcium concentration of 290 nM and increased with a power of 3.7 with peak calcium concentration. These studies suggest that reversible desensitization of InsP(3)-induced calcium release serves as a ''saw-tooth'' parameter that controls the termination of each spike and the frequency of calcium spikes.	DUMC, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University				Meyer, Tobias/0000-0003-4339-3804	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048113, R55GM048113] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48113] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUKAL AJ, 1988, J BIOL CHEM, V263, P6087; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KEIZER J, 1992, BIOPHYS J, V61, P649, DOI 10.1016/S0006-3495(92)81870-2; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MUALLEM S, 1989, J BIOL CHEM, V264, P205; ODGEN DC, 1990, J PHYSIOL-LONDON, V422, P585; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; Parker I, 1996, BIOPHYS J, V70, P222, DOI 10.1016/S0006-3495(96)79565-6; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0	32	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17253	17260		10.1074/jbc.271.29.17253	http://dx.doi.org/10.1074/jbc.271.29.17253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663416	hybrid			2022-12-25	WOS:A1996UX94300044
J	Yoo, SH; Lewis, MS				Yoo, SH; Lewis, MS			Effects of pH and Ca2+ on heterodimer and heterotetramer formation by chromogranin A and chromogranin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR STORES; VESICLE MEMBRANE; COIL TRANSITION; CALCIUM RELEASE; PROTEINS; MOBILIZATION; AGGREGATION; ENDOCRINE; SEQUENCE	The two major proteins of the secretory vesicles of neuroendocrine cells, chromogranin A (CGA) and chromogranin B (CGB), have been shown to undergo pH- and Ca2+-dependent conformational changes and aggregation and have been suggested to play essential roles during secretory vesicle biogenesis in the trans-Gels network, CGA has been shown to exist primarily in a tetrameric state at pH 5.5 and primarily in a dimeric state at pH 7.5, and CGB has been shown to exist in a monomeric state at both pH 5.5 and pH 7.5, Using purified CGA and CGB, it recently has been shown that CGA interacts with CGB at pH 5.5 (Yoo, S, H, (1996) J. Biol, Chem, 271, 1558-1565), In expanding this investigation, we have studied the temperature dependence of the pH-dependent interaction of CGA and CGB by analytical ultracentrifugation and found that two molecules of CGA bound to two molecules of CGB at pH 5.5 with Delta G(0) values of -43.6 kcal/mol in the absence of Ca2+ at 37 degrees C and -40.3 kcal/mol in the presence of 0.1 mM Ca2+, However, one molecule of CGA bound to one molecule of CGB at pH 7.5 with Delta G(0) values of -13.6 kcal/mol in the absence of Ca2+ at 37 degrees C, The magnitude of Delta G(0) values increased with increasing temperatures at both pH values, However, the values for enthalpy and entropy changes decreased with increasing temperatures in both pH levels, suggesting formation of more ordered structures, In the absence of Ca2+ at pH 5,5, the heterotetramerization reaction at 37 degrees C was entropically driven, whereas in the presence of Ca2+ (0.1 mM) the heterotetramerization was virtually an enthalpic reaction, On the other hand, the heterodimer formation in the absence of Ca2+ at pH 7.5 showed large negative enthalpy and entropy changes at 37 degrees C, indicating an enthalpic interaction compensated by entropic changes, In view of the interaction of tetrameric CGA with tetrameric inositol 1,4,5-trisphosphate (Ip(3)) receptor and the existence of heterotetrameric IP3 receptor in the cell, the heterotetramer formation by CGA and CGB not only raises the possibility of interaction between the heterotetrameric chromogranin and heterotetrameric IP3 receptor but also appears to reflect their important roles in the cell.	NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Yoo, SH (corresponding author), NIDCD,NEUROCHEM LAB,NIH,5 RES COURT,2A37,BETHESDA,MD 20892, USA.							ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; MATA M, 1989, J HISTOCHEM CYTOCHEM, V37, P971, DOI 10.1177/37.7.2525142; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; OOI T, 1991, P NATL ACAD SCI USA, V88, P2859, DOI 10.1073/pnas.88.7.2859; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; SCHMID KW, 1989, HISTOCHEM J, V21, P365, DOI 10.1007/BF01798500; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; WEILER R, 1990, BRAIN RES, V532, P87, DOI 10.1016/0006-8993(90)91746-4; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; YOO SH, 1995, BIOCHEMISTRY-US, V34, P8680, DOI 10.1021/bi00027a017; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1990, J BIOL CHEM, V265, P14414; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	31	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17041	17046		10.1074/jbc.271.29.17041	http://dx.doi.org/10.1074/jbc.271.29.17041			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663344	hybrid			2022-12-25	WOS:A1996UX94300012
J	Komaromy, M; Azhar, S; Cooper, AD				Komaromy, M; Azhar, S; Cooper, AD			Chinese hamster ovary cells expressing a cell surface-anchored form of hepatic lipase - Characterization of low density lipoprotein and chylomicron remnant uptake and selective uptake of high density lipoprotein-cholesteryl ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-LIVER; HUMAN-FIBROBLASTS; BINDING; ADRENALS; PURIFICATION; METABOLISM; RECEPTOR; REMOVAL; INSITU; DEGRADATION	The enzyme hepatic lipase may play several roles in lipoprotein metabolism, Recent investigation has suggested a role for the enzyme in lipoprotein and/or lipoprotein lipid uptake, To study this, a simple isolated system that mimics the in vivo system would be desirable, The enzyme is secreted by the hepatic parenchymal cell but exists, and presumably exerts its effects, while bound to capillary endothelial cells in the liver, adrenal gland, and the ovary, We constructed a cDNA that encodes the expression of a chimeric protein composed of rat hepatic lipase and the signal sequence for the addition of the glycophosphatidylinositol (GPI) anchor from human decay-accelerating factor, When transfected into Chinese hamster ovary (CHO) cells this gave rise to a cell population that had immunoreactive hepatic lipase on the cell surface, Cloning of the transfected cells produced several cell lines that expressed the chimeric protein bound to the cell surface by a GPI anchor, This was documented by demonstrating incorporation of [H-3]ethanolamine into anti-hepatic lipase immunoprecipitable material; in addition, hepatic lipase was released from the cells by phosphatidylinositol-specific phospholipase C but not by heparin, Phosphatidylinositol-phospholipase C treatment of cells expressing the anchored lipase released material that comigrated with hepatic lipase on SDS-polyacrylamide gel electrophoresis and was immunoreactive with antibody to the cross-reacting determinant of GPI anchors, Cell lysates containing the anchored protein contained salt-resistant lipase activity, a known feature of the secreted hepatic lipase; thus it appears that these cells have a surface-anchored hepatic lipase molecule, Although it was not possible to demonstrate lipolysis by the enzyme while it was on the cell surface for technical reasons, the protein produced by these cells was active when studied in cell membranes, The ability of the cells to take up lipoproteins was studied, The cells demonstrated an increased affinity for low density lipoprotein (LDL) receptor mediated uptake of LDL, They did not, however, demonstrate any enhanced binding or removal of chylomicron remnants, With respect to LDL and remnants, the cells expressing anchored lipase behaved similarly to CHO cell that expressed secreted hepatic lipase, The cells expressing anchored hepatic lipase had a marked increase in the uptake of high density lipoprotein and high density lipoprotein cholesteryl ester when compared to that seen with CHO cells secreting hepatic lipase, This increase occurred primarily via the selective pathway, and was not reduced by addition of anti-LDL receptor or anti-hepatic lipase antibodies or the receptor-associated protein, Together the results suggest that hepatic lipase, when bound to the cell surface by a GPI anchor, plays a role in enhancing lipoprotein uptake. For LDL this may involve the provision of a second foot for particle binding, thus enhancing affinity for the LDL receptor, For chylomicron remnants an additional molecule or molecules are necessary to mediate this effect, For HDL, the enzyme facilitates uptake of cholesteryl ester primarily by the selective pathway.	PALO ALTO MED FDN,RES INST,PALO ALTO,CA 94301; STANFORD UNIV,DEPT MED,STANFORD,CA 94305; VET ADM PALO ALTO HLTH CARE,CTR GERIATR RES EDUC & CLIN,PALO ALTO,CA 94301	Palo Alto Medical Foundation Research Institute; Stanford University; Geriatric Research Education & Clinical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R01DK038318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39362] Funding Source: Medline; NIDDK NIH HHS [DK-38318, DK 38707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ARBEENY CM, 1987, BIOCHIM BIOPHYS ACTA, V917, P9, DOI 10.1016/0005-2760(87)90277-3; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AZHAR S, 1989, BIOCHIM BIOPHYS ACTA, V1004, P61, DOI 10.1016/0005-2760(89)90213-0; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BAMBERGER M, 1983, J LIPID RES, V24, P869; BENGTSSON G, 1980, FEBS LETT, V119, P290, DOI 10.1016/0014-5793(80)80274-2; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; BILLHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212; BORENSZTAJN J, 1988, J LIPID RES, V29, P1087; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1992, GPI MEMBRANE ANCHERS, P73; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOI SSY, 1994, J LIPID RES, V35, P848; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CONNELLY PW, 1990, ARTERIOSCLEROSIS, V10, P40, DOI 10.1161/01.ATV.10.1.40; COOPER AD, 1987, J LIPID RES, V28, P59; COOPER AD, 1978, J LIPID RES, V19, P635; deFaria E, 1996, J LIPID RES, V37, P197; DESPRES JP, 1988, AM J PHYSIOL, V254, pE667, DOI 10.1152/ajpendo.1988.254.5.E667; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; EHNHOLM C, 1986, PLASMA LIPOPROTEINS, P716; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIXENBAUGH EA, 1993, ANAT REC, V235, P487, DOI 10.1002/ar.1092350402; Hooper NM, 1992, LIPID MODIFICATION P, P89; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; JAHN CE, 1981, FEBS LETT, V131, P366, DOI 10.1016/0014-5793(81)80405-X; JANSEN H, 1981, BIOCHEM J, V196, P739, DOI 10.1042/bj1960739; JANSEN H, 1978, BIOCHEM BIOPH RES CO, V85, P148, DOI 10.1016/S0006-291X(78)80022-9; JANSEN H, 1980, FEBS LETT, V112, P30, DOI 10.1016/0014-5793(80)80119-0; JANSEN H, 1981, METABOLISM, V30, P428, DOI 10.1016/0026-0495(81)90175-X; JENSEN GL, 1981, ANAL BIOCHEM, V113, P246, DOI 10.1016/0003-2697(81)90073-7; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KOMAROMY MC, 1991, J LIPID RES, V32, P963; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KRAPP A, 1995, J LIPID RES, V36, P23662; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISETHERTON PM, 1980, J LIPID RES, V21, P435; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUUSI T, 1979, FEBS LETT, V98, P314, DOI 10.1016/0014-5793(79)80207-0; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOWRI HO, 1992, J LIPID RES, V33, P1269; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PIERCE A, 1992, J BIOL CHEM, V267, P3894; PITTMAN RC, 1984, J LIPID RES, V25, P1577; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; REDGRAVE TG, 1977, ATHEROSCLEROSIS, V28, P69, DOI 10.1016/0021-9150(77)90200-3; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1994, ATHEROSCLEROSIS, V105, P145, DOI 10.1016/0021-9150(94)90044-2; SHAFI S, 1994, J LIPID RES, V35, P709; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; TWU JS, 1984, BIOCHIM BIOPHYS ACTA, V792, P330, DOI 10.1016/0005-2760(84)90201-7; WISHART R, 1990, BIOCHIM BIOPHYS ACTA, V1044, P375, DOI 10.1016/0005-2760(90)90083-A	68	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16906	16914		10.1074/jbc.271.28.16906	http://dx.doi.org/10.1074/jbc.271.28.16906			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663289	hybrid			2022-12-25	WOS:A1996UX12600073
J	Ovadia, H; Rosenmann, H; Shezen, E; Halimi, M; Ofran, I; Gabizon, R				Ovadia, H; Rosenmann, H; Shezen, E; Halimi, M; Ofran, I; Gabizon, R			Effect of scrapie infection on the activity of neuronal nitric-oxide synthase in brain and neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR-CLONING; NADPH-DIAPHORASE; ALZHEIMERS-DISEASE; RELAXING FACTOR; BLASTOMA CELLS; PRION PROTEINS; EXPRESSION; MESSENGER; RESISTANT	Nitric-oxide synthase (NOS) is responsible for the synthesis of nitric oxide which serves as a neural messenger in the central nervous system. NOS activity was markedly inhibited in brains of mice and hamsters and neuroblastoma cells infected with scrapie (ScN2a). The decrease in activity was in accordance with decreased NADPH-diaphorase-positive cells and decreased staining of NOS-positive cells demonstrated by specific anti-NOS antibodies. However, the specific nNOS mRNA in ScN2a was elevated when compared with normal neuroblastoma cells (N2a). Immunoblotting of fractions from these cell lines with an anti-nNOS monoclonal antibody revealed a band of nNOS from N2a and two bands with a lower molecular weight in ScN2a cells. Furthermore, NOS in ScN2a cells was insoluble in nondenaturing detergents. This insolubility is one of the landmark properties of PrPSc. It is, therefore, possible that nNOS in scrapie-infected cells and brains is aberrantly folded, resulting in an insoluble and inactive enzyme.	HADASSAH UNIV HOSP, DEPT NEUROL, IL-91120 JERUSALEM, ISRAEL	Hebrew University of Jerusalem				Ofran, Yishai/0000-0002-5521-1337				AKAIKE T, 1995, J NEUROVIROL, V1, P118, DOI 10.3109/13550289509111016; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2; CROSS AJ, 1985, J NEUROL SCI, V70, P231, DOI 10.1016/0022-510X(85)90090-5; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DESAIAH D, 1994, NEUROLOGY, V44, pA369; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HAMOS JE, 1991, NEUROLOGY, V41, P345, DOI 10.1212/WNL.41.3.345; HYMAN BT, 1992, ANN NEUROL, V32, P818, DOI 10.1002/ana.410320618; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KENWARD N, 1994, J NEUROCHEM, V62, P1870; KOH JY, 1986, SCIENCE, V234, P73, DOI 10.1126/science.2875522; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Liautard J P, 1993, Arch Virol Suppl, V7, P227; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MCCALL TB, 1991, EUR J IMMUNOL, V21, P2523, DOI 10.1002/eji.1830211032; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PEREZ N, 1991, MOL BRAIN RES, V11, P249, DOI 10.1016/0169-328X(91)90033-T; PRICE DL, 1993, P NATL ACAD SCI USA, V90, P6381, DOI 10.1073/pnas.90.14.6381; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; RADI R, 1991, J BIOL CHEM, V266, P4244; RUBENSTEIN R, 1991, J GEN VIROL, V72, P1279, DOI 10.1099/0022-1317-72-6-1279; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; UEMURA Y, 1990, ANN NEUROL, V27, P620, DOI 10.1002/ana.410270606; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	55	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16856	16861		10.1074/jbc.271.28.16856	http://dx.doi.org/10.1074/jbc.271.28.16856			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663207	hybrid			2022-12-25	WOS:A1996UX12600067
J	Pryzdial, ELG; Kessler, GE				Pryzdial, ELG; Kessler, GE			Kinetics of blood coagulation factor Xa alpha autoproteolytic conversion to factor Xa beta - Effect on inhibition by antithrombin, prothrombinase assembly, and enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTEASE INACTIVATION; ACTIVATED FACTOR-X; FACTOR-VA; MOLECULAR RECOGNITION; FUNCTIONAL-PROPERTIES; BOVINE PROTHROMBIN; TRANSIENT KINETICS; THROMBIN; HEPARIN; MECHANISM	Autoproteolysis of blood coagulation factor Xa (FXa) results in the excision of a 4-kDa fragment (beta-peptide) from the intact subform, factor Xa alpha (FXa alpha), to yield factor Xa beta (FXa beta) In the preceding paper, we showed that generation of FXa beta leads to expression of a plasminogen binding site, FXa beta may consequently participate in fibrinolysis; therefore, the timing of subform conversion compared with thrombin production is important. In the current study we evaluated the kinetics of FXa beta generation, which showed that autoproteolysis of FXa alpha followed a second order mechanism where FXa alpha and FXa beta behaved as identical enzymes, Rate constants of 9 and 172 M(-1) s(-1) were derived, respectively, in the absence and presence of FXa alpha binding to procoagulant phospholipid. Under identical conditions the latter is estimated to be 6 orders of magnitude slower than thrombin generation by prothrombinase. Since heparin binding and prothrombin recognition have been previously attributed to a region of FXa alpha proximal to the beta-peptide, functional comparisons were conducted using homogeneous and stabilized preparations of FXa alpha and FXa beta. Comparisons included 1) the recognition of small substrates; 2) the rate of interaction with antithrombin/heparin; 3) the assembly of prothrombinase; and 4) the activation of prothrombin by prothrombinase, Although the beta-peptide neighbors a probable functional region in FXa alpha, conversion to FXa beta was not observed to influence these functions, The data support a model where FXa alpha is predominantly responsible for thrombin generation and where slow conversion to FXa beta coordinates coagulation and the initiation of fibrinolysis at sites of prothrombinase assembly.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1G 4J5,CANADA	University of Ottawa	Pryzdial, ELG (corresponding author), UNIV OTTAWA,CANADIAN RED CROSS SOC,RES DEPT,1800 ALTA VISTA DR,OTTAWA,ON K1G 4J5,CANADA.							BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BRICE BA, 1952, J OPT SOC AM, V41, P1033; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EBY CS, 1992, BLOOD S, V80, P306; FUJIKAWA K, 1975, P NATL ACAD SCI USA, V72, P3359, DOI 10.1073/pnas.72.9.3359; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GIARDINO EC, 1993, CIRCULATION S, V4, P2240; Gutfreund H., 1972, ENZYMES PHYSICAL PRI, P116; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; HOLLENBACH S, 1994, THROMB HAEMOSTASIS, V71, P357; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4506, DOI 10.1021/bi00852a047; JESTY J, 1974, J BIOL CHEM, V249, P5614; JESTY J, 1974, J BIOL CHEM, V249, P509; JESTY J, 1973, BIOCHEM J, V131, P791, DOI 10.1042/bj1310791; Jesty J, 1976, Methods Enzymol, V45, P95; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KRISHNASWAMY S, 1994, METHOD ENZYMOL, V222, P260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LINK RP, 1982, ARCH BIOCHEM BIOPHYS, V215, P215, DOI 10.1016/0003-9861(82)90297-1; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MIZUOCHI T, 1980, J BIOL CHEM, V255, P3526; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OMAR MN, 1987, J BIOL CHEM, V262, P9720; OWEN WG, 1974, J BIOL CHEM, V249, P594; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; PRYZDIAL ELG, 1995, J BIOL CHEM, V270, P17871, DOI 10.1074/jbc.270.30.17871; ROSING J, 1980, J BIOL CHEM, V255, P274; SHEFFIELD WP, 1994, MOL BIOL THROMBOSIS, P355; SINHA U, 1993, J BIOL CHEM, V268, P3048; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x	48	16	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16621	16626		10.1074/jbc.271.28.16621	http://dx.doi.org/10.1074/jbc.271.28.16621			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663222				2022-12-25	WOS:A1996UX12600033
J	Becq, F; Verrier, B; Chang, XB; Riordan, JR; Hanrahan, JW				Becq, F; Verrier, B; Chang, XB; Riordan, JR; Hanrahan, JW			cAMP- and Ca2+-independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR-CHLORIDE CHANNELS; ALKALINE-PHOSPHATASE; CL CHANNEL; PHOSPHOTYROSINE PHOSPHATASE; DUCT CELLS; R-DOMAIN; PHOSPHORYLATION; IDENTIFICATION; MEMBRANE; GENE	Patch-clamp, iodide efflux, and biochemical techniques were used to evaluate the ability of phenylimidazothiazoles to open normal and mutated cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels and to investigate the mechanism of activation. As reported previously for bromotetramisole, levamisole activated wild-type CFTR channels stably expressed in Chinese hamster ovary cells in the absence of other secretagogues and without elevating intracellular cAMP or calcium. The protein kinase A (PKA) inhibitor N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide abolished activation by forskolin but only partially inhibited stimulation by levamisole, suggesting the involvement of other kinases. CFTR channels bearing mutations at multiple phosphorylation sites, in the membrane domains, and in the first nucleotide binding domain (including the disease-causing mutations G551D and Delta F508) all responded to phenylimidazothiazoles. Moreover, levamisole and bromotetramisole increased the activity of wild-type and mutant channels already exposed to PKA + MgATP, consistent with the inhibition of a constitutive, membrane-associated phosphatase activity. We conclude that phenylimidazothiazole drugs can open normal and mutated CFTR channels by stabilization of phosphoforms of CFTR that are produced by basal activity of PKA and alternative protein kinases. If similar stimulation is observed in humans in vivo, phenylimidazothiazoles may be useful in the development of pharmacological therapies for cystic fibrosis.	MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA; FAC MED NORD, INSERM U270, F-13326 MARSEILLE, FRANCE; MAYO CLIN SCOTTSDALE, S C JOHNSON MED RES CTR, SCOTTSDALE, AZ 85259 USA	McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Mayo Clinic; Mayo Clinic Phoenix			Becq, Frederic/P-9233-2016; Hanrahan, John/AGG-1926-2022	Becq, Frederic/0000-0003-3915-0973; Hanrahan, John/0000-0001-9080-2039				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BECQ F, 1993, FEBS LETT, V327, P337, DOI 10.1016/0014-5793(93)81016-S; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BHARGAVA KK, 1977, J MED CHEM, V20, P563, DOI 10.1021/jm00214a021; BORGERS M, 1973, J HISTOCHEM CYTOCHEM, V21, P812, DOI 10.1177/21.9.812; BORGERS M, 1975, HISTOCHEMISTRY, V44, P277, DOI 10.1007/BF00491496; CHAMPIGNY G, 1990, FEBS LETT, V259, P263, DOI 10.1016/0014-5793(90)80024-D; CHAN JRA, 1986, J BIOL CHEM, V261, P7635; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CONSTANTOPOULOS A, 1977, EXPERIENTIA, V33, P395, DOI 10.1007/BF02002848; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DILS F, 1979, J INT MED RES, V7, P302, DOI 10.1177/030006057900700408; DOUSMANIS AG, 1995, PEDIATR PULM, V20, P418; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EIDELMAN O, 1992, P NATL ACAD SCI USA, V89, P5562, DOI 10.1073/pnas.89.12.5562; ELKOUNI MH, 1982, P NATL ACAD SCI-BIOL, V79, P1037; FERNLEY HN, 1967, BIOCHEM J, V104, P1011, DOI 10.1042/bj1041011; FIRTH JA, 1974, J HISTOCHEM CYTOCHEM, V22, P1163, DOI 10.1177/22.12.1163; GETTINS P, 1985, J BIOL CHEM, V260, P2875; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREM JL, 1990, CANCER CELL-MON REV, V2, P131; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HANRAHAN JW, 1995, SOC GEN PHY, V50, P125; HARRIS RA, 1993, AM J PHYSIOL, V265, pC781, DOI 10.1152/ajpcell.1993.265.3.C781; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; HOFFMANN WE, 1983, ENZYME, V30, P269, DOI 10.1159/000469588; HWANG TC, 1993, J GEN PHYSIOL, V101, P629, DOI 10.1085/jgp.101.5.629; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KERSTING U, 1993, P NATL ACAD SCI USA, V90, P4047, DOI 10.1073/pnas.90.9.4047; KHODAPARASTSHARIFI SH, 1989, INT J BIOCHEM, V21, P401, DOI 10.1016/0020-711X(89)90364-9; LEAKE DS, 1983, BIOCHIM BIOPHYS ACTA, V762, P52, DOI 10.1016/0167-4889(83)90116-7; LEBEL D, 1980, J BIOL CHEM, V255, P1227; MAGNUSSON BC, 1974, HISTOCHEMISTRY, V42, P221, DOI 10.1007/BF00492654; METAYE T, 1992, BIOCHEM PHARMACOL, V43, P1507, DOI 10.1016/0006-2952(92)90208-Z; MOTOYAMA N, 1987, J BIOCHEM-TOKYO, V101, P939, DOI 10.1093/oxfordjournals.jbchem.a121963; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; REDDY M, 1994, PEDIATR PULM S, V10, P183; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROTENBERG SA, 1987, BIOCHEM J, V243, P747, DOI 10.1042/bj2430747; SARROUILHE D, 1992, BIOCHIM BIOPHYS ACTA, V1118, P116, DOI 10.1016/0167-4838(92)90137-3; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SWARUP G, 1981, J BIOL CHEM, V256, P8197; Symoens J., 1979, PHARMACOLOGICAL BIOC, V2, P407; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VANBELLE H, 1977, CLIN CHEM, V23, P454; VANEYGEN M, 1979, EUR J PEDIATR, V131, P147, DOI 10.1007/BF00538939; VANEYGEN M, 1976, LANCET, V1, P382	58	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16171	16179		10.1074/jbc.271.27.16171	http://dx.doi.org/10.1074/jbc.271.27.16171			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663098	hybrid			2022-12-25	WOS:A1996UW35200048
J	OBrien, MC; Flaherty, KM; McKay, DB				OBrien, MC; Flaherty, KM; McKay, DB			Lysine 71 of the chaperone protein Hsc70 is essential for ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; UNCOATING PROTEIN; STRUCTURAL BASIS; BINDING; FRAGMENT; DOMAIN	It has been proposed that lysine 71 of the bovine 70-kDa heat shock cognate protein might participate in catalysis of ATP hydrolysis by stabilizing an H2O molecule or an OH- ion for nucleophilic attack on the gamma-phosphate of the nucleotide (Flaherty, K, M., Wilbanks, S, M,, DeLuca-Flaherty, C., and McKay, D. B, (1994) J, Biol. Chem, 12899-12907; Wilbanks, S, M,, DeLuca-Flaherty, C,, and McKay, D, B. (1994) J. Biol. Chem, 269, 12893-12898), To test this hypothesis, lysine 71 of the ATPase fragment 70-kDa heat shock cognate protein has been mutated to glutamic acid, methionine, and alanine; and the kinetic and structural properties of the mutantproteins have been determined. All three mutant proteins are devoid of measurable ATP hydrolysis activity. Crystal structures of the mutant proteins have bben determined to a resolution of 1.7 Angstrom; all three have ATP in the nucleotide binding site. These data identify lysine 71 as a residue that is essential for chemical hydrolysis of ATP.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM-39928, GM 15141] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928, F32GM015141] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DELUCAFLAHERTY C, 1988, J MOL BIOL, V200, P749, DOI 10.1016/0022-2836(88)90487-1; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; STEIGEMANN W, 1974, THESIS TU MUNCHEN; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251	23	110	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15874	15878		10.1074/jbc.271.27.15874	http://dx.doi.org/10.1074/jbc.271.27.15874			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663302	hybrid			2022-12-25	WOS:A1996UW35200008
J	Zhu, YX; Kang, LY; Luo, W; Li, CCH; Yang, L; Yang, YC				Zhu, YX; Kang, LY; Luo, W; Li, CCH; Yang, L; Yang, YC			Multiple transcription factors are required for activation of human interleukin 9 gene in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS FACTOR-ALPHA; NF-KAPPA-B; GROWTH-FACTOR; EXPRESSION; MURINE; ELEMENT; IDENTIFICATION; PROLIFERATION; LYMPHOCYTES; LYMPHOMAS	The genetic elements and regulatory mechanisms responsible for human interleukin 9 (IL-9) gene expression in a human T cell leukemia virus type I-transformed human T cell line, C5MJ2, were investigated. We demonstrated that IL-9 gene expression is controlled, at least in part, by transcriptional activation. Transient expression of the luciferase reporter gene Linked to serially deleted sequences of the 5'-flanking region of the IL-9 gene has revealed several positive and negative regulatory elements involved in the basal and inducible expression of the IL-9 gene in C5MJ2 cells. An AP-1 site at -146 to -140 was shown to be involved in the expression of the IL-9 gene. A proximal region between -46 and -80 was identified as the minimum sequence for the basal and inducible expression of the IL-9 gene in C5MJ2 cells. Within this region, an NF-kappa B site at -59 to -50 and its adjacent 20-base pair upstream sequence were demonstrated to play a critical role for the IL-9 promoter activity. DNA-protein binding studies indicated that NF-kappa B, c-Jun, and potentially novel proteins (around 35 kDa) can bind to this important sequence. Mutations at different sites within this proximal promoter region abolished the promoter activity as well as the DNA binding. Taken together, these results suggest that the cooperation of different transcription factors is essential for IL-9 gene expression in T cells.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; NCI,FREDERICK CANC RES & DEV CTR,BIOL CARCINOGENESIS & DEV PROGRAM,SAIC,FREDERICK,MD	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONAHUE RE, 1990, BLOOD, V75, P2271; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; FURTH M, 1989, CANC CELLS MOL DIAGN, P53; GRUSS HJ, 1992, CANCER RES, V52, P1026; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; HULTNER L, 1989, J IMMUNOL, V142, P3440; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; JENKINS F, 1995, J IMMUNOL, V155, P1240; KAUSHANSKY K, 1994, J IMMUNOL, V152, P1812; KELLEHER K, 1991, BLOOD, V77, P1436; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MERZ H, 1991, BLOOD, V78, P1311; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MOCK BA, 1990, IMMUNOGENETICS, V31, P265, DOI 10.1007/BF00204898; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NAORA H, 1994, J IMMUNOL, V153, P3466; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1992, BLOOD, V80, P575; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; RENAULD JC, 1990, J IMMUNOL, V144, P4235; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Sambrook J., 2002, MOL CLONING LAB MANU; SHRECK R, 1990, MOL CELL BIOL, V10, P1281; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SUDA T, 1990, J IMMUNOL, V144, P1783; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6943; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; WILLIAMS DE, 1990, BLOOD, V76, P906; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG YC, 1989, BLOOD, V74, P1880; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	49	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15815	15822		10.1074/jbc.271.26.15815	http://dx.doi.org/10.1074/jbc.271.26.15815			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663174	hybrid			2022-12-25	WOS:A1996UV29900077
J	Chevalier, S; Fourcin, M; Robledo, O; Wijdenes, J; PouplardBarthelaix, A; Gascan, H				Chevalier, S; Fourcin, M; Robledo, O; Wijdenes, J; PouplardBarthelaix, A; Gascan, H			Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; IL-6 SIGNAL TRANSDUCER; HEPATOCYTE-STIMULATING FACTOR; RECEPTOR GAMMA-CHAIN; ONCOSTATIN-M; GM-CSF; MOLECULAR-CLONING; CNTF RECEPTOR; GROWTH-FACTOR	Gp130 transducing protein was shown to be involved in the formation of the high affinity receptors for interleukin 6 (IL-6), interleukin-11 (IL-11), leukemia inhibitory factor, oncostatin M (OSM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1. In the present study we have characterized the functional properties of antibodies directed against this protein and identified a group of monoclonal antibodies able to antagonize the biological activities of all the cytokines belonging to the IL-6 cytokine family, The B-R3 pan-blocking antibody weakly interfered with the binding of the radiolabeled ligands (with the exception of OSM, whose binding was abrogated in the presence of B-R3 monoclonal antibody) but inhibited the gp130 homodimerization or its association with gp190/leukemia inhibitory factor receptor, as well as the subsequent tyrosine phosphorylation events, In addition we identified antibodies that were able to neutralize only one single cytokine of the IL-6 family, This was the case for the B-K5 antibody, which antagonized the binding of OSM to gp130 but did not interfere with the signals provided by the related cytokines triggering the proliferation of the TF1 erythroleukemia cell line or the induction of haptoglobin synthesis in the HepG2 hepatoma cell line, Similarly, we also characterized two additional antibodies B-P8 and B-P4, which inhibited the TF1 cell proliferation observed in the presence of CNTF and IL-11, respectively, B-P8 antibody only faintly interfered with the binding of the gp130-ligands and might modulate the signal transduction pathways, This study indicates that in addition to functional site(s) required by the whole family of IL-6 type cytokines to transduce the signal insight the cell, specific cognate functional sites were recruited by OSM, CNTF, or IL-11.	CHU ANGERS,BIOL CELLULAIRE LAB,F-49033 ANGERS,FRANCE; DIACLONE,F-25020 BESANCON,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers								BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CONOVER JC, 1993, DEVELOPMENT, V119, P559; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GASCAN H, 1989, J BIOL CHEM, V264, P21509; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOBAYASHI S, 1993, BLOOD, V81, P889; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LEARY AG, 1990, BLOOD, V75, P1960; LECRON JC, 1993, CLIN EXP IMMUNOL, V92, P23; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUSASHI M, 1991, BLOOD, V78, P1448; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPORENO E, 1994, J BIOL CHEM, V269, P10991; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TEJEDOR F, 1982, ANAL BIOCHEM, V127, P143, DOI 10.1016/0003-2697(82)90156-7; THOMA B, 1994, J BIOL CHEM, V269, P6215; VANDERHEYDEN J, 1991, J IMMUNOL, V147, P3413; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	56	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14764	14772		10.1074/jbc.271.25.14764	http://dx.doi.org/10.1074/jbc.271.25.14764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662918	hybrid			2022-12-25	WOS:A1996UT10600022
J	Ellis, V				Ellis, V			Functional analysis of the cellular receptor for urokinase in plasminogen activation - Receptor binding has no influence on the zymogenic nature of pro-urokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; MONOCLONAL-ANTIBODY; BOUND UROKINASE; PROENZYME FORM; SARCOMA-CELLS; PLASMA; INACTIVATION; POTENTIATION; INHIBITORS; MECHANISM	Plasminogen activation catalyzed by the urokinase-type plasminogen activator (uPA) constitutes a reciprocal zymogen activation system, as plasmin can efficiently activate pro-uPA, the single-chain zymogenic form of the protease, We have previously shown that the overall efficiency of this plasminogen activation system is greatly enhanced by its assembly on the cell surface, involving binding of pro-uPA to its cellular binding site uPAR, and the concurrent cellular binding of plasminogen. We have now studied the effect of a recombinant soluble form of uPAR (residues 1-277) on the proteolytic reactions of this system. In contrast to the increased efficiencies of plasminogen activation and pro-uPA activation observed with cell-surface uPAR, soluble uPAR had an inhibitory effect on both of these individual reactions, Soluble uPAR also caused no increase in the low, but discernible, intrinsic activity of pro-uPA, Consistent with the observations on the isolated reactions, the overall activity of the pro-uPA-mediated plasminogen activation system was significantly inhibited. These observations confirm the previous interpretation of the observations made with cell-surface uPAR that the mechanism of the enhanced plasmin generation is due to the catalytically favorable interaction of uPAR-bound uPA/pro-uPA with cell-bound plasminogen/plasmin, rather than direct effects on the properties of uPA or pro-uPA on binding to uPAR.			Ellis, V (corresponding author), THROMBOSIS RES INST,EMMANUEL KAYE BLDG,MANRESA RD,LONDON SW3 6LR,ENGLAND.		Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X				ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BRUNNER G, 1990, FEBS LETT, V260, P141, DOI 10.1016/0014-5793(90)80087-Y; COLLEN D, 1986, J BIOL CHEM, V261, P1259; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; Ellis Vincent, 1994, Fibrinolysis, V8, P1, DOI 10.1016/0268-9499(94)90288-7; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P15418, DOI 10.1021/bi00255a023; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P4847, DOI 10.1021/bi00182a013; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; KIELBERG V, 1985, FEBS LETT, V182, P441, DOI 10.1016/0014-5793(85)80350-1; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; LEE SW, 1994, J BIOL CHEM, V269, P2411; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1986, BIOCHIM BIOPHYS ACTA, V884, P402, DOI 10.1016/0304-4165(86)90190-X; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANCHANDA N, 1985, J BIOL CHEM, V270, P20032; MANN KG, 1990, BLOOD, V76, P1; MARCOTTE PA, 1993, BIOCHIM BIOPHYS ACTA, V1161, P105, DOI 10.1016/0167-4838(93)90203-4; MORGAN PH, 1972, P NATL ACAD SCI USA, V69, P3312, DOI 10.1073/pnas.69.11.3312; NEURATH H, 1976, P NATL ACAD SCI USA, V73, P3825, DOI 10.1073/pnas.73.11.3825; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; PANNELL R, 1986, BLOOD, V67, P1215; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; STACK MS, 1994, J BIOL CHEM, V269, P9416; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; WUN TC, 1982, J BIOL CHEM, V257, P7262	39	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14779	14784		10.1074/jbc.271.25.14779	http://dx.doi.org/10.1074/jbc.271.25.14779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662951	hybrid			2022-12-25	WOS:A1996UT10600024
J	Nystedt, S; Ramakrishnan, V; Sundelin, J				Nystedt, S; Ramakrishnan, V; Sundelin, J			The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells - Comparison with the thrombin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; LEUKOCYTE ADHESION MOLECULE-1; EXPRESSION; CLONING; INTERLEUKIN-1; MECHANISM; SURFACE; CULTURE; ALPHA	The proteinase-activated receptor 2 (PAR-2) belongs to the family of seven transmembrane region receptors, and, like the related thrombin receptor, it is activated by specific proteolytic cleavage of its extracellular amino terminus. It is not known which proteinase is the physiological activator of the PAR-2, but candidates can be found among the enzymes involved in the inflammatory cascade systems. Here, we have studied the effects of various mediators on the expression of the PAR-S and the thrombin receptor in cultured human umbilical vein endothelial cells. Stimulation with the cytokines tumor necrosis factor alpha or interleukin-1 alpha as well as bacterial lipopolysaccharide elevated the expression of PAR-S in a dose-dependent manner. The time course of induction after cytokine stimulation was similar to those published for the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. After 20 h of stimulation, PAR-2 mRNA and protein levels were increased to 5-10-fold basal values, and, in the continued presence of tumor necrosis factor cu, PAR-2 mRNA expression was found to remain elevated for up to 4 days, In contrast, the thrombin receptor gene was not induced by any of these inflammatory mediators, The responses to phorbol ester treatment also differed between the two genes. Thrombin receptor mRNA levels decreased steadily up to 20 h, whereas PAR-2 mRNA levels first rose to about 3-fold basal values at 4 h before decreasing again. Cell surface protein levels of both receptors were decreased after 20 h of phorbol ester stimulation, Elevating intracellular cAMP levels by treatment with forskolin resulted in decreased expression of both receptors, and inhibition of cAMP degradation appeared to blunt the cytokine-induced increase in PAR-2 expression. The induction of the PAR-2 by cytokine treatment supports the concept of PAR-2 involvement in the acute inflammatory response.	COR THERAPEUT INC,SAN FRANCISCO,CA 94080		Nystedt, S (corresponding author), LUND UNIV,WALLENBERG NEUROCTR,DIV MOLEC NEUROBIOL,WALLENBERG LAB,SOLVEGATAN 17,S-22362 LUND,SWEDEN.							BERMAN RS, 1993, BRIT J PHARMACOL, V110, P1282, DOI 10.1111/j.1476-5381.1993.tb13956.x; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHEN J, 1994, J BIOL CHEM, V269, P16041; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, J CELL SCI, V108, P1155; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KOGA S, 1995, AM J PHYSIOL-CELL PH, V268, pC1104, DOI 10.1152/ajpcell.1995.268.5.C1104; MOORE KL, 1989, BLOOD, V73, P159; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NORTON KJ, 1993, BLOOD, V82, P2125; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1986, J IMMUNOL, V137, P1893; POBER JS, 1990, TRANSPLANTATION, V50, P427; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROYALL JA, 1989, AM J PHYSIOL, V257, pL399, DOI 10.1152/ajplung.1989.257.6.L399; SOIFER SJ, 1994, AM J PATHOL, V144, P60; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; XIE W, 1991, BIOTECHNIQUES, V11, P325; ZACHARIAS U, 1995, J BIOL CHEM, V270, P545, DOI 10.1074/jbc.270.2.545	31	311	317	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14910	14915		10.1074/jbc.271.25.14910	http://dx.doi.org/10.1074/jbc.271.25.14910			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663011	hybrid			2022-12-25	WOS:A1996UT10600043
J	Kumari, M; Stroud, JC; Anji, A; McCarrey, JR				Kumari, M; Stroud, JC; Anji, A; McCarrey, JR			Differential appearance of DNase I-hypersensitive sites correlates with differential transcription of Pgk genes during spermatogenesis in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED PHOSPHOGLYCERATE KINASE; X-CHROMOSOME INACTIVATION; SEX-DETERMINING REGION; PDGF-B GENE; CHROMATIN STRUCTURE; MORPHOLOGICAL CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; EXPRESSION; TESTIS; PROMOTER	Two functional genes encoding phosphoglycerate kinase are differentially expressed during spermatogenesis in the mouse. Expression of the X-linked Pgh-l gene is repressed coincident with X chromosome inactivation during prophase of meiosis I. At this same stage, expression of the autosomal Pgk-2 gene is initiated by tissue specific mechanisms, To investigate the role of chromatin structure in these processes, we have examined the appearance and disappearance of DNase I-hypersensitive (DH) sites in each gene, and correlated this with transcriptional activity as measured by nuclear run off analysis at specific stages of spermatogenesis, Our results demonstrate that the occurrence of DH sites is related to periods of active transcription, Results with the Pgk-1 gene indicate that transcriptional inactivation of the X chromosome in spermatogenic cells may not be as complete as that in somatic cells, and that maximum repression may be limited to a very transient period during the pachytene stage of first meiotic prophase. Results with the Pgk-2 gene indicate that DH sites appear coincident with, or just prior to, transcriptional activation of this gene, The implications of these results are discussed with respect to the role of X chromosome inactivation in spermatogenic cells and the developmental order of molecular events that regulate differential gene expression during spermatogenesis.	SW FDN BIOMED RES, DEPT GENET, SAN ANTONIO, TX 78245 USA	Texas Biomedical Research Institute			Stroud, James C/B-3230-2012	Stroud, James C/0000-0003-0850-4812	NICHD NIH HHS [HD 23126] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023126] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; BECK KM, 1991, NUCLEIC ACIDS RES, V19, P4975, DOI 10.1093/nar/19.18.4975; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BERG WM, 1993, LIFE SCI ADV MOL BIO, V12, P85; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CHOUDHARY SK, 1995, J BIOL CHEM, V270, P8755, DOI 10.1074/jbc.270.15.8755; DIRKS RPH, 1993, EUR J BIOCHEM, V211, P509, DOI 10.1111/j.1432-1033.1993.tb17577.x; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; ELGIN SCR, 1984, NATURE, V309, P213, DOI 10.1038/309213a0; Forejt J., 1982, Genetic control of gamete production and function, P135; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GOTO M, 1990, EXP CELL RES, V186, P273, DOI 10.1016/0014-4827(90)90306-U; GRANT M, 1992, NAT GENET, V2, P161, DOI 10.1038/ng1092-161; GREEN GR, 1994, MOL REPROD DEV, V37, P255, DOI 10.1002/mrd.1080370303; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Handel M A, 1987, Results Probl Cell Differ, V15, P1; HANDELMAN SL, 1987, COMMUNITY DENT ORAL, V15, P1, DOI 10.1111/j.1600-0528.1987.tb00470.x; HENDRIKSEN PJM, 1995, DEV BIOL, V170, P730, DOI 10.1006/dbio.1995.1252; HENKEL G, 1992, J IMMUNOL, V149, P3239; KUHNERT P, 1992, NUCLEIC ACIDS RES, V20, P1943, DOI 10.1093/nar/20.8.1943; LIFSCHYTZ E, 1972, P NATL ACAD SCI USA, V69, P182, DOI 10.1073/pnas.69.1.182; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P515, DOI 10.1007/BF02255842; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MCCARREY JR, 1992, GENET ANAL-BIOMOL E, V9, P117, DOI 10.1016/1050-3862(92)90051-6; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; MCKEE BD, 1993, CHROMOSOMA, V102, P71, DOI 10.1007/BF00356023; MIZUNO K, 1992, GENE, V119, P293, DOI 10.1016/0378-1119(92)90286-X; MONESI V, 1967, ARCH ANAT MICROSC MO, V56, P61; MORI N, 1986, GENE, V45, P275; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; RILEY DE, 1984, NUCLEIC ACIDS RES, V12, P1829, DOI 10.1093/nar/12.4.1829; RILEY DE, 1986, SOMAT CELL MOLEC GEN, V12, P73, DOI 10.1007/BF01560729; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINGERSAM J, 1992, P NATL ACAD SCI USA, V89, P1413, DOI 10.1073/pnas.89.4.1413; SINGERSAM J, 1990, NUCLEIC ACID METHYLA, V128, P285; SINGH S, 1991, BIOCHEM BIOPH RES CO, V181, P131, DOI 10.1016/S0006-291X(05)81391-9; Stott D, 1991, Methods Mol Biol, V7, P327, DOI 10.1385/0-89603-178-0:327; Sutherland Leslie C., 1995, Gene Expression, V4, P265; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TUNNACLIFFE A, 1990, NUCLEIC ACIDS RES, V18, P459, DOI 10.1093/nar/18.3.459; VANDEBERG JL, 1985, ISOZYMES-CURR T BIOL, V12, P133; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YANG TP, 1988, SOMAT CELL MOLEC GEN, V14, P461, DOI 10.1007/BF01534712; YANG TP, 1987, MOL CELL BIOL, V7, P2994, DOI 10.1128/MCB.7.8.2994	58	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14390	14397		10.1074/jbc.271.24.14390	http://dx.doi.org/10.1074/jbc.271.24.14390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662942	hybrid			2022-12-25	WOS:A1996UQ66000068
J	Watabe, M; Masuda, Y; Nakajo, S; Yoshida, T; Kuroiwa, Y; Nakaya, K				Watabe, M; Masuda, Y; Nakajo, S; Yoshida, T; Kuroiwa, Y; Nakaya, K			The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED MAP KINASE; HL-60 CELLS; TOPOISOMERASE INHIBITORS; ANTICANCER DRUGS; PROTEIN; INDUCTION; CAMPTOTHECIN; PHOSPHATASE; THYMOCYTES	Bufalin, an active principle of Chinese medicine, chan'su, induced typical apoptosis in human leukemia U937 cells. When U937 cells were treated with 10(-8) bufalin in the absence of serum, mitogen-activated protein (MAP) kinase activity was markedly increased 6 h after the start of treatment and elevated so for 12 h. Prior to the activation of MAP kinase, increased activities of Pas, Raf-1, and MAP kinase kinase were found, but these enzymes were transiently activated by the treatment with bufalin. These results suggest that the signal was transmitted sequentially from Pas, Raf-1, and MAP kinase kinase to MAP kinase. In association with this signal transduction, the concentration of cAMP in the cells decreased markedly, suggesting that Raf-1 was also activated by a decrease in the extent of phosphorylation by protein kinase A. In fact, pretreatment of U937 cells with forskolin and 3-isobutyl-1-methylxanthine, which are known to increase the concentration of cAMP in the cells, and subsequent treatment with bufalin resulted in a decrease in both Raf-1 activity and DNA fragmentation. To confirm the participation of MAP kinase in the apoptotic process, antisense cDNA for MAP kinase kinase 1 was expressed in U937 cells. The transformants were significantly resistant to both DNA fragmentation and cell death in response to bufalin. Our findings suggest that a pathway with the persistent activation of MAP kinase in U937 cells in response to bufalin is at least one of the signal transduction pathways involved in the induction of apoptosis.	SHOWA UNIV,SCH PHARMACEUT SCI,BIOL CHEM LAB,SHINAGAWA KU,TOKYO 142,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,LAB BIOCHEM TOXICOL,SHINAGAWA KU,TOKYO 142,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,CLIN PHARM LAB,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University; Showa University; Showa University								BALL RL, 1990, J BIOL CHEM, V265, P12836; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; Bertrand R., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU S, 1990, BIOCHEM BIOPH RES CO, V166, P160, DOI 10.1016/0006-291X(90)91925-I; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DREWES G, 1992, EMBO J, V11, P2121; EVANS DL, 1993, CANCER RES, V53, P2133; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; JING YK, 1994, JPN J CANCER RES, V85, P645, DOI 10.1111/j.1349-7006.1994.tb02408.x; JING YK, 1993, ANTICANCER RES, V13, P1049; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVANDERO S, 1990, RES COMMUN CHEM PATH, V69, P317; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NAKAYA K, 1991, JPN J CANCER RES, V82, P184, DOI 10.1111/j.1349-7006.1991.tb01827.x; NOGUCHI K, 1995, JPN J CANCER RES, V86, P217, DOI 10.1111/j.1349-7006.1995.tb03042.x; ONISHI Y, 1993, BIOCHIM BIOPHYS ACTA, V1175, P147, DOI 10.1016/0167-4889(93)90017-J; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SAKAI I, 1993, BIOCHEM BIOPH RES CO, V191, P873, DOI 10.1006/bbrc.1993.1298; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YOSHIDA A, 1993, JPN J CANCER RES, V84, P566, DOI 10.1111/j.1349-7006.1993.tb00177.x; ZHANG LS, 1992, CANCER RES, V52, P4634	36	123	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14067	14073		10.1074/jbc.271.24.14067	http://dx.doi.org/10.1074/jbc.271.24.14067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662906	hybrid			2022-12-25	WOS:A1996UQ66000023
J	Stuart, RO; Sun, A; Bush, KT; Nigam, SK				Stuart, RO; Sun, A; Bush, KT; Nigam, SK			Dependence of epithelial intercellular junction biogenesis on thapsigargin-sensitive intracellular calcium stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CELL CONTACT; TIGHT JUNCTION; ENDOPLASMIC-RETICULUM; PROTEIN; LOCALIZATION; RECEPTORS; POLARITY; MOUSE; ZO-1	Perturbation of potentially regulatable endoplasmic reticulum (ER) calcium stores with the Ca-ATPase inhibitor, thapsigargin (TG), perturbs the formation of desmosomes and tight junctions during polarized epithelial cell biogenesis, despite the development of cell contact. In Madin-Darby canine kidney cell model for intercellular junction assembly, TG treatment inhibited the development of transepithelial electrical resistance (TER), a measure of tight junction assembly, in a dose-dependent manner. The TG-induced inhibition of tight junction assembly was paralleled by a defect in the sorting of the tight junction protein, ZO-1. An even more dramatic delay in sorting of the desmosomal protein, desmoplakin, was observed in the presence of TG. In addition, while both ZO-1 and desmoplakin-I in control cells were shown to become associated with the Triton X-100 insoluble cytoskeleton during intercellular junction assembly, prior treatment with 100 nM TG diminished this biochemical stabilization into the detergent-insoluble fraction, particularly in the case of ZO-1. Although spectrofluorimetric measurements in fura-2 loaded Madin-Darby canine kidney cells confirmed the occurrence of TG-mediated release of calcium form internal stores, total cytosolic calcium during junction assembly remained similar to untreated cells. Therefore, the normal intercellular junction biogenesis if intracellular stores are perturbed by TG. The results indicate the presence of calcium-sensitive intracellular mechanisms involved in the sorting and cytoskeletal stabilization of both tight junction and desmosomes and suggest a role for calcium-dependent signaling pathways at an early (possible common) step in polarized epithelial biogenesis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV RENAL,DEPT MED,BOSTON,MA 02115; BROWN UNIV,RHODE ISL HOSP,SCH MED,DIV RENAL,PROVIDENCE,RI 02903	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital					NIDDK NIH HHS [5-T32-DK07527-09, R01DK44503, 1 F32 DK08822-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008822, R01DK044503, T32DK007527] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BUSH KT, 1994, J BIOL CHEM, V269, P23694; BUSH KT, 1990, ANAT EMBRYOL, V181, P49; CEREIJIDO M, 1981, AM J PHYSIOL, V240, pC96, DOI 10.1152/ajpcell.1981.240.3.C96; CONTRERAS R G, 1992, News in Physiological Sciences, V7, P105; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GONZALEZMARISCAL L, 1990, AM J PHYSIOL, V259, pC978, DOI 10.1152/ajpcell.1990.259.6.C978; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HANDLER JS, 1989, ANNU REV PHYSIOL, V51, P729, DOI 10.1146/annurev.ph.51.030189.003501; LYTTON J, 1992, Current Opinion in Cell Biology, V4, P220, DOI 10.1016/0955-0674(92)90036-C; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PUTNEY JW, 1987, TRENDS PHARMACOL SCI, V8, P481, DOI 10.1016/0165-6147(87)90043-5; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; SIMONS K, 1991, MORPHOREGULATORY MOL, P341; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186	24	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13636	13641		10.1074/jbc.271.23.13636	http://dx.doi.org/10.1074/jbc.271.23.13636			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662885	hybrid			2022-12-25	WOS:A1996UP38500051
J	Doolan, DL; Hedstrom, RC; Rogers, WO; Charoenvit, Y; Rogers, M; delaVega, P; Hoffman, SL				Doolan, DL; Hedstrom, RC; Rogers, WO; Charoenvit, Y; Rogers, M; delaVega, P; Hoffman, SL			Identification and characterization of the protective Hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEROZOITE SURFACE PROTEIN-1; HUMAN MALARIA PARASITE; BLOOD-STAGE ANTIGEN; MYCOBACTERIUM-TUBERCULOSIS; CIRCUMSPOROZOITE PROTEIN; HOST ERYTHROCYTE; SPOROZOITE; ANTIBODIES; SEQUENCE; DNA	We recently reported the discovery of a 17-kDa Plasmodium yoelii protein expressed in infected hepatocytes and erythrocytes, P. yoelii hepatocyte erythrocyte protein 17 (PyHEP17), and have demonstrated that this protein is a target of protective antibodies and T cells, Here, we report the identification and characterization of the gene encoding this protein and reveal that it is composed of two exons, Immunization of mice with PyHEP17 plasmid DNA induces antibodies, cytotoxic T lymphocytes, and protective immunity directed against the infected hepatocyte, Based on extensive sequence homology, expression pattern, and antigenic cross-reactivity, the Plasmodium falciparum homolog of PyHEP17 is identified as the protein known as exported protein-1 (PfExp-1), also called antigen 5.1, circumsporozoite related antigen, or QF116. Identity between PyHEP17 and PfExp-1 is 37% at the amino acid level (60/161 residues), mapping primarily to two regions within the second exon of 73% (16/22 residues) and 71% (25/35 residues) identity, On this basis, PfExp-1 is proposed as an important component of pre-erythrocytic human malaria vaccines.	UNIV MARYLAND,BALTIMORE,MD 21201; USN,MED RES INST,MALARIA PROGRAM,BETHESDA,MD 20889	University System of Maryland; University of Maryland Baltimore; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy			Doolan, Denise L/F-1969-2015	Doolan, Denise/0000-0001-7354-8817				ABOUZEID C, 1988, J GEN MICROBIOL, V134, P531; ANDERSEN P, 1991, INFECT IMMUN, V59, P1558, DOI 10.1128/IAI.59.4.1558-1563.1991; BROWN HJ, 1991, MOL BIOCHEM PARASIT, V49, P99, DOI 10.1016/0166-6851(91)90133-Q; CHAROENVIT Y, 1995, EXP PARASITOL, V80, P419, DOI 10.1006/expr.1995.1054; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPPEL RL, 1985, P NATL ACAD SCI USA, V82, P5121, DOI 10.1073/pnas.82.15.5121; DALY TM, 1992, MOL BIOCHEM PARASIT, V52, P279, DOI 10.1016/0166-6851(92)90061-N; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; FARLEY PJ, 1993, GENE AMST, V151, P335; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNTHER K, 1991, MOL BIOCHEM PARASIT, V46, P148; HARTIKKA J, 1996, IN PRESS HUM GENE TH, V7; HEDSTROM RC, 1990, B WORLD HEALTH ORGAN, V68, P152; HILL A, 1995, P NATL ACAD SCI USA, V92, P341, DOI 10.1073/pnas.92.2.341; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; HOPE IA, 1985, NUCLEIC ACIDS RES, V13, P369, DOI 10.1093/nar/13.2.369; KARA U, 1990, MOL BIOCHEM PARASIT, V38, P19, DOI 10.1016/0166-6851(90)90200-6; KEEN JK, 1994, MOL BIOCHEM PARASIT, V65, P171, DOI 10.1016/0166-6851(94)90125-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAL AA, 1987, J BIOL CHEM, V262, P2937; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; MCKERROW JH, 1990, EXP PARASITOL, V70, P134, DOI 10.1016/0014-4894(90)90094-S; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; ORME IM, 1992, J IMMUNOL, V148, P189; RAPTIS A, 1989, INFECT IMMUN, V57, P1725, DOI 10.1128/IAI.57.6.1725-1730.1989; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ GI, 1994, EXP PARASITOL, V79, P59, DOI 10.1006/expr.1994.1060; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SIMMONS D, 1987, EMBO J, V6, P485, DOI 10.1002/j.1460-2075.1987.tb04779.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TUNGPRADABKUL S, 1985, APPLICATION GENETIC, P51; UNANUE ER, 1992, CURR OPIN IMMUNOL, V4, P63, DOI 10.1016/0952-7915(92)90127-Z; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEBER JL, 1988, EXP PARASITOL, V66, P143, DOI 10.1016/0014-4894(88)90087-2; WORTMAN A, 1989, MICROB PATHOGENESIS, V6, P227, DOI 10.1016/0882-4010(89)90072-7; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	44	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17861	17868		10.1074/jbc.271.30.17861	http://dx.doi.org/10.1074/jbc.271.30.17861			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663412	hybrid			2022-12-25	WOS:A1996UY93500043
J	Bowen, MA; Bajorath, J; Siadak, AW; Modrell, B; Malacko, AR; Marquardt, H; Nadler, SG; Aruffo, A				Bowen, MA; Bajorath, J; Siadak, AW; Modrell, B; Malacko, AR; Marquardt, H; Nadler, SG; Aruffo, A			The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T DIFFERENTIATION ANTIGEN; HUMAN LYMPHOCYTES-T; MONOCLONAL-ANTIBODY; SURFACE; SUPERFAMILY; EXPRESSION; GLYCOPROTEIN; PROTEIN; FAMILY; PHOSPHORYLATION	Activated leukocyte cell adhesion molecule (ALCAM) was recently identified as a ligand for CD6, a signaling receptor expressed on T cells, a subset of B cells, and some cells in the brain. Receptor-Ligand binding assays, antibody blocking experiments, and examination of the tissue distribution of these two cell surface proteins suggest that CD6-ALCAM interactions play an important role in mediating the binding of thymocytes to thymic epithelial cells and of T cells to activated leukocytes. Presently, the details of CD6-ALCAM interactions and of signaling through CD6 are unknown, A series of truncated human ALCAM and CD6 immunoglobulin fusion proteins were produced and tested in different binding assays to analyze ALCAM-CD6 interactions in more detail, In this study, we report that the amino-terminal Ig-like domain of human ALCAM specifically binds to the third membrane-proximal scavenger receptor cysteine-rich (SRCR) domain of human CD6. Using thrombin-cleaved Ig fusion proteins containing single or multiple ALCAM or CD6 domains, we were able to determine that the stoichiometry of the interaction between the amino-terminal ALCAM domains and the membrane-proximal CD6 SRCR domain is 1:1. These results provide the first example of an Ig-like domain mediating an interaction with an SRCR domain.			Bowen, MA (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.		Bajorath, Jürgen/F-7493-2014					ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BAJORATH J, 1995, PROTEIN SCI, V4, P1644, DOI 10.1002/pro.5560040822; BASTIN JM, 1981, CLIN EXP IMMUNOL, V46, P597; BOTT CM, 1993, INT IMMUNOL, V5, P783, DOI 10.1093/intimm/5.7.783; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CARDENAS L, 1990, J IMMUNOL, V145, P1450; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; FARGEAS CA, 1995, J EXP MED, V182, P667, DOI 10.1084/jem.182.3.667; GANGEMI RMR, 1989, J IMMUNOL, V143, P2439; GUO Y, 1995, J EXP MED, V181, P1345, DOI 10.1084/jem.181.4.1345; KAMOUN M, 1981, J IMMUNOL, V127, P987; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KIENER PA, 1995, J IMMUNOL, V155, P4917; LANE RD, 1985, J IMMUNOL METHODS, V81, P223, DOI 10.1016/0022-1759(85)90207-8; LEDBETTER JA, 1989, MOL IMMUNOL, V26, P137, DOI 10.1016/0161-5890(89)90095-3; LINSLEY PS, 1995, RES IMMUNOL, V146, P130, DOI 10.1016/0923-2494(96)80246-X; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; MAYER B, 1990, J NEUROIMMUNOL, V29, P193, DOI 10.1016/0165-5728(90)90162-G; MORIMOTO C, 1988, J IMMUNOL, V140, P2165; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; PEACH RJ, 1995, J BIOL CHEM, V270, P21181, DOI 10.1074/jbc.270.36.21181; PEDUZZI JD, 1994, BRAIN RES, V640, P296, DOI 10.1016/0006-8993(94)91885-6; PESANDO JM, 1986, J IMMUNOL, V137, P3689; POURQUIE O, 1992, P NATL ACAD SCI USA, V89, P5261, DOI 10.1073/pnas.89.12.5261; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; SWACK JA, 1989, MOL IMMUNOL, V26, P1037, DOI 10.1016/0161-5890(89)90068-0; SWACK JA, 1991, J BIOL CHEM, V266, P7137; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; WEE SF, 1993, J EXP MED, V177, P219, DOI 10.1084/jem.177.1.219; WEE SF, 1994, CELL IMMUNOL, V158, P353, DOI 10.1006/cimm.1994.1282; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187	36	86	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17390	17396		10.1074/jbc.271.29.17390	http://dx.doi.org/10.1074/jbc.271.29.17390			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663238	hybrid			2022-12-25	WOS:A1996UX94300064
J	Jarosch, E; Tuller, G; Daum, G; Waldherr, M; Voskova, A; Schweyen, RJ				Jarosch, E; Tuller, G; Daum, G; Waldherr, M; Voskova, A; Schweyen, RJ			Mrs5p, an essential protein of the mitochondrial intermembrane space, affects protein import into yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL ACTIVATOR PROTEINS; COLI SHUTTLE VECTORS; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; INNER MEMBRANE; RESTRICTION SITES; SPLICING DEFECTS; GENE DISRUPTION; NUCLEAR; DNA	We have isolated a yeast nuclear gene that suppresses the previously described respiration-deficient mrs2-1 mutation when present on a multicopy plasmid, Elevated gene dosage of this new gene, termed MRS5, suppresses also the pet phenotype of a mitochondrial splicing-deficient group II intron mutation M1301. The MRS5 gene product, a 13-kDa protein of low abundance, shows no similarity to other known proteins and is associated with the inner mitochondrial membrane, protruding into the intermembrane space, MRS5 codes for an essential protein, as the disruption of this gene is lethal even during growth on fermentable carbon sources, Thus, the Mrs5 protein seems to be involved in mitochondrial key functions aside from oxidative energy conservation, which is dispensable in fermenting yeast cells, Depletion of MRs5p in yeast cells causes accumulation of unprocessed precursors of the mitochondrial hsp60 protein and defects in all cytochrome complexes, These findings suggest an essential role of Mrs5p in mitochondrial biogenesis.	UNIV VIENNA,INST MIKROBIOL & GENET,A-1030 VIENNA,AUSTRIA; GRAZ TECH UNIV,INST BIOCHEM & LEBENSMITTELCHEM,A-8010 GRAZ,AUSTRIA	University of Vienna; Graz University of Technology				Jarosch, Ernst/0000-0002-5897-3492				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUGUSTIN S, 1990, THESIS U VIENNA; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CIRIACY M, 1976, MOL GEN GENET, V145, P327, DOI 10.1007/BF00325831; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; *GEN COMP GROUP, 1994, GEN COMP GROUP VERS; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; KOLL H, 1987, CURR GENET, V12, P503; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD AT, 1992, NUCLEIC ACIDS RES, V20, P5289, DOI 10.1093/nar/20.20.5289; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MCCONNELL SJ, 1992, J CELL BIOL, V118, P385, DOI 10.1083/jcb.118.2.385; MCCONNELL SJ, 1990, J CELL BIOL, V111, P967, DOI 10.1083/jcb.111.3.967; MCMULLIN TW, 1993, J BIOL CHEM, V268, P11737; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RAGNINI A, 1994, CURR GENET, V26, P308, DOI 10.1007/BF00310494; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; VANDYCK E, 1995, MOL GEN GENET, V246, P426, DOI 10.1007/BF00290446; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; WIESENBERGER G, 1992, J BIOL CHEM, V267, P6963; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	48	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17219	17225		10.1074/jbc.271.29.17219	http://dx.doi.org/10.1074/jbc.271.29.17219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663351	hybrid			2022-12-25	WOS:A1996UX94300039
J	Kotenko, SV; Izotova, LS; Pollack, BP; Muthukumaran, G; Paukku, K; Silvennoinen, O; Ihle, JN; Pestka, S				Kotenko, SV; Izotova, LS; Pollack, BP; Muthukumaran, G; Paukku, K; Silvennoinen, O; Ihle, JN; Pestka, S			Other kinases can substitute for Jak2 in signal transduction by interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MUTANT-CELL LINE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; IL-2 RECEPTOR; ACCESSORY FACTOR; GROWTH-HORMONE; GENE FAMILY; ERYTHROPOIETIN RECEPTOR; PROLACTIN RECEPTORS	Each cytokine which utilizes the Jak-Stat signal transduction pathway activates a distinct combination of members of the Jak and Stat families. Thus, either the Jaks, the Stats, or both could contribute to the specificity of ligand action. With the use of chimeric receptors involving the interferon gamma receptor (IFN-gamma R) complex as a model system, we demonstrate that Jak2 activation is not an absolute requirement for IFN-gamma signaling. Other members of the Jak family can functionally substitute for Jak2. IFN-gamma can signal through the activation of Jak family members other than Jak2 as measured by Statl alpha homodimerization and major histocompatibility complex class I antigen expression. This indicates that Jaks are interchangeable and indiscriminative in the Jak-Stat signal transduction pathway. The necessity for the activation of one particular kinase during signaling can be overcome by recruiting another kinase to the receptor complex. The results may suggest that the Jaks do not contribute to the specificity of signal transduction in the Jak-Stat pathway to the same degree as Stats.	HELSINKI UNIV, DEPT VIROL, HELSINKI, FINLAND; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	University of Helsinki; St Jude Children's Research Hospital	Kotenko, SV (corresponding author), UNIV MED & DENT NEW JERSEY, DEPT MOLEC GENET & MICROBIOL, ROBERT WOOD JOHNSON MED SCH, PISCATAWAY, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R01CA046465, R01CA052363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA46465, R01-CA52363] Funding Source: Medline; NIAID NIH HHS [R01 AI36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AQUET M, 1988, CELL, V55, P273; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACH EA, 1995, FASEB J, V9, pA1021; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; BRISCOE J, 1995, J INTERFERON CYTOKIN, V15, pS56; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COHEN B, 1995, MOL CELL BIOL, V15, P4208; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EMANUEL S, 1995, THESIS RUTGERS U; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; LAI SY, 1995, FASEB J, V9, pA1021; LANGER JA, 1994, P NATL ACAD SCI USA, V91, P5818, DOI 10.1073/pnas.91.13.5818; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LIM J, 1995, THESIS RUTGERS U PIS; LIU Y, 1994, J IMMUNOL, V152, P1821; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARIANO TM, 1991, RECEPTOR BINDING STU, P95; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MUTHUKUMARAN G, 1995, J INTERFERON CYTOKIN, V15, pS70; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; REHBERG E, 1982, J BIOL CHEM, V257, P1497; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOH JM, 1994, J BIOL CHEM, V269, P18102; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TIAN SS, 1994, BLOOD, V84, P1760; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	99	82	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17174	17182		10.1074/jbc.271.29.17174	http://dx.doi.org/10.1074/jbc.271.29.17174			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663414	hybrid			2022-12-25	WOS:A1996UX94300032
J	Nikovits, W; Wang, GF; Feldman, JL; Miller, JB; Wade, R; Nelson, L; Stockdale, FE				Nikovits, W; Wang, GF; Feldman, JL; Miller, JB; Wade, R; Nelson, L; Stockdale, FE			Isolation and characterization of an avian slow myosin heavy chain gene expressed during embryonic skeletal muscle fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY REGULATED EXPRESSION; CELL-SPECIFIC EXPRESSION; ENHANCER-BINDING FACTOR; MESSENGER-RNAS; ALPHA-MYOSIN; THYROID-HORMONE; CARDIAC-MUSCLE; RETINOIC ACID; BETA; SEQUENCE	We have isolated and begun characterization of the quail slow myosin heavy chain (My HC) 3 gene, the first reported avian slow MyHC gene. Expression of slow MyHC 3 in skeletal muscle is restricted to the embryonic period of development, when the fiber pattern of future fast and slow muscle is established. In embryonic hind limb development, slow My HC 3 gene expression coincides with slow muscle fiber formation as distinguished by slow MyHC-specific antibody staining. In addition to expression in embryonic appendicular muscle, slow MyHC 3 is expressed continuously in the atria. Transfection of slow My HC 3 promoter-reporter constructs into embryonic myoblasts that form slow MyHC expressing fibers identified two regions regulating expression of this gene in skeletal muscle, The proximal promoter, containing potential muscle specific regulatory motifs, permits expression of a reporter gene in embryonic slow muscle fibers, while a distal element, located greater than 2600 base pairs upstream, further enhances expression 5-fold. The slow muscle fiber-restricted expression of slow MyHC 3 during embryonic development, and expression of slow MyHC 3 promoter-reporter constructs in embryonic muscle fibers in vitro, makes this gene a useful marker to study the mechanism establishing the slow fiber lineage in the embryo.	STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University				Miller, Jeffrey/0000-0001-5273-2201	NATIONAL CANCER INSTITUTE [T32CA009287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002822] Funding Source: NIH RePORTER; NCI NIH HHS [CA09287] Funding Source: Medline; NIA NIH HHS [AG02822] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; ASAKURA A, 1993, MOL CELL BIOL, V13, P7153, DOI 10.1128/MCB.13.11.7153; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BANDMAN E, 1982, DEV BIOL, V93, P508, DOI 10.1016/0012-1606(82)90138-5; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; CROW MT, 1986, DEV BIOL, V118, P333, DOI 10.1016/0012-1606(86)90002-3; CROW MT, 1986, DEV BIOL, V113, P238, DOI 10.1016/0012-1606(86)90126-0; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIMARIO JX, 1993, NATURE, V362, P165, DOI 10.1038/362165a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS D, 1988, DEV BIOL, V127, P376, DOI 10.1016/0012-1606(88)90324-7; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FRIEDMAN DJ, 1984, P NATL ACAD SCI-BIOL, V81, P3044, DOI 10.1073/pnas.81.10.3044; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GULICK J, 1991, J BIOL CHEM, V266, P9180; GULICK J, 1987, EUR J BIOCHEM, V169, P79, DOI 10.1111/j.1432-1033.1987.tb13583.x; HOH JFY, 1976, BIOCHEM J, V157, P87, DOI 10.1042/bj1570087; HOH JFY, 1979, FEBS LETT, V98, P267, DOI 10.1016/0014-5793(79)80197-0; HUGHES SM, 1993, DEV BIOL, V158, P183, DOI 10.1006/dbio.1993.1178; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KENNEDY JM, 1986, J CELL BIOL, V103, P977, DOI 10.1083/jcb.103.3.977; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KROPP K, 1986, J BIOL CHEM, V261, P6613; KROPP KE, 1987, J BIOL CHEM, V262, P16536; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; Maniatis T., 1982, MOL CLONING; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MATSUDA R, 1982, DIFFERENTIATION, V23, P36, DOI 10.1111/j.1432-0436.1982.tb01265.x; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; MILLER DM, 1986, P NATL ACAD SCI USA, V83, P2305, DOI 10.1073/pnas.83.8.2305; MILLER JB, 1985, J CELL BIOL, V101, P1643, DOI 10.1083/jcb.101.5.1643; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; PAGE S, 1992, DEV BIOL, V154, P118, DOI 10.1016/0012-1606(92)90053-J; PARKERTHORNBURG J, 1992, DEV BIOL, V150, P99, DOI 10.1016/0012-1606(92)90010-E; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PIEROBON BORMIOLI S, 1980, J CELL BIOL, V85, P672, DOI 10.1083/jcb.85.3.672; REISER PJ, 1988, DEV BIOL, V129, P400, DOI 10.1016/0012-1606(88)90387-9; ROBBINS J, 1986, J BIOL CHEM, V261, P6606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SCHAFER DA, 1987, CELL, V48, P659, DOI 10.1016/0092-8674(87)90244-3; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TERMIN A, 1989, HISTOCHEMISTRY, V92, P453, DOI 10.1007/BF00524756; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; UMEDA PK, 1981, P NATL ACAD SCI-BIOL, V78, P2843, DOI 10.1073/pnas.78.5.2843; VIVARELLI E, 1988, J CELL BIOL, V107, P2191, DOI 10.1083/jcb.107.6.2191; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	63	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17047	17056		10.1074/jbc.271.29.17047	http://dx.doi.org/10.1074/jbc.271.29.17047			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663323	hybrid			2022-12-25	WOS:A1996UX94300013
J	Rzymkiewicz, DM; Tetsuka, T; DaphnaIken, D; Srivastava, S; Morrison, AR				Rzymkiewicz, DM; Tetsuka, T; DaphnaIken, D; Srivastava, S; Morrison, AR			Interleukin-1 beta activates protein kinase C zeta in renal mesangial cells - Potential role in prostaglandin E(2) up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-INDUCED DIFFERENTIATION; PHORBOL ESTER; SIGNAL-TRANSDUCTION; PC12 CELLS; RAT; ALPHA; ISOENZYMES; EXPRESSION; INHIBITION; EPSILON	Protein kinase C (PKC) plays a rob in signal transduction mediated by interleukin-1 beta (IL-1 beta) leading to the increase in prostaglandin E(2) (PGE(2)) production. In the present study we suggest that there are at least two distinct PKC isotypes involved in the signaling mechanism. Staurosporine potentiated the effect of IL-1 beta on coxII mRNA expression while calphostin C totally inhibited mRNA expression. The down-regulation of PKC by growing mesangial cells in the presence of phorbol 12-myristate 13-acetate for 24 h failed to modify the upregulated response in PGE(2) formation by IL-1 beta. Furthermore, incubation of mesangial cells with IL-1 beta causes translocation of PKC zeta from cytosol to a presumed membrane compartment, and this translocation phenomenon was not inhibited by incubating the cells with staurosporine but was inhibited with calphostin C. Gel retardation assays also demonstrated that staurosporine did not inhibit the IL-1 beta-stimulated binding of nuclear extracts to the NF kappa B motif. In contrast, calphostin C inhibited binding to the kappa B motif in a dose-dependent manner. Finally, antisense oligonucleotides to PKC zeta partially inhibited the IL-1 beta-induced PGE(2) formation while control sense oligonucleotides were without effect. Taken together, these data suggest that PKC zeta is involved in the IL-1 beta signaling responses.	WASHINGTON UNIV, DEPT MED, SCH MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOLEC BIOL, SCH MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT PHARMACOL, SCH MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL 20787] Funding Source: Medline; NIDDK NIH HHS [DK 38111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; COLEMAN ES, 1994, J MOL NEUROSCI, V5, P39, DOI 10.1007/BF02736693; COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97; DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; HABIB T, 1994, J BIOL CHEM, V269, P25243; HATA A, 1993, J BIOL CHEM, V268, P9122; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUWILER A, 1991, BIOCHEM BIOPH RES CO, V180, P1422, DOI 10.1016/S0006-291X(05)81355-5; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; LARIVEE P, 1994, AM J RESP CELL MOL, V11, P199, DOI 10.1165/ajrcmb.11.2.8049080; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RZYMKIEWICZ DM, 1995, KIDNEY INT, V47, P1354, DOI 10.1038/ki.1995.191; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TISCHLER AS, 1991, J BIOL CHEM, V266, P1141; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WOLF M, 1985, J BIOL CHEM, V260, P5718; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395	29	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17241	17246		10.1074/jbc.271.29.17241	http://dx.doi.org/10.1074/jbc.271.29.17241			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663336	hybrid			2022-12-25	WOS:A1996UX94300042
J	Sun, WM; Williams, CH; Massey, V				Sun, WM; Williams, CH; Massey, V			Site-directed mutagenesis of glycine 99 to alanine in L-lactate monooxygenase from Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH GLYCOLATE OXIDASE; AMINO-ACID-SEQUENCE; ACTIVE-SITE; ESCHERICHIA-COLI; BAKERS-YEAST; FLAVOCYTOCHROME-B2; MECHANISM; SUBSTRATE; DEHYDROGENASE; FLAVOPROTEINS	L-Lactate monooxygenase (LMO) hom Mycobacterium smegmatis was mutated at glycine 99 to alanine, and the properties of the resulting mutant (referred to as G99A) were studied, Mutant G99A of LMO was designed to test the postulate that the smaller glycine residue in the vicinity of the alpha-carbon methyl group of lactate in wild-type LMO has less steric hindrance, leading to the retention and oxidative decarboxylation of pyruvate in the active site, a unique property of LMO in contrast to other members of the FMN-dependent oxidase/dehydrogenase family, G99A has been shown to be readily reduced by L-lactate at a rate similar to that of the wild-type enzyme. The binding of pyruvate to reduced G99A is 4-fold weaker than that to the wild-type enzyme. A dramatic change of this mutation is that G99A has a much lower oxygen reactivity than the wild-type enzyme. Pyruvate-bound reduced G99A reacts with O-2 at a rate similar to 10(5)-fold slower than the wild-type enzyme, and free reduced G99A reacts with O-2 at a rate similar to 100-fold slower than the wild-type enzyme. Due to the very low oxygen reactivity of the pyruvate-bound reduced enzyme, G99A has been shown to catalyze the oxidation of L-lactate to pyruvate and hydrogen peroxide instead of acetate, carbon dioxide, and water, the normal decarboxylation products of pyruvate and hydrogen peroxide. Thus, the mutation alters the enzyme from its L-lactate monooxygenase activity to L-lactate oxidase activity, However, compared with L-lactate oxidase, G99A has a much lower reactivity toward oxygen Our results also reveal that the small steric change around N-5 of the flavin causes a profound change in the electronic distribution in the catalytic cavity of the enzyme and imply that electrostatic interactions in the active site provide an important factor for control of O-2 reactivity.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; DEPT VET AFFAIRS MED CTR,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21444, GM 11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bevington P. R., 1969, DATA REDUCTION ERROR, P235; CEDERLUND E, 1988, EUR J BIOCHEM, V173, P523, DOI 10.1111/j.1432-1033.1988.tb14029.x; CHOONG YS, 1980, J BIOL CHEM, V255, P8672; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1976, BIOCHEMISTRY-US, V15, P1791, DOI 10.1021/bi00654a002; GHISLA S, 1975, J BIOL CHEM, V250, P577; GHISLA S, 1979, J BIOL CHEM, V254, P662; GHISLA S, 1976, FLAVINS FLAVOPROTEIN, P213; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIEGEL DA, 1990, J BIOL CHEM, V265, P6626; HAYAISHI O, 1957, J AM CHEM SOC, V79, P4809, DOI 10.1021/ja01574a060; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE KHD, 1991, J BIOL CHEM, V266, P20877; LEDERER F, 1985, EUR J BIOCHEM, V152, P419, DOI 10.1111/j.1432-1033.1985.tb09213.x; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MANSTEIN DJ, 1988, BIOCHEMISTRY-US, V27, P2300, DOI 10.1021/bi00407a009; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1980, J BIOL CHEM, V255, P2796; MASSEY V, 1977, J BIOL CHEM, V252, P5612; Muh U, 1994, FLAVINS AND FLAVOPROTEINS 1993, P201; MUH U, 1994, J BIOL CHEM, V269, P7982; MUH U, 1994, J BIOL CHEM, V269, P7994; MUH U, 1994, J BIOL CHEM, V269, P7989; SCHONBRUNN A, 1976, BIOCHEMISTRY-US, V15, P1798, DOI 10.1021/bi00654a003; SMEKAL O, 1993, BIOCHEM J, V290, P103, DOI 10.1042/bj2900103; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; SULLIVAN PA, 1977, BIOCHEM J, V165, P375, DOI 10.1042/bj1650375; SULLIVAN PA, 1968, BIOCHEM J, V110, P363, DOI 10.1042/bj1100363; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; VOLOKITA M, 1987, J BIOL CHEM, V262, P15825; WALSH CT, 1971, J BIOL CHEM, V246, P6855; WALSH CT, 1972, J BIOL CHEM, V247, P6004; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	39	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17226	17233		10.1074/jbc.271.29.17226	http://dx.doi.org/10.1074/jbc.271.29.17226			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663383	hybrid			2022-12-25	WOS:A1996UX94300040
J	Jensen, PE; Gibson, LCD; Henningsen, KW; Hunter, CN				Jensen, PE; Gibson, LCD; Henningsen, KW; Hunter, CN			Expression of the chlI, chlD, and chlH genes from the cyanobacterium Synechocystis PCC6803 in Escherichia coli and demonstration that the three cognate proteins are required for magnesium-protoporphyrin chelatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MG-CHELATASE; CHLOROPHYLL BIOSYNTHESIS; ARABIDOPSIS-THALIANA; CLUSTER; ASSAY; ATP; IX	Magnesium-protoporphyrin chelatase catalyzes the first step unique to chlorophyll synthesis: the insertion of Mg2+ into protoporphyrin IX, Genes from Synechocystis sp, PCC6803 with homology to the bchI and bchD genes of Rhodobacter sp, were cloned using degenerate oligonucleotides. The function of these genes, putatively encoding subunits of magnesium chelatase, was established by overexpression in Escherichia coli, including the overexpression of Synechocystis chlH, previously cloned as a homolog of the Rhodobacter bchH gene, The combined cell-free extracts were able to catalyze the insertion of Mg2+ into protoporphyrin IX in an ATP-dependent manner and only when the products of all three genes were present, The ChlH, ChlI, and ChlD gene products are therefore assigned to the magnesium chelatase step in chlorophyll a biosynthesis in Synechocystis PCC6803, The primary structure of the Synechocystis ChlD protein reveals some interesting features; the N-terminal half of the protein shows 40-41% identity to Rhodobacter BchI and Synechocystis ChlI, whereas the C-terminal half displays 33% identity to Rhodobacter BchD, This suggests a functional as well as an evolutionary relationship between the ''I'' and ''D'' genes.	UNIV SHEFFIELD,ROBERT HILLS INST PHOTOSYNTHESIS,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; ROYAL VET & AGR UNIV,DEPT ECOL & MOLEC BIOL,DK-1870 FREDERIKSBERG C,DENMARK; CARLSBERG LAB,DEPT PHYSIOL,DK-2500 COPENHAGEN,DENMARK	University of Sheffield; University of Copenhagen	Jensen, PE (corresponding author), UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND.		Jensen, Poul Erik/A-4862-2014	Jensen, Poul Erik/0000-0001-6524-7723				ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CASTELFRANCO PA, 1979, ARCH BIOCHEM BIOPHYS, V192, P592, DOI 10.1016/0003-9861(79)90130-9; COOMBER SA, 1990, MOL MICROBIOL, V4, P977, DOI 10.1111/j.1365-2958.1990.tb00670.x; COWAN PM, 1955, NATURE, V176, P501, DOI 10.1038/176501a0; FUESLER TP, 1981, PLANT PHYSIOL, V67, P246, DOI 10.1104/pp.67.2.246; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; Gibson LCD, 1996, PLANT PHYSIOL, V111, P61, DOI 10.1104/pp.111.1.61; HENNINGSEN KW, 1993, BIOL SKRIFTER, V42, P1; HUDSON A, 1993, EMBO J, V12, P3711, DOI 10.1002/j.1460-2075.1993.tb06048.x; Jensen P., 1996, PLANT MOL BIOL, V30, P1075; Jensen PE, 1996, MOL GEN GENET, V250, P383; KONCZ C, 1990, EMBO J, V9, P1337, DOI 10.1002/j.1460-2075.1990.tb08248.x; Kotani H, 1995, DNA Res, V2, P133, DOI 10.1093/dnares/2.3.133; Kotani H, 1994, DNA Res, V1, P303, DOI 10.1093/dnares/1.6.303; LEE HJ, 1992, PLANT PHYSIOL, V99, P1134, DOI 10.1104/pp.99.3.1134; ORSAT B, 1992, FEBS LETT, V303, P181, DOI 10.1016/0014-5793(92)80514-H; PARDO AD, 1980, PLANT PHYSIOL, V65, P956, DOI 10.1104/pp.65.5.956; RICHTER ML, 1982, BIOCHIM BIOPHYS ACTA, V717, P255, DOI 10.1016/0304-4165(82)90177-5; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 2002, MOL CLONING LAB MANU; von Wettstein D., 1971, AUTONOMY BIOGENESIS, P205; WALKER CJ, 1991, P NATL ACAD SCI USA, V88, P5789, DOI 10.1073/pnas.88.13.5789; WALKER CJ, 1994, BIOCHEM J, V299, P277, DOI 10.1042/bj2990277; WALKER CJ, 1992, PLANT PHYSIOL BIOCH, V30, P263; WALKER CJ, 1995, PHYSIOL PLANTARUM, V94, P419, DOI 10.1111/j.1399-3054.1995.tb00948.x; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8	28	118	130	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16662	16667		10.1074/jbc.271.28.16662	http://dx.doi.org/10.1074/jbc.271.28.16662			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663186	hybrid			2022-12-25	WOS:A1996UX12600039
J	Jiang, N; He, TC; Miyajima, A; Wojchowski, DM				Jiang, N; He, TC; Miyajima, A; Wojchowski, DM			The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CYTOKINE RECEPTORS; SIGNAL-TRANSDUCTION; TYROSINE KINASES; GROWTH; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; SUPERFAMILY; JAK	Several distinct classes of cytokine receptors engage Jak kinases as primary effecters. Among type 1 receptors, Janus activated kinase (Jak) recruitment is mediated by membrane-proximal cytoplasmic domains, which typically contain conserved box motifs. In the erythropoietin receptor (Epo-R), two such motifs (box1 and box2) have been suggested to be essential for the activation of Jak2 and mitogenesis, Presently, an Epo-R chimera containing the extracellular and box1 domains of the Epo-R (Jak2-associated receptor) and the box2 and carboxyl-terminal domains of the interleukin 2 beta-receptor (IL2 beta-R; a Jak1-associated subunit) is shown to activate Jak2. Interestingly, Jak2 also was activated in FDC-beta 1 cells by a control Epo-R chimera containing the complete IL2 beta-R cytoplasmic domain, and mitogenesis was supported by each of these above chimeras. By comparison, in BaF3 cells expressing IL2 receptor alpha and gamma subunits, an ectopically expressed IL2 beta-R chimera containing the box1 domain of the Epo-R, activated Jak2 and Jak3 and was as mitogenically active as the wild-type IL2 beta-R (Jak1 and Jak3 activation). Thus, the box1 domain of the Epo-R specifies Jak2 activation and functions efficiently within a heterologous IL2 receptor complex that normally activates Jak1 and Jak8.	PENN STATE UNIV,GRAD PROGRAM PATHOBIOL & VET SCI,UNIVERSITY PK,PA 16802; PENN STATE UNIV,GRAD PROGRAM GENET,UNIVERSITY PK,PA 16802; PENN STATE UNIV,GRAD PROGRAM BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIVERSITY PK,PA 16802; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,TOKYO,JAPAN	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Tokyo					NHLBI NIH HHS [HL03042] Funding Source: Medline; NIDDK NIH HHS [DK40242] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040242, R01DK040242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V186, P1236, DOI 10.1016/S0006-291X(05)81538-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EDERY M, 1994, MOL CELL ENDOCRINOL, V102, P39, DOI 10.1016/0303-7207(94)90095-7; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HE TC, 1994, J BIOL CHEM, V269, P18291; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANO H, 1995, BLOOD, V85, P343; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	39	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16472	16476		10.1074/jbc.271.28.16472	http://dx.doi.org/10.1074/jbc.271.28.16472			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663338	hybrid			2022-12-25	WOS:A1996UX12600010
J	Krause, U; Rider, MH; Hue, L				Krause, U; Rider, MH; Hue, L			Protein kinase signaling pathway triggered by cell swelling and involved in the activation of glycogen synthase and Acetyl-CoA carboxylase in isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; GROWTH-FACTOR; S6 KINASE; LIVER; MECHANISM; GLUCOSE; PURIFICATION; STIMULATION; INHIBITION	Incubation of isolated hepatocytes with glutamine or proline or in hypotonic media is known to activate glycogen synthase and acetyl-CoA carboxylase as a result of cell swelling, We report here that the same experimental conditions caused an activation of phosphatidylinositol 3-kinase and p70 ribosomal protein S6 kinase (p70 S6 kinase) but did not modify the activity of p42 mitogen activated protein kinase, In addition, rapamycin, an inhibitor of p70 S6 kinase activation, prevented the amino acid and hypotonicity-induced activation of p70 S6 kinase but did not block the activation of glycogen synthase and acetyl-CoA carboxylase, thus ruling out p70 Se kinase as a necessary component in the activation pathway, By contrast, wortmannin or LY294002, inhibitors of phosphatidylinositol 3-kinase, completely blocked the activation of phosphatidylinositol 3-kinase and p70 S6 kinase and partly blocked the activation of glycogen synthase and acetyl-CoA carboxylase, Therefore, phosphatidylinositol 3-kinase might be a component of the signaling pathway that is triggered by cell swelling and is responsible, at least in part, for the activation of glycogen synthase and acetyl CoA carboxylase, Incubation of hepatocytes with 0.1 mu M epidermal growth factor doubled the activity of p42 mitogen-activated protein kinase without activating glycogen synthase.	UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								AGIUS L, 1994, BIOCHEM SOC T, V22, P516, DOI 10.1042/bst0220516; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAQUET A, 1991, BIOCHEM J, V278, P887, DOI 10.1042/bj2780887; BAQUET A, 1990, J BIOL CHEM, V265, P955; BAQUET A, 1993, EUR J BIOCHEM, V217, P1083, DOI 10.1111/j.1432-1033.1993.tb18340.x; BIJLEVELD C, 1987, BIOCHIM BIOPHYS ACTA, V918, P274, DOI 10.1016/0005-2760(87)90231-1; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BORTHWICK AC, 1990, BIOCHEM J, V270, P795, DOI 10.1042/bj2700795; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BURGERING MT, 1995, NATURE, V276, P599; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gaussin V, 1996, BIOCHEM J, V316, P217, DOI 10.1042/bj3160217; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HUE L, 1978, BIOCHEM J, V176, P791, DOI 10.1042/bj1760791; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; ITOH T, 1995, FEBS LETT, V373, P123, DOI 10.1016/0014-5793(95)01028-D; KOHN AD, 1995, AMBO J, V14, P4288; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAVOINNE A, 1987, BIOCHEM J, V248, P429, DOI 10.1042/bj2480429; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; TILLY BC, 1993, J BIOL CHEM, V268, P19919; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729	45	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16668	16673		10.1074/jbc.271.28.16668	http://dx.doi.org/10.1074/jbc.271.28.16668			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663301	hybrid			2022-12-25	WOS:A1996UX12600040
J	PuzonMcLaughlin, W; Yednock, TA; Takada, Y				PuzonMcLaughlin, W; Yednock, TA; Takada, Y			Regulation of conformation and ligand binding function of integrin alpha 5 beta 1 by the beta 1 cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBRONECTIN RECEPTOR; SITE-DIRECTED MUTAGENESIS; PLATELET GLYCOPROTEIN-IIB; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; CROSS-LINKING; GPIIB-IIIA; T-CELLS; SUBUNIT; ADHESION	We have studied the role of the cytoplasmic domain in the conformation and affinity modulation of the integrin beta 1. Expression of a conformation dependent anti-beta 1 antibody 15/7 correlates with activation in wild-type beta 1. Truncation of 16 carboxyl-terminal residues in the cytoplasmic domain (the 762t beta 1 mutant) induces constitutive expression of the 15/7 epitope at a high level (which probably reflects a major conformational change of the extracellular domain) but does not activate ligand binding. The dissociation of epitope expression and affinity suggests that the epitope expression reflects the conformation of nonligand binding sites of the extracellular domain of beta 1 but does not necessarily reflect that of the ligand binding sites. Indeed we discovered that the 15/7 epitope is in fact located in the nonligand binding region of beta 1 (within residues 354-425). The 762t mutant has apparently normal alpha/beta association, suggesting that the overexpression of the 15/7 epitope is not due to alpha/beta dissociation. The data suggest that the carboxyl-terminal 16 residues of the beta 1 cytoplasmic domain are critical for properly modulating conformation and affinity of beta 1 integrins.	Scripps Res Inst, RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; ATHENA NEUROSCI, San Francisco, CA 94080 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; CARLOS TM, 1994, BLOOD, V84, P2068; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CROWE DT, 1994, J BIOL CHEM, V269, P14411; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GULINO D, 1995, EUR J BIOCHEM, V227, P108, DOI 10.1111/j.1432-1033.1995.tb20365.x; HAAS TA, 1993, THROMB HAEMOSTASIS, V69, P1022; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; Hemler M.E, 1994, INTEGRINS BIOL PROBL, P1; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PHILLIPS DR, 1988, BLOOD, V71, P831; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUB R, 1989, J BIOL CHEM, V264, P259; THE TH, 1970, IMMUNOLOGY, V18, P865; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; YAMADA A, 1991, EUR J IMMUNOL, V21, P319, DOI 10.1002/eji.1830210212; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	62	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16580	16585		10.1074/jbc.271.28.16580	http://dx.doi.org/10.1074/jbc.271.28.16580			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663265				2022-12-25	WOS:A1996UX12600026
J	Yanai, K; Nibu, Y; Murakami, K; Fukamizu, A				Yanai, K; Nibu, Y; Murakami, K; Fukamizu, A			A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; TRANSGENIC MICE; BINDING PROTEIN; TFIID COMPLEX; HUMAN RENIN; PROMOTER; EXPRESSION; MECHANISM; ENHANCER; SYSTEM	The promoter of the human angiotensinogen (hAG) gene functioned in its own core promoter context but not when replaced with simian virus 40 (SV40) core promoter, suggesting the presence of a transcriptionally important cis-acting sequence, Electrophoretic mobility shift assays demonstrated that a ubiquitously expressed nuclear factor, AGCF1, bound to AGCE1 (hAG core promoter element I; positions -25 to -1) located between the TATA box and transcription initiation site. Substitution mutation in AGCE 1 which disrupted AGCF1 binding affected the promoter activity more severely than a nonsense mutation of the hAG TATA sequences did, When AGCE1 was placed at the downstream of SV40 core promoter, the responsiveness to hAG upstream re gion was significantly restored. Furthermore, mutation and in vivo competition experiments suggested that AGCF1 acts as a critical regulator of hAG transcription by mediating the activity of the hAG upstream and downstream enhancer elements, DNase I footprinting and UV cross-linking analyses showed that AGCF1 with apparent molecular masses of 31, 33, and 43 kDa as the components protected the region from -26 to -9 which partially overlapped with the TATA box consensus sequences, These findings indicate that AGCE 1 in addition to the TATA box plays a key role in mediating the hAG regulatory elements.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba			fukamizu, akiyoshi/J-5350-2012; Nibu, Yutaka/J-4136-2019	fukamizu, akiyoshi/0000-0002-8786-6020; Nibu, Yutaka/0000-0002-4696-7503				AIRD WC, 1994, J BIOL CHEM, V269, P883; BKER KM, 1992, ANN REV PHYSL, V54, P227; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1994, J BIOL CHEM, V269, P31252; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERNANDEZ N, 1993, GENE DEV, V7, P1219; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4458; LANG D, 1993, J VIROL, V67, P323, DOI 10.1128/JVI.67.1.323-331.1993; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NIBU Y, 1994, J BIOL CHEM, V269, P28598; NIBU Y, 1994, BIOCHEM BIOPH RES CO, V205, P1102, DOI 10.1006/bbrc.1994.2779; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SHIMADA S, 1995, ENDOCRINE, V3, P543, DOI 10.1007/BF02738831; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TERRIEN M, 1991, MOL CELL BIOL, V11, P3492; THEILL LE, 1987, MOL CELL BIOL, V7, P4329, DOI 10.1128/MCB.7.12.4329; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V	40	78	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15981	15986		10.1074/jbc.271.27.15981	http://dx.doi.org/10.1074/jbc.271.27.15981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663141	hybrid			2022-12-25	WOS:A1996UW35200023
J	Leterrier, JF; Kas, J; Hartwig, J; Vegners, R; Janmey, PA				Leterrier, JF; Kas, J; Hartwig, J; Vegners, R; Janmey, PA			Mechanical effects of neurofilament cross-bridges - Modulation by phosphorylation, lipids, and interactions with F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT PROTEIN VIMENTIN; SLOW AXONAL-TRANSPORT; QUICK-FREEZE; INVITRO; VISCOELASTICITY; MICROTUBULES; CYTOSKELETON; PURIFICATION; IMPAIRMENT; SUBUNITS	The structure of gels formed by bovine spinal cord neurofilaments was determined by fluorescence and electron microscopy and compared to mechanical properties measured by their elastic and viscous response to shear forces. Neurofilaments formed gels of high elastic modulus (>100 Pa) after addition of millimolar Mg2+. Gelation caused a slow increase in shear moduli to levels similar to those of vimentin intermediate filament networks, followed by a rapid rise due to formation of links between neurofilaments, mediated by cross-bridging structures that vimentin filaments lack. Neurofilament gels are more resistant to large deformations than are vimentin networks, suggesting the importance of cross-bridges for neurofilament mechanical properties. Fluorescence imaging of single neurofilaments showed flexible filaments that became straighter when they adhered to glass or were incorporated into filament bundles. Electron microscopy of neurofilament gels showed a system of bundles intertwined within a more isotropic network of individual filaments. Neurofilament gel formation was stimulated in vitro by acid phosphatase treatment or by inositol phospholipids. In contrast, addition of actin filaments reduced the resistance of neurofilament gels to large stresses. These results suggest that dynamic and regulated interactions occur between neurofilaments to form viscoelastic networks with properties distinct from other cytoskeletal structures.	BRIGHAM & WOMENS HOSP,DIV EXPTL MED,BOSTON,MA 02115; CHRU,U298 INSERM,F-49033 ANGERS,FRANCE; LATVIAN INST ORGAN SYNTH,RIGA 1006,LATVIA; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Latvian Institute of Organic Synthesis; Harvard University; Harvard Medical School				Kas, Josef A./0000-0003-3158-2480	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038910, R01AR038910] Funding Source: NIH RePORTER; FIC NIH HHS [TW00100] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALMAHBOHI G, 1990, J CELL SCI, P679; BIZZI A, 1984, J NEUROSCI, V4, P722; BROWN A, 1995, CELL MOTIL CYTOSKEL, V31, P9, DOI 10.1002/cm.970310103; CARY RB, 1994, J CELL SCI, V107, P1609; EAGLES PAM, 1990, CELLULAR MOL BIOL IN, P37; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; EYER J, 1989, J NEUROCHEM, V52, P1759, DOI 10.1111/j.1471-4159.1989.tb07254.x; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FARGE E, 1993, MACROMOLECULES, V26, P5041, DOI 10.1021/ma00071a009; FATH KR, 1988, J CELL BIOL, V107, P613, DOI 10.1083/jcb.107.2.613; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; GOTOW T, 1992, EUR J CELL BIOL, V58, P331; GOTOW T, 1994, J CELL SCI, V107, P1949; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; GOU JP, 1995, BIOCHEM BIOPH RES CO, V215, P368, DOI 10.1006/bbrc.1995.2475; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; HERIOT K, 1985, J CELL BIOL, V100, P1167, DOI 10.1083/jcb.100.4.1167; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; HISANAGA SI, 1988, J MOL BIOL, V20, P297; HORKOVICSKOVATS S, 1990, BIOCHEMISTRY-US, V29, P8652, DOI 10.1021/bi00489a022; ITOH T, 1992, ACTA NEUROPATHOL, V83, P240, DOI 10.1007/BF00296785; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; JANMEY PA, 1994, ANN T NORDIC RHEOLOG, P8; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LETERRIER JF, 1984, J NEUROCHEM, V43, P1385, DOI 10.1111/j.1471-4159.1984.tb05398.x; LETERRIER JF, 1992, J NEUROCHEM, V58, P2060, DOI 10.1111/j.1471-4159.1992.tb10947.x; LETERRIER JF, 1991, AIP CONF PROC, V226, P91; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; LETERRIER JF, 1987, BIOCHEM J, V245, P93, DOI 10.1042/bj2450093; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; MACKINTOSH FC, 1995, PHYS REV LETT, V75, P4425, DOI 10.1103/PhysRevLett.75.4425; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; MIYASAKA H, 1993, J BIOL CHEM, V268, P22695; NAGELE RG, 1988, BRAIN RES, V474, P279, DOI 10.1016/0006-8993(88)90441-6; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; NELSON WJ, 1982, J BIOL CHEM, V257, P5536; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; PAPASOZOMENOS SC, 1985, J CELL BIOL, V100, P74, DOI 10.1083/jcb.100.1.74; ROGERS KR, 1995, EUR J CELL BIOL, V66, P136; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STARR R, 1995, J NEUROCHEM, V64, P1860; TRAUB P, 1987, EUR J CELL BIOL, V43, P55; YAMAUCHI PS, 1993, BIOCHEM BIOPH RES CO, V190, P710, DOI 10.1006/bbrc.1993.1107	51	149	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15687	15694		10.1074/jbc.271.26.15687	http://dx.doi.org/10.1074/jbc.271.26.15687			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663092	hybrid			2022-12-25	WOS:A1996UV29900059
J	Sun, DM; Leung, CL; Liem, RKH				Sun, DM; Leung, CL; Liem, RKH			Phosphorylation of the high molecular weight neurofilament protein (NF-H) by Cdk5 and p35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES DISTINGUISH; NEURONAL INTERMEDIATE FILAMENTS; TAU-PROTEIN; KINASE-II; MAMMALIAN NEUROFILAMENTS; CDC2 KINASE; EXPRESSION; SEQUENCE; SUBUNIT; POLYPEPTIDES	The high molecular weight neurofilament protein (NF-H) is highly phosphorylated in the axon. The phosphorylation sites have been identified as KSP (Lys-Ser-Pro) repeats in the tail domain of NF-H. These KSP sequences are present more than 50 times in the NF-H tail, and most of these sites are normally phosphorylated in vivo. These RSP sites can be further divided into two separate consensus sequences, KSPXK and KSPXY (where Y is not K). The extensive phosphorylation of NF-H has been proposed to play a critical role in the determination of axonal diameter. Recent studies have shown that Cdk5, a kinase related to the cell cycle-dependent kinase Cdc2, is expressed in the brain and associates with the cytoskeleton. In vitro phosphorylation studies have shown that Cdk5 in conjunction with its activator, p35, is able to phosphorylate histone H1, dephosphorylated NF-H, as well as a synthetic peptide with the repetitive KSP motif. We have cloned the cDNAs for rat Cdk5 and p35 by reverse transcription-polymerase chain reaction and cDNA library screening and studied the phosphorylation of NF-H both in vivo and in vitro. By transient transfection assays, we have shown that NF-H can only be extensively phosphorylated in the presence of both Cdk5 and p35. This phosphorylation can be inhibited by a Cdk5-dominant negative mutant, an observation which further supports that Cdk5 is a kinase that is able to phosphorylate NF-H. By immunoprecipitating Cdk5 and p35 from the transfected cells, we have been able to show that the KSPXK repeats are the preferred phosphorylation sites for Cdk5, while the KSPXY repeats are not directly phosphorylated by Cdk5 and p35.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013185] Funding Source: NIH RePORTER; NIA NIH HHS [AG00189, AG13185] Funding Source: Medline; NINDS NIH HHS [NS15182] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; DOSEMECI A, 1990, CELL MOL NEUROBIOL, V10, P369, DOI 10.1007/BF00711181; DOSEMECI A, 1992, BIOCHEM J, V282, P477, DOI 10.1042/bj2820477; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; FLIEGNER KH, 1991, INT REV CYTOL, V131, P109, DOI 10.1016/S0074-7696(08)62018-5; FLOYD CC, 1991, J BIOL CHEM, V266, P4987; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1989, J NEUROSCI, V9, P959; HISANAGA S, 1993, J BIOL CHEM, V268, P15056; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; KAPLAN MP, 1991, J NEUROSCI RES, V30, P45; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LIEM RKH, 1985, ANN NY ACAD SCI, V455, P492, DOI 10.1111/j.1749-6632.1985.tb50431.x; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Sambrook J., 2002, MOL CLONING LAB MANU; SATTIA AJ, 1990, J CELL BIOL, V111, P553; SHAW G, 1991, NEURONAL CYTOSKELETO, P185; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; SHETTY KTV, 1995, J NEUROCHEM, V64, P2681; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VALLANO ML, 1985, BIOCHEM BIOPH RES CO, V130, P957, DOI 10.1016/0006-291X(85)91708-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WONG J, 1984, J BIOL CHEM, V259, P867; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; XIAO J, 1994, J NEUROSCI, V14, P820; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	57	123	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14245	14251		10.1074/jbc.271.24.14245	http://dx.doi.org/10.1074/jbc.271.24.14245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662984	hybrid			2022-12-25	WOS:A1996UQ66000048
J	Tolchinsky, S; Yuk, MH; Ayalon, M; Lodish, HF; Lederkremer, GZ				Tolchinsky, S; Yuk, MH; Ayalon, M; Lodish, HF; Lederkremer, GZ			Membrane-bound versus secreted forms of human asialoglycoprotein receptor subunits - Role of a juxtamembrane pentapeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL SIGNAL SEQUENCE; ENDOPLASMIC-RETICULUM; PRE-GOLGI; TRANSMEMBRANE PROTEIN; DEGRADATION; CLEAVAGE; RETENTION; PEPTIDE; DOMAIN; H2	The H2a alternatively spliced variant of the human asialoglycoprotein receptor H2 subunit differs from the H2b variant by an extra pentapeptide, EGHRG, present in the ectodomain next to the membrane-span. This difference causes retention and degradation in the endoplasmic reticulum (ER) of H2a when expressed without the H1 subunit in 3T3 cells (1). In contrast, a significant portion of singly expressed H2b is Golgi-processed and reaches the cell surface. Using a new specific anti-H2a antibody, we found that in HepG2 cells, H2a is rapidly cleaved to a 35-kDa fragment, comprising the entire ectodomain, most of which is secreted into the medium. The cleavage site for the secreted fragment was located at the lumenal end of the membrane span. No membrane-bound H2a exits the ER, indicating that the pentapeptide is a signal for ER retention and degradation of the membrane form but does not hinder secretion of the cleaved soluble form, H2a does not form a membrane receptor complex with H1 as H2b does, H2a is therefore not a subunit of the receptor but a precursor for a secreted form of the protein; signal peptidase is probably responsible for the cleavage to the soluble fragment (2). Therefore, the juxtamembrane sequence regulates the function of the transmembrane domain of a type ZI membrane protein as either a signal-anchor sequence (H2b) or as a cleaved signal sequence, which generates a secreted product (H2a).	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Tel Aviv University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)				Lederkremer, Gerardo/0000-0002-9857-7152	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVICH C, 1994, FEBS LETT, V338, P295, DOI 10.1016/0014-5793(94)80287-4; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; CROWE PD, 1993, J IMMUNOL, V151, P6882; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FISCHER DG, 1993, SCIENCE, V262, P250, DOI 10.1126/science.8211145; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GARROUSTE F, 1991, INT J CANCER, V47, P760, DOI 10.1002/ijc.2910470523; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HOGUE BG, 1994, J GEN VIROL, V75, P1015, DOI 10.1099/0022-1317-75-5-1015; KHIRE J, 1990, FEBS LETT, V272, P69, DOI 10.1016/0014-5793(90)80451-N; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LOUGHNAN MS, 1990, J MOL CELL IMMUNOL, V4, P307; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; ROY P, 1993, J BIOL CHEM, V268, P2699; SAUTES C, 1991, EUR J IMMUNOL, V21, P231, DOI 10.1002/eji.1830210135; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STEWART WW, 1990, IMMUNOLOGY, V71, P328; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; YAGO H, 1995, HEPATOLOGY, V21, P383, DOI 10.1016/0270-9139(95)90096-9; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	39	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14496	14503		10.1074/jbc.271.24.14496	http://dx.doi.org/10.1074/jbc.271.24.14496			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662943	hybrid			2022-12-25	WOS:A1996UQ66000082
J	Shintani, F; Kinoshita, T; Kanba, S; Ishikawa, T; Suzuki, E; Sasakawa, N; Kato, R; Asai, M; Nakaki, T				Shintani, F; Kinoshita, T; Kanba, S; Ishikawa, T; Suzuki, E; Sasakawa, N; Kato, R; Asai, M; Nakaki, T			Bioactive 6-nitronorepinephrine identified in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL-O-METHYLTRANSFERASE; NITRIC-OXIDE; RELEASE; NOREPINEPHRINE; DOPAMINE; SLICES	Norepinephrine (NE) (von Euler, U.S. (1972) in Catecholamines (Blaschko, H., and Muscholl, E., eds.) pp. 186-230, Springer-Verlag, Berlin) and nitric oxide (NO.) function as neurotransmitters in the nervous system. We have shown that NE levels in the rat hypothalamic paraventricular nucleus (Shintani, F., Kato, R., Kinoshita, N., Kanba, S., Asai, M., and Nakaki, T. (1995) Proceedings of the Satellite Symposium, 4th IBRO World Congress on Neuroscience, Otsu, 1995) diminish in the presence of NO.. This observation prompted us to explore the possibility of an in vivo interaction between NE and NO. or NO.-related molecules. In fact, nitration of NE has been shown to occur in vitro (d'Ischia, M., and Constantini, C. (1995) Bioorg. Med. Chem. 3, 923-927). We now report the identification of 6-nitronorepinephrine in the mammalian brain. Amounts of 6-nitronorepinephrine in the rat brain were attenuated by intraperitoneal administration of an inhibitor of nitric oxide synthase, N-G-nitro-L-arginine methyl ester (L-NAME). This was reversed by coadministration of L-arginine, suggesting that nitric oxide synthase participated in the formation of 6-nitronorepinephrine. Moreover, we found that 6-nitronorepinephrine inhibits the activity of catechol O-methyltransferase, as well as NE transport into rat synaptosomes. A rat brain microdialysis experiment showed that perfusion of 6-nitronorepinephrine into the rat paraventricular nucleus significantly elevated NE while decreasing 3-methoxy-4-hydroxyphenylglycol and that L-NAME administered intraperitoneally decreased NE and increased 3-methoxy-4-hydroxyphenylglycol. These observations suggest that 6-nitronorepinephrine generated in nuclei containing both adrenergic and nitrergic neurons inhibits NE inactivation. We propose that 6-nitronorepinephrine is a potential signal molecule linking the actions of NE and NO..	KEIO UNIV, SCH MED, DEPT PHARMACOL, SHINJUKU KU, TOKYO 160, JAPAN; KEIO UNIV, SCH MED, DEPT NEUROPSYCHIAT, SHINJUKU KU, TOKYO 160, JAPAN; SANKYO CO LTD, ANALYT & METAB RES LABS, TOKYO 140, JAPAN	Keio University; Keio University; Daiichi Sankyo Company Limited			Nakaki, Toshio/C-4832-2009					AXELROD J, 1958, J BIOL CHEM, V233, P702; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; DELABRETECHE ML, 1994, TETRAHEDRON LETT, V35, P7231, DOI 10.1016/0040-4039(94)85368-1; DISCHIA M, 1995, BIOORGAN MED CHEM, V3, P923, DOI 10.1016/0968-0896(95)00083-S; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GRONBERG M, 1990, BIOCHEM PHARMACOL, V40, P351, DOI 10.1016/0006-2952(90)90698-K; HANBAUER I, 1992, NEUROREPORT, V3, P409, DOI 10.1097/00001756-199205000-00008; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KAAKKOLA S, 1994, GEN PHARMACOL-VASC S, V25, P813, DOI 10.1016/0306-3623(94)90082-5; LONART G, 1992, EUR J PHARMACOL, V220, P271, DOI 10.1016/0014-2999(92)90759-W; MA SX, 1991, EUR J PHARMACOL, V199, P27, DOI 10.1016/0014-2999(91)90633-2; MANNISTO PT, 1988, LIFE SCI, V43, P1465, DOI 10.1016/0024-3205(88)90258-5; NAKADATE T, 1980, EUR J PHARMACOL, V64, P107, DOI 10.1016/0014-2999(80)90033-3; NISSINEN E, 1992, N-S ARCH PHARMACOL, V346, P262; PORZIG H, 1982, N-S ARCH PHARMACOL, V321, P89, DOI 10.1007/BF00518474; RICHELSON E, 1984, EUR J PHARMACOL, V103, P197, DOI 10.1016/0014-2999(84)90478-3; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; SHINTANI F, 1995, J NEUROSCI, V15, P1961, DOI 10.1523/JNEUROSCI.15-03-01961.1995; SHINTANI F, 1993, J NEUROSCI, V13, P3574; SHINTANI F, 1995, P SAT S 4 IBRO WORLD; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VONEULER US, 1972, CATECHOLAMINES, P186; WURTMAN RJ, 1963, BIOCHEM PHARMACOL, V12, P1439, DOI 10.1016/0006-2952(63)90215-6; XU ZQ, 1994, EXP BRAIN RES, V98, P75	25	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13561	13565		10.1074/jbc.271.23.13561	http://dx.doi.org/10.1074/jbc.271.23.13561			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662880	hybrid			2022-12-25	WOS:A1996UP38500040
J	Zelicof, A; Protopopov, V; David, D; Lin, XY; Lustgarten, V; Gerst, JE				Zelicof, A; Protopopov, V; David, D; Lin, XY; Lustgarten, V; Gerst, JE			Two separate functions are encoded by the carboxyl-terminal domains of the yeast cyclase-associated protein and its mammalian homologs - Dimerization and actin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE ADENYLYL CYCLASE; SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; CAP; IDENTIFICATION; PROFILIN; CLONING; COMPLEX; FAMILY	The yeast adenylyl cyclase-associated protein, CAP, was identified as a component of the RAS-activated cyclase complex. CAP consists of two functional domains separated by a proline-rich region, One domain, which localizes to the amino terminus, mediates RAS signaling through adenylyl cyclase, while a domain at the carboxyl terminus is involved in the regulation of cell growth and morphogenesis. Recently, the carboxyl terminus of yeast CAP was shown to sequester actin, but whether this function has been conserved, and is the sole function of this domain, is unclear, Here, we demonstrate that the carboxyl-terminal domains of CAP and CAP homologs have two separate functions, We show that carboxyl-terminals of both yeast CAP and a mammalian CAP homolog, MCH1, bind to actin, We also show that this domain contains a signal for dimerization, allowing both CAP and MCH1 to form homodimers and heterodimers. The properties of actin binding and dimerization are mediated by separate regions on the carboxyl terminus; the last 27 amino acids of CAP being critical for actin binding, Finally, we present evidence that links a segment of the proline rich region of CAP to its localization in yeast, Together, these results suggest that all three domains of CAP proteins are functional.	WEIZMANN INST SCI,DEPT MOLEC GENET,IL-76100 REHOVOT,ISRAEL; CUNY MT SINAI SCH MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10029	Weizmann Institute of Science; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; COUVE A, 1994, J BIOL CHEM, V269, P23391; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Freeman NL, 1996, MOL CELL BIOL, V16, P548; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GIESELMANN R, 1992, FEBS LETT, V298, P149, DOI 10.1016/0014-5793(92)80043-G; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; Miller J.H., 1972, EXPT MOL GENETICS; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; VOJTEK AB, 1993, J CELL SCI, V105, P777; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; YU G, 1994, J CELL SCI, V107, P1671; ZELICOF A, 1993, J BIOL CHEM, V268, P13448	32	53	54	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18243	18252		10.1074/jbc.271.30.18243	http://dx.doi.org/10.1074/jbc.271.30.18243			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663401	hybrid			2022-12-25	WOS:A1996UY93500098
J	Lin, YL; Chen, C; Keshav, KF; Winchester, E; Dutta, A				Lin, YL; Chen, C; Keshav, KF; Winchester, E; Dutta, A			Dissection of functional domains of the human DNA replication protein complex replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; POLYMERASE-ALPHA-PRIMASE; SIMIAN VIRUS-40 DNA; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; T-ANTIGEN; SUBUNIT; INVITRO; PHOSPHORYLATION; EXTRACTS	Replication protein A (RPA) is a mammalian single-stranded DNA binding factor essential for DNA replication, repair, and recombination. It is composed of three subunits of 70, 34, and 13 kDa (Rpa1, Rpa2, and Rpa3, respectively), Deletion mapping of the Rpa2 subunit identified the domain required for interaction with Rpa1 and Rpa3 which does not include the N-terminal domain that is phosphorylated during S phase, Deletion mapping of Rpa1 defined three domains. The C-terminal third of the Rpa1 polypeptide binds Rpa2 which itself forms a bridge between Rpa1 and Rpa3, The N-terminal third of Rpa1 bound single-stranded DNA under low stringency conditions only (0.1 M NaCl), while a central domain binds to single-stranded DNA under both low and high stringency conditions (0.5 M NaCl), Binding to p53 requires the N-terminal third of Rpa1 with some contribution from the C-terminal third. The evolutionarily conserved putative zinc finger near the C terminus of Rpa1 was not required for binding to single-stranded DNA, Rpa2, or p53, However, all three subdomains of Rpa1 and the zinc finger were essential for supporting DNA replication in vitro. These experiments are a first step toward defining peptide components responsible for the many functions of the RPA protein complex.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV MOLEC ONCOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital			Chen, Clark C/C-8714-2013; Dutta, Anindya/P-3203-2016	Chen, Clark C/0000-0001-6258-9277; Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01 CA060499-02S1, CA60499, R01 CA060499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KESHAV KF, 1995, MOL CELL BIOL, V15, P3119; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; MELENDY T, 1993, J BIOL CHEM, V268, P3389; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	76	77	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17190	17198		10.1074/jbc.271.29.17190	http://dx.doi.org/10.1074/jbc.271.29.17190			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663296	hybrid			2022-12-25	WOS:A1996UX94300034
J	Meisinger, C; Zeschnigk, C; Grothe, C				Meisinger, C; Zeschnigk, C; Grothe, C			In vivo and in vitro effect of glucocorticoids on fibroblast growth factor (FGF)-2 and FGF receptor 1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CHROMAFFIN CELLS; MOLECULAR-WEIGHT FORMS; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT BRAIN; ADRENAL-GLAND; NEURONAL DIFFERENTIATION; PC12 CELLS; BASIC FGF; NEURITE OUTGROWTH; BFGF	In order to clarify the physiological function of fibroblast growth factor (FGF-2) in the adrenal medulla the regulation of FGF-2 and FGF receptor 1 (FGFR1) was studied in vitro and in vivo in response to glucocorticoids. To assess the effects of glucocorticoids, in vivo extracts of adrenal medulla and adrenal cortex were analyzed by RNase protection assay and Western blot analysis, PC12 cells were chosen as a model system to study the effects of glucocorticoids in vitro. In PC12 cells, dexamethasone (DEX) was found to stimulate dramatically the expression of both FGF-S mRNA and protein. Western blot analysis revealed that exclusively the 21-kDa FGF-8 isoform was enhanced. In contrast to the FGF-2 mRNA level FGFR1 was not affected by treatment with glucocorticoids. In vivo FGF-2 mRNA level and 21-kDa FGF-2 isoform level are significantly enhanced in the adrenal medulla 24 h after DEX injection. In vivo application of DEX leads to an increase of the medullary and cortical FGFR1 transcript levels, Glucocorticoid effects on FGF-2 expression were not Found in adrenal cortex, heart, skeletal muscle, and kidney, respectively, in vivo and in L6 rat myoblasts in vitro. In addition to adrenal medullary cells glucocorticoids elevated the FGF-2 mRNA and protein level also in vivo in the brain and in, vitro in immortalized Schwann cells. The present results suggest that the 21-kDa FGF-8 isoform mediates a physiological function specific for neuronal tissue which is modulated by glucocorticoids.	UNIV FREIBURG,INST ANAT 2,D-79104 FREIBURG,GERMANY	University of Freiburg			Meisinger, Chris/J-1110-2014	Meisinger, Chris/0000-0002-8326-3548				Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BARBANY G, 1992, EUR J NEUROSCI, V4, P396, DOI 10.1111/j.1460-9568.1992.tb00888.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BLOTTNER D, 1989, EUR J NEUROSCI, V1, P471, DOI 10.1111/j.1460-9568.1989.tb00353.x; Bohlen P., 1989, MACROPHAGE DERIVED C, V1, P204; BOHN MC, 1981, DEV BIOL, V82, P1, DOI 10.1016/0012-1606(81)90423-1; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; Brigstock DR, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011009; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; CHAO HM, 1994, MOL BRAIN RES, V26, P271, DOI 10.1016/0169-328X(94)90099-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; ERNFORS P, 1990, J NEUROSCI RES, V27, P10, DOI 10.1002/jnr.490270103; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; FRODIN M, 1994, P NATL ACAD SCI USA, V91, P1771, DOI 10.1073/pnas.91.5.1771; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; Gould E, 1993, Curr Opin Neurobiol, V3, P676, DOI 10.1016/0959-4388(93)90138-O; GROTHE C, 1995, NEUROSCI LETT, V197, P175, DOI 10.1016/0304-3940(95)11917-L; GROTHE C, 1989, J HISTOCHEM CYTOCHEM, V37, P1877, DOI 10.1177/37.12.2685112; GROTHE C, 1995, J COMP NEUROL, V353, P18, DOI 10.1002/cne.903530104; GROTHE C, 1991, J COMP NEUROL, V305, P328, DOI 10.1002/cne.903050213; GROTHE C, 1990, FEBS LETT, V260, P35, DOI 10.1016/0014-5793(90)80059-R; GROTHE C, 1990, HISTOCHEMISTRY, V94, P141, DOI 10.1007/BF02440180; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; LILLIEN LE, 1985, EXP CELL RES, V161, P255, DOI 10.1016/0014-4827(85)90083-7; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; Meisinger C, 1996, MOL BRAIN RES, V36, P70, DOI 10.1016/0169-328X(95)00246-O; MORGAN L, 1994, DEVELOPMENT, V120, P1399; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; NEUBERGER TJ, 1994, J NEUROSCI RES, V38, P300, DOI 10.1002/jnr.490380308; NEUFELD G, 1987, ENDOCRINOLOGY, V121, P597, DOI 10.1210/endo-121-2-597; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; PRESTA M, 1988, BIOCHEM BIOPH RES CO, V155, P1161, DOI 10.1016/S0006-291X(88)81262-2; PUCHACZ E, 1993, BRAIN RES, V610, P39, DOI 10.1016/0006-8993(93)91214-D; QUATRO N, 1991, CELL REGUL, V2, P699; RANE SG, 1994, J NEUROSCI RES, V38, P590, DOI 10.1002/jnr.490380511; RIVA MA, 1995, J NEUROCHEM, V64, P2526; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SAPOLSKY RM, 1991, EXP NEUROL, V114, P246, DOI 10.1016/0014-4886(91)90041-A; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SEIDL K, 1989, DEV BIOL, V136, P481, DOI 10.1016/0012-1606(89)90273-X; SHERMAN L, 1991, ANN NY ACAD SCI, V638, P470, DOI 10.1111/j.1749-6632.1991.tb49072.x; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; STAPF C, 1996, NEUROSCIENCE, V69, P1253; STARK KL, 1991, DEVELOPMENT, V113, P641; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; TENNEKOON GI, 1987, J CELL BIOL, V105, P2315, DOI 10.1083/jcb.105.5.2315; TISCHLER AS, 1993, J NEUROSCI, V13, P1533; TOGARI A, 1985, J NEUROSCI, V5, P307; UNSICKER K, 1992, DEV BRAIN RES, V65, P211, DOI 10.1016/0165-3806(92)90181-U; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; Unsicker K, 1992, Curr Opin Neurobiol, V2, P671, DOI 10.1016/0959-4388(92)90037-L; WEISE B, 1993, J NEUROSCI RES, V34, P442, DOI 10.1002/jnr.490340409; WESTERMANN R, 1990, J NEUROCHEM, V55, P285, DOI 10.1111/j.1471-4159.1990.tb08850.x; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; ZHANG SM, 1995, J NEUROSCI RES, V40, P241, DOI 10.1002/jnr.490400213	70	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16520	16525		10.1074/jbc.271.28.16520	http://dx.doi.org/10.1074/jbc.271.28.16520			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663254	hybrid			2022-12-25	WOS:A1996UX12600018
J	Bouckaert, J; Poortmans, F; Wyns, L; Loris, R				Bouckaert, J; Poortmans, F; Wyns, L; Loris, R			Sequential structural changes upon zinc and calcium binding to metal-free concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHARIDE-BINDING; ION BINDING; MANGANESE; SITE; CONFORMATION; TRANSITIONS; RESOLUTION; CRYSTAL	The lectin concanavalin A (ConA) sequentially binds a transition metal ion in the metal-binding site S1 and a calcium ion in the metal-binding site S2 to form its saccharide-binding site. Metal-free ConA crystals soaked with either Zn2+ (apoZn-ConA) or Co2+ (apoCo-ConA) display partial binding of these ions in the proto-transition metal-binding site, but no further conformational changes are observed, These structures can represent the very first step in going from metal-free ConA toward the holoprotein. In the co-crystals of metal-free ConA with Zn2+ (Zn-ConA), the zinc ion can fully occupy the S1 site, The positions of the carboxylate ligands Asp(10) and Asp(19) that bridge the S1 and S2 sites are affected, The ligation to Zn2+ orients Asp(10) optimally for calcium ligation and stabilizes Asp(19) by a hydrogen bond to one of its water ligands, The neutralizing and stabilizing effect of the binding of Zn2+ in S1 is necessary to allow for subsequent Ca2+ binding in the S2 site. However, the S2 site of monometallized ConA is still disrupted, The co crystals of met al-free ConA with both Zn2+ and Ca2+ contain the active holoprotein (ConA ZnCa). Ca2+ has induced large conformational changes to stabilize its hepta-coordination in the S2 site, which comprise the trans to cts isomerization of the Ala(207)-Asp(208) peptide bond accompanied by the formation of the saccharide-binding site, The Zn2+ Ligation in ConA ZnCa is similar to Mn2+, Cd2+, Co2+, or Ni2+ ligation in the S1 site, in disagreement with earlier extended x-ray absorption fine structure results that suggested a lower coordination number for Zn2+.	FREE UNIV BRUSSELS VIB, LAB ULTRASTRUCT, B-2400 BRUSSELS, BELGIUM; VLAAMSE INSTELLING TECHNOL ONDERZOEK, MOL, BELGIUM	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; VITO			Loris, Remy/GPG-0894-2022	Loris, Remy/0000-0002-8862-3338; Bouckaert, Julie/0000-0001-8112-1442				BARBER BH, 1975, BIOCHEMISTRY-US, V14, P4075, DOI 10.1021/bi00689a024; BECKER JW, 1975, J BIOL CHEM, V250, P1513; Bertini I., 1994, BIOINORG CHEM, P37; Bouckaert J, 1995, PROTEINS, V23, P510, DOI 10.1002/prot.340230406; BOUCKAERT J, 1995, IN PREESS LECTINS BI, V11; BREWER CF, 1983, BIOCHEMISTRY-US, V22, P3691, DOI 10.1021/bi00284a024; BREWER CF, 1983, J BIOMOL STRUCT DYN, V1, P961, DOI 10.1080/07391102.1983.10507497; BROWN RD, 1982, BIOCHEMISTRY-US, V21, P465, DOI 10.1021/bi00532a008; BROWN RD, 1977, BIOCHEMISTRY-US, V16, P3883, DOI 10.1021/bi00636a026; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; EMMERICH C, 1994, ACTA CRYSTALLOGR D, V50, P749, DOI 10.1107/S0907444994002143; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P3; GRIMALDI JJ, 1975, J BIOL CHEM, V250, P1618; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HARRINGTON PC, 1978, BIOCHEMISTRY-US, V17, P4245, DOI 10.1021/bi00613a021; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALB AJ, 1979, J MOL BIOL, V135, P501, DOI 10.1016/0022-2836(79)90449-2; KALB AJ, 1968, BIOCHEM J, V109, P669, DOI 10.1042/bj1090669; KLEYWEGT GJ, 1994, ESF CCP 4 NEWSL 1131, P9; KOENIG SH, 1978, BIOCHEMISTRY-US, V17, P4251, DOI 10.1021/bi00613a022; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIN SL, 1991, BIOCHEMISTRY-US, V30, P2323, DOI 10.1021/bi00223a006; LIN SL, 1991, BIOCHEMISTRY-US, V30, P9705, DOI 10.1021/bi00104a019; LIN SL, 1990, BIOCHEMISTRY-US, V29, P3599, DOI 10.1021/bi00467a002; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NAISMITH JH, 1993, ACTA CRYSTALLOGR D, V49, P561, DOI 10.1107/S0907444993006390; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PALMER AR, 1980, BIOCHEMISTRY-US, V19, P5063, DOI 10.1021/bi00563a020; PFLUGRATH JW, 1989, MADNESS MANUAL FAST; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHERRY AD, 1973, ARCH BIOCHEM BIOPHYS, V156, P665, DOI 10.1016/0003-9861(73)90319-6; SHOHAM M, 1973, BIOCHEMISTRY-US, V12, P1914, DOI 10.1021/bi00734a012; WEISGERBER S, 1993, J CHEM SOC FARADAY T, V89, P2667, DOI 10.1039/ft9938902667	38	58	59	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16144	16150		10.1074/jbc.271.27.16144	http://dx.doi.org/10.1074/jbc.271.27.16144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663112	hybrid			2022-12-25	WOS:A1996UW35200045
J	Mayer, T; Touchot, N; Elazar, Z				Mayer, T; Touchot, N; Elazar, Z			Transport between cis and medial Golgi cisternae requires the function of the Ras-related protein Rab6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; YPT1 GENE-PRODUCT; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; EPITHELIAL-CELLS; MEMBRANE-FUSION; YEAST; SECRETION; COMPARTMENTS	The small GTP-binding protein Rab6, a member of the Ras superfamily, is localized on the membranes of the Golgi apparatus and the trans Golgi network. Recent studies revealed that the Rab6 protein might be involved in the transit of proteins through the Golgi complex. In this report we demonstrate the essential function of the Rab6 protein in a distinct step of reconstituted Golgi transport, Polyclonal antibodies and Fab fragments directed against the C-terminal part of the Rab6 protein inhibit transport between the cis and the medial Golgi cisternae, Inhibition also occurred when a trans-dominant mutant form of the Rab6 protein (N126I) was added to the reconstituted transport. Furthermore, Rab6 antibodies inhibit uncoupled fusion of Golgi membranes. From these data we conclude that Rab6 is involved in a process related to membrane fusion at the cisternal membranes of the Golgi apparatus and therefore is needed for the consumption of Golgi-derived vesicles by their target membranes.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	Mayer, T (corresponding author), UNIV MUNSTER,DEPT EXPT TUMOR BIOL,BADESTR 9,D-48149 MUNSTER,GERMANY.			Mayer, Thomas/0000-0001-6954-2287				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKERS CJM, 1992, METHOD ENZYMOL, V219, P5; BEDNAREK SY, 1994, PLANT PHYSIOL, V104, P591, DOI 10.1104/pp.104.2.591; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; FEIG L, 1990, MOL CELL BIOL, V8, P3225; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GROVEL JP, 1991, CELL, V64, P915; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; KAHN RA, 1992, J BIOL CHEM, V267, P13039; LI GP, 1994, J BIOL CHEM, V269, P14631; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Melancon P, 1989, Soc Gen Physiol Ser, V44, P175; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	44	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16097	16103		10.1074/jbc.271.27.16097	http://dx.doi.org/10.1074/jbc.271.27.16097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663167	hybrid			2022-12-25	WOS:A1996UW35200038
J	Prasad, R; Singhal, RK; Srivastava, DK; Molina, JT; Tomkinson, AE; Wilson, SH				Prasad, R; Singhal, RK; Srivastava, DK; Molina, JT; Tomkinson, AE; Wilson, SH			Specific interaction of DNA polymerase beta and DNA ligase I in a multiprotein base excision repair complex from bovine testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC ABASIC SITE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CATALYTIC DOMAIN; HUMAN-CELLS; REPLICATION; RESIDUES; IDENTIFICATION; MECHANISM; EXTRACT	Base excision repair (EER) is a cellular defense mechanism repairing modified bases in DNA. Recently, a G:U repair reaction has been reconstituted with several purified enzymes from Escherichia coli (Dianov, G,, and Lindahl, T. (1994) Curr. Biol. 4, 1069-1076), Using bovine testis crude nuclear extract, we have shown that G:U is repaired efficiently in vitro, and DNA polymerase beta (beta-pol) is responsible for the single nucleotide gap-filling synthesis (Singhal, R. It., Prasad, R,, and Wilson, S, H. (1995) J, Biol, Chem, 270, 949-957), To investigate potential interaction of beta-pol with other BER protein(s), we developed affinity chromatography matrices by cross-linking purified rat beta-pol or antibody against beta-pol to solid supports. Crude nuclear extract from bovine testis was applied to these affinity columns, which were then extensively washed, Proteins that bound specifically to the affinity columns were co-eluted in a complex with beta-pol, This complex had a molecular mass of approximately 180 kDa and was able to conduct the complete uracil-initiated EER reaction, The EER complex contained both beta-pol. and DNA ligase I. An antibody to beta-pol was able to shift the complex in sucrose gradients to a much larger molecular mass (>300 kDa) that again contained both beta-pol and DNA ligase I, Furthermore, DNA ligase I and beta-pol were co-immunoprecipitated from the testis nuclear extract with anti beta-pol IgG, Thus, we conclude that beta-pol and DNA ligase I are components of a multiprotein complex that performs BER.	UNIV TEXAS, MED BRANCH, SEALY CTR MOLEC SCI, GALVESTON, TX 77555 USA; UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, INST BIOTECHNOL, SAN ANTONIO, TX 78245 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Health San Antonio			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492, R01ES006839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047251, R29GM047251] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 06492, ES 06839] Funding Source: Medline; NIGMS NIH HHS [GM 47251] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; Beard WA, 1995, METHOD ENZYMOL, V262, P98; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; DATE T, 1990, BIOCHEMISTRY-US, V29, P3075; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1986, BIOCHEMISTRY-US, V25, P2212, DOI 10.1021/bi00356a054; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRY M, 1986, ANIMAL CELL DNA POLY, P75; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; Harlow E., 1988, ANTIBODIES LAB MANUA; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; HUSAIN I, 1995, J BIOL CHEM, V270, P9683, DOI 10.1074/jbc.270.16.9683; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; KIM SJ, 1994, J MOL BIOL, V244, P224, DOI 10.1006/jmbi.1994.1720; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LINDAHL T, 1995, PHILOS T ROY SOC B, V347, P57, DOI 10.1098/rstb.1995.0009; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P16402, DOI 10.1074/jbc.270.27.16402; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SWEASY JB, 1995, J BACTERIOL, V177, P2923, DOI 10.1128/jb.177.10.2923-2925.1995; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	52	221	224	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16000	16007		10.1074/jbc.271.27.16000	http://dx.doi.org/10.1074/jbc.271.27.16000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663274	hybrid			2022-12-25	WOS:A1996UW35200026
J	Servant, MJ; Giasson, E; Meloche, S				Servant, MJ; Giasson, E; Meloche, S			Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE-KINASE; TYROSINE PHOSPHORYLATION; IN-VITRO; ACTIVATION; RAF; P44(MAPK); PROGRESS; INVITRO; INSULIN	A common response of cells to mitogenic and hypertrophic factors is the activation of high rates of protein synthesis. To investigate the molecular basis of this action, we have used the recently developed MAP kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor PD 98059 to examine the involvement of the ERK pathway in the regulation of global protein synthesis by growth factors in rat aortic smooth muscle cells (SMC). Incubation with PD 98059 blocked angiotensin II (AII)-dependent phosphorylation and enzymatic activity of both MEK1 and MEK2 isoforms, leading to inhibition of the phosphorylation and activation of p44(mapk) and p42(mapk). The compound was found to selectively inhibit activation of the ERK pathway by AII, but not the stimulation of p70 S6 kinase, phospholipase C, or tyrosine phosphorylation. Most importantly, treatment of aortic SMC with PD 98059 potently inhibited AII-stimulated protein synthesis with a half-maximal inhibitory concentration of 4.3 mu M. The effect of PD 98059 was not restricted to AII, since the compound also blocked to various extent the induction of protein synthesis by growth factors acting through tyrosine kinase receptors, G protein-coupled receptors, or protein kinase C, These results provide strong evidence that activation of ERK isoforms is an obligatory step for growth factor-induced protein synthesis in aortic SMC.	UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H2W 1T8,CANADA	Universite de Montreal	Servant, MJ (corresponding author), HOP HOTEL DIEU,CTR RECH,3850 ST URBAIN ST,MONTREAL,PQ H2W 1T8,CANADA.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; Chiu A T, 1991, Receptor, V1, P133; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; FUKUDA M, 1995, ONCOGENE, V11, P239; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEDUC L, 1995, MOL PHARMACOL, V48, P582; LENORMAND P, 1993, ADV SEC MESS PHOSPH, V28, P237; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PATTON WF, 1995, J BIOL CHEM, V270, P21404, DOI 10.1074/jbc.270.36.21404; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SERVANT M, 1995, BIOCHEM J, V305, P103, DOI 10.1042/bj3050103; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; TURNER CE, 1995, J CELL SCI, V108, P333; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625	73	140	141	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16047	16052		10.1074/jbc.271.27.16047	http://dx.doi.org/10.1074/jbc.271.27.16047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663242	hybrid			2022-12-25	WOS:A1996UW35200032
J	Li, DX; Dobrowolska, G; Krebs, EG				Li, DX; Dobrowolska, G; Krebs, EG			The physical association of casein kinase 2 with nucleolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR SUPPRESSOR PROTEIN; HEAT-SHOCK PROTEIN; II ACTIVITY; CELLULAR-REGULATION; MOLECULAR-COMPLEX; ALPHA-SUBUNIT; BETA-SUBUNIT; CHO CELLS; PHOSPHORYLATION	CK2 (formerly called casein kinase 2) is a ubiquitous messenger-independent serine/threonine protein kinase implicated in cell growth and proliferation. To investigate the regulation and functions of this enzyme, experiments were carried out to search for CK2-interacting proteins. The methods employed included an overlay technique, co-purification, co-immunoprecipitation, and the use of glutathione S-transferase (GST) CK2 fusion proteins, By the CK2 overlay technique, one protein of 110 kDa was found to bind to CK2 with very high affinity. The binding was inhibited by CK2 effectors such as heparin, polyarginine, and histone H1, but was not affected by the CK2 substrate, casein. Protein p110 was also detected by co-immunoprecipitation using anti-CK2 antiserum, suggesting an in vivo association of this protein with CK2. Go-purification of p110 with CK2 from Sf-9 cells that overexpressed CK2 was also observed through sequential chromatographic steps. Using GST fusion proteins of CK2, the CK2-p110 interaction was investigated further and was found to occur primarily through CK2 alpha or alpha' subunits, but not the beta subunit. Protein p110 was purified from 3T3 LI mouse fibroblast cell lines using a GST-CK2 affinity resin. Amino acid sequence analysis of peptides obtained from the protein indicated that it is the nuclear protein, nucleolin. Furthermore, p110 was recognized by anti-nucleolin antiserum. At present, the physiological significance of the strong interaction between CK2 and nucleolin, an excellent substrate for the enzyme, is not clear. However, this association may be important for regulating rDNA transcription.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Dobrowolska, Grazyna/0000-0002-2598-9666	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42528] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6626; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; DELPECH M, 1986, EUR J BIOCHEM, V160, P333, DOI 10.1111/j.1432-1033.1986.tb09976.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIAZNIDO J, 1992, SEC MESS PHOSPHOPROT, V14, P39; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; ESCANDE ML, 1985, BIOL CELL, V53, P99, DOI 10.1111/j.1768-322X.1985.tb00359.x; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P126; HEI YJ, 1994, BIOCHEM CELL BIOL, V72, P49, DOI 10.1139/o94-008; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1985, BIOCHIM BIOPHYS ACTA, V846, P248, DOI 10.1016/0167-4889(85)90072-2; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SARNO S, 1995, BIOCHEM BIOPH RES CO, V206, P171, DOI 10.1006/bbrc.1995.1024; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; Stone K.L., 1992, TECHNIQUES PROTEIN C, P23; SUZUKI N, 1987, J BIOL CHEM, V262, P4696; SUZUKI N, 1992, J STEROID BIOCHEM, V42, P305, DOI 10.1016/0960-0760(92)90133-4; SUZUKI T, 1993, BIOCHEM J, V289, P109, DOI 10.1042/bj2890109; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068	58	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15662	15668		10.1074/jbc.271.26.15662	http://dx.doi.org/10.1074/jbc.271.26.15662			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663258	hybrid			2022-12-25	WOS:A1996UV29900055
J	Morris, JC; PingSheng, L; Zhai, HX; Shen, TY; MensaWilmot, K				Morris, JC; PingSheng, L; Zhai, HX; Shen, TY; MensaWilmot, K			Phosphatidylinositol phospholipase C is activated allosterically by the aminoglycoside G418 - 2-deoxy-2-fluoro-scyllo-inositol-1-O-dodecylphosphonate and its analogs inhibit glycosylphosphatidylinositol phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; TRYPANOSOMA-BRUCEI; SUBSTRATE; THURINGIENSIS	Phosphatidylinositol-specific phospholipase C (PI-PLC) from Bacillus cereus is inhibited by myo-inositol-1-O-dodecylphosphonate (Ins-1-O-dodecylphosphonate) (Morris, J, C,, Ping-Sheng, L,, Shen, T, Y,, and Mensa-Wilmot, K, (1995) J, Biol, Chem, 270, 2517-2524), A set of novel fluorinated 2-deoxy-Ins-1-Q-dodecylphosphonates were tested against PI-PLC, with potent competitive inhibition by 2-deoxy-2-fluoro-scyllo-Ins-1-O-dodecylphosphonate (VP-616L) (X(i(50)) = 0.09), 2-Deoxy-2-fluoro-myo-Ins-1-O-dodecylphosphonate and 2-deoxy-2,2-difluoro-myo-Ins-1-O-dodecylphosphonate were 8.3 fold and 4.8-fold less effective, respectively, than VP-616L, Methyl 2-deoxy-2,2-difluoro-myo-Ins-1-O-dodecylphosphonate was inactive, Also, a hundredfold less PI-PLC is required to cleave a glycosylphosphatidylinositol (GPI) than is needed to cleave PI, Implied in these observations are the following: (i) in powerful inhibitors an active site residue probably interacts with the equatorially oriented fluoro substituent; (ii) substrate recognition requires a negative charge on the phosphoryl at the Ins-1 position, and (iii) a GPI is better substrate than PI, for PI-PLC. Aminoglycoside antibiotics kanamycin A, gentamycin, and G418 stimulated PI-PLC cleavage of the GPI anchor of variant surface glycoprotein (VSG) from Trypanosoma brucei 2- to 4-fold, G418, which appears to act on the enzyme substrate complex, increased k(cat) and K-m 6.4-fold and 9.9-fold, respectively, PI-PLC was activated by G418 even in the presence of the inhibitor VP-616L, In control experiments, the lectin concanavalin A (ConA), which probably acts by substrate sequestration, inhibited both PI-PLC (X(i(50)) = 0.00025) and GPI-specific phospholipase D (X(i(50)) = 0.00018), G418 failed to activate PI-PLC when ConA was present, These observations indicate that G418 is an allosteric activator of Bacillus cereus PI-PLC, Since G418 stimulates a purified enzyme that is not involved in aminoglycoside metabolism, we propose that binding of aminoglycosides to cellular proteins could contribute to the development of the nephrotoxicity associated with the use of these aminoglycoside antibiotics.	UNIV GEORGIA, DEPT CELLULAR BIOL, ATHENS, GA 30602 USA; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA	University System of Georgia; University of Georgia; University of Virginia				Morris, James/0000-0003-2515-5714	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033383, R29AI033383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047109] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33383, 1-T32-AIO-4322] Funding Source: Medline; NIGMS NIH HHS [GM47109] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANGS JD, 1988, J BIOL CHEM, V263, P17697; BRUZIK KS, 1994, BIOCHEMISTRY-US, V33, P8367, DOI 10.1021/bi00193a026; DEEG MA, 1995, METHOD ENZYMOL, V250, P630; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; GUPTA D, 1988, SCIENCE, V242, P1446, DOI 10.1126/science.2904699; HELLER M, 1994, EUR J BIOCHEM, V224, P823, DOI 10.1111/j.1432-1033.1994.00823.x; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; JAGER K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P45, DOI 10.1016/0304-4165(91)90037-H; JONES GA, 1993, J BIOL CHEM, V268, P20845; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; Low M.G., 1992, LIPID MODIFICATION P, P117; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; MINGEOTLECLERCQ MP, 1995, J TOXICOL ENV HEALTH, V44, P263, DOI 10.1080/15287399509531960; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; SAGAWA N, 1983, BIOCHIM BIOPHYS ACTA, V752, P153, DOI 10.1016/0005-2760(83)90243-6; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; SCHRODER G, 1992, BIOCHEMISTRY-US, V31, P631, DOI 10.1021/bi00118a001; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V231, P48; SHASHIDHAR MS, 1990, BIOCHIM BIOPHYS ACTA, V1042, P410, DOI 10.1016/0005-2760(90)90172-T; STIEGER S, 1991, BIOCHIMIE, V73, P1179, DOI 10.1016/0300-9084(91)90002-I; VANBAMBEKE F, 1995, EUR J PHARM-MOLEC PH, V289, P321, DOI 10.1016/0922-4106(95)90110-8; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALLIS MG, 1995, CHEM BIOL, V2, P543, DOI 10.1016/1074-5521(95)90188-4; WANG Y, 1995, CHEM BIOL, V2, P281, DOI 10.1016/1074-5521(95)90047-0; ZHAI HX, 1995, TETRAHEDRON LETT, V36, P7403, DOI 10.1016/0040-4039(95)01579-5	35	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15468	15477		10.1074/jbc.271.26.15468	http://dx.doi.org/10.1074/jbc.271.26.15468			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663028	hybrid			2022-12-25	WOS:A1996UV29900027
J	Poland, BW; Hou, ZL; Bruns, C; Fromm, HJ; Honzatko, RB				Poland, BW; Hou, ZL; Bruns, C; Fromm, HJ; Honzatko, RB			Refined crystal structures of guanine nucleotide complexes of adenylosuccinate synthetase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSENSUS SEQUENCE; MOLECULAR-CLONING; ISOTOPE EXCHANGE; MECHANISM; PURIFICATION; PROTEINS; PURA	Structures of adenylosuccinate synthetase from Escherichia coli complexed with guanosine-5'-(beta,gamma-imido) triphosphate and guanosine-5'-(beta,gamma-methylene)triphosphate in the presence and the absence of Mg2+ have been refined to R-factors below 0.2 against data to a nominal resolution of 2.7 Angstrom. Asp(333) of the synthetase hydrogen bonds to the exocyclic 2-amino and endocyclic N1 groups of the guanine nucleotide base, whereas the hydroxyl of Ser(414) and the backbone amide of Lys(331) hydrogen bond to the 6-oxo position. The side chains of Lys(331) and pro(417) pack against opposite faces of the guanine nucleotide base. The synthetase recognizes neither the N7 position of guanine nucleotides nor the ribose group. Electron density for the guanine-5'-(beta,gamma-imido) triphosphate complex is consistent with a mixture of the triphosphate nucleoside and its hydrolyzed diphosphate nucleoside bound to the active site. The base, ribose, and alpha-phosphate positions overlap, but the beta-phosphates occupy different binding sites. The binding of guanosine-5'-(beta,gamma-methylene)triphosphate to the active site is comparable with that of guanosine-5'-(beta,gamma-imido)triphosphate. No electron density, however, for the corresponding diphosphate nucleoside is observed. In addition, electron density for bound Mg2+ is absent in these nucleotide complexes. The guanine nucleotide complexes of the synthetase are compared with complexes of other GTP-binding proteins and to a preliminary structure of the complex of GDP, IMP, Mg2+, and succinate with the synthetase. The enzyme, under conditions reported here, does not undergo a conformational change in response to the binding of guanine nucleotides, and minimally IMP and/or Mg2+ must be present in order to facilitate the complete recognition of the guanine nucleotide by the synthetase.			Poland, BW (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,1210 MOL BIOL BLDG,AMES,IA 50011, USA.							ALEXEEV D, 1994, STRUCTURE, V2, P1061, DOI 10.1016/S0969-2126(94)00109-X; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BASS MB, 1984, J BIOL CHEM, V259, P2330; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CLARK SW, 1976, BIOCHIM BIOPHYS ACTA, V437, P87, DOI 10.1016/0304-4165(76)90349-4; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P87; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUANG WJ, 1994, STRUCTURE, V2, P407, DOI 10.1016/S0969-2126(00)00042-3; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KANG C, 1994, J BIOL CHEM, V269, P24046; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KANG CH, 1995, J BIOL CHEM, V270, P15539, DOI 10.1074/jbc.270.26.15539; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LIU F, 1992, J BIOL CHEM, V267, P2388; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MANTSALA P, 1992, J BACTERIOL, V174, P1883; MARKHAM DG, 1977, ARCH BIOCHEM BIOPHYS, V184, P24; MILLER RW, 1962, J BIOL CHEM, V237, P485; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RANDERATH K, 1966, THIN LAYER CHROMATOG, P229; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; Saenger W, 1984, PRINCIPLES NUCL ACID, P16; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; Soans C, 1991, ARCH BIOCHEM BIOPHYS, V310, P475; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; VANDERWE.MB, 1974, J BIOL CHEM, V249, P7282; WEBB MR, 1984, J BIOL CHEM, V259, P3044; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147; WYNGAARDEN JB, 1963, J BIOL CHEM, V238, P1054; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	46	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15407	15413		10.1074/jbc.271.26.15407	http://dx.doi.org/10.1074/jbc.271.26.15407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663109	hybrid			2022-12-25	WOS:A1996UV29900019
J	Stein, T; Vater, J; Kruft, V; Otto, A; WittmannLiebold, B; Franke, P; Panico, M; McDowell, R; Morris, HR				Stein, T; Vater, J; Kruft, V; Otto, A; WittmannLiebold, B; Franke, P; Panico, M; McDowell, R; Morris, HR			The multiple carrier model of nonribosomal peptide biosynthesis at modular multienzymatic templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAMICIDIN-S SYNTHETASE; BACILLUS-SUBTILIS; SEQUENCE; ACTIVATION; BINDING; GRSB; GENE	Gramicidin S synthetase 1 and 2 were affinity-labeled at their thiolation centers either by thioesterification with the amino acid substrate or by specific alkylation with the thiol reagent N-ethylmaleimide in combination with a substrate protection technique. The labeled proteins were digested either chemically by cyanogen bromide or by proteases. An efficient multistep high pressure liquid chromatography methodology was developed and used to isolate the active site peptide fragments of all five thiolation centers of gramicidin S synthetase in pure form. The structures of these fragments are investigated by N-terminal sequencing, mass spectrometry, and amino acid analysis. Each of the active site peptide fragments contains the consensus motif LGG(HID)S(LII), which is specific for thioester formation in nonribosomal peptide biosynthesis. It was demonstrated that a 4'-phosphopantetheine cofactor is attached to the central serine of the thiolation motif in each amino acid-activating module of the gramicidin S synthetase multienzyme system forming the thioester binding sites for the amino acid substrates and catalyzing the elongation process. Our data are strong support for a ''multiple carrier model'' of nonribosomal peptide biosynthesis at multifunctional templates, which is discussed in detail.	TECH UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,D-10587 BERLIN,GERMANY; MAX DELBRUCK CENTRUM MOLEK MED,D-13122 BERLIN,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,D-14195 BERLIN,GERMANY; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND	Technical University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Imperial College London				Vater, Joachim/0000-0002-4478-4244	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALVAREZ E, 1993, EUR J BIOCHEM, V215, P323, DOI 10.1111/j.1432-1033.1993.tb18038.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU CW, 1984, THESIS TU BERLIN; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; DECRECYLAGARD V, 1995, CR ACAD SCI III-VIE, V318, P927; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; FUMA S, 1993, NUCLEIC ACIDS RES, V21, P93, DOI 10.1093/nar/21.1.93; GEVERS W, 1969, P NATL ACAD SCI USA, V63, P1335, DOI 10.1073/pnas.63.4.1335; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; KURAHASHI K, 1974, ANNU REV BIOCHEM, V43, P445, DOI 10.1146/annurev.bi.43.070174.002305; Laland S G, 1973, Essays Biochem, V9, P31; LALAND SG, 1972, NATURE-NEW BIOL, V239, P43, DOI 10.1038/newbio239043a0; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; LIPMANN F, 1954, MECHANISM ENZYME ACT, P599; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; PAVELAVRANCIC M, 1994, J BIOL CHEM, V269, P14962; PFEIFER E, 1995, BIOCHEMISTRY-US, V34, P7450, DOI 10.1021/bi00022a019; SAITO M, 1995, J BIOCHEM-TOKYO, V117, P276, DOI 10.1093/jb/117.2.276; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; Stein T, 1996, AMINO ACIDS, V10, P201, DOI 10.1007/BF00807324; STEIN T, 1994, FEBS LETT, V340, P39, DOI 10.1016/0014-5793(94)80169-X; TOKITA K, 1993, J BIOCHEM-TOKYO, V114, P522, DOI 10.1093/oxfordjournals.jbchem.a124210; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VATER J, 1987, EUR J BIOCHEM, V163, P297, DOI 10.1111/j.1432-1033.1987.tb10800.x; VATER J, 1985, BIOCHEMISTRY-US, V24, P2022, DOI 10.1021/bi00329a033; VATER J, 1990, BIOCH PEPTIDE ANTIBI, V2, P33; Warburg O., 1942, BIOCHEM Z, V310, P384	35	165	175	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15428	15435		10.1074/jbc.271.26.15428	http://dx.doi.org/10.1074/jbc.271.26.15428			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663196	hybrid			2022-12-25	WOS:A1996UV29900022
J	Wylie, JL; Wang, LL; Tipples, G; McClarty, G				Wylie, JL; Wang, LL; Tipples, G; McClarty, G			A single point mutation in CTP synthetase of Chlamydia trachomatis confers resistance to cyclopentenyl cytosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; CHINESE-HAMSTER CELLS; ESCHERICHIA-COLI; RELA GENE; PURIFICATION; INFECTIONS; MUTANTS	A Chlamydia trachomatis strain (L2/CPEC) resistant to the cytotoxic effects of cyclopentenyl cytosine (CPEC) was isolated by a stepwise selection procedure. This strain showed an approximate 350-fold increase in resistance to CPEC. Sequencing of the gene encoding CTP synthetase from this resistant strain revealed a single point mutation, resulting in a change of amino acid 149 from Asp to Glu, This appeared to be the only mutation in L2/CPEC, because no changes in CTP transport, CTP synthetase expression, or incorporation of CPEC into DNA or RNA could be detected, The mutation in the chlamydial CTP synthetase resulted in a loss of CTP feedback inhibition. This was demonstrated both in vivo using Escherichia coli cells carrying the cloned gene, and an in vitro assay using partially purified preparations of CTP synthetase, As a result of the loss of feedback inhibition, E. coli cells carrying the CPEC(R) CTP synthetase showed a 22-fold increase in their CTP pools, However, examination of the CTP pools of L2/CPEC revealed no change in CTP levels when compared with wild type C. trachomatis.	UNIV MANITOBA, DEPT MED MICROBIOL, WINNIPEG, MB R3E 0W3, CANADA	University of Manitoba								ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BIRKELUND S, 1992, J BACTERIOL, V174, P2742, DOI 10.1128/JB.174.9.2742-2747.1992; BLANEY SM, 1993, BIOCHEM PHARMACOL, V45, P1493, DOI 10.1016/0006-2952(93)90050-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; FRAIZ J, 1988, ANNU REV MED, V39, P357, DOI 10.1146/annurev.me.39.020188.002041; FRIESEN JD, 1976, J BACTERIOL, V127, P917, DOI 10.1128/JB.127.2.917-922.1976; FRIESEN JD, 1978, CELL, V15, P1187, DOI 10.1016/0092-8674(78)90045-4; FUKUSHI H, 1993, MICROBIOL IMMUNOL, V27, P515; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; KANG GJ, 1989, J BIOL CHEM, V264, P713; KELLSALL A, 1988, SOMAT CELL MOLEC GEN, V14, P149; Long C, 1978, Methods Enzymol, V51, P79; LONG CW, 1967, J BIOL CHEM, V242, P4715; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; McClarty Grant, 1994, Trends in Microbiology, V2, P157, DOI 10.1016/0966-842X(94)90665-3; MCPARTLAND RP, 1979, J BIOL CHEM, V254, P1394; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; PLAGEMANN PGW, 1978, J CELL PHYSIOL, V97, P49, DOI 10.1002/jcp.1040970107; QIN B, 1992, J BACTERIOL, V174, P2865, DOI 10.1128/JB.174.9.2865-2873.1992; Sambrook J., 2002, MOL CLONING LAB MANU; STEPHENS RS, 1992, INFECT AGENT DIS, V1, P279; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TIPPLES G, 1991, J BACTERIOL, V173, P4932, DOI 10.1128/jb.173.16.4932-4940.1991; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; VANHAVERBEKE DA, 1978, J LIQ CHROMATOGR, V1, P507; WANG LL, 1994, MOL MICROBIOL, V14, P271, DOI 10.1111/j.1365-2958.1994.tb01288.x; WHELAN J, 1993, NAT GENET, V3, P317, DOI 10.1038/ng0493-317; ZHANG H, 1993, CANCER RES, V53, P5714; ZHANG LH, 1992, J MOL BIOL, V223, P627, DOI 10.1016/0022-2836(92)90979-T	35	27	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15393	15400		10.1074/jbc.271.26.15393	http://dx.doi.org/10.1074/jbc.271.26.15393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663065	hybrid			2022-12-25	WOS:A1996UV29900017
J	Sheppard, DN; Travis, SM; Ishihara, H; Welsh, MJ				Sheppard, DN; Travis, SM; Ishihara, H; Welsh, MJ			Contribution of proline residues in the membrane-spanning domains of cystic fibrosis transmembrane conductance regulator to chloride channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR; EXPRESSION; MUTATIONS; CELLS; IDENTIFICATION; LOCALIZATION; TRANSPORT; EPITHELIA; GENE	Proline residues located in membrane spanning domains of transport proteins are thought to play an important structural role, In the cystic fibrosis transmembrane conductance regulator (CFTR), the predicted transmembrane segments contain four prolines: Pro(99), Pro(205), Pro(324), and Pro(1021). These residues are conserved across species, and mutations of two (P99L and P205S) are associated with cystic fibrosis, To evaluate the contribution of these prolines to CFTR Cl- channel function, we mutated each residue individually to either alanine or glycine or mutated all four simultaneously to alanine (P-Quad-A), We also constructed the two cystic fibrosis-associated mutations, cAMP agonists stimulated whole cell Cl- currents in HeLa cells expressing the individual constructs that resembled those produced by wild-type CFTR, However, the amount of current was decreased in the rank order: wild-type CFTR = Pro(324) > Pro(1021) > Pro(99) greater than or equal to Pro(205) mutants, The anion selectivity sequence of the mutants (Br- greater than or equal to Cl- > I-) resembled wild-type except for P99L (Br- greater than or equal to Cl- = I-). Although the Pro(99), Pro(324) , and Pro(1021) mutants produced mature protein, the amount of mature protein was much reduced with the pro205 mutants, and the P-Quad-A made none. Because the Pro(99) constructs produced mature protein but had altered whole cell currents, we investigated their single-channel properties, Mutant channels were regulated like wild-type CFTR; however, single-channel conductance was decreased in the rank order: wild-type CFTR greater than or equal to P99G > P99L greater than or equal to P99A. These results suggest that proline residues in the transmembrane segments are important for CFTR function, Pro(205) is critical for correct protein processing, and Pro(99) may contribute either directly or indirectly to the Cl- channel pore.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa	Sheppard, DN (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,500 EMRB,IOWA CITY,IA 52242, USA.		Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130; Welsh, Michael/0000-0002-1646-6206				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHILLON M, 1993, HUM MOL GENET, V2, P1741, DOI 10.1093/hmg/2.10.1741; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GRIBKOFF VK, 1994, J BIOL CHEM, V269, P10983; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P28683; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SCHWARTZ M, 1995, PEDIATR PULM, V12, P207; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; VOGEL H, 1986, BIOPHYS J, V50, P573, DOI 10.1016/S0006-3495(86)83497-X; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799	32	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14995	15001		10.1074/jbc.271.25.14995	http://dx.doi.org/10.1074/jbc.271.25.14995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663008	hybrid			2022-12-25	WOS:A1996UT10600055
J	Harnish, DC; Malik, S; Kilbourne, E; Costa, R; Karathanasis, SK				Harnish, DC; Malik, S; Kilbourne, E; Costa, R; Karathanasis, SK			Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE; TRANSCRIPTIONAL ACTIVATION; RECEPTOR SUPERFAMILY; ESTROGEN-RECEPTOR; RETINOIC ACID; PROTEIN; HNF-4; PROMOTERS; ESTRADIOL; MEMBER	Apolipoprotein AI (apoAI) gene expression in liver depends on synergistic interactions between transcription factors bound to three distinct sites (A, B, and C) within a hepatocyte-specific enhancer in the 5'-flanking region of the gene, In this study, we showed that a segment spanning sites A and B retains substantial levels of enhancer activity in hepatoblastoma HepG2 cells and that sites A and B are occupied by the liver-enriched hepatocyte nuclear factors (HNFs) 4 and 3, respectively, in these cells, In non-hepatic CV-1 cells, HNF-4 and HNF-3 beta activated this minimal enhancer synergistically, This synergy was dependent upon simultaneous binding of these factors to their cognate sites, but it was not due to cooperativity in DNA binding, Separation of these sites by varying helical turns of DNA did not affect simultaneous binding of HNF-3 beta and HNF-4 nor did it influence their functional synergy, The synergy was, however, dependent upon the cell type used for functional analysis, In addition, this synergy was further potentiated by estrogen treatment of cells cotransfected with the estrogen receptor, These data indicate that a cell type-restricted intermediary factor jointly recruited by HNF-4 and HNF-3 participates in activation of the apoAI enhancer in liver cells and suggest that the activity of this factor is regulated by estrogen.	LEDERLE LABS,DEPT CARDIOVASC MOL BIOL,PEARL RIVER,NY 10965; UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; FUERNKRANZ HA, 1994, NUCLEIC ACIDS RES, V22, P5665, DOI 10.1093/nar/22.25.5665; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GE RW, 1994, J BIOL CHEM, V269, P13185; HALL RB, 1994, P NATL ACAD SCI USA, V92, P412; HARNISH DC, 1994, J BIOL CHEM, V269, P28220; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; KARATHANASIS SK, 1992, MONOGR HUM GENET, V14, P140; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1993, NATURE, V363, P741; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; METZGER S, 1993, J BIOL CHEM, V268, P16831; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; Sambrook J., 2002, MOL CLONING LAB MANU; SEISHIMA M, 1991, J LIPID RES, V32, P941; SHELDON M, 1995, CURR BIOL, V5, P43, DOI 10.1016/S0960-9822(95)00014-5; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SRIVASTAVA RAK, 1993, EUR J BIOCHEM, V216, P527; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; TANG JJ, 1991, J LIPID RES, V32, P1571; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WU KJ, 1994, J BIOL CHEM, V269, P1177; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x	41	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13621	13628		10.1074/jbc.271.23.13621	http://dx.doi.org/10.1074/jbc.271.23.13621			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662915	hybrid			2022-12-25	WOS:A1996UP38500049
J	Asai, N; Murakami, H; Iwashita, T; Takahashi, M				Asai, N; Murakami, H; Iwashita, T; Takahashi, M			A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE PRODUCTS; KINASE-ACTIVITY; PDGF RECEPTOR; DOMAIN; ACTIVATION; SEQUENCE; DISEASE; PHOSPHORYLATION; NEUROBLASTOMA; PP60C-SRC	Germ line mutations of the ret proto-oncogene are associated with the development of three dominantly inherited neoplastic disorders, multiple endocrine neoplasia (MEN) 2A, MEN 2B, and familial medullary thyroid carcinoma, It has been demonstrated that the mutations result in constitutive activation of the Ret protein, leading to transformation of MH 3T3 cells, In the present study we investigated the role of tyrosine residues present in the carboxyl-terminal sequence for the transforming activity of Ret with the MEN 2A or MEN 2B mutation (MENSA-Ret or MEN2B-Ret). Substitution of phenylalanine for tyrosine 1062 (designated Y1062F) markedly impaired the transforming activity of both MEN2A-Ret and MEN2B-Ret, whereas substitution or deletion for four other tyrosines (codons 981, 1015, 1090, and 1096) did not affect their activity, The She adaptor proteins bound to the MEN2A-Ret and MEN2B-Ret proteins and were phosphorylated on tyrosine in the transfectants. The binding of She to the Y1062F mutant proteins was reduced by approximately 80%, indicating that tyrosine 1062 is a major binding site for She. In addition, phosphopeptide analysis of MENSA-Ret demonstrated that tyrosine 1062 represents an autophosphorylation site of the mutant Ret proteins.	NAGOYA UNIV, SCH MED, DEPT PATHOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN	Nagoya University			TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Geer P.V.D., 1991, MOL CELL BIOL, V11, P4698; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Iwashita T, 1996, ONCOGENE, V12, P481; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	154	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17644	17649		10.1074/jbc.271.30.17644	http://dx.doi.org/10.1074/jbc.271.30.17644			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663426	hybrid			2022-12-25	WOS:A1996UY93500012
J	Osawa, H; Robey, RB; Printz, RL; Granner, DK				Osawa, H; Robey, RB; Printz, RL; Granner, DK			Identification and characterization of basal and cyclic AMP response elements in the promoter of the rat hexokinase II genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING-FACTOR; BROWN ADIPOSE-TISSUE; NUCLEAR FACTOR CREB; MHC CLASS-II; NF-Y; SOMATOSTATIN GENE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MAXIMUM CAPACITY; MAMMALIAN-CELLS	Hexokinases catalyze the phosphorylation of glucose and initiate cellular glucose metabolism. Hexokinase II (HKII) is the principal hexokinase isoform in skeletal muscle, heart, and adipose tissue. Isoproterenol and exogenous cyclic AMP (cAMP) increase HKII gene transcription in L6 myotubes. Various segments of the HKII promoter that direct the expression of the chloramphenicol acetyltransferase reporter gene were transfected into L6 myotubes to identify basal and cAMP response elements. The 5'-flanking region that extends 90 base pairs upstream of the transcription start site includes a CCAAT box and a cAMP response element (CRE); both contribute to basal promoter activity and each provides an independent, maximal response 60 cAMP. An inverted CCAAT motif, or Y box, located just upstream of the CCAAT box, contributes to basal promoter activity but is not involved in the cAMP response. Home- and heterodimers composed of the CRE-binding protein and activating transcription factor-1 bind specifically to the CRE. The Y box and the CCAAT box specifically bind the factor NF-Y (also known as CBF).	VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University			Robey, R. Brooks/J-7099-2013	Robey, R. Brooks/0000-0001-5059-3965	NIDDK NIH HHS [DK 35107, DK46867, DK42502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, R01DK046867, R37DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BELL GI, 1993, J BIOL CHEM, V268, P19161; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; COONEY GJ, 1982, FEBS LETT, V148, P198, DOI 10.1016/0014-5793(82)80807-7; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEVLIN JT, 1992, DIABETES CARE, V15, P1690, DOI 10.2337/diacare.15.11.1690; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONG YH, 1993, NUCLEIC ACIDS RES, V21, P771, DOI 10.1093/nar/21.3.771; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HARRI MNE, 1975, ACTA PHYSIOL SCAND, V95, P391, DOI 10.1111/j.1748-1716.1975.tb10066.x; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG L, 1994, J VIROL, V68, P2108, DOI 10.1128/JVI.68.4.2108-2117.1994; ICHIHARA J, 1995, BBA-GENE STRUCT EXPR, V1260, P365, DOI 10.1016/0167-4781(94)00226-S; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KINANE TB, 1993, J BIOL CHEM, V268, P24669; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LIU F, 1993, J BIOL CHEM, V268, P6714; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; ODOHERTY RM, 1994, MED SCI SPORT EXER S, V26, pS90; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Robey RB, 1996, BIOTECHNIQUES, V20, P40; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SUZUKI H, 1990, ANAT RECORD, V226, P314, DOI 10.1002/ar.1092260307; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; TRONCHE F, 1991, J MOL BIOL, V221, P31; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG P, 1984, FEBS LETT, V176, P16, DOI 10.1016/0014-5793(84)80903-5	71	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17296	17303		10.1074/jbc.271.29.17296	http://dx.doi.org/10.1074/jbc.271.29.17296			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663388	hybrid			2022-12-25	WOS:A1996UX94300050
J	Ribeiro, RCJ; Cavalieri, RR; Lomri, N; Rahmaoui, CM; Baxter, JD; Scharschmidt, BF				Ribeiro, RCJ; Cavalieri, RR; Lomri, N; Rahmaoui, CM; Baxter, JD; Scharschmidt, BF			Thyroid hormone export regulates cellular hormone content and response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CELLS; NATRIURETIC FACTOR GENE; L-TRI-IODOTHYRONINE; P-GLYCOPROTEIN; ISOLATED HEPATOCYTES; TRANSPORT; TRIIODOTHYRONINE; DEXAMETHASONE; RESISTANCE; EXPRESSION	Actions of thyroid hormones (THs) are determined by intracellular free hormone concentration, Here we report that enhanced TH extrusion via a saturable, cold-sensitive mechanism lowers intracellular TH and causes TH resistance in hepatoma cells, Since these cells overexpress multidrug resistance P-glycoproteins and TH extrusion and resistance are blunted by verapamil, P-glycoproteins may mediate this resistance, Verapamil-inhibitable TH efflux was also found in primary hepatocytes, cardiocytes, and fibroblasts. These findings demonstrate that TH extrusion can modulate TH availability and action in mammalian cells.	UNIV CALIF SAN FRANCISCO,DIV GASTROENTEROL,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ribeiro, RCJ (corresponding author), UNIV CALIF SAN FRANCISCO,METAB RES UNIT,HSW 1141,POB 0540,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK41842, DK26270, DK26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK026270, R01DK041842] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI K, 1995, STEROIDS, V60, P173, DOI 10.1016/0039-128X(94)00007-Y; BECKPECCOZ P, 1994, THYROID, V4, P225, DOI 10.1089/thy.1994.4.225; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BLONDEAU JP, 1988, J BIOL CHEM, V263, P2685; BOURGEOIS S, 1993, MOL ENDOCRINOL, V7, P840, DOI 10.1210/me.7.7.840; BROWN RS, 1995, P NATL ACAD SCI USA, V92, P5421, DOI 10.1073/pnas.92.12.5421; CAVALIERI RR, 1984, ENDOCRINOLOGY, V114, P215, DOI 10.1210/endo-114-1-215; CHALMERS DK, 1993, J MED CHEM, V36, P1272, DOI 10.1021/jm00061a019; DOCTER R, 1988, ENDOCRINOLOGY, V123, P1520, DOI 10.1210/endo-123-3-1520; ECKEL J, 1979, BIOCHEM J, V182, P473, DOI 10.1042/bj1820473; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HENNEMANN G, 1986, ENDOCRINOLOGY, V119, P1870, DOI 10.1210/endo-119-4-1870; KRAGIE L, 1992, ENDOCRINOLOGY, V130, P1211, DOI 10.1210/en.130.3.1211; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KRENNING EP, 1978, FEBS LETT, V91, P113, DOI 10.1016/0014-5793(78)80029-5; KRENNING EP, 1982, FEBS LETT, V140, P229, DOI 10.1016/0014-5793(82)80900-9; LAKSHMANAN M, 1992, BIOCHIM BIOPHYS ACTA, V1133, P213, DOI 10.1016/0167-4889(92)90071-I; LAPOINTE MC, 1988, J BIOL CHEM, V263, P9075; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; MITCHELL AM, 1992, MOL CELL ENDOCRINOL, V87, P139, DOI 10.1016/0303-7207(92)90242-X; MOORADIAN AD, 1985, ENDOCRINOLOGY, V117, P2449, DOI 10.1210/endo-117-6-2449; MORENO M, 1994, ENDOCRINOLOGY, V135, P1004, DOI 10.1210/en.135.3.1004; MOVIUS EG, 1989, ENDOCRINOLOGY, V124, P1988, DOI 10.1210/endo-124-4-1988; MULLER B, 1995, NEW ENGL J MED, V333, P964, DOI 10.1056/NEJM199510123331503; NELSON EJ, 1992, ENDOCRINOLOGY, V130, P3246, DOI 10.1210/en.130.6.3246; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; OPPENHEIMER JH, 1985, J CLIN INVEST, V75, P147, DOI 10.1172/JCI111667; RAO GS, 1981, BIOCHEM J, V198, P457, DOI 10.1042/bj1980457; RAO GS, 1976, BIOCHEM BIOPH RES CO, V73, P98, DOI 10.1016/0006-291X(76)90502-7; RENNER EL, 1989, J CLIN INVEST, V83, P1225, DOI 10.1172/JCI114005; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SCHARSCHMIDT BF, 1981, P NATL ACAD SCI-BIOL, V78, P986, DOI 10.1073/pnas.78.2.986; TOPLISS DJ, 1993, METABOLISM, V42, P376, DOI 10.1016/0026-0495(93)90090-B; UEDA K, 1992, J BIOL CHEM, V267, P24248; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; WOLF DC, 1992, INT J CANCER, V52, P141, DOI 10.1002/ijc.2910520125; WU JP, 1989, J BIOL CHEM, V264, P6472; ZEMEL LR, 1988, ACTA ENDOCRINOL-COP, V117, P392, DOI 10.1530/acta.0.1170392	43	44	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17147	17151		10.1074/jbc.271.29.17147	http://dx.doi.org/10.1074/jbc.271.29.17147			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663353	hybrid			2022-12-25	WOS:A1996UX94300027
J	Bajzar, L; Morser, J; Nesheim, M				Bajzar, L; Morser, J; Nesheim, M			TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; CARBOXYPEPTIDASE; PROTHROMBIN; MODULATION; MECHANISM; INHIBITOR; SYSTEM; SITE	TAFI (thrombin-activatable fibrinolysis inhibitor) is a recently discovered plasma protein that can be activated by thrombin-catalyzed proteolysis to a carboxypeptidase B-like enzyme that inhibits fibrinolysis, This work shows that the thrombin-thrombomodulin complex, rather than free thrombin, is the most likely physiologic activator, Thrombomodulin increases the catalytic efficiency of the reaction by a factor of 1250, an effect expressed almost exclusively through an increase in k(cat). The kinetics of the reaction conform to a model whereby thrombin can interact with either TAFI (K-m = 1.0 mu M) or thrombomodulin (K-d = 8.6 nM), and either binary complex so formed can then interact with the third component to form the ternary thrombin-thrombomodulin-TAFI complex from which activated TAFI is produced with kcat = 1.2 s(-1). This work also shows that activated TAFI down-regulates tPA-induced fibrinolysis half maximally at a concentration of 1.0 nM in a system of purified components. This concentration of TAFI is about 2% of the level of the zymogen in plasma, which indicates that ample activated TAFI could be generated to very significantly modulate fibrinolysis in vivo. Therefore, TAFI in vitro and possibly in vivo defines an explicit molecular connection between the coagulation and fibrinolytic cascades, such that expression of activity in the former down-regulates the activity of the latter.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT MED, KINGSTON, ON K7L 3N6, CANADA; BERLEX BIOSCI, RICHMOND, CA 94804 USA	Queens University - Canada; Queens University - Canada								ASTRUP T, 1991, SEMIN THROMB HEMOST, V17, P161, DOI 10.1055/s-2007-1002606; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BURDICK MD, 1987, THROMB RES, V45, P413, DOI 10.1016/0049-3848(87)90230-1; COLLEN D, 1991, BLOOD, V78, P3114; DEFOUW NJ, 1990, ADV EXP MED BIOL, V281, P235; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MANN KG, 1991, ANN NY ACAD SCI, V614, P63; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; RAN AK, 1995, BIOCHEMISTRY-US, V34, P5811; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; WANG W, 1994, J BIOL CHEM, V269, P15937	24	542	562	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16603	16608		10.1074/jbc.271.28.16603	http://dx.doi.org/10.1074/jbc.271.28.16603			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663147	hybrid			2022-12-25	WOS:A1996UX12600030
J	Herrlich, A; Kuhn, B; Grosse, R; Schmid, A; Schultz, G; Gudermann, T				Herrlich, A; Kuhn, B; Grosse, R; Schmid, A; Schultz, G; Gudermann, T			Involvement of G(s) and G(i) proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA-GAMMA-SUBUNITS; LEYDIG TUMOR-CELLS; ALPHA-SUBUNITS; CA2+ MOBILIZATION; ACTIVATION; GONADOTROPIN; CLONING; IDENTIFICATION; VASOPRESSIN	Binding of lutropin/choriogonadotropin to its cognate receptor results in the activation of adenylyl cyclase and phospholipase C, The mechanism underlying the generation of this bifurcating signal is presently not known. To analyze the coupling mechanism of the LH receptor, activated G proteins were labeled with [alpha-P-32]GTP azidoanilide and identified by selective immunoprecipitation, In membranes of bovine corpora lutea and of L cells stably expressing the murine LH receptor (LHR cells), human chorionic gonadotropin (hCG) led to incorporation of the label into alpha(s) and alpha(i2). Stimulation of LHR cells or of L cells expressing the M(5) muscarinic receptor (LM5 cells) with the respective agonist resulted in activation of phospholipase C in both cell lines, However, alpha(q) and alpha(11) were only labeled upon stimulation of the Ms muscarinic receptor, Agonist-induced Ca2+ mobilization and inositol phosphate accumulation were partially sensitive to pertussis toxin, and the expression of the beta gamma-stimulable phospholipase C isoforms beta 2 and beta 3 could be demonstrated in LHR cells, Overexpression of phospholipase C-beta 2 led to increased hCG-stimulated inositol phosphate accumulation, and expression of a beta-ARK1 C-terminal polypeptide effectively suppressed hCG-mediated phosphatidylinositol hydrolysis, Thus, the LH receptor couples to both G(s) and G(i), and beta gamma-subunits released from either G protein contribute to the stimulation of phospholipase C-beta isoforms.	FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Free University of Berlin				Grosse, Robert/0000-0002-3380-5273				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ASCOLI M, 1989, J BIOL CHEM, V264, P6674; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BRISTOL JA, 1994, TRENDS ENDOCRIN MET, V5, P402, DOI 10.1016/1043-2760(95)92522-K; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; EASON MG, 1992, J BIOL CHEM, V267, P15795; FAURE M, 1994, J BIOL CHEM, V269, P7851; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUDERMANN T, 1992, MOL ENDOCRINOL, V6, P272, DOI 10.1210/me.6.2.272; GUDERMANN T, 1995, MOL CELL ENDOCRINOL, V110, P125, DOI 10.1016/0303-7207(95)03538-I; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUERMANN T, 1996, ANN REV PHARM TOXICO, V36, P429; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; INOUE Y, 1989, J BIOL CHEM, V264, P8504; JHON DY, 1993, J BIOL CHEM, V268, P6654; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LAUGWITZ KL, 1993, NEURON, V10, P23; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; PARK D, 1992, J BIOL CHEM, V267, P16048; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; QUINTANA J, 1994, J BIOL CHEM, V269, P8772; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; ROSENTHAL W, 1983, THESIS J LIEBIG U GI; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMID A, 1995, EUR J BIOCHEM, V228, P23, DOI 10.1111/j.1432-1033.1995.tb20223.x; SHI H, 1995, MOL ENDOCRINOL, V9, P734, DOI 10.1210/me.9.6.734; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TOMIC M, 1995, ENDOCRINOLOGY, V136, P3422, DOI 10.1210/en.136.8.3422; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141; ZHU X, 1993, J BIOL CHEM, V268, P1723; ZHU X, 1994, MOL PHARMACOL, V46, P460	54	117	121	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16764	16772		10.1074/jbc.271.28.16764	http://dx.doi.org/10.1074/jbc.271.28.16764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663226	hybrid			2022-12-25	WOS:A1996UX12600055
J	Lee, SL; Steinberg, RA				Lee, SL; Steinberg, RA			Pathways for degradation of the catalytic subunit of cAMP-dependent protein kinase differ in wild-type and kinase-negative S49 mouse lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ALPHA; CYTOPLASMIC CHAPERONIN; MESSENGER-RNA; UBIQUITIN; EXPRESSION; COMPLEX; MUTANT; SYSTEM; CONJUGATION; PROTEASES	The catalytic subunit of cAMP-dependent protein kinase radiolabeled with [S-35]methionine in wild-type S49 mouse lymphoma cells was degraded with half-lives of similar to 9.2 h in unstimulated cells and similar to 4.5 h in cells stimulated with a membrane-permeable cAMP analog. Turnover in kinase-negative mutant cells was about three times faster than in stimulated wild-type cells and appeared to involve a unique 47-kDa intermediate. Levels of catalytic subunit protein revealed by Western immunoblotting were consistent with the measured differences in turnover, but whereas the protein was mostly soluble in wild-type cell extracts, it was almost entirely insoluble in the mutant cell extracts. A substantial fraction of the catalytic subunit labeled in a 5-min pulse was soluble in kinase negative cell extracts, but most of this material was rendered insoluble by incubating the cells for an additional 30 min before extraction. Degradation of the catalytic subunit in kinase-negative, but not in wild-type, cells was inhibited strongly by two specific peptide aldehyde inhibitors of the proteasomal chymotrypsin-like activity. An inhibitor of the proteasomal protease that prefers branched-chain amino acids had less of an effect on catalytic subunit degradation in the mutant cells.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center								BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HADARI T, 1992, J BIOL CHEM, V267, P719; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGE G, 1990, MOL ENDOCRINOL, V4, P481, DOI 10.1210/mend-4-3-481; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SL, 1996, MOL CELL ENDOCRINOL, V116, P233, DOI 10.1016/0303-7207(95)03719-5; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STEINBERG RA, 1983, METHOD ENZYMOL, V99, P233; STEINBERG RA, 1978, CELL, V15, P1351, DOI 10.1016/0092-8674(78)90060-0; STEINBERG RA, 1991, MOL CELL BIOL, V11, P705, DOI 10.1128/MCB.11.2.705; TASKEN K, 1993, J BIOL CHEM, V268, P23483; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WETTERS TV, 1983, CELL, V35, P311, DOI 10.1016/0092-8674(83)90234-9; Zilversmit DB, 1943, J GEN PHYSIOL, V26, P325, DOI 10.1085/jgp.26.3.325	35	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16553	16558		10.1074/jbc.271.28.16553	http://dx.doi.org/10.1074/jbc.271.28.16553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663257	hybrid			2022-12-25	WOS:A1996UX12600022
J	Berry, DM; Antochi, R; Bhatia, M; MecklingGill, KA				Berry, DM; Antochi, R; Bhatia, M; MecklingGill, KA			1,25-dihydroxyvitamin D-3 stimulates expression and translocation of protein kinase C alpha and C delta via a nongenomic mechanism and rapidly induces phosphorylation of a 33-kDa protein in acute promyelocytic NB4 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC BIOLOGICAL RESPONSES; INDUCED DIFFERENTIATION; BINDING PROTEIN; IN-VITRO; LEUKEMIA; SUBSTRATE; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; IDENTIFICATION; PURIFICATION; MATURATION	1,25-Dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) primes NB4 cells for 12-O-tetradecanoylphorbol-13-acetate-induced monocytic differentiation in a dose- and sequence-dependent fashion, Experiments utilizing 1,25-(OH)(2)D-3 analogues and kinase/phosphatase inhibitors suggested that tyrosine kinase and serine/threonine phosphorylation cascades, rather than vitamin D-3 receptor-mediated signals, were involved in 1,25-(OH)(2)D-3 action. Here we show that NB4 cells express the alpha and delta (but not the beta, epsilon, and theta) isoforms of protein kinase C (PKC). Both authentic 1,25-(OH)(2)D-3 and the nongenomic analogue 1 alpha,25-dihydroxyprevitamin D-3 (HF) increased expression of PKC alpha and PKC delta. PKC alpha and PKC delta were translocated to the nucleus of the cell in response to 1,25-(OH)(2)D-3 or HF. The effects of HF were attenuated by the nongenomic antagonist 1 beta,25-dihydroxyvitamin D-3, suggesting that changes in PKC expression are mediated by a nongenomic signaling pathway. Consistent with the involvement of serine, threonine, and tyrosine phosphorylation cascades mediating 1,25-(OH)(2)D-3 action, enhanced phosphorylation of a variety of cellular proteins at serine and threonine residues and the specific enhanced phosphotyrosyl content of a 33-kDa protein (vdrp33) were observed immediately after 1,25-(OH)(2)D-3 addition. We propose that 1,25-(OH)(2)D-3 primes NB4 cells for 12-O-tetradecanoylphorbol-13-acetate-induced monocytic differentiation by increasing the expression of specific PRC isoforms and inducing the specific phosphorylation of key protein signaling intermediates.	UNIV GUELPH,DEPT HUMAN BIOL & NUTR SCI,GUELPH,ON N1G 2W1,CANADA	University of Guelph								AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131; BHATIA M, 1994, LEUKEMIA, V8, P1744; Bhatia M, 1996, EXP CELL RES, V222, P61, DOI 10.1006/excr.1996.0008; BHATIA M, 1995, J BIOL CHEM, V270, P15962, DOI 10.1074/jbc.270.27.15962; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN TC, 1993, J NUTR BIOCHEM, V4, P49, DOI 10.1016/0955-2863(93)90020-W; CIMLER BM, 1985, J BIOL CHEM, V260, P784; DELVA L, 1993, BLOOD, V82, P2175; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; ELDAR H, 1992, MOL BIOL CELL, V3, P1049, DOI 10.1091/mbc.3.9.1049; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; GUPTAROY B, 1992, J BIOL CHEM, V267, P15326; HASS R, 1993, CELL GROWTH DIFFER, V4, P657; JONES G, 1993, TRENDS ENDOCRIN MET, V4, P297, DOI 10.1016/1043-2760(93)90049-K; JURUTKA PW, 1993, BIOCHEMISTRY-US, V32, P8184, DOI 10.1021/bi00083a019; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KOBAYASHI T, 1993, BIOCHEM BIOPH RES CO, V196, P487, DOI 10.1006/bbrc.1993.2276; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANOTTE M, 1991, BLOOD, V77, P1080; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; OMAY SB, 1995, CANCER RES, V55, P774; RYVES WJ, 1994, CARCINOGENESIS, V15, P2501, DOI 10.1093/carcin/15.11.2501; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; YADA Y, 1989, BIOCHEM BIOPH RES CO, V163, P1517, DOI 10.1016/0006-291X(89)91152-2	34	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16090	16096		10.1074/jbc.271.27.16090	http://dx.doi.org/10.1074/jbc.271.27.16090			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663234	hybrid			2022-12-25	WOS:A1996UW35200037
J	Frolov, A; Woodford, JK; Murphy, EJ; Billheimer, JT; Schroeder, F				Frolov, A; Woodford, JK; Murphy, EJ; Billheimer, JT; Schroeder, F			Spontaneous and protein-mediated sterol transfer between intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; LIPID-TRANSFER PROTEIN; L-CELL FIBROBLASTS; CARRIER PROTEIN-2; PLASMA-MEMBRANE; SUBCELLULAR MEMBRANES; ESCHERICHIA-COLI; CHOLESTEROL; EXCHANGE; DEHYDROERGOSTEROL	Relatively little is known regarding intracellular cholesterol trafficking pathways. To resolve some of these potential pathways, spontaneous and protein-mediated sterol transfer was examined between different donor acceptor membrane pairs in vitro using L-cell fibroblast plasma membrane (PM) and microsomal (MICRO) and mitochondrial (MITO) membranes, Several new exciting insights were provided, First, the initial rate of spontaneous molecular sterol transfer was more dependent on the type of acceptor than donor membrane, i.e. spontaneous intracellular sterol trafficking was vectorial. Therefore, the rate of sterol desorption from the donor membrane was not necessarily the rate-limiting step in molecular sterol transfer. Second, the rate of molecular sterol transfer was not obligatorily correlated with the direction of the cholesterol gradient. For example, although PM had a 3.2-fold higher cholesterol/phospholipid ratio than MITO, spontaneous sterol transfer was 4-5 fold faster up (MITO to PM) rather than down (PM to MITO) the concentration gradient. Third, sterol carrier protein-2 differentially stimulated the initial rate of sterol transfer for all donor-acceptor combinations, being most effective with PM donors: PM-MICRO, 27-fold; and PM-MITO, Ig-fold, Sterol carrier protein-2 was less effective in enhancing sterol transfer in the reverse direction, i.e. MICRO-PM and MITO-PM (5- and 4-fold, respectively), Fourth, liver fatty acid-binding protein was limited in stimulating the initial rate of sterol transfer from PM to PM (1.5-fold), from PM to MITO (3-fold), and from MICRO to MITO (3-fold). In summary, these observations present important insights into potential sterol trafficking pathways between the major membrane components of the cell.	TEXAS A&M UNIV,TVMC,DEPT PHYSIOL & PHARMACOL,COLLEGE STN,TX 77843; ANDREW JERGENS CO,CINCINNATI,OH 45214; DUPONT MERCK PHARMACEUT CO,CARDIOVASC DEPT,WILMINGTON,DE 19898	Texas A&M University System; Texas A&M University College Station; DuPont					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41402] Funding Source: Medline; NIGMS NIH HHS [GM31651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Billheimer J T, 1990, Subcell Biochem, V16, P301; BILLHEIMER JT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P136, DOI 10.1016/0005-2760(90)90180-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH K, 1991, BIOCH LIPIDS LIPOPRO, P363; BORCHERS T, 1989, BIOCHIM BIOPHYS ACTA, V1002, P54, DOI 10.1016/0005-2760(89)90063-5; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BROWN RE, 1992, BIOCHIM BIOPHYS ACTA, V1113, P3375; BUTKO P, 1992, J BIOCHEM BIOPH METH, V24, P15, DOI 10.1016/0165-022X(92)90043-A; BUTKO P, 1990, BIOCHEMISTRY-US, V29, P4070, DOI 10.1021/bi00469a007; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; CORNELL RB, 1983, BIOCHIM BIOPHYS ACTA, V750, P504, DOI 10.1016/0005-2760(83)90191-1; CORNELL RB, 1980, J CELL BIOL, V86, P810, DOI 10.1083/jcb.86.3.810; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; EDWARDS PA, 1991, BIOCH LIPIDS LIPOPRO, P383; FISHER RT, 1984, CHEM PHYS LIPIDS, V36, P1; FISHER RT, 1985, J BIOL PHYS, V13, P13; GADELLA TWJ, 1994, EUR J BIOCHEM, V220, P1019, DOI 10.1111/j.1432-1033.1994.tb18707.x; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; HALE JE, 1982, EUR J BIOCHEM, V122, P649; HAPALA I, 1994, BIOCHEMISTRY-US, V33, P7682, DOI 10.1021/bi00190a023; INCERPI S, 1992, ARCH BIOCHEM BIOPHYS, V298, P35, DOI 10.1016/0003-9861(92)90090-J; JOHNSON WJ, 1994, J LIPID RES, V35, P563; KANDUTSCH AA, 1977, J BIOL CHEM, V252, P409; KAVECANSKY J, 1994, BIOCHEMISTRY-US, V33, P2880, DOI 10.1021/bi00176a018; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; Moncecchi DM, 1991, PHYSL BIOCH STEROLS, P1; MUCZYNSKI KA, 1983, BIOCHEMISTRY-US, V22, P6037, DOI 10.1021/bi00294a052; NEMECZ G, 1988, BIOCHEMISTRY-US, V27, P7740, DOI 10.1021/bi00420a024; NEMECZ G, 1988, BIOCHIM BIOPHYS ACTA, V943, P511, DOI 10.1016/0005-2736(88)90384-7; Nestler J. E., 1990, ADV CHOLESTEROL RES, P133; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P1889, DOI 10.1021/bi00406a014; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; Paulussen R J, 1990, Subcell Biochem, V16, P175; PAULUSSEN RJA, 1989, BIOCHIM BIOPHYS ACTA, V1001, P201, DOI 10.1016/0005-2760(89)90149-5; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; SCHROEDER F, 1989, BIOCHEMISTRY-US, V28, P5992, DOI 10.1021/bi00440a041; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P47; SCHROEDER F, 1990, LIPIDS, V25, P664; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; VANHEUSDEN GPH, 1985, BIOCHIM BIOPHYS ACTA, V846, P21, DOI 10.1016/0167-4889(85)90105-3; VOLPE JJ, 1981, J BIOL CHEM, V256, P2016; WIRTZ KWA, 1990, EXPERIENTIA, V46, P592, DOI 10.1007/BF01939698; WOODFORD JK, 1995, MOL CELL BIOCHEM, V152, P51; WOODFORD JK, 1994, BBA-BIOMEMBRANES, V1189, P52, DOI 10.1016/0005-2736(94)90279-8; WOODFORD JK, 1993, BIOCHIM BIOPHYS ACTA, V1145, P257, DOI 10.1016/0005-2736(93)90297-D; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; YEAGLE PL, 1990, ADV CHOLESTEROL RES, P111	64	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16075	16083		10.1074/jbc.271.27.16075	http://dx.doi.org/10.1074/jbc.271.27.16075			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663152	hybrid			2022-12-25	WOS:A1996UW35200035
J	Kobayashi, M; Matsuo, Y; Takimoto, A; Suzuki, S; Maruo, F; Shoun, H				Kobayashi, M; Matsuo, Y; Takimoto, A; Suzuki, S; Maruo, F; Shoun, H			Denitrification, a novel type of respiratory metabolism in fungal mitochondrion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRITE-INDUCIBLE CYTOCHROME-P-450; FUSARIUM-OXYSPORUM; NITRATE NITRITE; PARACOCCUS-DENITRIFICANS; ORIGINS; CDNA	Subcellular localization and coupling to ATP synthesis were investigated with respect to the denitrifying systems of two fungi, Fusarium oxysporum and Cylindrocarpon tonkinense. Dissimilatory nitrate reductase of F. oxysporum or nitrite reductase of C. tonkinense could be detected in the mitochondrial fraction prepared from denitrifying cells of each fungus. Fluorescence immunolocalization, cofractionation with mitochondrial marker enzymes, and cytochromes provided evidence that the denitrifying enzymes are co-purified with mitochondria. Respiratory substrates such as malate plus pyruvate, succinate, and formate were effective donors of electrons to these activities in the mitochondrial fractions, Moreover, nitrite and nitrate reduction were shown to be coupled to the synthesis of ATP with energy yields (P:NO3- or P:2e ratios) of 0.88 to 1.4, depending upon whether malate/pyruvate or succinate were provided as substrates, Nitrate or nitrite reductase activity was inhibited by inhibitors such as rotenone, antimycin A, and thenoyltrifluoroaeetone. Thus, fungal denitrification activities are localized to mitochondria and are coupled to the synthesis of ATP. The existence of these novel respiration systems are discussed with regard to the origin and evolution of mitochondria.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba								FERGUSON SJ, 1994, ANTON LEEUW INT J G, V66, P89, DOI 10.1007/BF00871634; FERRY JG, 1990, FEMS MICROBIOL LETT, V87, P377, DOI 10.1111/j.1574-6968.1990.tb04940.x; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KOBAYASHI M, 1995, J BIOL CHEM, V270, P4146, DOI 10.1074/jbc.270.8.4146; MARGULIS L, 1993, SYMBIOSIS CELL EVOLU, P305; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; NICHOLAS DJD, 1957, METHOD ENZYMOL, V3, P981; OBIKA K, 1993, BIOCHEM BIOPH RES CO, V196, P1255, DOI 10.1006/bbrc.1993.2387; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SHOUN H, 1992, FEMS MICROBIOL LETT, V94, P277, DOI 10.1111/j.1574-6968.1992.tb05331.x; SHOUN H, 1989, FEBS LETT, V244, P11, DOI 10.1016/0014-5793(89)81151-2; SHOUN H, 1991, J BIOL CHEM, V266, P11078; STOUTHAMER AH, 1992, ANTON LEEUW INT J G, V61, P1, DOI 10.1007/BF00572119; TANIMOTO T, 1992, BIOSCI BIOTECH BIOCH, V56, P2058, DOI 10.1271/bbb.56.2058; TOMURA D, 1994, J BIOCHEM-TOKYO, V116, P88, DOI 10.1093/oxfordjournals.jbchem.a124508; USUDA K, 1995, APPL ENVIRON MICROB, V61, P883, DOI 10.1128/AEM.61.3.883-889.1995; VANDEPEER Y, 1990, J MOL EVOL, V30, P463, DOI 10.1007/BF02101118; YAMANAKA T, 1962, J BIOCHEM-TOKYO, V51, P253, DOI 10.1093/oxfordjournals.jbchem.a127529; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; Zumft WG, 1992, PROKARYOTES, P554	22	142	150	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16263	16267		10.1074/jbc.271.27.16263	http://dx.doi.org/10.1074/jbc.271.27.16263			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663075	hybrid			2022-12-25	WOS:A1996UW35200060
J	Ricci, G; Caccuri, AM; LoBello, M; Rosato, N; Mei, G; Nicotra, M; Chiessi, E; Mazzetti, AO; Federici, G				Ricci, G; Caccuri, AM; LoBello, M; Rosato, N; Mei, G; Nicotra, M; Chiessi, E; Mazzetti, AO; Federici, G			Structural flexibility modulates the activity of human glutathione transferase P1-1 - Role of helix 2 flexibility in the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; HUMAN PLACENTA; SITE; PI	Presteady-state and steady-state kinetic studies performed on human glutathione transferase P1-1 (EC 2.5.1.18) with 1-chloro-2,4-dinitrobenzene as co-substrate indicate that the rate-determining step is a physical event that occurs after binding of the two substrates and before the sigma-complex formation, It may be a structural transition involving the ternary complex, This event can be related to diffusion-controlled motions of protein portions as k(cat)degrees/k(cat) linearly increases by raising the relative viscosity of the solution, Similar viscosity dependence has been observed for K-m(GSH), while K-m(CDNB) is independent, No change of the enzyme structure by viscosogen has been found by circular dichroism analysis. Thus, k(cat) and K-m(GSH) Seem to be related to the frequency and extent of enzyme structural motions modulated by viscosity. Interestingly, the reactivity of Cys-47 which can act as a probe for the flexibility of helix 2 is also modulated by viscosity, Its viscosity dependence parallels that observed for k(cat) and K-m(GSH), thereby suggesting a possible correlation between k(cat), K-m(GSH), and diffusion-controlled motion of helix 2, The viscosity effect on the kinetic parameters of C47S and C47S/C101S mutants confirms the involvement of helix 2 motions in the modulation of K,GSH, whereas a similar role on k(cat) cannot be ascertained unequivocally, The flexibility of helix 2 modulates also the homotropic behavior of GSH in these mutants, Furthermore, fluorescence experiments support a structural motion of about 4 Angstrom occurring between helix 2 and helix 4 when GSH binds to the G-site.	UNIV ROMA TOR VERGATA,DEPT EXPTL MED & BIOCHEM SCI,I-00133 ROME,ITALY; UNIV ROMA TOR VERGATA,DEPT CHEM SCI & TECHNOL,I-00133 ROME,ITALY; OSP PEDIAT IRCCS BAMBIN GESU,I-00165 ROME,ITALY	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Bambino Gesu	Ricci, G (corresponding author), UNIV ROMA TOR VERGATA,DEPT BIOL,I-00133 ROME,ITALY.		CACCURI, ANNA MARIA/AFU-2643-2022	Chiessi, Ester/0000-0001-7529-2755; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163				BROOKS CL, 1988, PROTEINS THEORETICAL, P1; CACCURI AM, 1994, BIOCHEM BIOPH RES CO, V200, P1428, DOI 10.1006/bbrc.1994.1610; CACCURI AM, 1991, ITAL J BIOCHEM, V40, P304; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; DESIDERI A, 1991, J BIOL CHEM, V266, P2063; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Habig W H, 1981, Methods Enzymol, V77, P398; IVANETICH KM, 1989, BIOCHIM BIOPHYS ACTA, V998, P7, DOI 10.1016/0167-4838(89)90111-8; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LOBELLO M, 1993, BIOCHEM BIOPH RES CO, V194, P804, DOI 10.1006/bbrc.1993.1893; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RICCI G, 1991, J BIOL CHEM, V266, P21409; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; Wolf AV, 1985, HDB CHEM PHYSICS, pD	22	74	75	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16187	16192		10.1074/jbc.271.27.16187	http://dx.doi.org/10.1074/jbc.271.27.16187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663072	hybrid			2022-12-25	WOS:A1996UW35200050
J	Das, A; Peterson, GC; Kanner, SB; Frevert, U; Parsons, M				Das, A; Peterson, GC; Kanner, SB; Frevert, U; Parsons, M			A major tyrosine-phosphorylated protein of Trypanosoma brucei is a nucleolar RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEIC-ACID BINDING; MOLECULAR-CLONING; POLYMERASE-I; CODING GENES; TRANSCRIPTION; FIBRILLARIN; SEQUENCE; GLYCINE; DOMAIN	We have previously identified a set of tyrosine-phosphorylated proteins with apparent molecular masses of 44-46 kDa as some of the major tyrosine phosphorylated species in the protozoan parasite Trypanosoma brucei. We now show that these molecules, herein named Nopp44/46, are localized in the nucleolus. Using monoclonal antibodies, we have isolated Nopp44/46 cDNA clones from expression libraries. Sequence analysis reveals that the predicted amino acid sequence of the molecule is composed of an N-terminal unique region, an internal acidic region, and C-terminal repeat region. Analysis of the cDNA clones and genomic Southern analysis indicated that Nopp44/46 belongs to a multigene family in which different gene copies are very similar but vary in the number of repeats. Interestingly, the repetitive amino acid sequence moth contains multiple RGG (Arg-Gly-Gly) boxes characteristic of RNA-binding proteins. In vitro binding experiments demonstrated that Nopp44/46 is indeed capable of binding nucleic acids. Competition experiments with different RNA homopolymers demonstrated that Nopp44/46 preferentially binds to poly(U). These studies suggest that Nopp44/46 may play a role in RNA metabolism in trypanosomes and raise the possibility that tyrosine phosphorylation may regulate the process.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; NYU,MED CTR,DEPT MED & MOLEC PARASITOL,NEW YORK,NY 10010	Center for Infectious Disease Research; University of Washington; University of Washington Seattle; Bristol-Myers Squibb; New York University				Parsons, Marilyn/0000-0003-3994-8096	NIAID NIH HHS [AI R01-31077] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031077] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; CAPPAI R, 1994, MOL BIOCHEM PARASIT, V64, P353, DOI 10.1016/0166-6851(94)00047-6; DAS A, 1994, J CELL SCI, V107, P3477; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; HARTSHORNE T, 1993, MOL CELL BIOL, V13, P144, DOI 10.1128/MCB.13.1.144; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIROSE T, 1994, MOL GEN GENET, V244, P360, DOI 10.1007/BF00286687; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KILEDJIAN M, 1992, EMBO J, V11, P2656; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; OHNO T, 1994, ONCOGENE, V9, P3087; PARSONS M, 1994, MOL BIOCHEM PARASIT, V63, P69, DOI 10.1016/0166-6851(94)90009-4; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; PYPE S, 1994, J BIOL CHEM, V269, P31457; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1989, EMBO J, V13, P4259; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; STAURT K, 1984, PARASITOLOGY, V70, P747; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0	33	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15675	15681		10.1074/jbc.271.26.15675	http://dx.doi.org/10.1074/jbc.271.26.15675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663171	hybrid			2022-12-25	WOS:A1996UV29900057
J	Schubert, C; Carel, K; DePaolo, D; Leitner, W; Draznin, B				Schubert, C; Carel, K; DePaolo, D; Leitner, W; Draznin, B			Interactions of protein kinase C with insulin signaling - Influence on GAP and SOS activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RAT ADIPOCYTES; PHORBOL ESTERS; RECEPTOR; P21RAS; CELLS; STIMULATION; PHOSPHORYLATION; ACID; METABOLISM	In this study, we investigated the influence of the protein kinase C (PKC)-dependent system upon the ability of insulin to stimulate p21(ras)-GTP loading in 3T3-L1 adipocytes, Activation of PRC by 12-0-tetradecanoyl-phorbol-13-acetate (TPA) did not affect the basal amount of p21(ras)-GTP GTP but significantly reduced insulin-induced increases in p21(ras)-GTP. This reduction was due to inhibition of the insulin's ability to stimulate guanine nucleotide exchange activity of Sos in cells incubated with 100 nw TPA for either 30 min or 3 h, TPA had no effect on basal activity of Sos. Depletion of PKC by an 18-h incubation with TPA or inhibition by bisindolylmaleimide resulted in profound inhibition of the insulin-induced p21(ras)-GTP loading. In contrast to PRC activation, removal of PK did not influence Sos activity but resulted in a 2-fold stimulation of GTPase activating protein (GAP), This effect of PB;C depletion is unique to 3T3-L1 adipocytes and was not observed in either 3T3-L1 fibroblasts or Rat-1 fibroblasts. Thus, it appears that in 3T3-L1 adipocytes, PKC has a constitutive inhibitory effect on GAP that permits insulin to activate Sos and p21(ras). Removal of this inhibitory influence activates GAP and reduces insulin-stimulated p21(ras)-GTP loading.	VET AFFAIRS MED CTR,SECT ENDOCRINOL 111H,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BERTI L, 1994, J BIOL CHEM, V269, P3381; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHERQUI G, 1986, ENDOCRINOLOGY, V118, P1759, DOI 10.1210/endo-118-5-1759; CHIN JE, 1993, J BIOL CHEM, V268, P6338; COGHLAN MP, 1994, BIOCHEM J, V303, P893, DOI 10.1042/bj3030893; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; FARESE RV, 1988, AM J MED, V85, P36, DOI 10.1016/0002-9343(88)90396-8; FARESE RV, 1984, J BIOL CHEM, V259, P7094; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KIRSCH D, 1985, BIOCHEM BIOPH RES CO, V128, P824, DOI 10.1016/0006-291X(85)90121-4; LANGLOIS J, 1995, ENDOCRINE, V3, P475, DOI 10.1007/BF02738820; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; LIN F, 1994, FEBS LETT, V352, P389; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MESSINA JL, 1987, ENDOCRINOLOGY, V121, P1227, DOI 10.1210/endo-121-4-1227; MUHLBACHER C, 1988, BIOCHEM J, V249, P865; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; RESNICK RJ, 1994, J BIOL CHEM, V269, P32336; SATOH T, 1992, J BIOL CHEM, V267, P24149; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STANDAERT ML, 1987, ENDOCRINOLOGY, V121, P941, DOI 10.1210/endo-121-3-941; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANDEWERVE G, 1985, BIOCHEM J, V225, P523, DOI 10.1042/bj2250523; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	34	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15311	15314		10.1074/jbc.271.26.15311	http://dx.doi.org/10.1074/jbc.271.26.15311			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663173	hybrid			2022-12-25	WOS:A1996UV29900004
J	Chang, PY; Jensen, J; Printz, RL; Granner, DK; Ivy, JL; Moller, DE				Chang, PY; Jensen, J; Printz, RL; Granner, DK; Ivy, JL; Moller, DE			Overexpression of hexokinase II in transgenic mice - Evidence that increased phosphorylation augments muscle glucose uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; DIABETIC RATS; MESSENGER-RNA; INSULIN; TRANSPORT; EXPRESSION; KINETICS; HYPERINSULINEMIA; METABOLISM; GLYCOLYSIS	Hexokinase II (HKII) is the predominant isozyme expressed in peripheral insulin-responsive tissues, To explore the role of HKII in muscle glucose metabolism, two lines of transgenic mice were generated where overexpression was restricted to striated muscle; HKII protein levels and activity were increased by 3-8-fold, Oral glucose tolerance, intravenous insulin tolerance, and insulin and lactate levels were unaffected in transgenic mice, There was a trend toward increased levels of muscle glycogen; however, glucose-6-phosphate levels were increased by 43% in transgenic skeletal muscle following in vivo glucose and insulin administration, Using 2-[H-3]deoxyglucose as a tracer, in. vitro basal and insulin-stimulated glucose uptake were determined in extensor digitorum longus, soleus, and epitrochlearis muscles. Maximal insulin-stimulated glucose uptake was increased by 17% (extensor digitorum longus), 34% (soleus), and 90% (epitrochlearis) in transgenic muscles; basal and submaximal glucose uptake was also modestly increased in soleus and epitrochlearis. These data suggest that increased muscle HKII (corresponding to the upper end of the physiologic range) may not be sufficient to augment net in vivo glucose homeostasis, However, glucose phosphorylation can represent a rate-limiting step for skeletal muscle glucose utilization since muscle glucose-6-phosphate levels are increased during in vivo hyperinsulinemia and hyperglycemia; furthermore, basal and insulin-mediated muscle glucose uptake can be increased by a selective increase in HKII expression.	BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; UNIV TEXAS,DEPT KINESIOL,EXERCISE PHYSIOL & METAB LAB,AUSTIN,TX 78712; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Texas System; University of Texas Austin; Vanderbilt University			Jensen, Jørgen/O-2245-2013		NIDDK NIH HHS [NIH-P30DK20593] Funding Source: Medline; PHS HHS [R01 45878, R01 46867] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alzaid Aus, 1993, P143; BENECKE H, 1993, DIABETES, V42, P206, DOI 10.2337/diabetes.42.1.206; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; Brozinick JT, 1996, BIOCHEM J, V313, P133, DOI 10.1042/bj3130133; BURCELIN R, 1993, AM J PHYSIOL, V265, pE392, DOI 10.1152/ajpendo.1993.265.3.E392; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; CHANG PY, 1994, J BIOL CHEM, V269, P16034; CHEUNG JY, 1978, AM J PHYSIOL, V234, pE70, DOI 10.1152/ajpendo.1978.234.1.E70; GALANTE P, 1995, DIABETES, V44, P646, DOI 10.2337/diabetes.44.6.646; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HINTZ CS, 1982, AM J PHYSIOL, V242, pC218, DOI 10.1152/ajpcell.1982.242.3.C218; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KATZ A, 1991, AM J PHYSIOL, V260, pE411, DOI 10.1152/ajpendo.1991.260.3.E411; KATZ A, 1988, AM J PHYSIOL, V255, pE942, DOI 10.1152/ajpendo.1988.255.6.E942; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; KONG XM, 1994, J BIOL CHEM, V269, P12963; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; LANG G, 1972, FLEXIBLE SYSTEM ENZY, P1238; LUECK JD, 1974, J BIOL CHEM, V249, P1341; MANCHESTER J, 1994, AM J PHYSIOL, V266, pE236; MANDARINO L, 1995, DIABETES, V44, pA75; MANDARINO LJ, 1986, AM J PHYSIOL, V251, pE489, DOI 10.1152/ajpendo.1986.251.4.E489; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; PENDERGRASS M, 1995, DIABETES, V44, pA197; PENDERGRASS M, 1994, DIABETES, V43, pA72; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; PRINTZ RL, 1995, DIABETES, V44, P290, DOI 10.2337/diabetes.44.3.290; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; REN JM, 1993, J BIOL CHEM, V268, P16113; REN JM, 1994, J BIOL CHEM, V269, P14396; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; SACCOMANI MP, 1996, IN PRESS AM J PHYSL; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VIITANEN PV, 1984, J BIOL CHEM, V259, P9679; WALTERS E, 1967, BIOCHEM J, V104, P778, DOI 10.1042/bj1040778; WEBER FE, 1990, EUR J BIOCHEM, V191, P85, DOI 10.1111/j.1432-1033.1990.tb19096.x; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	44	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14834	14839		10.1074/jbc.271.25.14834	http://dx.doi.org/10.1074/jbc.271.25.14834			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662926	hybrid			2022-12-25	WOS:A1996UT10600032
J	Dannelly, HK; Roseman, S				Dannelly, HK; Roseman, S			Active site phosphorylation of enzyme I of the bacterial phosphotransferase system by an ATP-dependent kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUGAR-TRANSPORT; SALMONELLA-TYPHIMURIUM; ISOCITRATE DEHYDROGENASE; ACETATE KINASE; PYRUVATE; PROTEINS; LYASE; PHOSPHOENOLPYRUVATE; PURIFICATION	Enzyme I (EI) of the bacterial phosphoenolpyruvate: glycose phosphotransferase system (PTS) is autocatalytically phosphorylated by P-enolpyruvate. We report here an ATP-dependent kinase (EI-K) from Escherichia coli that reversibly phosphorylates EI at its active site histidine; ATP and EI-K can therefore replace P-enolpyruvate. EI-K contains a bound cofactor that is lost during purification with concomitant loss of activity. NAD(+) and NADP(+) substitute for the cofactor and restore activity to the apoenzyme, whereas their analogues are inactive. The pyridine nucleotides do not activate EI-K by covalent modification (e.g. ADP-ribosylation), but must be present during the kinase reaction. NADH and NADPH are potent inhibitors of EI-K at all stages of purity, and enzyme activity in a mixture of NAD(+) and NADH depends on the ratio of the two pyridine nucleotides. Inhibition is observed with reduced beta-NMN and alpha-NADH, but neither is as effective as beta-NADH. The reverse reaction, the transfer of the phosphoryl moiety from phospho-EI to ADP, also requires NAD(+) or NADP(+). In the absence of NAD(+) or NADH, [P-32]phospho-EI is hydrolyzed to P-32(i), suggesting that EI-K can act as a phospho-EI phosphatase. EI kinase may serve as a link between PTS-driven sugar transport and the electron transport chain.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; BENESKI DA, 1982, J BIOL CHEM, V257, P4492; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; DANNELLY HK, 1992, P NATL ACAD SCI USA, V89, P11274, DOI 10.1073/pnas.89.23.11274; DANNELLY HK, 1989, BIOCHIMIE, V71, P1095, DOI 10.1016/0300-9084(89)90116-8; DANNELLY HK, 1991, P 91 ANN M AM SOC MI, P238; FOX DK, 1986, J BIOL CHEM, V261, P3487; FOX DK, 1986, J BIOL CHEM, V261, P3498; GARNAK M, 1979, SCIENCE, V203, P1111, DOI 10.1126/science.34215; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINN TC, 1979, J BIOL CHEM, V254, P1691; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MASON PW, 1981, J BIOL CHEM, V256, P1861; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P447; NIMMO GA, 1984, EUR J BIOCHEM, V141, P409, DOI 10.1111/j.1432-1033.1984.tb08206.x; PEKALA PH, 1982, PYRIDINE NUCLEOTIDE, P350; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reed L J, 1981, Curr Top Cell Regul, V18, P95; ROBERTSON EF, 1987, CURR MICROBIOL, V14, P347; ROBERTSON EF, 1988, J BIOL CHEM, V263, P2477; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; SAIER MH, 1994, MOL MICROBIOL, V13, P755; SNOEP JL, 1992, J GEN MICROBIOL, V138, P2015, DOI 10.1099/00221287-138-10-2015; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	36	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15285	15291		10.1074/jbc.271.25.15285	http://dx.doi.org/10.1074/jbc.271.25.15285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662900				2022-12-25	WOS:A1996UT10600093
J	Mukhopadhyay, CK; Ehrenwald, E; Fox, PL				Mukhopadhyay, CK; Ehrenwald, E; Fox, PL			Ceruloplasmin enhances smooth muscle cell and endothelial cell-mediated low density lipoprotein oxidation by a superoxide-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ATHEROSCLEROTIC LESIONS; MACROPHAGE DEGRADATION; SERUM CERULOPLASMIN; FERRITIN; PROTEINS; CULTURE; INVITRO; INFLAMMATION; NEUTROPHILS	Cultured vascular smooth muscle cells (SMC) and endothelial cells (EC) stimulate low density lipoprotein (LDL) oxidation by free radical-mediated, transition metal-dependent mechanisms. The physiological source(s) of metal ions is not known; however, purified ceruloplasmin, a plasma protein containing 7 coppers, oxidizes LDL in vitro, We now show that ceruloplasmin also increases LDL oxidation by vascular cells, In metal ion-free medium, human ceruloplasmin increased bovine aortic SMC- and EC-mediated LDL oxidation by up to 30- and 15-fold, respectively, The maximal response was at 100-300 mu g ceruloplasmin/ml, a level at or below the unevoked physiological plasma concentration, Oxidant activity was dependent on protein structure as a specific proteolytic cleavage or removal of one of the seven ceruloplasmin copper atoms inhibited activity, Three lines of evidence indicated a critical role for cellular superoxide (O-2(radical anion)) in ceruloplasmin-stimulated oxidation, First, the rate of production of O-2(radical anion) by cells correlated with their rates of LDL oxidation, Second, superoxide dismutase effectively blocked ceruloplasmin-stimulated oxidation by both cell types, Finally, O-2(radical anion) production by SMC quantitatively accounted for the observed rate of LDL oxidation, To show this, the course of O-2(radical anion) production by SMC was simulated by repeated addition of xanthine and xanthine oxidase to culture medium under cell free conditions, Neither ceruloplasmin nor O-2(radical anion) alone increased LDL oxidation, but together they completely reconstituted the oxidation rate of ceruloplasmin-stimulated SMC, These results are the first to show that ceruloplasmin stimulates EC- and SMC-mediated oxidation of LDL and that cell-derived O-2(radical anion) accounts quantitatively for metal-dependent, free radical-initiated oxidation of LDL by these cells.	CLEVELAND CLIN FDN, RES INST, DEPT CELL BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052692, P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52692, HL29582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDALLA DSP, 1992, ATHEROSCLEROSIS, V97, P149, DOI 10.1016/0021-9150(92)90128-4; AUTIO I, 1990, FEBS LETT, V277, P247, DOI 10.1016/0014-5793(90)80857-F; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; BELCH JJF, 1989, FREE RADICAL BIO MED, V6, P375, DOI 10.1016/0891-5849(89)90082-8; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BIEMOND P, 1984, J CLIN INVEST, V73, P1576, DOI 10.1172/JCI111364; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHISOLM GM, 1995, ATHEROSCLEROSIS CORO; CRAIG WY, 1995, ARTERIOSCL THROM VAS, V15, P733, DOI 10.1161/01.ATV.15.6.733; Czapski G, 1988, Free Radic Res Commun, V4, P231, DOI 10.3109/10715768809055147; DABBAGH AJ, 1995, J CLIN INVEST, V96, P1958, DOI 10.1172/JCI118242; EHRENWALD E, 1994, ARCH BIOCHEM BIOPHYS, V309, P392, DOI 10.1006/abbi.1994.1129; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FOX PL, 1995, LIFE SCI, V56, P1749, DOI 10.1016/0024-3205(95)00146-W; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HEINECKE JW, 1993, J LIPID RES, V34, P2051; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HIRAMATSU K, 1987, ARTERIOSCLEROSIS, V7, P55, DOI 10.1161/01.ATV.7.1.55; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOLLANDER W, 1979, ATHEROSCLEROSIS, V34, P391, DOI 10.1016/0021-9150(79)90064-9; JESSUP W, 1993, ATHEROSCLEROSIS, V99, P107, DOI 10.1016/0021-9150(93)90056-Z; KALANT N, 1992, BIOCHIM BIOPHYS ACTA, V1128, P211, DOI 10.1016/0005-2760(92)90310-R; KELNER MJ, 1990, J BIOL CHEM, V265, P1306; LAMB DJ, 1994, FEBS LETT, V352, P15, DOI 10.1016/0014-5793(94)00903-1; LAMB DJ, 1994, FEBS LETT, V338, P122, DOI 10.1016/0014-5793(94)80348-X; LOGAN JI, 1994, Q J MED, V87, P663; MANTTARI M, 1994, EUR HEART J, V15, P1599; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PAGANO PJ, 1995, AM J PHYSIOL-HEART C, V268, pH2274, DOI 10.1152/ajpheart.1995.268.6.H2274; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; Parthasarathys S., 1994, MODIFIED LIPOPROTEIN, P91; POWELL JT, 1987, J CARDIOVASC SURG, V28, P528; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REUNANEN A, 1992, AM J EPIDEMIOL, V136, P1082, DOI 10.1093/oxfordjournals.aje.a116573; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; STEINBRECHER UP, 1988, BIOCHIM BIOPHYS ACTA, V959, P20, DOI 10.1016/0005-2760(88)90145-2; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUNDERMAN FW, 1970, CLIN CHEM, V16, P903; SVINGEN BA, 1979, J BIOL CHEM, V254, P5892; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; SWAIN JA, 1994, FEBS LETT, V342, P49, DOI 10.1016/0014-5793(94)80582-2; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; VANHINSBERGH VWM, 1986, BIOCHIM BIOPHYS ACTA, V878, P49, DOI 10.1016/0005-2760(86)90343-7; WIELAND E, 1993, P NATL ACAD SCI USA, V90, P5929, DOI 10.1073/pnas.90.13.5929; YLAHERTTUALA S, 1991, ANN MED, V23, P561, DOI 10.3109/07853899109150518; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOSHIDA K, 1995, GENET, V9, P267	69	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14773	14778		10.1074/jbc.271.25.14773	http://dx.doi.org/10.1074/jbc.271.25.14773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663020	hybrid			2022-12-25	WOS:A1996UT10600023
J	Rintamaki, E; Kettunen, R; Aro, EM				Rintamaki, E; Kettunen, R; Aro, EM			Differential D1 dephosphorylation in functional and photodamaged photosystem II centers - Dephosphorylation is a prerequisite for degradation of damaged D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; CHLOROPLAST THYLAKOIDS; PHOTOINHIBITION; LIGHT; PHOTOSYNTHESIS; HETEROGENEITY; TEMPERATURE; MEMBRANES; LEAVES; CORE	Light dependence and kinetics of reversible phosphorylation of the D1 reaction center protein of Photosystem LI was studied in pumpkin leaves, At growth light, maximal phosphorylation of D1 was observed after illumination of 1 h, with higher phosphorylation rates at stronger irradiances, 70-85% of D1 became phosphorylated, corresponding to the proportion of the protein in appressed thylakoid membranes, Comparison of the kinetics of D1 phosphorylation and photoinactivation of Photosystem II revealed that D1 phosphorylation became saturated before any significant photoinhibition of Photosystem II could be detected. Dephosphorylation of D1 in both dim light and darkness was determined in leaves preilluminated with high light for various periods. Similar rates of D1 dephosphorylation were observed after short preillumination conditions that induce no significant loss of functional Photosystem II centers, In contrast, photodamage to Photosystem ZI centers significantly decreased the dephosphorylation rate of D1 in darkness, and no dephosphorylation occurred in leaves containing mainly damaged Photosystem II centers, Darkness also blocked the degradation of damaged D1 after photoinhibitory preillumination. Degradation of damaged D1 could be prevented even in dim light by sodium fluoride, an inhibitor of protein phosphatases, indicating that dephosphorylation is a prerequisite for D1 proteolysis. We conclude that in higher plants (i) high light induced photodamage to Photosystem II occurs in the centers containing phosphorylated D1. (ii) Dephosphorylation of phosphorylated and photodamaged D1 is associated with the repair cycle of inactivated Photosystem II and is a light-dependent reaction in. vivo, (iii) Dephosphorylation of D1 in functional Photosystem II, centers, however, occurs rapidly and independent of light, We suggest that two reversible phosphorylation cycles with spatially segregated protein phosphatases are involved in dephosphorylation of functional and damaged phosphorylated D1, respectively.			Rintamaki, E (corresponding author), UNIV TURKU,DEPT BIOL,FIN-20014 TURKU,FINLAND.		Aro, Eva-Mari/Q-8664-2017; Rintamaki, Eevi/T-6903-2017	Aro, Eva-Mari/0000-0002-2922-1435; Rintamaki, Eevi/0000-0002-1353-3995				ADIR N, 1990, J BIOL CHEM, V265, P12562; ALLEN JF, 1995, PHYSIOL PLANTARUM, V93, P196, DOI 10.1034/j.1399-3054.1995.930128.x; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANDERSON JM, 1994, PHOTOSYNTH RES, V41, P315, DOI 10.1007/BF00019409; ARO EM, 1993, PLANT PHYSIOL, V103, P835, DOI 10.1104/pp.103.3.835; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ARO EM, 1992, FEBS LETT, V297, P29, DOI 10.1016/0014-5793(92)80320-G; ARO EM, 1994, PLANT PHYSIOL, V104, P1033, DOI 10.1104/pp.104.3.1033; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1980, EUR J BIOCHEM, V104, P85, DOI 10.1111/j.1432-1033.1980.tb04403.x; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BRACHT E, 1994, Z NATURFORSCH C, V49, P439; CALLAHAN FE, 1990, J BIOL CHEM, V265, P15357; CLELAND RE, 1990, AUST J PLANT PHYSIOL, V17, P641, DOI 10.1071/PP9900641; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; EBBERT V, 1994, BBA-BIOENERGETICS, V1187, P335, DOI 10.1016/0005-2728(94)90007-8; ELICH TD, 1993, EMBO J, V12, P4857, DOI 10.1002/j.1460-2075.1993.tb06175.x; GIARDI MT, 1993, PLANTA, V190, P107, DOI 10.1007/BF00195681; GONG HS, 1995, BBA-BIOENERGETICS, V1228, P181, DOI 10.1016/0005-2728(94)00170-A; GREER DH, 1986, PLANTA, V168, P253, DOI 10.1007/BF00402971; GUENTHER JE, 1990, PHOTOSYNTH RES, V23, P105, DOI 10.1007/BF00030070; HAMMER MF, 1995, PHOTOSYNTH RES, V44, P107, DOI 10.1007/BF00018301; IKEUCHI M, 1987, PLANT PHYSIOL, V85, P638, DOI 10.1104/pp.85.3.638; KETTUNEN R, 1991, FEBS LETT, V290, P153, DOI 10.1016/0014-5793(91)81247-6; KETTUNEN R, 1992, RES PHOTOSYNTHESIS, V4, P309; Koivuniemi A, 1995, BIOCHEMISTRY-US, V34, P16022, DOI 10.1021/bi00049a016; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MIYAO M, 1994, BIOCHEMISTRY-US, V33, P9722, DOI 10.1021/bi00198a043; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P293; Rintamaki E, 1996, PLANT SCI, V115, P175, DOI 10.1016/0168-9452(96)04343-9; RINTAMAKI E, 1995, PLANTA, V195, P379, DOI 10.1007/BF00202595; RINTAMAKI E, 1994, PLANTA, V193, P520, DOI 10.1007/BF02411557; RNTAMAKI E, 1995, PHYSIOL PLANTARUM, V93, P191; SCHNETTGER B, 1994, PLANT CELL ENVIRON, V17, P55, DOI 10.1111/j.1365-3040.1994.tb00265.x; SILVERSTEIN T, 1993, FEBS LETT, V334, P101, DOI 10.1016/0014-5793(93)81690-2; SILVERSTEIN T, 1993, BIOCHIM BIOPHYS ACTA, V1183, P215, DOI 10.1016/0005-2728(93)90022-8; TYYSTJARVI E, 1990, PHOTOSYNTH RES, V26, P109, DOI 10.1007/BF00047082; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225	45	150	167	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14870	14875		10.1074/jbc.271.25.14870	http://dx.doi.org/10.1074/jbc.271.25.14870			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663006	hybrid			2022-12-25	WOS:A1996UT10600037
J	Thevissen, K; Ghazi, A; DeSamblanx, GW; Brownlee, C; Osborn, RW; Broekaert, WF				Thevissen, K; Ghazi, A; DeSamblanx, GW; Brownlee, C; Osborn, RW; Broekaert, WF			Fungal membrane responses induced by plant defensins and thionins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED TOBACCO CELLS; ACTIVATED CHANNELS; PYRULARIA THIONIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; INSECT DEFENSIN; MAMMALIAN-CELLS; ION CHANNELS; TIP GROWTH; PEPTIDES	Treatment of hyphae of Neurospora crassa with anti fungal plant defensins, i.e. Rs-AFP2 and Dm-AMP1 isolated from radish and dahlia seed, respectively, induced a rapid K+ efflux, Ca2+ uptake, and alkalinization of the incubation medium, The Rs-AFP2-induced alkalinization of the incubation medium could be inhibited with G-protein inhibitors. alpha-Hordothionin, an antifungal thionin from barley seed, caused a sustained increased Ca2+ uptake at subinhibitory concentrations but only a transient increased uptake at inhibitory concentrations, alpha-Hordothionin also caused increased K+ efflux and alkalinization of the medium, but these fluxes occurred more rapidly compared to those caused by plant defensins. Furthermore, alpha-hordothionin caused permeabilization of fungal hyphae to the non-metabolite alpha aminoisobutyric acid and, in addition, altered the electrical properties of artificial lipid bilayers, consistently leading to rupture of the lipid bilayers, The plant defensins did not form ion permeable pores in artificial membranes and did not exhibit substantial hyphal membrane permeabilization activity, Our results are consistent with the notion that thionins inhibit fungal growth as a result of direct protein-membrane interactions, whereas plant defensins might act via a different, possibly receptor-mediated, mechanism.	KATHOLIEKE UNIV LEUVEN,FA JANSSENS LAB GENET,B-3001 HEVERLEE,BELGIUM; UNIV PARIS 11,URA CNRS 1116,LAB BIOMEMBRANES,F-91405 ORSAY,FRANCE; MARINE BIOL ASSOC UNITED KINGDOM LAB,PLYMOUTH PL1 2PB,DEVON,ENGLAND; ZENECA AGROCHEM,JEALOTTS HILL RES STN,BRACKNELL RG42 6ET,BERKS,ENGLAND	KU Leuven; UDICE-French Research Universities; Universite Paris Saclay; Marine Biological Association United Kingdom			Thevissen, Karin/B-7003-2015	Thevissen, Karin/0000-0003-0275-9072				ATKINSON MM, 1985, PLANT PHYSIOL, V79, P843, DOI 10.1104/pp.79.3.843; BATTEY NH, 1993, NEW PHYTOL, V125, P307, DOI 10.1111/j.1469-8137.1993.tb03883.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BLEIN JP, 1991, PLANT PHYSIOL, V95, P486, DOI 10.1104/pp.95.2.486; BOHLMANN H, 1991, ANNU REV PLANT PHYS, V42, P227, DOI 10.1146/annurev.pp.42.060191.001303; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; Burland T. G., 1984, Mode of action of antifungal agents, P299; CARRASCO L, 1981, EUR J BIOCHEM, V116, P185, DOI 10.1111/j.1432-1033.1981.tb05317.x; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; EVANS J, 1989, P NATL ACAD SCI USA, V86, P5849, DOI 10.1073/pnas.86.15.5849; FELIX G, 1993, PLANT J, V4, P307, DOI 10.1046/j.1365-313X.1993.04020307.x; FLORACK DEA, 1994, PLANT MOL BIOL, V26, P25, DOI 10.1007/BF00039517; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Garcia-Olmedo F., 1989, OXFORD SURV PLANT MO, V6, P31; GARRILL A, 1993, EUR J CELL BIOL, V60, P358; GRANADO J, 1995, PLANT PHYSIOL, V107, P485, DOI 10.1104/pp.107.2.485; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOLZ R, 1970, J GEN PHYSIOL, V56, P125, DOI 10.1085/jgp.56.1.125; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Losel D. M., 1990, BIOCH CELL WALLS MEM, P119, DOI DOI 10.1007/978-3-642-74215-6_9; MALHO E, 1995, PLANT CELL, V7, P1173; MALHO R, 1994, PLANT J, V5, P331, DOI 10.1111/j.1365-313X.1994.00331.x; MATHIEU Y, 1991, PLANT J, V1, P333, DOI 10.1046/j.1365-313X.1991.t01-10-00999.x; MILLER AJ, 1990, P NATL ACAD SCI USA, V87, P9348, DOI 10.1073/pnas.87.23.9348; MORENO M, 1994, EUR J BIOCHEM, V223, P135, DOI 10.1111/j.1432-1033.1994.tb18974.x; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; NURNBERGER T, 1995, P NATL ACAD SCI USA, V92, P2338, DOI 10.1073/pnas.92.6.2338; OKADA T, 1973, AGR BIOL CHEM TOKYO, V37, P2289, DOI 10.1080/00021369.1973.10861004; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; SCHEEL D, 1991, ADV MOL GENETICS PLA, V1, P373; SLAYMAN CL, 1965, J GEN PHYSIOL, V49, P93, DOI 10.1085/jgp.49.1.93; SLAYMAN CL, 1965, J GEN PHYSIOL, V49, P69, DOI 10.1085/jgp.49.1.69; TEETER MM, 1990, PROTEINS, V8, P118, DOI 10.1002/prot.340080203; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TERRAS FRG, 1995, PLANT CELL, V7, P573, DOI 10.1105/tpc.7.5.573; TERRAS FRG, 1993, PLANT PHYSIOL, V103, P1311, DOI 10.1104/pp.103.4.1311; VERNON LP, 1992, TOXICON, V30, P701, DOI 10.1016/0041-0101(92)90004-O; VIARD MP, 1994, PLANT PHYSIOL, V104, P1245, DOI 10.1104/pp.104.4.1245; WALL F, 1995, MOL MEMBR BIOL, V12, P183	49	246	269	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15018	15025		10.1074/jbc.271.25.15018	http://dx.doi.org/10.1074/jbc.271.25.15018			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663029				2022-12-25	WOS:A1996UT10600058
J	Zhang, JS; Pratt, RE				Zhang, JS; Pratt, RE			The AT(2) receptor selectively associates with G(i alpha 2) and G(i alpha 3) in the rat fetus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ANGIOTENSIN-II; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; SUBTYPES; EXPRESSION; INHIBITION; CLONING; GI; IDENTIFICATION	The effects of angiotensin II are mediated by a family of seven transmembrane receptors. In the adult, the majority of the receptors are of the AT(1) isoform, which is coupled to heterotrimeric G proteins (either G(q alpha) or G(i alpha)). In contrast, the AT(2) receptor is expressed at low levels in the adult but is the major form expressed in the fetal and neonatal animal. Previous results have failed to show G protein coupling of the AT(2) receptor in the fetus. We now provide evidence that the AT(2) receptor is G protein-coupled. An antibody that binds several G(alpha) subunits immunoselected angiotensin II receptor-G(alpha) complexes. In addition, G(i alpha 1-3) antibody, which recognizes G(i alpha 1), G(i alpha 2) and G(i alpha 3), also co-immunoselect the AT(2) recep tor. Anti-G(i alpha 2) and anti-G(i alpha 3) antibodies were both able to co-immunoselected AT(2) receptor-G(i alpha) complexes, but consistent with the lack of G(i alpha 1) in the fetal extracts, anti-G(i alpha 1), antibodies did not nor did any other G protein-directed antisera. The finding that AT(2) receptor couples to both G(i alpha 2) and G(i alpha 3) raises the possibility that selective interactions between AT(2) receptor and different G proteins may result in specific cellular effects mediated by AT(2) stimulation.	STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, DIV CARDIOVASC MED, STANFORD, CA 94305 USA	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042663, P01HL048638] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48638, HL 42663] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BAUKAL AJ, 1994, J BIOL CHEM, V269, P24546; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOTTARI SP, 1991, EUR J PHARM-MOLEC PH, V207, P157, DOI 10.1016/0922-4106(91)90091-U; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; CIUFFO GM, 1993, P NATL ACAD SCI USA, V90, P11009, DOI 10.1073/pnas.90.23.11009; CODINA J, 1991, METHOD ENZYMOL, V195, P177; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; DZAU VJ, 1991, HYPERTENSION, V18, P100, DOI 10.1161/01.HYP.18.4_Suppl.II100; EDWARDS RM, 1993, J AM SOC NEPHROL, V3, P1643; FEUILLAN PP, 1993, REGUL PEPTIDES, V44, P159, DOI 10.1016/0167-0115(93)90239-5; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P177; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOIBUCHI Y, 1993, HYPERTENSION, V21, P1046, DOI 10.1161/01.HYP.21.6.1046; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V203, P1842, DOI 10.1006/bbrc.1994.2402; LYNCH CJ, 1989, J CLIN INVEST, V83, P2050, DOI 10.1172/JCI114116; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MUMBY S, 1988, J BIOL CHEM, V263, P2020; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OHMURA T, 1992, J EXP MED, V176, P887, DOI 10.1084/jem.176.3.887; POBINER BF, 1991, MOL PHARMACOL, V40, P156; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; REMAURY A, 1993, BIOCHEM J, V292, P283, DOI 10.1042/bj2920283; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SECHI LA, 1992, CIRC RES, V71, P1482, DOI 10.1161/01.RES.71.6.1482; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SHINOHARA H, 1992, J NEUROSCI, V12, P1275; SIEMENS IR, 1994, J NEUROCHEM, V62, P2106; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SUNG CP, 1994, J PHARMACOL EXP THER, V271, P429; TAKAHASI K, 1994, BIOCHEM BIOPH RES CO, V198, P60, DOI 10.1006/bbrc.1994.1009; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TIAN Y, 1995, AM J PHYSIOL-ENDOC M, V268, pE135, DOI 10.1152/ajpendo.1995.268.1.E135; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; TSUTSUMI K, 1993, BRAIN RES, V631, P212, DOI 10.1016/0006-8993(93)91537-3; VISWANATHAN M, 1991, BIOCHEM BIOPH RES CO, V179, P1361, DOI 10.1016/0006-291X(91)91723-P; WILLIAMS AG, 1990, BLOOD, V76, P721; WONG PC, 1990, J PHARMACOL EXP THER, V255, P584; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	49	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15026	15033		10.1074/jbc.271.25.15026	http://dx.doi.org/10.1074/jbc.271.25.15026			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663053	hybrid			2022-12-25	WOS:A1996UT10600059
J	Glerum, DM; Shtanko, A; Tzagoloff, A				Glerum, DM; Shtanko, A; Tzagoloff, A			Characterization of COX17, a yeast gene involved in copper metabolism and assembly of cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBUNIT-II; PET GENES; PROTEIN; LOCALIZATION; TRANSLATION; EXPRESSION; PRODUCTS	Mutations in the COX17 gene of Saccharomyces cerevisiae cause a respiratory deficiency due to a block. in the production of a functional cytochrome oxidase complex, Because cox17 mutants are able to express both the mitochondrially and nuclearly encoded subunits of cytochrome oxidase, the Cox17p most likely affects some late posttranslational step of the assembly pathway, A fragment of yeast nuclear DNA capable of complementing the mutation has been cloned by transformation of the cox17 mutant with a library of genomic DNA. Subcloning and sequencing of the COX17 gene revealed that it codes for a cysteine-rich protein with a molecular weight of 8,057. Unlike other previously described accessory factors involved in cytochrome oxidase assembly, all of which are components of mitochondria, Cox17p is a cytoplasmic protein, The cytoplasmic location of Cox17p suggested that it might have a function in delivery of a prosthetic group to the holoenzyme. A requirement of Cox17p in providing the copper prosthetic group of cytochrome oxidase is supported by the finding that a cox17 null mutant is rescued by the addition of copper to the growth medium. Evidence is presented indicating that Cox17p is not involved in general copper metabolism in yeast but rather has a more specific function in the delivery of copper to mitochondria.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University			Glerum, Moira/AHD-3271-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; POUTRE CG, 1987, GENETICS, V115, P637; RIPMASTER TL, 1992, P NATL ACAD SCI USA, V89, P11131, DOI 10.1073/pnas.89.23.11131; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SPENO H, 1995, J BIOL CHEM, V270, P25363, DOI 10.1074/jbc.270.43.25363; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	37	399	408	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14504	14509		10.1074/jbc.271.24.14504	http://dx.doi.org/10.1074/jbc.271.24.14504			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662933	hybrid			2022-12-25	WOS:A1996UQ66000083
J	Mao, ZX; NadalGinard, B				Mao, ZX; NadalGinard, B			Functional and physical interactions between mammalian achaete-scute homolog 1 and myocyte enhancer factor 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; DNA-BINDING; REGULATORY ELEMENTS; CARCINOMA-CELLS; GENE; DIFFERENTIATION; EXPRESSION; PROTEIN; IDENTIFICATION; INDUCTION	The mammalian achaete-scute homolog 1 (MASH1) protein is required for the early development of the nervous system. However, the molecular and biochemical mechanism by which MASH1 acts to determine neurogenesis are still unknown. The myocyte enhancer factor 2A (MEF2A) is a MADS transcription factor that is essential for the specification and differentiation of the muscle lineage. Here we show that MEF2A and MASH1 are coordinately induced during the differentiation of the teratocarcinoma cell line P19 along a neuronal lineage and that in transient transfection assays, MEF2A and MASH1 cooperatively activate gene expression, This cooperativity appears to be due to a specific physical interaction between MEF2A and MASH1. Taken together, these findings suggest that MASH1 via a cooperative interaction with MEF2A may regulate the expression of specific genes that are critical for neuronal differentiation.	HARVARD UNIV,SCH MED,DEPT CELL BIOL & PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	Mao, ZX (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT CARDIOL,DIV NEUROSCI,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007009] Funding Source: NIH RePORTER; NINDS NIH HHS [5-T32-NS07009-16] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; HOBSON GM, 1988, NUCLEIC ACIDS RES, V16, P8925, DOI 10.1093/nar/16.18.8925; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	26	38	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14371	14375		10.1074/jbc.271.24.14371	http://dx.doi.org/10.1074/jbc.271.24.14371			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662987	hybrid			2022-12-25	WOS:A1996UQ66000065
J	Odermatt, A; Kurzydlowski, K; MacLennan, DH				Odermatt, A; Kurzydlowski, K; MacLennan, DH			The V-max of the Ca2+-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) is not altered by Ca2+/Calmodulin dependent phosphorylation or by interaction with phospholamban	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-TRANSPORT; PROTEIN-KINASE; CA-2+ PUMP; MONOCLONAL-ANTIBODY; RYANODINE RECEPTOR; SKELETAL-MUSCLE; CALMODULIN; ATPASE; CA-2+-ATPASE; STIMULATION	Earlier studies (Hawkins, C., Xu, A., and Narayanan, N. (1994) J. Biol. Chem. 269, 31198-31206) have suggested that the V-max of Ca2+ uptake is enhanced up to 2-fold through phosphorylation of Ser(38) in the cardiac Ca2+-ATPase (SERCA2a) by calmodulin-dependent protein kinase (CaM kinase), It is difficult, however, to determine whether stimulation is caused by phosphorylation of the Ca2+-ATPase or by phosphorylation of phospholamban in cardiac microsomes. We have expressed SERCA2a in HEK-293 cells in the presence or absence of phospholamban and measured the effects on Ca2+ uptake activity of phosphorylation of microsomal proteins by CaM kinase or protein kinase A (PKA), We found no effect on the V-max of Ca2+ uptake following phosphorylation by CaM kinase or PKA in either the presence or absence of phospholamban, The K-0.5 for Ca2+ dependence of Ca2+ transport, however, was shifted following phosphorylation by either CaM kinase or PKA in those microsomes containing both SERCA2a and phospholamban, but not in those expressing only SERCA2a. Thus, we cannot confirm earlier reports of stimulation of SERCA2a activity by CaM kinase II phosphorylation of Ser(38). Our studies, however, emphasize the need for adequate controls for measurement of V-max.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA	University of Toronto				Odermatt, Alex/0000-0002-6820-2712				BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; BURK SE, 1989, J BIOL CHEM, V264, P18561; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHANG KH, 1992, BIOCHEMISTRY-US, V31, P4074; CHIESI M, 1989, FEBS LETT, V244, P240; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUJII J, 1988, FEBS LETT, V277, P51; GASSER JT, 1986, BIOCHEMISTRY-US, V25, P7615, DOI 10.1021/bi00371a052; GUPTA RC, 1988, MEMBRANE BIOCHEM, V7, P73; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HAWKINS C, 1995, MOL CELL BIOCHEM, V142, P131, DOI 10.1007/BF00928934; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; INUI M, 1986, J BIOL CHEM, V261, P1794; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIM HW, 1990, J BIOL CHEM, V265, P1702; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; KIRCHBERGER MA, 1982, J BIOL CHEM, V257, P5685; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KRANIAS EG, 1985, J BIOL CHEM, V260, P1006; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LOPASCHUK G, 1980, BIOCHEMISTRY-US, V19, P5603, DOI 10.1021/bi00565a022; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Mac Lennan D H, 1974, Recent Adv Stud Cardiac Struct Metab, V4, P507; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MCINTOSH DB, 1978, J BIOL CHEM, V253, P5140; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SEIFERT J, 1986, BIOCHIM BIOPHYS ACTA, V861, P399, DOI 10.1016/0005-2736(86)90447-5; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P1333; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1979, J BIOL CHEM, V254, P319; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TUANA BS, 1984, J BIOL CHEM, V259, P6979; VORHERR T, 1993, PROTEIN SCI, V2, P339; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; XU A, 1993, J BIOL CHEM, V268, P8394; XU ZC, 1989, J BIOL CHEM, V264, P16644; ZAHRADNIKOVA A, 1993, BIOPHYS J, V64, P991, DOI 10.1016/S0006-3495(93)81465-6	52	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14206	14213		10.1074/jbc.271.24.14206	http://dx.doi.org/10.1074/jbc.271.24.14206			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662932				2022-12-25	WOS:A1996UQ66000042
J	Piedrafita, FJ; Molander, RB; Vansant, G; Orlova, EA; Pfahl, M; Reynolds, WF				Piedrafita, FJ; Molander, RB; Vansant, G; Orlova, EA; Pfahl, M; Reynolds, WF			An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; THYROID-HORMONE; GENE-EXPRESSION; MYELOID-LEUKEMIA; RECEPTOR-ALPHA; RAR-ALPHA; SIGNALING PATHWAYS; DNA-BINDING; HL-60 CELLS; X-RECEPTOR	An Alu element preceding the myeloperoxidase gene (MPO) contains four hexamer motifs related to the consensus recognition sequence for nuclear hormone receptors (AGGTCA), arranged as direct repeats with spacing of 2, 4, and 2 nucleotides (DR-2-4-2), Gel shift experiments and transient transfection assays demonstrate that these sequences include binding sites for retinoic acid and thyroid hormone receptors and function in vivo to activate transcription of a chloramphenicol acetyl-transferase reporter gene, The first DR-2 elements of the series do not bind known receptors but do bind the SP1 transcription factor, Two alleles of the MPO gene exist that differ at one position within this element, resulting in one allele with and one without a strong SP1 binding site, The element with the SP1 site activates transcription by 25-fold in transient transfection assays, while the alternative allele confers severalfold less transcriptional activity, Most cases of acute myelocytic leukemia are homozygous for the allele with the SP1 binding site, suggesting this element plays an important role in regulating the MPO gene in myeloid leukemias, This MPO-Alu is a representative of an Alu subclass numbering similar to 400,000 copies, suggesting many genes may be regulated by such elements.	SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121						NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009118] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09118-09] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AUSTIN GE, 1993, LEUKEMIA, V7, P1145; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BRINI AT, 1993, J BIOL CHEM, V268, P1355; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P5992, DOI 10.1073/pnas.91.13.5992; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P6148, DOI 10.1073/pnas.91.13.6148; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CONSTANTIN D, 1994, ENVIRON HEALTH PERSP, V102, P161, DOI 10.2307/3431947; DEININGER PL, 1992, TRENDS GENET, V8, P307, DOI 10.1016/0168-9525(92)90262-3; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HELLSTRAND K, 1992, J INTERFERON RES, V12, P199, DOI 10.1089/jir.1992.12.199; HERMANN T, 1993, ONCOGENE, V8, P55; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOEFFLER HP, 1985, BLOOD, V65, P484; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; PFAHL M, 1994, VITAM HORM, V49, P327; PIEDRAFITA FJ, 1994, INDUCIBLE GENE EXPRE, V2, P157; PIEDRAFITA RJ, 1995, MOL ENDOCRINOL, V9, P563; RAMOS CL, 1995, BIOCHEM PHARMACOL, V49, P1079, DOI 10.1016/0006-2952(95)98504-3; ROBERTSON KA, 1992, BLOOD, V80, P1885; SAFFER JD, 1989, MOL CELL BIOL, V9, P355, DOI 10.1128/MCB.9.2.355; SAGOH T, 1988, ARCH BIOCHEM BIOPHYS, V262, P599, DOI 10.1016/0003-9861(88)90411-0; SUTCLIFFE JG, 1984, SCIENCE, V225, P1308, DOI 10.1126/science.6474179; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; TOBLER A, 1988, J CELL PHYSIOL, V136, P215, DOI 10.1002/jcp.1041360203; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANRENSBURG CEJ, 1992, MUTAT RES, V265, P255, DOI 10.1016/0027-5107(92)90054-6; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; YAMADA M, 1984, J BIOL CHEM, V259, P3021; ZAKI SR, 1989, BLOOD, V74, P2096; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	59	352	366	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14412	14420		10.1074/jbc.271.24.14412	http://dx.doi.org/10.1074/jbc.271.24.14412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662930	hybrid			2022-12-25	WOS:A1996UQ66000071
J	RodriguezCampos, A				RodriguezCampos, A			DNA knotting abolishes in vitro chromatin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID GYRASE; TOPOISOMERASE-II; DROSOPHILA-MELANOGASTER; SUPERCOILED DNA; DOUBLE HELIX; PROTEIN; RELAXATION; MICROSCOPY; COMPLEXES; INVITRO	Topological knots can be formed in vitro by incubating covalently closed double stranded DNA and purified topoisomerase II from the yeast Saccharomyces cerevisiae in an ATP-dependent reaction. Knotting production requires a starting enzyme/DNA mass ratio of 1. Analysis of knotted DNA was carried out by using both one- and two-dimensional agarose gel electrophoresis. The knots generated are efficiently untied, and give relaxed DNA rings, by catalytic amounts of topoisomerase II, but not by topoisomerase I. Time course analysis shows the knotting formation over relaxed and supercoiled DNA. When supercoiled DNA was used as a susbtrate, knots appear immediately whereas no transient relaxed rings were observed. The cell-free extract from Xenopus oocytes S-150 cannot assemble nucleosomes on knotted DNA templates as revealed by topological and micrococcal nuclease analysis. Nevertheless, the presence of knotted DNA templates does not inhibit the assembly over the relaxed plasmid. Finally, a pretreatment of knotted DNA with trace amounts of topoisomerase II before the addition of the S-150 yields a canonical minichromosome assembled in vitro. Taking into account these results, I suggest a mechanism of chromatin assembly regulation directed by topoisomerase II.	CSIC, CTR INVEST & DESARROLLO, DEPT BIOL MOLEC & CELULAR, E-08034 BARCELONA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC)								CHAMPOUX JJ, 1978, ANNU REV BIOCHEM, V47, P449, DOI 10.1146/annurev.bi.47.070178.002313; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GOTO T, 1982, J BIOL CHEM, V257, P5866; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HSIEH T, 1983, J BIOL CHEM, V258, P8413; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1981, NUCLEIC ACIDS RES, V9, P3979, DOI 10.1093/nar/9.16.3979; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LIU LF, 1976, J MOL BIOL, V106, P439, DOI 10.1016/0022-2836(76)90095-4; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1995, TRENDS BIOCHEM SCI, V20, P156, DOI 10.1016/S0968-0004(00)88993-8; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SHIMAMURA A, 1989, METHOD ENZYMOL, V170, P603; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SUGINO A, 1980, J BACTERIOL, V141, P1331, DOI 10.1128/JB.141.3.1331-1339.1980; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; van Holde KE., 1989, SPRINGER SERIES MOL; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WOLFFE A, 1992, CHROMATIN STRUCTURE; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14150	14155		10.1074/jbc.271.24.14150	http://dx.doi.org/10.1074/jbc.271.24.14150			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662864	hybrid			2022-12-25	WOS:A1996UQ66000034
J	Takimoto, GS; Hovland, AR; Tasset, DM; Melville, MY; Tung, L; Horwitz, KB				Takimoto, GS; Hovland, AR; Tasset, DM; Melville, MY; Tung, L; Horwitz, KB			Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOUSE GLUCOCORTICOID RECEPTOR; STEROID-HORMONE RECEPTORS; A-RECEPTORS; B-RECEPTORS; SITES; CAMP; ACTIVATION; LIGAND; IDENTIFICATION	To study the function of human progesterone receptor (hPR) phosphorylation, we have tested four sets of serine to alanine substitution mutants: 10 serine clusters, located in regions common tee both hPR isoforms (the M-series:mutants) were mutated in A-receptors and B-receptors; 6 serine clusters located in the B-upstream segment (BUS; the B-series mutants) were mutated individually and collectively and cloned into B-receptors and into BUS-DBD-NLS, a constitutive transactivator, in which the AF3 function of BUS is fused to the DNA binding domain (DBD) and nuclear localization signal (NLS) of hPR. Transcription by most of the M-series mutants resembles that of wild-type A- or B-receptors. Mutation of 3 sites, Ser(190) at the N terminus of A-receptors, a cluster of serines just upstream of the DBD, or Ser(676) in the hinge region, inhibits A transcription by 20-50% depending on cell or promotes context, These sites lie outside the AF1 activation function. M-series mutants are substrates for a hormone-dependent phosphorylation step, and they all bind well to DNA. Progressive mutation of the B-series clusters leads to the gradual dephosphorylation of BUS, but only the 6-site mutant, involving 10 serine residues, is completely dephosphorylated, These data suggest that in BUS alternate serines are phosphorylated or dephosphorylated at any time. However, even when EUS is completely dephosphorylated, both BUS-DBD-NLS and full-length th S-receptors remain strong transactivators. Mutant B-receptors also do not acquire the dominant negative properties of A-receptors, and they retain the ability to activate transcription in synergy with 8-Br-cAMP and antiprogestins. We conclude that phosphorylation has subtle effects on thee complex transcriptional repertoire that distinguishes the two hPR isoforms and does not influence transactivation mediated by AF1 or AF3, but subserves other functions.	UNIV COLORADO,HLTH SCI CTR,DIV ENDOCRINOL DIABET & METAB,PROGRAM MOLEC BIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Horwitz, Kathryn/0000-0001-7402-6455	NATIONAL CANCER INSTITUTE [R01CA026869, R37CA026869, R01CA055595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER; NCI NIH HHS [CA55595, CA26869] Funding Source: Medline; NIDDK NIH HHS [DK48238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; ARNOLD SF, 1995, P NATL ACAD SCI USA, V92, P7475, DOI 10.1073/pnas.92.16.7475; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; CHAUCHEREAU A, 1994, BIOCHEMISTRY-US, V33, P13295, DOI 10.1021/bi00249a016; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DENNER LA, 1987, J STEROID BIOCHEM, V27, P235, DOI 10.1016/0022-4731(87)90315-3; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; GILNEUR C, 1989, ONCOGENE, V4, P1247; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAHAM ML, 1992, CANCER RES, V52, P593; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HOECK W, 1990, J BIOL CHEM, V265, P5403; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; MASON SA, 1993, J BIOL CHEM, V268, P21501; MCDONNELL DP, 1994, J BIOL CHEM, V269, P11945; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; NAKAO M, 1992, ARCH BIOCHEM BIOPHYS, V298, P340, DOI 10.1016/0003-9861(92)90420-2; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; POLETTI A, 1992, GENE, V114, P51, DOI 10.1016/0378-1119(92)90706-U; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SHERIDAN PL, 1989, J BIOL CHEM, V264, P7054; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TAKIMOTO GS, 1993, TRENDS ENDOCRIN MET, V4, P1, DOI 10.1016/1043-2760(93)90056-K; TAKIMOTO GS, 1991, J STEROID BIOCHEM, V39, P687, DOI 10.1016/0960-0760(91)90368-F; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; WEIGEL NL, 1989, ENDOCRINOLOGY, V125, P2494, DOI 10.1210/endo-125-5-2494; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; WOO DDL, 1986, J BIOL CHEM, V261, P460; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	55	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13308	13316		10.1074/jbc.271.23.13308	http://dx.doi.org/10.1074/jbc.271.23.13308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662865	hybrid			2022-12-25	WOS:A1996UP38500005
J	Aharonovitz, O; Granot, Y				Aharonovitz, O; Granot, Y			Stimulation of mitogen-activated protein kinase and Na+/H+ exchanger in human platelets differential effect of phorbol ester and vasopressin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN BLOOD-PLATELETS; SMOOTH-MUSCLE CELLS; MAP KINASE; TYROSINE PHOSPHORYLATION; XENOPUS-OOCYTES; INTRACELLULAR PH; OKADAIC ACID; SET-POINT; PHOSPHATASE	Treatment of human platelets with phorbol 12-myris tate 13-acetate (PMA) and arginine vasopressin (AVP) increase the phosphorylation and activation of mitogen-activated protein kinase (MAPK). Electrophoretic retardation of MAPK mobility on SDS polyacrylamide gels was used for determination of MAPK phosphorylation, The activity of MAPK was tested in myelin basic protein (MBP)-containing polyacrylamide gels, In this study we compared the PMA and AVP signal transduction pathways leading to the activation of MAPKs and Na+/H+ exchanger (NHE). Both agonists stimulate MAPK and NHE activities in a similar time frame and concentration dependence, The MAPK and NHE activities induced by PMA were inhibited by staurosporine, a potent inhibitor for protein kinase C (PKC), and by MAPK kinase (MEK) inhibitor, PD98059, but were not affected by the tyrosine kinase inhibitor genistein, In contrast, both AVP-induced MAPK and NHE activities were inhibited by genistein and MEK inhibitor but were not affected by staurosporine, Immunoprecipitation studies demonstrate that PMA, but not AVP, enhances the basal phosphorylation of the NHE-1. In this study, MAPKs are suggested to be a part of converging signaling leading to NHE activation by PKC-dependent and AVP-tyrosine kinase-dependent pathways. We propose that the MAPK activation of the NHE-1 does not involve phosphorylation of this exchanger protein, On the other hand, PKC can lead to phosphorylation and to additional activation of the NHE-1 through a MAPK-independent pathway.	BEN GURION UNIV NEGEV,DEPT LIFE SCI,IL-84105 BEER SHEVA,ISRAEL	Ben Gurion University								AHARONOVITS O, 1992, BIOCHIM BIOPHYS ACTA, V1112, P181, DOI 10.1016/0005-2736(92)90390-8; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1993, ONCOGENE, V8, P2015; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; DEGROOT PG, 1990, BRIT J HAEMATOL, V75, P308; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1993, J BIOL CHEM, V268, P26037; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRANOT Y, 1990, BIOCHEM BIOPH RES CO, V168, P566, DOI 10.1016/0006-291X(90)92358-7; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; INABA K, 1988, CLIN ENDOCRINOL, V29, P377, DOI 10.1111/j.1365-2265.1988.tb02886.x; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIVNE AA, 1991, J HYPERTENS, V9, P1013, DOI 10.1097/00004872-199111000-00006; LIVNE AA, 1992, BIOCHIM BIOPHYS ACTA, V1135, P13, DOI 10.1016/0167-4889(92)90160-D; LIVNE AA, 1991, BIOCHIM BIOPHYS ACTA, V1068, P161, DOI 10.1016/0005-2736(91)90205-M; LIVNE AA, 1991, FEBS LETT, V284, P219, DOI 10.1016/0014-5793(91)80689-Z; NAKASHIMA S, 1994, BIOCHEM BIOPH RES CO, V198, P497, DOI 10.1006/bbrc.1994.1073; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; POUYSSEGUR J, 1994, RENAL PHYSIOL BIOCH, V17, P190; REZAI K, 1994, AM J PHYSIOL-CELL PH, V267, pC1717; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SAWYER WH, 1984, FED PROC, V43, P87; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	47	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16494	16499		10.1074/jbc.271.28.16494	http://dx.doi.org/10.1074/jbc.271.28.16494			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663100	hybrid			2022-12-25	WOS:A1996UX12600013
J	Annila, A; Lehtimaki, J; Mattila, K; Eriksson, JE; Sivonen, K; Rantala, TT; Drakenberg, T				Annila, A; Lehtimaki, J; Mattila, K; Eriksson, JE; Sivonen, K; Rantala, TT; Drakenberg, T			Solution structure of nodularin - An inhibitor of serine/threonine-specific protein phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC PEPTIDE TOXIN; MICROCYSTIN-LR; DIHYDROMICROCYSTIN-LR; HEPATOCELLULAR UPTAKE; AQUEOUS-SOLUTIONS; NMR-SPECTRA; BALTIC SEA; SPUMIGENA; DYNAMICS; POTENT	The three dimensional solution structure of nodularin was studied by NMR and molecular dynamics simulations. The conformation in water was determined from the distance and dihedral data by distance geometry and refined by iterative relaxation matrix analysis. The cyclic backbone adopts a well defined conformation but the remote parts of the side chains of arginine as well as the amino acid derivative Adda have a large spatial dispersion. For the unusual amino acids the partial charges were calculated and nodularin was subjected to molecular dynamic simulations in water. A good agreement was found between experimental and computational data with hydrogen bonds, solvent accessibility, molecular motion, and conformational exchange. The three-dimensional structure resembles very closely that of microcystin-LR in the chemically equivalent segment. Therefore, it is expected that the binding of both microcystins and nodularins to serine/threonine specific protein phosphatases is similar on an atomic level.	UNIV HELSINKI, DEPT APPL CHEM & MICROBIOL, FIN-00014 HELSINKI, FINLAND; UNIV OULU, DEPT PHYS SCI, FIN-90571 OULU, FINLAND; UNIV OULU, DIV BIOPHYS, FIN-90571 OULU, FINLAND; UNIV OULU, DIV PHYS, FIN-90571 OULU, FINLAND; TURKU CTR BIOTECHNOL, FIN-20150 TURKU, FINLAND	University of Helsinki; University of Oulu; University of Oulu; University of Oulu	Annila, A (corresponding author), VTT CHEM TECHNOL, POB 1401, FIN-02044 Espoo, FINLAND.		Rantala, Tapio T./B-7789-2013	Rantala, Tapio T./0000-0001-8581-502X; Sivonen, Kaarina/0000-0002-2904-0458				BAGU JR, 1995, STRUCT BIOL, V2, P114; BARFORD D, 1994, J MOL BIOL, V235, P763, DOI 10.1006/jmbi.1994.1027; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; *BIOS TECHN, 1994, NMRCHIT US GUID, V5; *BIOS TECHN, 1993, DMOL US GUID, V5; BOELENS R, 1988, J MOL STRUCT, V173, P299, DOI 10.1016/0022-2860(88)80062-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Bystrov V. F., 1976, PROGR NMR SPECTROSCO, V10, P41; Carmichael W. W., 1998, HDB NATURAL TOXINS, V3, P121; CARMICHAEL WW, 1988, APPL ENVIRON MICROB, V54, P2257, DOI 10.1128/AEM.54.9.2257-2263.1988; CARMICHAEL WW, 1988, TOXICON, V26, P971, DOI 10.1016/0041-0101(88)90195-X; CAVANAGH J, 1990, J MAGN RESON, V88, P72, DOI 10.1016/0022-2364(90)90109-M; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DESILVA ED, 1992, TETRAHEDRON LETT, V33, P1561, DOI 10.1016/S0040-4039(00)91674-5; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; ERIKSSON JE, 1990, BIOCHIM BIOPHYS ACTA, V1025, P60, DOI 10.1016/0005-2736(90)90190-Y; ERIKSSON JE, 1990, BIOCHEM BIOPH RES CO, V173, P1347, DOI 10.1016/S0006-291X(05)80936-2; ERIKSSON JE, 1988, TOXICON, V26, P161, DOI 10.1016/0041-0101(88)90168-7; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HALKIDES CJ, 1995, J BIOMOL NMR, V5, P362; HARADA K, 1990, CHEM RES TOXICOL, V3, P473, DOI 10.1021/tx00017a014; HAVEL TF, 1979, BIOPOLYMERS, V18, P73, DOI 10.1002/bip.1979.360180108; HIRSHFELD FL, 1977, THEOR CHIM ACTA, V44, P129, DOI 10.1007/BF00549096; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JORGENSEN WL, 1982, J CHEM PHYS, V77, P4156, DOI 10.1063/1.444325; LAAKSONEN L, 1992, J MOL GRAPHICS, V10, P33, DOI 10.1016/0263-7855(92)80007-Z; LEHTIMAKI J, 1994, ARCH HYDROBIOL, V130, P269; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Martin M. L., 1980, PRACTICAL NMR SPECTR; MATSUSHIMA R, 1990, BIOCHEM BIOPH RES CO, V171, P867, DOI 10.1016/0006-291X(90)91226-I; MCINTYRE L, 1992, J MAGN RESON, V96, P425, DOI 10.1016/0022-2364(92)90098-R; MELLGREN G, 1993, EXP CELL RES, V205, P293, DOI 10.1006/excr.1993.1089; MERILUOTO JAO, 1990, TOXICON, V28, P1439, DOI 10.1016/0041-0101(90)90157-3; *MOL SIM INC, 1992, CHARMM; *MOL SIM INC, 1994, QUANT; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; NAMIKOSHI M, 1994, J ORG CHEM, V59, P2349, DOI 10.1021/jo00088a014; NISHIWAKIMATSUSHIMA R, 1992, J CANCER RES CLIN, V118, P420, DOI 10.1007/BF01629424; RANTALA TT, 1986, CHEM PHYS, V109, P261, DOI 10.1016/0301-0104(86)87056-2; RINEHART KL, 1988, J AM CHEM SOC, V110, P8557, DOI 10.1021/ja00233a049; ROUHIAINEN L, 1995, J BACTERIOL, V177, P6021, DOI 10.1128/jb.177.20.6021-6026.1995; RUDOLPHBOHNER S, 1994, FEBS LETT, V349, P319, DOI 10.1016/0014-5793(94)00680-6; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SIVONEN K, 1989, APPL ENVIRON MICROB, V55, P1990, DOI 10.1128/AEM.55.8.1990-1995.1989; SIVONEN K, 1989, HYDROBIOLOGIA, V185, P3, DOI 10.1007/BF00006062; SODANO P, 1993, J MAGN RESON SER A, V104, P88, DOI 10.1006/jmra.1993.1192; STATES DJ, 1982, J MAGN RESON, V55, P151; Trogen GB, 1996, BIOCHEMISTRY-US, V35, P3197, DOI 10.1021/bi952368s; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VOSKO SH, 1980, CAN J PHYS, V58, P1200, DOI 10.1139/p80-159; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; [No title captured]	58	47	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16695	16702		10.1074/jbc.271.28.16695	http://dx.doi.org/10.1074/jbc.271.28.16695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663277	hybrid			2022-12-25	WOS:A1996UX12600045
J	Blackhart, BD; Emilsson, K; Nguyen, D; Teng, W; Martelli, AJ; Nystedt, S; Sundelin, J; Scarborough, RM				Blackhart, BD; Emilsson, K; Nguyen, D; Teng, W; Martelli, AJ; Nystedt, S; Sundelin, J; Scarborough, RM			Ligand cross-reactivity within the protease-activated receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THROMBIN RECEPTOR; MOLECULAR-CLONING; AGONIST PEPTIDES; SMOOTH-MUSCLE; PLATELET; PHENYLALANINE; ENDOTHELIUM; MECHANISM	Recently, a second member of the protease-activated receptor (PAR) family, named PAR-2, has been identified, Similar to the thrombin receptor, PAR-2 appears to be activated by proteolytic-mediated exposure of a ''tethered ligand'' sequence and can also be activated by the corresponding synthetic peptides, Similarities in the amino acid sequence of the receptors' tethered ligand sequences suggest that their respective agonist peptides might not be absolutely specific for their particular receptors, To test this, the receptor specificity of each agonist has been determined by measuring the responses of Xenopus oocytes expressing the thrombin receptor or PAR-2 to agonist peptides or enzymes, Thrombin receptors responded to thrombin, the human thrombin receptor-activating peptide SFLLRNP-NH2 (TRAP) (EC(50) = 0.1 mu m), and Xenopus TRAP, TFRIFD-NH2 (EC(50) = 1 mu M), but did not show any increase in calcium efflux over control levels with trypsin (50 mu M) or PAR-2 agonist peptides (100 mu M). Human and murine PAR-2 receptors responded comparably to human and murine PAR-2 agonist peptides (SLIGKVD and SLIGRL, respectively) (EC(50) = 0.5-2.0 mu M) and trypsin, but not to thrombin, PAR-2 was also found to be responsive to TRAP (EC(50) = 1 mu M) but was unresponsive to Xenopus TRAP (50 mu M). Responses to additional peptide agonist analogs suggest that an amino-terminal serine is critical for PAR-2 agonist activity.	LUND UNIV,WALLENBERG LAB,DIV MOLEC NEUROBIOL,S-22007 LUND,SWEDEN	Lund University	Blackhart, BD (corresponding author), COR THERAPEUT INC,256 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							ANTONACCIO MJ, 1994, EUR J PHARMACOL, V256, P37, DOI 10.1016/0014-2999(94)90613-0; BAHOU WF, 1993, BLOOD, V82, P1532, DOI 10.1182/blood.V82.5.1532.bloodjournal8251532; BLACKHART BD, 1994, GROWTH FACTORS, V11, P17, DOI 10.3109/08977199409015048; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; CHEN J, 1994, J BIOL CHEM, V269, P16041; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; COUGHLIN SR, 1994, P NATL ACAD SCI USA, V91, P9200, DOI 10.1073/pnas.91.20.9200; COUGHLIN SR, 1992, Patent No. 9214750; DERIAN CK, 1995, GHROMB RES, V78, P505; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; Hollenberg MD, 1996, MOL PHARMACOL, V49, P229; HOLLENBERG MD, 1993, MOL PHARMACOL, V43, P921; JENKINS AL, 1995, J CELL SCI, V108, P3059; JENKINS AL, 1994, J BIOL CHEM, V269, P17104; JONES LG, 1989, MOL PHARMACOL, V36, P142; MURAMATSU I, 1992, CAN J PHYSIOL PHARM, V70, P996, DOI 10.1139/y92-137; NATARAJAN S, 1985, INT J PEPT PROT RES, V45, P141; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NOSE T, 1993, BIOCHEM BIOPH RES CO, V193, P694, DOI 10.1006/bbrc.1993.1680; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PICKETT WC, 1976, BIOCHEM J, V160, P405, DOI 10.1042/bj1600405; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Seiler SM, 1996, MOL PHARMACOL, V49, P190; SHIMOHIGASHI Y, 1994, BIOCHEM BIOPH RES CO, V203, P366, DOI 10.1006/bbrc.1994.2191; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TESFAMARIAM B, 1994, CIRC RES, V74, P930, DOI 10.1161/01.RES.74.5.930; TESFAMARIAM B, 1993, AM J PHYSIOL, V265, pH1744, DOI 10.1152/ajpheart.1993.265.5.H1744; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YANG SG, 1992, LIFE SCI, V51, P1325, DOI 10.1016/0024-3205(92)90631-X	35	202	211	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16466	16471		10.1074/jbc.271.28.16466	http://dx.doi.org/10.1074/jbc.271.28.16466			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663335	hybrid			2022-12-25	WOS:A1996UX12600009
J	Bitting, L; Naidu, A; Cordell, B; Murphy, GM				Bitting, L; Naidu, A; Cordell, B; Murphy, GM			beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MESSENGER-RNA; QUANTIFICATION; EXPRESSION; ASTROCYTES; DEPOSITS; PLAQUES; DOMAIN; BRAIN	beta-Amyloid protein (beta AP) deposition is a neuropathologic hallmark of Alzheimer's disease (AD). Yet, the source of cerebral beta AP in AD is controversial. We examined the production of beta AP by the BV-2 immortalized microglial cell Line using a sensitive enzyme immunoassay. Constitutive production of beta AP was detected in conditioned media from unstimulated BV-2 cells. Further, production of beta AP was induced by treatment of cultures by lipopolysaccharide (LPS) or beta AP-(25-35) and was inhibited by the calpain protease inhibitor MDL 28170. Treatment of BV-2 cells with LPS or beta AP-(25-35) did not affect cell-associated beta-amyloid precursor protein levels. These findings suggest that microglia may be an important source of beta AP in AD, and that microglial production of beta AP may be augmented by proinflammatory stimuli or by beta AP itself.	STANFORD UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,NEUROSCI RES LABS,STANFORD,CA 94305; SCIOS NOVA INC,MT VIEW,CA 94043	Stanford University; Scios								ALLEN JS, 1991, NEUROSCI LETT, V132, P109, DOI 10.1016/0304-3940(91)90445-Y; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Auger M. J., 1992, MACROPHAGE, P1; BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BITTING L, 1994, NEUROSCI LETT, V165, P117, DOI 10.1016/0304-3940(94)90723-4; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CRAS P, 1990, AM J PATHOL, V137, P241; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; DICKSON DW, 1991, LAB INVEST, V64, P135; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GARDELLA JE, 1992, LAB INVEST, V67, P303; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1991, J NEUROSCI, V11, P3783; HAGA S, 1989, ACTA NEUROPATHOL, V77, P569, DOI 10.1007/BF00687883; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MONNING U, 1994, FEBS LETT, V342, P267, DOI 10.1016/0014-5793(94)80514-8; MORATO E, 1993, FEBS LETT, V336, P275, DOI 10.1016/0014-5793(93)80819-G; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; MURPHY GM, 1995, NEUROSCI LETT, V196, P153, DOI 10.1016/0304-3940(95)11862-Q; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SOLA C, 1993, NEUROSCIENCE, V53, P267, DOI 10.1016/0306-4522(93)90304-X; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Wisniewski HM, 1973, PROGR NEUROPATHOLOGY, V2, P1; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	40	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16084	16089		10.1074/jbc.271.27.16084	http://dx.doi.org/10.1074/jbc.271.27.16084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663228	hybrid			2022-12-25	WOS:A1996UW35200036
J	Kuo, SM; Aronson, PS				Kuo, SM; Aronson, PS			Pathways for oxalate transport in rabbit renal microvillus membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; BASOLATERAL MEMBRANE; SULFATE TRANSPORT; ANION-EXCHANGE; OH EXCHANGE; ABSORPTION; FORMATE; TUBULE; CORTEX	Recent evidence suggests that apical membrane Cl--oxalate exchange plays a major role in mediating Cl--absorption in the renal proximal tubule. To sustain steady-state Cl- absorption by a mechanism of exchange for intracellular oxalate requires the presence of one or more pathways for recycling oxalate from lumen to cell. Accordingly, we evaluated the mechanisms of oxalate transport in luminal membrane vesicles isolated from the rabbit renal cortex, We found that transport of oxalate by Na+ cotransport is negligible compared to the transport of sulfate, In contrast, we demonstrated that oxalate shares the electroneutral pathway mediating Na+-independent sulfate-carbonate exchange. We also demonstrated the presence of OH--oxalate exchange (indistinguishable from H+-oxalate cotransport). The process of OH--oxalate exchange was electrogenic and partially inhibited by Cl-, indicating that it occurs, at least in part, as a mode of the Cl--oxalate exchanger described previously. An additional component of OH--oxalate exchange was insensitive to inhibition by either Cl- or sulfate, suggesting that it takes place by neither the Cl--oxalate exchanger nor the sulfate-carbonate exchanger, We conclude that multiple anion exchange mechanisms exist by which oxalate can recycle from lumen to cell to sustain Cl- absorption occurring via apical membrane Cl--oxalate exchange in the renal proximal tubule.	YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Yale University; Yale University					NIDDK NIH HHS [DK-17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; BASTLEIN C, 1986, AM J PHYSIOL, V250, pF226, DOI 10.1152/ajprenal.1986.250.2.F226; JENNINGS ML, 1988, J GEN PHYSIOL, V92, P161, DOI 10.1085/jgp.92.2.161; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; KUO SM, 1988, J BIOL CHEM, V263, P9710; KUO SM, 1988, FASEB J, V2, pA753; LOW I, 1984, AM J PHYSIOL, V246, pF334, DOI 10.1152/ajprenal.1984.246.3.F334; LUCKE H, 1979, BIOCHEM J, V182, P223; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PRITCHARD JB, 1983, P NATL ACAD SCI-BIOL, V80, P2603, DOI 10.1073/pnas.80.9.2603; PRITCHARD JB, 1987, AM J PHYSIOL, V252, pF346, DOI 10.1152/ajprenal.1987.252.2.F346; SCHNEIDER EG, 1984, J BIOL CHEM, V259, P4591; WANG T, 1992, AM J PHYSIOL, V263, pF37, DOI 10.1152/ajprenal.1992.263.1.F37; WANG T, 1993, AM J PHYSIOL, V264, pF730, DOI 10.1152/ajprenal.1993.264.4.F730; WAREING M, 1994, J PHYSIOL-LONDON, V477, P347, DOI 10.1113/jphysiol.1994.sp020196; YAMAKAWA K, 1990, KIDNEY INT, V37, P1105, DOI 10.1038/ki.1990.92	16	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15491	15497		10.1074/jbc.271.26.15491	http://dx.doi.org/10.1074/jbc.271.26.15491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663096	hybrid			2022-12-25	WOS:A1996UV29900030
J	Ishikawa, T; Bao, JJ; Yamane, Y; Akimaru, K; Frindrich, K; Wright, CD; Kuo, MT				Ishikawa, T; Bao, JJ; Yamane, Y; Akimaru, K; Frindrich, K; Wright, CD; Kuo, MT			Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE; S-CONJUGATE; CARDIAC TRANSPORT; MDR1 GENE; RAT-HEART; GLUTATHIONE; METABOLISM; LINE; OVEREXPRESSION; LEISHMANIA	We recently reported that GS-X pump activity, as assessed by ATP-dependent transport of the glutathione-platinum complex and leukotriene C-4, and intracellular glutathione (GSH) levels were remarkably enhanced in cis-diamminedichloroplatinum(II) (cisplatin)-resistant human leukemia HL-60 cells (Ishikawa, T,, Wright, C, D,, and Ishizuka, H, (1994) J, Biol, Chem, 269, 29085-29093), Now, using Northern hybridization and RNase protection assay, we provide evidence that the multidrug resistance-associated protein (MRP) gene, which encodes a human GS-X pump, is expressed at higher levels in cisplatin-resistant (HL-60/R-CP) cells than in sensitive cells, whereas amplification of the MRP gene is not detected by Southern hybridization, Culturing HL-60/R-CP cells in cisplatin-free medium resulted in reduced MRP mRNA levels, but these levels could be induced to rise within 30 h by cisplatin and heavy metals such as arsenite, cadmium, and zinc, The increased levels of MRP mRNA were closely related with enhanced activities of ATP-dependent transport of leukotriene C-4 (LTC(4)) in plasma membrane vesicles, The glutathione-platinum (GS-Pt) complex, but not cisplatin, inhibited ATP-dependent LTC(4) transport, suggesting that the MRP/GS-X pump transports both LTC, and the GS-Pt complex, Expression of gamma-glutamylcysteine synthetase in the cisplatin-resistant cells was also co induced within 24 h in response to cisplatin exposure, resulting in a significant increase in cellular GSH level, The resistant cells exposed to cisplatin were cross-resistant to melphalan, chlorambucil, arsenite, and cadmium, These observations suggest that elevated expression of the MRP/GS-X pump and increased GSH biosynthesis together may be important factors in the cellular metabolism and disposition of cisplatin, alkylating agents, and heavy metals.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT EXPT PEDIAT, SECT MOL THERAPEUT, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, SECT EUCARYOT CELL RES, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA060486, R01CA056846] Funding Source: NIH RePORTER; NCI NIH HHS [CA56846, R01 CA60486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DELNOMDEDIEU M, 1994, CHEM-BIOL INTERACT, V90, P139, DOI 10.1016/0009-2797(94)90099-X; DEVRIES EGE, 1995, J NATL CANCER I, V87, P537, DOI 10.1093/jnci/87.7.537; FUJII R, 1994, J NATL CANCER I, V86, P1781, DOI 10.1093/jnci/86.23.1781; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOTO S, 1995, CANCER RES, V55, P4297; HOSPERS GAP, 1988, CANCER RES, V48, P6803; HUANG CS, 1993, J BIOL CHEM, V268, P19675; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1990, TRENDS BIOCHEM SCI, V15, P219, DOI 10.1016/0968-0004(90)90032-7; ISHIKAWA T, 1995, J NATL CANCER I, V87, P1639, DOI 10.1093/jnci/87.21.1639; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; ISHIKAWA T, 1984, J BIOL CHEM, V259, P3838; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; ISHIKAWA T, 1993, STRUCTURE FUNCTION G, P211; ISHIKAWA T, 1996, GLUTATHIONE S TRANSF, P199; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; JOHNSON SW, 1994, CANCER RES, V54, P5911; KUROKAWA H, 1995, BIOCHEM BIOPH RES CO, V216, P258, DOI 10.1006/bbrc.1995.2618; LEIER I, 1994, J BIOL CHEM, V269, P27807; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MULCAHY RT, 1994, MOL PHARMACOL, V46, P909; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; MULCAHY RT, 1995, CANCER RES, V55, P4771; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NAREDI P, 1994, CANCER RES, V54, P6464; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P11980; PEI J, 1990, J BIOL CHEM, V265, P14061; PERRIN DD, 1971, BIOCHIM BIOPHYS ACTA, V230, P96, DOI 10.1016/0304-4165(71)90057-2; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YAO KS, 1995, CANCER RES, V55, P4367; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZHENG YW, 1994, J BIOL CHEM, V269, P22593; ZHU QC, 1994, CANCER RES, V54, P4488; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780	51	249	253	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14981	14988		10.1074/jbc.271.25.14981	http://dx.doi.org/10.1074/jbc.271.25.14981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663001	hybrid			2022-12-25	WOS:A1996UT10600053
J	Ito, A; Mukaiyama, A; Itoh, Y; Nagase, H; Thogersen, IB; Enghild, JJ; Sasaguri, Y; Mori, Y				Ito, A; Mukaiyama, A; Itoh, Y; Nagase, H; Thogersen, IB; Enghild, JJ; Sasaguri, Y; Mori, Y			Degradation of interleukin 1 beta by matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-1-BETA; RHEUMATOID SYNOVIAL FIBROBLASTS; SEQUENCE SPECIFICITIES; CLEAVAGE SITES; COLLAGENASE; STROMELYSIN; PURIFICATION; INHIBITORS; EXPRESSION; ARTHRITIS	Matrix metalloproteinases (MMPs) and interleukin 1 (IL-1) are implicated in inflammation and tissue destruction, where IL-1 is a potent stimulator of connective tissue cells to produce the extracellular matrix-degrading MMPs. Here, we report that IL-1 beta, but not IL-1 alpha, is degraded by MMP-1 (interstitial collagenase), MMP-2 (gelatinase A), MMP-3 (stromelysin 1), and MMP-9 (gelatinase B). This degradation was effectively blocked by tissue inhibitor of metalloproteinases (TIMP)-1. When IL-1 beta was treated with MMPs it lost the ability to enhance the synthesis of prostaglandin E(2) and pro-MMP-3 in human fibroblasts. The primary cleavage site of IL-1 beta by MMP-2 was identified at the Glu(25)-Leu(26) bond. These results suggest that IL-1 beta stimulates connective tissue cells to produce MMPs, but activated MMPs in turn negatively regulate the activity of IL-1 beta.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66160 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; UNIV OCCUPAT & ENVIRONM HLTH, SCH MED, DEPT PATHOL 2, KITAKYUSHU, FUKUOKA 807, JAPAN	University of Kansas; University of Kansas Medical Center; Duke University; University of Occupational & Environmental Health - Japan	Ito, A (corresponding author), TOKYO COLL PHARM, DEPT BIOCHEM, 1432 HORINOUCHI, HACHIOJI, TOKYO 19203, JAPAN.			Itoh, Yoshifumi/0000-0002-2128-2823; Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [HL49542] Funding Source: Medline; NIAMS NIH HHS [AR 39819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DINARELLO CA, 1992, CHEM IMMUNOL, V51, P1; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; ITO A, 1991, J BIOL CHEM, V266, P13598; KIKUMOTO Y, 1987, BIOCHEM BIOPH RES CO, V147, P315, DOI 10.1016/S0006-291X(87)80123-7; KIMURA A, 1991, IMMUNOL LETT, V28, P109, DOI 10.1016/0165-2478(91)90107-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MAST AE, 1991, J BIOL CHEM, V266, P15810; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MITCHELL TI, 1993, BIOCHIM BIOPHYS ACTA, V1156, P245, DOI 10.1016/0304-4165(93)90038-A; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; Nagase H., 1996, ZINC METALLOPROTEINA; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; NISHIDA T, 1987, BIOCHEM BIOPH RES CO, V143, P345, DOI 10.1016/0006-291X(87)90671-1; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PEI DQ, 1994, J BIOL CHEM, V269, P25849; PIERART ME, 1988, J IMMUNOL, V140, P3808; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; TAKAHASHI S, 1993, BIOCHIM BIOPHYS ACTA, V1220, P57, DOI 10.1016/0167-4889(93)90097-9; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TETLOW LC, 1993, RHEUMATOL INT, V13, P53, DOI 10.1007/BF00307734; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	38	314	328	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14657	14660		10.1074/jbc.271.25.14657	http://dx.doi.org/10.1074/jbc.271.25.14657			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663297	hybrid			2022-12-25	WOS:A1996UT10600003
J	Karpen, SJ; Sun, AQ; Kudish, B; Hagenbuch, B; Meier, PJ; Ananthanarayanan, M; Suchy, FJ				Karpen, SJ; Sun, AQ; Kudish, B; Hagenbuch, B; Meier, PJ; Ananthanarayanan, M; Suchy, FJ			Multiple factors regulate the rat liver basolateral sodium-dependent bile acid cotransporter gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; TYROSINE AMINOTRANSFERASE GENE; DNA-BINDING-PROTEINS; FUNCTIONAL EXPRESSION; SEQUENCE-ANALYSIS; NUCLEAR PROTEINS; ALBUMIN GENE; TRANSCRIPTION; TRANSPORT; SITES	The hepatic uptake of bile acids from the portal circulation is primarily dependent upon a sodium-dependent basolateral membrane transporter, In order to bean to investigate the factors controlling rat liver sodium-dependent bile acid cotransporter (ntcp) gene expression, we isolated approximate to 30 kilobase pairs of rat genomic DNA in three overlapping lambda phage clones, The rat ntcp gene is distributed over 16.5 kilobase pairs as five exons, Primer extension analysis revealed two closely spaced transcription initiation sites, 27 and 41 nucleotides downstream of a TATA sequence, Regulation of transcription was investigated first by transfection of primary rat hepatocytes by a series of 5'-deleted rat ntcp promoter-driven luciferase constructs (from approximate to -6 kilobase pairs to -59 base pairs of upstream sequences, terminating at nucleotide +47), identifying a minimal promoter element: nucleotide -158 to +47, This minimal promoter was active in transfected HepG2, but inactive in NIH3T3, Caco-2, and Madin-Darby canine kidney cells, indicating that the determinants of hepatocyte-specific expression reside within this region, The individual elements within the minimal promoter were investigated via transfection of HepG2 cells by a series of 20 mutant plasmids, each containing a 10-base pair sequential block mutation, Eight mutant constructs profoundly suppressed promoter activity; encompassing sequences from -66 to +4 nt, and +15 to +24 nucleotides, while no other 10-base pair mutation significantly interfered with minimal promoter activity, Deoxyribonuclease I footprint analysis of the minimal promoter revealed three bound regions; -92 to -74 (footprint C), -50 to -37 (footprint B), and -17 to +12 (footprint A), Gel mobility shift assays provided evidence for hepatocyte nuclear factor 1 binding within footprint A and a liver-enriched factor(s) that binds within a novel palindrome in footprint B, These studies indicate that three elements direct the basal and tissue-restricted expression of the rat ntcp promoter; a TATA element, the liver-enriched transcription factor hepatocyte nuclear factor 1, and an unknown liver-enriched factor that binds within a novel palindrome in footprint B.	UNIV ZURICH HOSP,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital	Karpen, SJ (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Hagenbuch, Bruno/M-5294-2016	Hagenbuch, Bruno/0000-0002-2938-8630	NICHD NIH HHS [HD-07388, HD-20632] Funding Source: Medline; NIDDK NIH HHS [DK-02318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002318] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BANERJEE R, 1989, HEPATOLOGY, V10, P1008, DOI 10.1002/hep.1840100620; BAUMHUETER S, 1989, ANN NY ACAD SCI, V557, P272; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOYER JL, 1990, METHOD ENZYMOL, V192, P517; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; COHN MA, 1995, MAMM GENOME, V6, P60, DOI 10.1007/BF00350902; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DARLINGTON GJ, 1987, IN VITRO CELL DEV B, V23, P349; DEVACK C, 1993, EUR J BIOCHEM, V211, P459, DOI 10.1111/j.1432-1033.1993.tb17571.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ETZOLD T, 1993, COMPUT APPL BIOSCI, V9, P49; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; HARDIKAR W, 1995, J BIOL CHEM, V270, P20841, DOI 10.1074/jbc.270.35.20841; HOFMANN AF, 1991, ANN MED, V23, P169, DOI 10.3109/07853899109148043; HOFMANN AF, 1993, GASTROINTESTINAL DIS, P127; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KARPEN S, 1993, GASTROENTEROLOGY, V104, pA925; KEMLER I, 1990, FASEB J, V4, P144; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMAIGRE FP, 1991, MOL CELL BIOL, V11, P1099, DOI 10.1128/MCB.11.2.1099; LIANG D, 1993, HEPATOLOGY, V18, P1162; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OLSEN J, 1991, J BIOL CHEM, V266, P18089; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PONDER KP, 1991, HUM GENE THER, V2, P41, DOI 10.1089/hum.1991.2.1-41; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sambrook J., 2002, MOL CLONING LAB MANU; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; SUCHY FJ, 1993, SEMIN LIVER DIS, V13, P235, DOI 10.1055/s-2007-1007352; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tronche F., 1994, LIVER GENE EXPRESSIO, P155; TURK E, 1994, J BIOL CHEM, V269, P15204; TZUNG KW, 1994, GENOMICS, V21, P244, DOI 10.1006/geno.1994.1250; VANDENHOFF MJB, 1994, HISTOCHEM J, V26, P20; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331; WANG XD, 1993, J BIOL CHEM, V268, P14497; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8; WONG MH, 1994, J BIOL CHEM, V269, P1340; WU GD, 1994, J BIOL CHEM, V269, P17080	69	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15211	15221		10.1074/jbc.271.25.15211	http://dx.doi.org/10.1074/jbc.271.25.15211			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662994	hybrid			2022-12-25	WOS:A1996UT10600083
J	Turck, J; Pollock, AS; Lee, LK; Marti, HP; Lovett, DH				Turck, J; Pollock, AS; Lee, LK; Marti, HP; Lovett, DH			Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGRADING NEUTRAL PROTEINASE; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; ENZYMATIC-PROPERTIES; FIBROSARCOMA CELLS; TRANSFORMED-CELLS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; IV COLLAGENASE; PURIFICATION	A biologic role for the 72-kDa gelatinase A (matrix metalloproteinase 2; MMP-2), beyond simple extracellular matrix turnover, was evaluated in glomerular mesangial cells, To determine the significance of MMP-2 secretion for the acquisition of the inflammatory phenotype, we reduced the constitutive secretion of MMP-2 by cultured mesangial cells with antisense RNA expressed by an episomally replicating vector or with specific anti-MMP-2 ribozymes expressed by a retroviral transducing vector. The phenotype of the transfected, or retrovirally infected, cells was profoundly altered from the activated state and closely approximated that of quiescent cells in vivo. The prominent differences included a change in the synthesis and organization of the extracellular matrix, loss of activation markers, and a virtually total exit from the cell cycle. Reconstitution with exogenous active, but not latent MMP-2, induced a rapid return to the inflammatory phenotype in vitro. This effect was specific to MMP-2, because the closely related MMP-2 did not reproduce these changes, Furthermore, this pro-inflammatory effect of MMP-2 is dependent upon the active form of the enzyme, which can be produced by an autocatalytic activation process on the mesangial cell plasma membrane. It is concluded that MMP-2 acts directly upon mesangial cells to permit the development of an inflammatory phenotype. Specific inhibition of MMP-2 activity in vivo may represent an alternate means of ameliorating complex inflammatory processes by affecting the phenotype of the synthesizing cells, per se.	VET AFFAIRS MED CTR, MED SERV 111J, DEPT MED, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94121 USA; UNIV BERN, MED KLIN, CH-3006 BERN, SWITZERLAND	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Bern					NIDDK NIH HHS [P30 DK 47766, DK 39776, DK 31398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, P30DK047766, R01DK039776, R01DK031398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BURSTEN SL, 1991, AM J PATHOL, V139, P371; CELIS JE, 1984, LEUKEMIA RES, V8, P143, DOI 10.1016/0145-2126(84)90135-8; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; CONNOLLY JA, 1988, EXP CELL RES, V174, P461, DOI 10.1016/0014-4827(88)90315-1; COURTOY PJ, 1980, J CELL BIOL, V87, P691, DOI 10.1083/jcb.87.3.691; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; DAVIES M, 1988, BIOCHEM J, V251, P419, DOI 10.1042/bj2510419; DAVIES M, 1992, KIDNEY INT, V41, P671, DOI 10.1038/ki.1992.103; DAVIES M, 1990, KLIN WOCHENSCHR, V68, P1145, DOI 10.1007/BF01798066; DEBENEDETTI A, 1991, NUCLEIC ACIDS RES, V19, P1925, DOI 10.1093/nar/19.8.1925; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ELGER M, 1993, AM J PATHOL, V142, P497; FIRESTEIN GS, 1992, AM J PATHOL, V140, P1309; FLOEGE J, 1992, LAB INVEST, V66, P485; FUNABIKI K, 1990, CLIN NEPHROL, V34, P239; HARALSON MA, 1987, LAB INVEST, V57, P513; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISHIMURA E, 1989, AM J PATHOL, V134, P843; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; KERR LD, 1988, J BIOL CHEM, V263, P16999; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KURKI P, 1988, J IMMUNOL METHODS, V109, P49, DOI 10.1016/0022-1759(88)90441-3; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOVETT DH, 1983, KIDNEY INT, V23, P342, DOI 10.1038/ki.1983.25; LOVETT DH, 1988, KIDNEY INT, V34, P26, DOI 10.1038/ki.1988.141; LOVETT DH, 1992, AM J PATHOL, V141, P85; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; MARTIN J, 1989, KIDNEY INT, V36, P790, DOI 10.1038/ki.1989.264; MARTIN J, 1994, KIDNEY INT, V46, P877, DOI 10.1038/ki.1994.345; MCCALL MJ, 1992, P NATL ACAD SCI USA, V89, P5710, DOI 10.1073/pnas.89.13.5710; McMillan JI, 1996, J CLIN INVEST, V97, P1094, DOI 10.1172/JCI118502; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OOMURA A, 1989, VIRCHOWS ARCH A, V415, P151, DOI 10.1007/BF00784353; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; POLLOCK AS, 1992, BIOCHEM J, V284, P725, DOI 10.1042/bj2840725; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHER W, 1987, LAB INVEST, V57, P607; STERZEL RB, 1982, KLIN WOCHENSCHR, V60, P1077, DOI 10.1007/BF01715838; STERZEL RB, 1988, IMMUNOPATHOLOGY RENA, P137; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; WANG E, 1989, J CELL PHYSIOL, V140, P418, DOI 10.1002/jcp.1041400303; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YOSHIOKA K, 1989, KIDNEY INT, V35, P1203, DOI 10.1038/ki.1989.111	57	142	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15074	15083		10.1074/jbc.271.25.15074	http://dx.doi.org/10.1074/jbc.271.25.15074			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663054	hybrid			2022-12-25	WOS:A1996UT10600065
J	Welter, JF; Gali, H; Crish, JF; Eckert, RL				Welter, JF; Gali, H; Crish, JF; Eckert, RL			Regulation of human involucrin promoter activity by POU domain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SCIP; TRANSGENIC MICE; EXPRESSION; CELLS; GENE; ACTIVATION; BINDS; DIFFERENTIATION; EPIDERMIS; EVOLUTION	POU domain transcription factors are expressed in the epidermis and are thought to be important regulators of keratinocyte gene expression, In the present article we demonstrate that POU transcription factors suppress transcription of the human involucrin (hINV) promoter, Cotransfection of pINV-2473, a construct containing 2473 base pairs of hINV upstream sequence linked to luciferase, with POU homeodomain transcription factors Oct1, Oct2, Brn4, SCIP, Skn1a or Sknli, results in a strong suppression of basal promoter activity, The hINV upstream region includes a consensus POU transcription factor binding site, 5'-ATGCAAAT-3', centered around nucleotide -1277, Although this site interacts with POU factors, assays of promoter activity for a series of progressive 5' end truncations demonstrate that this site is not required for POU factor-dependent transcriptional suppression, Suppression is observed with the shortest truncation construct tested, pINV-41, suggesting that this inhibition may be mediated by effects on TATA box proteins, SCIP mutants that lack transactivation or DNA binding domains were shown to suppress transcription, suggesting that the DNA binding and transactivation domains are not required for suppression, Moreover, cotransfection of the pINV-2473 with pKSM13(+)OCT, which contains a single consensus OCT binding site, results in an increase in basal promoter activity, suggesting that endogenous POU factors suppress hINV promoter activity, In addition to inhibiting basal transcription, POU transcription factors also suppress phorbol ester-stimulated hINV promoter activity, These studies suggest that suppression of hINV promoter activity does not require the amino-terminal segment of the POU factor or direct POU factor interaction with DNA and suggest that the suppression may be via indirect interaction with other proteins in the vicinity of the TATA box, Thus, involucrin joins the ranks of a small set of genes that are regulated by POU factors in an octamer binding site-independent manner.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT ONCOL,CLEVELAND,OH 44106; AMER UNIV BEIRUT,DEPT BIOL,BEIRUT,LEBANON	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; American University of Beirut					NIAMS NIH HHS [AR39750, AR41456] Funding Source: Medline; NIDDK NIH HHS [DK07678] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR041456, P30AR039750, R01AR041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL VR, 1991, DEV BIOL, V147, P363, DOI 10.1016/0012-1606(91)90294-D; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; NAKSHATRI H, 1995, J BIOL CHEM, V270, P19613, DOI 10.1074/jbc.270.33.19613; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TREACY MN, 1992, ANNU REV NEUROSCI, V15, P139, DOI 10.1146/annurev.ne.15.030192.001035; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YANG XD, 1994, J BIOL CHEM, V269, P10252; YUKAWA K, 1993, GENE, V133, P163; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	37	54	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14727	14733		10.1074/jbc.271.25.14727	http://dx.doi.org/10.1074/jbc.271.25.14727			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663077				2022-12-25	WOS:A1996UT10600017
J	Zhang, X; Jeyakumar, M; Bagchi, MK				Zhang, X; Jeyakumar, M; Bagchi, MK			Ligand-dependent cross-talk between steroid and thyroid hormone receptors - Evidence for common transcriptional coactivator(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; CELL-FREE TRANSCRIPTION; PREINITIATION COMPLEX; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; RETINOIC ACID; MECHANISM; ELEMENT; GENES	Steroid and thyroid hormone receptors exhibit striking structural and functional similarity, suggesting that these nuclear receptors may enhance transcription of target genes by similar mechanisms, To address this issue, we studied transcriptional interference between progesterone and thyroid hormone receptors in vivo and in vitro, We observed that transcriptional interference occurred in a ligand-dependent manner between progesterone receptor-B (PR-B) and thyroid hormone receptor (TR) alpha or beta in transient transfection experiments. Ligand-occupied TR alpha or TR beta, but not the unliganded receptor, strongly suppressed transactivation of a progesterone responsive reporter gene by endogenous PRs in human breast carcinoma T47D cells, Ligand dependent inhibitory cross-talk also occurred between transfected PR-B and TR alpha or TR beta and vice versa in CV1 cells, This phenomenon did not require DNA binding by the ''interfering'' receptor but required it to be hormone-bound, indicating that a transcriptionally active form of the interfering receptor is essential for the interfering effect, To analyze further the mechanism of the ligand-dependent cross talk, we reproduced transcriptional interference between PR and TR in a cell-free transcription system, We observed that the addition of triiodothyronine-bound recombinant TR beta or a ligand binding domain (LED) peptide (145-456) inhibited specifically transcriptional activation of a progesterone-responsive gene by endogenous PRs in nuclear extracts of T47D cells, while the basal level of transcription from a minimal TATA promoter or transcription from an adenovirus major-late promoter remained unaffected. These results indicated that a transactivation function within the LED of the interfering receptor TR beta was likely to interact with a mediator protein(s), termed coactivator, that is distinct from basal transcription factors and is critical for efficient PR-induced transactivation, This concept was reinforced by biochemical evidence that treatment of T47D extracts with immobilized TR beta LED depleted the extract of the coactivator function in a triiodothyronine-dependent manner and markedly impaired progesterone-induced transactivation of progesterone response element-linked genes. Deletion of six amino acids (451-456) in the extreme COOH terminus of TR beta resulted in a receptor that retained the ability to bind thyroid hormone but failed to inhibit progesterone-dependent transcription, Interestingly, these six amino acids are present in a region that is highly conserved among various nuclear hormone receptors and contains a ligand-dependent transactivation function, AF-2. Based on these results, we propose that a limiting coactivator protein(s) interacts with the AF-2 of PR or TR and mediates transactivation by the ligand-bound receptor. This regulatory molecule(s) may therefore serve as a common functional link between the pathways of hormone-inducible gene activation by various members of the nuclear receptor superfamily.	POPULAT COUNCIL, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Population Council; Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50257-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; ONATE SA, 1995, SCIENCE, V270, P1354; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YEN PM, 1995, ENDOCRINOLOGY, V136, P440, DOI 10.1210/en.136.2.440; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	50	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14825	14833		10.1074/jbc.271.25.14825	http://dx.doi.org/10.1074/jbc.271.25.14825			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662980				2022-12-25	WOS:A1996UT10600031
J	Kimura, EA; Couto, AS; Peres, VJ; Casal, OL; Katzin, AM				Kimura, EA; Couto, AS; Peres, VJ; Casal, OL; Katzin, AM			N-linked glycoproteins are related to schizogony of the intraerythrocytic stage in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH PROTEIN; HUMAN-ERYTHROCYTES; MALARIA; SURFACE; BIOSYNTHESIS; ANTIGENS; CELLS; GLYCOSYLATION; MEROZOITES; PARASITE	Although the existence of O-linked oligosaccharide residues in glycoproteins of Plasmodium falciparum has been shown, the existence of N-linked glycoproteins is still a matter of controversy and skepticism. This report demonstrates the unequivocal presence of N-linked glycoproteins in P. falciparum, principally in the ring and young trophozoite stages of the intraerythrocytic cycle. These glycoproteins lose their capacity to bind to concanavalin A-Sepharose after treatment of cultures with tunicamycin under conditions that do not affect protein synthesis. When the glycoproteins were treated with N-Glycanase(R), oligosaccharides were released, It was possible to identify an N-linked glycoprotein of >200 kDa in the ring stage and also N-linked glycoproteins in the range of 200-30 kDa in the trophozoite stage. Treatment of trophozoites with 12 mu M tunicamycin inhibited differentiation to the schizont stage. To our knowledge, this is the first report in the literature unequivocally showing N-linked glycoproteins in trophozoites of P. falciparum as well as their importance for the differentiation of the intraerythrocytic stages of this parasite.	UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS & NAT, DEPT QUIM ORGAN, RA-1428 BUENOS AIRES, DF, ARGENTINA; UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, BR-05508 SAO PAULO, BRAZIL	University of Buenos Aires; Universidade de Sao Paulo	Kimura, EA (corresponding author), UNIV SAO PAULO, INST CIENCIAS BIOMED, DEPT PARASITOL, AV LINEU PRESTES 1374, BR-05508900 SAO PAULO, SP, BRAZIL.		Katzin, Alejandro/E-9862-2013	Katzin, Alejandro/0000-0002-4782-2162				BLANKEN WM, 1985, ANAL BIOCHEM, V145, P322, DOI 10.1016/0003-2697(85)90369-0; BRAUNBRETON C, 1986, MOL BIOCHEM PARASIT, V20, P33, DOI 10.1016/0166-6851(86)90140-4; DIECKMANN-SCHUPPERT A, 1992, Biochemical Society Transactions, V20, p184S; DIECKMANNSCHUPPERT A, 1992, EUR J BIOCHEM, V205, P815, DOI 10.1111/j.1432-1033.1992.tb16846.x; DIECKMANNSCHUPPERT A, 1994, BBA-GEN SUBJECTS, V1199, P37, DOI 10.1016/0304-4165(94)90093-0; DIECKMANNSCHUPPERT A, 1993, EUR J BIOCHEM, V216, P779, DOI 10.1111/j.1432-1033.1993.tb18198.x; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FUNK VA, 1994, MOL BIOCHEM PARASIT, V63, P23, DOI 10.1016/0166-6851(94)90005-1; HALDAR K, 1989, J CELL BIOL, V108, P2183, DOI 10.1083/jcb.108.6.2183; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; HOLDER AA, 1982, J EXP MED, V156, P1528, DOI 10.1084/jem.156.5.1528; HOWARD RF, 1984, MOL BIOCHEM PARASIT, V10, P319, DOI 10.1016/0166-6851(84)90030-6; HOWARD RJ, 1984, MOL BIOCHEM PARASIT, V11, P349, DOI 10.1016/0166-6851(84)90078-1; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; KATZIN AM, 1983, BIOCHIM BIOPHYS ACTA, V727, P403, DOI 10.1016/0005-2736(83)90425-X; KATZIN AM, 1991, AM J TROP MED HYG, V45, P453, DOI 10.4269/ajtmh.1991.45.453; KILEJIAN A, 1980, P NATL ACAD SCI-BIOL, V77, P3695, DOI 10.1073/pnas.77.6.3695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON O, 1993, J CELL SCI, V106, P299; Lis H., 1986, LECTINS PROPERTIES F, P293; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; POLOGE LG, 1987, P NATL ACAD SCI USA, V84, P7139, DOI 10.1073/pnas.84.20.7139; RAGGE K, 1990, MOL BIOCHEM PARASIT, V42, P93, DOI 10.1016/0166-6851(90)90116-4; RAMASAMY R, 1987, IMMUNOL CELL BIOL, V65, P147, DOI 10.1038/icb.1987.16; REARICK JI, 1981, J BIOL CHEM, V256, P6255; SCHMIDTULLRICH R, 1986, J EXP MED, V163, P179, DOI 10.1084/jem.163.1.179; SCHWARZ RT, 1987, HOST PARASITIC CELLU, P275; STANLEY P, 1993, CELL SURFACE EXTRACE, P181; THOTAKURA NR, 1987, METHOD ENZYMOL, V138, P350; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; UDDIN N, 1992, BIOCH INT, V27, P55; UDEINYA IJ, 1981, PHARMACOLOGY, V23, P165, DOI 10.1159/000137545; VARKI A, 1994, METHOD ENZYMOL, V230, P16; WERNSDORFER WH, 1980, B WORLD HEALTH ORGAN, V58, P341; WILSON ME, 1989, J IMMUNOL, V143, P678; WILSON RJM, 1980, NATURE, V284, P451, DOI 10.1038/284451a0; WRIGHT IG, 1988, PARASITOL TODAY, V4, P214, DOI 10.1016/0169-4758(88)90161-5; ZINGALES B, 1985, MOL BIOCHEM PARASIT, V16, P21, DOI 10.1016/0166-6851(85)90046-5; 1993, WEEKLY EPIDEMIOL REC, V68, P245	46	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14452	14461		10.1074/jbc.271.24.14452	http://dx.doi.org/10.1074/jbc.271.24.14452			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662869	hybrid			2022-12-25	WOS:A1996UQ66000076
J	Prins, BA; Weber, MJ; Hu, RM; Pedram, A; Daniels, M; Levin, ER				Prins, BA; Weber, MJ; Hu, RM; Pedram, A; Daniels, M; Levin, ER			Atrial natriuretic peptide inhibits mitogen-activated protein kinase through the clearance receptor - Potential role in the inhibition of astrocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; RAT MESANGIAL CELLS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; C-RECEPTOR; PHOSPHORYLATION; CAMP; PATHWAY; GENE	The modulation of the activity of mitogen-activated protein kinase (MAPK) by endogenous growth factors or growth inhibitors provides a potential means of regulating cell proliferation. We determined the effect of the endogenous anti proliferative peptide, atrial natriuretic peptide (ANP), on the ability of MAPK to phosphorylate myelin basic protein. In astrocytes, MAPK activity was significantly stimulated (up to 3-fold) by three known glial mitogens, endothelin-3, platelet-derived growth factor, or phorbol la-myristate 13-acetate. ANP inhibited by 55-70% the ability of each of these mitogens to activate MAPK. The effects of ANP were equipotent to those caused by C-ANP 4-23, a peptide that specifically binds to the natriuretic peptide clearance receptor. Additionally, both natriuretic peptides caused a 70-80% inhibition of the sodium vanadate stimulated MAPK activity, complete inhibition of the okadaic acid stimulated activity, and inhibition of the mitogen-stimulated phosphorylation of MAPK. To understand the potential mechanism by which the natriuretic peptides act, we found that both ANP and C-ANP inhibited the mitogen-stimulated activity of the immediate upstream kinase in the cascade, MAPK kinase (MEK). C-ANP also strongly inhibited the endothelin-3-, platelet-derived growth factor-, and phorbol 12-myristate 13-acetate-induced stimulation of DNA synthesis in the astrocytes, while both okadaic acid and sodium vanadate significantly reversed these anti-proliferative actions. Our results identify ANP as a peptide hormone that inhibits growth factor-stimulated MAPK. These data suggest that the ability of the natriuretic peptides to inhibit MAPK may be important for their anti-growth actions. This effect likely occurs via the inhibition of upstream kinase(s), including MEK, uniquely resulting from ligand binding to the natriuretic peptide clearance receptor.	VET ADM MED CTR,MED SERV 111I,LONG BEACH,CA 90822; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Virginia			Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50161] Funding Source: Medline; NIGMS NIH HHS [GM47332] Funding Source: Medline; NINDS NIH HHS [NS-30521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANANDSRIVASTAVA.MB, 1990, J BIOL CHEM, V265, P8526; ARENANDER AT, 1989, J NEUROSCI RES, V23, P257, DOI 10.1002/jnr.490230303; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAHILL PA, 1994, AM J PHYSIOL, V266, pR194, DOI 10.1152/ajpregu.1994.266.1.R194; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIN E R, 1991, Molecular and Cellular Neuroscience, V2, P189, DOI 10.1016/1044-7431(91)90044-O; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LEVIN ER, 1990, J BIOL CHEM, V265, P10019; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LEVIN ER, 1992, J NEUROCHEM, V58, P659, DOI 10.1111/j.1471-4159.1992.tb09768.x; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; OKOLICANY J, 1990, KIDNEY INT, V37, P342; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SUGIMOTO T, 1993, BIOCHEM BIOPH RES CO, V195, P72, DOI 10.1006/bbrc.1993.2011; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHOU W, 1993, J BIOL CHEM, V268, P23041	34	89	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14156	14162		10.1074/jbc.271.24.14156	http://dx.doi.org/10.1074/jbc.271.24.14156			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662898	hybrid			2022-12-25	WOS:A1996UQ66000035
J	Gundimeda, U; Chen, ZH; Gopalakrishna, R				Gundimeda, U; Chen, ZH; Gopalakrishna, R			Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; TUMOR-PROMOTING ACTIVITY; LIPID-PEROXIDATION; MOUSE SKIN; NONSTEROIDAL ANTIESTROGEN; HYDROGEN-PEROXIDE; TISSUE-CULTURE; BINDING-SITES; RAT; ACTIVATION	Nonsteroidal agent tamoxifen (Tam), a therapeutic/chemopreventive agent for breast cancer, inhibits protein kinase C (PKC), which is considered tea be one of its extra-estrogen receptor sites of action, This drug is required at higher (> 100 mu M) concentrations to inhibit PKC in the test tube, whereas it is required at lower (1-10 mu M) concentrations to induce inhibition of cell growth in estrogen receptor-negative cell types, To identify additional mechanisms of action of Tam on PKC and cell growth, studies with MDA-MB-231, an estrogen receptor-negative breast carcinoma cell type, have been carried out, Upon treatment with 5-20 mu M Tam, a cytosol to membrane translocation of PKC occurred within 30 min, which was then followed by a down-regulation of the enzyme within 2 h. A transient generation of Ca2+/lipid-independent activated form of PKC was observed during this period, Rapidly growing cells require nearly 2-3-fold lower concentrations (2-5 mu M) of Tam than do confluent cells to induce changes in PKC, Furthermore, phorbol ester binding observed with intact cells also decreased in Tam-treated cells only under the conditions PKC was inactivated, Unlike phorbol esters, Tam did not directly support the membrane association of PKC. The release of arachidonic acid correlated with the PKC membrane translocation. Studies carried out with [H-3]Tam revealed that Tam partitioned into the membrane, and there was no appreciable covalent association of [3H]Tam with cellular proteins within this limited time period (2 h). Various antioxidants (vitamin E, vitamin C, beta-carotene, catalase, and superoxide dismutase) inhibited all these cellular effects of Tam. Moreover, vitamin E strikingly blocked Tam-induced growth inhibition. To determine whether oxymetabolites of Tam can affect PKC permanently, OH-Tam was tested with purified PKC. In contrast to Tam, which reversibly inhibited PKC, OH-Tam permanently inactivated the enzyme by modifying the catalytic domain at lower concentrations. The vicinal thiols present within this domain were found to be required to induce this inactivation. This effect was partially blocked by various antioxidants. This is the first report showing the role of oxidative stress in mediating the actions of Tam. Taken together these results suggest that Tam, by initially partitioning into the membranes, induces a generation of transmembrane signals and an oxidative stress to elicit the membrane association of PKC, followed by an irreversible activation, and subsequent down-regulation of this enzyme, which, in part, may lead to cell growth inhibition.	UNIV SO CALIF, SCH MED, DEPT CELL & NEUROBIOL, LOS ANGELES, CA 90033 USA	University of Southern California					NATIONAL CANCER INSTITUTE [R01CA062146] Funding Source: NIH RePORTER; NCI NIH HHS [CA62146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BHATTACHARYYA B, 1983, BIOCHEM PHARMACOL, V32, P2965, DOI 10.1016/0006-2952(83)90403-3; BIGNON E, 1990, FEBS LETT, V271, P54, DOI 10.1016/0014-5793(90)80370-X; BRUNNER N, 1993, CANCER RES, V53, P3229; CADENAS E, 1990, OXIDATIVE DAMAGE REP, P607; CHAN JKT, 1983, ENDOCRINOLOGY, V113, P2202, DOI 10.1210/endo-113-6-2202; CLARKE R, 1990, J NATL CANCER I, V82, P1702, DOI 10.1093/jnci/82.21.1702; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; COONEY RV, 1992, CARCINOGENESIS, V13, P1107, DOI 10.1093/carcin/13.7.1107; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; DARBRE PD, 1984, CANCER RES, V44, P2790; DAVIES AM, 1995, CARCINOGENESIS, V16, P539, DOI 10.1093/carcin/16.3.539; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DLUGOSZ AA, 1991, CANCER RES, V51, P4677; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; EDASHIGE K, 1991, CELL STRUCT FUNCT, V16, P273, DOI 10.1247/csf.16.273; FISCHER SM, 1987, CANCER RES, V47, P3174; FRENKEL K, 1987, CARCINOGENESIS, V8, P455, DOI 10.1093/carcin/8.3.455; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; GOLDSTEIN BD, 1981, CANCER LETT, V11, P257, DOI 10.1016/0304-3835(81)90117-8; GOPALAKRISHNA R, 1995, METHOD ENZYMOL, V252, P132; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; GOPALAKRISHNA R, 1992, BIOCHEM BIOPH RES CO, V189, P950, DOI 10.1016/0006-291X(92)92296-A; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GOPALAKRISHNA R, 1992, ANAL BIOCHEM, V206, P24, DOI 10.1016/S0003-2697(05)80006-5; GREENLEE WF, 1981, TOXICOL APPL PHARM, V59, P187, DOI 10.1016/0041-008X(81)90189-7; HAN XL, 1992, CANCER RES, V52, P1360; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; ISSANDOU M, 1990, CANCER RES, V50, P5845; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; JORDAN VC, 1994, BREAST CANCER RES TR, V31, P41, DOI 10.1007/BF00689675; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; KALYANARAMAN B, 1985, ENVIRON HEALTH PERSP, V64, P185, DOI 10.2307/3430009; KARNIK PS, 1994, CANCER RES, V54, P349; KENSLER TW, 1984, ENVIRON MUTAGEN, V6, P593, DOI 10.1002/em.2860060412; KILEY SC, 1992, CARCINOGENESIS, V13, P1997, DOI 10.1093/carcin/13.11.1997; KING CM, 1995, CARCINOGENESIS, V16, P1449, DOI 10.1093/carcin/16.7.1449; KISS Z, 1994, FEBS LETT, V355, P173, DOI 10.1016/0014-5793(94)01200-8; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5; LIPPMAN M, 1976, CANCER RES, V36, P4595; LIPPMAN ME, 1980, HORMONES CANCER, P3; MANI C, 1991, CANCER RES, V51, P6052; MARKS F, 1991, CARCINOGENESIS, V12, P1491, DOI 10.1093/carcin/12.8.1491; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1988, J NATL CANCER I, V80, P1628, DOI 10.1093/jnci/80.20.1628; OBRIAN CA, 1985, CANCER RES, V45, P2462; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; PARR IB, 1987, BIOCHEM PHARMACOL, V36, P1513, DOI 10.1016/0006-2952(87)90119-5; PENTLAND AP, 1992, J BIOL CHEM, V267, P15578; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; REDDEL RR, 1983, CANCER RES, V43, P4618; ROY D, 1991, CANCER RES, V51, P3882; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; SIPE HJ, 1994, CARCINOGENESIS, V15, P2637, DOI 10.1093/carcin/15.11.2637; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SLAGA TJ, 1981, SCIENCE, V213, P1023, DOI 10.1126/science.6791284; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V317, P315, DOI 10.1006/abbi.1995.1169; SU HD, 1985, BIOCHEM PHARMACOL, V34, P3649; SUDO K, 1983, ENDOCRINOLOGY, V112, P425, DOI 10.1210/endo-112-2-425; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; WATTS CKW, 1984, J BIOL CHEM, V259, P4223; WHITE INH, 1992, CARCINOGENESIS, V13, P2197, DOI 10.1093/carcin/13.12.2197; WILLIAMS GM, 1993, CARCINOGENESIS, V14, P315; WISEMAN H, 1990, FEBS LETT, V263, P192, DOI 10.1016/0014-5793(90)81371-T; YAGER JD, 1991, PREV MED, V20, P27, DOI 10.1016/0091-7435(91)90004-N; YOSHIZAWA S, 1990, CANCER RES, V50, P4974	74	133	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13504	13514		10.1074/jbc.271.23.13504	http://dx.doi.org/10.1074/jbc.271.23.13504			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662863	hybrid			2022-12-25	WOS:A1996UP38500032
J	Florini, JR; Samuel, DS; Ewton, DZ; Kirk, C; Sklar, RM				Florini, JR; Samuel, DS; Ewton, DZ; Kirk, C; Sklar, RM			Stimulation of myogenic differentiation by a Neuregulin, glial growth factor 2 - Are neuregulins the long-sought muscle trophic factors secreted by nerves?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INDUCING ACTIVITY; ACETYLCHOLINE-RECEPTOR; GENE; EXPRESSION; LIGAND; ARIA	It has long been known that nerves stimulate growth and maintenance of skeletal muscles in ways not dependent on physical contacts, but numerous attempts to identify and characterize the myotrophic agent(s) secreted by nerves have been unsuccessful. We here suggest that products of the neuregulin gene may be these agents. The neuregulins are a family of proteins made by alternative splicing of a single transcript to give as many as 15 protein products. One member of this family, glial growth factor 2 (rhGGF2) is a very potent stimulator of myogenesis in L6A1 myoblasts, giving a maximal stimulation of cell fusion and creatine kinase elevation at a concentration of 1 ng/ml (18 pM). The stimulation of myogenesis is not rapid, but it is prolonged, continuing over a period of at least 6 days. The effects of rhGGF2 are additive with those of insulin-like growth factor I (IGF-I) or its analog R3-IGF-I, suggesting that the actions of these two myotrophic agents differ in at least one rate-limiting step. We have observed one possible difference; unlike the IGFs, rhGGF2 does not induce elevation of the steady state level of myogenin mRNA.	CAMBRIDGE NEUROSCI,CAMBRIDGE,MA 02139		Florini, JR (corresponding author), SYRACUSE UNIV,DEPT BIOL,130 COLL PL,SYRACUSE,NY 13244, USA.				NHLBI NIH HHS [HL11551] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL011551, R37HL011551] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CORFAS G, 1993, J NEUROSCI, V13, P2118; CUSELLADEANGELE.MG, 1992, J CELL BIOL, V268, P14553; DEMEYTS P, 1995, METABOLISM, V44, P2, DOI 10.1016/0026-0495(95)90214-7; EWTON DZ, 1995, J ENDOCRINOL, V144, P539, DOI 10.1677/joe.0.1440539; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLORINI JR, 1989, ANAL BIOCHEM, V182, P399, DOI 10.1016/0003-2697(89)90614-3; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; Florini JR, 1995, DIABETES REV, V3, P73; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GUTMANN E, 1976, ANNU REV PHYSIOL, V38, P177, DOI 10.1146/annurev.ph.38.030176.001141; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KIMURA I, 1981, P JPN ACAD, V51, P200; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARKELONIS GJ, 1982, J NEUROCHEM, V39, P315, DOI 10.1111/j.1471-4159.1982.tb03949.x; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; SANCHEZ A, 1994, J BIOL CHEM, V269, P1587; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; SASSOON DA, 1988, DEVELOPMENT, V104, P155; Sklar R. M., 1994, Society for Neuroscience Abstracts, V20, P1692; WEN D, 1992, MOL CELL BIOL, V14, P1909	35	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12699	12702		10.1074/jbc.271.22.12699	http://dx.doi.org/10.1074/jbc.271.22.12699			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663030	hybrid			2022-12-25	WOS:A1996UN47400004
J	Wasmeier, C; Hutton, JC				Wasmeier, C; Hutton, JC			Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; RAT; IDENTIFICATION; EXPRESSION; BIOSYNTHESIS; LANGERHANS; ISLETS; EXOCYTOSIS; INHIBITORS; VESICLES	An insulin granule membrane protein-tyrosine phosphatase (PTP) homologue, phogrin, was cloned by expression screening of a rat insulinoma cDNA library, The 3723-base pair cDNA encoded a transmembrane glycoprotein of 1004 amino acids (M(r) 111876) that underwent post-translational proteolysis to 60-64-kDa products after a 30-min delay. The kinetics of proteolytic conversion (t(1/2) = 45 min) and turnover (t(1/2) = 12 h) were consistent with sorting and conversion in a late compartment of the secretory pathway. Studies on the native beta-cell protein suggested that the COOH-terminal PTP domain was on the cytosolic face of the secretory granule, The lumenal segment was comprised of a pro tease-resistant globular domain of around 25 kDa, Its localization and topology is thus consistent with a transmembrane receptor function related to granule biogenesis, exocytosis, or subsequent membrane recovery, and it should prove to be a useful cell biological marker for the granule membrane. High expression of the mRNA (5.4 kilobases) and protein was evident in islets, pancreatic alpha- and beta-cell tumor lines, brain cells, and other cells of neuroendocrine lineage. It is closely related to the diabetic autoantigen ICA512 (IA-2) (42% identity overall; 80% in the 260-amino acid PTP domain) and thus a potential target of autoimmunity in diabetes mellitus.	UNIV COLORADO,HLTH SCI CTR,BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO 80262; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1992, J BIOL CHEM, V267, P22401; GUEST PC, 1989, BIOCHEM J, V264, P503, DOI 10.1042/bj2640503; HALBAN PA, 1994, BIOCHEM J, V299, P1; HUTTON JC, 1987, BIOCHEM J, V244, P449, DOI 10.1042/bj2440449; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; JENA BP, 1991, J BIOL CHEM, V266, P17744; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LU J, 1994, BIOCHEM BIOPH RES CO, V204, P930, DOI 10.1006/bbrc.1994.2549; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; PAPINI E, 1995, J BIOL CHEM, V270, P1332, DOI 10.1074/jbc.270.3.1332; RABIN DU, 1992, DIABETES, V41, P183, DOI 10.2337/diabetes.41.2.183; RABIN DU, 1994, J IMMUNOL, V152, P3183; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SCHEELE GA, 1982, SECRETORY GRANULE, P213; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORENSON RL, 1994, ENDOCRINOLOGY, V134, P1975, DOI 10.1210/en.134.4.1975; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TOOKE NE, 1984, BIOCHEM J, V219, P471, DOI 10.1042/bj2190471; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WALCHSOLIMENA C, 1993, J NEUROSCI, V13, P3895; Winkler H, 1982, SECRETORY GRANULE, P3	42	189	197	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18161	18170		10.1074/jbc.271.30.18161	http://dx.doi.org/10.1074/jbc.271.30.18161			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663434	hybrid			2022-12-25	WOS:A1996UY93500086
J	Bankston, LA; Guidotti, G				Bankston, LA; Guidotti, G			Characterization of ATP transport into chromaffin granule ghosts - Synergy of ATP and serotonin accumulation in chromaffin granule ghosts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN SYNAPTIC VESICLES; BOVINE ADRENAL-MEDULLA; GLUTAMATE UPTAKE; ENDOPLASMIC-RETICULUM; CEREBRAL-CORTEX; MEMBRANE; PROTON; CATECHOLAMINE; CELLS; TRANSLOCATION	ATP is an excitatory neurotransmitter that is stored and cosecreted with catecholamines from cells of the adrenal medulla, While the transport of catecholamines into chromaffin granule ghosts has been extensively characterized, there is little information on the mechanism of ATP transport into these structures, Here Fee show that ATP transport is driven by the electrical component of the electrochemical proton gradient created by the chromaffin granule membrane H+-ATPase, and that the accumulated nucleotide is released from the vesicles by inhibition of the H+-ATPase, GTP and UTP are also substrates for this transporter, distinguishing it from the mitochondrial ADP/ATP exchanger, Accumulation of ADP and ATP (rather than exchange with intravesicular ATP) is demonstrated by high pressure liquid chromatography measurements, The anion transport inhibitor 4,4-diisothiocyanatostilbene-2,2-disulfonic acid (K-i = 27 mu M) inhibits ATP transport, while atractyloside, the inhibitor of the mitochondrial ATP/ADP exchanger, is a very poor inhibitor, Finally, we have demonstrated a synergy between the accumulation of ATP and that of serotonin (i.e. more of each solute accumulates when the two are accumulated together), supporting the view that there is an interaction between serotonin and ATP that reduces their effective concentration within the ghosts.	HARVARD UNIV,DEPT CELLULAR & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007598] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08893] Funding Source: Medline; NIGMS NIH HHS [5T32GM07598-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERER W, 1978, BIOCHEM J, V172, P353, DOI 10.1042/bj1720353b; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P227, DOI 10.1007/BF01870089; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAUGHEY B, 1987, J NEUROCHEM, V49, P563, DOI 10.1111/j.1471-4159.1987.tb02901.x; CIDON S, 1989, J BIOL CHEM, V264, P8281; CIDON S, 1986, J BIOL CHEM, V261, P9222; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FILLINGAME RH, 1980, ANNU REV BIOCHEM, V49, P1079, DOI 10.1146/annurev.bi.49.070180.005243; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRUNINGER HA, 1983, NEUROSCIENCE, V9, P917, DOI 10.1016/0306-4522(83)90280-4; HILLARP NA, 1958, ACTA PHYSIOL SCAND, V42, P321, DOI 10.1111/j.1748-1716.1958.tb01566.x; HILLARP NA, 1959, ACTA PHYSIOL SCAND, V45, P328, DOI 10.1111/j.1748-1716.1959.tb01705.x; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; JOHNSON RG, 1981, J BIOL CHEM, V256, P5773; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; KOPELL WN, 1982, J BIOL CHEM, V257, P5707; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PHILLIPS JH, 1974, BIOCHEM J, V144, P311, DOI 10.1042/bj1440311; PHILLIPS JH, 1978, BIOCHEM J, V170, P673, DOI 10.1042/bj1700673; PHILLIPS JH, 1980, BIOCHEM J, V192, P273, DOI 10.1042/bj1920273; POGOLOTTI AL, 1982, ANAL BIOCHEM, V126, P335, DOI 10.1016/0003-2697(82)90524-3; POISNER AM, 1982, SECRETORY GRANULE; RAINNIE DG, 1994, SCIENCE, V263, P689, DOI 10.1126/science.8303279; SCHULDINER S, 1978, P NATL ACAD SCI USA, V75, P3713, DOI 10.1073/pnas.75.8.3713; SHIOI J, 1989, BIOCHEM J, V258, P499, DOI 10.1042/bj2580499; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; SILLERO MAG, 1994, BIOCHIMIE, V76, P404; WEBER A, 1983, BIOCHEM J, V210, P789, DOI 10.1042/bj2100789; WEBER A, 1981, NEUROSCIENCE, V6, P2269, DOI 10.1016/0306-4522(81)90016-6	37	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17132	17138		10.1074/jbc.271.29.17132	http://dx.doi.org/10.1074/jbc.271.29.17132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663306	hybrid			2022-12-25	WOS:A1996UX94300025
J	Sierralta, J; Fill, M; SuarezIsla, BA				Sierralta, J; Fill, M; SuarezIsla, BA			Functionally heterogenous ryanodine receptors in avian cerebellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM RELEASE CHANNEL; FOOT PROTEIN ISOFORMS; BRAIN MICROSOMAL-MEMBRANES; SKELETAL-MUSCLE; H-3 RYANODINE; CA-2+ RELEASE; BINDING-SITES; RAT-BRAIN; PURKINJE NEURONS	The functional heterogeneity of the ryanodine receptor (RyR) channels in avian cerebellum was defined, Heavy endoplasmic reticulum microsomes had significant levels of ryanodine and inositol 1,4,5-trisphosphate binding. Scatchard analysis and kinetic studies indicated the existence of at least two distinct ryanodine binding sites, Ryanodine binding was calcium-dependent but was not significantly enhanced by caffeine, Incorporation of microsomes into planar lipid bilayers revealed ion channels with pharmacological features (calcium, magnesium, ATP, and caffeine sensitivity) similar to the RyR channels found in mammalian striated muscle, Despite a wide range of unitary conductances (220-500 picosiemens, symmetrical cesium methanesulfonate), ryanodine locked both channels into a characteristic slow gating subconductance state, positively identifying them as RyR channels. Two populations of avian RyR channels were functionally distinguished by single channel calcium sensitivity, One population was defined by a bell-shaped calcium sensitivity analogous to the skeletal muscle RyR isoform (type I). The calcium sensitivity of the second RyR population was sigmoidal and analogous to the cardiac muscle RyR isoform (type II), These data show that there are at least two functionally distinct RyR channel populations in avian cerebellum, This leads to the possibility that these functionally distinct RyR channels are involved in different intracellular calcium signaling pathways.	UNIV CHILE,FAC MED,DEPT FISIOL & BIOFIS,SANTIAGO 7,CHILE; LOYOLA UNIV,DEPT PHYSIOL,MAYWOOD,IL 60153	Universidad de Chile; Loyola University Chicago			Sierralta, Jimena Alejandra/AAG-8877-2021; Sierralta, Jimena/A-7591-2008	Sierralta, Jimena/0000-0002-0257-146X	NINDS NIH HHS [NS29640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029640] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; AIREY JA, 1990, J BIOL CHEM, V265, P14187; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BUCK E, 1992, J BIOL CHEM, V267, P23560; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHU A, 1993, J MEMBRANE BIOL, V135, P49; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FILL M, 1990, BIOPHYS J, V50, P471; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GYORKE S, 1994, BIOPHYS J, V66, P1879; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; MCPHERSON P, 1990, J BIOL CHEM, V265, P18464; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OBRIEN J, 1995, BIOPHYS J, V68, P471, DOI 10.1016/S0006-3495(95)80208-0; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P894, DOI 10.1093/oxfordjournals.jbchem.a123144; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OUYANG Y, 1993, BRAIN RES, V620, P629; PADUA RA, 1991, BRAIN RES, V542, P135, DOI 10.1016/0006-8993(91)91007-N; PADUA RA, 1994, J NEUROCHEM, V62, P2340; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SHARP AH, 1993, J NEUROSCI, V13, P3051; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUAREZISLA BA, 1988, BIOPHYS J, V54, P737, DOI 10.1016/S0006-3495(88)83009-1; SUTKO JL, 1991, J CELL BIOL, V113, P793, DOI 10.1083/jcb.113.4.793; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; VOLPE P, 1991, EMBO J, V10, P3183, DOI 10.1002/j.1460-2075.1991.tb04880.x; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WANG JP, 1993, J BIOL CHEM, V268, P20974; ZIMANYI I, 1992, MOL PHARMACOL, V42, P1049; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; ZIMANYI I, 1991, BRAIN RES, V561, P181, DOI 10.1016/0006-8993(91)91594-Q	40	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17028	17034		10.1074/jbc.271.29.17028	http://dx.doi.org/10.1074/jbc.271.29.17028			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663321	hybrid			2022-12-25	WOS:A1996UX94300010
J	Abe, J; Kusuhara, M; Ulevitch, RJ; Berk, BC; Lee, JD				Abe, J; Kusuhara, M; Ulevitch, RJ; Berk, BC; Lee, JD			Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HYDROGEN-PEROXIDE; ARACHIDONIC-ACID; C-JUN; EXPRESSION; GROWTH; IDENTIFICATION; DOMAIN; ERKS; FOS	Mitogen-activated protein (MAP) kinases are a multigene family activated by many extracellular stimuli. There are three groups of MAP kinases based on their dual phosphorylation motifs, TEY, TPY, and TGY, which are termed extracellular signal regulated protein kinases (ERK1/2), c-Jun N-terminal kinases, and p38, respectively. A new MAP kinase family member termed Big MAP kinase 1 (BMK1) or ERK5 was recently cloned, BMK1 has a TEY sequence similar to ERK1/2 but has unique COOH-terminal and loop-12 domains, To define BMK1 regulation, its activation in cultured rat vascular smooth muscle cells was characterized. Angiotensin II, phorbol ester, platelet-derived growth factor, and tumor necrosis factor-alpha were the strongest stimuli for ERK1/2 but were weak activators of BMK1. In contrast, H2O2 caused concentration-dependent activation of BMK1 but not ERK1/2. Sorbitol activated both BMK1 and ERK1/2. BMK1 activation by H2O2 was calcium-dependent and appeared ubiquitous as shown by stimulation in human skin fibroblasts, human vascular smooth muscle cells, and human umbilical vein endothelial cells, These findings demonstrate that activation of BMK1 is different from ERK1/2 and suggest an important role for BMK1 as a redox-sensitive kinase.	UNIV WASHINGTON, DEPT MED, DIV CARDIOL, SEATTLE, WA 98195 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Washington; University of Washington Seattle; Scripps Research Institute			Ulevitch, Richard J/Q-3393-2017	Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HL44721, HL49192] Funding Source: Medline; NIGMS NIH HHS [GM37694] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192, R01HL044721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037694] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE J, 1994, CANCER RES, V54, P3407; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRINTON EA, 1986, J BIOL CHEM, V261, P495; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; ZHOU G, 1995, J BIOL CHEM, V270, P12664; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	35	372	384	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16586	16590		10.1074/jbc.271.28.16586	http://dx.doi.org/10.1074/jbc.271.28.16586			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663194	hybrid			2022-12-25	WOS:A1996UX12600027
J	Broome, MA; Hunter, T				Broome, MA; Hunter, T			Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASES; PHOSPHORYLATION; PP60C-SRC; PROTEIN; ASSOCIATION; FIBROBLASTS; RECEPTOR; CELLS; MUTAGENESIS; CONTAINS	The Src family protein-tyrosine kinases are required for mitogenic signaling from the platelet-derived growth factor (PDGF), colony stimulating factor-1, and epidermal growth factor (EGF) receptor protein-tyrosine kinases (RPTK) (Twamley-Stein, G. M., Pepperkok, R., Ansorge, W., and Courtneidge, S. A. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 7696-7700; Roche, S., Koegl, M., Barone, M. V., Roussel, M. F., and Courtneidge, S. A. (1995) Mel. Cell. Biol. 15, 1102-1109). In NIH3T3 fibroblasts, c-Src, Fyn, and c-Yes associate with the activated PDGF receptor, are substrates for receptor phosphorylation, and are themselves activated. Src family catalytic function is required for RPTK mitogenic signaling as evidenced by the SH2-dependent dominant negative phenotype exhibited by kinase-inactive Src and Fyn mutants (Twamley-Stein, G. M., Pepperkok, R., Ansorge, W., and Courtneidge, S. A. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 7696-7700). Here, we have generated clonal Src(-) murine fibroblast cell lines overexpressing various murine c-Src mutants and studied the effect of these mutant Src proteins on PDGF- and EGF-induced mitogenesis. Two c-Src SH3 domain mutants, Y133F and Y138F, each inhibited PDGF BB- and EGF-induced DNA synthesis in quiescent cells. This demonstrates an involvement of the Src SH3 domain in PDGF beta and EGF receptor mitogenic signaling. Since both Tyr-133 and Tyr-138 are located on the ligand binding surface of the SH3 domain, these results suggest that the c-Src SH3 domain is required for PDGF and EGF mitogenic signaling. The dominant negative effect of either single mutant on PDGF receptor signaling was reversed by a second SH2-inactivating mutation. We conclude that the c-Src SH3 domain function requires the SH2 domain in the case of the PDGF receptor, presumably because binding of c-Src to the receptor via its SH2 domain is a prerequisite for the SH3 domain function. In contrast, SH2 function is apparently not essential for the SH3 function in EGF receptor signaling.	SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; ESPINO PC, 1990, ONCOGENE, V5, P283; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KARN J, 1989, ONCOGENE, V4, P773; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MOOLENAAR WH, 1992, COLD SPRING HARB SYM, V57, P163, DOI 10.1101/SQB.1992.057.01.021; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKAMURA H, 1994, ONCOGENE, V9, P2293; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Potts W M, 1988, Oncogene Res, V3, P343; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SORIANO P, 1991, CELL, V64, P6983; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	52	121	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16798	16806		10.1074/jbc.271.28.16798	http://dx.doi.org/10.1074/jbc.271.28.16798			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663329	hybrid			2022-12-25	WOS:A1996UX12600059
J	Fang, H; Panzner, S; Mullins, C; Hartmann, E; Green, N				Fang, H; Panzner, S; Mullins, C; Hartmann, E; Green, N			The homologue of mammalian SPC12 is important for efficient signal peptidase activity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SEC11 PROTEIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SHUTTLE VECTORS; HOST STRAINS; GENE; PURIFICATION; GLYCOPROTEIN; SEQUENCE; MEMBRANE	The multisubunit signal peptidase catalyzes the cleavage of signal peptides and the degradation of some membrane proteins within the endoplasmic reticulum (ER). The only subunit of this enzyme functionally examined to date, yeast Sec11p, is related to signal peptidase I from bacteria. Since bacterial signal peptidase is capable of processing both prokaryotic and eukaryotic signal sequences as a monomer, it is unclear why the analogous enzyme in the ER contains proteins unrelated to signal peptidase I. To address this issue, the gene encoding Spc1p, the yeast homologue to mammalian SPC12, is isolated from the yeast Saccharomyces cerevisiae, Spc1p co-purifies and genetically interacts with Sec11p, but unlike Sec11p, Spc1p is not required for cell growth or the proteolytic processing of tested proteins in yeast, This indicates that only a subset of the ER signal peptidase subunits is required for signal peptidase and protein degradation activities in vivo. Through both genetic and biochemical criteria. Spc1p appears, however, to be important for efficient signal peptidase activity.	MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Fang, H (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.		Hartmann, Enno/C-5687-2013		NCI NIH HHS [2 T32 CA09425] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; ESNAULT Y, 1993, EMBO J, V12, P4283; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FANG H, 1994, MOL BIOL CELL, V5, P933, DOI 10.1091/mbc.5.9.933; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; INNIS MA, 1984, P NATL ACAD SCI USA, V81, P4308; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1442; KALIES KU, 1996, J BIOL CHEM, V271, P4325; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIVELY MO, 1994, SIGNAL PEPTIDASES, P59; MULLIS C, 1995, J BIOL CHEM, V270, P17143; NEWSOME AL, 1992, BIOCHEM J, V282, P447, DOI 10.1042/bj2820447; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SHERMAN F, 1986, METHODS YEAST GENETI, P127; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS TB, 1982, CELL, V30, P443; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; Von Heijne Gunnar, 1994, V22, P1; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU F, 1984, FEBS LETT, V173, P264, DOI 10.1016/0014-5793(84)81060-1; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	42	26	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16460	16465		10.1074/jbc.271.28.16460	http://dx.doi.org/10.1074/jbc.271.28.16460			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663399	hybrid			2022-12-25	WOS:A1996UX12600008
J	Fujino, T; Kang, MJ; Suzuki, H; Iijima, H; Yamamoto, T				Fujino, T; Kang, MJ; Suzuki, H; Iijima, H; Yamamoto, T			Molecular characterization and expression of rat acyl-CoA synthetase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; NUCLEOTIDE-SEQUENCE; BACILLUS-BREVIS; CLONING; GENE; DNA; PURIFICATION; BRAIN; CDNA; INHIBITORS	Isolation and characterization of a rat brain cDNA identified a third acyl-CoA synthetase (ACS) designated ACS3. The deduced amino acid sequence of the cDNA revealed that ACS3 consists of 720 amino acids and exhibits a structural architecture common to ACSs from various origins, ACS3 expressed in COS cells was purified to near homogeneity, The purified ACS3 resolved by SDS-polyacrylamide gel electrophoresis into two major proteins of 79 and 80 kDa. Cell-free translation of a synthetic mRNA encoding the entire region of ACS3 revealed that the two isoforms were derived from the same mRNA, The purified ACS3 utilizes laurate and myristate most efficiently among C-8-C-22 saturated fatty acids and arachidonate and eicosapentaenoate among C-16-C-20 unsaturated fatty acids, Northern blot analysis revealed that ACS3 mRNA is most abundant in brain and, to a much lesser extent, in lung, adrenal gland, kidney, and small intestine. During the development of the rat brain, expression of ACS3 mRNA reached a maximum level at 15 days after birth and then declined gradually to 10% of the maximum in the adult brain.	TOHOKU UNIV,CTR GENE RES,AOBA KU,SENDAI,MIYAGI 981,JAPAN	Tohoku University								ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; BAZAN NG, 1986, PROG LIPID RES, V25, P595, DOI 10.1016/0163-7827(86)90122-0; BRONFMAN M, 1989, BIOCHEM BIOPH RES CO, V159, P1026, DOI 10.1016/0006-291X(89)92211-0; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEZ B, 1990, J BIOL CHEM, V265, P16358; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HORI K, 1989, J BIOCHEM-TOKYO, V106, P639, DOI 10.1093/oxfordjournals.jbchem.a122909; Kabara J J, 1973, Prog Brain Res, V40, P363; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KURIBAYASHIOHTA K, 1993, BIOCHIM BIOPHYS ACTA, V1156, P204, DOI 10.1016/0304-4165(93)90137-W; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; REDDY TS, 1984, INT J DEV NEUROSCI, V2, P447, DOI 10.1016/0736-5748(84)90046-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SINGH I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P44, DOI 10.1016/0005-2760(93)90174-8; SINGH I, 1988, BIOCHIM BIOPHYS ACTA, V963, P509, DOI 10.1016/0005-2760(88)90319-0; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TANAKA T, 1979, EUR J BIOCHEM, V98, P165, DOI 10.1111/j.1432-1033.1979.tb13173.x; TOH H, 1991, Protein Sequences and Data Analysis, V4, P111; WANDERS RJA, 1987, BIOCHIM BIOPHYS ACTA, V919, P21, DOI 10.1016/0005-2760(87)90213-X; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; WILSON DB, 1982, J BIOL CHEM, V257, P3510; WOOD KV, 1989, SCIENCE, V244, P700, DOI 10.1126/science.2655091	36	159	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16748	16752		10.1074/jbc.271.28.16748	http://dx.doi.org/10.1074/jbc.271.28.16748			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663269	hybrid			2022-12-25	WOS:A1996UX12600052
J	Masaki, R; Yamamoto, A; Tashiro, Y				Masaki, R; Yamamoto, A; Tashiro, Y			Membrane topology and retention of microsomal aldehyde dehydrogenase in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; GOLGI-COMPLEX; VESICULAR TRANSPORT; BREFELDIN-A; PROTEINS; CYTOCHROME-P-450; LIVER; ER; REDISTRIBUTION; GLYCOSYLATION	Microsomal aldehyde dehydrogenase (msALDH) is anchored to the endoplasmic reticulum (ER) membrane by the hydrophobic domain at its carboxyl terminus, and most of the molecule is exposed to the cytoplasm (Masaki, R., Yamamoto, A., and Tashiro, Y. (1994) J. Cell Biol, 126, 1407-1420), To determine the membrane topology and the intracellular localization of msALDH, the amino-terminal region of bovine opsin containing N-glycosylation sites was fused to the carboxyl terminus of msALDH, and three chimeric proteins with extensions of different sizes were expressed in COS cells, Indirect immunofluorescence microscopy showed the ER localization of all of the chimeric proteins similar to wildtype msALDH. Immunoblotting revealed that the two chimeric proteins containing longer extensions, those with the N-glycosylation site at distances of 13 and 21 amino acids from the membrane anchor, respectively, were glycosylated, These results indicate that the membrane binding domain of msALDH spans the bilayer of the ER, The carbohydrate chain of the chimeras was sensitive to endoglycosidase H but resistant to endoglycosidase D. Upon treatment of transfected COS cells with brefeldin A, the carbohydrate chain was processed to an endoglycosidase II-resistant form, presumably by cis/medial Golgi-specific enzymes redistributed in the ER, These biochemical results in addition to immunofluorescence microscopic observations suggest that msALDH is retained in the ER by blockading of the exit from the ER.	KANSAI MED UNIV,LIVER RES CTR,DIV CELL BIOL,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University	Masaki, R (corresponding author), KANSAI MED UNIV,DEPT PHYSIOL,10-15 FUMIZONO CHO,MORIGUCHI,OSAKA 570,JAPAN.							AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; AHN KS, 1993, J BIOL CHEM, V268, P18726; BARNUN S, 1980, P NATL ACAD SCI-BIOL, V77, P965, DOI 10.1073/pnas.77.2.965; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; FUJIIKURIYAMA Y, 1979, J CELL BIOL, V81, P510, DOI 10.1083/jcb.81.3.510; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; INOUE A, 1992, J BIOL CHEM, V267, P10613; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KOU CH, 1986, MOL BRAIN RES, V1, P251; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OZOLS J, 1982, BIOCHIM BIOPHYS ACTA, V704, P163, DOI 10.1016/0167-4838(82)90143-1; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOZAWA O, 1993, J BIOL CHEM, V268, P21399; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; TAKAGI Y, 1985, J BIOCHEM-TOKYO, V98, P1647, DOI 10.1093/oxfordjournals.jbchem.a135435; VERGERES G, 1995, J BIOL CHEM, V270, P3414, DOI 10.1074/jbc.270.7.3414; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Yamamoto A, 1996, J CELL SCI, V109, P1727; YAMAMOTO A, 1985, J CELL BIOL, V101, P1733, DOI 10.1083/jcb.101.5.1733	37	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16939	16944		10.1074/jbc.271.28.16939	http://dx.doi.org/10.1074/jbc.271.28.16939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663312	hybrid			2022-12-25	WOS:A1996UX12600078
J	Laderman, KA; Penny, JR; Mazzucchelli, F; Bresolin, N; Scarlato, G; Attardi, G				Laderman, KA; Penny, JR; Mazzucchelli, F; Bresolin, N; Scarlato, G; Attardi, G			Aging-dependent functional alterations of mitochondrial DNA (mtDNA) from human fibroblasts transferred into mtDNA-less cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRADIENT GEL-ELECTROPHORESIS; AGE-ASSOCIATED ACCUMULATION; DEGENERATIVE DISEASES; HUMAN BRAIN; PROTEIN-SYNTHESIS; OXIDATIVE DAMAGE; HUMAN HEARTS; DELETIONS; MUTATIONS; TISSUES	To investigate the role that aging-dependent accumulation of mitochondrial DNA (mtDNA) mutations plays in the senescence processes, mitochondria from fibroblasts of 21 normal human individuals between 20 weeks (fetal) and 103 years of age were introduced into human mtDNA-less (rho degrees) 206 cells by cytoplast x rho degrees cell fusion, and 7-31 transformant clones were isolated from each fusion, A slight cell donor age-dependent decrease in growth rate was detected in the transformants. Using an O-2 consumption rate of 1 fmol/min/cell, which was not observed in any transformant among 158 derived from individuals 20 weeks (fetal) to 37 years of age, as a cutoff to identify respiratory-deficient clones, 11 such clones were found among 198 transformants derived from individuals 39-103 years of age. Furthermore, conventional and nonparametric analysis of the respiratory rates of 356 clones revealed a very significant decrease with donor age, In other analyses, a very significant age-dependent decline in the mtDNA content of the clones was observed, without, however, any significant correlation with the decrease in O-2 consumption rate in the defective transformants, These observations clearly indicate the occurrence in the fibroblast-derived trans formants of two independent, age-related functional alterations of mtDNA, presumably resulting from structural damage to this genome.	CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV MILAN,IST CLIN NEUROL,CTR DINO FERRARI,I-20122 MILAN,ITALY; UNIV MILAN,IST CLIN NEUROL,CTR DINO FERRARI,OSPED MAGGIORE POLICLIN,IRCCS,I-20122 MILAN,ITALY	California Institute of Technology; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan				Bresolin, Nereo/0000-0001-6694-3595	NATIONAL INSTITUTE ON AGING [F32AG005612] Funding Source: NIH RePORTER; NIA NIH HHS [AG05612-03, AG12117-05] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMS ES, 1992, METHOD ENZYMOL, V212, P71; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHOMYN A, 1994, AM J HUM GENET, V54, P966; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; COSTES B, 1993, HUM MOL GENET, V2, P393, DOI 10.1093/hmg/2.4.393; Gibbons J.D., 1993, NONPARAMETRIC STAT I, P30; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127; Norwood T. H., 1982, TECHNIQUES SOMATIC C, P35; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; REIS RJS, 1983, J BIOL CHEM, V258, P9078; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V; SOONG NW, 1992, NAT GENET, V2, P318; SUGIYAMA S, 1991, BIOCHEM BIOPH RES CO, V180, P894, DOI 10.1016/S0006-291X(05)81149-0; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; VEOMETT GE, 1982, TECHNIQUES SOMATIC C, P67; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; YONEDA M, 1984, MOL CELL BIOL, V14, P2899; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	50	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15891	15897		10.1074/jbc.271.27.15891	http://dx.doi.org/10.1074/jbc.271.27.15891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663253	hybrid, Green Accepted			2022-12-25	WOS:A1996UW35200011
J	Balbin, M; Hannon, GJ; Pendas, AM; Ferrando, AA; Vizoso, F; Fueyo, A; LopezOtin, C				Balbin, M; Hannon, GJ; Pendas, AM; Ferrando, AA; Vizoso, F; Fueyo, A; LopezOtin, C			Functional analysis of a p21(WAF1,CIP1,SDI1) mutant (Arg(94)->trp) identified in a human breast carcinoma - Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; SUBUNIT	Human p21 (also known as WAF1, CIP1, or SDI1) is a dual inhibitor of cyclin dependent kinases (CDKs) and the replication factor PCNA, which plays a role as a downstream mediator of the cell-cycle arrest induced by the tumor suppressor p53. To determine whether inactivation of downstream targets of p53 might contribute to cellular transformation, we have examined the integrity of the p21 gene in 36 invasive ductal breast carcinomas. Direct sequence analysis of the polymerase chain reaction-amplified p21 gene revealed a C to T transition in codon 94 that caused the substitution of a tryptophan for an arginine in a tumor specimen. This mutation was not detected in normal DNA extracted from the same patient nor in a polymerase chain reaction-restriction fragment length polymorphism of 50 unrelated individuals, indicating that it corresponds to a tumor specific alteration. Functional analysis of the p21(R94W) protein produced in different eukaryotic and prokaryotic expression systems revealed that this mutation impaired the ability of p21 to inhibit CDKs. By contrast, the R94W mutant was unaltered in its ability to promote cyclin-CDK association as well gs in its ability to bind proliferating cell nuclear antigen, thus leaving its putative functions as kinase activator or as inhibitor of replicative DNA synthesis intact. On the basis of these functional analysis, we propose that the Arg residue at position 94 is important for the CDK inhibitory role of p21.	UNIV OVIEDO,FAC MED,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; HOSP DE JOVE,SERV CIRUGIA,E-33290 GIJON,SPAIN	University of Oviedo; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Balbín, Milagros/I-4206-2015; Pendas, Alberto M/L-1017-2014; Fueyo, Antonio/ABH-3243-2020; López-Otín, Carlos/AAB-2106-2020; Hannon, Gregory/AAB-3568-2019	Balbín, Milagros/0000-0001-5325-0407; Fueyo, Antonio/0000-0002-7121-9398; López-Otín, Carlos/0000-0001-6964-1904; Pendas, Alberto M/0000-0001-9264-3721				BALBIN M, 1993, HUM GENET, V90, P668; BHATIA K, 1995, CANCER RES, V55, P1431; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1019; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HIRAMA T, 1995, BLOOD, V86, P841; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG H, 1994, ONCOGENE, V9, P3389; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI YJ, 1995, ONCOGENE, V10, P599; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH ML, 1994, SCIENCE, V266, P1375; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	47	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15782	15786		10.1074/jbc.271.26.15782	http://dx.doi.org/10.1074/jbc.271.26.15782			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663132	hybrid			2022-12-25	WOS:A1996UV29900072
J	Kurlandsky, SB; Duell, EA; Kang, S; Voorhees, JJ; Fisher, GJ				Kurlandsky, SB; Duell, EA; Kang, S; Voorhees, JJ; Fisher, GJ			Auto-regulation of retinoic acid biosynthesis through regulation of retinol esterification in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN KERATINOCYTES; VITAMIN-A; BINDING PROTEIN; RAT-LIVER; ACYLTRANSFERASE ACTIVITY; TERMINAL DIFFERENTIATION; HEPATIC LECITHIN; HUMAN-EPIDERMIS; METABOLISM; MICROSOMES	In this report, we describe an auto-reguIatory loop in human keratinocytes, whereby all-trans retinoic acid (retinoic acid) regulates its own biosynthesis from all-trans retinol (retinol) through regulation of retinol esterification. Retinol esterification activity was low in normal proliferating human keratinocytes, cultured in retinoid-free media. Treatment of keratinocytes with retinoic acid induced retinol esterifying activity (8-fold). Induction of retinol esterifying activity was blocked by either actinomycin D or cycloheximide. Based an substrate specificity and inhibitor sensitivity, lecithin:retinol acyltransferase (LRAT) was identified as the retinoic acid-inducible retinol esterifying enzyme, Induction of LRAT by retinoic acid reduced conversion of retinol to retinoic acid by 50%. This reduction in retinoic acid synthesis resulted from sequestration of retinol as retinyl esters, since inhibition of LRAT restored retinoic acid synthesis to control levels. In normal human skin, undifferentiated keratinocytes, in the lowest cell layer, esterified retinol 4 times greater, than differentiating keratinocytes, in upper cell layers, reflecting an induced state, under conditions of retinol sufficiency, Regulation of LRAT activity by retinoic acid provides a novel mechanism through which retinoic acid can regulate its own level by controlling availability of retinol for conversion to retinoic acid. In human skin in vivo, retinyl esters synthesized in basal keratinocytes could undergo hydrolysis during differentiation and thus serve as a source of retinol for keratinocytes in upper layers of skin.	UNIV MICHIGAN,MED CTR,DEPT DERMATOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIAMS NIH HHS [AR07197-19] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ANSKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; Blaner William S., 1994, P229; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; CONNOR MJ, 1986, LIFE SCI, V38, P1807, DOI 10.1016/0024-3205(86)90134-7; CREEK KE, 1993, J NUTR, V123, P356, DOI 10.1093/jn/123.suppl_2.356; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FISHER GJ, 1988, J INVEST DERMATOL, V91, P142, DOI 10.1111/1523-1747.ep12464387; FROLIK CA, 1984, RETINOIDS, P177; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GODA T, 1993, BIOCHIM BIOPHYS ACTA, V1168, P153; HERR FM, 1991, J NUTR BIOCHEM, V2, P503, DOI 10.1016/0955-2863(91)90108-H; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KANG SW, 1995, J INVEST DERMATOL, V105, P549, DOI 10.1111/1523-1747.ep12323445; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; MARCELO CL, 1992, J INVEST DERMATOL, V99, P703, DOI 10.1111/1523-1747.ep12614196; MATSUURA T, 1993, ARCH BIOCHEM BIOPHYS, V301, P221, DOI 10.1006/abbi.1993.1137; ONG DE, 1991, J LIPID RES, V32, P1521; ONG DE, 1988, J BIOL CHEM, V263, P5789; ONG DE, 1994, NUTR REV, V52, pS24; PEMRICK SM, 1994, LEUKEMIA, V8, P1787; PITTELKOW MR, 1986, MAYO CLIN PROC, V61, P771, DOI 10.1016/S0025-6196(12)64815-0; QUICK TC, 1990, BIOCHEMISTRY-US, V29, P11116, DOI 10.1021/bi00502a015; RANDOLPH RK, 1995, ARCH BIOCHEM BIOPHYS, V318, P6, DOI 10.1006/abbi.1995.1197; RANDOLPH RK, 1991, J BIOL CHEM, V266, P16453; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; ROLLMAN O, 1993, BIOCHEM J, V293, P675, DOI 10.1042/bj2930675; ROSS AC, 1990, METHOD ENZYMOL, V189, P442; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9647, DOI 10.1021/bi00451a016; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; TIMMERS AMM, 1986, J LIPID RES, V27, P979; TORMA H, 1990, J INVEST DERMATOL, V94, P132, DOI 10.1111/1523-1747.ep12873990; TORMA H, 1991, SKIN PHARMACOL, V4, P154; WANG XD, 1993, J NUTR, V123, P1277, DOI 10.1093/jn/123.7.1277; YOST RW, 1988, J BIOL CHEM, V263, P18693	46	107	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15346	15352		10.1074/jbc.271.26.15346	http://dx.doi.org/10.1074/jbc.271.26.15346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663081				2022-12-25	WOS:A1996UV29900010
J	Mano, I; Lamed, Y; Teichberg, VI				Mano, I; Lamed, Y; Teichberg, VI			A Venus flytrap mechanism for activation and desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-BINDING PROTEIN; AMPA KAINATE RECEPTORS; RAT HIPPOCAMPAL SLICES; SYNAPTIC TRANSMISSION; GLUTAMATE; NEURONS; CHANNELS; PATCHES; LIGAND	Desensitization of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) subtype of glutamate receptor channels is an important process shaping the time course of synaptic excitation. Upon desensitization, the receptor channel closes and the agonist affinity increases. So far, the nature of the structural rearrangements leading to these events was unknown. On the basis of the structural homology of the ligand binding domains of AMPA receptors and of the bilobated bacterial periplasmic proteins, we now show that agonist interaction with one lobe of the GluR1 subunit of homomeric AMPA receptors controls channel activation while additional interactions with the other lobe cause channel desensitization. Accordingly, we suggest that the transition of the AMPA receptor channel to the desensitized state involves the agonist-mediated stabilization of the closed lobe conformation of its binding domain and is a process akin to that used by the venus flytrap.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; BENVENISTE M, 1995, J PHYSIOL-LONDON, V483, P367, DOI 10.1113/jphysiol.1995.sp020591; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DANI JA, 1995, CURR OPIN NEUROBIOL, V5, P310, DOI 10.1016/0959-4388(95)80043-3; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; KANG CH, 1991, J BIOL CHEM, V266, P23893; KISKIN NI, 1990, EUR J NEUROSCI, V2, P461, DOI 10.1111/j.1460-9568.1990.tb00437.x; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LARSON J, 1994, NEUROREPORT, V5, P389, DOI 10.1097/00001756-199401120-00004; LI F, 1995, MOL PHARMACOL, V47, P148; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Paas Y, 1996, EMBO J, V15, P1548, DOI 10.1002/j.1460-2075.1996.tb00499.x; PARSONS CG, 1994, NEUROPHARMACOLOGY, V33, P589, DOI 10.1016/0028-3908(94)90163-5; PARTIN KM, 1995, NEURON, V14, P833, DOI 10.1016/0896-6273(95)90227-9; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; THIO LL, 1991, J NEUROSCI, V11, P3430; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; YAMADA KA, 1993, J NEUROSCI, V13, P3904	38	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15299	15302		10.1074/jbc.271.26.15299	http://dx.doi.org/10.1074/jbc.271.26.15299			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663365	hybrid			2022-12-25	WOS:A1996UV29900001
J	Cui, Z; Houweling, M; Chen, MH; Record, M; Chap, H; Vance, DE; Terce, F				Cui, Z; Houweling, M; Chen, MH; Record, M; Chap, H; Vance, DE; Terce, F			A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITION	We have investigated the cell death of a Chinese hamster ovary mutant (MT-58) with a thermo-sensitive CTP: phosphocholine cytidylyltransferase, the rate-limiting enzyme of the CDP choline pathway for phosphatidylcholine biosynthesis (Esko, J. D., Wermuth, M. M., and Raetz, C. R. H. (1981) J. Biol. Chem, 256, 7388-7393), After MT-58 cells were shifted to the restrictive temperature of 40 degrees C, the cytidylyltransferase was inactivated immediately leading to a decrease in phosphatidylcholine biosynthesis and cell death, DNA content and number of cells in the S phase decreased significantly in the dying MT-58 cells according to flow cytometrical analyses, The fragmentation of genomic DNA was detected by DNA ladders in agarose gel and release of the prelabeled genomic DNA into cytosolic fractions 14 h after the temperature shift, The dying cells underwent a dramatic reduction of cellular volume while maintaining the membrane containment of cellular contents, These events indicated that the inactivation of cytidylyltransferase triggered apoptosis in Chinese hamster ovary cells, This is the first report that apoptosis was induced in cultured cells, not by an added agent, but by a mutation in phospholipid biosynthesis.	HOP PURPAN, INSERM, U326, F-31059 TOULOUSE, FRANCE; UNIV ALBERTA, LIPID & LIPOPROT RES GRP, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, SURG MED RES INST, EDMONTON, AB T6G 2S2, CANADA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Alberta; University of Alberta; University of Alberta			Tercé, François/M-5863-2018; RECORD, Michel/G-3493-2017	Tercé, François/0000-0003-4488-2167; RECORD, Michel/0000-0003-1893-0022				BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HAUG JS, 1994, BBA-MOL CELL RES, V1223, P133, DOI 10.1016/0167-4889(94)90082-5; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJNO G, 1995, AM J PATHOL, V146, P3; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MEYN MS, 1995, CANCER RES, V55, P5991; OISHI K, 1988, BIOCHEM BIOPH RES CO, V157, P1000, DOI 10.1016/S0006-291X(88)80973-2; Osborne Barbara A., 1994, Trends in Cell Biology, V4, P394; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; POWIS G, 1992, CANCER RES, V52, P2835; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SCHWARTZ LM, 1995, METHOD CELL BIOL, V46, P107; TERCE F, 1994, J LIPID RES, V35, P2130; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; Vance D E, 1981, Methods Enzymol, V71 Pt C, P576; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Vindelov L, 1990, Methods Cell Biol, V33, P127	33	182	187	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14668	14671		10.1074/jbc.271.25.14668	http://dx.doi.org/10.1074/jbc.271.25.14668			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663247	hybrid			2022-12-25	WOS:A1996UT10600006
J	Cao, GQ; Goldstein, JL; Brown, MS				Cao, GQ; Goldstein, JL; Brown, MS			Complementation of mutation in acyl-CoA:cholesterol acyltransferase (ACAT) fails to restore sterol regulation in ACAT-defective sterol-resistant hamster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; COENZYME-A; TRANSCRIPTION; DEFICIENT	A previously described mutant line of Chinese hamster ovary cells, designated SRD-4, fails to synthesize cholesteryl esters, owing to a deficiency in the activity of acyl-CoA:cholesterol acyltransferase (ACAT). These cells also fail to suppress low density lipoprotein receptors or cholesterol synthesizing enzymes in the presence of 25-hydroxycholesterol. In the current studies we show that SRD-4 cells have three defects: 1) a point mutation in one allele at the ACAT locus that changes codon 265 from Ser to Leu, resulting in an inactive enzyme; 2) a silent allele at the other ACAT locus that does not produce detectable mRNA; and 3) a mutation, as yet undefined, that abolishes the ability of 25-hydroxycholesterol to inhibit the cleavage of both sterol regulatory element binding proteins (SREBP-1 and SREBP-2), Correction of the ACAT deficiency by transfection of a wildtype cDNA failed to restore inhibition of SREBP cleavage by 25-hydroxycholesterol, indicating that the ACAT deficiency and the sterol regulatory defect are caused by independent mutations. These data provide further insight into the interplay between ACAT activation and inhibition of SREBP cleavage by 25-hydroxycholesterol, and they indicate that these two processes can be disrupted independently by mutation.			Cao, GQ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BROWN MS, 1975, J BIOL CHEM, V250, P4025; CADIGAN KM, 1989, J CELL BIOL, V108, P2201, DOI 10.1083/jcb.108.6.2201; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1983, ENZYMES, P523; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HOLLIDAY R, 1991, MUTAT RES, V250, P351, DOI 10.1016/0027-5107(91)90192-Q; HOLLIDAY R, 1990, New Biologist, V2, P719; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Sambrook J., 2002, MOL CLONING LAB MANU; SATO R, 1994, J BIOL CHEM, V269, P17267; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	28	47	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14642	14648		10.1074/jbc.271.24.14642	http://dx.doi.org/10.1074/jbc.271.24.14642			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662991	hybrid			2022-12-25	WOS:A1996UQ66000104
J	Chen, HF; Campisi, J; Padmanabhan, R				Chen, HF; Campisi, J; Padmanabhan, R			SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA GENE-PRODUCT; HUMAN-DIPLOID FIBROBLASTS; E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; HUMAN HSP70 PROMOTER; HUMAN MYC PROMOTER; FISSION YEAST; SENESCENT HUMAN; SUSCEPTIBILITY GENE	Cyclin-dependent protein kinases (Cdks) play a key role in the cell division cycle of eukaryotic cells. Cdc2, the first mammalian Cdk that was discovered, is expressed in S phase and functions in the G(2) to M phase transition. By transfecting segments of the human cdc2 promoter linked to a reporter gene into monkey kidney (CV-1) cells, we identified the region containing the Spl, E2F, and two CCAAT box binding sites as essential and sufficient for basal transcription. SV40 large T antigen (SV40-LT) is a viral oncoprotein that transactivates viral and cellular promoters and induces DNA synthesis in quiescent cells. SV40-LT transactivated wild-type cdc2 promoter/reporter constructs in a dose-dependent manner, coinciding with an increase in endogenous cdc2 mRNA. A mutant promoter from which the two CCAAT box motifs were deleted was 8-fold less sensitive to SV40-LT. Activation by SV40-LT did not require its ability to bind the retinoblastoma or p53 tumor suppressor proteins. SV40-LT induced a specific CCAAT box-binding factor (CBF) in CV-1 and COS-7 cells, as judged by gel shift and Southwestern analyses, Similar results were obtained in human fibroblasts expressing a conditional SV40-LT. The SV40-LT-inducible CBF appears to be novel and differs from the CBF that activates heat shock protein 70 gene expression.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160; UNIV CALIF BERKELEY,BERKELEY NATL LAB,DEPT CANC BIOL,BERKELEY,CA 94720	University of Kansas; University of Kansas Medical Center; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R01CA033099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909, R01AG011658] Funding Source: NIH RePORTER; NCI NIH HHS [CA33099] Funding Source: Medline; NIA NIH HHS [AG11658, AG09909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Campisi Judith, 1996, P121; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN HF, 1994, VIROLOGY, V205, P364, DOI 10.1006/viro.1994.1654; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; Hara E, 1996, DEV GENET, V18, P161; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PANG JH, 1993, J BIOL CHEM, V268, P2909; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICE PW, 1993, J VIROL, V67, P6689, DOI 10.1128/JVI.67.11.6689-6697.1993; RICHTER KH, 1991, CANCER RES, V51, P6010; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SALA A, 1994, CANCER RES, V54, P1402; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; TEVETHIA MJ, 1988, VIROLOGY, V62, P76; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUJI Y, 1983, EXP CELL RES, V144, P165, DOI 10.1016/0014-4827(83)90450-0; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	84	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13959	13967		10.1074/jbc.271.24.13959	http://dx.doi.org/10.1074/jbc.271.24.13959			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662914	hybrid			2022-12-25	WOS:A1996UQ66000008
J	Liu, YC; Elly, C; Yoshida, H; BonnefoyBerard, N; Altman, A				Liu, YC; Elly, C; Yoshida, H; BonnefoyBerard, N; Altman, A			Activation-modulated association of 14-3-3 proteins with Cbl in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-CBL; TRANSFORMATION; ONCOGENE	14-3-3 proteins have recently been implicated in the regulation of intracellular signaling pathways via their interaction with several oncogene and protooncogene products. We found recently that 14-3-3 associates with several tyrosine-phosphorylated proteins and phosphatidylinositol 3-kinase (PI3-K) in T cells. We report here the identification of the 120-kDa 14-3-3 tau-binding phosphoprotein present in activated T cell lysates as Cbl, a protooncogene product of unknown function which was found recently to be a major protein-tyrosine kinase (PTK) substrate, and to interact with several signaling molecules including PI3-K, in T lymphocytes. The association between 14-3-3 tau and Cbl was detected both in vitro and in intact T cells and, in contrast to Raf-1, was markedly increased following T cell activation. The use of truncated 14-3-3 tau fusion proteins demonstrated that the 15 C-terminal residues are required for the association between 14-3-3 and three of its target proteins, namely, Cbl, Raf-1, and PI3-K. The findings that 14-3-3 tau binds both PI3-K and Cbl, together with recent reports of an association between Cbl and PI3-K, suggest that 14-3-3 dimers play a critical role in signal transduction processes by promoting and coordinating protein-protein interactions of signaling proteins.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, LA JOLLA, CA 92037 USA; LA JOLLA INST ALLERGY & IMMUNOL, DIV IMMUNOBIOL, LA JOLLA, CA 92037 USA; INST CYTOSIGNAL RES INC, TOKYO 140, JAPAN	La Jolla Institute for Immunology; La Jolla Institute for Immunology			Bonnefoy, Nathalie/J-2536-2012	Bonnefoy, Nathalie/0000-0003-4814-6722; LIU, YUN-CAI/0000-0002-0996-7109	NCI NIH HHS [CA35299] Funding Source: Medline; NIGMS NIH HHS [GM50819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LIU YC, 1994, P NATL ACAD SCI USA, V91, P11227, DOI 10.1073/pnas.91.23.11227; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROTH D, 1994, BIOCHEM J, V301, P305, DOI 10.1042/bj3010305; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	37	99	106	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14591	14595		10.1074/jbc.271.24.14591	http://dx.doi.org/10.1074/jbc.271.24.14591			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663231	hybrid			2022-12-25	WOS:A1996UQ66000096
J	Janosch, P; Schellerer, M; Seitz, T; Reim, P; Eulitz, M; Brielmeier, M; Kolch, W; Sedivy, JM; Mischak, H				Janosch, P; Schellerer, M; Seitz, T; Reim, P; Eulitz, M; Brielmeier, M; Kolch, W; Sedivy, JM; Mischak, H			Characterization of I kappa B kinases - I kappa B-alpha is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA; CELLS	The NF-kappa B transcription factor is activated by a wide variety of stimuli, including phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate. In its inactive state, NF-kappa B is sequestered in the cytoplasm tethered to an inhibitor protein, I kappa B, Activation comprises the rapid phosphorylation of I kappa B-alpha at N-terminal sites, which presumably marks I kappa B-alpha for proteolytic degradation and leads to release of NF-kappa B into the nucleus, In addition, I kappa B-alpha is constitutively phosphorylated at the C terminus, which may be a prerequisite for proper I kappa B function, Protein kinase C (PKC) is activated by 12-O-tetradecanoylphorbol-13-acetate and has been previously reported to phosphorylate I kappa B-alpha in vitro. As PBC has turned out to constitute a multigene family encoding isozymes with different biological functions, we have reinvestigated I kappa B-alpha phosphorylation by PKC using recombinant PKC isozymes expressed in insect cells, While crude PKC preparations were efficient I kappa B-alpha kinases, highly purified PKC isozymes completely failed to phosphorylate I kappa B-alpha. Biochemical separation of porcine spleen yielded at least two fractions with I kappa B-alpha kinase activity, both of which were devoid of detectable PKC isozymes, One peak contained both Raf-l and casein kinase Il (CKII), Purified Raf-1 does not phosphorylate I kappa B-alpha directly, hut associates with CKII, which efficiently phosphorylates the C terminus of I kappa B-alpha. Two-dimensional phosphopeptide mapping and high pressure liquid chromatography-mass spectroscopy analysis showed that all I kappa B-alpha kinases induced phosphorylation at the same prominent sites in the C terminus. Our results clearly indicate that PRC isozymes alpha, beta, gamma, delta, epsilon, eta, and zeta as well as Raf-1 are not I kappa B-alpha kinases, They furthermore demonstrate that I kappa B-alpha is targeted by several kinases, one of which appears to be CKII.	FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOL BIOL & TUMOR GENET, D-81377 MUNICH, GERMANY; BROWN UNIV, DEPT BIOL MOLEC, PROVIDENCE, RI 02912 USA	Brown University			Mischak, Harald/E-8685-2011; Brielmeier, Markus/M-7352-2014; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Brielmeier, Markus/0000-0002-8715-869X; Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041690] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-R01-41690] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GOSH S, 1990, NATURE, V344, P678; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LOZANO J, 1994, J BIOL CHEM, V269, P19200; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; SIEBENLIST U, 1995, INDUCIBLE GENE EXPRE, V1, P93; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAECKNER EBM, 1994, EMBO J, V14, P2876; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	21	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13868	13874		10.1074/jbc.271.23.13868	http://dx.doi.org/10.1074/jbc.271.23.13868			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662925	hybrid			2022-12-25	WOS:A1996UP38500084
J	Martin, A; Brown, FD; Hodgkin, MN; Bradwell, AJ; Cook, SJ; Hart, M; Wakelam, MJO				Martin, A; Brown, FD; Hodgkin, MN; Bradwell, AJ; Cook, SJ; Hart, M; Wakelam, MJO			Activation of phospholipase D and phosphatidylinositol 4-phosphate 5-kinase in HL60 membranes is mediated by endogenous Arf but not Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; EXCHANGE; BOMBESIN; CELLS	Membrane-associated phospholipase D (PLD) in HL60 cells can be activated by the small GTP-binding proteins Arf and RhoA, but polyphosphorylated inositol lipids were required for maximum activity, The intact lipid was required because neither inositol 1,4,5-trisphosphate nor stearoyl-arachidonyl glycerol could substitute for phosphatidylinositol 4,5-bisphosphate (PIP2), Arf-stimulated but not Rho-stimulated PLD activity was increased by the inclusion of Mg2+ and ATP, ATP-dependent PLD activation occurred when phosphatidylinositol 4-phosphate (PIP), PIP2, or phosphatidylinositol 3,4,5-trisphosphate (PIP3) were included, but PIP2 formation was only detected with PIP; no PIP3 production was detected under any conditions, Therefore, the ATP-dependent increase in PLD activity cannot be explained by PIP2 or PIP3 formation, Association of endogenous Arf and RhoA with membranes was increased by incubation with GTP gamma S, This treatment increased membrane PLD and PIP kinase activities in the absence of exogenous p21 proteins, Reduction of Arf translocation suppressed the increase in PLD and PIP kinase activities, whereas complete removal of Rho but not Arf from membranes with RhoGDI was without effect on PLD activity but increased PIP kinase activity, Therefore, although recombinant Arf and Rho can activate PLD and PIP kinase in HL60 cells, it is the endogenous Arf but not Rho that regulates PLD, and thus a role for Rho in the physiological regulation of PLD in HL60 cells is unlikely.	UNIV BIRMINGHAM,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,IMMUNO DIAGNOST RES LAB,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; ONYX PHARMACEUT,RICHMOND,CA 94806	University of Birmingham; University of Birmingham				Wakelam, Michael/0000-0003-4059-9276; Hart, Matthew/0000-0002-2683-480X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANNO Y, 1987, BIOCHEM BIOPH RES CO, V146, P861, DOI 10.1016/0006-291X(87)90610-3; BOKOCH GM, 1994, J BIOL CHEM, V269, P31694; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1992, REV PHYSL BIOCH PHAR, V119, P14; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Harian J. E., 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HODGKIN M, 1994, BIOCHEM J, V297, P637, DOI 10.1042/bj2970637; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0	21	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17397	17403		10.1074/jbc.271.29.17397	http://dx.doi.org/10.1074/jbc.271.29.17397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663246	hybrid			2022-12-25	WOS:A1996UX94300065
J	Molkentin, JD; Li, L; Olson, EN				Molkentin, JD; Li, L; Olson, EN			Phosphorylation of the MADS-box transcription factor MEF2C enhances its DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; HEAVY-CHAIN GENE; CASEIN KINASE-II; MYOGENIC LINEAGE; SITE; IDENTIFICATION; EMBRYOGENESIS; PROTEINS; ELEMENTS; MESODERM	Members of the myocyte enhancer factor-2 (MEF2) family of transcription factors activate muscle gene expression by binding an A/T-rich DNA sequence in the control regions of muscle-specific genes. There are four MEF2 factors in vertebrates, MEF2A-D, which share homology in an amino-terminal MADS domain and an adjacent region known as the MEF2 domain, that together mediate DNA binding and dimerization. We show that serine 59 located between the MADS and MEF2 domains of MEF2C is phosphorylated in vivo and can be phosphorylated in vitro by casein kinase-II (CKII). Phosphorylation of this site enhanced the DNA binding and transcriptional activity of MEF2C by increasing its DNA binding activity 5-fold. In vivo P-32 labeling experiments showed that serine 59 is the only phosphorylation site in the MADS and MEF2 domains, Mutagenesis of this serine to an aspartic acid resulted in an increase in DNA binding and transcriptional activity of MEF2 comparable to that observed when this site was phosphorylated, suggesting that phosphorylation augments DNA binding activity by introducing negative charge, This phosphorylation site, which corresponds to a CKII recognition site, is conserved in all known MEF2 factors in organisms ranging from flies to humans, consistent with its importance for the functions of MEF2C.	UNIV TEXAS,SW MED CTR,DEPT MOLEC BIOL & ONCOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HUMAN CTR BASIC CANC RES,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Molkentin, Jeffery/0000-0002-3558-6529				BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	36	87	91	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17199	17204		10.1074/jbc.271.29.17199	http://dx.doi.org/10.1074/jbc.271.29.17199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663403	hybrid			2022-12-25	WOS:A1996UX94300035
J	Fuchs, M; Muller, T; Lerch, MM; Ullrich, A				Fuchs, M; Muller, T; Lerch, MM; Ullrich, A			Association of human protein tyrosine phosphatase kappa with members of the armadillo family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT POLARITY GENE; CELL CELL-ADHESION; UVOMORULIN-CATENIN COMPLEX; BETA-CATENIN; E-CADHERIN; N-CADHERIN; RECEPTOR; PHOSPHORYLATION; PLAKOGLOBIN; PHOSPHOTYROSINE	We have identified a human receptor-like protein-tyrosine phosphatase (PTP) in the mammary carcinoma cell line SK-BR-3, which represents the human homolog of murine PTP kappa (Jiang, Y.-P., Wang, H., D'Eustachio, P., Musacchio, J. M., Schlessinger, J., and Sap, J. (1993) Mot. Cell, Biol, 13, 2942-2951) and was therefore termed hPTP kappa. We show here that hPTP kappa expression is dependent on cell density and find it colocalized with two members of the arm family of proteins, beta-catenin and gamma-catenin/plakoglobin, at adherens junctions, Using both in vitro and in vivo binding assays, we demonstrate specific complex formation between endogenous hPTP kappa and beta- and gamma-catenin/plakoglobin. In addition, we present evidence that suggests that beta-catenin may represent a substrate for the catalytic activity of hPTP kappa, The identification of specific binding partners for this receptor-like PTP provides insight into the mechanisms of its biological action and suggests a role for hPTP kappa in the regulation of processes involving cell contact and adhesion such as growth control, tumor invasion, and metastasis.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263				ABERLE H, 1994, J CELL SCI, V107, P3655; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brady-Kalnay S, 1994, ADV PROTEIN PHOSPHAT, V8, P241; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8345; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GEIGER B, 1992, ANN REV CELL BIOL, V8, P207; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MANSKE M, 1994, INT REV CYTOL, V155, P49, DOI 10.1016/S0074-7696(08)62096-3; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P1; SERGIENKO EA, 1992, FEBS LETT, V304, P21, DOI 10.1016/0014-5793(92)80580-A; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMMERS CL, 1994, CANCER RES, V54, P3544; STREULI M, 1988, J EXP MED, V168, P1553; STREULI M, 1992, EMBO J, V11, P697; SU LK, 1993, SCIENCE, V262, P1374; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TIAN SS, 1994, J BIOL CHEM, V269, P28478; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; YAN H, 1993, J BIOL CHEM, V268, P24880; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	74	181	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16712	16719		10.1074/jbc.271.28.16712	http://dx.doi.org/10.1074/jbc.271.28.16712			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663237	hybrid			2022-12-25	WOS:A1996UX12600047
J	Luthria, DL; Mohammed, BS; Sprecher, H				Luthria, DL; Mohammed, BS; Sprecher, H			Regulation of the biosynthesis of 4,7,10,13,16,19-docosahexaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; COENZYME-A SYNTHETASE; RAT-LIVER MICROSOMES; ACYL-COA SYNTHETASE; FATTY-ACIDS; CHAIN ELONGATION; PURIFICATION; MITOCHONDRIA; DESATURASE	The synthesis of 4,7,10,13,16,19-docosahexaenoic acid (22:6(n-3)) requires that when 6,9,12,15,18,21-tetracosahexaenoic acid (24:6(n-3)) is produced in the endoplasmic reticulum, it preferentially moves to peroxisomes for one cycle of beta-oxidation rather than serving as a substrate for membrane lipid synthesis. Both 24:6(n-3) and its precursor, 9,12,15,18,21-tetracosapentaenoic acid (24:5(n-3)), were poor substrates for acylation into 1-acyl-sn-glycero-3-phosphocholine (l-acyl-GPC) by rat liver microsomes. When peroxisomes were incubated with 1-C-14- Or 3-C-14-labeled 7,10,13,16,19-docosapentaenoic acid (22:5(n-3)), [1-C-14]22:6(n-3), [3-C-14]24:5(n-3), or [3-C-14]24:6(n-3), only small amounts of acid-soluble radioactivity were produced when double bond removal at positions 4 and 5 was required. When microsomes and l-acyl-GPC were included in incubations, the preferred metabolic fate of acids, with their first double bond at either positions 4 or 5, was to move out of peroxisomes for esterification into the acceptor rather than serving as substrates for continued beta-oxidation. When [1-C-14]22: 6(n-3) or [3-C-14]24:6(n-3) was incubated with peroxisomes, 2-trans-4,7,10,13,16,19-22:7 accumulated. The first cycle of 20:5(n-3) beta-oxidation proceeds through 2-trans-4,8,11,14,17-20:6 and thus requires both Delta(3,5),Delta(2,4)-dienoyl-CoA isomerase and 2,4-dienoyl-CoA reductase. The accumulation of the substrate for 2,4-dienoyl-CoA reductase, as generated from 22:6(n-3), but not from 20: 5(n-3), suggests that this enzyme distinguishes between subtle structural differences. When 22:6(n-3) is produced from 24:6(n-3), its continued degradation is impaired because of low a,4-dienoyl-CoA reductase activity. This slow reaction rate likely contributes to the transport of 22:6(n-3) out of peroxisomes for rapid acylation into l-acyl-GPC by microsomes.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048744, R01DK020387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20387, DK48744] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Tana J, 1975, Methods Enzymol, V35, P117, DOI 10.1016/0076-6879(75)35146-X; BARTLETT K, 1990, BIOCHEM J, V270, P175, DOI 10.1042/bj2700175; BAYKOUSHEVA SP, 1995, FEBS LETT, V367, P198, DOI 10.1016/0014-5793(95)00565-Q; BAYKOUSHEVA SP, 1994, J BIOL CHEM, V269, P18390; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BERNERT JT, 1979, BIOCHIM BIOPHYS ACTA, V573, P436, DOI 10.1016/0005-2760(79)90218-2; CHRISTENSEN E, 1993, SCAND J CLIN LA S215, V536, P61; DAS AK, 1992, J BIOL CHEM, V267, P9724; DeMar JC, 1996, J BIOL CHEM, V271, P5007; DOMMES V, 1982, EUR J BIOCHEM, V125, P335, DOI 10.1111/j.1432-1033.1982.tb06688.x; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; HORIE S, 1989, ARCH BIOCHEM BIOPHYS, V274, P64, DOI 10.1016/0003-9861(89)90415-3; LAGEWEG W, 1991, EUR J BIOCHEM, V196, P519, DOI 10.1111/j.1432-1033.1991.tb15844.x; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LUTHRIA DL, 1995, J BIOL CHEM, V270, P13771, DOI 10.1074/jbc.270.23.13771; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; MARTINEZ M, 1989, LIPIDS, V24, P261, DOI 10.1007/BF02535160; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; MOHAMMED BS, 1995, ARCH BIOCHEM BIOPHYS, V317, P179, DOI 10.1006/abbi.1995.1151; MOORE SA, 1995, J LIPID RES, V36, P2433; OKAYASU T, 1981, ARCH BIOCHEM BIOPHYS, V206, P21, DOI 10.1016/0003-9861(81)90061-8; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PHILIPP DP, 1979, J BIOL CHEM, V254, P776; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; TANAKA T, 1979, EUR J BIOCHEM, V98, P165, DOI 10.1111/j.1432-1033.1979.tb13173.x; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOSS A, 1991, J BIOL CHEM, V266, P19995; VOSS A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P33, DOI 10.1016/0005-2760(92)90198-5; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017	33	69	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16020	16025		10.1074/jbc.271.27.16020	http://dx.doi.org/10.1074/jbc.271.27.16020			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663162	hybrid			2022-12-25	WOS:A1996UW35200028
J	Strobel, RS; Nagy, AK; Knowles, AF; Buegel, J; Rosenberg, MD				Strobel, RS; Nagy, AK; Knowles, AF; Buegel, J; Rosenberg, MD			Chicken oviductal ecto-ATP-diphosphohydrolase - Purification and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; BOVINE AORTA; ASSAY; IDENTIFICATION; PHOSPHATE; PROTEINS; ELECTROPHORESIS; SYNAPTOSOMES; LOCALIZATION; MEMBRANES	An ecto-ATP diphosphohydrolase (ATPDase) was purified to homogeneity from vesiculosomes shed from chicken oviduct, First, the ecto-ATPDase-enriched vesiculosomes were concentrated by filtration, differential centrifugation, and exclusion chromatography, Next, the nonionic detergent, Nonidet P-40, was used to extract the ecto-ATPDase from vesiculosomal membranes, and the solubilized enzyme was further purified by ion by ion exchange (DEAE-Bio-Gel) and lentil lectin-Sepharose 4B chromatography, In the final stage, immunoaffinity chromatography was utilized to obtain purified ecto-ATPDase, More than 25,000-fold purification was achieved, Specific activity of the purified enzyme was greater than 800 mu mol/min/mg of protein with MgATP as the substrate, the highest ever reported for an ATPDase, The enzyme also hydrolyzed other nucleoside triphosphates in the presence of magnesium at similar rates and CaATP and MgADP at lower rates, The molecular mass of the purified glycoprotein was 80 kDa as deter mined by SDS-polyacrylamide gel electrophoresis and Western blot analysis, Based on its enzymatic properties, the relationship of the chicken oviduct ecto-ATPDase with other reported ATPDases and ecto-ATPases is discussed.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV CALIF LOS ANGELES,DEPT NEUROL & MED,LOS ANGELES,CA; W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073; SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center								ANDERSON B, 1974, DEV BIOL, V37, P306, DOI 10.1016/0012-1606(74)90151-1; ANDERSON B, 1976, BIOL REPROD, V14, P253, DOI 10.1095/biolreprod14.3.253; BARBER BH, 1982, J IMMUNOL METHODS, V48, P87, DOI 10.1016/0022-1759(82)90213-7; BEAUDOIN AR, 1986, FEBS LETT, V203, P1, DOI 10.1016/0014-5793(86)81423-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COTE YP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P187, DOI 10.1016/0167-4838(91)99008-G; DAWSON JM, 1986, BIOCHIM BIOPHYS ACTA, V856, P566, DOI 10.1016/0005-2736(86)90148-3; DEBRUYNE I, 1973, ARCH INT PHYSIOL BIO, V81, P963; ERNSTER L, 1962, J CELL BIOL, V15, P563, DOI 10.1083/jcb.15.3.563; ETHEREDGE E, 1971, BIOCHIM BIOPHYS ACTA, V233, P145, DOI 10.1016/0005-2736(71)90367-1; GEFFTER ML, 1977, SOMATIC CELL GENET, V3, P231; GODING JW, 1987, MONOCLONAL ANTIBODIE, P230; HAALAND JE, 1969, NATURE, V223, P1275, DOI 10.1038/2231275a0; HAALAND JE, 1971, BIOCHIM BIOPHYS ACTA, V233, P137, DOI 10.1016/0005-2736(71)90366-X; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P412, DOI 10.1016/0003-2697(88)90208-4; HOWARD IK, 1971, J BIOL CHEM, V246, P1590; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P220; KETTLUN AM, 1992, PHYTOCHEMISTRY, V31, P3691; KNOWLES AF, 1983, BIOCHIM BIOPHYS ACTA, V731, P88, DOI 10.1016/0005-2736(83)90401-7; KNOWLES AF, 1988, ARCH BIOCHEM BIOPHYS, V263, P264, DOI 10.1016/0003-9861(88)90635-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALIBERTE JF, 1982, J BIOL CHEM, V257, P3869; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEBEL D, 1980, J BIOL CHEM, V255, P1227; LEE K, 1978, THESIS U MINNESOTA; LEE K, 1980, ENZYME, V25, P276; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MAGOCSI M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P163, DOI 10.1016/0005-2736(91)90159-6; MARCUS AJ, 1991, J CLIN INVEST, V88, P1690, DOI 10.1172/JCI115485; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; MOODIE FDL, 1991, EUR J BIOCHEM, V202, P1209, DOI 10.1111/j.1432-1033.1991.tb16492.x; NAGY A, 1983, J NEUROCHEM, V40, P226, DOI 10.1111/j.1471-4159.1983.tb12675.x; NAGY AK, 1986, J NEUROCHEM, V47, P976; NIMMO HG, 1982, ANAL BIOCHEM, V121, P17, DOI 10.1016/0003-2697(82)90551-6; PAPAMARCAKI T, 1990, MOL CELL BIOCHEM, V97, P1; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICHER M, 1993, J BIOL CHEM, V268, P4699; PLESNER L, 1995, INT REV CYTOL, V158, P141; RHEA RP, 1974, FERTIL STERIL, V25, P788; Richardson KC, 1935, PHILOS T ROY SOC B, V225, P149, DOI 10.1098/rstb.1935.0010; ROSENBERG MD, 1980, ENZYME, V25, P276, DOI 10.1159/000459264; ROSENBERG MD, 1977, BIOCHIM BIOPHYS ACTA, V482, P197, DOI 10.1016/0005-2744(77)90366-7; SABBADINI RA, 1989, J BIOENERG BIOMEMBR, V21, P163, DOI 10.1007/BF00812068; SARKIS JJF, 1991, BRAIN RES BULL, V26, P871, DOI 10.1016/0361-9230(91)90251-E; SHUSTER TA, 1983, ENZYME, V30, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPIELMAN H, 1974, ANAL BIOCHEM, V59, P462, DOI 10.1016/0003-2697(74)90299-1; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; TREUHEIT MJ, 1992, J BIOL CHEM, V267, P11777; VALENZUELA MA, 1989, COMP BIOCHEM PHYS B, V93, P911, DOI 10.1016/0305-0491(89)90066-7; VONK JR, 1977, BIOCHEM PHARMACOL, V27, P397; YAGI K, 1989, EUR J BIOCHEM, V180, P509, DOI 10.1111/j.1432-1033.1989.tb14675.x; YAGI K, 1991, BIOCHEM BIOPH RES CO, V180, P1200, DOI 10.1016/S0006-291X(05)81323-3; YELTON D, 1982, HYBRIDOMA, V1, P1	56	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16323	16331		10.1074/jbc.271.27.16323	http://dx.doi.org/10.1074/jbc.271.27.16323			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663133	hybrid			2022-12-25	WOS:A1996UW35200069
J	Blahos, J; Wenthold, RJ				Blahos, J; Wenthold, RJ			Relationship between N-methyl-D-aspartate receptor NR1 splice variants and NR2 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NMDA-RECEPTOR; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; SYNAPTIC PLASTICITY; NERVOUS-SYSTEM; SOLUBILIZATION; POLYAMINES; INVITRO; CLONING	The N-methyl-D-aspartate (NMDA) subtype of ionotropic glutamate receptor is assembled from one NR1 subunit, expressed in eight splice variants, and four NR2 subunits (NR2A-D). The combination of subunits and splice variants determines the pharmacological and physiological properties of the receptor. In the present study we investigated the relationship between NR1 splice variants and NR2 subunits in rat brain using a series of antibodies selective for the four NR1 cassettes, which vary in the NR1 splice variants, and for NR2A and NR2B. Sodium deoxycholate at pH 9.0 solubilized about 35% of the receptor, which was intact based on co-immunoprecipitation of NR1 and NR2 subunits and chemical cross-linking of the solubilized receptor. The crosslinked product contained three high molecular weight components, M(r) = 603,000, 700,000, and 750,000, which were immunolabeled with antibodies to NR1 and to NR2 subunits. Immunoprecipitation analyses using antibodies selective for NR2A and NR2B showed no preferential assembly between NR2 subunits and NR1 splice variants. There was little co-immunoprecipitation of NR2A and NR2B, suggesting that most NMDA receptor complexes contain only one of these subunits. However, receptor complexes can contain at least two different NR1 splice variants. In developing conditions for the solubilization of intact NMDA receptor complexes, we observed a differential solubilization of NR1 and NR2 subunits. NR2 was nearly insoluble in Triton X-100 in both microsomal and synaptic membrane fractions, while NR1 was readily soluble in the microsomal fraction but insoluble in the synaptic membrane fraction. These results suggest that the NR1 subunit is modified when it is incorporated into the synaptic membrane, possibly by strengthening its interaction with NR2 or another synaptic protein.	NIDCD,NIH,NEUROCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)			Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061				AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; BROSE N, 1993, J BIOL CHEM, V268, P22663; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; BUTLER AL, 1994, J NEUROSCI, V14, P5471; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DETOMASO AW, 1994, J CELL BIOL, V127, P55, DOI 10.1083/jcb.127.1.55; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; GURD JW, 1973, J NEUROCHEM, V22, P281; HAMMOND C, 1994, TRENDS NEUROSCI, V17, P497, DOI 10.1016/0166-2236(94)90140-6; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; ISHII T, 1993, J BIOL CHEM, V268, P2836; KATSUWADA T, 1992, NATURE, V358, P36; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MCKERNAN RM, 1989, J NEUROCHEM, V52, P777, DOI 10.1111/j.1471-4159.1989.tb02522.x; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; OGITA K, 1990, J NEUROCHEM, V55, P1515, DOI 10.1111/j.1471-4159.1990.tb04933.x; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TOLLE TR, 1995, EUR J NEUROSCI, V7, P1235, DOI 10.1111/j.1460-9568.1995.tb01114.x; TOLLE TR, 1993, J NEUROSCI, V13, P5009, DOI 10.1523/JNEUROSCI.13-12-05009.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VICKERS JC, 1993, J NEUROSCI, V13, P2982; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; WANG YH, 1995, J NEUROCHEM, V65, P176; WATANABE M, 1994, J COMP NEUROL, V343, P520, DOI 10.1002/cne.903430403; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; ZHENG X, 1994, NEURON, V12, P811; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	54	132	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15669	15674		10.1074/jbc.271.26.15669	http://dx.doi.org/10.1074/jbc.271.26.15669			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663041	hybrid			2022-12-25	WOS:A1996UV29900056
J	Blobe, GC; Stribling, DS; Fabbro, D; Stabel, S; Hannun, YA				Blobe, GC; Stribling, DS; Fabbro, D; Stabel, S; Hannun, YA			Protein kinase C beta II specifically binds to and is activated by F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE REGULATION; VIMENTIN FILAMENTS; EXPRESSION; PHOSPHORYLATION; ISOENZYMES; ASSOCIATION; TISSUE; FAMILY; ALPHA	The two most closely related isoenzymes of protein kinase C (PRC), PKC beta I and beta II, are distinct but highly homologous isoenzymes derived via alternative splicing of the same gene product. In this study, PKC beta II, but not PKC beta I, translocated to the actin cytoskeleton upon stimulation of cells with phorbol esters. In cells, antibodies to PKC beta II, but not to PKC beta I, co-immunoprecipitated actin. Using an actin-binding co-sedimentation assay, we show in vitro that PKC beta II, but not PKC beta I, binds to actin specifically, This binding was inhibited by peptides based on sequences unique to PKC beta II; thus defining an actin-binding site in PKC beta II that is not present in PKC beta I. The binding of PKC beta II to actin was not inhibited by kinase inhibitors of PKC (sphingosine and staurosporine), suggesting that prior activation and/or substrate phosphorylation are not required for the interaction of PKC beta II with actin. On the other hand, the interaction of PKC beta II with actin resulted in marked enhancement of autophosphorylation of PKC beta II and in an alteration in substrate specificity. These studies serve to define a novel functional domain in the carboxyl-terminal region of PKC beta, which is involved in directing isoenzyme-specific protein-protein interactions, and consequently, isoenzyme-specific functions in vivo.	DUKE UNIV, MED CTR, DIV HEMATOL ONCOL, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; CIBA GEIGY LTD, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND; MAX PLANCK GESELL, MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY	Duke University; Duke University; Novartis; Max Planck Society			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Bell R M, 1986, Methods Enzymol, V124, P353; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOLAND TA, 1992, BIOCHEM J, V288, P123, DOI 10.1042/bj2880123; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STABEL S, 1993, METH NEUROSCI, V18, P154; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	24	126	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15823	15830		10.1074/jbc.271.26.15823	http://dx.doi.org/10.1074/jbc.271.26.15823			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663149	hybrid			2022-12-25	WOS:A1996UV29900078
J	Munnik, T; deVrije, T; Irvine, RF; Musgrave, A				Munnik, T; deVrije, T; Irvine, RF; Musgrave, A			Identification of diacylglycerol pyrophosphate as a novel metabolic product of phosphatidic acid during G-protein activation in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; KINASE-C; SUBCELLULAR-LOCALIZATION; CHLAMYDOMONAS-EUGAMETOS; SIGNAL TRANSDUCTION; HUMAN NEUTROPHILS; NADPH OXIDASE; STIMULATION; CELLS; PHOSPHOINOSITIDES	We provide evidence that phosphatidic acid (PtdOH) formed during signaling in plants is metabolized by a novel pathways. In much of this study, P-32(i)-labeled Chlamydomonas cells were used, and signalling was activated by adding the G-protein activator mastoparan. Within seconds of activation, large amounts of [P-32]Pt-dOH were formed, with peak production at about 4 min, when the level was 5-25-fold higher than the control. As the level of [P-32]PtdOH subsequently decreased, an unknown phospholipid (PLX) increased in radiolabeling; before activation it was barely detectable. The chromatographic properties of PLX resembled those of lyso-PtdOH and CMP . PtdOH but on close inspection were found to be different. PLX was shown to be diacylglycerol pyrophosphate (DGPP), the product of a newly discovered enzyme, phosphatidate kinase, whose in vitro activity was described recently (Wissing, J.B., and Behrbohm, H. (1993) Plant Physiol. 102, 1243-1249). The identity of DGPP was established by co-chromatrography with a standard and by degradation analysis as follows: [P-32]DGPP was deacylated, adn the product mild acid treatment or pyrophosphatase to produce GroP and P-i as the only radioactive products. Since DGPP is the pyrophosphate derivative of PtdOH and is formed as the concentration of PtdOH decreases, we assumed that PtdOH was converted in vivo to DGPP. This was confirmed by showing that during a short labeling protocol while the specific radioactivity of DGPP was increasing, the specific radioactivity of the P-32(i) derived from DGPP as above was higher than that of [P-32]GroP. DGPP was also formed in suspension cultures of tomato and potato cells, and its synthesis was activated by mastoparan. Moreover, it was also found in intact tissues of a number of higher plants, for example, carnation flower petals, vetch roots, leaves of fig-leaved goosefoot, and common persicaria and microspores of rape seed. Our results suggest that DGPP is a common but minor plant lipid that increases in concentration when signaling is activated. Possible functions of DGPP in phospholpase C and D signaling cascades are discussed.	DLO,ATO,AGROTECHNOL RES INST,NL-6700 AA WAGENINGEN,NETHERLANDS; BABRAHAM INST,INOSITIDE LAB,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Munnik, T (corresponding author), UNIV AMSTERDAM,BIOCTR,INST MOLEC CELL BIOL,KRUISLAAN 318,NL-1098 SM AMSTERDAM,NETHERLANDS.		Munnik, Teun/G-8624-2012; Munnik, Teun/N-2778-2019	Munnik, Teun/0000-0002-4919-4913; Munnik, Teun/0000-0002-4919-4913				BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; CHO MH, 1995, PLANT PHYSIOL, V107, P845, DOI 10.1104/pp.107.3.845; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COTE GG, 1994, BIOESSAYS, V16, P39, DOI 10.1002/bies.950160106; COTE GG, 1993, ANNU REV PLANT PHYS, V44, P333, DOI 10.1146/annurev.pp.44.060193.002001; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DROBAK BK, 1994, BIOCHEM BIOPH RES CO, V205, P739, DOI 10.1006/bbrc.1994.2727; DROBAK BK, 1993, PLANT PHYSIOL, V102, P705, DOI 10.1104/pp.102.3.705; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; EPAND RM, 1992, EUR J BIOCHEM, V208, P327, DOI 10.1111/j.1432-1033.1992.tb17190.x; EXTON JH, 1994, CURR OPIN CELL BIOL, V6, P226, DOI 10.1016/0955-0674(94)90140-6; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HA KS, 1993, J CELL BIOL, V123, P178; HASHIZUME T, 1992, BIOCHEM INT, V26, P491; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; HORSTMAN DA, 1995, PROTEIN EXPRES PURIF, V6, P278, DOI 10.1006/prep.1995.1036; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JACOB G, 1993, COMP BIOCHEM PHYS B, V106, P895, DOI 10.1016/0305-0491(93)90047-9; JONES GA, 1993, J BIOL CHEM, V268, P20845; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; LAW GJ, 1994, ANN NY ACAD SCI, V710, P196, DOI 10.1111/j.1749-6632.1994.tb26628.x; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEGENDRE L, 1993, J BIOL CHEM, V268, P24559; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LUNDBERG GA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P177, DOI 10.1016/0005-2760(92)90109-9; MARTIN T, 1995, CURR BIOL, V5, P990, DOI 10.1016/S0960-9822(95)00196-5; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; MUNNIK T, 1994, BIOCHEM J, V298, P269, DOI 10.1042/bj2980269; MUNNIK T, 1994, PLANTA, V193, P89, DOI 10.1007/BF00191611; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MUSGRAVE A, 1992, PLANTA, V186, P442, DOI 10.1007/BF00195326; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; QUARMBY LM, 1992, J CELL BIOL, V116, P737, DOI 10.1083/jcb.116.3.737; RARA RS, 1990, PHYSIOL REV, V70, P125; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; SCHURING F, 1987, PLANTA, V170, P322, DOI 10.1007/BF00395023; SEIFFERT UB, 1965, BIOCHIM BIOPHYS ACTA, V98, P574, DOI 10.1016/0005-2760(65)90154-2; STASEK JE, 1993, BIOCHEM BIOPH RES CO, V191, P134, DOI 10.1006/bbrc.1993.1194; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VANBLITTERSWIJK WJ, 1993, EMBO J, V12, P2655, DOI 10.1002/j.1460-2075.1993.tb05926.x; VANBLITTERSWIJK WJ, 1994, CURR TOP MEMBR, V40, P413, DOI 10.1016/S0070-2161(08)60990-9; WISSING JB, 1992, PLANT PHYSIOL, V98, P1148, DOI 10.1104/pp.98.3.1148; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; WISSING JB, 1994, PLANT PHYSIOL, V105, P903, DOI 10.1104/pp.105.3.903; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; ZHOU D, 1995, J BIOL CHEM, V270, P25549, DOI 10.1074/jbc.270.43.25549	68	118	124	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15708	15715		10.1074/jbc.271.26.15708	http://dx.doi.org/10.1074/jbc.271.26.15708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663116	hybrid			2022-12-25	WOS:A1996UV29900062
J	Portilla, D; Dai, GH				Portilla, D; Dai, GH			Purification of a novel calcium-independent phospholipase A(2) from rabbit kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; GLYCEROPHOSPHOLIPIDS; IDENTIFICATION; ACTIVATION; MEMBRANE; PROTEIN; U937	We have recently identified a cytosolic calcium-independent phospholipase A(2) (PLt(2)) that represents the major measurable PLA, activity in rabbit proximal tubules (Portilla, D,, Shah, S, V., Lehman, P, A, and Creer, M, H, (1994) J, Clin. Invest, 93, 1609-1615), We now report the 3200-fold purification of this PLA(2) to homogeneity from rabbit kidney cortex through sequential column chromatography including anion exchange, hydrophobic interaction, Mono Q, hydroxylapatite, phenyl-sepharose, and chromatofocusing fast protein liquid chromatography from rabbit kidney cortex, The purified enzyme had a molecular mass of 28 kDa, possessed a specific activity of 1.2 mu mol/mg min and a neutral pH optimum, and exhibited a preferential hydrolysis toward sn-2 fatty acid from diradylglycerophospholipids. The purified polypeptide hydrolyzed plasmenylcholine > phosphatidylcholine glycerophospholipids and selectively cleaved phospholipids containing arachidonic acid at the sn-2 position in comparison to oleic acid, Antibodies against the purified protein precipitated all of the soluble calcium-independent PLA(2) activity from rabbit kidney cortex, These data altogether suggest that the 28-kDa protein in the kidney represents a novel class of calcium-independent PLA(2).	VET ADM MED CTR,LITTLE ROCK,AR 72205	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Portilla, D (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT MED,DIV NEPHROL,4301 W MARKHAM,SLOT 501,LITTLE ROCK,AR 72205, USA.				NIDDK NIH HHS [R29 DK46914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1983, ENZYMES, P307; FUKUSHIMA T, 1994, LIPIDS, V29, P163, DOI 10.1007/BF02536724; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GROSS RW, 1983, J BIOL CHEM, V258, P5165; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; PORTILLA D, 1992, AM J PHYSIOL, V262, pF354, DOI 10.1152/ajprenal.1992.262.3.F354; PORTILLA D, 1994, J CLIN INVEST, V93, P1609, DOI 10.1172/JCI117141; PORTILLA D, 1995, KIDNEY INT, V47, P1087, DOI 10.1038/ki.1995.155; SCHONEFELD M, 1994, J AM SOC NEPHROL, V5, P908; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WAITE M, 1987, HDB LIPID RES, V5; WOLF RA, 1985, J BIOL CHEM, V260, P7295; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	24	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15451	15457		10.1074/jbc.271.26.15451	http://dx.doi.org/10.1074/jbc.271.26.15451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663076	hybrid			2022-12-25	WOS:A1996UV29900025
J	Saito, Y; Maruyama, K; Kawano, H; HaginoYamagishi, K; Kawamura, K; Saido, TC; Kawashima, S				Saito, Y; Maruyama, K; Kawano, H; HaginoYamagishi, K; Kawamura, K; Saido, TC; Kawashima, S			Molecular cloning and characterization of a novel form of neuropeptide gene as a developmentally regulated molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROENKEPHALIN MESSENGER-RNA; ENDOGENOUS OPIOID SYSTEMS; CYCLIC-AMP; SECRETORY PROTEINS; COMPLEMENTARY-DNA; GROWTH CONES; TUMOR-CELLS; EXPRESSION; NEURONS; DIFFERENTIATION	To examine the molecular basis controlling neuronal differentiation, subtraction library construction and differential screening were used to identify cDNAs whose mRNA levels are regulated in mouse NS20Y cells by dibutyryl cyclic AMP treatment, One of them, N27K, whose mRNA increases transiently during both neuronal differentiation in NS20Y cells and development in mouse brain. The deduced amino acid sequence of N27K comprises 212 amino acid residues and is a novel form of a precursor protein for a new neuropeptide nociceptin/ orphanin FQ, which we independently cloned as N23K. That is, the putative protein encoded by N27K is 25 amino acids longer than that encoded by N23R, Using an antibody against a C-terminal peptide of the N27K: protein that recognizes a 27-kDa protein in Western blot analysis, a punctate structure in the perinuclear region and areas near the tip of neurites is visualized in neurally differentiating NS20Y cells, The time of maximal expression correlates with periods of neurite extension, and expression decreases as the neuritic network develops. Immunohistochemistry of tissue sections of the mouse central nervous system revealed that reactivity for the anti-N27K protein antibody can detected in early generated neurons at embryonic day 14, in virtually all immature neurons at postnatal day 1, and in subsets of neurons of discrete brain regions such as the hypothalamus and spinal cord in adults. This remarkable redistribution suggests that N27K may be involved in a process in neurite outgrowth and nervous system development.	TOKYO METROPOLITAN INST MED SCI,DEPT DEV BIOL & CANC PREVENT,BUNKYO KU,TOKYO 113,JAPAN; NATL INST PHYSIOL SCI,NEUROCHEM LAB,OKAZAKI,AICHI 444,JAPAN; KEIO UNIV,SCH MED,DEPT ANAT,SHINJUKU KU,TOKYO 160,JAPAN	Tokyo Metropolitan Institute of Medical Science; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Keio University	Saito, Y (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.		Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				AFFOLTER HU, 1985, J BIOL CHEM, V260, P5477; AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; BASI GS, 1987, P ACAD NATL SCI US, V77, P1496; Bjorklund A.H.T., 1988, HATLDBOOK CHEM NEURO, V6, P599; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; DEFELIPE C, 1995, SCIENCE, V267, P899, DOI 10.1126/science.7531367; DENISDONINI S, 1989, NATURE, V339, P701, DOI 10.1038/339701a0; FOLKESSON R, 1989, MOL BRAIN RES, V5, P211, DOI 10.1016/0169-328X(89)90037-5; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GORODINSKY A, 1995, J NEUROCHEM, V65, P1481; GROUSE LD, 1980, J BIOL CHEM, V255, P3871; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAUSER KF, 1992, DEV BRAIN RES, V70, P291, DOI 10.1016/0165-3806(92)90210-N; HAUSER KF, 1989, J COMP NEUROL, V281, P13, DOI 10.1002/cne.902810103; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KAWANO H, 1995, DEV BRAIN RES, V86, P101, DOI 10.1016/0165-3806(95)00018-9; KAWANO H, 1991, J COMP NEUROL, V307, P531, DOI 10.1002/cne.903070402; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KIRSHNER JA, 1986, J NEUROCHEM, V46, P817, DOI 10.1111/j.1471-4159.1986.tb13045.x; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOWICZ J, 1995, J NEUROCHEM, V64, P34; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMURRAY CT, 1989, ENDOCRINOLOGY, V124, P49, DOI 10.1210/endo-124-1-49; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MELNER MH, 1990, EMBO J, V9, P791, DOI 10.1002/j.1460-2075.1990.tb08175.x; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; Saito Y, 1995, BIOCHEM BIOPH RES CO, V217, P539, DOI 10.1006/bbrc.1995.2809; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1991, BRAIN RES, V541, P41, DOI 10.1016/0006-8993(91)91071-8; SPRUCE BA, 1990, EMBO J, V9, P1787, DOI 10.1002/j.1460-2075.1990.tb08303.x; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; VILLIJIN MH, 1989, J NEUROCHEM, V53, P1487; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WICK MJ, 1994, MOL BRAIN RES, V27, P37, DOI 10.1016/0169-328X(94)90181-3; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOSHIKAWA K, 1988, MOL BRAIN RES, V4, P87, DOI 10.1016/0169-328X(88)90001-0; YOSHIKAWA K, 1986, BIOCHEM BIOPH RES CO, V139, P1, DOI 10.1016/S0006-291X(86)80071-7; ZAGON IS, 1989, BRAIN RES, V490, P14, DOI 10.1016/0006-8993(89)90425-3; ZAGON IS, 1994, MOL BRAIN RES, V21, P85, DOI 10.1016/0169-328X(94)90381-6; ZAGON IS, 1985, SCIENCE, P1049	54	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15615	15622		10.1074/jbc.271.26.15615	http://dx.doi.org/10.1074/jbc.271.26.15615			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663129	hybrid			2022-12-25	WOS:A1996UV29900048
J	Amara, FM; Entwistle, J; Kuschak, TI; Turley, EA; Wright, JA				Amara, FM; Entwistle, J; Kuschak, TI; Turley, EA; Wright, JA			Transforming growth factor-beta(1) stimulates multiple protein interactions at a unique cis-element in the 3'-untranslated region of the hyaluronan receptor RHAMM mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; BINDING-PROTEIN; MAMMALIAN-CELLS; FACTOR-BETA; FIBROBLASTS; EXPRESSION; PROMOTER	The receptor for hyaluronan mediated motility (RHAMMM) gene expression is markedly elevated in fibrosarcomas exposed to transforming growth factor-beta(1) (TGF-beta(1)), The half-life of RHAMM mRNA was increased by 3 fold in cells treated with TGF-beta(1), indicating that growth factor regulation of RHAMM gene expression at least in part involves a posttranscriptional mechanism, Our studies demonstrated that a unique 30-nucleotide (nt) region that has three copies of the sequence, GCU-UGC, was the TGF-beta(1)-responsive region in the 3'-untranslated region (3'-UTR) that mediated message stability, This region interacted specifically with cytoplasmic trans-factors to form multiple protein com plexes of approximately 175, 97, 63, 26, and 17 kDa post-TGF-beta(1) treatment, suggesting a role for these complexes in the mechanism of action of TGF-beta(1)-induced message stabilization, Insertion of the 3'-UTR into the chloramphenicol acetyltransferase gene conferred TGF-beta(1) induced stability of chloramphenicol acetyltransferase-hybrid RNA in stably transfected cells, while the same insert carrying a deletion containing the 30-nt region had no significant effect on mRNA stability, These results provide a model of RHAMM message regulation in which TGF-beta(1)-mediated alteration of RHAMM message stability involves the up-regulation of multiple protein interactions with a 30-nt cis-element stability determinant in the 3'-UTR, This model also suggests that this 30-nt base region functions in cis to destabilize RHAMM mRNA in resting normal cells.	UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV MANITOBA,DEPT BIOCHEM & MOLEC BIOL,WINNIPEG,MB R3E 0V9,CANADA	University of Manitoba; University of Manitoba								AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; AMARA FM, 1995, NUCLEIC ACIDS RES, V23, P1461, DOI 10.1093/nar/23.9.1461; AMARA FM, 1994, J BIOL CHEM, V269, P6709; BLOSMANIS R, 1987, CANCER RES, V47, P1273; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHEN FY, 1994, NUCLEIC ACIDS RES, V22, P4796, DOI 10.1093/nar/22.22.4796; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENTWISTLE J, 1995, IN PRESS GENE AMST; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HURTA RAR, 1995, J CELL BIOCHEM, V57, P543, DOI 10.1002/jcb.240570319; KARTAOKA R, 1993, J BIOL CHEM, V268, P19851; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANZELLA JM, 1992, J BIOL CHEM, V267, P7077; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAMUEL SK, 1993, J CELL BIOL, V123, P749, DOI 10.1083/jcb.123.3.749; SCHWARZ LC, 1988, CANCER RES, V48, P6999; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WEISS MI, 1995, MOL CELL BIOL, V15, P2457; WRANA LJ, 1994, NATURE, V340, P341; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000	35	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15279	15284		10.1074/jbc.271.25.15279	http://dx.doi.org/10.1074/jbc.271.25.15279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663000	hybrid			2022-12-25	WOS:A1996UT10600092
J	MunierLehmann, H; Mauxion, F; Bauer, U; Lobel, P; Hoflack, B				MunierLehmann, H; Mauxion, F; Bauer, U; Lobel, P; Hoflack, B			Re-expression of the mannose 6-phosphate receptors in receptor-deficient fibroblasts - Complementary function of the two mannose 6-phosphate receptors in lysosomal enzyme targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; BREAST-CANCER CELLS; PHOSPHORYLATED OLIGOSACCHARIDES; BOVINE LIVER; BINDING; CLONING; SEQUENCE; GENE; IDENTIFICATION; GLYCOPROTEINS	We have previously generated primary embryonic fibroblasts lacking either the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor (MPR) or the cation-dependent MPR, two trans-membrane proteins that bind the mannose 6-phosphate (Man-6-P) recognition marker on soluble lysosomal enzymes (Ludwig, T., Munier-Lehmann, H., Bauer, U., Hollinshead, M., Ovitt, C., Lobel, P., and Hoflack, B. (1994) EMBO J, 13, 3430-3437), These two cell types partially missort phosphorylated lysosomal enzymes, Using two dimensional gel electrophoresis, we show here that they secrete, in a large part, different phosphorylated ligands, In order to better understand the sorting function of the MPRs, we have re expressed each MPR in MPR-negative fibroblasts. We show that the MPRs have similar capacities for transporting the bulk of the newly synthesized lysosomal enzymes and that they target individual ligands with various efficiencies, However, high levels of one MPR do not fully compensate for the absence of the other, demonstrating that the two MPRs have complementary targeting functions, perhaps by recognizing different features on lysosomal enzymes, The analysis of the phosphorylated oligosaccharides shows that the ligands missorted in the absence of the cation dependent MPR are slightly but significantly depleted in oligosaccharides with two Man-6-P residues, when compared with those missorted in the absence of the cation independent MPR, While these results could explain some differences between the structure and the sorting function of the two MPRs, they strongly suggest that the reason why cells express two different but related MPRs is to maintain an efficient Man-B-P-dependent targeting process that could be potentially regulated by MPR expression.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,D-69012 HEIDELBERG,GERMANY; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854	European Molecular Biology Laboratory (EMBL); Rutgers State University New Brunswick			Munier-Lehmann, Helene/N-9889-2017; HOFLACK, Bernard/AAZ-6668-2020; Munier-Lehmann, Hélène/Q-1867-2019; MAUXION, Fabienne/ABE-3546-2021	Munier-Lehmann, Helene/0000-0001-7579-8561; Munier-Lehmann, Hélène/0000-0001-7579-8561; MAUXION, Fabienne/0000-0003-0554-8211	NIDDK NIH HHS [R01-DK45992] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN HJ, 1993, J BIOL CHEM, V268, P2238; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DONG JM, 1990, J BIOL CHEM, V265, P4210; FILSON AJ, 1993, DEVELOPMENT, V118, P731; FISHER HD, 1982, J BIOL CHEM, V257, P9938; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GAL S, 1986, BIOCHEM BIOPH RES CO, V139, P156, DOI 10.1016/S0006-291X(86)80093-6; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; LUDWIG T, 1992, J BIOL CHEM, V267, P12211; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MA ZM, 1991, J BIOL CHEM, V266, P10589; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; MATZNER U, 1992, DEVELOPMENT, V114, P965; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; VARKI A, 1983, J BIOL CHEM, V258, P2808; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WESTLUND B, 1991, J BIOL CHEM, V266, P23233	45	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15166	15174		10.1074/jbc.271.25.15166	http://dx.doi.org/10.1074/jbc.271.25.15166			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662879	hybrid			2022-12-25	WOS:A1996UT10600077
J	Ornitz, DM; Xu, JS; Colvin, JS; McEwen, DG; MacArthur, CA; Coulier, F; Gao, GX; Goldfarb, M				Ornitz, DM; Xu, JS; Colvin, JS; McEwen, DG; MacArthur, CA; Coulier, F; Gao, GX; Goldfarb, M			Receptor specificity of the fibroblast growth factor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SPECIFICITY; PROTO-ONCOGENE INT-2; MESSENGER-RNA; FGF-RECEPTOR; IMMUNOGLOBULIN DOMAIN; SIGNAL TRANSDUCTION; EXPRESSION PATTERN; CYTOPLASMIC REGION; SKELETAL-MUSCLE; K-SAM	Fibroblast growth factors (FGFs) are essential molecules for mammalian development. The nine known FGF ligands and the four signaling FGF receptors (and their alternatively spliced variants) are expressed in specific spatial and temporal patterns, The activity of this signaling pathway is regulated by ligand binding specificity, heparan sulfate proteoglycans, and the differential signaling capacity of individual FGF receptors. To determine potentially relevant ligand-receptor pairs we have engineered mitogenically responsive cell lines expressing the major splice variants of all the known FGF receptors. We have assayed the mitogenic activity of the nine known FGF ligands on these cell lines. These studies demonstrate that FGF 1 is the only FGF that can activate all FGF receptor splice variants. Using FGF las an internal standard we have determined the relative activity of all the other members of the FGF family. These data should serve as a biochemical foundation for determining developmental, physiological, and patho physiological processes that involve FGF signaling pathways.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA; INSERM U119, F-13009 MARSEILLE, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA	Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University; Icahn School of Medicine at Mount Sinai	Ornitz, DM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA.		Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773; Ornitz, David/0000-0003-1592-7629	NCI NIH HHS [CA60673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1991, ONCOGENE, V6, P659; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; ASAI T, 1993, MOL BRAIN RES, V17, P174, DOI 10.1016/0169-328X(93)90088-7; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DELL KR, 1992, J BIOL CHEM, V267, P21225; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GOSPODAROWICZ D, 1975, J CELL BIOL, V66, P451, DOI 10.1083/jcb.66.2.451; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KOBRIN MS, 1993, CANCER RES, V53, P4741; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NISWANDER L, 1992, DEVELOPMENT, V114, P755; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PIZETTE S, 1991, CELL GROWTH DIFFER, V2, P561; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SAFRAN A, 1990, ONCOGENE, V5, P635; SantosOcampo S, 1996, J BIOL CHEM, V271, P1726, DOI 10.1074/jbc.271.3.1726; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	68	1365	1485	1	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15292	15297		10.1074/jbc.271.25.15292	http://dx.doi.org/10.1074/jbc.271.25.15292			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663044	hybrid			2022-12-25	WOS:A1996UT10600094
J	Berkhout, TA; Simon, HM; Patel, DD; Bentzen, C; Niesor, E; Jackson, B; Suckling, KE				Berkhout, TA; Simon, HM; Patel, DD; Bentzen, C; Niesor, E; Jackson, B; Suckling, KE			The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; LOW-DENSITY-LIPOPROTEIN; HMG-COA REDUCTASE; HEPATOMA-CELL LINE; MEVALONATE-DERIVED PRODUCT; HEP G2; MESSENGER-RNA; RAT-LIVER; REVERSIBLE PHOSPHORYLATION; REGULATED DEGRADATION	SR-12813 (tetra-ethyl 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)ethenyl-1,1-bisphosphonate) lowers plasma cholesterol in five species, In this paper we investigate the underlying mechanism using Hep G2 cells. SR-12813 inhibited incorporation of tritiated water into cholesterol with an IC50 of 1.2 mu M but had no effect on fatty acid synthesis. Furthermore, SR-12813 reduced cellular 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity with an IC50 of 0.85 mu M. The inhibition of HMG-CoA reductase activity was rapid with a T-1/2 of 10 min. After a 16-h incubation with SR-12813, mRNA levels of HMG-CoA reductase and low density lipoprotein (LDL) receptor were increased. The increased expression of LDL receptor translated into a higher LDL uptake, which can explain the primary hypocholesterolemic effect of SR-12813 in vivo. Western blot analysis indicated that the amount of HMG-CoA reductase protein rapidly decreased in the presence of SR-12813. Pulse-chase experiments with [S-35]methionine showed that the T-1/2 of HMG-CoA reductase degradation decreased in the presence of SR-12813 from 90 to 20 min. Pre-incubation with 50 mu M Of lovastatin did not prevent the effects of SR-12813 on HMG-CoA reductase degradation, indicating that the compound does not need mevalonate-derived regulators for its action, It is concluded that SR-12813 inhibits cholesterol synthesis mainly by an enhanced degradation of HMG-CoA reductase.	HAMMERSMITH HOSP,MRC,LIPOPROT TEAM,LONDON W12 0HS,ENGLAND; SYMPHAR RES LABS,CH-1290 VERSOIX,GENEVA,SWITZERLAND	Imperial College London	Berkhout, TA (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT VASC BIOL,THE FRYTHE,WELWYN GARDEN CIT AL6 9AR,HERTS,ENGLAND.							ALBRIGHTSON CR, 1995, J PHARMACOL EXP THER, V272, P689; BEG ZH, 1987, METABOLISM, V36, P900, DOI 10.1016/0026-0495(87)90101-6; BERKHOUT TA, 1990, BIOCHEM J, V272, P181, DOI 10.1042/bj2720181; BERKHOUT TA, 1994, ATHEROSCLEROSIS, V109, P167; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; COHEN LH, 1988, BIOCHEM J, V255, P61, DOI 10.1042/bj2550061; CORRELL CC, 1994, J BIOL CHEM, V269, P633; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; ERICKSON SK, 1986, J LIPID RES, V27, P875; GHERARDI E, 1992, J CELL SCI, V103, P531; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GIRON MD, 1994, P NATL ACAD SCI USA, V91, P6398, DOI 10.1073/pnas.91.14.6398; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDEMAN EC, 1983, P NATL ACAD SCI-BIOL, V80, P1516, DOI 10.1073/pnas.80.6.1516; HARWOOD HJ, 1991, J LIPID RES, V32, P1237; INOUE S, 1991, J BIOL CHEM, V266, P13311; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KENNELLY PJ, 1985, J LIPID RES, V26, P903; KITO M, 1995, P JPN ACAD B-PHYS, V71, P189, DOI 10.2183/pjab.71.189; KNIGHT BL, 1988, EUR J BIOCHEM, V178, P555, DOI 10.1111/j.1432-1033.1988.tb14482.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER RJ, 1991, J BIOL CHEM, V266, P20070; MOLOWA DT, 1989, BIOCHEM J, V260, P731, DOI 10.1042/bj2600731; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NESS GC, 1985, J BIOL CHEM, V260, P6395; NIESOR E, 1994, ATHEROSCLEROSIS, V109, P167; OMKUMAR RV, 1993, BIOCHIM BIOPHYS ACTA, V1156, P267, DOI 10.1016/0304-4165(93)90041-6; PANINI SR, 1992, J BIOL CHEM, V267, P12647; PARKER RA, 1993, J BIOL CHEM, V268, P11230; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PEFFLEY DM, 1992, SOMAT CELL MOLEC GEN, V18, P19, DOI 10.1007/BF01233446; Rodwell V W, 1976, Adv Lipid Res, V14, P1; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SINENSKY M, 1983, J BIOL CHEM, V258, P8547; SUCKLING KE, 1994, ATHEROSCLEROSIS, V109, P166; TRZASKOS JM, 1993, J BIOL CHEM, V268, P22591; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VONGUNTEN CF, 1989, BIOCHIM BIOPHYS ACTA, V1001, P218, DOI 10.1016/0005-2760(89)90151-3; WILKINS GM, 1994, BBA-LIPID LIPID MET, V1211, P69, DOI 10.1016/0005-2760(94)90140-6	48	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14376	14382		10.1074/jbc.271.24.14376	http://dx.doi.org/10.1074/jbc.271.24.14376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662919	hybrid			2022-12-25	WOS:A1996UQ66000066
J	Eguchi, S; Matsumoto, T; Motley, ED; Utsunomiya, H; Inagami, T				Eguchi, S; Matsumoto, T; Motley, ED; Utsunomiya, H; Inagami, T			Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells - Possible requirement of G(q)-mediated p21(ras) activation coupled to a Ca2+/calmodulin-sensitive tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHORBOL ESTER; MAP KINASES; CARDIAC FIBROBLASTS; PHOSPHOLIPASE-C; RECEPTOR; PHOSPHORYLATION; TRANSDUCTION; HYPERTROPHY; HYPERPLASIA	In cultured rat vascular smooth muscle cells, angiotensin II (Ang II) induced a rapid increase in mitogen-activated protein kinase (MAPK) activity through the Ang II type 1 receptor, which was insensitive to pertussis toxin but was abolished by the phospholipase C inhibitor, U73122. The Ang II-induced MAPK activation was not affected by the protein kinase C inhibitor, GF109203X, and was only partially impaired by pretreatment with a phorbol ester, whereas both treatments completely prevented MAPR activation by the phorbol ester. Intracellular Ca2+ chelation by TMB-8, but not extracellular Ca2+ chelation or inhibition of Ca2+ influx, abolished Ang II-induced MAPK activation. The calmodulin inhibitor, calmidazolium, and the tyrosine kinase inhibitor, genistein, completely blocked MAPR activation by Ang II as well as by the Ca2+ ionophore A23187. Ang II caused a rapid increase in the binding of GTP to p21(ras), and this was inhibited by genistein, TMB-8, and calmidazolium but not by pertussis toxin or GF109203X These data suggest that Ang II-induced MAPK activation through the Ang II type 1 receptor could be mediated by p21(ras) activation through a currently unidentified tyrosine kinase that lies downstream of G(q)-coupled Ca2+/calmodulin signals.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; MEHARRY MED COLL, DEPT PHYSIOL, NASHVILLE, TN 37208 USA	Vanderbilt University; Meharry Medical College					NHLBI NIH HHS [HL-14192, HL-35323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014192, R01HL035323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAUKAL AJ, 1988, J BIOL CHEM, V263, P6087; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; BROCK TA, 1985, J BIOL CHEM, V260, P4158; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EGUCHI S, 1994, ENDOCRINOLOGY, V134, P222, DOI 10.1210/en.134.1.222; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOMMA T, 1992, J BIOL CHEM, V267, P23129; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ITOH H, 1984, J BIOCHEM-TOKYO, V96, P1721, DOI 10.1093/oxfordjournals.jbchem.a135004; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRUSE HJ, 1994, J CARDIOVASC PHARM, V24, P328, DOI 10.1097/00005344-199424020-00020; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANG U, 1989, BIOCHEM J, V259, P477, DOI 10.1042/bj2590477; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNISHI J, 1992, BIOCHEM BIOPH RES CO, V186, P1094, DOI 10.1016/0006-291X(92)90859-J; OWENS GK, 1987, HYPERTENSION, V9, P178, DOI 10.1161/01.HYP.9.2.178; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAISHI T, 1989, CANCER RES, V49, P2374; SMITH JB, 1986, AM J PHYSIOL, V250, pF759, DOI 10.1152/ajprenal.1986.250.5.F759; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; YULE DI, 1992, J BIOL CHEM, V267, P13830	77	262	268	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14169	14175		10.1074/jbc.271.24.14169	http://dx.doi.org/10.1074/jbc.271.24.14169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662912	hybrid			2022-12-25	WOS:A1996UQ66000037
J	Zhang, ZS; Hocker, M; Koh, TJ; Wang, TC				Zhang, ZS; Hocker, M; Koh, TJ; Wang, TC			The human histidine decarboxylase promoter is regulated by gastrin and phorbol 12-myristate 13-acetate through a downstream cis-acting element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYRISTATE ACETATE; ENHANCER ELEMENT; GENE; HISTAMINE; IDENTIFICATION; CELLS; INDUCTION; RECEPTOR; MOUSE; FOS	Transcriptional regulation of the human histidine decarboxylase (HDC) gene by gastrin and the phorbol ester phorbol 12-myristate 13 acetate (PMA) was studied using transient transfection of human HDC promoter-luciferase constructs in a human gastric carcinoma cell line (AGS-B) that expresses the human cholecystokinin-B/gastrin receptor, The transcriptional activity of the human HDC promoter was stimulated 3-4-fold by gastrin and 13-fold by PMA, effects that could be blocked by down-regulation or antagonism of protein kinase C. 5'- and 3'-deletion analysis demonstrated that the sequence responsible for gastrin- and PMA-stimulated transactivation (gastrin response element (GAS-RE)) was located in a region (+2 to +24) downstream of the transcriptional start site (+1) in the human HDC promoter and contained a palindrome (5'-CCCTTTAAATAAAGGG-3'). When ligated upstream of the herpes simplex virus 1 thymidine kinase promoter, a single copy of the GAS-RE was sufficient to confer responsiveness to gastrin and PMA, Electrophoretic mobility shift assays with specific competitors and factor-specific antibody supershifts showed that the labeled GAS-RE bound a novel nuclear factor(s). In addition, both gastrin and PMA increased binding of this factor to the GAS-RE, Hence, the palindromic GAS-RE site is sufficient to explain the gastrin/PMA responsiveness of the human HDC promoter and appears to bind a novel transcription factor.	MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048077] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 48077] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; BARTHOLEYNS J, 1984, CANCER RES, V44, P639; BEAVEN MA, 1982, PHARM HISTAMINE RECE, P101; CHATTON B, 1994, ONCOGENE, V9, P375; CHEW C, 1982, AM J PHYSIOL, V250, pG912; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DIMALINE R, 1991, FEBS LETT, V281, P20, DOI 10.1016/0014-5793(91)80348-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJIMOTO K, 1992, J CLIN INVEST, V89, P126, DOI 10.1172/JCI115552; HAKANSON R, 1986, HISTOCHEMISTRY, V86, P5, DOI 10.1007/BF00492340; HAKANSON R, 1991, SCAND J GASTROENTERO, V26, P130, DOI 10.3109/00365529109093190; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; HOSODA S, 1985, BIOCHEM PHARMACOL, V34, P4327, DOI 10.1016/0006-2952(85)90293-X; ISHIKAWA E, 1970, J BIOCHEM-TOKYO, V68, P347, DOI 10.1093/oxfordjournals.jbchem.a129365; ITO M, 1993, J BIOL CHEM, V268, P18300; KAHLSON G, 1968, PHYSIOL REV, V48, P155, DOI 10.1152/physrev.1968.48.1.155; KAHLSON G, 1959, NATURE, V184, P1238, DOI 10.1038/1841238a0; KAHLSON G, 1958, J PHYSIOL-LONDON, V144, P337, DOI 10.1113/jphysiol.1958.sp006105; KAHLSON G, 1972, EXPERIENTIA, V28, P993, DOI 10.1007/BF01918636; KAWAI H, 1992, BIOCHIM BIOPHYS ACTA, V1133, P172, DOI 10.1016/0167-4889(92)90066-K; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; LEE YM, 1993, J BIOL CHEM, V268, P8164; MAEYAMA K, 1988, BIOCHEM BIOPH RES CO, V151, P1402, DOI 10.1016/S0006-291X(88)80518-7; MAMUNESATO R, 1990, BIOCHEM PHARMACOL, V40, P1125; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RANGACHARI PK, 1992, AM J PHYSIOL, V262, pG1; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; ROEBUCK KA, 1993, J CLIN INVEST, V92, P1336, DOI 10.1172/JCI116707; SANDVIK AK, 1994, AM J PHYSIOL, V267, pG254, DOI 10.1152/ajpgi.1994.267.2.G254; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P5419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WANG TC, 1990, J BIOL CHEM, V265, P8908; WATANABE T, 1981, BIOCHEM BIOPH RES CO, V100, P427, DOI 10.1016/S0006-291X(81)80114-3; YAMAUCHI K, 1990, NUCLEIC ACIDS RES, V18, P5891, DOI 10.1093/nar/18.19.5891; YASSIN RR, 1993, PEPTIDES, V14, P1119, DOI 10.1016/0196-9781(93)90164-C; YATSUNAMI K, 1994, J BIOL CHEM, V269, P1554; YATSUNAMI K, 1993, AGENTS ACTIONS, V38, pC155, DOI 10.1007/BF01996445; Zahnow C A, 1991, DNA Seq, V1, P395, DOI 10.3109/10425179109020795	46	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14188	14197		10.1074/jbc.271.24.14188	http://dx.doi.org/10.1074/jbc.271.24.14188			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662934	hybrid			2022-12-25	WOS:A1996UQ66000040
J	Durick, K; Wu, RY; Gill, GN; Taylor, SS				Durick, K; Wu, RY; Gill, GN; Taylor, SS			Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE; SEQUENCE; PROTEIN; INTERACTS; KINASE	The ret/ptc2 papillary thyroid cancer oncogene, an oncogenic form of the c-Ret receptor tyrosine kinase, is the product of a somatic crossover event fusing the dimerization domain of the type I alpha regulatory subunit of cyclic AMP-dependent protein kinase (RI) with the tyrosine kinase domain of c-Ret. Mitogenic activity of Ret/ptc2 required dimerization via the N terminus of RI and a tyrosine residue located C-terminal to the kinase core of Ret, Tyr-586 (Durick, K., Yao, V. J., Borrello, M. G., Bongarzone, I., Pierotti, M. A. and Taylor, S. S. (1995) J. Biol. Chem. 270, 24642-24645). Using the yeast two-hybrid system, Ret/ptc2 binding proteins were identified, and the sites of interaction with Ret/ptc2 were mapped. The SH2 domains of phospholipase C gamma and Grb10 were both identified, and binding depended on phosphorylation of Tyr-539 and Tyr-429, respectively. These interactions, however, were not required for mitogenic signaling. The second of the three LIM domains in Enigma (Wu, R. Y., and Gill, G. N. (1994) J. Biol. Chem. 269, 25085-25090) was also identified as a Ret/ptc2 binding domain. Enigma, a 455-residue protein, was discovered based on its interaction with the insulin receptor through the C-terminal LIM domain. Although the association with Enigma required Tyr-586 of Ret/ptc2, the interaction was phosphorylation-independent. In contrast to the SH2 interactions, disruption of the interaction with Enigma abolished Ret/ptc2 mitogenic signaling, suggesting that LIM domain recognition of an unphosphorylated tyrosine-based motif is required for Ret signal transduction.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [T32 CA09523] Funding Source: Medline; NIDDK NIH HHS [DK13149] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BORRELLO MG, 1994, ONCOGENE, V9, P1661; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LANZI C, 1992, ONCOGENE, V7, P2189; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WU RY, 1994, J BIOL CHEM, V269, P25085; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	26	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12691	12694		10.1074/jbc.271.22.12691	http://dx.doi.org/10.1074/jbc.271.22.12691			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662982	hybrid			2022-12-25	WOS:A1996UN47400002
J	Gelissen, IC; Brown, AJ; Mander, EL; Kritharides, L; Dean, RT; Jessup, W				Gelissen, IC; Brown, AJ; Mander, EL; Kritharides, L; Dean, RT; Jessup, W			Sterol efflux is impaired from macrophage foam cells selectively enriched with 7-ketocholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OXIDATION-PRODUCTS; UNESTERIFIED CHOLESTEROL; APOLIPOPROTEINS; OXYSTEROLS; MEMBRANES; CLEAVAGE; ESTER; LDL	The aim of the present study was to investigate whether impairment of cholesterol efflux previously found from mouse peritoneal macrophages loaded with oxidized low density lipoprotein (OxLDL) could be ascribed to the presence of oxysterols in these cells, 7-Ketocholesterol (7KC), the major oxysterol present in OxLDL-loaded cells, was selectively incorporated into unoxidized LDL, which was subsequently acetylated to produce a high uptake form, Mouse macrophages incubated with 7KC-enriched acetylated LDL (7kAcLDL) did not reveal cytotoxicity judged by cell protein and trypan blue exclusion, A large proportion of cellular 7KC was esterified, indicating that it is a substrate for acyl CoA: cholesterol acyltransferase. Cholesterol efflux from mouse macrophages loaded with 7kAcLDL, using apoA-I as a sterol acceptor, was impaired in cells containing >50 nmol of 7KC/mg of cell protein compared with cells loaded with oxysterol-free acetylated LDL, Thus impairment of cholesterol efflux could be reproduced in cells loaded with 7kAcLDL containing similar proportions of 7KC as OxLDL, 7KC itself was exported very poorly, even when the levels of 7KC in the cells were low. These results suggest that oxysterols present in foam cells in vitro can affect reverse sterol transport and may be potentially important in foam cell formation in vivo.			Gelissen, IC (corresponding author), HEART RES INST,CELL BIOL UNIT,145 MISSENDEN RD,CAMPERDOWN,NSW 2050,AUSTRALIA.		Kritharides, Leonard/AAQ-2720-2020	Dean, Roger Thornton/0000-0002-8859-8902				ADDIS PB, 1993, CAN J CARDIOL, V9, pB6; ADDIS PB, 1989, FREE RADICAL BIO MED, V7, P179, DOI 10.1016/0891-5849(89)90011-7; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BREUER O, 1995, J LIPID RES, V36, P2275; Brown AJ, 1996, J LIPID RES, V37, P320; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CLARE K, 1995, ATHEROSCLEROSIS, V118, P67, DOI 10.1016/0021-9150(95)05594-M; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; FONG LG, 1987, J LIPID RES, V28, P1466; HARA H, 1991, J BIOL CHEM, V266, P3080; JAILAL I, 1991, ARTERIOSCLER THROMB, V11, P482; KAN CC, 1992, BIOCHEMISTRY-US, V31, P1866, DOI 10.1021/bi00121a040; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KILSDONK EPC, 1995, J LIPID RES, V36, P505; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEVRE M, 1988, J LIPID RES, V29, P1139; MANDER EL, 1994, BBA-LIPID LIPID MET, V1212, P80, DOI 10.1016/0005-2760(94)90192-9; MAOR I, 1994, J LIPID RES, V35, P803; MAOR I, 1995, ARTERIOSCL THROM VAS, V15, P1378, DOI 10.1161/01.ATV.15.9.1378; MATTSSONHULTEN L, 1996, J CLIN INVEST, V97, P461; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; ROHEIM PS, 1990, EUR HEART J, V11, P225, DOI 10.1093/eurheartj/11.suppl_E.225; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SNEDECOR GW, 1980, STATISTICAL METHODS, P83; SZEDLACSEK SE, 1995, J BIOL CHEM, V270, P11812, DOI 10.1074/jbc.270.20.11812; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; THEUNISSEN JJH, 1986, BIOCHIM BIOPHYS ACTA, V860, P66, DOI 10.1016/0005-2736(86)90499-2; VANREYK DM, 1995, FREE RADICAL RES, V23, P533, DOI 10.3109/10715769509065274; WARNICK GR, 1982, CLIN CHEM, V28, P1379; ZHANG HF, 1990, J LIPID RES, V31, P1361	35	120	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17852	17860		10.1074/jbc.271.30.17852	http://dx.doi.org/10.1074/jbc.271.30.17852			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663356	hybrid			2022-12-25	WOS:A1996UY93500042
J	Zhang, L; Plow, EF				Zhang, L; Plow, EF			Overlapping, but not identical, sites are involved in the recognition of C3bi, neutrophil inhibitory factor, and adhesive ligands by the alpha(M)beta(2) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAC-1 CD11B CD18; I-DOMAIN; CR3 CD11B/CD18; BINDING-SITE; A-DOMAIN; COMPLEMENT RECEPTOR; BETA-2 INTEGRINS; CATION-BINDING; ADHERENCE; SUBUNIT	The alpha(M) beta(2) (CD11b/CD18, Mac-1) integrin receptor binds numerous ligands, including neutrophil inhibitory factor (NIF), C3bi, and certain immobilized protein substrates, represented by denatured ovalbumin. These ligands share no obvious structural similarities, yet their interactions with receptor are inhibited by NIF and involve the I domain, a stretch of similar to 200 amino acids in the alpha(M) subunit. Recombinant wild-type and mutant forms of alpha(M) beta(2) have been used to compare the recognition requirements of these ligands. The various constructs were expressed efficiently on the surface of human embryonic kidney 293 cells and formed alpha .beta heterodimeric complexes. The wild-type transfectants bound the three ligands in a similar fashion to naturally occurring alpha(M) beta(2). NIF inhibited these interactions, and deletion of the D(248)PLGY from within the I domain abolished binding of all three ligands, suggesting an overlapping recognition specificity. A single point mutation of Ser(138) to Ala in the beta(2) subunit abolished C3bi binding and cell adhesion but did not affect NIF binding. A switch of the R(281)QELNTI sequence in helix 6 of the alpha(M) I domain to the corresponding sequence in the I domain of the alpha(L) (QETLHKF) subunit completely abrogated adhesion while not affecting C3bi and NIF binding. The two mutant receptors also did not support activation-dependent adhesion to fibrinogen. Thus, the contact sites for NIF, C3bi, and adhesive proteins, represented by denatured ovalbumin and fibrinogen, in alpha(M) beta(2) are overlapping but not identical.			Zhang, L (corresponding author), CLEVELAND CLIN FDN,DEPT MOL CARDIOL,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NHLBI NIH HHS [HL38292] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; ARNAOUT MA, 1990, BLOOD, V75, P1037; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DIRENZO L, 1991, EUR J IMMUNOL, V21, P1755, DOI 10.1002/eji.1830210726; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KERN A, 1994, J BIOL CHEM, V269, P22811; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SCHMALSTIEG FC, 1988, PEDIATR INFECT DIS J, V867, P872; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	38	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18211	18216		10.1074/jbc.271.30.18211	http://dx.doi.org/10.1074/jbc.271.30.18211			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663418	hybrid			2022-12-25	WOS:A1996UY93500093
J	Collins, LR; Minden, A; Karin, M; Brown, JH				Collins, LR; Minden, A; Karin, M; Brown, JH			G alpha(12) stimulates c-Jun NH2-terminal kinase through the small G proteins Ras and Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION DOMAIN; CELLS; JNK; PHOSPHORYLATION; TRANSFORMATION; PROLIFERATION; FIBROBLASTS; MITOGENESIS; INHIBITION; INDUCTION	The pertussis toxin (PTX) insensitive heterotrimeric G protein G(12) has been implicated in mitogenesis and transformation, but its direct effecters remain unknown, To define potential signaling pathways utilized by G(12), we expressed an activated mutant of its alpha subunit, G alpha(12)(Q229L), in HEK293 cells and examined its effects on Ras and mitogen-activated protein kinases (MAPKs), Transient expression of activated G alpha(12) increased the percentage of has in the active, GTP-bound state, stimulated c-Jun NH2-terminal kinase (JNK) activity, and enhanced the transcriptional activity of c-Jun, Dominant negative Ras (N17Ras) inhibited G alpha(12)-mediated JNK activation in NIH3T3 cells but failed to do so in HEK293 cells, In contrast, dominant negative Rac (N17Rac1) inhibited JNK activation by G alpha(12), in HEK293 cells as well as three other cell lines. In 1321N1 cells, where thrombin stimulates G(12)-dependent mitogenesis, coexpression of N17Rac1 or a dominant negative mutant of MEKK1 (MEKK Delta(K432M)) inhibits c-Jun/AP-1 sensitive reporter gene expression stimulated by thrombin or G alpha(12). These data demonstrate that the alpha subunit of the heterotrimeric G protein G(12), like tyrosine kinase growth factor receptors, activates has and recruits a signal transduction pathway involving the small GTP-binding protein Rac that leads to JNK activation.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NHLBI NIH HHS [HL35018] Funding Source: Medline; NIGMS NIH HHS [GM17277, GM36927] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927, R56GM036927, F31GM017277] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; OBBERGHENSCHILL.EV, 1985, EMBO J, V4, P2927; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POST GR, 1996, IN PRESS MOL BIOL CE; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396	37	135	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17349	17353		10.1074/jbc.271.29.17349	http://dx.doi.org/10.1074/jbc.271.29.17349			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663428	hybrid			2022-12-25	WOS:A1996UX94300057
J	Medh, JD; Bowen, SL; Fry, GL; Ruben, S; Andracki, M; Inoue, I; Lalouel, JM; Strickland, DK; Chappell, DA				Medh, JD; Bowen, SL; Fry, GL; Ruben, S; Andracki, M; Inoue, I; Lalouel, JM; Strickland, DK; Chappell, DA			Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; CHYLOMICRON-REMNANT CLEARANCE; HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE CELLS; IN-VITRO; MONOCLONAL-ANTIBODIES; HEPATIC LIPASE; BOVINE-MILK; ALPHA(2)-MACROGLOBULIN RECEPTOR	Lipoprotein lipase (LPL), the major enzyme responsible for the hydrolysis of plasma triglycerides, promotes binding and catabolism of triglyceride-rich lipoproteins by various cultured cells, Recent studies demonstrate that LPL binds to three members of the low density lipoprotein (LDL) receptor family, including the LDL receptor-related protein (LRP), GP330/LRP-2, and very low density lipoprotein (VLDL) receptors and induces receptor-mediated lipoprotein catabolism. We show here that LDL receptors also bind LPL and mediate LPL-dependent catabolism of large VLDL with S-f 100-400. Up-regulation of LDL receptors by lovastatin treatment of normal human foreskin fibroblasts (FSF cells) resulted in an increase in LPL-induced VLDL binding and catabolism to a level that was 10-15-fold greater than in LDL receptor-negative fibroblasts, despite similar LRP activity in both cell lines, This indicates that the contribution of LRP to LPL-dependent degradation of VLDL is small when LDL receptors are maximally up-regulated, Furthermore studies in LRP-deficient murine embryonic fibroblasts showed that the level of LPL-dependent degradation of VLDL was similar to that in normal murine embryonic fibroblasts. LPL also promoted the internalization of protein-free triglyceride emulsions; lovastatin-treatment resulted in a-fold higher uptake in FSF cells, indicating that LPL itself could bind to LDL receptors, However, the lower induction of emulsion catabolism as compared with native VLDL suggests that LPL-induced catabolism via LDL receptors is only partially dependent on receptor binding by LPL and instead is primarily due to activation of apolipoproteins such as apoE, A fusion protein between glutathione S-transferase and the catalytically inactive carboxyl-terminal domain of LPL (GST-LPLC) also induced binding and catabolism of VLDL, However GST-LPLC was not as active as native LPL, indicating that lipolysis is required for a maximal LPL effect, Mutations of critical tryptophan residues in GST-LPLC that abolished binding to VLDL converted the protein to an inhibitor of lipoprotein binding to LDL receptors, In solid-phase assays using immobilized receptors, LDL receptors bound to LPL in a dose-dependent manner, Both LPL and GST-LPLC promoted binding of VLDL to LDL receptor-coated wells, These results indicate that LPL binds to LDL receptors and suggest that the carboxyl-terminal domain of LPL contributes to this interaction.	UNIV UTAH,SALT LAKE CITY,UT 84248; AMER RED CROSS,ROCKVILLE,MD 20855	Utah System of Higher Education; University of Utah; American Red Cross	Medh, JD (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,17 MRC,IOWA CITY,IA 52242, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOWLER A, 1991, BIOCHEM J, V276, P381, DOI 10.1042/bj2760381; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CATAPANO AL, 1979, J BIOL CHEM, V254, P1007; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1992, J BIOL CHEM, V267, P270; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622; COOPER AD, 1992, SEMIN LIVER DIS, V12, P386, DOI 10.1055/s-2008-1040408; COREY JE, 1977, ATHEROSCLEROSIS, V27, P201, DOI 10.1016/0021-9150(77)90057-0; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; GIANTURCO SH, 1993, ARTERIOSCLER THROMB, V13, P472, DOI 10.1161/01.ATV.13.4.472; GIBSON JC, 1987, ARTERIOSCLEROSIS, V7, P401, DOI 10.1161/01.ATV.7.4.401; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; HAMILTONATTWELL VL, 1986, J MICROSC, V145, P347; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HUSSAIN MM, 1995, J BIOL CHEM, V270, P8578, DOI 10.1074/jbc.270.15.8578; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JAFFE EA, 1980, TRANSPL P, V12, P49; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LABARCA C, 1980, ANAL CHEM, V133, P437; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MULDER M, 1993, J BIOL CHEM, V268, P9369; MUSLINER TA, 1979, BIOCHIM BIOPHYS ACTA, V575, P227; NORDENSTROM J, 1991, EUR J CLIN INVEST, V21, P580, DOI 10.1111/j.1365-2362.1991.tb01412.x; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; OSTLUNDLINDQVIST AM, 1983, ARTERIOSCLEROSIS, V3, P433, DOI 10.1161/01.ATV.3.5.433; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; RUTLEDGE JC, 1994, J LIPID RES, V35, P1152; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SANTAMARINAFOJO S, 1991, JAMA-J AM MED ASSOC, V265, P904, DOI 10.1001/jama.265.7.904; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SCHONFELD G, 1979, J CLIN INVEST, V64, P1288, DOI 10.1172/JCI109584; SKARLATOS SI, 1993, J CLIN ENDOCR METAB, V76, P793, DOI 10.1210/jc.76.3.793; STEIN O, 1993, ATHEROSCLEROSIS, V99, P15, DOI 10.1016/0021-9150(93)90046-W; TABAS I, 1993, J BIOL CHEM, V268, P20419; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TENG B, 1985, J BIOL CHEM, V260, P5067; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; VILARO S, 1986, BIOCHEM J, V236, P273, DOI 10.1042/bj2360273; VILELLA E, 1993, J LIPID RES, V34, P1555; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13285; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLIAMS SE, 1993, J BIOL CHEM, V268, P8653; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	80	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17073	17080		10.1074/jbc.271.29.17073	http://dx.doi.org/10.1074/jbc.271.29.17073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663292	hybrid			2022-12-25	WOS:A1996UX94300017
J	Erpel, T; Alonso, G; Roche, S; Courtneidge, SA				Erpel, T; Alonso, G; Roche, S; Courtneidge, SA			The Src SH3 domain is required for DNA synthesis induced by platelet-derived growth factor and epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; FAMILY TYROSINE KINASES; C-SRC; MITOGENIC RESPONSIVENESS; SIGNAL-TRANSDUCTION; RECEPTOR; PROTEIN; GRB2; RAS; ASSOCIATION	The Src family of protein tyrosine kinases has been implicated in the response of cells to platelet-derived growth factor (PDGF) or epidermal growth factor (EGF). We recently described a microinjection approach that we used to demonstrate that kinase activity of Src family members is required for PDGF- and EGF-induced S-phase entry of fibroblasts. We have now used this approach to ask whether a functional SH3 domain of Src is required to transduce the mitogenic signal upon PDGF or EGF stimulation. Microinjection of plasmids encoding Src mutants lacking the SH3 domain (Src Delta SH3) or point-mutated within the ligand binding surface of the SH3 domain, but with intact kinase domains, inhibited the mitogenic effect of PDGF and EGF in fibroblasts. Src Delta SH3 could still associate with the PDGF receptor, suggesting that the inhibitory effect of the Src SH3 mutants was brought about by a failure of the PDGF receptor Src Delta SH3 complex to relay the mitogenic signal further downstream. Chimeric molecules in which the Src SH3 domain was replaced with that of spectrin or Lck also blocked PDGF-induced DNA synthesis, whereas a chimera containing the Fyn SH3 domain did not. These data suggest that the Src or Fyn SH3 domain is required either for correct substrate selection or to recruit other proteins to the PDGF receptor.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)				roche, serge/0000-0003-3413-3859				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16807	16812		10.1074/jbc.271.28.16807	http://dx.doi.org/10.1074/jbc.271.28.16807			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663328	hybrid			2022-12-25	WOS:A1996UX12600060
J	Davidson, JS; McArdle, CA; Davies, P; Elario, R; Flanagan, CA; Millar, RP				Davidson, JS; McArdle, CA; Davies, P; Elario, R; Flanagan, CA; Millar, RP			Asn(102) of the gonadotropin releasing hormone receptor is a critical determinant of potency for agonists containing C-terminal glycinamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GNRH RECEPTOR; EXPRESSION; CELLS; SPECIFICITY; ANTAGONISTS; ANALOG; DNA	We demonstrate a critical role for Asn(102) of the human gonadotropin-releasing hormone (GnRH) receptor in the binding of GnRH, Mutation of Asn(102), located at the top of the second transmembrane helix, to Ala resulted in a 225-fold loss of potency for GnRH. Eight GnRH analogs, all containing glycinamide C termini like GnRH, showed similar losses of potency between 95- and 750-foId for the [Ala(102)]GnRHR, compared with wildtype receptor, In contrast, four GnRH analogs that had ethylamide in place of the C-terminal glycinamide residue, showed much smaller decreases in potency between 2.4- and 11-fold, In comparisons of three agonist pairs, differing only at the C terminus, glycinamide derivatives showed an 11-20-fold greater loss of potency for the mutant receptor than their respective ethylamide derivatives, Thus Asn(102) is a critical determinant of potency specifically for ligands with C terminal glycinamide, while ligands with C-terminal ethylamide are less dependent on Asn(102), These findings indicate a role for Asn(102) in the docking of the glycinamide C terminus and are consistent with hydrogen bonding of the Asn(102) side chain with the C-terminal amide moiety, Taken with previous data, they suggest a region of the GnRH receptor formed by the top of helices 2 and 7 as a binding pocket for the C-terminal part of the ligand.	UNIV BRISTOL, DEPT MED, BRISTOL BS2 8HW, AVON, ENGLAND; UNIV CAPE TOWN, SCH MED, ENDOCRINE LAB, DEPT MED, CAPE TOWN 7925, SOUTH AFRICA	University of Bristol; University of Cape Town	Davidson, JS (corresponding author), UNIV CAPE TOWN, SCH MED, DEPT CHEM PATHOL, MRC, REGULATORY PEPTIDES RES UNIT, CAPE TOWN 7925, SOUTH AFRICA.		Flanagan, Colleen/ABG-2109-2020; McArdle, Craig/AAQ-5660-2021	McArdle, Craig/0000-0003-4836-5351; Millar, Robert P/0000-0003-3606-2708; Flanagan, Colleen A./0000-0003-2803-8986				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; CHI L, 1993, MOL CELL ENDOCRINOL, V91, pR1, DOI 10.1016/0303-7207(93)90278-R; DAVIDSON J, 1991, MOL CELL ENDOCRINOL, V76, pC33, DOI 10.1016/0303-7207(91)90278-Z; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; DAVIDSON JS, 1995, MOL CELL ENDOCRINOL, V107, P241, DOI 10.1016/0303-7207(94)03449-4; FLANAGAN CA, 1994, J BIOL CHEM, V269, P22639; FREIDINGER RM, 1980, SCIENCE, V210, P656, DOI 10.1126/science.7001627; FUJINO M, 1972, BIOCHEM BIOPH RES CO, V49, P863, DOI 10.1016/0006-291X(72)90490-1; GETHER U, 1993, J BIOL CHEM, V268, P7893; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; ILLING N, 1993, BIOCHEM BIOPH RES CO, V196, P745, DOI 10.1006/bbrc.1993.2312; KAISER UB, 1992, BIOCHEM BIOPH RES CO, V189, P1645, DOI 10.1016/0006-291X(92)90266-N; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KAKAR SS, 1993, DOMEST ANIM ENDOCRIN, V10, P335, DOI 10.1016/0739-7240(93)90037-C; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; Kenakin TP, 1993, PHARM ANAL DRUG RECE, P39; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LESLIE FM, 1987, PHARMACOL REV, V39, P197; MILLAR RP, 1987, S AFR MED J, V72, P748; MONAHAN MW, 1973, BIOCHEMISTRY-US, V12, P4616, DOI 10.1021/bi00747a012; REINHART J, 1992, J BIOL CHEM, V267, P21281; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHOU W, 1995, J BIOL CHEM, V270, P18853, DOI 10.1074/jbc.270.32.18853	29	83	85	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15510	15514		10.1074/jbc.271.26.15510	http://dx.doi.org/10.1074/jbc.271.26.15510			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663086	Green Published, hybrid			2022-12-25	WOS:A1996UV29900033
J	Fine, SM; Angel, RA; Perry, SW; Epstein, LG; Rothstein, JD; Dewhurst, S; Gelbard, HA				Fine, SM; Angel, RA; Perry, SW; Epstein, LG; Rothstein, JD; Dewhurst, S; Gelbard, HA			Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes - Implications for pathogenesis of HIV-1 dementia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; FACTOR RECEPTORS; CYTOKINES; BINDING; BRAIN	Human immunodeficiency virus (HIV) infection is commonly associated with neurological disease that occurs in the apparent absence of extensive infection of brain cells by HIV, suggesting that indirect mechanisms account for neuropathogenesis in the CNS, perhaps including changes in the normal neuroprotective functions of astrocytes. To test this hypothesis, we examined the effect of the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF alpha), produced by HIV-1-infected macrophages and microglia, on glutamate transport by primary human fetal astrocytes (PHFAs). A dose-dependent inhibition of high affinity glutamate uptake sites was observed 12-24 h after addition of exogenous recombinant human TNF alpha to PHFAs. This effect was specific since it was blocked by a neutralizing monoclonal antibody directed against TNF alpha. Furthermore, the inhibitory effect was reproduced by a monoclonal antibody that is an agonist at the 55-kDa TNF receptor. These results suggest that the neurotoxic effects of TNF alpha may be due in part to its ability to inhibit glutamate uptake by astrocytes, which in turn may result in excitotoxic concentrations of glutamate in synapses.	UNIV ROCHESTER,MED CTR,DEPT NEUROL,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,DEPT MED INFECT DIS,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,DEPT PEDIAT,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,DEPT PHYSIOL & PHARMACOL,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,CTR CANC,ROCHESTER,NY 14842; JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21287	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; Johns Hopkins University			Gelbard, Harris/M-9260-2019; rothstein, jeffrey d/C-9470-2013	Epstein, Leon/0000-0003-4264-3867; Dewhurst, Stephen/0000-0001-7729-7920; Gelbard, Harris/0000-0001-5095-7976; Perry, Seth W/0000-0002-1503-6634	NIAID NIH HHS [KO4 AI01240, T32-AI08894] Funding Source: Medline; NINDS NIH HHS [P01 NS31492-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001240, F32AI008894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CASADO M, 1993, J BIOL CHEM, V268, P27313; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; NOKTA MA, 1995, VIROLOGY, V205, P590; PIANI D, 1993, J NEUROIMMUNOL, V48, P99, DOI 10.1016/0165-5728(93)90063-5; PIANI D, 1994, J IMMUNOL, V152, P3578; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Sambrook J., 2002, MOL CLONING LAB MANU; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; ZERANGUE N, 1995, J BIOL CHEM, V270, P6433, DOI 10.1074/jbc.270.12.6433	28	269	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15303	15306		10.1074/jbc.271.26.15303	http://dx.doi.org/10.1074/jbc.271.26.15303			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663435	hybrid			2022-12-25	WOS:A1996UV29900002
J	Ungefroren, H; Krull, NB				Ungefroren, H; Krull, NB			Transcriptional regulation of the human biglycan gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DERMATAN SULFATE PROTEOGLYCAN; VASCULAR SMOOTH-MUSCLE; NUCLEAR FACTOR-I; EXTRACELLULAR-MATRIX; HUMAN FIBROBLASTS; CORE PROTEIN; EXPRESSION; DECORIN; CELLS	The small leucine-rich proteoglycan biglycan is involved in several physiological and pathophysiological processes through the ability of its core protein to interact with other extracellular matrix molecules and transforming growth factor-beta (TGF-beta). To learn more about the regulation of biglycan core protein expression, we have cloned and sequenced 1218 base pairs from the 5'-flanking region of the human biglycan gene, demonstrated functional promoter activity, and investigated the molecular mechanisms through which various agents modulate its transcriptional activity. Sequencing revealed the presence of several cis-acting elements including multiple AP-2 sites and interleukin-6 response elements, a NF-kappa B site, a TGF-beta negative element, and an E-box. The TATA and CAAT box-lacking promoter possesses many features of a growth-related gene, e.g. a GC-rich immediate 5' region, many Sp1 sites, and the use of multiple transcriptional start sites. Transient transfections of the tumor cell lines MG-63, SK-UT-1, and T47D with various biglycan 5'-flanking region-luciferase reporter gene constructs showed that the proximal 78 base pairs are sufficient for full promoter activity. Several agents among them interleukin-6, and tumor necrosis factor-alpha. were capable of altering biglycan promoter activity. However, in MG-63 cells, TGF-beta 1 failed to increase either activity of the biglycan promoter constructs or specific transcription from the endogenous biglycan gene. Since TGF-beta 1 also did not alter the stability of cytoplasmic biglycan mRNA as determined from Northern analysis after inhibition of transcription with 5,6-dichloro-1 beta-D-ribofuranosylbenzimidazole, an as yet unidentified nuclear post-transcriptional mechanism was considered responsible for the TGF-beta effect in this cell type. These results might help to elucidate the molecular pathways leading to pathological alterations of biglycan expression observed in atherosclerosis, glomerulonephritis, and fibrosis.	UNIV HAMBURG,INST ANAT,D-20246 HAMBURG,GERMANY; MED LAB DR HR EBERSOLD,CH-3001 BERN,SWITZERLAND	University of Hamburg								ASUNDI V, 1990, EUR J CELL BIOL, V52, P98; BEAVAN LA, 1993, J BIOL CHEM, V268, P9856; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; CHANDLER LA, 1994, MOL CELL BIOL, V14, P3085, DOI 10.1128/MCB.14.5.3085; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI I, 1994, CLIN EXP IMMUNOL, V95, P530; DODGE GR, 1990, J BIOL CHEM, V265, P18023; FEDARKO NS, 1992, J CELL PHYSIOL, V151, P215, DOI 10.1002/jcp.1041510202; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GEERKENS C, 1995, HUM GENET, V96, P44, DOI 10.1007/BF00214185; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; HUTSON JC, 1993, J REPROD IMMUNOL, V23, P63, DOI 10.1016/0165-0378(93)90027-F; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; KAHARI VM, 1995, J INVEST DERMATOL, V104, P503, DOI 10.1111/1523-1747.ep12605969; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIMOTO S, 1994, ENDOCRINOLOGY, V135, P2423, DOI 10.1210/en.135.6.2423; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORNBLIHTT AR, 1983, P NATL ACAD SCI-BIOL, V80, P3218, DOI 10.1073/pnas.80.11.3218; Kresse H, 1994, EXS, V70, P73; KRULL NB, 1993, HEPATOLOGY, V18, P581, DOI 10.1016/0270-9139(93)90359-U; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LI YP, 1993, MOL CELL BIOL, V13, P3714, DOI 10.1128/MCB.13.6.3714; LIN YCA, 1992, J IMMUNOL, V149, P2914; LIU YH, 1994, J BIOL CHEM, V269, P4152; MAATTA A, 1994, BBA-MOL BASIS DIS, V1225, P264, DOI 10.1016/0925-4439(94)90005-1; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; OGATA Y, 1995, EUR J BIOCHEM, V230, P183; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; RAMASAMY S, 1995, J CELL PHYSIOL, V162, P119, DOI 10.1002/jcp.1041620114; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; RIESSEN R, 1994, AM J PATHOL, V144, P962; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROUGHLEY PJ, 1994, MATRIX BIOL, V14, P51, DOI 10.1016/0945-053X(94)90029-9; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTRA M, 1994, J BIOL CHEM, V269, P579; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SENGER M, 1995, COMPUT METH PROG BIO, V46, P131, DOI 10.1016/0169-2607(94)01610-R; SKINNER MK, 1989, MOL ENDOCRINOL, V3, P625, DOI 10.1210/mend-3-4-625; TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303; TOKUNAGA K, 1987, CANCER RES, V47, P5616; UNGEFROREN H, 1995, BIOL REPROD, V52, P1095, DOI 10.1095/biolreprod52.5.1095; VENESSMEEHAN KA, 1994, AM J RESP CELL MOL, V11, P509, DOI 10.1165/ajrcmb.11.5.7946380; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; WESTERGRENTHORSSON G, 1991, MATRIX, V11, P177, DOI 10.1016/S0934-8832(11)80156-3; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; XIE JF, 1994, J IMMUNOL, V153, P378; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YOUNG MF, 1989, J BIOL CHEM, V264, P450	71	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15787	15795		10.1074/jbc.271.26.15787	http://dx.doi.org/10.1074/jbc.271.26.15787			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662974				2022-12-25	WOS:A1996UV29900073
J	Balbin, M; LopezOtin, C				Balbin, M; LopezOtin, C			Hormonal regulation of the human pepsinogen C gene in breast cancer cells - Identification of a cis-acting element mediating its induction by androgens, glucocorticoids, and progesterone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROSS CYSTIC-DISEASE; HUMAN RENIN GENE; TRANSCRIPTIONAL REGULATION; PLASMINOGEN-ACTIVATOR; STEROID-HORMONES; APOLIPOPROTEIN-D; INHIBITOR PAI-1; FLUID PROTEINS; RECEPTOR; EXPRESSION	Pepsinogen C is an aspartic proteinase mainly involved in the digestion of proteins in the stomach, which is also synthesized by certain human breast tumors. To examine the possibility that extragastric production of this proteolytic enzyme could be mediated by hormonal factors, we have analyzed pepsinogen C gene expression in human breast cancer cells subjected to different hormonal treatments. Northern blot analyses revealed the expression of pepsinogen C gene by T-47D breast cancer cells after induction with dihydrotestosterone, dexamethasone, and progesterone but not with estradiol, retinoic acid, or ethanol. Reverse transcription-polymerase chain reaction analysis in a series of breast cancer cell lines confirmed the amplification of pepsinogen C mRNA after induction with dihydrotestosterone, in those cells expressing the androgen receptor mRNA. The promoter region of the pepsinogen C gene was functionally characterized by transient expression of a vector containing the promoter region cloned in front of the chloramphenicol acetyltransferase (CAT) reporter gene. CAT activity in T 47D cells was stimulated in the presence of dihydrotestosterone, dexamethasone, and progesterone but not by estradiol. By further deletion mapping of the pepsinogen C promoter, a minimal region (AGAACTattTGTTCC) was identified as being responsible for glucocorticoid, androgen-, and progesterone-regulated gene expression.	UNIV OVIEDO, FAC MED, DEPT BIOL FUNC, E-33006 OVIEDO, SPAIN	University of Oviedo			Balbín, Milagros/I-4206-2015; López-Otín, Carlos/AAB-2106-2020	Balbín, Milagros/0000-0001-5325-0407; López-Otín, Carlos/0000-0001-6964-1904				ALLEGRA JC, 1979, CANCER RES, V39, P1447; AZUMA T, 1992, J BIOL CHEM, V267, P1609; BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BELASZECSI P, 1995, BIOL REPROD, V53, P227, DOI 10.1095/biolreprod53.1.227; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CHAUHAN SS, 1991, CANCER RES, V51, P1478; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON NE, 1989, ONCOGENESIS, V1, P89; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DIEZITZA I, 1993, BRIT J CANCER, V68, P637, DOI 10.1038/bjc.1993.399; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABRE S, 1994, J BIOL CHEM, V269, P5857; FOEKENS JA, 1992, CANCER RES, V52, P6101; FOLTMANN B, 1981, ESSAYS BIOCHEM, V17, P52; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; FURIHATA C, 1980, EUR J BIOCHEM, V105, P43, DOI 10.1111/j.1432-1033.1980.tb04472.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; HAAGENSEN DE, 1992, BREAST CANCER RES TR, V23, P77, DOI 10.1007/BF01831479; HAYANO T, 1988, J BIOL CHEM, V263, P1382; HOBART PM, 1984, P NATL ACAD SCI-BIOL, V81, P5026, DOI 10.1073/pnas.81.16.5026; ICHINOSE M, 1990, BIOCHEM BIOPH RES CO, V172, P1086, DOI 10.1016/0006-291X(90)91558-A; ISHIHARA T, 1989, J BIOL CHEM, V264, P10193; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; LOPEZBOADO YS, 1994, BREAST CANCER RES TR, V29, P247, DOI 10.1007/BF00666478; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAY FEB, 1988, J BIOL CHEM, V263, P12901; MAZOUJIAN G, 1990, ANN NY ACAD SCI, V586, P188, DOI 10.1111/j.1749-6632.1990.tb17806.x; MIYAZAKI H, 1984, P NATL ACAD SCI-BIOL, V81, P5999, DOI 10.1073/pnas.81.19.5999; MONNE M, 1994, CANCER RES, V54, P6344; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MOORE SA, 1995, J MOL BIOL, V247, P466, DOI 10.1006/jmbi.1994.0154; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; PALS G, 1989, GENOMICS, V4, P137, DOI 10.1016/0888-7543(89)90292-9; POLIMENO L, 1994, DIGEST DIS SCI, V39, P635, DOI 10.1007/BF02088353; REDECKER B, 1991, DNA CELL BIOL, V10, P423, DOI 10.1089/dna.1991.10.423; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMLOFF IM, 1989, GASTROENTEROLOGY, V96, P586, DOI 10.1016/S0016-5085(89)80054-X; SANCHEZ LM, 1992, J BIOL CHEM, V267, P24725; SANCHEZ LM, 1992, CANCER RES, V52, P95; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SIMARD J, 1992, ENDOCRINOLOGY, V130, P1115, DOI 10.1210/en.130.3.1115; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; SOGAWA K, 1983, J BIOL CHEM, V258, P5306; TAGGART RT, 1989, J BIOL CHEM, V264, P375; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TSUKADA S, 1994, BIOCHEM BIOPH RES CO, V202, P1, DOI 10.1006/bbrc.1994.1885; VIZOSO F, 1995, J CLIN ONCOL, V13, P54, DOI 10.1200/JCO.1995.13.1.54; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; WU CW, 1994, DIGEST DIS SCI, V39, P2689, DOI 10.1007/BF02087711; YOUNG CYF, 1991, CANCER RES, V51, P3748; YU H, 1994, BREAST CANCER RES TR, V32, P291, DOI 10.1007/BF00666006; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	63	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15175	15181		10.1074/jbc.271.25.15175	http://dx.doi.org/10.1074/jbc.271.25.15175			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663058	hybrid			2022-12-25	WOS:A1996UT10600078
J	Fowlkes, JL; Serra, DM				Fowlkes, JL; Serra, DM			Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; POTENTIATION; MECHANISM; CELLS	Matrix metalloproteinase 3 cleaves insulin-like growth factor-binding protein 3 (IGFBP-3) into six fragments, four of which bind heparin-Sepharose (Fowlkes, J. L., Enghild, J. J., Suzuki, K., and Nagase, H. (1994) J. Biol. Chem. 269, 25742-25746). Sequence analysis of IGFBP-3 heparin-binding fragments shows that all fragments contain at least one of two highly basic, putative heparin-binding consensus sequences present in IGFBP-3. Epitope-specific antibodies generated against synthetic peptides containing these domains recognized IGFBP-3, yet were significantly inhibited from binding in the presence of heparin, demonstrating that these regions of IGFBP-3 contain functional heparin binding domains, IGFBP-3 peptides containing one of the two heparin-binding consensus sequences bound heparin in a solid phase binding assay in a dose-dependent and saturable manner. However, the IGFBP-3 peptide containing the heparin-binding consensus sequence (KK)-K-149-GHA(153) bound heparin with similar to 4-fold less affinity than the IGFBP-3 peptide containing the longer heparin-binding consensus sequence (219)YKKKQCRP(226). Examination of several well characterized glycosaminoglycans to inhibit the binding of heparin to both heparin-binding IGFBP-3 peptides revealed that the most potent inhibitors were heparin, heparan sulfate, and dermatan sulfate; chondroitin sulfate A and hyaluronic acid were intermediate in their inhibitory activities; and chondroitin sulfate C caused no inhibition, These studies identify and characterize the glycosaminoglycan-binding domains in IGFBP-3, providing a basis for the better understanding of IGFBP-3 glycosaminoglycan interactions at the cellular and extracellular interface.			Fowlkes, JL (corresponding author), DUKE UNIV, MED CTR, DEPT PEDIAT, DIV ENDOCRINOL, BOX 3080, DURHAM, NC 27710 USA.				NIDDK NIH HHS [DK02276] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002276] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; Bach LA, 1995, DIABETES REV, V3, P38; BAR RS, 1994, INT CONGR SER, V1056, P237; BOOTH BA, 1995, GROWTH REGULAT, V2, P1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P3259, DOI 10.1210/endo-129-6-3259; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FOWLKES JL, 1995, J BIOL CHEM, V270, P27481, DOI 10.1074/jbc.270.46.27481; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; HODGKINSON SC, 1994, J MOL ENDOCRINOL, V13, P105, DOI 10.1677/jme.0.0130105; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MCCUSKER RH, 1990, J CELL PHYSL, V144, P2444; OH YM, 1993, J BIOL CHEM, V268, P14964; Rechler Matthew M., 1995, P155; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SMITH EP, 1994, ENDOCRINOLOGY, V135, P359, DOI 10.1210/en.135.1.359; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; TRESSEL TJ, 1991, BIOCHEM BIOPH RES CO, V178, P625, DOI 10.1016/0006-291X(91)90154-Y; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; YU Q, 1995, BIOTECHNIQUES, V19, P122	31	58	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14676	14679		10.1074/jbc.271.25.14676	http://dx.doi.org/10.1074/jbc.271.25.14676			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663298	hybrid			2022-12-25	WOS:A1996UT10600008
J	Heding, A; Gill, R; Ogawa, Y; DeMeyts, P; Shymko, RM				Heding, A; Gill, R; Ogawa, Y; DeMeyts, P; Shymko, RM			Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; HUMAN-SERUM; B-DOMAIN; PURIFICATION; AFFINITY; RECEPTOR; COMPLEX; SUBUNIT; SURFACE; PLASMA	Most insulin-like growth factor (IGF) molecules in the circulation are found in a 150-kDa complex containing IGF-binding protein-3 (IGFBP-3) and an acid-labile subunit, which does not itself bind IGF, Affinities (K-d values) between 0.03 and 0.5 nM have been reported for IGF-I/IGFBP-3 binding, but no kinetic data are available, In this study we measured the high affinity binding of unlabeled IGFs and IGF analogues to recombinant unglycosylated IGFBP-3, using a BIAcore(TM) instrument (Pharmacia Biosensor AB), IGF-I binding showed fast association and slow non-first-order dissociation kinetics, and an equilibrium K-d of 0.23 nM. IGF-II had similar kinetics with slightly higher affinity. Analogues with mutations in the first 3 amino acids of the B-region (des(1-3) IGF-I and long IGF-I) showed 25 and 50 times lower affinity than IGF-I, Replacement of residues 28-37 by Gly-Gly-Gly-Gly or deletion of residues 29-41 in the C-region had little effect on the kinetic parameters, contrasting with the markedly impaired binding of these analogues to the IGF-I receptor, Swapping of the disulfide bridges in IGF-I and the C-region mutants decreased the affinity dramatically for IGFBP-3, primarily by decreasing the association rate. Insulin had approximately 1000 times lower affinity than IGF-I.	HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND; CELTRIX PHARMACEUT INC,SANTA CLARA,CA 95052	Novo Nordisk; Hagedorn Research Institute; University of London; Birkbeck University London			Gill, Raj/A-5410-2009	De Meyts, Pierre/0000-0001-6214-0824				[Anonymous], 1991, INSULIN LIKE GROWTH; BALLARD FJ, 1987, BIOCHEM BIOPH RES CO, V149, P398, DOI 10.1016/0006-291X(87)90380-9; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; CASCIERI MA, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P285; DEVROEDE MA, 1985, P NATL ACAD SCI USA, V82, P3010; ELLIOTT S, 1990, J PROTEIN CHEM, V9, P95, DOI 10.1007/BF01024990; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FORBES B, 1988, BIOCHEM BIOPH RES CO, V157, P196, DOI 10.1016/S0006-291X(88)80032-9; FURLANETTO RW, 1980, J CLIN ENDOCR METAB, V51, P12, DOI 10.1210/jcem-51-1-12; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; HEJNAES KR, 1992, PROTEIN ENG, V5, P797, DOI 10.1093/protein/5.8.797; HINTZ RL, 1981, J CLIN ENDOCR METAB, V53, P100, DOI 10.1210/jcem-53-1-100; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JOSHI S, 1985, BIOCHEMISTRY-US, V24, P4208, DOI 10.1021/bi00336a059; JOSHI S, 1985, BIOCHEM BIOPH RES CO, V133, P423, DOI 10.1016/0006-291X(85)90923-4; KAUFMANN U, 1977, J CLIN ENDOCR METAB, V44, P160, DOI 10.1210/jcem-44-1-160; LEROITH D, 1992, ANN INTERN MED, V116, P854, DOI 10.7326/0003-4819-116-10-854; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1994, CURR OPIN ENDOCRINOL, V1, P16; MENG H, 1988, J CHROMATOGR, V443, P183, DOI 10.1016/S0021-9673(00)94792-7; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; PRESS WH, 1986, NUMERICAL RECIPES AR; SOMMER A, 1993, GROWTH REGULAT, V3, P46; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; TRESSEL TJ, 1991, BIOCHEM BIOPH RES CO, V178, P625, DOI 10.1016/0006-291X(91)90154-Y; WHITE RM, 1981, J CLIN ENDOCR METAB, V53, P49, DOI 10.1210/jcem-53-1-49	31	55	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13948	13952		10.1074/jbc.271.24.13948	http://dx.doi.org/10.1074/jbc.271.24.13948			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662901	hybrid			2022-12-25	WOS:A1996UQ66000006
J	Hidari, KIPJ; Ichikawa, S; Fujita, T; Sakiyama, H; Hirabayashi, Y				Hidari, KIPJ; Ichikawa, S; Fujita, T; Sakiyama, H; Hirabayashi, Y			Complete removal of sphingolipids from the plasma membrane disrupts cell to substratum adhesion of mouse melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BALB/C 3T3 CELLS; MONOCLONAL-ANTIBODY; GANGLIOSIDE; MUTANT; MATRIX; GM3; GLYCOSPHINGOLIPIDS; BIOSYNTHESIS; FIBRONECTIN; EXPRESSION	GM-95, a mutant cell line derived from mouse melanoma MEB-4 cells, is deficient in glycosphingolipids (GSLs) due to the lack of ceramide glucosyltransferase-1 activity (Ichikawa, S., Nakajo, N., Sakiyama, H., and Hirabayashi, Y. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2703-2707). In this study, we examined the involvement of the complex sphingolipids in cell to substratum adhesion. Immunofluorescent and chemical analyses revealed that the complex sphingolipids were significantly concentrated in the detergent-insoluble substrate attachment matrix of both GM-95 and MEB-4 cells. In spite of the absence of GSLs, GM-95 cells retained the ability to adhere to extracellular matrix (ECM) proteins such as fibronectin, collagen, and laminin. When both GM-95 and MEB-4 cells were treated with neutral sphingomyelinase, GM-95 cells were rounded up and detached from all ECM proteins examined. In contrast, neither the morphology nor the adherence of MEB-4 cells was altered. Under this treatment, sphingomyelin (SM) became undetectable in both cells. A similar inhibition was observed upon pretreatment of cells with fumonisin B1 or ISP-1, both of which block the synthesis of ceramide, a common precursor of both GSLs and SM. Stable transfectants expressing GSLs, which were established by transfection of glucosyltransferase-1 cDNA into GM-95 cells, became resistant to neutral sphingomyelinase-mediated rounding up and detachment from ECM proteins. In conclusion, the complex sphingolipids play critical roles in cell to substratum adhesion, and the presence of either GSLs or SM is sufficient for the adhesion.	RIKEN,INST PHYS & CHEM RES,LB CELLULAR GLYCOBIOL,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; SETSUNAN UNIV,FAC PHARMACEUT SCI,HIRAKATA,OSAKA 57301,JAPAN; NATL INST RADIOL SCI,DIV PHYSIOL & PATHOL,CHIBA 260,JAPAN	RIKEN; Setsunan University; National Institutes for Quantum Science & Technology				Hirabayashi, Yoshio/0000-0002-5774-7354				BARLETTA E, 1993, BIOCHEM BIOPH RES CO, V192, P214, DOI 10.1006/bbrc.1993.1402; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GRIFFITHS SL, 1986, J CELL BIOL, V102, P469, DOI 10.1083/jcb.102.2.469; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANADA K, 1990, J BIOL CHEM, V265, P22137; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1994, J BIOL CHEM, V269, P315; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; ICHIKAWA S, 1996, IN PRESS P NAT AC SC; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MUGNAI G, 1984, BIOCHEM BIOPH RES CO, V125, P142, DOI 10.1016/S0006-291X(84)80346-0; NOZUE M, 1988, INT J CANCER, V42, P734, DOI 10.1002/ijc.2910420518; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; SAKIYAMA H, 1987, CELL STRUCT FUNCT, V12, P93, DOI 10.1247/csf.12.93; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TSURUOKA T, 1993, J BIOL CHEM, V268, P2211; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YAMADA KM, 1983, EXP CELL RES, V143, P295, DOI 10.1016/0014-4827(83)90054-X; ZHENG MZ, 1992, BIOCHEM BIOPH RES CO, V186, P1397, DOI 10.1016/S0006-291X(05)81561-X; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	33	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14636	14641		10.1074/jbc.271.24.14636	http://dx.doi.org/10.1074/jbc.271.24.14636			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662871	hybrid			2022-12-25	WOS:A1996UQ66000103
J	Jones, SL; Brown, EJ				Jones, SL; Brown, EJ			Fc gamma RII-mediated adhesion and phagocytosis induce L-plastin phosphorylation in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							65-KILODALTON PHOSPHOPROTEIN; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; IMMUNE-COMPLEXES; ACTIN; CALCIUM; ACTIVATION; RECEPTOR; FIMBRIN; PROTEIN	L-Plastin is a calcium-regulated actin bundling protein expressed in leukocytes and some transformed cells, which is phosphorylated on serine in response to several different leukocyte-activating stimuli. Adhesion to immune complexes induced L-plastin phosphorylation in neutrophils, as did phagocytosis of IgG-opsonized particles, but insoluble immune complexes in suspension were very inefficient activators of L-plastin phosphorylation. Neutrophils express two IgG Fc receptors, the transmembrane Fc gamma RII and the glycan phosphoinositol-linked Fc gamma RIIIB. Use of monoclonal antibodies that distinguished the two Fc receptors demonstrated that Fc gamma RII ligation was 100-fold more potent at signaling L-plastin phosphorylation than occupancy of Fc gamma RIIIB, Depletion of intracellular calcium did not affect Fc gamma RII-activated L-plastin phosphorylation, demonstrating that any potential regulation of plastin function by calcium did not affect its phosphorylation, Adhesion to immune complexes caused L-plastin to localize to podosomes, since it colocalized with actin to discrete, punctate Triton X-100-insoluble sites on the adherent neutrophil surface in a pattern indistinguishable from vinculin and alpha-actinin, Nonetheless, localization to podosomes was not required for L-plastin phosphorylation, since both neutrophils from a patient with leukocyte adhesion deficiency (CD18 deficiency) and neutrophils treated with anti-CD18 F(ab')a, which do not form podosomes upon adhesion to immune complexes, phosphorylated L-plastin normally, Indeed, L-plastin was normally phosphorylated in response to adhesion to immune complexes even when the actin cytoskeleton was disrupted with cytochalasin D. We conclude that efficient Fc gamma RII-mediated phosphorylation of L-plastin requires cell adhesion but does not require IgG-induced rearrangements of the actin cytoskeleton. These data suggest a model in which plastin phosphorylation and localization to the actin cytoskeleton can act as two distinct mechanisms regulating L-plastin functions in neutrophils adherent to immune complexes.	WASHINGTON UNIV,SCH MED,DIV INFECT DIS,ST LOUIS,MO 63110	Washington University (WUSTL)				jones, samuel/0000-0003-3040-8157	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035811, K11AI001275] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI35811, K11-AI01275] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; ADAMS AEM, 1995, MOL CELL BIOL, V15, P69, DOI 10.1128/MCB.15.1.69; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BLACKBURN WD, 1989, BIOCHEM BIOPH RES CO, V164, P983, DOI 10.1016/0006-291X(89)91766-X; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BRENNAN PJ, 1991, J IMMUNOL, V146, P4282; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CROCKETTTORABI E, 1990, J IMMUNOL, V145, P3026; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; EGGLETON P, 1991, BIOCHEM SOC T, V19, P1129, DOI 10.1042/bst0191129; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GAIDANO G, 1990, LEUKEMIA, V4, P682; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; Greenberg Steven, 1993, P941; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LIN CS, 1994, MOL CELL BIOL, V14, P2457, DOI 10.1128/MCB.14.4.2457; LIN CS, 1993, J BIOL CHEM, V268, P2781; LOONEY RJ, 1986, J EXP MED, V163, P826, DOI 10.1084/jem.163.4.826; MATSUSHIMA K, 1987, J IMMUNOL, V139, P3367; MATSUSHIMA K, 1988, BIOCHEMISTRY-US, V27, P3765, DOI 10.1021/bi00410a037; MESSIER JM, 1993, CELL MOTIL CYTOSKEL, V25, P223, DOI 10.1002/cm.970250303; NAMBA Y, 1992, J BIOCHEM-TOKYO, V112, P503, DOI 10.1093/oxfordjournals.jbchem.a123929; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PACAUD M, 1993, BIOCHEMISTRY-US, V32, P3448, DOI 10.1021/bi00064a031; ROMER LH, 1992, COLD SPRING HARB SYM, V57, P193, DOI 10.1101/SQB.1992.057.01.024; ROSALES C, 1992, J BIOL CHEM, V267, P1443; ROSALES C, 1994, P NATL ACAD SCI USA, V91, P3534, DOI 10.1073/pnas.91.9.3534; ROSALES C, 1992, J BIOL CHEM, V267, P5265; SHIBATA M, 1993, J LEUKOCYTE BIOL, V54, P1; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; SIGMOND S, 1972, EXP CELL RES, V73, P383; SOUTHWICK FS, 1989, BLOOD, V73, P1973; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZU Y, 1990, BIOCHEMISTRY-US, V29, P1055, DOI 10.1021/bi00456a030	43	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14623	14630		10.1074/jbc.271.24.14623	http://dx.doi.org/10.1074/jbc.271.24.14623			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663066	hybrid			2022-12-25	WOS:A1996UQ66000101
J	Lewin, TM; Webster, RE				Lewin, TM; Webster, RE			Membrane insertion characteristics of the various transmembrane domains of the Escherichia coli TolQ protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M13 COAT PROTEIN; PERIPLASMIC PROTEINS; PLASMA-MEMBRANE; SECA-PROTEIN; GENES; TOPOLOGY; EXPORT; TRANSLOCATION; LOCALIZATION; EXPRESSION	The Escherichia coli TolQ protein is a 230-amino acid integral cytoplasmic membrane protein required for the import of group A colicins, for infection by the filamentous phage, and for maintenance of the integrity of the bacterial envelope, TolQ is a polytopic protein with three membrane-spanning regions, The first membrane-spanning region has a 19-residue periplasmic NH2-terminal tail, while the second and third membrane-spanning segments are separated by a short 17-amino acid periplasmic loop. To study the membrane assembly of TolQ, fusions of different membrane-spanning regions were examined for their ability to insert in the absence of functional SecA or the membrane potential, Fusions containing the first membrane-spanning region plus the adjacent cytoplasmic domain and a construct containing the ''hairpin loop,'' formed by the second and third membrane-spanning regions, insert in the absence of functional SecA. The fusion containing the second and third membrane-spanning regions required the membrane potential for insertion while the first membrane-spanning region was able to insert even in the absence of a membrane potential, Taken together, these results suggest that insertion of intact TolQ is not dependent on the Sec system, but does require the membrane potential.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM07184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CAO GQ, 1994, J BIOL CHEM, V269, P26898; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FOGNINILEFEBVRE N, 1987, MOL GEN GENET, V209, P391, DOI 10.1007/BF00329670; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HORABIN JI, 1988, J BIOL CHEM, V263, P11575; HORABIN JI, 1986, J MOL BIOL, V188, P403, DOI 10.1016/0022-2836(86)90164-6; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; LAZZARONI JC, 1989, MOL GEN GENET, V218, P460, DOI 10.1007/BF00332410; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; MULLER MM, 1993, J BACTERIOL, V175, P6059, DOI 10.1128/JB.175.18.6059-6061.1993; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; SWIDERSKY UE, 1992, EUR J BIOCHEM, V207, P803, DOI 10.1111/j.1432-1033.1992.tb17111.x; VIANNEY A, 1994, J BACTERIOL, V176, P822, DOI 10.1128/jb.176.3.822-829.1994; VONHEIJNE G, 1994, FEBS LETT, V346, P69, DOI 10.1016/0014-5793(94)00296-7; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YAMATO I, 1992, J BIOCHEM-TOKYO, V111, P444, DOI 10.1093/oxfordjournals.jbchem.a123777; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529	34	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14143	14149		10.1074/jbc.271.24.14143	http://dx.doi.org/10.1074/jbc.271.24.14143			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662905	hybrid			2022-12-25	WOS:A1996UQ66000033
J	Matsuda, M; Ota, S; Tanimura, R; Nakamura, H; Matuoka, K; Takenawa, T; Nagashima, K; Kurata, T				Matsuda, M; Ota, S; Tanimura, R; Nakamura, H; Matuoka, K; Takenawa, T; Nagashima, K; Kurata, T			Interaction between the amino-terminal SH3 domain of CRK and its natural target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; PHOSPHOLIPASE-C; SIMILARITY; RECEPTOR; REGION; SRC	CRK is a human homolog of chichen v-Crk, which is an adaptor protein. The SH2 domain of CRK binds to several tyrosine-phosphorylated proteins, including the epidermal growth factor receptor, p130(Cas), She, and paxillin. The SH3 domain, in turn, binds to cytosolic proteins of 135-145, 160, 180, and 220 kDa. We screened expression libraries by Far Western blotting, using CRK SH3 as a probe, and identified partial cDNA sequences of four distinct proteins, including C3G, DOCK180, EPS15, and clone ST12. The consensus sequence of the CRK SH3 binding sites as deduced from their amino acid sequences was Pro(+3)-Pro(+2)-X(+1)-Leu(0)-Pro(-1)-X(-2)-Lys(-3). The interaction of the CRK SH3 domain with the DOCK180 peptide was examined with an optical biosensor, based on the principles of surface plasmon resonance. A low dissociation constant of the order of 10(-7) resulted from a high association rate constant (k(assoc) = 3 x 10(4)) and low dissociation rate constant (k(assoc) = 3 x 10(-3)). All CRK-binding proteins except clone ST12 also bound to another adaptor protein, Grb2. Mutational analysis revealed that glycine at position +1 of ST12 inhibited the binding to Grb2 while retaining the high affinity binding to CRK SH3. The result suggests that the amino acid at position +1 also contributes to the high affinity binding of the peptides to the SH3 domain of Grb2, but not to that of CRK.	HOKKAIDO UNIV,SCH MED,DEPT PATHOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; TOKYO METROPOLITAN INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	Hokkaido University; Tokyo Metropolitan Institute of Gerontology; University of Tokyo	Matsuda, M (corresponding author), NATL INST HLTH,DEPT PATHOL,SHINJUKU KU,1-23-1 TOYAMA,TOKYO 162,JAPAN.		Tanimura, Ryuji/GOH-0166-2022; Nakamura, Haruki/O-4028-2014	Tanimura, Ryuji/0000-0002-7865-5686; Matsuda, Michiyuki/0000-0002-5876-9969				BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CICCHETTI P, 1992, NATURE, V257, P803; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Harlow E., 1988, ANTIBODIES LAB MANUA, P27; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Ishino Masaho, 1994, Tumor Research, V29, P59; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI H, 1994, J BIOL CHEM, V269, P5489; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NATSUME T, 1994, J BIOL CHEM, V269, P31224; OGAWA S, 1994, ONCOGENE, V9, P1669; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SARASTE M, 1994, NAT STRUCT BIOL, V1, P835, DOI 10.1038/nsb1294-835; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YU HT, 1994, NAT STRUCT BIOL, V1, P417, DOI 10.1038/nsb0794-417; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	52	68	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14468	14472		10.1074/jbc.271.24.14468	http://dx.doi.org/10.1074/jbc.271.24.14468			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662907	hybrid			2022-12-25	WOS:A1996UQ66000078
J	Chillaron, J; Estevez, R; Mora, C; Wagner, CA; Suessbrich, H; Lang, F; Gelpi, JL; Testar, X; Busch, AE; Zorzano, A; Palacin, M				Chillaron, J; Estevez, R; Mora, C; Wagner, CA; Suessbrich, H; Lang, F; Gelpi, JL; Testar, X; Busch, AE; Zorzano, A; Palacin, M			Obligatory amino acid exchange via systems b(o,+)-like and y(+)L-like - A tertiary active transport mechanism for renal reabsorption of cystine and dibasic amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; PROXIMAL STRAIGHT TUBULES; RABBIT KIDNEY CORTEX; RAT-KIDNEY; EXPRESSION CLONING; HUMAN ERYTHROCYTES; HEAVY-CHAIN; LYSINE TRANSPORT; MESSENGER-RNA; HIGH-AFFINITY	Mutations in the rBAT gene cause type I cystinuria, a common inherited aminoaciduria of cystine and dibasic amino acids due to their defective renal and intestinal reabsorption (Calonge, M. J., Gasparini, P., Chillaron, J., Chillon, M., Gallucci, M., Rousaud, F., Zelante, L., Testar, X., Dallapiccola, B., Di Silverio, F., Barcelo, P., Estivill, X., Zorzano, A., Nunes, V., and Palacin, M. (1994) Not. Genet. 6, 420-426; Calonge, M. J., Volipini, V., Bisceglia, L., Rousaud, F., De Sanctis, L., Beccia, E., Zelante, L., Testar, X., Zorzano, A., Estivill, X., Gasparini, P., Nunes, V., and Palacin, M. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 9667-9671). One important question that remains to be clarified is how the apparently non-concentrative system b(o,+)-like, associated with rBAT expression, participates in the active renal reabsorption of these amino acids. Several studies have demonstrated exchange of amino acids induced by rBAT in Xenopus oocytes. Here we offer evidence that system b(o,+)-like is an obligatory amino acid exchanger in oocytes and in the ''renal proximal tubular'' cell line OK. System b(o,+)-like showed a 1:1 stoichiometry of exchange, and the hetero-exchange dibasic (inward) with neutral (outward) amino acids were favored in oocytes. Obligatory exchange of amino acids via system b(o,+)-like fully explained the amino acid-induced current in rBAT-injected oocytes. Exchange via system b(o,+)-like is coupled enough to ensure a specific accumulation of substrates until the complete replacement of the internal oocyte substrates. Due to structural and functional analogies of the cell surface antigen 4F2hc to rBAT, we tested for amino acid exchange via system y(+)L-like. 4F2hc-injected oocytes accumulated substrates to a level higher than CAT1-injected oocytes (i.e. oocytes expressing system y(+)) and showed exchange of amino acids with the substrate specificity of system y(+)L and L-leucine-induced outward currents in the absence of extracellular sodium. In contrast to L-arginine, system y(+)L-like did not mediate measurable L-leucine efflux from the oocyte. We propose a role of systems b(o,+)-like and y(+)L-like in the renal reabsorption of cystine and dibasic amino acids that is based on their active tertiary transport mechanism and on the apical and basolateral localization of rBAT and 4F2hc, respectively, in the epithelial cells of the proximal tubule of the nephron.	UNIV BARCELONA,FAC BIOL,DEPT BIOCHEM & MOLEC BIOL,BARCELONA 08028,SPAIN; UNIV TUBINGEN,INST PHYSIOL 1,D-72076 TUBINGEN,GERMANY	University of Barcelona; Eberhard Karls University of Tubingen			Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015; Mora, Conchi/A-8280-2010; Chillaron, Josep/ABF-7663-2021; Estevez, Raul/D-8610-2015; Gelpi, Josep Lluis/M-6401-2013	Mora, Conchi/0000-0002-5644-0537; Chillaron, Josep/0000-0003-3068-7598; Estevez, Raul/0000-0003-1579-650X; Gelpi, Josep Lluis/0000-0002-0566-7723; Palacin, Manuel/0000-0002-8670-293X				AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; ANGELO S, 1994, J MEMBRANE BIOL, V141, P183; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BIBER J, 1985, AM J PHYSIOL, V249, pC430, DOI 10.1152/ajpcell.1985.249.5.C430; BUSCH AE, 1994, J BIOL CHEM, V269, P25581; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P455; CALONGE MJ, 1995, HUM GENET, V95, P633; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; CHA S, 1968, J BIOL CHEM, V243, P820; CHEESEMAN C, 1992, AM J PHYSIOL, V263, pR482, DOI 10.1152/ajpregu.1992.263.3.R482; CHEESEMAN CI, 1983, J PHYSIOL-LONDON, V338, P87, DOI 10.1113/jphysiol.1983.sp014662; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; DEVES R, 1993, J PHYSIOL-LONDON, V468, P753, DOI 10.1113/jphysiol.1993.sp019799; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; ELENO N, 1994, J PHYSIOL-LONDON, V479, P291, DOI 10.1113/jphysiol.1994.sp020296; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GASPARINI P, 1995, AM J HUM GENET, V57, P781; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HEMLER ME, 1982, J IMMUNOL, V129, P623; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOYAMA H, 1978, IN VITRO CELL DEV B, V14, P239; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; Mora C, 1996, J BIOL CHEM, V271, P10569, DOI 10.1074/jbc.271.18.10569; MUNCK BG, 1969, BIOCHIM BIOPHYS ACTA, V183, P182, DOI 10.1016/0005-2736(69)90142-4; PALACIN M, 1994, J EXP BIOL, V196, P123; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; ROSENBERG LE, 1965, NEW ENGL J MED, V273, P1239, DOI 10.1056/NEJM196512022732303; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; SCHAFER JA, 1984, PFLUG ARCH EUR J PHY, V401, P143, DOI 10.1007/BF00583874; SEGAL S, 1995, METABOLIC MOL BASES, V3, P581; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TAYLOR MA, 1987, DEV BIOL, V124, P287, DOI 10.1016/0012-1606(87)90480-5; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; YAN N, 1992, P NATL ACAD SCI USA, V89, P9982, DOI 10.1073/pnas.89.21.9982	50	145	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17761	17770		10.1074/jbc.271.30.17761	http://dx.doi.org/10.1074/jbc.271.30.17761			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663357	Green Published, hybrid			2022-12-25	WOS:A1996UY93500029
J	Nara, T; Kawagishi, I; Nishiyama, S; Homma, M; Imae, Y				Nara, T; Kawagishi, I; Nishiyama, S; Homma, M; Imae, Y			Modulation of the thermosensing profile of the Escherichia coli aspartate receptor Tar by covalent modification of its methyl-accepting sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; SENSORY RECEPTOR; ETHYLENE-GLYCOL; GENE-PRODUCT; CHEMORECEPTOR; MUTANTS; COMPLEX; TSR	The Escherichia coli aspartate receptor Tar is involved in the thermotactic response, We have studied how its thermosensing function is affected by the modification of the four methyl-accepting residues (Gln(295), Glu(302), Gln(309), and Glu(491)), which play essential roles in adaptation, We found that the primary translational product of tar mediates a chemoresponse, but not a thermoresponse, and that Tar comes to function as a thermoreceptor, once Gln(295) or Gln(309) is deamidated. This is the first identification of a thermosensing-specific mutant form, suggesting that the methylation sites of Tar constitute at least a part of the region required for thermoreception, signaling, or both, We have also investigated the inverted thermoresponse mediated by Tar in the presence of aspartate, We found that, whereas the deamidated-and-unmethylated form functions as a warm receptor, eliciting a smooth-swimming signal upon increase of temperature, the heavily methylated form functions as a cold receptor, eliciting a smooth-swimming signal upon decrease of temperature, Thus, it is suggested that Tar exists in at least three distinct states, each of which allows it to function as a warm, cold, or null thermoreceptor, depending on the modification patterns of its methylation sites.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGANO 46401,JAPAN	Nagoya University								AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BURROWS GG, 1989, J BIOL CHEM, V264, P17309; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GOMI S, 1993, J BIOCHEM-TOKYO, V133, P208; GOMI S, 1994, OLFACTION TASTE, V9, P210; HAZELBAUER GL, 1990, SOC GENERAL MICROBIO, V46, P107; HEDBLOM ML, 1980, J BACTERIOL, V144, P1048, DOI 10.1128/JB.144.3.1048-1060.1980; IMAE Y, 1984, J BACTERIOL, V159, P368, DOI 10.1128/JB.159.1.368-374.1984; Imae Y., 1985, SENSING RESPONSE MIC, P73; IWAMA T, 1995, J BACTERIOL, V177, P2218, DOI 10.1128/jb.177.8.2218-2221.1995; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; KEHRY MR, 1982, J BIOL CHEM, V257, P378; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LEE L, 1988, J BACTERIOL, V170, P4769, DOI 10.1128/jb.170.10.4769-4774.1988; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MADDOCK JR, 1993, SCIENCE, V259, P1717; MAEDA K, 1979, P NATL ACAD SCI USA, V76, P91, DOI 10.1073/pnas.76.1.91; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MCCLEARY WR, 1993, J BACTERIOL, V175, P2793, DOI 10.1128/JB.175.10.2793-2798.1993; MIZUNO T, 1984, J BACTERIOL, V159, P360, DOI 10.1128/JB.159.1.360-367.1984; NARA T, 1991, J BACTERIOL, V173, P1120, DOI 10.1128/jb.173.3.1120-1124.1991; OOSAWA K, 1983, J BACTERIOL, V154, P104, DOI 10.1128/JB.154.1.104-112.1983; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; OOSAWA K, 1984, J BACTERIOL, V157, P576, DOI 10.1128/JB.157.2.576-581.1984; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHERRIS D, 1981, P NATL ACAD SCI-BIOL, V78, P6051, DOI 10.1073/pnas.78.10.6051; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988	45	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17932	17936		10.1074/jbc.271.30.17932	http://dx.doi.org/10.1074/jbc.271.30.17932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663384	hybrid			2022-12-25	WOS:A1996UY93500053
J	Surette, MG; Stock, JB				Surette, MG; Stock, JB			Role of alpha-helical coiled-coil interactions in receptor dimerization, signaling, and adaptation during bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; ASPARTATE RECEPTOR; KINASE-ACTIVITY; SALMONELLA-TYPHIMURIUM; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; CROSS-LINKING; CHEA PROTEIN	The aspartate receptor, Tar, is a member of a large family of signal transducing membrane receptors that interact with CheA and CheW proteins to mediate the chemotactic responses of bacteria, A highly conserved cytoplasmic region, the signaling domain, is flanked by two sequences, methylated helices 1 and 2 (MH1 and MH2), that are predicted to form alpha-helical coiled-coils, MH1 and MH2 contain glutamine and glutamate residues that are subject to deamidation, methylation, and demethylation. We show that the signaling domain is an independently folding unit that binds CheW, When expressed in vivo the signaling domain inhibits CheA kinase activity, but if MH1 or an unrelated leucine zipper coiled-coil sequence is attached to the signaling domain, CheA is activated, A construct that contains a leucine zipper fused to MH1-signaling domain-MH2 also activates the kinase, both in vivo and in vitro, and this activation is regulated by the level of glutamate modification, These findings support a model for receptor signaling where aspartate binding controls the relative orientation of receptor monomers to favor the formation of coiled-coils between MH1 and/or MH2 between subunits, Glutamate modification may stabilize these coiled-coils by reducing electrostatic repulsion between helices.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University					NIAID NIH HHS [AI20980] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; COPELAND RA, 1994, METHODS PROTEIN ANAL, P195; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GU J, 1994, BIOTECHNIQUES, V17, P257; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KAPLAN N, 1988, J BACTERIOL, V170, P5134, DOI 10.1128/jb.170.11.5134-5140.1988; KIM SH, 1994, PROTEIN SCI, V3, P159; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE GF, 1995, P NATL ACAD SCI USA, V92, P5416, DOI 10.1073/pnas.92.12.5416; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SEELEY SK, 1994, BIOPHYS J, V66, pA172; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK A, 1987, J BIOL CHEM, V262, P535; STOCK AM, 1987, J BACTERIOL, V169, P3301, DOI 10.1128/jb.169.7.3301-3311.1987; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WU ZN, 1994, PROTEIN ENG, V7, P1137, DOI 10.1093/protein/7.9.1137; YEH JI, 1993, J BIOL CHEM, V268, P9787	55	84	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17966	17973		10.1074/jbc.271.30.17966	http://dx.doi.org/10.1074/jbc.271.30.17966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663397	hybrid			2022-12-25	WOS:A1996UY93500059
J	Brady, WA; Kokoris, MS; Fitzgibbon, M; Black, ME				Brady, WA; Kokoris, MS; Fitzgibbon, M; Black, ME			Cloning, characterization, and modeling of mouse and human guanylate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR GENE; PROTEIN; PHOSPHORYLATION; MONOPHOSPHATE; SEQUENCE; HOMOLOG; PRODUCT; BRAIN; YEAST; GMP	Guanylate kinase catalyzes the phosphorylation of either GMP to GDP or dGMP to dGDP and is an essential enzyme in nucleotide metabolism pathways, Despite its involvement in antiviral drug activation in humans and in mouse model systems and as a target for chemotherapy, the human and mouse primary structures have never been elucidated, Full-length cDNA clones encoding enzymatically active guanylate kinase were isolated from mouse B-cell lymphoma and human peripheral blood lymphocyte cDNA libraries, Multiple tissue Northern blots demonstrated an mRNA species of approximately 1 kilobase for both mice and humans in all tissue types examined, The mouse cDNA is predicted to encode a 198-amino acid protein with a molecular mass of 21,904 daltons, The human cDNA is predicted to encode a 197-amino acid protein with a molecular mass of 21,696 daltons, These proteins share 88% sequence identity with each other and 52-54% identity with the yeast guanylate kinase. Molecular modeling using the yeast diffraction coordinates indicates a high degree of conservation within the active site and maintenance of the overall structural integrity, despite a lack of similarity along the periphery of the enzyme.	DARWIN MOLEC CORP,BOTHELL,WA 98021									Agarwal K C, 1978, Methods Enzymol, V51, P483; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BOEHME RE, 1984, J BIOL CHEM, V259, P2346; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALLAPICCOLA B, 1980, ANN GENET-PARIS, V23, P83; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; GAIDAROV IO, 1993, FEBS LETT, V335, P81, DOI 10.1016/0014-5793(93)80444-Y; GENTRY D, 1993, J BIOL CHEM, V268, P14316; Harlow E., 1988, ANTIBODIES LAB MANUA; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kawasaki E S, 1990, AMPLIFICATION RNA PC, P21; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KONRAD M, 1992, J BIOL CHEM, V267, P25652; MIECH RP, 1969, MOL PHARMACOL, V5, P30; MILLER WH, 1980, J BIOL CHEM, V255, P7204; Mueller Bettina M., 1995, Journal of Neuroscience, V15, P2354; NAVE JF, 1992, ARCH BIOCHEM BIOPHYS, V295, P253, DOI 10.1016/0003-9861(92)90515-X; PAPPU HR, 1988, FOCUS IDAHO, V11, P6; Sambrook J., 2002, MOL CLONING LAB MANU; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZSCHOCKE PD, 1993, EUR J BIOCHEM, V213, P263, DOI 10.1111/j.1432-1033.1993.tb17757.x	27	44	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16734	16740		10.1074/jbc.271.28.16734	http://dx.doi.org/10.1074/jbc.271.28.16734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663313	hybrid			2022-12-25	WOS:A1996UX12600050
J	Gao, BC; Eisenberg, E; Greene, L				Gao, BC; Eisenberg, E; Greene, L			Effect of constitutive 70-kDa heat shock protein polymerization on its interaction with protein substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE BIP; UNCOATING ATPASE; COATED VESICLES; CLATHRIN; DISSOCIATION; GRP78	Constitutive 70-kDa heat shock protein (hsc70) is a mixture of monomers and oligomers in ADP, while in ATP it is monomeric unless certain DnaJ homologs are present which induce hsc70 to form large polymers in an ATP-dependent reaction. A key question regarding polymerized hsc70 is whether it is able to bind protein substrates. Polymerized BiP, the hsc70 present in the endoplasmic reticulum, has been found to bind substrates in vitro although substrates appear to bind only to monomeric BiP in vivo. In this study, we investigated whether substrate binds to polymerized cytoplasmic hsc70 in vitro. Although both stoichiometric ATP and high concentrations of cytochrome c peptide monomerized hsc70, direct binding studies provided no evidence that cytochrome c peptide binds to polymerized hsc70. Furthermore, the time course of cytochrome c peptide and clathrin binding to hsc70 suggested that rather than binding to polymerized hsc70, they monomerized it by reducing free monomer, thereby shifting the monomer-polymer equilibrium toward monomer. We conclude that peptide and protein substrates bind at least an order of magnitude more weakly to polymerized hsc70 than to monomer, suggesting that polymerization of hsc70 in vivo, perhaps by DnaJ homologs, may store it in an inactive form.			Gao, BC (corresponding author), NHLBI,CELL BIOL LAB,NIH,BLDG 3,ROOM B1-22,3 CTR DR,MSC,BETHESDA,MD 20892, USA.							BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BROT N, 1994, P NATL ACAD SCI USA, V91, P12120, DOI 10.1073/pnas.91.25.12120; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CYR DM, 1992, J BIOL CHEM, V267, P20927; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAO BC, 1991, J BIOL CHEM, V266, P19565; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAO BC, 1995, BIOCHEMISTRY-US, V34, P11882, DOI 10.1021/bi00037a028; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; King C., 1995, Molecular Biology of the Cell, V6, p411A; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; TOLEDO H, 1993, P NATL ACAD SCI USA, V90, P2505, DOI 10.1073/pnas.90.6.2505; UNANUE ER, 1995, J BIOL CHEM, V270, P26670	25	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16792	16797		10.1074/jbc.271.28.16792	http://dx.doi.org/10.1074/jbc.271.28.16792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663341	hybrid			2022-12-25	WOS:A1996UX12600058
J	Heise, N; Raper, J; Buxbaum, LU; Peranovich, TMS; deAlmeida, MLC				Heise, N; Raper, J; Buxbaum, LU; Peranovich, TMS; deAlmeida, MLC			Identification of complete precursors for the glycosylphosphatidylinositol protein anchors of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; MEMBRANE ANCHOR; METACYCLIC TRYPOMASTIGOTES; PHOSPHOLIPASE-C; SACCHAROMYCES-CEREVISIAE; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; BRUCEI; PHOSPHATIDYLINOSITOL; BIOSYNTHESIS	The survival of Trypanosoma cruzi, the causative agent of Chagas' disease, depends vitally on proteins and glycoconjugates that mediate the parasite/host interaction. Since most of these molecules are attached to the membrane by glycosylphosphatidylinositol (GPI), alternative means of chemotherapeutic intervention might emerge from GPI biosynthesis studies. The structure of the major 1G7 antigen GPI has been fully characterized by us (Guther, M. L. S., Cardoso de Almeida, M. L., Yoshida, N., and Ferguson, M. A. J. (1992) J. Biol. Chem. 267, 6820-6828; Heise, N., Cardoso de Almeida, M. L., and Ferguson, M. A. J. (1995) Mel. Biochem. Parasitol. 70, 71-84), and based on its properties we now report the complete precursor glycolipids predicted to be transferred to the nascent protein. Migrating closely to Trypanosoma brucei glycolipid A on TLC, such species, named glycolipids A-like 1 and A-like 2, were labeled with tritiated palmitic acid, myo-inositol, glucosamine, and mannose, but surprisingly only the less polar glycolipid A-like 1 incorporated ethanolamine. The predicted products following nitrous acid deamination and digestion with phospholipases A(2), C, and D confirmed their GPI nature. Evidence that they may represent the anchor transferred to the 1G7 antigen came from the following analyses: (i) alpha-mannosidase treatments indicated that only one mannose was amenable to removal; (ii) their lipid moiety was identified as sn-l-alkyl-a-acylglycerol due to their sensitivity to phospholipase A(2) (PLA(2)), mild base and by direct high performance TLC analysis of the corresponding benzoylated diradylglycerol components; and (iii) both glycolipids incorporated H-3-fatty acid only in the sn-2- and not in the sn-l-alkyl position as previously found in the GPI of the mature 1G7 antigen. Based on the differential [H-3]ethanolamine incorporation pattern and the recent report that an aminoethylphosphonic acid (AEP) replaces ethanolamine phosphate (EtNH(2)-PO4) in the GPI in epimastigote sialoglycoproteins (Previato, J. O., Jones, C., Xavier, M. T., Wait, R., Travassos, L. R., Parodi, A. J., and Mendonca-Previato, L. (1995) J. Biol. Chem. 270, 7241-7250) it is proposed that glycolipid A-like 2 contains AEP and A-like 1 EtNH(2)-PO4. In the in vitro cell-free system both glycolipids were synthesized simultaneously and do not seem to bear a precursor/product relationship. Among the various components synthesized in vitro a glycolipid C-like corresponding to a form of glycolipid A-like 1 acylated on the inositol was also characterized. Phenylmethylsulfonyl fluoride, an inhibitor known to block the addition of ethanolamine phosphate in T. brucei but not in mammalian cells, also inhibits the synthesis of glycolipids A like and C-like in T. cruzi, indicating that the putative trypanosome EtNH(2)-PO4/AEP transferase(s) might represent a potential target for chemotherapy.	UNIV FED SAO PAULO, ESCOLA PAULISTA MED, DEPT MICROBIOL IMMUNOL & PARASITOL, BR-04023062 SAO PAULO, SP, BRAZIL; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Universidade Federal de Sao Paulo (UNIFESP); Johns Hopkins University			Heise, Norton/I-4098-2013	Heise, Norton/0000-0003-0154-7406; Raper, Jayne/0000-0002-8723-9748				ABUIN G, 1994, MEM I OSWALDO CRUZ, V89, P90; ADROHER FJ, 1988, CELL DIFFER DEV, V22, P165, DOI 10.1016/0045-6039(88)90029-2; ARAGUTH MF, 1988, PARASITE IMMUNOL, V10, P707, DOI 10.1111/j.1365-3024.1988.tb00256.x; ARAYA JE, 1994, MOL BIOCHEM PARASIT, V65, P161, DOI 10.1016/0166-6851(94)90124-4; BARRY RJ, 1988, BIOCHEM BIOPH RES CO, V153, P177, DOI 10.1016/S0006-291X(88)81205-1; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BERTELLI MSM, 1977, J PARASITOL, V63, P434, DOI 10.2307/3279994; BERTELLO LE, 1995, BIOCHEM J, V310, P255, DOI 10.1042/bj3100255; BLANK ML, 1984, J CHROMATOGR, V298, P473, DOI 10.1016/S0021-9673(01)92744-X; BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349; BUTIKOFER P, 1990, J BIOL CHEM, V265, P18983; BUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; Cardoso de Almeida M. Lucia, 1993, Biological Research, V26, P285; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; COUTO AS, 1993, EUR J BIOCHEM, V217, P597, DOI 10.1111/j.1432-1033.1993.tb18282.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEALMEIDA IC, 1994, BIOCHEM J, V304, P793; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DEALMEIDA MLC, 1988, BIOCHEM BIOPH RES CO, V150, P476; DELEDERKREMER RM, 1993, EUR J BIOCHEM, V218, P929, DOI 10.1111/j.1432-1033.1993.tb18449.x; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DOERING T L, 1990, Methods (Orlando), V1, P288, DOI 10.1016/S1046-2023(05)80330-5; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; Fernandes J. F., 1976, Revista do Instituto de Medicina Tropical de Sao Paulo, V18, P130; GOLGHER DB, 1993, MOL BIOCHEM PARASIT, V60, P249, DOI 10.1016/0166-6851(93)90136-L; GONCALVES MF, 1991, EXP PARASITOL, V72, P43, DOI 10.1016/0014-4894(91)90119-H; GONZALEZ J, 1991, INFECT IMMUN, V59, P863; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; GUTHER MLS, 1992, J BIOL CHEM, V267, P6820; HEISE N, 1994, BRAZ J MED BIOL RES, V27, P233; HEISE N, 1995, MOL BIOCHEM PARASIT, V70, P71, DOI 10.1016/0166-6851(95)00009-P; HEISE N, 1995, THESIS U FEDERAL SAO; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; Krettli A. U., 1984, Memorias do Instituto Oswaldo Cruz, V79, P157, DOI 10.1590/S0074-02761984000500027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1988, J BIOL CHEM, V263, P1970; PAN CT, 1971, J PROTOZOOL, V18, P556, DOI 10.1111/j.1550-7408.1971.tb03375.x; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; RAMIREZ MI, 1993, INFECT IMMUN, V61, P3636, DOI 10.1128/IAI.61.9.3636-3641.1993; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROSENBERRY TL, 1991, CELL BIOL INT REP, V15, P1133, DOI 10.1016/0309-1651(91)90060-V; RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1988, MOL BIOCHEM PARASIT, V29, P141, DOI 10.1016/0166-6851(88)90069-2; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; SINGH BN, 1994, J BIOL CHEM, V269, P21972; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; STAMBUK BU, 1994, BRAZ J MED BIOL RES, V27, P383; SULLIVAN JJ, 1982, T ROY SOC TROP MED H, V76, P300, DOI 10.1016/0035-9203(82)90173-0; TEIXEIRA MMG, 1986, MOL BIOCHEM PARASIT, V18, P271, DOI 10.1016/0166-6851(86)90085-X; WARD J, 1987, MOL BIOCHEM PARASIT, V23, P1, DOI 10.1016/0166-6851(87)90180-0; YOSHIDA N, 1983, INFECT IMMUN, V40, P836, DOI 10.1128/IAI.40.2.836-839.1983; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; ZINGALES B, 1985, CURR TOP MICROBIOL, V117, P129	70	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16877	16887		10.1074/jbc.271.28.16877	http://dx.doi.org/10.1074/jbc.271.28.16877			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663209	hybrid			2022-12-25	WOS:A1996UX12600070
J	Schrock, RD; Alberts, B				Schrock, RD; Alberts, B			Processivity of the gene 41 DNA helicase at the bacteriophage T4 DNA replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA PRIMER SYNTHESIS; LEADING-STRAND; PROTEINS; POLYMERASE; APPARATUS; TEMPLATE; SEQUENCE; INVITRO; STARTS; SYSTEM	The gene 41 protein is the DNA helicase associated with the bacteriophage T4 DNA replication fork. This protein is a major component of the primosome, being essential for coordinated leading and lagging strand DNA synthesis, Models suggest that such DNA helicases are loaded only onto DNA at origins of replication, and that they remain with the ensuing replication fork until replication is terminated. To test this idea, we have measured the extent of processivity of the 41 protein in the context of an in vitro DNA replication system composed of eight purified proteins (the gene 43, 44/62, 45, 32, 41, 59, and 61 proteins), After starting DNA replication in the presence of these proteins, we diluted the 41 helicase enough to prevent any association of new helicase molecules and analyzed the replication products, We measured an association half-life of 11 min, revealing that the 41 protein is processive enough to finish replicating the entire 169-kilobase T4 genome at the observed replication rate of similar to 400 nucleotides/s. This processivity of the 41 protein does not require the 59 protein, the protein that catalyzes 41 protein assembly onto 32 protein-covered single-stranded DNA, The stability we measure for the 41 protein as part of the replication fork is greater than estimated for it alone on single-stranded DNA, We suggest that the 41 protein interacts with the polymerase holoenzyme at the fork, both stabilizing the other protein components and being stabilized thereby.			Schrock, RD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024020, R37GM024020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1989, J BIOL CHEM, V264, P12220; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; HUANG CC, 1981, J BIOL CHEM, V256, P4087; KORNBERG A, 1992, DNA REPLICATION, P275; KREUZER KN, 1994, MOL BIOL BACTERIOPHA, P28; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Nossal Nancy G., 1994, P43; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; WERNER R, 1968, J MOL BIOL, V33, P679, DOI 10.1016/0022-2836(68)90313-6; WU CA, 1992, J BIOL CHEM, V267, P4030; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	30	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16678	16682		10.1074/jbc.271.28.16678	http://dx.doi.org/10.1074/jbc.271.28.16678			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663273	hybrid			2022-12-25	WOS:A1996UX12600042
J	Reaven, E; Tsai, L; Azhar, S				Reaven, E; Tsai, L; Azhar, S			Intracellular events in the ''selective'' transport of lipoprotein-derived cholesteryl esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; EGG PHOSPHATIDYLCHOLINE VESICLES; OVARY PLASMA-MEMBRANES; LUTEINIZED OVARY; INTERMEDIATE FILAMENTS; RICH LIPOPROTEINS; GOLGI-COMPLEX; ANIMAL-CELLS; OKADAIC ACID; BREFELDIN-A	The current study utilizes human, apoE-free high density lipoprotein reconstituted with a highly specific fluorescent-cholesteryl ester probe to define the initial steps and regulatory sites associated with the ''selective'' uptake and intracellular itinerary of lipoprotein-derived cholesteryl esters. Bt(2)cAMP-stimulated ovarian granulosa cells were used as the experimental model, and both morphological and biochemical fluorescence data were obtained. The data show that cholesteryl ester provided through the selective pathway is a process which begins with a temperature-independent transfer of cholesteryl ester to the cell's plasma membrane. Thereafter transfer of the lipid proceeds rapidly and accumulates prominently in a perinuclear region (presumed to be the Golgi/membrane sorting compartment) and in lipid storage droplets of the cells. The data suggest that lipid transfer proteins (or other small soluble proteins) are not required for the intracellular transport of the cholesteryl esters, nor is an intact Golgi complex or an intact cell cytoskeleton (although the transfer is less efficient in the presence of certain microtubule-disrupting agents). The intracellular transfer of the cholesteryl esters is also somewhat dependent on an energy source in that a glucose-deficient culture medium or a combination of metabolic inhibitors reduces the efficiency of the transfer. A protein-mediated event may be required for cholesteryl ester internalization from the plasma membrane, in that N-ethylmaleimide dramatically blocks the internalization phase of the selective uptake process. Taken together these data suggest that the selective pathway is a factor-dependent, energy-requiring cholesteryl ester transport system, in which lipoprotein-donated cholesteryl esters probably flow through vesicles or intracellular membrane sheets and their connections, rather than through the cell cytosol.	STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94304	Stanford University	Reaven, E (corresponding author), VET AFFAIRS PALO ALTO HLTH CARE SYST,GRECC 182B,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL033881, R01HL033881] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33881] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1988, J LIPID RES, V29, P869; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; AZHAR S, 1994, J LIPID RES, V35, P1161; BACALLAO R, 1994, J CELL SCI, V107, P3301; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN RE, 1992, BIOCHIM BIOPHYS ACTA, V1113, P375, DOI 10.1016/0304-4157(92)90007-W; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; DELAMATRE JG, 1991, J CELL PHYSIOL, V146, P18, DOI 10.1002/jcp.1041460104; DURHAM HD, 1983, MUSCLE NERVE, V6, P631, DOI 10.1002/mus.880060903; ECKERT BS, 1986, CELL MOTIL CYTOSKEL, V6, P15, DOI 10.1002/cm.970060104; ESPARISOGANDO A, 1994, AM J PHYSIOL, V267, pC166, DOI 10.1152/ajpcell.1994.267.1.C166; FEDER TJ, 1994, J CELL PHYSIOL, V158, P7, DOI 10.1002/jcp.1041580103; FIELDING CJ, 1995, BIOCHEMISTRY-US, V34, P14237, DOI 10.1021/bi00043a031; FURUCHI T, 1993, J BIOL CHEM, V268, P27345; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HAMILTON JA, 1983, J BIOL CHEM, V258, P2821; HAMILTON JA, 1982, J BIOL CHEM, V257, P7318; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; JACKLE S, 1993, HEPATOLOGY, V17, P455, DOI 10.1016/0270-9139(93)90058-U; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KHOO JC, 1995, J LIPID RES, V36, P593; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; LI QT, 1992, J LIPID RES, V33, P503; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOREAU P, 1994, BBA-REV BIOMEMBRANES, V1197, P257; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Pedersen R.C., 1988, BIOL CHOLESTEROL, P39; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REAVEN E, 1989, J LIPID RES, V30, P1551; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1988, ARTERIOSCLEROSIS, V8, P298, DOI 10.1161/01.ATV.8.3.298; REAVEN E, 1986, J CLIN INVEST, V77, P1971, DOI 10.1172/JCI112526; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; REAVEN E, 1990, J BIOL CHEM, V265, P19100; REAVEN EP, 1980, J CELL BIOL, V84, P28, DOI 10.1083/jcb.84.1.28; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; SHI XY, 1992, BIOCHEMISTRY-US, V31, P3230, DOI 10.1021/bi00127a026; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STONE DK, 1988, KIDNEY INT, V33, P767, DOI 10.1038/ki.1988.65; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; THYBERG J, 1992, J CELL SCI, V103, P1167; TOCANNE JF, 1994, PROG LIPID RES, V33, P203, DOI 10.1016/0163-7827(94)90027-2; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; UL M, 1995, TRENDS BIOCHEM SCI, V20, P303; URBANI L, 1990, J BIOL CHEM, V265, P1919; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; YAHARA I, 1982, J CELL BIOL, V92, P69, DOI 10.1083/jcb.92.1.69	81	99	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16208	16217		10.1074/jbc.271.27.16208	http://dx.doi.org/10.1074/jbc.271.27.16208			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663101	hybrid			2022-12-25	WOS:A1996UW35200053
J	Butikofer, P; Boschung, M; Brodbeck, U; Menon, AK				Butikofer, P; Boschung, M; Brodbeck, U; Menon, AK			Phosphatidylinositol hydrolysis by Trypanosoma brucei glycosylphosphatidylinositol phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; BACILLUS-CEREUS; CROSSREACTING DETERMINANTS; AFRICAN TRYPANOSOMES; MEMBRANE-PROTEINS; PURIFICATION; RELEASE; ANCHOR; GLYCAN; ANTIGENS	Detergent-solubilized glycosylphosphatidylinositol (GPI)-anchored structures can be cleaved by C-type phospholipases isolated from peanuts and bloodstream cells of the African trypanosome, Trypanosoma brucei. The two enzymes differ in their reported ability to hydrolyze phosphatidylinositol (PI); while the peanut enzyme readily hydrolyzes PI in vitro, the T. brucei enzyme was reported to be virtually inactive against PI and consequently named GPI-specific phospholipase C (GPI-PLC). In this paper, we describe experiments in which we reinvestigated the substrate specificity of T. brucei GPI-PLC by incubating the purified enzyme with Triton X-100/PI-mixed micelles and by studying PI hydrolysis. We found that PI hydrolysis occurred in a detergent-dependent fashion over the range of concentrations tested (5 mu M to 1 mM PI). At 5 mu M PI, hydrolysis was maximal at 0.005% Triton X-100, whereas at 1 mM PI, maximal hydrolysis required 0.05% Triton X-100. Hydrolysis of both PI and GPI was strongly affected by the presence of phospholipids. Endogenous PI was hydrolyzed during osmotic and detergent lysis of trypanosomes under conditions used to obtain quantitative hydrolysis of the GPI-anchored trypanosome variant surface glycoprotein. PI hydrolysis in the lysates was inhibited by sodium p-chloromercuriphenyIsulfonate but unaffected by EGTA, consistent with the proposal that hydrolysis is due to GPI-PLC. These results suggest that the function of T. brucei GPI-PLC may be to regulate PI as well as (or instead of) GPI levels.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Butikofer, P (corresponding author), UNIV BERN, INST BIOCHEM & MOLEC BIOL, BUHLSTR 28, CH-3012 BERN, SWITZERLAND.			Menon, Anant Kumar/0000-0001-6924-2698	NIAID NIH HHS [AI28858] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028858] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBET AF, 1978, P NATL ACAD SCI USA, V75, P1989, DOI 10.1073/pnas.75.4.1989; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAUNBRETON C, 1992, EXP PARASITOL, V74, P452, DOI 10.1016/0014-4894(92)90207-Q; BRODBECK U, 1994, BRAZ J MED BIOL RES, V27, P369; BRODBECK U, 1981, MEMBRANE PROTEINS LA, P85; BULOW R, 1989, J CELL SCI, V93, P233; BULOW R, 1986, J BIOL CHEM, V261, P1918; BUTIKOFER P, 1995, ANAL BIOCHEM, V229, P125, DOI 10.1006/abio.1995.1388; BUTIKOFER P, 1993, J BIOL CHEM, V268, P17794; BUTIKOFER P, 1990, J BIOL CHEM, V265, P16035; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARRINGTON M, 1991, CELL BIOL INT REP, V15, P1101, DOI 10.1016/0309-1651(91)90058-Q; CROSS GAM, 1979, NATURE, V277, P310, DOI 10.1038/277310a0; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; Field M. C., 1992, LIPID MODIFICATION P, P155; FOUCHIER F, 1990, BIOCHEM J, V269, P321, DOI 10.1042/bj2690321; FOX JA, 1987, P NATL ACAD SCI USA, V84, P2663, DOI 10.1073/pnas.84.9.2663; FOX JA, 1986, J BIOL CHEM, V261, P5767; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HENDERSON LE, 1979, ANAL BIOCHEM, V93, P153, DOI 10.1016/S0003-2697(79)80129-3; HERELD D, 1986, J BIOL CHEM, V261, P3813; HERELD D, 1988, POST TRANSLATIONAL M, P9; HIGGINS JA, 1989, BIOCHEM J, V259, P913, DOI 10.1042/bj2590913; HIROSE S, 1995, METHOD ENZYMOL, V250, P582; HOENER MC, 1992, EUR J BIOCHEM, V206, P747, DOI 10.1111/j.1432-1033.1992.tb16981.x; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; JACKSON DG, 1985, J BIOL CHEM, V260, P5179; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Low M G, 1981, Methods Enzymol, V71 Pt C, P741; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1986, TRENDS BIOCHEM SCI, V11, P212, DOI 10.1016/0968-0004(86)90009-5; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; PATNAIK PK, 1993, MOL BIOCHEM PARASIT, V58, P97, DOI 10.1016/0166-6851(93)90094-E; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SCHENKMAN S, 1988, MOL BIOCHEM PARASIT, V29, P141, DOI 10.1016/0166-6851(88)90069-2; STIEGER S, 1991, BIOCHIMIE, V73, P1179, DOI 10.1016/0300-9084(91)90002-I; TAKENAWA T, 1991, METHOD ENZYMOL, V197, P511; VIDUGIRIENE J, 1995, METHOD ENZYMOL, V250, P513; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WEBB H, 1994, BRAZ J MED BIOL RES, V27, P349; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZIEGELBAUER K, 1993, BIOCHEMISTRY-US, V32, P3737, DOI 10.1021/bi00065a028	58	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15533	15541						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663180	hybrid			2022-12-25	WOS:A1996UV29900037
J	Verkruyse, LA; Hofmann, SL				Verkruyse, LA; Hofmann, SL			Lysosomal targeting of palmitoyl-protein thioesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; INFANTILE TYPE; PURIFICATION; RECEPTOR; STORAGE	Palmitoyl-protein thioesterase is a newly described long chain fatty-acid hydrolase that removes fatty acyl groups from modified cysteines in proteins. We have recently identified palmitoyl-protein thioesterase as the defective enzyme in the recessive hereditary neurological degenerative disorder infantile neuronal ceroid Lipofuscinosis (Vesa, J., Hellsten, E., Verkruyse, L. A., Camp, L. A. Rapola, J., Santavuori, P., Hofmann, S. L., and Peltonen, L. (1995) Nature 376, 584-587). A defect in a lysosomal enzyme had been postulated for the disease, but until recently, the relevant defective lysosomal enzyme had not been identified. In this paper, we present evidence for the lysosomal localization of palmitoyl-protein thioesterase. We show that COS cells take up exogenously supplied palmitoyl-protein thioesterase intracellularly and that the cellular uptake is blocked by mannose 6-phosphate, a hallmark of lysosomal enzyme trafficking. The enzyme contains endoglycosidase H-sensitive oligosaccharides that contain phosphate groups. Furthermore, palmitoyl-protein thioesterase cosediments with lysosomal enzyme markers by Percoll density gradient centrifugation. Interestingly, the pH optimum for the enzyme is in the neutral range, a property shared by two other lysosomal enzymes that remove post-translational protein modifications. These findings suggest that palmitoyl-protein thioesterase is a lysosomal enzyme and that infantile neuronal ceroid lipofuscinosis is properly classified as a lysosomal storage disorder.	UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA061823] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong D, 1981, AGE PIGMENTS, P355; BUTOR C, 1995, J CELL SCI, V108, P2213; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; HALTIA M, 1973, J NEUROL SCI, V18, P269, DOI 10.1016/0022-510X(73)90076-2; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HIGA HH, 1989, J BIOL CHEM, V264, P19435; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; RAPOLA J, 1973, BRAIN, V96, P833, DOI 10.1093/brain/96.4.833; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SANTAVUORI P, 1974, DEV MED CHILD NEUROL, V16, P644; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAYAMA M, 1992, J MOL NEUROSCI, V3, P171, DOI 10.1007/BF03380135; TOLLERSRUD OK, 1989, BIOCHEM J, V260, P101, DOI 10.1042/bj2600101; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYYNELA J, 1993, FEBS LETT, V330, P8, DOI 10.1016/0014-5793(93)80908-D; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; WEDEGAERTNER P, 1994, FASEB J, V8, pA1430; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001	28	203	205	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15831	15836		10.1074/jbc.271.26.15831	http://dx.doi.org/10.1074/jbc.271.26.15831			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663305	hybrid			2022-12-25	WOS:A1996UV29900079
J	Rai, SS; Wolff, J				Rai, SS; Wolff, J			Localization of the vinblastine-binding site on beta-tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCA ALKALOIDS; MICROTUBULES INVITRO; TAXOL BINDS; COLCHICINE; PODOPHYLLOTOXIN; POLYMERIZATION; IDENTIFICATION; HYDROLYSIS	A fluorescent vinblastine derivative, vinblastine-4'-anthranilate, has been shown to inhibit polymerization of rat brain tubulin (IC50 = 4.8 mu M). Binding of the drug to tubulin increases fluorescence intensity, causes a small emission blue shift, and has a quantum yield of 0.037. Fluorescence increases as a function of drug concentration, with a high affinity site and an undetermined number of lower affinity sites. Photolabeling, by exciting the fluorescent drug-tubulin complex at the absorption maximum of anthranilate, yields a covalent adduct confined to beta-tubulin. Its formation is specific in that it is blocked by maytansine or vinblastine, Tryptic hydrolysis identifies a single fluorescent beta-peptide coinciding with residues 175-213. The interactions between various ligands at this central portion of beta-tubulin are discussed.	NIDDK,BIOCHEM PHARMACOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BENSCH KG, 1969, J CELL BIOL, V40, P95, DOI 10.1083/jcb.40.1.95; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; BHATTACHARYYA B, 1976, P NATL ACAD SCI USA, V73, P2375, DOI 10.1073/pnas.73.7.2375; BHATTACHARYYA B, 1977, FEBS LETT, V75, P159, DOI 10.1016/0014-5793(77)80075-6; BHATTACHARYYA B, 1975, ARCH BIOCHEM BIOPHYS, V167, P264, DOI 10.1016/0003-9861(75)90462-2; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; CORTESE F, 1977, J BIOL CHEM, V252, P1134; DAVIDPFEUTY T, 1979, J BIOL CHEM, V254, P1696; Dustin P., 1984, MICROTUBULES; GARLAND D, 1975, ANN NY ACAD SCI, V253, P232, DOI 10.1111/j.1749-6632.1975.tb19202.x; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; Hamel E., 2018, MICROTUBULE PROTEINS, P89, DOI [10.1201/9781351074643-4, DOI 10.1201/9781351074643-4]; HIMES RH, 1991, PHARMACOL THERAPEUT, V51, P257, DOI 10.1016/0163-7258(91)90081-V; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; KRALOVIC RC, 1977, EXP CELL RES, V106, P205, DOI 10.1016/0014-4827(77)90257-9; LIN CM, 1981, J BIOL CHEM, V256, P9242; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MANDELBAUMSHAVIT F, 1976, BIOCHEM BIOPH RES CO, V72, P47, DOI 10.1016/0006-291X(76)90958-X; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MAS MT, 1985, BIOCHEMISTRY-US, V24, P1634, DOI 10.1021/bi00328a011; MORGAN JL, 1983, J BIOL CHEM, V258, P3127; NASIOULAS G, 1990, EUR J BIOCHEM, V192, P69, DOI 10.1111/j.1432-1033.1990.tb19196.x; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; PFEFFER TA, 1976, J CELL BIOL, V69, P599, DOI 10.1083/jcb.69.3.599; PRAKASH V, 1992, ARCH BIOCHEM BIOPHYS, V295, P137, DOI 10.1016/0003-9861(92)90499-M; RAI SS, 1993, ARCH BIOCHEM BIOPHYS, V306, P133, DOI 10.1006/abbi.1993.1490; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; SACKETT DL, 1995, BIOCHEMISTRY-US, V34, P7010, DOI 10.1021/bi00021a012; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; SACKETT DL, 1992, PROTEIN EXPRES PURIF, V2, P390; SAFA AR, 1987, BIOCHEMISTRY-US, V26, P97, DOI 10.1021/bi00375a014; SAWADA T, 1993, BIOCHEM PHARMACOL, V45, P1387; SENGUPTA S, 1995, BIOCHEMISTRY-US, V34, P11889, DOI 10.1021/bi00037a029; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; WARFIELD RK, 1974, SCIENCE, V186, P1219, DOI 10.1126/science.186.4170.1219; WILSON L, 1982, J MOL BIOL, V159, P125, DOI 10.1016/0022-2836(82)90035-3; WILSON L, 1970, BIOCHEMISTRY-US, V9, P4999, DOI 10.1021/bi00827a026; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820	42	152	162	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14707	14711		10.1074/jbc.271.25.14707	http://dx.doi.org/10.1074/jbc.271.25.14707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663038	hybrid			2022-12-25	WOS:A1996UT10600013
J	Zhou, DJ; Clarke, P; Wang, JF; Chen, SA				Zhou, DJ; Clarke, P; Wang, JF; Chen, SA			Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P450 GENE-EXPRESSION; TISSUE-SPECIFIC EXPRESSION; MAMMALIAN-CELLS; TUMOR TISSUES; GROWTH; ESTROGEN; ADENOSINE-3',5'-MONOPHOSPHATE; TRANSCRIPTION; ELEMENTS; BINDING	Aromatase, a cytochrome P450, catalyzes three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogens, In this study, the regulatory properties of a 696-base pair region, that contains the promoter II and is situated immediately upstream of exon II of the human aromatase gene, were investigated, Chloramphenicol acetyltransferase (CAT) functional studies with DNA segments derived from this genomic region and primer extension analysis revealed the presence of a second promoter which is functional in adipose stromal cells and in breast cancer cells. Detailed DNase-l footprinting analysis, DNA mobility shift assays, and CAT functional studies of this genomic region were performed and led to the identification of a segment (B1) that could act as a promoter (probably promoter 1.3) in adipose stromal and breast cancer cells, The study revealed further that the B1 region could be divided into two domains which were designated RE1 and RE2, RE1 was found to have the promoter activity, and RE2 was found to regulate the promoter activity of RE1, but in different manners in MCF-7 cells (as an example of breast cancer cells) and in adipose stromal cells. RE2 was found to function as a positive regulatory element in MCF-7 cells and as a negative regulatory element in adipose stromal cells, respectively. DNA mobility shift and W-cross-linking experiments with BrUrd-substituted B1 fragment and nuclear extracts isolated from two types of cells were performed, The experiments identified DNA-bound proteins with molecular masses around 50 kDa. These findings serve as the basis for further examination of the regulatory mechanism of aromatase expression in human breast cancer and adipose stromal cells.	BECKMAN RES INST CITY HOPE,DIV IMMUNOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NCI NIH HHS [CA 33572, CA 44735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA044735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLOW HL, 1982, CANCER RES, V42, P3382; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; JAMES V H T, 1987, Steroids, V50, P269, DOI 10.1016/0039-128X(83)90077-6; KILLINGER D W, 1987, Steroids, V50, P61, DOI 10.1016/0039-128X(83)90062-4; KINGSTON RE, 1992, CURRENT PROTOCOLS MO, V1; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KITAWAKI J, 1992, J STEROID BIOCHEM, V42, P267, DOI 10.1016/0960-0760(92)90129-7; LIPPMAN ME, 1986, J STEROID BIOCHEM, V24, P147, DOI 10.1016/0022-4731(86)90044-0; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; Maxam A M, 1980, Methods Enzymol, V65, P499; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MENDELSON CR, 1986, ENDOCRINOLOGY, V118, P968, DOI 10.1210/endo-118-3-968; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; REED MJ, 1989, INT J CANCER, V44, P233, DOI 10.1002/ijc.2910440208; REED MJ, 1994, BREAST CANCER RES TR, V30, P7, DOI 10.1007/BF00682737; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P705; SANTNER SJ, 1993, J STEROID BIOCHEM, V44, P611, DOI 10.1016/0960-0760(93)90267-Z; SELDEN RF, 1991, CURRENT PROTOCOLS MO; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TODA K, 1994, MOL ENDOCRINOL, V8, P210, DOI 10.1210/me.8.2.210; TODA K, 1994, J BIOL CHEM, V269, P8099; WANG JF, 1992, MOL ENDOCRINOL, V6, P1479, DOI 10.1210/me.6.9.1479; YUE W, 1994, CANCER RES, V54, P5092; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340; ZHOU D, 1990, CANCER RES, V50, P6949	35	42	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15194	15202		10.1074/jbc.271.25.15194	http://dx.doi.org/10.1074/jbc.271.25.15194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662988	Green Published			2022-12-25	WOS:A1996UT10600081
J	Chen, PF; Tsai, AL; Berka, V; Wu, KK				Chen, PF; Tsai, AL; Berka, V; Wu, KK			Endothelial nitric-oxide synthase - Evidence for bidomain structure and successful reconstitution of catalytic activity from two separate domains generated by a baculovirus expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; PURIFICATION; BRAIN; HEME; FLAVOPROTEIN; HEMOPROTEIN; ENZYME; CYTOCHROME-P-450BM-3; IDENTIFICATION; CALMODULIN	A baculovirus system was used to express the oxygenase and reductase domains of human endothelial nitric-oxide synthase (ecNOS) as distinct proteins. The oxygenase domain (residues 1-491) was expressed using a vector containing a His(6) tag at the N terminus. The purified oxygenase domain had an apparent molecular mass of similar to 54 kDa, and retained the ability to bind L-arginine and form the ferrous CO complex. The purified reductase domain (residues 492-1244) had an apparent molecular mass of similar to 82 kDa and retained the ability to catalyze NADPH-dependent cytochrome c reduction, which was enhanced 10-fold by the presence of Ca2+/calmodulin. Both purified domains exhibited immunoreactivity to rabbit anti-ecNOS IgG. The NOS activity was successfully reconstituted by mixing the two domains. These results demonstrate for the first time that the two domains of ecNOS are catalytically intact and can be reconstituted in vitro.	UNIV TEXAS, HLTH SCI CTR, VASC BIOL RES CTR, HOUSTON, TX 77030 USA; UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, DIV HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Wu, Kenneth Kun-Yu/B-1070-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50675] Funding Source: Medline; NIGMS NIH HHS [GM-44911] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CULLEN BR, 1987, METHOD ENZYMOL, V152, P8125; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3683; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; REIF DW, 1995, ARCH BIOCHEM BIOPHYS, V320, P170, DOI 10.1006/abbi.1995.1356; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL REALT AR, V65, P287; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	42	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14631	14635		10.1074/jbc.271.24.14631	http://dx.doi.org/10.1074/jbc.271.24.14631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663033	hybrid			2022-12-25	WOS:A1996UQ66000102
J	Coustry, F; Maity, SN; Sinha, S; deCrombrugghe, B				Coustry, F; Maity, SN; Sinha, S; deCrombrugghe, B			The transcriptional activity of the CCAAT-binding factor CBF is mediated by two distinct activation domains, one in the CBF-B subunit and the other in the CBF-C subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SEQUENCE IDENTITY; COLLAGEN PROMOTER; DNA-BINDING; YEAST HAP2; PROTEINS; COMPLEX; CELLS	CBF-A, CBF-B, and CBF-C together form the heterotrimeric mammalian CCAAT-binding factor, CBF, which binds to DNA to form a CBF-DNA complex. Here we examined the transcription activation function of CBF in an in vitro reconstituted system using the three purified recombinant CBF subunits expressed in Escherichia coli, Two of the subunits, CBF-A and CBF-C, were coexpressed and purified as a CBF-A/CBF-C complex. Addition of the three wild-type recombinant CBF subunits to EL4 cell nuclear extracts depleted of CBF stimulated transcription 5-20-fold from pro alpha 2(1) collagen promoters and 10-fold from the Rous sarcoma virus long terminal repeat, Two CBF deletion mutants, one containing full-length CBF-A and CBF-C and a CBF-B lacking the NH2-terminal residues 1-224, and the other containing full- length CBF-A and CBF-B and a CBF-C lacking the COOH-terminal residues 114-309, also stimulated transcription from these promoters, but the level of activation was reduced to half that obtained with the full-length CBF subunits, In contrast, a CBF deletion mutant protein containing full-length CBF-A and deleted forms of both CBF-B and CBF-C showed very little transcription activation from these promoters, Hence, this study demonstrates that the heterotrimeric CBF protein consists of two transcription activation domains, one present in CBF-B and the other in CBF-C, and that the two domains act additively in the in vitro assay, The activation domains of both CBF-B and CBF-C, which are rich in glutamine and hydrophobic residues, showed amino acid sequence similarities with each other and with the glutamine-rich activation domain of transcription factor Sp1.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center				Maity, Sankar/0000-0002-2387-6545	NATIONAL CANCER INSTITUTE [R01CA049515, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043660] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672-21, CA 49515] Funding Source: Medline; NIAMS NIH HHS [AR 43660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; HAHN S, 1988, SCIENCE, V240, P317, DOI 10.1126/science.2832951; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; LIWEBER M, 1994, J IMMUNOL, V153, P4122; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MUDRYJ M, 1988, NUCLEIC ACIDS RES, V16, P7513, DOI 10.1093/nar/16.15.7513; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; ROY B, 1995, MOL CELL BIOL, V15, P2263; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x	32	69	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14485	14491		10.1074/jbc.271.24.14485	http://dx.doi.org/10.1074/jbc.271.24.14485			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662945	hybrid			2022-12-25	WOS:A1996UQ66000080
J	Harte, MT; Hildebrand, JD; Burnham, MR; Bouton, AH; Parsons, JT				Harte, MT; Hildebrand, JD; Burnham, MR; Bouton, AH; Parsons, JT			p130(Cas), a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; CELL-ADHESION; PHOSPHORYLATION; PP125(FAK); TRANSFORMATION; IDENTIFICATION; CYTOSKELETON; EXPRESSION; PP125FAK	p130(Cas) (crk associated substrate) has the structural characteristics of an adapter protein, containing multiple consensus SH2 binding sites, an SH3 domain, and a proline-rich domain, The structure of p130(Cas) suggests that it may act to provide a framework for protein-protein interactions; however, as yet, its functional role in cells is unknown, In this report we show that p130(Cas) is localized to focal adhesions, We demonstrate that p130(Cas) associates both in, vitro and in vive with pp125(FAK) (focal adhesion kinase), a kinase implicated in signaling by the integrin family of cell adhesion receptors, p130(Cas) also associates with pp41/43(FRNK) (ppl25(FAK)-related non-kinase), an autonomously expressed form of pp125(FAK) composed of only the C-terminal noncatalytic domain, We show that the association of p130(Cas) with pp125(Fak) and pp41/43(FRNK) is direct, and is mediated by the binding of the SH3 domain of p130(Cas) to a proline-rich sequence present in both the C terminus of pp125(FAK) and in pp41/43(FRNK). In agreement with recent studies we show that p130(Cas) is tyrosine-phosphorylated upon integrin mediated cell adhesion,The association of p130(Cas) with pp125(FAK), a kinase which is activated upon cell adhesion, is likely to be functionally important in integrin mediated signal transduction.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R37CA029243, R01CA029243] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40042, CA 29243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BURNHAM MR, 1996, IN PRESS ONCOGENE, V12; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HILDEBRAND JD, 1996, IN PRESS MOL CELL BI, V16; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Ishino M, 1995, ONCOGENE, V11, P2331; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WOODS A, 1992, J CELL SCI, V101, P277; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	43	314	317	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13649	13655		10.1074/jbc.271.23.13649	http://dx.doi.org/10.1074/jbc.271.23.13649			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662921	hybrid			2022-12-25	WOS:A1996UP38500053
J	Ishibashi, S; Schwarz, M; Frykman, PK; Herz, J; Russell, DW				Ishibashi, S; Schwarz, M; Frykman, PK; Herz, J; Russell, DW			Disruption of cholesterol 7 alpha-hydroxylase gene in mice .1. Postnatal lethality reversed by bile acid and vitamin supplementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; BIOSYNTHESIS; HEPATITIS; MUTATIONS; ENZYME	Mice deficient in cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme of bile acid biosynthesis, were constructed by targeted disruption of the Cyp7 gene. The introduced mutation removed exons 3-5 of the gene and gave rise to a null allele that encoded no immunoreactive or enzymatically active protein. Heterozygous carriers of the disrupted gene (Cyp7(+/-)) were phenotypically normal. Homozygous animals (Cyp7(-/-)) appeared normal at birth, but died within the first 18 days of life. Approximately 40% of the animals died between postnatal days 1 and 4 and 45% between days 11 and 18. The addition of vitamins to the water of nursing mothers prevented deaths in the early period, whereas the addition of cholic acid to chow prevented deaths in the later period. Newborn Cyp7(-/-) mice whose mothers were maintained on unsupplemented chow failed to gain weight at a normal rate and developed oily coats, hyperkeratosis, and apparent vision defects. These symptoms waned at 3 weeks of life, and their disappearance was accompanied by a marked increase in survival. In the accompanying study, the induction of an alternate pathway of bile acid biosynthesis is shown to underlie this unusual time course (Schwarz, M., Lund, E. G., Setchell, K. D. R., Kayden, H. J., Zerwekh, J. E., Bjorkhem, I., Herz, J., and Russell, D. W. (1996) J. Biol. Chem. 271, 18024-18031). We conclude that cholesterol 7 alpha hydroxylase is an essential enzyme for normal post natal development.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Russell, David/0000-0002-0277-403X	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Bjorkhem I., 1995, METABOLIC MOL BASES, P2073; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CLAYTON PT, 1987, J CLIN INVEST, V79, P1031, DOI 10.1172/JCI112915; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DARBY WJ, 1945, P SOC EXP BIOL MED, V60, P259, DOI 10.3181/00379727-60-15154P; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HOLMAN R. T., 1968, Progress in the Chemistry of Fats and Other Lipids, V9, P275; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Jones James H., 1945, JOUR NUTRITION, V29, P127; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SETCHELL KDR, 1988, J CLIN INVEST, V82, P2148, DOI 10.1172/JCI113837; TURLEY SD, 1982, LIVER BIOL PATHOBIOL, P467; TZUNG KW, 1994, GENOMICS, V21, P244, DOI 10.1006/geno.1994.1250; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WONG MH, 1994, J BIOL CHEM, V269, P1340; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365	19	181	186	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18017	18023		10.1074/jbc.271.30.18017	http://dx.doi.org/10.1074/jbc.271.30.18017			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663429	Green Submitted, hybrid, Green Accepted			2022-12-25	WOS:A1996UY93500066
J	vonDippe, P; Amoui, M; Stellwagen, RH; Levy, D				vonDippe, P; Amoui, M; Stellwagen, RH; Levy, D			The functional expression of sodium-dependent bile acid transport in Madin-Darby canine kidney cells transfected with the cDNA for microsomal epoxide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; COTRANSPORT SYSTEM; PLASMA-MEMBRANES; LIVER; PROTEIN; TAUROCHOLATE; NA+; OXIDATION; DNA	Previous studies have suggested that the enzyme microsomal epoxide hydrolase (mEH) is able to mediate sodium-dependent transport of bile acids such as taurocholate into hepatocytes (von Dippe, P,, Amoui, M,, Alves, C,, and Levy, D, (1993) Am, J, Physiol, 264, G528-G534), In order to characterize directly the putative transport properties of the enzyme, a pCB6 vector containing the cDNA for this protein (pCB6-mEH) was transfected into Madin-Darby canine kidney (MDCK) cells, and stable transformants were isolated that could express mEH at levels comparable with the levels expressed in hepatocytes. Sodium-dependent transport of taurocholate was shown to be dependent on the expression of mEH and to be inhibited by the bile acid transport inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), as well as by other bile acids, Kinetic analysis of this system indicated a K-m of 26.3 mu M and a V-max of 117 pmol/mg protein/min, The K-m value is essentially the same as that observed in intact hepatocytes. The transfected MDCK cells also exhibited sodium-dependent transport of cholate at levels 150% of taurocholate in contrast to hepatocytes where cholate transport is only 30% of taurocholate levels, suggesting that total hepatocyte bile acid transport is a function of multiple transport systems with different substrate specificities, where mEH preferentially transports cholate, This hypothesis is further supported by the observation that a monoclonal antibody that partially protects (26%) taurocholate transport from inhibition by DIDS in hepatocytes provides almost complete protection (88%) from DIDS inhibition of hepatocyte cholate transport, suggesting that taurocholate is also taken up by an alternative system not recognized by this antibody, Additional support for this concept is provided by the observation that the taurocholate transport system is almost completely protected (92%) from DIDS inhibition by this antibody in MDCK cells that express mEH as the only bile acid transporter, These results demonstrate that mEH is expressed on the surface of hepatocytes as well as on transfected MDCK cells and is able to mediate sodium-dependent transport of taurocholate and cholate.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVES C, 1993, J BIOL CHEM, V268, P20148; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; ANANTHANARAYANAN M, 1991, AM J PHYSIOL, V261, pG810, DOI 10.1152/ajpgi.1991.261.5.G810; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; BOYER JL, 1994, AM J PHYSIOL, V266, pG382, DOI 10.1152/ajpgi.1994.266.3.G382; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HAGENBUCH B, 1994, CELL PHYSIOL BIOCHEM, V4, P198, DOI 10.1159/000154726; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HARDIKAR W, 1995, J BIOL CHEM, V270, P20841, DOI 10.1074/jbc.270.35.20841; HONSCHA W, 1995, BIOCHEM J, V311, P975, DOI 10.1042/bj3110975; HONSCHA W, 1993, EUR J PHARM-MOLEC PH, V246, P227, DOI 10.1016/0922-4106(93)90035-8; HORSEFIELD BP, 1992, BIOCHEM PHARMACOL, V44, P815, DOI 10.1016/0006-2952(92)90420-N; KHANG JT, 1991, J BIOL CHEM, V266, P18224; KOHLI KK, 1990, J CELL PHYSIOL, V142, P194, DOI 10.1002/jcp.1041420124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEPER J, 1990, HEPATOLOGY, V11, P850, DOI 10.1002/hep.1840110521; PETZINGER E, 1994, REV PHYSIOL BIOCH P, V123, P47, DOI 10.1007/BFb0030903; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; ROBIN MA, 1995, GASTROENTEROLOGY, V108, P1110, DOI 10.1016/0016-5085(95)90210-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SKACH WR, 1993, J BIOL CHEM, V268, P6903; STASIECKI P, 1980, EUR J CELL BIOL, V21, P79; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; STOMING TA, 1974, CANCER RES, V34, P2810; SUCHY FJ, 1982, PEDIATR RES, V16, P282, DOI 10.1203/00006450-198204000-00007; Tavoloni N., 1993, HEPATIC TRANSPORT BI; THOMAS H, 1990, PRINCIPLES MECH BIOL, P278; VONDIPPE P, 1993, AM J PHYSIOL, V264, pG528, DOI 10.1152/ajpgi.1993.264.3.G528; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; VONDIPPE P, 1983, J BIOL CHEM, V258, P8890; VONDIPPE P, 1990, J BIOL CHEM, V265, P5942; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; WIXTROM RN, 1985, BIOCH PHARM TOXICOLO, V1, P1; WU DF, 1992, HEPATOLOGY, V15, P515, DOI 10.1002/hep.1840150326; YAMAZAKI M, 1993, AM J PHYSIOL, V264, pG693, DOI 10.1152/ajpgi.1993.264.4.G693; ZAHLTEN RN, 1973, P NATL ACAD SCI USA, V70, P3213, DOI 10.1073/pnas.70.11.3213; ZIEGLER K, 1989, BIOCHIM BIOPHYS ACTA, V980, P161, DOI 10.1016/0005-2736(89)90395-7; [No title captured]	44	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18176	18180		10.1074/jbc.271.30.18176	http://dx.doi.org/10.1074/jbc.271.30.18176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663355	hybrid			2022-12-25	WOS:A1996UY93500088
J	Doi, T; Fakler, B; Schultz, JH; Schulte, U; Brandle, U; Weidemann, S; Zenner, HP; Lang, F; Ruppersberg, JP				Doi, T; Fakler, B; Schultz, JH; Schulte, U; Brandle, U; Weidemann, S; Zenner, HP; Lang, F; Ruppersberg, JP			Extracellular K+ and intracellular pH allosterically regulate renal K(ir)1.1 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNEL; INWARD-RECTIFIER; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; RAT-BRAIN; RECTIFICATION; MODULATION; MECHANISM; TUBULE; FAMILY	The channels that control K+ homeostasis by mediating K+ secretion across the apical membrane of renal tubular cells have recently been cloned and designated ROMK1, -2, and -3. Native apical K+ channels are indirectly regulated by the K+ concentration at the basolateral membrane through a cascade of intracellular second messengers. It is shown here that ROMK1 (K(ir)1.1) channels are also directly regulated by the extracellular (apical) K+ concentration, and that this K+ regulation is coupled to intracellular pH. The K+ regulation and its coupling to pH were assigned to different structural parts of the channel protein. K+ regulation is determined by the core region, which comprises the two hydrophobic segments M1 and M2 and the P region. Decoupling from pH was achieved by exchanging the N terminus of ROMK1 by that of the pH-insensitive channel IRK1 (K(ir)2.1). These results suggest an allosteric regulation of ROMK1 channels by extracellular K+ and intracellular pH, which may represent a novel link between K+ homeostasis and pH control.	UNIV TUBINGEN, EAR NOSE & THROAT HOSP, DEPT SENSORY BIOPHYS, TUBINGEN, GERMANY; UNIV TUBINGEN, INST PHYSIOL, D-72076 TUBINGEN, GERMANY	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen								ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BIELEN FV, 1993, J PHYSIOL-LONDON, V465, P699, DOI 10.1113/jphysiol.1993.sp019701; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOND CT, 1995, FEBS LETT, V367, P61, DOI 10.1016/0014-5793(95)00497-W; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHEPILKO S, 1995, AM J PHYSIOL-CELL PH, V268, pC389, DOI 10.1152/ajpcell.1995.268.2.C389; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FALKER B, 1994, NEURON, V13, P1413; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LANG F, 1992, PHYSIOL REV, V72, P1, DOI 10.1152/physrev.1992.72.1.1; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; MOODY WJ, 1982, J GEN PHYSIOL, V79, P115, DOI 10.1085/jgp.79.1.115; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TANG WM, 1994, FEBS LETT, V348, P239, DOI 10.1016/0014-5793(94)00612-1; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; WANG WH, 1993, J GEN PHYSIOL, V101, P673, DOI 10.1085/jgp.101.5.673; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	37	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17261	17266		10.1074/jbc.271.29.17261	http://dx.doi.org/10.1074/jbc.271.29.17261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663367	hybrid			2022-12-25	WOS:A1996UX94300045
J	Waggoner, DW; GomezMunoz, A; Dewald, J; Brindley, DN				Waggoner, DW; GomezMunoz, A; Dewald, J; Brindley, DN			Phosphatidate phosphohydrolase catalyzes the hydrolysis of ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; 2ND MESSENGER; PHOSPHOLIPASE-D; RAT-LIVER; INDEPENDENT PATHWAY; PLASMA-MEMBRANE; MIXED MICELLES; NADPH OXIDASE; ACID; ACTIVATION	A Mg2+-independent phosphatidate phosphohydrolase was purified from rat liver plasma membranes in two distinct forms, an anionic protein and a cationic protein. Both forms of the enzyme dephosphorylated phosphatidate, ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate. When assayed at a constant molar ratio of lipid to Triton X-100 of 1:500, the apparent K-m values of the anionic phosphohydrolase for the lipid substrates was 3.5, 1.9, 0.4, and 4.0 mu M, respectively. The relative catalytic efficiency of the enzyme for phosphatidate, ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate was 0.16, 0.14, 0.48, and 0.04 liter (min . mg)(-1), respectively. The hydrolysis of phosphatidate was inhibited competitively by ceramide l-phosphate, lysophosphatidate, and sphingosine 1-phosphate. The K-i(app) values were 5.5, 5.9, and 4.0 mu M, respectively. The hydrolysis of phosphatidate by the phosphohydrolase conformed to a surface dilution kinetic model. It is concluded that the enzyme is a lipid phosphomonoesterase that could modify the balance of phosphatidate, ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate relative to diacylglycerol, ceramide, monoacylglycerol, and sphingosine, respectively. The enzyme could thus play an important role in regulating cell activation and signal transduction.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,SIGNAL TRANSDUCT LABS,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BELOCOPITOW E, 1982, EUR J BIOCHEM, V125, P167, DOI 10.1111/j.1432-1033.1982.tb06664.x; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUDKER O, 1993, J BIOL CHEM, V268, P22150; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; CHAO CP, 1994, J BIOL CHEM, V269, P5849; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANOH H, 1992, J BIOL CHEM, V267, P25309; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MERRILL AH, 1992, NUTR REV, V50, P78; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; MORITZ A, 1992, J BIOL CHEM, V267, P7207; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; RIP JW, 1981, J BIOL CHEM, V256, P1929; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SEGEL IH, 1973, ENZYME KINETICS, P108; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WEDGWOOD JF, 1980, J BIOL CHEM, V255, P1120; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG H, 1990, J BIOL CHEM, V265, P76	47	121	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16506	16509		10.1074/jbc.271.28.16506	http://dx.doi.org/10.1074/jbc.271.28.16506			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663293	hybrid			2022-12-25	WOS:A1996UX12600015
J	Dascher, C; Balch, WE				Dascher, C; Balch, WE			Mammalian Sly1 regulates syntaxin 5 function in endoplasmic reticulum to Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; PROTEIN; HOMOLOG; ALIGNMENT; SEQUENCE; COMPLEX; ELEGANS; MUTANTS; N-SEC1; YPT1	Members of the syntaxin gene family are components of protein complexes which regulate vesicle docking and/or fusion during transport of cargo through the secretory pathway of eukaryotic cells, We have previously demonstrated that syntaxin 5 is specifically required for endoplasmic reticulum to Golgi transport (Dascher, C., Matteson, J., and Balch, W. E, (1994) J. Biol. Chem, 269, 29363-29366). To extend these observations we have now cloned a protein from rat liver membranes which forms a native complex with syntaxin 5. We demonstrate that this protein is the mammalian homologue to yeast Sly1p, previously identified as a protein which genetically and biochemically interacts with the small GTPase Ypt1p and Sed5p, proteins involved in docking/fusion in the early secretory pathway of yeast. Using transient expression we find that overexpression of rat liver Sly1 (rSly1) can neutralize the dominant negative effects of excess syntaxin 5 on endoplasmic reticulum to Golgi transport. These results suggest that rSly1 functions to positively regulate syntaxin 5 function.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92130 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92130 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR08176, RRO7273] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARLOWE C, 1995, FEBS LETT, V369, P93, DOI 10.1016/0014-5793(95)00618-J; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; Fleischer S, 1974, Methods Enzymol, V31, P6; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Halachmi N, 1996, J NEUROCHEM, V66, P889; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR, P312; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HODEL A, 1994, J BIOL CHEM, V269, P8623; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; NUOFFER C, 1996, METHOD ENZYMOL, V257, P3; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PALADE GE, 1976, SCIENCE, V189, P347; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	33	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15866	15869		10.1074/jbc.271.27.15866	http://dx.doi.org/10.1074/jbc.271.27.15866			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663406	hybrid			2022-12-25	WOS:A1996UW35200006
J	Maru, I; Ohta, Y; Murata, K; Tsukada, Y				Maru, I; Ohta, Y; Murata, K; Tsukada, Y			Molecular cloning and identification of N-acyl-D-glucosamine 2-epimerase from porcine kidney as a renin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER MOTIF; HOG KIDNEY; RNBP; PURIFICATION; GENE	N-Acetylneuraminic acid (NeuAc) is an important molecule in biological recognition systems, NeuAc is known to be biosynthesized either from UDP-N-acetyl-D-glucosamine by an action of UDP-N-acetyl-D-glucosamine 2-epimerase or from N-acetyl-D-glucosamine by N-acyl-D-glucosamine 2-epimerase (GlcNAc 2-epimerase), However, the physiological function of the GlcNAc a epimerase in NeuAc biosynthesis has not been fully evaluated, To clarify the role of GlcNAc 2-epimerase in NeuAc biosynthesis, the enzyme and its gene were isolated from porcine kidney cortex, Escherichia coli cells transformed with the gene expressed the GlcNAc 2-epimerase having the same properties as those of the GlcNAc 2-epimerase from porcine kidney. Sequence analysis indicated that the gene was capable of synthesizing a 46.5-kDa protein (402 amino acids) with a conserved leucine zipper motif, Homology search for the cloned gene revealed that the GlcNAc 2-epimerase was identical with renin-binding protein (RnBP) in porcine kidney (Inoue, H., Fukui, K., Takahashi, S., and Miyake, Y. (1990) J. Biol. Chem. 265, 6556-6561) (identity: 99.6% in nucleotide sequence, 99.0% in amino acid sequence), That GlcNAc 2-epimerase is a RnBP was confirmed by its ability to bind porcine kidney renin and mask its protease activity, These findings provide unequivocal evidence that the enzyme GlcNAc 2-epimerase is a Rnp.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN; MARUKIN SHOYA CO LTD,KYOTO RES LABS,UJI,KYOTO 611,JAPAN	Kyoto University								BOYD GW, 1974, CIRC RES, V35, P426, DOI 10.1161/01.RES.35.3.426; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTA A, 1970, BIOCHEMISTRY-US, V9, P3363, DOI 10.1021/bi00819a011; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; FARANDA S, 1995, GENE, V155, P237, DOI 10.1016/0378-1119(94)00810-F; GHOSH S, 1965, J BIOL CHEM, V240, P1531; GINSBURG V, 1964, ADV ENZYMOL REL S BI, V26, P35; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HONDA S, 1989, ANAL BIOCHEM, V180, P351, DOI 10.1016/0003-2697(89)90444-2; INAGAMI T, 1977, J BIOL CHEM, V252, P2978; INOUE H, 1991, J BIOCHEM-TOKYO, V110, P493, DOI 10.1093/oxfordjournals.jbchem.a123609; INOUE H, 1990, J BIOL CHEM, V265, P6556; INOUE H, 1991, J BIOL CHEM, V266, P11896; KLEMM P, 1982, EUR J BIOCHEM, V124, P339; KONDO M, 1991, ELECTROPHORESIS, V12, P685, DOI 10.1002/elps.1150120918; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKIE BJ, 1975, CIRC RES, V36, P513, DOI 10.1161/01.RES.36.4.513; McGuire E. J., 1976, BIOL ROLES SIALIC AC, P123; MURAKAMI K, 1980, BIOMED RES-TOKYO, V1, P476, DOI 10.2220/biomedres.1.476; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131; TADA M, 1992, J BIOCHEM, V112, P175, DOI 10.1093/oxfordjournals.jbchem.a123874; TAKAHASHI S, 1983, J BIOCHEM, V93, P1583, DOI 10.1093/oxfordjournals.jbchem.a134297; TAKAHASHI S, 1992, J BIOL CHEM, V267, P13007; TAKAHASHI S, 1983, J BIOCHEM-TOKYO, V93, P265, DOI 10.1093/oxfordjournals.jbchem.a134162; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; VANRINSUM J, 1983, BIOCHEM J, V210, P21, DOI 10.1042/bj2100021; WARREN L, 1972, GLYCOPROTEINS, P1097	30	104	115	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16294	16299		10.1074/jbc.271.27.16294	http://dx.doi.org/10.1074/jbc.271.27.16294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663114	hybrid			2022-12-25	WOS:A1996UW35200065
J	Yancey, PG; Rodriqueza, WV; Kilsdonk, EPC; Stoudt, GW; Johnson, WJ; Phillips, MC; Rothblat, GH				Yancey, PG; Rodriqueza, WV; Kilsdonk, EPC; Stoudt, GW; Johnson, WJ; Phillips, MC; Rothblat, GH			Cellular cholesterol effect mediated by cyclodextrins - Demonstration of kinetic pools and mechanism of efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; DENSITY-LIPOPROTEINS; LIPID-COMPOSITION; PLASMA-MEMBRANE; PHYSICAL STATE; CELLS; FIBROBLASTS; TRANSPORT; EXCHANGE; RECEPTOR	In this study, we compared the kinetics of cholesterol efflux from cells with 2-hydroxypropyl-beta-cyclodextrins and with discoidal high density lipoprotein (HDL) particles to probe the mechanisms governing the remarkably rapid rates of cyclodextrin-mediated efflux. The rate of cholesterol efflux was enhanced by shaking cells growing in a monolayer and further enhanced by placing cells in suspension to achieve maximal efflux rates, The extent of efflux was dependent on cyclodextrin concentration, and maximal efflux was observed at concentrations >50 mM. For several cell types, biexponential kinetics of cellular cholesterol efflux were observed, indicating the existence of two kinetic pools of cholesterol: a fast pool (half-time (t(1/2)) similar to 19-23 s) and a slow pool with t(1/2) of 15-30 min. Two distinct kinetic pools of cholesterol were also observed with model membranes (large unilamellar cholesterol-containing vesicles), implying that the cellular pools are in the plasma membrane, Cellular cholesterol content was altered by incubating cells with solutions of cyclodextrins complexed with increasing levels of cholesterol. The number of kinetic pools was unaffected by raising the cellular cholesterol content, but the size of the fast pool increased, After depleting cells of the fast pool of cholesterol, this pool was completely restored after a 40-min recovery period. The temperature dependence of cyclodextrin-mediated cholesterol efflux from cells and model membranes was compared; the activation energies were 7 kcal/mol and 2 kcal/mol, respectively. The equivalent activation energy observed with apo-HDL-phospholipid acceptor particles was 20 kcal/mol, It seems that cyclodextrin molecules are substantially more efficient than phospholipid accepters, because cholesterol molecules desorbing from a membrane surface can diffuse directly into the hydrophobic core of a cyclodextrin molecule without having to desorb completely into the aqueous phase before being sequestered by the acceptor.	MED COLL PENN & HAHNEMANN UNIV,DEPT BIOCHEM,PHILADELPHIA,PA 19129	Drexel University			Yancey, Patricia/ABB-5856-2021	Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633, HL07443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN SJ, 1984, J BIOL CHEM, V259, P3844; BAR LK, 1989, BIOCHIM BIOPHYS ACTA, V983, P109, DOI 10.1016/0005-2736(89)90386-6; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; BRASAEMLE DL, 1988, J LIPID RES, V29, P481; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHONG PLG, 1994, P NATL ACAD SCI USA, V91, P10069, DOI 10.1073/pnas.91.21.10069; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; DECAPRIO J, 1992, J LIPID RES, V33, P441; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; DUCHENE D, 1990, 5 INT S CYCL PAR FRA; ELYANDOUZI E, 1994, BIOCHEMISTRY-US, V33, P2329, DOI 10.1021/bi00174a046; ELYANDOUZI EH, 1993, BIOCHEMISTRY-US, V32, P2047, DOI 10.1021/bi00059a023; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRIJLINK HW, 1991, PHARMACEUT RES, V8, P9, DOI 10.1023/A:1015861719134; GLOMSET JA, 1968, J LIPID RES, V9, P155; Hatch F T, 1968, Adv Lipid Res, V6, P1; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAVECANSKY J, 1994, BIOCHEMISTRY-US, V33, P2880, DOI 10.1021/bi00176a018; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUAN P, 1995, BIOCHEMISTRY-US, V34, P9874, DOI 10.1021/bi00031a008; LUNDKATZ S, 1982, BIOCHEMISTRY-US, V21, P2964, DOI 10.1021/bi00541a025; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCINTOSH TJ, 1995, BIOCHEMISTRY-US, V34, P8520, DOI 10.1021/bi00027a002; PHILLIPS MC, 1980, ATHEROSCLEROSIS, V36, P409, DOI 10.1016/0021-9150(80)90220-8; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; RODRIGUEZA WV, 1995, BIOCHEMISTRY-US, V34, P6208, DOI 10.1021/bi00018a025; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Rothblat G H, 1986, Methods Enzymol, V129, P628; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; SCHROEDER, 1995, MOL MEMBR BIOL, V12, P113; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P48; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1235, P419, DOI 10.1016/0005-2736(95)80031-A; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; WOODFORD JK, 1993, BIOCHIM BIOPHYS ACTA, V1145, P257, DOI 10.1016/0005-2736(93)90297-D; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; YANDOUZI EHE, 1992, BIOCHEMISTRY-US, V31, P547; 1992, SIGMA TECHNICAL B, V7	54	392	396	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16026	16034		10.1074/jbc.271.27.16026	http://dx.doi.org/10.1074/jbc.271.27.16026			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663188	hybrid			2022-12-25	WOS:A1996UW35200029
J	Cruse, WBT; Saludjian, P; Leroux, Y; Leger, G; ElManouni, D; Prange, T				Cruse, WBT; Saludjian, P; Leroux, Y; Leger, G; ElManouni, D; Prange, T			A continuous transition from A-DNA to B-DNA in the 1:1 complex between nogalamycin and the hexamer dCCCGGG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG NOGALAMYCIN; ORDERED WATER-STRUCTURE; CRYSTAL-STRUCTURE; MOLECULAR-STRUCTURE; DAUNOMYCIN; BINDING; PSEUDOROTATION; RESOLUTION; REFINEMENT; DODECAMER	The antibiotic nogalamycin, a drug with high specificity for TG and CG steps in double-stranded DNA, has been crystallized as a 1:1 complex with the hexamer d(CCCGGG). The antibiotic is inserted at the central CG step of the duplex, with the two sugars oriented in the same direction and with strong interactions with the DNA within the grooves, The amino-glucose residue makes an integral part of a well defined major groove hydration network with van der Waals contacts and several strong hydrogen bonds to the duplex, The nogalose residue resides in the minor groove, making primarily van der Waals contacts, The single site allows an accurate molecular description of the intercalation, without perturbations from end effects observed previously, The local unwinding induced by nogalamycin is completely relaxed 2 base pairs away from the intercalation site. The two strands of the DNA show a continuous deformation from the A to the B form: 1) the cytosines toward the 5' end of the nogalomycin site in each strand have c3'-endo conformations while 5 guanosines toward the 3' ends have c2'-endo conformations; 2) within each strand, the phosphate-phosphate distances increase in a continuous manner from 5.7 Angstrom (A-form) to 7.1 Angstrom (B-form).	UNIV PARIS 11,LURE,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay	Cruse, WBT (corresponding author), UFR BIOMED,URA 1430 CNRS,74 RUE M CACHIN,F-93012 BOBIGNY,FRANCE.		Prangé, Thierry/AAA-4009-2022	Prangé, Thierry/0000-0002-7129-7396				ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARORA SK, 1983, J AM CHEM SOC, V105, P1328, DOI 10.1021/ja00343a042; BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; BERMAN HM, 1978, P NATL ACAD SCI USA, V75, P828, DOI 10.1073/pnas.75.2.828; BERMAN HM, 1979, BIOPOLYMERS, V18, P2405, DOI 10.1002/bip.1979.360181004; BRUNGER AT, 1988, XPLOR MANUAL; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; DICKERSON RE, 1993, NEWHEL 93 PROGRAM; DOUCET J, 1989, NATURE, V337, P190, DOI 10.1038/337190a0; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; FOURME R, 1992, REV SCI INSTRUM, V63, P982, DOI 10.1063/1.1143716; FOX KR, 1986, BIOCHEMISTRY-US, V25, P4349, DOI 10.1021/bi00363a026; FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016; GAO YG, 1990, BIOCHEMISTRY-US, V29, P10307, DOI 10.1021/bi00497a004; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; ISLAM SA, 1985, J MED CHEM, V28, P857, DOI 10.1021/jm00145a003; KENNARD O, 1986, J BIOMOL STRUCT DYN, V3, P623, DOI 10.1080/07391102.1986.10508452; KOPKA ML, 1983, J MOL BIOL, V163, P129, DOI 10.1016/0022-2836(83)90033-5; LESLIE A, 1994, MOSFLM USER GUIDE MO; LI LH, 1979, CANCER RES, V39, P4816; MCCALL M, 1985, J MOL BIOL, V183, P385, DOI 10.1016/0022-2836(85)90009-9; MOORE MH, 1989, J MOL BIOL, V206, P693, DOI 10.1016/0022-2836(89)90577-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NUNN CM, 1991, J MOL BIOL, V222, P167, DOI 10.1016/0022-2836(91)90203-I; SAENGER W, 1983, PRINCIPLES NUCLEIC A, P350; SHAKKED Z, 1989, NATURE, V342, P456, DOI 10.1038/342456a0; VANHOUTE LPA, 1993, BIOCHEMISTRY-US, V32, P1667, DOI 10.1021/bi00057a034; WAKELIN LPG, 1980, J MOL BIOL, V144, P183, DOI 10.1016/0022-2836(80)90032-7; WANG AHJ, 1987, BIOCHEMISTRY-US, V26, P1152, DOI 10.1021/bi00378a025; WESTHOF E, 1985, BIOCHIMIE, V67, P811, DOI 10.1016/S0300-9084(85)80172-3; WESTHOF E, 1980, J AM CHEM SOC, V102, P1493, DOI 10.1021/ja00525a004; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WESTHOF E, 1990, WATER SCI REV, V5, P24; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15558	15567		10.1074/jbc.271.26.15558	http://dx.doi.org/10.1074/jbc.271.26.15558			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662899	hybrid			2022-12-25	WOS:A1996UV29900040
J	Netto, LES; Chae, HZ; Kang, SW; Rhee, SG; Stadtman, ER				Netto, LES; Chae, HZ; Kang, SW; Rhee, SG; Stadtman, ER			Removal of hydrogen peroxide by thiol-specific antioxidant enzyme (TSA) is involved with its antioxidant properties - TSA possesses thiol peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; OXIDATION; PROTEIN	The thiol-specific antioxidant protein (TSA) protects glutamine synthetase from inactivation by a metal-catalyzed oxidation (MCO) system comprised of dithiothreitol (DTT)/Fe3+/O-2 but not by the ascorbate/Fe3+/O-2 MCO system. The removal of sulfur-centered radicals or H2O2 has been proposed as the protective mechanism of TSA. Like catalase, TSA prevents the initiation of the rapid O-2 uptake phase during MCO of DTT but causes only partial inhibition when added after the reaction is well into the propagation phase. Stoichiometric studies showed that the antioxidant property of TSA is, at least in part, due to its ability to catalyze the destruction of H2O2 by the overall reaction 2 RSH + H2O2 --> RSSR + H2O. Results of kinetic studies demonstrate that the removal of H2O2 by TSA correlates with its ability to protect glutamine synthetase from inactivation. In the presence of thioredoxin, TSA is more active, whereas C170S (an active mutant of TSA in which cysteine 170 was replaced by a serine) and open reading frame 6 (a human antioxidant protein homologous to TSA with only one conserved cysteine residue) are only slightly affected. The thiol specificity of the protective activity of TSA derives from the fact that the oxidized form of TSA can be converted back to its sulfhydryl form by treatment with thiols but not by ascorbate.	NHLBI,NIH,BIOCHEM LAB,BETHESDA,MD 20892; NHLBI,NIH,LAB CELL SIGNALLING,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Netto, Luis/A-3783-2008	Netto, Luis/0000-0002-4250-9177				AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GUIBAULT GG, 1968, ANAL CHEM, V40, P1256; Halliwell B., 1989, FREE RADICAL BIO MED, P86; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; JOCELYN PC, 1972, BIOCH SH GROUP, P79; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; NETTO LES, 1994, FASEB J, V8, pA1412; POOLE LB, 1989, J BIOL CHEM, V264, P12330; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROBINSON J, 1970, ANAL BIOCHEM, V20, P525; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; YIM MB, 1994, J BIOL CHEM, V269, P1621	26	196	203	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15315	15321		10.1074/jbc.271.26.15315	http://dx.doi.org/10.1074/jbc.271.26.15315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663080	hybrid			2022-12-25	WOS:A1996UV29900005
J	Ng, JY; Marians, KJ				Ng, JY; Marians, KJ			The ordered assembly of the phi X174-type primosome .2. Preservation of primosome composition from assembly through replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; DNA-REPLICATION; INITIATION SIGNALS; SITE SELECTION; PROTEIN-I; STRAND; INVITRO; REGION; PURIFICATION; ASSOCIATION	Gel filtration chromatography was used to isolate both preprimosomal and primosomal complexes formed on single-stranded DNA-binding protein-coated phi X174 DNA by the combination of PriA, PriB, PriC, DnaT, DnaB, DnaC, and DnaG, The presence and relative amounts of primosomal proteins in these complexes were determined by Western blotting, Protein-DNA complexes isolated (i) after assembly in the presence of 10 mu M ATP, (ii) after preprimosome movement in the presence of 1 mM ATP, (iii) after priming in the presence of the four ribonucleoside triphosphates, or (iv) after complementary strand DNA replication in the presence of the DNA polymerase III holoenzyme all had the same protein composition; preprimosomes contained PriA, PriB, PriC, DnaT, and DnaB, whereas primosomes included DnaG, The stable association of DnaG with the protein-DNA complex could be attributed partially to its ability to remain bound to the primers synthesized, In the absence of PriC, the efficiencies of priming and replication were reduced by one-third and one-half, respectively, even though PriC was not required for the formation of stable protein-DNA complexes on a 304-nucleotide-long single strand of DNA containing a primosome assembly site (Ng, J. Y., and Marians, K. J. (1996) J. Biol. Chem, 271, 15642-15648), We hypothesize that maintenance of the primosome on the replicated DNA may provide a mechanism to allow primosomes to participate in the resolution of recombination intermediates and intermediates formed during double strand break repair by permitting the re-establishment of a replication fork.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Ng, JY (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1993, J BIOL CHEM, V268, P19204; ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5281; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; FRANCKE B, 1971, VIROLOGY, V44, P168, DOI 10.1016/0042-6822(71)90163-2; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1989, FEBS LETT, V246, P21, DOI 10.1016/0014-5793(89)80245-5; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LEE MS, 1989, J BIOL CHEM, V264, P14531; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; LOW RL, 1981, P NATL ACAD SCI-BIOL, V78, P1436, DOI 10.1073/pnas.78.3.1436; LOW RL, 1982, J BIOL CHEM, V257, P6242; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1982, J BIOL CHEM, V257, P5665; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1986, P NATL ACAD SCI USA, V83, P1256, DOI 10.1073/pnas.83.5.1256; MASAI H, 1988, J BIOL CHEM, V263, P15083; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P2304; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; OGAWA T, 1983, J BIOL CHEM, V258, P3353; PRATT D, 1968, J MOL BIOL, V181, P37; Sandler SJ, 1996, GENETICS, V143, P5; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; STUITJE AR, 1984, NUCLEIC ACIDS RES, V12, P3321, DOI 10.1093/nar/12.7.3321; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WICKNER S, 1978, SINGLE STRANDED DNA, P255; WU CA, 1992, J BIOL CHEM, V267, P4030	35	55	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15649	15655		10.1074/jbc.271.26.15649	http://dx.doi.org/10.1074/jbc.271.26.15649			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663105	hybrid			2022-12-25	WOS:A1996UV29900053
J	Favre, CJ; Schrenzel, J; Jacquet, J; Lew, DP; Krause, KH				Favre, CJ; Schrenzel, J; Jacquet, J; Lew, DP; Krause, KH			Highly supralinear feedback inhibition of Ca2+ uptake by the Ca2+ load of intracellular stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; CA-2+ TRANSPORT; CALCIUM-PUMP; CA-2+-ATPASE; PROTEINS; MEMBRANE; ATPASES; STATE; CELLS	Net Ca2+ uptake into intracellular Ca2+ stores of homogenized cells is transient, even when the extravesicular Ca2+ concentration is kept constant. To study the mechanism underlying the phenomenon, we have investigated Ca-45(2+) uptake by HL-60 cell homogenates. The initial rate of Ca2+ uptake as well as the final amount of stored Ca2+ were a function of the extravesicular Ca2+ concentration. However, Ca2+ uptake stopped independently of the extravesicular Ca2+ concentration after approximately 10 min. Studies using Ca2+-ATPase inhibitors demonstrated that the transient nature of the net uptake was not due to Ca2+ efflux. Monovalent cat ion ionophores did not influence the Ca2+ uptake curves, excluding a relevant involvement of pH and membrane potential. Together with the observation of a continued Ca2+ uptake in the presence of the intralumenal Ca2+ chelator oxalate, these results strongly suggest a feedback inhibition of Ca2+ uptake by the Ca2+ load of intracellular stores. The concentration-inhibition relationship between the Ca2+ load and the rate of Ca2+ uptake was highly supralinear (slope factor greater than or equal to 4). IC50 and maximum of the dose-inhibition curve, but not the slope factor were a function of the extravesicular free Ca2+ concentration. A series of three logistic equations derived from our data allowed an appropriate description of the behavior of Ca2+ uptake. Our results suggest, in addition to its well known activation by cytosolic Ca2+ concentration, a highly supralinear feedback inhibition of Ca2+ uptake by the Ca2+ load of intracellular stores. The steepness of the feedback inhibition might have a profound effect on spatial and temporal behavior of the Ca2+ signal.	UNIV GENEVA,HOP CANTONAL,DIV INFECT DIS,CH-1211 GENEVA 14,SWITZERLAND; CTR MED UNIV GENEVA,SICMU,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva; University of Geneva			Schrenzel, Jacques/AAC-5685-2021; Krause, Karl-Heinz/E-8030-2011; Schrenzel, Jacques/P-8525-2017	Schrenzel, Jacques/0000-0001-5464-7764; Krause, Karl-Heinz/0000-0002-9033-6768; Schrenzel, Jacques/0000-0001-5464-7764				CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; DACOSTA AG, 1994, BBA-BIOMEMBRANES, V1189, P181, DOI 10.1016/0005-2736(94)90064-7; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; FAVRE CJ, 1994, BIOCHEM J, V302, P155, DOI 10.1042/bj3020155; FAVRE CJ, 1996, IN PRESS BIOCH J, V313; FORGE V, 1995, J BIOL CHEM, V270, P18271, DOI 10.1074/jbc.270.31.18271; GILL DL, 1985, J BIOL CHEM, V260, P9289; GOMEZFERNANDEZ JC, 1994, BIOCHEM SOC T, V22, P826, DOI 10.1042/bst0220826; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; HEILMANN C, 1983, BIOCHEM BIOPH RES CO, V114, P584, DOI 10.1016/0006-291X(83)90820-3; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; MACER DRJ, 1988, J CELL SCI, V91, P61; MADEIRA VMC, 1982, CELL CALCIUM, V3, P62; MCINTOSH DB, 1988, J BIOL CHEM, V263, P12220; MISSIAEN L, 1993, BIOCHEM BIOPH RES CO, V193, P6, DOI 10.1006/bbrc.1993.1582; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS D, 1994, METHOD CELL BIOL, V40, P65; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	26	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14925	14930		10.1074/jbc.271.25.14925	http://dx.doi.org/10.1074/jbc.271.25.14925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662967	hybrid			2022-12-25	WOS:A1996UT10600045
J	KrijnseLocker, J; Schleich, S; Rodriguez, D; Goud, B; Snijder, EJ; Griffiths, G				KrijnseLocker, J; Schleich, S; Rodriguez, D; Goud, B; Snijder, EJ; Griffiths, G			The role of a 21-kDa viral membrane protein in the assembly of vaccinia virus from the intermediate compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL ENDOMEMBRANE SYSTEM; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; CIS ELEMENT; PRE-GOLGI; GLYCOPROTEIN; TRANSPORT; GENE; CELL; ER	We have recently provided morphological evidence that a key event in the assembly of vaccinia virus is the formation of a novel cisternal domain of the intermediate compartment (IC) between the endoplasmic reticulum and the Golgi complex (Sodeik, B., Doms, R. W., Ericsson, M., Hiller, G., Machamer, C. E., van't Hof, W., van Meer, G., Moss, B., and Griffiths, G. (1993) J. Cell Biol. 121, 521-541). This tightly apposed cisternal domain incompletely surrounds the spherical immature virus that matures into the first of the two distinct infectious forms of vaccinia, the intracellular mature virus (IMV). In this study we describe the characterization of an abundant membrane protein of the IMV, the gene product of A17L, a 21-kDa protein that has recently been shown to be essential for the formation of the viral mem branes (Rodriguez, D., Esteban, M., and Rodriguez, J. R. (1995) J. Virol. 69, 4640-4648). Upon translation in vitro, p21 associated with rough microsomal membranes in a co-translational manner. Using NH2- and COOH-terminal specific antibodies, we show that both in vitro as well as in vivo, p21 adopts a topology where the NH, and COOH termini are cytoplasmically orientated. Immuno cytochemical experiments demonstrated that p21 is a component of the inner of the two cisternal membranes of the immature virus as well as of membranes of the IC, identified using antibodies against Rab1. Taken together, these data provide the first molecular evidence in support of our assembly model; they show that an essential membrane protein of the IMV inserts into the rough endoplasmic reticulum, but gets efficiently targeted to the IC and membranes of the viral factory.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, D-69118 HEIDELBERG, GERMANY; UNIV AUTONOMA MADRID, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN; INST PASTEUR, UNITE GENET SOMAT, F-75231 PARIS 05, FRANCE	European Molecular Biology Laboratory (EMBL); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Locker, Jacomine Krijnse/AAX-1185-2020; Locker, Jacomine Krijnse/E-1009-2016; Goud, Bruno/GWC-4807-2022; Snijder, Eric J./E-6073-2018; Rodriguez, Dolores/ABF-9855-2020	Snijder, Eric J./0000-0003-3297-2309; Rodriguez, Dolores/0000-0001-6365-4501				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BALDICK CJ, 1987, VIROLOGY, V156, P138, DOI 10.1016/0042-6822(87)90444-2; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991; CAIRNS J, 1960, VIROLOGY, V11, P603, DOI 10.1016/0042-6822(60)90103-3; CLAUDE A, 1970, J CELL BIOL, V47, P745, DOI 10.1083/jcb.47.3.745; CLERMONT Y, 1994, ANAT REC, V240, P469, DOI 10.1002/ar.1092400405; Dales S, 1981, Virol Monogr, V18, P1; DALES S, 1963, J CELL BIOL, V18, P51, DOI 10.1083/jcb.18.1.51; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ERICSSON M, 1995, J VIROL, V69, P7072, DOI 10.1128/JVI.69.11.7072-7086.1995; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GARON CF, 1971, VIROLOGY, V46, P233, DOI 10.1016/0042-6822(71)90026-2; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Griffiths G, 1992, Semin Cell Biol, V3, P367, DOI 10.1016/1043-4682(92)90022-N; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; ICHIHASHI Y, 1994, VIROLOGY, V202, P834, DOI 10.1006/viro.1994.1405; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LINDSEY JD, 1985, J NEUROSCI, V5, P3124; LINDSEY JD, 1985, J NEUROSCI, V5, P3111; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; LOCKER JK, 1995, MOL BIOL CELL, V6, P1315; MAA JS, 1987, J VIROL, V61, P3910, DOI 10.1128/JVI.61.12.3910-3919.1987; Mohandas AR, 1995, VIROLOGY, V214, P494, DOI 10.1006/viro.1995.0060; MORGAN, 1976, SCIENCE, V193, P591, DOI 10.1126/science.959819; MOSS B, 1969, NATURE, V224, P1280, DOI 10.1038/2241280a0; MOSS B, 1990, P2079; NILES EG, 1988, J VIROL, V62, P3772, DOI 10.1128/JVI.62.10.3772-3778.1988; OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339; PAABO S, 1986, EMBO J, V5, P1921, DOI 10.1002/j.1460-2075.1986.tb04445.x; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; RAPOPORT TA, 1986, CRC CR REV BIOCH MOL, V20, P73, DOI 10.3109/10409238609115901; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RODRIGUEZ D, 1993, J VIROL, V67, P3435, DOI 10.1128/JVI.67.6.3435-3440.1993; RODRIGUEZ D, 1995, J VIROL, V69, P4640; ROOS N, 1996, IN PRESS EMBO J; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROTTIER P, 1985, J BIOL CHEM, V260, P4648; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1995, J CELL SCI, V108, P1541; SARASTE J, 1991, J CELL SCI, V100, P415; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SESSO A, 1994, J CELL SCI, V107, P517; SODEIK B, 1995, J VIROL, V69, P3560, DOI 10.1128/JVI.69.6.3560-3574.1995; SODEIK B, 1994, J VIROL, V68, P1103, DOI 10.1128/JVI.68.2.1103-1114.1994; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; TARTAGLIA J, 1986, VIROLOGY, V150, P45, DOI 10.1016/0042-6822(86)90264-3; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WHITEHEAD SS, 1994, VIROLOGY, V200, P154, DOI 10.1006/viro.1994.1174; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wilton S, 1995, VIROLOGY, V214, P503, DOI 10.1006/viro.1995.0061	66	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14950	14958		10.1074/jbc.271.25.14950	http://dx.doi.org/10.1074/jbc.271.25.14950			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662995	hybrid			2022-12-25	WOS:A1996UT10600049
J	Shi, WX; Chammas, R; Varki, A				Shi, WX; Chammas, R; Varki, A			Linkage-specific action of endogenous sialic acid O-acetyltransferase in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; N-LINKED OLIGOSACCHARIDES; HUMAN-MELANOMA CELLS; DE-ORTHO-ACETYLATION; RAT-LIVER; MAACKIA-AMURENSIS; GOLGI-APPARATUS; GD3 GANGLIOSIDE; EXPRESSION; GENE	9-O-Acetylation of sialic acids shows cell type-specific and developmentally regulated expression in various systems, In a given cell type, O-acetylation can also be specific to a particular type of glycoconjugate. It is assumed that this regulation is achieved by control of expression of specific 9-O-acetyltransferases. However, it has been difficult to test this hypothesis, as these enzymes have so far proven intractable to purification or molecular cloning, During a cloning attempt, we discovered that while polyoma T antigen-positive Chinese hamster ovary cells (CHO-Tag cells) do not normally express cell surface 9-O-acetylation, they do so when transiently transfected with a cDNA encoding the lactosamine-specific alpha 2-6-sialyltransferase (Gal beta 1-4Glc-NAc:alpha 2-6 sialyltransferase (ST6Gal I); formerly ST6N), This phenomenon is reproducible by stable expression of ST6Gal I in parental CHO cells, but not upon transfection of the competing lactosamine specific (alpha 2-3-sialyltransferase (Gal beta 1-(3)4GlcNAc:alpha 23-sialyltransferase (ST6Gal III) formerly ST3N) into either cell type, Further analyses of stably transfected parental CHO-K1 cells indicated that expression of the STGGa1 I gene causes selective 9-O-acetylation of alpha 2-6-linked sialic acid residues on N-linked oligosaccharides, In a similar manner, while the alpha 2-3 linked sialic acid residue of the endogenous G(M3) ganglioside of CHO cells is not O-acetylated, transfection of an alpha 2-8-sialyltransferase (G(M3):alpha 2-8-sialyltransferase (ST8Sia I); formerly G(D3) synthase) caused expression of 9-O-acetylation of the alpha 2-8-linked sialic acid residues of newly synthesized G(D3). These data indicate either that linkage-specific sialic acid O-acetyltransferase(s) are constitutively expressed in CHO cells or that expression of these enzymes is secondarily induced upon expression of certain sialyltransferases. The former explanation is supported by a low level of background 9-O-acetylation found in parental CHO-K1 cells and by the finding that O-acetylation is not induced when the ST6Gal I or ST8Sia I cDNAs are overexpressed in SV40 T antigen-expressing primate (COS) cells, Taken together, these results indicate that expression of sialic acid 9-O-acetylation can be regulated by the action of specific sialyltransferases that alter the predominant linkage of the terminal sialic acids found on specific classes of glycoconjugates.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	University of California System; University of California San Diego			Chammas, Roger/A-8004-2011	Chammas, Roger/0000-0003-0342-8726	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA5869] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BUTOR C, 1993, J BIOL CHEM, V268, P10197; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DO SI, 1990, J BIOL CHEM, V265, P114; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FURUKAWA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P70, DOI 10.1016/0003-9861(90)90414-T; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KNIEP B, 1993, BLOOD, V82, P1776; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1994, J BIOL CHEM, V269, P1432; LANCE P, 1989, BIOCHEM BIOPH RES CO, V164, P225, DOI 10.1016/0006-291X(89)91706-3; LAU JTY, 1992, GLYCONCONJUGATES COM, P499; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEE YC, 1994, J BIOL CHEM, V269, P10028; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MATTOX S, 1992, ANAL BIOCHEM, V206, P430, DOI 10.1016/0003-2697(92)90389-O; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; MOSTAFAPOUR MK, 1993, ARCH BIOCHEM BIOPHYS, V303, P255, DOI 10.1006/abbi.1993.1280; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAHLSSON P, 1994, GLYCOCONJUGATE J, V11, P43, DOI 10.1007/BF00732431; PATON MC, 1986, NATURE, V324, P459; PAULSON JC, 1984, EUR J BIOCHEM, V140, P523, DOI 10.1111/j.1432-1033.1984.tb08133.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POWELL LD, 1994, J BIOL CHEM, V269, P10628; REUTER G, 1983, EUR J BIOCHEM, V134, P139, DOI 10.1111/j.1432-1033.1983.tb07542.x; REUTER G, 1990, BIOCHEM BIOPH RES CO, V94, P567; SANAI Y, 1990, J BIOCHEM-TOKYO, V107, P740, DOI 10.1093/oxfordjournals.jbchem.a123118; SARRIS AH, 1979, J BIOL CHEM, V254, P6724; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SCHAUER R, 1987, METHOD ENZYMOL, V138, P611; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SCHUZHENNINGER R, 1989, EUR J BIOCHEM, V185, P327, DOI 10.1111/j.1432-1033.1989.tb15119.x; SHAH S, 1992, J BIOL CHEM, V267, P10652; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SHIGETA S, 1994, CARBOHYD RES, V264, P111, DOI 10.1016/0008-6215(94)00192-8; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1994, Subcell Biochem, V22, P71; VERTINOBELL A, 1994, DEV BIOL, V165, P126, DOI 10.1006/dbio.1994.1240; WANG WC, 1988, J BIOL CHEM, V263, P4576; WANG XC, 1993, J BIOL CHEM, V268, P4355; WANG XC, 1989, J BIOL CHEM, V264, P1854; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; YAMASHIRO S, 1995, GLYCOCONJUGATE J, V12, P894, DOI 10.1007/BF00731251; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343	74	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15130	15138		10.1074/jbc.271.25.15130	http://dx.doi.org/10.1074/jbc.271.25.15130			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662976	hybrid			2022-12-25	WOS:A1996UT10600072
J	Urata, Y; Yamamoto, H; Goto, S; Tsushima, H; Akazawa, S; Yamashita, S; Nagataki, S; Kondo, T				Urata, Y; Yamamoto, H; Goto, S; Tsushima, H; Akazawa, S; Yamashita, S; Nagataki, S; Kondo, T			Long exposure to high glucose concentration impairs the responsive expression of gamma-glutamylcysteine synthetase by interleukin-1 beta and tumor necrosis factor-alpha in mouse endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; OXYGEN RADICALS; GLUTATHIONE; TOXICITY; MECHANISMS; INHIBITION; TRANSPORT; RECEPTOR; SUBUNIT	To elucidate the pathological metabolism of glutathione synthesis in diabetic endothelial cells, we studied the expression of gamma-glutamylcysteine synthetase (gamma-GCS) using a mouse vascular endothelial cell line. Exposing normoglycemic endothelial cells to tumor necrosis factor-alpha (TNF-alpha) or interleukin-1 beta (IL-1 beta) increased the activity and the mRNA expression of gamma-GCS, The addition of inhibitors for nuclear factor kappa B (NF-kappa B) to the cells caused a loss of the gamma-GCS mRNA expression in response to TNF-alpha. A shift of the concentration of glucose in the medium from 5.5 to 28 mM glucose and a following incubation for 7 days decreased the expression of gamma-GCS mRNA. These cells showed no apparent responses of gamma-GCS mRNA or the activity of NF-kappa B to TNF-alpha or IL-beta. Increase in the GSH concentration of the cells treated with 28 mM glucose restored the expression of gamma-GCS mRNA and its response to TNF-alpha or IL-beta, suggesting that redox regulation is involved in the expression of gamma-GCS. In summary, the expression of gamma-GCS is regulated by TNF-alpha or IL-1 beta in endothelial cells mediated by NF-kappa B stimulation, and impairment of the regulation of gamma-GCS in hyperglycemic cells may be a cause of medical complications that develop in diabetes mellitus.	NAGASAKI UNIV, SCH MED, INST ATOM DIS, DEPT PATHOL BIOCHEM, NAGASAKI 852, JAPAN; NAGASAKI UNIV, SCH MED, INST ATOM DIS, DEPT CELLULAR PHYSIOL, NAGASAKI 852, JAPAN; NAGASAKI UNIV, SCH MED, DEPT MED 1, NAGASAKI 852, JAPAN	Nagasaki University; Nagasaki University; Nagasaki University			Yamashita, Shunichi/GVS-9508-2022	Yamashita, Shunichi/0000-0001-6399-6261; nagataki, shigenobu/0000-0002-9974-3554				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BEUTLER E, 1986, CLIN CHIM ACTA, V158, P115, DOI 10.1016/0009-8981(86)90122-1; Beutler E, 1984, RED CELL METABOLISM, P77; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; DINARELLO CA, 1991, BLOOD, V77, P1627; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070; GOTO S, 1995, CANCER RES, V55, P4297; HALLIWELL B, 1984, LANCET, V1, P1396; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOSODA C, 1995, ENDOCR J, V42, P341, DOI 10.1507/endocrj.42.341; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASHIWAGI A, 1994, DIABETOLOGIA, V37, P264, DOI 10.1007/BF00398053; KONDO T, 1993, J BIOL CHEM, V268, P20366; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MANDRUPPOULSEN T, 1987, J IMMUNOL, V139, P4077; MANJI SS, 1995, J BIOL CHEM, V270, P8958, DOI 10.1074/jbc.270.15.8958; MARCHO Z, 1991, AM J RESP CELL MOL, V5, P556, DOI 10.1165/ajrcmb/5.6.556; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MURAMATSU M, 1974, EXP CELL RES, V88, P345, DOI 10.1016/0014-4827(74)90250-X; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STOCKER R, 1985, P NATL ACAD SCI USA, V82, P548, DOI 10.1073/pnas.82.2.548; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; TAGAMI S, 1992, METABOLISM, V41, P1053, DOI 10.1016/0026-0495(92)90285-I; TOLENADO MB, 1990, P NATL ACAD SCI USA, V88, P4328; TROCINO AT, 1995, DIABETES, V44, P1; TSAN MF, 1991, J APPL PHYSIOL, V71, P688, DOI 10.1152/jappl.1991.71.2.688; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WU GY, 1992, J BIOL CHEM, V267, P12436; YAN N, 1990, J BIOL CHEM, V265, P1588	45	131	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15146	15152		10.1074/jbc.271.25.15146	http://dx.doi.org/10.1074/jbc.271.25.15146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662965	hybrid			2022-12-25	WOS:A1996UT10600074
J	Ponzetto, C; Zhen, Z; Audero, E; Maina, F; Bardelli, A; Basile, ML; Giordano, S; Narsimhan, R; Comoglio, P				Ponzetto, C; Zhen, Z; Audero, E; Maina, F; Bardelli, A; Basile, ML; Giordano, S; Narsimhan, R; Comoglio, P			Specific uncoupling of GRB2 from the met receptor - Differential effects on transformation and motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; C-MET; PROTEIN	The biological effects of hepatocyte growth factor/scatter scatter factor are mediated by autophosphorylation of its receptor, the Met tyrosine kinase, on two carboxyl-terminal tyrosines. These phosphotyrosines (Y(1349)VHVNATY(1356)VNV) are multifunctional docking sites for several effecters. Grb2, the adaptor for the Res guanyl-nucleotide exchanger SOS, binds to Tyr(1356) in the <YV(N)under bar V> motif. By site-directed mutagenesis we either abrogated or duplicated the Grb2 consensus, without interfering with the other effecters. Loss of the Link with Grb2 severely impaired transformation. The same mutation, however, had no effect on the ''scattering'' response, indicating that the level of signal which can be reached by Grb2-independent routes is permissive for motility. Duplication of the Grb2 binding site enhanced transformation and left motility unchanged. Thus, two Met-mediated biological responses, motility and growth, can be dissociated on the basis of their differential requirement for a direct link with Ras.	UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of Turin; Ludwig Institute for Cancer Research			Maina, Flavio/J-9962-2019; Giordano, Silvia/J-9858-2018; BARDELLI, Alberto/J-9721-2018	Maina, Flavio/0000-0001-6100-4695; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070; Audero, Enrica/0000-0002-6138-244X				BASU T, 1994, ONCOGENE, V9, P3483; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; DOWNWARD J, 1995, CELL, V83, P631; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIXMAN ED, 1995, ONCOGENE, V10, P237; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1993, CELL, V72, P1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; ZHU H, 1994, J BIOL CHEM, V269, P29943	29	144	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14119	14123		10.1074/jbc.271.24.14119	http://dx.doi.org/10.1074/jbc.271.24.14119			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662889	hybrid			2022-12-25	WOS:A1996UQ66000030
J	Seabra, MC				Seabra, MC			Nucleotide dependence of Rab geranylgeranylation - Rab escort protein interacts preferentially with GDP-bound Rab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CHOROIDEREMIA GENE; ALPHA-SUBUNIT; CDNA CLONING; COMPONENT-A; SMG P25A; TRANSFERASE; PURIFICATION; GERANYLGERANYLTRANSFERASE; ISOPRENYLATION	Geranylgeranylation of Rab GTPases is an essential post-translational modification that enables Rabs to associate with intracellular membranes where they regulate exocytic and endocytic pathways. Geranylgeranylation is initiated by formation of a stable complex between newly synthesized Rab proteins and Rab escort protein (REP). The complex is recognized by Rab geranylgeranyl (GG) transferase, which transfers two GG groups to Rabs. The geranylgeranylated Rabs regulate vesicular movement by oscillating between an inactive GDP-bound form and an active GTP-bound form. In this study, I show that the kinetics of geranylgeranylation is influenced by the nucleotide status of nascent Rab. GDP-bound Rab is geranylgeranylated with 10-50 fold higher affinity than GTP-bound Rab (or GTP analog-bound Rab), as indicated by the apparent K-m of the reaction. In vitro REP Rab binding assays demonstrate that REP forms a stable complex only with the GDP-bound form of Rab but not the GTP-bound form, suggesting that the apparent K-m effect in the prenylation reaction is due to a discrimination between the two different nucleotide-bound forms of Rab by REP. Inasmuch as Rabs are likely GTP-bound after synthesis and REP does not possess GTPase-activating protein activity, these results raise the possibility that a Rab GTPase-activating protein enhances the REP Rab interaction prior to prenylation.			Seabra, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel/AAC-3099-2019; Seabra, Miguel C/M-3280-2013	Seabra, Miguel C/0000-0002-6404-4892	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SANFORD JC, 1995, J BIOL CHEM, V270, P26904, DOI 10.1074/jbc.270.45.26904; SANFORD JC, 1995, MOL BIOL CELL, V6, P71, DOI 10.1091/mbc.6.1.71; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHIEDEL AC, 1995, FEBS LETT, V376, P113, DOI 10.1016/0014-5793(95)01258-0; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHAPIRO AD, 1993, J BIOL CHEM, V268, P2925; Shen F, 1996, J BIOL CHEM, V271, P3692; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; TAN TJ, 1991, FEBS LETT, V291, P322, DOI 10.1016/0014-5793(91)81312-V; TAVITIAN A, 1992, METHOD ENZYMOL, V219, P387; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WILSON AL, 1993, J BIOL CHEM, V268, P14561; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	47	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14398	14404		10.1074/jbc.271.24.14398	http://dx.doi.org/10.1074/jbc.271.24.14398			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662963	hybrid			2022-12-25	WOS:A1996UQ66000069
J	Xie, WW; Kaetzel, MA; Bruzik, KS; Dedman, JR; Shears, SB; Nelson, DJ				Xie, WW; Kaetzel, MA; Bruzik, KS; Dedman, JR; Shears, SB; Nelson, DJ			Inositol 3,4,5,6-tetrakisphosphate inhibits the calmodulin-dependent protein kinase II-activated chloride conductance in T84 colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; AIRWAY EPITHELIA; BINDING PROTEIN; ACINAR-CELLS; LINE T84; CALCIUM; CHANNELS; STIMULATION; PHOSPHATES; SECRETION	The mechanism by which inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4) regulates chloride (Cl-) secretion was evaluated in the colonic epithelial cell line T84 using whole cell voltage clamp techniques. Our studies focused on the calcium-dependent chloride conductance (gCl(Ca)) that was activated either by mobilizing intracellular calcium (Ca-i) stores with thapsigargin or by introduction of the autonomous, autophosphorylated calmodulin-dependent protein kinase II (CaMKII) into the cell via the patch pipette. Basal concentrations of Ins(3,4,5,6)P-4 (1 mu M) present in the pipette solution had no significant effect on Cl- current; however, as the concentration of the polyphosphate was increased there was a corresponding reduction in anion current, with near complete inhibition at 8-10 mu M Ins(3,4,5,6)P-4. Corresponding levels are found in cells after sustained receptor-dependent activation of phospholipase C. The Ins(3,4,5,6)P-4-induced inhibition of gCl(Ca) was isomer specific; neither Ins(1,3,4,5)P-4, Ins(1,3,4,6)P-4, Ins(1,4,5,6)P-4, nor Ins(1,3,4,5,6)P-5 induced current inhibition at concentrations of up to 100 mu M. Annexin TV also plays an inhibitory role in modulating gCl(Ca) in T84 cells. When 2 mu M annexin IV was present in the pipette solution, a concentration that by itself has no effect on gCl(Ca), the potency of Ins(3,4,5,6)P-4 was approximately doubled. The combination of Ins(3,4,5,6)P-4 and annexin TV did not alter the in vitro activity of CaMKII. These data demonstrate that Ins(3,4,5,6)P-4 is an additional cellular signal that participates in the control of salt and fluid secretion, pH balance, osmoregulation, and other physiological activities that depend upon gCl(Ca) activation. Ins(3,4,5,6)P-4 metabolism and action should also be taken into account when designing treatment strategies for cystic fibrosis.	UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637; UNIV ILLINOIS,COLL PHARM,DEPT MED CHEM & PHARMACOGNOSY,CHICAGO,IL 60612; UNIV CINCINNATI,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,CINCINNATI,OH 45267; NIEHS,CELLULAR & MOLEC PHARMACOL LAB,NIH,RES TRIANGLE PK,NC 27709	University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46433] Funding Source: Medline; NIGMS NIH HHS [R01 GM36823] Funding Source: Medline; PHS HHS [R01 41470] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BRUZIK KS, 1989, CARBOHYD RES, V195, P67, DOI 10.1016/0008-6215(89)85089-X; CHAN HC, 1994, J BIOL CHEM, V269, P32464; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHAN HC, 1992, SCIENCE, V257, P669, DOI 10.1126/science.1379742; CHAO AC, 1994, BRIT J PHARMACOL, V112, P169, DOI 10.1111/j.1476-5381.1994.tb13047.x; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; DESAI T, 1992, CARBOHYD RES, V228, P65, DOI 10.1016/S0008-6215(00)90549-4; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; KAETZEL MA, 1994, J BIOL CHEM, V269, P5297; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAETZEL MA, 1987, J BIOL CHEM, V262, P1818; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KNOWLES MR, 1995, CHEST, V107, P715; KORN SJ, 1991, J PHYSIOL-LONDON, V439, P423, DOI 10.1113/jphysiol.1991.sp018674; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; PAPP Z, 1995, J PHYSIOL-LONDON, V483, P319, DOI 10.1113/jphysiol.1995.sp020588; PETERSEN OH, 1992, J PHYSIOL-LONDON, V488, P1; PIETRUSIEWICZ KM, 1992, TETRAHEDRON, V48, P5523, DOI 10.1016/S0040-4020(01)88305-8; PIETRUSIEWICZ KM, 1994, TETRAHEDRON, V50, P573; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SEATON BA, 1990, J BIOL CHEM, V265, P4567; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	36	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14092	14097		10.1074/jbc.271.24.14092	http://dx.doi.org/10.1074/jbc.271.24.14092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662902	hybrid			2022-12-25	WOS:A1996UQ66000026
J	Potaman, VN; Ussery, DW; Sinden, RR				Potaman, VN; Ussery, DW; Sinden, RR			Formation of a combined H-DNA/open TATA box structure in the promoter sequence of the human Na,K-ATPase alpha 2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; KI-RAS PROMOTER; NON-B-DNA; TRANSCRIPTION INITIATION; INTRAMOLECULAR TRIPLEX; 5'-FLANKING REGION; EXPRESSION; CONFORMATION; ELEMENT; SITES	Structural variation of DNA within the promoter of the human Na,K-ATPase alpha 2 gene, which contains a 35-base pair (bp) homopyrimidine homopurine (Py . Pu) tract adjacent to a TATA box has been studied. The Py . Pu tract contains a 26-bp quasi-mirror repeat sequence with a potential for intramolecular triplex formation. As analyzed by two-dimensional agarose gel electrophoresis, a plasmid containing 151 bp of the pro meter sequence including the 35-bp Py . Pu tract undergoes structural transitions under moderately acidic pH. Chemical probing with chloroacetaldehyde, dimethyl sulfate, and potassium permanganate is consistent with the formation of tripler DNA within the Py . Pu tract at native superhelical density as isolated from Escherichia coli. Chemical probing was used to determine a supercoil dependence for the formation of this combined unwound structure, At the superhelical density sufficient to locally unwind DNA, an H-y3 isomer of intermolecular tripler likely forms, However, at higher superhelical tension an H-y5 structure forms in the Py . Pu tract, and with increasing supercoiling the local DNA unwinding extends into the abutting TATA box. The H-y5/open TATA box combination structure might be favorable at higher superhelical densities since it relaxes more supercoils, The possible involvement of the H-y5/open TATA box structure in transcription is discussed.			Potaman, VN (corresponding author), TEXAS A&M UNIV,INST BIOCHEM & BIOTECHNOL,2121 W HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Ussery, David/J-2026-2019; Sinden, Richard/AAE-3086-2019	Ussery, David/0000-0003-3632-5512; 				BEHE MJ, 1995, NUCLEIC ACIDS RES, V23, P689, DOI 10.1093/nar/23.4.689; BELOTSERKOVSKII BP, 1990, NUCLEIC ACIDS RES, V18, P6621, DOI 10.1093/nar/18.22.6621; BIRNBOIM HC, 1979, EUR J BIOCHEM, V98, P301, DOI 10.1111/j.1432-1033.1979.tb13189.x; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; Bucher P, 1991, DNA Seq, V1, P157, DOI 10.3109/10425179109020767; CHEN AH, 1993, GENE, V128, P211, DOI 10.1016/0378-1119(93)90565-K; CHRISTOPHE D, 1985, NUCLEIC ACIDS RES, V13, P5127, DOI 10.1093/nar/13.14.5127; CHUNG YT, 1990, MOL CELL BIOL, V10, P206, DOI 10.1128/MCB.10.1.206; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HTUN H, 1984, P NATL ACAD SCI-BIOL, V81, P7288, DOI 10.1073/pnas.81.23.7288; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KANG S, 1992, J BIOL CHEM, V267, P20889; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KLYSIK J, 1995, J MOL BIOL, V245, P499, DOI 10.1006/jmbi.1994.0041; KOCHEL TJ, 1988, BIOTECHNIQUES, V6, P532; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; LAFYATIS R, 1991, NUCLEIC ACIDS RES, V16, P6419; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEROY JL, 1994, NUCLEIC ACIDS RES, V22, P1600, DOI 10.1093/nar/22.9.1600; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; LYAMICHEV VI, 1985, J BIOMOL STRUCT DYN, V3, P327, DOI 10.1080/07391102.1985.10508420; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MANZINI G, 1994, NUCLEIC ACIDS RES, V22, P4634, DOI 10.1093/nar/22.22.4634; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PATHAK BG, 1990, GENOMICS, V8, P641, DOI 10.1016/0888-7543(90)90250-X; PEI D, 1991, SCIENCE, V253, P1408, DOI 10.1126/science.1716784; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POTAMAN VN, 1995, BIOCHEMISTRY-US, V34, P14885, DOI 10.1021/bi00045a033; RAGHU G, 1994, NUCLEIC ACIDS RES, V22, P3271, DOI 10.1093/nar/22.16.3271; ROBERTS RW, 1991, P NATL ACAD SCI USA, V88, P9397, DOI 10.1073/pnas.88.21.9397; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SANTRA M, 1994, J BIOL CHEM, V269, P579; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; SCHROTH GP, 1995, NUCLEIC ACIDS RES, V23, P1977, DOI 10.1093/nar/23.11.1977; SHIMIZU M, 1994, J MOL BIOL, V235, P185, DOI 10.1016/S0022-2836(05)80025-7; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SHULL MM, 1990, GENOMICS, V6, P451, DOI 10.1016/0888-7543(90)90475-A; SIEGFRIED E, 1986, NUCLEIC ACIDS RES, V14, P9125; SINDEN RR, 1994, DNA STRUCTURE FUNCTI, P217; Soyfer V. N., 1995, TRIPLE HELICAL NUCL; TRIPATHI J, 1991, J BIOMOL STRUCT DYN, V9, P387, DOI 10.1080/07391102.1991.10507919; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; USDIN K, 1989, J BIOL CHEM, V264, P20736; USSERY DW, 1993, BIOCHEMISTRY-US, V32, P6206, DOI 10.1021/bi00075a013; WONG AKC, 1990, CHROMOSOMA, V99, P344, DOI 10.1007/BF01731722	63	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13441	13447		10.1074/jbc.271.23.13441	http://dx.doi.org/10.1074/jbc.271.23.13441			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662935	hybrid			2022-12-25	WOS:A1996UP38500023
J	Chai, YC; Howe, PH; DiCorleto, PE; Chisolm, GM				Chai, YC; Howe, PH; DiCorleto, PE; Chisolm, GM			Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells - Evidence for release of fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OXIDATIVELY MODIFIED LDL; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; PERITONEAL-MACROPHAGES; ALPHA-TOCOPHEROL; MESSENGER-RNA; DNA-SYNTHESIS; EXPRESSION; PROLIFERATION	We have previously shown that oxidized low density lipoprotein (LDL) but not native LDL stimulated DNA synthesis in cultured smooth muscle cells (SMC) and that alpha-tocopherol (vitamin E) inhibited this proliferative response (Lafont, A., Chai, Y. C., Cornhill, J, F., Whitlow, P. L., Howe, P. H., and Chisolm, G. M. (1995) J. Chin, Invest. 95, 1018-1025). The moiety of oxidized LDL that stimulates DNA synthesis and the cellular mechanism for this potentially mitogenic effect are not known. We now report that lipid fractions containing lysophospholipids from oxidized LDL or phospholipase A(2)-treated native LDL stimulated SMC DNA synthesis as did palmitoyl lysophosphatidylcholine (lysoPC). Protein kinase C inhibitors and down regulation of protein kinase C activity by phorbol ester inhibited oxidized LDL- and lysoPC-induced DNA synthesis. A neutralizing monoclonal antibody against fibroblast growth factor-a significantly inhibited oxidized LDL and lysoPC-induced DNA synthesis in SMC; irrelevant antibodies were ineffective. Vitamin E inhibited the DNA synthesis stimulated by lysoPC, an observation that distinguished this effect from DNA synthesis induced by another detergent, digitonin, These results suggest that oxidized LDL and its lysoPC moiety stimulate SMC to enter the cell cycle via an oxidative mechanism that causes the release of fibroblast growth factor-2 and a subsequent autocrine or paracrine response.	CLEVELAND CLIN FDN, RES INST, DEPT CELL BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047852, P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29582, HL 47852] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; BROWN BG, 1976, CIRC RES, V39, P415, DOI 10.1161/01.RES.39.3.415; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CHEN Y, 1995, ATHEROSCLEROSIS, V112, P69, DOI 10.1016/0021-9150(94)05400-D; Cheng GC, 1996, CIRCULATION, V93, P99, DOI 10.1161/01.CIR.93.1.99; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; CHISOLM GM, 1996, ATHEROSCLEROSIS CORO, P129; COFFEY MD, 1995, J CLIN INVEST, V96, P1866, DOI 10.1172/JCI118232; CUTHBERT JA, 1986, BIOCHIM BIOPHYS ACTA, V876, P210, DOI 10.1016/0005-2760(86)90276-6; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DRAKE TA, 1991, AM J PATHOL, V138, P601; FISCHERDZOGA K, 1976, EXP MOL PATHOL, V24, P346, DOI 10.1016/0014-4800(76)90070-8; FUKUO K, 1995, J CLIN INVEST, V95, P669, DOI 10.1172/JCI117712; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Hatch F T, 1968, Adv Lipid Res, V6, P1; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; JOUGASAKI M, 1992, CIRC RES, V71, P614, DOI 10.1161/01.RES.71.3.614; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KOSUGI K, 1987, J CELL PHYSIOL, V130, P311, DOI 10.1002/jcp.1041300302; KRAEMER R, 1993, J BIOL CHEM, V268, P8040; KUZUYA M, 1991, J LIPID RES, V32, P197; LAFONT AM, 1995, J CLIN INVEST, V95, P1018, DOI 10.1172/JCI117746; LOCHER R, 1992, BIOCHEM BIOPH RES CO, V183, P156, DOI 10.1016/0006-291X(92)91622-W; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MANGIN EL, 1993, CIRC RES, V72, P161, DOI 10.1161/01.RES.72.1.161; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OZER NK, 1993, FEBS LETT, V322, P307, DOI 10.1016/0014-5793(93)81592-N; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; REDDY KB, 1993, J CELL PHYSIOL, V156, P48, DOI 10.1002/jcp.1041560108; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SHIRHATTI V, 1985, ANAL BIOCHEM, V147, P410, DOI 10.1016/0003-2697(85)90290-8; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; TAKAGI Y, 1988, ATHEROSCLEROSIS, V74, P227, DOI 10.1016/0021-9150(88)90241-9; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; WEISS RH, 1993, J BIOL CHEM, V268, P5724; WELTZIEN HU, 1977, BIOCHIM BIOPHYS ACTA, V466, P411, DOI 10.1016/0005-2736(77)90334-0; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WINKLES JA, 1993, AM J PATHOL, V143, P518; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOKODE M, 1988, J CLIN INVEST, V81, P720, DOI 10.1172/JCI113377; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	57	134	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17791	17797		10.1074/jbc.271.30.17791	http://dx.doi.org/10.1074/jbc.271.30.17791			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663300	hybrid			2022-12-25	WOS:A1996UY93500033
J	Deeney, JT; Cunningham, BA; Chheda, S; Bokvist, K; JunttiBerggren, L; Lam, K; Korchak, HM; Corkey, BE; Berggren, PO				Deeney, JT; Cunningham, BA; Chheda, S; Bokvist, K; JunttiBerggren, L; Lam, K; Korchak, HM; Corkey, BE; Berggren, PO			Reversible Ca2+-dependent translocation of protein kinase C and glucose-induced insulin release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; K+ CHANNELS; FREE CA2+; B-CELL; SECRETION; ISLETS; DIACYLGLYCEROL; ACTIVATION; CA-2+; INHIBITION	It has been reported that protein kinase C (PKC) interacts at multiple sites in beta-cell stimulus-secretion coupling, Nevertheless, there is still controversy concerning the importance of this enzyme in glucose-induced insulin release, The present study was undertaken to clarify whether glucose, directly, or through changes in cytoplasmic free Ca2+ concentration, [Ca2+](i), could promote translocation of PKC from the soluble to the membrane compartment, Whereas glucose, which increases [Ca2+](i), did not affect long-term distribution of PKC activity between soluble and membrane fractions, this distribution was reversibly affected acutely by the Ca2+ concentration in the extraction media, Translocation of PKC to the membrane by incubation of HIT cells for 10 min in the presence of 20 nM phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) resulted in a 5-fold increase in glucose-induced insulin release, This was prevented by 50 nM concentration of the PKC inhibitor staurosporine, provided that the cells were exposed to the inhibitor before the phorbol ester, Cells pretreated with TPA demonstrated increased insulin secretion in response to glucose for several hours, This time course extended beyond the disappearance of [H-3] TPA from the cells, which was complete after 1 h, Activation of PKC increased both average insulin release and the amplitude of oscillations a-fold, but did not affect oscillation frequency, The stimulatory effect of increased PKC activity on insulin release was not matched by changes in [Ca2+](i), We suggest that stimulation of the pancreatic beta-cell with glucose promotes transient translocation of certain PKC isoforms from the cytoplasm to the plasma membrane as a direct consequence of the increase in [Ca2+](i). Such a translocation may promote phosphorylation of one or several proteins involved in the regulation of the beta-cell stimulus-secretion coupling, This results in potentiation of glucose-induced activation of insulin exocytosis, an effect then not mediated by an increase in [Ca2+](i) per se, Hence, pulsatile insulin release can be obtained under conditions where overall [Ca2+](i) does not change, challenging the view that oscillations in [Ca2+](i) are indeed driving the oscillations in hormone release.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT MOLEC MED,ROLF LUFT CTR DIABET RES,S-17176 STOCKHOLM,SWEDEN; BOSTON UNIV,MED CTR,DIABET & METAB UNIT,BOSTON,MA 02118; UNIV PENN,CHILDRENS HOSP,DIV IMMUNOL,PHILADELPHIA,PA 19104	Karolinska Institutet; Karolinska University Hospital; Boston University; University of Pennsylvania; Childrens Hospital of Philadelphia			; Corkey, Barbara/E-7712-2015	Berggren, Per-Olof/0000-0001-8991-413X; Deeney, Jude/0000-0003-0988-9419; Corkey, Barbara/0000-0002-5467-1630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, P30DK046200, R37DK035914, R56DK035914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35914, DK-46200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERGGREN PO, 1989, BIOCHEM BIOPH RES CO, V165, P416, DOI 10.1016/0006-291X(89)91086-3; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; EASOM RA, 1989, BIOCHEM J, V264, P27, DOI 10.1042/bj2640027; EASOM RA, 1990, J BIOL CHEM, V265, P14938; EFENDIC S, 1993, J INT MED, V229, P9; GANESAN S, 1992, J CELL BIOL, V119, P313, DOI 10.1083/jcb.119.2.313; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; HOWELL SL, 1990, BIOCHEM SOC T, V18, P114, DOI 10.1042/bst0180114; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; KINDMARK H, 1992, FEBS LETT, V303, P85, DOI 10.1016/0014-5793(92)80483-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1145; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1989, J BIOL CHEM, V264, P9939; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; THAMS P, 1990, BIOCHEM J, V265, P777, DOI 10.1042/bj2650777; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; ZAITSEV SV, 1995, P NATL ACAD SCI USA, V92, P9712, DOI 10.1073/pnas.92.21.9712; ZAWALICH WS, 1991, BIOCHEM J, V278, P49, DOI 10.1042/bj2780049	35	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18154	18160		10.1074/jbc.271.30.18154	http://dx.doi.org/10.1074/jbc.271.30.18154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663368	hybrid			2022-12-25	WOS:A1996UY93500085
J	Schwarz, M; Lund, EG; Setchell, KDR; Kayden, HJ; Zerwekh, JE; Bjorkhem, I; Herz, J; Russell, DW				Schwarz, M; Lund, EG; Setchell, KDR; Kayden, HJ; Zerwekh, JE; Bjorkhem, I; Herz, J; Russell, DW			Disruption of cholesterol 7 alpha-hydroxylase gene in mice .2. Bile acid deficiency is overcome by induction of oxysterol 7 alpha-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPIDS; RATS	Past experiments and current paradigms of cholesterol homeostasis suggest that cholesterol 7 alpha-hydroxylase plays a crucial role in sterol metabolism by controlling the conversion of cholesterol into bile acids, Consistent with this conclusion, we show in the accompanying paper that mice deficient in cholesterol 7 alpha-hydroxylase (Cyp7(-/-) mice) exhibit a complex phenotype consisting of abnormal lipid excretion, skin pathologies, and behavioral irregularities (Ishibashi, S., Schwarz, M., Frykman, P, K., Herz, J., and Russell, D. W. (1996) J. Biol. Chem, 261, 18017-18023), Aspects of lipid metabolism in the Cyp7(-/-) mice are characterized here to deduce the physiological basis of this phenotype. Serum lipid, cholesterol, and lipoprotein contents are indistinguishable between wild-type and Cyp7(-/-) mice, Vitamin D-3 and E levels are low to undetectable in knockout animals, Stool fat content is significantly elevated in newborn Cyp7(-/-) mice and gradually declines to wild-type levels at 28 days of age, Several species of 7 alpha-hydroxylated bile acids are detected in the bile and stool of adult Cyp7(-/-) animals, A hepatic oxysterol 7 alpha-hydroxylase enzyme activity that may account for the 7 alpha-hydroxylated bile acids is induced between days 21 and 30 in both wild-type and deficient mice, An anomalous oily coat in the Cyp7(-/-) animals is due to the presence of excess monoglyceride esters in the fur, These data show that 7 alpha-hydroxylase and the pathway of bile acid synthesis initiated by this enzyme are essential for proper absorption of dietary lipids and fat-soluble vitamins in newborn mice, but not for the maintenance of serum cholesterol and lipid levels, In older animals, an alternate pathway of bile acid synthesis involving an inducible oxysterol 7 alpha-hydroxylase plays a crucial role in lipid and bile acid metabolism.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; CHILDRENS HOSP,MED CTR,DEPT PEDIAT,CINCINNATI,OH 45229; NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cincinnati Children's Hospital Medical Center; New York University; Karolinska Institutet				Bjorkhem, Ingemar/0000-0001-6087-9190; Russell, David/0000-0002-0277-403X; Bjorkhem, Ingemar/0000-0002-0575-9425	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, P01 HL020948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1992, J BIOL CHEM, V267, P1701; BERGSTROM S, 1959, ACTA CHEM SCAND, V13, P776, DOI 10.3891/acta.chem.scand.13-0776; BJORKHEM I, 1992, J LIPID RES, V33, P455; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; GRIGOR MR, 1977, LIPID METABOLISM MAM, P209; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1996, J BIOL CHEM, V261, P18017; LUND E, 1991, J BIOL CHEM, V266, P4929; NICOLAIDES N, 1970, LIPIDS, V5, P299, DOI 10.1007/BF02531461; PAYNE DW, 1995, J BIOL CHEM, V270, P18888, DOI 10.1074/jbc.270.32.18888; POPOFF SN, 1994, BONE, V15, P515, DOI 10.1016/8756-3282(94)90275-5; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SAKHAEE K, 1994, J UROLOGY, V152, P324, DOI 10.1016/S0022-5347(17)32730-1; SCHENCK GO, 1957, LIEBIGS ANN CHEM, V603, P46; SCHENCK GO, 1958, ANGEW CHEM, V19, P595; SETCHELL KDR, 1995, BIOCHEMISTRY-US, V34, P4169, DOI 10.1021/bi00013a004; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; STEWART ME, 1991, ADV LIPID RES, V24, P263; SUCHY FJ, 1982, PEDIATR RES, V16, P282, DOI 10.1203/00006450-198204000-00007; TOLL A, 1994, EUR J BIOCHEM, V224, P309, DOI 10.1111/j.1432-1033.1994.00309.x; TRABER MG, 1987, AM J CLIN NUTR, V46, P488, DOI 10.1093/ajcn/46.3.488; UCHIDA K, 1984, J LIPID RES, V25, P236; ZHANG J, 1995, BBA-LIPID LIPID MET, V1256, P353	26	220	222	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18024	18031		10.1074/jbc.271.30.18024	http://dx.doi.org/10.1074/jbc.271.30.18024			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663430	Green Accepted, hybrid			2022-12-25	WOS:A1996UY93500067
J	Tedin, K; Blasi, U				Tedin, K; Blasi, U			The RNA chain elongation rate of the lambda late mRNA is unaffected by high levels of ppGpp in the absence of amino acid starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							COLI RIBOSOMAL-RNA; GUANOSINE 5'-DIPHOSPHATE 3'-DIPHOSPHATE; GROWTH-RATE CONTROL; DIFFERENTIAL STRINGENT CONTROL; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; FEEDBACK-REGULATION; COLIPHAGE LAMBDA; TRANSCRIPTION-TERMINATION; PROTEIN-SYNTHESIS	In this study, the effects of high levels of guanosine tetraphosphate (ppGpp) on the decay and RNA chain elongation kinetics of the bacteriophage lambda late transcript in Escherichia coli were examined in the absence of amino acid starvation. The accumulation, mRNA decay kinetics, and RNA chain elongation rate of the lambda late mRNA were determined after heat induction of lambda cI857 lysogens in the presence of high levels of ppGpp induced from a RelA alpha fragment-overproducing plasmid. The accumulation kinetics and elongation rate determinations of the late mRNA were made at long times after induction to allow a new steady state of transcriptional activities under conditions of elevated intracellular levels of ppGpp. The results indicate no prolonged or significant effect on either mRNA decay or the RNA chain elongation rate of the late mRNA as a result of elevated ppGpp levels. Surprisingly, the RNA chain elongation rate determinations indicate an RNA polymerase processivity of approximately 90-100 nucleotides/s for the lambda late transcript despite the presence of high levels of ppGpp. The results are discussed in terms of various models for regulation of stable and messenger RNA synthesis in E. coli.			Tedin, K (corresponding author), UNIV VIENNA, INST GENET & MICROBIOL, DR BOHR GASSE 9, A-1030 VIENNA, AUSTRIA.			Tedin, Karsten/0000-0003-2109-0730				ALFOLDI L, 1962, J MOL BIOL, V5, P348, DOI 10.1016/S0022-2836(62)80077-1; ALMOND N, 1989, MOL GEN GENET, V216, P195, DOI 10.1007/BF00334356; Arber W., 1983, LAMBDA, P433; BARACCHINI E, 1991, J BIOL CHEM, V266, P11753; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BARACCHINI E, 1987, ANAL BIOCHEM, V167, P245, DOI 10.1016/0003-2697(87)90160-6; BEDWELL DM, 1986, MOL GEN GENET, V204, P17, DOI 10.1007/BF00330181; BREMER H, 1968, J MOL BIOL, V38, P163, DOI 10.1016/0022-2836(68)90404-X; BREMER H, 1995, BBA-GENE STRUCT EXPR, V1262, P15, DOI 10.1016/0167-4781(95)00042-F; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BREMER H, 1988, NATO ADV SCI I SER H, V14, P63; BRUNSCHEDE H, 1977, J BACTERIOL, V129, P1020, DOI 10.1128/JB.129.2.1020-1033.1977; BURT DW, 1982, MOL GEN GENET, V185, P462, DOI 10.1007/BF00334141; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; CHAMPOUX JJ, 1970, COLD SPRING HARB SYM, V35, P319, DOI 10.1101/SQB.1970.035.01.042; CHASHEL M, 1969, NATURE, V221, P838, DOI 10.1038/221838a0; CHOWDHURY DM, 1973, NATURE-NEW BIOL, V241, P196, DOI 10.1038/newbio241196a0; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; COLE JR, 1988, NATO ADV SCI I SER H, V14, P56; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; DALBOW DG, 1973, J MOL BIOL, V75, P181, DOI 10.1016/0022-2836(73)90537-8; DOVE WF, 1966, J MOL BIOL, V19, P187, DOI 10.1016/S0022-2836(66)80060-8; DOVE WF, 1971, BACTERIOPHAGE LAMBDA, P747; Echols H., 1971, BACTERIOPHAGE LAMBDA, P247; FIIL N, 1968, J BACTERIOL, V95, P729, DOI 10.1128/JB.95.2.729-731.1968; FIIL NP, 1972, J MOL BIOL, V71, P769; FORBES D, 1982, J MOL BIOL, V160, P549, DOI 10.1016/0022-2836(82)90314-X; Furth M., 1983, LAMBDA 2, P145; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; Goldberg A R, 1969, Virology, V38, P200, DOI 10.1016/0042-6822(69)90148-2; GOURSE RL, 1983, CELL, V32, P1347, DOI 10.1016/0092-8674(83)90315-X; HASE T, 1989, MOL GEN GENET, V216, P120, DOI 10.1007/BF00332239; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HEINEMEYER EA, 1978, P NATL ACAD SCI USA, V75, P4180, DOI 10.1073/pnas.75.9.4180; HERNANDEZ VJ, 1993, J BIOL CHEM, V268, P10851; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; Jinks-Robertson S., 1987, ESCHERICHIA COLI SAL, P1358; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LITTLE R, 1982, ANAL BIOCHEM, V126, P381, DOI 10.1016/0003-2697(82)90531-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUK KC, 1983, MOL GEN GENET, V189, P289, DOI 10.1007/BF00337819; MANOR H, 1969, J MOL BIOL, V39, P1, DOI 10.1016/0022-2836(69)90329-5; MATSUBARA K, 1981, PLASMID, V5, P32, DOI 10.1016/0147-619X(81)90076-7; MATZURA H, 1973, J MOL BIOL, V74, P9, DOI 10.1016/0022-2836(73)90350-1; METZGER S, 1989, J BIOL CHEM, V264, P21146; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; MIZUSHIMASUGANO J, 1983, MOL GEN GENET, V189, P185, DOI 10.1007/BF00337802; MOLIN S, 1976, P 9 A BENZ S, P333; MORGAN EA, 1986, J BACTERIOL, V168, P1; MUELLER K, 1968, J MOL BIOL, V38, P329, DOI 10.1016/0022-2836(68)90390-2; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; Nomura M, 1987, RNA POLYMERASE REGUL, P137; OWENS JR, 1987, BIOCHEM BIOPH RES CO, V142, P964, DOI 10.1016/0006-291X(87)91508-7; PEDERSEN S, 1978, MOL GEN GENET, V166, P329, DOI 10.1007/BF00267626; PETRENKO LA, 1989, GENE, V78, P85, DOI 10.1016/0378-1119(89)90316-8; PRIMAKOFF P, 1979, P NATL ACAD SCI USA, V76, P1726, DOI 10.1073/pnas.76.4.1726; PRIMAKOFF P, 1981, J BACTERIOL, V145, P410, DOI 10.1128/JB.145.1.410-416.1981; RAY PN, 1974, J MOL BIOL, V85, P163, DOI 10.1016/0022-2836(74)90135-1; RAY PN, 1975, NATURE, V253, P647, DOI 10.1038/253647a0; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; REINESS G, 1975, P NATL ACAD SCI USA, V72, P2881, DOI 10.1073/pnas.72.8.2881; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; ROBERTS JW, 1975, P NATL ACAD SCI USA, V72, P3300, DOI 10.1073/pnas.72.9.3300; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; RYALS J, 1982, J BACTERIOL, V150, P168, DOI 10.1128/JB.150.1.168-179.1982; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMPSON LL, 1988, P NATL ACAD SCI USA, V85, P5439, DOI 10.1073/pnas.85.15.5439; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SHEPHERD N, 1980, J BACTERIOL, V143, P1332, DOI 10.1128/JB.143.3.1332-1344.1980; SHEPHERD NS, 1980, J BACTERIOL, V141, P1098, DOI 10.1128/JB.141.3.1098-1108.1980; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; SVITIL AL, 1993, J BIOL CHEM, V268, P2307; SZALEWSKAPALASZ A, 1994, EMBO J, V13, P5779, DOI 10.1002/j.1460-2075.1994.tb06916.x; TEDIN K, 1992, J BIOL CHEM, V267, P2337; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; VANOOYEN AJJ, 1975, NATURE, V254, P530, DOI 10.1038/254530a0; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; VOGEL U, 1994, J BIOL CHEM, V269, P16236; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x; WEGRZYN G, 1991, MOL GEN GENET, V225, P94, DOI 10.1007/BF00282646; XIAO H, 1991, J BIOL CHEM, V266, P5980; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x	103	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17675	17686		10.1074/jbc.271.30.17675	http://dx.doi.org/10.1074/jbc.271.30.17675			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663373	hybrid			2022-12-25	WOS:A1996UY93500016
J	Charest, H; Zhang, WW; Matlashewski, G				Charest, H; Zhang, WW; Matlashewski, G			The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3'-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-83; TRYPANOSOMA-BRUCEI; GENOMIC ORGANIZATION; TUBULIN GENES; ARRANGEMENT; ENRIETTII; AMAZONENSIS; SEQUENCE; RNA	Leishmania donovani is a protozoan parasite that exists as a free-living promastigote in the sandfly insect vector and as an amastigote inside the mammalian host macrophage phagolysosome compartment. The L. donovani A2 genes have been described previously as developmentally expressed in amastigotes but can be induced experimentally in promastigotes by a combination of pH and temperature shifts, conditions that mimic the phagolysosomal compartment of the macrophage cell. Considering the importance of the amastigote stage in human infections, we have examined the molecular basis for amastigote stage-specific gene expression. Our results provide evidence that A2 developmental expression during the promastigote-to-amastigote cytodiffer entiation is mediated through differential RNA stability and involves the A2 mRNA 3'-untranslated region. The site of processing in the S' untranslated region was a major factor for the accumulation of A2 mRNAs in cells incubated under phagolysosomal conditions. The stability of reporter gene transcripts bearing the A2 8'-untranslated region was increased in cells incubated at low pH, further confirming the importance of pH shift as an inducer for A2 expression. These observations contribute to defining the mechanism of amastigote-specific gene regulation in L. donovani. We also demonstrate the feasibility of using the A2 locus to express heterologous genes differentially in the amastigote form of the L. donovani parasite.	MCGILL UNIV, INST PARASITOL, Ste Anne De Bellevue, PQ H9X 3V9, CANADA	McGill University				Zhang, Wenwei/0000-0003-1996-876X				ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; Beverley S M, 1993, Methods Mol Biol, V21, P333; BOCK JH, 1993, MOL BIOCHEM PARASIT, V62, P187, DOI 10.1016/0166-6851(93)90108-A; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BRANDAU S, 1995, BIOCHEM J, V310, P225, DOI 10.1042/bj3100225; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; DESCOTEAUX A, 1989, MOL CELL BIOL, V9, P5223, DOI 10.1128/MCB.9.11.5223; FLINN HM, 1992, NUCLEIC ACIDS RES, V20, P755, DOI 10.1093/nar/20.4.755; HUANG PL, 1984, MOL CELL BIOL, V4, P1372, DOI 10.1128/MCB.4.7.1372; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LEE MGS, 1988, NUCLEIC ACIDS RES, V16, P9567, DOI 10.1093/nar/16.20.9567; Molyneux DH, 1987, LEISHMANIASES BIOL M, V1, P121; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; PAYS E, 1993, EUKARYOTIC MICROBIAL, P99; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPIRA M, 1989, EUR J BIOCHEM, V185, P231, DOI 10.1111/j.1432-1033.1989.tb15107.x; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; WALTON BC, 1987, LEISHMANIASIS BIOL M, V2; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787; World Health Organization (WHO), 1993, TROP DIS RES PROGR 1; ZHANG WW, 1996, IN PRESS MOL BIOCH P	31	117	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17081	17090		10.1074/jbc.271.29.17081	http://dx.doi.org/10.1074/jbc.271.29.17081			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663340	hybrid			2022-12-25	WOS:A1996UX94300018
J	Yanagihara, N; Oishi, Y; Yamamoto, H; Tsutsui, M; Kondoh, J; Sugiura, T; Miyamoto, E; Izumi, F				Yanagihara, N; Oishi, Y; Yamamoto, H; Tsutsui, M; Kondoh, J; Sugiura, T; Miyamoto, E; Izumi, F			Phosphorylation of chromogranin A and catecholamine secretion stimulated by elevation of intracellular Ca2+ in cultured bovine adrenal medullary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; 56 MM K+; TYROSINE-HYDROXYLASE; CHROMAFFIN CELLS; NERVOUS-TISSUE; PC12 CELLS; RAT-BRAIN; ACTIVATION; PURIFICATION; STAUROSPORINE	We have recently isolated a new endogenous substrate of 70 kDa for Ca2+/calmodulin dependent protein kinase II (CaM kinase II) from bovine adrenal medullary cells (Yanagihara, N., Toyohira, Y., Yamamoto, H., Ohta, Y., Tsutsui, M., Miyamoto, E., and Izumi, F. (1994) Mol. Pharmacol. 46, 423-430). Here we report the sequence analysis of the 70-kDa protein and examine its phosphorylation by various protein kinases in vitro and by depolarization of the cultured cells, Protein sequencing and immunoblotting revealed that the 70-kDa protein is chromogranin A (CgA) or a closely related protein. Partially purified CgA was phosphorylated by cyclic AMP-dependent protein kinase and protein kinase C as well as CaM kinase II, Tryptic phosphopeptide mapping patterns of CgA differed among these protein kinases. In P-32-labeled bovine adrenal medullary cells, 56 mM K+ increased the phosphorylation of CgA and catecholamine secretion in similar time- and concentration-dependent manners, both of which were inhibited by 20 mM MgSO4, an inhibitor of voltage-dependent Ca2+ channels. These findings suggest that CgA serves as a substrate for several multifunctional protein kinases and that the elevation of the intracellular Ca2+ stimulates the phosphorylation of CgA associated with catecholamine secretion in cultured adrenal medullary cells.	UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT IMMUNOL,KITAKYUSHU,FUKUOKA 807,JAPAN; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT INTERNAL MED 2,KITAKYUSHU,FUKUOKA 807,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT PHARMACOL,KUMAMOTO 860,JAPAN; MITSUBISHI KAGAKU CORP,RES CTR,YOKOHAMA,KANAGAWA 224,JAPAN	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kumamoto University	Yanagihara, N (corresponding author), UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT PHARMACOL,YAHATANISHI KU,1-1 ISEIGAOKA,KITAKYUSHU,FUKUOKA 807,JAPAN.							AMY CM, 1981, J NEUROCHEM, V36, P847, DOI 10.1111/j.1471-4159.1981.tb01671.x; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTE A, 1986, NEUROSCIENCE, V19, P629, DOI 10.1016/0306-4522(86)90286-1; DOUGLAS WW, 1961, J PHYSIOL-LONDON, V159, P40, DOI 10.1113/jphysiol.1961.sp006791; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FUKUNAGA K, 1982, J NEUROCHEM, V39, P1607, DOI 10.1111/j.1471-4159.1982.tb07994.x; GEORGE RJ, 1989, J NEUROCHEM, V52, P274, DOI 10.1111/j.1471-4159.1989.tb10928.x; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HAYCOCK JW, 1982, J BIOL CHEM, V257, P2641; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KONDO N, 1992, J BIOL CHEM, V267, P473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MIYAMOTO E, 1974, J BIOL CHEM, V249, P2769; MIYAMOTO E, 1973, J BIOL CHEM, V248, P179; NAGATSU T, 1973, BIOCH CATECHOLAMINES, P170; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; POCOTTE SL, 1986, J NEUROCHEM, V46, P610, DOI 10.1111/j.1471-4159.1986.tb13011.x; POLLARD HB, 1976, J BIOL CHEM, V251, P4544; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSKOSKI R, 1983, METHOD ENZYMOL, V79, P3; SOMOGYI P, 1984, BRAIN RES REV, V8, P193, DOI 10.1016/0165-0173(84)90007-9; SUGIURA T, 1994, INT ARCH ALLERGY IMM, V103, P341, DOI 10.1159/000236652; TACHIKAWA E, 1986, MOL PHARMACOL, V30, P476; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TSUTSUI M, 1994, MOL PHARMACOL, V46, P1041; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WAYMIRE JC, 1988, J BIOL CHEM, V263, P12439; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2; WEILMALHERBE H, 1952, BIOCHEM J, V51, P311, DOI 10.1042/bj0510311; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1993, J ANAT, V183, P237; WOOTEN MW, 1987, EUR J BIOCHEM, V164, P461, DOI 10.1111/j.1432-1033.1987.tb11079.x; YANAGIHARA N, 1987, BIOCHEM PHARMACOL, V36, P3823, DOI 10.1016/0006-2952(87)90444-8; YANAGIHARA N, 1994, MOL PHARMACOL, V46, P423; YANAGIHARA N, 1984, MOL PHARMACOL, V26, P141; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; YANAGIHARA N, 1979, FEBS LETT, V105, P296, DOI 10.1016/0014-5793(79)80633-X; YOO SH, 1990, J BIOL CHEM, V265, P14414	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17463	17468		10.1074/jbc.271.29.17463	http://dx.doi.org/10.1074/jbc.271.29.17463			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663339	hybrid			2022-12-25	WOS:A1996UX94300074
J	Holst, C; Zipfel, PF				Holst, C; Zipfel, PF			A zinc finger gene from Onchocerca volvulus encodes a protein with a functional signal peptide and an unusual Ser-His finger motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; BINDING-PROTEIN; POLYADENYLATION; CLEAVAGE; SEQUENCES; HOMOLOGY; DOMAINS; KRUPPEL; ELEMENT; MEMBER	The filarial parasite Onchocerca volvulus is the causative agent of river blindness. In order to identify genes potentially involved in parasite development we cloned a zinc finger-encoding gene from this species. The ovzf-1 gene represents one member of a family of related zinc finger genes. The predicted ovzf-1 translation product of 447 amino acids includes a hydrophobic signal peptide, which is followed by 13 contiguous finger motifs. The domains of fingers II-XIII display several conserved amino acids and a typical Kruppel-like Cys(2)-His(2) motif. The first finger domain has the two conserved Cys residues replaced with Ser residues; however, it includes all additional amino acids typical of zinc finger domains. The N-terminal domain functions as a signal peptide, as it directs secretion of a reporter protein and a truncated Ovzf protein. Expression of an Ovzf protein via the secretory pathway was also confirmed by demonstrating attachment of N-linked carbohydrates to the recombinant protein. Although the recombinant Ovzf protein also includes a signal peptide, immunofluorescence analyses localize it inside a specific compartment of the infected insect cell. Expression of ovzf mRNA is developmentally regulated; no specific transcript is detected in adult female worms but in the infective L3. Identification of a secreted protein that might function in modulating gene expression of host cells provides an interesting tool for the study of parasite-host interaction on a biochemical and molecular level.	BERNHARD NOCHT INST TROP MED,DEPT MOLEC BIOL,D-20359 HAMBURG,GERMANY	Bernhard Nocht Institut fur Tropenmedizin								BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; Bianco A.E., 1991, P138; BLACKLOCK D. B., 1926, ANN TROP MED & PARASITOL, V20, P1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; GREENE BM, 1992, J INFECT DIS, V166, P15, DOI 10.1093/infdis/166.1.15; Haehling E, 1995, INT J PARASITOL, V25, P1393, DOI 10.1016/0020-7519(95)00080-1; HAMMOND MP, 1992, PARASITOL TODAY, V8, P299, DOI 10.1016/0169-4758(92)90100-G; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; HEUCKESHOVEN J, 1986, ELECTROPHORESIS, V6, P103; HOLST C, 1993, TROP MED PARASITOL, V44, P147; JASMER DP, 1994, MOL BIOCHEM PARASIT, V67, P225, DOI 10.1016/0166-6851(94)00131-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRISTENSEN T, 1986, J IMMUNOL, V136, P3407; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; KUHN S, 1995, J IMMUNOL, V155, P5663; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFEAR J, 1991, BIOCHEM BIOPH RES CO, V179, P1220, DOI 10.1016/0006-291X(91)91702-E; LIEBAU E, 1994, MOL BIOCHEM PARASIT, V63, P305, DOI 10.1016/0166-6851(94)90067-1; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MAYER RJ, 1987, IMMUNOCHEMICAL METHO; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SCHULZKEY H, 1977, TROPENMED PARASITOL, V28, P428; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; VASSILATIS DK, 1992, J BIOL CHEM, V267, P18459; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; *WHO EXP COMM ONCH, 3 WHO EXP COMM ONCH; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	45	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16725	16733		10.1074/jbc.271.28.16725	http://dx.doi.org/10.1074/jbc.271.28.16725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663215	hybrid			2022-12-25	WOS:A1996UX12600049
J	Wojcikiewicz, RJH; Oberdorf, JA				Wojcikiewicz, RJH; Oberdorf, JA			Degradation of inositol 1,4,5-trisphosphate receptors during cell stimulation is a specific process mediated by cysteine protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; NEUROBLASTOMA-CELLS; KINASE-C; CALCIUM; PROTEINS; BINDING; TRISPHOSPHATE; INHIBITION; AUTOPHAGY	Inositol 1,4,5-trisphosphate (InsP(3)) receptors are down-regulated in response to chronic activation of certain cell surface receptors because their degradation is accelerated, Studies on the nature of the down-regulatory process and the protease(s) responsible for receptor degradation are described here, InsP(3) receptor down-regulation was not accompanied by parallel changes in the concentrations of several other relevant proteins (endoplasmic reticulum Ca2+-ATPase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and protein kinases alpha and epsilon). Thus, the down-regulatory process selectively targets InsP(3) receptors for degradation, Furthermore, down-regulation was unaffected by brefeldin A and NH4Cl, indicating that InsP(3) receptor degradation occurs without removal of receptors from the endoplasmic reticulum and independently of functional lysosomes, Analysis of InsP(3) receptor immunofluorescence confirmed that the receptors are not redistributed prior to or during down-regulation, Finally, of a range of protease inhibitors tested, only N-acetyl-Leu-Leu-norleucinal blocked down-regulation. Thus, cysteine protease activity accounts for InsP(3) receptor degradation and analysis of proteolysis in permeabilized cells indicates that this activity is calpain, Thus, InsP(3) receptor downregulation appears to result from the highly selective calpain-mediated degradation of InsP(3) receptors, Calpain activity may be stimulated by the high concentrations of Ca2+ that are thought to be found in the vicinity of activated InsP(3) receptors.			Wojcikiewicz, RJH (corresponding author), SUNY HLTH SCI CTR, COLL MED, DEPT PHARMACOL, 750 E ADAMS ST, SYRACUSE, NY 13210 USA.			Oberdorf, Jon/0000-0002-0589-7115	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049194, R29DK049194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAWSON AP, 1995, BIOCHEM J, V310, P371, DOI 10.1042/bj3100371; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GORDON PB, 1993, J BIOL CHEM, V268, P26107; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KILEY SC, 1991, J BIOL CHEM, V266, P23761; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MA H, 1994, J BIOL CHEM, V269, P24430; MAGNUSSON A, 1993, FEBS LETT, V323, P229, DOI 10.1016/0014-5793(93)81345-Z; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIMURA Y, 1995, BIOL PHARM BULL, V18, P945; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEA TB, 1994, FEBS LETT, V350, P223, DOI 10.1016/0014-5793(94)00769-1; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TAYLOR CW, 1995, BIOCHEM SOC T, V23, P637, DOI 10.1042/bst0230637; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; WUWONG JYR, 1993, MOL PHARMACOL, V44, P422; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	44	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16652	16655		10.1074/jbc.271.28.16652	http://dx.doi.org/10.1074/jbc.271.28.16652			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663308	hybrid			2022-12-25	WOS:A1996UX12600037
J	Crawley, JB; Williams, LM; Mander, T; Brennan, FM; Foxwell, BMJ				Crawley, JB; Williams, LM; Mander, T; Brennan, FM; Foxwell, BMJ			Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-10; CELLS; ACTIVATION; RAPAMYCIN; RECEPTORS; PROTEIN; 3,4,5-TRISPHOSPHATE; PHOSPHORYLATION; LYMPHOCYTES; EXPRESSION	Interleukin-10 (IL-10) is a powerful suppressor of the proinflammatory monokine production by lipopolysaccharide-stimulated monocytes as well as a T- and B-cell growth cofactor, The signal transduction cascades initiated by IL-10 ligation to its cognate receptor remain to be elucidated, Here, we demonstrate that in both primary monocytes and the D36 cell line, IL-10 rapidly and transiently stimulated phosphatidylinositol 5-kinase activity associated with the p85 subunit of the enzyme, IL-10 also activated p70 S6 kinase in both cell types, The activation of both of these kinases was sensitive to wortmannin, an inhibitor of phosphatidylinositol 3-kinase, The activation of p70 S6 kinase was also inhibited by the immunosuppressive drug rapamycin. Both rapamycin and wortmannin inhibited the IL-10-induced proliferation of D36 cells but in contrast had no effect on the antiinflammatory effects of the cytokine on lipopolysaccharide-stimulated monocytes, Similar results on D36 proliferation and lipopolysaccharide stimulated monocyte inhibition by IL-10 were obtained with another phosphatidylinositol 3-kinase inhibitor, LY294002, This suggests that the activation of phosphatidylinositol 3-kinase and p70 S6 kinase is involved in the proliferative functions of IL-10 and that other as yet uncharacterized pathways affect the suppressive effects on monocytes, indicating that multiple and distinct signaling pathways mediate the various pleiotropic activities of IL-10. Furthermore, these findings suggest that it may be possible in the future to modulate the antiinflammatory effects of IL-10 for therapeutic benefit without disrupting other functions of the cytokine.	KENNEDY INST,SUNLEY DIV,LONDON W6 8LW,ENGLAND; XENOVA LTD,SLOUGH SL1 4EQ,BERKS,ENGLAND	University of Oxford								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUTLER DM, 1994, EUR CYTOKINE NETW, V5, P441; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CHUI M, 1994, P NATL ACAD SCI USA, V91, P12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DADI H, 1994, BLOOD, V84, P1579; DING L, 1993, J IMMUNOL, V151, P1224; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ENGELBERTS I, 1991, LYMPHOKINE CYTOK RES, V10, P69; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FLUCKIGER AC, 1993, J EXP MED, V178, P1473, DOI 10.1084/jem.178.5.1473; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HARA K, 1995, BIOCHEM BIOPH RES CO, V208, P735, DOI 10.1006/bbrc.1995.1399; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HURME M, 1994, IMMUNOL LETT, V42, P129, DOI 10.1016/0165-2478(94)90075-2; JOYCE DA, 1994, EUR J IMMUNOL, V24, P2699, DOI 10.1002/eji.1830241119; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEHMANN J, 1994, J IMMUNOL, V153, P165; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; MACNEIL IA, 1990, J IMMUNOL, V145, P4167; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MERIDA I, 1991, J IMMUNOL, V147, P2202; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MOWER DA, 1994, J IMMUNOL, V152, P4832; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PAI SY, 1994, EUR J IMMUNOL, V24, P2364, DOI 10.1002/eji.1830241016; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHLAAK JF, 1994, J IMMUNOL METHODS, V168, P49, DOI 10.1016/0022-1759(94)90208-9; TAGA K, 1993, INT IMMUNOL, V5, P1599, DOI 10.1093/intimm/5.12.1599; TAYLORFISHWICK DA, 1993, TRANSPLANTATION, V56, P368, DOI 10.1097/00007890-199308000-00023; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; VENTIKARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; YANO H, 1993, J BIOL CHEM, V268, P25846	54	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16357	16362		10.1074/jbc.271.27.16357	http://dx.doi.org/10.1074/jbc.271.27.16357			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663063	hybrid			2022-12-25	WOS:A1996UW35200074
J	Dodig, M; Kronenberg, MS; Bedalov, A; Kream, BE; Gronowicz, G; Clark, SH; Mack, K; Liu, YH; Maxon, R; Pan, ZZ; Upholt, WB; Rowe, DW; Lichtler, AC				Dodig, M; Kronenberg, MS; Bedalov, A; Kream, BE; Gronowicz, G; Clark, SH; Mack, K; Liu, YH; Maxon, R; Pan, ZZ; Upholt, WB; Rowe, DW; Lichtler, AC			Identification of a TAAT-containing motif required for high level expression of the COL1A1 promoter in differentiated osteoblasts of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) COLLAGEN PROMOTER; MESSENGER-RNA LEVELS; FETAL-RAT CALVARIA; GROWTH FACTOR-BETA; NUCLEAR FACTOR-I; PARATHYROID-HORMONE; INSITU HYBRIDIZATION; CELL REPLICATION; MC3T3-E1 CELLS; DNA-SEQUENCES	Our previous studies have shown that the 49-base pair region of promoter DNA between -1719 and -1670 base pairs is necessary for transcription of the rat COL1A1 gene in transgenic mouse calvariae, In this study, we further define this element to the 13-base pair region between -1683 and -1670. This element contains a TAAT motif that binds homeodomain-containing proteins, Site-directed mutagenesis of this element in the context of a COL1A1-chloramphenicol acetyltransferase construct extending to -3518 base pairs decreased the ratio of reporter gene activity in calvariae to tendon from 3:1 to 1:1, suggesting a preferential effect on activity in calvariae, Moreover, chloramphenicol acetyltransferase-specific immunofluorescence microscopy of transgenic calvariae showed that the mutation preferentially reduced levels of chloramphenicol acetyltransferase-protein in differentiated osteoblasts, Gel mobility shift assays demonstrate that differentiated osteoblasts contain a nuclear factor that binds to this site, This binding activity is not present in undifferentiated osteoblasts, Ne show that Msx2, a homeodomain protein, binds to this motif; however, Northern blot analysis revealed that Msx2 mRNA is present in undifferentiated bone cells but not in fully differentiated osteoblasts, In addition, cotransfection studies in ROS 17/2.8 osteosarcoma cells using an Msx2 expression vector showed that Msx2 inhibits a COL1A1 promoter-chloramphenicol acetyltransferase construct, Our results suggest that high COL1A1 expression in bone is mediated by a protein that is induced during osteoblast differentiation. This protein may contain a homeodomain; however, it is distinct from homeodomain proteins reported previously to be present in bone.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT ORTHOPAED SURG,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06030; DEPT VET AFFAIRS MED CTR,NEWINGTON,CT 06111; UNIV SO CALIF,SCH MED,KENNETH R NORRIS HOSP & INST,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Southern California			Pan, Zhong-Zong/B-6964-2012	Gronowicz, Gloria/0000-0001-7158-3598	NIAMS NIH HHS [AR29850, AR38933, AR29983] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR029983, R01AR029850, P01AR038933] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BELL JR, 1993, GENOMICS, V16, P123, DOI 10.1006/geno.1993.1149; BIRNBAUM RS, 1994, ENDOCRINOLOGY, V135, P223, DOI 10.1210/en.135.1.223; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; HARRISON JR, 1990, MOL ENDOCRINOL, V4, P184, DOI 10.1210/mend-4-2-184; HEINRICHS AAJ, 1995, J CELL BIOCHEM, V57, P90, DOI 10.1002/jcb.240570110; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HOCK JM, 1990, ENDOCRINOLOGY, V126, P421, DOI 10.1210/endo-126-1-421; HODGKINSON JE, 1993, BIOCHIM BIOPHYS ACTA, V1174, P11, DOI 10.1016/0167-4781(93)90086-S; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; HOGAN B, 1986, MANIPULATING MOUSE E; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KREAM BE, 1986, ENDOCRINOLOGY, V119, P1922, DOI 10.1210/endo-119-5-1922; KREAM BE, 1980, P NATL ACAD SCI-BIOL, V77, P5654, DOI 10.1073/pnas.77.10.5654; KREAM BE, 1993, MOL ENDOCRINOL, V7, P399, DOI 10.1210/me.7.3.399; KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PAGE KM, 1982, THEORY PRACTICE HIST, P324; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QUARLES LD, 1992, J BONE MINER RES, V7, P683; RAISZ LG, 1983, NEW ENGL J MED, V309, P83, DOI 10.1056/NEJM198307143090206; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; ROWE DW, 1982, J BIOL CHEM, V257, P8009; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; SOKOLOV BP, 1995, J BIOL CHEM, V270, P9622, DOI 10.1074/jbc.270.16.9622; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; WEINREB M, 1990, J BONE MINER RES, V5, P831; WONG G, 1974, NATURE, V252, P713, DOI 10.1038/252713a0	50	82	82	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16422	16429		10.1074/jbc.271.27.16422	http://dx.doi.org/10.1074/jbc.271.27.16422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663211	hybrid			2022-12-25	WOS:A1996UW35200083
J	Knezevic, I; Leisner, TM; Lam, SCT				Knezevic, I; Leisner, TM; Lam, SCT			Direct binding of the platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa) to talin - Evidence that interaction is mediated through the cytoplasmic domains of both alpha(IIb) and beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ACTIVATED PLATELETS; FOCAL ADHESIONS; LIGAND-BINDING; RECEPTOR; PROTEIN; VINCULIN; CYTOSKELETON; PURIFICATION; ASSOCIATION	As a consequence of platelet activation and fibrinogen binding, glycoprotein (GP)IIb-IIIa (integrin alpha(IIb)beta(3)) becomes associated with the cytoskeleton. Although talin has been suggested to act as a Linkage protein mediating the attachment of GPIIb-IIIa to actin filaments, direct binding of GPIIb-IIIa to this cytoskeletal protein has not been demonstrated, in the present study, we examined the interaction of GPIIb-IIIa with purified talin using a solid-phase binding assay, Soluble GPIIb-IIIa bound in a time- and dose dependent manner to microtiter wells coated with talin but not with BSA. Time course studies demonstrated that steady-state binding was achieved after 4-5 h incubation at 37 degrees C. Binding isotherms with varying concentrations of GPIIb-IIIa showed that half-saturation binding was achieved at approximately 15 nM GPIIb-IIIa. At saturation, there was 211 +/- 8 fmol of GPIIb-IIIa bound per well containing 117 +/- 10 fmol of immobilized talin. Besides binding to immobilized talin, GPIIb-IIIa also bound to talin captured by the anti-talin monoclonal antibody 8d4, Moreover, the interaction of GPIIb-IIIa to 8d4-captured talin was blocked by mAb10B2, a monoclonal antibody raised against a synthetic peptide encompassing the entire cytoplasmic sequence of GPIIb. The interaction of talin with the cytoplasmic domain of GPIIb-IIIa was further investigated using peptide-coated wells, Purified talin was found to bind to both synthetic peptides corresponding 60 the cytoplasmic sequences of GPIIb (P2b) and GPIIIa (P3a), As expected, the binding of talin to P2b-coated wells was specifically blocked by mAb10B2. Thus, these results demonstrate direct binding of GPIIb-IIIa to talin and suggest a role of the cytoplasmic sequences of both GPIIb and GPIIIa in mediating this interaction.	UNIV ILLINOIS,DEPT PHARMACOL MC868,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NHLBI NIH HHS [HL-41793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041793, R29HL041793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKERLE MC, 1989, J CELL BIOL, V109, P3333, DOI 10.1083/jcb.109.6.3333; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERTAGNOLLI ME, 1993, J CELL BIOL, V121, P1329, DOI 10.1083/jcb.121.6.1329; BERTAGNOLLI ME, 1993, J CELL SCI, V106, P1189; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; COLLIER NC, 1982, J BIOL CHEM, V257, P6937; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GILMORE AP, 1992, J CELL SCI, V103, P719; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; ISENBERG WM, 1987, J CELL BIOL, V150, pA130; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LEE SW, 1992, J BIOL CHEM, V267, P16355; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; OTEY C, 1990, HYBRIDOMA, V9, P57, DOI 10.1089/hyb.1990.9.57; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PAINTER RG, 1985, J CELL BIOL, V100, P652, DOI 10.1083/jcb.100.2.652; PAVALKO FM, 1994, P SOC EXP BIOL MED, V205, P282; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1986, BIOCH PLATELETS, P226; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SIMMON KO, 1991, J CELL BIOL, V115, pA351; TAPLEY P, 1989, ONCOGENE, V4, P325; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; TUSZYNSKI GP, 1984, J BIOL CHEM, V259, P5247; WENCELDRAKE JD, 1990, AM J PATHOL, V136, P61; WENCELDRAKE JD, 1993, BLOOD, V81, P62; WHEELER ME, 1984, J CLIN INVEST, V74, P1080, DOI 10.1172/JCI111475; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; 1968, J BIOL CHEM, V243, P3557	53	113	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16416	16421		10.1074/jbc.271.27.16416	http://dx.doi.org/10.1074/jbc.271.27.16416			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663236	hybrid			2022-12-25	WOS:A1996UW35200082
J	Valenzuela, CF; Xiong, ZG; MacDonald, JF; Weiner, JL; Frazier, CJ; Dunwiddie, TV; Kazlauskas, A; Whiting, PJ; Harris, RA				Valenzuela, CF; Xiong, ZG; MacDonald, JF; Weiner, JL; Frazier, CJ; Dunwiddie, TV; Kazlauskas, A; Whiting, PJ; Harris, RA			Platelet-derived growth factor induces a long-term inhibition of N-methyl-D-aspartate receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT HIPPOCAMPAL-NEURONS; DEVELOPMENTAL EXPRESSION; ALPHA-RECEPTOR; PDGF; CALCIUM; CHANNELS; PROTEIN; SUPPRESSION; CULTURE	Platelet-derived growth factor (PDGF) is a multifunctional protein that plays important roles in many tissues, including the mammalian central nervous system. PDGF and PDGF receptors (PDGFRs) are expressed in virtually every region of the central nervous system where they are involved in the development, survival, growth, and differentiation of both neuronal and glial cells. We now report that a brief activation of PDGFRs produced a long-lasting inhibition of N-methyl-D-aspartate (NMDA) dependent excitatory postsynaptic currents in CA1 pyramidal neurons in rat hippocampal slices. PDGF also inhibited NMDA receptors (NMDA-Rs) in cultured hippocampal neurons by a mechanism that involves a decrease in single channel open probability. Non-NMDA receptor function was not affected by PDGF in hippocampal neurons. Experiments with mutant PDGFRs and chelation of intracellular Ca2+ in Xenopus oocytes indicate that this inhibition depends on a phospholipase C-gamma-induced elevation of intracellular Ca2+ levels. The PDGF-induced inhibition of NMDA-Rs is produced by a mechanism different than the well characterized phenomenon of Ca2+-dependent NMDA-R run down because the effect of PDGF was blocked by the phosphatase inhibitor, calyculin A, and was not affected by the microtubule polymerizing agent, phalloidin. Because elevations of PDGF levels are associated with neurological trauma or disease, we propose that PDGF can exert neuroprotective effects by inhibiting NMDA-R-dependent excitotoxicity.	UNIV COLORADO,HLTH SCI CTR,PROGRAM NEUROSCI,DENVER,CO 80262; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 1A8,CANADA; VET ADM MED CTR,DENVER,CO 80220; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; MERCK SHARP & DOHME RES LABS,HARLOW,ESSEX,ENGLAND	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Toronto; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Jewish Health; Merck & Company	Valenzuela, CF (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,BOX C236,4200 E 9TH AVE,DENVER,CO 80262, USA.			Whiting, Paul/0000-0002-4121-1379	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, R37AA006399, P50AA003527, F32AA005399] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA03527, AA05399, AA06399] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; CHENG B, 1995, J NEUROCHEM, V65, P2525; CHENG B, 1995, J NEUROSCI, V15, P7095; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; HANAI K, 1987, J CELL BIOL, V104, P1675, DOI 10.1083/jcb.104.6.1675; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; IIHARA K, 1994, J CEREBR BLOOD F MET, V14, P818, DOI 10.1038/jcbfm.1994.102; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LEBOURDELLES B, 1994, J NEUROCHEM, V62, P2091; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU LF, 1995, NEUROSCI LETT, V192, P5, DOI 10.1016/0304-3940(95)11593-L; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LUPICA CR, 1992, J NEUROSCI, V12, P3753; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MEDINA L, 1995, J PHYSIOL-LONDON, V482, P567; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NISTER M, 1994, BRIT J CANCER, V69, P952, DOI 10.1038/bjc.1994.184; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; OTHBERG A, 1995, EXP BRAIN RES, V105, P111; PLATASALAMAN CR, 1988, NEUROSCI LETT, V94, P161, DOI 10.1016/0304-3940(88)90288-1; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; SMITS A, 1993, EUR J NEUROSCI, V5, P986, DOI 10.1111/j.1460-9568.1993.tb00950.x; STANLEY BG, 1993, BRAIN RES, V630, P41; TAKAYAMA S, 1994, BRAIN RES, V653, P131, DOI 10.1016/0006-8993(94)90381-6; TIMPE LC, 1994, J NEUROSCI, V14, P1195, DOI 10.1523/JNEUROSCI.14-03-01195.1994; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Valenzuela CF, 1995, MOL PHARMACOL, V48, P1099; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; VIGNAIS L, 1995, NEUROREPORT, V6, P1993, DOI 10.1097/00001756-199510010-00010; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WILLIAMS JP, 1995, J CELL BIOCHEM, V57, P415, DOI 10.1002/jcb.240570307; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; YU HJ, 1993, MOL PHARMACOL, V44, P689; ZHONG J, 1995, J NEUROCHEM, V64, P531	56	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16151	16159		10.1074/jbc.271.27.16151	http://dx.doi.org/10.1074/jbc.271.27.16151			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663218	hybrid			2022-12-25	WOS:A1996UW35200046
J	Barr, DP; Gunther, MR; Deterding, LJ; Tomer, KB; Mason, RP				Barr, DP; Gunther, MR; Deterding, LJ; Tomer, KB; Mason, RP			ESR spin-trapping of a protein-derived tyrosyl radical from the reaction of cytochrome c with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; HYDROPEROXIDE; RESONANCE; METMYOGLOBIN; CATALASE; TYR-151; DAMAGE; HEART	The reaction of horse heart cytochrome c with hydrogen peroxide was investigated using the ESR spin-trapping technique and the nitroso spin traps 3,5-dibromo-4-nitrosobenzenesulfonic acid (DBNBS) and 2-methyl-2-nitrosopropane (MNP). The ESR spectra obtained using both spin traps were typical of an immobilized nitroxide and indicated that the adduct was a macromolecule, The intensity of the ESR spectrum corresponding to the DBNBS/(.)cytochrome c radical adduct was greatly enhanced by performing the reaction under anaerobic conditions, which suggested that the spin trap was competing with O-2 for reaction with the radical site(s), Nonspecific proteolysis of either the DBNBS or the MNP adducts revealed isotropic three-line spectra, In addition, a high resolution ESR spectrum for the protease-treated MNP cytochrome c-derived protein radical adduct was obtained. The superhyperfine couplings detected in this spectra were identical to those detected from an authentic MNP/tyrosyl adduct, Carbon-13 labeling of the aromatic ring positions of tyrosine yielded additional hyperfine coupling, demonstrating that the radical site was definitely located on the ring of tyrosine, Mass spectrometry detected as many as four DBNBS/(.)cytochrome c-derived adducts from the reaction of cytochrome with H2O2, Thus, it would appear four radical sites are formed during the reaction, at least one of which is tyrosine.			Barr, DP (corresponding author), NIEHS, MOLEC BIOPHYS LAB, NIH, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Tomer, Kenneth B/E-8018-2013; Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				Barr DP, 1996, CHEM RES TOXICOL, V9, P318, DOI 10.1021/tx9501501; Brigellius R., 1985, OXIDATIVE STRESS, P243; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHOE YS, 1994, ARCH BIOCHEM BIOPHYS, V314, P126, DOI 10.1006/abbi.1994.1420; DAVIES MJ, 1991, FREE RADICAL RES COM, V15, P111, DOI 10.3109/10715769109049131; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; DYER C, 1979, BIOCHIM BIOPHYS ACTA, V579, P253, DOI 10.1016/0005-2795(79)90053-9; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; FLORENCE TM, 1985, J INORG BIOCHEM, V23, P131, DOI 10.1016/0162-0134(85)83017-8; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; HIRAMOTO K, 1994, FREE RADICAL RES, V21, P341, DOI 10.3109/10715769409056586; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; KAUR H, 1981, J CHEM SOC CHEM COMM, P142, DOI 10.1039/c39810000142; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; LION Y, 1982, PHOTOCHEM PHOTOBIOL, V35, P53, DOI 10.1111/j.1751-1097.1982.tb03810.x; LION Y, 1982, PHOTOCHEM PHOTOBIOL, V35, P43, DOI 10.1111/j.1751-1097.1982.tb03809.x; MAIORINO M, 1994, FREE RADICAL BIO MED, V16, P661, DOI 10.1016/0891-5849(94)90067-1; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; OMalley PJ, 1995, BBA-BIOENERGETICS, V1232, P175, DOI 10.1016/0005-2728(95)00102-6; OSHEROFF N, 1980, J BIOL CHEM, V255, P1689; RADI R, 1993, FREE RADICAL BIO MED, V15, P653, DOI 10.1016/0891-5849(93)90169-U; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; RADI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P409, DOI 10.1006/abbi.1993.1055; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROUBAL WT, 1966, ARCH BIOCHEM BIOPHYS, V113, P150, DOI 10.1016/0003-9861(66)90168-8; TAPPEL AL, 1953, FOOD RES, V18, P560; TEW D, 1988, J BIOL CHEM, V263, P17880; TURRENS JF, 1988, FEBS LETT, V227, P43, DOI 10.1016/0014-5793(88)81410-8; WUTHRICH K, 1971, BIOCHIM BIOPHYS ACTA, V253, P98, DOI 10.1016/0005-2728(71)90237-4	41	131	133	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15498	15503		10.1074/jbc.271.26.15498	http://dx.doi.org/10.1074/jbc.271.26.15498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663160	hybrid			2022-12-25	WOS:A1996UV29900031
J	Duan, WR; Linzer, DIH; Gibori, G				Duan, WR; Linzer, DIH; Gibori, G			Cloning and characterization of an ovarian-specific protein that associates with the short form of the prolactin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; LUTEAL CELL; RAT OVARY; EXPRESSION; ALPHA-2-MACROGLOBULIN; PREGNANCY; ESTRADIOL; LIVER	Prolactin (PRL) is essential for progesterone biosynthesis and luteal cell hypertrophy of the rat corpus luteum during pregnancy. Both the long and short form of the PRL receptor have been identified in the corpus luteum of pregnant rat. The long form has been shown to transduce PRL signal in other cells, whereas no information is available on the role of the short form, especially in the corpus luteum. In the present study, we have cloned a rat ovarian specific phosphoprotein, FRAP (PRL Receptor Associated Protein), which has no significant homology to other known proteins, We have demonstrated that this protein is immunoprecipitated by anti-PRL receptor and anti-phosphotyrosine antibodies. To determine whether FRAP associates with either the long or the short form of the PRL receptor, fusion proteins with glutathione S-transferase containing the cytoplasmic domain of the long or short form of the PRL receptor were produced, purified, and incubated with luteal proteins. Our results indicate that FRAP preferentially binds to the short form of the PRL receptor. Thus, the long form and short forms of the PRL receptor may signal through distinct pathways. These data provide evidence for the involvement of a novel protein in PRL signal transduction and suggest that FRAP may contribute to the luteotropic effects of PRL on the corpus luteum during pregnancy.	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011119, R37HD011119] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11119, HD21921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBARRACIN CT, 1994, J BIOL CHEM, V269, P7772; ALBARRACIN CT, 1994, ENDOCRINOLOGY, V134, P2453, DOI 10.1210/en.134.6.2453; ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; BASURAY R, 1983, BIOL REPROD, V28, P551, DOI 10.1095/biolreprod28.3.551; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CLARKE DL, 1993, ENDOCRINOLOGY, V133, P2594, DOI 10.1210/en.133.6.2594; CLARKE DL, 1994, OVARIAN CELL INTERAC, P110; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; DAJEE M, 1995, BIOL REPROD S, V52, pA353; DAS R, 1995, MOL ENDOCRINOL, V9, P1750, DOI 10.1210/me.9.12.1750; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GADDYKURTEN D, 1989, ENDOCRINOLOGY, V125, P2985; GADDYKURTEN D, 1991, MOL ENDOCRINOL, V5, P1280, DOI 10.1210/mend-5-9-1280; GIBORI G, 1988, RECENT PROG HORM RES, V44, P377; GIBORI G, 1979, BIOL REPROD, V21, P419, DOI 10.1095/biolreprod21.2.419; GIBORI G, 1978, ENDOCRINOLOGY, V102, P767, DOI 10.1210/endo-102-3-767; GIBORI G, 1978, ENDOCRINOLOGY, V102, P1176, DOI 10.1210/endo-102-4-1176; Gibori G., 1993, OVARY, P261; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P74; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MACDONALD GJ, 1971, P SOC EXP BIOL MED, V136, P687; MCLEAN MP, 1990, ENDOCRINOLOGY, V126, P1796, DOI 10.1210/endo-126-4-1796; NAGANO M, 1994, J BIOL CHEM, V269, P13337; Nisson P E, 1991, PCR Methods Appl, V1, P120; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; PARMER TG, 1992, ENDOCRINOLOGY, V131, P2213, DOI 10.1210/en.131.5.2213; RUI H, 1994, J BIOL CHEM, V269, P5364; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y; ZHONG L, 1995, BIOL REPROD S, V52, pA379	50	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15602	15607		10.1074/jbc.271.26.15602	http://dx.doi.org/10.1074/jbc.271.26.15602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663045	hybrid			2022-12-25	WOS:A1996UV29900046
J	Lenormand, P; McMahon, M; Pouyssegur, J				Lenormand, P; McMahon, M; Pouyssegur, J			Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; GROWTH-FACTORS; INHIBITION; PHOSPHORYLATION; FIBROBLASTS; PHOSPHATASE; P42(MAPK); P44(MAPK); ENCODES; INDUCE	Cell proliferation requires the co-ordinate triggering of several protein kinases of Ser/Thr specificity such as p70 S6 kinase (S6K), which phosphorylates the ribosomal S6 protein and thus increases translation of mRNAs with polypyrimidine tracts. The multiplicity of signaling pathways leading to p70 S6K activation are not fully elucidated, However, several reports have indicated that the activation of p70 S6K is independent of mitogen activated protein kinase (MAPK) activation, Interestingly, we and others have shown that constitutive activation of the MAPK pathway promotes cell proliferation, suggesting that this cascade is able to activate p70 S6K, a key step to trigger cell cycle entry, In this report we demonstrate that transfection of constitutively active mitogen activated protein kinase kinase 1 in CCL 39 cells leads to activation of p70 S6K. Furthermore, we have established a cell line that stably expresses Delta Raf-1:ER, an estradiol-regulated form of oncogenic Raf-1. The addition of estradiol to these cells was sufficient to elicit rapid activation of mitogen-activated protein kinase kinase 1, MAPK, and p70 S6K. Surprisingly, the activation of p70 S6K is not mediated by MAPK because blocking MAPK activation by expression of the phosphatase MKP-1 did not prevent p70 S6K activation by Delta Raf-1:ER, In conclusion, we have demonstrated that activation of p70 S6K by Delta Raf-1:ER is mediated by a new MAPK-independent pathway. This pathway is resistant to low nanomolar concentrations of wortmannin, indicating that it does not involve membrane-bound phosphatidylinositol-trisphosphate kinase activation.	DNAX RES INST MOLEC & CELLULAR BIOL INC, RES INST, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Lenormand, P (corresponding author), UNIV NICE, CTR BIOCHIM, CNRS UMR 135, PARC VALROSE, F-06108 NICE 02, FRANCE.		McMahon, Martin/L-3303-2013; Lenormand, Philippe/N-5996-2018	McMahon, Martin/0000-0003-2812-1042; 				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BALLOU LM, 1991, NATURE, V349, P848; BLENIS J, 1984, J VIROL, V50, P966, DOI 10.1128/JVI.50.3.966-969.1984; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUNET A, 1994, ONCOGENE, V9, P3379; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI S, 1993, P NATL ACAD SCI USA, V90, P2947; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333	50	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15762	15768		10.1074/jbc.271.26.15762	http://dx.doi.org/10.1074/jbc.271.26.15762			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663120	hybrid			2022-12-25	WOS:A1996UV29900069
J	Maru, Y; Afar, DE; Witte, ON; Shibuya, M				Maru, Y; Afar, DE; Witte, ON; Shibuya, M			The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; ONCOGENE PRODUCT; C-ABL; TRANSFORMATION; PROTEIN; EXON; CELLS	Bcr-Abl oncoproteins are responsible for the pathogenesis of human leukemias with a reciprocal chromosome translocation t(9;22). The amino-terminal Bcr sequence has a potential to form a homotetramer (tetramer domain), and destructions of the tetramer domain cause a complete loss of biological activities in Bcr-Abl. Here we show that Bcr-Abl in which the tetramer domain is replaced with glutathione S-transferase (GST) with a dimerizing ability (GST/Bcr-Abl-(Delta 1-160)) can no longer induce an interleukin-3 (IL-3) independence in Ba/F3 cells or transform mouse bone marrow cells but still retains by 30-40% the ability to transform Rat1 cells, Compared with the wild type Bcr-Abl, autophosphorylation of GST/Bcr-Abl-(Delta 1-160) in vivo was reduced by more than 50%. The Grb-2 binding to GST/Bcr-Abl-(Delta 1-160) was 50% reduced in Rat1 cells and undetectable in Ba/F3 cells. In Rat1 cells expressing GST/Bcr-Abl-(Delta 1-160), phosphotyrosine contents of p62 and She were 70% decreased.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Maru, Y (corresponding author), UNIV TOKYO, INST MED SCI, DEPT GENET, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.							CAMPBELL ML, 1990, ONCOGENE, V5, P773; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LIFSHITZ B, 1988, ONCOGENE, V2, P113; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1995, MOL CELL BIOL, V15, P835; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MARU Y, 1993, BRIS MYER C, V15, P123; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS GL, 1994, BLOOD, V84, P2912; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TENHOEVE J, 1994, CANCER RES, V54, P2563; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	28	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15353	15357		10.1074/jbc.271.26.15353	http://dx.doi.org/10.1074/jbc.271.26.15353			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663064	hybrid			2022-12-25	WOS:A1996UV29900011
J	Banno, Y; Nakashima, S; Ohzawa, M; Nozawa, Y				Banno, Y; Nakashima, S; Ohzawa, M; Nozawa, Y			Differential translocation of phospholipase C isozymes to integrin-mediated cytoskeletal complexes in thrombin stimulated human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; TYROSINE PHOSPHORYLATION; MEMBRANE SKELETON; AGGREGATION; PP60C-SRC; ASSOCIATION; PP60(C-SRC); ACTIVATION; C-GAMMA-1; PROTEIN	To investigate a role of phospholipase C (PLC) isozymes in the integrin alpha(IIb)beta(3)-mediated signaling, their location was examined in thrombin-activated human platelets, revealing different regulation of their translocation to the cytoskeleton (CSK). In resting platelets, the major PLCs such as PLC beta 2, PLC beta 3a (155 kDa), and PLC gamma 2 and the minor PLCs (PLC beta 1 and PLC gamma 1) were located in the Triton X-100-soluble (Tx . Sol) fraction and the membrane skeleton, whereas PLC beta 3b (140 kDa) was present only in Tx . Sol fraction when examined by Western immunoblotting, Thrombin stimulation caused a rapid and transient translocation of PLC beta 3a and PLC beta 3b and a slower accumulation of PLC beta 2 and PLC gamma 2 in the reorganized CSK. The translocation to CSK of both PLC beta 3a and PLC beta 3b, but not PLC beta 2, was dependent on integrin alpha(IIb)beta(3)-mediated aggregation, Furthermore, an actin polymerization inhibitor, genistein, abolished the CSK association of alpha(IIb)beta(3), PLC beta 3a, and PLC beta 3b. In the genistein pretreated platelets, pp60(c-src), G(q), and protein kinase C alpha were no longer able to associate with CSK, In contrast, these agents had no or marginal inhibitory effects on the CSK association of PLC beta 2 and G(i2). The late diacylglycerol generation induced by thrombin stimulation was significantly reduced by the genistein treatment, These results suggest that the inte grin alpha(IIb)beta 3-mediated cytoskeletal association of PLC beta 3 is regulated by protein tyrosine kinase and also that the activation of the relocated PLC may play a role in the late platelet-to-platelet aggregation in thrombin-stimulated human platelets.	GIFU UNIV, SCH MED, DEPT BIOCHEM, GIFU 500, JAPAN	Gifu University								BANNO Y, 1994, FEBS LETT, V340, P185, DOI 10.1016/0014-5793(94)80134-7; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FOX JEB, 1993, ADV EXP MED BIOL, V344, P175; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HASEN CA, 1994, J CELL BIOL, V126, P811; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NAKASHIMA S, 1991, BIOCHEM J, V275, P355, DOI 10.1042/bj2750355; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; ODA A, 1992, J BIOL CHEM, V267, P20075; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; YAMAGUCHI A, 1990, BIOCHIM BIOPHYS ACTA, V1054, P8, DOI 10.1016/0167-4889(90)90198-M; YANO S, 1994, J BIOCHEM, V116, P778, DOI 10.1093/oxfordjournals.jbchem.a124596; ZHANG J, 1992, J BIOL CHEM, V267, P4686	39	36	36	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14989	14994		10.1074/jbc.271.25.14989	http://dx.doi.org/10.1074/jbc.271.25.14989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663010	hybrid			2022-12-25	WOS:A1996UT10600054
J	Ettinger, SL; Lauener, RW; Duronio, V				Ettinger, SL; Lauener, RW; Duronio, V			Protein kinase C delta specifically associates with phosphatidylinositol 3-kinase following cytokine stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; GM-CSF; ACTIVATION; INTERLEUKIN-3; GROWTH; RECEPTOR; LINE; 3,4,5-TRISPHOSPHATE	Phosphatidylinositol (PI) 3-kinase is activated as a result of cytokine-induced association of the enzyme with specific tyrosine phosphorylated proteins. PI 3-kinase lipid products, PI 3,4-P-2 and PI 3,4,5-P-3, have been shown, in vitro, to directly activate novel and atypical protein kinase C (PKC) isozymes. However, the mechanism by which PI 3-kinase may be involved in regulation of PKC isoforms in vivo is presently unknown. We investigated a possible relationship by looking for associations between these enzymes. We found that in a human erythroleukemia cell line, as well as in rabbit platelets, PI 3-kinase and PKC delta associate in a specific manner that is modulated by cell activation. Granulocyte-macrophage colony-stimulating factor treatment of cells caused increased association of PKC delta and PI S-kinase as did treatment of platelets with platelet-activating factor. Results using two PIS-kinase inhibitors, wortmannin and LY-294002, showed that the former inhibited this association, while the latter did not, suggesting that PI 3-kinase lipid products may not be a prerequisite for the PI 3-kinase/PKC delta association. Our results also suggest that tyrosine phosphorylation of PKC delta is not involved in its association with PI 3-kinase.	UNIV BRITISH COLUMBIA,JACK BELL RES CTR,DEPT MED,VANCOUVER,BC V6H 3Z6,CANADA	University of British Columbia								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V81, P3204; DURONIO V, 1989, BIOCHEM BIOPH RES CO, V164, P804, DOI 10.1016/0006-291X(89)91530-1; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOLD MR, 1992, J IMMUNOL, V148, P2012; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LI WQ, 1994, J BIOL CHEM, V269, P2349; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MYERS MG, 1994, J BIOL CHEM, V269, P28788; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OHNO S, 1994, J BIOL CHEM, V269, P17495; OKUDA K, 1992, BLOOD, V79, P2880; PELECH SL, 1990, J IMMUNOL, V144, P1759; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; PINKARD RN, 1984, J IMMUNOL, V123, P1847; ROBINSON M, 1991, J IMMUNOL, V147, P2624; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; TOKER A, 1994, J BIOL CHEM, V269, P32358; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P1683	40	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14514	14518		10.1074/jbc.271.24.14514	http://dx.doi.org/10.1074/jbc.271.24.14514			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663229	hybrid			2022-12-25	WOS:A1996UQ66000085
J	Prudovsky, IA; Savion, N; LaVallee, TM; Maciag, T				Prudovsky, IA; Savion, N; LaVallee, TM; Maciag, T			The nuclear trafficking of extracellular fibroblast growth factor (FGF)-1 correlates with the perinuclear association of the FGF receptor-1 alpha isoforms but not the FGF receptor-1 beta isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; TYROSINE PHOSPHORYLATION; CELL-CYCLE; 3T3 CELLS; BINDING; FORMS; EXPRESSION; CLONING; BFGF; TRANSLOCATION	The alternatively spliced fibroblast growth factor receptor (FGFR)-1 isoforms, FGFR-1 alpha and FGFR-1 beta, are characterized by the presence of either three or two Ig-like loops in the extracellular domain and are differentially expressed during embryonic development and tumor progression, We have previously shown that in cells irreversibly committed to DNA synthesis by FGF-1, approximately 15% of cell surface FGFR-1 traffics to a perinuclear locale as a structurally intact and functional tyrosine kinase (Prudovsky, I., Savion, N., Zhan, X., Friesel, R., Xu, J., Hou, J., McKeehan, W, L., and Maciag, T. (1994) J. Biol, Chem. 269, 31720-31724). In order to define the structural requirement for association of FGFR-1 with the nucleus, the expression and trafficking of FGFR-1 in FGFR-1 alpha and FGFR-1 beta L6 myoblast transfectants was studied, Although FGFR-1 alpha was expressed as p145 and p125 forms, FGFR-1 beta was expressed as p120 and p100 forms in the L6 myoblast transfectants. Tunicamycin and N-glyconase experiments suggest that these forms of FGFR-1 alpha and FGFR-1 beta are the result of differential glycosylation. However, only the p145 form of FGFR-1 alpha and the p120 form of FGFR-1 beta were able to bind FGF-1 and activate tyrosine phosphorylation. Pulse-chase analysis of FGFR-1 biosynthesis suggests that the p125 and p100 proteins are the precursor forms of p145 FGFR-1 alpha and p120 FGFR-1 beta, respectively, Because ligand chase analysis demonstrated that FGFR-1 beta L6 myoblast transfectants exhibited a reduced efficiency of nuclear translocation of exogenous FGF-1 when compared with FGFR-1 alpha transfectants, the intracellular trafficking of the FGFR-1 alpha and FGFR-1 beta isoforms was studied using an in vitro kinase assay to amplify immunoprecipitated FGFR-1, Indeed, the appearance of the FGFR-1 alpha but not FGFR-1 beta isoform in the nuclear fraction of L6 myoblast transfectants suggests that the distal Ig-like loop in FGFR-1 alpha mediates the differential nuclear association of FGFR-1 alpha as a structurally intact and functional tyrosine kinase. Further, the FGFR-1 beta L6 myoblast transfectants but not the FGFR-1 alpha myoblast transfectants exhibited a pronounced morphologic change in response to exogenous FGF-1. Because this phenotype change involves the induction of a rounded cellular shape, it is possible that the FGFR-1 alpha and FGFR-1 beta may ultimately exhibit differential trafficking to adhesion sites.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross			Savion, Naphtali/K-1013-2019; Prudovsky, Igor/GVU-1521-2022	Savion, Naphtali/0000-0001-8899-0624	NHLBI NIH HHS [HL32348, HL35627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; HAWKER JR, 1993, IN VITRO CELL DEV-AN, V30, P653; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MOROIANU J, 1994, BIOCHEMISTRY-US, V33, P12535, DOI 10.1021/bi00208a001; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XU JM, 1992, J BIOL CHEM, V267, P17792; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	62	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14198	14205		10.1074/jbc.271.24.14198	http://dx.doi.org/10.1074/jbc.271.24.14198			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662999	hybrid			2022-12-25	WOS:A1996UQ66000041
J	Surolia, A; Sharon, N; Schwarz, FP				Surolia, A; Sharon, N; Schwarz, FP			Thermodynamics of monosaccharide and disaccharide binding to Erythrina corallodendron lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEAN PSOPHOCARPUS-TETRAGONOLOBUS; FLUORESCENT-INDICATOR LIGAND; CONCANAVALIN-A; CARBOHYDRATE COMPLEXES; THERMAL-DENATURATION; RIBONUCLEASE-A; PROTEIN; AGGLUTININ; OLIGOSACCHARIDES; ENERGETICS	Isothermal titration calorimetry measurements of the binding of 2'-fucosyllactose, lactose, N-acetyllactosamine, galactopyranose, 2-acetamido-2-deoxygalactopyranoside, methyl alpha-N-dansylgalactosaminide (Me-alpha-DNS-GalN), methyl alpha-D-galactopyranoside, methyl beta-D-galactopyranoside, and fucose to Erythrina corallodendron lectin (ECorL), a dimer with one binding site per subunit, were performed at 283-286 and 297-299 K. The site binding enthalpies, Delta H-b, with the exception of Me-alpha-DNS-GalN, are the same at both temperatures and range from -47.1 +/- 1.0 kJ mol(-1) for N-acetyllactosamine to -4.4 +/- 0.3 kJ mol(-1) for fucose, and the site binding constants range from 3.82 +/- 0.9 x 10(5) M(-1) for Me-alpha-DNS-GalN at 283.2 K to 0.46 +/- 0.05 x 10(3) M(-1) for fucose at 297.2 K, The binding reactions are mainly enthalpically driven except for fucose and exhibit enthalpy-entropy compensation, The binding enthalpies of the disaccharides are about twice the binding enthalpies of the monosaccharides in contrast to concanavalin A where the binding enthalpies do not double for the disaccharides, Differential scanning calorimetry measurements show that denaturation of the ECorL dimer results in dissociation into its monomer subunits, The binding constants from the increase in denaturation temperature of ECorL in the presence of saccharides are in agreement with values from isothermal titration calorimetry results, The thermal denaturation of ECorL occurs around 333 K, well below the 344-360 K denaturation temperature of other legume lectins of similar size and tertiary structure, undoubtedly due to the difference in its quaternary structure relative to other legume lectins, This is also apparent from the independent unfolding of its two domains.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; NIST,ROCKVILLE,MD 20850	Weizmann Institute of Science; National Institute of Standards & Technology (NIST) - USA	Surolia, A (corresponding author), INDIAN INST SCI,MOLEC BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA.		SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; ADAR R, 1996, IN PRESS EUR J BIOCH; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BRADEN BC, 1994, J MOL BIOL, V243, P767, DOI 10.1016/0022-2836(94)90046-9; DEBOECK H, 1984, ARCH BIOCHEM BIOPHYS, V234, P297, DOI 10.1016/0003-9861(84)90352-7; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P3884, DOI 10.1021/bi00285a025; FUKADA H, 1983, J BIOL CHEM, V258, P3193; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; KINZY WR, 1992, GLYCOCONJUGATE J, V9, P225, DOI 10.1007/BF00731133; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX RU, 1994, CAN J CHEM, V72, P158, DOI 10.1139/v94-024; LIS H, 1985, PHYTOCHEMISTRY, V24, P2803, DOI 10.1016/0031-9422(85)80004-2; MANLY SP, 1985, BIOCHEMISTRY-US, V24, P3842, DOI 10.1021/bi00336a004; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; PURI KD, 1994, PURE APPL CHEM, V66, P497, DOI 10.1351/pac199466030497; RAMKUMAR R, 1995, BIOCHEM J, V308, P237, DOI 10.1042/bj3080237; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SCHWARZ FP, 1988, BIOCHEMISTRY-US, V27, P8429, DOI 10.1021/bi00422a020; SCHWARZ FP, 1988, THERMOCHIM ACTA, V128, P267, DOI 10.1016/0040-6031(88)85371-1; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SCHWARZ FP, 1996, IN PRESS BIOCH J; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHARON N, 1989, LECTINS; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8; VANLANDSCHOOT A, 1980, EUR J BIOCHEM, V103, P307; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66; YOUNG NM, 1995, J BIOL CHEM, V270, P2563, DOI 10.1074/jbc.270.6.2563	34	78	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17697	17703		10.1074/jbc.271.30.17697	http://dx.doi.org/10.1074/jbc.271.30.17697			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663419	hybrid			2022-12-25	WOS:A1996UY93500019
J	Kohn, EC; Alessandro, R; Probst, J; Jacobs, W; Brilley, E; Felder, CC				Kohn, EC; Alessandro, R; Probst, J; Jacobs, W; Brilley, E; Felder, CC			Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells - Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PROTEIN-KINASE-C; A9 L-CELLS; ACETYLCHOLINE-RECEPTOR; CALCIUM INFLUX; PHOSPHOINOSITIDE TURNOVER; INTRACELLULAR CALCIUM; CEREBRAL-CORTEX; MESSENGER-RNAS; CA2+ INFLUX	We report the identification and biochemical characterization of an endogenous m5 muscarinic acetylcholine receptor (mAChR) in the A2058 human melanoma cell line. This is the first demonstration of a m5AChR outside the central nervous system. The unusual effector coupling of this endogenous m5AChR is presented. The coding region amplified by polymerase chain reaction was identical to the known m5AChR sequence. Binding studies indicated a K-d of 99 +/- 6 pM and a B-max of 45 +/- 4 fmol/mg membrane protein. This m5AChR coupled to stimulation of arachidonic acid release and to a 50% inhibition of forskolin-stimulated cAMP accumulation. The inhibition of cAMP production was insensitive to pertussis toxin treatment, but was dependent upon extracellular calcium. In contrast to the odd mAChR pattern, no cAMP was produced in response 60 carbachol (CC) stimulation. Moreover, no release of inositol phosphates could be measured after CC treatment despite the presence of at least 2 phospholipase C isoforms in A2058 cells. CC-stimulated arachidonic acid release (EC(50) = 17.8 +/- 0.1 mu M) was dependent upon external Ca2+, with marked reduction after coincubation with EGTA, Co2+, Or high doses of verapamil (IC50 = 166 mu M) or diltiazem (IC50 = 243 mu M). Brief exposure to phorbol la-myristate 13-acetate augmented CC-stimulated arachidonic acid release, whereas prolonged phorbol 12-myristate 13-acetate treatment resulted in down-regulation of release. Activation of the m5AChR resulted in Ca2+ influx that was attenuated by muscarinic antagonism and removal of extracellular Ca2+. A2058 cells exposed to CC had no alteration of cell shape or growth potential in monolayer culture, however, a statistically significant reduction in density-independent growth was observed over the range of CC concentrations from 0.1 to 100 mu M. This endogenous m5AChR has a novel signal transduction coupling profile and receptor activation reduces clonogenic potential.	NIMH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kohn, EC (corresponding author), NCI,PATHOL LAB,SIGNAL TRANSDUCT & PREVENT UNIT,BLDG 10,RM 2A33,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Felder, Christian/0000-0003-1134-8881				ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BAUMGOLD J, 1994, CELL SIGNAL, V6, P103, DOI 10.1016/0898-6568(94)90065-5; BLUML K, 1994, J BIOL CHEM, V269, P11537; BONNER TI, 1992, TRENDS PHARMACOL SCI, V13, P48, DOI 10.1016/0165-6147(92)90021-W; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BRANN MR, 1988, FEBS LETT, V230, P90, DOI 10.1016/0014-5793(88)80648-3; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHALLISS RAJ, 1994, NEUROPHARMACOLOGY, V33, P15, DOI 10.1016/0028-3908(94)90092-2; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DORJE F, 1991, MOL PHARMACOL, V40, P459; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FELDER CC, 1990, J PHARMACOL EXP THER, V255, P1140; FELDER CC, 1991, P NATL ACAD SCI USA, V88, P6477, DOI 10.1073/pnas.88.15.6477; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1990, P NATL ACAD SCI USA, V87, P2187, DOI 10.1073/pnas.87.6.2187; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; HULME EC, 1993, CELL SIGNAL, V5, P687, DOI 10.1016/0898-6568(93)90030-P; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KOHN EC, 1990, BIOCHEM BIOPH RES CO, V166, P757, DOI 10.1016/0006-291X(90)90874-M; KOHN EC, 1994, CANCER RES, V54, P935; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; MAUDUIT P, 1993, AM J PHYSIOL, V264, pC1550, DOI 10.1152/ajpcell.1993.264.6.C1550; OETTLING G, 1992, J DEV PHYSIOL, V17, P147; ROCHE S, 1993, BIOCHEM J, V289, P117, DOI 10.1042/bj2890117; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; TENCE M, 1994, J PHARMACOL EXP THER, V269, P646; VILARO MT, 1994, MOL BRAIN RES, V21, P30, DOI 10.1016/0169-328X(94)90375-1	44	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17476	17484		10.1074/jbc.271.29.17476	http://dx.doi.org/10.1074/jbc.271.29.17476			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663391	hybrid			2022-12-25	WOS:A1996UX94300076
J	Raman, B; Ramakrishna, T; Rao, CM				Raman, B; Ramakrishna, T; Rao, CM			Refolding of denatured and denatured/reduced lysozyme at high concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EGG-WHITE LYSOZYME; PARTIALLY FOLDED STATE; LACTIC-DEHYDROGENASE; ESCHERICHIA-COLI; REDUCED LYSOZYME; MOLECULAR CHAPERONES; ALPHA-LACTALBUMIN; RENATURATION; REACTIVATION	Refolding of proteins at high concentrations often results in aggregation, To gain insight into the molecular aspects of refolding and to improve the yield of active protein, we have studied the refolding of lysozyme either from its denatured state or from its denatured/ reduced state. Refolding of denatured lysozyme, even at 1 mg/ml, yields fully active enzyme without aggregation, However, refolding of denatured/reduced lysozyme into buffer that lacks thiol/disulfide reagents leads to aggregation. Thiol/disulfide redox reagents such as cysteine/cystine and reduced/oxidized glutathione facilitate the renaturation, with the yield depending on their absolute concentrations, We have obtained an similar to 70% renaturation yield upon refolding of lysozyme at 150 mu g/ml. The cysteine/cystine redox system is more efficient compared with the glutathione redox system, When lysozyme is refolded in the absence of redox reagents, a transient intermediate that has regained a significant amount of secondary structure is formed. The tryptophans in this intermediate are as exposed to water as in the fully unfolded protein, It shows increased exposure of hydrophobic surfaces compared with the native or completely unfolded enzyme, This aggregation-prone intermediate folds to active enzyme upon addition of oxidized glutathione before the aggregation process starts. These properties of the intermediate in the refolding pathway of lysozyme are similar to those proposed for the molten globule.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)				Tangirala, Ramakrishna/0000-0002-0738-329X				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; ALEXANDRESCU AT, 1994, J MOL BIOL, V235, P587, DOI 10.1006/jmbi.1994.1015; ANDERSON WL, 1976, J BIOL CHEM, V251, P3147; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BUCK M, 1993, BIOCHEMISTRY-US, V32, P669, DOI 10.1021/bi00053a036; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; FISCHER B, 1993, ARCH BIOCHEM BIOPHYS, V306, P183, DOI 10.1006/abbi.1993.1498; FISCHER B, 1992, PROTEIN ENG, V5, P593, DOI 10.1093/protein/5.6.593; FISCHER B, 1992, ARCH BIOCHEM BIOPHYS, V298, P361, DOI 10.1016/0003-9861(92)90422-S; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GOLDBERG ME, 1994, PROTEIN SCI, V3, P883; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1974, EUR J BIOCHEM, V46, P149, DOI 10.1111/j.1432-1033.1974.tb03607.x; KANE JF, 1988, TRENDS BIOCHTECHNOL, V6, P87; KUMAR TKS, 1994, INT J BIOL MACROMOL, V16, P171; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; NOIVA R, 1992, J BIOL CHEM, V267, P3553; ORSINI G, 1978, J BIOL CHEM, V253, P3453; ORSINI G, 1975, EUR J BIOCHEM, V59, P433, DOI 10.1111/j.1432-1033.1975.tb02471.x; PERRAUDIN JP, 1983, J BIOL CHEM, V258, P1834; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PUIG A, 1994, J BIOL CHEM, V269, P7764; RUDOLPH R, 1976, EUR J BIOCHEM, V63, P409, DOI 10.1111/j.1432-1033.1976.tb10242.x; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SOPHIANOPOULOS AJ, 1962, J BIOL CHEM, V237, P1107; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; WILLS PR, 1980, BIOPHYS CHEM, V11, P71, DOI 10.1016/0301-4622(80)85009-5; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	41	92	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17067	17072		10.1074/jbc.271.29.17067	http://dx.doi.org/10.1074/jbc.271.29.17067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663382	hybrid			2022-12-25	WOS:A1996UX94300016
J	Will, H; Atkinson, SJ; Butler, GS; Smith, B; Murphy, G				Will, H; Atkinson, SJ; Butler, GS; Smith, B; Murphy, G			The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation - Regulation by TIMP-2 and TIMP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TISSUE INHIBITOR; 72-KDA GELATINASE; HUMAN FIBROBLASTS; IV COLLAGENASE; PURIFICATION; INDUCTION; SURFACE; BINDING; CELLS	It has been proposed that the cell-mediated activation of progelatinase A requires binding of the C-terminal domain of the proenzyme to a membrane-associated complex of the membrane type matrix metalloproteinase MT1-MMP and TIMP-2. Subsequent sequential proteolysis of the propeptide by MT1-MMP and gelatinase A is thought to generate the active form of gelatinase A, We have prepared the preform of the catalytic domain of the MT1-MMP and demonstrated that this may be activated in vitro by trypsin proteolysis to yield a functional proteinase capable of cleaving typical metalloproteinase peptide substrates, gelatin and casein, The active catalytic domain of MT1-MMP was also shown to activate progelatinase A to a fully active form, Using the inactive mutant pro-E375A gelatinase A, we dissected the propeptide processing events that occur, MT1-MMP cleaves the propeptide at the sequence Asn(37)-Leu(38) only, Further cleavage of the mutant enzyme propeptide at Asn(80)-Tyr(81), equivalent to that of the active wild type gelatinase A, could only be effected by addition of gelatinase A to the system, TIMP-1 was essentially unable to prevent MT1-MMP processing of wild type or E375A progelatinase A, whereas TIMP-2 and TIMP-3 were good inhibitors of these events. Analysis of the rate of binding of TIMPs to the catalytic domain of MT1-MMP using kinetic methods showed that TIMP-1 is an extremely poor inhibitor of MT1-MMP, In comparison, TIMP-2 and TIMP-3 are excellent inhibitors, binding more rapidly to the catalytic domain of MT1-MMP than to the catalytic domain of gelatinase A, These data demonstrate the basic mechanism of MT1-MMP action on progelatinase A and the reason for the lack of inhibition by TIMP-1 previously demonstrated in cell-based activation studies.	STRANGEWAYS RES LAB,DEPT MOLEC & CELL BIOL,CAMBRIDGE CB1 4RN,ENGLAND; IN VITEK GMBH,D-13125 BERLIN,GERMANY; CELLTECH LTD,RES,SLOUGH SL1 4EN,BERKS,ENGLAND	Celltech Group Ltd			Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CRABBE T, 1994, FEBS LETT, V345, P14, DOI 10.1016/0014-5793(94)00412-9; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; HIPPS DS, 1991, BIOL CHEM H-S, V372, P287, DOI 10.1515/bchm3.1991.372.1.287; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TSUCHIYA Y, 1994, INT J CANCER, V56, P46; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023	27	488	506	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17119	17123		10.1074/jbc.271.29.17119	http://dx.doi.org/10.1074/jbc.271.29.17119			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663332	hybrid			2022-12-25	WOS:A1996UX94300023
J	Chaudhary, LR; Avioli, LV				Chaudhary, LR; Avioli, LV			Regulation of interleukin-8 gene expression by interleukin-1 beta, osteotropic hormones, and protein kinase inhibitors in normal human bone marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OSTEOBLAST-LIKE CELLS; ARACHIDONIC-ACID METABOLISM; 3' UNTRANSLATED REGION; MESSENGER-RNA; C-FOS; HUMAN-FIBROBLASTS; BINDING-PROTEIN; FACTOR ACTIVATE; FACTOR-ALPHA	Interleukin-8 (IL-8), a potent neutrophil chemotactic peptide that elicits pleiotropic biological effects is secreted in large amounts by normal human osteoblastic and bone marrow osteoprogenitor stromal (HEMS) cells in response to IL-1 beta and tumor necrosis factor-alpha, In the present study we investigated the regulation of IL-8 gene expression by IL-1 beta, osteotropic hormones, and protein kinase inhibitors in primary cultures of HEMS cells, The treatment of HEMS cells with IL-1 beta increased the steady-state levels of IL-8 mRNA in a dose and time-dependent fashion and was detectable within 1 h, reached maximal by 4 h, and remained elevated at 24 h, whereas parathyroid hormone (10(-7) and 10(-8) M) had no effect on IL-8 mRNA, Both synthetic and natural glucocorticoids dexamethasone (10(-7)-10(-10) M) and hydrocortisone (10(-6)-10(-8) M) inhibited IL-1 beta-stimulated IL-8 mRNA expression, The suppressive effect of dexamethasone on IL-1 beta-induced IL-8 mRNA was not observed in the presence of cycloheximide (5 mu g/ml), indicating that the dexamethasone-mediated repression of IL-8 gene expression also depends on new protein synthesis, Experiments with actinomycin D demonstrated that IL-8 mRNA is long-lived and that glucocorticoids down-regulate IL 8 gene expression mainly by decreasing the mRNA stability in normal HEMS cells. Furthermore, as determined by nuclear run-on analysis, IL-1 beta increased the rate of transcription of IL-8 gene and dexamethasone did not affect the IL-1 beta-induced transcription of IL-8. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine, HCl (50 mu M) and staurosporine (1 mu M), potent inhibitors of protein kinase C, and genistein (100 mu M), a specific protein tyrosine kinase inhibitor blocked IL-1 beta-induced IL-8 gene expression, Because curcumin (20 mu M), an inhibitor of c-jun/AP-1 and protein kinases, also blocked IL-1 beta stimulated IL-8 gene expression implicating c-JUN/AP-1 and protein phosphorylation in the induction of PL-8 gene expression by IL-1 beta, we conclude that the regulation of IL-8 mRNA by IL-1 beta is mediated via protein kinase-dependent signal transduction pathways, Our accumulated results have demonstrated that glucocorticoid suppression of IL-1 beta-induced IL-8 mRNA occurs at the levels of post-transcription (mRNA stability) and protein synthesis.			Chaudhary, LR (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT INTERNAL MED, DIV BONE & MINERAL DIS, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, T32AR007033] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32 AR07033, P01 AR32087] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMMON HPT, 1993, J ETHNOPHARMACOL, V38, P113, DOI 10.1016/0378-8741(93)90005-P; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BENAYAHU D, 1989, J CELL PHYSIOL, V140, P1, DOI 10.1002/jcp.1041400102; BIRCH MA, 1993, J BONE MINER RES, V8, P1155; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAUDHARY LR, 1994, CALCIFIED TISSUE INT, V55, P16, DOI 10.1007/BF00310163; CHAUDHARY LR, 1992, ENDOCRINOLOGY, V130, P2528, DOI 10.1210/en.130.5.2528; CHEN Y, 1994, J BONE MINER RES  S1, V9, P368; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; CONNEY AH, 1991, ADV ENZYME REGUL, V31, P385, DOI 10.1016/0065-2571(91)90025-H; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FUJITA T, 1990, ANN NY ACAD SCI, V587, P371, DOI 10.1111/j.1749-6632.1990.tb00178.x; FULLER K, 1995, J IMMUNOL, V154, P6065; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GOWEN M, 1990, ENDOCRINOLOGY, V126, P1250, DOI 10.1210/endo-126-2-1250; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; GREENBERG ME, 1994, CURRENT PROTOCOLS MO, V1; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; KAMALIA N, 1992, BLOOD, V79, P320; KAUSHANSKY K, 1987, BLOOD CELLS, V13, P3; KEETING PE, 1991, J BONE MINER RES, V6, P827; KOVACS EJ, 1986, J IMMUNOL, V137, P3649; LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306; LIN GF, 1994, J BIOL CHEM, V269, P77; LIN JX, 1987, J BIOL CHEM, V262, P11908; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; Muegge K, 1990, Cytokine, V2, P1, DOI 10.1016/1043-4666(90)90036-S; Mukaida N, 1992, Cytokines, V4, P41; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1992, MICROBIOL IMMUNOL, V36, P773, DOI 10.1111/j.1348-0421.1992.tb02080.x; MUNOZ E, 1991, J IMMUNOL, V146, P136; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; OWEN M, 1988, CIBA F SYMP, V136, P42; Owen M., 1985, BONE MINERAL RES ANN, V1, P1; PACIFICI R, 1987, P NATL ACAD SCI USA, V84, P4616, DOI 10.1073/pnas.84.13.4616; PACIFICI R, 1991, J CLIN INVEST, V87, P221, DOI 10.1172/JCI114975; PACIFICI R, 1989, P NATL ACAD SCI USA, V86, P2398, DOI 10.1073/pnas.86.7.2398; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; RAO CV, 1993, CARCINOGENESIS, V14, P2219, DOI 10.1093/carcin/14.11.2219; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; Sambrook J, 1989, MOL CLONING LAB MANN; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; SIMMONS DJ, 1991, CALCIFIED TISSUE INT, V48, P326, DOI 10.1007/BF02556152; THOMSON BM, 1987, J IMMUNOL, V138, P775; TOBLER A, 1992, BLOOD, V79, P45; WLODARSKI KH, 1990, CLIN ORTHOP RELAT R, P276; WONG MM, 1990, J BONE MINER RES, V5, P803	61	77	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16591	16596		10.1074/jbc.271.28.16591	http://dx.doi.org/10.1074/jbc.271.28.16591			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663179	hybrid			2022-12-25	WOS:A1996UX12600028
J	Mehlen, P; SchulzeOsthoff, K; Arrigo, AP				Mehlen, P; SchulzeOsthoff, K; Arrigo, AP			Small stress proteins as novel regulators of apoptosis - Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; ALPHA-CRYSTALLIN; HSP27 GENE; EXPRESSION; RESISTANCE; INDUCTION; SURVIVAL; ABSENCE; GROWTH; BCL-2	Small stress protein expression enhances the survival of mammalian cells exposed to numerous injuries that induce necrotic cell death. The cell surface receptor Fas/APO-1 and its ligand have been recently identified as important mediators of apoptosis. Here, we show that constitutive expression of human heat shock protein (hsp)27 in murine L929 cells blocks Fas/APO-1-mediated cell death. Expression of human hsp27 prevented anti-APO-1-induced DNA fragmentation and morphological changes. These results strongly suggest that human hsp27 acts as a cellular inhibitor of Fas/APO-1-induced apoptosis. We also report that the expression of small stress proteins from different species, such as human hsp27, Drosophila Dhsp27, or human alpha B-crystallin, confers resistance to apoptotic cell death induced by staurosporine, a protein kinase C inhibitor. Hence, small stress proteins are novel regulators that are able to block apoptosis induced by different pathways.	UNIV LYON 1, CTR MOLEC GENET & CELLULAIRE, CNRS UMR 5534, LAB STRESS CELLULAIRE, F-69622 VILLEURBANNE, FRANCE; UNIV FREIBURG, INST BIOCHEM & MOLEC BIOL, D-79104 FREIBURG, GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Freiburg			Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; COULDWELL WT, 1994, FEBS LETT, V345, P43, DOI 10.1016/0014-5793(94)00415-3; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; HANASH SM, 1993, P NATL ACAD SCI USA, V90, P3314, DOI 10.1073/pnas.90.8.3314; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; Osborne Barbara A., 1994, Trends in Cell Biology, V4, P394; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOMASOVIC SP, 1994, INT J HYPERTHER, V10, P247, DOI 10.3109/02656739409009346; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	44	560	584	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16510	16514		10.1074/jbc.271.28.16510	http://dx.doi.org/10.1074/jbc.271.28.16510			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663291	hybrid			2022-12-25	WOS:A1996UX12600016
J	Murray, EW; Pihl, C; Morcos, A; Brown, CB				Murray, EW; Pihl, C; Morcos, A; Brown, CB			Ligand-independent cell surface expression of the human soluble granulocyte-macrophage colony-stimulating factor receptor alpha subunit depends on co-expression of the membrane-associated receptor beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; HUMAN MYELOID CELLS; SIGNAL-TRANSDUCTION; FUNCTIONAL RECEPTORS; HEMATOPOIETIC-CELLS; CYTOPLASMIC DOMAINS; HUMAN INTERLEUKIN-5; MOLECULAR-CLONING; GROWTH-FACTORS; RECONSTITUTION	The hematopoietic cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates its activity through binding to cell surface receptors, The receptor for GM-CSF belongs to a superfamily of cytokine receptors characterized by a conserved extracellular motif. The high affinity GM-CSF receptor (GMR) consists of two transmembrane anchored subunits; a ligand binding alpha subunit (transmembrane GMR alpha) and a signal transducing beta subunit (GMR beta), both of which belong to the cytokine receptor superfamily, The human GM-CSF receptor alpha subunit also exists in a soluble form (sol-GMR alpha), which antagonizes GM-CSF activity in vitro, We directly tested the potential for solGMR alpha to interact with GMR beta in vitro, Our experiments demonstrated that exogenous solGMR alpha, even in the presence of GM-CSF, does not interact with GMR beta on the cell surface, However, when solGMR alpha and GMR beta are co expressed in baby hamster kidney cells, solGMR alpha is retained on the cell surface and forms a functional intermediate affinity GM-CSF binding complex (K-d = 331 pM). In addition, the cell surface expression of solGMR alpha is independent of the presence of GM-CSF as demonstrated using flow cytometry, Cells expressing only solGMR alpha do not show cell surface retention or form functional GM-CSF cell surface binding complexes. Sequencing of our GMR beta clone revealed a nucleotide substitution (A --> C) resulting in the substitution of Ala for Glu at position 9 from the amino terminus of the mature GMR beta peptide. Because the GMR beta (A --> C) clone is capable of forming functional high affinity receptors with transmembrane GMR alpha (K-d = 64 pM), we feel that the cell surface retention of solGMR alpha is independent of the GMR beta mutation, We suggest that the co-expression and interaction of solGMR alpha and GMR beta represents a previously unrecognized GM-CSF receptor complex and a novel, ligand-independent mechanism of cytokine receptor assembly.	UNIV CALGARY,HLTH SCI CTR,DEPT MED,CANC BIOL RES GRP,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba				Murray, Elizabeth/0000-0003-3087-7578				ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROWN CB, 1995, BLOOD, V85, P1488, DOI 10.1182/blood.V85.6.1488.bloodjournal8561488; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; EDER M, 1994, J BIOL CHEM, V269, P30173; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; HEANEY ML, 1995, P NATL ACAD SCI USA, V92, P2365, DOI 10.1073/pnas.92.6.2365; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1992, BLOOD, V80, P84; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIYAJIMA A, 1993, BLOOD, V82, P1960; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; RAINES MA, 1991, P NATL ACAD SCI USA, V88, P8203, DOI 10.1073/pnas.88.18.8203; RONCO LV, 1994, J BIOL CHEM, V269, P277; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SIEFF CA, 1985, SCIENCE, V230, P1171, DOI 10.1126/science.3877981; SYMONS JA, 1990, FEBS LETT, V272, P133, DOI 10.1016/0014-5793(90)80466-V; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMONAGA M, 1986, BLOOD, V67, P31; WEISS M, 1993, BLOOD, V82, P3298; WILLIAMS WV, 1994, ARTHRITIS RHEUM, V37, P1468, DOI 10.1002/art.1780371010; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	43	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15330	15335		10.1074/jbc.271.26.15330	http://dx.doi.org/10.1074/jbc.271.26.15330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663062	hybrid			2022-12-25	WOS:A1996UV29900007
J	Pratico, D; Smyth, EM; Violi, F; FitzGerald, GA				Pratico, D; Smyth, EM; Violi, F; FitzGerald, GA			Local amplification of platelet function by 8-epi prostaglandin F-2 alpha is not mediated by thromboxane receptor isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGGREGATION; 8-EPI-PROSTAGLANDIN-F2-ALPHA; F2-ISOPROSTANE; ANTAGONIST; ACTIVATION; AGONIST; INVIVO; RAT	8-epi-Prostaglandin (PG) F-2 alpha may be formed by cyclooxygenases 1 and 2 or by a free radical catalyzed process as an isoprostane. Concentrations of 8-epi-PGF(2 alpha) in the range 1 nM to 1 mu M induce a dose-dependent increase in platelet shape change, in calcium release from intracellular stores [Ca2+](i) and in inositol phosphates; it also causes irreversible platelet aggregation, dependent on thromboxane generation, when incubated with subthreshold concentrations of ADP, thrombin, collagen, and arachidonic acid, Much higher concentrations of 8-epi-PGF(2 alpha) (10-20 mu M) alone induce weak, reversible aggregation. Although these effects are prevented by pharmacological thromboxane receptor antagonists, they are unlikely to be mediated by thromboxane receptors, Thus, 8-epi-PGF(2 alpha) does not compete for binding at the stably expressed placental or endothelial isoforms of the thromboxane receptor or for binding of thromboxane ligands to human platelets, Furthermore, the response to 8-epi PGF(2 alpha) exhibits structural specificity versus 8-epi PGF(3 alpha) and PGF(2 alpha). Concentrations in the range that evoke its effects on platelets do not desensitize the aggregation response stimulated by thromboxane or PGH(2) analogs, Unlike primary prostaglandins, which are rapidly metabolized to inactive products, 8-epi PGF(2 alpha) circulates in plasma, However, the systemic concentrations found in healthy volunteers (median 48 pmol/liter) and in patients with hepatic cirrhosis (median 147 pmol/liter), a syndrome of oxidant stress in vivo, fall well below those which modulate platelet function. 8-Epi PGF(2 alpha) may amplify the response to platelet agonists in syndromes where oxidant stress and platelet activation coincide, Despite blockade by thromboxane antagonists, 8-epi PGF(2 alpha) does not activate either of the thromboxane receptor isoforms described in platelets, Activation of a distinct receptor would be consistent with the enzymatic formation of 8-epi PGF(2 alpha) by cyclooxygenases. However, incidental activation of such a receptor by systemic concentrations of 8-epi PGF(2 alpha) is unlikely to occur, even in syndromes of excessive free radical generation in vivo.	UNIV PENN,CTR EXPTL THERAPEUT,PHILADELPHIA,PA 19104; UNIV ROMA LA SAPIENZA,MED CLIN 1,ROME,ITALY	University of Pennsylvania; Sapienza University Rome			Violi, Francesco/K-1509-2016; Pratico, Domenico/ABA-9590-2020; FitzGerald, Garret A/A-4222-2010	Violi, Francesco/0000-0002-6610-7068; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54500] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; BHAGWAT SS, 1985, NATURE, V315, P511, DOI 10.1038/315511a0; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DELANTY N, 1996, IN PRESS CIRCUALTION; DELANTY N, IN PRESS BR J CLIN P; DORN GW, 1990, J BIOL CHEM, V265, P4240; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; FURCI L, 1991, J PHARMACOL EXP THER, V258, P74; Habib A, 1996, J INVEST MED, V44, pA263; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HIRATA T, 1995, THROMB HAEMOSTASIS, V73, pA60; KINSELLA BT, 1994, ANN NY ACAD SCI, V714, P270, DOI 10.1111/j.1749-6632.1994.tb12054.x; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LAPETINA EG, 1987, METHOD ENZYMOL, V141, P176; LEFKOWITZ RJ, 1991, NATURE, V351, P353, DOI 10.1038/351353a0; LONGMIRE AW, 1994, PROSTAGLANDINS, V48, P247, DOI 10.1016/0090-6980(94)90011-6; MAIS DE, 1985, J PHARMACOL EXP THER, V233, P418; MAYEUX PR, 1988, BIOCHEM BIOPH RES CO, V157, P733, DOI 10.1016/S0006-291X(88)80311-5; Meagher EA, 1996, J INVEST MED, V44, pA300; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; OGLETREE ML, 1985, J PHARMACOL EXP THER, V234, P435; PRATICO D, 1992, J LAB CLIN MED, V119, P364; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D., 1995, Blood, V86, p509A; Pratico D, 1996, J INVEST MED, V44, pA301; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; REILLY IAG, 1987, BLOOD, V69, P180; REILLY M, 1996, IN PRESS CIRCULATION; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; WATSON SP, 1986, J BIOL CHEM, V261, P5368; YIN K, 1994, J PHARMACOL EXP THER, V270, P1192	41	178	182	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14916	14924		10.1074/jbc.271.25.14916	http://dx.doi.org/10.1074/jbc.271.25.14916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663015	hybrid			2022-12-25	WOS:A1996UT10600044
J	Seibert, FS; Linsdell, P; Loo, TW; Hanrahan, JW; Clarke, DM; Riordan, JR				Seibert, FS; Linsdell, P; Loo, TW; Hanrahan, JW; Clarke, DM; Riordan, JR			Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR GENE; PHOSPHORYLATION; IDENTIFICATION; DOMAINS; CELLS; POPULATION; MEMBRANE; SITES; DNA	A cluster of 18 point mutations in exon 17b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has been detected in patients with cystic fibrosis. These mutations cause single amino acid substitutions in the most C-terminal cytoplasmic loop (CL4, residues 1035-1102) of the CFTR chloride channel, Heterologous expression of the mutants showed that 12 produced only core-glycosylated CFTR, which was retained in the endoplasmic reticulum; the other six mutants matured and reached the cell surface, In some cases substitution of one member of pairs of adjacent residues resulted in misprocessing, whereas the other did not, Thus, the secondary structure of CL4 may contribute crucially to the proper folding of the entire CFTR molecule, Cyclic AMP stimulated iodide efflux was not detected from cells expressing the misprocessed variants but was from the other six, indicating that their mutations cause relatively subtle channel defects. Consistent with this, these latter mutations generally are present in patients who are pancreatic-sufficient, while the processing mutants are mostly from patients who are pancreatic-insufficient. Single-channel patch-clamp analysis demonstrated that the processed mutants had the same ohmic conductance as wild-type CFTR, but a lower open probability, generally due to an increase in channel mean closed time and a reduction in mean open time, This suggests that mutations in CL4 do not affect pore properties of CFTR, but disrupt the mechanism of channel gating.	MAYO CLIN SCOTTSDALE,MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,SCOTTSDALE,AZ 85259; MAYO CLIN SCOTTSDALE,MAYO FDN,SC JOHNSON MED RES CTR,SCOTTSDALE,AZ 85259; UNIV TORONTO,MRC,GRP MEMBRANE BIOL,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,MRC,GRP MEMBRANE BIOL,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son; University of Toronto; University of Toronto; McGill University			Hanrahan, John/AGG-1926-2022; Clarke, David M./A-1112-2008	Hanrahan, John/0000-0001-9080-2039; Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188; Linsdell, Paul/0000-0001-6257-6273				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BOZON D, 1994, HUM MUTAT, V3, P330, DOI 10.1002/humu.1380030329; CASALS T, 1995, HUM GENET, V95, P205; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; FANAN P, 1992, GENOMICS, V13, P770; FEREC C, 1992, NAT GENET, V1, P188, DOI 10.1038/ng0692-188; FEREC C, 1993, HUM MOL GENET, V2, P1557, DOI 10.1093/hmg/2.10.1557; GHANEM N, 1994, GENOMICS, V21, P434, DOI 10.1006/geno.1994.1290; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HANRAHAN JW, 1995, SOC GEN PHY, V50, P125; HANRAHAN JW, 1996, IN PRESS J EXP ZOOL, V275; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; LOO TW, 1994, J BIOL CHEM, V269, P28683; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MANAVALAN P, 1993, J PROTEIN CHEM, V12, P279, DOI 10.1007/BF01028190; MATHEWS CJ, 1995, 9 ANN N AM CYST FIBR; MERCIER B, 1993, GENOMICS, V16, P296, DOI 10.1006/geno.1993.1183; PIND S, 1994, J BIOL CHEM, V269, P12784; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAVOV A, 1994, HUM MOL GENET, V3, P57; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VENGLARIK CJ, 1994, J GEN PHYSIOL, V104, P123, DOI 10.1085/jgp.104.1.123; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; XIE JX, 1995, J BIOL CHEM, V270, P28084; ZIELENSKI J, 1995, HUM MUTAT, V5, P43, DOI 10.1002/humu.1380050106; ZIELENSKI J, 1993, AM J HUM GENET, V52, P609	38	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15139	15145		10.1074/jbc.271.25.15139	http://dx.doi.org/10.1074/jbc.271.25.15139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662892	hybrid			2022-12-25	WOS:A1996UT10600073
J	Waring, JD; Haq, R; Tamai, K; Sabourin, LA; Ikeda, JE; Korneluk, RG				Waring, JD; Haq, R; Tamai, K; Sabourin, LA; Ikeda, JE; Korneluk, RG			Investigation of myotonic dystrophy kinase isoform translocation and membrane association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSTABLE CTG REPEAT; TRIPLET REPEAT; MESSENGER-RNA; PROTEIN; GENE; EXPANSION; SEQUENCE; REGION	Myotonic dystrophy is caused by the expansion of a CTG repeat found in the 3'-untranslated region of the myotonic dystrophy kinase. The mechanism of disease and the role of the kinase are currently obscure. Here we begin the investigation of domain structure/function correlations to aid in determining its normal function. Expressed full-length protein and protein truncated before a C terminal hydrophobic domain were compared. In vitro, signal peptide function and protection of kinase by microsomal membranes were absent; thus, it is not translocated, as previously proposed. However, full-length kinase expressed in insect cells was found in fractions enriched for membranes and decorated mitochondria. The truncated form was found primarily in the cytosol. The kinase was present as two self-associated, disulfide-linked complexes, The majority of full-length kinase was found in the larger of the two complexes, while almost all of the truncated form was found in the smaller. Thus, the C-terminal region confers a higher order of self-association. Furthermore, full-length kinase expressed in COS-1 cells was present as high molecular weight complex, while the truncated form was present as monomer species. These experiments indicate that the myotonic dystrophy kinase is not membrane-integrated but that it may have a molecular organization which favors peripheral association with membranes.	CHILDRENS HOSP EASTERN ONTARIO,GENET MOLEC LAB,OTTAWA,ON K1H 8L1,CANADA; TOKAI UNIV,SCH MED,GENOSPHERE PROJECT,ISEHARA,KANAGAWA 25911,JAPAN; UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA,ON K1H 8M5,CANADA	University of Ottawa; Children's Hospital of Eastern Ontario; Tokai University; University of Ottawa			Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				BARCELO JM, 1993, HUM MOL GENET, V2, P705, DOI 10.1093/hmg/2.6.705; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BREWSTER BS, 1993, BIOCHEM BIOPH RES CO, V194, P1256, DOI 10.1006/bbrc.1993.1958; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; ETONGUEMAYER P, 1994, BIOCHEM BIOPH RES CO, V199, P89, DOI 10.1006/bbrc.1994.1198; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; Harper P.S., 1989, MYOTONIC DYSTROPHY; HERRERA GA, 1989, ULTRASTRUCT PATHOL, V13, P485, DOI 10.3109/01913128909074532; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; HOFFMANRADVANYI H, 1993, HUM MOL GENET, V2, P1263; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; KOGA R, 1994, BIOCHEM BIOPH RES CO, V202, P577, DOI 10.1006/bbrc.1994.1967; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; MAEDA M, 1995, J BIOL CHEM, V270, P20246, DOI 10.1074/jbc.270.35.20246; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Moore DD, 1995, GLOB MOB SURV; MOUNSEY JP, 1995, J CLIN INVEST, V95, P2379, DOI 10.1172/JCI117931; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; SASAGAWA N, 1994, FEBS LETT, V351, P22, DOI 10.1016/0014-5793(94)00808-6; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WHITING EJ, 1995, HUM MOL GENET, V4, P1063, DOI 10.1093/hmg/4.6.1063	30	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15187	15193		10.1074/jbc.271.25.15187	http://dx.doi.org/10.1074/jbc.271.25.15187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663097	hybrid			2022-12-25	WOS:A1996UT10600080
J	Friedl, EM; Matthias, P				Friedl, EM; Matthias, P			Mapping of the transcriptional repression domain of the lymphoid-specific transcription factor Oct-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU DOMAIN; GENE; CELLS; PROTEIN; ACTIVATION; EXPRESSION; PROMOTERS; PRODUCTS; DNA	The lymphoid-specific transcription factor Oct-Ba is implicated in B cell-specific transcriptional activity via the octamer motif. Structure/function analysis of various Oct-2a effector regions in the context of the GAL4 DNA-binding domain revealed that Oct-Ba contains two functionally different activation domains at the N and the C termini. The transcriptional activity of both domains is strongly potentiated by interactions with distinct B cell-specific coactivators. Recently, we have identified a repression domain located within the N terminus of Oct-Ba (amino acids 2-99). When this domain was transferred to a potent activator, transcription was strongly inhibited. In this study we present a deletion analysis of the N-terminal region of Oct-Ba to determine the minimal repression domain. We identified a stretch of 23 amino acids, rich in serine and threonine residues, which was responsible for most of the repression activity. We show that repression is strongly dependent on the type of enhancer present in the reporter plasmid as well as on the cell line tested. The possibility that Oct-Ba can act as an activator and/or a repressor may have important consequences for the function of Oct-Ba in B cell differentiation and other developmental processes.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CORCORAN LM, 1994, IMMUNITY, V1, P635, DOI 10.1016/1074-7613(94)90035-3; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; FRIEDL EM, 1995, EUR J BIOCHEM, V234, P308, DOI 10.1111/j.1432-1033.1995.308_c.x; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JUNKER S, 1988, EMBO J, V7, P3093, DOI 10.1002/j.1460-2075.1988.tb03175.x; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LILLYCROP KA, 1994, MOL CELL BIOL, V14, P7633, DOI 10.1128/MCB.14.11.7633; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UM M, 1995, MOL CELL BIOL, V15, P5007; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; YEUNG KC, 1994, TRENDS GENET, V11, P173	42	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13927	13930		10.1074/jbc.271.24.13927	http://dx.doi.org/10.1074/jbc.271.24.13927			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663230	hybrid			2022-12-25	WOS:A1996UQ66000001
J	McGuire, V; Alexander, S				McGuire, V; Alexander, S			PsB multiprotein complex of Dictyostelium discoideum - Demonstration of cellulose binding activity and order of protein subunit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE COAT PROTEINS; CRYSTALLINE CELLULOSE; EXTRACELLULAR-MATRIX; LECTIN EXPRESSION; PRESTALK CELLS; ADHESION; DIFFERENTIATION; GLYCOPROTEINS; ORGANIZATION; PRESPORE	The differentiated spores of Dictyostelium are surrounded by an extracellular matrix, the spore coat, which protects them from environmental factors allowing them to remain viable for extended periods of time. This presumably is a major evolutionary advantage. This unique extracellular matrix is composed of cellulose and glycoproteins. Previous work has shown that some of these spore coat glycoproteins exist as a preassembled multiprotein complex (the PsB multiprotein complex) which is stored in the prespore vesicles (Watson, N., McGuire, V., and Alexander, S (1994) J. Cell Sci. 107, 2567-2579), Later in development, the complex is synchronously secreted from the prespore vesicles and incorporated into the spore coat, We now have shown that the PsB complex has a specific in vitro cellulose binding activity, The analysis of mutants lacking individual subunits of the PsB complex revealed the relative order of assembly of the subunit proteins and demonstrated that the protein subunits must be assembled for cellulose binding activity, These results provide a biochemical explanation for the localization of this multiprotein complex in the spore coat.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia								ALEXANDER S, 1988, DIFFERENTIATION, V38, P82, DOI 10.1111/j.1432-0436.1988.tb00201.x; ALEXANDER S, 1991, MOL CELL BIOL, V11, P3171, DOI 10.1128/MCB.11.6.3171; ALEXANDER S, 1992, DIFFERENTIATION, V51, P149, DOI 10.1111/j.1432-0436.1992.tb00691.x; ALEXANDER S, 1990, DEV GENET, V11, P418, DOI 10.1002/dvg.1020110515; ALEXANDER S, 1983, DIFFERENTIATION, V24, P209, DOI 10.1111/j.1432-0436.1983.tb01321.x; BLANTON RL, 1993, DEVELOPMENT, V119, P703; BLUSCH J, 1995, DIFFERENTIATION, V58, P253, DOI 10.1046/j.1432-0436.1995.5840253.x; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CHAMPION A, 1995, MICROBIOL-UK, V141, P785, DOI 10.1099/13500872-141-4-785; CHAMPION A, 1991, J GEN MICROBIOL, V137, P2431, DOI 10.1099/00221287-137-10-2431; Creighton TE, 1983, PROTEINS STRUCTURES; DEVINE KM, 1982, P NATL ACAD SCI-BIOL, V79, P7361, DOI 10.1073/pnas.79.23.7361; DEVINE KM, 1983, DEV BIOL, V99, P437, DOI 10.1016/0012-1606(83)90293-2; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; ERDOS GW, 1989, EXP MYCOL, V13, P169, DOI 10.1016/0147-5975(89)90022-4; ERDOS GW, 1973, P NATL ACAD SCI USA, V70, P1828, DOI 10.1073/pnas.70.6.1828; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FOSNAUGH K, 1994, DEV BIOL, V166, P823, DOI 10.1006/dbio.1994.1362; FREEZE H, 1978, BIOCHIM BIOPHYS ACTA, V539, P529, DOI 10.1016/0304-4165(78)90086-7; FREEZE H, 1977, DEV BIOL, V56, P184, DOI 10.1016/0012-1606(77)90161-0; FREEZE H, 1977, J BIOL CHEM, V252, P820; FREEZE HH, 1989, J BIOL CHEM, V264, P19278; GEHIN A, 1995, RES MICROBIOL, V146, P251, DOI 10.1016/0923-2508(96)80281-6; GILKES NR, 1992, J BIOL CHEM, V267, P6743; GOLDSTEIN MA, 1994, J BACTERIOL, V176, P7328, DOI 10.1128/JB.176.23.7328-7334.1994; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; GRANT WN, 1983, EMBO J, V2, P935, DOI 10.1002/j.1460-2075.1983.tb01524.x; GUNAGYYI X, 1995, BIOCHEMISTRY-US, V34, P6993; HEMMES DE, 1972, J ULTRA MOL STRUCT R, V41, P406, DOI 10.1016/S0022-5320(72)90047-0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KUSPA A, 1994, METH MOL G, V3, P3; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; LOOMIS WF, 1988, ISI ATLAS-IMMUNOL, V1, P25; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MURRAY BA, 1983, MOL CELL BIOL, V3, P863, DOI 10.1128/MCB.3.5.863; NEWELL PC, 1969, J BACTERIOL, V100, P763, DOI 10.1128/JB.100.2.763-768.1969; OKANO T, 1989, CELLULOSE WOOD CHEM, P53; PROCHIANTZ A, 1995, BIOESSAYS, V17, P39, DOI 10.1002/bies.950170109; RAMALINGAM R, 1992, J BACTERIOL, V174, P7834, DOI 10.1128/JB.174.23.7834-7837.1992; RICHARDSON DL, 1992, GENE DEV, V6, P1058, DOI 10.1101/gad.6.6.1058; ROSEN SD, 1973, P NATL ACAD SCI USA, V70, P2554, DOI 10.1073/pnas.70.9.2554; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAXENA IM, 1994, J BACTERIOL, V176, P5735, DOI 10.1128/JB.176.18.5735-5752.1994; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHOSEYOV O, 1990, P NATL ACAD SCI USA, V87, P2192, DOI 10.1073/pnas.87.6.2192; SHOSEYOV O, 1992, P NATL ACAD SCI USA, V89, P3483, DOI 10.1073/pnas.89.8.3483; SMITH E, 1989, GENETICS, V122, P59; SOLL DR, 1987, METHOD CELL BIOL, V28, P413; STAHLBERG J, 1988, EUR J BIOCHEM, V173, P179, DOI 10.1111/j.1432-1033.1988.tb13982.x; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUSSMAN M, 1976, ANNU REV PLANT PHYS, V27, P229, DOI 10.1146/annurev.pp.27.060176.001305; SUSSMAN M, 1978, DIFFERENTIATION, V10, P1, DOI 10.1111/j.1432-0436.1978.tb00938.x; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WALLACE JS, 1984, CELL DIFFER DEV, V14, P205, DOI 10.1016/0045-6039(84)90047-2; Watson J. D., 1987, MOL BIOL GENE; WATSON N, 1993, J BIOL CHEM, V268, P22634; WATSON N, 1994, J CELL SCI, V107, P2567; WATSON N, 1994, THESIS U MISSOURI; WEST CM, 1985, J BIOL CHEM, V260, P3803; WEST CM, 1990, DEV GENET, V11, P492, DOI 10.1002/dvg.1020110526; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; WILLIAMS KL, 1993, NATO ADV SCI INST SE, V259, P345; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267; Zhou-Chou Ti, 1995, Developmental Biology, V168, P332, DOI 10.1006/dbio.1995.1084	69	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14596	14603		10.1074/jbc.271.24.14596	http://dx.doi.org/10.1074/jbc.271.24.14596			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662961	hybrid			2022-12-25	WOS:A1996UQ66000097
J	Wood, IC; Roopra, A; Buckley, NJ				Wood, IC; Roopra, A; Buckley, NJ			Neural specific expression of the m4 muscarinic acetylcholine receptor gene is mediated by a RE1/NRSE-type silencing element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL GENE; SYNAPSIN-I GENE; BINDING-PROPERTIES; RABBIT LUNG; RAT-BRAIN; PROMOTER; CELLS; IDENTIFICATION; FAMILY; HEART	Muscarinic receptor genes are members of the G-protein receptor superfamily that, with the inclusion of the odorant receptors, is believed to contain over a thousand members, Each member of this superfamily, which has been studied to date, appears to have a distinct pattern of expression, but little work has been done on the regulation of these complex expression patterns, We have recently isolated the rat m4 muscarinic receptor gene and identified a genomic 1520-nucleotide sequence that appeared capable of directing cell-specific expression (Wood, I, C., Roopra, A., Harrington, C., and Buckley, N. J. (1995) J, Biol, Chem. 270, 30933-30940), In the present study we have constructed a set of deletion promoter constructs to more closely define the DNA elements that are responsible for m4 gene expression, We have found that deletion of a RE1/NRSE silencer element between nucleotides -574 and -550, similar to that found in other neural specific genes, results in activation of reporter expression in non-m4-expressing cells. Gel mobility shift analysis has shown that a protein present in nonexpressing cells is capable of binding to this element and is probably the recently identified neural silencer, REST/NRSF, Of the constitutively active proximal promoter only a tandem Sp-l site appears to recruit DNA binding proteins that are present in all cells tested, This represents the first report documenting the role of this silencer in regulating expression of a member of the G-protein receptor family.			Wood, IC (corresponding author), UCL, WELLCOME LAB MOLEC PHARMACOL, LONDON WC1E 6BT, ENGLAND.		Buckley, Noel J/B-9675-2012; Wood, Ian/AAK-9423-2021	Buckley, Noel J/0000-0003-1152-0653; Wood, Ian/0000-0003-1886-2533	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; Brown D. A., 1995, MOL B INT U, P165; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; HASSALL CJS, 1993, NEUROSCIENCE, V56, P1041, DOI 10.1016/0306-4522(93)90149-A; HOWLAND DS, 1991, MOL BRAIN RES, V11, P345, DOI 10.1016/0169-328X(91)90044-X; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAZARENO S, 1990, MOL PHARMACOL, V38, P805; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MAK JCW, 1993, LIFE SCI, V53, P1501, DOI 10.1016/0024-3205(93)90624-C; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; Mieda M, 1996, J BIOL CHEM, V271, P5177; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wood IC, 1995, J BIOL CHEM, V270, P30933, DOI 10.1074/jbc.270.52.30933; WOOD IC, 1995, FORME, V5, P29; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	30	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14221	14225		10.1074/jbc.271.24.14221	http://dx.doi.org/10.1074/jbc.271.24.14221			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662964	hybrid			2022-12-25	WOS:A1996UQ66000044
J	Kovarik, A; Lu, PJ; Peat, N; Morris, J; TaylorPapadimitriou, J				Kovarik, A; Lu, PJ; Peat, N; Morris, J; TaylorPapadimitriou, J			Two GC boxes (Sp1 sites) are involved in regulation of the activity of the epithelium-specific MUC1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; BINDING-PROTEINS; GENE-EXPRESSION; CARCINOMA CELLS; CORE PROTEIN; CLONING; ACTIVATION; FAMILY; ASSAY; DNA	In this report, we have analyzed the function of two Spl sites present in the epithelium-specific MUC1 promoter, Using promoter-reporter gene (CAT) constructs, we found that mutagenesis of either of the Sp1 binding motifs at -576/-568 and -99/-90, reduced transcription in MUC1-expressing epithelial cell lines, However, abolition of the binding site at -99/-91 by mutagenesis also resulted in increased transcriptional activity in non-epithelial cell lines, suggesting involvement of the site in tissue-specific expression, In vitro binding assays revealed a novel binding motif at -101/-89 (AGGGGGCGGGGTT), which overlaps but differs from the Sp1 consensus motif by having an adenine residue in the 5'-flanking sequence, The 5'-flanking sequence appeared to be important for binding of an Sp1-unrelated factor (SpA) but not for binding of Sp1, Site-directed mutagenesis of the motif into a site able to bind Sp1, but unable to bind SpA, resulted in an increased level of transcription of the CAT reporter gene in all cell lines tested, suggesting a repressive effect of the novel factor on transcription, The ratio between the Sp1 and SpA binding activity in nuclear extracts correlated with both promoter activity and the levels of endogenous transcription in different breast cancer cell lines, Our results are consistent with the idea that the relative activities of the two factors may be involved in the upregulation of expression of the MUC1 gene seen in breast and other carcinomas.	IMPERIAL CANC RES FUND, EPITHELIAL CELL BIOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Kovarik, Ales/H-1952-2014	Kovarik, Ales/0000-0003-2896-0698; Morris, Joanna/0000-0001-9762-8133				ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; ABE M, 1990, J CELL PHYSIOL, V143, P226, DOI 10.1002/jcp.1041430205; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BURCHELL J, 1987, CANCER RES, V47, P5476; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM RA, 1995, INT J TUMOR TARGETIN, V1, P211; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; PEAT N, 1992, CANCER RES, V52, P1954; SHIROTANI K, 1994, J BIOL CHEM, V269, P15030; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	23	53	56	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18140	18147		10.1074/jbc.271.30.18140	http://dx.doi.org/10.1074/jbc.271.30.18140			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663395	hybrid			2022-12-25	WOS:A1996UY93500083
J	Muller, K; Gombert, FO; Manning, U; Grossmuller, F; Graff, P; Zaegel, H; Zuber, JF; Freuler, F; Tschopp, C; Baumann, G				Muller, K; Gombert, FO; Manning, U; Grossmuller, F; Graff, P; Zaegel, H; Zuber, JF; Freuler, F; Tschopp, C; Baumann, G			Rapid identification of phosphopeptide ligands for SH2 domains - Screening of peptide libraries by fluorescence-activated bead sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY-2 DOMAIN; SIGNAL-TRANSDUCTION; TYROSINE KINASES; ADAPTER PROTEIN; BINDING; GRB2; RAS; PHOSPHATASE; AFFINITY	A method for the identification of high-affinity ligands to SH2 domains by fluorescence-activated bead sorting (FABS) was established, Recombinant SH2 domains, expressed as glutathione S-transferase (GST) fusion proteins, were incubated with a phosphotyrosine (Y*) containing peptide library, 6.4 x 10(5) individual peptides of nine amino acids in length (EPX(6)Y*X(19)X(7)X(19)X(7)X(6)) were each displayed on beads, Phosphopeptide interaction of a given SH2 domain was monitored by binding of fluorescein isothiocyanate-labeled antibodies directed against GST. High-fluorescence beads were isolated by flow cytometric sorting, Subsequent pool sequencing of the selected beads revealed a distinct pattern of phosphotyrosine-containing motifs for each individual SH2 domain: the SH2 domain of the adapter protein Grb2 predominantly selected beads with the sequence Y*ENDP, whereas the C-terminal SH2 domain of the tyrosine kinase Syk, selected Y*EELD, each motif representing the most frequently found residues C-terminal to the phosphotyrosine, For deconvolution studies, soluble phosphopeptides comprising variations of the Grb2 motifs were resynthesized and analyzed by surface plasmon resonance.	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Novartis; Sandoz				GOMBERT, Frank Otto/0000-0002-7507-697X				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIXMAN ED, 1995, ONCOGENE, V10, P237; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; HELLBERG S, 1987, J MED CHEM, V30, P1126, DOI 10.1021/jm00390a003; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAW CL, 1994, J BIOL CHEM, V269, P12310; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MULLER W, 1992, FLOW CYTOMETRY CELL, P27; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEVANOVIC S, 1993, ANAL BIOCHEM, V212, P212, DOI 10.1006/abio.1993.1314; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WIENANDS J, 1995, INT IMMUNOL, V7, P1701, DOI 10.1093/intimm/7.11.1701; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16500	16505						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663178				2022-12-25	WOS:A1996UX12600014
J	Romagnolo, B; Cluzeaud, F; Lambert, M; Colnot, S; Porteu, A; Molina, T; Tomasset, M; Vandewalle, A; Kahn, A; Perret, C				Romagnolo, B; Cluzeaud, F; Lambert, M; Colnot, S; Porteu, A; Molina, T; Tomasset, M; Vandewalle, A; Kahn, A; Perret, C			Tissue-specific and hormonal regulation of Calbindin-D9K fusion genes in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; VITAMIN-D; RAT UTERUS; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; INSITU DETECTION; GUT EPITHELIUM; YOLK-SAC; EXPRESSION; ESTROGEN	The rat Calbindin-D9K (CaBP9K) gene is mainly expressed in intestine, uterus, and lung and is regulated in a complex tissue specific manner. To analyze the role of potential regulatory elements, previously defined by DNaseI hypersensivity, we made transgenic mice containing truncated rat CaBP9K fusion gene with simian virus 40 large T antigen and the chloramphenicol acetyltransferase as reporter genes. The transgenes contained CaBP9K promoter fragments with 5' end points at -4400, -1011, and -117 base pairs (bp), whereas the 3' end points was at +365 bp. Northern blot analysis of T antigen expression and chloramphenicol acetyltransferase enzyme-linked immunosorbent assay indicated that a positive element, probably the distal intestine-specific DNaseI HS, necessary to target the expression of the transgene in the intestine, is present between -4400 and -1011 bp. The cephalo-caudal gradient of expression of the transgene along the small intestine was similar to those of the endogenous gene, but an ectopic expression of the transgene was observed in the colon. The -1011 transgene was expressed in epithelial alveolar cells of the lung, in renal proximal tubule cells, and in uterine myometrium, as judged from immunocytochemical, histological, and Northern blot analyses. The shortest, -117 construct was only expressed in uterine myometrium, and it was under a strict estrogen dependence like the endogenous gene. Finally,res ness to vitamin D in the duodenum was observed with the largest, -4400 construct, Thus, different tissues utilize distinct cis-acting elements to direct and regulate the expression of the rat CaBP9K gene.	UNIV PARIS 05,INST COCHIN GENET MOLEC,INSERM U129,F-75014 PARIS,FRANCE; HOP ROBERT DEBRE,INSERM U120,F-75019 PARIS,FRANCE; LAB UNIV RECH HISTOPATHOL,F-75006 PARIS,FRANCE; UNIV PARIS 07,INST FEDERAT RECH,INSERM U246,F-75780 PARIS 18,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Colnot, Sabine/A-9169-2008; Perret-Mayeux, Christine/L-3297-2017; Romagnolo, Béatrice/D-5017-2017; Molina, Thierry/ABA-5214-2020	Colnot, Sabine/0000-0002-3949-9107; Romagnolo, Béatrice/0000-0001-8772-3604; Molina, Thierry/0000-0002-3929-9754; perret, christine/0000-0003-4710-7051				ARMBRECHT HJ, 1989, ENDOCRINOLOGY, V125, P2950, DOI 10.1210/endo-125-6-2950; BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; BRUNS MEH, 1985, ANAT REC, V213, P514, DOI 10.1002/ar.1092130406; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTAKOS S, 1991, ENDOCR REV, V10, P3; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DARWISH H, 1991, J BIOL CHEM, V266, P551; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DELORME AC, 1983, ENDOCRINOLOGY, V113, P1340, DOI 10.1210/endo-113-4-1340; DUPRET JM, 1992, ENDOCRINOLOGY, V131, P2643, DOI 10.1210/en.131.6.2643; DUPRET JM, 1987, J BIOL CHEM, V262, P16553; GALLAGHER JC, 1979, J CLIN INVEST, V64, P729, DOI 10.1172/JCI109516; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GARLAND CF, 1991, AM J CLIN NUTR, V54, P193; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GODBOUT R, 1988, GENE DEV, V2, P949, DOI 10.1101/gad.2.8.949; LHORSET F, 1994, ENDOCRINOLOGY, V134, P11, DOI 10.1210/en.134.1.11; LHORSET F, 1993, ENDOCRINOLOGY, V132, P489, DOI 10.1210/en.132.2.489; LI H, 1991, ENDOCRINOLOGY, V128, P2844, DOI 10.1210/endo-128-6-2844; LI S, 1994, MOL ENDOCRINOL, V8, P1328, DOI 10.1210/me.8.10.1328; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MATHIEU CL, 1989, P NATL ACAD SCI USA, V86, P3433, DOI 10.1073/pnas.86.9.3433; PERRET C, 1991, GENE, V108, P227, DOI 10.1016/0378-1119(91)90438-H; PERRET C, 1985, EUR J BIOCHEM, V150, P211, DOI 10.1111/j.1432-1033.1985.tb09009.x; PERRET C, 1988, EUR J BIOCHEM, V172, P43, DOI 10.1111/j.1432-1033.1988.tb13853.x; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SAMBROOK J, 1993, MOL CLONING LAB MANU; SANDGREN ME, 1991, BIOCHEM BIOPH RES CO, V181, P611, DOI 10.1016/0006-291X(91)91234-4; SCHREINER DS, 1983, ACTA ANAT, V117, P1; THOMASSET M, 1982, AM J PHYSIOL, V243, pE483, DOI 10.1152/ajpendo.1982.243.6.E483; THOMASSET M, 1996, EUR J BIOCHEM, V236, P778; WADA L, 1992, AM J PHYSIOL, V235, pE338; WAREMBOURG M, 1986, J HISTOCHEM CYTOCHEM, V34, P277, DOI 10.1177/34.2.3753716; WAREMBOURG M, 1987, CELL TISSUE RES, V247, P51, DOI 10.1007/BF00216546; WIKENHEISER KA, 1992, CANCER RES, V52, P5342	42	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16820	16826		10.1074/jbc.271.28.16820	http://dx.doi.org/10.1074/jbc.271.28.16820			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663193	hybrid			2022-12-25	WOS:A1996UX12600062
J	Meisenholder, GW; Martin, SJ; Green, DR; Nordberg, J; Babior, BM; Gottlieb, RA				Meisenholder, GW; Martin, SJ; Green, DR; Nordberg, J; Babior, BM; Gottlieb, RA			Events in apoptosis - Acidification is downstream of protease activation and BCL-2 protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Cytoplasmic acidification is now recognized as a feature of apoptosis in a variety of systems, However, its relation to other events in the process of apoptosis is not yet characterized, In this work, we examined the effect of BCL-2 overexpression on acidification mediated by cycloheximide treatment or Fas Ligation in Jurkat T-lymphoblasts. We find that BCL-2 overexpression attenuates cytoplasmic acidification and apoptosis detected by annexin V labeling, Acidification and phosphatidylserine externalization were found to occur concurrently. We also examined the requirement for protease activation for cytoplasmic acidification to occur and found that inhibition of interleukin-1 beta converting enzyme/CED-3 family proteases (using carbobenzoxy-Val-Ala-Asp-fluoromethylketone, an inhibitor of these proteases) prevents acidification and apoptosis mediated by Fas ligation, These studies suggest that BCL-2 acts at a point upstream of acidification and that protease activation is also upstream of acidification.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA; VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA	Scripps Research Institute; La Jolla Institute for Immunology; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01345] Funding Source: Medline; NIA NIH HHS [AG13501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; GOTTLIEB RA, 1995, BLOOD, V86, P2414, DOI 10.1182/blood.V86.6.2414.bloodjournal8662414; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; ITOH N, 1993, J IMMUNOL, V151, P621; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7	13	94	94	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16260	16262		10.1074/jbc.271.27.16260	http://dx.doi.org/10.1074/jbc.271.27.16260			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663307	hybrid			2022-12-25	WOS:A1996UW35200059
J	Torok, Z; Vigh, L; Goloubinoff, P				Torok, Z; Vigh, L; Goloubinoff, P			Fluorescence detection of symmetric GroEL(14)(GroES(7))(2) heterooligomers involved in protein release during the chaperonin cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; GROEL; HYDROLYSIS; SURFACE; HSP60; ATP	The GroEL(14) chaperonin from Escherichia coli was labeled with 5-((((2-iodoacetyl)amino)ethyl)amino) naphthalene-l-sulfonic acid (I-AEDANS), a hydrophobic probe whose fluorescent emission is sensitive to structural changes within the protein. Increasing concentrations of ATP or adenylyl imidodiphosphate but not ADP caused two successive GroES(7)-dependent changes in the fluorescence intensity of AEDANS-GroEL(14), corresponding to the sequential binding of two GroES(7) heptamers and the formation of two types of chaperonin heterooligomers, GroEL(14)GroES(7) and GroEL(14)(GroES(7))(2). The binding of thermally denatured malate dehydrogenase (MDH) caused a specific increase in fluorescence intensity of AEDANS-GroEL(14) that allowed the direct measurement in solution at equilibrium of ATP- and GroES(7)-dependent protein release from the chaperonin. Structure/function analysis during the generation of ATP from ADP indicated the following sequence of events: 1) ADP-stabilized MDH-GroEL(14)GroES(7) particles bind newly formed ATP. 2) MDH-GroEL(14)GroES(7) particles bind a second GroES(7). 3) MDH-GroEL(14)(GroES(7))(2) particles productively release MDH. 4) Released MDH completes folding. Therefore, the symmetrical GroEL(14)(GroES(7))(2) heterooligomer is an intermediate after the formation of which the protein substrate is productively released during the chaperonin-mediated protein folding cycle.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BOT,IL-91904 JERUSALEM,ISRAEL; BIOL RES CTR,INST BIOCHEM,H-6701 SZEGED,HUNGARY	Hebrew University of Jerusalem; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center				Goloubinoff, Pierre/0000-0002-4802-0807				ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DIAMANT S, 1995, J BIOL CHEM, V270, P28387; DIAMANT S, 1995, BIOCHEMISTRY-US, V34, P273, DOI 10.1021/bi00001a033; ENGEL A, 1995, SCIENCE, V265, P653; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HARRIS JR, 1994, J STRUCT BIOL, V112, P216, DOI 10.1006/jsbi.1994.1022; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1996, J BIOL CHEM, V271, P68, DOI 10.1074/jbc.271.1.68; LORIMER GH, 1996, FASEB J, V1, P5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	38	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16180	16186		10.1074/jbc.271.27.16180	http://dx.doi.org/10.1074/jbc.271.27.16180			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663256	hybrid			2022-12-25	WOS:A1996UW35200049
J	Grondin, B; Bazinet, M; Aubry, M				Grondin, B; Bazinet, M; Aubry, M			The KRAB zinc finger gene ZNF74 encodes an RNA-binding protein tightly associated with the nuclear matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIO-FACIAL SYNDROME; TUMOR SUPPRESSOR WT1; PRE-MESSENGER-RNA; DIGEORGE-SYNDROME; TRANSCRIPTION FACTOR; XENOPUS OOCYTES; DELETIONS; DOMAINS; FAMILY; TFIIIA	We previously cloned ZNF74, a developmentally expressed zinc finger gene commonly deleted in DiGeorge syndrome. Here, the intron/exon organization of the human gene and the functional properties of the expressed protein are presented. This zinc finger gene from the transcription factor IIIA/Kruppel family contains three exons. A truncated Kruppel-associated box (KRAB) located at the N terminus of the predicted 64-kDa zinc finger protein is encoded by exon 2. The remainder of the protein including the zinc finger domain as well as the 3'-untranslated region (UTR) is encoded by exon 3. Both 5'-UTR (exon 1) and 3'-UTR contain repetitive Alu elements. In vitro translation of a cDNA encoding the entire ZNF74 coding region produced a 63-kDa protein as determined on sodium dodecyl sulfate-polyacrylamide gel. A bacterially expressed fusion protein shown to bind tightly to (65)zinc was used to test the nucleic acid binding properties of ZNF74. By RNA binding assays, ZNF74 was found to bind specifically to poly(U) and poly(G) RNA homopolymers. The restricted binding to these homopolymers and not to poly(A) and poly(C) suggested that ZNF74 displays RNA sequence preferences. RNA binding was mediated by the zinc finger domain. Immunofluorescence studies on transfected cells revealed ZNF74 nuclear localization. The labeling pattern observed in the nuclei clearly excluded the nucleoli. The zinc finger region lacks a classical nuclear localization signal but was found to be responsible for nuclear targeting, Subcellular and in situ sequential fractionations further showed that ZNF74 is associated with the nuclear matrix. The RNA binding properties of this protein and its tight association with the nuclear matrix, a subnuclear compartment involved in DNA replication as well as RNA synthesis and processing, suggest a role for ZNF74 in RNA metabolism.	UNIV MONTREAL, INST RECH CLIN MONTREAL, MONTREAL, PQ H2W 1R7, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								ANDREAZZOLI M, 1993, NUCLEIC ACIDS RES, V21, P4218, DOI 10.1093/nar/21.18.4218; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; AUBRY M, 1993, HUM MOL GENET, V2, P1583, DOI 10.1093/hmg/2.10.1583; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; BISOTTO S, 1995, J CELL SCI, V108, P1873; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BUDARF ML, 1995, NAT GENET, V10, P269, DOI 10.1038/ng0795-269; BURN J, 1993, J MED GENET, V30, P822, DOI 10.1136/jmg.30.10.822; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLBEREGARAPIN F, 1983, DEV BIOLOGICALS, V55, P267; DEMCZUK S, 1995, HUM MOL GENET, V4, P551, DOI 10.1093/hmg/4.4.551; DESHAZER D, 1994, BIOTECHNIQUES, V17, P288; DRISCOLL DA, 1992, AM J MED GENET, V44, P261, DOI 10.1002/ajmg.1320440237; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FIBISON WJ, 1990, AM J HUM GENET, V46, P888; FISCHER U, 1994, J CELL BIOL, V125, P971, DOI 10.1083/jcb.125.5.971; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GLOVER TW, 1995, NAT GENET, V10, P257, DOI 10.1038/ng0795-257; GREENBERG F, 1988, AM J HUM GENET, V43, P605; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALFORD S, 1993, HUM MOL GENET, V2, P1577, DOI 10.1093/hmg/2.10.1577; HALFORD S, 1993, HUM MOL GENET, V2, P2099, DOI 10.1093/hmg/2.12.2099; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HEISTERKAMP N, 1995, GENOMICS, V29, P451, DOI 10.1006/geno.1995.9982; HOZAK P, 1995, J CELL SCI, V108, P635; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KAPELNER SN, 1994, BIOTECHNIQUES, V17, P64; KARAYIORGOU P, 1995, P NATL ACAD SCI USA, V92, P7612, DOI 10.1073/pnas.92.17.7612; KLOCKE B, 1994, BBA-GENE STRUCT EXPR, V1217, P81; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KURAHASHI H, 1995, HUM MOL GENET, V4, P541, DOI 10.1093/hmg/4.4.541; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; MAKOWSKI GS, 1991, BIOL TRACE ELEM RES, V29, P93, DOI 10.1007/BF03032687; Maniatis T., 1982, MOL CLONING; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MARINEAU C, 1992, NUCLEIC ACIDS RES, V20, P1430, DOI 10.1093/nar/20.6.1430; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; NICKERSON JA, 1992, J CELL BIOL, V116, P977, DOI 10.1083/jcb.116.4.977; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; RIGGS P, 1994, CURRENT PROTOCOLS MO; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; SCAMBLER PJ, 1992, LANCET, V339, P1138, DOI 10.1016/0140-6736(92)90734-K; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VANWIJK I, 1992, MECH DEVELOP, V39, P63, DOI 10.1016/0925-4773(92)90026-G; VINCENT A, 1986, NUCLEIC ACIDS RES, V14, P4385, DOI 10.1093/nar/14.11.4385; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WAN KM, 1994, P NATL ACAD SCI USA, V91, P594, DOI 10.1073/pnas.91.2.594; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WILSON DI, 1992, LANCET, V340, P573, DOI 10.1016/0140-6736(92)92107-Q; WILSON DI, 1991, BRIT HEART J, V66, P308; WILSON DI, 1993, J MED GENET, V30, P852, DOI 10.1136/jmg.30.10.852; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; ZAHS KR, 1993, GLIA, V7, P121, DOI 10.1002/glia.440070202; ZANG WQ, 1995, J MOL BIOL, V245, P549, DOI 10.1006/jmbi.1994.0045	86	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15458	15467		10.1074/jbc.271.26.15458	http://dx.doi.org/10.1074/jbc.271.26.15458			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663113	hybrid			2022-12-25	WOS:A1996UV29900026
J	Hoffmann, JS; Pillaire, MJ; GarciaEstefania, D; Lapalu, S; Villani, G				Hoffmann, JS; Pillaire, MJ; GarciaEstefania, D; Lapalu, S; Villani, G			In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-EXTRACTS; FRAMESHIFT MUTAGENESIS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; STRANDED-DNA; INVITRO; FIDELITY; CIS-DIAMMINEDICHLOROPLATINUM(II); MISALIGNMENT; SPECIFICITY	Eukaryotic DNA polymerase beta and the reverse transcriptases are the most inaccurate of the known DNA polymerases. We report here mutagenic replication in vitro past intrastrand N(7)G-N(7)G chelates of the cis-diamminedichloroplatinum(II), the major DNA adduct of the antitumor agent cisplatin by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase (42% and 26% mutations, respectively). The most frequent modifications generated by both enzymes were one-base frameshift deletions. Only one mutational hot spot opposite the platinated guanines was observed with human immunodeficiency virus type I reverse transcriptase, while two hot spots were generated by DNA polymerase beta, one at the base situated 5' to the lesion and the other situated 4-6 nucleotides 5' to the adduct. An unusual mutagenic event, tandem replication of a 12-base pair sequence, was observed with DNA polymerase beta. The mutational spectra of the two DNA polymerases suggest that template slip page occurred with higher frequency in the presence of the more distributive DNA polymerase beta.	ECOLE NORMALE SUPER LYON,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)	Hoffmann, JS (corresponding author), CNRS,INST PHARMACOL & BIOL STRUCT,205 ROUTE NARBONNE,F-31077 TOULOUSE,FRANCE.		Hoffmann, Jean-Sebastien/O-9183-2014; Pillaire, Marie-Jeanne/P-1579-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Pillaire, Marie-Jeanne/0000-0001-6866-7416				BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BELGUISEVALLADIER P, 1994, J MOL BIOL, V236, P151, DOI 10.1006/jmbi.1994.1125; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; CHANG LMS, 1973, J BIOL CHEM, V248, P3789; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; GREENE MH, 1992, J NATL CANCER I, V84, P306, DOI 10.1093/jnci/84.5.306; HERMAN F, 1990, EUR J BIOCHEM, V194, P119, DOI 10.1111/j.1432-1033.1990.tb19435.x; HOFFMANN JS, 1989, J BIOL CHEM, V264, P15130; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KADYK LC, 1993, GENETICS, V133, P469; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; NAEGELI H, 1994, BIOESSAYS, V16, P1; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PILLAIRE MJ, 1994, NUCLEIC ACIDS RES, V22, P2519, DOI 10.1093/nar/22.13.2519; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SPIVAK G, 1992, BIOCHEMISTRY-US, V31, P6794, DOI 10.1021/bi00144a021; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	41	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15386	15392		10.1074/jbc.271.26.15386	http://dx.doi.org/10.1074/jbc.271.26.15386			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663082	hybrid			2022-12-25	WOS:A1996UV29900016
J	Godde, JS; Wolffe, AP				Godde, JS; Wolffe, AP			Nucleosome assembly on CTG triplet repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MYOTONIC-DYSTROPHY; HISTONE OCTAMER; MESSENGER-RNA; CORE PARTICLE; 5S RNA; DNA; GENE; TRANSCRIPTION; INITIATION	Expansion of CTG repeat sequences is associated with several human genetic diseases. We have examined the consequences of CTG repeat expansion for nucleosome assembly and positioning. Short CTG repeats are found within the most favored DNA sequences yet defined for nucleosome assembly. We find that as few as six CTG repeats will facilitate nucleosome assembly to a similar extent as the 50 or more repeats found in disease genes. Thus an increase in nucleosome stability on expansion of existing triplet repeats is unlikely to explain the acquisition of the disease phenotype. However, the CTG repeat sequence is efficiently wrapped around the histone octamer, preferring to associate with histones at the nucleosomal dyad. Thus short segments CTG; repeat sequence will facilitate the assembly of a stable positioned nucleosome which might contribute to the expansion phenomenon and the functional organization of chromatin.			Godde, JS (corresponding author), NICHHD,MOLEC EMBRYOL LAB,NIH,BETHESDA,MD 20892, USA.							ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GACY AM, 1995, CELL, V81, P533; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HOGAN ME, 1987, NATURE, V328, P554, DOI 10.1038/328554a0; IMAGAWA M, 1995, J BIOL CHEM, V270, P20898, DOI 10.1074/jbc.270.36.20898; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KOHWI Y, 1995, NUCLEIC ACIDS RES, V21, P5651; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MORSE RH, 1988, CELL, V54, P285, DOI 10.1016/0092-8674(88)90190-0; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wolffe A., 1995, CHROMATIN STRUCTURE; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1993, METH MOL G, V2, P314; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; YANOYANAGISAWA H, 1995, NUCLEIC ACIDS RES, V23, P2654, DOI 10.1093/nar/23.14.2654; YU A, 1995, NUCLEIC ACIDS RES, V23, P4055, DOI 10.1093/nar/23.20.4055; 1993, CELL, V72, P971	62	95	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15222	15229		10.1074/jbc.271.25.15222	http://dx.doi.org/10.1074/jbc.271.25.15222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663027	hybrid			2022-12-25	WOS:A1996UT10600084
J	Kazzaz, JA; Xu, J; Palaia, TA; Mantell, L; Fein, AM; Horowitz, S				Kazzaz, JA; Xu, J; Palaia, TA; Mantell, L; Fein, AM; Horowitz, S			Cellular oxygen toxicity - Oxidant injury without apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HYDROGEN-PEROXIDE; NORMOBARIC HYPEROXIA; DEATH; DAMAGE	All forms of aerobic life are faced with the threat of oxidation from molecular oxygen (O-2) and have evolved antioxidant defenses to cope with this potential problem, However, cellular antioxidants can become overwhelmed by oxidative insults, including supraphysiologic concentrations of O-2 (hyperoxia), Oxidative cell injury involves the modification of cellular macromole cules by reactive oxygen intermediates (ROI), often leading to cell death, O-2 therapy, which is a widely used component of life-saving intensive care, can cause lung injury, It is generally thought that hyperoxia injures cells by virtue of the accumulation of toxic levels of ROI, including H2O2 and the superoxide anion (O-2(-)), which are not adequately scavenged by endogenous antioxidant defenses, These oxidants are cytotoxic and have been shown to kill cells via apoptosis, or programmed cell death, If hyperoxia-induced cell death is a result of increased ROI, then O-2 toxicity should kill cells via ap optosis, We studied cultured epithelial cells in 95% O-2 and assayed apoptosis using a DNA-binding fluorescent dye, in situ end-labeling of DNA, and electron microscopy, Using all approaches we found that hyperoxia kills cells via necrosis, not apoptosis, In contrast, lethal concentrations of either H2O2 or O-2(-) cause apoptosis, Paradoxically, apoptosis is a prominent event in the lungs of animals injured by breathing 100% O-2. These data indicate that O-2 toxicity is somewhat distinct from other forms of oxidative injury and suggest that apoptosis in vivo is not a direct effect of O-2.	SUNY STONY BROOK,WINTHROP UNIV HOSP,SCH MED,CARDIOPULM RES INST,MINEOLA,NY 11501; SUNY STONY BROOK,WINTHROP UNIV HOSP,SCH MED,DEPT MED NEPHROL,MINEOLA,NY 11501	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital								ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; BOWDEN DH, 1994, EXP LUNG RES, V20, P251, DOI 10.3109/01902149409064386; CAPPELLETTI G, 1994, CELL BIOL TOXICOL, V10, P255, DOI 10.1007/BF00756765; CHRISTIE NA, 1994, ARCH BIOCHEM BIOPHYS, V313, P131, DOI 10.1006/abbi.1994.1369; CLEMENT A, 1992, J CLIN INVEST, V90, P1812, DOI 10.1172/JCI116056; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; FAVIER A, 1994, CHEM-BIOL INTERACT, V91, P165, DOI 10.1016/0009-2797(94)90037-X; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; FUKUDA Y, 1992, TOXICOLOGY, V74, P185, DOI 10.1016/0300-483X(92)90138-5; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILLE JJP, 1989, MUTAT RES, V214, P89, DOI 10.1016/0027-5107(89)90201-7; GILLE JJP, 1992, MUTAT RES, V275, P405, DOI 10.1016/0921-8734(92)90043-O; GILLE JJP, 1989, MUTAT RES, V219, P17, DOI 10.1016/0921-8734(89)90037-4; GILLE JJP, 1994, CARCINOGENESIS, V15, P2695, DOI 10.1093/carcin/15.12.2695; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLLAN S, 1995, HAEMATOLOGIA, V26, P177; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; IWATA M, 1994, J AM SOC NEPHROL, V5, P1307; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JONES GRN, 1992, PHYSIOL CHEM PHYS ME, V24, P169; KAZZAZ JA, 1995, AM J RESP CRIT CARE, V151, pA547; MIESEL R, 1995, INFLAMMATION, V19, P379, DOI 10.1007/BF01534394; Morris A H, 1994, New Horiz, V2, P19; PIEDBOEUF B, 1994, AM J RESP CELL MOL, V10, P123, DOI 10.1165/ajrcmb.10.2.8110467; PIERCE GB, 1991, DIFFERENTIATION, V46, P181, DOI 10.1111/j.1432-0436.1991.tb00880.x; QUINLAN T, 1994, ENVIRON HEALTH PERSP, V102, P79, DOI 10.2307/3431823; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; SANDSTROM PA, 1993, AIDS RES HUM RETROV, V9, P1107, DOI 10.1089/aid.1993.9.1107; SCHACTER E, 1994, FREE RADICAL BIO MED, V17, P429; SCHOONEN WGEJ, 1990, J BIOL CHEM, V265, P11118; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; SPITZ DR, 1992, ARCH BIOCHEM BIOPHYS, V292, P221, DOI 10.1016/0003-9861(92)90071-4; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214; TORNUSCIOLO DRZ, 1995, BIOTECHNIQUES, V19, P800; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; WAGNER BA, 1994, BIOCHEMISTRY-US, V33, P4449, DOI 10.1021/bi00181a003; YUAN H, 1995, COMP BIOCHEM PHYS B, V110, P145, DOI 10.1016/0305-0491(94)00137-J; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	40	239	249	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15182	15186		10.1074/jbc.271.25.15182	http://dx.doi.org/10.1074/jbc.271.25.15182			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662947	hybrid			2022-12-25	WOS:A1996UT10600079
J	Tsao, TS; Burcelin, R; Charron, MJ				Tsao, TS; Burcelin, R; Charron, MJ			Regulation of hexokinase II gene expression by glucose flux in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE ADIPOSE-TISSUE; MESSENGER-RNA; TRANSGENIC MICE; INSULIN; RAT; TRANSPORT; TRANSCRIPTION; PROTEIN; CELLS	The in vivo studies of transcriptional regulation by glucose, in general, have yielded ambiguous interpretations due to the closed loop relationship between insulin and glucose. Insulin cannot be held as a constant since elevated glucose levels will elicit a corresponding rise in insulin and current animal models of insulinopenia are associated with a plethora of counter regulatory hormone responses. One potential solution to increase intracellular glucose flux without a further increase in insulin was achieved by transgenic overexpression of the insulin-sensitive glucose transporter, GLUT4, in specific skeletal muscles (previously described in Tsao, T.-S., Burcelin, R., Katz, E. B., Huang, L., and Charron, M. J. (1996) Diabetes 45, 28-36). Using these MLC GLUT4 transgenic mice as a model, we investigated the effects of increased glucose flux on hexokinase II (HK II) gene expression in skeletal muscle. Under conditions where blood glucose levels were normal and insulin levels decreased by 36%, HK II mRNA level was reduced in non-GLUT4-overexpressing tissues (i.e. heart and adipose tissue) of 2-4-month-old male MLC-GLUT4 transgenic mice. This reduction in HK II mRNA was prevented in skeletal muscle, where overexpression of GLUT4 caused a 2.5-fold increase in basal and insulin-stimulated glucose uptake. The levels of HK II mRNA in heart, muscle, and adipose tissue are paralleled by HK II enzymatic activity. In conclusion: 1) due to relative mild insulinopenia, HK II expression is decreased in non-GLUT4-overexpressing tissues of MLC-GLUT4 mice compared to age/sex-matched controls, and 2) GLUT4-mediated increase in cellular glucose flux can prevent the decrease in HK II expression (in GLUT4-overexpressing tissues) as a result of relative mild insulinopenia. Indeed, during the process of aging, the return of circulating insulin levels of MLC-GLUT4 mice to normal levels is associated with the normalization of HK II expression in all tissues of MLC GLUT4 and age/sex-matched control mice. We propose that: 1) glucose flux has an amplifying effect on the ability of insulin to stimulate skeletal muscle HK II gene expression and 2) insulin-dependent glucose flux may be a potential mechanism by which HK II gene expression is regulated by sensitivity to insulin.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				Tsao, Tsu-Shuen/0000-0002-1041-9687	NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, P30DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA1330] Funding Source: Medline; NIDDK NIH HHS [DK20541-17] Funding Source: Medline; NIGMS NIH HHS [5T32GM07491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERNSTEIN RS, 1973, DIABETES, V22, P913, DOI 10.2337/diab.22.12.913; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; BURCELIN R, 1993, AM J PHYSIOL, V265, pE392, DOI 10.1152/ajpendo.1993.265.3.E392; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; FERRE P, 1985, BIOCHEM J, V228, P103, DOI 10.1042/bj2280103; FINK RI, 1983, J CLIN INVEST, V71, P1523, DOI 10.1172/JCI110908; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GORDON JW, 1993, METHOD ENZYMOL, V225, P747; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTO Y, 1992, DIABETES, V41, P339, DOI 10.2337/diabetes.41.3.339; GULVE EA, 1993, AM J PHYSIOL, V264, pE319, DOI 10.1152/ajpendo.1993.264.3.E319; KATZ A, 1991, AM J PHYSIOL, V260, pE411, DOI 10.1152/ajpendo.1991.260.3.E411; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KATZEN HM, 1968, ANN NY ACAD SCI, V151, P351, DOI 10.1111/j.1749-6632.1968.tb11900.x; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; MANDARINO LJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE701; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; REN JM, 1993, J BIOL CHEM, V268, P16113; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SCHIMKE TR, 1968, ANN NY ACAD SCI, V151, P332, DOI 10.1111/j.1749-6632.1968.tb11899.x; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Vestergaard H, 1995, J CLIN INVEST, V96, P2639, DOI 10.1172/JCI118329; WALKER PS, 1990, J BIOL CHEM, V265, P1516	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14959	14963		10.1074/jbc.271.25.14959	http://dx.doi.org/10.1074/jbc.271.25.14959			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663067	hybrid			2022-12-25	WOS:A1996UT10600050
J	Adam, D; Wiegmann, K; AdamKlages, S; Ruff, A; Kronke, M				Adam, D; Wiegmann, K; AdamKlages, S; Ruff, A; Kronke, M			A novel cytoplasmic domain of the p55 tumor necrosis factor receptor initiates the neutral sphingomyelinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; NF-KAPPA-B; ACTIVATION; CELLS; KINASE	The human p55 tumor necrosis factor (TNF) receptor (TR55) initiates at least two independent signaling cascades. The acidic sphingomyelinase (A-SMase) pathway involves a phosphatidylcholine-specific phospholipase C, an endosomal A-SMase, and controls expression of multiple TNF-responsive genes through induction of transcription factors such as NF-kappa B. The neutral sphingomyelinase (N-SMase) pathway comprises a membrane-bound N-SMase, proline-directed protein kinases, as well as phospholipase A(2) and appears critical for the inflammatory responses induced by TNF. While the domain of TR55 that induces A-SMase is probably identical to the death domain, the exact location and extent of a putative N-SMase activation domain are still unknown. Structure-function analysis of TR55 deletion mutants revealed a novel region of 11 amino acids at position 309-319 that is both necessary and sufficient for activation of N-SMase. The N-SMase activation domain is distinct from the death domain and incapable of induction of A-SMase, NF-kappa B, and cytotoxicity. Taken together, our results suggest that a functionally independent region of TR55 is responsible for selectively initiating the N-SMase pathway that couples to an important inflammatory signaling cascade.			Adam, D (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL, INST IMMUNOL, D-24105 KIEL, GERMANY.		Adam-Klages, Sabine/E-9761-2010; Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032				BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kronke M, 1992, Immunol Ser, V56, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; QUINTERN LE, 1991, METHOD ENZYMOL, V197, P536; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	40	129	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14617	14622		10.1074/jbc.271.24.14617	http://dx.doi.org/10.1074/jbc.271.24.14617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663014	hybrid			2022-12-25	WOS:A1996UQ66000100
J	Gardner, AM; Johnson, GL				Gardner, AM; Johnson, GL			Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; C-MYC; GENE-EXPRESSION; CELL-DEATH; MOLECULAR-CLONING; FACTOR RECEPTOR; MAP KINASE; PHOSPHORYLATION; DOMAIN; DIFFERENTIATION	Treatment of L929 cells with tumor necrosis factor a (TNF alpha) activates a programmed cell death pathway resulting in apoptosis. We investigated the intracellular signaling pathways activated in L929 cells by TNF alpha. TNF alpha robustly activates Jun kinase (JNK), a member of the mitogen-activated protein kinase (MAPK) family, In addition, p42(MAPK) is activated, but a 10-fold greater concentration of TNF alpha was required for substantial MAPK activation than was needed for maximal JNK stimulation, Simultaneous treatment of L929 cells with fibroblast growth factor (FGF-2) significantly reduced the apoptotic response to TNF alpha. FGF-2 substantially activated the Raf/MEK/MAPK (where MER is mitogen-activated protein kinase kinase) pathway but did not affect TNF alpha activation of JNK. These results indicate that although JNK may play an important role in transmitting the TNF alpha signal from the cell surface to the nucleus, activation of the JNK pathway is not sufficient to induce apoptosis. Expression of dominant-negative Asn-17 Ras in L929 cells diminished the FGF-2 stimulation of p42(MAPK) and eliminated the protective effect of FGF-2, Asn-17 Ras expression did not affect JNK activity and had no effect on TNF alpha activation of JNK, Pharmacological inhibition of MEK-1 activity by incubation of cells with the compound PD 098059 blocked p42(MAPK) activation and FGF-2 protection against apoptosis. Interestingly, activated Val-12 Ras expression substantially enhanced TNF alpha-mediated apoptosis in L929 cells, but Val-12 Ras did not constitutively activate MAPK in L929 cells and FGF-2 partially protected Val-12 Ras-expressing cells from TNF alpha-mediated apoptosis. Our data indicate that activation of the MAPK pathway mediates an FGF-2 protective effect against apoptosis and highlights the important role that integration of multiple intracellular signaling pathways plays in the regulation of cell growth and death.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gardner, AM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,K1007,DENVER,CO 80206, USA.			Gardner, Anne/0000-0001-7095-772X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK048845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871, DK48845] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FESHEL K, 1991, AM J PATHOL, V139, P251; FINTER NB, 1969, J GEN VIROL, V5, P419, DOI 10.1099/0022-1317-5-3-419; FRUTH ME, 1982, J VIROL, V43, P294; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEASLEY LE, 1994, AM J PHYSIOL, V267, pF366, DOI 10.1152/ajprenal.1994.267.3.F366; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1992, CELL, V70, P47; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; ITOH N, 1993, J BIOL CHEM, V268, P10932; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM MY, 1991, J BIOL CHEM, V266, P484; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KYPRIANOU N, 1991, J NATL CANCER I, V83, P346, DOI 10.1093/jnci/83.5.346; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAFF MC, 1992, NATURE, V356, P297; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1991, J BIOL CHEM, V266, P23521; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TAPAROWSKY E, 1982, NATURE, V300, P149; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TOBIN CJ, 1982, NATURE, V300, P143; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRINCHIERI G, 1986, J EXP MED, V164, P1206, DOI 10.1084/jem.164.4.1206; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	69	204	206	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14560	14566		10.1074/jbc.271.24.14560	http://dx.doi.org/10.1074/jbc.271.24.14560			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662985	hybrid			2022-12-25	WOS:A1996UQ66000092
J	Miyazaki, T; Kanou, Y; Murata, Y; Ohmori, S; Niwa, T; Maeda, K; Yamamura, H; Seo, H				Miyazaki, T; Kanou, Y; Murata, Y; Ohmori, S; Niwa, T; Maeda, K; Yamamura, H; Seo, H			Molecular cloning of a novel thyroid hormone-responsive gene, ZAKI-4, in human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; DIFFERENTIAL DISPLAY; RESISTANCE; RNA; CELLS; MUTANT	Utilizing a method called ''differential display of mRNAs by means of polymerase chain reaction'', the cDNA fragment of a thyroid hormone-responsive gene ZAKI-4 was cloned from cultured human skin fibroblasts, Northern blot analysis revealed that there were two ZAKI-4 mRNA species (3.4 and 1.4 kilobases (kb)), and they were up-regulated by a physiological concentration of triiodothyronine (T-3). This T-3 effect was abolished by the treatment with cycloheximide, indicating the possibility that gene ZAKI-4 is regulated by T-3 in an indirect fashion, through an intermediate product of T-3, rather directly by T-3 itself, No effect of T-3 on ZAKI-4 mRNA stability suggested that T-3 induces the mRNA at the transcriptional level. Rapid amplification of cDNA ends confirmed the presence of two mRNA species. ZAKI-4 mRNA was detected in heart, brain, liver, and skeletal muscle but not in placenta, lung, kidney and pancreas. In skin fibroblasts and skeletal muscle, 3,4-kb mRNA was the major species, whereas 1.4-kb mRNA was dominant in heart, brain, and liver. The sequence analysis suggested that the two mRNA species arise from alternative polyadenylation and code a single protein of 192 amino acids. No homologous protein sequence was found in a data base. Elucidation of the function of ZAKI-4 gene product will provide new insights into an important role of T-3 in various organs.	NAGOYA UNIV,DEPT ENDOCRINOL & METAB,DIV MOL & CELLULAR ADAPTAT,ENVIRONM MED RES INST,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,DEPT TERATOL & GENET,DIV MOL & CELLULAR ADAPTAT,ENVIRONM MED RES INST,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,BRANCH HOSP,DEPT INTERNAL MED,NAGOYA,AICHI 461,JAPAN	Nagoya University; Nagoya University; Nagoya University								ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CHAIT A, 1982, J CLIN ENDOCR METAB, V54, P767, DOI 10.1210/jcem-54-4-767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANNIES PS, 1977, ENDOCRINOLOGY, V101, P1151, DOI 10.1210/endo-101-4-1151; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; HAYASHI Y, 1993, J CLIN ENDOCR METAB, V76, P64, DOI 10.1210/jc.76.1.64; ICHIKAWA K, 1986, METABOLISM, V35, P861, DOI 10.1016/0026-0495(86)90229-5; KLANN RC, 1993, J CLIN ENDOCR METAB, V77, P969, DOI 10.1210/jc.77.4.969; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; MIYAZAKI T, 1995, AM J NEPHROL, V15, P48, DOI 10.1159/000168801; MURATA Y, 1983, J CLIN ENDOCR METAB, V57, P1233, DOI 10.1210/jcem-57-6-1233; MURATA Y, 1987, J CLIN ENDOCR METAB, V64, P334, DOI 10.1210/jcem-64-2-334; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SAKURAI A, 1993, CLIN ENDOCRINOL, V38, P29, DOI 10.1111/j.1365-2265.1993.tb00969.x; SEO H, 1977, ENDOCRINOLOGY, V100, P216, DOI 10.1210/endo-100-1-216; SMITH TJ, 1982, J CLIN INVEST, V70, P1066, DOI 10.1172/JCI110694; SOBIEZCZYK S, 1988, ENDOCRINOLOGY S, V122, pT24; TRENTMANN SM, 1995, SCIENCE, V267, P1186, DOI 10.1126/science.7855603; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965	24	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14567	14571		10.1074/jbc.271.24.14567	http://dx.doi.org/10.1074/jbc.271.24.14567			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662924	hybrid			2022-12-25	WOS:A1996UQ66000093
J	Carlberg, M; Dricu, A; Blegen, H; Wang, M; Hjertman, M; Zickert, P; Hoog, A; Larsson, O				Carlberg, M; Dricu, A; Blegen, H; Wang, M; Hjertman, M; Zickert, P; Hoog, A; Larsson, O			Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface - Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; HUMAN-MELANOMA CELLS; HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; DOLICHYL-PHOSPHATE; GLYCOPROTEIN-SYNTHESIS; PROTEIN GLYCOSYLATION; ISOPRENOID SYNTHESIS; ATHYMIC MICE; TUNICAMYCIN	Depletion of mevalonic acid (MVA), obtained by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase using lovastatin, depressed the biosynthesis of dolichyl-phosphate and the rate of N-linked glycosylation and caused growth arrest in the melanoma cell line SK-MEL-2. The growth arrest was partially prevented by addition of high concentrations of insulin-like growth factor-1 (IGF-1) to the cells, indicating that MVA depletion may inhibit cell growth through decreasing the number of IGF-1 receptors (IGF-1R) at the cell surface, Such a decrease in receptor number might be a result of a lowered translocation of de novo synthesized receptors to the cell membrane which in turn might be a result of a decreased N-linked glycosylation of the receptor proteins, We could also demonstrate that IGF-1R became underglycosylated and that the amount of de novo synthesized IGF-1R proteins at the cell membrane was drastically decreased upon MVA depletion, Analysis of receptor proteins cross-linked with IGF-1, as well as binding assays and immunocytostaining confirmed that the number of functional membrane bound IGF-1R was substantially reduced. The N-linked glycosylation and the expression of de novo synthesized IGF-1R proteins at the cell surface as well as the number of IGF-1 binding sites were completely restored upon replenishment of MVA. These effects of MVA were efficiently abrogated by the glycosylation inhibitor tunicamycin, The translocation of IGF-1R to the cell membrane was shown to take place just prior to initiation of DNA synthesis in arrested cells stimulated with MVA, Additionally, there was a clear correlation between IGF-1 binding and initiation of DNA synthesis with regard to the MVA dose requirement, It was confirmed that inhibition of HMG-CoA reductase activity and N-linked glycosylation also depressed the expression of functional IGF-1R in other cell types (i.e. hepatoblastoma cells and colon cancer cells), Our data suggest that this mechanism is involved in MVA-regulated cell growth.	KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet								ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ADAIR WL, 1985, METHOD ENZYMOL, V111, P201; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BENNIS F, 1993, INT J CANCER, V55, P640, DOI 10.1002/ijc.2910550421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; BROWN MS, 1980, J LIPID RES, V21, P505; CARLBERG M, 1994, EXP CELL RES, V212, P359, DOI 10.1006/excr.1994.1155; CARSON DD, 1981, J BIOL CHEM, V256, P4679; CAVENEE WK, 1981, J BIOL CHEM, V256, P2675; CLARK JH, 1977, RECEPTORS HORMONE AC; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; DOYLE JW, 1993, J CELL PHYSIOL, V155, P171, DOI 10.1002/jcp.1041550122; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FURLANETTO RW, 1993, CANCER RES, V53, P2522; GAMMELTOFT S, 1985, EMBO J, V4, P3407, DOI 10.1002/j.1460-2075.1985.tb04097.x; GAMMELTOFT S, 1990, PEPTIDE HORMONE ACTI, P1; GAROFALO RS, 1992, J BIOL CHEM, V267, P11470; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KABAKOFF BD, 1990, ARCH BIOCHEM BIOPHYS, V276, P382, DOI 10.1016/0003-9861(90)90736-I; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PLANTNER JJ, 1980, ARCH BIOCHEM BIOPHYS, V201, P527, DOI 10.1016/0003-9861(80)90541-X; PRIVES J, 1980, TISSUE CULTURE NEURO, P35; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RESNICOFF M, 1994, CANCER RES, V54, P4848; RIP JW, 1985, PROG LIPID RES, V24, P269, DOI 10.1016/0163-7827(85)90008-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sheeler P., 1981, CENTRIFUGATION BIOL; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; STRUCK DK, 1978, J BIOL CHEM, V253, P5332; STRUCK DK, 1981, BIOCH GLYCOPROTEINS, P35; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; VU H, 1991, TETRAHEDRON LETT, V32, P3005, DOI 10.1016/0040-4039(91)80672-S; WARREN L, 1974, MEMBRANE TRANSFORMAT, P1	48	114	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17453	17462		10.1074/jbc.271.29.17453	http://dx.doi.org/10.1074/jbc.271.29.17453			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663239	hybrid			2022-12-25	WOS:A1996UX94300073
J	Hatakeyama, T; Furukawa, M; Nagatomo, H; Yamasaki, N; Mori, T				Hatakeyama, T; Furukawa, M; Nagatomo, H; Yamasaki, N; Mori, T			Oligomerization of the hemolytic lectin CEL-III from the marine invertebrate Cucumaria echinata induced by the binding of carbohydrate ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-TOXIN; PERTUSSIS TOXIN; LIPID DISPERSIONS; MEMBRANES; PROTEIN; AUREUS; MECHANISM; AEROLYSIN; CHANNEL; MONOMER	The hemolytic lectin GEL-III is a Ca2+-dependent, galactose/GalNAc-specific lectin purified from the marine invertebrate Cucumaria echinata (Holothuroidea). We found that this lectin forms ion-permeable pores in erythrocyte and artificial lipid membranes that have specific carbohydrate ligands on the surface. The hemolytic activity of GEL-III exhibited characteristic pH dependence; activity increased remarkably with pH in the alkaline region, especially above pH 9, When rabbit erythrocyte membrane was examined by immunoblot ting using anti-CEL-III antiserum after treatment with GEL-III, the irreversible binding of the GEL-III oligomer increased with pH, indicating that the increase in hemolytic activity at higher pH is associated closely with the amount of oligomer irreversibly bound to the membrane, Surface hydrophobicity of GEL-III, as measured by the fluorescent probe 8-anilino-1-naphthalenesulfonate, increased markedly with the binding of specific ligands such as lactose, lactulose, and N-acetyllactosamine at pH 9-10 in the presence of 1 M NaCl. The enhancement of surface hydrophobicity induced by the binding of carbohydrates was also accompanied by the formation of a GEL-III oligomer, which was found to be the same size on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as the oligomer that formed in CEL-III-treated erythrocyte membranes. Far-UV circular dichroism spectra of CEL-III and the oligomer revealed a definite difference in secondary structure, These data suggest that the binding of GEL-III to specific carbohydrate ligands on the erythrocyte surface induces a conformational change in the protein, leading to the exposure of a hydrophobic region which triggers oligomerization and the irreversible binding of the protein to the membrane.	KYUSHU UNIV, FAC AGR, BIOCHEM LAB, FUKUOKA 81281, JAPAN; KYUSHU UNIV, FAC AGR, ZOOL LAB, FUKUOKA 81281, JAPAN	Kyushu University; Kyushu University				Hatakeyama, Tomomitsu/0000-0002-9505-1980				BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; COWELL JL, 1978, BIOCHIM BIOPHYS ACTA, V507, P230, DOI 10.1016/0005-2736(78)90419-4; DONOVAN JJ, 1985, J BIOL CHEM, V260, P8817; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FREER JH, 1968, J BACTERIOL, V95, P1153, DOI 10.1128/JB.95.3.1153-1168.1968; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; HATAKEYAMA T, 1995, J BIOL CHEM, V270, P3560, DOI 10.1074/jbc.270.8.3560; HATAKEYAMA T, 1994, J BIOCHEM, V116, P209, DOI 10.1093/oxfordjournals.jbchem.a124495; HILAIRE PMS, 1994, BIOCHEMISTRY-US, V33, P14452; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; MORGAN PJ, 1994, J BIOL CHEM, V269, P25315; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; SAUKKONEN K, 1992, P NATL ACAD SCI USA, V89, P118, DOI 10.1073/pnas.89.1.118; SINGH Y, 1994, J BIOL CHEM, V269, P29039; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMYTH CJ, 1975, BIOCHIM BIOPHYS ACTA, V382, P479, DOI 10.1016/0005-2736(75)90216-3; SPANGLER BD, 1993, ARCH BIOCHEM BIOPHYS, V305, P153, DOI 10.1006/abbi.1993.1405; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; WALKER B, 1992, J BIOL CHEM, V267, P21782; WEBER G, 1964, J BIOL CHEM, V239, P1415; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208	33	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16915	16920		10.1074/jbc.271.28.16915	http://dx.doi.org/10.1074/jbc.271.28.16915			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663224	hybrid			2022-12-25	WOS:A1996UX12600074
J	Kurokawa, M; Tanaka, T; Tanaka, K; Hirano, N; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H				Kurokawa, M; Tanaka, T; Tanaka, K; Hirano, N; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H			A conserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; DROSOPHILA SEGMENTATION GENE; TRANSCRIPTION FACTOR; REDOX REGULATION; POLYOMAVIRUS ENHANCER; NUCLEAR FACTOR; ACTIVATION; PROTEIN; INVITRO	The AML1 gene encodes DNA-binding proteins that contain the runt homology domain and is found at the breakpoints of t(8;21), t(3;21), and t(12;21) translocations associated with myelogenous leukemias, AML1 heterodimerizes with PEBP2 beta/CBF beta, resulting in the enhanced affinity with DNA, The runt homology domain is responsible for binding with DNA and heterodimerizing with PEBP2 beta/CBF beta. AML1 is suggested to perform a pivotal role in myeloid cell differentiation, whereas it can cause neoplastic transformation when overexpressed in fibroblasts. In this study, we demonstrated that the reducing reagent, dithiothreitol (DTT), markedly enhances the DNA binding of AML1 expressed in COS7 cells, Oxidation by diamide or modification by N-ethylmaleimide of the free sulfhydryl residues inhibited the interaction of AML1 with DNA. The diamide effect was reversible with excess of DTT, whereas DTT could not restore the DNA binding of AML1 treated with N-ethylmaleimide. Site-directed mutagenesis of the amino acid residue 72, a highly conserved cysteine in the runt homology domain of AML1, to serine almost completely abolished DNA binding without altering the interaction with PEBP2 beta/CBF beta. This substitution also impaired transactivation through the consensus DNA sequence and transformation of fibroblasts induced by AML1b, These data indicate an essential role of the conserved cysteine residue in DNA binding of AML1, and it is possible that the redox state of AML1 could contribute to the regulation of its function.	UNIV TOKYO, FAC SCI, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008; Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; ERICKSON P, 1992, BLOOD, V80, P1825; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOODMAN MG, 1979, J IMMUNOL, V122, P1433; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HEDGE RS, 1992, NATURE, V359, P505; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kurokawa M, 1996, ONCOGENE, V12, P883; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1988, ONCOGENE, V3, P69; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	50	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16870	16876		10.1074/jbc.271.28.16870	http://dx.doi.org/10.1074/jbc.271.28.16870			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663420	hybrid			2022-12-25	WOS:A1996UX12600069
J	Li, BJ; Warner, JR				Li, BJ; Warner, JR			Mutation of the Rab6 homologue of Saccharomyces cerevisiae, YPT6, inhibits both early Golgi function and ribosome biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY; PROTEIN-TRANSPORT; YEAST; GENE; RNA; APPARATUS; COMPLEX; IDENTIFICATION; MORPHOGENESIS; COMPONENT	A screen was designed to identify temperature-sensitive mutants of Saccharomyces cerevisiae, whose transcription of both ribosomal RNA and ribosomal protein genes is repressed at the nonpermissive temperature, The gene from one such mutant was cloned by complementation, The gene encodes a predicted product that is nearly 65% identical to the human GTPase, Rab6, and is likely to be identical to the yeast gene YPT6. It is essential for growth only at elevated temperatures, The mutant strain is partially defective in the maturation of the vacuolar protein carboxypeptidase Y, as well as in the secretion of invertase, which accumulates as a core-glycosylated form characteristic of the endoplasmic reticulum or the cis-Golgi, suggesting that Ypt6p is involved in an early step of the secretory pathway, earlier than that reported for the mammalian Rab6., The mutant protein, a truncation at codon 64 of 215, has a stronger phenotype than the null allele of YPT6. Four other mutants selected for defective ribosome synthesis at the nonpermissive temperature were also found to have defects in carboxypeptidase Y maturation, giving emphasis to our previous finding that a functional secretory pathway is essential for continued ribosome synthesis, Cloning of extragenic suppressors of the ts allele of YPT6 has revealed two additional proteins that influence the secretory pathway: Ssd1p, a suppressor of many mutations, and Imh1p, which bears some homology to the C-terminal portion of the cytoskeletal proteins integrin and myosin.	ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIGMS NIH HHS [GM 25532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BERANGER F, 1994, MOL CELL BIOL, V14, P744, DOI 10.1128/MCB.14.1.744; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOSEFF AI, 1995, GENETICS, V141, P857; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GOUD B, 1994, ANN NY ACAD SCI, V710, P192, DOI 10.1111/j.1749-6632.1994.tb26627.x; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KAISER CA, 1986, MOL CELL BIOL, V6, P2382, DOI 10.1128/MCB.6.7.2382; KIM CH, 1983, MOL CELL BIOL, V3, P457, DOI 10.1128/MCB.3.3.457; KIM YJ, 1994, J CELL BIOL, V127, P1381, DOI 10.1083/jcb.127.5.1381; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; LIANG S, 1993, EUR J CELL BIOL, V62, P270; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Mondesert G, 1996, J CELL BIOL, V132, P137, DOI 10.1083/jcb.132.1.137; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SEOG DH, 1994, J BIOCHEM-TOKYO, V116, P1341, DOI 10.1093/oxfordjournals.jbchem.a124685; SHUAI K, 1991, NUCLEIC ACIDS RES, V19, P5059, DOI 10.1093/nar/19.18.5059; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; UESONO Y, 1994, GENE, V143, P135; WARNER JR, 1977, CELL, V11, P201, DOI 10.1016/0092-8674(77)90331-2; WARNER JR, 1978, NATURE, V275, P338, DOI 10.1038/275338a0; WILSON RB, 1991, MOL CELL BIOL, V11, P3369, DOI 10.1128/MCB.11.6.3369	44	87	89	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16813	16819		10.1074/jbc.271.28.16813	http://dx.doi.org/10.1074/jbc.271.28.16813			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663225	hybrid			2022-12-25	WOS:A1996UX12600061
J	Mucsi, I; Skorecki, KL; Goldberg, HJ				Mucsi, I; Skorecki, KL; Goldberg, HJ			Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-beta 1 on gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; COLLAGEN PROMOTER; ACTIVATION; P21RAS; CELLS; SITE	The kinases and regulatory proteins that convey signals initiated by transforming growth factor-beta (TGF-beta) to the nucleus are poorly characterized. To study the role of the extracellular signal-regulated kinase (ERK) pathway in this process, we transiently transfected NIH 3T3 fibroblasts with TGF-beta-responsive luciferase re porter genes and expression vectors designed to interrupt this kinase cascade. Mitogen-activated protein (MAP) kinase phosphatase-1 and a dominant negative MAP/ERK kinase 1 mutant reduced stimulation of plasminogen activator inhibitor-1 (PAI-1) promoter activity by TGF-beta 1 from 11.5 to 4-fold and 4.9-fold, respectively. Similar results were observed with the type I collagen promoters. TGF-beta 1 increased ERK1 activity 4.5 fold at 5 min and 3.1-fold at 3 h, while Jun kinase and p38 activity were not affected. Cotransfection of a dominant negative mutant of the small G protein, Rac, but not dominant negative Ras, Cdc42, or Rho mutants, reduced the effects of TGF-beta 1 on the PAI-1 promoter by approximately half. In support of a role for Rac in signaling by TGF-beta, GTP binding to Pac was increased 3.7-fold following exposure of NIH 3T3 cells to TGF-beta 1 for 3 min. These findings indicate that TGF-beta 1 modulates gene expression partly through ERK and Rac in NIH 3T3 cells.	UNIV TORONTO,DIV NEPHROL,DEPT PEDIAT,HOSP SICK CHILDREN,TORONTO,ON M5G 1X8,CANADA; TECHNION ISRAEL INST TECHNOL,DIV NEPHROL,IL-31096 HAIFA,ISRAEL; RAMBAM MED CTR,IL-31096 HAIFA,ISRAEL	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology								ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; AFTI A, 1995, P NATL ACAD SCI USA, V92, P12110; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIPSKIND RA, 1994, MOL CELL BIOL, V9, P621; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; IMAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JONES CL, 1991, KIDNEY INT, V40, P1020, DOI 10.1038/ki.1991.310; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Knoepp SM, 1996, J BIOL CHEM, V271, P1678, DOI 10.1074/jbc.271.3.1678; KOLEH W, 1993, NATURE, V364, P249; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULDER KM, 1992, J BIOL CHEM, V267, P5029; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; PANG L, 1995, BIOCHEM J, V307, P513, DOI 10.1042/bj3070513; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WARNER LC, 1993, ONCOGENE, V8, P3249; WEISER R, 1995, EMBO J, V14, P2199; WEISS RH, 1995, KIDNEY INT, V48, P738, DOI 10.1038/ki.1995.345; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN ZF, 1994, J BIOL CHEM, V269, P13231	68	161	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16567	16572		10.1074/jbc.271.28.16567	http://dx.doi.org/10.1074/jbc.271.28.16567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663331	hybrid			2022-12-25	WOS:A1996UX12600024
J	DeStefano, JJ				DeStefano, JJ			Interaction of human immunodeficiency virus nucleocapsid protein with a structure mimicking a replication intermediate - Effects on stability, reverse transcriptase binding, and strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMER TRANSFER-RNA; GENETIC-RECOMBINATION; RIBONUCLEASE H; ZINC-FINGERS; HIV-1; TYPE-1; GENOMES; ENDONUCLEASE; POLYMERASE; TEMPLATES	The interaction of human immunodeficiency virus (HIV) nucleocapsid protein (NCp) with a substrate closely mimicking a retrovirus replication intermediate was studied. The heteroduplex substrate consisted of a DNA and RNA of 80 and 63 nucleotides, respectively. The nucleotides at the 3' end of the DNA were complementary to those at the 3' end of the RNA such that a hybrid region of 30 base pairs could form. HIV-reverse transcriptase (RT) extended the DNA and cleaved the RNA strand of the substrate, The rates of extension and cleavage were significantly decreased when the substrate was prebound with NCp before HIV-RT addition. In assays assessing the integrity of the substrate by measuring release of the DNA strand from the heteroduplex, prebinding with NCp protected the substrate when HIV-RT was added, a result consistent with resistance to RT-mediated cleavage. In contrast, NCp significantly decreased the thermal stability of the substrate as judged by incubation of the substrate at various temperatures, In strand transfer assays, a 189-nucleotide RNA (acceptor) with an internal region complementary to all 80 nucleotides of the substrate DNA was incubated with the substrate in the presence or absence of NCp, Nucleocapsid protein stimulated strand transfer in which the substrate RNA was displaced upon binding of the DNA to the acceptor. Results are discussed with respect to the role of NCp in retroviral recombination.			DeStefano, JJ (corresponding author), UNIV MARYLAND,DEPT MICROBIOL,BLDG 231,COLLEGE PK,MD 20742, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051140, R01GM051140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51140-01, R29 GM051140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; DELAHUNTY MD, 1992, BIOCHEMISTRY-US, V31, P6461, DOI 10.1021/bi00143a015; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DICKSON C, 1985, RNA TUMOR VIRUSES, V1, P513; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HANSEN J, 1987, J BIOL CHEM, V262, P12393; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KHAN R, 1992, J BIOL CHEM, V267, P6689; KOLSTAEDT LA, 1992, SCIENCE, V256, P1783; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PRIEL E, 1995, FEBS LETT, V362, P59, DOI 10.1016/0014-5793(95)00208-Q; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; STARNES MC, 1989, J BIOL CHEM, V264, P7073; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; YOU JC, 1994, J BIOL CHEM, V269, P31491	42	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16350	16356						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663119				2022-12-25	WOS:A1996UW35200073
J	Habib, GM; Barrios, R; Shi, ZZ; Lieberman, MW				Habib, GM; Barrios, R; Shi, ZZ; Lieberman, MW			Four distinct membrane-bound dipeptidase RNAs are differentially expressed and show discordant regulation with gamma-glutamyl transpeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RENAL DIPEPTIDASE; TRANSFERASE TRANSPEPTIDASE; DEHYDROPEPTIDASE-I; MOLECULAR-CLONING; GLUTATHIONE; TRANSPORT; STEP; CDNA; DNA	Membrane-bound dipeptidase (MBD) participates in the degradation of glutathione by cleaving the cysteinylglycine bond of cystinyl bisglycine (oxidized cysteinylglycine) following removal of a gamma-glutamyl group by gamma-glutamyl transpeptidase (GGT). In the mouse, MBD RNA is most abundant in small intestine, kidney, and lung and is represented by four distinct RNA species, These are generated by transcription from two promoters located 6 kilobases apart in the 5' flanking region of the gene and by the use of two different poly(A) addition sites, Promoter I is used primarily in small intestine and kidney, whereas promoter II is most active in lung and kidney, We found a discordance in the expected co-expression of MBD and GGT; as expected, MBD and GGT are both expressed at high levels in the kidney and small intestine, However, in the lung, MBD is expressed at high levels, whereas GGT is almost undetectable, The reverse is true in the seminal vesicles and fetal liver. Thus, although both enzymes may function in concert to metabolize glutathione in kidney and small intestine, in other tissues they appear to act independently, suggesting that they have independent roles in other biological processes.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine								ADACHI H, 1993, BIOCHIM BIOPHYS ACTA, V1163, P42, DOI 10.1016/0167-4838(93)90276-W; AN SZ, 1994, BBA-MOL BASIS DIS, V1226, P337, DOI 10.1016/0925-4439(94)90046-9; ANDERSON ME, 1980, BIOCHEM BIOPH RES CO, V96, P848, DOI 10.1016/0006-291X(80)91433-3; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Curthoys N. P., 1990, GLUTATHIONE METABOLI, P217; GONZALEZ J, 1990, GLUTATHIONE METABOLI, P295; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P268, DOI 10.1073/pnas.76.1.268; HABIB GM, 1995, J BIOL CHEM, V270, P13711, DOI 10.1074/jbc.270.23.13711; HANNIGAN MH, 1993, BIOCHEMISTRY-US, V32, P6302; HIKIDA M, 1992, ANTIMICROB AGENTS CH, V36, P481, DOI 10.1128/AAC.36.2.481; HUBER M, 1988, GLUTATHIONE CONJUGAT, P449; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; KENNY AJ, 1987, MAMMALIAN ECTOENZYME, P329; KEPPLER D, 1992, REV PHYSIOL BIOCH P, V121, P1, DOI 10.1007/BFb0033192; KEYNAN S, 1994, FEBS LETT, V349, P50, DOI 10.1016/0014-5793(94)00637-7; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; KROPP H, 1982, ANTIMICROB AGENTS CH, V22, P62, DOI 10.1128/AAC.22.1.62; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175; Meister A., 1995, METABOLIC BASIS INHE, P1461; RACHED E, 1990, BIOCHEM J, V271, P755, DOI 10.1042/bj2710755; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1163, P234, DOI 10.1016/0167-4838(93)90157-M; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P181, DOI 10.1016/0167-4781(93)90289-P; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; TODA K, 1994, MOL ENDOCRINOL, V8, P210, DOI 10.1210/me.8.2.210; TURNER AJ, 1990, MOL CELL BIOL MEMBRA, P129	29	27	29	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16273	16280		10.1074/jbc.271.27.16273	http://dx.doi.org/10.1074/jbc.271.27.16273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663190	hybrid			2022-12-25	WOS:A1996UW35200062
J	Verghese, MW; Kneisler, TB; Boucheron, JA				Verghese, MW; Kneisler, TB; Boucheron, JA			P-2U agonists induce chemotaxis and actin polymerization in human neutrophils and differentiated HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PURINERGIC RECEPTOR; NUCLEOTIDES; ACTIVATION; LEUKOCYTES; ELEVATION; CALCIUM; CAMP; ATP	Human neutrophils or HL60 cells express P-2U receptors and respond to micromolar concentrations of ATP, adenosine 5'-O-(thiotriphosphate) (ATP gamma S), or UTP with immediate increases in intracellular Ca2+ through activation of phosphoinositide phospholipase C (Cowen, D. S., Lazarus, H, M,, Shurin, S. B,, Stoll, S, E., and Dubyak, G. R, (1989) J. Clin. Invest, 83, 1651-1660). P-2U agonists reportedly induce limited enzyme secretion and enhance the respiratory burst in response to chemotactic factors, We demonstrate here that P-2U agonists are chemotactic for neutrophils or differentiated HL60 cells. Rhodamine phalloidin staining indicates that ATP gamma S treatment induces actin polymerization and shape changes similar to those seen when these cells are treated with chemotactic peptide fMet-Leu-Phe. Although undifferentiated HL60 cells fail to mount a rise in Ca2+ when challenged with fMet-Leu-Phe, they increase Ca2+ in response to P-2U agonists, However, functional expression of phospholipase C-coupled receptors is not sufficient for chemotaxis since HL60 cell migration in response to these agonists or to fMet-Leu-Phe occurs only after exposure to differentiating agents such as BT(2)cAMP, In addition to the well known G protein-linked receptors for lipid or peptide chemotactic factors, neutrophils apparently also can utilize G protein-linked purino/pyrimidino receptors to recognize nucleotides as chemoattractants. High concentrations of ATP and UTP generated at sites of platelet aggregation and tissue injury could thus be important mediators of inflammation.	GLAXO WELLCOME INC,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709; ARMED FORCES RADIOBIOL RES INST,DEPT RADIAT PATHOPHYSIOL & TOXICOL,BETHESDA,MD 20889	GlaxoSmithKline; United States Department of Defense								AXTELL RA, 1990, BLOOD, V75, P1324; BOYER JL, 1989, J BIOL CHEM, V264, P884; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COOPER CL, 1989, J BIOL CHEM, V264, P6202; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; COWEN DS, 1990, J BIOL CHEM, V265, P16181; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; ERB L, 1993, P NATL ACAD SCI USA, V90, P10449, DOI 10.1073/pnas.90.22.10449; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HARVATH L, 1991, J IMMUNOL, V146, P224; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PIROTTON S, 1993, CELL SIGNAL, V5, P1, DOI 10.1016/0898-6568(93)90002-4; REIBMAN J, 1991, P NATL ACAD SCI USA, V88, P6805, DOI 10.1073/pnas.88.15.6805; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303	19	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15597	15601		10.1074/jbc.271.26.15597	http://dx.doi.org/10.1074/jbc.271.26.15597			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663069	hybrid			2022-12-25	WOS:A1996UV29900045
J	Johnson, RM; Buck, S; Chiu, CH; Schneider, H; Sampaio, I; Gage, DA; Shen, TL; Schneider, MPC; Muniz, JA; Gumucio, DL; Goodman, M				Johnson, RM; Buck, S; Chiu, CH; Schneider, H; Sampaio, I; Gage, DA; Shen, TL; Schneider, MPC; Muniz, JA; Gumucio, DL; Goodman, M			Fetal globin expression in new world monkeys	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYLOGENETIC FOOTPRINTING REVEALS; EPSILON-GLOBIN; NUCLEOTIDE-SEQUENCES; GAMMA; GENES; HEMOGLOBIN; PRIMATES; CAPUCHIN; CHAINS	Reverse phase chromatography of the globin chains of adult, newborn, and fetal erythrocytes from three species of New World monkeys (Cebus apella, Aotus azarae, and Callithrix jacchus) representing three of the seven platyrrhine clades showed that gamma-globin expression was fetal in these animals, The globins were identified by a combination of chemical sequencing and mass spectro metric analysis, Since gamma-globin expression is fetal in the other major simian branch, the catarrhines, but embryonic in prosimian primates and nonprimate placental mammals, the evolution of fetal recruitment can now be assigned to the period between the simian-prosimian divergence (55 million years ago) and the platyrrhine-catarrhine divergence (35 million years ago), The gamma-globin gene underwent tandem duplication during the same evolutionary epoch, in accord with a model that suggests that the downstream duplicated gamma-gene (gamma 2) was free to acquire the mutations necessary for fetal recruitment, Mass spectrometric analysis of tryptic digests of the gamma-globins verified the amino acid sequences deduced from genomic sequencing, Detailed analysis of high performance liquid chromatography and matrix-assisted laser desorption/ionization mass spectrometry data showed that gamma 2-globin in Cebus was expressed to a far greater extent than gamma 1-globin, supporting inferences drawn from a study of the promoter sequences, A ''pre-gamma''-globin was observed in C. apella and shown to be primarily the glutathionyl adduct, The other species, A. azarae and C. jacchus, also express only one gamma-globin polypeptide. This work provides biochemical evidence of an evolutionary trend in the platyrrhines to alter the duplicated gamma-globin gene locus so that only one gamma-globin polypeptide is expressed.	WAYNE STATE UNIV,SCH MED,DEPT ANAT & CELL BIOL,DETROIT,MI 48201; MICHIGAN STATE UNIV,DEPT BIOCHEM,MASS SPECT FACIL,E LANSING,MI 48824; UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109; UNIV FED PARA,DEPT GENET,BELEM,PARA,BRAZIL; CTR NACL PRIMATAS,ANANINDEUA,PARA,BRAZIL	Wayne State University; Michigan State University; University of Michigan System; University of Michigan; Universidade Federal do Para	Johnson, RM (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,540 E CANFIELD,DETROIT,MI 48201, USA.		SAMPAIO, IRACILDA/J-6514-2012; Schneider, Horacio/J-7131-2012	SAMPAIO, IRACILDA/0000-0002-2137-4656; Schneider, Horacio/0000-0002-5987-6395	NCRR NIH HHS [RR-00480] Funding Source: Medline; NHLBI NIH HHS [HL-33940] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033940] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DW, 1961, J CLIN INVEST, V40, P454, DOI 10.1172/JCI104273; BIRCHMEIER W, 1973, BIOCHEMISTRY-US, V12, P3667, DOI 10.1021/bi00743a015; BOYER SH, 1969, ANN NY ACAD SCI, V165, P360, DOI 10.1111/j.1749-6632.1969.tb27806.x; BOYER SH, 1970, BIOCH GENET, V5, P405; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHIU CH, 1996, IN PRESS P NATL ACAD; DESIMONE J, 1979, BLOOD, V53, P19, DOI 10.1182/blood.V53.1.19.19; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; FITCH DHA, 1990, J BIOL CHEM, V265, P781; GOODMAN M, 1996, IN PRESS GENE FAMILI; GROSVELD F, 1993, COLD SPRING HARB SYM, V58, P7, DOI 10.1101/SQB.1993.058.01.004; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; GUMUCIO DL, 1994, J BIOL CHEM, V269, P15371; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; HARADA ML, 1995, MOL PHYLOGENET EVOL, V4, P331, DOI 10.1006/mpev.1995.1029; HAYASAKA K, 1992, J MOL BIOL, V224, P875, DOI 10.1016/0022-2836(92)90568-5; HAYASAKA K, 1993, GENOMICS, V18, P20, DOI 10.1006/geno.1993.1422; HUISHMAN TH, 1966, J LAB CLIN MED, V67, P355; HUISMAN THJ, 1973, BIOCHEM GENET, V10, P309, DOI 10.1007/BF00485708; HUISMAN THJ, 1986, HEMOGLOBINOPATHIES, P1; MATSUDA G, 1973, H-S Z PHYSIOL CHEM, V354, P1513; MEIRELES CMM, 1995, P NATL ACAD SCI USA, V92, P2607, DOI 10.1073/pnas.92.7.2607; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NUTE PE, 1971, COMP BIOCHEM PHYSIOL, V39, P797, DOI 10.1016/0305-0491(71)90104-0; SCHNEIDER H, 1993, MOL PHYLOGENET EVOL, V2, P225, DOI 10.1006/mpev.1993.1022; SCHROEDER WA, 1986, HEMOGLOBIN, V10, P239, DOI 10.3109/03630268609042845; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; SLIGHTOM JL, 1988, J BIOL CHEM, V262, P7472; SPRITZ RA, 1988, MOL BIOL EVOL, V5, P21; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; TANIOKA Y, 1986, BIOL CHEM H-S, V367, P147, DOI 10.1515/bchm3.1986.367.1.147	31	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14684	14691		10.1074/jbc.271.25.14684	http://dx.doi.org/10.1074/jbc.271.25.14684			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663037	hybrid			2022-12-25	WOS:A1996UT10600010
J	Mukhija, S; Erni, B				Mukhija, S; Erni, B			Purification by Ni2+ affinity chromatography, and functional reconstitution of the transporter for N-acetylglucosamine of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; MEMBRANE-BOUND ENZYMES; SALMONELLA-TYPHIMURIUM; GLUCOSE-TRANSPORTER; CHITIN UTILIZATION; MARINE-BACTERIA; SUGAR-TRANSPORT; KLEBSIELLA-PNEUMONIAE; STREPTOCOCCUS-LACTIS; VIBRIO-FURNISSII	The N-acetyl-D-glucosamine transporter (IIGlcNAc) Of the bacterial phosphotransferase system couples vectorial translocation to phosphorylation of the transported GlcNAc, IIGlcNAc of Escherichia coli containing a carboxyl-terminal affinity tag of six histidines was purified by Ni2+ chelate affinity chromatography. 4 mg of purified protein was obtained from 10 g (wet weight) of cells. Purified IIGlcNAc was reconstituted into phospholipid vesicles by detergent dialysis and freeze/thaw sonication. IIGlcNAc was Oriented randomly in the vesicles as inferred from protein phosphorylation studies. Import and subsequent phosphorylation of GlcNAc were measured with proteoliposomes preloaded with enzyme I, histidine-containing phosphocarrier protein, and phosphoenolpyruvate. Uptake and phosphorylation occurred in a 1:1 ratio, Active extrusion of GlcNAc entrapped in vesicles was also measured by the addition of enzyme I, histidine-containing phosphocarrier protein, and phosphoenolpyruvate to the outside of the vesicles. The K-m for vectorial phosphorylation and non-vectorial phosphorylation were 66.6 +/- 8.2 mu m and 750 +/- 19.6 mu m, respectively, Non-vectorial phosphorylation was faster than vectorial phosphorylation with k(cat) 15.8 +/- 0.9 s(-1) and 6.2 +/- 0.7 s(-1), respectively. Using exactly the same conditions, the purified transporters for mannose (IIAB(Man), IICMan, IIDMan) and glucose (IICBGlc, IIA(Glc)) were also reconstituted for comparison. Although the vectorial transport activities of IICBA(GlcNAc) and IICBGlc IIA(Glc) are inhibited by non vectorial phosphorylation, no such effect was observed with the IIAB(Man) IICMan IIDMan complex, This suggests that the molecular mechanisms underlying solute transport and phosphorylation are different for different transporters of the phosphotransferase system.	UNIV BERN, INST BIOCHEM, CH-3012 BERN, SWITZERLAND	University of Bern								BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1994, J BIOL CHEM, V269, P23437; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; ELFERINK MGL, 1990, J BACTERIOL, V172, P7119, DOI 10.1128/jb.172.12.7119-7125.1990; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1982, J BIOL CHEM, V257, P13726; HUBER F, 1996, THESIS U BERN BERN; HUMMEL U, 1992, PROTEIN SCI, V1, P356; JACOBSON GR, 1979, J BIOL CHEM, V254, P249; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGELER J, 1981, MOL GEN GENET, V183, P163, DOI 10.1007/BF00270156; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LEVY D, 1990, J BIOL CHEM, V265, P19524; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MAC Q, 1995, J BIOL CHEM, V270, P5258; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1987, J BACTERIOL, V169, P4893, DOI 10.1128/jb.169.11.4893-4900.1987; MEINS M, 1993, J BIOL CHEM, V268, P11604; NUNN RS, 1996, IN PRESS J MOL BIOL; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PERI GK, 1991, BIOCH CELL BIOL, V68, P123; PERI KG, 1988, BIOCHEMISTRY-US, V27, P6054, DOI 10.1021/bi00416a034; PHILIPPOT J, 1983, BIOCHIM BIOPHYS ACTA, V734, P137, DOI 10.1016/0005-2736(83)90111-6; PLUMBRIDGE J, 1993, MOL MICROBIOL, V10, P973, DOI 10.1111/j.1365-2958.1993.tb00969.x; PLUMBRIDGE J, 1991, J MOL BIOL, V217, P661, DOI 10.1016/0022-2836(91)90524-A; PLUMBRIDGE JA, 1990, J BACTERIOL, V172, P2728, DOI 10.1128/jb.172.5.2728-2735.1990; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; ROGERS MJ, 1988, GENE, V62, P197; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Sambrook J., 1989, MOL CLONING LAB MANU, V2; THOMPSON J, 1985, J BACTERIOL, V162, P224, DOI 10.1128/JB.162.1.224-234.1985; THOMPSON J, 1985, J BACTERIOL, V162, P217, DOI 10.1128/JB.162.1.217-223.1985; VANDERVLAG J, 1995, MOL GEN GENET, V248, P236, DOI 10.1007/BF02190806; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; VOGLER AP, 1989, MOL GEN GENET, V219, P97, DOI 10.1007/BF00261163; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WAYGOOD EB, 1984, J CELL BIOCHEM, V25, P139, DOI 10.1002/jcb.240250304; WEIGEL N, 1982, J BIOL CHEM, V257, P4499; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; YU C, 1991, J BIOL CHEM, V266, P24260	51	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14819	14824		10.1074/jbc.271.25.14819	http://dx.doi.org/10.1074/jbc.271.25.14819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662917	hybrid			2022-12-25	WOS:A1996UT10600030
J	Pitt, RM; Marsters, SA; Ruppert, S; Donahue, CJ; Moore, A; Ashkenazi, A				Pitt, RM; Marsters, SA; Ruppert, S; Donahue, CJ; Moore, A; Ashkenazi, A			Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; CELL-DEATH; EXPRESSION; RESOLUTION; CLONING; SURFACE	Cytokines in the tumor necrosis factor (TNF) family regulate development and function of the immune system. We have isolated a new member of this family, designated Apo-2 ligand (Apo-2L), via an expressed sequence tag. Apo-2L is a 281-amino acid protein, related most closely to Fas/Apo-1 ligand. Transfected Apo-2L is expressed at the cell surface with its C terminus exposed, indicating a type II transmembrane protein topology. Like Fas/Apo-1 ligand and TNF, the C-terminal extracellular region of Apo-2L (amino acids 114-281) exhibits a homotrimeric subunit structure. Soluble Apo-2L induces extensive apoptosis in lymphoid as well as non-lymphoid tumor cell lines. The effect of Apo-2L is not inhibited by soluble Fas/Apo-1 and TNF receptors; moreover, expression of human Fas/Apo-1 in mouse fibroblasts, which confers sensitivity to induction of apoptosis by agonistic anti-Fas/Apo-1 antibody, does not confer sensitivity to Apo-2L. Hence, Apo-2L acts via a receptor which is distinct from Fas/Apo-1 and TNF receptors. These results suggest that, along with other family members such as Fas/Apo-1 ligand and TNF, Apo-2L may serve as an extracellular signal that triggers programmed cell death.	GENENTECH INC, DEPT MOLEC ONCOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT IMMUNOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT CELL BIOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FADOK VA, 1992, J IMMUNOL, V148, P2207; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; HOWARD OMZ, 1993, P NATL ACAD SCI USA, V90, P2335, DOI 10.1073/pnas.90.6.2335; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; MOORE A, 1995, CYTOTECHNOLOGY, V17, P1, DOI 10.1007/BF00749215; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHERWOOD SW, 1995, METHOD CELL BIOL, V46, P77; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	26	1564	1789	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12687	12690		10.1074/jbc.271.22.12687	http://dx.doi.org/10.1074/jbc.271.22.12687			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663110	hybrid			2022-12-25	WOS:A1996UN47400001
J	OFlaherty, JT; Kuroki, M; Nixon, AB; Wijkander, J; Yee, E; Lee, SL; Smitherman, PK; Wykle, RL; Daniel, LW				OFlaherty, JT; Kuroki, M; Nixon, AB; Wijkander, J; Yee, E; Lee, SL; Smitherman, PK; Wykle, RL; Daniel, LW			5-oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONYL-LEUCYL-PHENYLALANINE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PHORBOL-MYRISTATE ACETATE; TUMOR-NECROSIS-FACTOR; MAP KINASE; TYROSINE PHOSPHORYLATION; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; 5-LIPOXYGENASE PRODUCTS; ALVEOLAR MACROPHAGES; LEUKOTRIENES	The newly defined eicosatetraenoates (ETEs), 5-oxoETE and 5-oxo-15(OH)-ETE, share structural motifs, synthetic origins, and bioactions with leukotriene B-4 (LTB(4)). All three eicosanoids stimulate Ca2+ transients and chemotaxis in human neutrophils (PMN). However, unlike LTB(4), 5-oxoETE and 5-oxo-15(OH)-ETE alone cause little degranulation and no superoxide anion production. However, we show herein that, in PMN pretreated with granulocyte-macrophage or granulocyte colony-stimulating factor (GM-CSF or G-CSF), the oxoETEs become potent activators of the last responses. The oxoETEs also induce translocation of secretory vesicles from the cytosol to the plasmalemma, an effect not requiring cytokine priming. To study the mechanism of PMN activation in response to the eicosanoids, we examined the activation of mitogen-activated protein kinase (MAPK) and cytosolic phospholipase A(2) (cPLA(2)). PMN expressed three proteins (40, 42, and 44 kDa) that reacted with anti MAPK antibodies. The oxoETEs, LTB(4), GM-CSF, and G-CSF all stimulated PMN to activate the MAPKs and cPLA(2), as defined by shifts in these proteins' electrophoretic mobility and tyrosine phosphorylation of the MAPKs. However, the speed and duration of the MAPK response varied markedly depending on the stimulus. 5-OxoETE caused a very rapid and transient activation of MAPK. In contrast, the response to the cytokines was rather slow and persistent. PMN pretreated with GM-CSF demonstrated a dramatic increase in the extent of MAPK tyrosine phosphorylation and electrophoretic mobility shift in response to 5-oxoETE. Similarly, 5-oxoETE induced PMN to release some preincorporated [C-14]arachidonic acid, while GM-CSF greatly enhanced the extent of this release. Thus, the synergism exhibited by these agents is prominent at the level of MAPK stimulation and phospholipid deacylation. Pertussis toxin, but not Ca2+ depletion, inhibited MAPK responses to 5-oxoETE and LTB(4), indicating that responses to both agents are coupled through G proteins but not dependent upon Ca2+ transients. 15-OxoETE and 15(OH)-ETE were inactive while 5-oxo-15(OH)-ETE and 5(OH)-ETE had 3- and 10-fold less potency than 5-oxoETE, indicating a rather strict structural specificity for the 5-keto group. LY 255283, a LTB(4) antagonist, blocked the responses to LTB(4) but not to 5-oxoETE. Therefore, the oxoETEs do not appear to operate through the LTB(4) receptor. In summary, the oxoETEs are potent activators of PMN that share some but not all activities with LTB(4). The response to the oxoETEs is greatly enhanced by pretreatment with cytokines, indicating that combinations of these mediators may be very important in the pathogenesis of inflammation.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center			Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964; wijkander, jonny/0000-0002-2310-9039	NHLBI NIH HHS [HL-26257, HL-27799] Funding Source: Medline; NIAID NIH HHS [AI-17287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026257, R01HL027799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTIONE C, 1992, BIOCHIM BIOPHYS ACTA, V1128, P139; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BILLAH MM, 1985, J BIOL CHEM, V260, P6899; BORREGAARD N, 1992, J CLIN INVEST, V90, P86, DOI 10.1172/JCI115860; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; COPAS JL, 1982, PROSTA LEUKOTR MED, V8, P105, DOI 10.1016/S0262-1746(82)80002-4; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P403; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GOMEZCAMBRONERO J, 1993, BIOCHEM J, V291, P211, DOI 10.1042/bj2910211; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; JOHNSON GM, 1995, J LEUKOCYTE BIOL, V57, P692, DOI 10.1002/jlb.57.4.692; KEPPLER D, 1992, REV PHYSIOL BIOCH P, V121, P1, DOI 10.1007/BFb0033192; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAELO PE, 1989, PROSTAGLANDINS, V37, P539; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OFLAHERTY JT, 1988, J IMMUNOL, V140, P4323; OFLAHERTY JT, 1990, J CELL PHYSIOL, V142, P299, DOI 10.1002/jcp.1041420212; OFLAHERTY JT, 1982, LAB INVEST, V47, P314; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; OFLAHERTY JT, 1994, BBA-GEN SUBJECTS, V1201, P505, DOI 10.1016/0304-4165(94)90083-3; OFLAHERTY JT, 1992, BIOCHEM J, V288, P241, DOI 10.1042/bj2880241; OFLAHERTY JT, 1993, J BIOL CHEM, V268, P14708; OHTA S, 1992, EUR J BIOCHEM, V206, P895, DOI 10.1111/j.1432-1033.1992.tb16998.x; OKUDA K, 1992, BLOOD, V79, P2880; PACEASCIAK CR, 1991, ADV EXP MED BIOL, V314, P133; PALMANTIER R, 1994, LAB INVEST, V70, P696; PETERS SP, 1982, J IMMUNOL, V129, P797; POWELL WS, 1994, BIOCHEMISTRY-US, V33, P3927, DOI 10.1021/bi00179a019; POWELL WS, 1994, J BIOL CHEM, V269, P25373; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1995, J IMMUNOL, V154, P4123; PUERINGER RJ, 1992, J APPL PHYSIOL, V73, P781, DOI 10.1152/jappl.1992.73.2.781; RAFIEE P, 1995, J IMMUNOL, V154, P4785; RAINES MA, 1992, BLOOD, V79, P3350; RESICK MB, 1993, AM J RESPIR CELL MOL, V8, P349; ROBINSON DS, 1993, THORAX, V48, P845, DOI 10.1136/thx.48.8.845; ROLLET E, 1994, J IMMUNOL, V153, P353; ROSSI AG, 1991, LIPIDS, V26, P1184, DOI 10.1007/BF02536528; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAITO H, 1985, PROSTA LEUKOTR MED, V18, P271, DOI 10.1016/0262-1746(85)90059-9; SALARI H, 1985, J EXP MED, V162, P1904, DOI 10.1084/jem.162.6.1904; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHWENK U, 1992, J BIOL CHEM, V267, P12482; STERN A, 1991, ADV EXP MED BIOL, V314, P103; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TORRES M, 1993, J IMMUNOL, V150, P1563; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YOSS EB, 1990, AM J RESP CELL MOL, V2, P69, DOI 10.1165/ajrcmb/2.1.69; YUO A, 1993, BIOCHIM BIOPHYS ACTA, V1156, P197, DOI 10.1016/0304-4165(93)90136-V	62	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17821	17828		10.1074/jbc.271.30.17821	http://dx.doi.org/10.1074/jbc.271.30.17821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663432	hybrid			2022-12-25	WOS:A1996UY93500038
J	Park, CT; Wright, SD				Park, CT; Wright, SD			Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; HIGH-DENSITY LIPOPROTEINS; (LPS)-BINDING PROTEIN; MOLECULAR-CLONING; SERUM; CD14; NEUTROPHIL; ENDOTOXIN; LPS; VESICLES	Neutrophils exhibit a dramatic enhancement of integrin-mediated cell adhesion in response to lipopolysaccharide (LPS). This response requires CD14 on the neutrophil and plasma proteins in solution, We have purified the factor from plasma that facilitates the adhesive response of neutrophil to LPS by using a combination of affinity and ion-exchange chromatography. Previous work has shown that the activity is associated with apolipoprotein A-I (apoA-I), and here we show that this activity is associated with an apoA-I-bearing complex of protein and phospholipid, Native polyacrylamide gel electrophoresis (PAGE) analysis showed a ladder of bands in the M(r) 200,000 region, and electron microscopy revealed round, indented particles of 11.4 +/- 0.12 nm in diameter. Characterization of these particles revealed a density of 1.219-1.264 g/ml and similar to 10 molecules of lipid phosphate per M(r) 200,000 complex, SDS-PAGE showed that each of the bands seen in native PAGE was composed of several polypeptides. These were identified as apoA-I, LPS binding protein (LBP), and factor H-related proteins (FHRPs), Physical association of apoA-I, LBP, and FHRP in these particles was further confirmed using double immunodiffusion, and association of LBP and FHRP in plasma was confirmed by coimmunoprecipitation, FHRPs are the numerically dominant protein components in these particles, and all plasma FHRP-1 appears to be associated with these particles. We suggest that FHRPs may be the defining constituent of this novel ''lipoprotein'' particle.	ROCKEFELLER UNIV, CELLULAR PHYSIOL & IMMUNOL LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT PEDIAT, NEW YORK, NY 10021 USA	Rockefeller University; Memorial Sloan Kettering Cancer Center					NIAID NIH HHS [AI-30556, AI-01333-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001333, R01AI030556] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES BN, 1960, J BIOL CHEM, V235, P769; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CALVANO SE, 1994, ARCH SURG-CHICAGO, V129, P220; DARR WH, 1985, J LIPID RES, V26, P672; DAY JR, 1994, J BIOL CHEM, V269, P9388; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DETMERS PA, 1994, J IMMUNOL, V153, P2137; ESTALLER C, 1991, J IMMUNOL, V146, P3190; FONTAINE M, 1989, BIOCHEM J, V258, P927, DOI 10.1042/bj2580927; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; HASLETT C, 1987, AM REV RESPIR DIS, V136, P9, DOI 10.1164/ajrccm/136.1.9; IIDA M, 1994, BIOCHEM BIOPH RES CO, V203, P1295, DOI 10.1006/bbrc.1994.2323; JAESCHKE H, 1991, AM J PHYSIOL, V261, pG1051, DOI 10.1152/ajpgi.1991.261.6.G1051; Mills G. L., 1984, LABORATORY TECHNIQUE, P18; MORISAKI T, 1991, CLIN IMMUNOL IMMUNOP, V61, P365, DOI 10.1016/S0090-1229(05)80008-X; MUTA T, 1991, J BIOL CHEM, V266, P6554; ORAM JF, 1981, J BIOL CHEM, V256, P8348; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; POLZ E, 1979, FEBS LETT, V102, P183, DOI 10.1016/0014-5793(79)80955-2; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SCHWAEBLE W, 1991, IMMUNOBIOLOGY, V182, P307, DOI 10.1016/S0171-2985(11)80665-0; SKERKA C, 1991, J BIOL CHEM, V266, P12015; SKERKA C, 1992, J IMMUNOL, V148, P3313; SKERKA C, 1993, J BIOL CHEM, V268, P2904; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; TALL AR, 1983, J LIPID RES, V24, P277; TIMMANN C, 1991, J IMMUNOL, V146, P1265; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; VANKESSEL KPM, 1994, J IMMUNOL METHODS, V172, P25; VEZINA CA, 1988, J LIPID RES, V29, P573; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	40	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18054	18060		10.1074/jbc.271.30.18054	http://dx.doi.org/10.1074/jbc.271.30.18054			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663389	hybrid			2022-12-25	WOS:A1996UY93500070
J	Kralli, A; Yamamoto, KR				Kralli, A; Yamamoto, KR			An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; GLUCOCORTICOID RECEPTOR; MULTIDRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; MDR-GENE; MINERALOCORTICOID RECEPTOR; CYCLOSPORINE-A; FK506; YEAST; EXPRESSION	Steroid hormones bind and activate intracellular receptors that are ligand-regulated transcription factors. Mammalian steroid receptors can confer hormone-dependent transcriptional enhancement when expressed in yeast, thereby enabling the genetic identification of nonreceptor proteins that function in the hormone signal transduction pathway. Pdr5p (Lem1/Sts/Ydr1p), a yeast ATP-binding cassette transporter, selectively decreases the intracellular levels of particular steroid hormones, indicating that active processes can affect the passage of steroids across biological membranes. In yeast, the immunosuppressive drug FK506 inhibited Pdr5p, thereby potentiating activation of the glucocorticoid receptor by dexamethasone, a Ligand that is exported by Pdr5p. In mammalian L929 cells but not in HeLa cells, FK506 potentiated dexamethasone responsiveness and increased dexamethasone accumulation, without altering the hormone-binding properties of the glucocorticoid receptor. We suggest that an FK506-sensitive transporter in L929 cells selectively decreases intracellular hormone levels and, consequently, the potency of particular steroids. Thus, steroid transporters may modulate, in a cell-specific manner, an initial step in signaling, the availability of hormone to the receptor.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Kralli, A (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOLEC PHARMACOL, SAN FRANCISCO, CA 94143 USA.							ALLERA A, 1992, J STEROID BIOCHEM, V42, P737, DOI 10.1016/0960-0760(92)90115-Y; ARAI K, 1995, STEROIDS, V60, P173, DOI 10.1016/0039-128X(94)00007-Y; ARCECI RJ, 1992, BLOOD, V80, P1528; BACKMAN L, 1994, TRANSPLANTATION, V57, P519; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BOURGEOIS S, 1993, MOL ENDOCRINOL, V7, P840, DOI 10.1210/me.7.7.840; BRONNEGARD M, 1995, J STEROID BIOCHEM, V52, P345, DOI 10.1016/0960-0760(94)00178-O; CHILDS S, 1995, CANCER RES, V55, P2029; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; EGNER R, 1995, MOL CELL BIOL, V15, P5879; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROSS SR, 1970, J CELL BIOL, V44, P103, DOI 10.1083/jcb.44.1.103; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; KOMESAROFF PA, 1994, J CLIN ENDOCR METAB, V79, P27, DOI 10.1210/jc.79.1.27; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; MURLAS C, 1982, J APPL PHYSIOL, V52, P1084, DOI 10.1152/jappl.1982.52.4.1084; NAITO M, 1992, CANCER CHEMOTH PHARM, V29, P195, DOI 10.1007/BF00686252; NING YM, 1993, J BIOL CHEM, V268, P6073; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; OVERDUIN P, 1988, MOL MICROBIOL, V2, P767, DOI 10.1111/j.1365-2958.1988.tb00088.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; RAO US, 1994, MOL PHARMACOL, V45, P773; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; Ribeiro RCJ, 1996, J BIOL CHEM, V271, P17147, DOI 10.1074/jbc.271.29.17147; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; SHEPPARD KE, 1994, J STEROID BIOCHEM, V48, P337, DOI 10.1016/0960-0760(94)90073-6; SIKORSKI RS, 1989, GENETICS, V122, P19; TAI PKK, 1994, BIOCHEMISTRY-US, V33, P10666, DOI 10.1021/bi00201a014; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UEDA K, 1992, J BIOL CHEM, V267, P24248; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; VOGEL JP, 1993, J BIOL CHEM, V268, P3040; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; YEM AW, 1992, J BIOL CHEM, V267, P2868; ZENNARO MC, 1994, J CLIN ENDOCR METAB, V79, P32, DOI 10.1210/jc.79.1.32	48	111	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17152	17156		10.1074/jbc.271.29.17152	http://dx.doi.org/10.1074/jbc.271.29.17152			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663352	hybrid			2022-12-25	WOS:A1996UX94300028
J	Leonova, T; Qi, XY; Bencosme, A; Ponce, E; Sun, Y; Grabowski, GA				Leonova, T; Qi, XY; Bencosme, A; Ponce, E; Sun, Y; Grabowski, GA			Proteolytic processing patterns of prosaposin in insect and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID ACTIVATOR PROTEIN-2; LYSOSOMAL PROTECTIVE PROTEIN; MESSENGER-RNA; METACHROMATIC LEUKODYSTROPHY; SULFATIDE ACTIVATOR; BETA-GLUCOSIDASE; GAUCHER DISEASE; VARIANT FORM; GENE; SAP-2	Prosaposin is a multifunctional protein encoded at a single locus in humans and mice. The precursor contains, in tandem, four glycoprotein activators or saposins, termed A, B, C, and D, that are essential for specific glycosphingolipid hydrolase activities. Prosaposin appears to be a potent neurotrophic factor, To explore the proteolytic processing from prosaposin to mature activator proteins, metabolic labeling was done with human prosaposin expressed in insect cells, human fibroblasts, neuronal stem cells (NT2) and retinoic acid-differentiated NT2 neurons. In all cell types, the major processing pathway was through a tetrasaposin, A-B-C-D, from which saposin A was then removed. In mammalian cells monosaposins were derived from the trisaposin B-C-D by cleavage 60 the disaposins, B-C and C-D, that were processed to monosaposins. In insect cells the major end products were the disaposins, with A-B and C-D derived from the tetrasaposin, A-B-C-D, or with B-C and C-D derived from the trisaposin, B-C-D. In insect and mammalian cells, the nonsignal NH2-terminal peptide preceding saposin A (termed Nter) was usually removed prior to saposin A cleavage, In NH2-derived differentiated neurons, precursor tetrasaposins containing A-B-C-D were secreted with and without Nter. Immunofluorescence studies using prosaposin-specific antisera showed large steady state amounts of uncleaved prosaposin in Purkinje cells, cortical neurons, and other specific cell types in adult mice. These studies indicate that prosaposin processing is highly regulated at a proteolytic level to produce prosaposin, tetrasaposins, or mature monosaposins in specific mammalian cells.	CHILDRENS HOSP,MED CTR,DIV HUMAN GENET,RES FDN,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NINDS NIH HHS [NS 34071] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034071] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GAVRIELIRORMAN E, 1989, GENOMICS, V5, P486; GAVRIELIRORMAN E, 1992, GENOMICS, V13, P312; Harlow E., 1988, ANTIBODIES LAB MANUA; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; INUI K, 1985, HUM GENET, V69, P197, DOI 10.1007/BF00293023; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; KONDOH K, 1993, J COMP NEUROL, V334, P590, DOI 10.1002/cne.903340407; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; KOTANI Y, 1996, IN PRESS J NEUROCHEM; LEE VMY, 1986, J NEUROSCI, V6, P514; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, P NATL ACAD SCI USA, V87, P3493, DOI 10.1073/pnas.87.9.3493; MORREAU H, 1992, J BIOL CHEM, V267, P17949; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; QI XY, 1994, J BIOL CHEM, V269, P16746; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; RAFI MA, 1990, BIOCHEM BIOPH RES CO, V166, P1017, DOI 10.1016/0006-291X(90)90912-7; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; REINER O, 1989, J MOL NEUROSCI, V1, P225; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SANO A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P75, DOI 10.1016/0167-4838(92)90426-E; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SPRECHERLEVY H, 1993, CELL MOL BIOL, V39, P287; SUMMERS MD, 1987, TEX AGR EXP STA B, V1555, P5; SUN Y, 1994, AM J PATHOL, V145, P1390; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; Xu YH, 1996, PEDIATR RES, V39, P313, DOI 10.1203/00006450-199602000-00021; ZHANG XL, 1991, HUM GENET, V87, P211, DOI 10.1007/BF00204185; ZHANG XL, 1990, P NATL ACAD SCI USA, V87, P1426, DOI 10.1073/pnas.87.4.1426	46	74	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17312	17320		10.1074/jbc.271.29.17312	http://dx.doi.org/10.1074/jbc.271.29.17312			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663398	hybrid			2022-12-25	WOS:A1996UX94300052
J	Klarlund, JK; Cherniack, AD; McMahon, M; Czech, MP				Klarlund, JK; Cherniack, AD; McMahon, M; Czech, MP			Role of the Raf/mitogen-activated protein kinase pathway in p21(ras) desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RAS; GRB2; GROWTH; PHOSPHORYLATION; TRANSFORMATION; RECEPTOR; BINDING; DOMAIN; SH2	Desensitization of p21(ras) after stimulation of cells by growth factors and phorbol 12-myristate 13-acetate (PMA) correlates with hyperphosphorylation of the guanine nucleotide exchange factor Son-of-sevenless (Sos) and its dissociation from the adaptor protein Grb2 (Cherniack, A., Klarlund, J. K., Conway, B. R., and Czech, M. P. (1995) J. Biol. Chem. 270, 1485-1488). To test the role of the Raf/mitogen-activated protein (MAP) kinase pathway, we utilized cells expressing a chimera composed of the catalytic domain of p74Raf-1 and the hormone binding domain of the estradiol receptor (Delta Raf-1:ER), Estradiol markedly stimulated Delta Raf-1:ER and the downstream MEK and MAP kinases in these cells as well as Sos phosphorylation, However, the dissociation of Grb2 from Sos observed in response to PMA was not apparent upon Delta Raf-1:ER activation, Furthermore, stimulation of Delta Raf-1:ER did not impair GTP loading of p21(ras) in response to platelet derived growth factor or epidermal growth factor, We conclude that activation of the Raf/MAP kinase pathway alone in these cells is insufficient to cause disassembly of Sos from Grb2 or to interrupt the ability of Sos to catalyze activation of p21(ras).	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	University of Massachusetts System; University of Massachusetts Worcester; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Klarlund, JK (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.		Cherniack, Andrew D./AAY-8132-2020; McMahon, Martin/L-3303-2013	Cherniack, Andrew D./0000-0003-0470-0111; McMahon, Martin/0000-0003-2812-1042	NIDDK NIH HHS [DK 30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARUTA H, 1994, BIOESSAYS, V16, P489, DOI 10.1002/bies.950160708; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WEISMULLER L, 1994, CELL SIGNAL, V6, P247; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	44	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16674	16677		10.1074/jbc.271.28.16674	http://dx.doi.org/10.1074/jbc.271.28.16674			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663295	hybrid			2022-12-25	WOS:A1996UX12600041
J	Chen, HM; Zhang, P; Radomska, HS; Hetherington, CJ; Zhang, DE; Tenen, DG				Chen, HM; Zhang, P; Radomska, HS; Hetherington, CJ; Zhang, DE; Tenen, DG			Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN GENE-EXPRESSION; TRANSCRIPTION FACTOR; CELL-LINES; REGULATES EXPRESSION; HEMATOPOIETIC-CELLS; PUTATIVE ONCOGENE; PROTEIN-BINDING; CD11B PROMOTER; ETS ONCOGENE; CHAIN GENE	PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H. M., Ray-Gallet, D., Zhang, P., Hetherington, C. J., Gonzalez, D. A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D. G. (1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Spl binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site.	HARVARD UNIV, SCH MED,BETH ISRAEL HOSP,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456, R29CA059589] Funding Source: NIH RePORTER; NCI NIH HHS [CA59589, CA41456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN JH, 1993, ONCOGENE, V8, P3375; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKERILL PN, 1990, MOL CELL BIOL, V10, P1293, DOI 10.1128/MCB.10.3.1293; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DELGADO MD, 1994, ONCOGENE, V9, P1723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKHARDT LA, 1992, FASEB J, V6, P2553, DOI 10.1096/fasebj.6.8.1592208; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HROMAS R, 1993, BLOOD, V82, P2998; HUANG CC, 1974, J NATL CANCER I, V53, P655, DOI 10.1093/jnci/53.3.655; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RADOMSKA HS, 1994, IMMUNITY, V1, P623, DOI 10.1016/1074-7613(94)90034-5; RAY D, 1990, ONCOGENE, V5, P663; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSENBERG HF, 1990, BIOTECHNIQUES, V8, P384; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TORCZYNSKI RM, 1985, DNA-J MOLEC CELL BIO, V4, P283, DOI 10.1089/dna.1985.4.283; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	72	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15743	15752		10.1074/jbc.271.26.15743	http://dx.doi.org/10.1074/jbc.271.26.15743			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663022	hybrid			2022-12-25	WOS:A1996UV29900067
J	Huang, XC; Richards, EM; Sumners, C				Huang, XC; Richards, EM; Sumners, C			Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FOS GENE-EXPRESSION; SENSITIVE METHOD; MAP KINASE; SUBTYPES; CLONING; PHOSPHORYLATION; STIMULATION; MECHANISMS; PATHWAYS	Neurons cultured from neonatal rat hypothalamus and brainstem contain many angiotensin II (Ang II) type 2 (AT(2)) receptors, and we previously determined that activation of these sites elicited a stimulation of serine/threonine phosphatase 2A (PP2A). Here, we have investigated the effects of Ang II on neuronal mitogen-activated protein (MAP) kinases, potential targets for PP2A. Using in-gel kinase assays and immunoprecipitation analyses we have shown that Ang II (10 nM(-1) mu M) elicits significant increases in p44(MAPK) (Erk1) and p42(MAPK) (Erk2) activities in cultured neurons, mediated via Ang II type 1 (AT(1)) receptors. This stimulatory effect of Ang II on Erk1 and Erk2 activities was potentiated by blockade of AT(2) receptors with (S)-1-[4-(dimethylamino)-3-methylphenyl]methyl-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid (PD 123319, 1 mu M). Furthermore, the AT(2) receptor agonist N-alpha-nicotinoyl-Tyr-Lys-(N-alpha CBZ-Arg)-His-Pro-Ile-OH (CGP42112A) (10-50 nM) caused significant decreases in neuronal Erk1 and Erk2 activities, which were abolished by PD 123319 (1 mu M) and by the PP2A inhibitor okadaic acid (3 nM). This indicates that AT(1) and AT(2) receptors have opposite actions on Erb1 and Erk2 activities in neonatal neurons. Since MAP kinases are involved in the regulation of growth/differentiation and apoptosis, our data may provide an intracellular basis for modulatory effects of Ang II receptors on these processes.	UNIV FLORIDA, DEPT PHYSIOL, COLL MED, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida				Sumners, Colin/0000-0002-9689-2255	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019441] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-19441] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; FAURE M, 1994, J BIOL CHEM, V269, P7851; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; HUANG XC, 1995, J NEUROCHEM, V65, P2131; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; JANIAK P, 1992, HYPERTENSION, V20, P737, DOI 10.1161/01.HYP.20.6.737; JESSUS C, 1989, BIOCHEM J, V260, P45, DOI 10.1042/bj2600045; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; KANG J, 1992, BRAIN RES, V580, P317, DOI 10.1016/0006-8993(92)90960-H; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KRUG LM, 1992, HYPERTENSION, V20, P144, DOI 10.1161/01.HYP.20.2.144; LEBRUN CJ, 1995, NEUROSCIENCE, V65, P93, DOI 10.1016/0306-4522(94)00482-K; LYALL F, 1992, J HYPERTENS, V10, P1463, DOI 10.1097/00004872-199210120-00005; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MILLAN MA, 1991, PEPTIDES, V12, P723, DOI 10.1016/0196-9781(91)90125-9; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MORGAN JI, 1990, PROG BRAIN RES, V86, P287; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAHMIAS C, 1995, BIOCHEM J, V306, P87, DOI 10.1042/bj3060087; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PRATT RE, 1993, CELLULAR MOL BIOL RE, P471; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAIZADA MK, 1993, AM J PHYSIOL, V265, pC1046, DOI 10.1152/ajpcell.1993.265.4.C1046; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1995, CIRC RES, V76, P1; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; SUMNERS C, 1994, FRONT NEUROENDOCRIN, V15, P203; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209, DOI 10.1152/ajpregu.1991.261.1.R209; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	50	160	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15635	15641		10.1074/jbc.271.26.15635	http://dx.doi.org/10.1074/jbc.271.26.15635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663175	hybrid			2022-12-25	WOS:A1996UV29900051
J	Seksek, O; Biwersi, J; Verkman, AS				Seksek, O; Biwersi, J; Verkman, AS			Evidence against defective trans-Golgi acidification in cystic fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR; FIBROBLASTS; GLYCOPROTEINS; GLANDS; CELLS	Defective organelle acidification has been proposed as a unifying hypothesis to explain the pleiotropic cellular abnormalities associated with cystic fibrosis. To test whether cystic fibrosis transmembrane conductance regulator (CFTR) participates in trans-Golgi pH regulation, intraluminal trans-Golgi pH was measured in stably transfected Swiss 3T3 fibroblasts (expressing CFTR or Delta F508-CFTR) and CFTR-expressing and nonexpressing epithelial cells. trans-Golgi pH was measured by ratio-imaging confocal microscopy using a liposome injection procedure to label the lumen of trans-Golgi with fluid phase fluorescein and rhodamine chromophores (Seksek, O., Biwersi, J., and Verkman, A. S. (1995) J. Biol. Chem. 270, 4967-4970). Selective labeling of trans-Golgi was confirmed by colocalization of the delivered fluid phase fluorophores with N-(6-[(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino]caproyl)-sphingosine. In unstimulated fibroblasts in HCO3--free buffer, trans-Golgi pH was 6.25 +/- 0.04 (mean +/- S.E.; n = 80, vector control), 6.30 +/- 0.03 (n = 74, CFTR) and 6.23 +/- 0.06 (n = 60, Delta F508) (not significant). After stimulation of plasma membrane Cl- conductance by 8-(4-chlorophenylthio)-cAMP (CPT-cAMP), trans-Golgi pH was 6.42 +/- 0.07 (n = 22, control), 6.47 +/- 0.07 (n = 20, CFTR), and 6.35 +/- 0.07 (n = 22, Delta F508) (not significant). Similarly, significant pH differences were not found for control versus CFTR expressing cells in 25 mM HCO3- buffer. In epithelial cells, which do not express CFTR, trans-Golgi pH was (in 25 mM HCO3-) 6.36 +/- 0.04 (n = 33) and 6.34 +/- 0.08 (n = 23, CPT-cAMP) in MDCK cells and 6.25 +/- 0.04 (n = 18) and 6.24 +/- 0.06 (n = 15, CPT-cAMP) in SK-MES-1 cells. In Calu-3 cells, which natively express CFTR, trans-Golgi pH was (in 25 mM HCO3-) 6.19 +/- 0.05 (n = 25) and 6.17 +/- 0.08 (n = 23, CPT-cAMP). To test whether CFTR expression affects pH in the endosomal compartment in HCO3- buffer, pH was measured by ratio imaging in individual endosomes labeled with fluorescein-rhodamine dextrans. Comparing control and CFTR expressing fibroblasts, average endosome pH (range, 5.40-5.53 after 10 min; 4.79-4.89, 30 min) differed by <0.13 unit, both before and after cAMP stimulation. These results indicate that CFTR expression and activation do not influence pH in the trans-Golgi and endosomal compartments, providing direct evidence against the defective acidification hypothesis.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Seksek, Olivier/AAO-1837-2020	Seksek, Olivier/0000-0002-3053-3022	NHLBI NIH HHS [HL42368] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Barasch Jonathan, 1993, P191; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BIWERSI J, 1995, PEDIAT PULMONOL, V12, P179; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; CARROLL TP, 1993, CELL PHYSIOL BIOCHEM, V3, P388, DOI 10.1159/000154700; CHAO AC, 1989, BIOPHYS J, V56, P1071, DOI 10.1016/S0006-3495(89)82755-9; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DOSANJH A, 1994, AM J PHYSIOL, V266, pC360, DOI 10.1152/ajpcell.1994.266.2.C360; DUNN KW, 1994, J BIOL CHEM, V269, P5336; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; KRIVAN HC, 1988, ARCH BIOCHEM BIOPHYS, V260, P493, DOI 10.1016/0003-9861(88)90473-0; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MOLINARI A, 1994, INT J CANCER, V59, P789, DOI 10.1002/ijc.2910590614; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SCANLIN TF, 1985, PEDIATR RES, V19, P368, DOI 10.1203/00006450-198519040-00011; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340; YAMAYA M, 1991, AM J PHYSIOL, V261, pL491, DOI 10.1152/ajplung.1991.261.6.L491; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	35	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15542	15548		10.1074/jbc.271.26.15542	http://dx.doi.org/10.1074/jbc.271.26.15542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663158	hybrid			2022-12-25	WOS:A1996UV29900038
J	Sayeski, PP; Kudlow, JE				Sayeski, PP; Kudlow, JE			Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX GLYCOPROTEINS; SMOOTH-MUSCLE CELLS; HEXOSAMINE BIOSYNTHESIS; O-GLCNAC; EXPRESSION; GLYCOSYLATION; NUCLEAR; ATHEROSCLEROSIS; PATHWAY	Transforming growth factor-alpha (TGF alpha) gene transcription can be increased when arterial smooth muscle cells are exposed to supraphysiological concentrations of glucose, and this effect of glucose can be mimicked by glucosamine. To determine whether the metabolism of glucose to glucosamine is required for this glucose effect, the rate-limiting step in glucose metabolism to glucosamine through the enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT) was blocked using pharmacological and antisense strategies. We found that blockage of GFAT activity or expression significantly blunted the glucose-induced increase of TGF alpha expression, Blockage of GFAT also resulted in a decreased RL2 signal on intracellular proteins as detected by Western blotting and indirect immunofluorescence. The RL2 monoclonal antibody recognizes an epitope on proteins that contain N-acetylglucosamine and thus is a measure of protein glycosylation. Conversely, treatment of the cells with glucose and glucosamine resulted in an increase in the RL2 epitope on intracellular proteins. These results indicate that the metabolism of glucose to glucosamine is necessary for the transcriptional stimulation of TGF alpha expression in vascular smooth muscle cells by glucose, Furthermore, the level of glycosylation of some intracellular proteins can be modulated in response to physiological changes in the extracellular glucose concentration and the net activity of GFAT.	UNIV ALABAMA, DEPT MED, DIV ENDOCRINOL & METAB, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PHYSIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEKESI JG, 1969, J BIOL CHEM, V244, P5663; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLLENBERG MD, 1994, LIFE SCI, V54, P223, DOI 10.1016/0024-3205(94)00811-6; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LORENZI M, 1992, DIABETES METAB REV, V8, P85, DOI 10.1002/dmr.5610080202; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROOS MD, 1986, AM J PHYSIOL, V270, pC803; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; SAYESKI PP, 1994, GENE, V140, P289, DOI 10.1016/0378-1119(94)90560-6; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143	32	137	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15237	15243		10.1074/jbc.271.25.15237	http://dx.doi.org/10.1074/jbc.271.25.15237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663078	hybrid			2022-12-25	WOS:A1996UT10600086
J	Ohnishi, T; Wang, XJ; Ohnishi, K; Matsumoto, H; Takahashi, A				Ohnishi, T; Wang, XJ; Ohnishi, K; Matsumoto, H; Takahashi, A			p53-dependent induction of WAF1 by heat treatment in human glioblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53	Induction of WAF1 expression was investigated after heat treatment (44 degrees C, 30 min) in two human glioblastoma cell lines with the wild-type or a mutant p53 gene. WAF1 accumulation was induced by heat treatment in A-172 cells carrying the wild-type p53 gene but not in T98G cells carrying the mutant p53 gene. We examined whether this phenomenon was due to the induction of WAF1 expression. Northern blot analysis showed that heat treatment not only activated WAF1 but also upregulated p53 expression only in A-172 cells carrying the wild-type p53 gene. Gel mobility shift assay indicated an increase in p53 DNA binding activity after heat treatment. These findings suggest that the WAF1 expression is heat inducible in human glioblastoma cells and that this induction may be due to signal transduction mediated by p53 in response to heat stress.	NARA MED UNIV,DEPT PHYSIOL,KASHIHARA,NARA 634,JAPAN	Nara Medical University	Ohnishi, T (corresponding author), NARA MED UNIV,DEPT BIOL,840 SHIJO CHO,KASHIHARA,NARA 634,JAPAN.			Takahashi, Akihisa/0000-0002-9960-2153				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BAE IS, 1995, CANCER RES, V55, P2387; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; KASTAN MB, 1991, CANCER RES, V51, P6304; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; MATSUMOTO H, 1995, CANCER LETT, V92, P127, DOI 10.1016/0304-3835(95)03769-S; MICHIELI P, 1994, CANCER RES, V54, P3391; NAMBA H, 1995, CANCER RES, V55, P2075; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	20	95	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14510	14513		10.1074/jbc.271.24.14510	http://dx.doi.org/10.1074/jbc.271.24.14510			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662996	hybrid			2022-12-25	WOS:A1996UQ66000084
J	Ravichandran, V; Chawla, A; Roche, PA				Ravichandran, V; Chawla, A; Roche, PA			Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; RECEPTORS; TRANSPORT; SUBSTRATE; FUSION	The specificity of vesicular transport is regulated, in part, by the interaction of a vesicle-associated membrane protein termed synaptobrevin/VAMP with a target compartment membrane protein termed syntaxin. These proteins, together with SNAP-25 (synaptosome associated protein of 25 kDa), form a complex which serves as a binding site for the general membrane fusion machinery, Synaptobrevin/VAMP and syntaxin are ubiquitously expressed proteins and are believed to be involved in vesicular transport in mast (if not all) cells. However, SNAP-25 is present almost exclusively in the brain, suggesting that a ubiquitously expressed homolog of SNAP-25 exists to facilitate transport vesicle/target membrane fusion in other tissues, Using the yeast two-hybrid system, we have identified a 23-kDa protein from human B lymphocytes (termed SNAP-23) that binds tightly to multiple syntaxins and synaptobrevins/VAMPs in vitro. SNAP-23 is 59% identical with SNAP-25. Unlike SNAP-25, SNAP-23 was expressed in all tissues examined, These findings suggest that SNAP-23 is an essential component of the high affinity receptor for the general membrane fusion machinery and an important regulator of transport vesicle docking and fusion in all mammalian cells.	NIH,NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Roche, Paul/0000-0002-8949-9172				BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BARK IC, 1995, P NATL ACAD SCI USA, V92, P1510, DOI 10.1073/pnas.92.5.1510; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1994, GENE, V143, P303; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rossetto O, 1996, J CELL BIOL, V132, P167, DOI 10.1083/jcb.132.1.167; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; VOLCHUK A, 1994, BIOCHEM J, V304, P139, DOI 10.1042/bj3040139	27	279	287	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13300	13303		10.1074/jbc.271.23.13300	http://dx.doi.org/10.1074/jbc.271.23.13300			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8663154	hybrid			2022-12-25	WOS:A1996UP38500003
J	Holthuis, JCM; Jansen, EJR; Martens, GJM				Holthuis, JCM; Jansen, EJR; Martens, GJM			Secretogranin III is a sulfated protein undergoing proteolytic processing in the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASE PC2; CHROMOGRANIN-A; XENOPUS-LAEVIS; PEPTIDE; CELLS; 7B2; DOPAMINE; VESICLES; SEQUENCE; GRANULE	Secretogranin III (SgIII) is an acidic protein of unknown function that is present in the storage vesicles of many neuroendocrine cells, It is coexpressed with the prohormone proopiomelanocortin in the intermediate pituitary of Xenopus laevis, We developed an antiserum to investigate the biosynthesis of SgIII in pulse-chase incubated Xenopus neurointermediate lobes, SgIII was synthesized as a 61- or 63-kDa (N-glycosylated) protein and processed to a 48-kDa form which, in turn, was partially cleaved to fragments of 28 and 20 kDa, The 48-, 28-, and 20-kDa cleavage products, but not their precursors, were secreted, This secretion is regulated and can be blocked in parallel with that of proopiomelanocortin-derived peptides by the hypothalamic factors dopamine, gamma-aminobutyric acid, and neuropeptide Y. Coexpression of Xenopus SgIII with prohormone convertase (PC)1 or PC2 in transfected fibroblasts was sufficient to reconstitute the processing events observed in the neurointermediate lobes, Site-directed mutagenesis revealed that Xenopus SgIII is cleaved at two dibasic sites, namely Lys(68)-Arg(69) and Arg(237)-Arg(238), Pulse-chase incubations of lobes with Na-2[S-35]SO4 showed that SgIII is sulfated in the trans-Golgi network before it is processed, Finally, SgIII processing was found in several neuroendocrine cell types from various species, We conclude that SgIII is a precursor protein and that the intact molecule can only have an intracellular function, whereas an extracellular role can only be attributed to its cleavage products.	UNIV NIJMEGEN,DEPT ANIM PHYSIOL,NL-6525 ED NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			Jansen, Eric J.R./A-3158-2013; Holthuis, Joost/AAL-9157-2020; Martens, Gerard JM/D-1925-2010	Holthuis, Joost/0000-0001-8912-1586				BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRAKS JAM, 1992, FEBS LETT, V305, P45, DOI 10.1016/0014-5793(92)80652-W; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; DERIJK EPCT, 1992, J NEUROSCI, V12, P864; DEVAULT A, 1983, J BIOL CHEM, V259, P5146; GALINDO E, 1991, P NATL ACAD SCI USA, V88, P1426, DOI 10.1073/pnas.88.4.1426; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALBAN PA, 1994, BIOCHEM J, V299, P1; HOLTHUIS JCM, 1995, J CELL SCI, V108, P3295; HOLTHUIS JCM, 1996, IN PRESS J NEUROCHEM; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1995, CURR BIOL, V5, P242, DOI 10.1016/S0960-9822(95)00049-2; KINGSLEY DM, 1990, EMBO J, V9, P395, DOI 10.1002/j.1460-2075.1990.tb08123.x; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1985, J BIOL CHEM, V260, P3685; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; SARIA A, 1993, NEUROSCIENCE, V54, P1, DOI 10.1016/0306-4522(93)90377-R; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; SIGAFOOS J, 1993, J ANAT, V183, P253; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; VERBURGVANKEMENADE BML, 1986, BRAIN RES BULL, V17, P697, DOI 10.1016/0361-9230(86)90203-0; VERBURGVANKEMENADE BML, 1987, PEPTIDES, V8, P61, DOI 10.1016/0196-9781(87)90166-5; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	32	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17755	17760		10.1074/jbc.271.30.17755	http://dx.doi.org/10.1074/jbc.271.30.17755			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663421	Green Published, hybrid			2022-12-25	WOS:A1996UY93500028
J	Staels, B; Martin, G; Martinez, M; Albert, C; PeinadoOnsurbe, J; Saladin, R; Hum, DW; Reina, M; Vilaro, S; Auwerx, J				Staels, B; Martin, G; Martinez, M; Albert, C; PeinadoOnsurbe, J; Saladin, R; Hum, DW; Reina, M; Vilaro, S; Auwerx, J			Expression and regulation of the lipoprotein lipase gene in human adrenal cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SIDE-CHAIN CLEAVAGE; HEPARAN-SULFATE PROTEOGLYCANS; HORMONE-RECEPTOR SUPERFAMILY; STEROID HYDROXYLASE GENES; CAMP-RESPONSIVE ELEMENT; PROTEIN KINASE-A; MESSENGER-RNA; CYCLIC-AMP; TRANSCRIPTIONAL REGULATION	Lipoprotein lipase (LPL), an enzyme which hydrolyzes triglycerides and participates in the catabolism of remnant lipoproteins, plays a crucial role in energy and lipid metabolism, The goal of this study was to analyze the expression and regulation of the LPL gene in human adrenals, Reverse transcriptase-polymerase chain reaction amplification and sequence analysis demonstrated the presence of LPL mRNA in fetal and adult human adrenal cortex, Furthermore, the human adrenocortical carcinoma cell line, NCI-H295, expresses LPL mRNA and protein, which is localized to the outer cellular membrane as demonstrated by immunofluorescence confocal microscopy and can be released in the medium by heparin addition, To asses whether the LPL gene is regulated by agents regulating adrenal steroidogenesis, NCI-H295 cells were treated with activators of second messenger systems, Whereas the calcium-ionophore A23187 did not affect LPL gene expression, treatment with phorbol 12-myristate 13-acetate decreased LPL mRNA levels in a time- and dose-dependent manner. This decrease after phorbol 12-myristate 13-acetate was associated with diminished heparin-releasable LPL mass and activity in the culture medium, Addition of the cAMP analog 8-Br-cAMP to NCI-H295 cells resulted in a rapid, but transient dose-dependent induction of LPL mRNA, Treatment with the protein synthesis inhibitor cycloheximide gradually induced, whereas simultaneous addition of cAMP and cycloheximide superinduced LPL mRNA levels, Nuclear run-on analysis indicated that the effects of cAMP and cycloheximide occurred at the transcriptional and post-transcriptional level, respectively, Transient co-transfection assays demonstrated that the first 230 base pairs of the proximal LPL promoter contain a cAMP-responsive element activated by protein kinase A and transcription factors belonging to the CREB/CREM family, These data indicate that LPL is expressed in human adrenal cortex and regulated in NCI-H295 adrenocortical carcinoma cells by activators of the protein kinase A and protein kinase C second messenger pathways in a manner comparable to P450sec, which catalyzes the first step in adrenal steroidogenesis. These observations suggest a role for LPL in adrenal energy and/or lipid metabolism and possibly in steroidogenesis.	UNIV BARCELONA, DEPT CELL BIOL, E-08028 BARCELONA, SPAIN; UNIV BARCELONA, DEPT BIOCHEM & MOLEC BIOL, BARCELONA, SPAIN; CHU LAVAL, MOLEC ENDOCRINOL LAB, QUEBEC CITY, PQ G1V 4G2, CANADA	University of Barcelona; University of Barcelona; Laval University	Staels, B (corresponding author), INST PASTEUR, DEPT ATHEROSCLEROSE, U325 INSERM, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.		Staels, Bart/N-9497-2016; Auwerx, Johan/ABE-9307-2021; Reina, Manuel/D-4655-2014; Peinado-Onsurbe, Julia/A-4677-2016	Staels, Bart/0000-0002-3784-1503; Reina, Manuel/0000-0002-0701-200X; Peinado-Onsurbe, Julia/0000-0002-3880-5061; Auwerx, Johan/0000-0002-5065-5393				AUWERX J, 1992, CRIT REV CL LAB SCI, V29, P243, DOI 10.3109/10408369209114602; AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENSADOUN A, 1986, BIOCHIM BIOPHYS ACTA, V879, P253, DOI 10.1016/0005-2760(86)90214-6; BURGAYA F, 1989, BIOCHEM J, V259, P159, DOI 10.1042/bj2590159; BUSCA R, 1995, J LIPID RES, V36, P939; CARR BR, 1981, ENDOCR REV, V2, P306, DOI 10.1210/edrv-2-3-306; CHAJEK T, 1977, ATHEROSCLEROSIS, V26, P549, DOI 10.1016/0021-9150(77)90122-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIBLASIO AM, 1987, J CLIN ENDOCR METAB, V65, P170; ECKEL RH, 1984, P NATL ACAD SCI-BIOL, V81, P7604, DOI 10.1073/pnas.81.23.7604; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FRIEDMAN G, 1992, BIOCHIM BIOPHYS ACTA, V1137, P237, DOI 10.1016/0167-4889(92)90207-R; GAFVELS M, 1991, J ENDOCRINOL, V129, P213, DOI 10.1677/joe.0.1290213; GAZDAR AF, 1990, CANCER RES, V50, P5488; GOLDBERG IJ, 1989, J LIPID RES, V30, P1569; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTODA T, 1989, NUCLEIC ACIDS RES, V17, P2351, DOI 10.1093/nar/17.6.2351; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HASHIMOTO T, 1992, J BIOCHEM-TOKYO, V112, P573, DOI 10.1093/oxfordjournals.jbchem.a123941; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; ILLINGWORTH DR, 1983, METABOLISM, V32, P1045, DOI 10.1016/0026-0495(83)90075-6; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; JOHN ME, 1984, P NATL ACAD SCI-BIOL, V81, P5628, DOI 10.1073/pnas.81.18.5628; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KNOBLER H, 1984, BIOCHIM BIOPHYS ACTA, V795, P363, DOI 10.1016/0005-2760(84)90087-0; KOVANEN PT, 1979, ENDOCRINOLOGY, V104, P599, DOI 10.1210/endo-104-3-599; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAUE L, 1987, J CLIN ENDOCR METAB, V64, P531, DOI 10.1210/jcem-64-3-531; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; LUND J, 1990, J BIOL CHEM, V265, P3304; MILLER WL, 1995, ADRENAL CORTEX; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MULDER M, 1993, J BIOL CHEM, V268, P9369; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; PEINADOONSURBE J, 1992, BIOCHEMISTRY-US, V31, P10121, DOI 10.1021/bi00156a036; PEINADOONSURBE J, 1992, BIOCHIM BIOPHYS ACTA, V1131, P281, DOI 10.1016/0167-4781(92)90026-V; RAMIREZ I, 1985, BIOCHEM J, V232, P229, DOI 10.1042/bj2320229; REYLAND ME, 1993, MOL ENDOCRINOL, V7, P1021, DOI 10.1210/me.7.8.1021; RINGLER GE, 1989, MOL CELL ENDOCRINOL, V61, P13, DOI 10.1016/0303-7207(89)90185-8; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SCHOONJANS K, 1993, FEBS LETT, V329, P89, DOI 10.1016/0014-5793(93)80200-E; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; STAELS B, 1992, DEVELOPMENT, V115, P1035; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VILELLA E, 1993, J LIPID RES, V34, P1555; WATANABE N, 1993, EUR J BIOCHEM, V214, P521, DOI 10.1111/j.1432-1033.1993.tb17950.x; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG M, 1989, J BIOL CHEM, V264, P12867; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	76	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17425	17432		10.1074/jbc.271.29.17425	http://dx.doi.org/10.1074/jbc.271.29.17425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663337	hybrid			2022-12-25	WOS:A1996UX94300069
J	Jacoby, DB; Wensink, PC				Jacoby, DB; Wensink, PC			DNA binding specificities of YPF1, a Drosophila homolog to the DNA binding subunit of human DNA-dependent protein kinase, Ku	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-40 T-ANTIGEN; RNA POLYMERASE-II; AUTOANTIGEN-KU; PURIFICATION; SEQUENCE; IDENTIFICATION; MELANOGASTER; ELEMENT; PHOSPHORYLATION; AUTOANTIBODIES	YPF1, a heterodimeric protein from Drosophila melanogaster, is a homolog to Ku, the DNA binding subunit of human DNA-dependent protein kinase, This kinase is crucial in transcriptional activation, V(D)J recombination, double-strand break repair, and both topoisomerase and helicase activities. To investigate functional homology between YPF1 and Ku, we examined DNA binding properties of YPF1, Like Ku, at 100 mm KCl, YPF1 binding has no detectable DNA sequence specificity, requires a DNA terminus, and has a concentration-dependent stoichiometry consistent with subsequent translocation along DNA, YPF1 differs from Ku by having a 10(5)-fold higher affinity. At 400 mhz KCl, YPF1 still prefers DNA termini but shows binding specificities not observed previously with Ku. In descending order of affinity, YPF1 binds to: specific DNA sequences with a specific polarity and spacing relative to DNA termini; nonspecific linear DNA; and circular DNA, At this higher ionic strength, binding stoichiometry is concentration independent, indicating that YPF1 remains bound to ends, These results demonstrate a strong functional homology between YPF1 and Ku at physiological ionic strength. The strong binding of YPF1 has also allowed us to detect underlying binding specificities that may be specific to YPF1 and its function.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013334, R01GM021626] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM21626, F32 GM13334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BARNETT T, 1981, ICN UCLA S MOL CELL, V23, P97; Beall EL, 1996, GENE DEV, V10, P921, DOI 10.1101/gad.10.8.921; BEALL EL, 1994, P NATL ACAD SCI USA, V91, P12681, DOI 10.1073/pnas.91.26.12681; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; FROELICHAMMON SJ, 1994, J BIOL CHEM, V269, P7719; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HUNG MC, 1981, NUCLEIC ACIDS RES, V9, P6407, DOI 10.1093/nar/9.23.6407; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACOBY DB, 1994, J BIOL CHEM, V269, P11484; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; MARTIN KJ, 1987, J MOL BIOL, V195, P741, DOI 10.1016/0022-2836(87)90193-8; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITSIS PG, 1989, J BIOL CHEM, V264, P5188; MITSIS PG, 1989, J BIOL CHEM, V264, P5195; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; Niu Huifeng, 1995, Gene Expression, V4, P111; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PORGES AJ, 1990, J IMMUNOL, V145, P4222; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RIO DC, 1988, P NATL ACAD SCI USA, V85, P8929, DOI 10.1073/pnas.85.23.8929; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; ROBERTS MR, 1994, P NATL ACAD SCI USA, V91, P6354, DOI 10.1073/pnas.91.14.6354; Sambrook J., 2002, MOL CLONING LAB MANU; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	51	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16827	16832		10.1074/jbc.271.28.16827	http://dx.doi.org/10.1074/jbc.271.28.16827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663250	hybrid			2022-12-25	WOS:A1996UX12600063
J	Miyamoto, K; Segawa, H; Tatsumi, S; Katai, K; Yamamoto, H; Taketani, Y; Haga, H; Morita, K; Takeda, E				Miyamoto, K; Segawa, H; Tatsumi, S; Katai, K; Yamamoto, H; Taketani, Y; Haga, H; Morita, K; Takeda, E			Effects of truncation of the COOH-terminal region of a Na+-independent neutral and basic amino acid transporter on amino acid transport in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; HEAVY-CHAIN; RAT-KIDNEY; CDNA; 4F2; STIMULATION; CYSTINE; ANTIGEN; SYSTEM	To determine the role of a neutral and basic amino acid transporter (NEAT) in amino acid transport, we microinjected several COOH-terminal deletion mutants of NEAT cRNA into Xenopus oocytes and measured transport activity for arginine, leucine, and cystine in the presence and absence of sodium, Wild type NEAT significantly stimulated the uptake of all three amino acids 10-20-fold compared with controls, On the other hand, no mutant, except a Delta 511-685 mutant, stimulated the uptake of these amino acids, The Delta 511-685 mutant significantly increased the uptake of arginine. In the presence of sodium, the Delta 511-685 mutant also increased the uptake of leucine, The Delta 511-685 mutant did not stimulate cystine uptake in the presence or absence of sodium, The stimulation of arginine uptake by the Delta 511-685 mutant was inhibited by a 100-fold excess of unlabeled leucine in the presence of sodium, Inhibition of L-arginine uptake by L-homoserine was seen only in the presence of sodium, and an increase in the inhibition of L-arginine uptake by L-histidine was seen when the extracellular pH was decreased, Furthermore, an inward current in oocytes injected with the Delta 511-685 mutant was recorded electrophysiologically when basic amino acids were applied, Homoserine was also taken up, but sodium was necessary for their transport, These properties of the Delta 511-685 mutant correspond to those of the y(+) amino acid transporter, If NEAT is a component of the b(0,+)-like amino acid transport system, it is unlikely that a mutant protein (Delta 511-685) is able to stimulate an endogenous y(+)-like transport system, These results suggest that NEAT functions as a activator of the amino acid transport system in Xenopus oocytes.			Miyamoto, K (corresponding author), UNIV TOKUSHIMA,SCH MED,DEPT CLIN NUTR,KURAMOTO CHO 3,TOKUSHIMA 770,JAPAN.			Tatsumi, Sawako/0000-0002-4862-2955				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BUSH AE, 1994, J BIOL CHEM, V269, P25581; CALONGE MJ, 1995, HUM GENET, V95, P633; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HERMLER ME, 1982, J IMMUNOL, V129, P623; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; MCKUSICK VA, 1994, MENDELIAN INHERITANC, P1750; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; MIYAMOTO K, 1994, BIOCHEM J, V303, P877, DOI 10.1042/bj3030877; MIYAMOTO KI, 1995, BIOCHEM J, V305, P81, DOI 10.1042/bj3050081; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; PRAS E, 1995, AM J HUM GENET, V56, P1297; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; REBECCA WS, 1993, J CLIN NVEST, V91, P1959; SEGAL S, 1989, METABOLIC BASIS INHE, P2479; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	29	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16758	16763		10.1074/jbc.271.28.16758	http://dx.doi.org/10.1074/jbc.271.28.16758			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663184	hybrid			2022-12-25	WOS:A1996UX12600054
J	Mendoza, JA; DelCampo, G				Mendoza, JA; DelCampo, G			Ligand-induced conformational changes of GroEL are dependent on the bound substrate polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; ESCHERICHIA-COLI; PROTEIN; ATP; PURIFICATION; CARBOXYLASE; HYDROLYSIS; RHODANESE; MUTATION; CYCLE	Ligand-induced conformational changes of GroEL alone and with bound rhodanese, citrate synthase, or dihydrofolate reductase were studied by limited proteolysis. Similar digestion patterns of GroEL, with or without bound substrate polypeptide, were obtained in the absence and presence of the chaperonin ligands, K+, Mg2+, or ATP. The rates of formation and degradation of the six produced proteolytic fragments were significantly different, however. Strikingly, only with Mg2+/ATP or K+/Mg2+/ATP an additional fragment of approximately 25 kDa was generated during digestion of GroEL alone or with bound rhodanese or dihydrofolate reductase, but not with bound citrate synthase. Most of the trypsin-sensitive sites in GroEL were localized in the flexible apical domain, which contains the putative polypeptide-binding region. Our data indicate that subtle structural changes in the trypsin-sensitive regions of GroEL occur as a result of the binding of the chaperonin ligands, However, these structural changes are influenced by the GroEL substrate polypeptides.			Mendoza, JA (corresponding author), CALIF STATE UNIV,DEPT CHEM,SAN MARCOS,CA 92096, USA.							AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gibbons DL, 1996, J BIOL CHEM, V271, P238, DOI 10.1074/jbc.271.1.238; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOROVITS B, 1995, J BIOL CHEM, V270, P2061, DOI 10.1074/jbc.270.5.2061; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P25963; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; Ploegman J.H., 1978, NATURE, V273, P1245; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEDRYCHOWSKI A, 1986, ANAL BIOCHEM, V159, P323, DOI 10.1016/0003-2697(86)90349-0	39	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16344	16349		10.1074/jbc.271.27.16344	http://dx.doi.org/10.1074/jbc.271.27.16344			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663187	hybrid			2022-12-25	WOS:A1996UW35200072
J	Coburn, GA; Mackie, GA				Coburn, GA; Mackie, GA			Differential sensitivities of portions of the mRNA for ribosomal protein S20 to 3'-exonucleases dependent on oligoadenylation and RNA secondary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-E; POLYNUCLEOTIDE PHOSPHORYLASE; PCNB GENE; DECAY; AMS; CLEAVAGE; DEGRADATION; OVEREXPRESSION	The 5'-exonucleolytic decay of the mRNA for ribosomal protein S20 has been reconstituted in vitro using purified RNase II and crude extracts enriched for polynucleotide phosphorylase (PNPase) activity. We show that RNase II can catalyze the degradation of the 5' two-thirds of the S20 mRNA and that prior oligoadenylation of the 3' termini of truncated S20 mRNA substrates can significantly stimulate the initiation of degradation by RNase II. The intact S20 mRNA is, however, insensitive to attack by RNase II and polyadenylation of its 3'-end cannot overcome the natural resistance of the S20 mRNA to RNase II. Complete degradation of either the entire S20 mRNA without prior endonucleolytic cleavage or the 3'-terminal 147-residue fragment is de pendent on both oligoadenylation and PNPase activity. Moreover, this process can take place in the absence of RNase E activity. Our data point to the importance of oligoadenylation in facilitating 3'-exonucleolytic activity and indicate that there are alternative degradative pathways. The implications for mRNA decay are discussed.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia								BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BABITZKE P, 1993, J BACTERIOL, V175, P229, DOI 10.1128/JB.175.1.229-239.1993; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; DOTTIN RP, 1983, P NATL ACAD SCI USA, V70, P1078; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; JAHNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973; LITTAUER UZ, 1982, ENZYMES, V15, P517; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1989, J BACTERIOL, V171, P4112, DOI 10.1128/JB.171.8.4112-4120.1989; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MASTERS M, 1993, J BACTERIOL, V175, P4405, DOI 10.1128/JB.175.14.4405-4413.1993; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PEPE CM, 1994, MOL MICROBIOL, V13, P1133, DOI 10.1111/j.1365-2958.1994.tb00504.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; RAPAPORT LR, 1994, J BACTERIOL, V176, P992, DOI 10.1128/JB.176.4.992-998.1994; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; TAKIFF HE, 1989, J BACTERIOL, V171, P2581, DOI 10.1128/jb.171.5.2581-2590.1989; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	33	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15776	15781		10.1074/jbc.271.26.15776	http://dx.doi.org/10.1074/jbc.271.26.15776			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663115	hybrid			2022-12-25	WOS:A1996UV29900071
J	Fimia, GM; Gottifredi, V; Passananti, C; Maione, R				Fimia, GM; Gottifredi, V; Passananti, C; Maione, R			Double-stranded internucleosomal cleavage of apoptotic DNA is dependent on the degree of differentiation in muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; FRAGMENTS PRIOR; DEATH; ABSENCE; EXPRESSION; CALCIUM; GENE	Apoptotic cell death has been correlated to DNA fragmentation into discrete segments corresponding to the length of nucleosomal protected fragments of 180-200 base pairs or multiples of it, This DNA degradation has been ascribed to endonuclease activity that cleaves internucleosomally, thus giving rise to a ladder distribution upon electrophoretic migration. This strict correlation was, however, shown to have notable exceptions, since in some cases only single strand cleavage in the internucleosomal DNA regions has been observed (Tomei, D. L,, Shapiro, P, J,, and Cope, O. F. (1993) Proc, Natl. Acad. Sci, U. S. A. 90, 853-857), In the present work we show that mouse muscle cells, able to differentiate in vitro, if subjected to apoptosis present no DNA degradation into ladder form unless differentiation is previously induced. Furthermore, C3H/10T1/2 fibroblast cells, known to undergo apoptosis without DNA ladder formation, if converted to a myogenic program by MyoD expression, display internucleosomal DNA degradation upon induction of differentiation.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,I-00161 ROME,ITALY; CNR,IST TECNOL BIOMED,I-00161 ROME,ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)			Fimia, Gian Maria/K-3232-2016; Passananti, Claudio/K-9593-2016; Gottifredi, Vanesa/AAI-1788-2019	Fimia, Gian Maria/0000-0003-4438-3325; Gottifredi, Vanesa/0000-0001-9656-5951; PASSANANTI, CLAUDIO/0000-0002-9288-5736				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2352; BERTRAND R, 1991, BIOCHEM PHARMACOL, V42, P77, DOI 10.1016/0006-2952(91)90683-V; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORTNER DC, 1995, TRENDS BIOL SCI, V5, P21; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW SC, 1995, EXP CELL RES, V216, P149, DOI 10.1006/excr.1995.1019; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Eastman A, 1994, Cell Death Differ, V1, P7; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Hughes F M Jr, 1994, Cell Death Differ, V1, P11; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MARTELLI F, 1994, ONCOGENE, V9, P3579; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Peitsch M C, 1994, Cell Death Differ, V1, P1; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; Wyllie A H, 1980, Int Rev Cytol, V68, P251	29	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15575	15579		10.1074/jbc.271.26.15575	http://dx.doi.org/10.1074/jbc.271.26.15575			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663405	hybrid			2022-12-25	WOS:A1996UV29900042
J	Gamm, DM; Baude, EJ; Uhler, MD				Gamm, DM; Baude, EJ; Uhler, MD			The major catalytic subunit isoforms of cAMP-dependent protein kinase have distinct biochemical properties in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; I REGULATORY SUBUNIT; CYCLIC-AMP; MOLECULAR-CLONING; KINETIC MECHANISM; SKELETAL-MUSCLE; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; GENE-EXPRESSION; MOUSE-BRAIN	Two isoforms of the catalytic subunit of cAMP-dependent protein kinase, C alpha and C beta 1, are known to be widely expressed in mammals, Although much is known about the structure and function of C alpha, few studies have addressed the possibility of a distinct role for the C beta proteins, The present study is a detailed comparison of the biochemical properties of these two isoforms, which were initially expressed in Escherichia coli and purified to homogeneity, C beta 1 demonstrated higher K-m values for some peptide substrates than did C alpha but C beta 1 was insensitive to substrate inhibition, a phenomenon that was observed with C alpha at substrate concentrations above 100 mu M. C alpha and C beta l displayed distinct IC50 values for the a and beta isoforms of the protein kinase inhibitor, protein kinase inhibitor (5-24) peptide, and the type II alpha regulatory subunit (RII alpha), Of particular interest, purified type II holoenzyme containing C beta 1 exhibited a B-fold lower K-alpha value for cAMP (13 nM) than did type II holoenzyme containing C alpha (63 nM), This latter result was extended to in vivo conditions by employing a transcriptional activation assay, In these experiments, luciferase reporter activity in COS-l cells expressing RII alpha(2)C beta 1(2) holoenzyme was half-maximal at 12-fold lower concentrations of 8-(4-chlorophenylthio)-cAMP and 5-fold lower concentrations of forskolin than in COS-1 cells expressing RII alpha(2)Ca(2) holoenzyme. These results provide evidence that type II holoenzyme formed with C beta 1 is preferentially activated by cAMP in vivo and suggest that activation of the holoenzyme is determined in part by interactions between the regulatory and catalytic subunits that have not been described previously.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, NEUROSCI PROGRAM, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, MENTAL HLTH RES INST, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038788, R01GM038788] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38788] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; ADAVANI SR, 1987, EUR J BIOCHEM, V167, P221, DOI 10.1111/j.1432-1033.1987.tb13326.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; BAUDE EJ, 1994, J BIOL CHEM, V269, P18128; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1992, BIOCHEMISTRY-US, V31, P3720, DOI 10.1021/bi00129a023; Cohen P, 1978, Curr Top Cell Regul, V14, P117; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GOSSE ME, 1994, BIOCHEM J, V297, P79, DOI 10.1042/bj2970079; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GROVE JR, 1989, J BIOL CHEM, V264, P19506; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SLICE LW, 1989, J BIOL CHEM, V264, P20940; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; SUZUKI T, 1994, INT J BIOCHEM, V26, P735; TASKEN K, 1993, J BIOL CHEM, V268, P21276; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WIEMANN S, 1991, J BIOL CHEM, V266, P5940; YANG SM, 1995, BIOCHEMISTRY-US, V34, P6267, DOI 10.1021/bi00019a002; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; ZI M, 1996, P NATL ACAD SCI USA, V93, P1571	70	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15736	15742		10.1074/jbc.271.26.15736	http://dx.doi.org/10.1074/jbc.271.26.15736			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662989	hybrid			2022-12-25	WOS:A1996UV29900066
J	Navazo, MDP; Daviet, L; Savill, J; Ren, Y; Leung, LLK; McGregor, JL				Navazo, MDP; Daviet, L; Savill, J; Ren, Y; Leung, LLK; McGregor, JL			Identification of a domain (155-183) on CD36 implicated in the phagocytosis of apoptotic neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; MONOCLONAL-ANTIBODY; VITRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; THROMBOSPONDIN; BINDING; PLATELETS; ERYTHROCYTES; INFLAMMATION; RECOGNITION	Clearance of apoptotic neutrophils by macrophages is a crucial event following the resolution of acute inflammation. CD36, together with alpha(v) beta(3), has been identified as one of the adhesion molecules on the surface of macrophages implicated in the clearance of polymorphonuclear leukocytes. The domain on CD36 implicated in the phagocytosis of aged neutrophils remains to be elucidated. In this study, COS cells transfected with human CD36 cDNA had a significantly higher capacity to phagocytose human apoptotic neutrophils compared with murine CD36 cDNA. Moreover, monoclonal antibodies 10/5 or OKM5 (epitopes identified on amino acids 155-183) but not monoclonal antibody 13/10 (epitope identified on amino acids 30-76) inhibited phagocytosis of apoptotic neutrophils by COS cells transfected by human CD36. Swapping the human CD36 155-183 domain fi om human to murine CD36 (human-murine CD36 chimera) imparted to murine CD3B-transfected COS cells an increased capacity to phagocytose apoptotic neutrophils. Conversely, when the murine domain 155-185 was inserted in human CD36, a decreased phagocytic capacity was observed. In addition, a synthetic peptide (155-169) but not its scrambled form significantly inhibited phagocytosis. These results identify for the first time a functional domain encompassing amino acids 155-183 on human CD36 implicated in the recognition and phagocytosis of apoptotic neutrophils.	QUEENS MED CTR,DEPT RENAL & INFLAMMATORY DIS,NOTTINGHAM NG2 UH,ENGLAND; STANFORD UNIV,SCH MED,DIV HAEMATOL,STANFORD,CA 94305	Stanford University	Navazo, MDP (corresponding author), RTH LAENNEC,FAC MED,INSERM U331,RUE GUILLAUME PARADIN,F-69372 LYON,FRANCE.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042943] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01-HL42943] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		AIKEN ML, 1990, BLOOD, V76, P2501; AKBAR AN, 1994, J EXP MED, V180, P1943, DOI 10.1084/jem.180.5.1943; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; DAVIET L, 1995, BIOCHEM J, V305, P221, DOI 10.1042/bj3050221; DAVIET L, 1995, THROMB HAEMOSTASIS, V73, P543; DAVIET L, 1995, THROMB HAEMOSTASIS, V73, P1141; DECHAVANNE M, 1987, THROMB HAEMOSTASIS, V57, P106; Dransfield Ian, 1993, Tissue Antigens, V42, P416; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FADOK VA, 1993, J IMMUNOL, V151, P4274; GREENWALT DE, 1992, BLOOD, V80, P1105; HASLETT C, 1992, CLIN SCI, V83, P639, DOI 10.1042/cs0830639; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUH HY, 1995, J BIOL CHEM, V270, P6267, DOI 10.1074/jbc.270.11.6267; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; Navazo MDP, 1995, BLOOD, V86, P1490; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PARMENTIER S, 1991, BLOOD, V77, P1734; PEARCE SFA, 1995, J BIOL CHEM, V270, P2981, DOI 10.1074/jbc.270.7.2981; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; SAVILL J, 1994, EUR J CLIN INVEST, V24, P715, DOI 10.1111/j.1365-2362.1994.tb01067.x; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1995, J AM SOC NEPHROL, V6, P852; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; TANDON NN, 1989, J BIOL CHEM, V264, P7576	31	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15381	15385		10.1074/jbc.271.26.15381	http://dx.doi.org/10.1074/jbc.271.26.15381			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663130	hybrid			2022-12-25	WOS:A1996UV29900015
J	Yao, PM; Buhler, JM; dOrtho, MP; Lebargy, F; Delclaux, C; Harf, A; Lafuma, C				Yao, PM; Buhler, JM; dOrtho, MP; Lebargy, F; Delclaux, C; Harf, A; Lafuma, C			Expression of matrix metalloproteinase gelatinases A and B by cultured epithelial cells from human bronchial explants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE; HUMAN KERATINOCYTES; 72-KDA GELATINASE; TISSUE INHIBITOR; MACROPHAGES; INJURY; DIFFERENTIATION; IDENTIFICATION; MORPHOGENESIS; REGENERATION	To investigate the role of human bronchial epithelial cells (HBECs) in the maintenance and remodeling of the extracellular matrix, we evaluated the expression by HBECs of 72- and 92-kDa gelatinases under basal conditions and after exposure to bacterial lipopolysaccharides (LPS). Confluent HBECs from explants were cultured in plastic dishes coated with type I and III collagens, Gelatin zymography of HBEC-conditioned media showed constitutive major 92-kDa and minor 72-kDa gelatinases recognized by specific human antibodies and totally inhibited by the metalloproteinase inhibitor EDTA. The identification of the two matrix metaIloproteinases was confirmed by quantitative reverse transcription-polymerase chain reaction, Identical patterns of gelatinase expression were observed with repetitive primary cultures issued from the same explants, Zymography showed that exposure of HBECs to LPS induced 2- and 20-fold increases in 92-kDa gelatinase production and activation, respectively, as well as a smaller increase in activated 68-kDa gelatinase. With [H-3]gelatin substrate, elevated metallogelatinolytic activity (138 mu g of hydrolyzed gelatin/48 h/10(6) cells) was also observed, whereas no activity was detected in the absence of LPS. A human epithelial cell line (16HBE14o(-)) exhibited the same basal profile of gelatinase activity, but this profile remained unchanged after exposure to LPS, Quantitative reverse transcription-polymerase chain reaction demonstrated only minimal changes in 92-kDa mRNA levels in response to LPS, but the half-life of 92-kDa gelatinase mRNA was increased with exposure to EPS, In contrast, concomitant slight increases in 72-kDa gelatinase protein and mRNA were found, suggesting that the control mechanisms regulating the expression of 92- and 72-kDa gelatinases by HBECs in response to LPS are divergent. All these data allowed us to propose that HBECs may be actively involved in the physiological and physiopathological remodeling of the airway basement membrane.	FAC MED,INSERM U296,F-94010 CRETEIL,FRANCE; FAC MED,DEPT PHYSIOL,F-94010 CRETEIL,FRANCE; CEA SACLAY,DEPT BIOL CELLULAIRE & MOLEC,F-91191 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CEA; UDICE-French Research Universities; Universite Paris Saclay								BAEZASQUIBAN A, 1991, IN VITRO CELL DEV B, V27, P453; BENALI R, 1993, AM J PHYSIOL, V264, pL183, DOI 10.1152/ajplung.1993.264.2.L183; CANETESOLER R, 1994, AM J PATHOL, V144, P518; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRABBE T, 1994, FEBS LETT, V345, P14, DOI 10.1016/0014-5793(94)00412-9; DORTHO MP, 1994, AM J PHYSIOL, V266, pL209, DOI 10.1152/ajplung.1994.266.3.L209; DUFOUR S, 1986, BIOL CELL, V58, P1; EVANS MJ, 1986, AM J PATHOL, V123, P126; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; HAMAMOTO S, 1988, CELL DIFFER DEV, V22, P191, DOI 10.1016/0045-6039(88)90011-5; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; JEFFERY PK, 1992, EUR RESPIR J, V5, P93; JONES R, 1973, BRIT J EXP PATHOL, V54, P229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFUMA C, 1994, J INVEST DERMATOL, V102, P945, DOI 10.1111/1523-1747.ep12384118; LANE BP, 1974, P SOC EXP BIOL MED, V145, P1139; LEHTOVIRTA J, 1994, BBA-PROTEIN STRUCT M, V1206, P83, DOI 10.1016/0167-4838(94)90075-2; LEPPERT D, 1995, J IMMUNOL, V154, P4379; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MCDOWELL EM, 1987, AM J PATHOL, V129, P511; MOLL UM, 1990, CANCER RES, V50, P6162; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; RAY JM, 1994, EUR RESPIR J, V7, P2062; RIES C, 1994, BLOOD, V83, P3638; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SALO T, 1991, J BIOL CHEM, V266, P11436; SALO T, 1994, LAB INVEST, V70, P176; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHOJI S, 1989, AM J RESP CELL MOL, V1, P13, DOI 10.1165/ajrcmb/1.1.13; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SNIDER GL, 1984, AM REV RESPIR DIS, V129, P155; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STONER GD, 1981, IN VITRO CELL DEV B, V17, P577; SUZANNE M, 1995, FEBS LETT, V361, P61; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; TOURNIER JM, 1994, J BIOL CHEM, V269, P25454; TOURNIER JM, 1990, AM REV RESPIR DIS, V141, P1280, DOI 10.1164/ajrccm/141.5_Pt_1.1280; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689; WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721	47	97	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15580	15589		10.1074/jbc.271.26.15580	http://dx.doi.org/10.1074/jbc.271.26.15580			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663061	hybrid			2022-12-25	WOS:A1996UV29900043
J	Chen, AC; Gudas, LJ				Chen, AC; Gudas, LJ			An analysis of retinoic acid-induced gene expression and metabolism in AB1 embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F9 TERATOCARCINOMA CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; ACTIVATOR MESSENGER-RNA; BINDING-PROTEIN CRABP; MOUSE MELANOMA-CELLS; ALL-TRANS; CARCINOMA-CELLS; MOLECULAR-CLONING; INVIVO METABOLISM; THYROID-HORMONE	Murine embryonic stem cells such as the AB1 cell line undergo differentiation in the presence of retinoic acid (RA) into an extraembryonic epithelial cell type. This results in the activation of genes such as Hoxa-1, Hoxb-1, laminin, collagen IV(alpha 1), tissue plasminogen activator, RAR beta, and CRABPII, The CRABPI gene is regulated in an unusual fashion; CRABPI message and protein levels are induced at low concentrations of RA, but induction is diminished at higher concentrations. AB1 cells take up RA rapidly from the medium, and the addition of low, exogenous concentrations of RA to the culture medium results in very high intracellular RA concentrations, For example, AB1 stem cells cultured in 5 nM [H-3]RA have an internal [H-3]RA concentration of 1-2 mu M within the first hour. AB1 cells also metabolize [H-3]RA to more polar RA derivatives, The half-life of RA in AB1 cells not previously exposed to RA is about 2-2.5 h versus 40-45 min in cells cultured for 2-3 days in 1 mu M exogenous RA. Thus, the enzyme(s) which metabolize RA are induced or activated by RA, Furthermore, the local concentration of RA required to elicit some biological responses may be higher than previously thought.	CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Cornell University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007560] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043796] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA43796] Funding Source: Medline; NICHD NIH HHS [HD07560] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Armstrong Robert B., 1994, P545; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BARUA AB, 1991, BIOCHEM J, V277, P527, DOI 10.1042/bj2770527; BHAT PV, 1987, BIOCHIM BIOPHYS ACTA, V922, P18, DOI 10.1016/0005-2760(87)90240-2; Blaner William S., 1994, P229; Bloom W., 1975, TXB HISTOLOGY; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, BLOOD, V76, P1710; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DENCKER L, 1990, DEVELOPMENT, V110, P343; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; FROLIK CA, 1980, J BIOL CHEM, V255, P8057; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; GUBLER ML, 1985, J BIOL CHEM, V260, P9552; GUDAS LJ, 1991, SEMIN DEV BIOL, V2, P171; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HILL DL, 1992, ANNU REV NUTR, V12, P161, DOI 10.1146/annurev.nu.12.070192.001113; Hofmann Clementine, 1994, P387; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; JETTEN AM, 1990, INT J CANCER, V45, P195, DOI 10.1002/ijc.2910450135; JETTEN AM, 1979, EXP CELL RES, V119, P289, DOI 10.1016/0014-4827(79)90356-2; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; KOSA K, 1995, CANCER RES, V55, P4850; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1981, J CELL PHYSIOL, V106, P179, DOI 10.1002/jcp.1041060203; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINI R, 1993, ARCH BIOCHEM BIOPHYS, V303, P57, DOI 10.1006/abbi.1993.1255; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MUMMERY CL, 1990, DEV BIOL, V142, P406, DOI 10.1016/0012-1606(90)90362-M; Ong David E., 1994, P283; Peck Gary L., 1994, P631; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; REYNOLDS NJ, 1993, J PHARMACOL EXP THER, V266, P1636; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; RICKLES RJ, 1988, FEBS LETT, V229, P100, DOI 10.1016/0014-5793(88)80806-8; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; ROGERS MB, 1991, DEVELOPMENT, V113, P815; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SHIKONE T, 1994, MOL ENDOCRINOL, V8, P983, DOI 10.1210/me.8.8.983; SIEGENTHALER G, 1992, BIOCHEM J, V287, P383, DOI 10.1042/bj2870383; SIEGENTHALER G, 1987, EUR J BIOCHEM, V166, P209, DOI 10.1111/j.1432-1033.1987.tb13503.x; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPORN MB, 1983, CANCER RES, V43, P3034; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SULIK KK, 1988, DEVELOPMENT, V103, P213; VAESSEN MJ, 1990, DEVELOPMENT, V110, P371; Vanden Bossche H, 1988, Skin Pharmacol, V1, P176; VANWAUWE J, 1994, BIOCHEM PHARMACOL, V47, P737, DOI 10.1016/0006-2952(94)90137-6; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG SY, 1990, J BIOL CHEM, V265, P15818; WANG SY, 1992, J BIOL CHEM, V267, P15362; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	99	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14971	14980		10.1074/jbc.271.25.14971	http://dx.doi.org/10.1074/jbc.271.25.14971			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663043	hybrid			2022-12-25	WOS:A1996UT10600052
J	Holtmann, MH; Ganguli, S; Hadac, EM; Dolu, V; Miller, LJ				Holtmann, MH; Ganguli, S; Hadac, EM; Dolu, V; Miller, LJ			Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; EXPRESSION; MUTAGENESIS	Distinct themes exist for ligand-binding domains of G protein coupled receptors, The secretin receptor is prototypic of a recently described family in this superfamily which binds moderate-sized peptides possessing a diffuse pharmacophore. We recently demonstrated the importance of the N terminus and first loop of this receptor for secretin binding (Holtmann, M. H., Hadac, E. M., and Miller, L. J. (1995) J. Biol. Chem. 270:14394-14398), Here, we extend those findings to define another receptor domain important for agonist recognition and to focus on critical determinants within each of these domains, Extending the secretin-vasoactive intestinal polypeptide (VIP) chimeric receptor approach, we confirmed and refined the critical importance of the N terminus and the need to complement this with other domains of the secretin receptor, There was redundancy in the complementary determinants required, with the second extracellular loop able to compensate for the absence of the first loop, The first 10 residues of the N terminus of the secretin receptor were critical, Sequential segmental and site replacements permitted focusing on the His(189)-Lys(190) sequence at the C terminus of the first extracellular loop, and on four residues (phe(257), Leu(258), Asn(260), and Thr(261)) in the N-terminal half of the second loop as providing critical determinants, All receptor constructs which expressed sensitive cAMP responses to secretin (EC(50) <5 nM) bound this peptide with high affinity. Of note, one construct dissociated high affinity binding of secretin from its biological responsiveness, providing a clue to the conformational ''switch'' that activates this receptor.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905	Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046577, R01DK046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODANSZKY M, 1978, J MED CHEM, V21, P1171, DOI 10.1021/jm00209a018; BODANSZKY M, 1977, GASTROENTEROLOGY, V72, P801; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6	17	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14944	14949		10.1074/jbc.271.25.14944	http://dx.doi.org/10.1074/jbc.271.25.14944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663161	hybrid			2022-12-25	WOS:A1996UT10600048
J	Beers, MF				Beers, MF			Inhibition of cellular processing of surfactant protein C by drugs affecting intracellular pH gradients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG LAMELLAR BODIES; PULMONARY SURFACTANT; II CELLS; RAT LUNG; HYDROPHOBIC PROTEINS; NILE RED; LOCALIZATION; DEGRADATION; EXPRESSION; SECRETION	Surfactant protein C (SP-C) is a hydrophobic protein synthesized and secreted exclusively by alveolar type LI cells through proteolysis of a 21-kDa propeptide (SPC21) to produce the 3.7-kDa surface active form. Previous studies from this laboratory have demonstrated that early processing of proSP-C involves extensive intracellular proteolysis of the COOH terminus of proSP-C-21 in subcellular compartments, which include the acidic type II cell-specific subcellular organelle, the lamellar body. (Beers, M. F., Kim, C. Y., Dodia, C., and Fisher, A. B. (1994) J. Biol. Chem. 269, 20318-20328). The role of intracellular pH gradients in SP-C processing was studied in freshly isolated rat type II cells. Using vital fluorescence microscopy, the pH indicator acridine orange (AO) identified intense fluorescence staining of acidic cytoplasmic vesicles within fresh type II cells. The AO vesicular staining pattern was similar in cells labeled with the lamellar body marker phosphine 3R and the phospholipid dye nile red. AO fluorescence was quenched by the addition of a membrane-permeable weak base, methylamine. Immunoprecipitation of cell lysates with anti-proSP-C antisera following pulse-chase labeling (0-2 h) with S-35-Translabel demonstrated rapid synthesis of S-35-proSP-C-21 with a time-dependent appearance of 16- and 6-kDa intermediates (SP-C-16 and SP-C-6). Tricine polyacrylamide gel electrophoresis analysis of organic extracts of cell lysates showed time-dependent appearance of mature SP-C-3.7. The addition of 5 mM methylamine significantly blocked the post-translational processing of proSP-C resulting in disruption of normal precursor-product relationships and inhibition of SP-C-3.7 formation. Methylamine-treated cells exhibited slow accumulation of SP-C-16 and SP-C-6, a persistence of SP-C-21, and an absence of SP-C-3.7 for the duration of the chase period. The lysosomotropic agent chloroquine, the proton ionophore monensin, and bafilomycin A(1), a specific vacuolar H+-ATPase inhibitor, each caused inhibition of proSP-C processing in a similar manner. These results demonstrate that normal posttranslational proteolysis of proSP-C occurs in acidic intracellular compartments, which include the lamellar body, and that complete processing to SP-C-3.7 is dependent upon maintenance of transmembrane pH gradients by a vacuolar H+-ATPase.	HOSP UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104	University of Pennsylvania	Beers, MF (corresponding author), UNIV PENN,SCH MED,INST ENVIRONM MED,1 JOHN MORGAN BLDG,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL-02869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLARD PL, 1995, J PEDIATR, V96, P1046; BARITUSSIO A, 1992, AM J PHYSIOL, V263, pL607, DOI 10.1152/ajplung.1992.263.5.L607; BEERS MF, 1994, AM J RESP CELL MOL, V11, P240, DOI 10.1165/ajrcmb.11.2.8049085; Beers MF, 1995, AM J PHYSIOL-LUNG C, V269, pL744, DOI 10.1152/ajplung.1995.269.6.L744; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BEERS MF, 1982, ANN NY ACAD SCI, V402, P116, DOI 10.1111/j.1749-6632.1982.tb25736.x; BEERS MF, 1994, J BIOL CHEM, V269, P20318; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BIDANI A, 1995, J LEUKOCYTE BIOL, V57, P275, DOI 10.1002/jlb.57.2.275; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRESLIN JS, 1992, AM J PHYSIOL, V262, pL699, DOI 10.1152/ajplung.1992.262.6.L699; BROWN WJ, 1992, HISTOCHEMISTRY, V97, P349, DOI 10.1007/BF00270037; CHANDER A, 1986, J BIOL CHEM, V261, P6126; CHANDER A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P198, DOI 10.1016/0005-2760(92)90112-9; CHANDER A, 1989, AM J PHYSIOL, V257, pL354, DOI 10.1152/ajplung.1989.257.6.L354; DEMELLO DE, 1994, J PEDIATR-US, V125, P43, DOI 10.1016/S0022-3476(94)70119-9; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; FISHER JH, 1989, BIOCHIM BIOPHYS ACTA, V995, P225, DOI 10.1016/0167-4838(89)90040-X; GLASSER SW, 1988, J BIOL CHEM, V263, P9; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MASON RJ, 1977, AM REV RESPIR DIS, V115, P1015; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEM J, V274, P115, DOI 10.1042/bj2740115; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; QANBAR R, 1994, ANAL BIOCHEM, V216, P262, DOI 10.1006/abio.1994.1040; RADONS J, 1994, BIOCHEM J, V302, P581, DOI 10.1042/bj3020581; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VORBROKER DK, 1995, AM J PHYSIOL-LUNG C, V268, pL647, DOI 10.1152/ajplung.1995.268.4.L647; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; Vorbroker DK, 1995, AM J PHYSIOL-LUNG C, V269, pL727, DOI 10.1152/ajplung.1995.269.6.L727; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; XIE XS, 1986, J BIOL CHEM, V261, P2492; YOUNG SL, 1989, J APPL PHYSIOL, V66, P1336, DOI 10.1152/jappl.1989.66.3.1336	44	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14361	14370		10.1074/jbc.271.24.14361	http://dx.doi.org/10.1074/jbc.271.24.14361			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662952	hybrid			2022-12-25	WOS:A1996UQ66000064
J	Ikuta, T; Papayannopoulou, T; Stamatoyannopoulos, G; Kan, YW				Ikuta, T; Papayannopoulou, T; Stamatoyannopoulos, G; Kan, YW			Globin gene switching - In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; HUMAN GAMMA-GLOBIN; K562 ERYTHROLEUKEMIA-CELLS; HIGH-LEVEL EXPRESSION; TRANSCRIPTION FACTOR; TRANSGENIC MICE; HYPERSENSITIVE SITE; MINIMAL REQUIREMENTS; CHROMATIN STRUCTURE; ACTIVATION REGION	To characterize the protein-DNA interactions important for the developmental control of the human beta-globin locus, we analyzed by in vivo dimethyl sulfate footprinting erythroid cells expressing either the fetal or the adult globin developmental program, In the locus control region (LCR) of the beta-globin locus, in vivo footprints on NF-EB (or AP-1) and GATA-1 motifs remained the same regardless of whether the fetal or the adult globin genes are expressed. In contrast, in vivo footprints on GT (CACCC) motifs differed between the cells expressing the fetal or the adult globin program, In promoter regions, the actively transcribed genes demonstrated extensive and consistent footprints over the ca nonical elements, such as CACCC and CCAAT motifs, The adult globin expressing cells displayed more extensive footprints than the fetal globin expressing cells in the 3' regulatory sequences of both the (A) gamma- and the beta-globin genes, suggesting a role of these 3' elements in beta-globin gene expression, Our results suggest that the bulk of protein-DNA interactions that underlies the developmental control of globin genes takes place in the gamma- and beta-globin gene promoters, and that GT motifs of the beta-globin locus LCR may play a role in the developmental regulation of human beta-globin gene expression, perhaps by increasing the probability of interaction of the LCR holocomplex with the fetal or the adult globin gene.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,DIV MED GENET,SEATTLE,WA 98195	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK45365, DK30852, DK16666] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK045365, R01DK045365, R37DK045365, R01DK016666, R37DK016666, R01DK030852, R37DK030852] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BALTA G, 1994, BLOOD, V83, P3727; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; CUNNINGHAM JM, 1994, BLOOD, V84, P1298; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LONERGAN M, 1993, MOL CELL BIOL, V13, P6629, DOI 10.1128/MCB.13.11.6629; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MILLER JL, 1993, BLOOD, V82, P1900; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; ORKIN SH, 1984, ANNU REV GENET, V18, P131; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PAPAYANNOPOULOU T, 1986, CELL, V46, P469, DOI 10.1016/0092-8674(86)90667-7; PETERSON KR, 1996, IN PRESS P NATL ACAD; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; STARCK J, 1994, BLOOD, V84, P1656; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; ULRICH MJ, 1990, BLOOD, V75, P990; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089	64	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14082	14091		10.1074/jbc.271.24.14082	http://dx.doi.org/10.1074/jbc.271.24.14082			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662960				2022-12-25	WOS:A1996UQ66000025
J	Kinet, S; Goffin, V; Mainfroid, V; Martial, JA				Kinet, S; Goffin, V; Mainfroid, V; Martial, JA			Characterization of lactogen receptor-binding site 1 of human prolactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ALANINE-SCANNING MUTAGENESIS; METHIONYL BOVINE PROLACTIN; BIOLOGICAL PROPERTIES; RATIONAL DESIGN; FAMILY; ERYTHROPOIETIN; PURIFICATION; ANTAGONISTS; BIOACTIVITY	Prolactin (PRL) binds to two molecules of PRL receptor (PRLR) through two regions referred to as binding sites 1 and 2. Although binding site 1 has been generally assigned to the pocket delimited by helix 1, helix 4, and the second half of loop 1, the residues involved in receptor binding have not yet all been precisely identified. In an earlier alanine-scanning mutational study, we identified three major binding determinants in loop 1 of human PRL (hPRL) (Goffin, V., Norman, M. & Martial, J. A. (1992) Mol. Endocrinol. 6, 1381-1392). Here we focus on the two other regions that form binding site 1, namely helices 1 and 4. Putative binding residues, selected on the basis of a three-dimensional model of hPRL constructed in this laboratory, were mutated to alanine, and recombinant hPRL mutants produced in Escherichia coli were tested for their ability to bind to the PRLR and to stimulate Nb2 cell. proliferation. We thus identified nine single mutations (three in helix 1 and six in helix 4) whose effect was to reduce both binding and mitogenic activity by more than half as compared with wild-type hPRL, indicating the functional involvement of the corresponding residues. Adding these to the three binding determinants identified in loop 1, we now propose a complete picture of PRLR-binding site 1 of hPRL. As we earlier hypothesized, the binding site 1 determinants of hPRL differ from those of human growth hormone, a hPRL homolog.	UNIV LIEGE,LAB MOLEC BIOL & GENET ENGN,B-4000 SART,BELGIUM	University of Liege			GOFFIN, Vincent/G-3322-2013	GOFFIN, Vincent/0000-0002-8021-3086; kinet, sandrina/0000-0003-0699-108X				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clarke W.C., 1980, Hormonal Proteins and Peptides, V8, P105; CLARKSON T, 1995, SCIENCE, V267, P383; COOKE NE, 1981, J BIOL CHEM, V256, P4007; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOFFIN V, 1993, EUR J BIOCHEM, V214, P483, DOI 10.1111/j.1432-1033.1993.tb17945.x; GOFFIN V, 1996, PROTEIN ENG, V8, P1215; GOUT PW, 1980, CANCER RES, V40, P2433; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCK DN, 1991, MOL ENDOCRINOL, V5, P1880, DOI 10.1210/mend-5-12-1880; LUCK DN, 1989, MOL ENDOCRINOL, V3, P822, DOI 10.1210/mend-3-5-822; LUCK DN, 1990, MOL ENDOCRINOL, V4, P1011, DOI 10.1210/mend-4-7-1011; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1993, FASEB J, V7, P3387; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; Wallis M., 1988, Hormones and their actions. Part II. Specific actions of protein hormones., P265; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140	50	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14353	14360		10.1074/jbc.271.24.14353	http://dx.doi.org/10.1074/jbc.271.24.14353			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662911	hybrid			2022-12-25	WOS:A1996UQ66000063
J	Leung, CL; Liem, RKH				Leung, CL; Liem, RKH			Characterization of interactions between the neurofilament triplet proteins by the yeast two-hybrid system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTERMEDIATE FILAMENTS; NF-M; INVITRO; EXPRESSION; VIMENTIN; CELLS; FIBROBLASTS; SUBUNITS; BIOLOGY	In the adult axon, the neurofilaments (NFs) are heteropolymers formed from the low (NFL), middle (NFM), and high (NFH) molecular weight neurofilament triplet proteins (NFTPs). All three proteins have the basic intermediate filament protein tripartite structure, which consists of a short amino-terminal head region, an alpha-helical rod region of similar to 310 amino acids, and a carboxyl-terminal tail region of variable length. lit vitro polymerization studies have shown that only NFL can assemble into homopolymeric 10-nm filaments. The assembly of intermediate filaments, including the NFs, begins with the formation of a coiled-coil dimer involving the alpha-helical rod domains of two molecules. In order to determine whether homodimers or heterodimers of NFTPs are the preferred intermediates in the assembly of NFs, we have used the yeast two-hybrid system to study the interactions between the different NFTPs. By monitoring the activity of the lacZ reporter gene product, we are able to show that the interactions of Nn with NFL, NFM, or NFH are stronger than the interactions of NFM with NFM or NFH and the interaction of NFH with NFH. These results imply that NFM and NFH are more likely to form heterodimers with Nn than homodimers and are consistent with the inability of NFM and NFH to self-polymerize in vitro and in vivo.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NATIONAL EYE INSTITUTE [T32EY007105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015182] Funding Source: NIH RePORTER; NEI NIH HHS [EY07105] Funding Source: Medline; NIA NIH HHS [AG00189] Funding Source: Medline; NINDS NIH HHS [NS15182] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1991, J CELL SCI, V99, P335; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; COHLBERG JA, 1995, J BIOL CHEM, V270, P9334, DOI 10.1074/jbc.270.16.9334; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLIEGNER KH, 1991, INT REV CYTOL, V131, P109, DOI 10.1016/S0074-7696(08)62018-5; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; Miller J.H., 1972, EXPT MOL GENETICS; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MULLIGAN L, 1991, J STRUCT BIOL, V106, P145, DOI 10.1016/1047-8477(91)90084-A; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; QUINLAN RA, 1986, J MOL BIOL, V192, P233; Sambrook J., 2002, MOL CLONING LAB MANU; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P3692, DOI 10.1073/pnas.78.6.3692; VANDENHEUVEL RMM, 1987, J CELL SCI, V88, P475	22	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14041	14044		10.1074/jbc.271.24.14041	http://dx.doi.org/10.1074/jbc.271.24.14041			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663004	hybrid			2022-12-25	WOS:A1996UQ66000019
J	Su, JY; Erikson, E; Maller, JL				Su, JY; Erikson, E; Maller, JL			Cloning and characterization of a novel serine/threonine protein kinase expressed in early Xenopus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; TYROSINE PHOSPHORYLATION; CONSERVED FEATURES; CRYSTAL-STRUCTURE; YEAST; MITOSIS; GENE; IDENTIFICATION; INHIBITOR; SEQUENCE	We have cloned from a Xenopus ovary cDNA library a novel protein kinase gene whose expression peaks in the oocyte and unfertilized egg, beans to decrease gradually after fertilization, and disappears during the gastrulation stage of embryogenesis. The cloned gene, termed XEEK1 (for Xenopus egg and embryo kinase), encodes a protein with a predicted molecular mass of 49 kDa. Bacterially expressed XEEK1 migrates at 57 kDa upon polyacrylamide gel electrophoresis analysis, and a XEEK1-specific antibody recognizes a protein of 57 kDa in Xenopus oocyte and egg extracts. The XEEK1 kinase domain shares 35% identity (similar to 65% similarity) with the yeast SNF1 kinase and related kinases. However, expression of XEEK1 does not complement a snf1 deletion mutation in yeast, which suggests that it is probably not a Xenopus homolog of SNF1. Recombinant XEEK1 protein autophosphorylates on threonine residues in vitro in a reaction that prefers Mn2+ to Mg2+ ions. Site directed mutagenesis of the conserved lysine residue (Lys-81) within the kinase domain to isoleucine totally abolishes kinase activity, and threonine 192 has been identified as the autophosphorylation site. This site is distinct from the conserved threonine (Thr-215 in XEEK1) present in the protein kinase activation loop that is the site of autophosphorylation for many protein kinases. XEEK1 is a substrate for the cyclic AMP-dependent protein kinase both in vitro and in vivo, suggesting a possible mode of regulation of XEEK1. An immunoprecipitate of oocyte/egg extracts with anti-YEEK1 serum contains a protein of -155 kDa that may be a substrate and/or a regulatory component of the kinase.	UNIV COLORADO, SCH MED, HOWARD HUGHES MED INST, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26743] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERSON A, 1991, P NATL ACAD SCI USA, V88, P8602, DOI 10.1073/pnas.88.19.8602; Beavo J A, 1974, Methods Enzymol, V38, P299; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; CAMPBELL SD, 1995, MOL BIOL CELL, V6, P1333, DOI 10.1091/mbc.6.10.1333; CARLING D, 1994, J BIOL CHEM, V269, P11422; CARLSON M, 1981, GENETICS, V98, P25; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Harlow E., 1988, ANTIBODIES LAB MANUA; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURANAKA T, 1994, MOL CELL BIOL, V14, P2958, DOI 10.1128/MCB.14.5.2958; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PIPPIN J, 1994, BIOTECHNIQUES, V16, P676; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADLER SE, 1982, J BIOL CHEM, V257, P355; SAMBROOK J, 1989, MOL CLO NING LAB MAN; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SU JY, 1995, MOL GEN GENET, V246, P387, DOI 10.1007/BF00288613; SU JY, 1994, GENE, V145, P155, DOI 10.1016/0378-1119(94)90343-3; THOMAS J, 1991, J BIOL CHEM, V266, P10906; WOODS A, 1994, J BIOL CHEM, V269, P19509	42	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14430	14437		10.1074/jbc.271.24.14430	http://dx.doi.org/10.1074/jbc.271.24.14430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662877	hybrid			2022-12-25	WOS:A1996UQ66000073
J	Aggeler, R; Capaldi, RA				Aggeler, R; Capaldi, RA			Nucleotide-dependent movement of the epsilon subunit between alpha and beta subunits in the Escherichia coli F1F0-type ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; GAMMA-SUBUNIT; TRANSLOCATING ATPASE; ELECTRON-MICROSCOPY; CATALYTIC SITES; CROSS-LINKING; SYNTHASE; CHLOROPLASTS; F1-ATPASE	Mutants of ECF(1)-ATPase were generated, containing cysteine residues in one or more of the following positions: alpha Ser-411, beta Glu-381, and epsilon Ser-108, after which disulfide bridges could be created by CuCl2 induced oxidation in high yield between alpha and epsilon, beta and epsilon, alpha and gamma, beta and gamma (endogenous Cys-87), and alpha and beta. All of these cross-links lead to inhibition of ATP hydrolysis activity. In the two double mutants, containing a cysteine in epsilon Ser-108 along with either the DELSEED region of beta (Glu-381) or the homologous region in alpha (Ser-411), there was a clear nucleotide dependence of the cross-link formation with the epsilon subunit. In beta E381C/epsilon S108C the beta-epsilon cross-link was obtained preferentially with Mg2+ and ADP + P-i (addition of MgCl2 + ATP) was present, while the alpha-epsilon cross-link product was strongly favored in the alpha S411C/epsilon S108C mutant in the Mg2+ ATP state (addition of MgCl2 + 5'-adenylyl-beta,gamma-imidodiphosphate). In the triple mutant alpha S411C/beta E381C/epsilon S108C, the epsilon subunit bound to the beta subunit in Mg2+-ADP and to the alpha subunit in Mg2+-ATP, indicating a significant movement of this subunit. The gamma cross-linked to the beta subunit in higher yield in Mg2+-ATP than in Mg(2+)-ADP, and when possible, i.e. in the triple mutant, always preferred the interaction with the beta over the alpha subunit.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon					NHLBI NIH HHS [HL24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; Battey, 1986, BASIC METHODS MOL BI; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CAPALDI RA, 1995, T BIOCH SOC, V23, P767; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1982, J BIOL CHEM, V257, P7354; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; Maniatis T., 1982, MOL CLONING; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; TURINA P, 1994, J BIOL CHEM, V269, P13465; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	31	96	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13888	13891		10.1074/jbc.271.23.13888	http://dx.doi.org/10.1074/jbc.271.23.13888			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662953	hybrid			2022-12-25	WOS:A1996UP38500087
J	Esmon, CT; Lollar, P				Esmon, CT; Lollar, P			Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; HUMAN ALPHA-THROMBIN; PORCINE FACTOR-VIII; VONWILLEBRAND-FACTOR; SUBUNIT STRUCTURE; PROTHROMBIN FRAGMENT-2; PHOSPHOLIPID-VESICLES; COMPLETE CDNA; ACTIVE-SITE; LIGHT CHAIN	The role of anion-binding exosites of thrombin in the activation of factor V and factor VIII was studied using thrombin Arg(93) --> Ala, Arg(97) --> Ala, and Arg(101) --> Ala (thrombin RA), a recombinant exosite 2 defective mutant and a synthetic M-acetylated dodecapeptide, Ac-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-O-SO4-Leu (hirugen), which competitively inhibits binding of macromolecules to exosite 1. The catalytic efficiency of the activation of factor VIII or of the first step of factor V activations by thrombin RA was approximately 10% that of wild-type thrombin. The overall rate of conversion to factor Va was not influenced by the mutation. in contrast to factor V, the slow activation of factor VIII by thrombin RA was associated with a decreased rate of cleavage at all three proteolytic sites (Arg(372), Arg(740), and Arg(1689)). Hirugen inhibited factor V and factor VIII activation, These results indicate that both anion-binding exosites of thrombin are involved in the recognition of factor V and factor VIII.	UNIV OKLAHOMA,OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,DEPT PATHOL,RES LABS,HLTH SCI CTR,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104; EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,ATLANTA,GA 30322	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Emory University					NHLBI NIH HHS [R01 HL40921, R37 HL30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921, R37HL030340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARROW RT, 1994, J BIOL CHEM, V269, P593; BOCK PE, 1992, J BIOL CHEM, V267, P14974; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1982, J BIOL CHEM, V257, P7944; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HORTIN GL, 1990, BLOOD, V76, P946; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LIU LW, 1994, J BIOL CHEM, V269, P11807; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OFOSU FA, 1991, HAEMOSTASIS, V21, P240; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; PITTMAN DD, 1993, BLOOD, V81, P2925; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; PRIESTLE JP, 1993, PROTEIN SCI, V2, P1630, DOI 10.1002/pro.5560021009; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; THARAKAN J, 1990, VOX SANG, V58, P21, DOI 10.1111/j.1423-0410.1990.tb02050.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; TULINSKY A, 1993, BLOOD COAGUL FIBRIN, V4, P305, DOI 10.1097/00001721-199304000-00012; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; YE J, 1994, J BIOL CHEM, V269, P17965	59	99	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13882	13887		10.1074/jbc.271.23.13882	http://dx.doi.org/10.1074/jbc.271.23.13882			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662922	hybrid			2022-12-25	WOS:A1996UP38500086
J	GravesWoodward, KL; Weller, SK				GravesWoodward, KL; Weller, SK			Replacement of Gly(815) in helicase motif V alters the single-stranded DNA-dependent ATPase activity of the herpes simplex virus type 1 helicase-primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PUTATIVE HELICASES; EXCISION REPAIR; GENE-PRODUCTS; PROTEIN; REPLICATION; UL5; OVEREXPRESSION; IDENTIFICATION; RECOMBINATION	Herpes simplex virus type 1 encodes a helicase-primase complex composed of the products of the UL5, UL52, and UL8 genes, A subcomplex consisting of the UL5 and UL52 proteins purified from insect cells also displays ATPase, helicase, and primase activities, UL5 contains six motifs conserved in superfamily I of known and/or putative helicase proteins, Consistent with the ability to hydrolyze ATP, motifs I and II resemble a nucleotide binding site, Although the role of the other four motifs is not known, single amino acid substitutions created in conserved residues in all six motifs abolish the ability of UL5 to support viral DNA replication in vivo (Zhu, L., and Weller, S. K. (1992) J. Virol, 66, 469-479). In one such mutation, a highly conserved glycine in motif V (Gly(815)) is replaced with an alanine, Although the UL5(G815A) protein does not support viral DNA replication in vivo, the purified UL5(G815A). 52 subcomplex retains primase and helicase activities and supports strand displacement DNA synthesis on a preformed replication fork in the presence of the other HSV-1 replication proteins, The major difference between the wildtype and variant protein is that the UL5(G815A). 52 subcomplex displays an increased K-m for single-stranded DNA and decreased K-cat for single-stranded DNA-dependent ATPase activity, Several hypotheses for the role of motif V in the function of the UL5 helicase in HSV-I DNA replication are considered, This is the first report of a biochemical analysis of a motif V variant in any member of helicase superfamily I.	UNIV CONNECTICUT, CTR HLTH, DEPT MICROBIOL, FARMINGTON, CT 06030 USA	University of Connecticut			Weller, Sandra/N-3979-2013	Weller, Sandra/0000-0002-4519-6276	NIAID NIH HHS [AI21747] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021747, R01AI021747] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILIS AM, 1995, MOL CELL BIOL, V15, P3998; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; EARNSHAW DL, 1994, BIOCHEM BIOPH RES CO, V199, P1333, DOI 10.1006/bbrc.1994.1377; *GEN COMP GROUP, 1994, VERS 8; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, NUCLEIC ACIDS RES, V16, P7734, DOI 10.1093/nar/16.15.7734; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; LAHAYE A, 1993, J BIOL CHEM, V268, P26155; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIVINGSTONE C, 1989, NUCLEIC ACIDS RES, V17, P2366, DOI 10.1093/nar/17.6.2366; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lukonis CJ, 1996, J VIROL, V70, P1751, DOI 10.1128/JVI.70.3.1751-1758.1996; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; OLIVO PD, 1990, HERPESVIRUS TRANSCRI, P137; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELLER SK, 1995, IMPLICATIONS DNA PRO, P189; WELLER SK, 1988, CANCER CELL, V6, P53; WELLER SK, 1990, HERPESVIRUS TRANSCRI, P105; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992; ZHU L, 1988, VIROLOGY, V166, P366, DOI 10.1016/0042-6822(88)90507-7	45	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13629	13635		10.1074/jbc.271.23.13629	http://dx.doi.org/10.1074/jbc.271.23.13629			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662872	hybrid			2022-12-25	WOS:A1996UP38500050
J	Singh, N; Liang, LN; Tykocinski, ML; Tartakoff, AM				Singh, N; Liang, LN; Tykocinski, ML; Tartakoff, AM			A novel class of cell surface glycolipids of mammalian cells - Free glycosyl phosphatidylinositols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GLYCOINOSITOL PHOSPHOLIPID ANCHOR; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; MEMBRANE ANCHOR; TRYPANOSOMA-BRUCEI; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-TRANSPORT; THY-1 GLYCOPROTEIN; HEPATOMA-CELLS; MDCK CELLS	Glycosyl phosphatidylinositol (GPI) lipids function as anchors of membrane proteins, and free GPI units serve as intermediates along the path of GPI-anchor biosynthesis, By using in vivo cell surface biotinylation, we show that free GPIs: 1) can exit the rough endoplasmic reticulum and are present on the surface of a murine EL-4 T-lymphoma and a human carcinoma cell (HeLa), 2) arrive at the cell surface in a time and temperature-dependent fashion, and 3) are built on a base-labile glycerol backbone, unlike GPI anchors of surface proteins of the same cells, The free GPIs described in this study may serve as a source of hormone sensitive phosphoinositol glycans. The absence of free GPIs from the cell surface may also account for the growth advantage of blood cells in paroxysmal nocturnal hemoglobinuria.	CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CELL BIOL PROGRAM, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK38181] Funding Source: Medline; PHS HHS [1 F32 D07612] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALLOU CE, 1963, J BIOL CHEM, V238, P69; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BESSLER M, 1994, LANCET, V343, P951, DOI 10.1016/S0140-6736(94)90068-X; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CURATOLO W, 1987, BIOCHIM BIOPHYS ACTA, V906, P137, DOI 10.1016/0304-4157(87)90009-8; DEEG MA, 1992, J BIOL CHEM, V267, P18581; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DEVINE DV, 1987, J CLIN INVEST, V79, P314, DOI 10.1172/JCI112802; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1992, J BIOL CHEM, V267, P23527; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Issitt PD, 1985, APPL BLOOD GROUP SER; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; LAZAR DF, 1994, P NATL ACAD SCI USA, V91, P9665, DOI 10.1073/pnas.91.21.9665; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MATO JM, 1987, J BIOL CHEM, V262, P2131; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; MCNEELY TB, 1989, BIOCHEM J, V259, P601, DOI 10.1042/bj2590601; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; PARPAL S, 1995, J CELL BIOL, V131, P125, DOI 10.1083/jcb.131.1.125; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; PUOTI A, 1992, J BIOL CHEM, V267, P22673; REPRESA J, 1991, P NATL ACAD SCI USA, V88, P8016, DOI 10.1073/pnas.88.18.8016; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SHIAO YJ, 1993, J BIOL CHEM, V268, P26085; SINGH N, 1991, MOL CELL BIOL, V11, P391, DOI 10.1128/MCB.11.1.391; SINGH N, 1994, MOL CELL BIOL, V14, P21, DOI 10.1128/MCB.14.1.21; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; UEDA E, 1993, J BIOL CHEM, V268, P9998; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; Van Meer Gerrit, 1992, Trends in Cell Biology, V2, P332; VANTHOF W, 1995, J BIOL CHEM, V270, P24150; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; WALTER EI, 1990, J IMMUNOL, V144, P1030; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	66	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12879	12884		10.1074/jbc.271.22.12879	http://dx.doi.org/10.1074/jbc.271.22.12879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663031	hybrid			2022-12-25	WOS:A1996UN47400031
J	Rachez, C; Sautiere, P; Formstecher, P; Lefebvre, P				Rachez, C; Sautiere, P; Formstecher, P; Lefebvre, P			Identification of amino acids critical for the DNA binding and dimerization properties of the human retinoic acid receptor alpha - Importance of lysine 360, lysine 365, and valine 361	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; LIGAND-BINDING; NUCLEAR RECEPTOR; DIRECT REPEATS; X-RECEPTOR; STRUCTURAL DETERMINANTS; RESPONSE ELEMENTS; STEROID BINDING; RXR-ALPHA	Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) activate target genes by binding to retinoic acid response elements (RAREs) as heterodimeric, asymmetrical complexes, and display a high degree of cooperativity in binding to RAREs, We have examined here the effect of lysine, cysteine, arginine, histidine, and tyrosine side chain chemical modification on the DNA binding, homo and heterodimerization properties of the full-length human retinoic acid receptor alpha (hRAR alpha). Lysines are the only residues to be engaged in the dimerization with human retinoid X receptor alpha (hRXR alpha) in the absence of DNA, whereas histidines are selectively involved in the homodimerization of hRAR alpha in the presence of a RARE. Arginine modification affected the DNA binding activity of each type of dimer, whereas cysteines and tyrosines were primarily involved in the homo- or heterodimerization process in the presence of the same RARE. Modified lysines, interfering with the dimerization with hRXR alpha, were identified by receptor labeling and peptide mapping. They are located in the hormone binding domain eighth heptad repeat, at positions 360 and 365. In keeping with these results, mutation of Lys(360), Val(361), and Lys(365) diminished strongly the DNA binding activity of hRAR alpha as a homodimer or a heterodimer. Our results thus provide direct evidence for the differential involvement of basic, polar, or aromatic amino acids in the DNA binding, homodimerization, and heterodimerization properties of hRAR alpha. Furthermore, they demonstrate the use of distinct dimerization interfaces and identify the type of amino acids involved in these protein-protein interactions.	FAC MED LILLE,CJF INSERM 9203,LAB BIOCHIM STRUCT,F-59045 LILLE,FRANCE; INST PASTEUR,CNRS URA 1309,F-59019 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Rachez, Christophe/GLR-0102-2022; Lefebvre, Philippe/F-2685-2010	Lefebvre, Philippe/0000-0002-9366-5129; Rachez, Christophe/0000-0001-8502-4738				ALI M, 1992, BIOCHEM BIOPH RES CO, V182, P1032, DOI 10.1016/0006-291X(92)91835-E; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BLICQ S, 1988, BIOCHEMISTRY-US, V27, P8436, DOI 10.1021/bi00422a021; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BUROLLAUD T, 1993, J STEROID BIOCHEM, V44, P217, DOI 10.1016/0960-0760(93)90082-8; CHAKRABORTI PK, 1990, ENDOCRINOLOGY, V127, P2530, DOI 10.1210/endo-127-5-2530; CHENG KC, 1989, J BIOL CHEM, V264, P19666; DALLERY N, 1993, BIOCHEMISTRY-US, V32, P12428, DOI 10.1021/bi00097a022; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLAZER AN, 1985, LAB TECHNIQUES BIOCH, V4, P68; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNEGTEL RMA, 1993, J BIOMOL NMR, V3, P1, DOI 10.1007/BF00242472; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEE MS, 1994, EUR J BIOCHEM, V224, P639, DOI 10.1111/j.1432-1033.1994.00639.x; LEFEBVRE B, 1995, BIOCHEMISTRY-US, V34, P5477, DOI 10.1021/bi00016a019; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUPISELLA JA, 1995, J BIOL CHEM, V270, P24884, DOI 10.1074/jbc.270.42.24884; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NUROKAWA R, 1993, GENE DEV, V7, P1423; OPOKU J, 1994, J BIOL CHEM, V269, P503; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SAUTIERE P, 1988, J BIOL CHEM, V263, P11059; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; STANCATO LF, 1993, BIOCHEMISTRY-US, V32, P3729, DOI 10.1021/bi00065a027; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TULLY DB, 1994, FASEB J, V8, P343, DOI 10.1096/fasebj.8.3.8143940; YAMASAKI RB, 1980, ANAL BIOCHEM, V109, P32, DOI 10.1016/0003-2697(80)90006-8; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	49	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17996	18006		10.1074/jbc.271.30.17996	http://dx.doi.org/10.1074/jbc.271.30.17996			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663386	hybrid			2022-12-25	WOS:A1996UY93500064
J	Basse, F; Stout, JG; Sims, PJ; Wiedmer, T				Basse, F; Stout, JG; Sims, PJ; Wiedmer, T			Isolation of an erythrocyte membrane protein that mediates Ca2+-dependent transbilayer movement of phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; LIPID ASYMMETRY; PROCOAGULANT ACTIVITY; RED-CELLS; FACTOR-VA; PLATELETS; EXPOSURE; CALCIUM; PHOSPHATIDYLSERINE; REDISTRIBUTION	Elevation of intracellular Ca2+ in erythrocytes, platelets, and other cells initiates rapid redistribution of plasma membrane phospholipids (PL) between inner and outer leaflets, collapsing the normal asymmetric distribution. Consequently, phosphatidylserine and other lipids normally sequestered to the inner leaflet become exposed at the cell surface. This Ca2+-induced mobilization of phosphatidylserine to the surface of activated, injured, or apoptotic cells confers a procoagulant property to the plasma membrane, which promotes fibrin clotting and provides a signal for cell removal by the reticuloendothelial system, To identify the constituent of the membrane that mediates this Ca2+-dependent ''PL scramblase'' activity, we undertook purification and reconstitution of membrane component(s) with this activity from detergent extracts of erythrocyte ghosts depleted of cytoskeleton. Active fractions were identified by their capacity to mediate the Ca2+-dependent redistribution of 7-nitrobenz-2-oxa-1,3-diazol-4-yl-labeled PL between leaflets of reconstituted proteoliposomes. This PL scramblase activity co-eluted through multiple chromatographic steps with a single polypeptide of similar to 37 kDa, which was purified to apparent homogeneity as resolved by silver staining. The activity associated with this protein band was inactivated by trypsin, The isolated protein reconstituted in proteoliposomes mediated nonselective, bidirectional transport of 7-nitrobenz-2-oxa-1,3-diazol-4-yl-PL between membrane leaflets, with half-maximal activation between 20 and 60 mu M Ca2+ (saturation >100 mu M), mimicking the Ca2+-dependent transbilayer lipid movement intrinsic to the erythrocyte membrane.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53201	Versiti Blood Center of Wisconsin			Wunder, Stephanie L/B-5066-2012; Zdilla, Michael J/B-4145-2011		NHLBI NIH HHS [HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BEVERS EM, 1995, BLOOD, V86, P1983, DOI 10.1182/blood.V86.5.1983.bloodjournal8651983; BRATTON DL, 1994, J BIOL CHEM, V269, P22517; CHANG CP, 1993, J BIOL CHEM, V268, P7171; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FADOK VA, 1992, J IMMUNOL, V148, P2207; FOX JEB, 1990, BLOOD, V76, P2510; GAFFET P, 1995, BIOCHEMISTRY-US, V34, P6762, DOI 10.1021/bi00020a022; KOJIMA H, 1994, J CLIN INVEST, V94, P2237, DOI 10.1172/JCI117586; MARTIN DW, 1995, J BIOL CHEM, V270, P10468, DOI 10.1074/jbc.270.18.10468; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; POMORSKI T, 1994, MOL MEMBR BIOL, V11, P39, DOI 10.3109/09687689409161028; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Steck T L, 1974, Methods Enzymol, V31, P172; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; VERHOVEN B, 1992, BIOCHIM BIOPHYS ACTA, V1104, P15, DOI 10.1016/0005-2736(92)90126-7; VONDENHOF A, 1994, BIOCHEMISTRY-US, V33, P4517, DOI 10.1021/bi00181a011; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027	25	253	261	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17205	17210		10.1074/jbc.271.29.17205	http://dx.doi.org/10.1074/jbc.271.29.17205			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663431	hybrid			2022-12-25	WOS:A1996UX94300036
J	Duan, HJ; Orth, K; Chinnaiyan, AM; Poirier, GG; Froelich, CJ; He, WW; Dixit, VM				Duan, HJ; Orth, K; Chinnaiyan, AM; Poirier, GG; Froelich, CJ; He, WW; Dixit, VM			ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; DEATH; ENZYME; CED-3	Members of the ICE/Ced-3 gene family are likely effector components of the cell death machinery. Here, we characterize a novel member of this family designated ICE-LAP6. By phylogenetic analysis, ICE-LAP6 is classified into the Ced-3 subfamily which includes Ced-3, Yama/CPP32/apopain, Mch2, and ICE-LAP3/Mch3/CMH-1. Interestingly, ICE-LAP6 contains an active site QACGG pentapeptide, rather than the QACRG pentapeptide shared by other family members. Overexpression of ICE-LAP6 induces apoptosis in MCF7 breast carcinoma cells. More importantly, ICE-LAP6 is proteolytically processed into an active cysteine protease by granzyme B, an important component of cytotoxic T cell-mediated apoptosis. Once activated, ICE-LAP6 is able to cleave the death substrate poly(ADP ribose) polymerase into signature apoptotic fragments.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV LAVAL,CTR HOSP,DEPT MOLEC ENDOCRINOL,RES CTR,ST FOY,PQ G1V 4G2,CANADA; NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60201; EVANSTON HOSP CORP,DEPT MED,EVANSTON,IL 60201; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; Laval University; Northwestern University; NorthShore University Health System; GlaxoSmithKline; Human Genome Sciences Inc			Orth, Kim/AAV-4421-2021; dixit, vishva m/A-4496-2012	Orth, Kim/0000-0002-0678-7620; dixit, vishva m/0000-0001-6983-0326; Poirier, Guy/0000-0002-4869-1424	NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NCI NIH HHS [CA64803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUAN H, 1996, J BIOL CHEM, V271, P35013; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Sambrook J., 2002, MOL CLONING LAB MANU; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	36	282	305	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16720	16724		10.1074/jbc.271.28.16720	http://dx.doi.org/10.1074/jbc.271.28.16720			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663294	hybrid			2022-12-25	WOS:A1996UX12600048
J	Li, Y; Ndubuka, C; Rubin, CS				Li, Y; Ndubuka, C; Rubin, CS			A kinase anchor protein 75 targets regulatory (RII) subunits of cAMP-dependent protein kinase II to the cortical actin cytoskeleton in non-neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; EPITHELIAL-CELLS; GOLGI-COMPLEX; E-CADHERIN; EXPRESSION; BETA; CLONING; CALCIUM; PHOSPHORYLATION; IDENTIFICATION	Neuronal A kinase anchor protein (AKAP) homologs, such as AKAPs 75 and 150, tether cAMP-dependent protein kinase II (PKAII) isoforms to the postsynaptic cytoskeleton, thereby creating target sites for cAMP action, These AKAPs, which bind regulatory subunits (RIIs) of PKAII, are also expressed in certain non-neuronal cells, Non-neuronal cell lines that stably express wild type and mutant AKAP75 transgenes were generated to investigate the extraneuronal function of AKAPs, In non neuronal cells, AKAP75 accumulates selectively in the actin-rich, cortical cytoskeleton in close proximity with the plasma membrane, AKAP75 efficiently sequesters cytoplasmic RII alpha and RII beta (PKAII isoforms) and translocates these polypeptides to the cell cortex, Two structural modules in AKAP75, T-1 (residues 27-48), and T-2 (residues 77-100), are essential for targeting AKAP75 . RII complexes to the cortical cytoskeleton, Deletions or amino acid substitutions in T-1 and/or T-2 result in the dispersion of both AKAP75 and RII subunits throughout the cytoplasm, AKAP75 is co localized with F-actin and fodrin in the cortical cytoskeleton, Incubation of cells with 5 mu M cytochalasin D disrupts actin filaments and dissociates actin from the cell cortex, In contrast, the bulk of AKAP75 and fodrin remain associated with the cortical region of cytochalasin D-treated cells, Thus, targeting of AKAP75 does not depend upon direct binding with F-actin, Rather, AKAP75 (like fodrin) may be associated with a multiprotein complex that interacts with integral plasma membrane proteins.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,ATRAN LABS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM22792, GM7288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P793; ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BERG DT, 1993, BIOTECHNIQUES, V14, P972; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAND M, 1994, J BIOL CHEM, V269, P9234; LEISER M, 1986, J BIOL CHEM, V261, P1904; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	44	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16862	16869		10.1074/jbc.271.28.16862	http://dx.doi.org/10.1074/jbc.271.28.16862			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663279	hybrid			2022-12-25	WOS:A1996UX12600068
J	Liu, LM; Roberts, RM				Liu, LM; Roberts, RM			Silencing of the gene for the beta subunit of human chorionic gonadotropin by the embryonic transcription factor Oct-3/4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; CYCLIC-AMP; POU-DOMAIN; STEM-CELLS; EXPRESSION; MOUSE; ENHANCER; IDENTIFICATION; SECRETION; INVITRO	The transcription factor Oct-3/4 may be important in maintaining embryonic cells in an undifferentiated state, It is probably down-regulated at about the time that human chorionic gonadotropin (hCG) is first expressed in embryonic trophectoderm Here we report that Oct-3/4 strongly inhibits the hCG beta subunit (hCG beta) promoter in JAr choriocarcinoma cells. Oct-3/4 reduced chloramphenicol acetyltransferase (CAT) reporter expression from the -305hCG beta promoter by about 90% in transient co transfection assays, but had no effect on expression from the -249hCG beta promoter, The -305/-249 hCG beta fragment specifically bound synthetic Oct-3/4 protein as measured in electrophoretic mobility shift assays, and the Oct-3/4-binding site was localized around -270 by methylation interference footprinting, Site directed mutagenesis of this binding site abolished Oct-3/4 repression, When stably transfected into JAr cells, Oct-3/4 reduced the amounts of both endogenous hCG beta messenger RNA and hCG protein to less than 10% of controls. We suggest that silencing of Oct-3/4 in trophectoderm is a prerequisite for hCG up-regulation in early human embryos at the time of maternal recognition of pregnancy.	UNIV MISSOURI,DEPT ANIM SCI,ANIM SCI CTR 158,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT BIOL SCI,ANIM SCI CTR 158,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					NICHD NIH HHS [R37 HD21896, HD29483] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021896, R01HD029483] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BHAT K, 1988, MOL CELL BIOL, V8, P3251, DOI 10.1128/MCB.8.8.3251; BO M, 1992, J BIOL CHEM, V267, P3179; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DOKRAS A, 1991, HUM REPROD, V6, P1143, DOI 10.1093/oxfordjournals.humrep.a137500; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; HAY DL, 1988, J CLIN ENDOCR METAB, V67, P1322, DOI 10.1210/jcem-67-6-1322; HEARN JP, 1991, J REPROD FERTIL, V92, P497; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; JAMESON JL, 1987, J CLIN ENDOCR METAB, V64, P319, DOI 10.1210/jcem-64-2-319; JAMESON JL, 1988, MOL CELL BIOL, V8, P5100, DOI 10.1128/MCB.8.12.5100; JAMESON JL, 1993, ENDOCR REV, V14, P203, DOI 10.1210/er.14.2.203; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LILLYCROP KA, 1994, MOL CELL BIOL, V14, P7633, DOI 10.1128/MCB.14.11.7633; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OTANI T, 1988, J BIOL CHEM, V263, P7322; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Sambrook J., 2002, MOL CLONING LAB MANU; *SAS I INC, 1995, JMP STAT GRAPH GUID, P139; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SESHAGIRI PB, 1993, HUM REPROD, V8, P279, DOI 10.1093/oxfordjournals.humrep.a138038; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; TALMADGE K, 1984, NUCLEIC ACIDS RES, V12, P8415, DOI 10.1093/nar/12.22.8415; TALWAR GP, 1994, P NATL ACAD SCI USA, V91, P8532, DOI 10.1073/pnas.91.18.8532; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WEIS L, 1992, FASEB J, V6, P3330; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	50	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16683	16689		10.1074/jbc.271.28.16683	http://dx.doi.org/10.1074/jbc.271.28.16683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663260	hybrid			2022-12-25	WOS:A1996UX12600043
J	Olson, LK; Schroeder, W; Robertson, RP; Goldberg, ND; Walseth, TF				Olson, LK; Schroeder, W; Robertson, RP; Goldberg, ND; Walseth, TF			Suppression of adenylate kinase catalyzed phosphotransfer precedes and is associated with glucose-induced insulin secretion in intact HIT-T15 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SENSITIVE K-CHANNELS; HIT CELLS; POTASSIUM CHANNELS; B-CELLS; ATP; RELEASE; METABOLISM; ISLETS; LINE	Adenine nucleotide metabolism was characterized in intact insulin secreting HIT-T15 cells during the transition from non-stimulated (i.e. 0.2 mM glucose) to the glucose-stimulated secretory state. Metabolic dynamics were monitored by assessing rates of appearance of O-18-labeled phosphoryls of endogenous nucleotides in cells incubated in medium enriched in [O-18]water. Most prominent of the metabolic alterations associated with stimulated insulin secretion was the suppression in the rate of adenylate kinase (AK)-catalyzed phosphorylation of AMP by ATP, This was manifest as a graded decrease of up to 50% in the rate of appearance of beta-O-18-labeled species of ADP and ATP and corresponded to the magnitude of the secretory response elicited over a range of stimulatory glucose concentrations, The only nucleotide exhibiting a significant concentration change associated with suppression of AK activity was AMP, which decreased by about 50%, irrespective of the glucose concentration, Leucine-stimulated secretion also decreased the rate of AK-catalyzed phosphotransfer. This secretory stimulus-related suppression of AK-catalyzed phosphotransfer occurs within 45 s of glucose addition, precedes insulin secretion, depends on the internalization and metabolism of glucose, and is independent of membrane depolarization and the influx of extracellular calcium. The secretory stimulus-induced decrease in AK-catalyzed phosphotransfer, therefore occurs prior to or at the time of K-ATP(+) channel closure but it is not associated with or a consequence of events occurring subsequent to K-ATP(+) channel closure. These results indicate that AK-catalyzed phosphotransfer may be a determinant of ATP to ADP conversion rates in the K-ATP(+) channel microenvironment; secretory stimuli-linked decreased rates of AK-catalyzed ADP generation from ATP (and AMP) would translate into an increased probability of ATP-liganded and, therefore, closed state of the channel.	UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT MED,DIV ENDOCRINOL DIABET & METAB,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Walseth, Timothy F/F-9518-2010; Roberston, R Paul/AAX-5613-2021	Walseth, Timothy F/0000-0003-2558-7859; 	NIDDK NIH HHS [DK-38325] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK038325, R01DK038325] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; ASHCROFT SJH, 1986, DIABETOLOGIA, V29, P727, DOI 10.1007/BF00870283; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ASHCROFT SJH, 1987, FEBS LETT, V219, P311, DOI 10.1016/0014-5793(87)80242-9; ASPUND K, 1978, DIABETES, V27, P611; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; EDDLESTONE GT, 1989, J MEMBRANE BIOL, V109, P123, DOI 10.1007/BF01870851; GHOSH A, 1991, J BIOL CHEM, V266, P22887; HELLMAN B, 1969, DIABETES, V18, P509, DOI 10.2337/diab.18.8.509; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; KASPRZAK AA, 1980, EUR J BIOCHEM, V104, P443, DOI 10.1111/j.1432-1033.1980.tb04446.x; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LEVIN SR, 1978, J CLIN INVEST, V62, P692, DOI 10.1172/JCI109177; LOWRY OH, 1964, J BIOL CHEM, V239, P18; MALAISSE WJ, 1982, J BIOL CHEM, V257, P8731; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; MATSCHIN.FM, 1972, DIABETES, V21, P555, DOI 10.2337/diab.21.2.S555; MEGLASSON MD, 1987, DIABETES, V36, P477, DOI 10.2337/diabetes.36.4.477; MEGLASSON MD, 1986, DIABETES, V35, P1340, DOI 10.2337/diabetes.35.12.1340; MEGLASSON MD, 1989, AM J PHYSIOL, V256, pE173, DOI 10.1152/ajpendo.1989.256.1.E173; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NIKI I, 1989, PFLUG ARCH EUR J PHY, V415, P47, DOI 10.1007/BF00373140; OGUCHI M, 1973, J BIOL CHEM, V248, P5562; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; PIERCE M, 1978, ENDOCRINOLOGY, V103, P971, DOI 10.1210/endo-103-3-971; ROBERTSON RP, 1987, DIABETES, V36, P1047, DOI 10.2337/diabetes.36.9.1047; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; SHIMIZU T, 1988, DIABETES, V37, P563, DOI 10.2337/diabetes.37.5.563; STANFIELD PR, 1987, TRENDS NEUROSCI, V10, P335, DOI 10.1016/0166-2236(87)90091-9; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; WALSETH TF, 1988, METHOD ENZYMOL, V159, P60; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	38	43	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16544	16552		10.1074/jbc.271.28.16544	http://dx.doi.org/10.1074/jbc.271.28.16544			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663240	hybrid			2022-12-25	WOS:A1996UX12600021
J	Osawa, H; Sutherland, C; Robey, RB; Printz, RL; Granner, DK				Osawa, H; Sutherland, C; Robey, RB; Printz, RL; Granner, DK			Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN S6 KINASE; GLUCOSE-TRANSPORT; TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; PLASMA-MEMBRANE; MESSENGER-RNA; TRANSLOCATION	The hexokinases, by converting glucose to glucose 6-phosphate, help maintain the glucose concentration gradient that results in the movement of glucose into cells through the facilitative glucose transporters. Hexokinase II (HKII) is the major hexokinase isoform in skeletal muscle, heart, and adipose tissue, Insulin induces HKII gene transcription in L6 myotubes, and this, in turn, increases HKII mRNA and the rates of HKII protein synthesis and glucose phosphorylation in these cells. Inhibitors of distinct insulin signaling pathways were used to dissect the molecular mechanism by which HKII gene expression is induced by insulin in L6 myotubes, Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin, In contrast, treatment with PD98059, an inhibitor of mitogen-activated protein kinase activation, had no effect on insulin-induced HKII mRNA. In addition, rapamycin blocked the insulin-induced expression of an HKII promoter-chloramphenicol acetyltransferase fusion gene transiently transfected into L6 myotubes, whereas PD98059 had no such effect. These results suggest that a phosphatidylinositol 3-kinase/p70(s6k)-dependent pathway is required for regulation of HKII gene transcription by insulin and that the Ras-mitogen-activated protein kinase-dependent pathway is probably not involved.	VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,SCH MED,NASHVILLE,TN 37232	Vanderbilt University			Robey, R. Brooks/J-7099-2013	Robey, R. Brooks/0000-0001-5059-3965; Sutherland, Calum/0000-0003-4398-7434	NIDDK NIH HHS [DK46867, DK35107, DK42502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035107, R01DK046867, R01DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HANSEN R, 1967, ENDOCRINOLOGY, V81, P1397, DOI 10.1210/endo-81-6-1397; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MANDARINO LJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE701; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; Robey RB, 1996, BIOTECHNIQUES, V20, P40; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SOMMERCORN J, 1993, J CLIN INVEST, V91, P509, DOI 10.1172/JCI116229; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Vestergaard H, 1995, J CLIN INVEST, V96, P2639, DOI 10.1172/JCI118329; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	42	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16690	16694		10.1074/jbc.271.28.16690	http://dx.doi.org/10.1074/jbc.271.28.16690			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663315	hybrid			2022-12-25	WOS:A1996UX12600044
J	Salih, E; Zhou, HY; Glimcher, MJ				Salih, E; Zhou, HY; Glimcher, MJ			Phosphorylation of purified bovine bone sialoprotein and osteopontin by protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT BONE; SECRETED PHOSPHOPROTEIN; MATRIX; PURIFICATION; IDENTIFICATION; SEQUENCE; TRANSFORMATION; PROTEOGLYCAN; FIBRONECTIN; ATTACHMENT	The large number of covalently bound phosphates on the extracellular phosphoproteins osteopontin (OPN) and bone sialoprotein (BSP) have been implicated in biological functions such as mineral deposition and osteoclast binding. In the present study the state of phosphorylation of BSP and OPN was evaluated by in vitro P-32 labeling using a series of protein kinases and quantification. Both the purified bovine BSP and OPN were radiolabeled by [P-32]ATP and factor-independent protein kinase. Quantification of P-32 radioactivity incorporated on dephosphorylated BSP and OPN provided 6.6 and 8.9 mol of phosphate incorporated/mol, respectively. Native OPN incorporated 1.07 and BSP 2.46 mol of phosphate/mol by factor-independent protein kinase. These data led to calculations that OPN and BSP, respectively, contain 7.83 and 4.14 mol of phosphate/mol in their natural state. Thrombin digests of P-32-labeled BSP showed radioactivity to be associated with fragment of similar to molecular mass values 30 kDa (N-terminal half), with no observable radioactivity associated with the 40-kDa fragment (C-terminal half). Similar experiments with P-32-labeled OPN provided two radiolabeled thrombin fragments, with molecular mass 30 kDa (N-terminal half) and 20 kDa (C-terminal half), both were radioactive. The major phosphorylation was associated with the N-terminal half containing 7.0 mol of phosphate, and 1.9 mol of phosphate were associated with the C-terminal half. Additional experiments of in vitro phosphorylation of OPN and BSP by several other known protein kinases were carried out. cAMP-dependent protein kinase showed no phosphorylation of OPN or ESP, while protein kinase C and cGMP-dependent protein kinase led to minor phosphorylation, each of the latter introduced about 1 mol of phosphate/mol of OPN and BSP molecule.	CHILDRENS HOSP, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital	Salih, E (corresponding author), HARVARD UNIV, SCH MED, DEPT ORTHOPAED SURG, LAB STUDY SKELETAL DISORDERS & REHABIL, BOSTON, MA 02115 USA.			Salih, Erdjan/0000-0003-3322-2323	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR034078] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR34078] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS ATB, 1967, BIOCHEM J, V104, P705, DOI 10.1042/bj1040705; ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; ASHKAR S, 1991, BIOCHEM BIOPH RES CO, P126; CARR C, 1987, BIOCHEMISTRY-US, V26, P7090, DOI 10.1021/bi00396a034; CHENU C, 1994, J BONE MINER RES, V9, P417; COHENSOLAL L, 1979, BIOCHEM J, V177, P81, DOI 10.1042/bj1770081; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DIJIK SW, 1993, J BONE MINER RES, V8, P1499; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; ENDO A, 1989, CONNECT TISSUE RES, V21, P509, DOI 10.3109/03008208909050008; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FLORES ME, 1993, J BONE MINER RES, V8, pS397; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; FRANZEN A, 1985, CHEM BIOL MINERALIZE, P132; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; GOTOH Y, 1990, BIOCHEM BIOPH RES CO, V173, P471, DOI 10.1016/S0006-291X(05)81082-4; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HEINEGARD D, 1989, CONNECT TISSUE RES, V12, P3; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HORTON MA, 1995, ANN NY ACAD SCI, V760, P190, DOI 10.1111/j.1749-6632.1995.tb44630.x; KEMP BE, 1991, PEPTIDES PROTEIN PHO, P43; KINNE RW, 1987, J BIOL CHEM, V262, P10206; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LEE SL, 1981, CALCIFIED TISSUE INT, V33, P385, DOI 10.1007/BF02409461; MIKUNITAKAGAKI Y, 1990, BIOCHEM J, V268, P585, DOI 10.1042/bj2680585; MINTZ KP, 1993, J BONE MINER RES, V8, P985; NAGATA T, 1965, BIOCHEM BIOPH RES CO, P234; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; SALIH E, 1995, ANN NY ACAD SCI, V760, P357, DOI 10.1111/j.1749-6632.1995.tb44656.x; SALIH E, 1996, IN PRESS J BONE MINE; SALIH E, 1996, IN PRESS CONNECT TIS; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SFEIR C, 1995, J BONE MINER RES, V10, P607; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; SORENSEN ES, 1993, J DAIRY RES, V60, P535, DOI 10.1017/S0022029900027886; TANABE J, 1993, J BIOL CHEM, V268, P27143; TAUJON PT, 1991, ADV SEC MESS PHOSPH, P123; UCHIYAMA A, 1986, BIOCHEMISTRY-US, V25, P7572, DOI 10.1021/bi00371a047; UCHIYAMA A, 1985, CHEM BIOL MINERALIZE, P182; Veis A, 1983, BIOMINERALIZATION BI, V240, p[273, 35]; WU CB, 1992, J BIOL CHEM, V267, P16588; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; ZHANG R, 1990, J BIOL CHEM, V265, P15375; [No title captured]	57	51	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16897	16905		10.1074/jbc.271.28.16897	http://dx.doi.org/10.1074/jbc.271.28.16897			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663267	hybrid			2022-12-25	WOS:A1996UX12600072
J	Chroneos, ZC; Abdolrasulnia, R; Whitsett, JA; Rice, WR; Shepherd, VL				Chroneos, ZC; Abdolrasulnia, R; Whitsett, JA; Rice, WR; Shepherd, VL			Purification of a cell-surface receptor for surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALVEOLAR MACROPHAGES; APOPROTEIN SP-A; II CELLS; PULMONARY SURFACTANT; HIGH-AFFINITY; PHOSPHOLIPID SECRETION; MANNOSE RECEPTOR; BINDING PROTEINS; PHAGOCYTOSIS; EXPRESSION	In the present report we have characterized the binding of surfactant protein A (SP-A) to bone marrow-derived macrophages, U937 cells, alveolar macrophages, and type II epithelial cells. The binding of SP-A to all cell types is Ca2+-dependent and trypsin-sensitive, but type II cells express distinct Ca2+-independent binding sites. The binding of SP A to macrophages is independent of known cell surface carbohydrate-specific receptors and of glycoconjugate binding sites on the surface of the cells and is distinct from binding to Clq receptors. Based on ligand blot analysis, both type II cells and macrophages express a 210-kDa SP-A-binding protein. The 210-kDa protein was purified to apparent homogeneity from U937 macrophage membranes using affinity chromatography with noncovalently immobilized surfactant protein A, and was purified from rat lung by differential detergent and salt extraction of isolated rat lung membranes. Polyclonal antibodies against the rat lung SP-A-binding protein inhibit binding of SP-A to both type II cells and macrophages, indicating that the 210-kDa protein is expressed on the cell surface. The polyclonal antibodies also block the SP-A-mediated inhibition of phospholipid secretion by type II cells, indicating that the 210-kDa protein is a functional cell-surface receptor on type II cells. In a separate report we have determined that antibodies to the SP-A receptor block the SP-A-mediated uptake of Mycobacterium bovis, indicating that the macrophage SP-A receptor is involved in SP-A-mediated clearance of pathogens.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PATHOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,NASHVILLE,TN 37203	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Chroneos, ZC (corresponding author), CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229, USA.			, Zissis/0000-0002-9841-7917	NHLBI NIH HHS [HL-28623, 5P50 HL14214-23] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014214, R01HL028623] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARVIEUX J, 1984, BIOCHEM J, V218, P547, DOI 10.1042/bj2180547; BLAU H, 1994, AM J PHYSIOL, V266, pL148, DOI 10.1152/ajplung.1994.266.2.L148; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; Chroneos Z, 1995, AM J PHYSIOL-LUNG C, V269, pL721, DOI 10.1152/ajplung.1995.269.6.L721; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EGGLETON P, 1995, J CLIN INVEST, V95, P1569, DOI 10.1172/JCI117830; ERDEI A, 1988, BIOCHEM J, V255, P493; GEERTSMA MF, 1994, AM J PHYSIOL-LUNG C, V267, pL578, DOI 10.1152/ajplung.1994.267.5.L578; GRIESE M, 1991, AM J PHYSIOL, V261, pL434, DOI 10.1152/ajplung.1991.261.6.L434; GUAN E, 1991, J BIOL CHEM, V266, P20345; GUSTAFSON S, 1991, BIOCHIM BIOPHYS ACTA, V1091, P36, DOI 10.1016/0167-4889(91)90218-M; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311, DOI 10.1177/41.9.8354874; KLOTZ IM, 1986, INTRO BIOMOLECULAR E, P103; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MANZKEINKE H, 1991, EXP CELL RES, V192, P597, DOI 10.1016/0014-4827(91)90081-5; MANZKEINKE H, 1992, EUR J CELL BIOL, V57, P95; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MCNEELY TB, 1994, AM J RESP CELL MOL, V11, P114, DOI 10.1165/ajrcmb.11.1.8018334; MCNEELY TB, 1993, J INFECT DIS, V167, P91, DOI 10.1093/infdis/167.1.91; PISON U, 1992, AM J PHYSIOL, V262, pL412, DOI 10.1152/ajplung.1992.262.4.L412; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; RICE WR, 1986, BRIT J PHARMACOL, V89, P485, DOI 10.1111/j.1476-5381.1986.tb11148.x; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROSS GF, 1987, BIOCHIM BIOPHYS ACTA, V911, P294, DOI 10.1016/0167-4838(87)90070-7; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SHEPHERD VL, 1985, J BIOL CHEM, V260, P160; SHEPHERD VL, 1984, J BIOL CHEM, V259, P2257; SHEPHERD VL, 1990, J IMMUNOL, V145, P1530; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; STEVENS PA, 1995, BIOCHEM J, V308, P77, DOI 10.1042/bj3080077; STRAYER DS, 1993, J BIOL CHEM, V268, P18679; SUWABE A, 1991, AM J RESP CELL MOL, V4, P264, DOI 10.1165/ajrcmb/4.3.264; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; THORKELSSON T, 1992, J HISTOCHEM CYTOCHEM, V40, P643, DOI 10.1177/40.5.1573247; TOWNSEND R, 1981, BIOCHEM J, V194, P209, DOI 10.1042/bj1940209; TSIBILAYR EC, 1983, J HISTOCHEM CYTOCHEM, V31, P1298; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEIKERT L, 1996, AM REV RESPIR DIS, V153, pA130; WEISSBACH S, 1994, AM J PHYSIOL-LUNG C, V267, pL660, DOI 10.1152/ajplung.1994.267.6.L660; WHITSETT JA, 1985, J BIOL CHEM, V260, P5273; WHITSETT JA, 1985, EXP LUNG RES, V9, P135; WINTERGERST E, 1989, EUR J CELL BIOL, V50, P291; WRIGHT JR, 1993, AM J PHYSIOL, V264, pL338, DOI 10.1152/ajplung.1993.264.4.L338; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	59	161	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16375	16383		10.1074/jbc.271.27.16375	http://dx.doi.org/10.1074/jbc.271.27.16375			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663107	hybrid			2022-12-25	WOS:A1996UW35200077
J	Hebert, TE; Moffett, S; Morello, JP; Loisel, TP; Bichet, DG; Barret, C; Bouvier, M				Hebert, TE; Moffett, S; Morello, JP; Loisel, TP; Bichet, DG; Barret, C; Bouvier, M			A peptide derived from a beta(2)-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LINKED RECEPTORS; GROWTH-FACTOR RECEPTOR; PIG CEREBRAL-CORTEX; ADRENERGIC-RECEPTORS; SIGNAL-TRANSDUCTION; LIGAND-BINDING; BETA-2-ADRENERGIC RECEPTOR; MUSCARINIC RECEPTORS; COUPLED RECEPTORS; H-3 HISTAMINE	One of the assumptions of the mobile receptor hypothesis as it relates to G protein-coupled receptors is that the stoichiometry of receptor, G protein, and effector is 1:1:1 (Bourne, H. R,, Sanders, D, A, and McCormick, F, (1990) Nature 348, 125-132), Many studies on the cooperativity of agonist binding are incompatible with this notion and have suggested that both G proteins and their associated receptors can be oligomeric. However, a clear physical demonstration that G protein-coupled receptors can indeed interact as dimers and that such interactions may have functional consequences was lacking, Here, using differential epitope tagging we demonstrate that beta(2)-adrenergic receptors do form SDS-resistant homodimers and that transmembrane domain VI of the receptor may represent part of an interface for receptor dimerization, The functional importance of dimerization is supported by the observation that a peptide derived from this domain that inhibits dimerization also inhibits beta-adrenergic agonist-promoted stimulation of adenylyl cyclase activity. Moreover, agonist stimulation was found to stabilize the dimeric state of the receptor, while inverse agonists favored the monomeric species, which suggests that interconversion between monomeric and dimeric forms may be important for biological activity.	UNIV MONTREAL,DEPT BIOCHIM,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,GRP RECH SYST NERVEUX AUTONOME,MONTREAL,PQ H3C 3J7,CANADA; HOP SACRE COEUR,CTR RECH,MONTREAL,PQ H4J 1C5,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL,PQ H4J 1C5,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal			Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100; BICHET, DANIEL-G/0000-0003-2856-6850				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALI H, 1994, J BIOL CHEM, V269, P24557; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BICHET DG, 1994, AM J HUM GENET, V55, P278; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GARAVITO RM, 1983, J MOL BIOL, V164, P315; GETHER U, 1995, J BIOL CHEM, V270, P28268; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HAMILTON KK, 1993, J BIOL CHEM, V268, P3632; HARRIS HW, 1996, KIDNEY, V1, P516; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERBERG JT, 1985, J BIOL CHEM, V259, P9285; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; KIM SH, 1994, PROTEIN SCI, V3, P159; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MATTERA R, 1985, J BIOL CHEM, V260, P7410; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MONNOT C, 1993, J BIOL CHEM, V271, P1507; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PETERSON GL, 1986, BIOCHEMISTRY-US, V25, P3189, DOI 10.1021/bi00359a017; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; POTTER LT, 1991, MOL PHARMACOL, V39, P211; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHATZ G, 1983, CELL, V32, P316, DOI 10.1016/0092-8674(83)90450-6; SCHREURS J, 1995, J NEUROCHEM, V64, P1622; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHORR RGL, 1981, J BIOL CHEM, V256, P5820; SINKINS WG, 1993, MOL PHARMACOL, V43, P583; SINKINS WG, 1993, MOL PHARMACOL, V43, P569; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Stewart JM, 1984, SOLID PHASE PEPTIDE; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STRANGE PG, 1994, TRENDS PHARMACOL SCI, V15, P317, DOI 10.1016/0165-6147(94)90020-5; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TSCHOPP J, 1984, J BIOL CHEM, V259, P1922; TSCHOPP J, 1982, NATURE, V298, P534, DOI 10.1038/298534a0; VASUDEVAN S, 1995, EUR J BIOCHEM, V227, P466, DOI 10.1111/j.1432-1033.1995.tb20411.x; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	78	639	655	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16384	16392		10.1074/jbc.271.27.16384	http://dx.doi.org/10.1074/jbc.271.27.16384			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663163	hybrid			2022-12-25	WOS:A1996UW35200078
J	Wang, XS; Penzes, P; Napoli, JL				Wang, XS; Penzes, P; Napoli, JL			Cloning of a cDNA encoding an aldehyde dehydrogenase and its expression in Escherichia coli - Recognition of retinal as substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING PROPERTIES; MOUSE-LIVER; ACID; OXIDATION; RAT; IDENTIFICATION; BIOSYNTHESIS; DIVERSITY; CATALYZE; PROTEIN	The biosynthesis of the hormone retinoic acid from retinol (vitamin A) involves two sequential steps, catalyzed by retinol dehydrogenases and retinal dehydrogenases, respectively. This report describes the cloning of a cDNA encoding a heretofore unknown aldehyde dehydrogenase from a rat testis library and its expression in Escherichia coli, This enzyme has been designated retinal dehydrogenase, type II, RalDH(II). The deduced amino acid sequence of RalDH(II) had the highest identity with mammalian aldehyde dehydrogenases that feature low K-m values (mu M) for retinal: human ALDH1 (72.2%), rat retinal dehydrogenase, type I (71.5%), bovine retina (72.7%), and mouse AHD-2 (71.5%). RalDH(II) expressed in E. coli recognizes as substrates free retinal, with a K-m of similar to 0.7 mu M, and cellular retinol-binding protein-bound retinal, with a K-m of similar to 0.2 mu M. RalDH(II) also can utilize as substrate retinal generated in situ by microsomal retinol dehydrogenases, from the physiologically most abundant substrate: retinol bound to cellular retinol-binding protein. Rat testis expresses RalDH(II) mRNA most abundantly, followed by (relative to testis): lung (6.7%), brain (6.3%), heart (5.2%), liver (4.4%), and kidney (2.7%). RalDH(II) does not recognize citral, benzaldehyde, acetaldehyde, and propanal efficiently as substrates, but does metabolize octanal and decanal efficiently. These data support a function for RalDH(II) in the pathway of retinoic acid biogenesis.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Penzes, Peter/L-3987-2016	Penzes, Peter/0000-0001-5449-1640	NATIONAL INSTITUTE ON AGING [R01AG013566] Funding Source: NIH RePORTER; NIA NIH HHS [AG 13566] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; CHEN M, 1994, MOL PHARMACOL, V46, P88; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; FESUS L, 1991, EUR J CELL BIOL, V56, P170; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GODBOUT R, 1992, EXP EYE RES, V54, P297, DOI 10.1016/S0014-4835(05)80219-2; GOSS GD, 1992, CRIT REV CL LAB SCI, V29, P185, DOI 10.3109/10408369209114600; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HSU LC, 1989, GENOMICS, V5, P857, DOI 10.1016/0888-7543(89)90127-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1991, J BIOL CHEM, V266, P3622; LOHNES D, 1992, J CELL SCI, P69; NAPOLI JL, 1995, J STEROID BIOCHEM, V53, P497, DOI 10.1016/0960-0760(95)00096-I; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P228, DOI 10.1016/0304-4165(90)90081-7; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NAPOLI JL, 1990, CHEM BIOL SYNTHETIC, P229; POSCH KC, 1992, J BIOL CHEM, V267, P19676; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; RONGNOPARUT P, 1991, GENE, V101, P261, DOI 10.1016/0378-1119(91)90421-7; SAARI JC, 1995, VISUAL NEUROSCI, V12, P263, DOI 10.1017/S095252380000794X; SATRE MA, 1989, DEV BIOL, V133, P529, DOI 10.1016/0012-1606(89)90055-9; WOLF G, 1984, PHYSIOL REV, V64, P874; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794	34	143	145	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16288	16293		10.1074/jbc.271.27.16288	http://dx.doi.org/10.1074/jbc.271.27.16288			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663198	hybrid			2022-12-25	WOS:A1996UW35200064
J	Carmen, AA; Rundlett, SE; Grunstein, M				Carmen, AA; Rundlett, SE; Grunstein, M			HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL NUCLEAR MATRIX; GENE-EXPRESSION; ZEA-MAYS; ACETYLATION; INVIVO; TRANSCRIPTION; NUCLEOSOMES; CEREVISIAE; CHROMATIN; MARKER	Histone acetylation is maintained through the action of histone acetyltransferases and deacetylases and has been correlated with increased gene activity. To investigate the functional role of these enzymes in the regulation of transcription, we have purified from Saccharomyces cerevisiae two histone deacetylase activities, HDA and HDB, with molecular masses of similar to 350 and 600 kDa, respectively. In vitro, the HDA activity deacetylates all four core histones, has a preference for histone H3, and is strongly inhibited by trichostatin A (a specific inhibitor of histone deacetylases). HDB is considerably less sensitive to trichostatin A. We report the extensive purification of the HDA activity and the identification of peptides (p75, p73, p72, and p71) whose presence correlates with deacetylase activity on native polyacrylamide gels. An antibody to p75 immunoprecipitates peptides with molecular masses similar to those in the 350-kDa complex. Additionally, antibodies to p75 and p71 specifically precipitate histone deacetylase activity and coimmunoprecipitate each other. Gene disruptions of p75 (HDA1) or p71 (HDA3) cause the loss of the 350-kDa (but not the 600-kDa) activity from our chromatography profiles. These data argue strongly that HDA1 and HDA3 are subunits of the HDA complex, which is structurally distinct from the second, HDB complex.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023674, R01GM023674, R01GM042421] Funding Source: NIH RePORTER; NCI NIH HHS [2T32CA-09056] Funding Source: Medline; NIGMS NIH HHS [GM23674, GM42421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANSO WR, 1986, BIOCHIM BIOPHYS ACTA, V866, P161; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; DELPINO MMS, 1994, BIOCHEM J, V303, P723, DOI 10.1042/bj3030723; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; GEORGIEVA EI, 1991, J BIOL CHEM, V266, P18751; GRABHER A, 1994, BIOCHEMISTRY-US, V33, P14887, DOI 10.1021/bi00253a028; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HENDZEL MJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P307, DOI 10.1016/0167-4781(92)90443-4; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KIEFF S, 1995, J BIOL CHEM, V270, P24674; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; LOPEZRODAS G, 1992, FEBS LETT, V296, P82, DOI 10.1016/0014-5793(92)80408-9; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; NELSON DA, 1982, J BIOL CHEM, V257, P1565; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SUN JM, 1992, BIOCHEM CELL BIOL, V70, P822, DOI 10.1139/o92-125; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1991, J CELL SCI, V99, P13; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	36	172	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15837	15844		10.1074/jbc.271.26.15837	http://dx.doi.org/10.1074/jbc.271.26.15837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663039	hybrid			2022-12-25	WOS:A1996UV29900080
J	Gierse, JK; McDonald, JJ; Hauser, SD; Rangwala, SH; Koboldt, CM; Seibert, K				Gierse, JK; McDonald, JJ; Hauser, SD; Rangwala, SH; Koboldt, CM; Seibert, K			A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; PROSTAGLANDIN SYNTHASE; MESSENGER-RNA; EXPRESSION	Nonsteroidal anti-inflammatory drugs (NSAIDs) currently available for clinical use inhibit both COX-1 and COX-2. This suggests that clinically useful NSAIDs inhibit pro-inflammatory prostaglandins (PGs) derived from the activity of COX-2, as well as PGs in tissues like the stomach and kidney (via COX-1), A new class of compounds has recently been developed (SC-58125) that have a high degree of selectivity for the inducible form of cyxlooxygenase (COX-2) over the constitutive form (COX-1). This unique class of compounds exhibit a time-dependent irreversible inhibition of COX-2, while re versibly inhibiting COX-1. The molecular basis of this selectivity was probed by site-directed mutagenesis of the active site of COX-2. The sequence differences in the active site were determined by amino acid replacement of the COX-2 sequences based on the known crystal structure of COX-1, which revealed a single amino acid difference in the active site (valine 509 to isoleucine) and a series of differences at the mouth of the active site. Mutants with the single amino acid substitution in the active site and a combination of three changes in the mouth of the active site were made in human COX-2, expressed in insect cells and purified. The single amino acid change of valine 509 to isoleucine confers selectivity of COX-2 inhibitors in the class of SC-58125 and others of the same class (SC-236, NS-398), while commonly used NSAIDs such as indomethacin showed no change in selectivity. Substitutions of COX-1 sequences in COX-2 at the mouth of the active site of COX-2 did not change the selectivity of SC-58125. This indicates that the single amino acid substitution of isoleucine at position 509 for a valine is sufficient to confer COX-2 selectivity in this example of a diaryl-heterocycle COX inhibitor.			Gierse, JK (corresponding author), MONSANTO SEARLE,SEARLE RES & DEV,700 CHESTERFIELD PKWY N,AA21,CHESTERFIELD,MO 63198, USA.							BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; FU JY, 1990, J BIOL CHEM, V265, P16737; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; HAYNES RC, 1990, GOODMAN GILMANS PHAR, V8, P1431; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JONES DA, 1993, J BIOL CHEM, V268, P9049; KENNEDY BP, 1993, BIOCHEM BIOPH RES CO, V197, P494, DOI 10.1006/bbrc.1993.2506; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1988, J BIOL CHEM, V263, P3022; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SEBOLDT RJ, 1990, P NATL ACAD SCI USA, V87, P6971; TAKAHASHI Y, 1992, BIOCHEM BIOPH RES CO, V182, P443; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	25	345	358	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15810	15814		10.1074/jbc.271.26.15810	http://dx.doi.org/10.1074/jbc.271.26.15810			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663121	hybrid			2022-12-25	WOS:A1996UV29900076
J	Ng, JY; Marians, KJ				Ng, JY; Marians, KJ			The ordered assembly of the phi X174-type primosome .1. Isolation and identification of intermediate protein-DNA complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-Y; ESCHERICHIA-COLI PROTEIN; GENE-PRODUCT; HELICASE; STRAND; PURIFICATION; MECHANISM; ASSOCIATION; DIRECTION; MUTATION	The phi X-type primosome was discovered during the resolution and reconstitution in vitro of the complementary strand DNA replication step of the phi X174 viral life cycle, This multienzyme bidirectional helicase-primase complex can provide the DNA unwinding and Okazaki fragment-priming functions at the replication fork and has been implicated in cellular DNA replication, repair, and recombination. We have used gel mobility shift assays and enhanced chemiluminescence Western analysis to isolate and identify the pathway of primosome assembly at a primosome assembly site (PAS) on a 300-nucleotide-long single-stranded DNA fragment. The first three steps do not require ATP and are as follows: (i) PriA recognition and binding to the PAS, (ii) stabilization of the PriA-PAS complex by the addition of PriB, and (iii) formation of a PriA-PriB-DnaT-PAS complex. Subsequent formation of the preprimosome involves the ATP-dependent transfer of DnaB from a DnaB-DnaC complex to the PriA-PriB-DnaT-PAS complex. The final preprimosomal complex contains PriA, PriB, DnaT, and DnaB but not DnaC. A transient interaction between the preprimosome and DnaG generates the five-protein primosome. As described in an accompanying article (Ng, J. Y., and Marians, K. J. (1996) J. Biol. Chem. 271, 15649-15655), when assembled on intact phi X174 phage DNA, the primosome also contains PriC.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Ng, JY (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1993, J BIOL CHEM, V268, P19204; ALLEN GC, 1993, CELL, V74, P813; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5253; ARAI K, 1981, J BIOL CHEM, V256, P5281; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; GREENBAUM JH, 1984, J BIOL CHEM, V259, P2594; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LARK CA, 1978, J BACTERIOL, V136, P1008, DOI 10.1128/JB.136.3.1008-1017.1978; LARK KG, 1978, CSHSQB, V43, P537; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; LOW RL, 1981, P NATL ACAD SCI-BIOL, V78, P1436, DOI 10.1073/pnas.78.3.1436; LOW RL, 1982, J BIOL CHEM, V257, P6242; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1986, P NATL ACAD SCI USA, V83, P1256, DOI 10.1073/pnas.83.5.1256; MASAI H, 1988, J BIOL CHEM, V263, P15083; MOK M, 1987, J BIOL CHEM, V262, P2304; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Sandler SJ, 1996, MOL MICROBIOL, V19, P871, DOI 10.1046/j.1365-2958.1996.429959.x; Sandler SJ, 1996, GENETICS, V143, P5; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WICKNER S, 1978, SINGLE STRANDED DNA, P255; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; WU CA, 1992, J BIOL CHEM, V267, P4030; ZAVITZ KH, 1991, MOL MICROBIOL, V5, P2869, DOI 10.1111/j.1365-2958.1991.tb01846.x	47	88	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15642	15648		10.1074/jbc.271.26.15642	http://dx.doi.org/10.1074/jbc.271.26.15642			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663104	hybrid			2022-12-25	WOS:A1996UV29900052
J	Qadri, I; Ferrari, ME; Siddiqui, A				Qadri, I; Ferrari, ME; Siddiqui, A			The hepatitis B virus transactivator protein, HBx, interacts with single-stranded DNA (ssDNA) - Biochemical characterizations of the HBx-ssDNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-GENE PRODUCT; BINDING-PROPERTIES; ESCHERICHIA-COLI; TRANS-ACTIVATION; VIRAL ENHANCERS; U6 GENES; REPLICATION; TRANSCRIPTION; PURIFICATION; SPECIFICITY	Human hepatitis B virus X protein, HBx, is widely acknowledged as a transcriptional transactivator. While HBx has been shown to increase gene expression in trans, it is generally believed that it does not bind double-stranded DNA. Using several experimental approaches, we show that HBx interacts with single-stranded DNA in a manner that is not sequence-specific. Various heterologous single-stranded DNA (ssDNA) oligonucleotides were able to compete in HBx-ssDNA interactions in gel shift assays. Escherichia coli non-sequence-specific, single-stranded DNA binding protein, E. coli SSB, displaced the HBx-ssDNA interactions, confirming the ability of HBx to interact with single-stranded DNA in a non-sequence-specific manner. We have further characterized the HBx-ssDNA interactions under various biochemical conditions. These include the effects of mono- and divalent cations, the effect of cardiolipin and heparin, pH and temperature dependence, and variations in the incubation time. HBx bound more tightly to d(pyrimidines)(25) than to d(purines)(25), a property that is characteristic of other single-stranded DNA-binding proteins (SSBs). Collectively the results presented here provide the first evidence of HBx's interaction with ssDNA. The biochemical parameters of these interactions were similar to those of known viral and cellular SSBs.	UNIV COLORADO, DEPT MICROBIOL, PROGRAM MOLEC BIOL, HLTH SCI CTR, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOPHYS, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT GENET, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Qadri, Ishtiaq/0000-0003-4334-0585				BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; HANG X, 1995, J VIROL, V69, P3924, DOI 10.1128/JVI.69.6.3924-3928.1995; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HU KQ, 1990, P NATL ACAD SCI USA, V87, P721; JAMEEL S, 1990, J VIROL, V64, P3963, DOI 10.1128/JVI.64.8.3963-3966.1990; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NASAL M, 1993, TRENDS MICROBIOL, V6, P222; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SETO E, 1991, J VIROL, V65, P2351, DOI 10.1128/JVI.65.5.2351-2356.1991; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WALDSCHMIDT R, 1992, J BIOL CHEM, V267, P16359; WANANDI I, 1993, J BIOL CHEM, V268, P6629; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; ZAHM P, 1988, ONCOGENE, V3, P169	40	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15443	15450		10.1074/jbc.271.26.15443	http://dx.doi.org/10.1074/jbc.271.26.15443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663128	hybrid			2022-12-25	WOS:A1996UV29900024
J	Almaula, N; Ebersole, BJ; Zhang, DQ; Weinstein, H; Sealfon, SC				Almaula, N; Ebersole, BJ; Zhang, DQ; Weinstein, H; Sealfon, SC			Mapping the binding site pocket of the serotonin 5-hydroxytryptamine(2A) receptor - Ser(3.36(159)) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; LIGAND-BINDING; DIRECTED MUTAGENESIS; IDENTIFICATION; RESIDUES; ACTIVATION; MUTATION; PROTEINS; SERINE; ROLES	Like other amine neurotransmitters that activate G-protein coupled receptors, 5-hydroxytryptamine (5-HT) binds to the 5-HT2A receptor through the interaction of its cationic primary amino group with the conserved Asp(3.32(155)) in transmembrane helix 3. Computational experiments with a 5-HT2A receptor model suggest that the same functional group of B-hydroxytryptamine also forms a hydrogen bond with the side chain of Ser(3.36(159)), which is adjacent in space to Asp(3.32(155)), However, other 5-HT2A receptor ligands like lysergic acid diethylamide (LSD), in which the amine nitrogen is embedded in a heterocycle, or N,N-dimethyl 5-HT, in which the side chain is a tertiary amine, are found in the computational simulations to interact with the aspartate but not with the serine, due mainly to steric hindrance, The predicted difference in the interaction of various ligands in the same receptor binding pocket was tested with site directed mutagenesis of Ser(3.36(159)) --> Ala and Ser(3.36(159)) --> Cys, The alanine substitution led to an 18-fold reduction in 5-HT affinity and the cysteine substitution to an intermediate 5-fold decrease, LSD affinity, in contrast, was unaffected by either mutation, N,N-Dimethyl 5-HT affinity was unaffected by the cysteine mutation and had a comparatively small 3-fold decrease in affinity for the alanine mutant, These findings identify a mode of ligand-receptor complexation that involves two receptor side chains interacting with the same functional group of specific serotonergic ligands, This interaction serves to orient the ligands in the binding pocket and may influence the degree of receptor activation.	MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA; MT SINAI SCH MED, DEPT ANESTHESIOL, NEW YORK, NY 10029 USA; MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA; MT SINAI SCH MED, DEPT NEUROL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai			WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818; SEALFON, Stuart/0000-0001-5791-1217	NIDA NIH HHS [R01 DA09088, T32 DA07135, R01 DA09083] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135, R01DA009088, R01DA009083] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHOUDHARY MS, 1992, MOL PHARMACOL, V42, P627; CHOUDHARY MS, 1995, MOL PHARMACOL, V47, P450; CHOUDHARY MS, 1993, MOL PHARMACOL, V43, P755; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Glennon R. A., 1991, SEROTONIN RECEPTOR S, P19; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; JOHNSON MP, 1994, MOL PHARMACOL, V45, P277; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO XC, 1994, PROTEIN ENG, V7, P1441, DOI 10.1093/protein/7.12.1441; SALTZMAN AG, 1991, BIOCHEM BIOPH RES CO, V181, P1469, DOI 10.1016/0006-291X(91)92105-S; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P16470; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WANG CD, 1993, MOL PHARMACOL, V43, P931; WANG CD, 1991, MOL PHARMACOL, V40, P168; ZHANG DQ, 1994, FEBS LETT, V337, P207, DOI 10.1016/0014-5793(94)80274-2; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021; ZHANG DQ, 1993, MED CHEM RES, V3, P357	25	125	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14672	14675		10.1074/jbc.271.25.14672	http://dx.doi.org/10.1074/jbc.271.25.14672			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663249	hybrid			2022-12-25	WOS:A1996UT10600007
J	Fass, SH; Engels, JW				Fass, SH; Engels, JW			Influence of specific signal peptide mutations on the expression and secretion of the alpha-amylase inhibitor tendamistat in Streptomyces lividans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; ENDOPLASMIC-RETICULUM MEMBRANE; CHARGED AMINO-ACIDS; ESCHERICHIA-COLI; RECOGNITION PARTICLE; PROTEIN TRANSLOCATION; NUCLEOTIDE-SEQUENCE; PRESECRETORY PROTEINS; EFFICIENT SECRETION; POSITIVE CHARGE	The Streptomyces alpha-amylase inhibitor tendamistat is secreted by a signal peptide with an amino-terminal charge of +3. To elucidate the influence of the charged residues on protein secretion in Streptomyces, the amino-terminal charge was varied from +6 to neutral net charge. The effects of charge variation were analyzed in combination with three Streptomyces promoters and two transcriptional terminators, Introduction of additional positive charges significantly decreased the amount of secreted tendamistat. On the contrary, a charge reduction to +2 resulted in the doubling of inhibitor production. After exclusion of transcriptional effects, the observed alterations of inhibitor secretion by the mutants with a charge of +6 to +2 were attributed to a modulation of precursor synthesis, Furthermore, a tight coupling of synthesis and export was stated, Charge reduction to +1 or neutral charge generally reduced the yield of secreted tendamistat, yet remarkable differences were found for mutants with identical net charge. Elimination of the positive charge at a defined position resulted in the release of tendamistat precursor protein, which suggested a specific uncoupling of synthesis and translocation.	UNIV FRANKFURT,INST ORGAN CHEM,D-60439 FRANKFURT,GERMANY	Goethe University Frankfurt			Engels, Joachim W/A-9224-2012					AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANNE J, 1993, FEMS MICROBIOL LETT, V114, P121, DOI 10.1016/0378-1097(93)90507-X; ARKOWITZ RA, 1994, BBA-REV BIOMEMBRANES, V1197, P311; BENDER E, 1989, THESIS JW GOETHE U F; BENSON SA, 1987, J BACTERIOL, V169, P4686, DOI 10.1128/jb.169.10.4686-4691.1987; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERGMEYER HU, 1970, METHODEN ENZYMATISCH, V1, P394; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BIBB MJ, 1985, GENE, V38, P215, DOI 10.1016/0378-1119(85)90220-3; BORCHERT TV, 1991, J BACTERIOL, V173, P276, DOI 10.1128/jb.173.1.276-282.1991; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; Brawner M, 1991, Curr Opin Biotechnol, V2, P674, DOI 10.1016/0958-1669(91)90033-2; BURNETT WV, 1987, NUCLEIC ACIDS RES, V15, P3926, DOI 10.1093/nar/15.9.3926; CHEN M, 1994, J BACTERIOL, V176, P5796, DOI 10.1128/JB.176.18.5796-5801.1994; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN J, 1985, CELL, V43, P351, DOI 10.1016/0092-8674(85)90040-6; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; ENGELS JW, 1992, TRANSGENESIS, P31; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HALL MN, 1983, EMBO J, V2, P15, DOI 10.1002/j.1460-2075.1983.tb01373.x; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Hopwood D. A., 1985, GENETIC MANIPULATION; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; IBRAHIMI IM, 1986, EUR J BIOCHEM, V155, P571, DOI 10.1111/j.1432-1033.1986.tb09526.x; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; JONES JD, 1990, J BIOENERG BIOMEMBR, V22, P213, DOI 10.1007/BF00763166; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KIM H, 1994, MOL MICROBIOL, V11, P819, DOI 10.1111/j.1365-2958.1994.tb00360.x; KOLLER KP, 1989, J BACTERIOL, V171, P4953, DOI 10.1128/jb.171.9.4953-4957.1989; KOLLER KP, 1984, 3RD P EUR C BIOT MUN, V3, P273; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LEHNHARDT S, 1988, J BIOL CHEM, V263, P10300; LONG CM, 1987, J BACTERIOL, V169, P5745, DOI 10.1128/jb.169.12.5745-5754.1987; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OKUN MM, 1992, J BIOL CHEM, V267, P11476; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; PULIDO D, 1987, NUCLEIC ACIDS RES, V15, P4227, DOI 10.1093/nar/15.10.4227; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RAPOPORT TA, 1991, NATURE, V349, P107, DOI 10.1038/349107a0; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLENSTEDT G, 1992, J BIOL CHEM, V267, P24328; SCHMITTJOHN T, 1992, APPL MICROBIOL BIOT, V36, P493; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; TANJI Y, 1991, J BACTERIOL, V173, P1997, DOI 10.1128/jb.173.6.1997-2005.1991; VERTESY L, 1984, EUR J BIOCHEM, V141, P505, DOI 10.1111/j.1432-1033.1984.tb08221.x; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; YAMAMOTO Y, 1987, BIOCHEM BIOPH RES CO, V149, P431, DOI 10.1016/0006-291X(87)90385-8	69	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15244	15252						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662986				2022-12-25	WOS:A1996UT10600087
J	Hirschberg, K; Zisling, R; vanEchtenDeckert, G; Futerman, AH				Hirschberg, K; Zisling, R; vanEchtenDeckert, G; Futerman, AH			Ganglioside synthesis during the development of neuronal polarity - Major changes occur during axonogenesis and axon elongation, but not during dendrite growth or synaptogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; HIPPOCAMPAL-NEURONS; BRAIN GANGLIOSIDES; RAT-LIVER; CULTURE; BIOSYNTHESIS; DIFFERENTIATION; NEURITOGENESIS; SPHINGOLIPIDS; LOCALIZATION	Changes in the levels and types of gangliosides occur during neuronal differentiation and development, but no studies have correlated these changes with defined events in neuronal morphogenesis. Here, we have analyzed the relationship between ganglioside synthesis and the development of axons and dendrites in polarized neurons, using hippocampal neurons cultured in such a way that axons and dendrites are generated by a defined sequence of events and in which there is virtu ally no contamination by glial cells, Neurons were la beled with [4,5-H-3]dihydrosphingosine, which was rapidly incorporated into cells and metabolized to H-3-labeled glycosphingolipids, The rate of H-3-labeled glycosphingolipid synthesis was directly proportional to the initial rate of [4,5-H-3]dihydrosphingosilae uptake and was linear versus time for up to 9 h of incubation, The major changes in H-3-labeled ganglioside synthesis occurred during the period of axonogenesis and rapid axon growth, During axonogenesis, there was a significant increase in the synthesis of complex gangliosides (i.e. G(m1), G(D1a), G(D1b), and G(T1b)) with a corresponding reduction in the synthesis of glucosylceramide and ganglioside G(D3). During the stage of rapid axon growth, the ratio of a- to b-series gangliosides increased significantly, However, during dendritogenesis, dendrite growth, and synaptogenesis, there was little change in ganglioside synthesis, with a small and gradual increase in the ratio of a- to b-series gangliosides and an increase in the synthesis of gangliosides G(D1a) and G(T1b). These results indicate that despite major changes in neuronal morphology and functionality as neurons mature, changes in ganglioside synthesis are restricted to early stages of neuronal development, namely axonogenesis and rapid axon elongation.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL; UNIV BONN, INST ORGAN CHEM & BIOCHEM, D-53121 BONN, GERMANY	Weizmann Institute of Science; University of Bonn			Hirschberg, Koret/AAF-4566-2019	Futerman, Anthony/0000-0003-0013-0115				ARIGA T, 1995, BIOCHEMISTRY-US, V34, P11500, DOI 10.1021/bi00036a024; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES A, 1986, J NEUROSCI, V6, P714; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, J CELL SCI, P75; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FURUYA S, 1994, J BIOL CHEM, V269, P32418; FUTERMAN AH, 1994, CURR TOP MEMBR, V40, P93, DOI 10.1016/S0070-2161(08)60978-8; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; Goslin K., 1991, CULTURING NERVE CELL, P251; HAREL R, 1993, J BIOL CHEM, V268, P14476; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; LEDEEN RW, 1992, TRENDS GLYCOSCI GLYC, V4, P174; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; OHSAWA T, 1989, MECH AGEING DEV, V50, P169, DOI 10.1016/0047-6374(89)90012-2; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; Radin N S, 1981, Methods Enzymol, V72, P673; RIBONI L, 1990, NEUROCHEM RES, V15, P1175, DOI 10.1007/BF01208577; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; ROSENBERG A, 1992, J BIOL CHEM, V267, P10607; ROSENBERG A, 1989, J NEUROSCI RES, V24, P531, DOI 10.1002/jnr.490240411; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SIEGEL DA, 1994, J NEUROCHEM, V62, P1852; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; VALSECCHI M, 1993, J NEUROCHEM, V60, P193, DOI 10.1111/j.1471-4159.1993.tb05837.x; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WANG E, 1991, J BIOL CHEM, V266, P14486; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; Yu R.K., 1989, NEUROBIOLOGY GLYCOCO, P1; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	39	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14876	14882		10.1074/jbc.271.25.14876	http://dx.doi.org/10.1074/jbc.271.25.14876			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663007				2022-12-25	WOS:A1996UT10600038
J	Reddy, LG; Jones, LR; Pace, RC; Stokes, DL				Reddy, LG; Jones, LR; Pace, RC; Stokes, DL			Purified, reconstituted cardiac Ca2+-ATPase is regulated by phospholamban but not by direct phosphorylation with Ca2+/calmodulin-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; BETA-ADRENERGIC STIMULATION; CALCIUM-TRANSPORT; CA-2+ PUMP; DEPENDENT PHOSPHORYLATION; CA2+ UPTAKE; ATPASE; PURIFICATION; MUSCLE; MECHANISM	Regulation of calcium transport by sarcoplasmic reticulum provides increased cardiac contractility in response to beta-adrenergic stimulation. This is due to phosphorylation of phospholamban by cAMP-dependent protein kinase or by calcium/calmodulin-dependent protein kinase, which activates the calcium pump (Ca2+-ATPase), Recently, direct phosphorylation of Ca2+-ATPase by calcium/calmodulin-dependent protein kinase has been proposed to provide additional regulation. To investigate these effects in detail, we have purified Ca2+-ATPase from cardiac sarcoplasmic reticulum using affinity chromatography and reconstituted it with purified, recombinant phospholamban, The resulting proteoliposomes had high rates of calcium transport, which was tightly coupled to ATP hydrolysis (similar to 1.7 calcium ions transported per ATP molecule hydro lyzed). Co-reconstitution with phospholamban suppressed both calcium uptake and ATPase activities by similar to 50%, and this suppression was fully relieved by a phospholamban monoclonal antibody or by phosphorylation either with cAMP-dependent protein kinase or with calcium/calmodulin-dependent protein kinase, These effects were consistent with a change in the apparent calcium affinity of Ca2+-ATPase and not with a change in V-max. Neither the purified, reconstituted cardiac Ca2+-ATPase nor the Ca2+-ATPase in longitudinal cardiac sarcoplasmic reticulum vesicles was a substrate for calcium/calmodulin-dependent protein kinase, and accordingly, we found no effect of calcium/calmodulin-dependent protein kinase phosphorylation on V-max for calcium transport.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,DEPT MED,INDIANAPOLIS,IN 46202; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016	Indiana University System; Indiana University-Purdue University Indianapolis; University of Minnesota System; University of Minnesota Twin Cities; New York University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807, R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48807, HL28556, HL06308] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BIDLACK JM, 1982, J BIOL CHEM, V257, P4501; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; EDES I, 1989, MEMBRANE BIOCHEM, V7, P175; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HIDALGO C, 1978, J BIOL CHEM, V253, P6879; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; INUI M, 1986, J BIOL CHEM, V261, P1794; JAKAB G, 1988, BIOCHEMISTRY-US, V27, P3799, DOI 10.1021/bi00410a042; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1977, J BIOL CHEM, V252, P3315; JONES LR, 1981, BIOCHIM BIOPHYS ACTA, V641, P242, DOI 10.1016/0005-2736(81)90588-5; JONES LR, 1981, J BIOL CHEM, V256, P1809; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIRCHBERGER MA, 1982, J BIOL CHEM, V257, P5685; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LEVITSKY DO, 1976, BIOCHIM BIOPHYS ACTA, V443, P468, DOI 10.1016/0005-2787(76)90510-4; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; NAKAMURA J, 1983, J BIOL CHEM, V258, P5079; PLANK B, 1983, BIOCHIM BIOPHYS ACTA, V732, P99, DOI 10.1016/0005-2736(83)90191-8; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; SZYMANSKA G, 1990, MEMBRANE BIOCHEM, V9, P1; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TATULIAN SA, 1995, BIOCHEMISTRY-US, V34, P4448, DOI 10.1021/bi00013a038; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VANWINKLE WB, 1978, J BIOL CHEM, V253, P8671; VOSS J, 1994, BIOPHYS J, V67, P190, DOI 10.1016/S0006-3495(94)80469-2; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YAO Q, 1993, BIOPHYS J, V64, pA305	57	91	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14964	14970		10.1074/jbc.271.25.14964	http://dx.doi.org/10.1074/jbc.271.25.14964			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663079	hybrid			2022-12-25	WOS:A1996UT10600051
J	Moore, AN; Waxham, MN; Dash, PK				Moore, AN; Waxham, MN; Dash, PK			Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE EARLY GENES; NUCLEAR FACTOR CREB; C-FOS; CYCLIC-AMP; RECEPTOR ACTIVATION; SYNAPTIC PLASTICITY; INDUCED SEIZURES; MESSENGER-RNA; SPINAL-CORD; KINASE-II	Activity-mediated gene expression is thought to play an important role in many forms of neuronal plasticities. We have used pentylenetetrazol-induced seizure that produces synchronous and sustained neuronal activity as a model to examine the mechanism(s) of gene activation. The transcription factor CREB (Ca2+/cAMP response element-binding protein) is thought to be necessary for long-term memory formation both in invertebrates and vertebrates. When phosphorylated on Ser(133) either by cAMP-dependent protein kinase and/or Ca2+/calmodulin-dependent protein kinases, CREB increases transcription of genes containing the CRE (cAMP response element) sequence. Using an antibody that detects Ser(133)-phosphorylated CREB protein, we show that CREB phosphorylation is maximal between 3 and 8 min after the onset of seizure activity and declines slowly both in the hippocampus and the cortex. The total amount of CREB protein did not change at the time points examined. The increased phosphorylation of CREB protein is preceded by an increase in the amount of cAMP, suggestive of cAMP-dependent protein kinase activation, in the hippocampus and activation of Ca2+/calmodulin-dependent protein kinases in the cortex. Subsequent to CREE phosphorylation, the expression of the CRE-containing gene, c-fos, and the AP-1 complexes (heterodimers of Fos and Jun family members) is increased. These findings support the role of CREB-mediated gene expression in activity-dependent neuronal plasticities.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77225	University of Texas System; University of Texas Health Science Center Houston				Waxham, M. Neal/0000-0003-4801-1190	NIMH NIH HHS [MH49962] Funding Source: Medline; NINDS NIH HHS [NS01509] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001509] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ANOKHIN KV, 1991, BRAIN RES, V544, P101, DOI 10.1016/0006-8993(91)90890-8; ARONOWSKI J, 1992, J NEUROCHEM, V58, P1743, DOI 10.1111/j.1471-4159.1992.tb10049.x; BACSKAI BJ, 1995, NEURON, V14, P19, DOI 10.1016/0896-6273(95)90237-6; BEAR MF, 1990, J NEUROSCI, V10, P909; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BROWNING RA, 1990, EPILEPSY RES, V6, P1, DOI 10.1016/0920-1211(90)90002-D; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; COTMAN CW, 1984, SCIENCE, V225, P1287, DOI 10.1126/science.6382610; CURRAN T, 1987, ONCOGENE, V2, P79; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DASH PK, 1993, CELL MOL BIOL, V39, P35; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FIELDS RD, 1991, J NEUROSCI, V11, P134; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; Harlow E., 1988, ANTIBODIES LAB MANUA; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HERDEGEN T, 1993, J COMP NEUROL, V333, P271, DOI 10.1002/cne.903330212; HOFFLER JP, 1988, SCIENCE, V242, P1430; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; KEELY SL, 1975, J BIOL CHEM, V250, P4832; KIM KS, 1993, J BIOL CHEM, V268, P15689; KOLB SJ, 1995, J NEUROCHEM, V64, P2147; KONRADI C, 1994, J NEUROSCI, V14, P5623; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MATHEWS RP, 1994, MOL CELL BIOL, V14, P6107; MCNAUGHTON BL, 1983, NEUROBIOLOGY HIPPOCA, P233; MELLO CV, 1992, P NATL ACAD SCI USA, V89, P6818, DOI 10.1073/pnas.89.15.6818; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SANNA E, 1995, MOL PHARMACOL, V47, P213; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENBERG JL, 1989, NEURON, V4, P477; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; WAXHAM MN, 1989, J BIOL CHEM, V264, P7477; White J D, 1987, Brain Res, V427, P21; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	73	125	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14214	14220		10.1074/jbc.271.24.14214	http://dx.doi.org/10.1074/jbc.271.24.14214			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662977	hybrid			2022-12-25	WOS:A1996UQ66000043
J	Schubart, UK; Yu, JH; Amat, JA; Wang, ZQ; Hoffmann, MK; Edelmann, W				Schubart, UK; Yu, JH; Amat, JA; Wang, ZQ; Hoffmann, MK; Edelmann, W			Normal development of mice lacking metablastin (P19), a phosphoprotein implicated in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAGE-SPECIFIC EXPRESSION; NEURON-ENRICHED PHOSPHOPROTEIN; MULTIPLE SIGNAL-TRANSDUCTION; HAMSTER INSULINOMA CELLS; DEPENDENT PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; GENE FAMILY; PHYLOGENETIC CONSERVATION; RAPID PHOSPHORYLATION; DISTINCT PATTERNS	Metablastin, also called pig, stathmin, prosolin, Lap18, and oncoprotein18, is a highly conserved cytosolic protein that undergoes extracellular factor- and cell cycle-regulated serine phosphorylation and developmentally regulated expression in mammals. It has been implicated in a variety of cellular functions including growth and differentiation, and recent evidence suggests an involvement in cell cycle control. To explore its potential role in mammalian development, we have disrupted the gene encoding metablastin by gene targeting in mice. The metablastin null mutants have no overt phenotype regarding development, growth rate, behavior, T cell maturation, or fertility and do not exhibit an increased predisposition to tumors. SCG10, a protein closely related in structure to metablastin, shows no compensatory up-regulation in metablastin(-/-) mice. Although the data suggest that metablastin is not essential for mammalian development, the knockout mice should prove valuable in exploring the role of this protein in cell cycle regulation.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,BRONX,NY 10461; NEW YORK MED COLL,DEPT IMMUNOL,VALHALLA,NY 10595	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York Medical College	Schubart, UK (corresponding author), ALBERT EINSTEIN COLL MED,DEPT MED,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NINDS NIH HHS [R01 NS26333] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026333] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; AMAT JA, 1990, MOL REPROD DEV, V26, P383, DOI 10.1002/mrd.1080260414; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; COOPER HL, 1989, J IMMUNOL, V143, P956; COOPER HL, 1991, J IMMUNOL, V146, P3689; COOPER HL, 1990, J IMMUNOL, V145, P1205; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANNECKER G, 1991, J IMMUNOL, V146, P2083; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; FERRARI AC, 1990, GENE CHROMOSOME CANC, V2, P125, DOI 10.1002/gcc.2870020208; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HANASH SM, 1988, J BIOL CHEM, V263, P12813; JOHNSON WEB, 1995, FEBS LETT, V364, P309; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LUO XN, 1994, J BIOL CHEM, V269, P10312; LUO XN, 1991, J BIOL CHEM, V266, P21004; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MARKLUND U, 1994, J BIOL CHEM, V269, P30628; MAUCUER A, 1990, FEBS LETT, V264, P275, DOI 10.1016/0014-5793(90)80266-L; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MOCK BA, 1993, MAMM GENOME, V4, P461, DOI 10.1007/BF00296823; OKAZAKI T, 1993, GENOMICS, V18, P360, DOI 10.1006/geno.1993.1477; OKAZAKI T, 1993, FEBS LETT, V336, P8, DOI 10.1016/0014-5793(93)81598-T; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROOS G, 1993, LEUKEMIA, V7, P1538; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUBART UK, 1982, J BIOL CHEM, V257, P2231; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUBART UK, 1988, J BIOL CHEM, V263, P12156; SCHUBART UK, 1986, ENDOCRINOLOGY, V119, P1741, DOI 10.1210/endo-119-4-1741; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; STRAHLER JR, 1992, J IMMUNOL, V149, P1191; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; ZHU XX, 1989, J BIOL CHEM, V264, P14556	60	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14062	14066		10.1074/jbc.271.24.14062	http://dx.doi.org/10.1074/jbc.271.24.14062			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662897	hybrid			2022-12-25	WOS:A1996UQ66000022
J	Takahashi, Y; Yamaguchi, M; Hirose, F; Cotterill, S; Kobayashi, J; Miyajima, S; Matsukage, A				Takahashi, Y; Yamaguchi, M; Hirose, F; Cotterill, S; Kobayashi, J; Miyajima, S; Matsukage, A			DNA replication-related elements cooperate to enhance promoter activity of the Drosophila DNA polymerase a 73-kDa subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; PRIMASE COMPLEX; ALPHA-PRIMASE; BUDDING YEAST; EXPRESSION; PROTEIN; MELANOGASTER; CYCLE	An analysis was carried out on the promoter region of the Drosophila DNA polymerase alpha 73-kDa subunit gene and the factor(s) activating the promoter. Transcription initiation sites were newly identified in the region downstream of the previously determined sites. Full promoter activity resided within the region from -285 to +129 base pairs with respect to the newly determined major site. Within this region, we found three sequences identical or similar to the DNA replication-related element (DRE), 5'-TATCGATA, which is known as a common promoter-activating element for the Drosophila DNA polymerase a 180-kDa subunit gene and the proliferating cell nuclear antigen gene. These sites were located at positions -77 to -70 (DRE alpha-I), -44 to -37 (DRE alpha-Il), and +3 to +10 (DRE alpha-LZI). Footprinting analysis using the recombinant DRE-binding factor (DREF) or Kc cell nuclear extract demonstrated that DREF can bind to all three DRE-related sites. Introduction of mutation in even one of the three DRE-related sequences caused extensive reductions of the promoter activity and also the DREF-binding activity of the promoter-containing fragment. The results indicate that the three DREF-binding sites cooperate to enhance promoter activity of the DNA polymerase alpha 73-kDa subunit gene.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; MIE UNIV,FAC ENGN,LAB MOL BIOENGN,TSU,MIE 514,JAPAN; MARIE CURIE RES INST,OXTED RH8 OTL,SURREY,ENGLAND	Aichi Cancer Center; Mie University				Yamaguchi, Masamitsu/0000-0002-6321-9750				ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTERILL S, 1992, NUCLEIC ACIDS RES, V20, P4325, DOI 10.1093/nar/20.16.4325; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; HAO XF, 1995, J CELL SCI, V108, P2945; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; LI R, 1993, P NATL ACAD SCI USA, V90, P3554; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PEARSON BE, 1991, MOL CELL BIOL, V11, P2296; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1986, J BIOL CHEM, V261, P7958; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773	35	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14541	14547		10.1074/jbc.271.24.14541	http://dx.doi.org/10.1074/jbc.271.24.14541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662923	hybrid			2022-12-25	WOS:A1996UQ66000089
J	Follesa, P; Ticku, MK				Follesa, P; Ticku, MK			Chronic ethanol-mediated up-regulation of the N-methyl-D-aspartate receptor polypeptide subunits in mouse cortical neurons in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONOPHORE COMPLEX; BRAIN	The goal of this study was to determine whether chronic ethanol-mediated up-regulation of the N-methyl-D-aspartate receptors (NMDAR) was associated with an augmentation of the NMDAR polypeptide subunits in the mammalian cortical neurons. The results show that chronic ethanol treatment produced an increase in the R1 and R2B polypeptide subunits. The R2A subunit was not expressed in these neurons. Chronic NMDAR antagonist ((+)-3-2-(carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP)) treatment also increased the R1 and R2B polypeptide subunits. A similar increase was observed when ethanol and CPP were used in combination. Binding studies using [H-3]MK-801 ((+)-5-methyl-10,11-dihydro -5H-dibenzo[a,d]cyclophenptan-5,10-imine maleate), a noncompetitive NMDAR antagonist, confirmed that concomitant exposure of ethanol and CPP up-regulated the NMDAR. Our results demonstrate for the first time that chronic ethanol treatment increased the NMDA receptor polypeptide subunit synthesis and that it was associated with an increase in [H-3]MK-801 binding sites.	UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio			Follesa, Paolo/K-5416-2015	Follesa, Paolo/0000-0003-4857-476X	NIAAA NIH HHS [AA10552] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010552] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Follesa P, 1996, J NEUROSCI, V16, P2172; FOLLESA P, 1995, MOL BRAIN RES, V29, P99, DOI 10.1016/0169-328X(94)00235-7; GODFREY EW, 1975, BRAIN RES, V90, P1, DOI 10.1016/0006-8993(75)90679-4; GULYA K, 1991, BRAIN RES, V547, P129; HU XJ, 1995, MOL BRAIN RES, V30, P347, DOI 10.1016/0169-328X(95)00019-O; Hu XJ, 1996, MOL BRAIN RES, V36, P211, DOI 10.1016/0169-328X(95)00223-F; KRANZLER HR, 1995, HDB EXP PHARM, V114, P75; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MASOOD K, 1994, MOL PHARMACOL, V45, P324; MHATRE MC, 1992, MOL PHARMACOL, V42, P415; SANNA E, 1993, ALCOHOL CLIN EXP RES, V17, P115, DOI 10.1111/j.1530-0277.1993.tb00735.x; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SNELL LD, 1993, BRAIN RES, V602, P91, DOI 10.1016/0006-8993(93)90246-J; TREVISAN L, 1994, J NEUROCHEM, V62, P1635; WILLIAMS K, 1992, MOL PHARMACOL, V42, P147; ZHONG J, 1994, MOL PHARMACOL, V45, P846	17	124	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13297	13299		10.1074/jbc.271.23.13297	http://dx.doi.org/10.1074/jbc.271.23.13297			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8663153	hybrid			2022-12-25	WOS:A1996UP38500002
J	Cox, D; Chang, P; Kurosaki, T; Greenberg, S				Cox, D; Chang, P; Kurosaki, T; Greenberg, S			Syk tyrosine kinase is required for immunoreceptor tyrosine activation motif-dependent actin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-RECEPTOR; PHAGOCYTOSIS; NEUTROPHILS; LEUKOCYTES; SUBUNIT; CHAIN	Clustering of several multisubunit receptors on hematopoetic cells results in a signaling cascade involving the phosphorylation of immunoreceptor tyrosine activation motifs, or ''ITAMs,'' and actin polymerization. Recent experiments indicate that direct clustering of the ITAM-binding protein, p72(syk) (Syk), is capable of transmitting a phagocytic signal in COS cells (Greenberg, S., Chang, P., Wang, D., Xavier, R., and Seed, B. (1996) Proc. Natl. Acad. Sci. U. S. A, 93, 1103-1107). However, the possibility of redundant signaling pathways makes it difficult to test the requirement for Syk in ITAM-dependent actin polymerization in hematopoetic cells. We developed a model system to study ITAM dependent actin assembly. DT40 lymphocytes were transfected with fusion proteins encoding the transmembrane and cytosolic domains of the ITAM-containing gamma subunit of Fc receptors. Clustering the gamma-containing fusion proteins with IgG-coated erythrocytes triggered submembranous actin assembly. This response depended on an intact ITAM, was absent in cell lines that had been engineered to lack Syk, and was augmented in cell lines that stably overexpressed Syk. These experiments demonstrate an absolute requirement for Syk tyrosine kinase in ITAM-dependent actin assembly in transfected lymphocytes.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DIV PULM,NEW YORK,NY 10032; LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,NEW YORK,NY 10965; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Columbia University; Columbia University; Yale University			Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Cox, Dianne/0000-0002-0591-9767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054164] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02641, HL54164] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DARBY C, 1994, J IMMUNOL, V152, P5429; EDBERG JC, 1992, J IMMUNOL METHODS, V148, P179, DOI 10.1016/0022-1759(92)90171-O; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; GREENBERG S, 1993, J EXP MED, V177, P539; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUTCHINSON MJ, 1995, EUR J IMMUNOL, V25, P481, DOI 10.1002/eji.1830250226; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MICHL J, 1983, J EXP MED, V157, P1746, DOI 10.1084/jem.157.6.1746; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PARK JG, 1993, J CLIN INVEST, V92, P2073, DOI 10.1172/JCI116804; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; REDMOND T, 1993, CELL MOTIL CYTOSKEL, V26, P7, DOI 10.1002/cm.970260103; SALMON JE, 1991, J IMMUNOL, V146, P997; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; SHEETZ MP, 1992, CELL MOTIL CYTOSKEL, V22, P160, DOI 10.1002/cm.970220303; SHETERLINE P, 1984, EUR J CELL BIOL, V34, P80; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	39	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16597	16602		10.1074/jbc.271.28.16597	http://dx.doi.org/10.1074/jbc.271.28.16597			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663235	hybrid			2022-12-25	WOS:A1996UX12600029
J	Niviere, V; Fieschi, F; Decout, JL; Fontecave, M				Niviere, V; Fieschi, F; Decout, JL; Fontecave, M			Is the NAD(P)H:flavin oxidoreductase from Escherichia coli a member of the ferredoxin-NADP(+) reductase family? Evidence for the catalytic role of serine 49 residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-SULFITE REDUCTASE; AMINO-ACID SEQUENCE; FLAVIN REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; IDENTIFICATION; MUTAGENESIS; ENZYME; DOMAIN; LIVER; GENE	The NAD(P)H:flavin oxidoreductase from Escherichia coli, Fre, is a monomer of 26.1 kDa which catalyzes the reduction of free flavins by NADPH or NADH. The flavin reductase Fre is the prototype of a new class of flavin reductases able to transfer electrons with no prosthetic group. It has been suggested that the flavin reductase could belong to the ferredoxin-NADP(+) reductase (FNR) family, on the basis of limited sequence homologies. A sequence, conserved within the ferredoxin-NADP(+) reductase family and present in the flavin reductase, is important for recognition of the isoalloxazine ring, Within this sequence, we have mutated serine 49 of the flavin reductase into alanine or threonine. k(cat) value of the S49A mutant was 35-fold lower than k(cat) of the wildtype enzyme. Determination of real K-d values for NADPH and lumichrome, a flavin analog, showed that recognition of the flavin is strongly affected by the S49A mutation, whereas affinity for the nicotinamide cofactor is only weakly modified. This suggests that serine 49 is involved in the binding of the isoalloxazine ring. Moreover, the K-d value for 5-deazariboflavin, in which the N-5 position of the isoalloxazine ring has been changed to a carbon atom, is not affected by the serine 49 to alanine mutation. This is consistent with the concept that the N-5 position is the main site for serine 49-flavin interaction. In the ferredoxin-NADP(+) reductase family, the equivalent serine residue, which has been shown to be essential for activity, is hydrogen-bonded to the N-5 of the FAD cofactor. Taken together, these data provide the first experimental support to the hypothesis that the flavin reductase Fre may belong to the ferredoxin-NADP(+) reductase family.	UNIV GRENOBLE 1, CNRS, UMR C5616, ETUD DYNAM & STRUCT SELECT LAB, F-38041 GRENOBLE 9, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)			Fieschi, Franck/W-2748-2019	FIESCHI, Franck/0000-0003-1194-8107; Niviere, Vincent/0000-0002-5132-457X				ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; ASHTON WT, 1978, J HETEROCYCLIC CHEM, V15, P489, DOI 10.1002/jhet.5570150324; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; DALZIEL K, 1973, ENZYMES, V11, P2; DWIVEDI UN, 1994, J BIOL CHEM, V269, P13785; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; Fieschi F, 1996, EUR J BIOCHEM, V237, P870, DOI 10.1111/j.1432-1033.1996.0870p.x; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1994, BIOMETALS, V7, P3; GAUDU P, 1994, J BIOL CHEM, V269, P8182; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; QUANDT KS, 1994, P NATL ACAD SCI USA, V91, P9322, DOI 10.1073/pnas.91.20.9322; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPECTOR T, 1981, BIOCHEM PHARMACOL, V30, P1, DOI 10.1016/0006-2952(81)90277-X; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; TOMATSU S, 1989, GENE, V80, P353; YUBISUI T, 1979, J BIOCHEM, V85, P719; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994; ZENNO S, 1994, J BACTERIOL, V176, P3544, DOI 10.1128/JB.176.12.3544-3551.1994	36	30	30	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16656	16661		10.1074/jbc.271.28.16656	http://dx.doi.org/10.1074/jbc.271.28.16656			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663185	hybrid			2022-12-25	WOS:A1996UX12600038
J	RamseyEwing, A; Moss, B				RamseyEwing, A; Moss, B			Recombinant protein synthesis in Chinese hamster ovary cells using a vaccinia virus/bacteriophage T7 hybrid expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; MAMMALIAN-CELLS; VIRUS; GENES	The vaccinia virus/bacteriophage T7 expression system was adapted to Chinese hamster ovary (CHO) cells, Vaccinia virus undergoes abortive infection in CHO cells, which is characterized by a sharp reduction in protein synthesis at the stage of viral intermediate gene expression. We determined that expression of a T7 promoter-regulated chloramphenicol acetyltransferase gene was at least 20 times more efficient in permissive BS-C-1 than in CHO cells. The encephalomyocarditis virus 5'-untranslated region, which confers cap-independent translatability to mRNA, stimulated recombinant protein synthesis by 10-fold in both cell lines, maintaining the advantage of the BS-C-1 cells over CHO cells, Since the cowpox virus hr gene overcomes vaccinia virus host range restriction in CHO cells, we constructed a recombinant virus that carries an intact hr gene in addition to the T7 RNA polymerase gene, With this virus, synthesis of T7 RNA polymerase was enhanced and production of a recombinant protein occurred in CHO cells at the level observed in permissive cell lines. Extension of the vaccinia virus/bacteriophage T7 expression system to CHO cells should be of wide interest, as these cells have advantages for preparation of recombinant proteins in research and biotechnology.	NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Moss, Bernard/0000-0002-2154-8564				ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEN D, 1984, J PHARMACOL EXP THER, V231, P146; DRILLIEN R, 1978, J VIROL, V28, P843, DOI 10.1128/JVI.28.3.843-850.1978; Earl P, 1991, CURRENT PROTOCOLS MO; EGRIE JC, 1985, EXPT APPROACHES STUD, P339; ELBEIN AD, 1991, TRENDS BIOTECHNOL, V9, P346, DOI 10.1016/0167-7799(91)90117-Z; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; INK BS, 1995, J VIROL, V69, P661, DOI 10.1128/JVI.69.2.661-668.1995; KOTWAL GJ, 1988, VIROLOGY, V167, P524, DOI 10.1016/S0042-6822(88)90115-8; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; PATZER EJ, 1986, BIO-TECHNOL, V4, P630, DOI 10.1038/nbt0786-630; RAMSEYEWING A, 1995, VIROLOGY, V206, P984, DOI 10.1006/viro.1995.1021; SCAHILL SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4654, DOI 10.1073/pnas.80.15.4654; SPEHNER D, 1988, J VIROL, V62, P1297, DOI 10.1128/JVI.62.4.1297-1304.1988; WARD GA, 1995, P NATL ACAD SCI USA, V92, P6773, DOI 10.1073/pnas.92.15.6773; ZETTLMEISSL G, 1987, BIO-TECHNOL, V5, P720, DOI 10.1038/nbt0787-720	22	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16962	16966		10.1074/jbc.271.28.16962	http://dx.doi.org/10.1074/jbc.271.28.16962			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663285	hybrid			2022-12-25	WOS:A1996UX12600081
J	Simon, JP; Ivanov, IE; Bo, SS; Hersh, D; Adesnik, M; Sabatini, DD				Simon, JP; Ivanov, IE; Bo, SS; Hersh, D; Adesnik, M; Sabatini, DD			The in vitro generation of post-Golgi vesicles carrying viral envelope glycoproteins requires an ARF-like GTP-binding protein and a protein kinase C associated with the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; CONSTITUTIVE SECRETORY VESICLES; AMYLOID PRECURSOR PROTEIN; COP-COATED VESICLES; TRIMERIC G-PROTEINS; CELL-FREE SYSTEM; BREFELDIN-A; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; PHOSPHOLIPASE-D	We have developed a system that recreates in vitro the generation of post-Golgi vesicles from an isolated Golgi fraction prepared from vesicular stomatitis virus- or influenza virus infected Madin-Darby canine kidney or HepG2 cells. In this system, vesicle generation is temperature and ATP-dependent and requires a supply of cytosolic proteins, including an N-ethylmaleimide-sensitive factor distinct from NSF, Cytosolic proteins obtained from yeast were as effective as mammalian cytosolic proteins in supporting vesicle formation and had the same requirements, The vesicles produced (50-80 nm in diameter) are depleted of the trans Golgi marker sialyltransferase, contain the viral glycoprotein molecules with their cytoplasmic tails exposed, and do not show an easily recognizable protein coat, Vesicle generation was inhibited by brefeldin A, which indicates that it requires the activation of an Arf-like GTP-binding protein that promotes assembly of a vesicle coat, Vesicles formed in the presence of the nonhydrolyzable GTP analogue guanosine 5'-3-O-(thio)triphosphate retained a nonclathrin protein coat resembling that of COP-coated vesicles, and sedimented more rapidly in a sucrose gradient than the uncoated ones generated in its absence, This indicates that GTP hydrolysis is not required for vesicle generation but that it is for vesicle uncoating, The activity of a Golgi-associated protein kinase C (PKC) was found to be necessary for the release of post-Golgi vesicles, as indicated by the capacity of a variety of inhibitors and antibodies to PKC to suppress it, as well as by the stimulatory effect of the PRC activator 12-O-tetradecanoylphorbol-13-acetate.	NYU,SCH MED,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BREWER CB, 1995, J CELL SCI, V108, P789; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUNPHY WG, 1986, P NATL ACAD SCI USA, V83, P1622, DOI 10.1073/pnas.83.6.1622; FABBRI M, 1994, J BIOL CHEM, V269, P26848; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHASHI M, 1994, J BIOL CHEM, V269, P24897; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OLSON SC, 1991, J BIOL CHEM, V266, P17236; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROSA P, 1992, EUR J CELL BIOL, V59, P265; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SABATINI DD, 1995, METABOLIC BASIS INHE, V1, P459; SAGIEISENBERG R, 1989, TRENDS BIOCHEM SCI, V14, P355, DOI 10.1016/0968-0004(89)90001-7; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STROUS GJ, 1985, J CELL BIOL, V101, P531, DOI 10.1083/jcb.101.2.531; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	87	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16952	16961		10.1074/jbc.271.28.16952	http://dx.doi.org/10.1074/jbc.271.28.16952			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663371	hybrid			2022-12-25	WOS:A1996UX12600080
J	Brosnan, JT; Brosnan, ME; Charron, R; Nissim, I				Brosnan, JT; Brosnan, ME; Charron, R; Nissim, I			A mass isotopomer study of urea and glutamine synthesis from N-15-labeled ammonia in the perfused rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; TERM METABOLIC-FATE; CHROMATOGRAPHY; N-15; SPECTROMETRY; BIOSYNTHESIS; UREAGENESIS; INSITU; CYCLE; CELLS	This study examines the incorporation of N-15 from (NH4Cl)-N-15 into urea and glutamine, predicts the pattern of isotopomers produced as a function of the N-15 enrich ment of the relevant precursor pools, and presents a means of determining the isotopic enrichment of these pools, Rat livers were perfused, in the nonrecirculating mode, with 0.3 mM (NH4Cl)-N-15, and the isotopomers of urea and of glutamine produced were determined by gas chromatography-mass spectrometry methodology, Three different nitrogen mass isotopomers of urea were found, containing no, one, or two atoms of N-15. Four glutamine isotopomers were found, containing no N-15, one atom of N-15 in either the amino or amide position, or two N-15 atoms, A mathematical relationship was deduced that predicts that the relative proportions of the urea isotopomers depends not only on the relative enrichment of N-15 in the two precursor pools of urea nitrogen (mitochondrial ammonia and cytoplasmic aspartate) but on their absolute enrichment, This relationship was validated in experiments in which the isotopic enrichment of the substrate, (NH4Cl)-N-15, was varied, The proportions of the urea isotopomers produced can be predicted if one knows the N-15 enrichment in the two precursor pools, We found that when the N-15 enrichment of citrulline and aspartate in the perfusate were used as proxies for that in the mitochondrial ammonia and cytoplasmic aspartate pools we could accurately predict the relative proportion of the three isotopomers. The production of the four nitrogen isotopomers of glutamine could be used to determine the N-15 enrichment in the two precursor pools of glutamine nitrogen, the cytoplasmic ammonia and glutamate pools of the perivenous hepatocytes.	MEM UNIV NEWFOUNDLAND,DEPT MATH & STAT,ST JOHNS,NF A1C 5S7,CANADA; CHILDRENS HOSP PHILADELPHIA,ABRAMSON PEDIAT RES CTR,PHILADELPHIA,PA 19104	Memorial University Newfoundland; University of Pennsylvania; Childrens Hospital of Philadelphia	Brosnan, JT (corresponding author), MEM UNIV NEWFOUNDLAND,DEPT BIOCHEM,ST JOHNS,NF A1B 3X9,CANADA.				NIDDK NIH HHS [DK-39348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON LW, 1987, ANAL BIOCHEM, V163, P358, DOI 10.1016/0003-2697(87)90236-3; BROSNAN JT, 1970, BIOCHEM J, V117, P91, DOI 10.1042/bj1170091; BROSNAN JT, 1976, UREA CYCLE, P443; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; COOPER AJL, 1987, J BIOL CHEM, V262, P1073; COOPER AJL, 1988, J BIOL CHEM, V263, P12268; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GEISSLER A, 1992, BIOCHEM J, V287, P813, DOI 10.1042/bj2870813; GEYER JW, 1971, ANAL BIOCHEM, V39, P412, DOI 10.1016/0003-2697(71)90431-3; HAUSSINGER D, 1983, EUR J BIOCHEM, V133, P269, DOI 10.1111/j.1432-1033.1983.tb07458.x; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; Jacobs M. H., 1940, Cold Spring Harbor Symposia on Quantitative Biology, V8, P30; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; KHARROUBI AT, 1992, AM J PHYSIOL, V263, pE667, DOI 10.1152/ajpendo.1992.263.4.E667; KIRSTEN E, 1963, BIOCHEM Z, V337, P312; KUO FC, 1991, P NATL ACAD SCI USA, V88, P9468, DOI 10.1073/pnas.88.21.9468; LOBLEY GE, 1995, BRIT J NUTR, V73, P667, DOI 10.1079/BJN19950072; LUO QJ, 1995, EUR J BIOCHEM, V228, P912, DOI 10.1111/j.1432-1033.1995.0912m.x; MEIJER AJ, 1985, FEBS LETT, V191, P249, DOI 10.1016/0014-5793(85)80018-1; NEESE RA, 1993, AM J PHYSIOL, V264, pE136, DOI 10.1152/ajpendo.1993.264.1.E136; NISSIM I, 1984, ANAL BIOCHEM, V143, P14, DOI 10.1016/0003-2697(84)90550-5; NISSIM I, 1993, J AM SOC NEPHROL, V3, P1416; NISSIM I, 1985, J BIOL CHEM, V260, P3955; NISSIM I, 1992, ARCH BIOCHEM BIOPHYS, V292, P393, DOI 10.1016/0003-9861(92)90008-K; PAUSCH J, 1985, EUR J BIOCHEM, V150, P189, DOI 10.1111/j.1432-1033.1985.tb09006.x; Sies H, 1978, Methods Enzymol, V52, P48; WATFORD M, 1983, FASEB J, V7, P1468; WETTSTEIN M, 1994, HEPATOLOGY, V19, P641, DOI 10.1002/hep.1840190315; WOLFE RR, 1992, RADIOACTIVE STABLE I, P49	33	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16199	16207		10.1074/jbc.271.27.16199	http://dx.doi.org/10.1074/jbc.271.27.16199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663091	hybrid			2022-12-25	WOS:A1996UW35200052
J	Paolini, R; Serra, A; Kinet, JP				Paolini, R; Serra, A; Kinet, JP			Persistence of tyrosine-phosphorylated Fc epsilon RI in deactivated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; IMMUNOGLOBULIN-E RECEPTORS; ANTIGEN RECEPTOR; CROSS-LINKING; MAST-CELLS; SIGNAL TRANSDUCTION; RBL-2H3 CELLS; KINASES; DEPHOSPHORYLATION	Engagement of the high affinity IgE receptor (Fc epsilon RI) with a multimeric antigen leads to immediate tyrosine phosphorylation of its beta and gamma subunits, recruitment, and activation of the tyrosine kinase Syk, and later to cell degranulation, Monovalent hapten treatment reverses these events, resulting in receptor dephosphorylation and an abrupt arrest of cell degranulation, Thus far, it has been assumed that there is a direct linkage between receptor tyrosine phosphorylation, Syk activation and phosphorylation, and cell degranulation. However, we show here that when Fc epsilon RI receptors are crosslinked for extended periods of time, hapten-mediated receptor dephosphorylation is delayed, These receptors, which remain tyrosine-phosphorylated despite the addition of hapten, are progressively targeted to a Triton X-100-insoluble fraction, suggesting their progressive association with the membrane skeleton, In contrast to Fc epsilon RI receptors, hapten-induced Syk dephosphorylation and the consequent arrest of degranulation are not affected by prolonged cross-linking, Thus, some tyrosine-phosphorylated receptors persist in deactivated cells, We propose that, with time, some tyrosine-phosphorylated receptors become unaccessible to phosphatases and, in addition, unable to activate Syk. This inactive status of tyrosine-phosphorylated Fc epsilon RI may be the result of membrane skeleton compartmentalization. However, another population of clustered receptors that includes the ones most recently formed is still immediately sensitive to hapten deactivation, This latter population is critical in maintaining Syk activity and cell degranulation. The shift from a transiently active state of phosphorylated receptors toward an inactive state could be a general mechanism of desensitization also utilized by other antigen receptors.	NIAID,MOLEC ALLERGY & IMMUNOL SECT,NIH,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				PAOLINI, Rossella/0000-0001-7605-1531				ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ADAMCZEWSKI MA, 1991, CHEM IMMUNOL, V59, P173; APGAR JR, 1990, J IMMUNOL, V145, P3814; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; EISEMAN E, 1992, NATURE, V355, P78; FEWTRELL C, 1985, CALCIUM BIOL SYSTEMS, P129; HOLOWKA D, 1990, CELLULAR MOL MECHANI, V1, P173; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KAGEYSOBOTKA A, 1982, FED PROC, V41, P12; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KINET JP, 1990, FC RECEPTORS ACTION, P239; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LUO K, 1990, ONCOGENE, V5, P921; METZGER H, 1992, J IMMUNOL, V149, P1477; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Paolini R, 1994, Immunomethods, V4, P35, DOI 10.1006/immu.1994.1005; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SEAGRAVE J, 1990, J CELL PHYSIOL, V144, P128, DOI 10.1002/jcp.1041440117; SEAGRAVE JC, 1987, CYTOMETRY, V8, P287, DOI 10.1002/cyto.990080309; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; VALLE A, 1995, FEBS LETT, V357, P41, DOI 10.1016/0014-5793(94)01329-Y; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	41	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15987	15992		10.1074/jbc.271.27.15987	http://dx.doi.org/10.1074/jbc.271.27.15987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663241	hybrid			2022-12-25	WOS:A1996UW35200024
J	Clark, EA; Hynes, RO				Clark, EA; Hynes, RO			Ras activation is necessary for integrin-mediated activation of extracellular signal-regulated kinase 2 and cytosolic phospholipase A(2) but not for cytoskeletal organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; FIBROBLASTS; PROTEIN; CELLS	Cell adhesion to the extracellular matrix triggers a cascade of intracellular biochemical signals regulated by the integrin family of receptors, Recent evidence suggests that integrin engagement may activate a mitogen-activated protein (MAP) kinase cascade that may cooperate with more clearly defined mitogenic signaling pathways to regulate cell proliferation, adhesion, and migration. Here we report that the adhesion-dependent activation of the MAP kinase Erk2 (extracellular signal-regulated kinase 2) occurs in serum-starved NIH3T3 cells, and that this activation of Erk2 is preceded by the activation of the small GTP-binding protein Ras in fibronectin adherent cells, Inhibition of Ras signaling by expression of a dominant inhibitory mutant of Ras (N17Ras) in NIH3T3 cells blocked adhesion-dependent activation of Erk2, although the focal adhesion kinase (FAK) was still activated in these cells, Furthermore, activation of this Ras-MAP kinase pathway activated cytosolic phospholipase A(2), leading to the release of arachidonic acid metabolites, and N17Ras also inhibited these events, However, N17Ras expression does not inhibit cell adhesion, spreading, or focal contact and stress fiber formation, These results suggest that, while integrin-dependent activation of this MAP kinase pathway is Ras-dependent, the integrin-dependent activation of FAK and several morphological events are Ras independent, Thus, integrin-mediated signals involved in regulating cell morphology appear to diverge from those regulating MAP kinase activation at a level upstream of Ras activation.	MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA017007] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA17007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUER KL, 1995, MOL BIOL CELL, V6, P1305, DOI 10.1091/mbc.6.10.1305; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUN JS, 1992, MOL BIOL CELL, V3, P481, DOI 10.1091/mbc.3.5.481; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PLOPPER CE, 1995, MOL BIOL CELL, V6, P1349; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WARNER LC, 1993, ONCOGENE, V8, P3249; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	31	157	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14814	14818		10.1074/jbc.271.25.14814	http://dx.doi.org/10.1074/jbc.271.25.14814			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663348	hybrid			2022-12-25	WOS:A1996UT10600029
J	Thorner, PS; Zheng, KQ; Kalluri, R; Jacobs, R; Hudson, BG				Thorner, PS; Zheng, KQ; Kalluri, R; Jacobs, R; Hudson, BG			Coordinate gene expression of the alpha 3, alpha 4, and alpha 5 chains of collagen type IV - Evidence from a canine model of X-linked nephritis with a COL4A5 gene mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAMOYED HEREDITARY GLOMERULOPATHY; BASEMENT-MEMBRANE COLLAGEN; COMMON PROMOTER REGION; AMINO-ACID-SEQUENCE; ALPORT SYNDROME; NC1 DOMAIN; BIDIRECTIONAL PROMOTER; GOODPASTURE ANTIGEN; MOLECULAR-GENETICS; MESSENGER-RNA	Canine X-linked hereditary nephritis is an animal model for human X-linked hereditary nephritis with a premature stop codon in the alpha 5(IV) gene of collagen type IV. We used this model to examine the other alpha(IV) chains at the mRNA and protein level in the kidney, since in human X-linked hereditary nephritis, the alpha 3(IV) and alpha 4(IV) chains are often absent from the glomerular basement membrane, although both are encoded by autosomal genes, cDNA probes for the alpha 1(IV)-alpha 6(IV) chains were generated from normal dog kidney using the polymerase chain reaction, Sequences were greater than or equal to 88% identical at the DNA level and greater than or equal to 92% identical at the protein level to the respective human alpha(IV) chains, By Northern analysis, transcripts for the alpha 1(IV), alpha 2(IV), and alpha 6(IV) chains were detected at comparable levels in both normal and affected male dog kidney RNA, As previously shown, the transcript for the alpha 5(IV) chain was reduced to similar to 10% of normal. Unexpectedly, the alpha 3(IV) and alpha 4(IV) transcripts were both decreased greater than or equal to 77% in affected male dog kidney, suggesting a mechanism coordinating the expression of these three basement membrane components, The NC1 domain of collagen type IV isolated from normal dog glomeruli was positive for the alpha 3(IV), alpha 4(IV), and alpha 5(IV) chains by Western blotting, In contrast, in the NC1 domain isolated from affected dog glomeruli, these three chains were not detectable, except for a trace of alpha 3(IV) dimer. In X-linked hereditary nephritis, the absence of the alpha 3(IV) and alpha 4(IV) chains from glomerular basement membrane may reflect factors acting at the transcriptional and/or translational level in addition to the protein assembly level.	UNIV TORONTO,TORONTO,ON M5G 1X8,CANADA; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160; UNIV GUELPH,GUELPH,ON N1G 2W1,CANADA; ONTARIO VET COLL,DEPT PATHOL,GUELPH,ON N1G 2W1,CANADA	University of Toronto; University of Kansas; University of Kansas Medical Center; University of Guelph	Thorner, PS (corresponding author), HOSP SICK CHILDREN,DEPT PATHOL,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18381] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMAL R, 1991, AM J PATHOL, V139, P751; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; DING J, 1995, J AM SOC NEPHROL, V5, P1714; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINGOLD J, 1985, KIDNEY INT, V27, P672, DOI 10.1038/ki.1985.63; FISCHER G, 1993, BIOCHEM J, V292, P687, DOI 10.1042/bj2920687; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; GRUNFELD JP, 1985, KIDNEY INT, V27, P83, DOI 10.1038/ki.1985.14; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUO CY, 1993, KIDNEY INT, V44, P1316, DOI 10.1038/ki.1993.384; Habib R, 1982, Kidney Int Suppl, V11, pS20; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HILAL L, 1993, NAT GENET, V5, P287, DOI 10.1038/ng1193-287; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P30; JANSEN B, 1986, J LAB CLIN MED, V107, P551; JANSEN B, 1986, AM J PATHOL, V125, P536; KALLURI R, 1994, KIDNEY INT, V45, P721, DOI 10.1038/ki.1994.96; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269; LEMMINK HH, 1994, HUM MOL GENET, V3, P313; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NONOMIYA Y, 1995, J CELL BIOL, V130, P1219; OBERBAUMER I, 1985, EUR J BIOCHEM, V147, P212; OOHASHI T, 1994, J BIOL CHEM, V269, P7520; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; REEDERS ST, 1992, KIDNEY INT, V42, P783, DOI 10.1038/ki.1992.348; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAMBROOK J, 1989, MOL CLONING LABORATO, P60; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHMIDT C, 1993, BIOCHIM BIOPHYS ACTA, V1174, P1, DOI 10.1016/0167-4781(93)90085-R; SPEAR GS, 1972, AM J PATHOL, V69, P213; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/BF01959208; STOVER ML, 1993, J CLIN INVEST, V92, P1994, DOI 10.1172/JCI116794; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TANAKA S, 1993, J BIOL CHEM, V268, P8862; THORNER P, 1989, KIDNEY INT, V35, P843, DOI 10.1038/ki.1989.62; THORNER P, 1987, LAB INVEST, V56, P435; THORNER PS, 1992, VIRCHOWS ARCH A, V421, P467, DOI 10.1007/BF01606875; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WILLING MC, 1992, AM J HUM GENET, V51, P508; YOSHIOKA K, 1994, AM J PATHOL, V144, P986; ZHENG KQ, 1994, P NATL ACAD SCI USA, V91, P3989, DOI 10.1073/pnas.91.9.3989; ZHOU J, 1994, J BIOL CHEM, V269, P13193; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1993, KIDNEY INT, V43, P722, DOI 10.1038/ki.1993.103; ZHOU J, 1992, J BIOL CHEM, V267, P12475	65	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13821	13828		10.1074/jbc.271.23.13821	http://dx.doi.org/10.1074/jbc.271.23.13821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662866	hybrid			2022-12-25	WOS:A1996UP38500078
J	Hu, JF; Vu, TH; Hoffman, AR				Hu, JF; Vu, TH; Hoffman, AR			Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR; GENE; MOUSE; IGF2; EXPRESSION; ACTIVATION; H19; RELAXATION; PROTEIN; ALLELE	The insulin-like growth factor II (IGF-II) gene is maternally imprinted in most normal tissues with only the paternal allele being transcribed, In several human tumors, however, IGF-II is expressed from both parental alleles. To explore the underlying mechanism of IGF-II imprinting, we have examined the effect of DNA demethylation in cultured human and mouse astrocyte cells. An increased expression of IGF-II was observed when these cells were treated with the DNA demethylating agents, 5-azacytidine or 2-deoxy-5-azacytidine. Allelic analysis indicated that, following DNA demethylation, the increment in IGF-II mRNA was primarily derived from the normally suppressed maternal allele. Examination of promoter usage revealed that only the most proximal promoter (mP3 in mouse and hP4 in human) responded to DNA demethylating agents, whereas the expression of IGF-II from the other promoters remained unchanged. The enhanced expression of IGF-II from these promoters suggests the presence of a methylation response element in or near mP3 and hP4. This study indicates that DNA demethylating agents increase IGF-II expression primarily by stimulating the normally imprinted allele through the activation of the most proximal IGF-II promoter.	DEPT VET AFFAIRS MED CTR,MED SERV 111,PALO ALTO,CA 94304; STANFORD UNIV,DEPT MED,DIV ENDOCRINOL GERONTOL & METAB,PALO ALTO,CA 94304	Stanford University			Hu, Jifan/Q-3003-2019	HU, Jifan/0000-0002-2174-0361	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036054] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36054] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CARR BI, 1988, BRIT J CANCER, V57, P395, DOI 10.1038/bjc.1988.89; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TANIGUCHI T, 1995, ONCOGENE, V11, P751; TAYLOR SM, 1982, J MOL BIOL, V162, P679, DOI 10.1016/0022-2836(82)90395-3; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	37	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18253	18262		10.1074/jbc.271.30.18253	http://dx.doi.org/10.1074/jbc.271.30.18253			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663390	hybrid			2022-12-25	WOS:A1996UY93500099
J	Hudrisier, D; Mazarguil, H; Laval, F; Oldstone, MBA; Gairin, JE				Hudrisier, D; Mazarguil, H; Laval, F; Oldstone, MBA; Gairin, JE			Binding of viral antigens to major histocompatibility complex class I H-2D(b) molecules is controlled by dominant negative elements at peptide non-anchor residues - Implications for peptide selection and presentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL EPITOPES; 3-DIMENSIONAL STRUCTURE; GLYCOPROTEIN EPITOPE; ANGSTROM RESOLUTION; CTL RECOGNITION; MHC; NUCLEOPROTEIN; AFFINITY; POCKETS	Binding of viral antigens to major histocompatibility complex (MHC) class I molecules is a critical step in the activation process of CD8(+) cytotoxic T lymphocytes, In this study, we investigated the impact of structural factors at non-anchor residues in peptide-MHC interaction using the model of lymphocytic choriomeningitis virus (LCMV) infection of its natural host, the mouse, Altering viral genes by making reassortants, recombinants, and using synthetic peptides, CD8(+) cytotoxic T lymphocytes were shown to recognize only three H-2D(b)-restricted epitopes, GP amino acids 33-41/43, GP 276-286, and NP 396-404, However, LCMV NP and GP proteins contain 31 other peptides bearing the H-2D(b) motif, These 34 LCMV peptides and 11 other known H2-D-b-restricted peptides were synthesized and examined for MHC binding properties, Despite the presence of the H-2D(b) binding motif, the majority of LCMV peptides showed weak or no affinity for H-2D(b), We observed that dominant negative structural elements located at non-anchor positions played a crucial role in peptide-MHC interaction, By comparative sequence analysis of strong versus non-binders and using molecular modeling, we delineated these negative elements and evaluated their impact on peptide-MHC interaction, Our findings were validated by showing that a single mutation of a favorable non-anchor residue in the sequence of known viral epitopes for a negative element resulted in dramatic reduction of antigen presentation properties, while conversely, substitution of one negative for a positive element in the sequence of a non-binder conferred to the peptide an ability to now bind to MHC molecules.	INST PHARMACOL & BIOL STRUCT, CNRS, F-31400 TOULOUSE, FRANCE; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Scripps Research Institute			LAUZERAL-VIZCAINO, Françoise/W-8898-2019	LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252; Hudrisier, Denis/0000-0002-3631-9561	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009484, R01AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09484] Funding Source: Medline; NIA NIH HHS [AG04342] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; BARBER LD, 1994, J EXP MED, V180, P1191, DOI 10.1084/jem.180.4.1191; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CHEN WS, 1994, J EXP MED, V180, P1471, DOI 10.1084/jem.180.4.1471; COLBERT RA, 1994, IMMUNITY, V1, P121, DOI 10.1016/1074-7613(94)90105-8; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; DECKHUT AM, 1992, J VIROL, V66, P440, DOI 10.1128/JVI.66.1.440-447.1992; Dockter J, 1996, J VIROL, V70, P1799, DOI 10.1128/JVI.70.3.1799-1803.1996; ELLIOTT T, 1993, CURR BIOL, V3, P854, DOI 10.1016/0960-9822(93)90219-E; ENGELHARD VH, 1994, CURR OPIN IMMUNOL, V6, P13, DOI 10.1016/0952-7915(94)90028-0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GAIRIN JE, 1992, J VIROL, V66, P6755, DOI 10.1128/JVI.66.11.6755-6762.1992; GAIRIN JE, 1995, J VIROL, V69, P2297, DOI 10.1128/JVI.69.4.2297-2305.1995; GAIRIN JE, 1993, J VIROL, V67, P2903, DOI 10.1128/JVI.67.5.2903-2907.1993; Gavin Marc A., 1993, Journal of Cellular Biochemistry Supplement, V17, P45; GREY HM, 1995, CANCER SURV, V22, P37; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HIOE CE, 1994, IMMUNOGENETICS, V40, P222, DOI 10.1007/BF00167083; HUDRISIER D, 1995, MOL IMMUNOL, V32, P895, DOI 10.1016/0161-5890(95)00043-E; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KLAVINSKIS LS, 1990, VIROLOGY, V178, P393, DOI 10.1016/0042-6822(90)90336-P; KOUP RA, 1994, J EXP MED, V180, P779, DOI 10.1084/jem.180.3.779; LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARRACK P, 1994, NATURE, V368, P397, DOI 10.1038/368397a0; MATSUI M, 1993, P NATL ACAD SCI USA, V90, P674, DOI 10.1073/pnas.90.2.674; MATSUI M, 1994, HUM IMMUNOL, V41, P160, DOI 10.1016/0198-8859(94)90010-8; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1995, J VIROL, V69, P7423, DOI 10.1128/JVI.69.12.7423-7429.1995; OUKKA M, 1994, J IMMUNOL, V152, P4843; OZATO K, 1980, J IMMUNOL, V125, P2473; PARKER KC, 1994, J IMMUNOL, V152, P163; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; POGUE RR, 1995, P NATL ACAD SCI USA, V92, P8166, DOI 10.1073/pnas.92.18.8166; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROHREN EM, 1993, J EXP MED, V177, P1713, DOI 10.1084/jem.177.6.1713; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SCHONBACH C, 1995, J IMMUNOL, V154, P5951; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SETTE A, 1994, J IMMUNOL, V153, P5586; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; VONHERRATH MG, 1994, J EXP MED, V180, P1901, DOI 10.1084/jem.180.5.1901; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	57	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17829	17836		10.1074/jbc.271.30.17829	http://dx.doi.org/10.1074/jbc.271.30.17829			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663374	hybrid			2022-12-25	WOS:A1996UY93500039
J	Sadar, MD; Ash, R; Sundqvist, J; Olsson, PE; Andersson, TB				Sadar, MD; Ash, R; Sundqvist, J; Olsson, PE; Andersson, TB			Phenobarbital induction of CYP1A1 gene expression in a primary culture of rainbow trout hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARYL-HYDROCARBON HYDROXYLASE; ADULT-RAT HEPATOCYTES; HEPATOMA-CELL LINE; AH RECEPTOR; DIOXIN RECEPTOR; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL EXPRESSION; METABOLIZING-ENZYMES	In mammals, phenobarbital (PB) is an in vivo inducer of the cytochrome P4502B (CYP2B) family, whereas in teleosts PB induction of cytochrome P450 is unclear. We show that teleost cytochrome P4502K1 (CYP2K1) protein levels and 7-pentoxyresorufin-O-deethylase activity were not induced by exposure of primary cultures of rainbow trout hepatocytes to PB. Instead, cytochrome P4501A1 (CYP1A1) gene expression was strongly induced by PB, based upon observations of marked increases in CYP1A1 mRNA, CYP1A1 protein, and 7-ethoxyresorufin-O-deethylase activity. In accordance with these data we provide a temporal study employing antibodies for the aromatic hydrocarbon (Ah) receptor that showed an increase in Ah receptor in nuclear extracts prepared from cells exposed to PB, Employment of the electrophoretic mobility shift assay (EMSA) showed PB to cause activation or ''transformation'' of the Ah receptor in nuclear extracts. Studies employing actinomycin D and cycloheximide indicated that PB induction of CYP1A1 was regulated at both the transcriptional and post-transcriptional levels. Nuclear run-off experiments confirm that PB causes an increase in CYP1A1 transcription. Inhibition of protein synthesis led to the superinduction of CYP1A1 mRNA, suggesting the regulation of teleost CYP1A1 may involve a labile repressor protein. These findings suggest that PB induction of the CYP1A1 gene involves the Ah receptor and is via transcriptional activation.	GOTHENBURG UNIV,DEPT ZOOPHYSIOL,S-40031 GOTHENBURG,SWEDEN; UNIV BRADFORD,DEPT BIOMED SCI,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND; ASTRA HASSLE AB,DEPT PHARMACOKINET & DRUG METAB,S-43183 MOLNDAL,SWEDEN	University of Gothenburg; University of Bradford			Sadar, Marianne/E-9136-2012	Sadar, Marianne/0000-0003-0599-9215; Olsson, Per-Erik/0000-0001-7336-6335				AIX L, 1994, BIOCHEM BIOPH RES CO, V202, P1483, DOI 10.1006/bbrc.1994.2098; ALBAYATI ZAF, 1988, RES COMMUN CHEM PATH, V60, P47; ANDERSSON T, 1992, AQUAT TOXICOL, V24, P1, DOI 10.1016/0166-445X(92)90014-E; ANKLEY GT, 1987, BIOCHEM PHARMACOL, V36, P1379, DOI 10.1016/0006-2952(87)90099-2; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; AUBRECHT J, 1993, BIOCHEM BIOPH RES CO, V190, P1023, DOI 10.1006/bbrc.1993.1151; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACH J, 1989, XENOBIOTICA, V19, P1; BAYAD J, 1991, BIOCHEM PHARMACOL, V42, P1345, DOI 10.1016/0006-2952(91)90444-A; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BERNDTSON AK, 1994, ARCH BIOCHEM BIOPHYS, V310, P187, DOI 10.1006/abbi.1994.1156; BOMBICK DW, 1988, P NATL ACAD SCI USA, V85, P4128, DOI 10.1073/pnas.85.12.4128; BOMBICK DW, 1985, BIOCHEM BIOPH RES CO, V127, P296, DOI 10.1016/S0006-291X(85)80158-3; BOOBIS AR, 1986, XENOBIOTICA, V16, P233, DOI 10.3109/00498258609043526; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BROCKENBROUGH JS, 1991, CANCER RES, V51, P130; BUHLER DR, 1994, ARCH BIOCHEM BIOPHYS, V312, P45, DOI 10.1006/abbi.1994.1278; BURKE MD, 1994, BIOCHEM PHARMACOL, V48, P923, DOI 10.1016/0006-2952(94)90363-8; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; BURKE MD, 1974, DRUG METAB DISPOS, V2, P583; BURNS KA, 1976, COMP BIOCHEM PHYS B, V53, P443, DOI 10.1016/0305-0491(76)90195-4; BYUS CV, 1976, P NATL ACAD SCI USA, V73, P1241, DOI 10.1073/pnas.73.4.1241; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHAUHAN VPS, 1987, LIFE SCI, V40, P89, DOI 10.1016/0024-3205(87)90256-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMCZYNSKI P, 1989, TEL TEST INC B, V3; COLLIER TK, 1991, ARCH ENVIRON CON TOX, V20, P462, DOI 10.1007/BF01065834; CURIPEDROSA R, 1994, J PHARMACOL EXP THER, V269, P384; DAUJAT M, 1992, BIOCHEM BIOPH RES CO, V188, P820, DOI 10.1016/0006-291X(92)91130-I; EISELE TA, 1984, AQUAT TOXICOL, V5, P211, DOI 10.1016/0166-445X(84)90021-3; FORLIN L, 1978, COMP BIOCHEM PHYS C, V60, P193, DOI 10.1016/0306-4492(78)90093-X; FORLIN L, 1982, ECOTOX ENVIRON SAFE, V6, P41, DOI 10.1016/0147-6513(82)90079-3; FORSTER U, 1986, DRUG METAB DISPOS, V14, P353; FRY JR, 1980, BIOCHEM PHARMACOL, V29, P577, DOI 10.1016/0006-2952(80)90379-2; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GIACHELLI CM, 1991, J BIOL CHEM, V266, P3981; GOKSOYR A, 1992, AQUAT TOXICOL, V22, P287, DOI 10.1016/0166-445X(92)90046-P; GOKSOYR A, 1987, TOXICOL APPL PHARM, V89, P347, DOI 10.1016/0041-008X(87)90154-2; GRADIN K, 1994, J BIOL CHEM, V269, P23800; GUTMAN Y, 1971, BIOCHEM PHARMACOL, V20, P3547, DOI 10.1016/0006-2952(71)90463-1; HAASCH ML, 1994, BIOCHEM PHARMACOL, V47, P893, DOI 10.1016/0006-2952(94)90490-1; HAHN ME, 1993, AQUAT TOXICOL, V26, P185, DOI 10.1016/0166-445X(93)90030-5; HEILMANN LJ, 1988, DNA-J MOLEC CELL BIO, V7, P379, DOI 10.1089/dna.1.1988.7.379; ISREAL DI, 1985, J BIOL CHEM, V260, P5648; JENSEN EG, 1991, AQUAT TOXICOL, V21, P81, DOI 10.1016/0166-445X(91)90007-V; KARENLAMPI SO, 1989, BIOCHEM PHARMACOL, V38, P1517, DOI 10.1016/0006-2952(89)90192-5; KAUFMANN WK, 1988, CARCINOGENESIS, V9, P779, DOI 10.1093/carcin/9.5.779; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KLEINOW KM, 1990, COMP BIOCHEM PHYS C, V96, P259, DOI 10.1016/0742-8413(90)90006-U; LAPEYRE JN, 1974, J MOL BIOL, V89, P137, DOI 10.1016/0022-2836(74)90167-3; LOCKWOOD AP, 1961, COMP BIOCHEM PHYSIOL, V2, P241, DOI 10.1016/0010-406X(61)90113-X; LORENZEN A, 1990, TOXICOL APPL PHARM, V106, P53, DOI 10.1016/0041-008X(90)90105-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBET RA, 1985, ARCH BIOCHEM BIOPHYS, V238, P43, DOI 10.1016/0003-9861(85)90138-9; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; Maniatis T., 1982, MOL CLONING; MCMANUS ME, 1986, BIOCHEM BIOPH RES CO, V137, P120, DOI 10.1016/0006-291X(86)91184-8; MERCHANT M, 1990, ARCH BIOCHEM BIOPHYS, V281, P84, DOI 10.1016/0003-9861(90)90416-V; MIRANDA CL, 1990, BIOCHIM BIOPHYS ACTA, V1037, P155, DOI 10.1016/0167-4838(90)90161-8; NEBERT DW, 1970, J BIOL CHEM, V245, P160; NEWMAN S, 1982, P NATL ACAD SCI-BIOL, V79, P2922, DOI 10.1073/pnas.79.9.2922; OKEY AB, 1980, J BIOL CHEM, V255, P1415; OKEY AB, 1984, BIOCHEM PHARMACOL, V33, P531, DOI 10.1016/0006-2952(84)90303-4; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; OKINO ST, 1992, J BIOL CHEM, V267, P6991; OWENS IS, 1975, MOL PHARMACOL, V11, P94; PAINE AJ, 1990, CHEM-BIOL INTERACT, V74, P1, DOI 10.1016/0009-2797(90)90055-R; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; PESONEN M, 1991, XENOBIOTICA, V21, P461, DOI 10.3109/00498259109039486; PESONEN M, 1992, ARCH BIOCHEM BIOPHYS, V292, P228, DOI 10.1016/0003-9861(92)90072-5; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; PUGA A, 1992, FASEB J, V6, P777, DOI 10.1096/fasebj.6.2.1311272; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; REINERS JJ, 1993, ARCH BIOCHEM BIOPHYS, V301, P449, DOI 10.1006/abbi.1993.1170; REINERS JJ, 1992, BIOCHEM BIOPH RES CO, V183, P193, DOI 10.1016/0006-291X(92)91627-3; RIDDICK DS, 1994, J BIOL CHEM, V269, P12118; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SCHUETZ EG, 1986, BIOCHEMISTRY-US, V25, P1124, DOI 10.1021/bi00353a027; SCHWARZ LR, 1993, HDB EXPT PHARM, V105, P399; Schwarzbauer J., 1990, EXTRACELLULAR MATRIX, P195; SILVER G, 1988, J BIOL CHEM, V263, P11802; SODERKVIST P, 1988, CANCER RES, V48, P3045; STEGEMAN JJ, 1990, BIOCHEM SOC T, V18, P19, DOI 10.1042/bst0180019; Stegeman JJ, 1993, AQUATIC TOXICOLOGY M, P87; SWANSON HI, 1991, TOXICOL LETT, V58, P85, DOI 10.1016/0378-4274(91)90194-B; TEIFELD RM, 1989, DNA-J MOLEC CELL BIO, V8, P329, DOI 10.1089/dna.1.1989.8.329; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER NA, 1988, ARCH BIOCHEM BIOPHYS, V263, P204, DOI 10.1016/0003-9861(88)90629-7; UENG TH, 1992, AQUAT TOXICOL, V23, P49; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WIEBEL FJ, 1984, CHEM-BIOL INTERACT, V52, P151, DOI 10.1016/0009-2797(84)90069-3; XU LC, 1990, BIOCHEM PHARMACOL, V40, P1399	96	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17635	17643		10.1074/jbc.271.30.17635	http://dx.doi.org/10.1074/jbc.271.30.17635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663422	hybrid			2022-12-25	WOS:A1996UY93500011
J	Caput, D; Laurent, P; Kaghad, M; Lelias, JM; Lefort, S; Vita, N; Ferrara, P				Caput, D; Laurent, P; Kaghad, M; Lelias, JM; Lefort, S; Vita, N; Ferrara, P			Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; IGE SYNTHESIS; GAMMA-CHAIN; EXPRESSION; COMPONENT; IGG4	Interleukin-13 (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4. These overlapping activities are probably due to the existence of common receptor components, Two proteins have been described as constituents of the IL-4 receptor, a similar to 140-kDa glycoprotein (IL-4R) and the gamma chain (gamma c) of the IL-2 receptor, but neither of these proteins binds IL-13, We have cloned a cDNA encoding an IL-13 binding protein (IL-13R) from the Caki-1 human renal carcinoma cell line. The cloned cDNA encodes a 380-amino acid protein with two consensus patterns characteristic of the hematopoietic cytokine receptor family and a short cytoplasmic tail, The IL-13R shows homology with the IL-5 receptor, and to a lesser extent, with the prolactin receptor, COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4, COS-7 cells co transfected with the cloned IL-13R cDNA and IL-CR cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13, Reverse transcription-polymerase chain reaction analysis detected the receptor transcript only in cell lines known to bind IL-13.	SANOFI RECH,F-31676 LABEGE,FRANCE	Sanofi-Aventis; Sanofi France								AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; GIRI J, 1993, EMBO J, V14, P3654; Honjo T, 1991, Curr Biol, V1, P201, DOI 10.1016/0960-9822(91)90055-2; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	25	250	284	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16921	16926		10.1074/jbc.271.28.16921	http://dx.doi.org/10.1074/jbc.271.28.16921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663118	hybrid			2022-12-25	WOS:A1996UX12600075
J	Neumann, A; Wohlfarth, G; Diekert, G				Neumann, A; Wohlfarth, G; Diekert, G			Purification and characterization of tetrachloroethene reductive dehalogenase from Dehalospirillum multivorans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; QUANTITATION; IRON	Tetrachloroethene reductive dehalogenase from the tetrachloroethene-utilizing anaerobe, Dehalospirillum multivorans, was purified approximately 100-fold to apparent homogeneity. The purified dehalogenase catalyzed the reductive dechlorination of tetrachloroethene (PCE) to trichloroethene and of trichloroethene to cis-1,2-dichloroethene with reduced methyl viologen as the electron donor at a specific activity of 2.6 microkatal/mg. The apparent K-m values for tetrachloroethene and trichloroethene were 0.20 and 0.24 mM, respectively. The apparent molecular mass of the native enzyme was determined by gel filtration to be 58 kDa. Sodium dodecyl sulfate-gel electrophoresis revealed a single protein band with a molecular mass of 57 kDa. One mol of dehalogenase contained 1.0 mol of corrinoid, 9.8 mol of iron, and 8.0 mol of acid-labile sulfur. The pH optimum was about 8.0. The enzyme had a temperature optimum of 42 degrees C. It was slightly oxygen-sensitive and was ther molabile above 50 degrees C. The dechlorination of PCE was stimulated by ammonium ions. Chlorinated methanes severely inhibited PCE dehalogenase activity.	UNIV STUTTGART,INST MIKROBIOL,DEPT MICROBIOL,D-70550 STUTTGART,GERMANY	University of Stuttgart				Neumann, Anke/0000-0002-9969-7586				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FETZNER S, 1994, MICROBIOL REV, V58, P641, DOI 10.1128/MMBR.58.4.641-685.1994; FISCHER R, 1992, ARCH MICROBIOL, V158, P208, DOI 10.1007/BF00290817; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HOLLIGER C, 1994, ANTON LEEUW INT J G, V66, P239, DOI 10.1007/BF00871642; JANSSEN DB, 1994, ANNU REV MICROBIOL, V48, P163, DOI 10.1146/annurev.mi.48.100194.001115; NEUMANN A, 1994, ARCH MICROBIOL, V162, P295, DOI 10.1007/s002030050141; NEUMANN A, 1995, ARCH MICROBIOL, V163, P276, DOI 10.1007/BF00393380; NI SS, 1995, J BACTERIOL, V177, P5135, DOI 10.1128/jb.177.17.5135-5139.1995; NICHOLLS DG, 1992, BIOENERGETICS, V2, P76; Rabinowitz J C, 1978, Methods Enzymol, V53, P275; SATOWATANABE M, 1995, FEBS LETT, V374, P265, DOI 10.1016/0014-5793(95)01125-X; SCHOLZMURAMATSU H, 1995, ARCH MICROBIOL, V163, P48, DOI 10.1007/BF00262203; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	16	168	174	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16515	16519		10.1074/jbc.271.28.16515	http://dx.doi.org/10.1074/jbc.271.28.16515			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663199				2022-12-25	WOS:A1996UX12600017
J	Odani, N; Negishi, M; Takahashi, S; Kitano, Y; Kozutsumi, Y; Ichikawa, A				Odani, N; Negishi, M; Takahashi, S; Kitano, Y; Kozutsumi, Y; Ichikawa, A			Regulation of BiP gene expression by cyclopentenone prostaglandins through unfolded protein response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR GLUTATHIONE; ANTIPROLIFERATIVE ACTIVITY; CELLS; 9-DEOXY-DELTA-9,DELTA-12(E)-PROSTAGLANDIN-D2	Delta(12)-Prostaglandin (PG) J(2), a cyclopentenone prostaglandin, plays a role in various stress responses, BiP, a stress-inducible chaperone protein, is implicated in protein folding and translocation in endoplasmic reticulum and induced in the condition of accumulation of unfolded proteins, Here, we examined the effect of Delta(12)-PGJ(2) on the expression of the BiP gene, Delta(12)-PGJ(2) markedly stimulated the expression of the BiP gene in a time- and concentration-dependent manner in HeLa cells, This stimulation was specific for cyclopentenone PGs among various PGs. Cycloheximide pretreatment completely inhibited the Delta(12)-PGJ(2)-induced expression of the BiP gene, suggesting that the effects on nascent protein synthesis are involved in the signaling mechanism, Delta(12)-PGJ(2) markedly stimulated the promoter activity of the 5'-flanking region of the BiP gene through the unfolded protein response element. Furthermore, Delta(12)-PGJ(2) stimulated the enhancer activity of the 3'-half of the unfolded protein response element, and this stimulation required three nucleotides within this region, Gel mobility shift assay demonstrated that this region was occupied with two specific nuclear protein factors with different mobilities in the control cells, and Delta(12)-PGJ(2) induced the dissociation of the protein-DNA complex with lower mobility, These findings indicate that Delta(12)-PGJ(2) stimulates the expression of BiP gene through the 3'-half of the unfolded protein response element.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM, SAKYO KU, KYOTO 606, JAPAN	Kyoto University; Kyoto University								AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CAGEN LM, 1976, J BIOL CHEM, V251, P6550; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOIZUMI T, 1995, J BIOL CHEM, V270, P21779, DOI 10.1074/jbc.270.37.21779; KOIZUMI T, 1993, BIOCHEM PHARMACOL, V45, P2457, DOI 10.1016/0006-2952(93)90227-N; KOIZUMI T, 1992, BIOCHEM PHARMACOL, V44, P1597; KOZUTSUMI Y, 1989, J CELL SCI, P115; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P443, DOI 10.1016/0929-7855(95)00029-P; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; REINBOTHE S, 1994, P NATL ACAD SCI USA, V91, P7012, DOI 10.1073/pnas.91.15.7012; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275	26	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16609	16613		10.1074/jbc.271.28.16609	http://dx.doi.org/10.1074/jbc.271.28.16609			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663202	hybrid			2022-12-25	WOS:A1996UX12600031
J	Sette, C; Conti, M				Sette, C; Conti, M			Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase - Involvement of serine 54 in the enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CATESBIANA ROD PHOTORECEPTORS; CGMP PHOSPHODIESTERASE; AMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; RAT ADIPOCYTES; STIMULATING-HORMONE; HUMAN-PLATELETS; SERTOLI-CELL; INSULIN	A cAMP-specific phosphodiesterase (PDE4D3) is activated in rat thyroid cells by TSH through a cAMP-dependent phosphorylation (Sette, C., Iona, S., and Conti, M. (1994) J. Biol. Chem, 269, 9245-9252). This short term activation may be involved in the termination of the hormonal stimulation and/or in the induction of desensitization. Here, we have further characterized the protein kinase A (PKA)-dependent phosphorylation of this PDE4D3 variant and identified the phosphorylation site involved in the PDE activation, The PKA-dependent incorporation of phosphate in the partially purified, re-combinant rat PDE4D3 followed a time course similar to that of activation, Half-maximal activation of the enzyme was obtained with 0.6 mu M ATP and 30 nM of the catalytic subunit of PKA, Phosphorylation altered the V-max of the PDE without affecting the K-m for cAMP. Phosphorylation also modified the Mg2+ requirements and the pattern of inhibition by rolipram, Cyanogen bromide cleavage of the P-32-labeled rat PDE4D3 yielded two or three major phosphopeptide bands, providing a first indication that the enzyme may be phosphorylated at multiple sites in a cell free system, Site-directed mutagenesis was performed on the serine residues present at the amino terminus of this PDE in the context of preferred motifs for PKA phosphorylation. The PKA-dependent incorporation of P-32 was reduced to the largest extent in mutants with both Ser(13) --> Ala and Ser(54) --> Ala substitutions, confirming the presence of more than one phosphorylation site in rat PDE4D3, While substitution of serine 13 with alanine did not affect the activation by PKA, substitution of Ser(54) completely suppressed the kinase activation, Similar conclusions were reached with wild type and mutated PDE4D3 proteins expressed in MA-10 cells, where the endogenous PKA was activated by dibutyryl cAMP. Again, the PDE with the Ser(54) --> Ala substitution could not be activated by the endogenous PKA in the intact cell, These findings support the hypothesis that the PDE4D3 variant contains a regulatory domain target for phosphorylation at the amino terminus of the protein and that Ser(54) in this domain plays a crucial role in activation.	STANFORD UNIV, MED CTR, DEPT GYNECOL & OBSTET, DIV REPROD BIOL, STANFORD, CA 94305 USA	Stanford University			Sette, Claudio/S-4307-2019	Sette, Claudio/0000-0003-2864-8266	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KOVALA T, 1994, J BIOL CHEM, V269, P8680; LOPEZAPARICIO P, 1993, BIOCHEM BIOPH RES CO, V193, P1137, DOI 10.1006/bbrc.1993.1744; LOTEN EG, 1978, J BIOL CHEM, V253, P746; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MANGANIELLO VC, 1992, ADV SEC MESS PHOSPH, V25, P147; MARCHMONT RJ, 1980, NATURE, V286, P904, DOI 10.1038/286904a0; MONACO L, 1994, J BIOL CHEM, V269, P347; MUCA C, 1994, ONCOGENE, V9, P3647; NEMOZ G, 1995, MOL ENDOCRINOL, V9, P1279, DOI 10.1210/me.9.10.1279; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; RASCON A, 1994, J BIOL CHEM, V269, P11962; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SETTE C, 1994, MOL CELL ENDOCRINOL, V100, P75, DOI 10.1016/0303-7207(94)90282-8; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; SHIBATA H, 1991, J BIOL CHEM, V266, P17948; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1995, J BIOL CHEM, V270, P23598, DOI 10.1074/jbc.270.40.23598; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; UDOVICHENKO IP, 1993, BIOCHEM J, V295, P49, DOI 10.1042/bj2950049; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164; WHALIN ME, 1988, BIOCHIM BIOPHYS ACTA, V972, P79; WYATT TA, 1994, FASEB J, V8, pA372	57	339	353	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16526	16534		10.1074/jbc.271.28.16526	http://dx.doi.org/10.1074/jbc.271.28.16526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663227				2022-12-25	WOS:A1996UX12600019
J	Wall, L; Destroismaisons, N; Delvoye, N; Guy, LG				Wall, L; Destroismaisons, N; Delvoye, N; Guy, LG			CAAT/enhancer-binding proteins are involved in beta-globin gene expression and are differentially expressed in murine erythroleukemia and K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-RELATED PROTEINS; LOCUS-CONTROL REGION; HUMAN GAMMA-GLOBIN; MOLECULAR-CLONING; TRANSGENIC MICE; NUCLEAR-PROTEIN; DNA-BINDING; PROMOTER; ENHANCER; FAMILY	Acting in cis with the beta-globin locus control region, the CAAT box of the beta-globin gene promoter stimulates transcription 10 fold in murine erythroleukemia (MEL) cells but is without effect in K562 cells. Our previous studies suggested that of four proteins from MEL cells that bind to this CAAT box region (CP1, GATA-1, and two factors that were denoted DSFr and DSF1) DSFr is involved in the up regulation of transcription. In the present report, the DSFr protein in MEL cells was identified as C/EBP gamma through expression cloning and antibody studies, C/EBP gamma DNA binding activity could not be detected in K562 cells, However, K562 cells, but not MEL cells, were found to express LIP, which is a truncated form of C/EBP beta and is an inhibitor of transcription, Thus, the differential expression of C/EBP members could account for the ability of the beta-globin CAAT box to stimulate transcription in MEL cells, but not function in K562 cells, Juxtaposing a specific C/EBP binding sequence next to the >beta-globin promoter, in constructs in which the CAAT box had been rendered inactive by mutation or deletion, restored full promoter activity in MEL cells only if CP1 still bound to the promoter, In conjunction with previous mutation analyses, these results suggest that C/EBP gamma may collaborate with CP1 to enhance transcription through the beta-globin CAAT box.	UNIV MONTREAL,DEPT MED,MONTREAL,PQ H2L 4M1,CANADA	Universite de Montreal	Wall, L (corresponding author), UNIV MONTREAL,INST CANC MONTREAL,CTR RECH LC SIMARD,MONTREAL,PQ H2L 4M1,CANADA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; AUMONT FL, 1993, DIFFERENTIATION, V52, P169, DOI 10.1111/j.1432-0436.1993.tb00627.x; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; COOPER C, 1992, J IMMUNOL, V149, P3225; DELVOYE NL, 1993, MOL CELL BIOL, V13, P6969, DOI 10.1128/MCB.13.11.6969; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DILLON N, 1995, MOL BIOL HEMOGLOBIN, P23; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FENG WC, 1913, J BIOL CHEM, V269, P269; HANSCOMBE O, 1991, GENE DEV, V5, P1384; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LUMELSKY N, 1991, MOL CELL BIOL, V11, P352; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; NISHIZAWA M, 1991, FEBS LETT, V282, P95, DOI 10.1016/0014-5793(91)80452-9; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; STAMATOYANNOPOU.G, 1987, DEV CONTROL GLOBIN G; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONASSENDELFT B, 1989, CELL, V56, P969; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	36	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16477	16484		10.1074/jbc.271.28.16477	http://dx.doi.org/10.1074/jbc.271.28.16477			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663270	hybrid			2022-12-25	WOS:A1996UX12600011
J	Chen, H; Strickland, DK; Mosher, DF				Chen, H; Strickland, DK; Mosher, DF			Metabolism of thrombospondin 2 - Binding and degradation by 3T3 cells and glycosaminoglycan-variant Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN CARCINOMA-CELLS; HUMAN-MELANOMA CELLS; PLATELET THROMBOSPONDIN; HEPARIN-BINDING; I REPEATS; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; GENE FAMILY; WEAK BASES	Thrombospondin 1 (TSP1) and thrombospondin 2 (TSP2) are members of the thrombospondin family that have a similar structural organization but somewhat different functional activities. Iodinated recombinant mouse TSP2 bound to NIH 3T3 cells and was internalized and degraded through a chloroquine-inhibitable pathway. TSP2 degradation was saturable, specific, and similar to the kinetics of degradation of TSP1. Human platelet TSP1, recombinant mouse TSP1, and recombinant mouse TSP2 cross-competed with one another for degradation by 3T3 cells. Degradation of TSP2 was less sensitive to inhibition by heparin than degradation of TSP1. This is in agreement with differences in heparin-binding affinity of the two TSPs. Degradation of TSP2 was slower in cultures of Chinese hamster ovary (CHO) cells lacking heparan sulfate proteoglycans than in wild type CHO cells or in cultures of 3T3 cells treated with heparitinase than in untreated 3T3 cells. Degradation of TSP2 was inhibited by antibodies against the low density lipoprotein receptor-related protein (LRP) or by the 39-kDa receptor-associated protein, a known antagonist of LRP. This study indicates that TSP2 and TSP1 are metabolized by a common internalization and degradation pathway involving heparan sulfate proteoglycan and LRP. Competition for this pathway is a possible mechanism whereby cells can control the levels and ratio of TSP1 and TSP2 in the extracellular milieu.	UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA; AMER RED CROSS, DEPT BIOCHEM, ROCKVILLE, MD 20855 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462, R01HL049111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462, HL49111] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; ADAMS JC, 1993, J CELL SCI, V104, P1061; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BORNSTEIN P, 1993, GENOMICS, V15, P607, DOI 10.1006/geno.1993.1114; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BORNSTEIN PG, 1964, J CLIN INVEST, V43, P1813, DOI 10.1172/JCI105055; CHEN H, 1994, J BIOL CHEM, V269, P32226; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; LABELL TL, 1993, GENOMICS, V17, P225, DOI 10.1006/geno.1993.1308; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1987, SEMIN THROMB HEMOST, V13, P245, DOI 10.1055/s-2007-1003499; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LISKA DJ, 1994, J CELL PHYSIOL, V158, P495, DOI 10.1002/jcp.1041580314; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1987, SEMIN THROMB HEMOST, V13, P343, DOI 10.1055/s-2007-1003510; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; NICKOLOFF BJ, 1988, AM J PATHOL, V132, P543; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PELLERIN S, 1994, MOL CELL ENDOCRINOL, V106, P181, DOI 10.1016/0303-7207(94)90201-1; PELLERIN S, 1993, J BIOL CHEM, V268, P4304; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; QABAR AN, 1994, J BIOL CHEM, V269, P1262; RAUGI GJ, 1984, THROMB RES, V36, P165, DOI 10.1016/0049-3848(84)90338-4; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHINGU T, 1993, GENOMICS, V16, P78, DOI 10.1006/geno.1993.1143; SUN X, 1992, SEMIN THROMB HEMOST, V18, P243, DOI 10.1055/s-2007-1002430; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1989, EXP CELL RES, V182, P473, DOI 10.1016/0014-4827(89)90251-6; TUSZYNSKI GP, 1987, SCIENCE, V236, P1570, DOI 10.1126/science.2438772; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; VOS HL, 1992, J BIOL CHEM, V267, P12192; WATSON JB, 1994, J CLIN INVEST, V94, P261, DOI 10.1172/JCI117316; WILLIAMS SE, 1994, ANN NY ACAD SCI, V737, P1, DOI 10.1111/j.1749-6632.1994.tb44297.x; YABKOWITZ R, 1993, J CELL PHYSIOL, V157, P24, DOI 10.1002/jcp.1041570104; YABKOWITZ R, 1991, CANCER RES, V51, P3648; YABKOWITZ R, 1993, CANCER RES, V53, P378	79	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15993	15999		10.1074/jbc.271.27.15993	http://dx.doi.org/10.1074/jbc.271.27.15993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663244	hybrid			2022-12-25	WOS:A1996UW35200025
J	Grune, T; Reinheckel, T; Davies, KJA				Grune, T; Reinheckel, T; Davies, KJA			Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; RED BLOOD-CELLS; MULTICATALYTIC PROTEINASE; MAMMALIAN-CELLS; GLUTAMINE-SYNTHETASE; HUMAN-ERYTHROCYTES; YEAST PROTEASOME; PURIFICATION; UBIQUITIN; COMPLEX	Exposure to various forms of oxidative stress (H2O2 and O-2(radical ion)) significantly increased the intracellular degradation of both ''short-lived'' and ''long-lived'' cellular proteins in the human hematopoietic cell line K562. Oxidatively modified hemoglobin and superoxide dismutase used as purified proteolytic substrates were also selectively degraded by K562 cell lysates, but exposure of these protein substrates to very high hydrogen peroxide concentrations actually decreased their proteolytic susceptibility, Our studies found little or no change in the overall capacity of cells and cell lysates to degrade ''foreign'' oxidized proteins after treatment of K562 cells with hydrogen peroxide or paraquat, a finding supported by proteasome Western blots and unchanged capacity of cell lysates to degrade the fluorogenic peptide succinyl-leucine leucine-valine-tyrosine coumarin-7 amide. Six days of daily treatment of K562 cells with an antisense oligodeoxynucleotide directed against the initiation codon region of the human proteasome C2 subunit gene dramatically depressed hydrogen peroxide-induced degradation of metabolically radiolabeled intracellular proteins, The actual amount of proteasome in antisense-treated K562 cells was also severely depressed, as revealed by Western blots and by measurements of the degradation of the fluorogenic peptide succinyl-leucine-leucine-valine-tyrosine-4-methylcoumarin-7-amide. The degradation of oxidatively modified foreign protein substrates was also markedly depressed in lysates prepared from K562 cells treated with the proteasome C2 antisense dideoxynucleotide, The inhibitor profile for the degradation of H2O2-modified hemoglobin by R562 cell lysates was consistent with a major role for the ATP-independent 20 S ''core'' proteasome complex, We conclude that proteasome, probably the 20 S core proteasome complex, is primarily responsible for the selective degradation of oxidatively damaged proteins in human hematopoietic cells, Since ''oxidative marking'' of cellular proteins by lipoxygenase has been proposed as an important step in red blood cell maturation, it is important to determine which protease or proteases could recognize and degrade such modified substrates, Our results provide evidence that proteasome can, indeed, conduct such selective degradation and appears to be the major cellular protease capable of fulfilling such a role in maturation.	UNIV SO CALIF,ANDRUS GERONTOL CTR,LOS ANGELES,CA 90089; ALBANY MED COLL,DEPT BIOCHEM & MOLEC BIOL,ALBANY,NY 12208	University of Southern California; Albany Medical College			Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Grune, Tilman/0000-0003-4775-9973; Davies, Kelvin/0000-0001-7790-3003	NIEHS NIH HHS [ES-03598] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R56ES003598, R23ES003598] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; DAHLMANN B, 1983, FEBS LETT, V160, P243, DOI 10.1016/0014-5793(83)80975-2; DAHLMANN B, 1988, BIOCHEM J, V255, P750; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; DEMARTINO GN, 1979, J BIOL CHEM, V254, P3712; DUBIEL W, 1987, BIOMED BIOCHIM ACTA, V46, P565; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HILT W, 1993, J BIOL CHEM, V268, P3479; HIPKISS AR, 1983, BIOMED BIOCHIM ACTA, V42, pS212; HOUGH R, 1987, J BIOL CHEM, V262, P8303; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; RIEDER RF, 1985, J BIOL CHEM, V260, P2015; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SALO DC, 1990, J BIOL CHEM, V265, P11919; SAVORY PJ, 1993, BIOCHEM J, V296, P601, DOI 10.1042/bj2960601; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399	41	292	295	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15504	15509		10.1074/jbc.271.26.15504	http://dx.doi.org/10.1074/jbc.271.26.15504			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663134	hybrid			2022-12-25	WOS:A1996UV29900032
J	Arnet, UA; McMillan, A; Dinerman, JL; Ballermann, B; Lowenstein, CJ				Arnet, UA; McMillan, A; Dinerman, JL; Ballermann, B; Lowenstein, CJ			Regulation of endothelial nitric-oxide synthase during hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; CELL; RNA; VASODILATATION; LOCALIZATION; MESSENGER; RELEASE; DNA	The mechanism by which nitric-oxide (NO) production increases during hypoxia is unknown, To explore the effect of hypoxia upon endothelial nitric-oxide synthase (ecNOS) activity and expression, we exposed bovine aortic endothelial cells (BAEC) to hypoxia (1% O-2) for 0-24 h and measured levels of ecNOS mRNA, protein, and activity, The amount of ecNOS mRNA increases to more than twice the basal level after 6 h of hypoxia, Incubation of BAEC with actinomycin D during hypoxia prevents this increase, demonstrating that higher levels of mRNA observed during hypoxia are due to increased synthesis, not to increased stability of ecNOS mRNA, Levels of ecNOS protein increase throughout 24 h of hypoxia to more than twice normoxic levels. Although ecNOS expression increases within 2 h of hypoxia, total activity remains unchanged, To explore the transcriptional regulation of ecNOS, we constructed a reporter plasmid containing the ecNOS promoter region upstream of the luc gene and transfected this reporter plasmid into BAEC. In this system, hypoxia induces a linear increase over time in the expression of luciferase driven by the ecNOS promoter, It is concluded that hypoxia induces an increase in transcription of ecNOS in endothelial cells, activating the regulatory region of ecNOS by undefined transcription factors.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV NEPHROL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University			Ballermann, Barbara J/G-5349-2016	Ballermann, Barbara J/0000-0002-8220-6381; Lowenstein, Charles/0000-0003-0485-7514	NHLBI NIH HHS [HL52315] Funding Source: Medline; PHS HHS [K1102451] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARROYO CM, 1990, BIOCHEM BIOPH RES CO, V170, P1177, DOI 10.1016/0006-291X(90)90517-Q; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BROWN IP, 1993, AM J PHYSIOL, V264, pH821, DOI 10.1152/ajpheart.1993.264.3.H821; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; GOETZ RM, 1994, BIOCHEM BIOPH RES CO, V205, P905, DOI 10.1006/bbrc.1994.2750; GREENBERG B, 1993, AM J PHYSIOL, V265, pH1712, DOI 10.1152/ajpheart.1993.265.5.H1712; HAMPL V, 1995, EUR RESPIR J, V8, P515; HARLOW E, 1988, ANTIBODIES LABORATOR, P72; HISHIKAWA K, 1995, FEBS LETT, V360, P291, DOI 10.1016/0014-5793(95)00124-R; IGNARRO LJ, 1993, THROMB HAEMOSTASIS, V70, P148; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Isozumi Kazuo, 1994, Keio Journal of Medicine, V43, P31; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KOLLER A, 1994, AM J PHYSIOL, V267, pH326, DOI 10.1152/ajpheart.1994.267.1.H326; KORENAGA R, 1994, BIOCHEM BIOPH RES CO, V198, P213, DOI 10.1006/bbrc.1994.1030; KOZNIEWSKA E, 1992, J CEREBR BLOOD F MET, V12, P311; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LUSCHER TF, 1993, AM J HYPERTENS, V6, pS283; Maniatis T., 1989, MOL CLONING LAB MAN; MARLETTA M A, 1990, Biofactors, V2, P219; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MCPHERSON RW, 1994, AM J PHYSIOL, V266, pH476, DOI 10.1152/ajpheart.1994.266.2.H476; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NORIS M, 1995, CIRC RES, V76, P536, DOI 10.1161/01.RES.76.4.536; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; POHL U, 1989, AM J PHYSIOL, V256, pH1595, DOI 10.1152/ajpheart.1989.256.6.H1595; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; Schwartz SE, 1983, TRACE ATMOSPHERIC CO, P1; SHAUL PW, 1994, AM J RESP CELL MOL, V11, P432, DOI 10.1165/ajrcmb.11.4.7522486; SHAUL PW, 1992, AM J PHYSIOL, V262, pH355, DOI 10.1152/ajpheart.1992.262.2.H355; SHAUL PW, 1995, AM J RESP CELL MOL, V13, P167, DOI 10.1165/ajrcmb.13.2.7542896; SUN M, 1992, LIFE SCI, V50, P555, DOI 10.1016/0024-3205(92)90367-X; UCHIDA K, 1992, AM J PHYSIOL, V263, pC200, DOI 10.1152/ajpcell.1992.263.1.C200; VANBUREN GA, 1992, AM J OBSTET GYNECOL, V167, P828, DOI 10.1016/S0002-9378(11)91597-X; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	51	166	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15069	15073		10.1074/jbc.271.25.15069	http://dx.doi.org/10.1074/jbc.271.25.15069			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663208	hybrid			2022-12-25	WOS:A1996UT10600064
J	Lin, DL; Chang, CS				Lin, DL; Chang, CS			p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN; DNA	p53 may function as a checkpoint by arresting the G(1) cell cycle in response to DNA damage induced by radiation or other stimuli. We have found that the expression of the TR2 orphan receptor (TR2), a member of the steroid receptor superfamily, was down-regulated by ionizing irradiation, Our data shown in the present study demonstrate that irradiation can repress TR2 at both the translational and transcriptional levels. Transient transfection assays further link p53 to this repression by proving that endogenously induced or exogenously transfected p53 can repress TR2 gene expression, and this repression can be reversed by the co-transfection of SV40 large T antigen. Together, our data demonstrate for the first time that radiation and p53 can repress TR2, possibly providing a new pathway to link ionizing irradiation and p53 to members of the steroid receptor superfamily.	UNIV WISCONSIN,WISCONSIN CLIN CANC CTR,DEPT MED,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison					NIDDK NIH HHS [DK47258] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; Gupta N, 1996, RADIAT RES, V145, P289, DOI 10.2307/3578984; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JIANG D, 1993, ONCOGENE, V8, P2805; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UEMURA H, 1995, J BIOL CHEM, V270, P5427, DOI 10.1074/jbc.270.10.5427; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WARD JF, 1994, RADIAT RES, V138, P585; WEICHSELBAUM R, 1993, MOL BIOL ONCOLOGISTS, P213; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8	30	43	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14649	14652		10.1074/jbc.271.25.14649	http://dx.doi.org/10.1074/jbc.271.25.14649			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663350	hybrid			2022-12-25	WOS:A1996UT10600001
J	Avent, ND; Liu, W; Warner, KM; Mawby, WJ; Jones, JW; Ridgwell, K; Tanner, MJA				Avent, ND; Liu, W; Warner, KM; Mawby, WJ; Jones, JW; Ridgwell, K; Tanner, MJA			Immunochemical analysis of the human erythrocyte Rh polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP SYSTEM; RED-CELL MEMBRANE; MOLECULAR-CLONING; RHO(D) ANTIGEN; PROTEINS; IDENTIFICATION; LOCALIZATION; GLYCOPROTEIN; EXPRESSION; RH(D)	We have used rabbit polyclonal antisera raised against synthetic peptides complementary to different domains of the Rh polypeptides and Rh glycoprotein to examine the topography and organization of these proteins in the human erythrocyte membrane, Previously unrecognized exofacial protease sites have been identified on Rh CcEe, D proteins, and Rh glycoprotein. The Rh D protein has two specific bromelain cleavage sites located within the first and sixth predicted external domains, with the site of cleavage localized in the sixth domain to lie between residues 353 and 354. All Rh polypeptide species were found to be susceptible to cleavage with trypsin and subtilisin within the first external domain of these proteins, The Rh glycoprotein has two bromelain cleavage sites within the first external domain, These flank the single N-glycosylation site (Asn(37)), with the cleavage site toward the C-terminal side of this residue being between residues 39 and 40, Bromelain treatment was found to deglycosylate the Rh glycoprotein, Immunoprecipitation experiments have revealed that anti-C, -c,E, -e, and -D immune complexes are reactive with antisera raised against the fourth predicted external loop of the Rh proteins and the C-terminal domain, These data indicate that the hypothesis that suggests Rh C/c antigens are expressed on truncated Rh polypeptides by a mechanism of alternate splicing is incorrect and support the hypothesis that Rh Cc and Ee antigens are expressed on a single polypeptide chain.	BRISTOL INST TRANSFUS SCI,BRISTOL BS10 5ND,AVON,ENGLAND; UNIV W ENGLAND,FAC SCI APPL,BRISTOL BS16 1QY,AVON,ENGLAND; UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of West England; University of Bristol	Avent, ND (corresponding author), INT BLOOD GRP REFERENCE LAB,SOUTHMEAD RD,BRISTOL BS10 5ND,AVON,ENGLAND.							ARCE MA, 1993, BLOOD, V82, P651; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1992, J BIOL CHEM, V267, P15134; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BLANCHARD D, 1988, BLOOD, V72, P1424; CARTRON JP, 1994, BLOOD REV, V8, P199, DOI 10.1016/0268-960X(94)90108-2; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; Daniels G., 1995, HUMAN BLOOD GROUPS, P257; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; GAHMBERG CG, 1983, EMBO J, V2, P223, DOI 10.1002/j.1460-2075.1983.tb01409.x; GAHMBERG CG, 1982, FEBS LETT, V140, P93, DOI 10.1016/0014-5793(82)80528-0; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; HERMAND P, 1993, BLOOD, V82, P669; HUGHESJONES NC, 1971, VOX SANG, V21, P210, DOI 10.1111/j.1423-0410.1971.tb00578.x; KAJII E, 1993, HUM GENET, V91, P157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LEVANKIM C, 1992, BLOOD, V80, P1074; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; Mollison PL, 1993, BLOOD TRANSFUSION CL, P543; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; MOURO I, 1993, NAT GENET, V5, P62, DOI 10.1038/ng0993-62; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SKOV F, 1977, VOX SANG, V33, P170, DOI 10.1111/j.1423-0410.1977.tb02249.x; Smythe JS, 1996, BLOOD, V87, P2968, DOI 10.1182/blood.V87.7.2968.bloodjournal8772968; SUYAMA K, 1992, BLOOD, V79, P808	31	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14233	14239		10.1074/jbc.271.24.14233	http://dx.doi.org/10.1074/jbc.271.24.14233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663003	hybrid			2022-12-25	WOS:A1996UQ66000046
J	Han, ZY; Johnston, C; Reeves, WH; Carter, T; Wyche, JH; Hendrickson, EA				Han, ZY; Johnston, C; Reeves, WH; Carter, T; Wyche, JH; Hendrickson, EA			Characterization of a Ku86 variant protein that results in altered DNA binding and diminished DNA-dependent protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; HAMSTER OVARY CELLS; V(D)J RECOMBINATION; IONIZING-RADIATION; SCID MUTATION; ANTIGENIC DETERMINANTS; MOUSE THYMOCYTES; MUTANTS; AUTOANTIGEN; MECHANISMS	Three proteins known to play a critical role in mammalian DNA double strand break repair and lymphoid V(D)J recombination are the autoantigens Ku86 and Ku70 and a 465-kDa serine/threonine protein kinase catalytic subunit (DNA-PKcs). These proteins physically associate to form a complex (DNA . PK) with DNA-dependent protein kinase activity. In this study, we demonstrate using electrophoretic mobility shift assays (EMSAs) that the nuclear DNA end-binding activity of Ku is altered in the human promyelocytic leukemic HL-60 cell line. Western blot and EMSA supershift analyses revealed that HL-60 cells expressed both full-length and variant Ku86 proteins. However, a combined EMSA and immunoanalysis revealed that the Ru heterodimers complexed with DNA in HL-60 cells contained only the variant Ku86 proteins. Finally, UV cross-linking experiments and DNA . PK assays demonstrated that the Ku complexes containing variant Ku86 had a greatly reduced ability to interact with DNA-PKcs and that consequently HL-60 cells had severely diminished DNA . PK activity. These data provide important insights into the interaction between Ku and DNA-PKcs and into the role of DNA . PK in DNA double-strand break repair.	BROWN UNIV, DEPT MOLEC BIOL CELL BIOL & BIOCHEM, PROVIDENCE, RI 02912 USA; UNIV N CAROLINA, DEPT MED & MICROBIOL IMMUNOL, THRUSTON ARTHRIT RES CTR, CHAPEL HILL, NC USA; UNIV N CAROLINA, UNC LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC USA; ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Brown University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Saint John's University					NIAID NIH HHS [K23 AI079394, AI35763] Funding Source: Medline; NIAMS NIH HHS [AR40391] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI079394, R01AI035763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040391] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Errami A, 1996, MOL CELL BIOL, V16, P1519; EVANS HH, 1993, RADIAT RES, V134, P307, DOI 10.2307/3578190; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANKENBERGSCHWAGER M, 1990, INT J RADIAT BIOL, V58, P569, DOI 10.1080/09553009014551931; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500, DOI 10.1016/0968-0004(94)90138-4; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Han ZY, 1996, CANCER RES, V56, P1621; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HE DM, 1996, IN PRESS MUTAT RES; HENDRICKSON EA, 1993, AM J PATHOL, V143, P1511; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KLAR AJS, 1984, COLD SPRING HARB SYM, V49, P77, DOI 10.1101/SQB.1984.049.01.011; KONNOSATO S, 1993, BIOCHEM MOL BIOL INT, V31, P113; LEE SE, 1995, MUTAT RES-DNA REPAIR, V336, P279, DOI 10.1016/0921-8777(95)00002-2; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIMORI T, 1986, J BIOL CHEM, V261, P375; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAILLARD S, 1993, PROTEINS, V15, P330, DOI 10.1002/prot.340150310; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; POLTORATSKY VP, 1995, J IMMUNOL, V155, P4529; PORGES AJ, 1990, J IMMUNOL, V145, P4222; PRICE A, 1993, SEMIN CANCER BIOL, V4, P61; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, J BIOL CHEM, V269, P7439; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THOMPSON LH, 1995, IN PRESS MUTAT RES; TROELSTRA C, 1994, CURR BIOL, V4, P1149, DOI 10.1016/S0960-9822(00)00260-8; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; WANG JS, 1994, J CELL SCI, V107, P3223; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEIBEZAHN KF, 1985, MUTAT RES, V145, P177, DOI 10.1016/0167-8817(85)90025-2; ZDZIENICKA MZ, 1995, MUTAT RES-DNA REPAIR, V336, P203, DOI 10.1016/0921-8777(95)00003-3; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	67	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14098	14104		10.1074/jbc.271.24.14098	http://dx.doi.org/10.1074/jbc.271.24.14098			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662896	Green Published, hybrid			2022-12-25	WOS:A1996UQ66000027
J	Liang, F; Jasin, M				Liang, F; Jasin, M			Ku80-deficient cells exhibit excess degradation of extrachromosomal DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; RECOMBINATION; REPAIR; MUTANTS; ANTIGEN; DEFECT	Mammalian cells possess a protein complex, termed DNA-PII, which binds to DNA double strand breaks in vitro. The complex consists of the heterodimeric Ru autoantigen and a DNA-dependent protein kinase, DNA-PKcs. Cell lines that are deficient for components of this complex are sensitive to ionizing radiation and have impaired V(D)J recombination, a site-specific recombination process. We have tested these cell lines for their ability to repair double strand breaks in transfected DNA. The xrs-6 cell line, which is deficient for the 80-kDa subunit of the Ru autoantigen, exhibited reduced stability of transfected DNA. Prior to obvious reductions in DNA stability, the levels of homologous recombination and DNA end joining were unaffected. However, the recovery of end joining products with precisely joined ends was reduced, with a concomitant increase in products containing deletions. Unlike the Ku80-deficient cells, no reduction in DNA stability was detected in DNA-PKcs-deficient scid cells. Scid cells also exhibited normal levels of homologous recombination and DNA end joining. These experiments implicate the Ru autoantigen, but not DNA-PKcs, in a direct role in protecting DNA ends from degradation.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University								ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BUHLER B, 1995, IMMUNOGENETICS, V42, P181; CHANG C, 1993, CANCER RES, V53, P1244; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LIANG F, 1995, J BIOL CHEM, V270, P23838, DOI 10.1074/jbc.270.40.23838; LUKACSOVICH T, 1994, NUCLEIC ACIDS RES, V22, P5649, DOI 10.1093/nar/22.25.5649; Maniatis T., 1982, MOL CLONING; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOORE PD, 1986, MUTAT RES, V160, P149, DOI 10.1016/0027-5107(86)90038-2; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SMITHRAVIN J, 1989, INT J RADIAT BIOL, V56, P951, DOI 10.1080/09553008914552411; SUBRAMANI S, 1988, GENETIC RECOMBINATIO, P549; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973	33	139	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14405	14411		10.1074/jbc.271.24.14405	http://dx.doi.org/10.1074/jbc.271.24.14405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662903	hybrid			2022-12-25	WOS:A1996UQ66000070
J	Sciorra, VA; Daniel, LW				Sciorra, VA; Daniel, LW			Phospholipase D-derived products in the regulation of 12-O-tetradecanoylphorbol-13-acetate-stimulated prostaglandin synthesis in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STIMULATED HUMAN FIBROBLASTS; ARACHIDONIC-ACID METABOLISM; HUMAN-NEUTROPHILS; PHOSPHATIDYLCHOLINE HYDROLYSIS; PHOSPHATIDIC-ACID; SUPEROXIDE GENERATION; DEPENDENT ACTIVATION; SIGNAL TRANSDUCTION; CHEMOTACTIC PEPTIDE	Madin-Darby canine kidney (MDCK) cells stimulated with 12-O-tetradecanoylphorbol-13-acetate (TPA) in the presence of ethanol synthesize phosphatidylethanol (PEt) instead of phosphatidic acid (PA) and diglyceride (DG). We have used ethanol to block the production of phospholipase D (PLD)-derived PA and DG (from PA hydrolysis) to study their role in signal transduction. In MDCK cells, TPA-stimulated prostaglandin E(2) (PGE(2)) synthesis was inhibited by ethanol at concentrations which inhibit PA and DG formation. In addition, TPA elicited a prolonged increase in PGE(2) synthesis that is dependent upon continuous activation of PLD. The TPA-stimulated translocation of protein kinase C alpha (PKC alpha) from cytosol to membrane was unaffected by ethanol. This suggests that PLD derived products act downstream of PKC in TPA-stimulated prostaglandin synthesis. The calcium ionophore, A23187, did not activate PLD, and PGE(2) synthesis in response to A23187 was unaffected by ethanol. TPA increased prostaglandin endoperoxide H synthase (PGHS) activity and increased the amount of immunodetectable prostaglandin endoperoxide H synthase 2 (PGHS-2). A23187 did not induce PGHS-2 and A23187-stimulated PGE(2) synthesis appears to be due to the constitutively expressed PGHS-1. Blocking the formation of PLD-derived products, PA and DG, inhibited the induction of PGHS-2 by TPA. These results indicate that prolonged PGE(2) synthesis in response to TPA is due to the continuous induction of PGHS-2, which is dependent upon PLD activation, In contrast, induction of PGHS-2 by epidermal growth factor was not affected by ethanol. Epidermal growth factor did not induce PKC alpha translocation nor activate PLD. Taken together, these data suggest that PLD-derived PA or DG act as second messengers in the induction of PGHS-2 by PKC-dependent pathways. The demonstration that inhibition of TPA-induced PA formation inhibits Raf-l translocation in MDCK cells (Ghosh, S., Strum, J. C., Sciorra, V. A., Daniel, L. W., and Bell, R. M. (1996) J. Biol. Chem, 271, 8472-8480) suggests that PA is the active PLD metabolite in TPA-stimulated signaling.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [R01CA043297, P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43297, CA-48955, CA-12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BALSINDE J, 1994, BBA-LIPID LIPID MET, V1210, P195, DOI 10.1016/0005-2760(94)90121-X; BASS DA, 1988, J BIOL CHEM, V263, P19610; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BEAUDRY GA, 1985, ARCH BIOCHEM BIOPHYS, V239, P242, DOI 10.1016/0003-9861(85)90832-X; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1991, BIOCHEM SOC T, V19, P324, DOI 10.1042/bst0190324; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; COOK SJ, 1992, BIOCHEM J, V268, P10534; DANIEL LW, 1984, BIOCHIM BIOPHYS ACTA, V792, P33, DOI 10.1016/0005-2760(84)90279-0; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V921, P82, DOI 10.1016/0005-2760(87)90173-1; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FERNANDEZ B, 1994, J BIOL CHEM, V269, P26711; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GODSON C, 1993, J BIOL CHEM, V268, P11946; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HUANG CF, 1990, J BIOL CHEM, V265, P14858; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JACKSON BA, 1993, BIOCHEM BIOPH RES CO, V197, P1465, DOI 10.1006/bbrc.1993.2642; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTIN TW, 1988, BIOCHEM BIOPH RES CO, V157, P1271, DOI 10.1016/S0006-291X(88)81012-X; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MCNAMARA MJG, 1948, BIOCHEM BIOPH RES CO, V122, P824; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OLSON SC, 1990, FEBS LETT, V272, P19, DOI 10.1016/0014-5793(90)80439-P; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PARKER J, 1987, J BIOL CHEM, V262, P5385; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RUBIN R, 1988, BIOCHEM BIOPH RES CO, V156, P1090, DOI 10.1016/S0006-291X(88)80744-7; SAMET JM, 1995, J BIOL CHEM, V270, P8044, DOI 10.1074/jbc.270.14.8044; SCHULZE S, 1991, J EXP MED, V174, P1975; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; SMITH WL, 1994, ANN NY ACAD SCI, V714, P136, DOI 10.1111/j.1749-6632.1994.tb12037.x; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZYGLEWSKA T, 1993, J LAB CLIN MED, V122, P542	73	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14226	14232		10.1074/jbc.271.24.14226	http://dx.doi.org/10.1074/jbc.271.24.14226			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663019	hybrid			2022-12-25	WOS:A1996UQ66000045
J	Peraldi, P; Hotamisligil, GS; Buurman, WA; White, MF; Spiegelman, BM				Peraldi, P; Hotamisligil, GS; Buurman, WA; White, MF; Spiegelman, BM			Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELLS; FACTOR-ALPHA; EXPRESSION; PHOSPHORYLATION; MONOCYTOGENES; RESISTANCE; ADIPOCYTES; INFECTION	Tumor necrosis factor (TNF)alpha plays a central role in the state of insulin resistance associated with obesity. It has previously been shown that one important mechanism by which TNF-alpha interferes with insulin signaling is through the serine phosphorylation of insulin receptor substrate-1 (IRS-1), which can then function as an inhibitor of the tyrosine kinase activity of the insulin receptor (IR), However, the receptors and the signaling pathway used by TNF-alpha that mediate the inhibition of IR activity are unknown. We show here that human TNF-alpha, which binds only to the murine p55 TNF receptor (TNFR), is as effective at inhibiting insulin-dependent tyrosine phosphorylation of IR and IRS-1 in adipocytes and myeloid 32D cells as murine TNF-alpha, which binds to both p55 TNFR and p75 TNFR. Likewise, antibodies that are specific agonists for p55 TNFR or p75 TNFR demonstrate that stimulation of p55 TNFR is sufficient to inhibit insulin signaling, though a small effect can also be seen with antibodies to p75 TNFR. Exogenous sphingomyelinase and ceramides, known to be formed by activat- ion of p55 TNFR, inhibit IR and IRS-1 tyrosine phosphorylation and convert IRS-1 into an inhibitor of IR tyrosine kinase in vitro. Myeloid 32D cells expressing LR and IRS-1 are sensitive to this inhibition, but cells expressing IR and IRS-2 are resistant, pointing to an important difference in the biological function between IRS-1 and IRS-2. These data strongly suggest that TNF-alpha inhibits insulin signaling via stimulation of p55 TNFR and sphingomyelinase activity, which results in the production of an inhibitory form of IRS-1.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; UNIV LIMBURG,DEPT SURG,6200 MD MAASTRICHT,NETHERLANDS; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Hasselt University; Maastricht University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Peraldi, Pascal/O-4592-2016	Peraldi, Pascal/0000-0003-0205-9252				BENNETT PH, 1990, DIABETES MELLITUS TH, P357; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JOSEPH C, 1993, J BIOL CHEM, V269, P3047; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MULLER G, 1995, EMBO J, V14, P1156; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; PALEOLOG EM, 1994, BLOOD, V84, P2578; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; Shepherd Peter R., 1993, P253; SONG H, 1994, J BIOL CHEM, V270, P3574; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	41	336	347	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13018	13022		10.1074/jbc.271.22.13018	http://dx.doi.org/10.1074/jbc.271.22.13018			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662983	Green Published, hybrid			2022-12-25	WOS:A1996UN47400053
J	Maiti, S; Doskow, J; Li, SL; Nhim, RP; Lindsey, JS; Wilkinson, MF				Maiti, S; Doskow, J; Li, SL; Nhim, RP; Lindsey, JS; Wilkinson, MF			The Pem homeobox gene - Androgen-dependent and -independent promoters and tissue-specific alternative RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOFETAL GENE; MESSENGER-RNA; CELL DEVELOPMENT; BINDING-PROTEIN; MOUSE TESTIS; GERM-CELL; BOX GENE; EXPRESSION; SPERMATOGENESIS; DIFFERENTIATION	The Pem gene encodes an atypical homeodomain protein, distantly related to Prd/Pax family members, that we demonstrate is regulated in a complex transcriptional and post-transcriptional manner. We show that the rat Pem genomic structure includes three 5'-untranslated (5'-UT) exons and four coding exons, three of which encode the homeodomain, Several alternatively spliced transcripts were identified, including one that skips an internal coding exon, enabling this mRNA to express a novel form of the Pem protein, Other alternatively spliced mRNAs were characterized that possess different 5'-UT regions, including a muscle specific transcript, The different 5'-UT termini present in Pem transcripts conferred different levels of translatability in vitro. Two promoters containing multiple transcription initiation sites were identified: a distal promoter (P-d) in the first 5'-UT exon and a proximal promoter (P-p) located in the ''intron'' upstream of the first coding exon, The P-d was active in placenta, ovary, tumor cell Lines, and to a lesser extent in skeletal muscle, In contrast, transcripts from the P-p were only detectable in testis and epididymis and were only expressed in epididymis in the presence of testosterone, To our knowledge no transcription factors have previously been identified that exhibit androgen-dependent expression in the epididymis.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA; OREGON HLTH SCI UNIV, DEPT MOLEC MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University			Li, Shulin/D-6478-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027233] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [T32EY007123] Funding Source: NIH RePORTER; NEI NIH HHS [T32 EY07123] Funding Source: Medline; NICHD NIH HHS [HD 27233] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSEN B, 1993, P NATL ACAD SCI USA, V90, P11084, DOI 10.1073/pnas.90.23.11084; ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BLAQUIER JA, 1988, ANN NY ACAD SCI, V541, P292, DOI 10.1111/j.1749-6632.1988.tb22266.x; CHAREST NJ, 1989, ENDOCRINOLOGY, V125, P942, DOI 10.1210/endo-125-2-942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; CORNWALL GA, 1995, J ANDROL, V16, P379; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GU W, 1995, J BIOL CHEM, V270, P236, DOI 10.1074/jbc.270.1.236; HACKER A, 1995, DEVELOPMENT, V121, P1603; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KAMPER J, 1995, CELL, V81, P73, DOI 10.1016/0092-8674(95)90372-0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LABOSKY PA, 1993, DEV BIOL, V159, P232, DOI 10.1006/dbio.1993.1236; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; MACLEOD CL, 1990, CELL GROWTH DIFFER, V1, P271; MAITI S, 1996, IN PRESS GENOMICS; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MOORE HDM, 1986, J REPROD FERTIL, V78, P327, DOI 10.1530/jrf.0.0780327; NORTON JN, 1989, ENDOCRINOLOGY, V124, P2711, DOI 10.1210/endo-124-6-2711; ORGEBINCRIST MC, 1996, IN PESS PHARM BIOL C; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Preslocsk J P, 1980, Endocr Rev, V1, P132; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; QIAN L, 1993, J IMMUNOL, V151, P6801; RAVNIK SE, 1995, DEV GENET, V16, P171, DOI 10.1002/dvg.1020160209; RAYLE RE, 1991, DEV BIOL, V146, P255, DOI 10.1016/0012-1606(91)90467-H; RESKO JA, 1980, J CLIN ENDOCR METAB, V50, P900, DOI 10.1210/jcem-50-5-900; Robaire B., 1988, P999; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTULLI R, 1990, ENDOCRINOLOGY, V126, P95, DOI 10.1210/endo-126-1-95; SAR M, 1993, SERTOLI CELL, P510; SASAKI AW, 1991, MECH DEVELOP, V34, P155, DOI 10.1016/0925-4773(91)90052-8; Schafer M, 1995, DEV BIOL, V172, P344, DOI 10.1006/dbio.1995.8049; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SINGH J, 1995, ENDOCRINOLOGY, V136, P5311, DOI 10.1210/en.136.12.5311; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; SUN YT, 1990, ENDOCRINOLOGY, V127, P1215, DOI 10.1210/endo-127-3-1215; TINDALL DJ, 1975, ENDOCRINOLOGY, V97, P636, DOI 10.1210/endo-97-3-636; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WANG YM, 1989, MOL CELL ENDOCRINOL, V63, P85, DOI 10.1016/0303-7207(89)90084-1; WATRIN F, 1993, DEV BIOL, V156, P136, DOI 10.1006/dbio.1993.1064; WILKINSON M, 1991, ESSENTIAL MOL BIOL, V1, P69; WILKINSON MF, 1990, DEV BIOL, V141, P451, DOI 10.1016/0012-1606(90)90400-D; WOLGEMUTH DJ, 1991, ANN NY ACAD SCI, V637, P300, DOI 10.1111/j.1749-6632.1991.tb27317.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YIU GK, 1994, NUCLEIC ACIDS RES, V22, P4599, DOI 10.1093/nar/22.22.4599	58	65	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17536	17546		10.1074/jbc.271.29.17536	http://dx.doi.org/10.1074/jbc.271.29.17536			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663309	hybrid			2022-12-25	WOS:A1996UX94300084
J	Milgram, SL; Mains, RE; Eipper, BA				Milgram, SL; Mains, RE; Eipper, BA			Identification of routing determinants in the cytosolic domain of a secretory granule-associated integral membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; TRANS-GOLGI NETWORK; PEPTIDE PROCESSING ENZYME; ATT-20 CELLS; CYTOPLASMIC DOMAIN; P-SELECTIN; TRAFFICKING; EXPRESSION; SIGNAL; LOCALIZATION	We have investigated the trafficking of integral membrane peptidylglycine alpha-amidating monooxygenase (PAM) in the neuroendocrine AtT-20 cell line, This bifunctional enzyme has two domains which together catalyze the COOH-terminal alpha-amidation of peptidylglycine substrates yielding amidated products stored in secretory granules, As soluble proteins, both catalytic domains were independently targeted to secretory granules, In contrast, membrane PAM was largely localized to the trans-Golgi network (TGN), Upon truncation of its cytoplasmic COOH-terminal domain, membrane PAM was less efficiently cleaved by secretory granule enzymes and accumulated on the plasma membrane, When transferred to the lumenal domain of the interleukin 2 receptor alpha-chain (Tac protein), the cytoplasmic domain of PAM caused rerouting of Tac from the surface to the TGN and supported internalization of Tac antibody from the plasma membrane, To define sequences in the cytoplasmic domain of integral membrane PAM involved in its trafficking, we expressed PAM proteins containing truncations, deletions, or point mutations in the COOH-terminal cytoplasmic domain. PAM proteins were not retained in the TGN when half of the cytoplasmic domain was deleted; such proteins accumulated on the plasma membrane, were not efficiently internalized, and were cleaved to generate a bifunctional PAM protein that was not stored in secretory granules, A tyrosine-based internalization motif was identified, which was not required for efficient cleavage of full-length integral membrane PAM by secretory granule enzymes, Deletion of an 18-amino acid domain surrounding this Tyr residue both diminished cleavage of membrane PAM by secretory granule enzymes and eliminated internalization of PAM from the plasma membrane, The cytoplasmic domain is responsible for retaining membrane PAM in the TGN and for retrieving membrane PAM from the cell surface, while the lumenal catalytic domains of PAM appear to be responsible for targeting the protein to secretory granules.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Milgram, SL (corresponding author), UNIV N CAROLINA, DEPT PHYSIOL, CB 7545, CHAPEL HILL, NC 27599 USA.				NIDDK NIH HHS [DK-32948] Funding Source: Medline; NIGMS NIH HHS [GM015293] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032948, R56DK032948, R37DK032948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015293] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHIDGEY MAJ, 1993, BIOESSAYS, V15, P317, DOI 10.1002/bies.950150505; COLOMER V, 1994, EMBO J, V13, P3711, DOI 10.1002/j.1460-2075.1994.tb06680.x; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HALBAN PA, 1994, BIOCHEM J, V299, P1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1994, J CELL SCI, V107, P737; MILGRAM SL, 1995, MOL BIOL CELL, V6, P412; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NJUS D, 1993, BIOCHIM BIOPHYS ACTA, V1144, P235, DOI 10.1016/0005-2728(93)90108-R; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; YUN HY, 1995, J BIOL CHEM, V270, P30075	43	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17526	17535		10.1074/jbc.271.29.17526	http://dx.doi.org/10.1074/jbc.271.29.17526			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663411	hybrid			2022-12-25	WOS:A1996UX94300083
J	Burns, EL; Nicholas, RA; Price, EM				Burns, EL; Nicholas, RA; Price, EM			Random mutagenesis of the sheep Na,K-ATPase alpha 1 subunit generating the ouabain-resistant mutant L793P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MUTATION; BINDING; ENZYME; CELLS; DNA	The polymerase chain reaction was used to randomly mutagenize a cDNA cassette encoding amino acids 691-946 of the sheep Na,K-ATPase alpha subunit, The mutagenized cassettes were used to replace the wild type region in the full-length cDNA, and pools of mutants were transfected into HeLa cells, After the generation of resistant cells via selection in 0.5 mu M ouabain, polymerase chain reaction was used to amplify the mutagenized cassette from the genomic DNA of the stable transfectants, Sequence analysis of the polymerase chain reaction product revealed three amino acid substitutions: I729V, L793P, and K836R, Subsequent site-directed mutagenesis experiments showed that only L793P was important for resistance, To elucidate the role of L793 in ouabain inhibition, additional mutations at this position were prepared. L793A and L793I mutants were constructed and expressed in HeLa cells, Only L793A survived selection using ouabain, which suggested that resistance is not due to the specific substitution of leucine with proline. To explore the mechanism of resistance, apparent affinities of the L793P mutant for sodium and potassium were compared to the wild-type HeLa pump, Although the apparent affinities were comparable for sodium, the mutant had a a-fold higher apparent affinity for potassium, This suggests that the mechanism of ouabain insensitivity of L793P is due to a perturbation in the region of the enzyme that may include the K+ binding site.	UNIV MISSOURI, DEPT VET BIOMED SCI, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DALTON CARDIOVASC RES CTR, COLUMBIA, MO 65211 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046469] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL46469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown A., 1982, ATP ATPASE DETERMINA, P223; BURNS EL, 1993, J BIOL CHEM, V268, P25632; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANTLEY LG, 1994, J BIOL CHEM, V269, P15358; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JOHNSON CL, 1995, ARCH BIOCHEM BIOPHYS, V317, P133, DOI 10.1006/abbi.1995.1145; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSUKAWA N, 1990, BIOTECHNIQUES, V9, P66; Leung DW, 1989, TECHNIQUE, V1, P11; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201	25	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15879	15883		10.1074/jbc.271.27.15879	http://dx.doi.org/10.1074/jbc.271.27.15879			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663108	hybrid, Green Published			2022-12-25	WOS:A1996UW35200009
J	Farwell, AP; Safran, M; Dubord, S; Leonard, JL				Farwell, AP; Safran, M; Dubord, S; Leonard, JL			Degradation and recycling of the substrate-binding subunit of type II iodothyronine 5'-deiodinase in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLIAL-CELLS; ACTIN POLYMERIZATION; ENZYME INACTIVATION; ORGANELLE STRUCTURE; THYROID-HORMONE; BREFELDIN-A; ENDOSOMES; INTERNALIZATION; RECEPTOR; PROTEINS	Thyroxine dynamically regulates levels of type II iodothyronine 5'-deiodinase (5'D-II) by modulating enzyme inactivation and targeting the enzyme to different pathways of internalization. 5'D-II is an similar to 200-kDa multimeric protein containing a 29-kDa substrate-binding subunit (p29) and an unknown number of other subunits, In the absence of thyroxine (T-4), p29 is slowly endocytosed and transported to the lysosomes, T-4 treatment rapidly activates an actin-mediated endocytotic pathway and targets the enzyme to the endosomes, In this study, we have characterized the influence of T-4 on the intracellular trafficking of 5'D-II. We show that T-4 accelerates the rate of 5'D-II inactivation by translocating the enzyme to the interior of the cell and by sequestering p29 in the endosomal pool without accelerating the rate of degradation of p29. This dichotomy between the rapid inactivation of catalytic activity and the much slower degradation of p29 is consistent with the reuse of p29 in the production of 5'D-II activity, Immunocytochemical analysis with a specific anti-p29 IgG shows that pulse affinity-labeled p29 reappears on the plasma membrane similar to 2 h after enzyme internalization in the presence of T-4, indicating that p29 is recycled, Despite the ability of p29 to be recycled in the T-4-treated cell, 5'D-II catalytic activity requires ongoing protein synthesis, presumably of another enzyme component(s) or an accessory enzyme-related protein, In the absence of T-4, enzyme inactivation and p29 degradation are temporally linked, and pulse affinity-labeled p29 is internalized and sequestered in discrete intracellular pools, These data suggest that T-4 regulates fundamental processes involved with the turnover of integral membrane proteins and participates in regulating the inter-relationships between the degradation, recycling, and synthetic pathways.	UNIV MASSACHUSETTS,SCH MED,MOLEC ENDOCRINOL LAB,DEPT MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,MOLEC ENDOCRINOL LAB,DEPT NUCL MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,MOLEC ENDOCRINOL LAB,DEPT MOLEC & CELLULAR PHYSIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Farwell, Alan/0000-0001-7716-2719	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002005, R01DK038772] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38772, DK 02005] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DAMKE H, 1991, J BIOL CHEM, V266, P24829; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; FARWELL AP, 1992, ENDOCRINOLOGY, V131, P721, DOI 10.1210/en.131.2.721; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; FEANY MB, 1993, NATURE, V364, P537, DOI 10.1038/364537a0; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; KELLY RB, 1993, NATURE, V364, P487, DOI 10.1038/364487a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEONARD JL, 1984, ENDOCRINOLOGY, V114, P998, DOI 10.1210/endo-114-3-998; LEONARD JL, 1990, J BIOL CHEM, V265, P940; LEONARD JL, 1994, ENDOCRINOLOGY, V135, P548, DOI 10.1210/en.135.2.548; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; Leonard JL, 1986, THYROID HORMONE META, P189; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCCARTHY KD, 1978, J CYCLIC NUCL PROT, V4, P15; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAFRAN M, 1993, J BIOL CHEM, V268, P14224; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAFRAN M, 1996, J BIOL CHEM, V261, P16363; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1993, CELL, V75, P1; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VISSER TJ, 1983, J CLIN INVEST, V71, P992, DOI 10.1172/JCI110854; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; WOLENSKI JS, 1993, J EXP ZOOL, V267, P33, DOI 10.1002/jez.1402670106	31	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16369	16374		10.1074/jbc.271.27.16369	http://dx.doi.org/10.1074/jbc.271.27.16369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663170	hybrid			2022-12-25	WOS:A1996UW35200076
J	Nanda, A; Brumell, JH; Nordstrom, T; Kjeldsen, L; Sengelov, H; Borregaard, N; Rotstein, OD; Grinstein, S				Nanda, A; Brumell, JH; Nordstrom, T; Kjeldsen, L; Sengelov, H; Borregaard, N; Rotstein, OD; Grinstein, S			Activation of proton pumping in human neutrophils occurs by exocytosis of vesicles bearing vacuolar-type H+-ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLASMA-MEMBRANE; NADPH OXIDASE; PH REGULATION; SUBCELLULAR-LOCALIZATION; MAMMALIAN KIDNEY; INTRACELLULAR PH; CYTOPLASMIC PH; MACROPHAGES; CELLS	Proton pump activity is not measurable in the plasma membrane of unstimulated neutrophils but becomes readily detectable upon activation by soluble agonists. The mechanism of pump activation was investigated in this report. V-type H+ pump activity, estimated as a bafilomycin A(1)-sensitive elevation of the cytosolic pH, was stimulated in suspended neutrophils by chemotactic peptides and by phorbol esters. Stimulation of pump activity induced by the agonists was greatly enhanced by cytochalasin B, an agent known to potentiate granular secretion in neutrophils. We therefore compared the rate and extent of pump activation with the pattern of exocytosis of the four types of secretory organelles present in neutrophils, using flow cytometry and enzyme-linked immunosorbent assay, The kinetics of exocytosis of secretory vesicles and secondary and tertiary granules but not primary granules paralleled the appearance of pump activity, The subcellular localization of the pump was defined by cellular fractionation and immunoblotting using an antibody to the C subunit of the V-type ATPase. The pump was abundant in tertiary granules, with significant amounts present also in primary granules and secretory vesicles. The pump was scarce in secondary granules and not detectable in the cytosol. Finally, the agonists failed to stimulate pump activity in neutrophil cytoplasts, which are intact cell fragments devoid of acidic granules, Together, our results suggest that the V-type H+-ATPase is not constitutively present in the plasma membrane of neutrophils but is delivered to the surface membrane by exocytosis during cellular activation, Tertiary granules and secretory vesicles are the most likely source of V-ATPases, Following insertion in the plasma membrane, the pump is poised to effectively extrude the excess metabolic acid that is generated during chemotaxis and bacterial killing.	HOSP SICK CHILDREN, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A8, CANADA; TORONTO HOSP, DEPT SURG, TORONTO, ON M5G 2C4, CANADA; RIGSHOSP, DEPT HAEMATOL L, CRANULOCYTE RES LAB, DK-2100 COPENHAGEN, DENMARK	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Rigshospitalet; University of Copenhagen			Kjeldsen, Lars/AAF-2096-2019; Nordström, Tommy/H-9111-2016	Nordström, Tommy/0000-0002-2153-5819; Sengelov, Henrik/0000-0002-5991-2958				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIDANI A, 1990, AM J PHYSIOL, V259, pC586, DOI 10.1152/ajpcell.1990.259.4.C586; BJERRUM OW, 1989, SCAND J CLIN LAB INV, V49, P613, DOI 10.3109/00365518909091536; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P318; BORREGAARD N, 1992, J CLIN INVEST, V90, P86, DOI 10.1172/JCI115860; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Cochrane CG, 1990, CELLULAR MOL MECHANI, P83; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; GALLIN JI, 1984, J IMMUNOL, V133, P415; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; Johnson K J, 1992, Immunol Ser, V57, P1; KALLIO DM, 1971, J ULTRA MOL STRUCT R, V37, P169, DOI 10.1016/S0022-5320(71)80048-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; KOZA EP, 1975, P SOC EXP BIOL MED, V149, P476; MOLLINEDO F, 1984, J BIOL CHEM, V259, P7143; MOLLINEDO F, 1986, J BIOL CHEM, V261, P1077; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1992, J BIOL CHEM, V267, P22740; NANDA A, 1995, J CELL PHYSIOL, V165, P588, DOI 10.1002/jcp.1041650317; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NIESSEN HWM, 1992, CELL SIGNAL, V4, P501, DOI 10.1016/0898-6568(92)90019-5; NORDSTROM T, 1994, FEBS LETT, V350, P82, DOI 10.1016/0014-5793(94)00738-1; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; SEGAL AW, 1995, PROTOPLASMA, V184, P86, DOI 10.1007/BF01276905; SENGELOV H, 1995, J IMMUNOL, V154, P4157; SENGELOV H, 1993, J IMMUNOL, V150, P1535; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; TAPPER H, 1996, IN PRESS J LEUKOCYTE; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; UMEKI S, 1994, ANN HEMATOL, V68, P267, DOI 10.1007/BF01695032; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; XIE XS, 1993, J BIOL CHEM, V268, P25063; ZHANG K, 1992, J BIOL CHEM, V267, P14539; ZHANG K, 1992, J BIOL CHEM, V267, P9701	53	86	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15963	15970		10.1074/jbc.271.27.15963	http://dx.doi.org/10.1074/jbc.271.27.15963			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663143	hybrid			2022-12-25	WOS:A1996UW35200021
J	Himeno, S; Chittum, HS; Burk, RF				Himeno, S; Chittum, HS; Burk, RF			Isoforms of selenoprotein P in rat plasma - Evidence for a full-length form and another form that terminates at the second UGA in the open reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE GENE; 3' UNTRANSLATED REGION; SELENOCYSTEINE; PROTEINS; SEQUENCES; DEIODINASE; CODON; CDNA; TGA; RNA	Several forms of selenoprotein P that share the same N-terminal sequence have been identified in rat plasma, but only one selenoprotein P mRNA has been characterized. The open reading frame of the mRNA contains 10 UGAs that presumably code for selenocysteine residues. Using heparin-Sepharose, we isolated two of the protein forms from immunoaffinity-purified selenoprotein P. One of the forms, Se-P-45B, migrates at 45 kDa on SDS-polyacrylamide gel electrophoresis, and the other, Se-P-57B, migrates at 57 kDa. These two forms were cleaved with cyanogen bromide, and both yielded 40-kDa fragments that were consistent with those fragments being an inter-methionine peptide near the N terminus of the predicted polypeptide. A 20-kDa fragment present in the cleavage products of Se-P-57B was absent from the products of Se-P-45B. This result suggested that Se-P-45B lacks the C-terminal region of the predicted polypeptide. Carboxypeptidase P digestion of Se-P-45B indicated that its C-terminal amino acid is Ser(244), the amino acid immediately upstream from the predicted second selenocysteine. C-terminal analysis of Se-P-57B indicated that its final residue is Asn(366), the last amino acid predicted by the cDNA sequence. Amino acid composition analyses of the two forms were consistent with both arising from the same mRNA Immunoaffinity-purified selenoprotein P was digested with proteases, and the resulting peptides were separated and sequenced. Only amino acid sequences predicted by the cDNA were found, and 80% of the predicted amino acid sequence was confirmed. These results are compatible with Se-P-45B arising from termination of translation at the second in-frame UGA codon and all of the 10 in-frame UGA codons being read through to produce Se-P-57B. These findings demonstrate that selenoprotein P isoforms of differing peptide lengths are present in plasma. They raise the possibility that the second UGA codon in selenoprotein P mRNA can have alternative functions: coding for the incorporation of selenocysteine or coding for termination of translation.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV GASTROENTEROL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University			Himeno, Seiichiro/AAW-3421-2020	Himeno, Seiichiro/0000-0002-0773-2373	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002497, R01ES002497, P30ES000267] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 26657] Funding Source: Medline; NIEHS NIH HHS [ES 00267, ES 02497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAROUCH W W, 1990, Peptide Research, V3, P73; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BERRY MJ, 1993, EMBO J, V12, P315; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOCK A, 1994, SELENIUM BIOL HUMAN, P9; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BURK RF, 1991, FASEB J, V5, P2274, DOI 10.1096/fasebj.5.9.1830557; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; HASELBECK A, 1990, GLYCOCONJUGATE J, V7, P63, DOI 10.1007/BF01050403; Hill K. E., 1994, Selenium in biology and human health., P117; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; READ R, 1990, J BIOL CHEM, V265, P17899; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAPPEL AL, 1984, METHOD ENZYMOL, V107, P602; WILKINSON JM, 1986, PRACTICAL PROTEIN CH, P122; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	26	65	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15769	15775		10.1074/jbc.271.26.15769	http://dx.doi.org/10.1074/jbc.271.26.15769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663023	hybrid			2022-12-25	WOS:A1996UV29900070
J	Mellgren, RL; Lu, Q; Zhang, WL; Lakkis, M; Shaw, E; Mericle, MT				Mellgren, RL; Lu, Q; Zhang, WL; Lakkis, M; Shaw, E; Mericle, MT			Isolation of a Chinese hamster ovary cell clone possessing decreased mu-calpain content and a reduced proliferative growth rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL PROTEINASES; NUCLEAR PROTEINS; HUMAN PLATELETS; INHIBITORS; DEGRADATION; CYCLIN; ASSAY; DNA	A Chinese hamster ovary cell line (CHOP) was cultured in the presence of benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone (ZLLY-CHN2), to select for resistance to this cell-permeant calpain inhibitor, A clone isolated after several courses of exposure (SHI cells) demonstrated decreased sensitivity to ZLLY-CHN2 toxicity and a decreased growth rate, SHI cells also possessed less mu-calpain isozyme relative to CHOP cells, as determined by activity measurement or by protein immunoblotting. Activities of m-calpain, calpastatin, cathepsin B, cathepsin L, and glycogen phosphorylase were not altered, SHI mu-calpain was partially purified by sequential chromatography on Bio-Gel A-1.5m and DEAE-Sepharose. Its chromatographic behavior in either system was the same as for CHOP mu-calpain, Further studies with the partially purified SHI and CHOP mu-calpain fractions failed to distinguish any difference in Ca2+ requirement or in sensitivity to inhibition by calpastatin or ZLLY-CHN2 for these enzymes, These experiments suggest that SHI cells underproduce a form of mu-calpain which is very similar to, if not identical with, CHOP mu-calpain. SHI cells displayed a population doubling time of 29 h compared with 19 h for CHOP cells, The decreased growth rate of SHI cells was the result of a prolonged G(1) phase, Introduction of purified human mu-calpain into SHI cells by electroporation transiently restored the growth rate and also increased toxicity associated with exposure to ZLLY-CHN2. SHI cells should be a valuable model in further studies to delineate the function of mu-calpain in cell proliferative growth.	MED COLL OHIO, DEPT THERAPEUT & PHARMACOL, TOLEDO, OH 43699 USA; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research					NHLBI NIH HHS [HL 36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; BARRETT AJ, 1972, ANAL BIOCHEM, V47, P280, DOI 10.1016/0003-2697(72)90302-8; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; CARILLO S, 1994, ONCOGENE, V9, P1679; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; Crawford C., 1990, INTRACELLULAR CALCIU, P75; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P236; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goll D E, 1985, Prog Clin Biol Res, V180, P151; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; ILLINGWORTH B, 1953, BIOCHEM PREPARAT, V3, P1; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; KATUNUMA N, 1983, CURR TOP CELL REGUL, V22, P71; KATZUNG BG, 1992, BASIC CLIN PHARM, P623; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKAS J, 1994, J IMMUNOL METHODS, V170, P255, DOI 10.1016/0022-1759(94)90400-6; Maki M., 1990, INTRACELLULAR CALCIU, P37; MARCH KL, 1993, CIRC RES, V72, P413, DOI 10.1161/01.RES.72.2.413; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MELLGREN RL, 1988, BIOCHEM BIOPH RES CO, V150, P170, DOI 10.1016/0006-291X(88)90501-3; MINSHULL J, 1989, J CELL SCI, P77; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURRAY A, 1994, CELL CYCLE, P106; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAW E, 1981, METHOD ENZYMOL, V80, P820; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TACK BF, 1980, J BIOL CHEM, V255, P8842; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L	43	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15568	15574		10.1074/jbc.271.26.15568	http://dx.doi.org/10.1074/jbc.271.26.15568			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663205	hybrid			2022-12-25	WOS:A1996UV29900041
J	Daniel, S; Zhang, SY; DePaoliRoach, AA; Kim, KH				Daniel, S; Zhang, SY; DePaoliRoach, AA; Kim, KH			Dephosphorylation of Sp1 by protein phosphatase 1 is involved in the glucose-mediated activation of the acetyl-CoA carboxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; RNA POLYMERASE-II; DNA-BINDING; MESSENGER-RNA; FATTY-ACIDS; TRANSCRIPTION; PHOSPHORYLATION; PROMOTER; EXPRESSION; DOMAINS	When mouse 30A5 preadipocytes are exposed to high glucose concentrations, acetyl-CoA carboxylase is induced through glucose activation of promoter II of the acetyl-CoA carboxylase gene. Glucose treatment of the cells increases Sp1 binding to two GC rich glucose response elements in promoter II. We have investigated the mechanism by which glucose increases Sp1 binding and transactivation of promoter II in 30A5 cells. DNA mobility shift assays have shown that nuclear extracts from glucose-treated cells exhibit increased Sp1 binding activity. This increase in the binding activity is not due to glucose-mediated changes in the amount of Sp1 in the nucleus but to an increase in the activity that modifies Sp1 so that it binds more effectively to the promoter sequence, This Sp1 modifying activity is inhibited by okadaic acid and phosphatase inhibitor 2, and has a molecular mass of 38-42 kDa. The catalytic subunit of type 1 protein phosphatase, whose molecular mass is 38 kDa, also increased the ability of Sp1 to bind to prometer II. Treatment of nuclear extract with antibodies against the catalytic subunit partially suppressed the nuclear activity for Sp1 activation. From these results, we conclude that the Sp1 transcription factor exhibits enhanced binding to promoter II and transcriptional activation is the result of glucose induced dephosphorylation by type 1 phosphatase.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis					NCI NIH HHS [CA46882] Funding Source: Medline; NIDDK NIH HHS [DK36569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRUN T, 1993, J BIOL CHEM, V268, P18905; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2628; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Numa S, 1974, Curr Top Cell Regul, V8, P197; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PARK IK, 1994, J BIOL CHEM, V269, P944; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SIVARAM P, 1990, J BIOL CHEM, V265, P5774; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZHANG S, 1995, J ENDOCRINOL, V147, P33, DOI 10.1677/joe.0.1470033	35	129	129	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14692	14697		10.1074/jbc.271.25.14692	http://dx.doi.org/10.1074/jbc.271.25.14692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663083	hybrid			2022-12-25	WOS:A1996UT10600011
J	Bu, CH; Pourmotabbed, T				Bu, CH; Pourmotabbed, T			Mechanism of Ca2+-dependent activity of human neutrophil gelatinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE REPEATS; MATRIX METALLOPROTEINASES; BASEMENT-MEMBRANE; 92-KDA GELATINASE; CRYSTAL-STRUCTURE; CELLS; PURIFICATION; COLLAGENASE; ACTIVATION; INVASION	Progelatinase B can be activated in vitro by organomercurial compounds and by proteolytic enzymes such as trypsin, chymotrypsin, and stromelysin, Activation of the proenzyme by either 4-aminophenylmercuric acetate or chymotrypsin yielded proteins that absolutely required Ca2+ for activity, regardless of the pH of the reaction mixture, The trypsin- and stromelysin-activated gelatinases, on the other hand, did not require Ca2+ for activity at pH 7.5, but the activity of the trypsin-activated enzyme became Ca2+ dependent as the pH increased. The pH study revealed that an amino acid residue with an apparent pK(alpha) of 8.8 was involved in this process. The NH2-terminal analyses showed that trypsin- and stromelysin-activated enzymes had the same NH2 termini (Phe(88)), but 4-aminophenylmercuric acetate- and chymotrypsin-activated enzymes had Met(75) and Gln(89) or Glu(92) as the NH2-terminal amino acid, respectively, These data, in conjunction with the x-ray crystal structure of collagenase, suggest that a salt linkage involving Phe(88) is responsible for the Ca2+-independent activity of trypsin- and stromelysin-activated gelatinase. Replacing Asp(432) in progelatinase with either Glu, Asn, Gly, or Lys resulted in the proteins that, upon activation by trypsin, required Ca2+ for activity, These substitutions did not significantly affect K-m for the synthetic substrate but decreased the k(cat) and increased the half-maximal Ca2+ concentration required for enzyme activity (K-Ca) by severalfold, The effects on k(cat) and K-Ca depended on both charge and size of the side chains of the substituted amino acids, The decrease in k(cat) correlated well with the increase in K-Ca of the mutants, The orders of decrease in k(cat) and increase in cat K-Ca were wild type greater than or equal to D432E > D432N > D432G > D432K and wild type less than or equal to D432E < D432N < D432G < D432K, respectively, These data suggest that in trypsin- or stromelysin-activated enzyme, the NH2-terminal Phe(88) forms a salt linkage with Asp(432), rendering the enzyme Ca2+ independent, Ca2+ affects catalytic activity of the 4-aminophenylmercuric acetate- and chymotrypsin-activated enzymes by substituting for the salt linkage and interacting with Asp(432), This interaction generates a similar, if not identical, conformational change to that generated by the salt linkage in the protein, leading to catalysis.	UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041843, R01AR041843] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-41843] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BU CH, 1995, J BIOL CHEM, V270, P18563, DOI 10.1074/jbc.270.31.18563; DECLERCK YA, 1991, CANCER RES, V51, P2151; DECLERCK YA, 1992, CANCER RES, V52, P701; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HOUSLEY TJ, 1993, J BIOL CHEM, V268, P4481; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEBIODA L, 1991, BIOCHEMISTRY-US, V30, P2817, DOI 10.1021/bi00225a012; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; Mareel MM, 1991, MECHANISMS INVASION, P73; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MORDOMI T, 1992, BIOCHEM J, V285, P603; NAGAI Y, 1972, BIOCHIM BIOPHYS ACTA, V263, P564, DOI 10.1016/0005-2795(72)90037-2; NAKAJIMA M, 1987, CANCER RES, V47, P4869; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; POURMOTABBED T, 1994, BBA-PROTEIN STRUCT M, V1204, P97, DOI 10.1016/0167-4838(94)90038-8; POURMOTABBED T, 1995, J PROTEIN CHEM, V14, P527, DOI 10.1007/BF01886879; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; Schultz R M, 1991, Cancer Treat Res, V54, P119; SELTZER JL, 1976, ARCH BIOCHEM BIOPHYS, V173, P355, DOI 10.1016/0003-9861(76)90270-8; SHIMA I, 1993, BRIT J CANCER, V67, P721, DOI 10.1038/bjc.1993.132; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILHELM SM, 1993, J BIOL CHEM, V268, P21906; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	45	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14308	14315		10.1074/jbc.271.24.14308	http://dx.doi.org/10.1074/jbc.271.24.14308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662913	hybrid			2022-12-25	WOS:A1996UQ66000058
J	Howard, GC; Yamaguchi, Y; Misra, UK; Gawdi, G; Nelsen, A; DeCamp, DL; Pizzo, SV				Howard, GC; Yamaguchi, Y; Misra, UK; Gawdi, G; Nelsen, A; DeCamp, DL; Pizzo, SV			Selective mutations in cloned and expressed alpha-macroglobulin receptor binding fragment alter binding to either the alpha(2)-macroglobulin signaling receptor or the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; HIGH-AFFINITY; DOMAIN; PROTEIN; MACROPHAGES; RECOGNITION; PLATELETS; THROMBIN; SITE	alpha(2)-Macroglobulin (alpha(2)M) activated with methylamine binds to two distinct cell-surface receptors: low density-lipoprotein receptor-related protein/alpha(2)M receptors and alpha(2)M signaling receptors, Binding to lipoprotein receptor-related protein/alpha(2)M receptor but not alpha(2)M signal receptor is inhibitable by another ligand, receptor-associated protein, Direct binding studies with a recombinant receptor binding fragment (RBF) from rat alpha(1)M and murine macrophages demonstrate two classes of binding sites of apparent K-d = 90 pM (1500 sites/cell) and 40 nM (60,400 sites/cell), Receptor-associated protein competes with RBF for binding to the lower but not the higher affinity site, Site-directed mutation of Lys-1374 (human numbering) in RBF to Arg or De residues almost completely abolishes signal transduction as compared to wild-type RBF. Direct binding studies with K1374R demonstrated no significant alteration in binding to the lower affinity site; however, binding to the high affinity site is reduced by 83%. Mutation of Lys-1370 to Ala resulted in a 4-5-fold increase in the K-d for binding to the lower affinity site with no significant alteration in binding to the high affinity site or signal transduction properties, Studies demonstrate comparable internalization and degradation of wild-type RBF and R1374R; however, internalization and degradation of K1370A is negligible. These studies suggest that regions around Lys-1370 and Lys-1374 are involved in lipoprotein receptor-related protein/alpha(2)M receptor and alpha(2)M signaling receptor binding, respectively.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Howard, GC (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710, USA.				NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29589] Funding Source: Medline; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1983, BIOCHEM J, V212, P709; CHU CT, 1993, J IMMUNOL, V150, P48; CHU CT, 1994, LAB INVEST, V71, P792; CHU CT, 1994, J IMMUNOL, V152, P1538; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HARMON JT, 1985, BIOCHEMISTRY-US, V24, P58, DOI 10.1021/bi00322a010; HERZ J, 1991, J BIOL CHEM, V266, P21232; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; MISRA UK, 1994, ANN NY ACAD SCI, V737, P486, DOI 10.1111/j.1749-6632.1994.tb44347.x; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MISRA UK, 1994, J BIOL CHEM, V269, P18303; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROCHE PA, 1988, J BIOL CHEM, V263, P6715; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUBENSTEIN DS, 1993, BIOCHEM J, V290, P85, DOI 10.1042/bj2900085; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x; WELINDER KG, 1984, J BIOL CHEM, V259, P8328	26	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14105	14111		10.1074/jbc.271.24.14105	http://dx.doi.org/10.1074/jbc.271.24.14105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662881	hybrid			2022-12-25	WOS:A1996UQ66000028
J	Lai, CF; Ripperger, J; Morella, KK; Jurlander, J; Hawley, TS; Carson, WE; Kordula, T; Caliguri, MA; Hawley, RG; Fey, GH; Baumann, H				Lai, CF; Ripperger, J; Morella, KK; Jurlander, J; Hawley, TS; Carson, WE; Kordula, T; Caliguri, MA; Hawley, RG; Fey, GH; Baumann, H			Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-2-MACROGLOBULIN GENE; EXPRESSION CLONING; GM-CSF; DNA; PROTEINS; SUBUNIT; CELLS	The cytoplasmic domain of the receptor for interleukin 10 (IL-10R) contains two box 3 sequence motifs that have been identified in the signal-transducing receptor subunits for IL-6-type cytokines and noted to be required for activating STAT3 and inducing transcription through IL-B-responsive elements, To determine whether the IL-10R has signaling functions similar to IL-6R in cells normally expressing these receptors, leukocytes of the B-, T-, and NK cell lineages were treated with either cytokine, Both cytokines activated factors that bound to the sis-inducible element and included STAT1 and STAT3, The cell response to IL-10 characteristically differed from that to IL-2/IL-15, IL-4, and interferon gamma. The signaling capabilities of the IL-10R for activating specific STAT proteins and inducing gene transcription were defined by reconstitution of receptor functions in transfected tissue culture cells, COS-1 cells, co-expressing the human IL-10R and individual STAT proteins, confirmed a preference of the IL-10R for STAT3 and STAT1, Unlike many hematopoietin receptors, the IL-10R did not detectably activate STAT5, The IL-10R, together with reporter gene constructs containing different IL-6-responsive gene elements, reconstituted in hepatoma cells an induction of transcription by IL-10 that was comparable to that by IL-6. This regulation could not be appreciably modified by enhanced expression of STAT proteins, The similar actions of IL-10R and IL GR on the induction of endogenous IL-6-responsive genes were demonstrated in hepatoma cells stably expressing the IL-10R. These receptor functions required the presence of the box 3 motifs, as shown by the analysis of the mouse IL-10R constructs containing progressively truncated cytoplasmic domains, The data demonstrate that the IL-10R, unlike other members of the interferon receptor family, is highly effective in recruiting the signaling pathways of IL-6-type cytokine receptors.	ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; ROSWELL PK CANC INST,DEPT MED & SURG,BUFFALO,NY 14263; UNIV ERLANGEN NURNBERG,D-91068 ERLANGEN,GERMANY; TORONTO HOSP,ONCOL RES LABS,TORONTO,ON M5G 2M1,CANADA; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	Roswell Park Cancer Institute; Roswell Park Cancer Institute; University of Erlangen Nuremberg; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University System of Georgia; University of Georgia			Carson, William E/E-2846-2011	Hawley, Robert/0000-0003-3512-5818; Carson, III, William E./0000-0001-7024-7533	NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN H, 1989, J IMMUNOL, V143, P1163; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; BERG DJ, 1995, J EXP MED, V182, P99, DOI 10.1084/jem.182.1.99; BIRON CA, 1994, CURR OPIN IMMUNOL, V6, P530, DOI 10.1016/0952-7915(94)90137-6; BRECHNER T, 1991, MOL BIOL MED, V8, P267; BURDIN N, 1995, J IMMUNOL, V154, P2533; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HART PH, 1995, J LEUKOCYTE BIOL, V57, P909, DOI 10.1002/jlb.57.6.909; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1995, ONCOGENE, V11, P1113; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jurlander J, 1995, BLOOD, V86, P1371; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LEHMANN J, 1994, J IMMUNOL, V153, P165; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LIEW FY, 1994, IMMUNOL LETT, V43, P95, DOI 10.1016/0165-2478(94)00157-X; LIU Y, 1994, J IMMUNOL, V152, P1821; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATOS ME, 1993, J EXP MED, V178, P1079, DOI 10.1084/jem.178.3.1079; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; NIIRO H, 1995, BLOOD, V85, P3736, DOI 10.1182/blood.V85.12.3736.bloodjournal85123736; NONOYAMA S, 1994, CLIN IMMUNOL IMMUNOP, V72, P373, DOI 10.1006/clin.1994.1155; NORTHEMANN W, 1988, BIOCHEMISTRY-US, V27, P9194, DOI 10.1021/bi00426a018; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAN JC, 1995, J BIOL CHEM, V270, P12906, DOI 10.1074/jbc.270.21.12906; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734	53	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13968	13975		10.1074/jbc.271.24.13968	http://dx.doi.org/10.1074/jbc.271.24.13968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662928	hybrid			2022-12-25	WOS:A1996UQ66000009
J	Reinscheid, RK; Ardati, A; Monsma, FJ; Civelli, O				Reinscheid, RK; Ardati, A; Monsma, FJ; Civelli, O			Structure-activity relationship studies on the novel neuropeptide orphanin FQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; BINDING; ANALOGS; DYNORPHIN-(1-13); PEPTIDES; RECEPTOR; LIGAND	The heptadecapeptide orphanin FQ (OFQ) is an endogenous ligand to an opioid-like G protein-coupled receptor. Although the primary structure of OFQ exhibits some similarity to the opioid peptides, OFQ is not recognized by opioid receptors nor does the OFQ receptor bind opioid ligands. In order to investigate the structural determinants of this ligand/receptor selectivity, we conducted a systematic structure-activity study on OFQ to characterize which sites of the molecule are important for receptor activation. Alanine- and D-amino acid-scanning mutagenesis revealed several residues in the amino-terminal half of OFQ which participate in both receptor binding and activation. Most strikingly, the Phe(1) position could be changed to a tyrosine without loss of biological activity, In addition, the OFQ receptor seemed to require recognition of the complete peptide molecule for activation. These results indicate that the mode of interaction of OFQ with its receptor may be different from that of the opioid peptides with their respective receptors and might therefore account for the observed selectivity.	HOFFMANN LA ROCHE AG,DIV PHARMA,CNS RES,CH-4070 BASEL,SWITZERLAND	Roche Holding			Civelli, Olivier/A-8392-2012					BEDDELL CR, 1977, PROC R SOC SER B-BIO, V198, P249, DOI 10.1098/rspb.1977.0096; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; DARLAK K, 1984, PEPTIDES, V5, P687, DOI 10.1016/0196-9781(84)90007-X; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GOLDSTEIN A, 1982, MOL GENETIC NEUROSCI, P249; HRUBY VJ, 1989, MED RES REV, V9, P343, DOI 10.1002/med.2610090306; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LEMAIRE S, 1986, INT J PEPT PROT RES, V27, P300; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MORLEY JS, 1980, ANNU REV PHARMACOL, V20, P81, DOI 10.1146/annurev.pa.20.040180.000501; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLAS P, 1984, P NATL ACAD SCI-BIOL, V81, P3074, DOI 10.1073/pnas.81.10.3074; PATERSON SJ, 1984, NEUROPEPTIDES, V5, P177, DOI 10.1016/0143-4179(84)90056-8; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; RUDINGER J, 1971, DRUG DESIGN, V2, P319; Sambrook J., 2002, MOL CLONING LAB MANU; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; TURCOTTE A, 1984, INT J PEPT PROT RES, V23, P361	21	180	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14163	14168		10.1074/jbc.271.24.14163	http://dx.doi.org/10.1074/jbc.271.24.14163			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662940	hybrid			2022-12-25	WOS:A1996UQ66000036
J	Saura, M; PerezSala, D; Canada, FJ; Lamas, S				Saura, M; PerezSala, D; Canada, FJ; Lamas, S			Role of tetrahydrobiopterin availability in the regulation of nitric-oxide synthase expression in human mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; L-ARGININE; SEPIAPTERIN REDUCTASE; BIOSYNTHESIS; PURIFICATION; REQUIREMENT; CYTOKINES; BIOPTERIN; COFACTOR; ENZYME	Human mesangial cells express an inducible form of nitric-oxide synthase (iNOS) after treatment with cytokines, Tetrahydrobiopterin (BH4), an essential cofactor for NOS, is required for cytokine-induced NO generation, We report here that BH4 is necessary not only for the activity but also for the expression of iNOS in human mesangial cells. Inhibition of de novo BH4 synthesis with 2,4-diamino-6-hydroxypyrimidine (DAHP) significantly attenuated iNOS activity as well as mRNA and protein expression in response to interleukin 1 beta plus tumor necrosis factor alpha (IL-1 beta/TNF-alpha). In contrast, sepiapterin, which provides BH4 through the pterin salvage pathway, strongly potentiated IL-1 beta/TNF-alpha-induced iNOS expression and abrogated the inhibitory effect of DAHP, Inhibition of the pterin salvage pathway with methotrexate abolished sepiapterin potentiation of iNOS induction but did not alter the effect of IL-1 beta/TNF-alpha. Determination of intracellular pteridines confirmed that sepiapterin markedly raised BH4 content, an effect that was blocked by methotrexate. These results suggest that BH4 availability plays an important role in the regulation of iNOS expression, The effect of BH4 appears to be mediated, at least in part, by an increase in mRNA stability, as indicated by the observation that DAHP shortened, whereas sepiapterin prolonged the half-life of IL-1 beta/TNF-alpha-induced iNOS mRNA. Taken together, our results suggest that the biosynthesis of BH4 contributes to cytokine induction of iNOS expression in human mesangial cells through the stabilization of iNOS mRNA.	CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN; CSIC,INST QUIM ORGAN GEN,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG)			Cañada, Francisco J./D-5837-2014; Perez-Sala, Dolores/L-5969-2014; Lamas, Santiago/G-7308-2015	Cañada, Francisco J./0000-0003-4462-1469; Perez-Sala, Dolores/0000-0003-0600-665X; Lamas, Santiago/0000-0001-5166-4155				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANTONOZZI I, 1988, J CHROMATOGR, V459, P319, DOI 10.1016/S0021-9673(01)82042-2; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BOGDAN C, 1995, FEBS LETT, V363, P69, DOI 10.1016/0014-5793(95)00284-G; BOGDAN C, 1982, J LEUKOCYTE, V182, P1155; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HYUN J, 1995, BIOCHEM BIOPH RES CO, V206, P380, DOI 10.1006/bbrc.1995.1052; JANSEN A, 1994, KIDNEY INT, V45, P1215, DOI 10.1038/ki.1994.161; KATOH S, 1982, BIOCHEM BIOPH RES CO, V105, P75, DOI 10.1016/S0006-291X(82)80012-0; KLATT P, 1993, J BIOL CHEM, V268, P14781; LASKIN JD, 1994, TRENDS ENDOCRIN MET, V5, P377, DOI 10.1016/1043-2760(94)90105-8; MARSDEN PA, 1990, J EXP MED, V172, P1843, DOI 10.1084/jem.172.6.1843; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MUHL H, 1995, J CLIN INVEST, V95, P1941, DOI 10.1172/JCI117876; MUHL H, 1994, KIDNEY INT, V46, P1302, DOI 10.1038/ki.1994.398; NAKAYAMA DK, 1994, AM J PHYSIOL, V266, pL455, DOI 10.1152/ajplung.1994.266.4.L455; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NICOLSON AG, 1993, BIOCHEM BIOPH RES CO, V193, P1269, DOI 10.1006/bbrc.1993.1762; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SAURA M, 1995, KIDNEY INT, V47, P500, DOI 10.1038/ki.1995.63; SCHAFFNER A, 1994, BIOCHEM BIOPH RES CO, V205, P516, DOI 10.1006/bbrc.1994.2695; SCHOEDON G, 1993, EUR J BIOCHEM, V213, P833, DOI 10.1111/j.1432-1033.1993.tb17826.x; SCHOEDON G, 1994, BIOCHEM BIOPH RES CO, V199, P504, DOI 10.1006/bbrc.1994.1257; SCHOEDON G, 1993, BIOCHEM BIOPH RES CO, V196, P1343, DOI 10.1006/bbrc.1993.2400; SCHULTZ PJ, 1991, AM J PHYSIOL, V261, pF600; SHEN R, 1988, BIOCHIM BIOPHYS ACTA, V965, P9, DOI 10.1016/0304-4165(88)90144-4; SUEOKA T, 1985, BIOCHIM BIOPHYS ACTA, V843, P193, DOI 10.1016/0304-4165(85)90139-4; WERNER ER, 1993, P SOC EXP BIOL MED, V203, P1; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842	48	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14290	14295		10.1074/jbc.271.24.14290	http://dx.doi.org/10.1074/jbc.271.24.14290			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662883	Green Published, hybrid			2022-12-25	WOS:A1996UQ66000055
J	Chernousov, MA; Stahl, RC; Carey, DJ				Chernousov, MA; Stahl, RC; Carey, DJ			Schwann cells secrete a novel collagen-like adhesive protein that binds N-syndecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; LAMININ RECEPTOR; EXTRACELLULAR-MATRIX; INTEGRIN EXPRESSION; MYELIN FORMATION; BASAL LAMINA; INVITRO; DIFFERENTIATION; IDENTIFICATION; ALPHA-6-BETA-4	A heparin-binding glycoprotein was purified from conditioned medium of cultured rat Schwann cells, The protein, p200, which has an apparent molecular mass of approximately 200 kDa, was identified by its ability to bind the cell surface heparan sulfate proteoglycan N-syndecan (syndecan-3) in a membrane overlay assay, Soluble heparan but not chondroitin sulfate inhibited the binding, suggesting the involvement of heparan sulfate chains of proteoglycan in the interaction. Purified p200 promoted the attachment and spreading of Schwann cells, Adhesion to p200 was blocked by heparin, suggesting that heparan sulfate proteoglycans are cell surface receptors for p200, The tissue distribution of p200 was determined by immunoblot analysis with anti-p200 antibodies, Among neonatal rat tissues examined p200 was detected only in sciatic nerve and, at newer levels, in skeletal muscle, p200 expression in sciatic nerve was detectable only during the first 23 weeks of postnatal development and was not detected in adult rats. Immunofluorescent staining of rat sciatic nerve showed that p200 was localized in the extracellular matrix surrounding individual Schwann cells-axon units, Two tryptic peptides from p280 were purified and sequenced, These contained multiple GXY collagen-like repeats, Bacterial collagenase digestion of p200 produced a product with an apparent molecular mass of approximately 90 kDa, These data suggest that Schwann cells secrete an apparently novel collagen-like adhesive protein that interacts with cells through cell surface heparan sulfate proteoglycans.			Chernousov, MA (corresponding author), GEISINGER MED CLIN,WEIS CTR RES,100 N ACAD AVE,DANVILLE,PA 17822, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOXBERG YV, 1994, ANAL BIOCHEM, V219, P32; BUNGE MB, 1993, PERIPHERAL NEUROPATH, P299; CAREY DJ, 1987, J CELL BIOL, V105, P1013, DOI 10.1083/jcb.105.2.1013; CAREY DJ, 1990, J BIOL CHEM, V265, P20627; CAREY DJ, 1993, EXP CELL RES, V208, P10, DOI 10.1006/excr.1993.1217; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CAREY DJ, 1983, J CELL BIOL, V97, P473, DOI 10.1083/jcb.97.2.473; CAREY DJ, 1986, J CELL BIOL, V102, P2224; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; CORNBROOKS CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3850, DOI 10.1073/pnas.80.12.3850; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HARLOW E, 1988, ANTIBODIES LABORATOR, P162; HSIAO LL, 1991, J CLIN INVEST, V87, P811, DOI 10.1172/JCI115084; KARLSSON JO, 1994, ANAL BIOCHEM, V219, P144, DOI 10.1006/abio.1994.1243; KATO M, 1994, J BIOL CHEM, V269, P18881; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LORIMIER P, 1992, J HISTOCHEM CYTOCHEM, V40, P859, DOI 10.1177/40.6.1588030; MCGARVEY ML, 1984, DEV BIOL, V105, P18, DOI 10.1016/0012-1606(84)90257-4; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13844	13853		10.1074/jbc.271.23.13844	http://dx.doi.org/10.1074/jbc.271.23.13844			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662884	hybrid			2022-12-25	WOS:A1996UP38500081
J	Hsu, DKW; Guo, Y; Alberts, GF; Copeland, NG; Gilbert, DJ; Jenkins, NA; Peifley, KA; Winkles, JA				Hsu, DKW; Guo, Y; Alberts, GF; Copeland, NG; Gilbert, DJ; Jenkins, NA; Peifley, KA; Winkles, JA			Identification of a murine TEF-1-related gene expressed after mitogenic stimulation of quiescent fibroblasts and during myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; GROWTH FACTOR-I; ENHANCER FACTOR-I; INTIMAL HYPERPLASIA; HEPARIN-BINDING; POINT MUTATION; SINGLE GENE; RECEPTOR; TRANSCRIPTION; CLONING	Fibroblast growth factor (FGF)-1 binding to cell surface receptors stimulates an intracellular signaling pathway that ultimately promotes the transcriptional activation of specific genes. We have used a mRNA differential display method to identify FGF-1-inducible genes in mouse NIH 3T3 fibroblasts. Here, we report that one of these genes, FGF-regulated (FR)-19, is predicted to encode a member of the transcriptional enhancer factor (TEF)-1 family of structurally related DNA-binding proteins. Specifically, the deduced FR-19 amino acid sequence has similar to 89, 77, and 68% overall identity to chicken TEF-1A, mouse TEF-1, and mouse embryonic TEA domain-containing factor, respectively. Gel mobility shift experiments indicate that FR-19, like TEF-1, and bind the GT-IIC motif found in the SV40 enhancer. The FR-19 gene maps in the distal region of mouse chromosome 6, and analysis of several FR-19 cDNA clones indicates that at least two FR-19 isoforms may be expressed from this locus. FGF-1 induction of FR-19 mRNA expression in mouse fibroblasts is first detectable at 4 h after FGF-1 addition and is dependent on de novo RNA and protein synthesis. FGF-2, calf serum, platelet-derived growth factor-BB, and phorbol 12-myristate 13-acetate can also induce FR-19 mRNA levels. We have also found that FR-19 mRNA expression increases during mouse C2C12 myoblast differentiation in vitro. The FR-19 gene is expressed in vivo in a tissue-specific manner, with a relatively high level detected in lung. These results indicate that increased expression of a TEF-1-related protein may be important for both mitogen-simulated fibroblast proliferation and skeletal muscle cell differentiation.	AMER RED CROSS, DEPT BIOL MOLEC, HOLLAND LAB, ROCKVILLE, MD 20855 USA; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20037 USA	American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; George Washington University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039727, R29HL039727, T32HL007698] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39727, HL-07698] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRIANOPOULOS A, 1994, MOL CELL BIOL, V14, P2503, DOI 10.1128/MCB.14.4.2503; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; Burgess W. H., 1996, P154; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DONOHUE PJ, 1994, J BIOL CHEM, V269, P8604; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Green EL, 1981, GENETICS PROBABILITY, P77; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; HOU JZ, 1993, PROTEIN SCI, V2, P86; Hsu DKW, 1996, J CELL PHYSIOL, V167, P261, DOI 10.1002/(SICI)1097-4652(199605)167:2<261::AID-JCP9>3.0.CO;2-N; HSU DKW, 1993, BIOCHEM BIOPH RES CO, V197, P1483, DOI 10.1006/bbrc.1993.2644; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PU LQ, 1993, CIRCULATION, V88, P208, DOI 10.1161/01.CIR.88.1.208; RON D, 1993, J BIOL CHEM, V268, P5388; SHAOUL E, 1995, ONCOGENE, V10, P1553; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; THINAKARAN G, 1993, FEBS LETT, V319, P271, DOI 10.1016/0014-5793(93)80561-8; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115; WINKLES JA, 1995, CARDIOVASCULAR DIS, V2, P109; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727	70	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13786	13795		10.1074/jbc.271.23.13786	http://dx.doi.org/10.1074/jbc.271.23.13786			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662936	hybrid			2022-12-25	WOS:A1996UP38500073
J	Moriguchi, T; Kuroyanagi, N; Yamaguchi, K; Gotoh, Y; Irie, K; Kano, T; Shirakabe, K; Muro, Y; Shibuya, H; Matsumoto, K; Nishida, E; Hagiwara, M				Moriguchi, T; Kuroyanagi, N; Yamaguchi, K; Gotoh, Y; Irie, K; Kano, T; Shirakabe, K; Muro, Y; Shibuya, H; Matsumoto, K; Nishida, E; Hagiwara, M			A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; FAMILY; CDNA	A cDNA encoding a novel member of the mitogen-activated protein kinase kinase (MAPKK) family, MAPKK6, was isolated and found to encode a protein of 334 amino acids, with a calculated molecular mass of 37 kDa that is 79% identical to MKK3. MAPKK6 was shown to phosphorylate and specifically activate the p38/MPK2 subgroup of the mitogen-activated protein kinase superfamily and could be demonstrated to be phosphorylated and activated in vitro by TAK1, a recently identified MAPKK kinase. MKK3 was also shown to be a good substrate for TAK1 in vitro. Furthermore, when co-expressed with TAK1 in cells in culture, both MAPKK6 and MKK3 were strongly activated. In addition, co-expression of TAK1 and p38/MPK2 in cells resulted in activation of p38/MPK2. These results indicate the existence of a novel kinase cascade consisting of TAK1, MAPKK6/MKK3, and p38/MPK2.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOL BIOL,SAKYO KU,KYOTO 60601,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT DERMATOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Kyoto University; Nagoya University; Nagoya University; Nagoya University; Hokkaido University			Moriguchi, Tetsuo/D-7061-2012; MURO, Yoshinao/M-8883-2014	Moriguchi, Tetsuo/0000-0002-9598-4991; Muro, Yoshinao/0000-0003-2329-8375				AHMAD MF, 1994, NATURE, V369, P156; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MERCURIO F, 1995, SCIENCE, V268, P286; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	28	406	415	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13675	13679		10.1074/jbc.271.23.13675	http://dx.doi.org/10.1074/jbc.271.23.13675			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8663074	hybrid			2022-12-25	WOS:A1996UP38500057
J	Yin, M; Yang, SQ; Lin, HZ; Lane, MD; Chatterjee, S; Diehl, AM				Yin, M; Yang, SQ; Lin, HZ; Lane, MD; Chatterjee, S; Diehl, AM			Tumor necrosis factor alpha promotes nuclear localization of cytokine-inducible CCAAT/enhancer binding protein isoforms in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; 3 C/EBP ISOFORMS; PARTIAL-HEPATECTOMY; LIVER-REGENERATION; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; GEL-ELECTROPHORESIS; GENE-EXPRESSION; LEUCINE ZIPPER; KAPPA-B	Hepatocytes were cultured in the presence of recombinant tumor necrosis factor (TNF) alpha or mutated TNF alpha peptides that specifically activate either p55 or p75 TNF receptors to determine if TNF alpha can activate cytokine inducible CCAAT/enhancer binding protein (C/EBP) isoforms by post-transcriptional mechanisms that are initiated by TNF receptors, Within 5-10 min after treatment with any of these agents, nuclear concentrations of C/EBP beta and C/EBP delta double and remain 2-4-fold greater than control cultures for 30 min (p < 0.01), Consistent with these results, gel mobility shift assays demonstrate S-fold increased nuclear C/EBP beta- and C/EBP delta-DNA binding activity in TNF alpha-treated cells, and immunocytochemistry confirms rapid redistribution of these C/EBP isoforms into the nucleus, In contrast, mRNA and whole cell protein concentrations of C/EBP beta and delta are not altered by TNF alpha exposure, and nuclear concentrations of another C/EBP isoform, C/EBP alpha, are decreased by 80%, This novel evidence that TNF alpha initiates post-transcriptional activation of cytokine-inducible C/EBP isoforms identifies a mechanism that enables hepatocytes to respond immediately to inflammatory stress.	JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALAM T, 1992, J BIOL CHEM, V267, P5021; BEG AA, 1994, ONCOGENE, V9, P1487; BRAISER A R, 1990, EMBO (European Molecular Biology Organization) Journal, V9, P3933; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CHUNG MK, 1990, CIRC RES, V67, P753, DOI 10.1161/01.RES.67.3.753; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; DIEHL AM, 1994, HEPATOLOGY, V19, P447; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; DIEHL AM, 1995, HEPATOLOGY, V22, P252, DOI 10.1016/0270-9139(95)90379-8; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEHR G, 1992, J IMMUNOL, V149, P911; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HIGASHITSUJI H, 1995, J SURG RES, V58, P267, DOI 10.1006/jsre.1995.1042; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MENON SD, 1995, J BIOL CHEM, V270, P18881; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MOHN KL, 1990, J BIOL CHEM, V265, P21914; NAUME B, 1991, J IMMUNOL, V146, P3045; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAN B, 1995, J BIOL CHEM, V270, P18123; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATOH M, 1991, Molecular Biotherapy, V3, P136; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391	45	93	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17974	17978		10.1074/jbc.271.30.17974	http://dx.doi.org/10.1074/jbc.271.30.17974			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663327	hybrid			2022-12-25	WOS:A1996UY93500060
J	Kempe, K; Hsu, FF; Bohrer, A; Turk, J				Kempe, K; Hsu, FF; Bohrer, A; Turk, J			Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; ISOLATED PANCREATIC-ISLETS; N-ACYLATED GLYCEROPHOSPHOLIPIDS; MEDIATED SIGNAL-TRANSDUCTION; ENZYMATIC-SYNTHESIS; INSULIN-SECRETION; ANANDAMIDE; IDENTIFICATION; PHOSPHOLIPIDS; LOCALIZATION	Arachidonylethanolamide (AEA) isolated from porcine brain binds to cannabinoid receptors, mimics nabinoid pharmacologic effects, and has been proposed as an endogenous cannabinoid receptor ligand, Demonstration of co-distribution of AEA and cannabinoid receptors in various brain regions could provide supportive evidence for this role, are have performed isotope dilution mass spectrometric measurements of AEA and have demonstrated AEA production by rat tissue homogenates in vitro from exogenous arachidonate and ethanolamine, No detectable endogenous AEA (<3.5 pmol/g of tissue) was observed in fresh rat brain, whether or not inhibitors of AEA hydrolysis were present during tissue processing, AEA (>1 nmol/g) was produced during saponification of brain phospholipid extracts, This appears not to reflect hydrolysis of N-arachidonylethanolamine phospholipid precursors of AEA, because Streptomyces chromfucsis phospholipase D, which is active against NAPE, failed to generate AEA from brain phospholipids despite substantial conversion of phospholipids to phosphatidic acid. Such experiments suggested that the abundance of N-arachidonylethanolamine phospholipid in fresh rat brain may be less than 1 in 10(6) phospholipid molecules, AEA generated during saponification of tissue phospholipids appears to arise from base-catalyzed aminolysis of arachidonate containing glycerolipids, because AEA was produced from synthetic (1-stearoyl, 2-arachidonoyl)-phosphatidylethanolamine under saponification conditions, and the amount produced increased 300-fold when free ethanolamine was included in the hydrolysis solution, Although AEA was not detectable (<0.17 pmol/mg of protein) in fresh rat brain, AEA accumulated post mortem to levels of 126 pmol/mg of brain protein. These findings do not exclude the possibility that AEA is rapidly synthesized and degraded locally in vivo, but they indicate that the AEA content of fresh rat brain and of NAPE precursors from which AEA might be derived are exceedingly low and that AEA can be produced artifactually from biological materials.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV DIABET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV METAB & LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV METAB & LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV DIABET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV ENDOCRINOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR-00954] Funding Source: Medline; NIDDK NIH HHS [R37-DK-34388] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURNSTEIN S, 1991, BIOCHEM PHARMACOL, V27, P1275; CHILDERS SR, 1994, BIOCHEM PHARMACOL, V47, P711, DOI 10.1016/0006-2952(94)90134-1; COREY EJ, 1984, J AM CHEM SOC, V106, P1503, DOI 10.1021/ja00317a064; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; DEVANE WA, 1994, TRENDS PHARMACOL SCI, V15, P40, DOI 10.1016/0165-6147(94)90106-6; DEVANE WA, 1992, SCIENCE, V258, P946; DEWEY WL, 1986, PHARMACOL REV, V38, P151; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; EVANS DM, 1994, J PHARMACOL EXP THER, V268, P1271; FELDER CC, 1992, MOL PHARMACOL, V42, P838; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; IVERSEN L, 1994, NATURE, V372, P619, DOI 10.1038/372619a0; JOHNSON DE, 1993, PROSTAG LEUKOTR ESS, V48, P429, DOI 10.1016/0952-3278(93)90048-2; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; LAYCHOCK SG, 1986, BIOCHEM PHARMACOL, V35, P2003, DOI 10.1016/0006-2952(86)90733-1; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1991, PHARMACOL BIOCHEM BE, V40, P461, DOI 10.1016/0091-3057(91)90347-5; NATARAJAN V, 1985, BIOCHIM BIOPHYS ACTA, V835, P426, DOI 10.1016/0005-2760(85)90111-0; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; REICHMAN M, 1991, MOL PHARMACOL, V40, P547; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHMID PC, 1986, CHEM PHYS LIPIDS, V41, P195, DOI 10.1016/0009-3084(86)90022-8; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V835, P1, DOI 10.1016/0005-2760(85)90023-2; TURK J, 1984, BIOCHIM BIOPHYS ACTA, V794, P125, DOI 10.1016/0005-2760(84)90305-9; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V834, P23, DOI 10.1016/0005-2760(85)90172-9; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WOLF BA, 1986, J BIOL CHEM, V261, P3510; WREN JJ, 1964, BIOCHEM J, V90, pP3	42	99	101	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17287	17295		10.1074/jbc.271.29.17287	http://dx.doi.org/10.1074/jbc.271.29.17287			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663381	hybrid			2022-12-25	WOS:A1996UX94300049
J	Revan, S; Montesinos, MC; Naime, D; Landau, S; Cronstein, BN				Revan, S; Montesinos, MC; Naime, D; Landau, S; Cronstein, BN			Adenosine A(2) receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; SUPEROXIDE ANION GENERATION; CHEMOATTRACTANT RECEPTORS; A2 RECEPTORS; CYCLIC-AMP; TRANSDUCTION; MODULATION; AFFINITY; SUBUNITS; OXIDASE	Adenosine modulates generation of superoxide anion by neutrophils via occupancy of specific adenosine A, receptors, However, the intracellular signal transduction pathways by which occupancy of neutrophil aden osine A, receptors inhibits superoxide anion generation (O-2 (radical ion)) are not web understood. We, therefore, tested the hypothesis that signaling at polymorphonuclear leukocyte (PMN) adenosine receptors proceeds via activation of a serine/threonine protein phosphatase (pp), Both the specific pp1 inhibitor calyculin A (10 nM) and the pp2A inhibitor okadaic acid (10 mu M) enhanced O-2(radical ion) generation (185 +/- 24 and 189 +/- 35% of control, respectively, p < 0.0001 for both, n = 8), as reported previously, Calyculin A, but not okadaic acid, completely reversed inhibition of stimulated O-2(radical ion) generation by the adenosine A2 receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA; IC50 = 30 nM ; p < 0.0001, analysis of variance). Calyculin A also reversed the adenosine receptor-mediated desensitization of bound chemoattractant receptors in neutrophils. Treatment of PMNs with NECA increased the pp1 activity of crude membrane preparations in a time- and dose-dependent fashion (EC(50) = 40 nM; p < 0.001, analysis of variance, n = 5). NECA inhibited cytosolic protein phosphatase activity by 78 +/- 12% (p < 0.003, n = 6) but did not shift pp1 catalytic subunit from cytosol to plasma membrane. Similar changes were observed in neutrophil cytoplasts depleted of organelles and nucleus. Moreover, the selective protein kinase A inhibitor KT5720 (10 mu M) reversed the capacity of dibutyryl cAMP but mt NECA to increase pp1 activity (p < 0.01, n = 5) in keeping with its effects on O-2 generation. Western blot analysis of PMN subcellular fractions demonstrated the presence of pp1 alpha and pp1 gamma 1 but not pp1 gamma(2) isotypes in both cytosol and plasma membrane but not in azurophil or specific granules. We conclude from these studies that signal transduction by adenosine in PMN proceeds via a novel pathway: cAMP-independent activation of a serine/threonine protein phosphatase in the plasma membrane.	NYU, MED CTR, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10016 USA	New York University			Cronstein, Bruce N/D-4678-2011; Montesinos, M. Carmen/G-8852-2015	Cronstein, Bruce N/0000-0002-4295-7383; Montesinos, M. Carmen/0000-0003-1801-311X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR011949, R01AR011949, R01AR041911] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19721] Funding Source: Medline; NIAMS NIH HHS [AR11949, AR/AI41911] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHUN YS, 1994, P NATL ACAD SCI USA, V91, P3319, DOI 10.1073/pnas.91.8.3319; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160; CRONSTEIN BN, 1988, BIOCHEM J, V252, P709, DOI 10.1042/bj2520709; CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366; CRONSTEIN BN, 1992, BIOCHEM J, V281, P631, DOI 10.1042/bj2810631; CRONSTEIN BN, 1992, BLOOD, V80, P1052; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DING JB, 1992, J BIOL CHEM, V267, P6442; DING JB, 1993, J BIOL CHEM, V268, P17326; FIRESTEIN GS, 1995, J IMMUNOL, V154, P326; GOLDSTEIN IM, 1975, J CLIN INVEST, V56, P1155, DOI 10.1172/JCI108191; GUPTA RC, 1993, J PHARMACOL EXP THER, V266, P16; HUBBARD MJ, 1991, METHOD ENZYMOL, V201, P414; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JESAITIS AJ, 1984, J CELL BIOL, V98, P1378, DOI 10.1083/jcb.98.4.1378; KIRNBAUER R, 1991, J INVEST DERMATOL, V96, P484, DOI 10.1111/1523-1747.ep12470181; KITAGAWA Y, 1990, BIOCHEM BIOPH RES CO, V171, P230, DOI 10.1016/0006-291X(90)91381-2; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LU DJ, 1993, BLOOD CELLS, V19, P343; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; MARQUARDT DL, 1994, AGENTS ACTIONS, V43, P7, DOI 10.1007/BF02005755; MATEO J, 1995, J NEUROCHEM, V64, P77; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; SALMON JE, 1990, J IMMUNOL, V145, P2235; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x	35	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17114	17118		10.1074/jbc.271.29.17114	http://dx.doi.org/10.1074/jbc.271.29.17114			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663342	hybrid			2022-12-25	WOS:A1996UX94300022
J	Tolbert, LM; Lameh, J				Tolbert, LM; Lameh, J			Human muscarinic cholinergic receptor Hm1 internalizes via clathrin-coated vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN RECEPTOR; 3RD CYTOPLASMIC LOOP; ACETYLCHOLINE-RECEPTORS; HUMAN-FIBROBLASTS; PLASMA-MEMBRANE; CAVEOLAE; LOCALIZATION; ENDOCYTOSIS; CELLS; DOMAIN	The mechanism by which muscarinic receptors internalize upon agonist exposure is poorly understood. To determine the endocytic pathways responsible for muscarinic receptor internalization, we have stably transfected human embryonic kidney (HEK 293) cells with the Hm1 (human muscarinic subtype 1) receptor tagged at the amino terminus with the epitope EYMPME. The subcellular location of the receptor was visualized by immunofluorescence confocal microscopy and quantified with the use of binding studies. The receptor redistributed into intracellular compartments following agonist treatment, This process was reversible upon removal of agonist and inhibited by antagonist, Acid treatment of the cells, which disrupts internalization via clathrin coated vesicles, inhibited carbachol-stimulated internalization. Phorbol 12-myristate 13-acetate, on the other hand, which inhibits caveolae-mediated endocytosis, had no effect on carbachol-induced endocytosis, Double-labeling confocal microscopy was used to characterize the intracellular vesicles containing Hm1 receptor following agonist treatment. The Hm1 receptor was shown to be colocalized with clathrin and alpha-adaptin, a subunit of the AP2 adaptor protein which links endocytosed proteins with clathrin in the intracellular vesicles, In addition, endosomes containing Hm1 also contained the transferrin receptor, which internalizes via clathrin-coated vesicles, In contrast, caveolin, the protein that comprises caveolae, did not colocalize with Hml in intracellular vesicles following agonist treatment, indicating that caveolae are not involved in the agonist-induced internalization of Hm1. These results indicate that agonist-induced internalization of the Hm1 receptor occurs via clathrin-coated vesicles in HEK cells.	UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM 08388, GM 43102] Funding Source: Medline; NIMH NIH HHS [K21 MH 00996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008388, R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000996] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; AOKI C, 1994, BRAIN RES, V650, P181, DOI 10.1016/0006-8993(94)91782-5; AOKI C, 1989, BRAIN RES, V493, P331, DOI 10.1016/0006-8993(89)91168-2; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; FONESCA ML, 1995, J BIOL CHEM, V270, P8902; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GARLAND EF, 1996, MOL PHARMACOL, V49, P438; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; HUET C, 1980, CELL, V21, P429, DOI 10.1016/0092-8674(80)90479-1; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SARGENT PB, 1994, NEUROIMAGE, V1, P288, DOI 10.1006/nimg.1994.1013; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SILVA WI, 1986, J BIOL CHEM, V261, P4788; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SNENOYSCARIA AM, 1994, J CELL BIOL, V126, P353; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171	39	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17335	17342		10.1074/jbc.271.29.17335	http://dx.doi.org/10.1074/jbc.271.29.17335			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663385	hybrid			2022-12-25	WOS:A1996UX94300055
J	Knol, J; Veenhoff, L; Liang, WJ; Henderson, PJF; Leblanc, G; Poolman, B				Knol, J; Veenhoff, L; Liang, WJ; Henderson, PJF; Leblanc, G; Poolman, B			Unidirectional reconstitution into detergent-destabilized liposomes of the purified lactose transport system of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN INSERTION; ESCHERICHIA-COLI; FUNCTIONAL RECONSTITUTION; SARCOPLASMIC-RETICULUM; CARRIER; SOLUBILIZATION; REQUIREMENT; MECHANISMS; BACTERIA	The lactose transport protein (LacS) of Streptococcus thermophilus was amplified to levels as high as 8 and 30% of total membrane protein in Escherichia coli and S, thermophilus, respectively, In both organisms the protein was functional and the expression levels were highest with the streptococcal lacS promoter, Also a LacS deletion mutant, lacking the carboxyl-terminal regulatory domain, could be amplified to levels >20% of membrane protein, Membranes from S, thermophilus proved to be superior in terms of efficient solubilization and ease and extent of purification of LacS; >95% of LacS was solubilized with relatively low concentrations of Triton X-100, n-octyl-beta-D-glucoside, n-dodecyl-beta-D-maltoside, or C(12)E(8). The LacS protein carrying a poly-histidine tag was purified in large quantities (similar to 5 mg/liter of culture) and with a purity >98% in a two-step process involving nickel chelate affinity and anion exchange chromatography, The membrane reconstitution of LacS was studied systematically by stepwise solubilization of preformed liposomes, prepared from E, coli phospholipid and phosphatidylcholine, and protein incorporation at the different stages of liposome solubilization. The detergents were removed by adsorption onto polystyrene beads and H+-lactose symport and lactose counterflow were measured, Highest transport activities were obtained when Triton X-100 was used throughout the solubilization/purification procedure, whereas activity was lost irreversibly with n-octyl-beta-D-glucoside. For reconstitutions mediated by n-dodecyl-beta-D-maltoside, C(12)E(8), and to a lesser extent Triton X-100, the highest transport activities were obtained when the liposomes were titrated with low amounts of detergent (onset of liposome solubilization), Importantly, under these conditions proteoliposomes were obtained in which LacS was reconstituted in an inside-out orientation, as suggested by the outside labeling of a single cysteine mutant with a membrane impermeable biotin maleimide, The results are consistent with a mechanism of reconstitution in which the hydrophilic regions of LacS prevent a random insertion of the protein into the membrane, Consistent with the in vivo lactose/galactose exchange catalyzed by the LacS protein, the maximal rate of lactose counterflow was almost 2 orders of magnitude higher than that of H+-lactose symport.	UNIV GRONINGEN, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS; UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; CEA, DEPT BIOL CELLULAIRE & MOL, LAB J MAETZ, F-06230 VILLEFRANCHE SUR MER, FRANCE	University of Groningen; University of Leeds; CEA			Henderson, Peter JF/Q-1907-2018; Knol, Jan/A-2178-2010; Knol, Jan/AAL-6487-2020	Knol, Jan/0000-0002-2103-5961; Knol, Jan/0000-0002-2103-5961; Veenhoff, Liesbeth/0000-0002-0158-4728; Henderson, Peter/0000-0002-9187-0938				BARON C, 1975, BIOCHIM BIOPHYS ACTA, V382, P276, DOI 10.1016/0005-2736(75)90270-9; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; CHEN CC, 1984, J BIOL CHEM, V259, P150; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; ELLIKER PR, 1956, J DAIRY SCI, V39, P1611, DOI 10.3168/jds.S0022-0302(56)94896-2; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; HJELMELAND LM, 1980, P NATL ACAD SCI-BIOL, V77, P6368, DOI 10.1073/pnas.77.11.6368; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P307; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND S, 1989, J BIOL CHEM, V264, P4907; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MOLLET B, 1993, J BACTERIOL, V175, P4315, DOI 10.1128/JB.175.14.4315-4324.1993; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POOLMAN B, 1995, J BIOL CHEM, V270, P12995, DOI 10.1074/jbc.270.22.12995; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POURCHER T, 1995, BIOCHEMISTRY-US, V34, P4412, DOI 10.1021/bi00013a033; RICHARD P, 1990, EUR J BIOCHEM, V193, P921, DOI 10.1111/j.1432-1033.1990.tb19418.x; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; RIGAUD JL, 1995, LIPOSOMES TOOLS BASI; SAMBROOPK J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WITHOLT B, 1978, BIOCHIM BIOPHYS ACTA, V508, P296, DOI 10.1016/0005-2736(78)90332-2	37	105	105	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15358	15366		10.1074/jbc.271.26.15358	http://dx.doi.org/10.1074/jbc.271.26.15358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662938	Green Published, hybrid			2022-12-25	WOS:A1996UV29900012
J	Blackburn, MR; Datta, SK; Wakamiya, M; Vartabedian, BS; Kellems, RE				Blackburn, MR; Datta, SK; Wakamiya, M; Vartabedian, BS; Kellems, RE			Metabolic and immunologic consequences of limited adenosine deaminase expression in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; SEVERE COMBINED IMMUNODEFICIENCY; DEOXYADENOSINE METABOLISM; DEFICIENT PATIENTS; MOUSE; INACTIVATION; 2'-DEOXYADENOSINE; DISEASE; CELLS; MODEL	Adenosine deaminase (ADA; EC 3.5.4.4) deficiency in humans is an autosomal recessive genetic disorder that results in severe combined immunodeficiency disease, ADA-deficient mice generated by targeted gene disruption die perinatally, preventing postnatal analysis of ADA deficiency. We have recently rescued ADA-deficient fetuses from perinatal lethality by expression of an ADA minigene in the placentas of ADA-deficient fetuses, thus generating postnatal mice admissible to analysis of ADA deficiency, The minigene used also directed ADA expression to the forestomach postnatally, producing adult animals that lacked ADA enzymatic activity in all tissues outside the gastrointestinal tract, Mice with limited ADA expression exhibited profound disturbances in purine metabolism, including thymus-specific accumulations of deoxyadenosine and dATP, and inhibition of S-adenosylhomocysteine hydrolase in the thymus, spleen, and, to a lesser extent, the liver, Lymphopenia and mild immunodeficiency were associated with these tissue-specific metabolic disturbances, These mice represent the first genetic animal model for ADA deficiency and provide insight into the tissue-specific requirements of ADA.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Blackburn, Michael/0000-0002-1394-9966	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042436] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30302] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM42436] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; BLAESE RM, 1995, METABOLIC MOL BASIS, V2, P3895; CARSON DA, 1980, J IMMUNOL, V124, P8; CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677; CHECHIK BE, 1983, J IMMUNOL, V126, P1003; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; DOHERTY PJ, 1991, SCAND J IMMUNOL, V33, P405, DOI 10.1111/j.1365-3083.1991.tb01788.x; GAO X, 1994, TERATOLOGY, V49, P1, DOI 10.1002/tera.1420490103; GIBLETT ER, 1972, LANCET, V2, P1067; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1981, J CLIN INVEST, V67, P696, DOI 10.1172/JCI110085; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; HOHMAN RJ, 1985, P NATL ACAD SCI USA, V82, P4578, DOI 10.1073/pnas.82.14.4578; JOHNSTON JM, 1979, J IMMUNOL, V123, P97; KAMINSKA JE, 1980, J LAB CLIN MED, V96, P141; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MORGAN G, 1987, CLIN EXP IMMUNOL, V70, P491; RATECH H, 1981, CLIN IMMUNOL IMMUNOP, V21, P119, DOI 10.1016/0090-1229(81)90200-2; RATECH H, 1985, AM J PATHOL, V119, P65; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; STILES GL, 1992, J BIOL CHEM, V267, P6451; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TEDDE A, 1980, P NATL ACAD SCI-BIOL, V77, P4899, DOI 10.1073/pnas.77.8.4899; ULLMAN B, 1981, J BIOL CHEM, V256, P848; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179	36	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15203	15210		10.1074/jbc.271.25.15203	http://dx.doi.org/10.1074/jbc.271.25.15203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663040	hybrid			2022-12-25	WOS:A1996UT10600082
J	Klamo, EM; Drew, ME; Landfear, SM; Kavanaugh, MP				Klamo, EM; Drew, ME; Landfear, SM; Kavanaugh, MP			Kinetics and stoichiometry of a proton/myo-inositol cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; ELECTROGENIC PROPERTIES; GLUCOSE; CHANNELS; CARRIER; MODELS	Voltage clamp recording was used to measure steady-state and presteady state currents mediated by a myoinositol transporter cloned from Leishmania donovani and expressed in Xenopus oocytes, Application of myoinositol resulted in inward currents, which did not require external sodium and which were increased by increasing the extracellular proton concentration and by membrane hyperpolarization, Alkalinization of the extracellular space occurred concomitantly with myo-inositol influx. Correlation of membrane currents with radiolabeled myo-inositol flux revealed that one positive charge is translocated with each molecule of myo-inositol, consistent with cotransport of one proton, The transport concentration dependence on both species suggested ordered binding of a proton followed by a molecule of myo-inositol, In the absence of myo-inositol, a voltage-dependent capacitance was observed that correlated with the transporter expression level, This charge movement obeyed a Boltzmann function, which was used to estimate a turnover of 0.70 +/- 0.06 s(-1) at -60 mV. The pH and voltage dependence of the charge movements were simulated with a model involving alternating access of internal and external protons to sites within an occluded pore.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOLEC MICROBIOL & IMMUNOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University					NIAID NIH HHS [AI25920, AI01162] Funding Source: Medline; NIGMS NIH HHS [GM400879] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOORER KJ, 1994, J BIOL CHEM, V269, P20417; CHRISTENSEN HN, 1969, P NATL ACAD SCI USA, V63, P948, DOI 10.1073/pnas.63.3.948; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; DREW ME, 1995, MOL CELL BIOL, V15, P5508; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; HOSHI T, 1986, BIOCHIM BIOPHYS ACTA, V861, P483, DOI 10.1016/0005-2736(86)90458-X; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; LAUGER P, 1980, J MEMBRANE BIOL, V57, P163, DOI 10.1007/BF01869585; Lauger P., 1991, ELECTROGENIC ION PUM, P61; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; NIIYA S, 1982, J BIOL CHEM, V257, P8902; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; STEIN WD, 1990, CHANNELS CARRIERS PU, P173; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	20	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14937	14943		10.1074/jbc.271.25.14937	http://dx.doi.org/10.1074/jbc.271.25.14937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663013	hybrid			2022-12-25	WOS:A1996UT10600047
J	Kole, HK; Garant, MJ; Kole, S; Bernier, M				Kole, HK; Garant, MJ; Kole, S; Bernier, M			A peptide-based protein-tyrosine phosphatase inhibitor specifically enhances insulin receptor function in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHOSPHOTYROSINE PHOSPHATASE; FATTY-ACIDS; PHOSPHATIDYLINOSITOL 3-KINASE; MULTISITE PHOSPHORYLATION; CATALYTIC FRAGMENT; SKELETAL-MUSCLE; RAT ADIPOCYTES; KINASE; ACTIVATION	3S-peptide-I is a synthetic tris-sulfotyrosyl dodecapeptide corresponding to the major site of insulin receptor autophosphorylation that potently inhibits dephosphorylation of the insulin receptor in a cell-free system and in digitonin-permeabilized Chinese hamster ovary (CHO) cells overexpressing the human insulin receptors (CHO/HIRc cells) (Liotta, A. S., Kole, H. K., Fales, H. M., Roth, J., and Bernier, M. (1994) J. Biol. Chem. 269, 22996-23001), In the present study, we found that 3S-peptide-I was not capable of inhibiting dephosphorylation of the epidermal growth factor (EGF) receptors in digitonin-permeabilized CHO cells that overexpress human EGF receptors (CHO/EGF-R cells), Moreover, the addition of a N-stearyl derivative of 3S-peptide-I to intact CHO/HIRc cells caused a concentration-dependent increase in insulin-stimulated phosphorylation of the insulin receptor, with a maximum effect (similar to 2.7-fold) at 50 mu M. In contrast, ligand-stimulated EGF receptor phosphorylation in CHO/EGF-R cells was not affected by the presence of stearyl 3S-peptide-I, Furthermore, treatment of CHO/HIRc cells with this N-stearyl peptide led to a significant enhancement of the insulin induced association of phosphatidylinositol (PI) 3-kinase activity with insulin receptor substrate 1 and the activation of mitogen-activated protein kinase, However, stearyl 3S-peptide-I had no effect on the EGF stimulated activation of PI-3-kinase and mitogen-activated protein kinase in CHO/EGF-R cells, These data indicate that this tris-sulfotyrosyl dodecapeptide selectively enhances insulin signal transduction by specifically inhibiting dephosphorylation of the insulin receptor in intact cells.			Kole, HK (corresponding author), NIA,DIABET SECT,LAB CLIN PHYSIOL,GERONTOL RES CTR,NIH,4940 EASTERN AVE,BALTIMORE,MD 21224, USA.		Bernier, Michel/Y-7139-2019; Bernier, Michel/AAO-3983-2021	Bernier, Michel/0000-0002-5948-368X				AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; AHN NG, 1991, J BIOL CHEM, V266, P4220; BENNETT PA, 1993, J CELL SCI, V106, P891; BERNIER M, 1994, BIOCHEMISTRY-US, V33, P4343, DOI 10.1021/bi00180a031; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CASABIELL X, 1991, BIOCHEM J, V278, P679, DOI 10.1042/bj2780679; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHATERJEEE J, 1992, PEPTIDES CHEM BIOL, P553; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; CUTHBERT JA, 1986, J BIOL CHEM, V261, P3620; DAFNIS E, 1994, NEPHRON, V67, P133, DOI 10.1159/000187913; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; HADARI YR, 1993, MOL CELL ENDOCRINOL, V97, P9, DOI 10.1016/0303-7207(93)90206-Y; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; INGEBRITSEN TS, 1989, J BIOL CHEM, V264, P7751; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KIDO Y, 1995, BIOCHEM BIOPH RES CO, V209, P131, DOI 10.1006/bbrc.1995.1480; KING MJ, 1990, BIOCHEM J, V266, P251, DOI 10.1042/bj2660251; KING MJ, 1991, BIOCHEM J, V275, P413, DOI 10.1042/bj2750413; KLAUSNER RD, 1980, J BIOL CHEM, V255, P1286; KOLE HK, 1995, BIOCHEM BIOPH RES CO, V209, P817, DOI 10.1006/bbrc.1995.1573; KOLE HK, 1995, BIOCHEM J, V311, P1025, DOI 10.1042/bj3111025; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JP, 1992, PROTEIN SCI, V1, P1353, DOI 10.1002/pro.5560011015; LIOTTA AS, 1994, J BIOL CHEM, V269, P22996; MCCALLUM CD, 1995, BIOCHEMISTRY-US, V34, P1815, DOI 10.1021/bi00006a001; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PILCH PF, 1980, P NATL ACAD SCI-BIOL, V77, P915, DOI 10.1073/pnas.77.2.915; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHISHEVA A, 1994, ENDOCRINOLOGY, V134, P507, DOI 10.1210/en.134.1.507; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SPARKS JW, 1985, J BIOL CHEM, V260, P2042; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAPPIA PS, 1993, BIOCHEM J, V292, P1; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040	63	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14302	14307		10.1074/jbc.271.24.14302	http://dx.doi.org/10.1074/jbc.271.24.14302			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662948				2022-12-25	WOS:A1996UQ66000057
J	OwensGrillo, JK; Czar, MJ; Hutchison, KA; Hoffman, K; Perdew, GH; Pratt, WB				OwensGrillo, JK; Czar, MJ; Hutchison, KA; Hoffman, K; Perdew, GH; Pratt, WB			A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ROUS-SARCOMA VIRUS; STEROID-RECEPTOR COMPLEXES; MITOCHONDRIAL OUTER-MEMBRANE; CELL-FREE SYSTEM; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; NUCLEAR-LOCALIZATION; TRANSFORMING PROTEIN; YEAST MITOCHONDRIA	We have shown recently that the CyP-40 and FKBP52/hsp56 bind to a hsp90 and that they exist in separate heterocomplexes with the glucocorticoid receptor (GR). FKBP52/hsp56 binds to hsp90 via its tetratricopeptide repeat (TPR) domains, it is not required for GR . hsp90 heterocomplex assembly, and it is thought to play a role in targeted movement of the GR In this work we examine the hsp90 binding of four proteins (FKBP52/hsp56, CyP-40, p50, Mas70p) thought to be involved in targeted protein trafficking. FKBP52/hsp56 and CyP-40 (each with three TPR), localize to the nucleus and nucleoli, respectively, and form relatively weak complexes with hsp90 that are competed by a CyP-40 fragment containing its three TPRs. The p50 component of the Src . hsp90 and Raf . hsp90 heterocomplexes localizes to cytoskeletal fibers extending from the perinuclear region to the plasma membrane and forming a rim under the plasma membrane of endothelial cells, p50, Mas70p (seven TPRs), which is a receptor for mitochondrial import, and the p60 (six to eight TPRs) component off the steroid receptor . hsp90 heterocomplex assembly system bind very tightly to hsp90 in a manner that is not competed by the CyP-40 fragment, However, bacterially expressed p60 blocks the binding of p50, Mas70p, FKBP52/hsp56, and CyP-40 to purified hsp90. The data are consistent with binding of all of these proteins to a site on hsp90 that is a general TPR domain acceptor. Our localization and binding data are used to develop a model in which proteins that tare chaperoned by hsp90 move as dynamic complexes to their cellular sites of action, with the TPR-containing protein participating in targeting the movement of the complexes.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; PENN STATE UNIV,DEPT VET SCI,UNIVERSITY PK,PA 16802	University of Michigan System; University of Michigan; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004869, R29ES004869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIEHS NIH HHS [ES04869] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DeFranco DB, 1995, VITAM HORM, V51, P315, DOI 10.1016/S0083-6729(08)61043-2; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MILAD M, 1995, MOL ENDOCRINOL, V9, P838, DOI 10.1210/me.9.7.838; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1996, IN PRESS STRESS INDU; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; REDMOND T, 1989, EUR J CELL BIOL, V50, P66; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; REXIN M, 1991, J BIOL CHEM, V266, P24601; REXIN M, 1992, J BIOL CHEM, V267, P9619; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHMITT J, 1993, GENE, V132, P267, DOI 10.1016/0378-1119(93)90206-I; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WELSH MJ, 1983, METHOD ENZYMOL, V102, P110; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	71	160	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13468	13475		10.1074/jbc.271.23.13468	http://dx.doi.org/10.1074/jbc.271.23.13468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662874				2022-12-25	WOS:A1996UP38500027
J	Wilson, JE; Aulabaugh, A; Caligan, B; McPherson, S; Wakefield, JK; Jablonski, S; Morrow, CD; Reardon, JE; Furman, PA				Wilson, JE; Aulabaugh, A; Caligan, B; McPherson, S; Wakefield, JK; Jablonski, S; Morrow, CD; Reardon, JE; Furman, PA			Human immunodeficiency virus type-1 reverse transcriptase - Contribution of Met-184 to binding of nucleoside 5'-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; THYMIDINE 5'-TRIPHOSPHATE; ENANTIOMERS; MUTANTS; INVITRO; RESISTANCE; SUBSTRATE; CARBOVIR; REGION; MOTIF	Mutations were made in recombinant human immunodeficiency virus type-1 reverse transcriptase (RT) by substituting methionine 184 with alanine (M184A) or valine (M184V), and steady-state and pre-steady-state kinetic constants were determined. The K-m values of M184A RT for dNTPs were larger than those of wt RT of RNA-directed synthesis; the k(cat) values of M184A RT for processive or distributive synthesis were similar. In contrast to M184A RT, the K-m and k(cat) values of M184V RT for dNTP substrates were similar to those of wt RT. The K-i values of M184V RT for 1-beta-L-nucleoside analogs were increased 30-500-fold relative to wt RT for both RNA- and DNA-directed synthesis. The K-d and k(p) values of wt RT and M184V RT for dCTP and cis-5-fluoro-1-[2-(hydroxy-methyl)-1,3-oxathiolan-5-yl]cytosine 5'-triphosphate (1-beta-L-FTCTP) were estimated from pre-steady-state kinetics for single nucleotide incorporation. The K-d value of M184V RT for 1-beta-L-FTCTP was 19-fold greater than that of wt RT; the k(p) values of the two enzymes were similar. These results support the hypothesis that methionine 184 in the highly conserved YMDD region of wt RT participates in the binding of the nucleoside (analog) 5'-triphosphate.	BURROUGHS WELLCOME CO, DIV BIOCHEM, RES TRIANGLE PK, NC 27709 USA; BURROUGHS WELLCOME CO, DIV VIROL, RES TRIANGLE PK, NC 27709 USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA	Burroughs Wellcome Fund; Burroughs Wellcome Fund; University of Alabama System; University of Alabama Birmingham				Jablonski, Sandra/0000-0001-7220-8159	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034749, R37AI034749, P01AI027290] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34749, AI-27290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DICKSON C, 1982, RNA TUMOR VIRUSES, P513; FARAJ A, 1994, ANTIMICROB AGENTS CH, V38, P2300, DOI 10.1128/AAC.38.10.2300; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; HAFFEY ML, 1990, J VIROL, V64, P5008, DOI 10.1128/JVI.64.10.5008-5018.1990; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MARCY AI, 1990, J VIROL, V64, P5883, DOI 10.1128/JVI.64.12.5883-5890.1990; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; MILLER WH, 1992, J BIOL CHEM, V267, P21220; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1993, J BIOL CHEM, V268, P8743; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TUNIS MJB, 1968, BIOPOLYMERS, V6, P1218, DOI 10.1002/bip.1968.360060816; TUNISSCHNEIDER MJ, 1970, J MOL BIOL, V52, P521, DOI 10.1016/0022-2836(70)90417-1; VANDRAANEN NA, 1992, J BIOL CHEM, V267, P25019; WAKEFIELD JK, 1992, J VIROL, V66, P6806, DOI 10.1128/JVI.66.11.6806-6812.1992; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9; WILSON JE, 1993, ANTIMICROB AGENTS CH, V37, P1720, DOI 10.1128/AAC.37.8.1720	31	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13656	13662		10.1074/jbc.271.23.13656	http://dx.doi.org/10.1074/jbc.271.23.13656			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662909				2022-12-25	WOS:A1996UP38500054
J	Borner, C				Borner, C			Diminished cell proliferation associated with the death-protective activity of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; C-MYC; APOPTOSIS; ACTIVATION; CYCLE; PROTEIN; DNA	The oncogene product Bcl-2 effectively spares cells from programmed cell death (apoptosis). The molecular mechanism underlying this death-protective activity has, however, remained enigmatic. Here we show that induction of Bcl-2 expression is consistently associated with a retardation of mammalian cell proliferation due to a prolongation of the G(1) phase of the cell cycle. Whereas cells lacking Bcl-2 expression die from any point of the cell cycle in response to apoptotic agents, Bcl-2-overexpressing cells accumulate in the G(0)/G(1) phase and are protected from cell death. Co-expression of Bax, a negative regulator of Bcl-2, reverts both the cell death protective and proliferation retarding activities of Bcl-2. Moreover, a Bcl-2 mutant defective in death protection does not affect cell division. These findings indicate that Bcl-2 contributes to cell survival by diminishing the rate of cell proliferation.			Borner, C (corresponding author), UNIV FRIBOURG,INST BIOCHEM,RUE MUSEE 5,CH-1700 FRIBOURG,SWITZERLAND.							BELIZARIO JE, 1991, CANCER RES, V51, P2379; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; COLOMBEL M, 1992, CANCER RES, V52, P4313; CRITCHFIELD JM, 1995, CLIN IMMUNOL IMMUNOP, V75, P13, DOI 10.1006/clin.1995.1046; DARZYNKIEWICZ Z, 1995, CELL GROWTH APOPTOSI, P143; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS CA, 1993, CANCER RES, V53, P1735; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOSHINA S, 1990, J CELL PHYSIOL, V145, P262, DOI 10.1002/jcp.1041450210; ISHIGAMI T, 1992, J IMMUNOL, V148, P360; JACOBSON MD, 1995, NATURE, V374, P813; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAZEBNIK YA, 1993, CANCER RES, V50, P7307; LINDENBOIM L, 1995, CANCER RES, V55, P1242; MARVEL J, 1994, ONCOGENE, V9, P1117; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PIETENPOL JA, 1994, CANCER RES, V54, P3714; POPPEMA S, 1992, IMMUNOL REV, V126, P163, DOI 10.1111/j.1600-065X.1992.tb00636.x; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	47	176	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12695	12698		10.1074/jbc.271.22.12695	http://dx.doi.org/10.1074/jbc.271.22.12695			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663032	hybrid			2022-12-25	WOS:A1996UN47400003
J	Tachibana, H; Ushio, Y; Krungkasem, C; Shirahata, S				Tachibana, H; Ushio, Y; Krungkasem, C; Shirahata, S			Inducing the loss of immunoglobulin lambda light chain production and the rearrangement of a previously excluded allele in human plasma B cell lines with concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION-ACTIVATING GENE; V(D)J RECOMBINATION; FEEDBACK INHIBITION; TRANSGENIC MICE; EXPRESSION; LYMPHOMA; MU; CARBOHYDRATE; ANTIBODIES; GENERATION	We investigated the expression of differential lambda light chains in human B cell lines secreting immunoglobulin (Ig), When these cell lines mere cultured with concanavalin A for a long period of time, a subpopulation of some but not all of these cell Lines was induced to express new lambda light chains replacing the original lambda chain (light chain shifting), Production of the new lambda chain, which replaces the original lambda chain, results from a VJ rearrangement at a previously excluded allele and a dramatic reduction of the original lambda chain transcript, although no difference was found in the level of heavy chain transcript, Recombination activating genes RAG-1 and RAG-2, which are normally expressed during specific early stages of lymphocyte development, were expressed in not only the light chain shifting-inducible lines but also in the non-inducible cells, Treatment of these Ig secreting cell lines with dibutyryl cAMP, which is known to enhance expression of the RAG genes, could not induce the creation of new lambda Light chain-producing cells from the inducible lines, suggesting that the expression of the two RAG genes is not sufficient for inducing new lambda light chain production. Concanavalin A induced a gradual but significant production lost of the original lambda chain in a subpopulation of the light chain shifting-inducible cells but not in the non-inducible cells, Association of new lambda light chain production with loss of original lambda chain raises the possibility that, when the RAG genes are expressed, concanavalin A may act on a novel intracellular mechanism controlling lambda light chain allelic exclusion in these plasma cell lines.			Tachibana, H (corresponding author), KYUSHU UNIV, GRAD SCH GENET RESOURCES TECHNOL, HIGASHI KU, 6-10-1 HAKOZAKI, FUKUOKA 812, JAPAN.							ABE T, 1994, J IMMUNOL, V152, P5504; AKAMATSU Y, 1994, J IMMUNOL, V153, P4520; BERINSTEIN N, 1989, SCIENCE, V244, P337, DOI 10.1126/science.2496466; CHANG LY, 1995, MOL IMMUNOL, V32, P49, DOI 10.1016/0161-5890(94)00135-N; CLARK EA, 1989, ADV CANCER RES, V52, P81; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; GURTSEVITCH VE, 1988, INT J CANCER, V41, P87, DOI 10.1002/ijc.2910410117; GUY K, 1990, INT J CANCER, V45, P109, DOI 10.1002/ijc.2910450120; HALLEK K, 1995, BLOOD, V85, P1289; HARADA K, 1991, J EXP MED, V173, P409, DOI 10.1084/jem.173.2.409; HARDY RR, 1986, P NATL ACAD SCI USA, V83, P1438, DOI 10.1073/pnas.83.5.1438; HESKETH R, 1990, J IMMUNOL, V145, P2571; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEVY S, 1989, J EXP MED, V170, P1, DOI 10.1084/jem.170.1.1; LING NR, 1987, LEUCOCYTE TYPING, V3, P302; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MURAKAMI H, 1985, IN VITRO CELL DEV B, V21, P593; NADKARNI JS, 1969, CANCER, V23, P64, DOI 10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OHARE MJ, 1982, PROTIDES BIOL FLUIDS, V30, P265; ROBBINS DL, 1990, ARTHRITIS RHEUM-US, V33, P1188; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; STIERNHOLM NBJ, 1995, J IMMUNOL, V154, P1748; STIERNHOLM NBJ, 1993, EUR J IMMUNOL, V23, P1501, DOI 10.1002/eji.1830230716; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TACHIBANA H, 1993, BIOCHIM BIOPHYS ACTA, V1182, P257, DOI 10.1016/0925-4439(93)90067-B; TACHIBANA H, 1992, BIOCHEM BIOPH RES CO, V189, P625, DOI 10.1016/0006-291X(92)92246-T; TACHIBANA H, 1994, J BIOL CHEM, V269, P29061; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARNER GL, 1991, CELL IMMUNOL, V138, P404, DOI 10.1016/0008-8749(91)90164-7; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	43	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17404	17410		10.1074/jbc.271.29.17404	http://dx.doi.org/10.1074/jbc.271.29.17404			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663345	hybrid			2022-12-25	WOS:A1996UX94300066
J	Goffin, V; Kinet, S; Ferrag, F; Binart, N; Martial, JA; Kelly, PA				Goffin, V; Kinet, S; Ferrag, F; Binart, N; Martial, JA; Kelly, PA			Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; EXTRACELLULAR DOMAIN; BIOLOGICAL PROPERTIES; LACTOGENIC HORMONES; BOVINE PROLACTIN; CELL-LINE; RECEPTOR; BINDING; BIOACTIVITY; CULTURES	Based on the assumption that the prolactin receptor (PRLR) is activated by PRL-induced sequential dimerization, potential human PRL (hPRL) antagonists were designed that sterically interfere with binding site 2. We previously reported the unexpected agonistic properties of these hPRL analogs in the rat Nb2 bioassay (Goffin, V., Struman, I., Mainfroid, V., Kinet, S., and Martial, J. A. (1994) J. Biol. Chem. 269, 3259832606). In order to investigate whether such paradoxical agonistic behavior might result from characteristic features of the Nb2 assay (e.g. species specificity), we transfected in the same cell system the cDNA encoding the PRLR from rat or human species along with reporter genes containing PRL-responsive DNA sequences. We characterized the agonistic, self-antagonistic and/or antagonistic effects of wild type rat PRL, wild type hPRL, and three hPRL analogs, mutated either at binding site 1 or at binding site 2. Our results clearly show that the agonistic/antagonistic properties of PRLs are species-specific. We thus propose different models of receptor activation, depending on the relative affinities of each hormonal binding site, which is directed by species specificity. Finally, this is the first report of hPRL binding site 2 analogs showing antagonistic properties on human and, to a lesser extent, rat receptors.	UNIV LIEGE, LAB MOLEC BIOL & GENET ENGN, B-4000 SART, BELGIUM	University of Liege	Goffin, V (corresponding author), INSERM U344, 156 RUE VAUGIRARD, F-75730 PARIS 15, FRANCE.		GOFFIN, Vincent/G-3322-2013; Binart, Nadine/F-2949-2013; Kelly, Paul/A-7951-2008	GOFFIN, Vincent/0000-0002-8021-3086; Binart, Nadine/0000-0002-5606-3866; kinet, sandrina/0000-0003-0699-108X				ALI S, 1991, J BIOL CHEM, V266, P20110; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BINDER L, 1990, MOL ENDOCRINOL, V4, P1060, DOI 10.1210/mend-4-7-1060; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN WY, 1995, MOL ENDOCRINOL, V9, P292, DOI 10.1210/me.9.3.292; CHEN WY, 1994, J BIOL CHEM, V269, P15892; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CLARKSON T, 1995, SCIENCE, V267, P383; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DATTANI MT, 1995, J BIOL CHEM, V270, P9222, DOI 10.1074/jbc.270.16.9222; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GERTLER A, 1993, FEBS LETT, V319, P277, DOI 10.1016/0014-5793(93)80562-9; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOFFIN V, 1993, EUR J BIOCHEM, V214, P483, DOI 10.1111/j.1432-1033.1993.tb17945.x; Goffin V, 1995, PROTEIN ENG, V8, P1215, DOI 10.1093/protein/8.12.1215; GOUT PW, 1980, CANCER RES, V40, P2433; HOOPER KP, 1993, J BIOL CHEM, V268, P22347; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kinet S, 1996, J BIOL CHEM, V271, P14353, DOI 10.1074/jbc.271.24.14353; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEWIS UJ, 1992, TRENDS ENDOCRIN MET, V3, P117, DOI 10.1016/1043-2760(92)90099-M; LOCHNAN HA, 1995, MOL CELL ENDOCRINOL, V114, P91, DOI 10.1016/0303-7207(95)03645-N; LUCK DN, 1991, MOL ENDOCRINOL, V5, P1880, DOI 10.1210/mend-5-12-1880; LUCK DN, 1990, MOL ENDOCRINOL, V4, P1011, DOI 10.1210/mend-4-7-1011; MEITES J, 1988, INT CONGR SER, V819, P123; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; Mode A, 1996, ENDOCRINOLOGY, V137, P447, DOI 10.1210/en.137.2.447; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x	47	99	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16573	16579		10.1074/jbc.271.28.16573	http://dx.doi.org/10.1074/jbc.271.28.16573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663214	hybrid			2022-12-25	WOS:A1996UX12600025
J	Isaacs, RJ; Harris, AL; Hickson, ID				Isaacs, RJ; Harris, AL; Hickson, ID			Regulation of the human topoisomerase II alpha gene promoter in confluence-arrested cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; DNA TOPOISOMERASES; NIH-3T3 CELLS; EXPRESSION; FORMS; PROLIFERATION; LOCALIZATION; SEQUENCE; CLONING; REGION	Expression of DNA topoisomerase II alpha mRNA and protein reflects the proliferative state of mammalian cell lines and tissues with high levels in actively cycling cells but marked down-regulation during serum deprivation or cell density-induced growth arrest, Using stably integrated gene fusions comprising the human topoisomerase II alpha promoter with a growth hormone reporter gene, we have localized elements required for the differential activity of the topoisomerase II alpha promoter in proliferating and confluence-arrested cells, Deletion analysis localized the region of the promoter that responded to changes in the cellular growth state to between -101 and -144 base pairs, Mutation analysis identified an inverted CCAAT box (ICE) located at -108 to -104 as necessary for promoter down-regulation in confluence-arrested cells, while several other potential cis-acting elements, including four additional ICBs, were shown not to be required, The critical ICE was recognized in vitro by the CCAAT box binding factor, NF-Y, with levels of binding activity higher in extracts from proliferating cells than from confluence-arrested cells, We conclude that the differential regulation of topoisomerase II alpha gene expression in cycling and confluence-arrested cells is mediated, at least in part, through proliferation-specific binding of factors to an ICE element in the gene promoter.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford			Hickson, Ian/AAJ-7548-2020; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Hickson, Ian/0000-0002-0583-566X				AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BECK WT, 1993, ADV ENZYME REGUL, V33, P113; BOEGE F, 1995, AM J PATHOL, V146, P1302; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DANDREA MR, 1994, APPL IMMUNOHISTOCHEM, V2, P177; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; FIRTH JD, 1992, J CLIN INVEST, V90, P1023, DOI 10.1172/JCI115915; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NG SW, 1995, J BIOL CHEM, V270, P25850, DOI 10.1074/jbc.270.43.25850; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SHARMA A, 1995, CURR OPIN STRUC BIOL, V5, P39, DOI 10.1016/0959-440X(95)80007-N; Sinha S, 1996, MOL CELL BIOL, V16, P328; TAN KB, 1992, CANCER RES, V52, P231; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WOESSNER RD, 1990, CANCER RES, V50, P2901; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	40	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16741	16747		10.1074/jbc.271.28.16741	http://dx.doi.org/10.1074/jbc.271.28.16741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663303	hybrid			2022-12-25	WOS:A1996UX12600051
J	Li, LT; Kaplan, J				Li, LT; Kaplan, J			Characterization of yeast methyl sterol oxidase (ERG25) and identification of a human homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MUTANTS; PROTEINS	A yeast mutant (LT06) was isolated that showed no growth on iron-limited medium but normal growth on iron-replete medium, A gene cloned from a genomic yeast library complemented the defect, allowing growth on low iron medium, Allelic segregation analysis demonstrated that the cloned gene was the normal allele rather than a high copy suppressor, A disruption mutant was nonviable, indicating that the gene was essential, Sequence analysis and functional assays indicated that the cloned gene was identical to ERG25, a gene that codes for methyl sterol oxidase, Incubation of LT06 in low iron medium resulted in marked changes in lipid metabolism, including the accumulation of fatty acids, triglycerides, methyl sterols, and other sterol precursors, A human homologue of ERG25 was cloned, sequenced, and mapped to human chromosome 4q32-34. Analysis of the data base with both ERG25 and the human homologue resulted in the identification of a putative set of metal binding motifs with similarity to that seen in a family of membrane desaturases hydroxylases. Western analysis using antibodies to an Erg25-GST fusion protein detected two proteins of 34 and 75 kDa. Both proteins are membrane bound and contain one N-glycosyl unit, Immunofluorescence data suggest that the proteins are present in the endoplasmic reticulum and plasma membrane, Although ERG25 transcripts are not iron regulated, there is a large increase in the concentration of transcript in the mutant LT06 grown in low iron medium, These results suggest that the enzyme is regulated not by iron but by an end product of the ergosterol pathway.	UNIV UTAH,SCH MED,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NCI NIH HHS [NCI BP 30CA 42014] Funding Source: Medline; NIDDK NIH HHS [NIDDK 5-30534, NIDDK 49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; EIDE D, 1992, J GEN MICROBIOL, V138, P34; FAUST JR, 1988, BIOL CHOLESTEROL; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; GEITZ RD, 1988, GENE, V74, P527; Harlow E., ANTIBODIES LAB MANUA; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PARKS LW, 1985, METHOD ENZYMOL, V111, P333; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Sambrook J., 2002, MOL CLONING LAB MANU; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SPENCE JT, 1977, J BIOL CHEM, V252, P5852; TURI TG, 1992, J BIOL CHEM, V267, P2046; WHITE JR, 1977, BIOCHEM BIOPH RES CO, V77, P387, DOI 10.1016/S0006-291X(77)80209-X; WILLIAMS MT, 1977, CANCER RES, V37, P1377; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	23	83	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16927	16933		10.1074/jbc.271.28.16927	http://dx.doi.org/10.1074/jbc.271.28.16927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663358	hybrid			2022-12-25	WOS:A1996UX12600076
J	Mata, M; Merritt, SE; Fan, G; Yu, GG; Holzman, LB				Mata, M; Merritt, SE; Fan, G; Yu, GG; Holzman, LB			Characterization of dual leucine zipper-bearing kinase, a mixed lineage kinase present in synaptic terminals whose phosphorylation state is regulated by membrane depolarization via calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; DROSOPHILA-MELANOGASTER; DYNAMIN GTPASE; VESICLES; DEPHOSPHORYLATION; PHOSPHOPROTEINS; IDENTIFICATION; JUNCTIONS; DOMAINS; CALCIUM	The biochemistry and regulation of dual leucine zipper bearing kinase (DLK), a member of the mixed lineage kinase or MLK subfamily of protein kinases, was examined in the nervous system, DLK transcript expression in the nervous system was predominantly neuronal, DLK protein was present in synaptic terminals where it was associated with both plasma membrane and cytosol fractions. Within these two fractions, DLK had differing characteristics. Cytosolic DLK existed in both a phosphorylated and dephosphorylated state; DLK associated with plasma membrane existed in the dephosphorylated state only, On nonreducing SDS-polyacrylamide gel electrophoresis, cytosolic DLK migrated at 130 kDa, while membrane associated DLK migrated with an apparent M(r) greater than or equal to 260,000, Similarly, DLK transiently expressed in COS 7 cells autophosphorylated in vivo and migrated at approximately 260 kDa when separated by nonreducing SDS polyacrylamide gel electrophoresis, In cotransfection experiments, FLAG-tagged DLK or a FLAG-tagged truncated DLK mutant (F-Delta 520) was coimmunoprecipitated with Myc-tagged DLK and formed complexes under nonreducing conditions consistent with the conclusion that DLK formed covalently associated homodimers in overexpressing COS 7 cells, In aggregating neuronal-glial cultures, depolarization of plasma membrane lead to dephosphorylation of DLK, Treatment of aggregates with 5 nM or 200 nM okadaic acid lead to a shift in electrophoretic mobility consistent with phosphorylation of DLK, Treatment with cyclosporin A, a specific inhibitor of the calcium/calmodulin-dependent protein phosphatase 2B (calcineurin), had no effect on DLK phosphorylation under basal conditions, However, cyclosporin A completely inhibited DLK dephosphorylation upon membrane depolarization.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109; UNIV PITTSBURGH,SCH MED,DEPT NEUROL,PITTSBURGH,PA 15261; DEPT VET AFFAIRS,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Holzman, Lawrence/0000-0002-8961-234X				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER P, 1985, CELL CULTURE NEUROSC, P223; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IKEDA K, 1976, NATURE, V259, P489, DOI 10.1038/259489a0; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KREUGER BK, 1977, J BIOL CHEM, V252, P2764; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MATA M, 1992, J NEUROCHEM, V59, P622, DOI 10.1111/j.1471-4159.1992.tb09415.x; MATA M, 1996, IN PRESS CELL MOL NE; MATTHIEU JM, 1990, NEUROL NEUR, V59, P109; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; RAMAKRISHNAN R, 1994, J VIROL, V68, P7083, DOI 10.1128/JVI.68.11.7083-7091.1994; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; SIM ATR, 1991, NEUROSCI LETT, V126, P203, DOI 10.1016/0304-3940(91)90554-7; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TUMA PL, 1993, J BIOL CHEM, V268, P17240; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; VICTOR RG, 1995, P NATL ACAD SCI USA, V92, P6269, DOI 10.1073/pnas.92.14.6269; WALAAS SI, 1991, PHARMACOL REV, V43, P299	45	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16888	16896		10.1074/jbc.271.28.16888	http://dx.doi.org/10.1074/jbc.271.28.16888			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663324	hybrid			2022-12-25	WOS:A1996UX12600071
J	Lullau, E; Heyse, S; Vogel, H; Marison, I; vonStockar, U; Kraehenbuhl, JP; Corthesy, B				Lullau, E; Heyse, S; Vogel, H; Marison, I; vonStockar, U; Kraehenbuhl, JP; Corthesy, B			Antigen binding properties of purified immunoglobulin A and reconstituted secretory immunoglobulin A antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; VIBRIO-CHOLERAE; IGA; COMPONENT; FILMS; LIPOPOLYSACCHARIDES; SPECTROSCOPY; COMPLEXES; MECHANISM; EPITOPES	The hybridoma cell line ZAC3 expresses Vibrio cholerae lipopolysaccharide (LPS)-specific mouse IgA molecules as a heterogeneous population of monomeric (IgA(m)), dimeric (IgA(d)), and polymeric (IgA(p)) forms. We describe a gentle method combining ultrafiltration, ion-exchange chromatography, and size exclusion chromatography for the simultaneous and qualitative separation of the three molecular forms. Milligram quantities of purified IgA molecules were recovered allowing for direct comparison of the biological properties of the three forms, LPS binding specificity was tested after purification; IgA(d) and IgA(p) mere found to bind strongly to LPS whereas IgA(m) did not. Secretory IgA (sIgA) could be reconstituted in vitro by combining recombinant secretory component (rSC) and purified IgA(d) or IgA(p), but not IgA(m). Surface plasmon resonance-based binding experiments using LPS monolayers indicated that purified reconstituted sIgA and IgA molecules recognize LPS with identical affinity (K-A 1.0 x 10(8) M(-1)). Thus, this very sensitive assay provides the first evidence that the function of SC in sIgA complex is not to modify the affinity for the antigen. K-A falls to 6.6 x 10(5) M(-1) when measured by calorimetry using detergent-solubilized LPS and IgA, suggesting that the LPS environment is critical for recognition by the antibody.	SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; ECOLE POLYTECH FED LAUSANNE, INST GENIE CHIM, CH-1015 LAUSANNE, SWITZERLAND; ECOLE POLYTECH FED LAUSANNE, INST CHIM PHYS, CH-1015 LAUSANNE, SWITZERLAND; UNIV LAUSANNE, INST BIOCHIM, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND	Swiss Institute Experimental Cancer Research; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; University of Lausanne			Vogel, Horst/AAJ-5490-2021					APTER FM, 1993, INFECT IMMUN, V61, P5279, DOI 10.1128/IAI.61.12.5279-5285.1993; BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; BLANCHARD TG, 1995, INFECT IMMUN, V63, P1394, DOI 10.1128/IAI.63.4.1394-1399.1995; BOUIGE P, 1990, HYBRIDOMA, V9, P519, DOI 10.1089/hyb.1990.9.519; BRANDENBURG K, 1993, BIOPHYS J, V64, P1215, DOI 10.1016/S0006-3495(93)81488-7; BRANDTZAEG P, 1970, IMMUNOCHEMISTRY, V7, P127, DOI 10.1016/0019-2791(70)90037-6; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; COOPER LJN, 1994, MOL IMMUNOL, V31, P577, DOI 10.1016/0161-5890(94)90165-1; Duschl C, 1996, BIOPHYS J, V70, P1985, DOI 10.1016/S0006-3495(96)79763-1; FUKUOKA S, 1994, MICROBIOS, V78, P169; GOTO Y, 1984, BIOCHEMISTRY-US, V23, P6736, DOI 10.1021/bi00321a070; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; HEREMANS JF, 1974, ANTIGENS, V2, P365; ISHIZAKA K, 1965, J IMMUNOL, V95, P197; KALB E, 1992, BIOCHIM BIOPHYS ACTA, V1103, P307, DOI 10.1016/0005-2736(92)90101-Q; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KNOLL W, 1991, MRS BULL, V16, P29, DOI 10.1557/S0883769400056517; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; Kretschmann E., 1972, Optics Communications, V6, P185, DOI 10.1016/0030-4018(72)90224-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CK, 1994, INFECT IMMUN, V62, P887, DOI 10.1128/IAI.62.3.887-891.1994; LEMAITRECOELHO I, 1977, EUR J IMMUNOL, V7, P588, DOI 10.1002/eji.1830070818; LINDH E, 1976, EUR J BIOCHEM, V62, P263, DOI 10.1111/j.1432-1033.1976.tb10156.x; MACH JP, 1970, NATURE, V228, P1278, DOI 10.1038/2281278a0; MESTECKY J, 1991, GASTROENTEROL CLIN N, V20, P441; MESTECKY J, 1985, METHOD ENZYMOL, V116, P37; MICHETTI P, 1992, INFECT IMMUN, V60, P1786, DOI 10.1128/IAI.60.5.1786-1792.1992; PARR EL, 1995, J IMMUNOL METHODS, V180, P147, DOI 10.1016/0022-1759(94)00310-S; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; TAYLOR HP, 1985, J EXP MED, V161, P198, DOI 10.1084/jem.161.1.198; TERRETTAZ S, 1993, LANGMUIR, V9, P1361, DOI 10.1021/la00029a033; TERSKIKH A, 1994, MOL IMMUNOL, V31, P1313, DOI 10.1016/0161-5890(94)90049-3; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Ulman A., 1991, INTRO ULTRATHIN ORGA; UNDERDOWN BJ, 1986, ANNU REV IMMUNOL, V4, P389, DOI 10.1146/annurev.iy.04.040186.002133; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; VAERMAN JP, 1995, IMMUNOL INVEST, V24, P631, DOI 10.3109/08820139509066863; VAERMAN JP, 1972, RES IMMUNOCHEM IMMUN, V3, P1; VANDENHEUVEL DJ, 1993, ANAL BIOCHEM, V215, P223, DOI 10.1006/abio.1993.1579; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEICKER J, 1975, J IMMUNOL, V114, P1337; WELTZIN R, 1994, ANTIMICROB AGENTS CH, V38, P2785, DOI 10.1128/AAC.38.12.2785; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOODARD CS, 1984, J IMMUNOL, V133, P2116; WRIGHT LL, 1988, BIOPHYS J, V54, P463, DOI 10.1016/S0006-3495(88)82979-5	50	58	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16300	16309		10.1074/jbc.271.27.16300	http://dx.doi.org/10.1074/jbc.271.27.16300			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663142	hybrid			2022-12-25	WOS:A1996UW35200066
J	Palmer, TM; Benovic, JL; Stiles, GL				Palmer, TM; Benovic, JL; Stiles, GL			Molecular basis for subtype-specific desensitization of inhibitory molecular adenosine receptors - Analysis of a chimeric A(1)-A(3) adenosine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-PROMOTED DESENSITIZATION; HETEROLOGOUS DESENSITIZATION; STRUCTURAL BASIS; KINASE FAMILY; CLONING; EXPRESSION; INTERNALIZATION; MECHANISMS; ADIPOCYTES; SYSTEM	The differing effects of short-term agonist exposure on the two inhibitory adenosine receptor (AR) subtypes have been examined using Chinese hamster ovary cells stably expressing the hemagglutinin epitope-tagged human A(1)AR and rat A(3)AR, Under conditions in which exposure of transfected cells to 5 mu M (-)-(R)-N-6-(phenylisopropyl)adenosine resulted in the functional desensitization and phosphorylation of the A(3)AR, neither property was exhibited by the A(1)AR, However, a stably expressed chimeric A(1)-A(3)AR, termed A(1)CT3AR, in which the C-terminal domain of the A(1)AR distal to its predicted palmitoylation site was replaced by the corresponding region of the A(3)AR, was able to undergo functional desensitization and agonist-stimulated phosphorylation in a manner similar to that exhibited by the A(3)AR, More over, purified G-protein-coupled receptor kinases 2, 3, and 5 were each capable of enhancing the agonist-dependent phosphorylation of the A(3)AR and A(1)CT3AR in vitro, Taken together, these data demonstrate that the C terminal domain of the A(3)AR distal to its predicted palmitoylation site is responsible for this receptor's ability to undergo a rapid agonist-dependent desensitization and are consistent with a model in which phosphorylation of the A(3)AR within this domain by one or more G-protein-coupled receptor kinases initiates the desensitization process.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Duke University; Jefferson University	Palmer, TM (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA.		Palmer, Timothy/E-7290-2013; Palmer, Timothy/C-4975-2009	Palmer, Timothy/0000-0002-9803-7164; 	NHLBI NIH HHS [P50HL54314, R01 HL35134] Funding Source: Medline; NIGMS NIH HHS [R01 GM44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054314, R01HL035134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APGAR JR, 1994, MOL BIOL CELL, V5, P313, DOI 10.1091/mbc.5.3.313; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DELEAN A, 1982, MOL PHARMACOL, V22, P290; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; EASON MG, 1992, J BIOL CHEM, V267, P25473; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GALLORODRIGUEZ C, 1994, J MED CHEM, V37, P636, DOI 10.1021/jm00031a014; GREEN A, 1992, J BIOL CHEM, V267, P3223; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KIM CM, 1993, RECEPTOR, V3, P39; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MORO O, 1993, J BIOL CHEM, V268, P6862; NAKATA H, 1992, EUR J BIOCHEM, V206, P171, DOI 10.1111/j.1432-1033.1992.tb16914.x; NANTEL F, 1993, MOL PHARMACOL, V43, P548; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; OLAH ME, 1994, J BIOL CHEM, V269, P24692; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALMER TM, 1995, J BIOL CHEM, V270, P29607, DOI 10.1074/jbc.270.49.29607; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; PEI G, 1995, MOL PHARMACOL, V48, P173; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; REN HZ, 1994, J BIOL CHEM, V269, P3104; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	40	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15272	15278		10.1074/jbc.271.25.15272	http://dx.doi.org/10.1074/jbc.271.25.15272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663009	hybrid			2022-12-25	WOS:A1996UT10600091
J	Roberts, S; Miller, SJ; Lane, WS; Lee, S; Hahn, S				Roberts, S; Miller, SJ; Lane, WS; Lee, S; Hahn, S			Cloning and functional characterization of the gene encoding the TFIIIB90 subunit of RNA polymerase III transcription factor TFIIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; U6 SNRNA GENE; SACCHAROMYCES-CEREVISIAE; ELEMENT; DNA; INITIATION; EXPRESSION; COMPLEXES; PROMOTER; HOMOLOGY	The yeast RNA polymerase III (pol III) general transcription factor TFIIIB is composed of three subunits; the TATA-binding protein (TBP)(1), the TFIIB-related factor (BRF1), and a third factor termed TFIIIB90 or B ''. Here we report the purification of yeast TFIIIB90, cloning of the gene encoding TFIIIB90, and reconstitution of TFIIIB from recombinant polypeptides. The TFIIIB90 open reading frame encodes a 68-kDa polypeptide and has no obvious similarity to any other known protein sequences. The gene encoding TFIIIB90 is essential for viability of yeast. Using recombinant TFIIIB subunits, we found that TFIIIB90 interacts weakly with TBP in the absence of BRF1, and that this interaction is enhanced at least 25-fold by BRF1. In addition, TFIIIB90 showed pol III specificity as it could not interact with the pol II-specific TFIIB-TBP-DNA complex. To localize the regions of the TBP-DNA complex that interact with BRF1 and TFIIIB90, we tested whether the pol II factors TFIIA and TFIIB interfered with the binding of BRF1 and TFIIIB90 to TBP-DNA. Our results suggest that the binding sites for BRF1 and TFIIIB90 on TBP-DNA both overlap the binding sites for TFIIA and TFIIB.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98109 USA; HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	Fred Hutchinson Cancer Center; Harvard University				Hahn, Steven/0000-0001-7240-2533	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053451] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CUPP JR, 1992, J BIOL CHEM, V267, P16417; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; DIECI G, 1993, J BIOL CHEM, V268, P11199; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, RNA POLYMERASE, V3, P247; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LANE WS, 1991, J PROTEIN CHEM, V10, P152; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SIKORSKI RS, 1989, GENETICS, V122, P19; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; WERNER M, 1993, J BIOL CHEM, V268, P20721	42	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14903	14909		10.1074/jbc.271.25.14903	http://dx.doi.org/10.1074/jbc.271.25.14903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662956	hybrid			2022-12-25	WOS:A1996UT10600042
J	Fukazawa, T; Miyake, S; Band, V; Band, H				Fukazawa, T; Miyake, S; Band, V; Band, H			Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; P53 PROTEIN; V-CBL; TRUNCATION; ONCOGENE; BINDING; DOMAIN	We and others have shown that Cbl, the protein product of the c-cbl proto-oncogene, is an early target of tyrosine phosphorylation upon stimulation through the immune cell surface receptors, which signal through noncovalently associated cytoplasmic tyrosine kinases. Using human mammary epithelial cells that express a natural epidermal growth factor (EGF) receptor and require EGF as an essential growth factor, we demonstrate here that Cbl is a prominent target of tyrosine phosphorylation upon stimulation through the EGF receptor tyrosine kinase, Phosphorylation of Cbl was EGF dose-dependent, rapid (detectable as early as 5 s and maximal by 2 min), and relatively sustained (detectable even after 1 h), Co-immunoprecipitation studies demonstrated that Cbl became associated with the EGF receptor in an EGF-dependent manner. Cbl was basally associated with the adaptor protein growth factor receptor-binding protein 2 (Grb2), and this interaction was further enhanced by EGF stimulation; however, the interaction was entirely mediated via the Grb2 Src homology 3 (SH3) domains, suggesting that binding of Grb2 SH2 domain to EGF receptor provides one mechanism of Cbl's association with the EGF receptor, EGF stimulation also induced the association of Cbl with Src homology and collagen (She) protein, p85 subunit of the phosphatidylinositol 3-kinase and Crk proteins, in particular with the CrkL isoform, Interactions of Cbl with the EGF receptor and multiple downstream signaling proteins suggest a role for this proto-oncogene product in mitogenic signaling through growth factor receptor kinases.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DEPT IMMUNOL & RHEUMATOL,BOSTON,MA 02115; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT RADIAT ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tufts Medical Center; Tufts University; Tufts University			Fukazawa, Takuya/GLR-7099-2022		NATIONAL CANCER INSTITUTE [R29CA056803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA56803] Funding Source: Medline; NIAMS NIH HHS [AR36308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOTH T, 1995, MOL CELL BIOL, V15, P6746; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	39	146	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14554	14559		10.1074/jbc.271.24.14554	http://dx.doi.org/10.1074/jbc.271.24.14554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662998	hybrid			2022-12-25	WOS:A1996UQ66000091
J	Knauper, V; Will, H; LopezOtin, C; Smith, B; Atkinson, SJ; Stanton, H; Hembry, RM; Murphy, G				Knauper, V; Will, H; LopezOtin, C; Smith, B; Atkinson, SJ; Stanton, H; Hembry, RM; Murphy, G			Cellular mechanisms for human procollagenase-3 (MMP-13) activation - Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; CYSTEINE SWITCH; COLLAGENASE; CELLS; PROGELATINASE; STROMELYSIN; CATALYSIS; RECEPTOR	Gelatinase A and membrane-type metalloproteinase (MT1-MMP) were able to process human procollagenase 3 (M(r) 60,000) to the fully active enzyme (Tyr(85) N terminus; M(r) 48,000). MT1-MMP activated procollagenase-3 via a M(r) 56,000 intermediate (Ile(36) N terminus) to 48,000 which was the result of the cleavage of the Glu(84)-Tyr(85) peptide bond. We have established that the activation rate of procollagenase-3 by MT1-MMP was enhanced in the presence of progelatinase A, thereby demonstrating a unique new activation cascade consisting of three members of the matrix metalloproteinase family. In addition, procollagenase-3 can be activated by plasmin, which cleaved the Lys(38)-GlU(39) and Arg(76)-Cys(77) peptide bonds in the propeptide domain, Autoproteolysis then resulted in the release of the rest of She propeptide domain generating Tyr(85) N-terminal active collagenase 3. However, plasmin cleaved the C-terminal domain of collagenase-3 which results in the loss of its collagenolytic activity. Concanavalin A-stimulated fibroblasts expressing MT1-MMP and fibroblast-derived plasma membranes were able to process human procollagenase-3 via a M, 56,000 intermediate form to the final M(r) 48,000 active enzyme which, by analogy with progelatinase A activation, may represent a model system for in vivo activation. Inhibition experiments using tissue inhibitor of metalloproteinases, plasminogen activator inhibitor-a, or aprotinin demonstrated that activation in the cellular model system was due to MT1-MMP/gelatinase A and excluded the participation of serine proteinases such as plasmin during procollagenase-3 activation, We have established that progelatinase A can considerably potentiate the activation rate of procollagenase-3 by crude plasma membrane preparations from concanavalin A-stimulated fibroblasts, thus confirming our results using purified progelatinase A and MT1-MMP. This new activation cascade may be significant in human breast cancer pathology, where all three enzymes have been implicated as playing important roles.	IN VITEK GMBH,D-13125 BERLIN,GERMANY; UNIV OVIEDO,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN; CELLTECH LTD,SLOUGH SL1 4EN,BERKS,ENGLAND	University of Oviedo; Celltech Group Ltd	Knauper, V (corresponding author), STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,WORTS CAUSEWAY,CAMBRIDGE CB1 4RN,ENGLAND.		López-Otín, Carlos/AAB-2106-2020	López-Otín, Carlos/0000-0001-6964-1904; STANTON, HEATHER/0000-0002-3427-5614; Knauper, Vera/0000-0002-3965-9924	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CAWSTON TE, 1981, BIOCHIM BIOPHYS ACTA, V657, P73, DOI 10.1016/0005-2744(81)90131-5; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; DANE K, 1985, ADV CANCER RES, V44, P139; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; FREIJE JMP, 1994, J BIOL CHEM, V269, P16765; HEMBRY RM, 1986, J CELL SCI, V81, P105; HOLZ RC, 1992, J AM CHEM SOC, V114, P9611, DOI 10.1021/ja00050a048; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Murphy G, 1992, Matrix Suppl, V1, P224; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OMURA TH, 1994, J BIOL CHEM, V269, P24994; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; POLETTE M, 1993, INVAS METAST, V13, P31; PUENTE XS, 1996, IN PRESS CANC RES; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WITTER JP, 1995, J BONE MINER RES, V10, pS439	40	584	599	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17124	17131		10.1074/jbc.271.29.17124	http://dx.doi.org/10.1074/jbc.271.29.17124			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663255	hybrid			2022-12-25	WOS:A1996UX94300024
J	Takahashi, T; Tanaka, M; Ogasawara, J; Suda, T; Murakami, H; Nagata, S				Takahashi, T; Tanaka, M; Ogasawara, J; Suda, T; Murakami, H; Nagata, S			Swapping between Fas and granulocyte colony-stimulating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; GROWTH-HORMONE; EXPRESSION; ACTIVATION; APOPTOSIS	Fas belongs to the tumor necrosis factor/nerve growth factor receptor family. The Fas ligand binds to its receptor, Fas, and induces apoptosis in Fas-bearing cells. The granulocyte colony-stimulating factor receptor (G-CSFR) is a member of the hemopoietic growth factor receptor family. G-CSF induces its dimerization and regulates the proliferation and differentiation of neutrophilic granulocytes, We constructed hybrid receptors between Fas and G-CSFR and expressed them in the mouse T cell line WR19L or the mouse myeloid interleukin-3-dependent FDC-P1 cell line. The Fas ligand or an agonistic anti-Fas antibody stimulated proliferation of the FDC-P1 transformants expressing a chimera consisting of the Fas extracellular and G-CSFR cytoplasmic regions. On the other hand, G-CSF could not induce apoptosis in the transformants expressing the chimera consisting of the G-CSFR extracellular and Fas cytoplasmic regions, but these cells were killed by a polyclonal antibody against G-CSFR. These results indicated that receptors belonging to different receptor families can be functionally exchanged and confirm that a homodimer of G-CSFR can transduce the growth signal, whereas Fas must be oligomerized (probably trimerized) to transduce the apoptotic signal.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	Osaka University			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIES DR, 1995, FASEB J, V9, P50, DOI 10.1096/fasebj.9.1.7821759; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DHEIN J, 1992, J IMMUNOL, V149, P3166; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; ITO Y, 1994, EUR J BIOCHEM, V220, P881, DOI 10.1111/j.1432-1033.1994.tb18691.x; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KISCHKEL F, 1995, EMBO J, V14, P6579; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1993, GROWTH FACTORS, V8, P99, DOI 10.3109/08977199309046930; NAGATA S, 1994, CYTOKINE HDB, P371; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x	42	24	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17555	17560		10.1074/jbc.271.29.17555	http://dx.doi.org/10.1074/jbc.271.29.17555			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663376	hybrid			2022-12-25	WOS:A1996UX94300086
J	Babichuk, CK; Duggan, BL; Bleackley, RC				Babichuk, CK; Duggan, BL; Bleackley, RC			In vivo regulation of murine granzyme B gene transcription in activated primary T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; SERINE PROTEASE GENES; LOCUS-CONTROL REGION; ENHANCER; EXPRESSION; CHAIN; PROMOTER; BINDING; PURIFICATION; CHROMATIN	A murine granzyme B promoter fragment that extends 243 base pairs upstream of the transcription start site confers high levels of luciferase reporter gene activity in transient transfection assays into T cells and mouse L cell fibroblasts, This promoter fragment contains canonical binding sites for the transcription factors AP-1, core binding factor (CBF), Ikaros, and the cyclic AMP responsive element binding protein (CREB). Oligonucleotides containing the granzyme B AP-1 or CBF elements form specific complexes with proteins present in nuclear extracts from activated CD8(+) splenocytes, MTL cells, EL4 T cells, and L cells, A strong DNase1 hypersensitive site that coincides with the closely associated AP-1, CBF, Ikaros, and CRE elements is present in activated CD8(+) T cells but not in resting T cells or L cells, Both in vitro and in vivo footprints are observed at these sequence elements in activated cytotoxic T cells (CTL) but not in resting T cells, The endogenous granzyme B gene is CTL-specific as no mRNA is detectable in EL4 or L cells, We propose that a condensed chromatin structure at the granzyme B promoter is responsible for transcription factor inaccessibility and repression of transcription in non T cells.			Babichuk, CK (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA.							BLEACKLEY RC, 1982, J IMMUNOL, V128, P758; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; CHIEN YH, 1993, IMMUNOL TODAY, V14, P597, DOI 10.1016/0167-5699(93)90199-U; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FELSENFELD G, 1993, GENE, V135, P119, DOI 10.1016/0378-1119(93)90056-9; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FREGEAU CJ, 1991, NUCLEIC ACIDS RES, V19, P5583; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HADDAD P, 1993, EUR J IMMUNOL, V23, P625, DOI 10.1002/eji.1830230307; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; HANSON RD, 1990, MOL CELL BIOL, V10, P5655, DOI 10.1128/MCB.10.11.5655; HANSON RD, 1993, BLOOD, V82, P2749; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HAVELE C, 1986, J IMMUNOL, V137, P1448; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KAUFMANN Y, 1981, P NATL ACAD SCI-BIOL, V78, P2502, DOI 10.1073/pnas.78.4.2502; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LU J, 1995, MOL CELL BIOL, V15, P1651; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MUELLER PR, 1992, CURRENT PROTOCOLS MO; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PAETKAU V, 1986, MEDIATORS IMMUNE REG, P3; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDMOND MJ, 1987, J IMMUNOL, V139, P3184; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sambrook J., MOL CLONING LAB MANU; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELDON RF, 1992, CURRENT PROTOCOLS MO; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	53	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16485	16493		10.1074/jbc.271.28.16485	http://dx.doi.org/10.1074/jbc.271.28.16485			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663264	hybrid			2022-12-25	WOS:A1996UX12600012
J	Gross, M; Hessefort, S				Gross, M; Hessefort, S			Purification and characterization of a 66-kDa protein from rabbit reticulocyte lysate which promotes the recycling of Hsp 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; REGULATED EIF-2-ALPHA KINASE; CHAIN BINDING-PROTEIN; NUCLEOTIDE-SEQUENCE; HSP70-LIKE PROTEIN; SUPERNATANT FACTOR; HEMIN; EXPRESSION; CHAPERONE; CLONING	We have purified to apparent homogeneity a 66-kDa protein from rabbit reticulocyte lysate which is associated with hsp 70. Our characterization of this 66-kDa protein demonstrates that its physiological role is to promote the recycling of hsp 70 by catalyzing the dissociation of hsp 70-bound ADP in exchange for ATP, We have therefore termed the 66-kDa protein RF-hsp 70, a recycling factor for hsp 70. RF-hsp 70 promotes stoichiometric binding of ATP to hsp 70, and it increases about B-fold the rate of dissociation of hsp 70 ADP in the presence of ATP. This process represents adenine nucleotide exchange, since dissociation of ADP does not occur unless ATP is added; dATP, GTP, and ITP cannot substitute for ATP, The mechanism of action of RF-hsp 70 is to lower the K-D of hsp 70 for ATP about 6-7-fold to a value that is close to the K-D of hsp 70 for ADP, RF-hsp 70 also stimulates the ATPase activity of hsp 70, including the 42-kDa amino-terminal portion of hsp 70 generated by chymotrypsin, demonstrating that RF hsp 70 interacts with that part of hsp 70 known to contain the ATP/ADP binding site. Confirming its recycling function, RF hsp 70 stimulates about 7-10-fold the ability of hsp 70 to reactivate heat-denatured firefly luciferase. In addition, RF-hsp 70 acts catalytically to recycle hsp 70, since, at 0.2 times the molar concentration of hsp 70, RF-hsp 70 increases the rate of renaturation of luciferase by hsp 70 about 3-4-fold, The action of RF-hsp 70 is also partially species-specific since it is most effective with rabbit reticulocyte hsp 70, less effective with bovine brain hsp 70, even less effective with human hsp 70, and ineffective with broad bean hsp 70.			Gross, M (corresponding author), UNIV CHICAGO,DEPT PATHOL,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CYR DM, 1992, J BIOL CHEM, V267, P20927; DELUCAFLAHERTY C, 1990, NUCLEIC ACIDS RES, V18, P5569, DOI 10.1093/nar/18.18.5569; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROSS M, 1987, J BIOL CHEM, V262, P6899; GROSS M, 1991, BIOCHEM BIOPH RES CO, V181, P1500, DOI 10.1016/0006-291X(91)92109-W; GROSS M, 1994, J BIOL CHEM, V269, P22738; GROSS M, 1992, J BIOL CHEM, V267, P2073; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; GROSS M, 1981, BIOCHIM BIOPHYS ACTA, V654, P219, DOI 10.1016/0005-2787(81)90175-1; GROSS M, 1976, BIOCHIM BIOPHYS ACTA, V447, P445, DOI 10.1016/0005-2787(76)90082-4; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HATTORI H, 1993, J CELL SCI, V104, P629; HONORE B, 1992, J BIOL CHEM, V267, P8485; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444	38	47	47	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16833	16841		10.1074/jbc.271.28.16833	http://dx.doi.org/10.1074/jbc.271.28.16833			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663320				2022-12-25	WOS:A1996UX12600064
J	Smith, KJ; Scotland, G; Beattie, J; Trayer, IP; Houslay, MD				Smith, KJ; Scotland, G; Beattie, J; Trayer, IP; Houslay, MD			Determination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by H-1 NMR and identification of the membrane association domain using chimeric constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HELIX DIPOLE; PEPTIDE-FRAGMENTS; PLASMA-MEMBRANE; S-PEPTIDE; PROTEIN; SEQUENCE; CHAIN; STABILIZATION; HOMOLOGS; CLONING	A 25-residue peptide representing the membrane targeting N-terminal splice region of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1) was synthesized, and its structure was determined by H-1 NMR, Two independently folding helical regions were identified, separated by a highly mobile ''hinge'' region, The first helical region was formed by an N-terminal amphipathic cu-helix, and the second consisted of multiple overlapping turns and contained a distinct compact, hydrophobic, tryptophan-rich domain (residues 14-20), Chimeric molecules, formed between the N-terminal region of RD1 and the soluble bacterial protein chloramphenicol acetyltransferase, were used in an in vitro system to determine the features within the splice region that were required for membrane association, The ability of RD1-chloramphenicol acetyltransferase chimera to become membrane-associated was not affected by deletion of any of the following regions: the apolar section (residues 2-7) of the first helical region, the polar part of this region together with the hinge region (residues 8-13), or the polar end of the C-terminal helical region (residues 21-25), In marked contrast, deletion of the compact, hydrophobic tryptophan-rich domain (residues 14-20) found in the second helical region obliterated membrane association, Replacement of this domain with a hydrophobic cassette of seven alanine residues also abolished membrane association, indicating that membrane association occurred by virtue of specific hydrophobic interactions with residues within the compact, tryptophan-rich domain, The structure of this domain is well defined in the peptide, and although the region is helical, both the backbone and the distribution of side chains are somewhat distorted as compared with an ideal cu-helix, Hydrophobic interactions, such as the ''stacked'' rings of residues Pro(14) and Trp(15), stabilize this domain with the side chain of residue Leu(16) adopting a central position, interacting with the side chains of all three tryptophan residues 15, 19, and 20, These bulky side chains thus form a hydrophobic cluster, In contrast, the side chain of residue Val(17) is relatively exposed, pointing out from the opposite ''face'' of the peptide, Although it appears that this compact, tryptophan-rich domain is responsible for membrane association, at present the target site and hence the specific interactions involved in membrane targeting by the RD1 splice region remain unidentified.	UNIV GLASGOW, INST LIFE & BIOMED SCI, DIV BIOCHEM & MOLEC BIOL, MOLEC PHARMACOL GRP, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV BIRMINGHAM, SCH BIOCHEM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; HANNAH RES INST, AYR KA6 5HL, SCOTLAND	University of Glasgow; University of Birmingham			Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Houslay, Miles/0000-0002-3826-8091	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1992, ADV SEC MESS PHOSPH, V25, P87; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; FIORI WR, 1995, BIOPOLYMERS, V37, P243, DOI 10.1002/bip.360370403; FIORI WR, 1994, NAT STRUCT BIOL, V1, P374, DOI 10.1038/nsb0694-374; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HORTON YM, 1995, BIOCHEM J, V308, P683, DOI 10.1042/bj3080683; HOUSLAY MD, 1981, BIOCHEM J, V198, P703, DOI 10.1042/bj1980703; HOUSLAY MD, 1995, BIOCHEM SOC T, V23, P393, DOI 10.1042/bst0230393; HOUSLAY MD, 1990, MOL PHARM CELL REGUL, V2, P185; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KLAUCK TM, 1995, CELL SIGNAL, V7, P747, DOI 10.1016/0898-6568(95)02003-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAU SYM, 1984, J BIOL CHEM, V259, P3253; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; MILATOVICH A, 1994, SOMAT CELL MOLEC GEN, V20, P75, DOI 10.1007/BF02290677; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; RICHARDSON JS, 1988, PROTEINS, V4, P229, DOI 10.1002/prot.340040402; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; SZPIRER C, 1995, CYTOGENET CELL GENET, V69, P11, DOI 10.1159/000133927; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009	40	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16703	16711		10.1074/jbc.271.28.16703	http://dx.doi.org/10.1074/jbc.271.28.16703			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663181	hybrid			2022-12-25	WOS:A1996UX12600046
J	True, HL; Celander, DW				True, HL; Celander, DW			Ribonuclease P of Tetrahymena thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL RNA COMPONENT; METAL-ION REQUIREMENTS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SUBSTRATE BINDING; RIBOSOMAL-RNA; CATALYTIC RNA; M1 RNA; GENE; SUBUNIT	Ribonuclease P (RNase P) is responsible for the generation of mature 5' termini of tRNA. The RNA component of this complex encodes the enzymatic activity in bacteria and is itself catalytically active under appropriate conditions in vitro. The role of the subunits in eucaryotes has not yet been established. We have partially purified RNase P activity from the ciliate protozoan Tetrahymena thermophila to learn more about the biochemical characteristics of RNase P from a lower eucaryote, The Tetrahymena RNase P displays a pH optimum and temperature optimum characteristic of RNase P enzymes isolated from other organisms, The K-m of the T. thermophila enzyme for pre-tRNA(Gln) is 1.6 x 10(-7) M, which is comparable to the values reported for other examples of RNase P, The Tetrahymena RNase P is a ribonucleoprotein complex, as supported by its sensitivity to micrococcal nuclease and proteinase K, The buoyant density of the enzyme in Cs2SO4 is 1.42 g/ml, which suggests that the RNA component of the Tetrahymena enzyme comprises a significantly greater percentage of the holoenzyme than that determined for RNase P of other Eucarya or Archaea. The holoenzyme has a requirement for divalent cations displaying characteristics that are unique for RNase P but closely resemble preferences reported for the Tetrahymena group I intron RNA. Puromycin inhibits pre-tRNA processing by the Tetrahymena complex, and implications of the similarities between recognition of tRNA by ribosomal components and RNase P are discussed.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,COLL MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			True, Heather/D-2979-2012		NIGMS NIH HHS [R01 GM47854] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047854] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABOSHI E, 1980, BIOCHEM BIOPH RES CO, V96, P831, DOI 10.1016/0006-291X(80)91430-8; ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; DARR SC, 1990, J BIOL CHEM, V265, P12927; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMILTON MG, 1971, METHOD ENZYMOL, V20, P512; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; KOLE R, 1980, CELL, V19, P881, DOI 10.1016/0092-8674(80)90079-3; KRUPP G, 1986, EMBO J, V5, P1697, DOI 10.1002/j.1460-2075.1986.tb04413.x; KUCHINO Y, 1985, P NATL ACAD SCI USA, V82, P4758, DOI 10.1073/pnas.82.14.4758; LATHAM JA, 1990, METHOD ENZYMOL, V181, P558; LAWRENCE N, 1987, COLD SPRING HARB SYM, V52, P233, DOI 10.1101/SQB.1987.052.01.028; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; MARCHFELDER A, 1994, PLANT PHYSIOL, V105, P1247, DOI 10.1104/pp.105.4.1247; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MCKEE T, 1991, J PROTOZOOL, V38, P465, DOI 10.1111/j.1550-7408.1991.tb04818.x; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NATHANS D, 1963, NATURE, V197, P1076, DOI 10.1038/1971076a0; Neff RJ, 1964, METHODS CELL PHYSL, P55; OLSEN GJ, 1993, FASEB J, V7, P113, DOI 10.1096/fasebj.7.1.8422957; PACE NR, 1995, J BACTERIOL, V177, P1919, DOI 10.1128/jb.177.8.1919-1928.1995; PALACIAN E, 1979, EUR J BIOCHEM, V101, P469, DOI 10.1111/j.1432-1033.1979.tb19741.x; POTUSCHAK T, 1993, NUCLEIC ACIDS RES, V21, P3239, DOI 10.1093/nar/21.14.3239; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; SAKANO H, 1974, NUCLEIC ACIDS RES, V1, P355, DOI 10.1093/nar/1.3.355; SCHEDL P, 1973, P NATL ACAD SCI USA, V70, P2091, DOI 10.1073/pnas.70.7.2091; SCHLEGEL M, 1991, J MOL EVOL, V32, P64, DOI 10.1007/BF02099930; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; STATHOPOULOS C, 1995, EUR J BIOCHEM, V228, P976, DOI 10.1111/j.1432-1033.1995.0976m.x; STRAUS JW, 1992, J PROTOZOOL, V39, P655, DOI 10.1111/j.1550-7408.1992.tb04445.x; VIOQUE A, 1989, FEBS LETT, V246, P137, DOI 10.1016/0014-5793(89)80269-8; WALLER CW, 1953, J AM CHEM SOC, V75, P2025, DOI 10.1021/ja01104a537; WANG MJ, 1990, NUCLEIC ACIDS RES, V18, P6625, DOI 10.1093/nar/18.22.6625; WANG MJ, 1988, EMBO J, V7, P1567, DOI 10.1002/j.1460-2075.1988.tb02981.x; WAUGH DS, 1990, J BACTERIOL, V172, P6316, DOI 10.1128/jb.172.11.6316-6322.1990; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; ZAUG AJ, 1980, CELL, V19, P331, DOI 10.1016/0092-8674(80)90507-3	55	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16559	16566		10.1074/jbc.271.28.16559	http://dx.doi.org/10.1074/jbc.271.28.16559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663280	hybrid			2022-12-25	WOS:A1996UX12600023
J	Umar, S; Malavasi, F; Mehta, K				Umar, S; Malavasi, F; Mehta, K			Post-translational modification of CD38 protein into a high molecular weight form alters its catalytic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; LYMPHOCYTE ANTIGEN CD38; LEUKEMIA HL-60 CELLS; EGG-SPECIFIC NADASE; RETINOIC ACID; RECEPTOR DIMERIZATION; 2ND-MESSENGER ENZYME; HUMAN ERYTHROCYTES; OUTER SURFACE; EXPRESSION	Human CD38 is a 45-kDa transmembrane protein that acts as a bifunctional ectoenzyme, catalyzing the synthesis of cyclic ADP-ribose (cADPR) from NAD(+) and the hydrolysis of cADPR to ADP-ribose, All-trans-retinoic acid (RA) is a potent and specific inducer of CD38 in myeloid cells, In this report, we demonstrate that RA-induced CD38 protein hom human myeloid (HL-60) leukemia cells coimmunoprecipitates with another protein of molecular mass approximate to 190 kDa (p190), The p190 protein is localized exclusively in the membranes and is a consequence of post-translational cross-linking of CD38 protein, This conclusion was based on the observations that purified CD38 effectively competes with p190, its accumulation is preceded by the accumulation of CD38, it immunoreacted with three different monospecific anti-CD38 antibodies on immunoblots, and its peptide map revealed several peptides in common with CD38. Furthermore, CD38 could serve as a suitable substrate for transglutaminase (TGase)-catalyzed cross-linking reactions in vitro, and the accumulation of p190 in RA-treated HL-60 cells is effectively blocked by the presence of TGase-specific inhibitor, The purified p190 showed at least three times more cyclase activity than CD38, Conversely, p190 was at least 2.5-fold less active than CD38 in hydrolyzing cADPR to ADPR. These results suggest that post-translational modification of CD38 may represent an important mechanism for regulating the two catalytic activities of this bifunctional enzyme.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOIMMUNOTHERAPY,HOUSTON,TX 77030; UNIV ANCONA,SCH MED,INST BIOL & GENET,I-60100 ANCONA,ITALY	University of Texas System; UTMD Anderson Cancer Center; Marche Polytechnic University				MALAVASI, Fabio/0000-0002-1844-174X	Telethon [E.0266] Funding Source: Medline; FDA HHS [FDR-000923] Funding Source: Medline	Telethon(Fondazione Telethon); FDA HHS		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCHET C, 1988, J BIOL CHEM, V263, P3290; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DRACH J, 1994, CANCER RES, V54, P1746; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GRAEFF RM, 1994, BIOCHEM BIOPH RES CO, V205, P722, DOI 10.1006/bbrc.1994.2725; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HARADA N, 1993, J IMMUNOL, V151, P3111; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KONTANI K, 1993, J BIOL CHEM, V268, P16895; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MULLER HM, 1983, BIOCHEM J, V212, P456; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TOHGO A, 1994, J BIOL CHEM, V269, P28555; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	35	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15922	15927		10.1074/jbc.271.27.15922	http://dx.doi.org/10.1074/jbc.271.27.15922			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663150	hybrid			2022-12-25	WOS:A1996UW35200016
J	Arvola, M; Keinanen, K				Arvola, M; Keinanen, K			Characterization of the ligand-binding domains of glutamate receptor (GluR)-B and GluR-D subunits expressed in Escherichia coli as periplasmic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; MODULATION; CHANNELS; PRODUCT; FAMILY	We recently reported that a functional ligand-binding site of an alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate (AMPA)-selective glutamate receptor (GluR)-D subunit can be expressed in insect cells as a soluble, N-glycosylated fusion protein consisting of two segments (S1 and S2) that are related by amino acid sequence to bacterial periplasmic binding proteins (Kuusinen, A., Arvola, M., and Keinanen, K., EMBO J. 14, 6327-6332). In an attempt to further characterize the structural determinants for ligand binding, we have now expressed the ligand-binding sites of GluR-B and GluR-D subunits in Escherichia coli as soluble periplasmic proteins. The bacterially expressed S1-S2 fusion proteins bound [H-3]AMPA with a high affinity (K-d of 12 nM for GluR-B, K-d of 60 nM for GluR-D) and with a ligand pharmacology typical of native AMPA receptors, indicating that N-linked glycosylation is not required for the formation or the maintenance of the ligand-binding site. The flip and Bop splice variants of the GluR-D S1-S2 fusion protein bound [H-3]AMPA with equal affinities, whereas deletion of the C-terminal one-third of the S2 segment including the flip/flop sequence resulted in a loss of binding activity, Our results highlight the potential of bacterial expression for the analysis of the binding site and support a close structural similarity between glutamate receptors and bacterial proteins.	VTT,BIOTECHNOL & FOOD RES,FIN-02044 ESPOO,FINLAND	VTT Technical Research Center Finland			Keinanen, Kari/E-9122-2010					BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BERTIN B, 1992, J BIOL CHEM, V267, P8200; EHRLICH YH, 1986, NATURE, V320, P67, DOI 10.1038/320067a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HULLEBROECK MF, 1992, BRAIN RES, V590, P187, DOI 10.1016/0006-8993(92)91094-U; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; HUNTER C, 1992, J NEUROCHEM, V58, P1379, DOI 10.1111/j.1471-4159.1992.tb11353.x; KAWAMOTO S, 1995, J NEUROCHEM, V64, P1258; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEINANEN K, 1994, BIO-TECHNOL, V12, P802, DOI 10.1038/nbt0894-802; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; LI F, 1995, MOL PHARMACOL, V47, P148; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAKAZAWA K, 1995, NEURON, V15, P697, DOI 10.1016/0896-6273(95)90157-4; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PARTIN KM, 1995, NEURON, V14, P833, DOI 10.1016/0896-6273(95)90227-9; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROCHE KW, 1994, J BIOL CHEM, V269, P11679; Sambrook J., 2002, MOL CLONING LAB MANU; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TAKKINEN K, 1991, PROTEIN ENG, V4, P837, DOI 10.1093/protein/4.7.837; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TAVERNA FA, 1994, J BIOL CHEM, V269, P14159; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; YAKEL JL, 1995, P NATL ACAD SCI USA, V92, P1376, DOI 10.1073/pnas.92.5.1376; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	43	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15527	15532		10.1074/jbc.271.26.15527	http://dx.doi.org/10.1074/jbc.271.26.15527			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663017	hybrid			2022-12-25	WOS:A1996UV29900036
J	Beyer, BM; Dunn, BM				Beyer, BM; Dunn, BM			Self-activation of recombinant human lysosomal procathepsin D at a newly engineered cleavage junction, ''short'' pseudocathepsin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME CATHEPSIN-D; ASPARTIC PROTEINASE; OLIGOSACCHARIDES; PHOSPHORYLATION; INTERMEDIATE; INHIBITORS; EXPRESSION; PEPSINOGEN; FRAGMENTS; CELLS	To obtain a recombinant model of human cathepsin D with kinetic properties that are identical with native human liver enzyme, we have addressed the significant differences in structure and catalytic function between naturally occurring enzyme and bacterially derived pseudocathepsin D, Human procathepsin D was expressed in a baculovirus system to obtain correctly folded, glycosylated enzyme that upon acidification completely converts to the active intermediate, pseudocathepsin D. The oligosaccharide moieties of this recombinant enzyme contributed to about 5% of the apparent molecular mass of the enzyme, and the carbohydrate composition was quite similar to the native material, However, specificity constants (k(cat)/K-m) of this glycosylated pseudoform for several synthetic chromogenic substrates were considerably less (33%-50%) than those for the native enzyme and were virtually identical with those observed with nonglycosylated pseudocathepsin D. A cleavable junction suitable for self-processing at the normal maturation point of human cathepsin D was en engineered into procathepsin D according to known specificity requirements of this enzyme, and the construct was expressed using baculovirus. Following experiments that demonstrated that the new proenzyme failed to process to the expected point, the new cleavage junction was moved 6 residues toward the amino terminus of procathepsin D and expressed in Escherichia coli, After refolding, the protein containing the newly engineered junction self-processed, generating a shortened mutant form of pseudocathepsin D that is 6 residues longer at the amino terminus than the native material. The kinetic properties of this newly engineered pseudoform proved to be identical with those of the native enzyme, thus establishing an improved recombinant model for this important aspartic proteinase.	UNIV FLORIDA, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018865] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18865] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN M, 1995, ANTICANCER RES, V15, P1033; AIKAWA J, 1990, J BIOL CHEM, V265, P13955; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Barrett A, 1977, PROTEINASES MAMMALIA, P209; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CHEN Z, 1991, J BIOL CHEM, V266, P11718; CONNER GE, 1990, DNA CELL BIOL, V9, P1, DOI 10.1089/dna.1990.9.1; CONNER GE, 1992, J BIOL CHEM, V267, P21738; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; CONNER GE, 1992, BIOCHEMISTRY-US, V31, P1142, DOI 10.1021/bi00119a024; CONNER GE, 1987, LYSOSOMES THEIR ROLE, P151; DEAN RT, 1976, ESSAYS BIOCHEM, P1; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DUNN BM, 1994, PEPTIDE ANAL PROTOCO, P225; ERICKSON AH, 1983, BIOCHEMISTRY-US, V22, P5201, DOI 10.1021/bi00291a021; FOTENBERRY S, 1995, J BIOL CHEM, V270, P9778; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI, P39; HENDERSON P, 1972, J BIOL CHEM, V247, P321; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUI KY, 1993, FEBS LETT, V327, P355, DOI 10.1016/0014-5793(93)81020-Z; JAMES M, 1995, ADV EXP MED BIOL, V362, P11; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KOELSCH G, 1994, FEBS LETT, V343, P6, DOI 10.1016/0014-5793(94)80596-2; KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367; LADROR US, 1994, J BIOL CHEM, V269, P18422; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7095; PILLAI S, 1986, J BIOL CHEM, V261, P4919; Rochefort H, 1990, Semin Cancer Biol, V1, P153; SAMAREL AM, 1989, AM J PHYSIOL, V257, pC1069, DOI 10.1152/ajpcell.1989.257.6.C1069; SANCHEZ LM, 1993, BRIT J CANCER, V67, P1076, DOI 10.1038/bjc.1993.197; SCARBOROUGH PE, 1994, PROTEIN ENG, V7, P495, DOI 10.1093/protein/7.4.495; SCARBOROUGH PE, 1993, PROTEIN SCI, V2, P264; SHEWALE JG, 1984, P NATL ACAD SCI-BIOL, V81, P3703, DOI 10.1073/pnas.81.12.3703; SIMAN R, 1993, J BIOL CHEM, V268, P16602	36	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15590	15596		10.1074/jbc.271.26.15590	http://dx.doi.org/10.1074/jbc.271.26.15590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663051	hybrid			2022-12-25	WOS:A1996UV29900044
J	Duche, D; Izard, J; GonzalezManas, JM; Parker, MW; Crest, M; Chartier, M; Baty, D				Duche, D; Izard, J; GonzalezManas, JM; Parker, MW; Crest, M; Chartier, M; Baty, D			Membrane topology of the colicin a pore-forming domain analyzed by disulfide bond engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-DEPENDENT CHANNEL; PLANAR LIPID BILAYERS; TERMINAL FRAGMENT; HELICAL HAIRPIN; TRANSLOCATION; INSERTION; PROTEIN; IDENTIFICATION; PHOSPHOLIPIDS; FLUORESCENCE	Four colicin A double-cysteine mutants possessing a disulfide bond in their pore-forming domain were constructed to study the translocation and the pore formation of colicin A. The disulfide bonds connected alpha-helices 1 and 2, 2 and 10, 3 and 9, or 3 and 10 of the pore-forming domain. The disulfide bonds did not prevent the colicin A translocation through the Escherichia coli envelope. However, the mutated colicins were able to exert their in vivo channel activity only after reduction of their disulfide bonds. In vitro studies with brominated phospholipid vesicles and planar lipid bilayers revealed that the disulfide bond that connects the alpha-helices 2 and 10 prevented the colicin A membrane insertion, whereas the other double-cysteine mutants inserted into Lipid vesicles. The disulfide bonds that connect either the alpha-helices 1 and 2 or 3 and 10 were unable to prevent the formation of a conducting channel in presence of membrane potential. These results indicate that alpha-helices 1, 2, 3, and 10 remain at the membrane surface after application of a membrane potential.	CNRS, INST BIOL STRUCT & MICROBIOL, LAB INGN & DYNAM SYST MEMBRANAIRES, F-13402 MARSEILLE 20, FRANCE; UNIV BASQUE COUNTRY, FAC SCI, DEPT BIOCHEM & MOLEC BIOL, E-48080 BILBAO, SPAIN; ST VINCENTS INST MED RES, FITZROY, VIC 3065, AUSTRALIA; NEUROBIOL LAB, F-13402 MARSEILLE 20, FRANCE	Centre National de la Recherche Scientifique (CNRS); University of Basque Country; St. Vincent's Institute of Medical Research			Izard, Jacques/A-6074-2012; Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138; Baty, Daniel/0000-0001-8443-4444; Izard, Jacques/0000-0002-5904-5436; GONZALEZ MANAS, JUAN MANUEL/0000-0002-1833-6982; Duche, Denis/0000-0002-4208-6661				ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BATY D, 1988, MOL MICROBIOL, V2, P807, DOI 10.1111/j.1365-2958.1988.tb00092.x; BATY D, 1990, EUR J BIOCHEM, V189, P409, DOI 10.1111/j.1432-1033.1990.tb15503.x; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; COLLARINI M, 1987, EUR BIOPHYS J BIOPHY, V14, P147, DOI 10.1007/BF00253839; DUCHE D, 1994, J BIOL CHEM, V269, P24820; DUCHE D, 1995, J BACTERIOL, V177, P4935, DOI 10.1128/jb.177.17.4935-4939.1995; DUCHE D, 1994, J BIOL CHEM, V269, P6332; GELI V, 1992, BIOCHEMISTRY-US, V31, P11089, DOI 10.1021/bi00160a019; GHOSH P, 1994, NAT STRUCT BIOL, V1, P597, DOI 10.1038/nsb0994-597; GONZALEZMANAS JM, 1993, EUR J BIOCHEM, V211, P625, DOI 10.1111/j.1432-1033.1993.tb17590.x; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; IZARD J, 1994, PROTEIN ENG, V7, P1495, DOI 10.1093/protein/7.12.1495; JAKES KS, 1990, J BIOL CHEM, V265, P6984; JEANTEUR D, 1994, J MOL BIOL, V235, P898, DOI 10.1006/jmbi.1994.1047; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LAKEY JH, 1994, EUR J BIOCHEM, V220, P155, DOI 10.1111/j.1432-1033.1994.tb18610.x; LLOUBES R, 1986, NUCLEIC ACIDS RES, V14, P2621, DOI 10.1093/nar/14.6.2621; MASSOTTE D, 1989, BIOCHEMISTRY-US, V28, P7713, DOI 10.1021/bi00445a029; MASSOTTE D, 1993, BIOCHEMISTRY-US, V32, P13787, DOI 10.1021/bi00213a006; MEL SF, 1993, BIOCHEMISTRY-US, V32, P9473, DOI 10.1021/bi00087a027; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; PALMER LR, 1994, J BIOL CHEM, V269, P4187; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; QIU XQ, 1994, J BIOL CHEM, V269, P7483; RAYMOND L, 1986, J MEMBRANE BIOL, V92, P255, DOI 10.1007/BF01869394; SCHEIN SJ, 1978, NATURE, V276, P159, DOI 10.1038/276159a0; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SLATIN SL, 1986, J MEMBRANE BIOL, V92, P247, DOI 10.1007/BF01869393; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; VANDERGOOT FG, 1993, EUR J BIOCHEM, V213, P217	41	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15401	15406		10.1074/jbc.271.26.15401	http://dx.doi.org/10.1074/jbc.271.26.15401			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663026	Green Published			2022-12-25	WOS:A1996UV29900018
J	Eckenhoff, RG				Eckenhoff, RG			Amino acid resolution of halothane binding sites in serum albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLATILE ANESTHETICS; TRIFLUOROACETIC-ACID; GENERAL-ANESTHETICS; PROTEINS; MEMBRANES; F-19-NMR	Saturable binding of various inhaled anesthetics to serum albumin has been shown with a variety of approaches, In order to determine the location of halothane binding sites in serum albumin, both human and bovine serum albumins (HSA and BSA) were photolabeled with [C-14]halothane, and subjected to proteolysis and microsequencing, BSA was found to have a higher affinity for halothane than HSA, and it contained two specifically labeled sites, One site was characterized by diffuse labeling from Trp(212)-Leu(217), and the other by a more discrete and higher affinity labeling at Trp(134)-Gly(135). HSA contained only a single labeled site, and although lower affinity, was determined to be analogous to BSA Trp(212). The position 130-140 region of HSA, having a leucine instead of tryptophan at position 134, was not labeled, These results demonstrate specific and discrete binding of an inhaled anesthetic to a mammalian-soluble protein, and further suggest the importance of aromatic residues as one feature of inhaled anesthetic binding sites.	UNIV PENN,MED CTR,DEPT ANESTHESIA,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Eckenhoff, Roderic/0000-0002-5581-746X	NIGMS NIH HHS [GM50595] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERFELDT KS, 1993, ACCOUNTS CHEM RES, V26, P191, DOI 10.1021/ar00028a009; BALASUBR.D, 1966, P NATL ACAD SCI USA, V55, P762, DOI 10.1073/pnas.55.4.762; BUCH HP, 1990, ACTA ANAESTH SCAND, V34, P35; CALVO R, 1989, ACTA ANAESTH SCAND, V33, P575, DOI 10.1111/j.1399-6576.1989.tb02969.x; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; DALE O, 1986, BIOCHEM PHARMACOL, V35, P557, DOI 10.1016/0006-2952(86)90347-3; DONG AC, 1994, J BIOL CHEM, V269, P23911; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DUBOIS BW, 1993, P NATL ACAD SCI USA, V90, P6478, DOI 10.1073/pnas.90.14.6478; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1996, P NATL ACAD SCI USA, V93, P2807, DOI 10.1073/pnas.93.7.2807; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; FERNANDEZBALLESTER G, 1994, BIOCHEMISTRY-US, V33, P4065, DOI 10.1021/bi00179a035; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1978, NATURE, V274, P339, DOI 10.1038/274339a0; HANSCH C, 1975, J MED CHEM, V18, P546, DOI 10.1021/jm00240a002; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; JOHANSSON JS, 1996, IN PRESS BIOCH BIOPH; JORGENSEN K, 1993, CHEM PHYS LIPIDS, V65, P205, DOI 10.1016/0009-3084(93)90018-X; MCDONAGH AF, 1992, EXPERIENTIA, V48, P246, DOI 10.1007/BF01930465; NAKAGAWA T, 1994, J MOL BIOL, V238, P297, DOI 10.1006/jmbi.1994.1292; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; RUOHO AE, 1984, MEMBRANES DETERGENTS, P119; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SCHOENBO.BP, 1967, NATURE, V214, P1120, DOI 10.1038/2141120a0; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SCHOENBORN BP, 1976, P NATL ACAD SCI USA, V73, P4195, DOI 10.1073/pnas.73.11.4195; SUAREZ E, 1991, METHOD FIND EXP CLIN, V13, P693; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; VEIRO JA, 1985, CHEM-BIOL INTERACT, V54, P337, DOI 10.1016/S0009-2797(85)80174-5; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0	34	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15521	15526		10.1074/jbc.271.26.15521	http://dx.doi.org/10.1074/jbc.271.26.15521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663164	hybrid			2022-12-25	WOS:A1996UV29900035
J	Gvakharia, BO; Hanson, E; Koonin, EK; Mathews, CK				Gvakharia, BO; Hanson, E; Koonin, EK; Mathews, CK			Identification of a second functional glutaredoxin encoded by the bacteriophage T4 genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; MUTANT THIOREDOXINS; THIOLTRANSFERASE; SEQUENCE; ENZYME; ACID	Thioredoxins and glutaredoxins are small ubiquitous redox proteins that were discovered as hydrogen donors for ribonucleotide reductase, the key enzyme for deoxyribonucleotide biosynthesis. Some organisms encode more than one redox protein. In this study, we demonstrate that an open reading frame in the bacteriophage T4 genome, reported earlier and designated as Y55.7 (Tomaschewski, J., and Ruger, W. (1987) Nucleic Acids Res. 15, 3632-3633), encodes a second functional redox protein. Gene y55.7 was cloned and expressed in Escherichia coli. Purified Y55.7 protein had glutathione-dependent thioltransferase and dehydroascorbate reductase activities indicative of a functional glutaredoxin. The protein is expressed at all stages of the T4 infection cycle and can serve as a hydrogen donor for the phage ribonucleotide reductase in in vitro experiments.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; NATL LIB MED,NIH,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894	Oregon State University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)					NIGMS NIH HHS [GM 87508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P7060, DOI 10.1073/pnas.89.15.7060; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROT N, 1982, TRENDS BIOCHEM SCI, V7, P137, DOI 10.1016/0968-0004(82)90204-3; DARLING AJ, 1988, J GEN VIROL, V69, P515, DOI 10.1099/0022-1317-69-3-515; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GAN ZR, 1990, BIOCHEM BIOPH RES CO, V168, P944, DOI 10.1016/0006-291X(90)91120-H; GAN ZR, 1987, J BIOL CHEM, V262, P6699; HOLMGREN A, 1978, J BIOL CHEM, V253, P7424; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1989, GENE, V43, P13; HOPPER S, 1983, J BIOL CHEM, V258, P3453; HUBER HE, 1986, J BIOL CHEM, V261, P5006; KOONIN EV, 1995, P NATL ACAD SCI USA, V92, P11921, DOI 10.1073/pnas.92.25.11921; KOONIN EV, 1996, IN PRESS CURR BIOL; MORELL S, 1995, FEBS LETT, V369, P149, DOI 10.1016/0014-5793(95)00690-B; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NIKKOLA MJ, 1991, THESIS SWEDICH U AGR; PAPAYANNOPOULOS IA, 1989, BIOCHEM BIOPH RES CO, V159, P1448, DOI 10.1016/0006-291X(89)92272-9; RAJAGOPAL I, 1995, J BIOL CHEM, V270, P27415, DOI 10.1074/jbc.270.46.27415; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SODERBERG BO, 1978, P NATL ACAD SCI USA, V75, P5827, DOI 10.1073/pnas.75.12.5827; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; TOMASCHEWSKI J, 1987, NUCLEIC ACIDS RES, V15, P3632, DOI 10.1093/nar/15.8.3632; TSENG MJ, 1992, J BACTERIOL, V174, P5740, DOI 10.1128/JB.174.17.5740-5744.1992; YOUNG P, 1994, J BIOL CHEM, V269, P20229	32	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15307	15310		10.1074/jbc.271.26.15307	http://dx.doi.org/10.1074/jbc.271.26.15307			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662944	hybrid			2022-12-25	WOS:A1996UV29900003
J	Li, XL; Bennett, V				Li, XL; Bennett, V			Identification of the spectrin subunit and domains required for formation of spectrin/adducin/actin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE SKELETON; PROTEIN KINASE-C; DROSOPHILA BETA-SPECTRIN; ACTIN-BINDING DOMAIN; ALPHA-ACTININ; TERMINAL DOMAIN; BRAIN SPECTRIN; CROSS-LINKING; F-ACTIN; SEQUENCE	Adducin is an actin-binding protein that has been proposed to function as a regulated assembly factor for the spectrin/actin network. This study has addressed the question of the subunit and domains of spectrin required for formation of spectrin/adducin/actin complexes in in vitro assays. Quantitative evidence is presented that the beta-spectrin N-terminal domain plus the first two alpha-helical domains are required for optimal participation of spectrin in spectrin/adducin/actin complexes. The alpha subunit exhibited no detectable activity either alone or following association with beta-spectrin. The critical domains of beta-spectrin involved in complex formation were determined using recombinant proteins expressed in bacteria. The N-terminal domain (residues 1-313) of beta-spectrin associated with F-actin with a K-d of 26 mu M, and promoted adducin binding to F-actin with half-maximal activation at 110 nM. Addition of the first cu-helical domain (residues 1-422) lowered the K-d for F-actin by 4-fold to 6 mu M, but also reduced the capacity by 3-fold and had no effect on interaction with adducin. Further addition of the second cu-helical domain (residues 1-528) did not alter binding to F-actin but resulted in a g-fold increased activity in promoting adducin binding with half-maximal activation at 50 nM. Addition of up to eight additional alpha-helical domains (residues 1-1388) resulted in no further change in F-actin binding or association with adducin. These results demonstrate an unanticipated role of the first repeat of beta-spectrin in actin binding activity and of the second repeat in association with adducin/actin, and imply the possibility of an extended contact between adducin, spectrin, and actin involving several actin subunits.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Li, XL (corresponding author), DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA.			Li, Xiaolin/0000-0001-9611-2434				BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; BYERS TJ, 1992, P NATL ACAD SCI USA, V89, P6187, DOI 10.1073/pnas.89.13.6187; CALVERT R, 1980, EUR J BIOCHEM, V107, P355; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DERICK LH, 1992, EUR J CELL BIOL, V57, P317; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; GARDNER K, 1988, P293; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HU RJ, 1992, J BIOL CHEM, V267, P18715; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; LEBART MC, 1990, BIOCHEM BIOPH RES CO, V173, P120, DOI 10.1016/S0006-291X(05)81030-7; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; LING E, 1986, J BIOL CHEM, V261, P13875; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MCGOUGH A, 1994, J CELL BIOL, V126, P433, DOI 10.1083/jcb.126.2.433; MIMURA N, 1987, J BIOL CHEM, V262, P4717; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WINDER SJ, 1995, J CELL SCI, V108, P63; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	51	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15695	15702		10.1074/jbc.271.26.15695	http://dx.doi.org/10.1074/jbc.271.26.15695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663089	hybrid			2022-12-25	WOS:A1996UV29900060
J	Lo, YYC; Wong, JMS; Cruz, TF				Lo, YYC; Wong, JMS; Cruz, TF			Reactive oxygen species mediate cytokine activation of c-jun NH2-terminal kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HYDROGEN-PEROXIDE; GENE-EXPRESSION; FREE-RADICALS; NITRIC-OXIDE; FACTOR-ALPHA; INTERLEUKIN-1; PHOSPHORYLATION; CHONDROCYTES; COLLAGENASE	Interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF alpha) are known to induce production of reactive oxygen species (ROS), which have been suggested to act as second messengers. Here we demonstrate that ROS production by bovine chondrocytes upon cytokine stimulation induces c-jun expression. Since c-jun expression is regulated by its own gene product via phosphorylation by c-Jun NH2-terminal kinases (JNKs), we investigated if cytokines and ROS could modulate JNK activity in chondrocyte monolayer cultures. Treatment of bovine chondrocytes with both IL-1 and TNF alpha leads to rapid induction of JNK activity, stimulating JNK activity 7- and 20-fold, respectively. Importantly, the observation that antioxidant treatment antagonizes IL-1 and TNF alpha activation of JNK provides strong evidence that ROS can act as mediators of JNK activity. Moreover, potent activation of JNK is also observed by direct addition of the ROS hydrogen peroxide (H2O2) to the chondrocyte cultures. Nitric oxide (NO), a multifunctional ROS, also appears to simulate JNK albeit to a lesser extent. These findings identify JNK as another molecular target for the actions of NO and H2O2. In addition, the inhibitory effect of diphenyleneiodonium on JNK activation implicates the involvement of flavonoid-containing enzymes in the ROS-mediated signaling process. Overstimulation of JNK activity by excessive production of ROS may, therefore, underlie pathological conditions such as arthritis and cancer.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,CONNECT TISSUE RES GRP,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,DEPT CELLULAR & MOLEC PATHOL,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1L5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto								AGNEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRETT J, 1989, J EXP MED, V169, P1977, DOI 10.1084/jem.169.6.1977; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CONQUER JA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P1, DOI 10.1016/0167-4889(92)90021-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRAWFORD D, 1988, ONCOGENE, V3, P27; CRUZ TF, 1990, BIOCHEM J, V269, P717, DOI 10.1042/bj2690717; DAI TN, 1995, ONCOGENE, V10, P849; DAMOULIS PD, 1994, BIOCHEM BIOPH RES CO, V201, P924, DOI 10.1006/bbrc.1994.1790; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUNO K, 1994, J LEUKOCYTE BIOL, V56, P542, DOI 10.1002/jlb.56.5.542; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MUEGGE K, 1993, P NATL ACAD SCI USA, V90, P7054, DOI 10.1073/pnas.90.15.7054; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; ONEILL LAJ, 1992, J IMMUNOL, V148, P484; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; ROSE RC, 1993, FASEB J, V7, P1135, DOI 10.1096/fasebj.7.12.8375611; SANTOS L, 1994, IMMUNOL CELL BIOL, V72, P406, DOI 10.1038/icb.1994.60; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STEFANOVICRACIC M, 1993, ARTHRITIS RHEUM, V36, P1036, DOI 10.1002/art.1780360803; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TIKU ML, 1990, J IMMUNOL, V145, P690; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZAFARULLAH M, 1992, FEBS LETT, V306, P169, DOI 10.1016/0014-5793(92)80992-P	57	442	450	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15703	15707		10.1074/jbc.271.26.15703	http://dx.doi.org/10.1074/jbc.271.26.15703			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663189	hybrid			2022-12-25	WOS:A1996UV29900061
J	NarayFejesToth, A; FejesToth, G				NarayFejesToth, A; FejesToth, G			Subcellular localization of the type 2 11 beta-hydroxysteroid dehydrogenase - A green fluorescent protein study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET-CELLS; TRANSLOCATION; ALDOSTERONE; RECEPTORS; MEMBRANE; ISOFORM	11 beta-Hydroxysteroid dehydrogenase (11 beta-HSD) is thought to confer aldosterone specificity to mineralocorticoid target cells by protecting the inherently nonselective mineralocorticoid receptor (MR) from occupancy by endogenous glucocorticoids. Recently, we characterized a novel isoform of 11 beta-HSD in aldosterone target cells, which has high affinity for its substrate, is unidirectional, and prefers NAD as cofactor, In this study we utilized a green fluorescent protein (GFP) technique to determine the subcellular localization of this isoform, 11 beta-HSD2, We generated a chimeric gene encoding the full-length rabbit 11 beta-HSD2 and, fused to its C terminus, the coding sequence of GFP. This construct was stably transfected into CHO cells, The enzymatic characteristics of the expressed 11 beta-HSD2/GFP fusion protein were undistinguishable from those of the native enzyme: high affinity for corticosterone (K-M 8-10 nar), NAD dependence, and lack of reductase activity, The intracellular location of the recombinant protein was determined by fluorescence microscopy. 11 beta-HSD2-associated fluorescence was observed as a reticular network over the cytoplasm and nuclear envelope, whereas the plasma membrane and the nucleus were negative, suggesting endoplasmic reticulum (ER) localization, Staining of CHO cells expressing 11 beta-HSD2/GFP with established subcellular organelle markers revealed a colocalization of 11 beta-HSD2/GFP only with ER markers and tubulin, To examine the orientation of 11 beta-HSD2 within the ER, we selectively permeabilized CHO cells and stained them with an anti-GFP antibody, Fluorescence microscopy indicated that the C-terminal region of 11 beta-HSD2 is on the cytoplasmic surface of the ER membrane, since it was accessible to the GFP antibody, This conclusion was confirmed by trypsin treatment of permeabilized cells followed by Western blotting, The C-terminal region of 11 beta-HSD2 was accessible to trypsin, indicating that it is on the cytoplasmic side of the ER membrane, These results indicate that 11 beta-HSD2 is localized exclusively to the ER, Since 11 beta-HSD2 does not contain any known ER retrieval signal, experiments are currently under way to determine what structural motifs are responsible for its FR localization.			NarayFejesToth, A (corresponding author), DARTMOUTH COLL SCH MED,DEPT PHYSIOL,LEBANON,NH 03758, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039523, R01DK045647, R01DK041841] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41841, DK 39523, DK 45647] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; FEJESTOTH G, 1994, J BIOL CHEM, V269, P26717; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNDER JW, 1993, SCIENCE, V259, P1132, DOI 10.1126/science.8382375; GomezSanchez EP, 1996, STEROIDS, V61, P110, DOI 10.1016/0039-128X(95)00201-Z; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; LEE SL, 1991, J CELL BIOL, V115, P409; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MERCER W, 1993, MOL CELL ENDOCRINOL, V92, P247, DOI 10.1016/0303-7207(93)90015-C; MONDER C, 1991, FASEB J, V5, P3047, DOI 10.1096/fasebj.5.15.1743437; MONDER C, 1984, STEROIDS, V44, P383, DOI 10.1016/S0039-128X(84)80001-X; MONDER C, 1991, J STEROID BIOCHEM, V40, P533, DOI 10.1016/0960-0760(91)90273-8; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; NARAYFEJESTOTH A, 1993, AM J PHYSIOL, V265, pF896, DOI 10.1152/ajprenal.1993.265.6.F896; NARAYFEJESTOTH A, 1995, ENDOCRINOLOGY, V136, P2579, DOI 10.1210/en.136.6.2579; NARAYFEJESTOTH A, 1994, AM J PHYSIOL, V266, pF76, DOI 10.1152/ajprenal.1994.266.1.F76; NARAYFEJESTOTH A, 1994, STEROIDS, V59, P105, DOI 10.1016/0039-128X(94)90085-X; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; THIGPEN AE, 1993, J BIOL CHEM, V268, P17404; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2263, DOI 10.1210/jc.80.7.2263; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P3145, DOI 10.1210/jc.80.11.3145; ZHOU MY, 1995, ENDOCRINOLOGY, V136, P3729, DOI 10.1210/en.136.9.3729	35	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15436	15442		10.1074/jbc.271.26.15436	http://dx.doi.org/10.1074/jbc.271.26.15436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663122	hybrid			2022-12-25	WOS:A1996UV29900023
J	Fertala, A; Holmes, DF; Kadler, KE; Sieron, AL; Prockop, DJ				Fertala, A; Holmes, DF; Kadler, KE; Sieron, AL; Prockop, DJ			Assembly in vitro of thin and thick fibrils of collagen II from recombinant procollagen II - The monomers in the tips of thick fibrils have the opposite orientation from monomers in the growing tips of collagen I fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR PACKING; POINTED TIPS; PC-COLLAGEN; INVITRO; CLEAVAGE; PROTEINASE; MECHANISM; DIAMETER; EXAMPLE; GROWTH	Human type II procollagen was prepared in a recombinant system and cleaved to pC-collagen II by procollagen N-proteinase. The pC-collagen II was then used as a substrate to generate collagen II fibrils by cleavage with procollagen C-proteinase at 37 degrees C. Electron microscopy of the fibrils demonstrated that, at the early stages of fibril assembly, very thin fibrils were formed, As the system approached equilibrium over 7-12 h, however, the thin fibrils were largely but not completely replaced by thick fibrils that had diameters of about 240 nm and a distinct D-period banding pattern, One typical fibril was photographed and analyzed in its entirety, The fibril was 776 D-periods (52 mu m) long, It had a central shaft with a uniform diameter that was about 516 D-periods long and two tips of about 100 D-periods each, Most of the central shaft had a symmetrical banding pattern flanked by two transition regions of about 30 D-periods each, Measurements by scanning transmission electron microscopy demonstrated that the mass per unit length from the tips to the shafts increased linearly over approximately 100 D-periods from the fibril end, The linear increase in mass per unit length was consistent with previous observations for collagen I fibrils and established that the tips of collagen II also had a near paraboloidal shape, However, the orientation of monomers in the tips differed from the tips of collagen I fibrils in that the C termini instead of the N termini were directed toward the tips, The thin fibrils that were present at early stages of assembly and at equilibrium were comparable to the collagen II fibrils seen in embryonic tissues and probably represented intermediates on the pathway of thick fibrils formation, The results indicated that the molecular events in the self-assembly of collagen II fibrils are apparently similar to those in self-assembly of collagen I fibrils, but that there are also important differences in the structural information contained in collagen I and collagen II monomers.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON INST MOLEC MED,PHILADELPHIA,PA 19107; UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	Jefferson University; University of Manchester			KADLER, KARL/ABI-2403-2020; Sieron, Aleksander L/G-1700-2013	KADLER, KARL/0000-0003-4977-4683; Sieron, Aleksander L./0000-0002-3894-9508	NIAMS NIH HHS [AR-39740] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRODSKY B, 1982, METHOD ENZYMOL, V82, P127; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; COOPER A, 1970, BIOCHEM J, V118, P355, DOI 10.1042/bj1180355; DOGTEROM M, 1993, PHYS REV LETT, V70, P1347, DOI 10.1103/PhysRevLett.70.1347; FERTALA A, 1994, J BIOL CHEM, V269, P11584; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; FRIEDEN C, 1985, ANNU REV BIOPHYS BIO, V14, P189, DOI 10.1146/annurev.bb.14.060185.001201; GUTLER PJG, 1984, J GEN VIROL, V65, P253; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLMES DF, 1986, INT J BIOL MACROMOL, V8, P161, DOI 10.1016/0141-8130(86)90020-6; HOLMES DF, 1992, P NATL ACAD SCI USA, V89, P9855, DOI 10.1073/pnas.89.20.9855; HULMES DJS, 1979, NATURE, V282, P878, DOI 10.1038/282878a0; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; HULMES DJS, 1995, BIOPHYS J, V68, P1661, DOI 10.1016/S0006-3495(95)80391-7; JONES EY, 1991, J MOL BIOL, V218, P209, DOI 10.1016/0022-2836(91)90885-A; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; Katz E P, 1989, Connect Tissue Res, V21, P149, DOI 10.3109/03008208909050005; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; LANDIS WJ, 1993, J STRUCT BIOL, V110, P39, DOI 10.1006/jsbi.1993.1003; LEE SL, 1983, COLLAGEN REL RES, V3, P89; MALLEINGERIN F, 1995, EXP CELL RES, V219, P257, DOI 10.1006/excr.1995.1226; MATSUSHITA M, 1984, PHYS REV LETT, V53, P286, DOI 10.1103/PhysRevLett.53.286; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; NA GC, 1986, J BIOL CHEM, V261, P2290; NITTMANN J, 1987, J PHYS A, V20, pL1184; PARKINSON J, 1994, PHYS REV E, V50, P2963, DOI 10.1103/PhysRevE.50.2963; Parkinson J, 1994, J MOL BIOL, V247, P823; PIEZ KA, 1981, BIOSCIENCE REP, V1, P801, DOI 10.1007/BF01114803; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SILVER D, 1992, P NATL ACAD SCI USA, V89, P9860, DOI 10.1073/pnas.89.20.9860; SILVER D, 1994, J MOL GRAPHICS, V12, P139, DOI 10.1016/0263-7855(94)80078-2; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; Veis A, 1988, COLLAGEN, V1, P113; WEINER S, 1991, FEBS LETT, V285, P49, DOI 10.1016/0014-5793(91)80722-F; WODHEADGALLOWAY J, 1984, CONNECTIVE TISSUE MA, P133; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P4907, DOI 10.1021/bi00365a027	44	34	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14864	14869		10.1074/jbc.271.25.14864	http://dx.doi.org/10.1074/jbc.271.25.14864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662997				2022-12-25	WOS:A1996UT10600036
J	Sepehrnia, B; Paz, IB; Dasgupta, G; Momand, J				Sepehrnia, B; Paz, IB; Dasgupta, G; Momand, J			Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; GLUCOCORTICOID RECEPTOR; ACTIVATING MUTATIONS; STEROID-RECEPTORS; BREAST-CANCER; TUMOR-ANTIGEN; GENE-PRODUCT; DNA-BINDING; COMMON; IDENTIFICATION	Cellular DNA damage results in the increased expression and accumulation of the p53 tumor suppressor protein within the nucleus which leads to cell cycle arrest or apoptosis, In some cases, however, wild-type p53 and some mutant forms of p53 reside in the cytoplasm of cancer cells, To understand the mechanism responsible for its cytoplasmic retention, studies were undertaken to determine if unique proteins form a complex with mutant p53 within the cytoplasm of transformed cells, One protein, with an apparent molecular mass of 92 kDa (p92), was observed to form a complex with a temperature-sensitive mutant p53 (TSp53(Val-135)) in the cytoplasm of transformed rat embryo fibroblasts at the non permissive temperature, p92 copurified with TSp53(Val-135) on a p53-specific immunoaffinity column and a gel filtration column, The protein was purified to homogeneity and identified as hsp84 by partial amino acid sequence analysis, hsp84 is a member of the hsp90 class of proteins, At the non-permissive temperature, TSp53(Val-135) and hsp84 colocalized in the cytoplasm near the nuclear envelope, At the permissive temperature, TSp53(Val-135) resides in the nucleus and expresses a ''wild-type like'' conformation, Under these conditions hsp84 continued to reside in the cytoplasm and little or no hsp84 formed a complex with p53, The results suggest that hsp84 binds mutant p53 in a spatial and/or conformation dependent manner.	CITY HOPE NATL MED CTR,DEPT CELL & TUMOR BIOL,DUARTE,CA 91010	City of Hope			Momand, Jamil/F-8154-2012					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BLONDAL JA, 1994, SEMIN CANCER BIOL, V5, P177; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13953; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; ZHANG W, 1992, ONCOGENE, V7, P1545	57	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15084	15090		10.1074/jbc.271.25.15084	http://dx.doi.org/10.1074/jbc.271.25.15084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663025	hybrid			2022-12-25	WOS:A1996UT10600066
J	Thompson, LJ; Fields, AP				Thompson, LJ; Fields, AP			beta(II) protein kinase C is required for the G(2)/M phase transition of cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR DIACYLGLYCEROL; GROWTH-FACTOR; LAMIN-B; CALCIUM; PHOSPHORYLATION; PROLIFERATION; FIBROBLASTS; INHIBITOR; MITOSIS; DIFFERENTIATION	Entry into mitosis requires the coordinated action of multiple mitotic protein kinases, In this report, we investigate the involvement of protein kinase C in the control of mitosis in human cells, Treatment of synchronized HL60 cells with the highly selective protein kinase C (PKC) inhibitor chelerythrine chloride leads to profound cell cycle arrest in G(2) phase. The cellular effects of chelerythrine are not due to either direct or indirect inhibition of the known mitotic regulator p34(cdc2)/cyclin B kinase, Rather, several lines of evidence demonstrate that chelerythrine-mediated G(2) phase arrest results from selective inhibition and degradation of beta(II) protein kinase C. First, chelerythrine causes dose-dependent inhibition of beta(II) PKC in vitro with an IC50 identical to that for G(2) phase blockade in whole cells, Second, chelerythrine specifically inhibits beta(II) PKC-mediated lamin B phosphorylation and mitotic nuclear lamina disassembly, Third, chelerythrine leads to selective loss of beta(II) PKC during G, phase in synchronized cells, Fourth, chelerythrine mediates activation-dependent degradation of PKC, indicating that beta(II) PKC is selectively activated during G, phase of cell cycle, Taken together, these data demonstrate that beta(II) PKC activation at G(2) phase is required for mitotic nuclear lamina disassembly and entry into mitosis and that beta(II) PKC-mediated phosphorylation of nuclear lamin B is important in these events.			Thompson, LJ (corresponding author), UNIV TEXAS, MED BRANCH,SEALY CTR ONCOL & HEMATOL,MED RES BLDG, RM 9104, 301 UNIV BLVD, GALVESTON, TX 77555 USA.				NCI NIH HHS [CA56869] Funding Source: Medline; NIGMS NIH HHS [GM43186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BEMENT WM, 1990, CELL REGUL, V1, P315, DOI 10.1091/mbc.1.3.315; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIVECHA N, 1993, BIOCHEM SOC T, V21, P877, DOI 10.1042/bst0210877; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Fields A P, 1995, Prog Cell Cycle Res, V1, P271; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOFMANN J, 1994, BIOCHEM BIOPH RES CO, V199, P937, DOI 10.1006/bbrc.1994.1319; Hunt T, 1991, Semin Cell Biol, V2, P213; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PICARD A, 1991, J CELL BIOL, V115, P337, DOI 10.1083/jcb.115.2.337; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RATAN RR, 1988, J CELL BIOL, V107, P993, DOI 10.1083/jcb.107.3.993; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416	42	133	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15045	15053		10.1074/jbc.271.25.15045	http://dx.doi.org/10.1074/jbc.271.25.15045			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663071	hybrid			2022-12-25	WOS:A1996UT10600061
J	North, MJ; Nicol, K; Sands, TW; Cotter, DA				North, MJ; Nicol, K; Sands, TW; Cotter, DA			Acid-activatable cysteine proteinases in the cellular slime mold Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE GERMINATION; CATHEPSIN-L; IDENTIFICATION; DIFFERENTIATION; SECRETION; PRECURSOR; VACUOLES; LATENT; GENES	Studies of the cysteine proteinases of the cellular slime mold Dictyostelium discoideum have been aided by a simple acid treatment step that was incorporated into the standard one-dimensional gelatin-sodium dodecyl sulfate-polyacrylamide gel electrophoresis assay procedure, The step involved immersing the separating gel in 10% (v/v) glacial acetic acid for 30-60 s immediately after electrophoresis, This modified approach revealed the presence of acid-activatable forms of some enzymes with noticeable increases in their ability to hydrolyze gelatin, a substrate present in the sodium dodecyl sulfate-polyacrylamide gels, and peptidyl amidomethylcoumarins, The activation has been analyzed using extracts of dormant spores from which cysteine proteinase activity had previously appeared low or virtually absent, The major acid-activatable proteinase had an apparent molecular mass of 48 kDa, Its activation was not due to autocatalysis as it was not prevented by mercuric chloride, an inhibitor of the enzyme, and was not accompanied by a significant change in electrophoretic mobility. It was most likely due to a conformational change and/or the removal of a low molecular weight inhibitor. The acid treatment has also revealed the presence of acid-activatable cysteine proteinases in vegetative cells, in which cysteine proteinase activity is present at high levels, as well as among enzymes from the developmental cells which have much lower cysteine proteinase activity, Indeed novel developmental forms were de tected at some stages, These results provide additional insight concerning cysteine proteinase expression at various stages during development in the slime molds, A developmental model is presented which suggests that the crypticity of the cysteine proteinases in dormant spores may be governed by proton pumps and endoge nous lysosomotropic agents.	UNIV WINDSOR,FAC SCI,OFF DEAN SCI,DEPT BIOL SCI,WINDSOR,ON N9B 3P4,CANADA; UNIV STIRLING,DEPT BIOL & MOLEC SCI,STIRLING FK9 4LA,SCOTLAND	University of Windsor; University of Stirling								BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BUSH JM, 1989, J BIOL CHEM, V264, P7630; CARDELLI JA, 1989, J BIOL CHEM, V264, P3454; COTTER DA, 1992, BIOCHEM CELL BIOL, V70, P892, DOI 10.1139/o92-137; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P237, DOI 10.1002/arch.940140404; GREGG JH, 1954, BIOL BULL, V107, P226, DOI 10.2307/1538609; HARA K, 1988, FEBS LETT, V231, P225; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KLEIN G, 1990, EUR J BIOCHEM, V193, P135, DOI 10.1111/j.1432-1033.1990.tb19314.x; KORTH MJ, 1988, ANAL BIOCHEM, V169, P181, DOI 10.1016/0003-2697(88)90270-9; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI, P1; MACH L, 1994, J BIOL CHEM, V269, P13030; MACIEWICZ RA, 1988, BIOCHEM SOC T, V16, P1056, DOI 10.1042/bst0161056; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MCDONALD JK, 1988, BIOCHEM BIOPH RES CO, V151, P827; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V261, P64, DOI 10.1016/0003-9861(88)90104-X; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; NORTH MJ, 1984, EXP MYCOL, V8, P47, DOI 10.1016/0147-5975(84)90019-7; NORTH MJ, 1988, BIOCHEM J, V254, P269, DOI 10.1042/bj2540269; NORTH MJ, 1990, J GEN MICROBIOL, V136, P827, DOI 10.1099/00221287-136-5-827; NORTH MJ, 1991, DEV GENET, V12, P154, DOI 10.1002/dvg.1020120124; NORTH MJ, 1990, J GEN MICROBIOL, V136, P835, DOI 10.1099/00221287-136-5-835; NORTH MJ, 1988, BIOCHEM J, V254, P261, DOI 10.1042/bj2540261; NORTH MJ, 1994, METHOD ENZYMOL, V244, P523; PADH H, 1991, J BIOL CHEM, V266, P5514; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PEARS CJ, 1985, NUCLEIC ACIDS RES, V13, P8853, DOI 10.1093/nar/13.24.8853; PRESSE F, 1986, MOL GEN GENET, V203, P333, DOI 10.1007/BF00333976; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; ROBERTSON CD, 1992, FEMS MICROBIOL LETT, V94, P127, DOI 10.1111/j.1574-6968.1992.tb05301.x; SOUZA GM, 1995, J BIOL CHEM, V270, P28938, DOI 10.1074/jbc.270.48.28938; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VERNET T, 1991, J BIOL CHEM, V266, P21451; WILLIAMS JG, 1985, EMBO J, V4, P99	35	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14462	14467		10.1074/jbc.271.24.14462	http://dx.doi.org/10.1074/jbc.271.24.14462			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662904				2022-12-25	WOS:A1996UQ66000077
J	Pfund, WP; Bourdage, JS; Farley, KA				Pfund, WP; Bourdage, JS; Farley, KA			Structural analysis of bovine somatotropin using monoclonal antibodies and the conformation-sensitive immunoassay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; FRAGMENTS; KINETICS; SUBUNIT	Bovine somatotropin was studied with respect to thermal stability, quantitative thermal denaturation kinetics, and refolding potential following thermal denaturation using a panel of 6 monoclonal antibodies and the Conformation-Sensitive Immunoassay (CSI). The antibody panel consisted of 4 conformation-dependent and 2 sequence-specific antibodies. Each of the antibodies revealed unique thermal stability profiles for their respective epitopes suggesting that they each recognize different antigenic determinants. Comparing the thermal stability profiles generated with these antibodies allowed the stability of bovine somatotropin to be ''dissected'' based on individual structural features. The degree to which bovine somatotropin is stabilized by disulfide bonds was examined using CSI-based quantitative thermal denaturation kinetics profiles generated under reducing and nonreducing conditions. All of the conformational epitopes unfolded faster under reducing conditions indicating that the two disulfide bonds within the somatotropin molecule impart some degree of global stabilization. The ability of bovine somatotropin to refold after reducing or nonreducing thermal denaturation was also examined using the antibody panel and the CSI. The results show that, although significant refolding was evident for some epitopes, bovine somatotropin cannot refold to the native state following thermal denaturation under either reducing or nonreducing conditions.	PHARMACIA & UPJOHN INC,ANALYT RES & SPECIFICAT DEV,KALAMAZOO,MI 49001	Pfizer			Farley, Kathleen A/K-3077-2017	Farley, Kathleen A/0000-0001-8935-6852				ALLEN MJ, 1994, BIOCHEMISTRY-US, V33, P3967, DOI 10.1021/bi00179a024; BELL JA, 1985, J BIOL CHEM, V260, P8520; BREMS DN, 1985, BIOCHEMISTRY-US, V24, P7662, DOI 10.1021/bi00347a025; BREMS DN, 1986, BIOCHEMISTRY-US, V25, P6539, DOI 10.1021/bi00369a030; BREMS DN, 1987, J BIOL CHEM, V262, P2590; BREMS DN, 1987, BIOCHEMISTRY-US, V26, P7774, DOI 10.1021/bi00398a036; CHEN CH, 1977, BIOCHEMISTRY-US, V16, P2110, DOI 10.1021/bi00629a010; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; DAVIO SR, 1993, STABILITY CHARACTERI, P59; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; HAVEL HA, 1986, BIOCHEMISTRY-US, V25, P6533, DOI 10.1021/bi00369a029; HOLZMAN TF, 1990, BIOCHEMISTRY-US, V29, P1255, DOI 10.1021/bi00457a022; HOLZMAN TF, 1986, BIOCHEMISTRY-US, V25, P6907, DOI 10.1021/bi00370a026; KLIBANOV AM, 1978, BIOCHEM BIOPH RES CO, V83, P1012, DOI 10.1016/0006-291X(78)91496-1; MACKENZIE NE, 1989, BIOCHIM BIOPHYS ACTA, V99, P166; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; PFUND WP, 1990, MOL IMMUNOL, V27, P495, DOI 10.1016/0161-5890(90)90068-B; SANTOME JA, 1973, EUR J BIOCHEM, V37, P164, DOI 10.1111/j.1432-1033.1973.tb02971.x; SECCHI C, 1991, HYBRIDOMA, V10, P499, DOI 10.1089/hyb.1991.10.499; Volkin DB, 1992, STABILITY PROTEIN A, P215; WALLIS M, 1973, FEBS LETT, V35, P11, DOI 10.1016/0014-5793(73)80566-6; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P17; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	23	9	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14055	14061		10.1074/jbc.271.24.14055	http://dx.doi.org/10.1074/jbc.271.24.14055			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662950	hybrid			2022-12-25	WOS:A1996UQ66000021
J	Zhang, YH; Mannering, DE; Davidson, AL; Yao, NH; Manson, MD				Zhang, YH; Mannering, DE; Davidson, AL; Yao, NH; Manson, MD			Maltose-binding protein containing an interdomain disulfide bridge confers a dominant-negative phenotype for transport and chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED CROSS-LINKING; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; MEMBRANE-COMPONENTS; 3-DIMENSIONAL STRUCTURES; RHODOBACTER-CAPSULATUS; SALMONELLA-TYPHIMURIUM; CYTOPLASMIC MEMBRANE; DEPENDENT TRANSPORT; ASPARTATE RECEPTOR	Bacterial substrate-binding proteins exist in an equilibrium among four forms: open/substrate-free, open/substrate-bound, closed/substrate-free, and closed/substrate-bound. Ligands stabilize the closed conformation, whereas the open conformation predominates in the substrate-free species, In its closed form, the NH2-terminal and COOH-terminal domains of maltose-binding protein (MBP) are proposed to be aligned to allow residues in both domains to interact simultaneously with complementary sites on the MalF and MalG proteins of the maltodextrin uptake system or with the Tar chemotactic signal transducer. However, the initial interaction might occur with an open/substrate-bound form of the binding protein, which would then close in contact with MalFG or Tar, Ligand would help stabilize this complex, We introduced cysteines (G69C and S337C) by site-directed mutagenesis into each domain of MBP and found that they formed an interdomain disulfide cross-link that should hold the protein in a closed conformation, This mutant MEP confers a dominant-negative phenotype for growth on maltose, for maltose transport, and for maltose chemotaxis. The growth and transport defects are partially reversed when the cells are exposed to the reducing agent dithiothreitol. We conclude that the cross-linked form of MBP competes with wild-type MBP in vivo for interaction with MalFG and Tar.	TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Texas A&M University System; Texas A&M University College Station; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine					NIGMS NIH HHS [GM49261, GM39736] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039736, R29GM049261, R01GM049261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DEBARBOUILLE M, 1978, J MOL BIOL, V124, P359, DOI 10.1016/0022-2836(78)90304-2; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; FROSHAUER S, 1984, J BIOL CHEM, V259, P896; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; GARDINA P, 1995, THESIS TEXAS A M U; HAZELBAUER GL, 1975, J BACTERIOL, V122, P206, DOI 10.1128/JB.122.1.206-214.1975; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; JACOBSON BL, 1992, J MOL BIOL, V223, P27, DOI 10.1016/0022-2836(92)90712-S; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; KONDO T, 1988, J BIOL CHEM, V263, P9470; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MANSON MD, 1986, J BACTERIOL, V165, P34, DOI 10.1128/jb.165.1.34-40.1986; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Miller J.H., 1972, EXPT MOL GENETICS; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; OH BH, 1993, J BIOL CHEM, V268, P11348; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHILTON BH, 1995, PROTEIN SCI, V4, P1346, DOI 10.1002/pro.5560040710; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STODDARD BL, 1992, NATURE, V358, P774, DOI 10.1038/358774a0; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; WOLF A, 1994, J BIOL CHEM, V269, P23051; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; ZHANG YH, 1992, J BIOL CHEM, V267, P22813	53	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17881	17889		10.1074/jbc.271.30.17881	http://dx.doi.org/10.1074/jbc.271.30.17881			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663400	hybrid			2022-12-25	WOS:A1996UY93500046
J	Lesecq, S; Baudin, V; Kister, J; Marden, MC; Poyart, C; Pagnier, J				Lesecq, S; Baudin, V; Kister, J; Marden, MC; Poyart, C; Pagnier, J			Functional studies and polymerization of recombinant hemoglobin Glu-alpha(2)beta(2)6(A3)->Val/Glu-7(A4)->Ala	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; DEOXYHEMOGLOBIN-S; ESCHERICHIA-COLI; FIBERS; BETA-7	In hemoglobin (Hb) S the hydrophobic mutated residue Val-beta 6(A3) (donor site) closely interacts with the hydrophobic side groups of Phe-beta 85(F1) and Leu-beta 88(F4) (EF pocket, acceptor site) of a neighboring tetramer, resulting in decreased solubility and polymerization of the deoxy-Hb. The beta 6(A3) residue is followed by two charged residues Glu-beta 7(A4) and Lys-beta 8(A5). This cluster has no attraction for the hydrophobic EF pocket. We have modified the beta 7(A4) residue next to the donor site Val-beta 6(A3), replacing the charged Glu by a hydrophobic Ala-(rHb beta E6V/E7A). The single mutant Glu-beta 7 --> Ala-(rHb beta E7A) was also engineered. Both rHbs exhibit a heat instability and an increased oxygen affinity compared to Hb A and Hb S. There was a concentration dependence of the ligand binding properties (1-300 mu M in heme) indicating an increased amount of dimers relative to Hb A. The deoxy form of rHb beta EGV/E7A polymerizes in vitro, with a decreased rate of polymer formation relative to Hb S, while the single mutant beta E7A does not polymerize in the same experimental conditions, The Glu-beta 7(A4) --> Ala substitution does not increase the hydrophobic interaction between donor and acceptor site. We speculate that the loss of the normal saline bridge between Glu-beta 7(A4) and Lys-beta 132(H10) leads to an increased flexibility of the A helix and may account for the difference of the polymerization for this Hb S mutant.	HOP BICETRE,INSERM U299,F-94275 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Marden, Michael C/G-3139-2012; Marden, Michael/AAA-5923-2020; BAUDIN-CREUZA, Véronique/K-7309-2017	Marden, Michael C/0000-0002-5254-6385; BAUDIN-CREUZA, Véronique/0000-0003-1032-3236				ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ADACHI K, 1991, HEMOGLOBIN, V15, P417, DOI 10.3109/03630269108998861; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ANDERSEN ME, 1971, J BIOL CHEM, V246, P4790; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BOOKCHIN RM, 1971, J MOL BIOL, V60, P263, DOI 10.1016/0022-2836(71)90292-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARRAGHER B, 1988, J MOL BIOL, V199, P315, DOI 10.1016/0022-2836(88)90316-6; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P118; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EDELSTEIN SJ, 1975, ANNU REV BIOCHEM, V44, P209, DOI 10.1146/annurev.bi.44.070175.001233; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FERMI G, 1981, ATLAS MOL STRUCTURE, V2, P56; KISTER J, 1987, J BIOL CHEM, V262, P12085; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAGEL RL, 1973, BIOCHEM BIOPH RES CO, V53, P1240, DOI 10.1016/0006-291X(73)90598-6; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; POYART C, 1981, NOUV REV FR HEMATOL, V23, P17; RHODA MD, 1986, HEMOGLOBIN, V10, P21, DOI 10.3109/03630268609072468; RODGERS DW, 1987, P NATL ACAD SCI USA, V84, P6157, DOI 10.1073/pnas.84.17.6157; ROTH EF, 1977, J LAB CLIN MED, V90, P837; WAJCMAN H, 1973, NOUV REV FR HEMATOL, V13, P89; YAMASHIRO DJ, 1994, J BIOL CHEM, V269, P23996	26	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17211	17214		10.1074/jbc.271.29.17211	http://dx.doi.org/10.1074/jbc.271.29.17211			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663330	hybrid, Green Published			2022-12-25	WOS:A1996UX94300037
J	Wang, J; Han, W; Zborowska, E; Liang, JR; Wang, XF; Willson, JKV; Sun, LZ; Brattain, MG				Wang, J; Han, W; Zborowska, E; Liang, JR; Wang, XF; Willson, JKV; Sun, LZ; Brattain, MG			Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; DIFFERENTIAL SENSITIVITY; GENE-EXPRESSION; CANCER CELLS; INHIBITION; FACTOR-BETA-1; CLONING; COMPLEX; LINES	Transforming growth factor beta (TGF beta) type I (RI) and type II (RII) receptors are essential for TGF beta signal transduction, A human colon carcinoma cell line, designated GEO, is marginally responsive to TGF beta and expresses a low level of RI mRNA relative to colon carcinoma cells, which are highly responsive to TGF beta, Hence, the role of RI as a limiting factor for TGF beta sensitivity and the contribution of low RI levels to the malignant phenotype of GEO cells were examined, Stable transfection of a tetracycline-regulatable rat RI cDNA increased TGF beta(1) binding to RI and resulted in increased growth inhibition by exogenous TGF beta(1). In contrast, although stable transfection of an RII expression vector into the same GEO cells increased TGF beta(1) binding to RII, growth inhibition by exogenous TGF beta(1) was not altered, This indicated that the low level of RI is a limiting factor for the growth-inhibitory effects of TGF beta in GEO cells, RI-transfected cells were growth-arrested at a lower saturation density than GEO control cells. They also showed reduced growth and clonogenicity in plating efficiency and soft agarose assays, whereas RII-transfected cells did not show any differences from the NEO control cells in these assays, Tetracycline repressed RI expression in transfected cells and reversed the reduction in plating efficiency of RI-transfected clones, confirming that growth effects were due to increased RI expression in transfected cells. TGF beta(1) neutralizing antibody stimulated the proliferation of RI-transfected cells but had little effect on GEO control cells, indicating that increased autocrine-negative TGF beta activity also resulted from increased RI expression. Tumorigenicity in athymic nude mice was significantly delayed in RI-transfected cells, These results indicate that low RI expression can be a limiting factor for response to exogenous TGF beta, as well as TGF beta autocrine-negative activity, and that reduction of RI expression can contribute to malignant progression.	MED COLL OHIO,DEPT BIOCHEM & MOLEC BIOL,TOLEDO,OH 43699; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,IRELAND CANC CTR,CLEVELAND,OH 44106; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; UNIV KENTUCKY,COLL MED,DEPT PHARMACOL,LEXINGTON,KY 40536	Case Western Reserve University; Case Western Reserve University; Duke University; University of Kentucky			, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R29CA063480, R37CA038173, R01CA038173, R01CA050457] Funding Source: NIH RePORTER; NCI NIH HHS [CA63480, CA50457, CA38173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V53, P4319; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KIMICHI A, 1988, SCIENCE, V240, P196; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SUN LZ, 1994, J BIOL CHEM, V269, P26449; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P186	40	115	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17366	17371		10.1074/jbc.271.29.17366	http://dx.doi.org/10.1074/jbc.271.29.17366			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663343	hybrid			2022-12-25	WOS:A1996UX94300060
J	Dessauer, CW; Gilman, AG				Dessauer, CW; Gilman, AG			Purification and characterization of a soluble form of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; SITE-MEDIATED INHIBITION; BETA-GAMMA-SUBUNITS; PROTEIN; IDENTIFICATION; REQUIREMENTS; ADENOVIRUS; EXPRESSION; FORSKOLIN; ADENOSINE	An engineered, soluble form of mammalian adenylyl cyclase has been expressed in Escherichia coli and purified by three chromatographic steps, The enzyme utilizes one molecule of ATP to synthesize one molecule of cyclic AMP and pyrophosphate at a maximal specific activity of 12.8 mu mol/min/mg, corresponding to a turnover number of 720 min(-1), Although devoid of membrane spans, the enzyme displays all of the regulatory properties that are common to mammalian adenylyl cyclases, It is activated synergistically by G(S alpha) and forskolin and is inhibited by adenosine (P-site) analogs with kinetic patterns that are identical to those displayed by the native enzymes, The purified enzyme is also inhibited directly by the G protein py subunit complex, After adenovirus-mediated expression in adenylyl cyclase-deficient HC-1 cells, the enzyme can be stimulated synergistically by G(S)-coupled receptors and forskolin.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16905, GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWAD JA, 1983, J BIOL CHEM, V258, P2960; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAYAISHI O, 1971, J BIOL CHEM, V246, P5840; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; INSEL PA, 1976, MOL PHARMACOL, V12, P1062; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MUMBY S, 1988, J BIOL CHEM, V263, P2020; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Segel I.H, 1968, BIOCH CALCULATIONS; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1978, ARCH BIOCHEM BIOPHYS, V191, P161, DOI 10.1016/0003-9861(78)90078-4; WU ZL, 1993, J BIOL CHEM, V268, P23766; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	44	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16967	16974		10.1074/jbc.271.28.16967	http://dx.doi.org/10.1074/jbc.271.28.16967			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663304	hybrid			2022-12-25	WOS:A1996UX12600082
J	Igal, RA; Coleman, RA				Igal, RA; Coleman, RA			Acylglycerol recycling from triacylglycerol to phospholipid, not lipase activity, is defective in neutral lipid storage disease fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; CULTURED FIBROBLASTS; METABOLISM; CELLS; ACID; BIOSYNTHESIS; LIPOPROTEIN; ICHTHYOSIS; INHIBITION; TRIACSINS	Neutral lipid storage disease (NLSD) is an autosomal recessive disorder in which excess triacylglycerol (TG) accumulates in most cells, Although it has been hypothesized that the TG accumulation is caused by a functional defect in cytosolic lipase activity, we were able to expose TG hydrolysis in NLSD cells by using triacsin C, an inhibitor of acyl-CoA synthetase that blocks the reincorporation of hydrolyzed fatty acids into glycerolipids, Our data suggest that TG lipolysis in NLSD cells is masked by rapid TG resynthesis, occurring because released acylglycerols cannot be used for phospholipid synthesis, In uptake studies, triacsin C blocked the incorporation of [H-3]glycerol into glycerolipids, incorporation of [C-14]oleate into TG, but not incorporation of [C-14]oleate into phospholipid, Thus, the drug inhibited both de novo synthesis of glycerolipids via the glycerol-3-phosphate pathway and the synthesis of TG from diacylglycerol. The drug did not appear to block reacylation of lysophospholipids. Triacsin C caused a loss of about 60% of the TG mass from both NLSD and oleate-loaded control cells, Rates of TG lipolysis were similar in NLSD cells and oleate-loaded control cells labeled with [6-(7-nitro-2,1,3-benzoxadiazol-4-yl)-amino]hexanoic acid or labeled with [C-14]oleate or [H-3]glycerol and chased in the presence of triacsin C, During a 96-h chase, [C-14]oleate reincorporation into the different phospholipid species increased only in control cells, Similar results were observed when NLSD, and control cells were chased after labeling with [H-3]glycerol. These data strongly suggest that normal human fibroblasts mobilize stored TG for phospholipid synthesis and that recycling to PC occurs via a TG-derived mono- or diacylglycerol intermediate, Normal recycling to phosphatidylethanolamine may primarily involve TG derived acyl groups rather than an acylglycerol precursor. NLSD cells appear to have a block in this recycling pathway with the result that both hydrolyzed fatty acids and the acylglycerol backbone are re-esterified to form TG, Because the NLSD phenotype includes ichthyosis, fatty liver, myopathy, cardiomyopathy, and mental retardation, the recycling pathway appears to be critical for the normal function of skin, liver, muscle, heart, and the central nervous system.	UNIV N CAROLINA,DEPT NUTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019068] Funding Source: NIH RePORTER; NIAMS NIH HHS [5-P60 AR3070] Funding Source: Medline; NICHD NIH HHS [HD 19068] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERGMAN R, 1991, J INHERIT METAB DIS, V14, P241, DOI 10.1007/BF01800597; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; COLEMAN R, 1977, J BIOL CHEM, V252, P3050; COOK HW, 1985, CAN J BIOCHEM CELL B, V63, P919, DOI 10.1139/o85-114; DIDONATO S, 1988, NEUROLOGY, V38, P1107; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P283, DOI 10.1016/0005-2760(89)90075-1; GIBBONS GF, 1990, BIOCHEM J, V268, P1; HILAIRE N, 1995, J BIOL CHEM, V270, P27027, DOI 10.1074/jbc.270.45.27027; HILAIRE N, 1993, FEBS LETT, V328, P230, DOI 10.1016/0014-5793(93)80933-L; HILAIRE N, 1994, BIOCHEM J, V297, P467, DOI 10.1042/bj2970467; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOLMSEN H, 1992, THROMB RES, V67, P313, DOI 10.1016/0049-3848(92)90006-V; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MCINTYRE JC, 1993, CHEM PHYS LIPIDS, V66, P171, DOI 10.1016/0009-3084(93)90002-K; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; RADOM J, 1989, BIOCHIM BIOPHYS ACTA, V1005, P130, DOI 10.1016/0005-2760(89)90178-1; SALVAYRE R, 1989, FEBS LETT, V250, P35, DOI 10.1016/0014-5793(89)80679-9; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WILLIAMS ML, 1991, BIOCHIM BIOPHYS ACTA, V1096, P162, DOI 10.1016/0925-4439(91)90055-E; WILLIAMS ML, 1988, J INHERIT METAB DIS, V11, P131, DOI 10.1007/BF01799862	26	102	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16644	16651		10.1074/jbc.271.28.16644	http://dx.doi.org/10.1074/jbc.271.28.16644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663220	Green Published, hybrid			2022-12-25	WOS:A1996UX12600036
J	Ohshima, K; Kang, S; Larson, JE; Wells, RD				Ohshima, K; Kang, S; Larson, JE; Wells, RD			TTA center dot TAA triplet repeats in plasmids form a non-H bonded structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVELY SUPERCOILED DNA; DIETHYL PYROCARBONATE; OSMIUM-TETROXIDE; CRUCIFORM EXTRUSION; IONIC ENVIRONMENT; TRANSGENIC MICE; CHEMICAL PROBE; SEQUENCE DNA; PM2 DNA; TEMPERATURE	CTG . CAG, CGG . CCG, and AAG . CTT triplet repeats proximal to or in disease genes expand by a non-Mendelian genetic process to cause several human hereditary syndromes, As part of our physical, biological, and genetic studies on the 10 possible triplet repeats, we discovered that the TTA . TAA repeat, isolated from the up-stream region of the variant surface glycoprotein gene of Trypanosoma brucei, shows a propensity to adopt a non-H bonded structure under appropriate conditions. The other nine triplet repeat sequences do not exhibit this property. (TTA . TAA)(n), where n = 90, 60, 30, and 18, cloned into pUC19 was studied by chemical and enzymatic probes as well as two-dimensional gel electrophoretic analyses under a variety of conditions. The helix opening was observed for all four inserts in supercoiled plasmids as a function of temperature, pH, metal ions, and buffer conditions using OsO4, diethyl pyrocarbonate, and chloroacetaldehyde probes, This unusual property of the TTA . TAA repeat suggests that it plays a different role from the other nine triplet repeats in gene expression.	TEXAS A&M UNIV, TEXAS MED CTR,CTR GENOME RES, DEPT BIOCHEM & BIOPHYS,INST BIOSCI & TECHNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BEER M, 1966, BIOCHEMISTRY-US, V5, P2283, DOI 10.1021/bi00871a017; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; BOWATER RP, 1994, NUCLEIC ACIDS RES, V22, P2042, DOI 10.1093/nar/22.11.2042; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CAMPBELL DA, 1984, NUCLEIC ACIDS RES, V12, P2759, DOI 10.1093/nar/12.6.2759; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHANG CH, 1977, BIOCHEMISTRY-US, V16, P33, DOI 10.1021/bi00620a006; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; DAYN A, 1991, J BACTERIOL, V173, P2658, DOI 10.1128/jb.173.8.2658-2664.1991; FURLONG JC, 1986, NUCLEIC ACIDS RES, V14, P3995, DOI 10.1093/nar/14.10.3995; FURLONG JC, 1989, BIOCHEMISTRY-US, V28, P2009, DOI 10.1021/bi00431a008; GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, NUCLEIC ACIDS RES, V12, P1725, DOI 10.1093/nar/12.3.1725; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; Haaf T, 1996, NAT GENET, V12, P183, DOI 10.1038/ng0296-183; HANIFORD DB, 1985, NUCLEIC ACIDS RES, V13, P4343, DOI 10.1093/nar/13.12.4343; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1992, J BIOL CHEM, V267, P20887; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KAYASUGAMIKADO K, 1980, CHEM PHARM BULL, V28, P932; KLYSIK J, 1992, J BIOL CHEM, V267, P17430; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; KOHWISHIGEMATSU T, 1987, P NATL ACAD SCI USA, V84, P2223, DOI 10.1073/pnas.84.8.2223; KOWALSKI D, 1984, NUCLEIC ACIDS RES, V12, P7071, DOI 10.1093/nar/12.18.7071; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LILLEY DMJ, 1984, EMBO J, V3, P1187, DOI 10.1002/j.1460-2075.1984.tb01949.x; LILLEY DMJ, 1983, NUCLEIC ACIDS RES, V11, P3097, DOI 10.1093/nar/11.10.3097; LINDBLAD K, 1994, NAT GENET, V7, P124, DOI 10.1038/ng0694-124; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCLELLAN JA, 1987, J MOL BIOL, V197, P707, DOI 10.1016/0022-2836(87)90477-3; MCCLELLAN JA, 1986, NUCLEIC ACIDS RES, V14, P9291, DOI 10.1093/nar/14.23.9291; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; OHSHIMA K, 1996, J BIOL CHEM, V271, P38696; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SCHOLTEN PM, 1986, NUCLEIC ACIDS RES, V14, P3981, DOI 10.1093/nar/14.10.3981; SHEFLIN LG, 1984, NUCLEIC ACIDS RES, V12, P7087, DOI 10.1093/nar/12.18.7087; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SINGLETON CK, 1983, J BIOL CHEM, V258, P7661; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STALLINGS RL, 1994, GENOMICS, V21, P116, DOI 10.1006/geno.1994.1232; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VOGT N, 1988, J MOL BIOL, V201, P773, DOI 10.1016/0022-2836(88)90474-3; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; ZACHARIAS W, 1983, BIOCHEMISTRY-US, V22, P2398, DOI 10.1021/bi00279a015	66	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16784	16791		10.1074/jbc.271.28.16784	http://dx.doi.org/10.1074/jbc.271.28.16784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663378				2022-12-25	WOS:A1996UX12600057
J	Arroyo, MP; Downey, KM; So, AG; Wang, TSF				Arroyo, MP; Downey, KM; So, AG; Wang, TSF			Schizosaccharomyces pombe proliferating cell nuclear antigen mutations affect DNA polymerase delta processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; LAGGING STRAND SYNTHESIS; REPLICATION FACTOR-C; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ACCESSORY PROTEINS; III HOLOENZYME; CALF THYMUS; PCNA	We introduced nine site-directed mutations into seven conserved fission yeast proliferative cell nuclear antigen (PCNA) residues, Leu(2), Asp(63), Arg(64), Gly(69), Gln(201), Glu(259), and Glu(260), either as single or as double mutants, Both the recombinant wild type and mutant PCNAs were able to form homotrimers in solution and to sustain growth of a null pcna strain (Delta pcna). Wild type Schizosaccharomyces pombe PCNA and PCNA proteins with mutations in Asp(63), Gln(201), Glu(259), Or Glu(260) to Ala were able to stimulate DNA synthetic activity and to enhance the processivity of calf thymus DNA polymerase delta holoenzyme similar to calf thymus PCNA, Mutations of Leu(2) to Val or Arg(64) to Ala, either singly eras a double mutant, yielded PCNA mutant proteins that had reduced capacity in enhancing the processivity of DNA polymerase delta but showed no deficiency in stimulation of the ATPase activity of replication factor C, S, pombe Delta pcna strains sustained by these two mutant-pcna alleles had moderate defects in growth and displayed elongated phenotypes, These cells, however, were not sensitive to UV irradiation, Together, these in vitro and in vivo studies suggest that the side chains of Leu(2) and Arg(64) in one face of the PCNA trimer ring structure are two of the several sites involved in tethering DNA polymerase delta for processive DNA synthesis during DNA replication.	STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; UNIV MIAMI, SCH MED, DEPT MED, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT BIOCHEM, MIAMI, FL 33101 USA	Stanford University; University of Miami; University of Miami					NCI NIH HHS [CA54415] Funding Source: Medline; NIDDK NIH HHS [DK26206] Funding Source: Medline; NIGMS NIH HHS [GM07365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, BIOCHIM BIOPHYS ACTA, V951, P274, DOI 10.1016/0167-4781(88)90097-8; BROWN WC, 1993, J BIOL CHEM, V268, P982; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; DONG Q, 1993, J BIOL CHEM, V268, P24163; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HINDGES R, 1995, GENE, V158, P241, DOI 10.1016/0378-1119(95)00065-E; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NG L, 1993, J BIOL CHEM, V268, P13571; NG L, 1990, J BIOL CHEM, V265, P11948; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; PARK H, 1995, NUCLEIC ACIDS RES, V23, P4337, DOI 10.1093/nar/23.21.4337; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SAZER S, 1990, J CELL SCI, V97, P509; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YODER BL, 1991, J BIOL CHEM, V266, P22689	53	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15971	15980		10.1074/jbc.271.27.15971	http://dx.doi.org/10.1074/jbc.271.27.15971			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663159	hybrid			2022-12-25	WOS:A1996UW35200022
J	Baugh, RJ; Krishnaswamy, S				Baugh, RJ; Krishnaswamy, S			Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-X; HUMAN FACTOR-VIIA; BOVINE FACTOR-X; TISSUE FACTOR; FACTOR-IX; STUART FACTOR; FACTOR-VA; PROTEOLYTIC ACTIVATION; HUMAN-PROTHROMBIN; CHRISTMAS-FACTOR	The activation of factor X by the extrinsic coagulation system results from the action of an enzyme complex composed of factor VIIa bound to tissue factor on phospholipid membranes in the presence of calcium ions (extrinsic Xase complex). Proteolysis at the Arg(52)-Ile(53) peptide bond in the heavy chain of factor X leads to the formation of the serine protease, factor Xa, and the generation of a heavily glycosylated activation peptide comprising residues 1-52 of the heavy chain. The role of the activation peptide region in mediating substrate recognition and cleavage by the extrinsic Xase complex is unclear, The protease Agkistrodon rhodostoma hydrolase gamma (ARH gamma), from the venom of the Malayan pit viper, was used to selectively cleave human factor X in the activation peptide region, Three cleavage sites were found within this region and gave products designated X(des1-34), X(des1-43), and X(des1-49). The products were purified to yield X(des 1-49) and a mixture of X(des 1-34) and X(des 1-43). Reversed phase high pressure liquid chromatography analysis indicated that the cleaved portion of the activation peptide was likely removed during purification. All cleaved species were inactive and could be completely activated to factor Xa by the extrinsic Xase complex or by a purified activator from Russell's viper venom, Steady state kinetic studies using tissue factor reconstituted into membranes yielded essentially equivalent kinetic constants for the activation of intact factor K and the cleaved derivatives under a wide range of conditions, Since X(des 1-49) lacks all but three residues of the activation peptide and is devoid of the carbohydrate present in this region, the data suggest that the specific recognition of human factor X by the extrinsic Xase complex is not achieved through specific interactions with residues 1-49 of the activation peptide or with carbohydrate structures attached to these residues.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL-52883, HL-47465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052883, R01HL047465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Bevington P. R., 1969, DATA REDUCTION ERROR; BHARADWAJ D, 1995, J BIOL CHEM, V270, P6537, DOI 10.1074/jbc.270.12.6537; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; CONTINO PB, 1994, BIOPHYS J, V67, P1113, DOI 10.1016/S0006-3495(94)80577-6; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; ESMON CT, 1974, J BIOL CHEM, V249, P7791; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; Furie B.C., 1976, Methods Enzymol, V45, P191; FURIE BC, 1974, BIOCHIM BIOPHYS ACTA, V365, P121, DOI 10.1016/0005-2795(74)90256-6; GOWDA DC, 1994, J BIOL CHEM, V269, P10644; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; IINO M, 1994, J BIOCHEM-TOKYO, V116, P335; INOUE K, 1993, EUR J BIOCHEM, V218, P153, DOI 10.1111/j.1432-1033.1993.tb18361.x; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KOSOW DP, 1974, THROMB RES, V4, P219, DOI 10.1016/0049-3848(74)90087-5; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOLLAR P, 1987, BIOCHEMISTRY-US, V26, P7627, DOI 10.1021/bi00398a015; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; PRYZDIAL ELG, 1994, BLOOD, V84, P194; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SINHA U, 1993, J BIOL CHEM, V268, P3048; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; VALCARCE C, 1994, J BIOL CHEM, V269, P26011; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; ZUR M, 1980, J BIOL CHEM, V255, P5703	52	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16126	16134		10.1074/jbc.271.27.16126	http://dx.doi.org/10.1074/jbc.271.27.16126			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663201	hybrid			2022-12-25	WOS:A1996UW35200042
J	Deng, P; Rettenmier, CW; Pattengale, PK				Deng, P; Rettenmier, CW; Pattengale, PK			Structural requirements for the ectodomain cleavage of human cell surface macrophage colony-stimulating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MEMBRANE-BOUND PRECURSOR; ANCHORED GROWTH-FACTORS; O-LINKED GLYCOSYLATION; FACTOR TNF RECEPTOR; FACTOR-I CSF-1; ALPHA PRECURSOR; TGF-ALPHA; EXPRESSION; FMS	One form of human macrophage colony-stimulating factor (CSF-1(256), M-CSF alpha) is a member of a restricted set of cell surface transmembrane proteins, which is selected to undergo proteolytic ectodomain cleavage. To determine the substrate requirements for this cleavage, we have constructed a series of mutations in the cytoplasmic tail, transmembrane domain, and juxtamembrane region of CSF-1(256) and stably expressed the mutated genes in NIH 3T3 cells. Our results demonstrate that membrane association of the CSF-1 precursor is required for cleavage of its growth factor ectodomain and furthermore that the juxtamembrane region Pro(161)-Gln(162)-Leu(163)-Gln(164)-Glu(165) (PQLQE) (residues 161-165 of the ectodomain) is an essential determinant of cell surface CSF-1(256) cleavage and that the cleavage site is partially sequence-specific. Furthermore, a mechanism of steric hindrance, which likely involves interference with protease accessibility, is postulated to explain the observed decreases in the cleavage efficiency in certain CSF-1 mutants. Finally, our results strongly suggest that the CSF-1 ectodomain is cleaved at or very near the cell surface by a membrane-associated proteolytic system.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040603] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40603] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HALENBECK R, 1988, J BIOTECHNOL, V8, P45, DOI 10.1016/0168-1656(88)90067-3; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; KUO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287, DOI 10.1016/0006-291X(74)90925-5; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MULLBERG J, 1995, J IMMUNOL, V155, P5198; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; REDDY P, 1989, J BIOL CHEM, V264, P17329; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1989, HEMATOL ONCOL CLIN N, V3, P479, DOI 10.1016/S0889-8588(18)30543-4; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; Steffan NH, 1989, GENE, V77, P51; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STEIN J, 1991, ONCOGENE, V6, P601; SUZU S, 1992, J BIOL CHEM, V267, P4345; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	49	27	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16338	16343		10.1074/jbc.271.27.16338	http://dx.doi.org/10.1074/jbc.271.27.16338			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663232	hybrid			2022-12-25	WOS:A1996UW35200071
J	Saito, H; Minamida, T; Arimoto, I; Handa, T; Miyajima, K				Saito, H; Minamida, T; Arimoto, I; Handa, T; Miyajima, K			Physical states of surface and core lipids in lipid emulsions and apolipoprotein binding to the emulsion surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; NUCLEAR-MAGNETIC-RESONANCE; CHOLESTERYL ESTER; UNESTERIFIED CHOLESTEROL; LECITHIN EMULSIONS; AMPHIPATHIC HELIX; MODEL MEMBRANES; PARTICLE-SIZE; PROTEIN	Plasma triglyceride-rich lipoproteins vary in lipid composition during their metabolism, We investigated the effects of the lipid composition of emulsion particles, specifically those of cholesterol enrichment and core replacement (replacing core triglyceride with cholesteryl oleate), on the physical states of surface and core lipids, Steady-state and time-resolved fluorescence anisotropies were measured in lipid emulsions using 1,6-diphenylhexatriene to probe the core and 1,6-diphenylhexatriene analogues for the outer and inner hydrophobic portions of surface phospholipids. In the absence of cholesterol, core replacement had little effect on the surface rigidity, despite the large difference in core mobility, However, core replacement caused a marked increase in surface rigidity in the presence of cholesterol. Quenching experiments using the fluorescent cholesterol analogue, dehydroergosterol, indicated that core replacement allowed surface dehydroergosterol to redistribute from the inner to the outer regions in the emulsion surface, These results indicated that core replacement modulates the surface properties of the emulsion particles through the redistribution of cholesterol in the surface layers, Furthermore, core replacement significantly decreased the binding of apolipoprotein E to the emulsion surface, whereas the binding of apolipoprotein CII responded to the cholesterol enrichment. This binding behavior of exchangeable apolipoproteins may closely correlate with the location of surface cholesterol and the mobility of core lipids.	KYOTO UNIV, FAC PHARMACEUT SCI, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University								ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; AVIRAM M, 1988, J BIOL CHEM, V263, P16842; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; DELMELLE M, 1980, BIOCHEMISTRY-US, V19, P698, DOI 10.1021/bi00545a014; FINEAN JB, 1990, CHEM PHYS LIPIDS, V54, P147, DOI 10.1016/0009-3084(90)90008-F; GINSBURG GS, 1982, J BIOL CHEM, V257, P8216; GRANOT E, 1994, BIOCHEMISTRY-US, V33, P15190, DOI 10.1021/bi00254a030; HANDA T, 1992, BIOCHEMISTRY-US, V31, P1415, DOI 10.1021/bi00120a018; HANDA T, 1994, PHARMACEUT RES, V11, P1283, DOI 10.1023/A:1018990327466; KALB E, 1989, BIOPHYS J, V56, P1245, DOI 10.1016/S0006-3495(89)82771-7; KINOSITA K, 1984, ADV BIOPHYS, V17, P147, DOI 10.1016/0065-227X(84)90027-3; KROON PA, 1994, BIOCHEMISTRY-US, V33, P4879, DOI 10.1021/bi00182a016; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LI QT, 1994, ARCH BIOCHEM BIOPHYS, V315, P473, DOI 10.1006/abbi.1994.1527; LI QT, 1993, BIOCHIM BIOPHYS ACTA, V1166, P145, DOI 10.1016/0005-2760(93)90090-V; LI QT, 1992, J LIPID RES, V33, P503; LI QT, 1990, BIOCHIM BIOPHYS ACTA, V1042, P42, DOI 10.1016/0005-2760(90)90054-2; LIPARI G, 1980, BIOPHYS J, V30, P489, DOI 10.1016/S0006-3495(80)85109-5; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARANHAO RC, 1986, BIOCHIM BIOPHYS ACTA, V875, P247, DOI 10.1016/0005-2760(86)90174-8; MILLER KW, 1983, J BIOL CHEM, V258, P3772; MILLER KW, 1982, J COLLOID INTERF SCI, V89, P466, DOI 10.1016/0021-9797(82)90197-7; MILLER KW, 1983, BIOCHEMISTRY-US, V22, P443, DOI 10.1021/bi00271a030; MIMS MP, 1990, BIOCHEMISTRY-US, V29, P6639, DOI 10.1021/bi00480a013; MIMS MP, 1986, BIOCHEMISTRY-US, V25, P474, DOI 10.1021/bi00350a030; QUARFORDT SH, 1995, BBA-LIPID LIPID MET, V1255, P82, DOI 10.1016/0005-2760(94)00218-N; REDGRAVE TG, 1987, BIOCHIM BIOPHYS ACTA, V921, P154, DOI 10.1016/0005-2760(87)90182-2; REISINGER RE, 1990, J LIPID RES, V31, P849; ROBINSON AJ, 1995, BIOPHYS J, V68, P164, DOI 10.1016/S0006-3495(95)80171-2; SAITO H, 1995, LANGMUIR, V11, P3742, DOI 10.1021/la00010a026; SAITO H, 1991, J BIOCHEM, V109, P559, DOI 10.1093/oxfordjournals.jbchem.a123419; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10676, DOI 10.1021/bi00499a015; SEELIG J, 1980, Q REV BIOPHYS, V13, P19, DOI 10.1017/S0033583500000305; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SMALL DM, 1992, PLASMA LIPOPROTEINS, P57; TAJIMA S, 1983, J BIOL CHEM, V258, P73; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	45	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15515	15520		10.1074/jbc.271.26.15515	http://dx.doi.org/10.1074/jbc.271.26.15515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663047	hybrid			2022-12-25	WOS:A1996UV29900034
J	Cousin, X; Bon, S; Duval, N; Massoulie, J; Bon, C				Cousin, X; Bon, S; Duval, N; Massoulie, J; Bon, C			Cloning and expression of acetylcholinesterase from Bungarus fasciatus venom - New type of COOH-terminal domain-involvement of a positively charged residue in the peripheral site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO-CALIFORNICA; NONAMPHIPHILIC FORMS; ANIONIC SUBSITES; CATALYTIC CENTER; BUTYRYLCHOLINESTERASE; CHOLINESTERASES; INHIBITION; BINDING; RAT	As deduced from cDNA clones, the catalytic domain of Bungarus fasciatus venom acetylcholinesterase (AChE) is highly homologous to those of other AChEs, It is, however, associated with a short hydrophilic carboxyl-terminal region, containing no cysteine, that bears no resemblance to the alternative COOH-terminal peptides of the GPI-anchored molecules (H) or of other homomeric or heteromeric tailed molecules (T). Expression of complete and truncated AChE in COS cells showed that active hydrophilic monomers are produced and secreted in all cases, and that cleavage of a very basic 8-residue carboxyl-terminal fragment occurs upon secretion. The COS cells produced Bungarus AChE about 30 times more efficiently than an equivalent secreted monomeric rat AChE. The recombinant Bungarus AChE, like the natural venom enzyme, showed a distinctive ladder pattern in nondenaturing electrophoresis, probably reflecting a variation in the number of sialic acids. By mutagenesis, we showed that two differences (methionine instead of tyrosine at position 70; lysine instead of aspartate or glutamate at position 285) explain the low sensitivity of Bungarus AChE to peripheral site inhibitors, compared to the Torpedo or mammalian AChEs. These results illustrate the importance of both the aromatic and the charged residues, and the fact that peripheral site ligands (propidium, gallamine, D-tubocurarine, and fasciculin 2) interact with diverse subsets of residues.	INST PASTEUR, UNITE VENINS, F-75015 PARIS, FRANCE; NEUROBIOL LAB, CNRS URA 1857, F-75005 PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Cousin, Xavier/E-2542-2013	Cousin, Xavier/0000-0002-8520-3610				ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; BARAK D, 1994, J BIOL CHEM, V269, P6296; BARRETT JC, 1979, BRIT J PHARMACOL, V67, P199, DOI 10.1111/j.1476-5381.1979.tb08667.x; BERMAN HA, 1980, BIOCHEMISTRY-US, V19, P2226, DOI 10.1021/bi00551a036; BON S, 1991, CELL MOL NEUROBIOL, V11, P157, DOI 10.1007/BF00712807; BON S, 1988, J NEUROCHEM, V51, P776, DOI 10.1111/j.1471-4159.1988.tb01812.x; BON S, 1988, J NEUROCHEM, V51, P786, DOI 10.1111/j.1471-4159.1988.tb01813.x; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Cervenansky C., 1991, P303; CERVENANSKY C, 1995, EUR J BIOCHEM, V229, P270, DOI 10.1111/j.1432-1033.1995.0270l.x; CERVENANSKY C, 1994, BBA-GEN SUBJECTS, V1199, P1, DOI 10.1016/0304-4165(94)90088-4; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1987, BIOCHIMIE, V69, P87, DOI 10.1016/0300-9084(87)90239-2; DREWS U, 1975, PROG HISTOCHEM CYTOC, V7, P3; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EICHLER J, 1994, MOL PHARMACOL, V45, P335; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KREIENKAMP HJ, 1991, P NATL ACAD SCI USA, V88, P6117, DOI 10.1073/pnas.88.14.6117; KUMAR V, 1973, EUR J BIOCHEM, V34, P586, DOI 10.1111/j.1432-1033.1973.tb02799.x; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LAYER P G, 1985, Journal of Neurochemistry, V44, pS129; LAYER PG, 1988, DEVELOPMENT, V102, P387; LEGAY C, 1993, FEBS LETT, V315, P163, DOI 10.1016/0014-5793(93)81155-S; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P17; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MASSOULIE J, 1976, EUR J BIOCHEM, V68, P531, DOI 10.1111/j.1432-1033.1976.tb10841.x; NEVILLE LF, 1990, J NEUROSCI RES, V27, P452, DOI 10.1002/jnr.490270404; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Porschke D, 1996, BIOPHYS J, V70, P1603, DOI 10.1016/S0006-3495(96)79759-X; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RANDALL WR, 1994, BBA-GENE STRUCT EXPR, V1218, P453, DOI 10.1016/0167-4781(94)90204-6; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SIKORAV JL, 1987, EMBO J, V6, P1865, DOI 10.1002/j.1460-2075.1987.tb02445.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TOUTANT JP, 1988, HDB EXP PHARM, V86, P225; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	53	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15099	15108		10.1074/jbc.271.25.15099	http://dx.doi.org/10.1074/jbc.271.25.15099			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662867	hybrid			2022-12-25	WOS:A1996UT10600068
J	Ohba, T; Seki, T; Azuma, Y; Nishimoto, T				Ohba, T; Seki, T; Azuma, Y; Nishimoto, T			Premature chromatin condensation induced by loss of RCC1 is inhibited by GTP- and GTP gamma S-Ran, but not GDP-Ran	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME CONDENSATION; BINDING PROTEIN; CELL-CYCLE; REGULATOR; MITOSIS	RCC1 is a guanine nucleotide exchanging factor acting on nuclear G protein Ran, Premature chromatin condensation occurs in the temperature sensitive rcc1(-) mutant of the BHK21 cell line, tsBN2, at the restrictive temperature, This observation can be explained if the premature activation of MPF is normally inhibited by GTP-Ran, In the absence of RCC1, GDP-Ran predominates, resulting in MPF activation, However, experiments with Ran mutants to determine whether GTP- or GDP-Ran prevents activation of MPF have yielded conflicting results, In order to clarify this point, we have microinjected nucleotide-bound Ran, instead of mutated Ran, into the nuclei of tsBN2 cells treated to reduce RCC1 mediated guanine nucleotide exchange, GTP-Ran, GTP gamma S-Ran, and GDP-Ran all inhibited chromatin condensation. However, the inhibition of chromatin condensation by GDP-Ran could be completely abolished by co-injection with GDP, but not GTP, Thus, we conclude that GTP-Ran blocks the activation of MPF and that hydrolysis of GTP is not required to prevent MPF activation.	KYUSHU UNIV, GRAD SCH MED SCI, DEPT BIOL MOLEC, HIGASHI KU, FUKUOKA 812, JAPAN	Kyushu University			Oba, Tomoyuki/ABT-2152-2022	Oba, Tomoyuki/0000-0002-6715-7892				BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; CLARKE PR, 1995, J CELL SCI, V108, P1217; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NISHIMOTO T, 1978, SOMAT CELL GENET, V4, P323, DOI 10.1007/BF01542846; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; SAZAR S, 1992, EMBO J, V13, P606; SEINO H, 1991, COLD SPRING HARB SYM, V56, P367; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577	22	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14665	14667		10.1074/jbc.271.25.14665	http://dx.doi.org/10.1074/jbc.271.25.14665			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663347	hybrid, Green Accepted			2022-12-25	WOS:A1996UT10600005
J	BrinkmanVanderLinden, ECM; Mollicone, R; Oriol, R; Larson, G; VandenEijnden, DH; VanDijk, W				BrinkmanVanderLinden, ECM; Mollicone, R; Oriol, R; Larson, G; VandenEijnden, DH; VanDijk, W			A missense mutation in the FUT6 gene results in total absence of alpha 3-fucosylation of human alpha(1)-acid glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 CHAIN POLYLACTOSAMINE; ALPHA-1-ACID GLYCOPROTEIN; HUMAN-SERUM; H-1-NMR SPECTROSCOPY; FUCOSYL-TRANSFERASE; CANCER; EXPRESSION; ANTIGEN; ALPHA-3-FUCOSYLTRANSFERASES; GLYCOSYLATION	The major alpha 3-fucosyltransferase activity in human plasma is encoded by the gene for fucosyltransferase VI (FUT6). A missense mutation (Gly 739-->Ala) in this gene is responsible for deficiency of enzyme activity in plasma. To examine whether this fucosyltransferase is the sole enzyme responsible for the alpha 3-fucosylation of serum glycoproteins in the liver, we studied the fucosylation of three glycoproteins in sera of individuals with or without inactivated FUT3 and/or FUTG gene(s) but with a functional FUT5 gene. alpha(1)-Acid glycoprotein was used as the principal reporter protein for liver alpha 3-fucosyltransferase activity, because of its high fucose content. In all individuals with the FUTG missense mutation Gly-739-->Ala in double dose, no fucosylation of alpha(1)-acid glycoprotein was found. This alpha(1)-acid glycoprotein was not intrinsically resistant to fucosylation, since it was susceptible to in vitro fucosylation using an alpha 3/4-fucosyltransferase isolated from human milk. The same result was found for alpha(1)-antichymotrypsin and alpha(1)-protease inhibitor. On the other hand in all individuals with alpha 3-fucosyltransferase activity in plasma, alpha 3-fucosylated glycoforms of the glycoproteins studied were found. The degree of fucosylation of alpha(1)-acid glycoprotein was correlated with alpha 3-fucosyltransferase activity (Rs = 0.82). These data indicate that the product of FUTG, but not of FUT3 or of FUT5, is responsible for the alpha 3-fucosylation of glycoproteins produced in liver and suggest that this organ is a major source of alpha 3-fucosyltransferase activity in plasma.	FREE UNIV AMSTERDAM, FAC MED, DEPT MED CHEM, 1081 BT AMSTERDAM, NETHERLANDS; INSERM U178, F-94807 VILLEJUIF, FRANCE; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM & TRANSFUS MED, S-41345 GOTHENBURG, SWEDEN	Vrije Universiteit Amsterdam; Institut National de la Sante et de la Recherche Medicale (Inserm); Sahlgrenska University Hospital; University of Gothenburg			Larson, Göran/AAF-3404-2019					BIERHUIZEN MFA, 1988, EUR J BIOCHEM, V175, P387, DOI 10.1111/j.1432-1033.1988.tb14208.x; BIOU D, 1987, BIOCHIM BIOPHYS ACTA, V913, P308, DOI 10.1016/0167-4838(87)90140-3; BOGHANSE.TC, 1973, ANAL BIOCHEM, V56, P480, DOI 10.1016/0003-2697(73)90215-7; BrinkmanVanderLinden ECM, 1996, GLYCOCONJUGATE J, V13, P27, DOI 10.1007/BF01049676; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CANDELIER JJ, 1993, LAB INVEST, V69, P449; CHANDRASEKARAN EV, 1992, J BIOL CHEM, V267, P23806; DEGRAAF TW, 1993, J EXP MED, V177, P657, DOI 10.1084/jem.177.3.657; DEGRAAF TW, 1994, J RHEUMATOL, V21, P2209; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1993, EUR J BIOCHEM, V216, P769, DOI 10.1111/j.1432-1033.1993.tb18197.x; Elmgren A, 1996, VOX SANG, V70, P97, DOI 10.1111/j.1423-0410.1996.tb01300.x; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; HADA T, 1995, GLYCOCONJUGATE J, V12, P627, DOI 10.1007/BF00731257; HADA T, 1990, Gastroenterologia Japonica, V25, P715; JOHNSON PH, 1995, GLYCOCONJUGATE J, V12, P879, DOI 10.1007/BF00731250; KANNAGI R, 1986, CANCER RES, V46, P2619; KODA Y, 1993, BLOOD, V82, P2915; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAINE A, 1991, EUR J BIOCHEM, V197, P209, DOI 10.1111/j.1432-1033.1991.tb15901.x; Lowe J B, 1991, Semin Cell Biol, V2, P289; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; SAITOH A, 1993, ARCH BIOCHEM BIOPHYS, V303, P281, DOI 10.1006/abbi.1993.1284; SASAKI K, 1994, J BIOL CHEM, V269, P14730; THOMPSON S, 1987, BRIT J CANCER, V56, P605, DOI 10.1038/bjc.1987.249; TUO XH, 1992, CANCER RES, V52, P5744; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; VANDIJK W, 1986, BIOCHEM CELL BIOL, V64, P79, DOI 10.1139/o86-014; VANDIJK W, 1995, ADV EXP MED BIOL, V376, P223; WIERUSZESKI JM, 1988, FEBS LETT, V238, P390, DOI 10.1016/0014-5793(88)80518-0; WOLOSKI BMRNJ, 1986, BIOCHIM BIOPHYS ACTA, V885, P185, DOI 10.1016/0167-4889(86)90087-X; YAZAWA S, 1989, J CANCER RES CLIN, V115, P451, DOI 10.1007/BF00393336; YAZAWA S, 1988, CANCER, V62, P516, DOI 10.1002/1097-0142(19880801)62:3<516::AID-CNCR2820620313>3.0.CO;2-4; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	40	57	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14492	14495		10.1074/jbc.271.24.14492	http://dx.doi.org/10.1074/jbc.271.24.14492			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662894	hybrid			2022-12-25	WOS:A1996UQ66000081
J	Fawcett, TW; Eastman, HB; Martindale, JL; Holbrook, NJ				Fawcett, TW; Eastman, HB; Martindale, JL; Holbrook, NJ			Physical and functional association between GADD153 and CCAAT/enhancer-binding protein beta during cellular stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; GROWTH ARREST; C/EBP; GENE; TRANSCRIPTION; EXPRESSION; ISOFORMS; CELLS; LAP	GADD153, a ubiquitously expressed member of the CCAAT/enhancer-binding protein (C/EBP) family is induced by a wide variety of growth-arresting and DNA-damaging agents. Functionally, GADD153 has been postulated to act as a dominant-negative regulator of C/EBPs. Therefore we sought to gain evidence for interactions between GADD153 and other C/EBPs during cellular responses to stress. In this report we have demonstrated that treatment of rat pheochromocytoma PC12 cells with sodium arsenite leads to enhanced expression of C/ERP-beta and GADD153 (growth arrest and DNA damage inducible gene 153) but not other C/EBPs. Coimmunoprecipitation experiments provided evidence for the formation of endogenous GADD153-C/EBP-beta complexes in arsenite-treated cells. Additional experiments were performed to determine the role of such complexes in regulating GADD153 expression. Previous studies in our laboratory demonstrated that the GADD153 promoter contains a C/EBP binding site through which other C/EBPs interact to transactivate GADD153 expression in liver hepatoma cells. Here, we demonstrate that extracts prepared from arsenite-treated PC12 cells likewise show increased amounts of factors capable of binding to the GADD153-C/EBP site and that these complexes are comprised at least in part of C/EBP-beta. Forced expression of C/EBP-beta was found to be capable of transactivating the GADD153 promoter in PC12 cells cotransfected with plasmids expressing a GADD153 reporter gene and C/EBP-beta protein. However, overexpression of GADD153 inhibited the transactivation of the GADD153 promoter by C/EBP-beta. These findings provide evidence for an autoregulatory loop in which stress-induced GADD153 feeds back to attenuate GADD153 expression during the cellular response to stress.	NIA,GENE EXPRESS & AGING SECT,GERONTOL RES CTR,NIH,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Martindale, Jennifer Luethy/AAD-1963-2022	Martindale, Jennifer Luethy/0000-0002-3234-6861				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIEHL AM, 1994, HEPATOLOGY, V19, P447; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119	24	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14285	14289		10.1074/jbc.271.24.14285	http://dx.doi.org/10.1074/jbc.271.24.14285			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662954	hybrid			2022-12-25	WOS:A1996UQ66000054
J	Middleton, SA; Johnson, DL; Jin, RZ; McMahon, FJ; Collins, A; Tullai, J; Gruninger, RH; Jolliffe, LK; Mulcahy, LS				Middleton, SA; Johnson, DL; Jin, RZ; McMahon, FJ; Collins, A; Tullai, J; Gruninger, RH; Jolliffe, LK; Mulcahy, LS			Identification of a critical ligand binding determinant of the human erythropoietin receptor - Evidence for common ligand binding motifs in the cytokine receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; SIGNAL TRANSDUCTION; PROLACTIN RECEPTOR; EXTRACELLULAR DOMAIN; MUTATIONAL ANALYSIS; ERYTHROID-CELLS; BETA-CHAIN; ACTIVATION; PROLIFERATION; INTERLEUKIN-2	The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains. We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding, Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays. Substitution of phenylalanine at position 93 (Phe(93)) with alanine (F93A mutation) resulted in a drastic reduction in EPO binding in the FBP. More conservative tyrosine or tryptophan substitutions at Phe(93) resulted in much less dramatic effects on EPO binding, Biophysical studies indicated that the F93A mutation does not result in gross structural alterations in the EBP, Furthermore, the F93A mutation in full-length EPOR expressed in COS cells abolished detectable EPO binding, This was not a result of processing or transport defects, since mutant receptor was present on the surface of the cells, Mutations in the region immediately around Phe(93) and in residues homologous to other reported ligand binding determinants of the cytokine receptor family had small to moderate effects on EPO binding. These data indicate that Phe(93) is a critical EPO binding determinant of the EPOR. Furthermore, since Phe(93) aligns with critical ligand binding determinants in other receptors of the cytokine receptor family, these data suggest that receptors of this family may use common structural motifs to bind their cognate ligands.			Middleton, SA (corresponding author), RW JOHNSON PHARMACEUT RES INST, 1000 ROUTE 202, POB 300, RARITAN, NJ 08869 USA.		McMahon, Francis J/A-7290-2009	McMahon, Francis J/0000-0002-9469-305X				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DONG YJ, 1993, EXP HEMATOL, V21, P483; DOSHI PD, 1994, BLOOD, V84, P2539, DOI 10.1182/blood.V84.8.2539.bloodjournal8482539; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; HERMINE O, 1994, BLOOD, V84, P811; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JOLLIFFE LK, 1995, NEPHROL DIAL TRANSPL, V10, P28, DOI 10.1093/ndt/10.supp2.28; JONES SS, 1990, BLOOD, V76, P31; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRANTZ SB, 1991, BLOOD, V77, P419; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LONGMORE GD, 1993, J CELL BIOL, V123, P1305, DOI 10.1083/jcb.123.6.1305; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P1565; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; NAGAO M, 1993, BLOOD, V81, P2503; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; RONCO LV, 1994, J BIOL CHEM, V269, P277; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; WANG HM, 1992, J BIOL CHEM, V267, P979; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YET MG, 1993, BLOOD, V82, P1713, DOI 10.1182/blood.V82.6.1713.bloodjournal8261713; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	46	45	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14045	14054		10.1074/jbc.271.24.14045	http://dx.doi.org/10.1074/jbc.271.24.14045			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662939	hybrid			2022-12-25	WOS:A1996UQ66000020
J	Palasis, M; Kuntzweiler, TA; Arguello, JM; Lingrel, JB				Palasis, M; Kuntzweiler, TA; Arguello, JM; Lingrel, JB			Ouabain interactions with the H5-H6 hairpin of the Na,K-ATPase reveal a possible inhibition mechanism via the cation binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; AMINO-ACIDS; CARDIAC-GLYCOSIDES; RESISTANT ENZYME; NA+,K+-ATPASE; SENSITIVITY; MUTATION; IDENTIFICATION; EXPRESSION	Cardiac glycosides such as ouabain and digoxin specifically inhibit the Na,K-ATPase. Three new residues in the carboxyl half of the Na,K-ATPase, Phe-786, Leu-793 (PFLIF(786)IIANIPL(793)PLGT(797)), and Phe-863 (FTYF(863)VIM) have been identified as ouabain sensitivity determinants using random mutagenesis. Polymerase chain reaction was utilized to randomly mutate the DNA sequence encoding the amino acids between Lys-691 and Lys-945 in the alpha subunit of the Na,K-ATPase. This region contains four transmembrane segments (H5, H6, H7, and H8) and the connecting extracellular and cytoplasmic loops, Diverse substitutions of these three residues resulted in proteins displaying 2.8-48-fold increases in the I-50 of different cardiac glycosides for inhibition of the Na,K-ATPase activity, By locating these residues, in conjunction with Thr-797 (Feng, J., and Lingrel, J. B (1994) Biochemistry 33, 4218-4224), a new region of the protein containing the H5-H6 hairpin and the H7 transmembrane segment emerges as a major determinant of ouabain inhibition. Thus, a link between the cardiac glycoside binding site and the cation transport sites of the Na,K-ATPase transpires giving a structural base to the cation antagonism of ouabain binding, Furthermore, this link suggests a possible mechanism for cardiac glycoside inhibition of the Na,K-ATPase, such that ouabain binding to the implicated region blocks the movement of the H5 and H6 transmembrane domains which may be required for energy transduction and cation transport.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University of Cincinnati			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NHLBI NIH HHS [HL08612-01, HL 28573, HL 03373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008612, R01HL028573, K14HL003373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1978, PHARMACOL REV, V29, P311; ANTOLOVIC R, 1995, FEBS LETT, V368, P169, DOI 10.1016/0014-5793(95)00637-O; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; ASKEW GR, 1994, J BIOL CHEM, V269, P24120; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAMBERG E, 1994, SODIUM PUMP STRUCTUR; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS EL, 1993, J BIOL CHEM, V268, P25632; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANFIELD V, 1990, MOL CELL BIOL, V10, P1367, DOI 10.1128/MCB.10.4.1367; EMANUEL JR, 1988, J BIOL CHEM, V263, P7726; Feller W., 1970, INTRO PROBABILITY TH, V3; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GREEN NM, 1994, SODIUM PUMP, P110; HANSEN O, 1984, PHARMACOL REV, V36, P143; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JORGENSEN PL, 1992, ACTA PHYSIOL SCAND, V146, P89; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE LK, 1973, J BIOL CHEM, V248, P7197; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MALIK B, 1993, PROTEIN SCI, V2, P2103, DOI 10.1002/pro.5560021211; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; ROSSI B, 1980, J BIOL CHEM, V255, P9936; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHONFEL W, 1985, N-S ARCH PHARMACOL, V329, P14; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; Thomas R., 1990, ADV DRUG RES, P311; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; YODA A, 1975, MOL PHARMACOL, V11, P653	53	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14176	14182		10.1074/jbc.271.24.14176	http://dx.doi.org/10.1074/jbc.271.24.14176			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662895	hybrid			2022-12-25	WOS:A1996UQ66000038
J	Fritz, LK; Suquet, C; Smerdon, MJ				Fritz, LK; Suquet, C; Smerdon, MJ			Strand breaks are repaired efficiently in human ribosomal genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-PATCH REPAIR; DNA-REPAIR; HUMAN-FIBROBLASTS; RNA GENES; PREFERENTIAL REPAIR; TRANSCRIBED STRAND; EXCISION REPAIR; SODIUM-BUTYRATE; BLEOMYCIN; CELLS	We examined repair of DNA strand breaks induced by the anti-cancer drug bleomycin in both Pol I and Pol IT transcribed genes in permeabilized human fibroblasts, The majority of these breaks (>80%) are single strand breaks (SSBs) thought to be repaired by base excision repair enzymes. Repair was examined in each strand of a 7.2-kilobase fragment, completely within the Pol I transcribed region of ribosomal DNA (rDNA) and an 8.3-kilobase fragment completely within the Pol II transcribed region of the dihydrofolate reductase (DHFR) gene. Bleomycin dose-response studies revealed no bias for SSBs in either strand of the rDNA fragment. Furthermore, repair of SSBs is rapid (similar to 80% resealed in 60 min) in both the transcribed and nontranscribed strands of rDNA Rapid repair of SSBs is also observed in both strands of the DBFR gene (similar to 60% resealed in 60 min). In contrast, little (or no) repair of UV photodimers occurs in either strand of human rDNA, regardless of whether cells are confluent or actively growing. Thus, DNA lesions in human ribosomal genes may be more accessible to base excision repair enzymes than those involved in nucleotide excision repair.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R01ES004106, R37ES002614] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02614, ES04106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; AFFENTRANGER MI, 1995, J HISTOCHEM CYTOCHEM, V43, P229, DOI 10.1177/43.2.7529787; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENNETT RAO, 1993, BIOCHEMISTRY-US, V32, P3188, DOI 10.1021/bi00063a034; BIANCHI NO, 1990, CANCER RES, V50, P2379; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; COQUERELLE TM, 1987, INT J RADIAT BIOL, V51, P209, DOI 10.1080/09553008714550711; DIGIUSEPPE JA, 1990, CARCINOGENESIS, V11, P1021, DOI 10.1093/carcin/11.6.1021; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DRESLER SL, 1985, BIOCHEMISTRY-US, V24, P6861, DOI 10.1021/bi00345a019; FRIEDBERG EC, 1995, DNA REPAIR; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P13117, DOI 10.1021/bi00040a024; FRITZ LK, 1994, THESIS WASHINGTON U; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KUWAHARA J, 1988, P NATL ACAD SCI USA, V85, P2459, DOI 10.1073/pnas.85.8.2459; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEYS EJ, 1981, MOL CELL BIOL, V1, P961, DOI 10.1128/MCB.1.11.961; LONG EO, 1980, ANNU REV BIOCHEM, V49, P727, DOI 10.1146/annurev.bi.49.070180.003455; LORENZ JD, 1988, MUTAT RES, V193, P167, DOI 10.1016/0167-8817(88)90047-8; Maniatis T., 1982, MOL CLONING; MOSBAUGH DW, 1984, J BIOL CHEM, V259, P247; MURAD AO, 1995, J BIOL CHEM, V270, P3949, DOI 10.1074/jbc.270.8.3949; OZENBERGER BA, 1991, MOL CELL BIOL, V11, P1222, DOI 10.1128/MCB.11.3.1222; POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N; REGAN JD, 1974, CANCER RES, V34, P3318; SIDIK K, 1990, CANCER RES, V50, P1613; SIDIK K, 1990, BIOCHEMISTRY-US, V29, P7501, DOI 10.1021/bi00484a020; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; SMITH CA, 1987, J CELL SCI, P225; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1591, DOI 10.1093/carcin/14.8.1591; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; THNG JPH, 1986, MUTAT RES, V165, P139, DOI 10.1016/0167-8817(86)90048-9; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; WAUTHIER EL, 1990, J CELL BIOCHEM, V43, P173, DOI 10.1002/jcb.240430208; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12972	12976		10.1074/jbc.271.22.12972	http://dx.doi.org/10.1074/jbc.271.22.12972			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662972	hybrid			2022-12-25	WOS:A1996UN47400046
J	Crechet, JB; Bernardi, A; Parmeggiani, A				Crechet, JB; Bernardi, A; Parmeggiani, A			Distal switch II region of Ras2p is required for interaction with guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SDC25 C-DOMAIN; SACCHAROMYCES-CEREVISIAE; H-RAS; GTP EXCHANGE; PROTEINS; CDC25; GDP; IDENTIFICATION; BINDING; MUTANTS	The interaction of Saccharomyces cerevisiae Ras2p with the catalytic domain of the GDP/GTP exchange factors (GEFs) mouse CDC25(Mm), yeast Cdc25p, and Sdc25p was analyzed by introducing the substitution R80D/N81D into Ras2p S24N, a mutant that is shown to interfere with the Ras2p wild type (wt)-GEF interaction by forming a stable complex. The triple mutant, Like Ras2p R80D/N81D, did not interfere with the action of GEF on Ras2p wt (or H-Ras p21) and was unable to form a stable complex with GEF. The GEF stimulation of the nucleotide dissociation of the triple mutant was virtually abolished and strongly decreased with the double mutant. The affinity of Ras2p S24N/R80D/N81D for GDP and GTP was decreased 3 and 4 orders of magnitude, respectively, hire that of Ras2p S24N, whereas the double mutant behaved as Ras2p wt. Like Ras2p S24N and unlike Ras2p R80D/N81D, the GTP-bound triple mutant did not activate adenylyl cyclase. Thus, the triple mutant and Ras2p S24N have opposite properties toward the binding to GEF but similarly modified behaviors toward GDP, GTP, and adenylyl cyclase. This work emphasizes the determinant role of the distal switch II region of Ras2p for the interaction with GEF and the different structural background of the interaction with adenylyl cyclase.	ECOLE POLYTECH,GRP BIOPHYS EQUIPE 2,F-91128 PALAISEAU,FRANCE; CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,F-75251 PARIS,FRANCE	Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite								BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN SY, 1994, ONCOGENE, V9, P2691; CRECHET JB, 1986, EUR J BIOCHEM, V161, P647, DOI 10.1111/j.1432-1033.1986.tb10489.x; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; CRECHET JB, 1993, J BIOL CHEM, V268, P14836; DEVENDITTIS E, 1986, EUR J BIOCHEM, V161, P473; DEVENDITTIS E, 1986, EMBO J, V15, P3657; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HALL A, 1986, J BIOL CHEM, V261, P10693; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOWE LR, 1993, ONCOGENE, V8, P2583; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; JOHN J, 1993, J BIOL CHEM, V268, P923; JUNG V, 1994, MOL CELL BIOL, V12, P2091; KAVOUNIS C, 1991, FEBS LETT, V281, P235, DOI 10.1016/0014-5793(91)80401-N; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILLER AF, 1992, BIOCHEMISTRY-US, V31, P10208, DOI 10.1021/bi00157a007; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMEGGIANI A, 1993, RAS SUPERFAMILIES GT, P467; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17234	17240		10.1074/jbc.271.29.17234	http://dx.doi.org/10.1074/jbc.271.29.17234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663268	hybrid			2022-12-25	WOS:A1996UX94300041
J	DeLeo, FR; Ulman, KV; Davis, AR; Jutila, KL; Quinn, MT				DeLeo, FR; Ulman, KV; Davis, AR; Jutila, KL; Quinn, MT			Assembly of the human neutrophil NADPH oxidase involves binding of p67(phox) and flavocytochrome b to a common functional domain in p47(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CYTOSOLIC PROTEINS P47-PHOX; CELL-FREE SYSTEM; PLASMA-MEMBRANE; DEFECTIVE TRANSLOCATION; CYTOCHROME B(558); ACTIVATION; COMPONENTS; P67-PHOX	The human neutrophil NADPH oxidase is a multi-component complex composed of membrane-bound and cytosolic proteins, During activation, cytosolic proteins p47(phox) P67(phox), Rac2, and possibly p40(phox) translocate to the plasma membrane and associate with flavocytochrome 5 to form the active superoxide-generating system, To further investigate the role of p67(phox), this complex assembly process, experiments were performed to identify possible regions of interaction between p67(phox) and other NADPH oxidase proteins, Using random sequence peptide phage display library analysis of p67(phox) we identified a novel region in p47(phox) encompassing residues 323-332 and a previously identified SH3 binding domain encompassing p47(phox) residues 361-370 as p67(phox) binding sites, Synthetic peptides mimicking p47(phox) residues 323-332 inhibited the p47(phox)-p67(phox) binding interaction in an affinity binding assay; however, peptides mimicking flanking regions were inactive, Surprisingly, this same region of p47(phox) was found previously to represent a site of binding interaction for flavocytochrome b (DeLeo, F, R,, Nauseef, W, M,, Jesaitis, A. J,, Burritt, J, B,, Clark, R, A., and Quinn, M. T, (1995) J, Biol. Chem, 270, 26246-26251), and this observation was confirmed in the present report using two different in vitro assays that were not evaluated previously, Using affinity binding assays, we also found that p67(phox) and flavocytochrome 5 competed for binding to p47(phox) after activation, suggesting that prior to full NADPH oxidase assembly the 323-332 region of p47(phox) is associated with p67(phox) and at some point in the activation process is transferred to flavocytochrome b, Thus, taken together our data demonstrate that both p67(phox) and flavocytochrome b utilize a common binding site in p47(phox) presumably at distinct stages during the activation process, and this p47(phox) region plays a key role in regulating NADPH oxidase assembly.	MONTANA STATE UNIV,DEPT VET MOL BIOL,BOZEMAN,MT 59715	Montana State University System; Montana State University Bozeman					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040929] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40929] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1995, J BIOL CHEM, V270, P6443; De Mendez I., 1995, Molecular Biology of the Cell, V6, p240A; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hong Y., 1995, Journal of Investigative Medicine, V43, p287A; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KOSHKIN V, 1993, FEBS LETT, V327, P67; Leto T. L., 1995, Molecular Biology of the Cell, V6, p241A; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LETO TL, 1990, SCIENCE, V248, P737; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALY FE, 1994, J BIOL CHEM, V269, P18743; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH DB, 1994, CURRENT PROTOCOLS MO; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SUMIMOTO H, 1994, P NATL AC SCI US, V91, P6845; TAMURA M, 1992, J BIOL CHEM, V267, P7629; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	55	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17013	17020		10.1074/jbc.271.29.17013	http://dx.doi.org/10.1074/jbc.271.29.17013			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663333	hybrid			2022-12-25	WOS:A1996UX94300008
J	Nakajima, Y; Yoshida, S; Inoue, Y; Ono, T				Nakajima, Y; Yoshida, S; Inoue, Y; Ono, T			Occupation of the Q(B)-binding pocket by a photosystem II inhibitor triggers dark cleavage of the D1 protein subjected to brief preillumination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; REACTION CENTER POLYPEPTIDES; CHLOROPLAST MEMBRANES; OXYGEN EVOLUTION; INVIVO DEGRADATION; HERBICIDE BINDING; SINGLET OXYGEN; QB SITE; LIGHT; PHOTOINHIBITION	The D1 protein of the photosystem (PS) II reaction center turns over very rapidly in a light-dependent man ner initiated by its selective and specific cleavage. The cleavage of D1 was studied by using a PS II inhibitor, N-octyl-3-nitro-2,4,6-trihydroxybenzamide (PNO8), as a molecular probe. The following results were obtained. (i) D1 was selectively cleaved into 23-kDa N-terminal and 9-kDa C-terminal fragments in complete darkness by PNO8 at a single site in a D-E loop connecting membrane-spanning helices D and E, (ii) The cleavage was markedly enhanced when PS II was illuminated for a brief period before the addition of PNO8 in darkness. (iii) The effect of preillumination was slowly lost during incubation in the dark, with a decay half-time of similar to 1 h at 25 degrees C. (iv) The light intensity of preillumination required for the cleavage was much lower than that required for O-2 evolution. (v) The light-triggered cleavage of D1 was observed in thylakoids, PS II membranes, and PS II core particles, but not in purified PS II reaction centers. More than 60% of D1 was cleaved into the two fragments with no other by-products. (vi) The cleavage reaction revealed a marked pH dependence that was considerably different from that for inhibition of PS II activity. The results are interpreted as indicating that the binding of PNO8 to the Q(B)-binding pocket triggers proteolytic cleavage of D1 that has been previously modified during illumination.	RIKEN, INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, PHOTOSYNTH RES LAB, WAKO, SAITAMA 35101, JAPAN; RIKEN, INST PHYS & CHEM RES, REGULAT PLANT FUNCT LAB, WAKO, SAITAMA 35101, JAPAN	RIKEN; RIKEN			Nakajima, Yoshihiro/M-6935-2018	Nakajima, Yoshihiro/0000-0002-7422-730X				ANANYEV G, 1994, PHOTOSYNTH RES, V41, P327, DOI 10.1007/BF00019410; Andersson B., 1994, P143; ANTONOV VK, 1993, CHEM PROTEOLYSIS, P33; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; CANOVAS PM, 1993, FEBS LETT, V324, P341, DOI 10.1016/0014-5793(93)80147-M; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DELASRIVAS J, 1992, FEBS LETT, V301, P246, DOI 10.1016/0014-5793(92)80250-K; DEPAULA JC, 1985, BIOCHEMISTRY-US, V24, P8114, DOI 10.1021/bi00348a042; ENAMI I, 1989, BIOCHIM BIOPHYS ACTA, V977, P33, DOI 10.1016/S0005-2728(89)80006-4; GIARDI MT, 1988, BIOCHIM BIOPHYS ACTA, V934, P64, DOI 10.1016/0005-2728(88)90120-X; GONG H, 1991, J BIOL CHEM, V266, P21293; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; HONDA I, 1990, AGR BIOL CHEM TOKYO, V54, P1071, DOI 10.1080/00021369.1990.10870085; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P695; ITOH S, 1986, FEBS LETT, V205, P275, DOI 10.1016/0014-5793(86)80912-7; JANSEN MAK, 1990, Z NATURFORSCH C, V45, P408; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; KIRILOVSKY D, 1994, BIOCHEMISTRY-US, V33, P3087, DOI 10.1021/bi00176a043; KUHN M, 1990, PHOTOSYNTH RES, V23, P291, DOI 10.1007/BF00034859; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MISHRA NP, 1994, BBA-BIOENERGETICS, V1186, P81, DOI 10.1016/0005-2728(94)90138-4; MIYAO M, 1995, BIOCHEMISTRY-US, V34, P10019, DOI 10.1021/bi00031a025; MIYAO M, 1994, BIOCHEMISTRY-US, V33, P9722, DOI 10.1021/bi00198a043; NAKAJIMA Y, 1995, BBA-BIOENERGETICS, V1230, P38, DOI 10.1016/0005-2728(95)00030-M; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; OETTMEIER W, 1992, PHOTOSYSTEMS STRUCTU, P349; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; ONO T, 1989, BIOCHIM BIOPHYS ACTA, V973, P443, DOI 10.1016/S0005-2728(89)80386-X; PAKRASI HB, 1992, PHOTOSYSTEMS STRUCTU, P231; POWLES SB, 1984, ANNU REV PLANT PHYS, V35, P15, DOI 10.1146/annurev.pp.35.060184.000311; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; RINTAMAKI E, 1995, PLANTA, V195, P379, DOI 10.1007/BF00202595; RINTAMAKI E, 1995, PHYSIOL PLANTARUM, V93, P191, DOI 10.1034/j.1399-3054.1995.930127.x; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; SHIPTON CA, 1990, Z NATURFORSCH C, V45, P388; TELFER A, 1994, J BIOL CHEM, V269, P13244; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREBST A, 1988, PHOTOSYNTH RES, V18, P163, DOI 10.1007/BF00042983; TREBST A, 1984, Z NATURFORSCH C, V39, P405; TREBST A, 1987, Z NATURFORSCH C, V42, P742; VANWIJK KJ, 1994, J BIOL CHEM, V269, P28382; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; YONEYAMA K, 1990, Z NATURFORSCH C, V45, P317; ZER H, 1994, J BIOL CHEM, V269, P17670; ZER H, 1995, EUR J BIOCHEM, V231, P448, DOI 10.1111/j.1432-1033.1995.tb20718.x	50	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17383	17389		10.1074/jbc.271.29.17383	http://dx.doi.org/10.1074/jbc.271.29.17383			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663245	hybrid			2022-12-25	WOS:A1996UX94300063
J	Pennybacker, M; Liessem, B; Moczall, H; Tifft, CJ; Sandhoff, K; Proia, RL				Pennybacker, M; Liessem, B; Moczall, H; Tifft, CJ; Sandhoff, K; Proia, RL			Identification of domains in human beta-hexosaminidase that determine substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS DISEASE; ACTIVATOR PROTEIN; EXTENSIVE HOMOLOGY; EXPRESSION; DEGRADATION; GENES; GM2	The lysosomal beta-hexosaminidases are dimers composed of alpha and beta subunits, beta-Hexosaminidase A (alpha beta) is a heterodimer, whereas hexosaminidase B (beta beta) and S (alpha alpha) are homodimers, Although containing a high degree of amino acid identity, each subunit expresses a unique active site that can be distinguished by a differential ability to hydrolyze charged substrates. The site on the beta-subunit primarily degrades neutral substrates, whereas the alpha-subunit site is, in addition, active against sulfated substrates. Isozyme specificity is also exhibited with glycolipid substrates, Among human isozymes, only beta-hexosaminidase A together with the G(M2) activator protein can degrade the natural substrate, G(M2) ganglioside, at physiologically significant rates. To identify the domains of the human beta-hexosaminidase subunits that determine substrate specificity, we have generated chimeric subunits containing both alpha- and beta-subunit sequences, The chimeric constructs were expressed in HeLa cells to screen for activity and then selected constructs were produced in the baculovirus expression system to assess their ability to degrade G(M2) ganglioside in the presence of G(M2) activator protein, Generation of activity against the sulfated substrate required the substitution of two noncontinuous alpha-subunit sequences (amino acids 1-191 and 403-529) into analogous positions of the beta-subunit, Chimeric constructs containing only one of these regions linked to the beta-subunit sequence showed either neutral substrate activity only (amino acids 1-191) or lacked enzyme activity entirely (amino acids 403-529), Neither the chimeras nor the wild-type subunits displayed activator-dependent G(M2)-hydrolyzing activity when expressed alone, However, one chimeric subunit containing alpha amino acids 1-191 fused with beta amino acids 225 to 556, when co-expressed with the wild-type alpha-subunit, showed activity comparable with that of recombinant beta-hexosaminidase A formed by the co-expression of the alpha- and beta subunits. This result indicates that the beta-subunit amino acids 225-556 contribute an essential function in the G(M2)-hydrolyzing activity of beta-hexosaminidase A.	NIDDK,SECT BIOCHEM GENET,GENET & BIOCHEM BRANCH,NIH,BETHESDA,MD 20892; UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Bonn			Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270				BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Boose J A, 1990, Protein Expr Purif, V1, P111, DOI 10.1016/1046-5928(90)90003-H; BROWN CA, 1991, J BIOL CHEM, V266, P15855; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; HASILIK A, 1980, J BIOL CHEM, V255, P4937; KLIMA H, 1993, BIOCHEM J, V292, P571, DOI 10.1042/bj2920571; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; Sambrook J., 2002, MOL CLONING LAB MANU; Sandhoff K, 1989, METABOLIC BASIS INHE, VII, P1807; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; SUZUKI K, 1991, DEV NEUROSCI-BASEL, V13, P288, DOI 10.1159/000112175; YAMANAKA S, 1994, GENOMICS, V21, P588, DOI 10.1006/geno.1994.1318	20	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17377	17382		10.1074/jbc.271.29.17377	http://dx.doi.org/10.1074/jbc.271.29.17377			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663217	hybrid			2022-12-25	WOS:A1996UX94300062
J	FigueiredoPereira, ME; Chen, WE; Li, JR; Johdo, O				FigueiredoPereira, ME; Chen, WE; Li, JR; Johdo, O			The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; PEPTIDE-HYDROLYZING ACTIVITY; CATALYTIC ACTIVITY; YEAST PROTEASOME; COMPLEX; SUBUNIT; IDENTIFICATION; GENE; PURIFICATION; SPECIFICITY	The antitumor drug aclacinomycin A was previously shown to inhibit the degradation of ubiquitinated proteins in rabbit reticulocyte lysates with an IC50 of 52 mu M (Isoe, T., Naito, M., Shirai, A., Hirai, R., and Tsuruo, T. (1992) Biochim. Biophys. Acta 1117, 131-135). We report here that from all the catalytic activities of the 20 S proteasome tested, the chymotrypsin-like activity was the only one affected by the antitumor drug, An important requirement for inhibition of the chymotrypsin-like activity seemed to be the presence of hydrophobic nonpolar residues in positions P-1 to P-3. Degradation of Z-E(OtBu)AL-pNA and Z-GGL-AMC at pH 7.5 was dramatically (87-98%) inhibited by 50 mu M of the drug, while that of Z-GGL-pNA (containing uncharged polar residues in positions P-2 and P-3) and succinyl-LLVY-AMC (containing an uncharged polar residue in the P-1 position) was inhibited only 11 and 24%, respectively, Aclacinomycin A had no effect on cathepsin B, stimulated trypsin, and inhibited chymotrypsin and, to a lesser extent, calpain, The aglycone and sugar moieties of the cytotoxic drug are essential for inhibition. The results presented here support a major role for the chymotrypsin-like activity in the degradation of ubiquitinated proteins, Aclacino mycin A is the first described non-peptidic inhibitor showing discrete selectivity for the chymotrypsin-like activity of the 20 S proteasome.	MERCIAN CORP,PROC DEV LABS,FUJISAWA,KANAGAWA 251,JAPAN		FigueiredoPereira, ME (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NINDS NIH HHS [NS-29936] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029936] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJKOWSKI AS, 1975, ANAL BIOCHEM, V68, P119, DOI 10.1016/0003-2697(75)90685-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; COUX O, 1994, MOL GEN GENET, V245, P769, DOI 10.1007/BF00297284; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREI.B, 1995, J NEUROCHEM, V63, P1578; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; FIGUEIREDOPEREIRA ME, 1994, J BIOL CHEM, V269, P621; FUGUEIREDOPEREI.ME, 1995, ARCH BIOCHEM BIOPHYS, V317, P69; FURONO K, 1990, J BIOL CHEM, V265, P8550; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GREGORI L, 1995, J BIOL CHEM, V270, P1702; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINMEYER W, 1983, J BIOL CHEM, V268, P5115; HILT W, 1993, J BIOL CHEM, V268, P3479; ISOE T, 1992, BIOCHIM BIOPHYS ACTA, V1117, P131, DOI 10.1016/0304-4165(92)90070-B; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; NISHIMURA C, 1993, FEBS LETT, V336, P462, DOI 10.1016/0014-5793(93)80856-P; OKI T, 1979, J ANTIBIOT, V32, P801, DOI 10.7164/antibiotics.32.801; OKI T, 1981, RECENT RES CANCER, V76, P21; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SATO S, 1990, BIOCHIM BIOPHYS ACTA, V1041, P269, DOI 10.1016/0167-4838(90)90283-L; SAVORY PJ, 1993, BIOCHEM J, V289, P45, DOI 10.1042/bj2890045; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEGEL IH, 1975, ENZYME KINETICS, P125; STRACK PR, 1992, INT J BIOCHEM, V24, P887, DOI 10.1016/0020-711X(92)90093-G; TSUBUKI S, 1994, FEBS LETT, V344, P229, DOI 10.1016/0014-5793(94)00388-2; WAGNER BJ, 1991, CURR EYE RES, V10, P485, DOI 10.3109/02713689109001756; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1979, LIFE SCI, V24, P457, DOI 10.1016/0024-3205(79)90218-2; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YANG DZ, 1994, BIOCHEMISTRY-US, V33, P6595, DOI 10.1021/bi00187a029; YU B, 1991, J BIOL CHEM, V266, P17396	43	57	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16455	16459		10.1074/jbc.271.28.16455	http://dx.doi.org/10.1074/jbc.271.28.16455			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663210				2022-12-25	WOS:A1996UX12600007
J	Si, KS; Das, K; Maitra, U				Si, KS; Das, K; Maitra, U			Characterization of multiple mRNAs that encode mammalian translation initiation factor 5 (eIF-5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; EXPRESSION; COMPLEX; MECHANISM; BINDING; RELEASE; CLONING; GENES; FORM	Eukaryotic translation initiation factor 5 (eIF-5) interacts with the 40 S initiation complex (40S . mRNA . Met-tRNA(f) . eIF-2 . GTP) to promote the hydrolysis of bound GTP with the concomitant joining of the 60 S ribosomal subunit to the 40 S initiation complex to form a functional 80 S initiation complex. In this paper, the multiple mRNAs that encode mammalian eIF-5 have been characterized. In rat tissues, three major eIF-5 mRNAs of 3.5, 2.8, and 2.2 kilobases in length are detected. All major eIF-5 mRNAs are initiated from a single transcription initiation site, contain identical 5'-untranslated and coding regions, but differ from one another only in the length of their 3'-untranslated regions, The different lengths of the 3'-untranslated region of eIF-5 mRNAs are generated by the use of alternative polyadenylation signals. Additionally, we demonstrate tissue-specific variations in eIF-5 mRNA expression as well as preference for polyadenylation sites, These results should lead to increased understanding of the regulation of eIF-5 gene expression.			Si, KS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,JACK & PEARL RESNICK CAMPUS,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GHOSH S, 1989, J BIOL CHEM, V264, P5134; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JARAMILLO M, 1991, J BIOL CHEM, V266, P10446; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204	27	20	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16934	16938		10.1074/jbc.271.28.16934	http://dx.doi.org/10.1074/jbc.271.28.16934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663286	hybrid			2022-12-25	WOS:A1996UX12600077
J	Smith, BL; Krushelnycky, BW; MochlyRosen, D; Berg, P				Smith, BL; Krushelnycky, BW; MochlyRosen, D; Berg, P			The HIV Nef protein associates with protein kinase C theta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; ANTIBODIES; ANTIGEN; PHOSPHORYLATION; LOCALIZATION; INHIBITION; ACTIVATION; INDUCTION; MEMBER; FAMILY	Expression of the human immunodeficiency virus (HIV) Nef protein has been linked to both decreased cell surface expression of CD4 and an impairment of signal transduction, The recently reported association of Nef with an unidentified serine kinase provides a clue as to how Nef might exert its effects, Considering the key role of protein kinase C (PKC) in T cell activation, we investigated the possibility that Nef interacts with PKC, Our results, using two approaches for detecting interactions between Nef and PKC isozymes in Jurkat cells, show that Nef interacts preferentially with beta PKC. The interaction of Nef and theta PKC is independent of calcium, enhanced by phospholipid activators of PKC and not affected by a PKC pseudosubstrate peptide, Phorbol 12-myristate 13-acetate and phytohemagglutinin stimulation of Jurkat cells expressing Nef fails to produce the usual translocation of theta PKC from the cytosol to the particulate fraction; translocation of beta PKC and epsilon PKC was unaffected, Indeed, there appears to be a net loss of theta PKC in Nef-expressing cells following stimulation, The loss of theta PKC, which may be a result of inhibition of its binding to RACKs due to Nef binding, could contribute to the various impairments of T cell function associated with HIV infection and Nef expression.	BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; BECKMAN CTR,DEPT MOLEC PHARMACOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,STANFORD,CA 94305	Stanford University				Mochly-Rosen, Daria/0000-0002-6691-8733				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; ALLEN BG, 1994, J BIOL CHEM, V269, P29288; AZAD AA, 1994, J GEN VIROL, V75, P651, DOI 10.1099/0022-1317-75-3-651; BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BARJA P, 1994, CELL IMMUNOL, V153, P28, DOI 10.1006/cimm.1994.1003; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BRODY JM, 1993, EMBO J, V12, P4923; COATES K, 1995, J GEN VIROL, V76, P837, DOI 10.1099/0022-1317-76-4-837; CULLEN BR, 1994, VIROLOGY, V205, P1, DOI 10.1006/viro.1994.1613; DE SK, 1994, J BIOL CHEM, V269, P6656; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ISAKOV N, 1987, J IMMUNOL, V138, P3100; KISHIMOTO A, 1983, J BIOL CHEM, V258, P11565; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lang Sabine M., 1994, Journal of Medical Primatology, V23, P233; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NEL AE, 1987, J IMMUNOL, V139, P2230; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OVOD V, 1992, AIDS, V6, P25, DOI 10.1097/00002030-199201000-00003; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; ZWAIG M, 1990, VIROLOGY, V179, P504	38	88	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16753	16757		10.1074/jbc.271.28.16753	http://dx.doi.org/10.1074/jbc.271.28.16753			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663223	hybrid			2022-12-25	WOS:A1996UX12600053
J	Spencer, JA; Misra, RP				Spencer, JA; Misra, RP			Expression of the serum response factor gene is regulated by serum response factor binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; GROWTH-FACTOR; TRANSCRIPTION FACTOR; FOS PROMOTER; ACTIN GENES; ELEMENT; ACTIVATION; INDUCTION; MUSCLE; STIMULATION	The serum response factor (SRF) is a ubiquitous transcription factor that plays a central role in the transcriptional response of mammalian cells to a variety of extracellular signals. Notably, SRF has been found to be a key regulator of members of a class of cellular response genes termed immediate-early genes (IEGs), many of which are believed to be involved in regulating cell growth and differentiation. The mechanism by which SRF activates transcription of IEGs in response to mitogenic agents has been extensively studied. Significantly less is known about how expression of the SRF gene itself is mediated. We and others have previously shown that the SRF gene is itself transiently induced by a variety of mitogenic agents and belongs to a class of ''delayed'' early response genes. We have cloned the SRF promoter and in the present study have analyzed the upstream regulatory sequences involved in mediating serum responsiveness of the SRF gene. Our analysis indicates that inducible SRF expression requires both SRF binding sites located within the first 63 nucleotides upstream from the start site of transcriptional initiation and an Sp1 site located 83 nucleotides upstream from the start site. Maximal transcriptional activity of the promoter also requires two CCAATT box sites located 90 and 123 nucleotides upstream of the start site.	MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin					NIGMS NIH HHS [R55 GM/OD51856] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051856] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; BUSCHER M, 1988, ONCOGENE, V3, P301; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1990, J CELL SCI, V97, P33; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELBLE R, 1992, MOL BIOL CELL, V3, P971, DOI 10.1091/mbc.3.9.971; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Groisman R, 1996, J BIOL CHEM, V271, P5258; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	60	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16535	16543		10.1074/jbc.271.28.16535	http://dx.doi.org/10.1074/jbc.271.28.16535			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663310	hybrid			2022-12-25	WOS:A1996UX12600020
J	JabrilCuenod, B; Zhang, C; Scharenberg, AM; Paolini, R; Numerof, R; Beaven, MA; Kinet, JP				JabrilCuenod, B; Zhang, C; Scharenberg, AM; Paolini, R; Numerof, R; Beaven, MA; Kinet, JP			Syk-dependent phosphorylation of Shc - A potential link between Fc epsilon RI and the Ras/mitogen-activated protein kinase signaling pathway through Sos and Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; T-CELL ACTIVATION; TYROSINE PHOSPHORYLATION; RBL-2H3 CELLS; RECEPTOR; RAS; TRANSDUCTION; DOMAIN; ASSOCIATION; ENGAGEMENT	Antigen receptors on T- and B-cells activate has through a signaling pathway that results in the tyrosine phosphorylation of She and the formation of a complex of Shc with the Grb2 adaptor protein. The high affinity receptor for immunoglobulin E (Fc epsilon RI) in cultured mast (RBL-2H3) cells has been reported to function differently. Here we show to the contrary that engagement of Fc epsilon RI with antigen leads to increased tyrosine phosphorylation of Shc and the association of Shc with Grb2 and other proteins (p120 and p140). Like the Fc epsilon RI-mediated activation of the mitogen-activated protein kinase cascade, these responses are dependent on the tyrosine kinase Syk; they are enhanced by overexpression of Syk and are blocked by expression of dominant-negative Syk. Sos is constitutively associated with Grb2 in these cells but dissociates from Shc on stimulation with antigen. These reactions are rapid, reversible, and associated with the activation of Ras. Therefore, the Syk-dependent tyrosine phosphorylation of Shc and its association with Grb2 may provide a pathway through Sos for activation of Ras by Fc epsilon RI.	NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892; NIAID,MOLEC ALLERGY & IMMUNOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				PAOLINI, Rossella/0000-0001-7605-1531				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CROWE AJ, 1994, ONCOGENE, V9, P537; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HABIB T, 1994, J BIOL CHEM, V269, P25243; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HU ZQ, 1994, IMMUNOLOGY, V82, P482; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMIT L, 1994, J BIOL CHEM, V269, P20209; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	49	103	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16268	16272		10.1074/jbc.271.27.16268	http://dx.doi.org/10.1074/jbc.271.27.16268			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663278	hybrid			2022-12-25	WOS:A1996UW35200061
J	Mohri, H; Tanabe, J; Katoh, K; Okubo, T				Mohri, H; Tanabe, J; Katoh, K; Okubo, T			Identification of a novel binding site to the integrin alpha(IIb)beta(3) located in the C-terminal heparin-binding domain of human plasma fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; INHIBITS PLATELET-AGGREGATION; STIMULATED HUMAN-PLATELETS; VONWILLEBRAND-FACTOR; FIBRINOGEN BINDING; ACTIVATED PLATELETS; CELL-ADHESION; GPIIB-IIIA; PEPTIDES; COMPLEX	Fibronectin has been shown to bind to integrin alpha(IIb)beta(3) in Arg-Gly-Asp (RGD)-dependent and -independent manners, A recent study has indicated that a 29-kDa dispase-digestive fragment from the C-terminal heparin-binding domain of human plasma fibronectin (lacking RGD sequence) inhibits binding of fibronectin to thrombin-stimulated platelets and ADP induced aggregation (Tanabe, J., Fujita, H., Iwamatsu, A., Mohri, H., and Ohkubo, T. (1993) J. Biol. Chem. 268, 27145-27147). We provide here the evidence that a peptide corresponding to residues from Ala(1704) to Glu(1718) (designated F1) from this fragment inhibited binding of I-125-labeled 29-kDa fragment of fibronectin to thrombin-stimulated platelets and ADP-induced aggregation, The F1 peptide bound directly to alpha(IIb)beta(3) integrin receptor. These results indicate that a novel binding site in the C-terminal heparin-binding region of fibronectin is localized within the residues from Ala(1704) to Glu(1718). Binding of I-125-labeled 29-kDa fragment of fibronectin to thrombin-stimulated platelets was not inhibited by RGDS peptide and the 12-residue peptide from the cell-binding domain of fibronectin, suggesting that binding site in the C-terminal heparin-binding domain may be different from those of RGDS and the 12-residue peptide, This additional alpha(IIb)beta(3)-binding domain(s) in fibronectin may also play some role for prevention of thrombus formation by direct interaction with alpha(IIb)beta(3).			Mohri, H (corresponding author), YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 1,KANAZAWA KU,3-9 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.							BERLINER S, 1988, J BIOL CHEM, V263, P7500; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; EY PL, 1978, IMMUNOCHEMISTRY, V15, P91; FRACKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849; FUUJITA H, 1995, EXP CELL RES, V217, P484; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1980, P NATL ACAD SCI-BIOL, V77, P1049, DOI 10.1073/pnas.77.2.1049; GINSBERG MH, 1986, FIBRONECTIN ITS ROLE, P86; HASHIMOTO Y, 1994, AM J CLIN PATHOL, V101, P370, DOI 10.1093/ajcp/101.3.370; HOUDIJK WPM, 1985, J CLIN INVEST, V75, P531, DOI 10.1172/JCI111729; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; INGHAM KC, 1994, ARCH BIOCHEM BIOPHYS, V314, P242, DOI 10.1006/abbi.1994.1436; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MOHRI H, 1995, PEPTIDES, V16, P263, DOI 10.1016/0196-9781(94)00180-4; MOHRI H, 1993, PEPTIDES, V14, P861, DOI 10.1016/0196-9781(93)90060-T; MOHRI H, 1993, PEPTIDES, V14, P353, DOI 10.1016/0196-9781(93)90052-I; MOHRI H, 1986, AM J HEMATOL, V22, P391, DOI 10.1002/ajh.2830220408; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; PARISE LV, 1985, J BIOL CHEM, V260, P698; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; STEINER B, 1993, J BIOL CHEM, V268, P6870; TANABE J, 1993, J BIOL CHEM, V268, P27143; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15724	15728		10.1074/jbc.271.26.15724	http://dx.doi.org/10.1074/jbc.271.26.15724			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663002	hybrid			2022-12-25	WOS:A1996UV29900064
J	Azarani, A; Goltzman, D; Orlowski, J				Azarani, A; Goltzman, D; Orlowski, J			Structurally diverse N-terminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) inhibit the Na+/H+ exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activating distinct signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; CYCLIC-AMP; PHEOCHROMOCYTOMA CELLS; EXPRESSION CLONING; OSTEOSARCOMA CELLS; PHORBOL ESTERS; KIDNEY-CELLS; ADENYLYLCYCLASE; IDENTIFICATION	N-terminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) elicit a wide variety of biological responses in target cells, including the inhibition of Na+/H+ exchanger NHE3 activity in renal cells, This response is believed to be mediated by ligand binding to a common receptor (i.e. PTH/PTHRP receptor type I) and activation of cAMP dependent and/or Ca2+/phospholipid-dependent protein kinases (PKA and PKC, respectively), However, the mechanism of action of these N-terminal peptides is now unclear because of recent data reporting the existence of additional receptor isoforms, Therefore, to directly examine the ligand binding and signaling characteristics of the PTH/PTHRP receptor type I and its ability to elicit a biological response, cDNAs encoding the rat type I receptor and the rat NHE3 isoform were transfected into Chinese hamster ovary (AP-1) cells that lack endogenous expression of these proteins, Competition binding assays using [I-125-Tyr(36)]PTHRP-(1-36)-NH2 radio-ligand indicated that several biologically active human N-terminal PTH and PTHRP fragments (PTH-(1-34), PTH- (3-34), PTH-(28-42), PTH-(28-48), and PTHRP-(1-34)) were capable of binding to the type I receptor, Both PTH-(1-34) and PTHRP-(1-34) stimulated adenylate cyclase and PKC activities in these cells, whereas PTH-(334), PTH-(28-42), and PTH-(28-48) selectively enhanced only PKC activity, PTHRP-(1-16), a biologically inert fragment, was incapable of binding to this receptor and influencing either the PKA or PKC pathway, Furthermore, all the analogues with the exception of PTHRP-(1-16) inhibited NHE3 activity, Inhibition of PKC by the potent antagonist chelerythrine chloride abolished the depression of NHE3 activity by PTH-(3-34), PTH-(28-42), and PTH-(28-48) but did not alleviate the effects of PTH-(1-34), Likewise, antagonism of PKA by H-89 was unable to prevent the inhibition caused by PTH-(1-34), However, inhibition of both PKA and PKC by the nonselective protein kinase antagonist H-7 abolished the reduction of NHE3 activity by PTH-(1-34), These data indicate that discrete N-terminal analogues of PTH and PTHRP can interact with the classical PTH/PTHRP receptor type I and activate PKA and/or PKC, Activation of either signaling pathway independently leads to inhibition of NHE3.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3A 1Y6,CANADA	McGill University; McGill University; McGill University; Royal Victoria Hospital				Orlowski, John/0000-0001-7371-175X				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AMEMIYA M, 1995, AM J PHYSIOL-CELL PH, V269, pC126, DOI 10.1152/ajpcell.1995.269.1.C126; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BERNIER SM, 1991, ENDOCRINOLOGY, V128, P2752, DOI 10.1210/endo-128-6-2752; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHESNOYMARCHAIS D, 1989, PFLUG ARCH EUR J PHY, V415, P104, DOI 10.1007/BF00373147; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; FUKAYAMA S, 1995, P NATL ACAD SCI USA, V92, P10182, DOI 10.1073/pnas.92.22.10182; GAGNON L, 1993, J BONE MINER RES, V8, P497; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HENDERSON JE, 1992, ENDOCRINOLOGY, V130, P449, DOI 10.1210/en.130.1.449; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; INOMATA N, 1995, ENDOCRINOLOGY, V136, P4732, DOI 10.1210/en.136.11.4732; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KAJI H, 1994, ENDOCRINOLOGY, V134, P1897, DOI 10.1210/en.134.4.1897; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KAUFMANN M, 1994, ENDOCRINOLOGY, V134, P1173, DOI 10.1210/en.134.3.1173; KREMER R, 1982, J BIOL CHEM, V257, P4048; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MACGREGOR RR, 1986, J BIOL CHEM, V261, P1929; MALMSTROM K, 1988, BIOCHEM J, V251, P207, DOI 10.1042/bj2510207; MURRAY TM, 1989, ENDOCRINOLOGY, V124, P1097, DOI 10.1210/endo-124-2-1097; ORLOFF JJ, 1995, ENDOCRINOLOGY, V136, P3016, DOI 10.1210/en.136.7.3016; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PAUSOVA Z, 1994, GENOMICS, V20, P20, DOI 10.1006/geno.1994.1122; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; RABBANI SA, 1990, BIOCHEMISTRY-US, V29, P10080, DOI 10.1021/bi00495a010; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSENBLATT M, 1986, NEW ENGL J MED, V315, P1004; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	54	56	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14931	14936		10.1074/jbc.271.25.14931	http://dx.doi.org/10.1074/jbc.271.25.14931			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663042	hybrid			2022-12-25	WOS:A1996UT10600046
J	Rustin, P; Parfait, B; Chretien, D; Bourgeron, T; Djouadi, F; Bastin, J; Rotig, A; Munnich, A				Rustin, P; Parfait, B; Chretien, D; Bourgeron, T; Djouadi, F; Bastin, J; Rotig, A; Munnich, A			Fluxes of nicotinamide adenine dinucleotides through mitochondrial membranes in human cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE ELECTRON-TRANSPORT; PLANT-MITOCHONDRIA; ROTENONE; MALATE; NAD+	We report on the loss of mitochondrial nicotinamide adenine dinucleotides in human cultured cells along with cell culture and acidification of the culture medium. This was established both by the direct measure ment of the decrease in the mitochondrial NAD content and by the alteration of the oxidative properties of the mitochondria. In situ, this loss could be reversed in less than 2 h by changing the culture medium or by readjusting the pH of the medium at physiological pH values. By studying the oxidative properties of intact, but NAD-depleted, mitochondria in digitonin-permeabilized cells, we found that a rapid influx of NAD could replenish the mitochondrial NAD pool. This allowed the restoration of an active NAD(+)-dependent substrate oxidation. Depletion of mitochondrial NAD in cells grown under quiescent conditions was further confirmed by fluorimetric measurement of mitochondrial NAD, as was the influx of NAD(+) into the mitochondrial matrix. These data constitute the first evidence of rapid fluxes of NAD through mitochondrial membranes in animal cells. They also point to the possible confusion between a loss of mitochondrial NAD and a defect of respiratory chain complex I in the context of screening procedures for respiratory chain disorder in human.	UNIV PARIS 07,INSERM U319,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Rustin, P (corresponding author), HOP NECKER ENFANTS MALAD,INSERM U393,UNITE RECH HANDICAPS GENET ENFANT,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		PARFAIT, Beatrice/O-7392-2017; DJOUADI, Fatima/C-6187-2019; Bastin, Jean/E-3083-2016; Rötig, Agnès/G-9592-2017	Rötig, Agnès/0000-0003-0589-0703; Djouadi, Fatima/0000-0003-0350-0935; Bastin, Jean/0000-0001-8350-8667				BERGMEYER HU, 1963, METHOD ENZYMAT AN, P1; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRETIEN D, 1990, BIOCHEM BIOPH RES CO, V173, P26, DOI 10.1016/S0006-291X(05)81016-2; Douce R., 1985, MITOCHONDRIA HIGHER, P1; GLOCK GE, 1955, BIOCHEM J, V61, P381, DOI 10.1042/bj0610381; NEUBURGER M, 1983, BIOCHEM J, V216, P443, DOI 10.1042/bj2160443; PALMER JM, 1982, BIOCHEM J, V208, P703, DOI 10.1042/bj2080703; ROBINSON BH, 1985, AM J HUM GENET, V37, P938; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; RUSTIN P, 1991, BIOCHEM J, V274, P249, DOI 10.1042/bj2740249; RUSTIN P, 1989, PLANT PHYSIOL BIOCH, V27, P855; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; RUSTIN P, 1979, BIOCHEM BIOPH RES CO, V88, P1123; TYLER DD, 1992, MITOCHONDRION HLTH D, P1; TZAGOLOFF A, 1982, MITOCHONDRIA, P1; Zuurendonk P F, 1979, Methods Enzymol, V56, P207	18	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14785	14790		10.1074/jbc.271.25.14785	http://dx.doi.org/10.1074/jbc.271.25.14785			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663005	hybrid			2022-12-25	WOS:A1996UT10600025
J	Sarndahl, E; Bokoch, GM; Boulay, F; Stendahl, O; Andersson, T				Sarndahl, E; Bokoch, GM; Boulay, F; Stendahl, O; Andersson, T			Direct or C5a-induced activation of heterotrimeric G(i2) proteins in human neutrophils is associated with interaction between formyl peptide receptors and the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C5A CHEMOATTRACTANT RECEPTORS; BETA-ADRENERGIC-RECEPTOR; CHEMOTACTIC PEPTIDE; HUMAN-GRANULOCYTES; ADENYLATE-CYCLASE; DESENSITIZATION; PHOSPHORYLATION; BINDING; FORMYLPEPTIDE; DISSOCIATION	The binding of ligands to N-formyl peptide chemoattractant receptors in human neutrophils results in a rapid association of these receptors with a cytoskeletal fraction and a specific activation and release of G(i2) alpha-subunits from this fraction. In the present study we could show that pretreating neutrophils with GDP beta S prevented the fMet Leu-Phe-induced association of its receptor with a cytoskeletal fraction and also blocked the release of G(i2) alpha-subunits from the same cytoskeletal fraction. In contrast, direct activation of G(i2) proteins by addition of GTP gamma S or AIF(4)(-) not only caused a release of G(i2) alpha-subunits from the cytoskeleton but also an association of formyl peptide receptors with the cytoskeleton. The receptor for complement fragment 5a, which transduces its signaling through the same G(i2) protein, triggers both a release of G(i2) alpha-subunits from the cytoskeleton fraction and, of even greater interest, an association between formyl peptide receptors and the cytoskeleton. The close relationship between the activation and release of G(i2) alpha-subunits from the cytoskeleton and the association of formyl peptide receptors with the cytoskeleton might, however, not be a matter of protein-protein exchange, since the increased binding of formyl peptide receptors to the cytoskeleton occurs more rapidly than the release of G(i2) alpha-subunits from the cytoskeleton. The present findings suggest a possible mechanism for the initiation of formyl peptide receptor desensitization during neutrophil locomotion.	LINKOPING UNIV, FAC HLTH SCI, DEPT MED MICROBIOL, S-58185 LINKOPING, SWEDEN; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; CEA GRENOBLE, BIOCHIM LAB, DBMS, F-38054 GRENOBLE, FRANCE	Linkoping University; Scripps Research Institute; Scripps Research Institute; CEA	Sarndahl, E (corresponding author), LINKOPING UNIV, FAC HLTH SCI, DEPT CELL BIOL, S-58185 LINKOPING, SWEDEN.				NIGMS NIH HHS [GM 39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1993, J BIOL CHEM, V268, P24247; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; JANECZEK AH, 1989, J CELL SCI, V94, P155; JESAITIS AJ, 1984, J CELL BIOL, V98, P1378, DOI 10.1083/jcb.98.4.1378; JESAITIS AJ, 1986, J BIOL CHEM, V261, P3662; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; JESAITIS AJ, 1992, COMMENTS MOL CELL BI, V8, P97; KLOTZ KN, 1994, BIOCHEM PHARMACOL, V48, P1297, DOI 10.1016/0006-2952(94)90168-6; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; POSNER RG, 1994, MOL PHARMACOL, V45, P65; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; SARNDAHL E, 1989, J CELL BIOL, V109, P2791, DOI 10.1083/jcb.109.6.2791; SARNDAHL E, 1993, P NATL ACAD SCI USA, V90, P6552, DOI 10.1073/pnas.90.14.6552; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; SHOWELL HJ, 1979, J RETICULOENDOTH SOC, V25, P139; SIBLEY DR, 1985, J BIOL CHEM, V260, P3883; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; TARDIF M, 1993, J IMMUNOL, V150, P3534; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	31	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15267	15271						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663057				2022-12-25	WOS:A1996UT10600090
J	Bai, YL; Zhang, SY; Kim, KS; Lee, JK; Kim, KH				Bai, YL; Zhang, SY; Kim, KS; Lee, JK; Kim, KH			Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR	Leptin, the product of the oh gene, controls food-intake and weight loss in the ob mouse. Although the target(s) of the circulating leptin is presumed to be the brain which then orchestrates food-intake and weight loss, how leptin functions in the process of weight loss is unknown. In this report, we present evidence that ob gene expression in cultured cells suppresses acetyl-CoA carboxylase gene expression and lipid synthesis which are induced by hormone treatment. This is the first example in which leptin has been found to suppress defined biochemical reactions that contribute to Lipid accumulation without the participation of the brain.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1974, J BIOL CHEM, V249, P5241; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; HA JH, 1994, P NATL ACAD SCI USA, V91, P9951, DOI 10.1073/pnas.91.21.9951; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; WILSON JE, 1982, ARCH BIOCHEM BIOPHYS, V215, P610, DOI 10.1016/0003-9861(82)90122-9; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	200	212	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13939	13942		10.1074/jbc.271.24.13939	http://dx.doi.org/10.1074/jbc.271.24.13939			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663251	hybrid			2022-12-25	WOS:A1996UQ66000004
J	Chang, DZ; Wu, ZN; Ciardelli, TL				Chang, DZ; Wu, ZN; Ciardelli, TL			A point mutation in interleukin-2 that alters ligand internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; HUMAN T-CELLS; IL-2 RECEPTOR; SIGNAL TRANSDUCTION; GAMMA-CHAIN; GROWTH; BINDING; GLYCOSYLPHOSPHATIDYLINOSITOL; DEGRADATION; EXPRESSION	In previous studies, we have identified an interleukin-2 (IL-2) analog containing a point mutation at position 51 (T51P) that expresses nearly wild-type bioactivity, yet has similar to 10-fold lower receptor binding affinity, Since ligand-dependent receptor internalization may be the rate-limiting step controlling the duration of IL-2 receptor signaling, a reduction in the receptor internalization rate could contribute to the observed response enhancement for this analog, To evaluate this possibility, we compared the internalization of IL-2 and T51P in three separate assays, While the internalization rate for IL-2 agreed with values determined by others, the internalization of T51P was markedly reduced, The receptor binding rate constants for this analog were only slightly different; thus, altered binding kinetics could not explain the decreased internalization rate, The effects of reduced internalization were also observable in bioassays, where T51P maintained T-cell proliferation for a longer period compared with IL-2. These results indicate that the T51P point mutation reduces the receptor internalization rate compared with IL-2 in a fashion that is independent of the dissociation rate. This analog may represent a new approach to the preparation of cytokine analogs with potentiated agonist and antagonist properties.	DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; VET ADM MED CTR,WHITE RIVER JCT,VT 05009	Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA23108] Funding Source: Medline; NIAID NIH HHS [AI23398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHANG DZ, 1995, MOL PHARMACOL, V47, P206; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; DUPREZ V, 1986, J BIOL CHEM, V261, P5450; DUPREZ V, 1991, J BIOL CHEM, V266, P1497; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; GILLIS S, 1978, J IMMUNOL, V121, P2077; GULLBERG M, 1986, J EXP MED, V163, P270, DOI 10.1084/jem.163.2.270; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HUNYADY L, 1994, KIDNEY INT, V46, P1496, DOI 10.1038/ki.1994.428; IMLER JL, 1992, J BIOL CHEM, V267, P13185; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KUMAR A, 1987, J IMMUNOL, V139, P3680; LANDGRAF B, 1989, J BIOL CHEM, V264, P816; LANDGRAF BE, 1991, PROTEINS, V9, P207, DOI 10.1002/prot.340090306; LANDGRAF BE, 1992, J BIOL CHEM, V267, P18511; LAUFFENBURGER DA, 1996, IN PRESS BIOTECHNOL; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MATSUOKA M, 1993, EUR J IMMUNOL, V23, P2472, DOI 10.1002/eji.1830231014; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUNCK A, 1976, RECEPTORS MECHANIS 1, P1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; ROBB RJ, 1987, J EXP MED, V165, P1201, DOI 10.1084/jem.165.4.1201; ROBB RJ, 1984, THYMIC HORMONES LYMP, P247; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Smith KA, 1995, ANN NY ACAD SCI, V766, P263, DOI 10.1111/j.1749-6632.1995.tb26674.x; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STEINMAN RM, 1974, J CELL BIOL, V63, P949, DOI 10.1083/jcb.63.3.949; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILLIAMS DP, 1988, NUCLEIC ACIDS RES, V16, P10453, DOI 10.1093/nar/16.22.10453; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WU ZN, 1995, J BIOL CHEM, V270, P16045, DOI 10.1074/jbc.270.27.16045; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	56	23	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13349	13355		10.1074/jbc.271.23.13349	http://dx.doi.org/10.1074/jbc.271.23.13349			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662876				2022-12-25	WOS:A1996UP38500010
J	Iwasaki, S; Hattori, A; Sato, M; Tsujimoto, M; Kohno, M				Iwasaki, S; Hattori, A; Sato, M; Tsujimoto, M; Kohno, M			Characterization of the bone morphogenetic protein-2 as a neurotrophic factor - Induction of neuronal differentiation of PC12 cells in the absence of mitogen-activated protein kinase activation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NIH 3T3 CELLS; MAP KINASE; FACTOR-BETA; SIGNAL-TRANSDUCTION; EMBRYONIC-DEVELOPMENT; OSTEOGENIC PROTEIN; FAMILY MEMBERS; RNA; IDENTIFICATION	Rat pheochromocytoma PC12 cells are shown to express a single class of high affinity binding sites for bone morphogenetic protein (BMP)-2 (1,300 receptors/cell, K-d = 31.3 pM). Affinity cross-linking using radiolabeled BMP-2 demonstrated the presence of six components with apparent molecular masses of 170, 155, 105, 90, 80, and 70 kDa. BMP-2 induced morphological changes in PC12 cells with the concomitant expression of three neurofilament proteins. Thus, BMP-2 would appear to be another neurotrophic factor that, like nerve growth factor or basic fibroblast growth factor, stimulates the neuronal differentiation of PC12 cells. Unlike nerve growth factor and basic fibroblast growth factor, how ever, BMP-2 failed to induce the activation of either 41- and 43-kDa mitogen-activated protein (MAP) kinases or the MAP kinase/extracellular signal-regulated kinase kinase (MEK). Also, BMP-2 did not induce the expression of the c-fos gene in PC12 cells. Activin A was also capable of inducing the neuronal differentiation of PC12 cells without activating MAP kinases and MEK. These findings show a clear dissociation between the requirement for the activation of the MAP kinase cascade and the ability of BMP-2 and activin A to induce PC12 cell neuronal differentiation. In addition, these results suggest that the activation of MAP kinases and MEK is not an absolute requirement for PC12 cell differentiation.	GIFU PHARMACEUT UNIV,CELL BIOL LAB,GIFU 502,JAPAN; SUNTORY INST BIOMED RES,MISHIMA,OSAKA 618,JAPAN	Gifu Pharmaceutical University; Suntory Holdings Ltd								AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDESON NG, 1990, NATURE, V843, P651; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DALE L, 1992, DEVELOPMENT, V115, P573; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FUKUDA M, 1995, ONCOGENE, V11, P239; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISHIDA N, 1994, J BIOCHEM-TOKYO, V115, P279, DOI 10.1093/oxfordjournals.jbchem.a124329; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINBENBAUM MH, 1987, J BIOL CHEM, V262, P605; LINBENBAUM MH, 1988, J BIOL CHEM, V263, P5662; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; PERIDES G, 1993, J BIOL CHEM, V268, P25197; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SAMMUELS ML, 1993, MOL CELL BIOL, V13, P6241; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SMITH DB, 1990, CURRENT PROTOCOLS MO, V2; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	54	75	85	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17360	17365		10.1074/jbc.271.29.17360	http://dx.doi.org/10.1074/jbc.271.29.17360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663261	hybrid			2022-12-25	WOS:A1996UX94300059
J	Parekh, R; Bag, J				Parekh, R; Bag, J			Inhibition of myogenesis in mouse C2 cells by double-stranded phosphorothioate oligodeoxynucleotides containing mef-1 sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; BINDING; MYOD; ENHANCER; OLIGONUCLEOTIDES; FIBROBLASTS; ACTIVATION; INVITRO; VIVO	Phosphorothioate oligonucleotides containing the muscle creatinine kinase enhancer sequence (mef-1) and a mutant of the enhancer sequence (mmef-1) were tested for their ability to block muscle differentiation in mouse C2 cells in culture, Maximum inhibition of fusion of myoblasts was observed at 10 mu M concentration of mef-1 oligomer. No appreciable inhibition of fusion with the mmef-1 oligomer at the same concentration was observed. Synthesis of myogenin, muscle creatinine kinase, and myosin heavy chain polypeptides were reduced in mef-1 oligomer-treated cells. In contrast, no significant reduction in the synthesis of these polypeptides in mmef-1-treated cells was detected, The overall protein synthesis was not affected. These results suggest that muscle differentiation may be disrupted by competition of the oligomer with the endogenous promoter for specific transcription factor(s).	UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH, ON N1G 2W1, CANADA	University of Guelph								BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BROWN DA, 1994, J BIOL CHEM, V269, P26801; BUCKINGHAM M, 1994, CELL, V78, P15, DOI 10.1016/0092-8674(94)90568-1; CLUSEL C, 1993, NUCLEIC ACIDS RES, V21, P3405, DOI 10.1093/nar/21.15.3405; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MARCUSSEKURA CJ, 1988, ANAL BIOCHEM, V172, P289, DOI 10.1016/0003-2697(88)90447-2; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; THINAKARAN G, 1991, EXP CELL RES, V192, P227, DOI 10.1016/0014-4827(91)90180-3; WANG XF, 1986, CELL, V47, P241, DOI 10.1016/0092-8674(86)90446-0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WU H, 1990, GENE, V89, P203, DOI 10.1016/0378-1119(90)90007-E	21	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17372	17376		10.1074/jbc.271.29.17372	http://dx.doi.org/10.1074/jbc.271.29.17372			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663396	hybrid			2022-12-25	WOS:A1996UX94300061
J	Hitoshi, S; Kusunoki, S; Kanazawa, I; Tsuji, S				Hitoshi, S; Kusunoki, S; Kanazawa, I; Tsuji, S			Molecular cloning and expression of a third type of rabbit GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM; TRANSFERASE; PURIFICATION; GENETICS; LEWIS; CDNA	Recent molecular investigation revealed that two closely related structural genes encode distinct GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferases (alpha 1,2-fucosyltransferases). Some human cancer cells or tissues may express an aberrant alpha 1,2-fucosyltransferase other than H- and Secretor-type alpha 1,2-fucosyltransferase. However, definite evidence of the existence of a third type of alpha 1,2-fucosyltransferase has not been demonstrated. Here we report the molecular cloning of a third type of rabbit alpha 1,2-fucosyltransferase (RFT-III) from a rabbit genomic DNA library. The DNA sequence included an open reading frame coding for 347 amino acids, and the deduced amino acid sequence of RFT-III showed 59 and 80% identity with those of the previously reported two types of rabbit alpha 1,2-fucosyltransferase, RFT-I and RFT-II, respectively. COS-7 cells transfected with the RFT-III gene exhibited alpha 1,2-fucosyltransferase activity toward phenyl-beta-Gal as a substrate. Neuro2a (a murine neuro blastoma cell line) cells transfected with the RFT-III gene expressed fucosyl G(M1) (type 3 H) but not Ulex europaeus agglutinin-l lectin reactive antigens (type 2 H). Kinetic studies revealed that RFT-III exhibits higher affinity to types 1 (Gal beta 1, 3GlcNAc) and 3 (Gal beta 1, 3GalNAc) than to type 2 (Gal beta 1, 4GlcNAc) oligosaccharides, which suggests that RFT-III as well as RFT-II is a Secretor-type alpha 1,2-fucosyltransferase. RFT-III was expressed in the adult gastrointestinal tract. The RFT-I, -II, and -III genes were assigned within 90 kilobases on pulsed field gel electrophoresis analysis. These results constitute direct evidence that, at least in one mammalian species, three active alpha 1,2-fucosyltransferases exist.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROL,TOKYO 113,JAPAN	RIKEN; University of Tokyo								BEYER TA, 1980, J BIOL CHEM, V255, P5373; BLASZCZYKTHURIN M, 1988, BIOCHEM BIOPH RES CO, V151, P100, DOI 10.1016/0006-291X(88)90564-5; HENRY SM, 1994, GLYCOCONJUGATE J, V11, P593, DOI 10.1007/BF00731311; HENRY SM, 1990, VOX SANG, V58, P61, DOI 10.1111/j.1423-0410.1990.tb02057.x; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KUMAZAKI T, 1984, P NATL ACAD SCI-BIOL, V81, P4193, DOI 10.1073/pnas.81.13.4193; KUSUNOKI S, 1992, NEUROSCI RES, V15, P74, DOI 10.1016/0168-0102(92)90019-9; KUSUNOKI S, 1994, BBA-LIPID LIPID MET, V1214, P27, DOI 10.1016/0005-2760(94)90005-1; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; LEPENDU J, 1982, AM J HUM GENET, V34, P402; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; Sambrook J., 2002, MOL CLONING LAB MANU; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THURIN J, 1995, J BIOL CHEM, V270, P26577, DOI 10.1074/jbc.270.44.26577; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAZAWA S, 1993, JPN J CANCER RES, V84, P989, DOI 10.1111/j.1349-7006.1993.tb00190.x	25	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16975	16981		10.1074/jbc.271.28.16975	http://dx.doi.org/10.1074/jbc.271.28.16975			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663168	hybrid			2022-12-25	WOS:A1996UX12600083
J	Haimovich, B; Regan, C; DiFazio, L; Ginalis, E; Ji, P; Purohit, U; Rowley, RB; Bolen, J; Greco, R				Haimovich, B; Regan, C; DiFazio, L; Ginalis, E; Ji, P; Purohit, U; Rowley, RB; Bolen, J; Greco, R			The Fc gamma RII receptor triggers pp125(FAK) phosphorylation in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; CELL ADHERENCE; ACTIVATION; GLYCOPROTEINS; AGGREGATION; ADHESION	Platelets express a single low affinity receptor for immunoglobulin, Fc gamma RII, that triggers multiple cellular responses upon interaction with multivalent immune complexes, In this study we show that immobilized IBG is also a potent stimulant of platelet activation triggering adhesion, aggregation, massive dense granule secretion, and thromboxane production, Platelet adhesion to IgG was blocked by the Fc gamma RII receptor-specific monoclonal antibody, IV.3. Pretreatment of the platelets with cytochalasin D to inhibit actin polymerization similarly prevented cell binding to IgQ having no effect on platelet binding to fibrinogen. Platelet adhesion to IgG also led to the induction of tyrosine phosphorylation of multiple proteins including pp125(FAK) and p72(SYK). These proteins were also tyrosine-phosphorylated in alpha(IIb)beta(3)-deficient IgG-adherent platelets from patients with Glanzmann's thrombasthenia. These data demonstrate that Fc gamma RII mediates pp125(FAK) phosphorylation and platelet adhesion to IgG independent of the integrin alpha(IIb)beta(3). Treatment of the platelets with bisindolylmaleimide to inhibit protein kinase C prevented phosphorylation of pp125(FAK) as well as several other proteins, but not p72(SYK) phosphorylation. This study establishes that the Fc gamma RII receptor mediates pp125(FAK) phosphorylation via protein kinase C.	BRISTOL MYERS SQUIBB,PRINCETON,NJ 08453; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Bristol-Myers Squibb; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Haimovich, B (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT SURG,MEB ROOM 434,NEW BRUNSWICK,NJ 08903, USA.							ANDERSON GP, 1990, BLOOD, V76, P1165; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, J BIOL CHEM, V269, P28859; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HEEMSKERK JWM, 1993, J BIOL CHEM, V268, P356; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUNTER S, 1993, EXP HEMATOL, V21, P1492; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANG JH, 1993, BLOOD, V81, P1505; KIEREN PA, 1993, J BIOL CHEM, V268, P24442; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW CL, 1994, J BIOL CHEM, V269, P12310; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MALAWISTA SE, 1971, YALE J BIOL MED, V44, P286; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YLANNE J, 1990, BLOOD, V76, P570; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	48	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16332	16337		10.1074/jbc.271.27.16332	http://dx.doi.org/10.1074/jbc.271.27.16332			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663117	hybrid			2022-12-25	WOS:A1996UW35200070
J	Shih, NY; FloydSmith, G				Shih, NY; FloydSmith, G			Protein kinase C-delta mRNA is down-regulated transcriptionally and post-transcriptionally by 12-O-tetradecanoylphorbol-13-acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; GENE-EXPRESSION; PHORBOL ESTER; MESSENGER-RNA; HEMATOPOIETIC-CELLS; NEGATIVE REGULATION; EPSILON; GROWTH; PHOSPHORYLATION	Activation of protein kinase C-delta (PKC-delta) by 12-O-tetrade anoylphorbol-13-acetate (TPA) is followed by a gradual decrease in detectable protein 12-24 h later in the mouse B lymphoma cell line A20. Down-regulation is associated with TPA-induced proteolysis and a 50-86% decrease in PKC-delta mRNA 0.5-24 h post-treatment which is due to both a 50% decrease in transcription and accelerated degradation of PKC-delta mRNA as determined using the pulse-chase method. Destabilization of PKC-delta mRNA is also observed when actinomycin D is added to cells pretreated with TPA for 2 h; however, addition of actinomycin D or cycloheximide prior to TPA treatment blocks destabilization. Addition of PKC inhibitors to TPA-treated cells also blocks destabilization of PKC-delta mRNA. Cells treated with TPA for 4 h contain an activity not found in control cells which destabilizes PKC-delta mRNA but not glyceraldehyde-3-phosphate dehydrogenase mRNA in vitro. Addition of TPA to control extracts fails to increase degradation of PKC-delta mRNA in vitro, suggesting that treatment of intact cells is required to induce the synthesis of a factor(s) that destabilizes PKC-delta mRNA. This factor(s) then acts along with transcriptional and post-translational regulatory mechanisms to down-regulate PKC-delta.	ARIZONA STATE UNIV,DEPT ZOOL,PROGRAM MOLEC & CELLULAR BIOL,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe			Shih, Neng-Yao/D-2086-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024915] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24915] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASHEERUDDIN K, 1992, J BIOL CHEM, V267, P1219; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Belasco J.G., 2012, CONTROL MESSENGER RN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKGHANNAM C, 1994, HUM IMMUNOL, V41, P216, DOI 10.1016/0198-8859(94)90039-6; BROOKS G, 1993, J BIOL CHEM, V268, P23868; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DENG GR, 1983, METHOD ENZYMOL, V100, P96; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENT CL, TRANSCRIPTION FACTOR, P1; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FARRELL RE, 1993, RNA METHODOLOGIES, P235; FERRY RC, 1994, J BIOL CHEM, V269, P31850; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GOODE NT, 1994, MOL BIOL CELL, V5, P907, DOI 10.1091/mbc.5.8.907; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HENDERSON GS, 1991, BIOTECHNIQUES, V10, P190; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; JUN CD, 1994, BIOCHEM BIOPH RES CO, V204, P105, DOI 10.1006/bbrc.1994.2432; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI WQ, 1994, J BIOL CHEM, V269, P2349; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; MAIZELS ET, 1992, J BIOL CHEM, V267, P17061; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OCONNER JL, 1992, BIOTECHNIQUES, V12, P238; ODRISCOLL KR, 1995, MOL BIOL CELL, V6, P449, DOI 10.1091/mbc.6.4.449; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1994, J BIOL CHEM, V269, P17495; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SHIH NY, 1995, MOL IMMUNOL, V32, P643, DOI 10.1016/0161-5890(95)00029-E; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; SRIVASTAVA KK, 1993, BIOTECHNIQUES, V15, P226; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; TERAJIMA J, 1992, CELL IMMUNOL, V142, P197, DOI 10.1016/0008-8749(92)90280-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZHU YY, 1991, J CELL BIOL, V115, P745, DOI 10.1083/jcb.115.3.745	61	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16040	16046		10.1074/jbc.271.27.16040	http://dx.doi.org/10.1074/jbc.271.27.16040			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663197	hybrid			2022-12-25	WOS:A1996UW35200031
J	VandenKoornhuyse, N; Libessart, N; Delrue, B; Zabawinski, C; Decq, A; Iglesias, A; Carton, A; Preiss, J; Ball, S				VandenKoornhuyse, N; Libessart, N; Delrue, B; Zabawinski, C; Decq, A; Iglesias, A; Carton, A; Preiss, J; Ball, S			Control of starch composition and structure through substrate supply in the monocellular alga Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; ARABIDOPSIS-THALIANA L; ADPGLUCOSE PYROPHOSPHORYLASE; DEFICIENT MUTANT; GRANULE; AMYLOPECTIN; INHIBITION; SYNTHASE; EXPRESSION; STORAGE	In Chlamydomonas, as in higher plants, synthesis of ADP glucose catalyzed by ADP-glucose pyrophosphorylase is rate-limiting for the building of starch in the chloroplast. We have isolated disruptions of the STA1 ADP-glucose pyrophosphorylase structural gene that rendered the enzyme less responsive to the allosteric activator 3-phosphoglycerate, The structure and composition of the residual starch synthesized by all mutants of the STA1 locus is dramatically altered. The residual polysaccharide is shown to be devoid of amylose despite the presence of granule-bound starch synthase, the amylose biosynthetic enzyme. In addition, the fine structure of the mutant amylopectin revealed the presence of an altered chain-length distribution. This distribution mimicks that which is observed during growth and photosynthesis and differs markedly from that observed during storage, We therefore propose that low nucleotide sugar concentrations are either directly or indirectly responsible for the major differences observed in the composition or structure of starch during storage and photosynthesis.	UNIV SCI & TECH LILLE FLANDRES ARTOIS,UMR CNRS 111,CHIM BIOL LAB,F-59655 VILLENEUVE DASCQ,FRANCE; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; INST TECHNOL CHASCOMUS,INTECH,RA-7130 CHASCOMUS,ARGENTINA	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Michigan State University				Ball, Steven/0000-0003-1629-1650; Iglesias, Alberto/0000-0001-9729-7338	NIAID NIH HHS [AI 022385] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H; BANKS W, 1971, CARBOHYD RES, V17, P25, DOI 10.1016/S0008-6215(00)81539-6; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; FONTAINE T, 1993, J BIOL CHEM, V268, P16223; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; GIDLEY MJ, 1985, CARBOHYD RES, V139, P85; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P399; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; IGLESIAS AA, 1994, PLANT PHYSIOL, V104, P1287, DOI 10.1104/pp.104.4.1287; JENKINS JPJ, 1993, STARCH-STARKE, V45, P417; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KLOECK G, 1991, Biochimica et Biophysica Acta, V1073, P410; KUIPERS AGJ, 1994, PLANT CELL, V6, P43, DOI 10.1105/tpc.6.1.43; LI L, 1992, CARBOHYD RES, V227, P227, DOI 10.1016/0008-6215(92)85074-A; LIBESSART N, 1995, PLANT CELL, V7, P1117; LIN TP, 1988, PLANT PHYSIOL, V86, P1131, DOI 10.1104/pp.86.4.1131; LIN TP, 1988, PLANT PHYSIOL, V88, P1175, DOI 10.1104/pp.88.4.1175; MACDONALD FD, 1985, PLANT PHYSIOL, V78, P849, DOI 10.1104/pp.78.4.849; MADDELEIN ML, 1994, J BIOL CHEM, V269, P25150; Maniatis T., 1982, MOL CLONING; MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0; MULLERROBER B, 1992, EMBO J, V11, P1229, DOI 10.1002/j.1460-2075.1992.tb05167.x; MULLERROBER B, 1994, PLANT CELL ENVIRON, V17, P601, DOI 10.1111/j.1365-3040.1994.tb00152.x; NELSON O, 1995, ANNU REV PLANT PHYS, V46, P475, DOI 10.1146/annurev.pp.46.060195.002355; NELSON OE, 1962, BIOCHEM BIOPH RES CO, V9, P297, DOI 10.1016/0006-291X(62)90043-8; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; Preiss J., 1996, PHOTOASSIMILATE DIST, V3, p63?96; Preiss J, 1993, DENPUN KAGAKU, V40, P117; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Shannon J., 1984, STARCH CHEM TECHNOLO, P25, DOI 10.1016/B978-0-12-746270-7.50009-4; SMITH AM, 1989, PLANT PHYSIOL, V89, P982, DOI 10.1104/pp.89.3.982; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; TSAI CY, 1974, BIOCHEM GENET, V11, P83, DOI 10.1007/BF00485766; TSAI CY, 1966, SCIENCE, V151, P341, DOI 10.1126/science.151.3708.341; VISSER RGF, 1991, MOL GEN GENET, V225, P289, DOI 10.1007/BF00269861; WANG ZY, 1995, PLANT J, V7, P613, DOI 10.1046/j.1365-313X.1995.7040613.x; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9	38	77	79	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16281	16287		10.1074/jbc.271.27.16281	http://dx.doi.org/10.1074/jbc.271.27.16281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663144	hybrid			2022-12-25	WOS:A1996UW35200063
J	Wu, RY; Durick, K; Zhou, SY; Cantley, LC; Taylor, SS; Gill, GN				Wu, RY; Durick, K; Zhou, SY; Cantley, LC; Taylor, SS; Gill, GN			Specificity of LIM domain interactions with receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; INSULIN-RECEPTOR; PROTEIN; GENE; MOTIF; INTERNALIZATION; BINDING; ENDOCYTOSIS; ELEGANS; SIGNALS	LIM domains, Cys-rich motifs containing approximately 50 amino acids found in a variety of proteins, are proposed to direct protein protein interactions, To identify structural targets recognized by LIM domains, we have utilized random peptide library selection, the yeast two-hybrid system, and glutathione S-transferase fusions, Enigma contains three LIM domains within its carboxyl terminus and LIM3 of Enigma specifically recognizes active but not mutant endocytic codes of the insulin receptor (InsR) (Wu, R Y,, and Gill, Gr, N, (1994) J. Biol, Chem. 269, 2508-25090). Interaction of two random peptide libraries nifh glutathione S-transferase-LIM3 of Enigma indicated specific binding to Gly-Pro-Hyd-Gly-Pro-Hyd-Tyr-Ala corresponding to the major endocytic code of InsR Peptide competition demonstrated that both Pro and Tyr residues were required for specific interaction of InsR with Enigma, In contrast to LIM3 of Enigma binding to InsR, LIM2 of Enigma associated specifically with the receptor tyrosine kinase, Ret. Ret was specific for LIM2 of Enigma and did not bind other LIM domains tested, Mutational analysis indicated that the residues responsible for binding to Enigma were localized to the carboxyl-terminal 61 amino acids of Ret, A peptide corresponding to the carboxyl-terminal 20 amino acids of Ret dissociated Enigma and Ret complexes, while a mutant that changed Asn-Lys-Leu-Tyr in the peptide to Ala-Lys-Leu-Ala or a peptide corresponding to exon16 of InsR failed to disrupt the complexes, indicating the Asn-Lys-Leu-Tyr sequence of Ret is essential to the recognition moth for LIM2 of Enigma, We conclude that LIM domains of Enigma recognize tyrosine-containing motifs with specificity residing in both the LIM domains and in the target structures.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; HARVARD UNIV, SCH MED, CAMBRIDGE, MA 02115 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [T32CA 02523] Funding Source: Medline; NIDDK NIH HHS [DK 13149] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SOOS MA, 1992, J BIOL CHEM, V267, P12955; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU RY, 1994, J BIOL CHEM, V269, P25085; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	46	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15934	15941		10.1074/jbc.271.27.15934	http://dx.doi.org/10.1074/jbc.271.27.15934			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663233	hybrid			2022-12-25	WOS:A1996UW35200018
J	Saiki, K; Nakamura, H; Mogi, T; Anraku, Y				Saiki, K; Nakamura, H; Mogi, T; Anraku, Y			Probing a role of subunit IV of the Escherichia coli bo-type ubiquinol oxidase by deletion and cross-linking analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; AEROBIC RESPIRATORY-CHAIN; SITE-DIRECTED MUTAGENESIS; TERMINAL OXIDASE; PARACOCCUS-DENITRIFICANS; BINUCLEAR CENTER; QUINOL OXIDASE; HEME-COPPER; O COMPLEX; CYOE GENE	Subunit TV of the Escherichia cell be-type ubiquinol oxidase is a 12-kDa membrane protein encoded by the cyoD gene and is conserved in the bacterial heme-copper terminal oxidases. To probe the functional role of subunit TV, we carried out deletion analysis and chemical cross-linking experiments with a homobifunctional and cleavable reagent. Spectroscopic properties of the mutant oxidases suggest that the C-terminal two-third (Val(45) to His(109)) containing helices II and III is essential for the functional expression of the oxidase complex and for the Cu-B binding to the heme-copper binuclear center in subunit I. Cross-linking studies indicate that subunit TV is in close vicinity to subunit III. Based on these observations, we propose that subunit IV is present in a cleft formed by subunits I and III and assists the Cu-B binding to subunit I during biosynthesis or assembly of the oxidase complex.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN; RIKEN,INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; RIKEN			Keitarou, Saiki/AAV-6909-2020					ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; AOYAMA H, 1995, BIOPHYSICS S, V35, P26; BROWN S, 1993, FEBS LETT, V316, P216, DOI 10.1016/0014-5793(93)81296-C; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P11524, DOI 10.1021/bi00094a008; CASTOR LN, 1959, J BIOL CHEM, V234, P1587; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; Denda K, 1995, BIOCHEM BIOPH RES CO, V217, P428, DOI 10.1006/bbrc.1995.2794; FUKAYA M, 1993, J BACTERIOL, V175, P4307, DOI 10.1128/JB.175.14.4307-4314.1993; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JARAUSCH J, 1985, EUR J BIOCHEM, V146, P211, DOI 10.1111/j.1432-1033.1985.tb08640.x; KITA K, 1982, J BIOL CHEM, V257, P7933; KITA K, 1984, J BIOL CHEM, V259, P3368; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; LEMMA E, 1995, ARCH MICROBIOL, V163, P432, DOI 10.1007/BF00272132; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; MA JX, 1993, BIOCHEMISTRY-US, V32, P7692, DOI 10.1021/bi00081a013; MATSUSHITA K, 1983, P NATL ACAD SCI-BIOL, V80, P4889, DOI 10.1073/pnas.80.16.4889; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P471, DOI 10.1093/oxfordjournals.jbchem.a124548; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; MOGI T, 1995, FEBS LETT, V370, P259; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; NAKAMURA H, 1991, THESIS U TOKYO; PAPA S, 1994, CELL BIOL INT, V18, P345, DOI 10.1006/cbir.1994.1084; PROCHASKA LJ, 1996, BIOPHYS J, V70, P252; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; QUIRK PG, 1993, J BIOL CHEM, V268, P678; RICHTER OMH, 1994, J BIOL CHEM, V269, P23079; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SATOWATANABE M, 1995, FEBS LETT, V374, P265, DOI 10.1016/0014-5793(95)01125-X; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28899; SONE N, 1990, FEBS LETT, V262, P249, DOI 10.1016/0014-5793(90)80202-T; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1994, J BIOL CHEM, V269, P30861; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; UNO T, 1994, J BIOL CHEM, V269, P11912; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VILLANI G, 1995, BBA-BIOENERGETICS, V1232, P67, DOI 10.1016/0005-2728(95)00112-5; WELTER R, 1994, J BIOL CHEM, V269, P28834; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	55	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15336	15340		10.1074/jbc.271.26.15336	http://dx.doi.org/10.1074/jbc.271.26.15336			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663126	hybrid			2022-12-25	WOS:A1996UV29900008
J	Hirsch, JR; Loo, DDF; Wright, EM				Hirsch, JR; Loo, DDF; Wright, EM			Regulation of Na+/glucose cotransporter expression by protein kinases in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; ACTIVATION; PHOSPHORYLATION; INHIBITION; MODULATION; ACID; CAMP	Cotransporters are proteins responsible for the accumulation of nutrients, neurotransmitters, and drugs in cells, As forskolin has been shown to stimulate intestinal Na+/glucose cotransport, we have used electrophysiological techniques to examine the role of protein kinases in regulating Na+/glucose cotransporters, SGLT1, expressed in Xenopus laevis oocytes, We monitored SGLT1 kinetics, the number of SGLT1 cotransporters in the plasma membrane, and plasma membrane area before and after activation of protein kinases, 8-Bromoadenosine 3',5' cyclic monophosphate (8-Br-cAMP) and sn-1,2-dioctanoylglycerol (DOG) were used as membrane permeable activators of protein kinases A (PKA) and C (PKC), respectively, In oocytes expressing rabbit SGLT1 8-Br-cAMP increased by 28 +/- 4% (n = 10), and DOG decreased by 51 +/- 5% (n = 13) the maximum rate of Na+/glucose cotransport, These reversible changes in the maximum transport rate occurred within minutes, and were accompanied by proportional changes in the number of cotransporters in the membrane and area of the plasma membrane, This suggests that protein kinases regulate rabbit SGLT1 activity by controlling the distribution of transporters between intracellular compartments and the plasma membrane, and that this occurs by exo and endocytosis, Similar increases in maximum transport were obtained with activation of PKA in oocytes expressing rabbit, human, and rat SGLT1 isoforms, but with activation of PKC the response was isoform-dependent, PKC activation decreased the maximum rate of transport by rabbit and rat SGLT1, but increased transport by human SGLT1, We conclude that: (i) the regulation of SGLT1 expression in oocytes by protein kinases occurs mainly by regulated endo- and exocytosis; (ii) it is independent of consensus phosphorylation sites in the transporter; and (iii) the effect of a given kinase depends upon the actual sequence of the cotransporter expressed, These considerations may also apply to the regulation of other cotransporters by protein kinases in oocytes, cells, and tissues.			Hirsch, JR (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, LOS ANGELES, CA 90095 USA.				NIDDK NIH HHS [DK 44602, DK 19567] Funding Source: Medline; NINDS NIH HHS [NS25554] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567, R01DK044602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025554] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; BREWER CB, 1995, J CELL SCI, V108, P789; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASADO M, 1993, J BIOL CHEM, V268, P27313; COREY JL, 1994, J BIOL CHEM, V269, P14759; DAVIS RJ, 1985, J BIOL CHEM, V260, P1562; DEBNAM ES, 1994, NEWS PHYSIOL SCI, V9, P84; GRUBB BR, 1995, AM J PHYSIOL-GASTR L, V268, pG505, DOI 10.1152/ajpgi.1995.268.3.G505; HARVEY WR, 1994, J EXP BIOL, V196, P1; HAYES G, 1995, PFLUG ARCH EUR J PHY, V430, P819, DOI 10.1007/BF00386181; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEI YJ, 1991, MOL PHARMACOL, V39, P233; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; LEE WS, 1994, J BIOL CHEM, V269, P12032; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PIPER RC, 1993, J BIOL CHEM, V268, P16557; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SATO K, 1995, J NEUROCHEM, V65, P1967; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	31	169	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14740	14746		10.1074/jbc.271.25.14740	http://dx.doi.org/10.1074/jbc.271.25.14740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663046	hybrid			2022-12-25	WOS:A1996UT10600019
J	Kuroda, S; Ohtsuka, T; Yamamori, B; Fukui, K; Shimizu, K; Takai, Y				Kuroda, S; Ohtsuka, T; Yamamori, B; Fukui, K; Shimizu, K; Takai, Y			Different effects of various phospholipids on Ki-Ras-, Ha-Ras-, and Rap1B-induced B-Raf activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; MAP KINASES; CELLS; GENE; TRANSFORMATION; BINDING; REGION; DOMAIN; RSK	We have recently purified a Ki-Ras- and Ha-Ras-dependent extracellular signal-regulated kinase kinase from bovine brain and identified it as B-Raf protein kinase complexed with 14-3-3 proteins (Yamamori, B., Kuroda, S., Shimizu, K., Fukui, K., Ohtsuka, T., and Takai, Y. (1995) J. Biol. Chem. 270, 11723-11726). Moreover, we found that Rap1B as well as Ki-Ras and Ha-Has stimulate the B-Raf activity. Since B-Raf contains a cysteine-rich domain originally found in protein kinase C as a domain responsible for interaction with phosphatidylserine (PS) and diacylglycerol or 12-O-tetradecanoylphorbol-13-acetate, we have examined here the effect of these compounds on the Ki-Ras-, Ha-Ras-, and Rap1B-induced activation of bovine brain B-Raf. Bovine brain PS enhanced Ki-Ras stimulated B-Raf activity. Phosphatidic acid was slightly active, but other phospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol (PI), PI-Li-monophosphate, PI-4,5-bisphosphate, and PI-3,4,5-trisphosphate, were inactive. However, none of the above phospholipids affected the Ha-Has-stimulated B-Raf activity, whereas PI, PS, phosphatidylethanolamine, and phosphatidic acid inhibited the Rap1B-stimulated B-Raf activity. Phosphatidylcholine or PI-4-monophosphate did not show any effect on the Rap1B-stimulated B-Raf activity. Synthetic PS with two unsaturated fatty acids, such as 1,2-dioleoyl-PS or 1,2-dilinoleoyl-PS, showed the same effect toward the Ki-Ras and Rap1B-stimulated B-Raf activities, but synthetic PS with two saturated fatty acids, such as 1,2-distearoyl-PS, was inactive. 12-O-Tetradecanoylphorbol-13-acetate did not affect the stimulatory or inhibitory effect of PS on the Ki Ras and Rap1B-stimulated B-Raf activities, respectively. PS did not affect the Ki-Ras-, Ha-Ras, or Rap1B-independent basal B-Raf activity or the mitogen-activated protein kinase kinase or extracellular signal-regulated kinase activity. These results indicate that various phospholipids differently affect Ki-Ras, Ha-Pas, and Rap1B induced B-Raf activation.	OSAKA UNIV, SCH MED, DEPT MOLEC BIOL & BIOCHEM, SUITA, OSAKA 565, JAPAN; NATL INST PHYSIOL SCI, DEPT CELL PHYSIOL, OKAZAKI, AICHI 444, JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			KURODA, SHINYA/G-4961-2014					AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, MOL CELL BIOL, V15, P4125; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HERBETTE L, 1984, ARCH BIOCHEM BIOPHYS, V234, P235, DOI 10.1016/0003-9861(84)90345-X; HORWITZ J, 1987, METHOD ENZYMOL, V141, P169; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PIZON V, 1988, ONCOGENE, V3, P201; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, CANCER RES, V54, P2563; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14680	14683		10.1074/jbc.271.25.14680	http://dx.doi.org/10.1074/jbc.271.25.14680			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663012	hybrid			2022-12-25	WOS:A1996UT10600009
J	Sivaram, P; VanniReyes, T; Goldberg, IJ				Sivaram, P; VanniReyes, T; Goldberg, IJ			Endothelial cells synthesize and process apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; MESSENGER-RNA; LIPASE BINDING; B-100; SECRETION; PLASMA; TRANSLOCATION; DEGRADATION; PROTEOLYSIS; EXPRESSION	We reported previously that a 116-kDa lipoprotein lipase (LPL)-binding protein from endothelial cells has sequence homology to the amino terminal region of apolipoprotein (ape) B. We now tested whether endothelial cells synthesize apoB mRNA and protein, Primers were designed to the human apoB cDNA sequence and reverse transcription polymerase chain reaction was performed using total RNA isolated from bovine and human endothelial cells, With primers to the 5' region of the apoB mRNA (amino-terminal region of apoB protein) expected size PCR products were generated from both bovine and human endothelial cells as well as from mouse liver RNA, which was used as a control, Primers designed to the 3' region of apoB mRNA generated PCR products from human endothelial cells and HepG2 cells but not from bovine or mouse cells, These data suggest that endothelial cells contain full-length apoB mRNA and that the 5' or the amino-terminal region of apoB is highly conserved from mouse to human, This was confirmed by direct sequencing of the mouse and bovine PCR products, To test whether apoB protein was pro produced, bovine endothelial cell proteins were metabolically labeled with [S-35]methionine/cysteine or [H-3]leucine and immunoprecipitated with anti human apoB antibodies, Using extracts from cells labeled for 1 h, monoclonal antibody 47, directed to the low density lipoprotein receptor binding region of apoB, precipitated a protein of approximate molecular mass 550,000, the size of full-length apoB. Immunoprecipitation of the 550-kDa protein was abolished in the presence of added unlabeled low density lipoprotein, From cells labeled for 16 h, a 11B-kDa protein was immunoprecipitated by polyclonal anti-apoB antibodies. This protein was partly released from cells by heparin treatment, Pulse-chase analysis showed that the 116-kDa fragment appeared at the same time as the full-length apoB began disappearing, The immunoprecipitated 116-kDa fragment also bound labeled LPL on ligand blot, further suggesting that it is an amino-terminal fragment of apoB. Incubation of endothelial cells with oleic acid (0.25 and 0.5 mM) did not significantly alter the production of either the full-length apoB or the 116-kDa fragment, These data show that endothelial cells synthesize apoB. The full-length apoB appears to be cleaved to form a 118-kDa fragment that can function as a LPL-binding protein.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV PREVENT MED & NUTR,NEW YORK,NY 10032	Columbia University					NHLBI NIH HHS [HL 21006 SCOR, HL 45095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045095, R37HL045095, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUE ML, 1980, J BIOL CHEM, V255, P48; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BYRNE RE, 1989, J LIPID RES, V30, P109; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN GC, 1989, BIOCHEMISTRY-US, V28, P2477, DOI 10.1021/bi00432a019; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DIXONJL, 1993, J LIPID RES, V34, P34167; DU EZ, 1994, J BIOL CHEM, V269, P24169; EBERT DL, 1989, J LIPID RES, V29, P1501; GREEVE J, 1993, J LIPID RES, V34, P1367; LAW A, 1990, J LIPID RES, V31, P1109; LING P, 1996, IN PRESS J BIOL CHEM, V261; MATSUMOTO A, 1987, BIOCHEM BIOPH RES CO, V142, P92, DOI 10.1016/0006-291X(87)90455-4; MILINE R, 1989, J BIOL CHEM, V264, P19754; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALLACH SM, 1995, BBA-MOL CELL RES, V1265, P29, DOI 10.1016/0167-4889(95)00239-O; Sambrook J., 2002, MOL CLONING LAB MANU; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SIVARAM P, 1993, ANAL BIOCHEM, V214, P511, DOI 10.1006/abio.1993.1531; STINS MF, 1993, J LIPID RES, V34, P1853; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WETTERAU JR, 1992, SCIENCE, V258, P899; WOLLE J, 1995, BIOCHEM BIOPH RES CO, V216, P906, DOI 10.1006/bbrc.1995.2707; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	37	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15261	15266		10.1074/jbc.271.25.15261	http://dx.doi.org/10.1074/jbc.271.25.15261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663087	hybrid			2022-12-25	WOS:A1996UT10600089
J	Abe, A; Shayman, JA; Radin, NS				Abe, A; Shayman, JA; Radin, NS			A novel enzyme that catalyzes the esterification of N-acetylsphingosine - Metabolism of C-2-ceramides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLUCOSYLCERAMIDE; CERAMIDE; GROWTH	A unique transacylase that catalyzes esterification of a short chain ceramide, N-acetylsphingosine, was found in Madin-Darby canine kidney cell and mouse tissue homogenates. It esterified the hydroxyl group at the carbon-1 position of the ceramide. The enzyme has a pH optimum of 4.2 and a K-m of 9.4 mu M for N-acetylsphingosine at pH 4.5, The transacylase activity is independent of free fatty acid or acyl-CoA and instead uses the a-acyl group of phosphatidylethanolamine or phosphatidylcholine. The transacylase activity in the homogenate was present in the 100,000 x g supernatant, and the lipid extracted from the membranous fraction could function as a donor of the acyl group. When liposomes consisting of dioleoylphosphatidylcholine:1-palmitoyl-2-[C-14]arachidonoyl-phosphatidylethanolamine:sulfatide (70:0.2:30) were incubated with the supernatant and N-acetyl-sphingosine, the formation of free arachidonic acid and O-arachidonoyl-n-acetylsphingosine was observed. The ratio of the two products depended on the concentration of ceramide; only the free acid was formed if the truncated ceramide was absent. Both deacylase and transacylase activities were inhibited 50-60% by 20 mu M D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-pro-panol, an inhibitor of several glucosphingolipid synthases. Neither activity was inhibited by nonadecyltetraenyl trifluoromethyl ketone, a potent inhibitor of cytosolic phospholipase A(2). N-Acetyldihydrosphingosine and N-octanoylsphingosine were only 55 and 10%, respectively, as effective as N-acetylsphingosine as acyl accepters, Oleoylsphingosine was only slightly reactive. An esterase that releases the truncated ceramide from its ester linkage appears to be membrane bound, Lecithin was less effective than phosphatidylethanolamine as an acyl donor in the transacylation. Madin-Darby canine kidney cell cultures treated with N-acetyl-[3-H-3]sphingosine formed radioactive polar sphingolipids, long chain ceramide, free sphingosine, and O-acyl-N-acetylsphingosine. This suggests that the deacylation and transacylation reactions observed in vitro occur in growing cells as well.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487, P50DK039255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41487, DK39255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; ABE A, 1995, J LIPID RES, V36, P611; Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; CHATTERJEE S, IN PRESS GLYCOCONJUG; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; INOKUCHI J, 1995, J BIOCHEM-TOKYO, V117, P766, DOI 10.1093/oxfordjournals.jbchem.a124774; INOKUCHI JI, 1987, J LIPID RES, V28, P565; KISS Z, 1995, FEBS LETT, V365, P146, DOI 10.1016/0014-5793(95)00445-F; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; OKABE H, 1977, J BIOL CHEM, V252, P7038; RADIN NS, 1991, ENZYME, V45, P67, DOI 10.1159/000468867; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; Skipski V P, 1975, Methods Enzymol, V35, P396, DOI 10.1016/0076-6879(75)35178-1; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052	27	83	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14383	14389		10.1074/jbc.271.24.14383	http://dx.doi.org/10.1074/jbc.271.24.14383			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662981	hybrid			2022-12-25	WOS:A1996UQ66000067
J	Liu, HY; DeWaard, M; Scott, VES; Gurnett, CA; Lennon, VA; Campbell, KP				Liu, HY; DeWaard, M; Scott, VES; Gurnett, CA; Lennon, VA; Campbell, KP			Identification of three subunits of the high affinity omega-conotoxin MVIIC-sensitive Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM CHANNELS; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; MAMMALIAN CNS; BRAIN; CLONING; BINDING; ALPHA-2-SUBUNIT; RECEPTOR; NEURONS	N-, P- and Q-type voltage-dependent Ca2+ channels control neurotransmitter release in the nervous system and are blocked by omega-conotoxin MVIIC. In this study, both a high affinity and a low affinity binding site for omega-conotoxin MVIIC were detected in rabbit brain. The low affinity binding site is shown to be present on the N-type Ca2+ channel. Using optimized conditions for specific labeling of the high affinity omega-conotoxin MVIIC receptor and a panel of subunit specific antibodies, the molecular structure of the high affinity receptor was investigated. We demonstrate for the first time that this receptor is composed of at least alpha(1A), alpha(2) delta, and any one of the four brain beta subunits. Such association of different beta subunits with alpha(1A) and alpha(2) delta components may produce Ca2+ channels with distinct functional properties, such as P- and Q-type.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,NEUROIMMUNOL LAB,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,NEUROIMMUNOL LAB,ROCHESTER,MN 55905	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Mayo Clinic; Mayo Clinic			Tuluc, Petronel/C-2527-2011; De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Gurnett, Christina/0000-0001-9129-315X; Campbell, Kevin/0000-0003-2066-5889	NCI NIH HHS [CA-37343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; GAUR S, 1994, NEUROPHARMACOLOGY, V33, P1211, DOI 10.1016/S0028-3908(05)80012-7; GURNETT CA, 1995, J BIOL CHEM, V270, P9035, DOI 10.1074/jbc.270.16.9035; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JAY SD, 1991, J BIOL CHEM, V266, P3287; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; KRIZANOVA O, 1993, CIRCULATION, V87, P44; KRYSTAL G, 1987, ANAL BIOCHEM, V167, P86, DOI 10.1016/0003-2697(87)90136-9; Lennon V. A., 1995, Society for Neuroscience Abstracts, V21, P1283; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; MAGNELLI Y, 1995, EUR J PHYSL, V429, P762; MARTINMOUTOT N, 1995, FEBS LETT, V366, P21, DOI 10.1016/0014-5793(95)00467-N; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; SUGIURA Y, 1995, J NEUROCYTOL, V24, P15, DOI 10.1007/BF01370157; TURNER TJ, 1995, NEUROPHARMACOLOGY, V34, P1469, DOI 10.1016/0028-3908(95)00133-Q; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	41	129	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13804	13810		10.1074/jbc.271.23.13804	http://dx.doi.org/10.1074/jbc.271.23.13804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662888	hybrid			2022-12-25	WOS:A1996UP38500075
J	Vaziri, C; Faller, DV				Vaziri, C; Faller, DV			Down-regulation of platelet-derived growth factor receptor expression during terminal differentiation of 3T3-L1 pre-adipocyte fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF ALPHA-RECEPTORS; TUMOR PROMOTERS; RESPONSIVENESS INVITRO; CELL-DIFFERENTIATION; SIGNAL TRANSDUCTION; HORMONE RECEPTORS; C-MYC; TRANSFORMATION; PROLIFERATION; CONVERSION	The transcription and expression of platelet-derived growth factor (PDGF) receptors (PDGFRS) is down-regulated as a consequence of entry into the replicative cell cycle (Vaziri, C., and Faller, D. V. (1995) Mol. Cell. Biol, 15, 1244-1253). In this study, we have investigated the expression of PDGFRs during terminal differentiation, a process in which cells exit from the cell cycle, When treated with appropriate hormonal stimuli, 3T3-L1 fibroblasts initiate a differentiation program resulting in conversion to lipid-accumulating, adipocyte-like cells. Pre-adipocytes express amounts of PDGF alpha R and PDGF beta R mRNA and protein that are similar to levels expressed in other murine 3T3 fibroblasts. In contrast, the expression of both alpha and beta receptor transcripts is greatly reduced in differentiated 3T3-L1 cells, The loss of PDGFR mRNA following induction of differentiation precedes morphological conversion as well as the induction of many adipocyte-specific genes, The amounts of cell surface PDGFR protein diminish in parallel with the mRNA levels during differentiation, as shown by Western blotting and PDGF-binding assays. The reduced expression of PDGFRs does not reflect a general down-regulation of growth factor receptors, as expression of the type 1 FGFR is unaffected by terminal differentiation. The PDGF beta R promoter drives strong expression of a luciferase reporter gene in pre-adipocytes, but not in differentiated cells, indicating that the decrease in PDGFR expression following induction of differentiation is a transcriptionally regulated event. Decreased PDGFR expression in differentiated cells is associated with impaired biological responsiveness to PDGF, as shown by reduced activation of mitogen-activated protein-kinase following PDGF stimulation, and decreased chemotactic responsiveness to PDGF. Our data suggest that PDGFR dawn-regulation is an important mechanism for reducing PDGF-responsiveness in terminally differentiated 3T3-L1 cells.	BOSTON UNIV,SCH MED,DEPT MED,CANC RES CTR,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University					NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER; NCI NIH HHS [CA50459] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DIAMOND L, 1977, NATURE, V269, P247, DOI 10.1038/269247a0; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAYASHI I, 1981, P NATL ACAD SCI-BIOL, V78, P3969, DOI 10.1073/pnas.78.6.3969; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; JIN P, 1990, J CELL BIOL, V110, P1665, DOI 10.1083/jcb.110.5.1665; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAZAROVICI P, 1987, J CELL BIOL, V104, P1611, DOI 10.1083/jcb.104.6.1611; MICHIELI P, 1994, CANCER RES, V54, P3391; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; SCHER CD, 1982, J CELL PHYSIOL, V113, P211, DOI 10.1002/jcp.1041130205; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHIMIZU Y, 1983, CANCER RES, V43, P4974; STILES CD, 1983, CELL, V33, P653, DOI 10.1016/0092-8674(83)90008-9; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WESTERMARK B, 1991, CANCER RES, V51, P5087; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YABLONKAREUVENI Z, 1990, J CELL BIOL, V111, P1623, DOI 10.1083/jcb.111.4.1623; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	35	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13642	13648		10.1074/jbc.271.23.13642	http://dx.doi.org/10.1074/jbc.271.23.13642			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662875	hybrid			2022-12-25	WOS:A1996UP38500052
J	Duclert, A; Savatier, N; Schaeffer, L; Changeux, JP				Duclert, A; Savatier, N; Schaeffer, L; Changeux, JP			Identification of an element crucial for the sub-synaptic expression of the acetylcholine receptor epsilon-subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-DEPENDENT REGULATION; ADULT MUSCLE-FIBERS; ALPHA-SUBUNIT; ELECTRICAL-ACTIVITY; MESSENGER-RNA; GAMMA-SUBUNIT; TRANSGENIC MICE; SKELETAL-MUSCLE; MOUSE MUSCLE; NEUROMUSCULAR SYNAPSES	The adult neuromuscular junction displays an accumulation of both the acetylcholine receptor (AChR) protein in the subneural domain of the post-synaptic membrane and the mRNAs coding for all its subunits at the level of the subjunctional ''fundamental nuclei,'' In the course of end plate development, the epsilon-subunit, at variance with other subunits, becomes exclusively expressed at the level of the fundamental nuclei, yet at a rather late stage (around birth). To analyze the promoter region of the epsilon-subunit gene which directs its specific expression at the synapse, we used a quantitative transient in vivo expression assay in intact muscle tissue using constructs of the epsilon-subunit promoter placed upstream of the beta-galactosidase reporter gene. One crucial element for synapse-specific expression was detected between the -11 and -6 positions, Disruption of this element, either by a scanning mutation or single base mutations, greatly diminishes, or even completely inhibits, preferential expression of the transgene at the end plate. Gel shift experiments reveal the presence of a complex in nuclear muscle extracts that bind the core sequence of this element, The identification of such a site opens the possibility to identify regulatory factors responsible for compartmentalized expression at the neuromuscular junction.	INST PASTEUR,DEPT BIOTECHNOL,URA CNRS 0210 NEUROBIOL MOLEC,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				schaeffer, laurent/0000-0001-6600-503X				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BRENNER HR, 1994, DEV BIOL, V165, P527, DOI 10.1006/dbio.1994.1272; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; DUCLERT A, 1993, P NATL ACAD SCI USA, V90, P3043, DOI 10.1073/pnas.90.7.3043; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; DUTTON EK, 1993, P NATL ACAD SCI USA, V90, P2040, DOI 10.1073/pnas.90.5.2040; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FONTAINE B, 1988, EMBO J, V7, P603, DOI 10.1002/j.1460-2075.1988.tb02853.x; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GUNDERSEN K, 1993, J CELL BIOL, V123, P1535, DOI 10.1083/jcb.123.6.1535; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; JIA HT, 1992, CELL MOL NEUROBIOL, V12, P241, DOI 10.1007/BF00712929; JO AS, 1995, NATURE, V373, P158; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KOELLE GB, 1949, P SOC EXP BIOL MED, V70, P617; KOIKE S, 1995, P NATL ACAD SCI USA, V92, P10624, DOI 10.1073/pnas.92.23.10624; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NUMBERGER M, 1991, EMBO J, V10, P2957, DOI 10.1002/j.1460-2075.1991.tb07846.x; PIETTE J, 1993, DEV BIOL, V157, P205, DOI 10.1006/dbio.1993.1124; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; SANES JR, 1991, DEVELOPMENT, V113, P1181; SIMON AM, 1992, DEVELOPMENT, V114, P545; TANG JC, 1994, DEVELOPMENT, V120, P1799; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523; WANG XM, 1990, EMBO J, V9, P783, DOI 10.1002/j.1460-2075.1990.tb08174.x; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	44	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17433	17438		10.1074/jbc.271.29.17433	http://dx.doi.org/10.1074/jbc.271.29.17433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663316	hybrid			2022-12-25	WOS:A1996UX94300070
J	Miralem, T; Wang, AM; Whiteside, CI; Templeton, DM				Miralem, T; Wang, AM; Whiteside, CI; Templeton, DM			Heparin inhibits mitogen-activated protein kinase-dependent and -independent c-fos induction in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE FACTOR; MYC MESSENGER-RNA; SELECTIVE-INHIBITION; SIGNAL-TRANSDUCTION; CALCIUM RELEASE; BINDING; TRANSCRIPTION; PHOSPHORYLATION	Heparin suppresses mitogenic responses in renal mesangial cells, and when quiescent mesangial cells are stimulated with serum, heparin blocks the induction of c-fos seen at 15 min, Because heparin is taken up by cells over a much longer time course, we addressed mechanisms whereby extracellular heparin might suppress c-fos induction at such early times, Quiescent cells were treated with serum, 12-O-tetradecanoylphorbol-13-acetate, or low concentrations of Ca2+ ionophores that produced increases in intracellular Ca2+ concentration ([Ca2+](i)) in the physiological range, Each treatment caused an increase in c-fos mRNA, but they did so by different mechanisms. Serum activated mitogen-activated protein kinase (MAPK) and increased [Ca2+](i) without affecting protein kinase C, Activation of protein kinase C with phorbol ester activated MAPK without much effect on [Ca2+](i). Ionophores increased [Ca2+](i) without affecting basal levels of protein kinase C or MAPK, Heparin (1 mu g/ml) suppressed the induction of c-fos initiated by all three treatments, It did not affect the activity of protein kinase C, but inhibited activation of MAPK by either serum or phorbol ester, suggesting a common site of action at or below the probable convergence of the induced signals at Ras/Raf-1 activation. Heparin also inhibited the serum-stimulated entry of extracellular Ca2+ to the same extent as verapamil, consistent with the ability of verapamil to block L-type Ca-2+ channels and the known presence of these channels in mesangial cells, However, this effect does not appear to be related to heparin's ability to inhibit induction of c-fos. First, verapamil had no effect on induction of c-fos by serum, Second, heparin had no effect on changes in [Ca2+](i) achieved by ionophores, we conclude that heparin suppresses induction of c-fos in mesangial cells by blocking at least two different points in signal transduction cascades, one upstream of MAPK and the other independent of MAPK but dependent on intracellular Ca2+.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5G 1L5,CANADA; HOSP SICK CHILDREN,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Miralem, Tihomir/F-7576-2013	Miralem, Tihomir/0000-0001-7705-0442; Templeton, Douglas/0000-0003-0693-662X				ABBOUD HE, 1993, KIDNEY INT, V43, P252, DOI 10.1038/ki.1993.39; AHN NG, 1990, J BIOL CHEM, V265, P11487; AU YPT, 1994, CIRC RES, V75, P15, DOI 10.1161/01.RES.75.1.15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CASTELLOT JJ, 1984, J CELL PHYSIOL, V120, P315, DOI 10.1002/jcp.1041200309; CASTELLOT JJ, 1986, AM J PATHOL, V125, P493; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CASTELLOT JJ, 1987, VASCULAR SMOOTH MUSC, P93; CURRAN T, 1987, ONCOGENE, V2, P79; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FLOEGE J, 1993, KIDNEY INT, V43, P369, DOI 10.1038/ki.1993.55; FLOEGE JF, 1992, KLIN WOCHENSCHR, V70, P857; GARCIA MC, 1995, PFLUG ARCH EUR J PHY, V431, P84, DOI 10.1007/BF00374380; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONG Z, 1992, BIOTECHNIQUES, V12, P74; GRANT D, 1994, AGENTS ACTIONS, V41, pC214, DOI 10.1007/BF01987642; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230; KNAUS HG, 1990, J BIOL CHEM, V265, P11156; KNAUS HG, 1992, P NATL ACAD SCI USA, V89, P3586, DOI 10.1073/pnas.89.8.3586; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LACINOVA L, 1993, J PHYSIOL-LONDON, V465, P181, DOI 10.1113/jphysiol.1993.sp019672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPENNA D, 1992, BIOCHEM PHARMACOL, V44, P188, DOI 10.1016/0006-2952(92)90057-P; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCDERMOTT GF, 1993, CELL CALCIUM, V14, P387, DOI 10.1016/0143-4160(93)90043-6; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MUHL H, 1994, BIOCHEM J, V303, P607; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; RAY LB, 1988, J BIOL CHEM, V263, P12721; REILLY CF, 1987, J CELL PHYSIOL, V131, P149, DOI 10.1002/jcp.1041310203; REILLY CF, 1986, J CELL PHYSIOL, V129, P11, DOI 10.1002/jcp.1041290103; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TEMPLETON DM, 1987, BIOCHIM BIOPHYS ACTA, V926, P94, DOI 10.1016/0304-4165(87)90186-3; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Wang A, 1996, KIDNEY INT, V69, P437; WANG AM, 1994, J CELL PHYSIOL, V159, P295, DOI 10.1002/jcp.1041590213; WILLIAMS B, 1993, J CLIN INVEST, V92, P2889, DOI 10.1172/JCI116911; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; WRENSHALL LE, 1995, J IMMUNOL, V154, P871; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; ZVIBEL I, 1991, MOL CELL BIOL, V11, P108, DOI 10.1128/MCB.11.1.108	63	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17100	17106		10.1074/jbc.271.29.17100	http://dx.doi.org/10.1074/jbc.271.29.17100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663360	hybrid			2022-12-25	WOS:A1996UX94300020
J	Oldenburg, KR; Epand, RF; DOrfani, A; Vo, K; Selick, H; Epand, RM				Oldenburg, KR; Epand, RF; DOrfani, A; Vo, K; Selick, H; Epand, RM			Conformational studies on analogs of recombinant parathyroid hormone and their interactions with phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; H-1-NMR SPECTROSCOPY; PROTEIN CONFORMATION; FRAGMENT; DESIGN; EXPRESSION; RECEPTORS; RESIDUES; BINDING; REGION	Through the use of oligonucleotide-directed mutagenesis we have generated variants of a recombinant human parathyroid (PTH) hormone-(1-34)-homoserine (RPTH) in which a positively charged residue (Arg or Lys), a negatively charged residue (Glu), or a neutral residue (Gly) has been substituted at every position throughout the peptide. These 106 PTH analogs have been tested for their ability to stimulate cAMP production in the rat osteosarcoma cell line, UMR106. Analysis of these peptides led to the construction of several analogs containing multiple substitutions at sites of potential structural importance. Several of these analogs were shown to have 3-5-fold enhanced activity and receptor affinity. Circular dichroism (CD) and lipid binding studies were then performed on these analogs. Circular dichroism demonstrates enhanced helical content in the presence of lipid vesicles, particularly anionic lipid. The [Arg(15,19,22),Lys(29)]RPTH (+6RPTH) analog requires higher concentrations of trifluoroethanol to attain enhanced helicity. The intrinsic tryptophan fluorescence of the peptides are blue shifted more in the presence of the anionic lipid dimyristoyl phosphatidylglycerol (DMPG) than with the zwitterionic lipid dimyristoyl phosphatidylcholine (DMPC), Effects of the peptides on the phase transition behavior of DMPC shows that +6RPTH has less effect on the lipid than does RPTH. This difference in lipid interaction is also exhibited with isothermal titration calorimetry, in which RPTH reacts exothermally with DMPG, while +6RPTH shows little or no heat change, The pH dependence of binding of the hydrophobic probe 1,1'-bis(4-anilino)naphthalene-5,5'-trisulfonic acid, also shows a difference in exposure of hydrophobic sites between RPTH and +6RPTH. The +6RPTH has about a 5-fold greater affinity for receptor binding, We suggest that this enhanced activity is a consequence of the altered lipid interaction of +6RPTH, combined with increased conformational flexibility, particularly in the carboxyl-terminal region of the molecule.	MCMASTER UNIV, HLTH SCI CTR, DEPT BIOCHEM, HAMILTON, ON L8N 3Z5, CANADA; AFFYMAX RES INST, PALO ALTO, CA 94304 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba			, Richard/R-2316-2019	, Richard/0000-0002-9602-9558				ABOUSAMRA AB, 1990, J BIOL CHEM, V265, P58; ARMSTRONG MD, 1949, J AM CHEM SOC, V71, P3399, DOI 10.1021/ja01178a037; AVNUR Z, 1994, 3 INT C NEW ACT PAR; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BUTKO P, 1994, FEBS LETT, V340, P89, DOI 10.1016/0014-5793(94)80178-9; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHOREV M, 1990, BIOCHEMISTRY-US, V29, P1580, DOI 10.1021/bi00458a032; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; EPAND RM, 1985, INT J PEPT PROT RES, V25, P594; EPAND RM, 1990, COMPREHENSIVE MED CH, V3, P1023; FRELINGER AL, 1986, ARCH BIOCHEM BIOPHYS, V244, P641, DOI 10.1016/0003-9861(86)90632-6; GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; MIOZZARI GF, 1978, J BACTERIOL, V133, P1457, DOI 10.1128/JB.133.3.1457-1466.1978; NEUGEBAUER W, 1992, BIOCHEMISTRY-US, V31, P2056, DOI 10.1021/bi00122a023; NUSSBAUM SR, 1985, J PROTEIN CHEM, V4, P391, DOI 10.1007/BF01025179; OLDENBURG KR, 1994, PROTEIN EXPRES PURIF, V5, P278, DOI 10.1006/prep.1994.1042; REPPE S, 1991, J BIOL CHEM, V266, P14198; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Rosenblatt M, 1981, Pathobiol Annu, V11, P53; ROSENBLATT M, 1976, J BIOL CHEM, V251, P159; SCHWYZER R, 1995, BIOPOLYMERS, V37, P5, DOI 10.1002/bip.360370104; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SOMJEN D, 1990, BIOCHEM J, V272, P781; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; UNENO S, 1992, CALCIFIED TISSUE INT, V51, P382, DOI 10.1007/BF00316884; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; ZULL JE, 1990, J BIOL CHEM, V265, P5671	36	17	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17582	17591						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663272				2022-12-25	WOS:A1996UX94300090
J	Ren, B; Thelen, A; Jump, DB				Ren, B; Thelen, A; Jump, DB			Peroxisome proliferator-activated receptor alpha inhibits hepatic S14 gene transcription - Evidence against the peroxisome proliferator-activated receptor a as the mediator of polyunsaturated fatty acid regulation of S14 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; BETA-OXIDATION ENZYMES; RETINOID-X-RECEPTOR; RAT-LIVER; HORMONE RECEPTOR; RESPONSE ELEMENT; CLOFIBRIC ACID; DESATURASE-1 GENE; OMEGA-HYDROXYLASE; LIPID-METABOLISM	The peroxisome proliferator-activated receptor (PPAR alpha) has been implicated in fatty acid regulation of gene transcription, Lipogenic gene transcription is inhibited by polyunsaturated fatty acids (PUFA), We have used the PUFA-sensitive rat liver S14 gene as a model to examine the role PPAR alpha plays in fatty acid regulation of hepatic lipogenic gene transcription, Both PPAR alpha and the potent peroxisome proliferator, WY14643, inhibit S14CAT activity in transfected primary hepatocytes. WY14643 and PPAR alpha target the S14 T-3 regulatory region (TRR, -2.8 to -2.5 kilobases), a region containing 3 T-3 response elements (TRE). Transfer of the TRR to the thymidine kinase (TK) promoter conferred negative control to the TKCAT gene following WY14643 and PPAR alpha treatment, Gel shift analysis showed that PPAR alpha, either alone or with RXR alpha, did not bind the S14TRR. However, PPAR alpha interfered with TR beta/RXR alpha binding to a TRE (DR+4). Functional studies showed that co-transfected RXR alpha, but not T-3 receptor beta(1) (TR beta 1), abrogated the inhibitory effect of PPAR alpha on S14 gene transcription. These results suggest that WY14643 and PPAR alpha functionally interfere with T-3 regulation of S14 gene transcription by inhibiting TR beta 1/RXR binding to S14 TREs. Previous studies had established that the cis-regulatory targets of PUFA control were located within the proximal promoter region of the S14 gene, i.e. between -220 and -80 bp. Finding that the cis-regulatory elements for WY14643/PPAR alpha and PUFA are functionally and spatially distinct argues against PPAR alpha as the mediator of PUFA suppression of S14 gene transcription.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824	Michigan State University; Michigan State University					NIDDK NIH HHS [R01 DK043220, DK43220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1993, BIOCHEM PHARMACOL, V46, P2177, DOI 10.1016/0006-2952(93)90607-X; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; JUMP DB, 1995, FATTY ACIDS, V52, P107; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KAIKAUS RM, 1993, J BIOL CHEM, V268, P26866; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MACDOUGALD OA, 1991, BIOCHEM J, V280, P761, DOI 10.1042/bj2800761; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEAT CE, 1980, BIOCHEM J, V186, P369, DOI 10.1042/bj1860369; NESTEL PJ, 1984, J CLIN INVEST, V74, P82, DOI 10.1172/JCI111422; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; OSUMI T, 1990, J BIOCHEM-TOKYO, V108, P614, DOI 10.1093/oxfordjournals.jbchem.a123252; OZASA H, 1985, J BIOCHEM, V97, P1273, DOI 10.1093/oxfordjournals.jbchem.a135178; PHILLIPSON BE, 1985, NEW ENGL J MED, V312, P1210, DOI 10.1056/NEJM198505093121902; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; RUSTAN AC, 1992, BIOCHEM J, V283, P333, DOI 10.1042/bj2830333; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; THOMASSEN MS, 1982, BIOCHEM J, V206, P195, DOI 10.1042/bj2060195; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VUDAC N, 1994, J BIOL CHEM, V269, P31012; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	55	68	68	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17167	17173		10.1074/jbc.271.29.17167	http://dx.doi.org/10.1074/jbc.271.29.17167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663275	hybrid			2022-12-25	WOS:A1996UX94300031
J	Ewart, KV; Yang, DSC; Ananthanarayanan, VS; Fletcher, GL; Hew, CL				Ewart, KV; Yang, DSC; Ananthanarayanan, VS; Fletcher, GL; Hew, CL			Ca2+-dependent antifreeze proteins - Modulation of conformation and activity by divalent metal ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; LIGAND-BINDING; POLYPEPTIDE; LECTINS; FISH; RAT; SIMILARITY; RECEPTOR; DOMAIN	The antifreeze proteins (AFPs) are structurally diverse molecules that share an ability to bind to ice crystals and inhibit their growth, The type II fish AFPs of Atlantic herring and smelt are unique among known AFPs in their requirement of a cofactor for antifreeze activity. These AFPs are homologous with the carbohydrate-recognition domains of Ca2+-dependent (C-type) lectins and require Ca2+ for their activity. To investigate the role of metal ions in the structure and function of type II AFPs, the binding of Ca2+ and other divalent cations to herring AFP was investigated. Binding studies using Ca-45(2+) demonstrated that the AFP has a single Ca2+-binding site with a K-d of 9 mu M. Proteolysis protection studies and measurement of antifreeze activity revealed a conformational change from a protease-sensitive and inactive apoAFP to a protease resistant active AFP upon Ca2+ binding. Other divalent metal ions including Mn2+, Ba2+, and Zn2+ bind at the Ca2+-binding site and induce a similar change. A saturatable increase in tryptophan emission intensity at 340 nm also occurred upon Ca2+ addition, Whereas antifreeze activity appeared normal when Ca2+ or Mn2+ were bound, it was much lower in the presence of other metal ions. When Ba2+ was bound to the AFP, ice crystals showed a distinct difference in morphology. These studies demonstrate that herring AFP specifically binds Ca2+ and, consequently, adopts a conformation that is essential for its ice binding activity.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5G 1L5,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA; MEM UNIV NEWFOUNDLAND,CTR OCEAN SCI,ST JOHNS,NF A1C 5S7,CANADA; MEM UNIV NEWFOUNDLAND,DEPT BIOL,ST JOHNS,NF A1C 5S7,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; Memorial University Newfoundland; Memorial University Newfoundland			Hew, Choy Leong/I-1501-2012	Hew, Choy Leong/0000-0002-9441-0064				Ananthanarayanan VS, 1989, LIFE CHEM REPORTS, V7, P1; ANOSTARIO M, 1995, J BIOL CHEM, V270, P8138, DOI 10.1074/jbc.270.14.8138; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; Ewart K. Vanya, 1993, Molecular Marine Biology and Biotechnology, V2, P20; EWART KV, 1992, BIOCHEM BIOPH RES CO, V185, P335, DOI 10.1016/S0006-291X(05)90005-3; EWART KV, 1990, CAN J ZOOL, V68, P1652, DOI 10.1139/z90-245; EWART KV, 1993, THESIS MEMORIAL U NE; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; KAO MH, 1986, CAN J ZOOL, V64, P578, DOI 10.1139/z86-085; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LOEB JA, 1988, J BIOL CHEM, V263, P9752; MARTIN RL, 1989, J BIOL CHEM, V264, P11768; McDonald D. G., 1992, P55; NG NFL, 1992, J BIOL CHEM, V267, P16069; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; SONNICHSEN FD, 1995, PROTEIN SCI, V4, P460; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	27	48	48	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16627	16632		10.1074/jbc.271.28.16627	http://dx.doi.org/10.1074/jbc.271.28.16627			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663288	hybrid			2022-12-25	WOS:A1996UX12600034
J	Morris, JK; Richards, JS				Morris, JK; Richards, JS			An E-box region within the prostaglandin endoperoxide synthase-2 (PGS-2) promoter is required for transcription in rat ovarian granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; DEPENDENT PROTEIN-KINASE; PREOVULATORY FOLLICLES; H SYNTHASE; REGULATORY SUBUNIT; ENZYME EXPRESSION; COMPLEMENTARY-DNA; G/H SYNTHASE; GENE; OVULATION	The prostaglandin endoperoxide synthase-2 (PGS-2) gene encodes an isoform of prostaglandin synthase that is transiently induced by protein kinase A (luteinizing hormone/cAMP) and protein kinase C (gonadotropin-releasing hormone) agonists in granulosa cells of ovulating follicles. The promoter of the rat PGS-2 gene contains a CAAT enhancer-binding protein consensus site (CAAT box) which can confer hormone inducibility to a PGS-2-CAT reporter gene, as well as a putative E-box region. To determine if the E-box region was involved in hormone induced trans-activation of the rat PGS-2 gene, constructs with the CAAT box and E-box regions (-192 PGS-2-CAT), only the putative E-box (-110 PGS-2 CAT), or neither region (-52 PGS-2-CAT) were transiently transfected into rat granulosa cell cultures. CAT activity was induced in both the -192 and -110 PGS-S-CAT vectors by luteinizing hormone (10-fold) and gonadotropin releasing hormone (6-fold), whereas CAT activity of the -52 PGS-S-CAT construct did not differ from the promoterless vector (pCAT-Basic). Deletion of 1 base pair from the E-box within the -110 PGS-S CAT construct, as well as point mutations within the CAAT box, E-box, or both regions of the -192 PGS-S CAT construct, demonstrated that the E-box is critical for basal transcription, and that regions, in addition to the CAAT box, are involved in hormone induction of the PGS-S gene. An oligonucleotide spanning the rat PGS-2 E-box bound two specific protein complexes which were supershifted in the presence of antibody specific for the upstream stimulatory factor. Thus, in rat granulosa cells, the PGS-2 E-box region appears to interact with upstream cis-acting elements other than the CAAT box to confer hormonal regulation of the gene. The E-box region of the rat PGS-2 promoter does not contain ATF/CRE activity found in the human and mouse PGS-2 promoters, but is critical for basal transcription of the PGS-2 gene in rat granulosa cells and binds the upstream stimulatory factor (as do E-box regions of other genes regulated in the ovary).			Morris, JK (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			Morris, Jacqueline/0000-0002-3515-0821	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165, R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229, R56HD016229] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16229, HD-07165] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AINSWORTH L, 1979, BIOL REPROD, V21, P401, DOI 10.1095/biolreprod21.2.401; ARMSTRONG DT, 1972, PROSTAGL, V1, P21, DOI 10.1016/0090-6980(72)90062-7; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Espey Lawrence L., 1994, P725; ESPEY LL, 1982, PROSTAGLANDINS, V23, P329, DOI 10.1016/0090-6980(82)90078-8; ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOETZ TL, 1995, BIOL REPROD S1, V50, P98; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LAU IF, 1974, J REPROD FERTIL, V40, P467, DOI 10.1530/jrf.0.0400467; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MORIS JK, 1995, ENDOCRINOLOGY, V136, P1549; MORRIS JK, 1993, ENDOCRINOLOGY, V133, P770, DOI 10.1210/en.133.2.770; NATRAJ U, 1993, ENDOCRINOLOGY, V133, P761, DOI 10.1210/en.133.2.761; NOMURA M, 1995, J BIOL CHEM, V270, P7453, DOI 10.1074/jbc.270.13.7453; OGRADY JP, 1972, PROSTAGLANDINS, V2, P1; ORCZYK GP, 1972, PROSTAGL, V1, P3, DOI 10.1016/0090-6980(72)90061-5; RATOOSH SL, 1985, ENDOCRINOLOGY, V117, P917, DOI 10.1210/endo-117-3-917; RICHARDS JS, 1980, PHYSIOL REV, V60, P51, DOI 10.1152/physrev.1980.60.1.51; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; Sambrook J., 2002, MOL CLONING LAB MANU; SINGH IS, 1994, MOL ENDOCRINOL, V8, P1163, DOI 10.1210/me.8.9.1163; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TILLY JL, 1992, ENDOCRINOLOGY, V130, P1296, DOI 10.1210/en.130.3.1296; TSAFRIRI A, 1972, PROSTAGL, V2, P1, DOI 10.1016/0090-6980(72)90024-X; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YOKAYAMA C, 1988, FEBS LETT, V231, P347; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	65	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16633	16643		10.1074/jbc.271.28.16633	http://dx.doi.org/10.1074/jbc.271.28.16633			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663219	hybrid			2022-12-25	WOS:A1996UX12600035
J	Ohshima, K; Kang, S; Larson, JE; Wells, RD				Ohshima, K; Kang, S; Larson, JE; Wells, RD			Cloning, characterization, and properties of seven triplet repeat DNA sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERCOILED DNA; REPLICATION; PLASMIDS; HELIX; ACCOUNTS; TRACTS; INVIVO; CELLS	Several neuromuscular and neurodegenerative diseases are caused by genetically unstable triplet repeat sequences (CTG . CAG, CGG . CCG, or AAG . CTT) in or near the responsible genes. We implemented novel cloning strategies with chemically synthesized oligonucleotides to clone seven of the triplet repeat sequences (GTA . TAC, GAT . ATC, GTT . AAC, CAC . GTG, AGG . CCT, TCG . CGA, and AAG . CTT), and the adjoining paper (Ohshima, K., hang, S., Larson, J. E., and Wells, R. D. (1996) J. Biol. Chem. 271, 16784-16791) describes studies on TTA . TAA. This approach in conjunction with in vivo expansion studies in Escherichia coli enabled the preparation of at least 81 plasmids containing the repeat sequences with lengths of similar to 16 up to 158 triplets in both orientations with varying extents of polymorphisms. The inserts were characterized by DNA sequencing as well as DNA polymerase pausings, two-dimensional agarose gel electrophoresis, and chemical probe analyses to evaluate the capacity to adopt negative supercoli induced non-B DNA conformations. AAG . CTT and AGG . CCT form intramolecular triplexes, and the other five repeat sequences do not form any previously characterized non-B structures. However, long tracts of TCG . CGA showed strong inhibition of DNA synthesis at specific loci in the repeats as seen in the cases of CTG . CAG and CGG . CCG (Kang, S., Ohshima, K., Shimizu, M., Amirhaeri, S., and Wells, R. D. (1995) J. Biol. Chem. 270, 27014-27021). This work along with other studies (Wells, R. D. (1996) J. Biol. Chem. 271, 2875-2878) on CTG . CAG, CGG . CCG, and TTA . TAA makes available long inserts of all 10 triplet repeat sequences for a variety of physical, molecular biological, genetic, and medical investigations, A model to explain the reduction in mRNA abundance in Friedreich's ataxia based on intermolecular tripler formation is proposed.	TEXAS A&M UNIV, TEXAS MED CTR,CTR GENOME RES, DEPT BIOCHEM & BIOPHYS,INST BIOSCI & TECHNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; BOWATER RP, 1994, NUCLEIC ACIDS RES, V22, P2042, DOI 10.1093/nar/22.11.2042; BRINTON BT, 1991, J BIOL CHEM, V266, P5153; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; DAVIES KE, 1993, GENOME ANAL, V7; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EICHLER EE, 1995, HUM MOL GENET, V4, P2199, DOI 10.1093/hmg/4.12.2199; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1995, CELL, V81, P533; GAO XL, 1995, J AM CHEM SOC, V117, P8883, DOI 10.1021/ja00139a035; GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; Haaf T, 1996, NAT GENET, V12, P183, DOI 10.1038/ng0296-183; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KOCH KS, 1995, NUCLEIC ACIDS RES, V23, P1098, DOI 10.1093/nar/23.7.1098; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; KRAHE R, 1995, HYPERVARIABLE GENETI, P29; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LAFLEUR GJ, 1995, J MOL EVOL, V41, P505, DOI 10.1007/BF00160323; LANZ RB, 1995, NUCLEIC ACIDS RES, V23, P138, DOI 10.1093/nar/23.1.138; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LINDBLAD K, 1994, NAT GENET, V7, P124, DOI 10.1038/ng0694-124; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; RICKE DO, 1995, GENOMICS, V26, P5210; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STALLINGS RL, 1994, GENOMICS, V21, P116, DOI 10.1006/geno.1994.1232; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WEISMANSHOMER P, 1989, BIOCHEM BIOPH RES CO, V164, P1149, DOI 10.1016/0006-291X(89)91789-0; WELLS RD, 1977, CRC CR REV BIOCH MOL, V4, P305, DOI 10.3109/10409237709102561; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WELLS RD, 1969, SCIENCE, V165, P75, DOI 10.1126/science.165.3888.75; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; ZHONG N, 1995, AM J HUM GENET, V57, P351	75	84	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16773	16783		10.1074/jbc.271.28.16773	http://dx.doi.org/10.1074/jbc.271.28.16773			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663377	hybrid			2022-12-25	WOS:A1996UX12600056
J	Pryzdial, ELG; Kessler, GE				Pryzdial, ELG; Kessler, GE			Autoproteolysis or plasmin-mediated cleavage of factor Xa alpha exposes a plasminogen binding site and inhibits coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-X; FACTOR-VA; ACTIVE-SITE; ACTIVATION; PROTEINS; SURFACE; PROTHROMBINASE; MECHANISM; PATHWAYS; CELLS	Blood coagulation factor Xa (FXa) has recently been shown to function as a plasminogen receptor in the presence of procoagulant phospholipid (phosphatidylserine; PS) and Ca2+. In the current work, the possible effect of autoproteolytic and plasmin-mediated cleavage of FXa on complex formation with plasminogen was investigated. I-125-plasminogen binding to derivatives of FXa electrotransferred to polyvinylidene difluoride revealed that the autoproteolytic conversion of FXa alpha to FXa beta was required for the expression of a plasminogen binding site. In the presence of PS and Ca2+, plasmin was shown to convert FXa alpha to a FXa beta-like species at least 3 orders of magnitude faster than the autoproteolytic mechanism. This also resulted in the exposure of a plasminogen binding site, Further processing by plasmin generated a fragment (33 kDa) due to cleavage at Gly(331) in, the FXa heavy chain. Production of this species enhanced apparent plasminogen binding compared with FXa beta and resulted in the loss of FXa amidolytic and clotting activity. In the absence of either PS or Ca2+, the plasmin mediated fragmentation of FXa alpha was altered to include a FXa beta-like molecule and a species (40 kDa) with intact beta-heavy chain disulfide linked to a COOH-terminal fragment of the light chain starting at Tyr(44). Neither of these products was observed to interact with plasminogen. The 40 kDa species had amidolytic activity comparable with FXa alpha but inhibited clotting activity. Cumulatively the data provide the first evidence for a functional difference between the FXa subforms and suggest a mechanism where autoproteolysis and plasmin-mediated cleavage modulate the function of FXa alpha from a procoagulant enzyme to a profibrinolytic plasminogen receptor.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1G 4J5,CANADA	University of Ottawa	Pryzdial, ELG (corresponding author), UNIV OTTAWA,CANADIAN RED CROSS SOC,RES DEPT,OTTAWA,ON K1G 4J5,CANADA.							BAJAJ SP, 1981, PREP BIOCHEM, V11, P387; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; DUDANI AK, 1993, THROMB RES, V69, P185, DOI 10.1016/0049-3848(93)90044-O; EBY CS, 1992, BLOOD S, V80, P306; FUJIKAWA K, 1975, P NATL ACAD SCI USA, V72, P3359, DOI 10.1073/pnas.72.9.3359; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HAJJAR KA, 1994, HEMOSTASIS THROMBOSI, P823; HOJRUP P, 1987, BIOCHEM J, V245, P887, DOI 10.1042/bj2450887; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JESTY J, 1974, J BIOL CHEM, V249, P5614; Jesty J, 1976, Methods Enzymol, V45, P95; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KRISHNASWAMY S, 1994, METHOD ENZYMOL, V222, P260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LINK RP, 1982, ARCH BIOCHEM BIOPHYS, V215, P215, DOI 10.1016/0003-9861(82)90297-1; Mann K.G., 1987, THROMB DIATH HAEMO, P505; MANN KG, 1990, BLOOD, V76, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OMAR MN, 1987, J BIOL CHEM, V262, P9720; PACKHAM MA, 1984, BLOOD PLATELET FUNCT, P61; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PRYZDIAL ELG, 1987, J BIOL CHEM, V262, P1519; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; PRYZDIAL ELG, 1995, J BIOL CHEM, V270, P1871; RADCLIFFE RD, 1972, J BIOL CHEM, V247, P7735; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	43	26	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16614	16620		10.1074/jbc.271.28.16614	http://dx.doi.org/10.1074/jbc.271.28.16614			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663221	hybrid			2022-12-25	WOS:A1996UX12600032
J	Yamamoto, H; Ueno, H; Ooshima, A; Takeshita, A				Yamamoto, H; Ueno, H; Ooshima, A; Takeshita, A			Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-beta) type II receptor completely and specifically abolishes diverse signaling by TGF-beta in vascular wall cells in primary culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; EXPRESSION; INHIBITION; CLONING; FACTOR-BETA-1; TRANSDUCTION; COMPLEX; REVEALS; MUTANT; FORM	We constructed an adenoviral vector expressing a mutated human type II transforming growth factor-beta (TGF-beta) receptor that was truncated of its kinase domain (AdexCAT beta TR) and examined whether this truncated receptor could abolish signaling by TGF-beta using arterial endothelial cells and smooth muscle cells, as well as a lung epithelial cell line (Mv1Lu). Infection of cells with AdexCAT beta TR induced expression of the truncated receptor, the amount of which would be excessive compared with those of both full length type I and type II receptors, as assessed by levels of their mRNAs. The antiproliferative effect of TGF-beta was completely eliminated in both endothelial cells and Mv1Lu that were infected with AdexCAT beta TR, The transcriptional activation by TGF-beta of plasminogen activator inhibitor-1 and fibronectin was entirely suppressed. Abrogation of the TGF-beta-enhanced production of type I collagen in infected smooth muscle cells was confirmed by immunocytostaining and by [C-14]proline incorporation in a quantitative manner, Mitogenic response to other growth factors remained unaffected in infected cells, Our data demonstrated that the adenovirus-mediated transfer of a truncated type II TGF-beta receptor completely and specifically abolishes the diverse effects of TGF-beta as a dominant-negative mutation, supporting the hypothesis that both the type I and type II receptors are required for all signaling by TGF-beta. This method may facilitate the clarification of the role of TGF-beta both in vitro and in vivo.	KYUSHU UNIV,SCH MED,DEPT CARDIOL,RES INST ANGIOCARDIOL,MOL CARDIOL UNIT,FUKUOKA 81282,JAPAN; WAKAYAMA MED COLL,DEPT PATHOL,WAKAYAMA 640,JAPAN	Kyushu University; Wakayama Medical University								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRAND T, 1993, J BIOL CHEM, V268, P11500; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P379, DOI 10.1083/jcb.89.2.379; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; COTTAPEREIRA G, 1980, J CELL PHYSL, V102, P83; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KUMAGAI J, 1994, J ANAT, V185, P279; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LI JJ, 1995, CARDIOVASC RES, V30, P97, DOI 10.1016/S0008-6363(95)00005-4; LI JJ, 1995, GENE THER, V2, P351; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MIMA T, 1995, P NATL ACAD SCI USA, V92, P467, DOI 10.1073/pnas.92.2.467; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROBERTS AB, 1990, TRANSFORMING GROWTH, P421; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	49	82	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16253	16259		10.1074/jbc.271.27.16253	http://dx.doi.org/10.1074/jbc.271.27.16253			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663151	hybrid			2022-12-25	WOS:A1996UW35200058
J	deCrouyChanel, A; Kohiyama, M; Richarme, G				deCrouyChanel, A; Kohiyama, M; Richarme, G			Specificity of DnaK for arginine/lysine and effect of DnaJ on the amino acid specificity of DnaK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; PEPTIDE-BINDING; REPLICATION PROTEIN; CHAPERONE; GRPE; PURIFICATION; AFFINITY; BIP	Molecular chaperones form a class of proteins that bind selectively to nascent, unfolded, misfolded, or aggregated polypeptides and are involved in protein folding, protein targeting to membranes, and protein renaturation after stress, Chaperones70, including the DnaK chaperone of Escherichia coli, interact specifically with peptides enriched in internal hydrophobic residues, with a preference for positively charged peptides, We previously reported that DnaK interacts with the hydrophobic amino acids Ile, Leu, Val, Ala, Phe, Trp, and Tyr. In the present study, we show that DnaK also possesses a specific binding site for the positively charged amino acids arginine and lysine. Furthermore, the binding of arginine and lysine to DnaK is strengthened when its hydrophobic binding sites are occupied, The specificity of DnaK for Arg/Lys is supported by DnaK-peptide binding studies; the homopolypeptides poly-Arg and poly-Lys interact with DnaK, contrasting with other hydrophilic homopolypeptides, and hydrophobic peptides interact more strongly with DnaK if they contain Arg/Lys at their N terminus. Interestingly, the cochaperone DnaJ attenuates the interaction of DnaK with hydrophobic amino acids while strengthening its interaction with arginine or lysine. The interaction of DnaK with both hydrophobic sequences and with arginine and lysine, and its modulation by DnaJ, may have important implications in both protein folding and protein insertion into membranes.	UNIV PARIS 07, INST JACQUES MONOD, F-75005 PARIS, FRANCE	UDICE-French Research Universities; Universite Paris Cite								BIN W, 1992, J BACTERIOL, V174, P5258, DOI 10.1128/JB.174.16.5258-5264.1992; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; CYR DM, 1994, J BIOL CHEM, V269, P9798; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DECROUYCHANEL A, 1995, J BIOL CHEM, V270, P10571, DOI 10.1074/jbc.270.18.10571; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MEURY J, 1991, J BACTERIOL, V173, P4404, DOI 10.1128/JB.173.14.4404-4410.1991; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RICHARME G, 1993, J BIOL CHEM, V268, P24074; RICHARME G, 1994, J BIOL CHEM, V269, P7095; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	43	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15486	15490		10.1074/jbc.271.26.15486	http://dx.doi.org/10.1074/jbc.271.26.15486			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663088	hybrid			2022-12-25	WOS:A1996UV29900029
J	Grilli, M; Goffi, F; Memo, M; Spano, P				Grilli, M; Goffi, F; Memo, M; Spano, P			Interleukin-1 beta and glutamate activate the NF-kappa B/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ALZHEIMERS-DISEASE; TRANSCRIPTION FACTOR; LYMPHOCYTES-T; EXPRESSION; BRAIN; PROMOTER; CELLS; APP; INDUCTION	We originally reported that members of the family of transcription factors NF-kappa B/Rel can specifically recognize two identical sequences, referred to as APP kappa B sites, which are present in the 5'-regulatory region of the APP gene, Here we show that the APP kappa B sites interact specifically with a complex which contains one of the subunits of the family, defined as p50 protein, and that they act as positive modulators of gene transcription in cells of neural origin, Additionally, the nuclear complex specifically binding to the APP kappa B sites is constitutively expressed in primary neurons from rat cerebellum and it is up-regulated in response to both the inflammatory cytokine interleukin-1 beta (IL-1 beta) and the excitatory amino acid glutamate. Since IL-1, whose levels are known to be induced in brain of individuals affected by Alzheimer's disease, and glutamate, are stimuli which have been regarded as major actors on the stage of neurodegenerative processes, we believe our evidence as potentially relevant for understanding the neuropathology associated with Alzheimer's disease.			Grilli, M (corresponding author), UNIV BRESCIA, SCH MED, DEPT BIOMED SCI & BIOTECHNOL, DIV PHARMACOL, VIA VALSABBINA 19, I-25124 BRESCIA, ITALY.		grilli, mariagrazia/ABF-1542-2020; Memo, Maurizio/C-2555-2011; Memo, Maurizio/AAK-7197-2020; Spano, Pier Franco F/J-9944-2016; Spano, Pier Franco A/E-7621-2010	grilli, mariagrazia/0000-0001-9165-5827; Spano, Pier Franco F/0000-0002-9906-0964; MEMO, Maurizio/0000-0002-7543-0289				ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GRILLI M, 1995, J BIOL CHEM, V270, P26774, DOI 10.1074/jbc.270.45.26774; GRILLI M, 1993, INT REV CYTOL, V143, P1; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOVACS DM, 1995, HUM MOL GENET, V4, P1527, DOI 10.1093/hmg/4.9.1527; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; POLLWEIN P, 1992, NUCLEIC ACIDS RES, V20, P63, DOI 10.1093/nar/20.1.63; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; TREJO J, 1994, J BIOL CHEM, V269, P21682; VALERIO A, 1995, NEUROREPORT, V6, P1317, DOI 10.1097/00001756-199506090-00022; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	44	126	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15002	15007		10.1074/jbc.271.25.15002	http://dx.doi.org/10.1074/jbc.271.25.15002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663145	hybrid			2022-12-25	WOS:A1996UT10600056
J	Jouni, ZE; Wells, MA				Jouni, ZE; Wells, MA			Purification and partial characterization of a lutein-binding protein from the midgut of the silkworm Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN; CANTHAXANTHIN-LIPOVITELLIN; BLUE CAROTENOPROTEIN; CIRCULAR-DICHROISM; CRUSTACEA; ANOSTRACA	A lutein-binding protein was purified from fifth instar larval midgut of Bombyx mori by a combination of ammonium sulfate fractionation and three chromatographic procedures, gel filtration, chromatofocusing, and anion exchange chromatography. The protein has a pi of 5.4 and an apparent molecular mass of 35,000 Da, as determined by a linear gradient SDS-polyacrylamide gel electrophoresis. The lutein-protein complex is water-soluble and more stable than the carotenoid or protein alone. The carotenoid moiety was identified by thin layer chromatography, light absorption spectroscopy, and high performance liquid chromatography as all-trans-lutein. Lutein is specifically and stoichiometrically bound to the protein, with a ratio of 3 mol of lutein per mol of protein. Binding of lutein (absorption maxi mum in hexane at 454 nm) to the apoprotein results in a marked red spectral shift of about 38 nm, giving rise to absorption maxima at 432, 462, and 492 nm in 20 mM Tris-HCl, pH 7.0. The lutein-protein complex is characterized by fine spectral structure indicating that lutein is in a relatively rigid environment. This protein is distributed in equal amounts throughout the midgut and in all developmental stages of the larval B. mori.			Jouni, ZE (corresponding author), UNIV ARIZONA,DEPT BIOCHEM,POB 210066,BIOL SCI W,TUCSON,AZ 85721, USA.				NIGMS NIH HHS [GM50008] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050008] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Britton G., 1982, CAROTENOID CHEM BIOC, P237; BRYANT JD, 1992, J AGR FOOD CHEM, V40, P545, DOI 10.1021/jf00016a003; BUCHWALD M, 1968, BIOCHEMISTRY-US, V7, P844, DOI 10.1021/bi00842a043; CHINO H, 1969, BIOCHIM BIOPHYS ACTA, V176, P1; FUJII H, 1988, Journal of Sericultural Science of Japan, V57, P94; GARATE AM, 1986, BIOCHIM BIOPHYS ACTA, V881, P446, DOI 10.1016/0304-4165(86)90038-3; GILBERT LI, 1974, J LIPID RES, V15, P439; GOODWIN TW, 1953, BIOCHEM J, V55, P834, DOI 10.1042/bj0550834; HARASHIMA K, 1972, INSECT BIOCHEM, V2, P29, DOI 10.1016/0020-1790(72)90064-9; KAWAI N, 1976, J INSECT PHYSIOL, V22, P207, DOI 10.1016/0022-1910(76)90027-5; Kayser H., 1985, P367; KAYSER H, 1975, INSECT BIOCHEM, V5, P861, DOI 10.1016/0020-1790(75)90031-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RACUSEN D, 1979, ANAL BIOCHEM, V99, P474, DOI 10.1016/S0003-2697(79)80035-4; RIVAS JDL, 1988, COMP BIOCHEM PHYS B, V89, P65, DOI 10.1016/0305-0491(88)90262-3; SALARES VR, 1979, BIOCHIM BIOPHYS ACTA, V576, P176, DOI 10.1016/0005-2795(79)90496-3; SALARES VR, 1977, J RAMAN SPECTROSC, V6, P282, DOI 10.1002/jrs.1250060605; SHAPIRO JP, 1984, ANNU REV ENTOMOL, V23, P297; SHONE CC, 1978, COMP BIOCH PHYSL, V62, P507; TAZIMA Y, 1978, SILKWORM IMPORTANT L, P53; TERRA WR, 1981, COMP BIOCHEM PHYS B, V68, P89, DOI 10.1016/0305-0491(81)90184-X; WEESIE RJ, 1995, FEBS LETT, V362, P34, DOI 10.1016/0014-5793(95)00191-B; YOSHIDA H, 1992, J LIPID RES, V33, P343; ZAGALSKY PF, 1976, PURE APPL CHEM, V47, P103, DOI 10.1351/pac197647020103; ZAGALSKY PF, 1983, COMP BIOCHEM PHYS B, V74, P647, DOI 10.1016/0305-0491(83)90244-4; ZAGALSKY PF, 1989, COMP BIOCHEM PHYS B, V93, P339, DOI 10.1016/0305-0491(89)90090-4; ZAGALSKY PF, 1983, COMP BIOCHEM PHYS B, V75, P163, DOI 10.1016/0305-0491(83)90055-X	29	43	50	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14722	14726		10.1074/jbc.271.25.14722	http://dx.doi.org/10.1074/jbc.271.25.14722			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663050				2022-12-25	WOS:A1996UT10600016
J	Kim, DK; Stigger, E; Lee, SH				Kim, DK; Stigger, E; Lee, SH			Role of the 70-kDa subunit of human replication protein A .1. Single-stranded DNA binding activity, but not polymerase stimulatory activity, is required for DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; ALPHA-PRIMASE; T-ANTIGEN; DELTA; INVITRO; CELLS	Replication protein A (RPA), also known as human single-stranded DNA-binding protein, is a three-subunit protein complex with multiple functions. Here, we investigated the role of the 70-kDa RPA subunit (p70) in DNA replication, by generating a series of deletion mutants. Mutant p70, which lacked 50 amino acids at the C-terminus, failed to interact with the 11-kDa RPA subunit (p11) and, when deleted further at the C terminus, was unable to interact with either the 34-kDa subunit (p54) or with pll, suggesting that p70 directly interacts with both p34 and pll. Studies with purified RPA mutants indicated that deletions at the N-terminal domain of p70 had very little effect on RPA's single-stranded DNA (ssDNA) binding activity, whereas deletion of amino acids 169-246 significantly weakened the DNA binding ability of RPA. By deleting amino acids 296-373 or 374-458, we totally abolished p70's ssDNA binding activity, suggesting that multiple p70 domains are involved in DNA binding. Two p70 domains, the N-terminal domain and the DNA binding domain, were required to stimulate DNA polymerase (pol) alpha, yet the DNA binding domain alone supported pol delta activity. Interestingly, RPA containing p70 with a zinc-finger domain deletion retained its DNA binding activity, but inhibited pol alpha and delta activity. RPA that lacked ssDNA binding activity failed to support simian virus 40 (SV40) DNA replication in vitro, whereas mutant RPA that lacked pol alpha stimulatory activity (including the zinc-finger p70 mutant) functioned normally. We conclude that RPA's DNA binding activity, but not its pol alpha stimulatory activity, is required for DNA replication.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital					NCI NIH HHS [5P30 CA 21765] Funding Source: Medline; NIGMS NIH HHS [1RO1 GM52358] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROWN GW, 1993, MOL BIOCHEM PARASIT, V59, P323, DOI 10.1016/0166-6851(93)90230-U; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LEE SH, 1991, J BIOL CHEM, V266, P594; LEE SH, 1993, NUCLEIC ACIDS RES, V21, P1935, DOI 10.1093/nar/21.8.1935; LI L, 1995, MOL CELL BIOL, V15, P5396; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	30	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15124	15129		10.1074/jbc.271.25.15124	http://dx.doi.org/10.1074/jbc.271.25.15124			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663111	hybrid			2022-12-25	WOS:A1996UT10600071
J	Silvente-Poirot, S; Wank, SA				Silvente-Poirot, S; Wank, SA			A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; NEUROKININ-1 RECEPTOR; BINDING; SPECIFICITY; DOMAINS; ASSAY	The two known receptors mediating the actions of cholecystokinin (CCK) and gastrin, CCK type A (CCKAR) and CCK type B (CCKBR) receptors, are G protein coupled receptors having approximately 50% amino acid homology. Both the CCKAR and CCKBR have high affinity for sulfated CCK peptides, while only the CCKBR has high affinity for gastrin peptides. To determine the structural basis for the selectivity of the CCKBR for gastrin, we first constructed a series of CCKB/AR chimeras in which restriction endonuclease-defined segments of the CCKBR were replaced with the corresponding segments of the CCKAR. Chimeras transiently expressed in COS-1 cells were screened for the selective loss of gastrin affinity according to the displacement of I-125-labeled Bolton-Hunter-CCK-8 binding by gastrin-17-I and CCK-8. The sequence spanning from transmembrane domain III (TM III) to TM. V was the only segment that resulted in the selective loss of gastrin affinity. This segment could account for 100 of the expected 300-fold lower affinity of gastrin-17-I observed for the control CCKAR compared to the control CCKBR. Using site-directed mutagenesis in this segment of the CCKBR, we identified a sequence of 5 amino acids in the second extracellular loop responsible for this 100 fold selective loss in gastrin affinity, I-125-labeled Bolton-Hunter-CCK-8 binding displacement by L365,260 (a CCKBR selective antagonist) was unaffected by the changes in these 5 amino acids. These results present for the first time the identification of the amino acid sequence of the CCKBR conferring the majority of the selectivity for gastrin.	NIDDK, DIGEST DIS BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Poirot, Sandrine/D-5448-2017	Silvente-Poirot, Sandrine/0000-0003-2245-9069				ADACHI M, 1993, J CARDIOVASC PHARM, V22, pS121, DOI 10.1097/00005344-199322008-00033; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CHANG RSL, 1986, BIOCHEM BIOPH RES CO, V134, P895, DOI 10.1016/S0006-291X(86)80504-6; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FITZPATRICK VD, 1994, J BIOL CHEM, V269, P24621; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GETHER U, 1993, J BIOL CHEM, V268, P7893; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; SAITO A, 1981, J NEUROCHEM, V37, P483, DOI 10.1111/j.1471-4159.1981.tb00481.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; WANG JB, 1994, J BIOL CHEM, V269, P25966; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691	34	57	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14698	14706		10.1074/jbc.271.25.14698	http://dx.doi.org/10.1074/jbc.271.25.14698			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663021	hybrid			2022-12-25	WOS:A1996UT10600012
J	Trejo, SR; Fahl, WE; Ratner, L				Trejo, SR; Fahl, WE; Ratner, L			c-sis/PDGF-B promoter transactivation by the tax protein of human T-cell leukemia virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I TRANSCRIPTIONAL ACTIVATOR; LONG TERMINAL REPEAT; SIMIAN SARCOMA-VIRUS; HTLV-I; GROWTH-FACTOR; GENE-EXPRESSION; DNA-BINDING; V-SIS; 21-BASE-PAIR REPEATS; HUMAN MEGAKARYOCYTES	The human c-sis proto-oncogene promoter is transactivated by the human T-cell leukemia virus type 1 Tax protein in human Jurkat T-cells, Transactivation was > 7-fold in Jurkat cells stably expressing the Tax protein (Jurkat-Tax) than in Jurkat E6.1 cells and was further enhanced in Jurkat-Tax cells stimulated with 12-O-tetradecanoylphorbol-13-acetate and the calcium ionophore, ionomycin. Deletion analysis showed that a 167-base pair promoter fragment retained full Tax responsiveness. Insertion of this minimal Tax-responsive region into a heterologous, minimal promoter resulted in approximately a 7-fold increase of transcriptional activation in the presence of Tax. Linker scanning insertion analysis of this region identified Tax-responsive elements at nucleotides -64 to -45 (TRE1) and -34 to -15 (TATA box region). TRE1 contains a consensus binding site for the Sp family of transcription factors. The TATA box region corresponds to the TATA box and its 3'-neighboring sequence, Gel-shift and antibody supershift analysis of TRE1-binding proteins in unstimulated Jurkat E6.1 and Jurkat-Tax nuclear extracts identified Spl and Sp3 as the main TRE1 binding factors. Nuclear extracts from stimulated Jurkat E6.1 and Jurkat Tax cells identified an additional TRE1 binding factor, Egr-1. These studies define a novel mechanism whereby Tax transactivates the c-sis promoter.	WASHINGTON UNIV, SCH MED, DIV MOLEC ONCOL, ST LOUIS, MO 63110 USA; UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison				Ratner, Lee/0000-0003-2744-7294	NATIONAL CANCER INSTITUTE [R01CA063417] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NCI NIH HHS [CA63417] Funding Source: Medline; NHLBI NIH HHS [5 T32 HL07088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOUD HE, 1987, J CLIN INVEST, V80, P675, DOI 10.1172/JCI113121; ALITALO R, 1987, EMBO J, V6, P1213, DOI 10.1002/j.1460-2075.1987.tb02356.x; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1989, J IMMUNOL, V142, P672; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GLADWIN AM, 1990, BRIT J HAEMATOL, V76, P333, DOI 10.1111/j.1365-2141.1990.tb06364.x; Goustin AS, 1990, GROWTH FACTORS, V2, P189, DOI 10.3109/08977199009071505; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KILBOURNE EJ, 1995, J BIOL CHEM, V270, P7004, DOI 10.1074/jbc.270.12.7004; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NIMER SD, 1989, ONCOGENE, V4, P671; NIMER SD, 1991, ONCOGENE, V2, P1034; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PANTAZIS P, 1987, ONCOGENE, V1, P285; RATNER L, 1987, NUCLEIC ACIDS RES, V15, P6017, DOI 10.1093/nar/15.15.6017; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; RATNER L, 1988, MEDICINE, V67, P401, DOI 10.1097/00005792-198811000-00004; ROSS R, 1978, CELL, V14, P203, DOI 10.1016/0092-8674(78)90107-1; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; THIELAN BJ, 1987, J GEN VIROL, V68, P2265, DOI 10.1099/0022-1317-68-8-2265; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; YU CY, 1991, J BIOL CHEM, V266, P8907; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	65	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14584	14590		10.1074/jbc.271.24.14584	http://dx.doi.org/10.1074/jbc.271.24.14584			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662878	hybrid			2022-12-25	WOS:A1996UQ66000095
J	Ventura, F; Liu, F; Doody, J; Massague, J				Ventura, F; Liu, F; Doody, J; Massague, J			Interaction of transforming growth factor-beta receptor I with farnesyl-protein transferase-alpha, in yeast and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING; KINASE; FARNESYLTRANSFERASE; EXPRESSION; COMPLEX; SUBUNIT	Transforming growth factor beta (TGF-beta) signals through two transmembrane serine/threonine kinases, known as T beta R-I and T beta R-II. Several lines of evidence suggest that T beta R-II acts as a primary receptor, binding TGF-beta and phosphorylating T beta R-I whose kinase activity then propagates the signal to unknown substrates. We report an interaction between T beta R-I and the farnesyl-protein transferase-alpha subunit (FT-alpha) both in a yeast two-hybrid system and in mammalian cells. These findings raise the possibility that TGF-beta might regulate cellular functions by altering the ability of FT-alpha to catalyze isoprenylation of targets such as G proteins, lamins, or cytoskeletal components, However, we provide evidence that TGF-beta action does not alter the overall protein isoprenyl transferase activity in Mv1Lu mink lung epithelial cells, In fact, the beta subunits of farnesyl transferase and geranylgeranyl transferase, which are necessary for the activity of FT-alpha, prevent the association of FT-alpha with T beta R-I, Furthermore, farnesyl transferase activity is shown to be dispensable for TGF-beta signaling of growth inhibitory and transcriptional responses in these cells, These results suggest that the interaction between T beta R-I and FT-alpha does not affect the known functions of these two proteins.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Ventura, Francesc/ABG-2285-2020; Ventura, Francesc/K-9700-2014	Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Ausubel FM, 1992, CURRENT PROTOCOLS MO; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	28	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13931	13934		10.1074/jbc.271.24.13931	http://dx.doi.org/10.1074/jbc.271.24.13931			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663177	Green Published, hybrid			2022-12-25	WOS:A1996UQ66000002
J	Zhuang, P; Li, H; Williams, JG; Wagner, NV; Seiffert, D; Peterson, CB				Zhuang, P; Li, H; Williams, JG; Wagner, NV; Seiffert, D; Peterson, CB			Characterization of the denaturation and renaturation of human plasma vitronectin .2. Investigation into the mechanism of formation of multimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING PROPERTIES; SERUM SPREADING FACTOR; HUMAN S-PROTEIN; ANTITHROMBIN-III; PURIFICATION; EXPRESSION; COMPLEMENT; THROMBIN; UREA; ACID	Unfolding and refolding of plasma vitronectin appear irreversible under near physiological conditions, with rearrangements of disulfides and self-association to a multimeric form observed as prominent structural alterations which accompany denaturation. A mechanism for the folding reactions of vitronectin has been proposed (Zhuang, P., Blackburn, M. N., and Peterson, C. B. (1996) J. Biol. Chem. 270, 14323-14332) in which vitronectin acquires a partially folded intermediate structure which is highly prone to oligomerize into a multimeric form. Strongly oxidizing conditions adopted for refolding from urea were effective at preventing disulfide rearrangement which disrupts distal disulfides near the C terminus of the protein. Prohibiting disulfide rearrangement under these conditions, however, was not sufficient to achieve reversibility in folding. In contrast, variations in the ionic strength of the refolding medium affect the partitioning of species so that refolded monomers are obtained at high ionic strength, and self-association is precluded. The effects of ionic strength on the partially folded intermediate in the vitronectin folding pathway appear to favor intramolecular hydrophobic collapse to form a stable hydrophobic core for the monomer versus intermolecular hydrophobic interactions which stabilize multimeric vitronectin. Although both ionic and hydrophobic interactions presumably contribute to subunit interfaces within the multimer, the basic heparin-binding region near the C terminus of the protein does not provide binding interactions which are important for self-association of vitronectin.	UNIV TENNESSEE, DEPT BIOCHEM & CELLULAR & MOLEC BIOL, KNOXVILLE, TN 37996 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	University of Tennessee System; University of Tennessee Knoxville; Scripps Research Institute					NHLBI NIH HHS [HL50676, HL50704] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676, R29HL050704] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1985, J BIOL CHEM, V260, P9117; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; HUTH JR, 1993, J BIOL CHEM, V268, P16472; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILIE H, 1994, J BIOL CHEM, V269, P14290; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; PREISSNER KT, 1991, BIOCHEM J, V7, P275; ROBYT JF, 1987, BICOH TECHNIQUES THE; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; ZHAO Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P434, DOI 10.1006/abbi.1993.1372; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	29	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14333	14343		10.1074/jbc.271.24.14333	http://dx.doi.org/10.1074/jbc.271.24.14333			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663085	hybrid			2022-12-25	WOS:A1996UQ66000061
J	Freter, RR; Alberta, JA; Hwang, GY; Wrentmore, AL; Stiles, CD				Freter, RR; Alberta, JA; Hwang, GY; Wrentmore, AL; Stiles, CD			Platelet-derived growth factor induction of the immediate-early gene MCP-1 is mediated by NF-kappa B and a 90-kDa phosphoprotein coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; C-FOS PROMOTER; MULTIPLE SEQUENCE ELEMENTS; FACTOR-INDUCIBLE GENE; 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; PROTO-ONCOGENE; CYCLIC-AMP; JE GENE; IDENTIFICATION	A broad panel of agents including serum, interleukin-1, double-stranded RNA, and platelet-derived growth factor (PDGF) stimulate transcription of the ''slow'' immediate-early gene MCP-1. These disparate inducers act through a tight cluster of regulatory elements in the distal 5'-flanking sequences of the MCP-1 gene, We describe a 22-base element in this cluster which, in single copy, confers PDGF-inducibility to a tagged MCP-1 reporter gene, In mobility shift assays, the element binds a PDGF-activated form of NF-kappa B, and a 90-kDa protein (p90) which binds constitutively, Antibody supershift and UV cross-linking experiments indicate that the PDGF-activated NF-kappa B species is a Rel A homodimer, The DNA binding form of p90 is a nuclear-restricted serine/threonine phosphoprotein. Mutagenesis of the 22-base element shows that the NF-kappa B and p90 binding sites overlap, but binding of the two species is mutually independent, Both sites, however, are required for optimum PDGF induction of MCP-1, Therefore, p90 appears to be a coactivator with NF-kappa B in PDGF-mediated induction of MCP-1.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, DIV CLIN ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DIV CELL & MOLEC BIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL CANCER INSTITUTE [R01CA022042] Funding Source: NIH RePORTER; NCI NIH HHS [CA22042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1989, ONCOGENE RES, V4, P177; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; KELLY K, 1988, J BIOL CHEM, V263, P4828; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAMEH LE, 1992, MOL CELL BIOL, V12, P4612, DOI 10.1128/MCB.12.10.4612; ROLLINS BJ, 1987, SCIENCE, V238, P1269, DOI 10.1126/science.3685976; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1995, HEMATOPOIETIC GROWTH, P357; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; UEDA A, 1994, J IMMUNOL, V153, P2052; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	63	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17417	17424		10.1074/jbc.271.29.17417	http://dx.doi.org/10.1074/jbc.271.29.17417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663287	hybrid			2022-12-25	WOS:A1996UX94300068
J	Gross, M; Hessefort, S; Olin, A; Reddy, G				Gross, M; Hessefort, S; Olin, A; Reddy, G			Extensive sequencing of tryptic peptides of a rabbit reticulocyte 66-kDa protein that promotes recycling of Hsp 70 - Homology to stress-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; OUTER-MEMBRANE; GENE; FAMILY; MITOCHONDRIA; RECEPTOR; CLONING; MITOSIS	Trypsinization and sequence analysis of the 66-kDa rabbit reticulocyte protein (RF-hsp 70), shown in the preceding article to function as a recycling protein for hsp 70, demonstrates striking similarity to the transformation-sensitive human protein IEF SSP 3521 (Honore, B., Leffers, H., Madsen, P., Rasmussen, H. H., Vandekerckhove, J., and Cells, J. E. (1992) J. Biol. Chem. 267, 8485-8491) and mouse extendin (Blatch, G.L., Lassie, M., Takatori, T., Gandhi, T., Kundra, V., and Zetter, B. R. (1995) Proc. Am. Assoc. Cancer Res. 36, 68). The human and mouse proteins share 97% sequence identity, and sequencing of 20 polypeptides (225 residues) from RF-hsp 70 reveals only 10 differences be tween the rabbit and human proteins and 13 differences between the rabbit and mouse proteins (96 and 94% identity, respectively). In addition, all three proteins are of similar size, and each contains 11 cysteines. These findings strongly suggest that these three proteins are homologs of the same activity. All differences (but one) between the human and mouse proteins occur within the amino-terminal half of the protein, and there is only one difference among 121 sequenced residues between RF-hsp 70 and the human or mouse protein which occurs within the carboxyl-terminal 70% of the molecule. In addition, where partial sequences of RF-hsp 70 and p60, a chick oviduct protein that shows 70% identity to the human protein (Smith, D. F., Sullivan, W. P., Marion, T. N., Zaitsu, K., Madden, B., McCormick, D. J., and Toft, D. O., (1993) Mol. Cell. Biol. 13, 869-876), overlap (a total of 54 residues), RF hsp 70 and chick p60 show 78% sequence identity, Studies of the initial digestion of RF-hsp 70 by trypsin indicate that it is first converted to 58- and 54-kDa components, each of which is then converted to a 43-kDa polypeptide. This 43-kDa component is located in the human and mouse proteins at position 124 to about 470. It is converted subsequently to a 31-kDa polypeptide by trypsin hydrolysis at position 207. This 31-kDa component is finally split into 17- and 14-kDa polypeptides that are located at positions 208 to approximately 351 and 352 to approximately 470, respectively. The 14-kDa polypeptide is relatively resistant to further digestion with trypsin, and seven tryptic peptides from other parts of RF-hsp 70 contain internal lysine and/or arginine residues (as do several tryptic peptides produced from IEF SSP 3521 and chick p60). Both features may be due to interference with trypsin action by secondary structure in the protein, since trypsinization of reduced and carboxymethylated RF-hsp 70 results in hydrolysis of the 14-kDa polypeptide and reduces the level of peptides that contain internal lysine and/or arginine, although it does not eliminate them.			Gross, M (corresponding author), UNIV CHICAGO,DEPT PATHOL,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blatch G. L., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P68; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; DOI A, 1990, GENE, V91, P123, DOI 10.1016/0378-1119(90)90172-N; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; GROSS M, 1992, J BIOL CHEM, V267, P2073; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HONORE B, 1992, J BIOL CHEM, V267, P8485; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; ODONNELL KL, 1991, J CELL SCI, V99, P711; RHEE SK, 1989, YEAST, V5, P149, DOI 10.1002/yea.320050304; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TORRES JH, 1995, PLANT MOL BIOL, V27, P1221, DOI 10.1007/BF00020896	22	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16842	16849		10.1074/jbc.271.28.16842	http://dx.doi.org/10.1074/jbc.271.28.16842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663319	hybrid			2022-12-25	WOS:A1996UX12600065
J	Safran, M; Farwell, AP; Leonard, JL				Safran, M; Farwell, AP; Leonard, JL			Catalytic activity of type II iodothyronine 5'-deiodinase polypeptide is dependent upon a cyclic AMP activation factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLIAL-CELLS; REVERSE TRIIODOTHYRONINE; GEL-ELECTROPHORESIS; CEREBRAL-CORTEX; THYROID-HORMONE; PINEAL-GLAND; THYROXINE; RAT; ASTROCYTES; PROTEIN	Type II iodothyronine 5'-deiodinase is an similar to 200-kDa multimeric enzyme in the brain that catalyzes the deiodination of thyroxine (T-4) to its active metabolite, 3,5,3'-triiodothyronine. In astrocytes, cAMP stimulation is required to express catalytically active type II iodothyronine 5'-deiodinase. The affinity ligand N-bromoacetyl-L-T-4 specifically labels the 29-kDa substrate-binding subunit (p29) of this enzyme in cAMP-stimulated astro cytes, To determine the requirements for cAMP-induced activation of this enzyme, we optimized N-bromoacetyl-L-T-4 labeling of p29 in astrocytes lacking type II iodothyronine 5'-deiodinase activity and examined the effects of cAMP on the hydrodynamic properties and subcellular location of the enzyme, We show that the p29 subunit is expressed in unstimulated astrocytes and requires 10-fold higher concentrations of N-bromoacetyl-L-T-4 to achieve incorporation levels equal to those of p29 in cAMP-stimulated cells, Gel filtration showed that p29 was part of a multimeric membrane-associated complex in both cAMP-stimulated and unstimulated astrocytes and that cAMP stimulation led to an increase of similar to 60 kDa in the mass of the holoenzyme, In unstimulated astrocytes, p29 resides in the perinuclear space, Cyclic AMP stimulation leads to the translocation of p29 to the plasma membrane coincident with the appearance of deiodinating activity. These data show that cAMP dependent activation of type II iodothyronine 5'-deiodinase activity results from the synthesis of additional activating factor(s) that associates with inactive enzyme and leads to the translocation of enzyme polypeptide(s) from the perinuclear space to the plasma membrane.	UNIV MASSACHUSETTS, SCH MED, DEPT NUCL MED, MOLEC ENDOCRINOL LAB, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MOLEC & CELLULAR PHYSIOL, MOLEC ENDOCRINOL LAB, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MED, MOLEC ENDOCRINOL LAB, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Farwell, Alan/0000-0001-7716-2719	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038772, K08DK002005] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02005, DK-38772] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BERRY MJ, 1991, ENDOCRINOLOGY, V129, P550, DOI 10.1210/endo-129-1-550; CHANOINE JP, 1992, ENDOCRINOLOGY, V131, P479, DOI 10.1210/en.131.1.479; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; GUERRERO JM, 1988, ENDOCRINOLOGY, V122, P236, DOI 10.1210/endo-122-1-236; HALPERIN Y, 1994, ENDOCRINOLOGY, V135, P1464, DOI 10.1210/en.135.4.1464; KAISER CA, 1986, ENDOCRINOLOGY, V119, P762, DOI 10.1210/endo-119-2-762; Kaplan MM, 1986, THYROID HORMONE META, P231; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; LEONARD JL, 1990, J BIOL CHEM, V265, P940; LEONARD JL, 1981, SCIENCE, V214, P571, DOI 10.1126/science.7291997; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; Leonard JL, 1986, THYROID HORMONE META, P189; NIKODEM V, 1979, ANAL BIOCHEM, V97, P382, DOI 10.1016/0003-2697(79)90089-7; OSUNA C, 1993, EXPERIENTIA, V49, P329, DOI 10.1007/BF01923413; RISKIND PN, 1987, BRAIN RES, V420, P194, DOI 10.1016/0006-8993(87)90260-5; RUBIO A, 1993, J PINEAL RES, V14, P53, DOI 10.1111/j.1600-079X.1993.tb00485.x; SAFRAN M, 1991, J BIOL CHEM, V266, P13477; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAFRAN M, 1991, ENDOCRINOLOGY, V129, P2011, DOI 10.1210/endo-129-4-2011; SCHOENMAKERS CHH, 1995, MOL CELL ENDOCRINOL, V107, P173, DOI 10.1016/0303-7207(94)03440-5; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; WYSS M, 1993, BIOCHEM J, V291, P463, DOI 10.1042/bj2910463	31	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16363	16368		10.1074/jbc.271.27.16363	http://dx.doi.org/10.1074/jbc.271.27.16363			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663169	hybrid			2022-12-25	WOS:A1996UW35200075
J	Xu, G; Goodridge, AG				Xu, G; Goodridge, AG			Characterization of a polypyrimidine/polypurine tract in the promoter of the gene for chicken malic enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; STRANDED-DNA; NUTRITIONAL REGULATION; EMBRYO HEPATOCYTES; NEUTRAL PH; H-DNA; TRANSCRIPTION; IDENTIFICATION; SEQUENCES; TRIPLEX	Starvation inhibits and refeeding stimulates transcription of the malic enzyme gene in chick liver. DNA between -320 and +72 base pairs (bp) is DNase I-hypersensitive in hepatic nuclei from fed but not starved chicks (Ma, X. J,, and Goodridge, A. G, (1992) Nucleic Acids Res. 20, 4997-5002). A polypyrimidine/polypurine (PPY/PPU) tract lies within the DNase I-hypersensitive region, In hepatocytes transiently transfected with plasmids containing triiodothyronine response elements and a minimal promoter from the malic enzyme gene linked to the chloramphenicol acetyltransferase gene, deletion of the PPY/PPU tract inhibited chloramphenicol acetyltransferase activity by about 90% with or without triiodothyronine, Fine mapping of S1 nuclease-sensitive sites suggests that the PPY/PPU tract can assume different isoforms of non-B-DNA, some of which may be tripler structures, The PPY/PPU tract contains specific binding sites for single- and double stranded DNA binding proteins and, with 8 bp 3' of the tract, can function as a promoter. A (CT)(7) repeat binds single-stranded DNA-binding protein and is essential for promoter activity, Two C-rich elements bind single-stranded DNA-binding proteins and may mediate inhibition of promoter function, The single- and double-stranded DNA-binding proteins that interact with the PPY/PPU tract may regulate transcription of the malic enzyme gene.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52240	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21954, DK 25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; BEHE MJ, 1987, BIOCHEMISTRY-US, V26, P7870, DOI 10.1021/bi00398a050; BIRNBOIM HC, 1978, J MOL BIOL, V121, P541, DOI 10.1016/0022-2836(78)90399-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; CONOVER W, 1986, PRACTICAL NONPARAMET, P1; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GARYHACK EJ, 1992, MOL CELL BIOL, V12, P3573; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GlucksmannKuis MA, 1996, CELL, V84, P147, DOI 10.1016/S0092-8674(00)81001-6; Goodridge AG, 1996, PROG NUCLEIC ACID RE, V52, P89, DOI 10.1016/S0079-6603(08)60965-4; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KANG S, 1992, J BIOL CHEM, V267, P20889; KOHWI Y, 1993, J MOL BIOL, V231, P1090, DOI 10.1006/jmbi.1993.1354; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEWIS CD, 1988, GENE DEV, V2, P863, DOI 10.1101/gad.2.7.863; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA XJ, 1990, J BIOL CHEM, V265, P18435; MA XJ, 1992, NUCLEIC ACIDS RES, V20, P4997, DOI 10.1093/nar/20.19.4997; MA XJ, 1991, THESIS U IOWA; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2366; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P105, DOI 10.1093/nar/21.1.105; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MARTINEZBALBAS A, 1993, NUCLEIC ACIDS RES, V21, P2557, DOI 10.1093/nar/21.11.2557; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moore DD, 1995, GLOB MOB SURV; MORGAN AR, 1994, INDIAN J BIOCH BIOPH, V3, P83; MURAISO T, 1992, NUCLEIC ACIDS RES, V20, P6631, DOI 10.1093/nar/20.24.6631; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; QUIVY JP, 1993, NUCLEIC ACIDS RES, V21, P2779, DOI 10.1093/nar/21.11.2779; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; Shishido K, 1982, NUCLEASES, P155; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WANG ZY, 1993, J BIOL CHEM, V268, P10681; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	64	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16008	16019		10.1074/jbc.271.27.16008	http://dx.doi.org/10.1074/jbc.271.27.16008			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663263	hybrid			2022-12-25	WOS:A1996UW35200027
J	Desai, D; Michalak, M; Singh, NK; Niles, RM				Desai, D; Michalak, M; Singh, NK; Niles, RM			Inhibition of retinoic acid receptor function and retinoic acid-regulated gene expression in mouse melanoma cells by calreticulin - A potential pathway for cyclic AMP regulation of retinoid action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; THYROID-HORMONE; NUCLEAR RECEPTOR; ENDOPLASMIC-RETICULUM; RESPONSE ELEMENT; NONMUSCLE CELLS; CLONING; GAMMA; BETA; DIFFERENTIATION	Calcium is a second messenger that controls a wide variety of cellular functions. Because of its multiple actions, there is a stringent requirement for calcium ho meostasis, and this is achieved in part by a system of transport and storage proteins such as calreticulin located in the endoplasmic reticulum, Calreticulin is also found in the nucleus, suggesting that it may have a role in transcriptional regulation. It has been reported that calreticulin can inhibit steroid-regulated gene transcription by preventing receptor binding to DNA, Here we report that overexpression of the calreticulin gene in B16 mouse melanoma cells resulted in a decrease in retinoic acid (RA)-stimulated reporter gene expression, Gel shift analysis showed that purified calreticulin inhibited the binding of endogenous RAR 60 a beta-RA response element oligonucleotide, only if added prior to the addition of the oligonucleotide. Co-immunoprecipitation studies suggest a physical interaction between RAR and calreticulin. Transfection of the calreticulin gene into B16 cells inhibited the RA induction of protein kinase C alpha, a marker of RA induced differentiation. We also found that cyclic AMP increased the expression of calreticulin, Cyclic AMP may act to antagonize RA action by both decreasing RAR expression (Y, Xiao, D, Desai, T, Quick, and R, M, Niles, J, Cell Physiol., in press) and stimulating calreticulin levels,	MARSHALL UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HUNTINGTON,WV 25755; UNIV ALBERTA,DEPT BIOCHEM,MED RES COUNCIL GRP MOLEC BIOL MEMBRANES,EDMONTON,AB T6G 2S2,CANADA; US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	Marshall University; University of Alberta; US Food & Drug Administration (FDA)					NATIONAL CANCER INSTITUTE [R01CA059530] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1990, J BIOL CHEM, V265, P6513; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; DE LUCA LM, 1991, FASEB J, V5, P2924; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GERSTEN DM, 1991, BIOCHIM BIOPHYS ACTA, V1096, P20; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NILES RM, 1991, J CELL PHYSIOL, V147, P176, DOI 10.1002/jcp.1041470122; OBANION MK, 1993, J VIROL, V67, P3427, DOI 10.1128/JVI.67.6.3427-3434.1993; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; PEREZ P, 1993, J BIOL CHEM, V268, P23538; QUICK TC, 1994, RECEPTOR, V4, P65; Sambrook J., 2002, MOL CLONING LAB MANU; SPORN MB, 1983, CANCER RES, V43, P3034; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THARIN S, 1992, CELL TISSUE RES, V269, P29, DOI 10.1007/BF00384723; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	34	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15153	15159		10.1074/jbc.271.25.15153	http://dx.doi.org/10.1074/jbc.271.25.15153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662962	hybrid			2022-12-25	WOS:A1996UT10600075
J	Estelles, A; Yokoyama, M; Nothias, F; Vincent, JD; Glowinski, J; Vernier, P; Chneiweiss, H				Estelles, A; Yokoyama, M; Nothias, F; Vincent, JD; Glowinski, J; Vernier, P; Chneiweiss, H			The major astrocytic phosphoprotein PEA-15 is encoded by two mRNAs conserved on their full length in mouse and human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; SEQUENCES; REGION; RNA; PHOSPHORYLATION; SUPPRESSION; TROPOMYOSIN; GROWTH	Specific phosphoproteins are targets of numerous extracellular signals received by astrocytes. One such target, which we previously described, is PEA-15, a protein kinase C substrate associated with microtubules, Two cDNAs differing in the length of their S'-untranslated region (3'UTR) were cloned from a mouse astrocytic library, Accordingly, Northern blots revealed two transcripts (1.7 and 2.5 kilobase pairs) abundant brain regions but also found in peripheral tissues. PEA-15-deduced protein sequence (130 amino acids) shared no similarity with known proteins but is 96% identical to its human counterpart, In addition, several regions of the 3'UTR share more than 90% identity between mouse and human, Different potential regulatory sequences are found in the 3'UTR, which also completely includes the proto-oncogene MAT1. The high level of conservation of both the coding and the untranslated regions and the differential tissular distribution of the two transcripts of this major brain phosphoprotein suggest that not only the protein but also the 3'UTR of PEA-15 mRNA play a role in astrocytic functions.	COLL FRANCE,INSERM U114,F-75231 PARIS 05,FRANCE; COLL FRANCE,CHAIRE NEUROPHARMACOL,F-75231 PARIS 05,FRANCE; INST ALFRED FESSARD,CNRS UPR2212,F-91998 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; PSL Research University Paris; College de France			herve, chneiweiss/Q-6818-2019	herve, chneiweiss/0000-0001-7675-5061; Nothias-Chahir, Fatiha/0000-0002-2497-2096				AHMED S, 1990, J BIOL CHEM, V265, P13899; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARRES BA, 1991, J NEUROSCI, V11, P3685; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BROWN AJP, 1993, TRENDS CELL BIOL, V3, P1808; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; FERRALLI J, 1994, J CELL SCI, V107, P3115; FRISQUE RJ, 1983, J VIROL, V46, P170, DOI 10.1128/JVI.46.1.170-176.1983; GABBIANI G, 1976, AM J PATHOL, V83, P457; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARRISON BC, 1992, J NEUROCHEM, V58, P320, DOI 10.1111/j.1471-4159.1992.tb09313.x; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KANAI Y, 1995, NEURON, V14, P421, DOI 10.1016/0896-6273(95)90298-8; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUBES M, 1994, EUR J NEUROSCI S, V7; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MALLET J, 1988, EBO PRACTICAL COURSE; MCCARTHY KD, 1985, J NEUROCHEM, V44, P723, DOI 10.1111/j.1471-4159.1985.tb12875.x; MURPHY B, 1993, ASTROCYTES PHARM FUN; NOTHIAS F, 1993, J COMP NEUROL, V334, P370, DOI 10.1002/cne.903340304; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960-9822(00)00178-0; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Vale Ronald D., 1993, P175	37	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14800	14806		10.1074/jbc.271.25.14800	http://dx.doi.org/10.1074/jbc.271.25.14800			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662970	hybrid			2022-12-25	WOS:A1996UT10600027
J	Louzao, MC; Ribeiro, CMP; Bird, GS; Putney, JW				Louzao, MC; Ribeiro, CMP; Bird, GS; Putney, JW			Cell type-specific modes of feedback regulation of capacitative calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATE; ACTIVATED CALCIUM; ACINAR-CELLS; MAST-CELLS; THAPSIGARGIN; INHIBITION; PATHWAY; RELEASE; POOL	The Ca2+ ATPase inhibitor, thapsigargin, activated Ca2+ entry into pancreatic acinar cells, a process known as capacitative calcium entry, In cells loaded with the calcium chelator BAPTA, the transient Ca2+ release was blunted and the rise of [Ca2+](i) on readdition of Ca2+ was slowed, However, the steady-state [Ca2+](i) due to Ca2+ entry was substantially augmented compared with control cells, This indicates that [Ca2+](i) exerts a negative feedback on Ca2+ entry from a compartment buffered by BAPTA and separated from the bulk of cytoplasmic Ca2+. This interaction probably occurs close to the calcium channel where [Ca2+] is higher than in the bulk of the cytoplasm, In support of this interpretation, the slower Ca2+ chelator, EGTA, also blunted the release of Ca2+ and slowed the rise of the sustained [Ca2+](i) phase but failed to augment steady-state [Ca2+](i). In contrast, Ca2+ entry in NIH 3T3 cells was characterized by a transient rise of [Ca2+](i) that decays to near prestimulus levels, This decay in Ca2+ entry also results from negative feedback by Ca2+ because the decrease in Ca2+ entry was reversed by incubation in a Ca2+ deficient medium, However, unlike its effects in acinar cells, BAPTA neither augmented steady-state [Ca2+](i) nor pre vented the inactivation of entry, Rather, in BAPTA-loaded cells, [Ca2+](i) failed to increase substantially suggesting that negative regulation by Ca2+ may occur at a site distinct from the cytoplasmic compartment and inaccessible to cytoplasmic BAPTA, These two distinct types of feedback behavior may indicate subtypes of store-operated calcium channels expressed in different cells or a single type of channel which is differentially regulated in a cell type-specific manner.	NIEHS,CALCIUM REGULAT SECT,CELLULAR & MOLEC PHARMACOL LAB,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Louzao, M. Carmen/AAD-3847-2019; Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019; Ribeiro, Carla Maria P/A-6955-2009	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789; Louzao, M. Carmen/0000-0002-3072-0637				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; GILON P, 1995, BIOCHEM J, V311, P649, DOI 10.1042/bj3110649; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MONTERO M, 1993, J BIOL CHEM, V268, P13055; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1981, PHILOS T ROY SOC B, V296, P37, DOI 10.1098/rstb.1981.0169; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; VANDERKOOI JM, 1971, ARCH BIOCHEM BIOPHYS, V144, P99, DOI 10.1016/0003-9861(71)90458-9; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P197; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	23	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14807	14813		10.1074/jbc.271.25.14807	http://dx.doi.org/10.1074/jbc.271.25.14807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662975	hybrid			2022-12-25	WOS:A1996UT10600028
J	Zahedi, K				Zahedi, K			Characterization of the binding of serum amyloid P to type IV collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; GLOMERULAR BASEMENT-MEMBRANE; BIOLOGICAL-ACTIVITY; HEPARAN-SULFATE; COMPONENT; REGION; LOCALIZATION; FIBRONECTIN; PENTRAXINS; INHIBITION	Serum amyloid P (SAP), a member of the evolutionarily conserved pentraxin family, is a normal component of a number of basement membranes, including glomerular and alveolar, In vitro SAP binds to a variety of proteins including fibronectin, proteoglycans, and the collagen-like region of the complement component C1q. In these studies, binding of SAP to type IV collagen, a major component of basement membrane, was examined, Purified SAP binds to human and mouse type IV collagen but not type I, II, or III collagens, Binding of SAP to type IV collagen is dependent on the presence of Ca2+. This binding is saturable with a K-d approximate to 1.2 x 10(-7) M based on solid phase binding and 4 x 10(-8) M based on the IC50 value from fluid phase binding data, Binding of SAP to type IV collagen was inhibited by both SAP and C-reactive protein (CRP), However, a 5-fold molar excess of CRP as compared with SAP was required to inhibit the SAP binding by 50%. Binding of SAP to type TV collagen was inhibited by both collagen IV and C1q but not by phosphatidylethanolamine or bovine serum albumin, The inhibition data indicate that SAP may bind to the triple helical region of type IV collagen via a site distinct from its galactan binding site, The most likely site of SAP involved in its interaction with type TV collagen may be the region spanning amino acid residues 108-120, which shows a great deal of sequence homology (60% strict identity) with the CRP region implicated in its binding to the collagen-like region of the C1q molecule.	UNIV CINCINNATI, COLL MED, DEPT PEDIAT, CINCINNATI, OH 45229 USA	University System of Ohio; University of Cincinnati	Zahedi, K (corresponding author), CHILDRENS HOSP RES FDN, DIV NEPHROL, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.		Zahedi, Kamyar/AAQ-3428-2021					AGRAWAL A, 1992, J BIOL CHEM, V267, P25352; AGRAWAL A, 1994, J IMMUNOL, V152, P5404; ALMUTLAQ H, 1993, HISTOCHEM J, V25, P219, DOI 10.1007/BF00163818; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; COE JE, 1977, P NATL ACAD SCI USA, V74, P730, DOI 10.1073/pnas.74.2.730; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DYCK RF, 1980, LANCET, V2, P607; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; GEWURZ H, 1982, ADV INTERNAL MED, V27, P345; HAMAZAKI H, 1995, J BIOL CHEM, V270, P10392, DOI 10.1074/jbc.270.18.10392; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; JIANG HX, 1991, J IMMUNOL, V146, P2324; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; LE PT, 1982, J IMMUNOL, V129, P665; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; MELVIN T, 1986, AM J PATHOL, V125, P460; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PAULSSON M, 1987, COLLAGEN REL RES, V7, P443; POTEMPA LA, 1985, J BIOL CHEM, V260, P2142; SCHITTNY JC, 1988, J CELL BIOL, V107, P1599, DOI 10.1083/jcb.107.4.1599; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TSENG J, 1986, IMMUNOL INVEST, V15, P749, DOI 10.3109/08820138609036360; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; WOO P, 1985, J BIOL CHEM, V260, P3384; YING SC, 1993, J IMMUNOL, V150, P169; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040	32	28	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14897	14902		10.1074/jbc.271.25.14897	http://dx.doi.org/10.1074/jbc.271.25.14897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662978	hybrid			2022-12-25	WOS:A1996UT10600041
J	Lerner, DJ; Chen, M; Tram, T; Coughlin, SR				Lerner, DJ; Chen, M; Tram, T; Coughlin, SR			Agonist recognition by proteinase-activated receptor 2 and thrombin receptor - Importance of extracellular loop interactions for receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; CLEAVAGE	Thrombin receptor and proteinase-activated receptor 2 (PAR2) define a family of G protein-coupled receptors that are activated by a novel proteolytic mechanism. Specific cleavage of their amino-terminal exodomains unmasks a new amino terminus which then serves as a tethered ligand, docking intramolecularly to the body of the receptor to effect signaling. Identification of the docking interactions between tethered ligand domain and receptor is critical for understanding transmembrane signaling by these receptors. Synthetic ''agonist peptides'' that mimic the tethered ligand domains of thrombin receptor and PAR2 act as agonists at their respective receptors, Toward defining the docking interactions which mediate receptor activation, we determined the specificity of the thrombin receptor and PAR2 for their respective agonist peptides and used receptor chimeras to identify the receptor domains responsible for such specificity. PARE responded to both thrombin receptor and PAR2 agonist peptides, In contrast, thrombin receptor was selective for its own agonist peptide. Substitution of the extracellular face of PAR2, its amino-terminal exodomain and three extracellular loops, for the cognate thrombin receptor structures yielded a chimeric receptor with PAR2-like agonist specificity. Substitution of individual extracellular domains revealed that the primary determinant of agonist specificity was extracellular loop 2, Strikingly, substitution of either the amino-terminal exodomain or third extracellular loop alone caused marked loss of receptor function, but the double substitution yielded a functional receptor. Thus, the extracellular domains of these G protein-coupled receptors are more than simply passive links between transmembrane domains. They participate in agonist recognition and must interact, directly or indirectly, for proper receptor function.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [T32 HL07731, HL44907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007731, R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAYKAL D, 1995, AM J CARDIOL, V75, pB82, DOI 10.1016/0002-9149(95)80019-O; CHEN J, 1995, J BIOL CHEM, V270, P23398, DOI 10.1074/jbc.270.40.23398; CHEN J, 1994, J BIOL CHEM, V269, P16041; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DONNELLY D, 1994, CURR OPIN STRUC BIOL, V4, P582, DOI 10.1016/S0959-440X(94)90221-6; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939	25	94	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13943	13947		10.1074/jbc.271.24.13943	http://dx.doi.org/10.1074/jbc.271.24.13943			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662993	hybrid			2022-12-25	WOS:A1996UQ66000005
